0001437749-24-030111S-1 FIREFLY NEUROSCIENCE, INC. 20240926202409270622020622020622202 0 0001437749-24-030111 S-1 149 20240927 20240927 FIREFLY NEUROSCIENCE, INC. 0000803578 7372 541167364 DE 1231 S-1 33 333-282357 241330434 1100 MILITARY ROAD KENMORE NY 14217 888-237-6412 1100 MILITARY ROAD KENMORE NY 14217 WAVEDANCER, INC. 20211215 INFORMATION ANALYSIS INC 19920703 S-1 1 wavd20240923_s1.htm FORM S-1 wavd20240923_s1.htm 0000803578 FIREFLY NEUROSCIENCE, INC. false Q2 2024 0.00001 0.00001 30,000,000 30,000,000 2,374,219 2,374,219 16,116,957 16,116,957 0.00001 0.00001 2,470,000,000 2,470,000,000 49,948,710 49,948,710 35,369,877 35,369,877 4 5 1 1 3 1 74 0 0 0 0 5 3 0 0.00001 0.00001 30,000,000 30,000,000 16,116,957 16,116,957 0 0 0.00001 0.00001 2,470,000,000 2,470,000,000 35,369,877 35,369,877 2,552,744 2,552,744 750 750 0 5 1 1 3 750 5 0 0 750 5 3 0 2018 2019 2020 2021 2022 2023 1 1 3 00008035782024-01-012024-06-30 thunderdome:item iso4217:USD 00008035782024-06-30 00008035782023-12-31 0000803578us-gaap:RelatedPartyMember2024-06-30 0000803578us-gaap:RelatedPartyMember2023-12-31 iso4217:USDxbrli:shares xbrli:shares 00008035782024-04-012024-06-30 00008035782023-04-012023-06-30 00008035782023-01-012023-06-30 0000803578us-gaap:PreferredStockMember2023-12-31 0000803578aiff:PreferredStockNumberOfSharesToBeIssuedMember2023-12-31 0000803578us-gaap:CommonStockMember2023-12-31 0000803578aiff:CommonStockNumberOfSharesToBeIssuedMember2023-12-31 0000803578us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000803578us-gaap:RetainedEarningsMember2023-12-31 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2024-01-012024-06-30 0000803578us-gaap:SeriesBPreferredStockMemberaiff:PreferredStockNumberOfSharesToBeIssuedMember2024-01-012024-06-30 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMember2024-01-012024-06-30 0000803578us-gaap:SeriesBPreferredStockMemberaiff:CommonStockNumberOfSharesToBeIssuedMember2024-01-012024-06-30 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2024-01-012024-06-30 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMember2024-01-012024-06-30 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-30 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:RetainedEarningsMember2024-01-012024-06-30 0000803578us-gaap:SeriesCPreferredStockMember2024-01-012024-06-30 0000803578us-gaap:PreferredStockMember2024-01-012024-06-30 0000803578us-gaap:CommonStockMember2024-01-012024-06-30 0000803578us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-30 0000803578us-gaap:RetainedEarningsMember2024-01-012024-06-30 0000803578us-gaap:PreferredStockMember2024-06-30 0000803578aiff:PreferredStockNumberOfSharesToBeIssuedMember2024-06-30 0000803578us-gaap:CommonStockMember2024-06-30 0000803578aiff:CommonStockNumberOfSharesToBeIssuedMember2024-06-30 0000803578us-gaap:AdditionalPaidInCapitalMember2024-06-30 0000803578us-gaap:RetainedEarningsMember2024-06-30 0000803578us-gaap:PreferredStockMember2022-12-31 0000803578aiff:PreferredStockNumberOfSharesToBeIssuedMember2022-12-31 0000803578us-gaap:CommonStockMember2022-12-31 0000803578aiff:CommonStockNumberOfSharesToBeIssuedMember2022-12-31 0000803578us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000803578us-gaap:RetainedEarningsMember2022-12-31 00008035782022-12-31 0000803578aiff:PreferredStockNumberOfSharesToBeIssuedMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-06-30 0000803578us-gaap:PreferredStockMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-06-30 0000803578aiff:CommonStockNumberOfSharesToBeIssuedMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-06-30 0000803578us-gaap:CommonStockMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-06-30 0000803578us-gaap:AdditionalPaidInCapitalMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-06-30 0000803578us-gaap:RetainedEarningsMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-06-30 0000803578aiff:CommonStockPrivatePlacementMember2023-01-012023-06-30 0000803578us-gaap:SeriesBPreferredStockMemberaiff:PreferredStockNumberOfSharesToBeIssuedMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-06-30 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-06-30 0000803578us-gaap:SeriesBPreferredStockMemberaiff:CommonStockNumberOfSharesToBeIssuedMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-06-30 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-06-30 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-06-30 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:RetainedEarningsMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-06-30 0000803578us-gaap:SeriesBPreferredStockMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-06-30 0000803578us-gaap:PreferredStockMember2023-01-012023-06-30 0000803578us-gaap:CommonStockMember2023-01-012023-06-30 0000803578us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-30 0000803578us-gaap:RetainedEarningsMember2023-01-012023-06-30 0000803578us-gaap:PreferredStockMember2023-06-30 0000803578aiff:PreferredStockNumberOfSharesToBeIssuedMember2023-06-30 0000803578us-gaap:CommonStockMember2023-06-30 0000803578aiff:CommonStockNumberOfSharesToBeIssuedMember2023-06-30 0000803578us-gaap:AdditionalPaidInCapitalMember2023-06-30 0000803578us-gaap:RetainedEarningsMember2023-06-30 00008035782023-06-30 xbrli:pure 0000803578aiff:FormerFirefly2023StockholdersMember2024-08-12 0000803578aiff:FormerFireflyStockholdersMember2024-08-12 utr:Y 0000803578aiff:MedicalEquipmentMember2024-06-30 0000803578aiff:MedicalEquipmentMember2023-12-31 0000803578us-gaap:ComputerSoftwareIntangibleAssetMember2024-06-30 0000803578aiff:IiaRoyaltyCommitmentMember2024-06-30 0000803578aiff:IiaRoyaltyCommitmentMember2023-12-31 0000803578us-gaap:SeriesCPreferredStockMember2023-08-29 0000803578aiff:SeriesCPreferredUnitWarrantsMember2023-08-29 0000803578aiff:SeriesCPreferredUnitWarrantsMemberus-gaap:SeriesCPreferredStockMember2023-08-29 0000803578aiff:SeriesCPreferredUnitWarrantsMember2024-06-30 0000803578aiff:ConversionOfSeriesBPreferredStockToCommonStockMember2023-12-31 0000803578aiff:ConversionOfSeriesBPreferredStockToCommonStockMember2024-01-012024-06-30 0000803578us-gaap:SeriesAPreferredStockMember2024-06-30 0000803578us-gaap:SeriesBPreferredStockMember2024-06-30 0000803578us-gaap:SeriesCPreferredStockMember2024-06-30 00008035782023-01-012023-12-31 0000803578aiff:SeriesCPreferredUnitWarrantsMember2024-01-012024-06-30 0000803578us-gaap:EmployeeStockOptionMember2024-04-012024-06-30 0000803578us-gaap:EmployeeStockOptionMember2024-01-012024-06-30 0000803578us-gaap:EmployeeStockOptionMember2023-04-012023-06-30 0000803578us-gaap:EmployeeStockOptionMember2023-01-012023-06-30 00008035782024-04-022024-04-02 0000803578aiff:SeriesAPerformanceWarrantsMember2024-03-15 00008035782024-03-15 0000803578us-gaap:WarrantMember2024-04-012024-06-30 0000803578us-gaap:WarrantMember2023-04-012023-06-30 0000803578srt:DirectorMember2024-06-30 0000803578srt:DirectorMember2023-06-30 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2024-04-012024-06-30 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2024-01-012024-06-30 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2023-04-012023-06-30 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2023-01-012023-06-30 0000803578us-gaap:ServiceMember2024-04-012024-06-30 0000803578us-gaap:ServiceMember2023-04-012023-06-30 0000803578us-gaap:ServiceMember2024-01-012024-06-30 0000803578us-gaap:ServiceMember2023-01-012023-06-30 0000803578us-gaap:TransferredAtPointInTimeMember2024-04-012024-06-30 0000803578us-gaap:TransferredAtPointInTimeMember2023-04-012023-06-30 0000803578us-gaap:TransferredAtPointInTimeMember2024-01-012024-06-30 0000803578us-gaap:TransferredAtPointInTimeMember2023-01-012023-06-30 0000803578us-gaap:TransferredOverTimeMember2024-04-012024-06-30 0000803578us-gaap:TransferredOverTimeMember2023-04-012023-06-30 0000803578us-gaap:TransferredOverTimeMember2024-01-012024-06-30 0000803578us-gaap:TransferredOverTimeMember2023-01-012023-06-30 0000803578us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-30 0000803578us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-30 0000803578us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-30 0000803578us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-30 0000803578us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-30 0000803578us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-30 0000803578us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-30 0000803578us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-30 0000803578us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-30 0000803578us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-30 0000803578us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-30 0000803578us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-30 0000803578aiff:SecuredPromissoryNotesMemberus-gaap:SubsequentEventMember2024-08-08 0000803578aiff:SecuredPromissoryNotesMemberus-gaap:SubsequentEventMember2024-08-082024-08-08 0000803578aiff:MergerReverseStockSplitMemberus-gaap:SubsequentEventMember2024-08-122024-08-12 0000803578aiff:FireflyMemberaiff:NewFireflyCommonStockMemberus-gaap:SubsequentEventMember2024-08-12 0000803578aiff:FireflyMemberus-gaap:SubsequentEventMember2024-08-12 0000803578aiff:PipeShareWithAccompanyingWarrantMemberus-gaap:SubsequentEventMember2024-07-26 0000803578aiff:PrefundedWarrantsMemberus-gaap:SubsequentEventMember2024-07-262024-07-26 0000803578aiff:CommonStockWarrantsMemberus-gaap:SubsequentEventMember2024-07-262024-07-26 0000803578aiff:PipeShareWithAccompanyingWarrantMemberus-gaap:SubsequentEventMember2024-07-26 0000803578aiff:PrefundedWarrantsMemberus-gaap:SubsequentEventMember2024-07-26 0000803578us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2024-07-262024-07-26 0000803578us-gaap:RelatedPartyMember2022-12-31 00008035782022-01-012022-12-31 0000803578us-gaap:PreferredStockMember2021-12-31 0000803578us-gaap:CommonStockMember2021-12-31 0000803578us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000803578us-gaap:RetainedEarningsMember2021-12-31 00008035782021-12-31 0000803578us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2022-01-012022-12-31 0000803578us-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMember2022-01-012022-12-31 0000803578us-gaap:SeriesAPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000803578us-gaap:SeriesAPreferredStockMemberus-gaap:RetainedEarningsMember2022-01-012022-12-31 0000803578us-gaap:SeriesAPreferredStockMember2022-01-012022-12-31 0000803578us-gaap:PreferredStockMember2022-01-012022-12-31 0000803578us-gaap:CommonStockMember2022-01-012022-12-31 0000803578us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000803578us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000803578us-gaap:PreferredStockMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-12-31 0000803578us-gaap:AdditionalPaidInCapitalMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-12-31 0000803578us-gaap:RetainedEarningsMemberaiff:CommonStockPrivatePlacementMember2023-01-012023-12-31 0000803578aiff:CommonStockPrivatePlacementMember2023-01-012023-12-31 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesBPreferredStockMemberus-gaap:RetainedEarningsMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesBPreferredStockMemberaiff:SeriesBPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMemberaiff:SeriesCPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMemberaiff:SeriesCPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:AdditionalPaidInCapitalMemberaiff:SeriesCPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:RetainedEarningsMemberaiff:SeriesCPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:SeriesCPreferredStockMemberaiff:SeriesCPreferredStockOfferingMember2023-01-012023-12-31 0000803578us-gaap:PreferredStockMember2023-01-012023-12-31 0000803578us-gaap:CommonStockMember2023-01-012023-12-31 0000803578us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-31 0000803578us-gaap:RetainedEarningsMember2023-01-012023-12-31 00008035782022-01-27 0000803578us-gaap:SeriesAPreferredStockMember2022-01-27 0000803578us-gaap:CommonStockMember2022-07-052022-07-05 0000803578us-gaap:SeriesAPreferredStockMember2022-07-052022-07-05 00008035782022-07-052022-07-05 0000803578aiff:ReverseStockSplitMember2022-11-232022-11-23 0000803578aiff:FormerFirefly2023StockholdersMember2023-11-16 0000803578aiff:FormerFireflyStockholdersMember2023-11-16 0000803578country:CA2023-01-012023-12-31 0000803578country:CA2022-01-012022-12-31 0000803578country:CA2023-12-31 0000803578country:CA2022-12-31 0000803578country:US2023-01-012023-12-31 0000803578country:US2022-01-012022-12-31 0000803578country:US2023-12-31 0000803578country:US2022-12-31 0000803578country:IL2023-01-012023-12-31 0000803578country:IL2022-01-012022-12-31 0000803578country:IL2023-12-31 0000803578country:IL2022-12-31 0000803578us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-31 0000803578aiff:SideLetterMemberaiff:WpcAndOrigaMember2021-12-31 0000803578aiff:SideLetterMemberaiff:WpcAndOrigaMember2022-02-02 0000803578aiff:ConvertibleDebtAndStockWarrantsMemberaiff:WpcAndOrigaMember2022-02-02 0000803578aiff:SideLetterMemberaiff:WpcAndOrigaMember2022-02-02-022022-02-02 0000803578aiff:SideLetterMemberaiff:WpcAndOrigaMember2022-07-04 0000803578aiff:ConvertibleDebtAndStockWarrantsMemberaiff:WpcAndOrigaMember2022-07-04 0000803578aiff:SideLetterMemberaiff:WpcAndOrigaMember2022-07-042022-07-04 0000803578aiff:PhytoIvLpMemberus-gaap:ConvertibleDebtMember2022-05-04 0000803578aiff:PhytoIvLpMemberus-gaap:ConvertibleDebtMember2022-07-04 0000803578aiff:PhytoIvLpMemberus-gaap:ConvertibleDebtMember2022-07-042022-07-04 0000803578aiff:ConversionOfDebtAndInterestIntoCommonStockMemberaiff:PhytoIvLpMember2022-09-302022-09-30 0000803578aiff:ConvertibleDebtIssuedToVariousInvestorsMember2022-07-04 0000803578aiff:ConversionOfDebtAndInterestIntoCommonStockMemberaiff:ConvertibleDebtIssuedToVariousInvestorsMember2022-09-302022-09-30 0000803578aiff:ConversionOfDirectorNotesIntoCommonStockMember2022-01-012022-12-31 0000803578aiff:RIMindGroupLtdMember2019-02-28 0000803578aiff:RIMindGroupLtdMember2019-02-012019-02-28 0000803578aiff:PasitheaClinicsIncMember2022-08-012022-08-31 0000803578aiff:PasitheaClinicsIncMember2022-11-012022-11-30 0000803578aiff:PasitheaClinicsIncMember2022-01-012022-12-31 0000803578aiff:RIMindGroupLtdMember2022-01-012022-12-31 0000803578aiff:PasitheaClinicsIncMember2023-01-012023-12-31 0000803578aiff:RIMindGroupLtdMember2023-01-012023-12-31 0000803578aiff:IiaRoyaltyCommitmentMember2022-12-31 0000803578us-gaap:SeriesAPreferredStockMemberaiff:SecuritiesPurchaseAgreementMember2022-08-172022-08-17 0000803578aiff:August2022SecuritiesPurchaseAgreementWarrantsMember2022-08-17 0000803578aiff:SecuritiesPurchaseAgreementMember2022-09-152022-09-15 0000803578aiff:SecuritiesPurchaseAgreementMember2022-09-15 0000803578aiff:SecuritiesPurchaseAgreementMember2023-02-162023-02-16 0000803578aiff:SecuritiesPurchaseAgreementMember2023-02-16 0000803578us-gaap:SeriesBPreferredStockMember2023-02-232023-02-23 0000803578us-gaap:SeriesBPreferredStockMember2023-02-23 0000803578us-gaap:SeriesBPreferredStockMember2023-03-152023-03-15 0000803578aiff:ConsultingFeesMemberus-gaap:RelatedPartyMember2023-05-012023-05-01 0000803578aiff:ConsultingFeesMemberus-gaap:RelatedPartyMember2023-05-01 0000803578us-gaap:SeriesCPreferredStockMember2023-12-312023-12-31 0000803578aiff:SeriesCPreferredUnitWarrantsMember2023-12-31 00008035782023-10-162023-10-16 0000803578aiff:ConversionOfSeriesBPreferredStockToCommonStockMember2023-12-312023-12-31 0000803578us-gaap:SeriesAPreferredStockMember2023-12-31 0000803578us-gaap:SeriesAPreferredStockMember2022-12-31 0000803578us-gaap:SeriesBPreferredStockMember2023-12-31 0000803578us-gaap:SeriesBPreferredStockMember2022-12-31 0000803578us-gaap:SeriesCPreferredStockMember2023-12-31 0000803578us-gaap:SeriesCPreferredStockMember2022-12-31 0000803578aiff:TrancheAWarrantsMember2023-12-31 0000803578aiff:TrancheBWarrantsMember2023-12-31 0000803578aiff:TrancheAWarrantsMember2022-07-04 0000803578aiff:ConvertibleDebtAndStockWarrantsMember2022-08-16 0000803578aiff:WpcWarrantsMember2023-02-17 0000803578aiff:SeriesCPreferredUnitWarrantsMember2023-01-012023-12-31 00008035782021-01-012021-12-31 0000803578aiff:SeriesAWarrantsMember2023-06-15 0000803578us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0000803578us-gaap:EmployeeStockOptionMember2022-01-

012022-12-31 00008035782023-07-082023-07-08 0000803578srt:DirectorMember2023-12-31 0000803578srt:DirectorMember2022-12-31 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2023-01-012023-12-31 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2022-01-012022-12-31 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2023-12-31 0000803578aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember2022-12-31 00008035782023-06-082023-06-08 0000803578us-gaap:RelatedPartyMember2023-06-082023-06-08 0000803578us-gaap:ServiceMember2023-01-012023-12-31 0000803578us-gaap:ServiceMember2022-01-012022-12-31 0000803578us-gaap:TransferredOverTimeMember2023-01-012023-12-31 0000803578us-gaap:TransferredOverTimeMember2022-01-012022-12-31 0000803578us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-31 0000803578us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-31 0000803578us-gaap:SellingAndMarketingExpenseMember2023-01-012023-12-31 0000803578us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-31 0000803578us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-31 0000803578us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-31 00008035782022-02-012022-02-28 0000803578us-gaap:CanadaRevenueAgencyMember2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMember2022-12-31 0000803578us-gaap:IsraelTaxAuthorityMember2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMember2022-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2034Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2034Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2034Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2035Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2035Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2035Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2036Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2036Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2036Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2037Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2037Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2037Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2038Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2038Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2038Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2039Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2039Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2039Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2040Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2040Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2040Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2041Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2041Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2041Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2042Member2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2042Member2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2042Member2023-12-31 0000803578us-gaap:CanadaRevenueAgencyMemberaiff:IndefiniteTaxYearMember2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMemberaiff:IndefiniteTaxYearMember2023-12-31 0000803578us-gaap:IsraelTaxAuthorityMemberaiff:IndefiniteTaxYearMember2023-12-31 0000803578us-gaap:InternalRevenueServiceIRSMember2023-12-31 0000803578us-gaap:ResearchMember2023-12-31 0000803578us-gaap:ResearchMember2022-12-31 0000803578srt:ScenarioPreviouslyReportedMember2022-12-31 0000803578srt:RestatementAdjustmentMember2022-12-31 0000803578srt:ScenarioPreviouslyReportedMember2022-01-012022-12-31 0000803578srt:RestatementAdjustmentMember2022-01-012022-12-31 0000803578us-gaap:SubsequentEventMember2024-02-282024-02-28 0000803578us-gaap:SeriesCPreferredStockMemberus-gaap:SubsequentEventMember2024-02-282024-02-28 0000803578aiff:UnitWarrantsMemberus-gaap:SubsequentEventMember2024-02-28 Â Â As filed with the Securities and Exchange Commission on September 26, 2024 Registration No.Â 333- Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ Â FORMÂ S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ Â FIREFLY NEUROSCIENCE, INC. Â (Exact name of registrant as specified in its charter) ____________________ Delaware Â 7372 Â 54-1167364 (State or other jurisdiction of incorporation or organization) Â (Primary Standard Industrial Classification Code Number) Â (IRS Employer Identification Number) Â Jon Olsen Chief Executive Officer 1100 Military Road Kenmore, NY 14217 (888) 237-6412 Â (Address, including zip code, and telephone number, including area code, of registrantâ€™s principal executive offices) ____________________ Â Jon Olsen Chief Executive Officer 1100 Military Road Kenmore, NY 14217 (888) 237-6412 Â (Name, address, including zip code, and telephone number, including area code, of agent for service) ____________________ Â Rick A. Werner, Esq. Alla Digilova, Esq. Haynes and Boone, LLP 30 Rockefeller Plaza, 26thÂ Floor New York, NY 10112 (212)Â 659-7300 ____________________ Â Approximate date of commencement of proposed offer to the public: From time to time after this Registration Statement becomes effective. Â If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to RuleÂ 415 under the Securities ActÂ ofÂ 1933 (the â€œSecurities Actâ€) check the following box:Â Â â˜’ Â If this Form is filed to register additional securities for an offering pursuant to RuleÂ 462(b)Â under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.Â Â â˜ Â If this Form is a post-effective amendment filed pursuant to RuleÂ 462(c)Â under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.Â Â â˜ Â Â Â Â If this Form is a post-effective amendment filed pursuant to RuleÂ 462(d)Â under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Â Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, aÂ non-acceleratedÂ filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge, accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2Â of the ExchangeÂ Act. Â Large,Â acceleratedÂ filer Â â˜ Â Accelerated filer Â â˜ Non-acceleratedÂ filer Â â˜’ Â SmallerÂ reportingÂ company Â â˜’ Â Â Â Â Emerging growth company Â â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 7(a)(2)(B)Â of the Securities Act.Â Â â˜ Â Â THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTIONÂ 8(A)Â OF THE SECURITIES ACTÂ OFÂ 1933 OR UNTIL THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SEC, ACTING PURSUANT TO SAID SECTIONÂ 8(A), MAY DETERMINE. Â Â Â Â Â Â Â Â Â The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S.Â Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and does not constitute the solicitation of offers to buy these securities in any jurisdiction where the offer or sale is not permitted. Â SUBJECT TO COMPLETION, DATED SEPTEMBER 26, 2024 Â PRELIMINARY PROSPECTUS Â FIREFLY NEUROSCIENCE, INC. Â 990,192 Shares of Common Stock Â Up to 504,323 Shares of Common Stock Underlying Pre-Funded Warrants Â Up to 823,530 Shares of Common Stock Underlying Private Placement Warrants Â Up to 168,071 Shares of Common Stock Underlying Series C Warrants Â Up to 61,866 Shares of Common Stock Underlying Series D Warrants Â Up to 11,663 Shares of Common Stock Underlying Broker Warrants Â Â This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus or their permitted transferees (the â€œselling securityholdersâ€) of an aggregate of 2,559,645 shares of common stock, par value $0.0001 per share (â€œCommon Stockâ€) of Firefly Neuroscience, Inc., a Delaware corporation (â€œFirefly,â€ the â€œCompany,â€ â€œwe,â€ â€œusâ€ or â€œourâ€), consisting of (A) 670,985 shares of Common Stock, which include: (i) 209,613 shares of Common Stock issued upon the conversion of certain shares of Series C Preferred Stock, par value $0.0001 per share, issued to the investors in a series of private placement transactions as part of the Series C units (the â€œSeries C Financingâ€), which such units consist of shares of Series C Preferred Stock and warrants (the â€œSeries C Warrantsâ€) to purchase shares of Common Stock (the â€œSeries C Unitsâ€) and (ii) 461,372 shares of Common Stock previously issued by Private Firefly after the Effectiveness Date (as defined below); (B)(i) 319,207 shares of Common Stock (the â€œPIPE Sharesâ€) issued to the investors in a private placement transaction (the â€œPrivate Placementâ€ and such investors, the â€œPIPE Investorsâ€) pursuant to that certain Securities Purchase Agreement, dated as of July 26, 2024, by and among us and the PIPE Investors, (ii) up to 504,323 shares of Common Stock issuable upon the exercise of the pre-funded warrants (the â€œPre-Funded Warrantsâ€) issued to the PIPE Investors, and (iii) up to 823,530 shares of Common Stock issuable upon the exercise of the private placement warrants (the â€œWarrantsâ€) issued to the PIPE Investors; (C) up to 168,071 shares of Common Stock issuable upon the exercise of the Series C Warrants issued to the investors in the Series C Financing; (D) up to 61,866 shares of Common Stock issuable upon the exercise of certain Series D Warrants issued to certain consultants of the Company for prior consulting services rendered (the â€œSeries D Warrantsâ€); and (E) up to 11,663 shares of Common Stock issuable upon the exercise of warrants issued to certain brokers as compensation in connection with certain transactions consummated prior to the Merger (as defined below) (the â€œBroker Warrantsâ€). Â Â Â Â The shares of Common Stock, including the PIPE Shares, the shares of Series C Preferred Stock, the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants were issued in reliance upon the exemption from the registration requirements in Section 4(a)(2) of the Securities Act of 1933, as amended (the â€œSecurities Actâ€) and Regulation D promulgated thereunder. Â On August 12, 2024 (the â€œClosing Dateâ€), we consummated the reverse merger transaction (the â€œMergerâ€) contemplated by that certain Agreement and Plan of Merger, dated as of November 15, 2023 (as amended from time to time, the â€œMerger Agreementâ€), by and among WaveDancer, Inc., a Delaware corporation (â€œWaveDancerâ€), FFN Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of WaveDancer (â€œFFNâ€), and Firefly Neuroscience, Inc., a Delaware corporation (â€œPrivate Fireflyâ€), pursuant to which FFN merged with and into Private Firefly, with Private Firefly surviving the merger as a wholly owned subsidiary of WaveDancer. On the Closing Date (i) pursuant to the Amended and Restated Certificate of Incorporation of WaveDancer, we changed our name to Firefly Neuroscience, Inc., and (ii) pursuant to an amendment to its Certificate of Incorporation, Private Firefly changed its name to Firefly Neuroscience 2023, Inc. and (iii) Private Firefly and FFN filed the Certificate of Merger with the State of Delaware. At the effective time of the Merger, among other things: (i) each outstanding share of Private Firefly common stock was converted into the right to receive the number of shares of the Company Common Stock equal to the Exchange Ratio, as described herein and (ii) we assumed all of Private Fireflyâ€™s rights and obligations under the warrants that were outstanding and unexercised as of immediately prior to the effective time of the Merger, and such warrants became become exercisable for shares of our Common Stock. Â In addition, in connection with the Merger, we filed a registration statement on Form S-4 on January 22, 2024, which such registration statement was declared effective by the Securities and Exchange Commission on February 6, 2024 (the â€œEffectiveness Dateâ€). Â The selling securityholders will receive all of the proceeds from any sales of the shares offered hereby. We will bear all costs, expenses and fees in connection with the registration of the shares of Common Stock. The selling securityholders will bear all commissions and discounts, if any, attributable to their respective sales of the shares of Common Stock. We will not receive any of the proceeds, but we will incur expenses in connection with the offering. To the extent the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants are exercised for cash, if at all, we will receive the exercise price of such warrants. We intend to use those proceeds, if any, for general corporate purposes. Â Our shares of Common Stock are listed on the Nasdaq Capital Market (â€œNasdaqâ€) under the symbol â€œAIFF.â€ On September 25, 2024, the closing sale price of shares of our Common Stock wasÂ $3.4699. Â Investing in our securities involves significant risks. Investing in shares of our Common Stock involves risks that are described in the â€œRiskÂ Factorsâ€ section beginning on page 8 of this prospectus to read about the factors you should consider before buying our securities. Â Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. Â Â The date of this prospectus isÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â , 2024. Â Â Â Â Â Â TABLE OF CONTENTS Â Â Â Page CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â 1 FREQUENTLY USED TERMS Â 2 MARKET AND INDUSTRY DATA Â 3 PROSPECTUS SUMMARY Â 4 RISK FACTORS Â 8 USE OF PROCEEDS Â 34 DETERMINATION OF OFFERING PRICE Â 34 MARKET PRICE OF OUR COMMON STOCK AND DIVIDENDS Â 35 MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â 36 BUSINESS Â 46 MANAGEMENT Â 63 EXECUTIVE COMPENSATION Â 70 DESCRIPTION OF CAPITAL STOCK Â 85 BENEFICIAL OWNERSHIP OF SECURITIES Â 91 SELLING SECURITYHOLDERS Â 93 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS Â 96 MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR HOLDERS OF COMMON STOCK AND WARRANTS Â 99 PLAN OF DISTRIBUTION Â 103 LEGAL MATTERS Â 105 EXPERTS Â 105 WHERE YOU CAN FIND ADDITIONAL INFORMATION Â 105 UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET Â 106 INDEX TO FINANCIAL STATEMENTS Â F-1 Â You should rely only on the information contained in this prospectus. No one has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date. Â For investors outside of the United States:Â We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States. Â This document contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without theÂ Â®Â orÂ â„¢Â symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. Firefly does not intend its use or display of other companiesâ€™ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of Firefly by, any other companies. Â Notwithstanding references thereto in this prospectus, Fireflyâ€™s website is not part of and is not incorporated in the prospectus, and you should not consider information found on Fireflyâ€™s website to be part of this prospectus. Â Â Â Â Â Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â Certain statements in this prospectus may constitute â€œforward-looking statementsâ€ for purposes of the federal securities laws and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that look to future events and include, but are not limited to, statements regarding our business strategy, plans and objectives; anticipated future operating results and operating expenses, cash flows, capital resources, and liquidity; trends, opportunities and risks affecting our business, industry and financial results; the expected benefits of use of our solutions; future expansion or growth plans and potential for future growth; our business prospects; our systems and technology, future profitability; the sufficiency of our existing cash and cash equivalents to meet our working capital and capital expenditure needs over the next twelveÂ months; acquisitions; and our expectations or beliefs concerning future events. In addition, the words â€œanticipates,â€ â€œappear,â€ â€œapproximate,â€ â€œbelieve,â€ â€œcontinue,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œforesee,â€ â€œintends,â€ â€œmay,â€ â€œmight,â€ â€œplan,â€ â€œpossible,â€ â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œseek,â€ â€œshould,â€ â€œwouldâ€ and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are neither historical facts nor assurances of future performance, and are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not place undue reliance on these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: Â Â â— fluctuation and volatility in market price of our Common Stock due to market and industry factors, as well as general economic, political and market conditions; Â â— the impact of dilution on our stockholders, including through the issuance of additional equity securities in the future; Â â— our ability to realize the intended benefits of the Merger; Â â— the impact of our ability to realize the anticipated tax impact of the Merger; Â â— the outcome of litigation or other proceedings may become subject to in the future; Â â— delisting of our Common Stock from Nasdaq or the failure for an active trading market to develop; Â â— the failure of our altered business operations, strategies and focus to result in an improvement for the value of our Common Stock; Â â— the availability of and our ability to continue to obtain sufficient funding to conduct planned operations and realize potential profits; Â â— our limited operating history; Â â— the impact of the complexity of the regulatory landscape on our ability to seek and obtain regulatory approval for its BNA Platform, both within and

outside of the U.S.; Â â— challenges that we may face with maintaining regulatory approval, if achieved; Â â— the impact of the concertation of capital stock ownership with our insiders on stockholdersâ€™Â ability to influence corporate matters. Â â— the impacts of future acquisitions of businesses or products and the potential to fail to realize intended benefits of such acquisition; Â â— the potential impact of changes in the legal and regulatory landscape, both within and outside of the U.S.; Â â— our dependence on third parties; Â â— challenges we may face with respect to our BNA Platform achieving market acceptance; Â â— the impact of pricing of our BNA Platform; Â â— emerging competition and rapidly advancing technology in our industry; Â â— our ability to obtain, maintain and protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on its proprietary rights; Â â— our ability to maintain adequate cyber security and information systems; Â â— our ability to generate sufficient revenue to achieve and sustain profitability; Â â— the risk that our significant increased expenses and administrative burdens as a public company could have an adverse effect on our business, financial condition and results of operations; and Â â— the other factors set forth in the section of this prospectus entitled â€œRisk Factors.â€ Â These forward-looking statements are based on information available as of the date of this prospectus and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Â 1 Â Â FREQUENTLY USED TERMS Â â€œ2024 Planâ€ means the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan. Â â€œAIâ€ means artificial intelligence. Â â€œBNA Platformâ€ means Fireflyâ€™s FDA-510(k) cleared Brain Network Analytics software platform. Â â€œBoardâ€ means the Board of Directors of Firefly. Â â€œBroker Warrantsâ€ means the warrants to purchase shares of Common Stock issued to certain brokers as compensation in connection with certain transactions consummated prior to the Merger. Â â€œBylawsâ€ means the Amended and Restated Bylaws of Firefly Neuroscience, Inc. Â â€œCharterâ€ means the Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc. Â â€œClosing Dateâ€ means August 12, 2024, the closing date of the Merger. Â â€œCommon Stockâ€ means the shares of common stock of Firefly Neuroscience, Inc., par value $0.0001 per share. Â â€œEEGâ€ means electroencephalograms. Â â€œEffectiveness Dateâ€ means February 6, 2024, the date on which the SEC declared the registration statement on Form S-4 (File No. 333-276649) effective. Â â€œExchange Actâ€ means the U.S. Securities Exchange Act of 1934, as amended. Â â€œExchange Ratioâ€ means 0.1040, the ratio in which the shares of WaveDancer Common Stock were converted to shares of Firefly Common Stock. Â â€œFDAâ€ means the U.S. Food and Drug Administration. Â â€œGAAPâ€ means U.S. generally accepted accounting principles. Â â€œMergerâ€ means the reverse merger transaction contemplated by the Merger Agreement. Â â€œMerger Agreementâ€ means that certain Agreement and Plan of Merger, dated as of November 15, 2023, as amended by that certain Amendment No. 1 on January 12, 2024, and that certain Amendment No. 2 on June 17, 2024, by and among Firefly Neuroscience, Inc. (formerly known as WaveDancer, Inc.), FFN Merger Sub, Inc. and Firefly Neuroscience 2023, Inc. (formerly known as Firefly Neuroscience, Inc.) Â â€œNasdaqâ€ means the Nasdaq Capital Market. Â â€œFFNâ€ or â€œMerger Subâ€ means FFN Merger Sub, Inc., a Delaware corporation. Â â€œFireflyâ€ means Firefly Neuroscience, Inc., a Delaware corporation (formerly known as WaveDancer, Inc. prior to the consummation of the Merger). Â â€œPIPE Investorsâ€ means the investors signatory to the Securities Purchase Agreement in the Private Placement. Â â€œPIPE Sharesâ€ means the shares of Common Stock issued and sold in the Private Placement pursuant to the Securities Purchase Agreement. Â â€œPre-Funded Warrantsâ€ means the pre-funded warrants to purchase up to an aggregate of 504,323 shares of Common Stock at an exercise price of $0.0001 per share, issued to the PIPE Investors in the Private Placement. Â â€œPrivate Fireflyâ€ means Firefly Neuroscience, Inc. a company incorporated under the State of Delaware Â â€œPrivate Placementâ€ means the private placement transaction contemplated by the Securities Purchase Agreement, which closed on August 12, 2024, simultaneously with the closing of the Merger. Â â€œSECâ€ means the U.S. Securities and Exchange Commission. Â â€œSecurities Actâ€ means the U.S.Â Securities ActÂ ofÂ 1933, as amended. Â â€œSecurities Purchase Agreementâ€ means that certain Securities Purchase Agreement to purchase shares of Common Stock, Pre-Funded Warrants and Warrants of Firefly, dated as of July 26, 2024, by and between Firefly and the purchasers named therein. Â 2 Â Â â€œselling securityholdersâ€ means the securityholders named in this prospectus. Â â€œSeries C Financingâ€ means a series of private placement transactions of Series C Units conducted by Private Firefly between February 6, 2024, and the date of this prospectus. Â â€œSeries C Preferred Stockâ€ means the shares of Series C Preferred Stock, par value $0.0001 per share, issued to investors to Series C Financing. Â â€œSeries C Unitsâ€ means the shares of Series C Preferred Stock and Series C Warrants issued in connection with the Series C Financing. Â â€œSeries C Warrantsâ€ means the warrants to purchase shares of Common Stock issued as part of the Series C Units to investors in Series C Financing. Â â€œSeries D Warrantsâ€ means the warrants to purchase shares of Common Stock issued as compensation to certain consultants of Private Firefly for prior consulting services rendered. Â â€œWarrantsâ€ means the warrants to purchase up to an aggregate of 823,530 shares of Common Stock at an exercise price of $0.71 per share, issued to the PIPE investors in the Private Placement. Â â€œWarrant Sharesâ€ means, collectively, the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants. Â â€œWaveDancerâ€ means WaveDancer, Inc., a Delaware corporation (which was renamed Firefly Neuroscience, Inc. in connection with the Merger). Â MARKET AND INDUSTRY DATA Â Certain industry data and market data included in this prospectus were obtained from independent third-party surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. All of managementâ€™s estimates presented herein are based upon managementâ€™s review of independent third-party surveys and industry publications prepared by a number of sources and other publicly available information. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the information from these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled â€œRisk Factors.â€ These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. Â BASIS OF PRESENTATION Â On the Closing Date, FFN merged with and into Private Firefly, with Private Firefly surviving the merger as a wholly owned subsidiary of WaveDancer, Inc. Additionally on the Closing Date, (i) pursuant to the Amended and Restated Certificate of Incorporation of WaveDancer, we changed our name to â€œFirefly Neuroscience, Inc.,â€ (ii) pursuant to an amendment to its Certificate of Incorporation, Private Firefly changed its name to Firefly Neuroscience 2023, Inc. and (iii) Private Firefly and FFN filed the Certificate of Merger with the State of Delaware. Unless the context indicates otherwise, references in this prospectus to the â€œCompany,â€ â€œFirefly,â€ â€œwe,â€ â€œus,â€ â€œourâ€ and similar terms refer to Firefly Neuroscience, Inc. (formerly known as WaveDancer, Inc.) and its consolidated subsidiaries after the consummation of the Merger. References to â€œWaveDancerâ€ refer to the predecessor company prior to the consummation of the Merger. References to â€œPrivate Fireflyâ€ refer to Firefly Neuroscience, Inc. and its consolidated subsidiaries prior to the consummation of the Merger. Â Additionally, unless otherwise noted, share and per-share figures reflect the 1-for-3 reverse stock split of WaveDancer effectuated on August 12, 2024, and the application of the Exchange Ratio, as applicable. Â 3 Â Â PROSPECTUS SUMMARY Â This summary highlights selected information from this prospectus and may not contain all of the information that is important to you in making an investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our financial statements and the related notes included in this prospectus and the information set forth under the headings â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ See also the section entitled â€œWhere You Can Find Additional Information.â€ Â Overview Firefly is an Artificial Intelligence (â€œAIâ€) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Its FDA-510(k) cleared Brain Network Analytics software platform (the â€œBNA Platformâ€) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It has taken a period of 15 years and an investment of approximately $60 million, to develop the software, compile the requisite database of brain wave tests, gain patent protection, and receive Federal Drug Administration (â€œFDAâ€) approval to market and sell the BNA Platform so, as of today, Firefly is in a position to undertake a commercial launch of the BNA Platform. Firefly believes there is great potential for such commercialization, both with respect to pharmaceutical companies in their drug research and clinical trial activities, as well as medical practitioners in their clinics. Â The BNA Platform is a software as a medical solution that was developed using AI and machine learning on Fireflyâ€™s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (â€œEEGâ€) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition). These insights can enhance a clinicianâ€™s ability to accurately diagnose mental illnesses and cognitive disorders and to evaluate what therapy or drug is best suited to optimize a patientâ€™s outcome. Â The clinical utility of EEG technology to support better outcomes for patients with mental illnesses and cognitive disorders has been well documented. Historically, clinical adoption of EEG by medical professionals, including psychiatrists, neurologists, nurse practitioners and general practitioners, has been limited due to the complexity of interpreting EEG recordings and the inability to practically compare a patientâ€™s brain function to that of a clinically normal age-matched patient. Firefly believes that without defining a standard deviation to the norm, it is not possible to objectively assess brain function. By establishing an objective baseline measurement of brain function, the BNA Platform enables clinicians to optimize patient care, leading to improved outcomes for people suffering from mental illnesses and cognitive disorders. Â Fireflyâ€™s value proposition is supported by real-world use of the BNA Platform. Incorporating the BNA Platform as part of a patient management protocol demonstrated improved response rates, enhanced therapy compliance, reduced non-responder rates and a reduction in need for medication switching among patients. Further, Firefly believes that its extensive clinical database, when combined with advanced AI, provides the opportunity to identify clinically relevant biomarkers that will support better patient outcomes through precision medicine and companion diagnostics. We expect to gather additional data through the clinical deployments and clinical studies conducted by drug companies. This additional data should allow us to discover new biomarkers and objectively measure the impact of therapeutic interventions on patients of different types, further enhancing our platformâ€™s effectiveness. Firefly believes that it will be able to enhance accurate diagnosis and predict what therapy or drug, or a combination thereof, is best suited to optimize patient outcomes. This represents a paradigm shift in how clinicians manage patients with mental illnesses and cognitive disorders holding the potential to transform brain health. Â Recent Developments Â Merger with WaveDancer, Inc. Â On November 15, 2023, Private Firefly entered into the Merger Agreement with WaveDancer and FFN. On August 12, 2024, FFN merged with and into Private Firefly, with Private Firefly surviving the Merger as a wholly owned subsidiary of WaveDancer. Additionally on August 12, 2024, (i) pursuant to the Amended and Restated Certificate of Incorporation of WaveDancer, we changed our name to â€œFirefly Neuroscience, Inc.,â€ (ii) pursuant to an amendment to its Certificate of Incorporation, Private Firefly changed its name to Firefly Neuroscience 2023, Inc. and (iii) Private Firefly and FFN filed the Certificate of Merger with the State of Delaware. Additionally on August 12, 2024, prior to the consummation of the Merger, WaveDancer effectuated a 1-for-3 reverse stock split of its common stock. On August 12, 2024, the Merger closed, and on August 13, 2024, we began trading on Nasdaq under the ticker symbol â€œAIFF.â€ Â 4 Â Â Private Placement Â On July 26, 2024, prior to the consummation of the Merger, we entered into a securities purchase agreement with certain institutional investors, pursuant to which we agreed to issue and sell an aggregate of (i) 319,207 PIPE Shares, (ii) pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 504,323 shares of our Common Stock, and (iii) warrants (the â€œWarrantsâ€) to purchase up to 823,530 shares of Common Stock in the Private Placement. The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the Merger. The aggregate gross proceeds from the transaction were approximately $3.5 million, before deducting estimated offering expenses payable by us. Â Series C Financing Â Between October 17, 2023, and June 30, 2024, we raised an aggregate of $3,039,000 from a private placement of 2,374,944 Series C units (the â€œSeries C Unitsâ€), which such Series C Units were comprised of shares of Series C Preferred Stock and the Series C Warrants to purchase up to 2,374,944 shares of Common Stock, which were sold at a combined purchase price of $1.28 per Series C Unit. Each Series C Warrant has an exercise price of $2.56 per share (subject to adjustment from time to time in accordance with the terms thereof), is exercisable immediately upon issuance and expires at 4:30 p.m. (New York time) three years following the initial date of issuance. Â RiskÂ Factors Â Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled â€œRisk Factorsâ€ immediately following this prospectus summary, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could cause a decline in the price of shares of our Common Stock and result in a loss of all or a portion of your investment: Â Â â€¢ We are in the development stage with minimum revenues and have no operating history in the broad commercialization of medical devices or platforms for consumer use. Â Â â€¢ Our financial statement footnotes include disclosure regarding the substantial doubt about our ability to continue as a going concern. Â Â â€¢ We may be unable to raise additional capital, which could harm our ability to compete. Â Â â€¢ We are subject to operating risks, including excess or constrained capacity and operational inefficiencies, which could adversely affect our results of operations. Â Â â€¢ If we are not successful in enhancing awareness of our BNA Platform, driving adoption across our current target population and expanding the population of eligible patients, our sales, business, financial condition and results of operations will be negatively affected. Â Â â€¢ Our commercial success will depend on the future adoption of the BNA platform into patient work streams in clinics. If we are unable to successfully drive interest in our BNA Platform, our business, financial condition and results of operations would be harmed. Â Â â€¢ We may be unable to compete successfully with competitive technologies, which could harm our sales, business, financial condition and results of operations. Â Â â€¢ Use of our BNA Platform requires appropriate training and inadequate training may lead to negative clinician experiences, which could harm our business, financial condition, and results of operations. Â 5 Â Â Â â€¢ We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success. Â Â â€¢ We may not be able to achieve or maintain satisfactory pricing and margins for our BNA Platform, which could harm our business and results of operations. Â Â â€¢ Future sales of our BNA Platform may depend on healthcare providersâ€™ or patientsâ€™ ability to obtain reimbursement from third-party payors, such as insurance carriers. Â Â â€¢ Complying with regulations enforced by FDA and other regulatory authorities is expensive and time consuming, and failure to comply could result in substantial penalties. Â Â â€¢ We may not receive the necessary authorizations to market our BNA Platform or any future new products, and any failure to timely do so may adversely affect our ability to grow our business. Â Â â€¢ Since our BNA Platform will utilize cloud-based information systems and the exchange of information between patents and doctors, we will be subject to numerous U.S. federal and state laws and regulations related to the privacy and security of personally identifiable information, including health information. Â Â â€¢ Our success depends in part on our proprietary technology, and if we are unable to successfully enforce our intellectual property rights, our competitive position may be harmed. Â Â â€¢ We use AI in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations. Â Â Corporate Information Â Our corporate history began in April 2006 with the formation of Elminda Ltd, a company organized under the laws of the State of Israel, for the purpose of developing a system to provide clinicians with an objective assessment of brain function to support better outcomes for people with mental illnesses and cognitive disorders. On November 15, 2023, we entered into the Merger Agreement with WaveDancer and FFN, and on August 12, 2024, FFN merged with and into Private Firefly, with Private Firefly surviving the Merger as a wholly owned subsidiary of WaveDancer. On the Closing Date (i) pursuant to the Amended and Restated Certificate of Incorporation of WaveDancer, we changed our name to â€œFirefly Neuroscience, Inc.,â€ (ii) pursuant to an amendment to its Certificate of Incorporation, Private Firefly changed its name to Firefly Neuroscience 2023, Inc. and (iii) Private Firefly and FFN filed the Certificate of Merger with the State of Delaware. Â Our principal executive offices are located at 1100 Military Road, Kenmore, NY 14217, and our telephone number is (888) 237-6412. Our website address is www.fireflyneuro.com. Information contained on our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. Â 6 Â Â THE OFFERING Â Shares of Common Stock Offered by the Selling Securityholders Â We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, of an aggregate of 2,559,645 shares of Common Stock, consisting of: Â Â Â Â Â Â Â Â Â â€¢ 670,985 shares of Common Stock, which include: (i) 209,613 shares of Common Stock issued upon the conversion of certain shares of Series C Preferred Stock and (ii) 461,372 shares of Common Stock previously issued by Private Firefly after the Effectiveness Date; Â Â Â Â Â Â Â Â Â â€¢ 319,207 shares of Common Stock issued to the PIPE Investors; Â Â Â Â Â Â Â Â Â Â Â â€¢ up to 504,323 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants issued to the PIPE Investors; Â Â Â Â Â Â Â Â Â â€¢ up to 823,530 shares of

Common Stock issuable upon the exercise of the Warrants issued to the PIPE Investors; Â Â Â Â Â Â Â Â Â â€¢ up to 168,071 shares of Common Stock issuable upon the exercise of the Series C Warrants issued and sold as part of the Series C Units in the Series C Financing; Â Â Â Â Â Â Â Â Â â€¢ up to 61,866 shares of Common Stock issuable upon the exercise of the Series D Warrants; and Â Â Â Â Â Â Â Â Â â€¢ up to 11,663 shares of Common Stock issuable upon the exercise of the Broker Warrants. Â Â Â Â Â Terms of the Offering Â The selling securityholders will determine when and how they will dispose of the securities registered for resale under this prospectus. Â Â Â Â Â Use of Proceeds Â We will not receive any proceeds from the sale of shares of Common Stock by the selling securityholders. We will receive any proceeds from the exercise of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants for cash, but not from the sale of the shares of Common Stock issuable upon such exercise. See the section titled â€œUse of Proceeds.â€ Â Â Â Â Â Risk Factors Â See â€œRisk Factorsâ€Â and the other information included in this prospectus for a discussion of factors you should consider before investing in our securities. Â Â Â Â Â Market for Common Stock Â Our shares of Common Stock are listed on Nasdaq under the symbol â€œAIFF.â€ Â For additional information concerning the offering, see the section titled â€œPlan of Distributionâ€ beginning on page 106 of this prospectus. Â 7 Â Â RISK FACTORS Â Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under â€œCautionary NoteÂ Regarding Forward-Looking Statements,â€ you should carefully consider the risks and uncertainties described below together with all of the other information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus and in the section titled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ before deciding to invest in our securities. If any of the events or developments described below were to occur, our business, prospects, operating results, and financial condition could suffer materially, the trading price of our securities could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Â Risks Related to our Financial Position Â We are in the development stage and faces all of the risks and uncertainties associated with a new and unproven business. Our future is based on an unproven business plan with no historical facts to support projections and assumptions. We have no operating history as a distributor of medical devices to clinicians. We are currently generating minimum revenues and do not expect to generate significant revenue until we have successfully launched broad commercialization of the BNA Platform. Â Investors should understand that an investment in a start-up business is significantly riskier than an investment in a business with any significant operating history. There can be no assurance that we will ever achieve revenues or profitability. Our operations are subject to all of the risks inherent in the establishment of a new business enterprise. The likelihood of our success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the formation of a pre-revenue business. Our lack of a significant and relevant operating history makes it difficult to manage operations and predict future operating results. Â Our financial statement footnotes include disclosure regarding the substantial doubt about our ability to continue as a going concern. Â Our financial statement footnotes include disclosure regarding the substantial doubt about our ability to continue as a going concern. As of each of June 30, 2024, and December 31, 2023, we had stockholderâ€™s equity of negative $1,215,000 and $109,000, respectively. In addition, we had negative cash flows from operating activities for the six months-ended June 30, 2024, of $2,418,000 and negative cash flows from operating activities for the six months ended June 30, 2023, of $936,000. Further, the footnotes to our financial statements indicated that, as of June 30, 2024, we had recurring losses with minimal revenue from operations. Â To strengthen our liquidity in the foreseeable future, we have taken the following measures: (i) negotiating with existing and new investors to raise additional capital; and (ii) taking various cost control measures to reduce the operational cash burn. While our management believes that we can continue raising additional equity capital to continue in operational existence for the foreseeable future, if we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity. No assurances can be provided that new financing will be available to us on commercially acceptable terms, if at all. Â We may be unable to raise additional capital, which could harm our ability to compete. Â We expect to expend significant capital to launch our commercialization program for the BNA Platform, build our brand, and continue to improve our product offerings. These initiatives may require us to raise additional capital over the next few years. We may consume available resources more rapidly than anticipated and we may not be able to raise additional funds when needed or on acceptable terms. Â If we raise additional funds through issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our Common Stock. While our management team believes that we can continue raising additional equity capital to continue in operational existence for the foreseeable future, if we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and our business, operating results, financial condition, and prospects could be materially adversely affected. Â 8 Â Â Risks Related to our Business and Operations Â We are subject to operating risks, including excess or constrained capacity and operational inefficiencies, which could adversely affect our results of operations. Â We are subject to operating risks, including excess or constrained capacity and pressure on our internal systems and personnel. In order to manage current and anticipated future operations effectively, we must continually implement and improve our operational, financial and management information systems, hire, train, motivate, manage and retain employees. We may be unable to balance near-term efforts to meet existing demand with future customer demand, including adding personnel, creating scalable, secure and robust systems and operations, and automating processes needed for long term efficiencies. Any such failure could have a material impact on our business, operations and prospects. Â Our products and information technology systems are critical to our business. Issues with product development or enhancements, IT system integration, implementation, updates and upgrades could disrupt our operations and have a material impact on our business and operating results. Â We rely on the efficient, uninterrupted and secure operation of our IT systems and are dependent on key third-party software embedded in our products and IT systems as well as third-party hosted IT systems to support our operations. All software and IT systems are vulnerable to damage, cyber attacks or interruption from a variety of sources. To effectively manage and improve our operations, our IT systems and applications require an ongoing commitment of significant expenditures and resources to maintain, protect, upgrade, enhance and restore existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving industry and regulatory standards, increasingly sophisticated cyber threats, and changing consumer preferences. Failure to adequately protect and maintain the integrity of our products and IT systems may result in a material effect on our financial position, results of operations and cash flows. Â We plan to continuously upgrade and issue new releases of our products and customer-facing software applications, upon which our operations depend. Software applications and products containing software frequently contain errors or defects, especially when first introduced or when new versions are released. Additionally, the third-party software integrated into or interoperable with our products and services will routinely reach end of life, and as a consequence, may be exposed to additional vulnerabilities, including increased security risks, errors and malfunctions that may be irreparable or difficult to repair. The discovery of a defect, error or security vulnerability in our products, software applications or IT systems, incompatibility with future customersâ€™ computer operating systems and hardware configurations with a new release or upgraded version or the failure of our products or primary IT systems may cause adverse consequences, including: delay or loss of revenues, significant remediation costs, delay in market acceptance, loss of data, disclosure of financial, health or other personal information of any customers or patients, product recalls, damage to our reputation, or increased service costs, any of which could have a material effect on our business, financial condition or results of our operations and the operations of our potential customers or our business partners. Â Our operations and financial performance depend on global and regional economic conditions. Inflation, fluctuations in currency exchange rates, changes in consumer confidence and demand, and weakness in general economic conditions and threats, or actual recessions, could materially affect our business, results of operations, and financial condition. Â Macroeconomic conditions impact consumer confidence and discretionary spending, which could adversely affect demand for any products we bring to market. Consumer spending habits are affected by, among other things, inflation, fluctuations in currency exchange rates, weakness in general economic conditions, threats or actual recessions, pandemics, wars and military actions, levels of employment, wages, debt obligations, discretionary income, interest rates, volatility in capital, and consumer confidence and perceptions of current and future economic conditions. Changes and uncertainty can, among other things, reduce or shift spending away from treatments and procedures to address mental illness and cognitive disorders, and could drive patients and clinicians towards other options in the marketplace that may cost less than our products, reduce patient traffic in cliniciansâ€™ offices or reduce demand for services to treat mental illness and cognitive disorder generally. The recent declines in, or uncertain economic outlooks for, the U.S., European and certain other international economies has and may continue to adversely affect consumer and healthcare practice spending. The increase in the cost of fuel and energy, food and other essential items along with elevated interest rates could reduce consumersâ€™ disposable income, resulting in less discretionary spending for products like ours. Decreases in disposable income and discretionary spending or change in consumer confidence and spending habits may adversely affect our revenues and operating results. Â 9 Â Â Inflation continues to adversely impact spending and trade activities and we are unable to predict the impacts of higher inflation on global and regional economies. Higher inflation has also increased domestic and international shipping costs, raw material prices, and labor rates, which could adversely impact the costs of producing, procuring and shipping any products we bring to market. If similar trends continue once we begin marketing our BNA Platform, our ability to recover these cost increases through price increases may have limited effectiveness, resulting in downward pressure on our operating results. Attempts to offset cost increases with price increases could reduce sales, increase customer dissatisfaction or otherwise harm our reputation. Further, we are unable to predict the impact of efforts by central banks and federal, state and local governments to combat elevated levels of inflation. If their efforts to reduce inflation are too aggressive, they may lead to a recession. Alternatively, if they are insufficient or are not sustained long enough to lower inflation to more acceptable levels, consumer spending may be adversely impacted for a prolonged period of time. Any of these events could materially affect our business and operating results. Â Our business could be impacted by political events, trade and other international disputes, war, and terrorism, including the military conflict between Russia and Ukraine. Â Political events, trade and other international disputes, war, and terrorism could harm or disrupt international commerce and the global economy and could have a material effect on our business as well as our potential customers, suppliers, contract manufacturers, distributors, and other business partners. Â Political events, trade and other international disputes, wars, and terrorism can lead to unexpected tariffs or trade restrictions, which could adversely impact our business. Once we begin marketing our products, these increased costs could adversely impact our gross margin and make our products less competitive or reduce demand. Countries could also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact our operations and supply chain and limit our ability to offer products and services. These measures could require us to take various actions, including changing suppliers or restructuring business relationships. Complying with new or changed trade restrictions is expensive, time-consuming and disruptive to our operations. Such restrictions can be announced with little or no advance notice and we may be unable to effectively mitigate the adverse impacts of such measures. If disputes and conflicts escalate in the future, actions by governments in response could be significantly more severe and restrictive and could materially affect our business. Â Political unrest, threats, tensions, actions and responses to any social, economic, business, geopolitical, military, terrorism, or acts of war involving key commercial, development or manufacturing markets such as China, Mexico, Israel, Europe, or other countries or regions could materially impact any international operations we undertake. For example, our employees in Israel could be obligated to perform annual reserve duty in the Israeli military and be called for additional active duty under emergency circumstances. If any of these events or conditions occur, the impact on us, our employees and potential customers is uncertain, particularly if emergency circumstances, armed conflicts or an escalation in political instability or violence disrupts our product development, data or information exchange, payroll or banking operations, product or materials shipping by us or our suppliers and other unanticipated business disruptions, interruptions and limitations in telecommunication services or critical systems or applications reliant on a stable and uninterrupted communications infrastructure. Â U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported. In response to the military conflict, the United States and other North Atlantic Treaty Organization member states, as well as non-member states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises, and the continuation of the conflict may trigger additional economic and other sanctions. The potential impacts of the conflict and related sanctions could include supply chain and logistics disruptions, macro financial impacts resulting from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy and heightened cybersecurity threats. We have no way to predict the progress or outcome of the conflict in Ukraine or the reactions by governments, businesses or consumers. A prolonged conflict, intensified military activities or more extensive sanctions impacting the region and the resulting economic impact could have a material effect on our business, results of operations, financial condition, liquidity, growth prospects and business outlook. Â 10 Â Â We conduct certain of our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israelâ€™s war against them, may affect our operations. Â We currently have seven full-time employees, who are located in and/or reside in Israel. As a result, our business and operations are directly affected by economic, political, geopolitical and military conditions in Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business conditions in Israel. Â In October 2023, Hamas terrorists infiltrated Israelâ€™s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israelâ€™s border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israelâ€™s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict. Â Any hostilities involving Israel could adversely affect our operations and results of operations. Shelter-in-place and work-from-home measures, government-imposed restrictions on movement and travel and other precautions taken to address the ongoing conflict may temporarily disrupt our employeesâ€™ ability to effectively perform their daily tasks. Â The Israel Defense Force (the â€œIDFâ€), the national military of Israel, is a conscripted military service, subject to certain exceptions. Several of our employees are subject to military service in the IDF and have been and may be called to serve. It is possible that there will be further or longer military reserve duty call-ups in the future, which may affect our business due to a shortage of skilled labor and loss of institutional knowledge, and necessary mitigation measures we may take to respond to a decrease in labor availability, such as overtime and third-party outsourcing, for example, which may have unintended negative effects and adversely impact our results of operations, liquidity or cash flows. Â It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt our business and operations. Â Our operations may be impacted by natural disasters, which may become more frequent or severe as a result of climate change and may adversely impact our business and operating results as well as those of our potential customers and suppliers. Â Natural disasters can impact us and our potential customers, as well as suppliers critical to our operations. Natural disasters include earthquakes, tsunamis, floods, droughts, hurricanes, wildfires, and other extreme weather conditions that can cause deaths, injuries, and critical health crises, power outages, restrictions and shortages of food, water, shelter, and medical supplies, telecommunications failures, materials scarcity, price volatility and other ramifications. Climate change is likely to increase both the frequency and severity of natural disasters and, consequently, risks to our business and operations. Â The effects of climate change on regional and global economies could change the supply, demand or availability of sources of energy or other resources material to our products and operations and affect the availability or cost of natural resources and goods and services on which we and our suppliers rely. Â 11 Â Â Risks Related to the BNA Platform Â If we are not successful in enhancing awareness of our BNA Platform, driving adoption across our current target population and expanding the population of eligible patients, our sales, business, financial condition and results of operations will be negatively affected. Â Our business currently depends primarily on our ability to successfully market our BNA Platform, which involves successfully launching our commercialization program, increasing adoption of and driving utilization our BNA Platform by target clinicians. We are aiming to increase awareness about our BNA Platform, as well as grow the number of clinicians that utilize our BNA Platform after the launch of our commercialization program, but there can be no assurance that we will succeed. Â The commercial success of our BNA Platform will continue to depend on a

number of factors, including the following: Â Â â— the actual and perceived effectiveness and clinical benefit, of our BNA Platform; Â â— the prevalence and severity of any adverse patient events involving our BNA Platform; Â â— our ability to provide earlier awareness of and education about our BNA Platform to patients and clinicians; Â â— the degree to which clinicians and patients adopt our BNA Platform; Â â— the availability, relative cost and perceived advantages and disadvantages of alternative technologies or treatment methods for cognitive disorders; Â â— the results of future clinical and other studies relating to the health, economic or other benefits of our BNA Platform; Â â— whether key thought leaders in the medical community accept that our future clinical utility is sufficiently meaningful to influence their decision to adopt our BNA Platform; Â â— the extent to which we are successful in educating clinicians and patients about the benefits of our BNA Platform; Â â— our reputation among clinicians and patients; Â â— our ability to predict product performance; Â â— the strength of our marketing and distribution infrastructure, including our ability to drive adoption and utilization of our BNA Platform; Â â— our ability to obtain, maintain, protect, enforce and defend our intellectual property rights, including those covering our BNA Platform; Â â— our ability to maintain compliance with all legal and regulatory requirements, including those applicable to our BNA Platform; and Â â— our ability to continue to attract and retain key talent. Â If we fail to successfully initiate our broad commercialization program, market and sell our BNA Platform cost-effectively, our sales, business, financial condition and results of operations will be negatively affected. Â Our commercial success will depend on the future adoption of the BNA Platform into patient work streams in clinics. If we are unable to successfully drive interest in our BNA Platform, our business, financial condition and results of operations would be harmed. Â Our commercial success will depend in large part on the future adoption of the BNA Platform into patient work streams in clinics. We cannot predict how quickly, if at all, clinicians and patients will adopt our BNA Platform. Moreover, we cannot predict how quickly, if at all, those currently living with mental illness or cognitive disorders but who are not being treated will seek treatment. Our ability to grow sales of our BNA Platform and drive market acceptance will depend on successfully educating clinicians and patients of the relative benefits of our BNA Platform. If we are unable to successfully drive interest in our BNA Platform, our business, financial condition and results of operations would be harmed. Â We may be unable to compete successfully with competitive technologies, which could harm our sales, business, financial condition and results of operations. Â Our industry is competitive and has been evolving rapidly. Our BNA Platform is indicated for use in in individuals 12 to 85 years of age for the post-hoc statistical analysis of the human electroencephalogram, including event-related potentials, and we currently market our device primarily to qualified medical professionals. Once we commence a broad commercialization program of our BNA Platform, we will face competition in the market for our BNA Platform from competing technologies, and we expect competition from new companies that may enter the market or introduce new technologies in the future. Third-party payors may encourage the use of competitorsâ€™ products due to lower costs of competing products or alternatives. Additionally, treating neurologists may promote the use of other competitorsâ€™ products or alternative therapies. Â 12 Â Â Our current and future competitors may include large, well-capitalized companies with significant market share and resources. They may have more established sales and marketing programs than we do and have greater name recognition. In addition to competing for market share, competitors may develop or acquire patents or other rights that may limit our ability to compete. Â We believe that the competitive advantages of our BNA Platform will be important factors in our future success. Our continued success depends on, among other things, our ability to: Â Â â— successfully launch our commercialization program to target clinicians; Â â— drive awareness to increase the number of mental illness and cognitive impairment patients referred to target clinicians; Â â— attract and retain skilled research, development, sales, marketing and clinical personnel; Â â— continue to innovate in order to improve our BNA Platform and enhance the patient and provider experience; Â â— adequately predict product performance; Â â— obtain and maintain regulatory clearances and approvals, including for expanded indications; Â â— cost-effectively market and sell our BNA Platform; Â â— obtain, maintain, protect, enforce and defend our intellectual property rights and operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others; and Â â— acquire products or technologies complementary to or necessary for our business. Â The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. There can be no assurance that other companies or institutions will not succeed in developing or marketing devices and products that are more effective than our BNA Platform or that would render our BNA Platform obsolete or noncompetitive. Â Use of our BNA Platform requires appropriate training and inadequate training may lead to negative clinician experiences, which could harm our business, financial condition, and results of operations. Â The successful use of our BNA Platform depends in part on the training and skill of the clinician performing EEG recording and reading BNA reports. Clinicians could experience difficulty interpreting the results of BNA reports. Moreover, clinicians rely on their previous medical training and experience when recommending or utilizing our BNA Platform, and we cannot guarantee that all clinicians will have the necessary skills to properly utilize the BNA Platform. We cannot be certain that clinicians that will use our BNA Platform will have received sufficient training, and clinicians who have not received adequate training may nonetheless attempt to use our BNA Platform with their patients. If clinicians utilize our BNA Platform incorrectly, or without adhering to or completing all relevant training, their patient outcomes may not be consistent with the outcomes achieved in our research studies and any future clinical studies. Adverse safety outcomes that arise from improper or incorrect use of our BNA Platform may negatively impact the perception of patient benefit and the safety of our BNA Platform, notwithstanding results from our research studies and any future clinical studies. These results could limit adoption of our BNA Platform, which would harm our sales, business, financial condition, and results of operations. Â We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success. Â We are highly dependent on our senior management and key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, engineers, scientists, data science specialists and other highly skilled personnel and to integrate current and additional personnel in all departments. Â Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued stock options that vest over time, restricted share units subject to vesting conditions, and certain performance warrants. The value to employees of stock options that vest over time may be significantly affected by fluctuations in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management and other key personnel may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain â€œkey manâ€ insurance policies on the lives of these individuals or the lives of any of our other employees. Â 13 Â Â As we launch the commercialization program for our BNA Platforms, expand our product offerings in the future and increase our future marketing efforts, we will need to build and expand the reach of our marketing and sales networks. Our future success will depend largely on our ability to continue to hire, train, retain and motivate skilled employees with significant technical knowledge in various areas. An inability to attract, hire, train and retain employees will harm our sales, business, financial condition, and results of operations. Â We expect to increase the size of our organization in the future, and we may experience difficulties in managing the operational elements or timing of this growth. If we are unable to manage or appropriately time the anticipated growth of our business, our future revenue and operating results may be harmed. Â As of the date of this prospectus, we have seven full time employees and six contractors. As our sales and marketing strategies evolve and as we launch commercialization of our BNA Platform, we may need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: Â Â â— identifying, recruiting, integrating, maintaining and motivating additional employees; Â â— managing our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties; and Â â— improving our operational, financial and management controls, reporting systems and procedures. Â Our future financial performance and our ability to successfully market and sell our BNA Platform will depend, in part, on our ability to effectively manage or time any future growth, and our management may also have to divert a disproportionate amount of attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. Â As demand for our BNA Platform increases in the future, we will need to expand customer service, billing and systems processes and enhance our internal quality assurance program. We cannot be certain that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business. If we encounter difficulty meeting market demand, quality standards or clinician expectations, our reputation will be harmed and our business will suffer. Additionally, additional growth may result in higher fixed costs and may slow our ability to reduce costs in the face of a sudden decline in demand for our products. Â We may not be able to achieve or maintain satisfactory pricing and margins for our BNA Platform, which could harm our business and results of operations. Â The medical device industry has a history of price competition, and we can give no assurance that we will be able to maintain satisfactory prices for our BNA Platform or any future products at competitive levels. The pricing of our products could be impacted by several factors, including pressure to reduce prices by our customers due to a decline in the amount that third-party payors reimburse for EEG tests for clinicians utilizing our BNA Platform. If we are forced to lower or are unable to increase the price we charge for our BNA Platform, our gross margins will decrease, which will harm our ability to invest in and grow our business. If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode, which could harm our business and results of operations. Â Future sales of our BNA Platform may depend on healthcare providersâ€™ or patientsâ€™ ability to obtain reimbursement from third-party payors, such as insurance carriers. Â Future sales of our BNA Platform may depend on healthcare providersâ€™ or patientsâ€™ ability to obtain reimbursement from third-party payors, such as insurance carriers. Where such insurance or third-party reimbursement becomes available in the future, any reduction in insurance or other third-party payor reimbursement for our BNA Platform may cause negative price pressure, which would reduce our revenues. Without a corresponding reduction in the cost to produce such products, the result would be a reduction in our overall gross profit. Similarly, any increase in the cost of such products would reduce our overall gross profit unless there was a corresponding increase in third-party payor reimbursement. Failure by our patients or healthcare provider customers to obtain or maintain coverage or to secure adequate reimbursement for our treatment by third-party payors could have an adverse effect on our business, results of operations, and financial condition. Â 14 Â Â Our results of operations may be harmed if we are unable to accurately forecast clinician demand for our BNA Platform or any future products. Â Our ability to accurately forecast demand for our BNA Platform or our future our products could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, our inability to forecast the lifecycle of our products, an increase or decrease in customer demand for our products or for competitor products, our failure to accurately forecast customer adoption of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand, which may negatively affect our business, financial condition, and results of operations. Â Adoption of our BNA Platform depends on positive clinical data as well as clinician acceptance of the data and our products, and negative clinical data or perceptions among these clinicians would harm our sales, business, financial condition, and results of operations. Â The rate of adoption and sales of our products is heavily influenced by clinical data. Although we have positive research data from a 2023 white paper study, there can be no assurance that future clinical studies, including those to demonstrate the efficacy of our BNA Platform or future products in current target patient populations and those to support label retention and expansion for our products, will demonstrate clinical utility and effectiveness. Unfavorable or inconsistent clinical data from future clinical studies conducted by us, our competitors, or third parties, or the negative interpretation of our clinical data internally and externally, including by customers, competitors, patients, and regulators could harm our business, financial condition, and results of operations. Â The rate of adoption and sales of our products are also influenced by clinician perceptions. Negative perceptions of our products by clinicians, including due to negative clinical data, could result in decreased adoption or use of our products, which would harm our business, financial condition, and results of operations. Further, if we are not able to attain strong working relationships with clinicians and receive their advice and input, the marketing of our products could suffer, which could harm our business, financial condition and results of operations. Â Our future success also depends upon patients having an experience with our products that meets their expectations in order to increase clinician demand for our products as a result of positive feedback and word-of-mouth. Patients may be dissatisfied if their expectations of the BNA Platform are not met or if the performing clinicians are not adequately trained on use of our BNA Platform. If the results of our products do not meet the expectations of the patient it could discourage the patient and/or their healthcare provider from continuing to use our device or referring our products to others. Dissatisfied patients may express negative opinions through social media, advocacy, or other publicity. Any failure to meet patient expectations and any resulting negative publicity could harm our reputation and future sales. Â We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions. Â We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with its existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent it from realizing our expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected to justify the transaction, which could result in a material adverse effect on our business and prospects. Â 15 Â Â Risks Related to Legal, Regulatory and Compliance Matters Â Complying with regulations enforced by FDA and other regulatory authorities is expensive and time consuming, and failure to comply could result in substantial penalties. Â Our product, the BNA Platform (for which we have obtained FDA 510(k) clearance), and our future products are considered medical devices and, accordingly, are subject to rigorous regulation by government agencies in the U.S. and other countries in which we intend to sell our products. Compliance with these rigorous regulations will affect capital expenditures, earnings and the competitive position of the Company. These regulations vary from country to country but cover, among other things, the following activities with respect to medical devices: Â Â â— design, development and manufacturing; Â â— testing, labeling, content and language of instructions for use and storage; Â â— product storage and safety; Â â— marketing, sales and distribution; Â â— pre-market clearance and approval; Â â— record keeping procedures; Â â— advertising and promotion; Â â— recalls and field safety corrective actions; Â â— post-market surveillance; Â â— post-market approval studies; and Â â— product import and export. Â The regulations to which we are subject are complex. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs, or lower than anticipated sales. Our failure to comply with applicable regulatory requirements could result in enforcement action by FDA or state agencies, which may include any of the following sanctions: Â Â â— warning letters, fines, injunctions, consent decrees, and civil penalties; Â â— repair, replacement, refunds, recall, or seizure of our products; Â â— operating restrictions or partial suspension or total shutdown of production; Â â— refusing our requests for 510(k) clearance or pre-market approval of new products, new intended uses, or modifications to existing products; Â â— withdrawing clearance or pre-market approvals that have already been granted; and Â â— criminal prosecution. Â If any of these events were to occur, they could harm our business. Â We may not receive the necessary authorizations to market our BNA Platform or any future new products, and any failure to timely do so may adversely affect our ability to grow our business. Â Before we can sell a new medical device in the U.S., or market a new use of, new claim for, or significant modification to a legally marketed device, we must first obtain either FDA 510(k) clearance or approval, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed, the applicant must submit a premarket notification to FDA under Section 510(k) of the FD&C Act, and FDA must determine that a proposed device is â€œsubstantially equivalentâ€ to a legally-marketed â€œpredicateâ€ device. To be â€œsubstantially equivalent,â€ the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics, not raise different questions of safety or effectiveness than the predicate device, and be as safe and as effective as the predicate device. The 510(k) clearance process can be expensive and uncertain and typically takes from three to 12 months, but may last significantly longer. Clinical data may be required in connection with an application for 510(k) clearance. Furthermore, even if we are granted regulatory clearances or approvals, they may include limitations on the indications for use or intended uses of the device, which may limit the market for the device. Â Our BNA Platform is a Class II medical device, which was cleared by FDA for commercialization in the U.S. pursuant to the 510(k) notification process for the post-hoc statistical analysis of the human electroencephalogram in December 2020 for use in individuals 12 to 85 years of age. Â FDA can delay, limit, or deny 510(k) clearance, or other approval or reclassification, of a device for many reasons, including: Â Â â— we may be unable to demonstrate to FDAâ€™s satisfaction that the products or modifications are substantially equivalent to a proposed predicate device or safe and

effective for their intended uses; Â â— we may be unable to demonstrate that the clinical and other benefits of the device outweigh the risks; and Â â— the applicable regulatory authority may identify deficiencies in our submissions or in the facilities or processes of our third party contract manufacturers. Â 16 Â Â Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. For example, if we decide to market the BNA Platform for a broader or additional indication(s) for use and/or make any material modifications to any element of the device and/or the manufacturing or distribution thereof in the future, an additional 510(k) submission, and FDA clearance thereof, will be required prior to making any promotional communications expressly or impliedly claiming that the device may be used for such indication(s) and/or prior to making such modification, respectively. Â In addition, FDA may change its policies, adopt additional regulations, revise existing regulations, or take other actions, or Congress may enact different or additional statutory requirements, which may prevent or delay clearance of our future products under development or impact our ability to modify our currently marketed products on a timely basis. Such policy, statutory, or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current marketing authorizations. Â We received our European CE mark, indicating that we affirm our productâ€™s conformity with European health, safety and environmental protection standards, in 2021. We will also need to obtain regulatory approval in other foreign jurisdictions in which we plan to market and sell our products. The time required to obtain registrations or approvals, if required by other countries, may be longer than that required for FDA clearance, and requirements for such registrations, clearances, or approvals may significantly differ from FDA requirements. If we modify our products, we may need to apply for additional regulatory approvals before we are permitted to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer be able to sell the applicable product in that country. Â Failure to comply with these rules, regulations, self-regulatory codes, circulars, and orders could result in significant civil and criminal penalties and costs and could have a material adverse impact on our business. Also, these regulations may be interpreted or applied by a prosecutorial, regulatory, or judicial authority in a manner that could require us to make changes in our operations or incur substantial defense and settlement expenses. Even unsuccessful challenges by regulatory authorities or private relators could result in reputational harm and the incurring of substantial costs. In addition, many of these laws are vague or indefinite and have not been interpreted by the courts and have been subject to frequent modification and varied interpretation by prosecutorial and regulatory authorities, increasing compliance risks. Â Certain modifications to our products may require new 510(k) clearance or other marketing authorizations. Â Once a medical device is permitted to be legally marketed in the U.S. pursuant to a 510(k) clearance, a medical device developer may be required to notify FDA of certain modifications to the device. Medical device developers determine in the first instance whether a change to a product requires a new premarket submission, but FDA may review any such decision. Â While our BNA Platform received 510(k) clearance in December 2020, we may in the future apply for 510(k) clearance for updated components of our BNA Platform, which must, then, be found by the FDA to be substantially equivalent to the cleared BNA Platform and, thus, may not be lawfully marketed in the U.S. until FDA make a substantial equivalence determination and issues the requisite 510(k) clearance for the updated BNA Platform. Although the development of our BNA Platform has been carefully monitored and documented by professionals who are experienced in the FDA clearance process, there is no assurance that the FDA will agree that an updated component of our BNA Platform is substantially equivalent to the cleared BNA Platform and allow the updated BNA Platform to be marketed in the United States. The FDA may determine that the device is not substantially equivalent and require a premarket approval (â€œPMAâ€) or, more likely, a de novo reclassification, and/or require further information, such as additional test data, including data from clinical studies, before it is able to make a determination regarding substantial equivalence. By requesting additional information, the FDA can delay market introduction of an updated BNA Platform. Delays in receipt of or failure to receive any necessary 510(k) clearance, de novo classification, or PMA, or the imposition of stringent restrictions for our BNA Platform, could have a material adverse effect on our business, results of operations and financial condition. Â In the future, we may make other modifications to our products, including our BNA Platform, and determine, based on our review of the applicable FDA regulations and guidance, that in certain instances new 510(k) clearances or other premarket submissions are not required. If FDA disagrees with our determinations, we may be subject to a wide range of enforcement actions, including, for example, a warning letter, among other consequences, after which we will likely have to cease marketing the applicable modified product and/or to recall distributed units of such modified product until we obtain the requisite clearance or approval. Â 17 Â Â Ongoing changes in healthcare regulation could negatively affect our revenues, business and financial condition. Â The United States healthcare system has been continually evolving at the federal and state level due to comprehensive reforms relating to the payment for, the availability of and reimbursement for healthcare services. Key reforms have ranged from fundamentally changing federal and state healthcare reimbursement programs, including providing comprehensive healthcare coverage to the public under government-funded programs, to minor modifications to existing programs, and many have been challenged (with some being overturned or modified) along the way. One example, among countless others, is the Patient Protection and Affordable Care Act (the â€œAffordable Care Actâ€), which was the most significant federal healthcare reform law enacted in the U.S. in recent history. The Affordable Care Act has undergone substantial challenges and changes since its enactment in 2010, and numerous other federal healthcare reform legislation, executive orders, and judicial rulings have been implemented in the years since, most of which have been or are aimed at lowering healthcare costs in the U.S. To the extent any such reform measures or any future initiatives reduce reimbursement or coverage eligibility or any amounts or funds available (such as by reductions in reimbursement to our healthcare provider customers) for our BNA Platform and/or any future products we may market in the U.S. (if any), our business may be adversely affected. Â Healthcare reform initiatives will continue to be proposed and may reduce healthcare related funding. It is impossible to predict the ultimate content and timing of any healthcare reform legislation and its resulting impact on us. If significant reforms are made to the healthcare system in the United States, or in other jurisdictions, those reforms may increase our costs or otherwise negatively effect on our business, results of operations, and financial condition. Â On April 5, 2017, the European Parliament passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU Medical Device Directive and became effective on May 26, 2021. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable, and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. The new regulations, among other things: Â Â â— strengthen the rules on placing devices on the market and reinforce surveillance once they are available; Â â— establish explicit provisions on manufacturersâ€™Â responsibilities for the follow-up of the quality, performance and safety of devices placed on the market; Â â— improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; Â â— set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and Â â— strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market. Â These modifications may have an effect on the way we conduct our business in the EEA. Â Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future products could make it more difficult and costly to obtain clearance or approval for new products or to produce, market and distribute existing products. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business. Â Our products may cause or contribute to adverse medical events that we are required to report to FDA and other governmental authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, results of operations, and financial condition. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of FDA or another governmental authority, could have a negative impact on us. Â We are required to timely file various reports with FDA, including reports required by the medical device reporting regulations which require us to report to FDA when we receive or become aware of information that reasonably suggests that one of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur in the device or a similar device that we market, could cause or contribute to a death or serious injury. If we fail to comply with our reporting obligations, FDA or other governmental authorities could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance, seizure of our products, or delay in clearance of future products. FDA and certain foreign regulatory bodies have the authority to require the recall of commercialized products under certain circumstances. Â 18 Â Â A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, labeling or design deficiencies, packaging defects, or other deficiencies, or failures to comply with applicable regulations. If we do not adequately address problems associated with our devices, we may face additional regulatory requirements or enforcement action, including required new marketing authorizations, FDA warning letters, product seizure, injunctions, administrative penalties, or civil or criminal proceedings. Â We may initiate voluntary withdrawals, removals, or corrections for our products in the future that we determine do not require notification of FDA because no material compliance issue or safety risk is involved. If FDA disagrees with our determinations, it could require us to report those actions and we may be subject to enforcement action. A future recall announcement or other corrective action could harm our financial results and reputation, potentially lead to product liability claims against us, require the dedication of our time and capital, and negatively affect our sales. Â In addition, FDAâ€™s and other regulatory authoritiesâ€™ policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our future products. For example, in November 2018, FDA announced that it plans to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. It is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances. Â We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad. For example, the Trump Administration previously enacted several executive actions that could impose significant burdens on, or otherwise materially delay, FDAâ€™s ability to engage in routine regulatory and oversight activities. It is difficult to predict how these executive actions and executive actions that may be taken under the Biden Administration may affect FDAâ€™s ability to exercise its regulatory authority. If these executive actions impose constraints on FDAâ€™s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. Â Changes in internet regulations could adversely affect our business. Â Laws, rules, and regulations governing internet communications, advertising, and e-commerce are dynamic, and the extent of future government regulation is uncertain. Federal and state regulations govern various aspects of our online business, including intellectual property ownership and infringement, trade secrets, the distribution of electronic communications, marketing and advertising, user privacy and data security, search engines, and internet tracking technologies. Future taxation on the use of the internet or e-commerce transactions could also be imposed. Existing or future regulation or taxation could increase our operating expenses and expose us to significant liabilities. Â Disruptions at the FDA, other agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved, or commercialized in a timely manner, or at all, which could negatively impact our business. Â The ability of the FDA, other agencies and notified bodies to review and authorize or certify for marketing new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, agencyâ€™s or notified bodyâ€™s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the agencyâ€™s or notified bodyâ€™s ability to perform routine functions. Average review times at the FDA and other agencies and notified bodies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA, other agencies and notified bodies may also slow the time necessary for new medical devices or modifications to be reviewed and/or cleared, approved or certified by necessary agencies or notified bodies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, in recent years, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points in response to the global COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns, including pandemics, were to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Â 19 Â Â In the EU, notified bodies must be officially designated to certify products and services in accordance with the MDR, which regulates the development and sale of medical devices in Europe. While several notified bodies have been designated, the COVID-19 pandemic significantly slowed down their designation process and the current designated notified bodies are facing a large amount of requests with the new regulation, as a consequence of which review times have lengthened although a regulation amending the EU MDR was adopted in March 2023, extending existing transitional provisions to December 31, 2028. This situation could significantly impact the ability of notified bodies to timely review and process our regulatory submissions, which could have a material adverse effect on our business in the EU and EEA (which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland). Â The misuse or off-label use of our BNA Platform may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies, particularly if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. Â Our BNA Platform is a Class II medical device cleared by FDA for commercialization in the U.S. pursuant to the 510(k) notification process for the post-hoc statistical analysis of the human electroencephalogram in December 2020 for use in individuals 12 to 85 years of age. We, thus, are not currently able to promote the BNA Platform for any other indications for use or make any promotional claims that are inconsistent with, or outside the scope of, such FDA clearance (often referred to as â€œoff-labelâ€ claims). However, the assessment of whether a given claim is or is not consistent with a given FDA clearance or approval can often be subjective, and we cannot guarantee that FDA will always agree with our position regarding a particular claim or that all of our employees, representatives, and agents will abide by our marketing policies. If FDA determines that we have promoted any product without the requisite clearance or approval and/or for an off-label or unapproved use, it could take any number of enforcement actions against us, including (among others), issuing untitled or warning letters and/or pursuing an injunction, seizure, civil fine and/or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as laws prohibiting false claims for reimbursement, any of which would have a material adverse effect on our financial condition and/or business as a whole. Â Additionally, we must have competent and reliable scientific evidence or, where applicable, other adequate substantiation for each reasonable interpretation of every promotional claim we make. In particular, comparative or superiority claims generally require adequate, well controlled, head-to-head clinical studies, comparing the product to the applicable competing products. To the extent we make any claims, or are otherwise held responsible for third-party claims about any product we may market in the United States, without the requisite clinical substantiation, we could be subject to enforcement action by FDA and/or the Federal Trade Commission (FTC), as well as a competitor challenge via the National Advertising Division (NAD) of the Better Business Bureau. Our plans to utilize social media as a primary promotional tool for our device(s) increases the applicable enforcement risk, as it makes it easier for our employees, affiliates, and any third parties with which we may have a relationship and/or arrangement under which we are deemed responsible for such partyâ€™s claims about our product(s) to disseminate promotional claims about our product(s) that may be inconsistent with applicable regulations governing device promotions. Further, consumers can bring private false-advertising lawsuits, including class actions, against us for any material misrepresentations and/or deceptive or unsubstantiated claims (among other similar causes of action) in our promotional materials or other advertising. Any of the foregoing could have a material adverse effect on our business. Â 20 Â Â We may be subject to certain federal, state, and foreign fraud and abuse laws, health information privacy and security laws, and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business. Â There are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false claims, and physician transparency laws. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. Our business practices and relationships with providers and patients are subject to scrutiny under these laws. We may also be subject to patient information privacy and security regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The healthcare laws and regulations that may affect our ability to operate include: Â Â â— the federal healthcare Medicare and Medicaid Patient Protection Act of 1987 (the â€œAnti-Kickback Statuteâ€), which prohibits, among other things, persons, and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral

of an individual for, or the purchase, lease, order, or arrange for or recommend a good or service, for which payment may be made, in whole or in part, under federal healthcare programs, such as Medicare and Medicaid. The term â€œremunerationâ€Â has been broadly interpreted to include anything of value. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the law or a specific intent to violate. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal healthcare Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exceptions and regulatory safe harbors to the federal healthcare Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration to those who prescribe, purchase, or recommend medical device products, including discounts, or engaging individuals as speakers, consultants, or advisors, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti- kickback liability. Moreover, there are no safe harbors for many common practices, such as reimbursement support programs, educational or research grants, or charitable donations; Â â— the federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment of federal government funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. Private individuals, commonly known as â€œwhistleblowers,â€Â can bring civil False Claims Act qui tam actions, on behalf of the government and such individuals and may share in amounts paid by the entity to the government in recovery or settlement. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties for each false or fraudulent claim or statement. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the federal civil False Claims Act. Many pharmaceutical and medical device manufacturers have been investigated and have reached substantial settlements under the federal civil False Claims Act in connection with alleged off-label promotion of their products and allegedly providing free products to customers with the expectation that the customers would bill federal health care programs for the product. In addition, manufacturers can be held liable under the federal civil False Claims Act even when they do not submit claims directly to government payers if they are deemed to â€œcauseâ€Â the submission of false or fraudulent claims. There are also criminal penalties, including imprisonment and criminal fines, for making or presenting false, fictitious or fraudulent claims to the federal government; Â â— Health Insurance Portability and Accountability Act of 1996 (â€œHIPAAâ€), which created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statements or representations, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal healthcare Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; Â â— the federal Physician Payments Sunshine Act under the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services, information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and group purchasing organizations, as well as ownership and investment interests held by physicians and their immediate family members. Since January 2022, applicable manufacturers are also required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives; Â 21 Â Â Â Â â— HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act (â€œHITECHâ€), and their respective implementing regulations, which imposes privacy, security, and breach reporting obligations with respect to Protected Health Information (â€œPHIâ€), upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, and their respective business associates that perform services on their behalf that involve PHI. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make HIPAA compliance as well as civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the HIPAA laws and seek attorneysâ€™Â fees and costs associated with pursuing federal civil actions; and Â â— analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers or patients; state laws that require device companies to comply with the industryâ€™s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws that require the licensure of sales representatives; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; data privacy and security laws and regulations in foreign jurisdictions that may be more stringent than those in the United States (such as the EU, which adopted the General Data Protection Regulation, which became effective in May 2018); state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers. Â These laws and regulations, among other things, may constrain our business, marketing, and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with physicians or other potential purchasers of our products and consulting agreements we enter into with physicians. Further, while we do not submit claims and our future customers will make the ultimate decision on whether or how to submit any potential claims, we may provide reimbursement guidance and support regarding our products, to the extent reimbursement may be available, which could implicate these laws. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws. Â To enforce compliance with healthcare regulatory laws, certain enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. For example, U.S. federal and state regulatory and enforcement agencies continue to actively investigate violations of healthcare laws and regulations, including pursuing novel theories of liability under these laws. These government agencies recently have increased regulatory scrutiny and enforcement activity with respect to manufacturer reimbursement support activities and patient support programs, including bringing criminal charges or civil enforcement actions under the federal healthcare Anti-Kickback statute, federal civil False Claims Act, the health care fraud statute, and HIPAA privacy provisions. Responding to investigations can be time and resource consuming and can divert managementâ€™s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity, and be costly to respond to. Â If our operations are found to be in violation of any of the healthcare laws or regulations described above or any other healthcare regulations that may apply to us, we may be subject to administrative, civil and criminal penalties, damages, fines, disgorgement, substantial monetary penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, additional reporting obligations, and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, reputational harm, and the curtailment or restructuring of our operations. Â 22 Â Â Since our BNA Platform will utilize cloud-based information systems and the exchange of information between patients and doctors, we will be subject to numerous U.S. federal and state laws and regulations related to the privacy and security of personally identifiable information, including health information. Â Among other data-privacy and/or confidentiality laws to which we may be subject, HIPAA establishes privacy and security standards that limit the use and disclosure of PHI and require covered entities and business associates to implement administrative, physical, and technical safeguards to ensure the confidentiality, integrity, and availability of individually identifiable health information in electronic form, among other requirements. Â Violations of HIPAA may result in civil and criminal penalties. We must also comply with HIPAAâ€™s breach notification rule which requires notification to affected individuals and the Secretary of Health and Human Services (â€œHHSâ€), and in certain cases to media outlets, in the case of a breach of unsecured PHI. The regulations also require business associates of covered entities to notify the covered entity of breaches by the business associate. Â State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states, and HIPAA standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates for compliance. Â Many states also have laws that protect the privacy and security of sensitive and personal information, including health information. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to, in addition to HIPAA. For example, California passed the California Consumer Privacy Act or CCPA on June 28, 2018, which went into effect January 1, 2020. On November 3, 2020, the California Privacy Rights Act of 2020 (â€œCPRAâ€), which amends the CCPA and adds new privacy protections that became effective on January 1, 2023, was enacted through a ballot initiative. While information we maintain that is covered by HIPAA may be exempt from the CCPA, other records and information we maintain related to patients or personnel may be subject to the CCPA. In certain cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some, unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused. In addition, state and federal privacy laws subject to frequent change. Â In addition to HIPAA and state health information privacy laws, we may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security, laws that place specific requirements on certain types of activities, such as data security and texting, and laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach. Â Foreign data protection, privacy, and other laws and regulations are often more restrictive than those in the U.S. The E.U., for example, traditionally has imposed stricter obligations under its laws and regulations relating to privacy, data protection and consumer protection than the U.S. In May 2018, the GDPR, governing data practices and privacy in the E.U., became effective and replaced the data protection laws of the individual member states. GDPR requires companies to meet stringent requirements regarding the handling of personal data of individuals in the E.U. These more stringent requirements include expanded disclosures to inform members about how we may use their personal data, increased controls on profiling members, and increased rights for members to access, control and delete their personal data. In addition, there are mandatory data breach notification requirements. The law also includes significant penalties for non-compliance, which may result in monetary penalties of up to 20 million Euros or 4% of a companyâ€™s worldwide turnover, whichever is higher. GDPR and other similar regulations require companies to give specific types of notice, and informed consent is required for the placement of a cookie or similar technologies on a userâ€™s device for online tracking for behavioral advertising and other purposes and for direct electronic marketing. The GDPR also imposes additional conditions in order to satisfy such consent, such as a prohibition on pre-checked consents. It remains unclear how the U.K. data protection laws or regulations will develop in the medium to longer term and how data transfer to the U.K. from the E.U. will be regulated. Outside of the E.U., there are many other countries with data protection laws, and new countries are adopting data protection legislation with increasing frequency. Â 23 Â Â Many of these laws may require consent from individuals for the use of data for various purposes, including marketing, which may reduce our ability to market our products. Â There is no harmonized approach to these laws and regulations globally. Consequently, we increase our risk of non-compliance with applicable foreign data protection laws and regulations when we expand internationally. We may need to change and limit the way we use personal information in operating our business and may have difficulty maintaining a single operating model that is compliant. Compliance with such laws and regulations will result in additional costs and may necessitate changes to our business practices and divergent operating models, limit the effectiveness of our marketing activities, adversely affect our business, results of operations, and financial condition, and subject us to additional liabilities. Â Our business could be adversely affected by professional and legal challenges to our business model or by new state actions restricting our ability to provide our products and services in certain states. Â Since the success of our business will be dependent on the widespread adaptation of our BNA Platform as a valid method for statistical analysis of EEG scans, neurologists across multiple geographies will be needed to use our BNA Platform and provide positive feedback and results. This will expose us to legal risk of patients or neurologists who may have a negative experience with our BNA Platform filing lawsuits claiming damages or other claims. Although we will seek insurance coverage for such legal actions, there is no assurance that the amount of coverage will be sufficient to cover these claims. In addition, such legal actions from consumers and neurologists may result in material and adverse effects on our ability to continue to conduct business due to negative press. Â Security breaches, data breaches, cyber attacks, other cybersecurity incidents or the failure to comply with privacy, security and data protection laws could materially impact our operations, patient care could suffer, we could be liable for damages, and our business, operations and reputation could be harmed. Â We expect to retain confidential customer personal and financial, patient health information and our own proprietary information and data essential to our business operations. We will rely upon the effective operation of our IT systems, and those of our service providers, vendors, and other third parties to safeguard the information and data. Additionally, our success may be dependent on the success of healthcare providers, many of whom are comprised of individual or small operations with limited IT experience and inadequate or untested security protocols, in managing data privacy and data security requirements. It is critical that the facilities, infrastructure and IT systems on which we depend to run our business and the products we develop remain secure and be perceived by the marketplace and our potential customers to be secure. Despite the implementation of security features in our products and security measures in our IT systems, we and our service providers, vendors, and other third parties may become subject to physical break-ins, computer viruses or other malicious code, unauthorized or fraudulent access, programming errors or other technical malfunctions, hacking or phishing attacks, malware, ransomware, employee error or malfeasance, cyber attacks, and other breaches of IT systems or similar disruptive actions, including by organized groups and nation-state actors. For example, we may experience cybersecurity incidents and unauthorized internal employee exfiltration of company information. Â Further, the frequency of third-party cyber-attacks has increased over the last several years. The military conflict in Ukraine may cause nation-state actors or hackers sympathetic to either side of the conflict to carry out cyber-attacks to achieve their goals, which may include espionage, information gathering operations, monetary gain, ransomware, disruption, and destruction. Significant service disruptions, breaches in our infrastructure and IT systems or other cybersecurity incidents could expose us to litigation or regulatory investigations, impair our reputation and competitive position, be distracting to our management, and require significant time and resources to address. Affected parties or regulatory agencies could initiate legal or regulatory action against us, which could prevent us from resolving the issues quickly or force us to resolve them in unanticipated ways, cause us to incur significant expense and liability, or result in judicial or governmental orders forcing us to cease operations or modify our business practices in ways that could materially limit or restrict the products and services we provide. Concerns over our privacy practices could adversely affect othersâ€™ perception of us and deter potential customers, patients and partners from using our products. In addition, patient care could suffer, and we could be liable if our products or IT systems fail to deliver accurate and complete information in a timely manner. We have internal monitoring and detection systems as well as cybersecurity and other forms of insurance coverage related to a breach event covering expenses for notification, credit monitoring, investigation, crisis management, public relations and legal advice. However, damages and claims arising from such incidents may not be covered or may exceed the amount of any coverage and do not cover the time and effort we may incur investigating and responding to any incidents, which may be material. The costs to eliminate, mitigate or recover from security problems and cyber attacks and incidents could be material and depending on the nature and extent of the problem and the networks or products impacted, may result in network or systems interruptions, decreased product sales, or data loss that may have a material impact on our operations, net revenues and operating results. Â 24 Â Â Our business will expose us to potential liability for the quality and safety of our products and services, how we advertise and market those products and services and how and to whom we sell them, and we may incur substantial expenses or be found liable for substantial damages or penalties if we are subject to claims or litigation. Â Our products and services involve an inherent risk of claims concerning their design, manufacture, safety and performance, how they are marketed and advertised in a complex framework of highly regulated

domestic and international laws and regulations, how we package, bundle or sell them to potential customers, who may be private individuals or companies or public entities such as hospitals and clinics, and how we train and support doctors, their staffs and patients who administer or use our products. Moreover, consumer products and services are routinely subject to claims of false, deceptive or misleading advertising, consumer fraud and unfair business practices. Additionally, we may be held liable if any product we develop or manufacture or services we offer or perform causes injury or is otherwise found unhealthy. If our products are safe but they are promoted for off-label usage, we may be investigated, fined or have our products or services enjoined or approvals rescinded or we may be required to defend ourselves in litigation. Although we maintain insurance for product liability, business practices and other types of activities we make or offer, coverage may not be available on acceptable terms, if at all, and may be insufficient for actual liabilities. Any claim for product liability, sales, advertising and business practices, regardless of its merit or eventual outcome, could result in material legal defense costs and damage our reputation, increase our expenses and divert managementâ€™s attention. Â Increased focus on current and anticipated environmental, social and governance (â€œESGâ€) laws and increased scrutiny of our ESG policies and practices may materially increase our costs, expose us to potential liability, adversely impact our reputation, employee retention, willingness of potential customers and suppliers to do business with us and willingness of investors to invest in us. Â Our operations are subject to a variety of existing local, regional and global ESG laws and regulations, and we will likely be required to comply with new, broader, more complex and more costly laws and regulations that focus on ESG matters. Our compliance obligations will likely span all aspects of our business and operations, including product design and development, materials sourcing and other procurement activities, product packaging, product safety, energy and natural resources usage, facilities design and utilization, recycling and collection, transportation, disposal activities and workersâ€™ rights. Â Environmental regulations related to greenhouse gases are expected to have an increasingly larger impact on our or our suppliersâ€™ energy sources. Many U.S. and foreign regulators have enacted or are considering enacting new or additional disclosure requirements or limits on the emissions of greenhouse gases, including, but not limited to, carbon dioxide and methane, from power generation units using fossil fuels. The effects of greenhouse gas emission limits on power generation are subject to significant uncertainties, including the timing of any new requirements, levels of emissions reductions and the scope and types of emissions regulated. These limits may have the effect of increasing our costs and those of our suppliers and could result in manufacturing, transportation and supply chain disruptions and delays if clean energy alternatives are not readily available in adequate amounts when required. Moreover, alternative energy sources, coupled with reduced investments in traditional energy sources and infrastructure, may fail to provide the predictable, reliable, and consistent energy that we, our suppliers and other businesses need for operations. Â Meeting our obligations under existing ESG laws, rules, or regulations is already costly to us and our suppliers, and we expect those costs to increase as new laws are enacted, possibly materially. Additionally, we expect regulators to perform investigations, inspections and periodically audit our compliance with these laws and regulations, and we cannot provide assurance that our efforts or operations will be compliant. If we fail to comply with any requirements, we could be subject to significant penalties or liabilities and we may be required to implement new and materially more costly processes and procedures to come into compliance. Further, these laws are subject to unpredictable changes. Even if we successfully comply with these laws and regulations, our suppliers may fail to comply. We may also suffer financial and reputational harm if future customers require, and we are unable to deliver, certification that our products are conflict free. In all of these situations, our future customers may stop purchasing products from us, and may take legal action against us, which could harm our reputation, revenues and results of operations. Â 25 Â Â Investor advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and consumers are also increasingly focused on corporate ESG practices. Additionally, public interest and legislative pressure related to public companiesâ€™ ESG practices continues to grow. If our ESG practices fail to meet investorsâ€™ or other industry stakeholdersâ€™ evolving expectations and standards, including environmental stewardship, support for local communities, board of director and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted, potential customers and suppliers may be unwilling to do business with us and investors may be unwilling to invest in us. In addition, as we work to align our ESG practices with industry standards, we have expanded and will likely continue to expand our disclosures in these areas. We also expect to incur additional costs and require additional resources to monitor, report, and comply with our various ESG practices. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the disclosure and other expectations of stakeholders, our reputation, business, financial performance, growth, and stock price may be adversely impacted. Â We are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business, and changes in such regulations or laws could require us to modify our products, marketing or advertising efforts. Â In connection with the marketing or advertisement of our products and services, we could be the target of claims relating to false, misleading, deceptive, or otherwise noncompliant advertising or marketing practices, including under the auspices of the FTC and state consumer protection statutes. If we rely on third parties to provide any marketing and advertising of our products and services, we could be liable for, or face reputational harm as a result of, their marketing practices if, for example, they fail to comply with applicable statutory and regulatory requirements. Â If we are found to have breached any consumer protection, advertising, unfair competition, or other laws or regulations, we may be subject to enforcement actions that require us to change our marketing and business practices in a manner which may negatively impact us. This could also result in litigation, fines, penalties, and adverse publicity that could cause reputational harm and loss of patient trust, which could have an adverse effect on our business. Â Risks Related to our Intellectual Property Â Our success depends in part on our proprietary technology, and if we are unable to successfully enforce our intellectual property rights, our competitive position may be harmed. Â Our success will depend in part on our ability to maintain existing intellectual property and to obtain and maintain further intellectual property protection for our products and services, both in the U.S. and in other countries. We intend to protect our intellectual property rights, including our AI technology and related algorithms, through a combination of patent, trademark, copyright, and trade secret laws, as well as third-party confidentiality and assignment agreements. Our inability to do so could harm our competitive position. Â We rely on our portfolio of issued and pending patent applications in the U.S. and other countries to protect a large part of our intellectual property and our competitive position; however, our currently pending or future patent filings may not result in the issuance of patents. While we generally apply for patents in those countries where we intend to make, have made, use, or sell patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file for a patent, we may be precluded from doing so at a later date. Â Patent rights are territorial, and patent protection extends only to those countries where we have issued patents. Filing, prosecuting and defending patents on our products and our future products in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Many countries do not protect intellectual property to the same extent as the U.S. or Europe, and their litigation processes differ. Competitors may successfully challenge or avoid our patents, or manufacture products in countries where we have not applied for patent protection. Changes in the patent laws in the U.S. or other countries may diminish the value of our patent rights. As a result of these and other factors, the scope, validity, enforceability, and commercial value of our patent rights are uncertain and unpredictable. Â 26 Â Â Furthermore, the patent positions of medical device companies involve complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. The issuance of a patent, while presumed valid and enforceable, is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Any patents issued to us may be challenged, invalidated, held unenforceable, circumvented, or may not be sufficiently broad to prevent third parties from producing competing products similar in design to our products. In addition, any protection afforded by foreign patents may be more limited than that provided under U.S. patent and intellectual property laws. There can be no assurance that any of our patents, any patents licensed to us, or any patents which we may be issued in the future, will provide us with a competitive advantage or afford us protection against infringement by others, or that the patents will not be successfully challenged or circumvented by third parties, including our competitors. Further, there can be no assurance that we will have adequate resources to enforce our patents. Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. Â Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitorâ€™s or potential competitorâ€™s product, particularly in litigation in countries other than the U.S. that do not provide an extensive discovery procedure. Any litigation to enforce or defend our patent rights, if any, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. Â Moreover, advances in AI technology may generate developments that existing IP laws do not adequately protect. The legislative and regulatory environment is out of our control, may change rapidly and unpredictably, and may negatively influence our revenue, costs, earnings, and growth. Some rules and regulations may be subject to litigation or other challenges that delay or modify their implementation and impact on us. Â We also may seek to rely on protection of copyright, trade secrets, know how, and confidential and proprietary information. We generally enter into confidentiality and non-compete agreements with our employees, consultants, and collaborative partners upon their commencement of a relationship with us. However, these agreements may not provide meaningful protection against the unauthorized use or disclosure of our trade secrets or other confidential information, and adequate remedies may not exist if unauthorized use or disclosure were to occur. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our operating results, financial condition, and future growth prospects. In particular, a failure to protect our proprietary rights might allow competitors to copy our technology, which could adversely affect our pricing and market share. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors, former employees and current employees. Further, other parties may independently develop substantially equivalent know-how and technology. Â We currently own registered trademarks for our BNA Platform, and we intend to rely on both registered and common law rights for our trademarks in the future. There can be no assurance that our future trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products and services, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. Further, there can be no assurance that competitors will not infringe our trademarks, or that we will have adequate resources to enforce our trademarks. Â Litigation, interferences, oppositions, re-exams, inter partes reviews, post grant reviews, or other proceedings are, have been, and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope, or non-infringement of certain proprietary rights claimed by third parties to be pertinent to the manufacture, use, or sale of our products or provision of our services. These types of proceedings are unpredictable and may be protracted, expensive, and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products and provide our services, require us to seek a license for the infringed product or technology, or result in the assessment of significant monetary damages. An unfavorable ruling could include monetary damages or, in cases where injunctive relief is sought, an injunction prohibiting us from selling our products or providing our services. Any of these results from litigation could adversely affect our business, financial condition, and results of operations. Â 27 Â Â Successful cybersecurity attacks, data breaches, unapproved use of machine learning or AI tools, or other security incidents could result in the loss of IP and key technological advantages. Security incidents could result in, for example, unauthorized access to, disclosure, modification, misuse, loss, or destruction of company, patient, or other third party data; theft or import of sensitive, regulated, or confidential data including personal information and IP, such as key innovations in AI; the loss of access to critical data or systems through ransomware; and business delays. Â If we infringe or violate the patents or proprietary rights of other parties or are subject to an intellectual property infringement or misappropriation claim, our ability to grow our business may be severely limited. Â Our commercial success also depends upon our ability, and the ability of any third party with which we may partner, to develop, manufacture, market and sell our products, if approved, and use our patent-protected technologies without infringing the patents of third parties. Extensive litigation over patents and other intellectual property rights is common in the medical device industry. Â We may not have identified all patents, published applications or published literature that affect our business either by blocking our ability to commercialize our products, by preventing the patentability of one or more aspects of our products, or by covering the same or similar technologies that may affect our ability to market our products. For example, we may not have conducted a patent clearance search sufficient to identify potentially obstructing third party patent rights. Moreover, patent applications in the United States are maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries outside of the United States are not typically published until at least 18 months from their first filing date. Similarly, publication of discoveries in the scientific or patent literature often lags behind actual discoveries. We cannot be certain that we were the first to invent, or the first to file, patent applications covering our products. We also may not know if our competitors filed patent applications for technology covered by our pending applications or if we were the first to invent the technology that is the subject of our patent applications. Competitors may have filed patent applications or received patents and may obtain additional patents and proprietary rights that block or compete with our patents. Â We may therefore in the future be the subject of patent or other litigation. From time to time, we may in the future receive letters from third parties drawing our attention to their patent rights. While we do not believe that we infringe upon any valid and enforceable rights that have been brought to our attention, and we take necessary steps to ensure that we do not infringe on the rights of others, there may be other more pertinent rights of which we are presently unaware. The defense and prosecution of intellectual property suits, interference proceedings, and related legal and administrative proceedings could result in substantial expense to us and significant diversion of effort by our technical and management personnel. An adverse determination of any litigation or interference proceeding to which we may become a party could subject us to significant liabilities. An adverse determination of this nature could also put our patents at risk of being invalidated or interpreted narrowly or require us to seek licenses from third parties. Licenses may not be available on commercially reasonable terms or at all, in which event, our business would be materially adversely affected. Intellectual property litigation or claims could force us to cease developing, selling or otherwise commercializing one or more of our products; to pay substantial damages for past use of the asserted intellectual property; and redesign, or rename in the case of trademark claims, our product(s) to avoid such third party rights, which may not be possible or which could be costly and time-consuming. Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects. Â Our failure to secure trademark registrations could adversely affect our ability to market our products and operate our business. Â Any future trademark applications in the United States and any other jurisdictions where we may file may not be allowed registration, and we may not be able to maintain or enforce our registered trademarks. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in corresponding foreign agencies, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our applications and/or registrations, and our applications and/or registrations may not survive such proceedings. Failure to secure such trademark registrations in the United States and in foreign jurisdictions could adversely affect our ability to market our products and our business. Â 28 Â Â We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. Â As is common in the medical device industry, we may employ individuals who were previously employed at other companies similar to ours, including our competitors or potential competitors. We may become subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Â Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case of non-compliance with these requirements. Â Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the relevant patent agencies in several stages over the lifetime of the patents and /or applications. The relevant patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the

applicable rules. However, there are situations in which the failure to comply with the relevant requirements can result in the abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our technologies and know-how which could have a material adverse effect on our business, prospects, financial condition and results of operation. Â Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. Â Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products are obtained, once the patent life has expired for a product, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Â We may be subject to claims challenging the inventorship of our patents and other intellectual property. Â We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor or an author. For example, we may have inventorship or ownership disputes arise from conflicting obligations of consultants or others who are involved in developing our products. Litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Â We use AI in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations. Â We incorporate AI solutions into our BNA platform, services, and features, and these applications are important in our operations. Our competitors or other third parties may incorporate AI into their products more quickly or more successfully than us, which could impair our ability to compete effectively and adversely affect our results of operations. Â 29 Â Â Additionally, if the content, analyses, or recommendations that AI applications assist in producing are or are alleged to be deficient, inaccurate, or biased, our business, financial condition, and results of operations may be adversely affected. Our use of AI and machine learning is subject to risks related to flaws in our algorithms and datasets that may be insufficient or contain biased information. The development of AI technologies is complex, and there are several challenges associated with achieving the desired level of accuracy, efficiency, and reliability. The algorithms and models used in our AI systems may have limitations, including biases, errors, or inability to handle certain data types or scenarios. There is a risk of system failures, disruptions, or vulnerabilities that could compromise the integrity, security, or privacy of our platform. These failures could result in reputational damage, legal liabilities, or loss of user confidence, which could materially affect our business. Â The use of AI applications has resulted in, and may in the future result in, cybersecurity incidents that implicate the personal data of patients and users of such applications. Any such cybersecurity incidents related to our use of AI applications could adversely affect our reputation and results of operations. AI also presents emerging ethical issues, and if our use of AI becomes controversial, we may experience brand or reputational harm, competitive harm, or legal liability. The rapid evolution of AI, including potential government regulation of AI, will require significant resources to develop, test and maintain our platform, services, and features to help us implement AI ethically in order to minimize unintended, harmful impact. Â Legislative and governmental activity in the privacy area may result in new laws or regulations that are applicable to us and that may hinder our business, for example, by restricting use or sharing of patient data, limiting our ability to provide certain data to our customers, limiting our ability to develop or modify our AI systems, or otherwise regulating AI and machine learning, including the use of algorithms and automated processing in ways that could materially affect our business, or which may lead to significant increases in the cost of compliance. Â General Risks Related To Us Â We may not continue to meet the continued listing requirements of Nasdaq, which could result in a delisting of our Common Stock.Â Â Our Common Stock is listed on Nasdaq. While we are currently in compliance, WaveDancer has been in the past been, and we may in the future be, unable to comply with certain of the listing standards that we are required to meet to maintain the listing of our Common Stock on Nasdaq. For instance, on August 8, 2024, WaveDancer received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (the â€œStaffâ€) indicating that in the former WaveDancerâ€™s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024, WaveDancer reported stockholdersâ€™ equity of $1,708,520 for the period ended March 31, 2024, which did not comply with Listing Rule 5550(b)(1) (the â€œMinimum Stockholdersâ€™ Equity Requirementâ€). Additionally, as previously reported, in a decision dated November 14, 2023, a Nasdaq Hearings Panel (the â€œPanelâ€) confirmed that we had regained compliance with the Minimum Stockholdersâ€™ Equity Requirement for a prior outstanding deficiency under the Minimum Stockholdersâ€™ Equity Requirement as related to the WaveDancerâ€™s stockholdersâ€™ equity for the period ended March 31, 2023. In the decision, the Panel imposed a Mandatory Panel Monitor for a period of one year or until November 14, 2024, which would require the Staff to issue a Delist Determination Letter in the event that WaveDancer, prior to the consummation of the Merger, or we, following the consummation of the Merger, failed to maintain compliance with the Minimum Stockholdersâ€™ Equity Rule. On August 13, 2024, we received a notice from the Nasdaq Stock Market LLC indicating that following the Staffâ€™s review of the Merger, the Staff determined that we now comply with the Minimum Stockholdersâ€™ Equity Requirement and that the matter is now closed.Â Â While we have regained compliance with the continued listing requirements for Nasdaq, it cannot be assured that we will continue to do so. If Nasdaq delists our Common Stock from trading on its exchange for failure to meet the listing standards, an investor would likely find it significantly more difficult to dispose of or obtain our shares, and our ability raise future capital through the sale of our shares could be severely limited. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities. Additionally, if we are unable to list on Nasdaq, it would likely be more difficult to trade in or obtain accurate quotations as to the market price of our Common Stock. If our securities are delisted from trading on Nasdaq, and we are not able to list its securities on another exchange or to have them quoted on Nasdaq, our securities could be quoted on the OTC Bulletin Board or on the â€œpink sheets.â€ As a result, we could face significant adverse consequences including: Â Â â— a limited availability of market quotations for its securities; Â 30 Â Â Â â— a determination that our Common Stock is a â€œpenny stock,â€Â which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; Â â— a limited amount of news and analyst coverage for us; and Â â— a decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3) or to obtain additional financing in the future. Â Our stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger. Â If we are unable to realize the full strategic and financial benefits currently anticipated from the Merger, our stockholders will have experienced substantial dilution of their ownership interests in their respective companies without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined organization is able to realize only part of the strategic and financial benefits currently anticipated from the merger. Furthermore, if we fail to realize the intended benefits of the Merger, the market price of our Common Stock could decline to the extent that the market price reflects those benefits. Â The market price of our Common Stock may be subject to significant fluctuations and volatility, and the stockholders of the company may be unable to resell their shares at a profit and may incur losses. Â Prior to the Merger, there has not been a public market for our Common Stock. The market price of our Common Stock could be subject to significant fluctuation. The previous business of WaveDancer differs from our business in important respects and, accordingly, our results of operations and the market price of our Common Stock following the Merger may be affected by factors different from those currently affecting the results of operations of WaveDancer. Market prices for securities of life sciences and medical technology companies in particular have historically been particularly volatile and have shown extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our Common Stock, regardless of our actual operating performance. Some of the factors that may cause the market price of our Common Stock to fluctuate include: Â Â Â Â Â Â Â Â Â Â Â â— investors reacting negatively to the effect of our business and prospects from the Merger; Â â— the announcement of new products, new developments, services or technological innovations by us or our competitors; Â â— actual or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and changes in our business, operations or prospects; Â â— announcements relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or other events by us or our competitors; Â â— conditions or trends in the life sciences and medical technology industries; Â â— changes in the economic performance or market valuations of other life sciences and medical technology companies; Â â— general market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition; Â â— sale of our Common Stock by stockholders, including executives and directors; Â â— volatility and limitations in trading volumes of our Common Stock; Â â— volatility in the market prices and trading volumes of the life sciences and medical technology stocks; Â â— our ability to finance our business; Â â— ability to secure resources and the necessary personnel to pursue our plans; Â â— failure to meet external expectations or management guidance; Â â— changes in our capital structure or dividend policy, future issuances of securities, sales or distributions of large blocks of Common Stock by stockholders; Â â— our cash position; Â â— announcements and events surrounding financing efforts, including debt and equity securities; Â â— analyst research reports, recommendations and changes in recommendations, price targets, and withdrawals of coverage; Â â— departures and additions of key personnel; Â â— disputes and litigation related to intellectual properties, proprietary rights, and contractual obligations; Â â— investigations by regulators into our operations or those of our competitors; Â â— changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and Â â— other events or factors, many of which may be out of our control. Â 31 Â Â In the past, following periods of volatility in the overall market and the market prices of particular companiesâ€™ securities, securities class action litigation has often been instituted against these companies. Litigation of this type, if instituted against us, could result in substantial costs and a diversion of our managementâ€™s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require us to make significant payments. Â We may issue additional equity securities in the future, which may result in dilution to existing investors. Â To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may, from time to time, sell additional equity securities in one or more transactions at prices and in a manner it determines. If we sell additional equity securities, existing stockholders may be materially diluted. In addition, new investors could gain rights superior to existing stockholders, such as liquidation and other preferences. In addition, the number of shares available for future grant under our equity compensation plans may be increased in the future. In addition, the exercise or conversion of outstanding options or warrants to purchase shares of capital stock may result in dilution to our stockholders upon any such exercise or conversion. Â All of WaveDancerâ€™s outstanding shares of common stock, and any shares of WaveDancer Common Stock that were issued in the Merger are, freely tradable without restrictions or further registration under the Securities Act, except for any shares held by our affiliates, as defined in Rule 144 under the Securities Act. Rule 144 defines an affiliate as a person who directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, us and would include persons such as our directors and executive officers and large stockholders. In turn, resales, or the perception by the market that a substantial number of resales could occur, could have the effect of depressing the market price of our Common Stock. Â The concentration of the capital stock ownership with our insiders will likely limit the ability of our stockholders to influence corporate matters. Â Following the Merger, our executive officers, directors, five percent or greater stockholders, and the respective affiliated entities beneficially own approximately 43% of our outstanding Common Stock. As a result, these stockholders, acting together, have control over matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a corporate transaction that other stockholders may view as beneficial. Â Certain stockholders could attempt to influence changes, which could adversely affect our operations, financial condition and the value of our Common Stock. Â Our stockholders may from time to time seek to acquire a controlling stake, engage in proxy solicitations, advance stockholder proposals or otherwise attempt to effect changes. Campaigns by stockholders to effect changes at publicly traded companies are sometimes led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders can be costly and time-consuming and could disrupt our operations and divert the attention of the Board and senior management from our business and operations. These actions could adversely affect our operations, financial condition and the value of our Common Stock. Â The sale or availability for sale of a substantial number of shares of Common Stock of could adversely affect the market price of such shares. Â Sales of a substantial number of shares of Common Stock in the public market and other legal restrictions on resale, or the perception that these sales could occur, could adversely affect the market price of such shares and could materially impair our ability to raise capital through equity offerings in the future. Immediately following the closing of the Merger on August 30, 2024, we had approximately have outstanding approximately 8,358,816 shares of Common Stock outstanding, without giving effect to the Reverse Stock Split, excluding securities underlying options and warrants, and based on the Exchange Ratio of 0.1040. This includes the shares being issued to our stockholders as merger consideration, which may be resold in the public market immediately without restriction. We are unable to predict what effect, if any, market sales of securities held by our significant stockholders, directors or officers or the availability of these securities for future sale will have on the market price of our Common Stock. Â 32 Â Â If securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our Common Stock could decline. Â The trading market for our Common Stock will rely in part on the availability of research and reports that third-party industry or financial analysts publish about us. There are many large, publicly traded companies active in the life sciences and medical technology industries, which may mean it will be less likely that we receive widespread analyst coverage. Furthermore, if one or more of the analysts who do cover us downgrades our stock, our stock price would likely decline. If one or more of these analysts cease coverage of us, we could lose visibility in the market, which in turn could cause our stock price to decline. Additionally, if securities analysts publish negative evaluations of competitors in the life sciences and medical technology industries, the comparative effect could cause our stock price to decline. Â Our management will be required to devote substantial time to comply with public company regulations. Â As a public company, we will incur significant legal, accounting and other expenses we did not incur as a private company. The Sarbanes-Oxley Act of 2002 (the â€œSarbanes-Oxley Actâ€), the Dodd-Frank Wall Street Reform and Consumer Protection Act (the â€œDodd-Frank Actâ€), as well as rules implemented by the SEC and Nasdaq, impose various requirements on public companies, including those related to corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs relative to those of we incurred as a private company, and will make some activities more time consuming and costly. Â The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of its internal control over financial reporting to allow management and our independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act (â€œSection 404â€). Our compliance with these requirements will require that we incur substantial accounting and related expenses and expend significant management efforts. We will likely need to hire additional accounting and financial staff to satisfy the ongoing requirements of Section 404. The costs of hiring such staff may be material and there can be no assurance that such staff will be immediately available to us. Moreover, if we are not able to comply with the requirements of Section 404, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, investors could lose confidence in the accuracy and completeness of our financial reports, the market price of our Common Stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Â We may not be able to timely and effectively implement controls and procedures required by Section 404 that are applicable to us as public company. Â The standards required for a public company under Section 404 of the Sarbanes-Oxley Act are significantly more stringent than those required of a privately held company. Management may not be able to effectively and timely implement controls and procedures that adequately respond to the increased regulatory compliance and reporting requirements that will be applicable to us as a public company. If management is not able to implement the additional requirements of Section 404 in a timely manner or with adequate compliance, it may not be able to assess whether its internal control over financial reporting is effective, which may subject us to adverse regulatory consequences and could harm investor confidence and cause the market price of our Common Stock to decline. Â We may be required to

take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on its financial condition, results of operations and stock price, which could cause you to lose some or all of your investment. Â Although WaveDancer and Private Firefly had conducted due diligence on each other prior to the consummation of the Merger, there can be no assurances that their diligence revealed all material issues that may be present in our business, that all material issues through a customary amount of due diligence will be uncovered, or that factors outside of our control will not later arise. As a result, we may be forced to later write-down or write-off assets, restructure operations, or incur impairment or other charges that could result in losses. Even if due diligence successfully identifies certain risks, unexpected risks may arise, and previously known risks may materialize in a manner not consistent with each companyâ€™s preliminary risk analysis. Even though these charges may be non-cash items and may not have an immediate impact on liquidity, the fact that we report charges of this nature could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may make future financing difficult to obtain on favorable terms or at all. Â 33 Â Â Anti-takeover provisions under Delaware corporate law may make it difficult for our stockholders to replace or remove our Board, and could deter or delay third parties from acquiring us, which may be beneficial to our stockholders. Â We are subject to the anti-takeover provisions of Delaware law, including Section 203 of the DGCL. Under these provisions, which became effective upon the closing of the Merger, if anyone becomes an â€œinterested stockholder,â€ we may not enter into a â€œbusiness combinationâ€ with that person for three (3) years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203 of the DGCL, â€œinterested stockholderâ€ means, generally, someone owning fifteen percent (15%) or more of our outstanding voting stock during the past three (3) years, subject to certain exceptions as described in Section 203 of the DGCL. Â We do not anticipate that we will pay any cash dividends in the foreseeable future. Â The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our Common Stock will be your sole source of gain, if any, for the foreseeable future. Â An active trading market for our Common Stock may not develop. Â The listing of our Common Stock on Nasdaq does not assure that a meaningful, consistent and liquid trading market exists. An active trading market for shares of our Common Stock may never develop or be sustained. If an active market for our Common Stock does not develop, it may be difficult for investors to sell their shares either without depressing the market price for the shares or at all. Â USE OF PROCEEDS Â All of the shares of Common Stock offered by the selling securityholders pursuant to this prospectus will be sold by the selling securityholders for their respective accounts. We will not receive any of the proceeds from these sales. We will pay certain expenses associated with the registration of the securities as described in the â€œPlan of Distributionâ€ section of this prospectus. Â We will receive up to an aggregate of approximately $9,815,436 from the exercise of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants, if such warrants are exercised in full for cash. We expect to use the net proceeds from the exercise of the aforementioned warrants for general corporate purposes. We will have broad discretion over the use of proceeds from the exercise of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants. There is no assurance that the holders of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants will elect to exercise any or all of such warrants. Â DETERMINATION OF OFFERING PRICE Â The offering price of the shares of Common Stock underlying the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants is determined by reference to the exercise price of such warrants. The exercise price of the Pre-Funded Warrants is $0.0001 per share, the exercise price of the Warrants is $0.71 per share, the exercise price of the Series C Warrants is $2.56 per share, the exercise price of the Series D Warrants is $0.104 per share, and the exercise price of the Broker Warrants is $5.98 per share. Â We cannot currently determine the price or prices at which shares of Common Stock may be sold by the selling securityholders under this prospectus. Â 34 Â Â MARKET PRICE OF OUR COMMON STOCK AND DIVIDENDS Â Market Information Â Our shares of Common Stock are listed on Nasdaq under the symbol â€œAIFF.â€ Â As of August 30, 2024, there were 8,358,816 shares of our Common Stock outstanding, held of record by 480 holders. Â Dividend Policy Â We have not declared or paid any dividends on shares of Common Stock to date. We anticipate that we will retain our future earnings to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of the Board and will depend on our financial condition, results of operations, capital requirements and future agreements and financing instruments, business prospects, and such other factors as the Board deems relevant. Â 35 Â Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the â€œUnaudited Condensed Consolidated Financial Statements of Firefly Neuroscience, Inc. for the three and six months ended June 30, 2024 and 2023â€ and the related notes that appear elsewhere in this prospectus and the â€œAudited Consolidated Financial Statements of Firefly Neuroscience, Inc. for the years ended December 31, 2023 and 2022â€ and the related notes that appear elsewhere in this prospectus. Our historical results do not necessarily reflect what our historical financial position and results of operations would have been had we been a stand-alone public company during the periods presented. In addition, our historical results are not necessarily indicative of the results to be expected for any future period. Â In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in the sections titled â€œRisk Factorsâ€ and â€œSpecial NoteÂ Regarding Forward-Looking Statementsâ€ in this prospectus. Â Unless the context otherwise requires, references in this â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ to â€œFirefly,â€ â€œweâ€, â€œusâ€, â€œourâ€, and the â€œCompanyâ€ are intended to refer to the business and operations of Firefly Neuroscience, Inc. and its consolidated subsidiaries following the Merger., and (ii) prior to the Merger, Firefly Neuroscience, Inc. (the predecessor entity in existence prior to the consummation of the Business Combination) and its consolidated subsidiaries. Â Overview Â Firefly is an Artificial Intelligence (â€œAIâ€) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Its FDA-510(k) cleared Brain Network Analytics software platform (the â€œBNA Platformâ€) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It has taken a period of 15 years and an investment of approximately $60 million, to develop the software, compile the requisite database of brain wave tests, gain patent protection, and receive Federal Drug Administration (â€œFDAâ€) approval to market and sell the BNA Platform so, as of today, Firefly is in a position to undertake a commercial launch of the BNA Platform. Firefly believes there is great potential for such commercialization, both with respect to pharmaceutical companies in their drug research and clinical trial activities, as well as medical practitioners in their clinics. Â The BNA Platform is a software as a medical solution that was developed using AI and machine learning on Fireflyâ€™s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (â€œEEGâ€) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition). These insights can enhance a clinicianâ€™s ability to accurately diagnose mental illnesses and cognitive disorders and to evaluate what therapy or drug is best suited to optimize a patientâ€™s outcome. Â The clinical utility of EEG technology to support better outcomes for patients with mental illnesses and cognitive disorders has been well documented. Historically, clinical adoption of EEG by medical professionals, including psychiatrists, neurologists, nurse practitioners and general practitioners, has been limited due to the complexity of interpreting EEG recordings and the inability to practically compare a patientâ€™s brain function to that of a clinically normal age-matched patient. Firefly believes that without defining a standard deviation to the norm, it is not possible to objectively assess brain function. By establishing an objective baseline measurement of brain function, the BNA Platform enables clinicians to optimize patient care, leading to improved outcomes for people suffering from mental illnesses and cognitive disorders. Â Fireflyâ€™s value proposition is supported by real-world use of the BNA Platform. Incorporating the BNA Platform as part of a patient management protocol demonstrated improved response rates, enhanced therapy compliance, reduced non-responder rates and a reduction in need for medication switching among patients. Further, Firefly believes that its extensive clinical database, when combined with advanced AI, provides the opportunity to identify clinically relevant biomarkers that will support better patient outcomes through precision medicine and companion diagnostics. We expect to gather additional data through the clinical deployments and clinical studies conducted by drug companies. This additional data should allow us to discover new biomarkers and objectively measure the impact of therapeutic interventions on patients of different types, further enhancing our platformâ€™s effectiveness. Firefly believes that it will be able to enhance accurate diagnosis and predict what therapy or drug, or a combination thereof, is best suited to optimize patient outcomes. This represents a paradigm shift in how clinicians manage patients with mental illnesses and cognitive disorders holding the potential to transform brain health. Â 36 Â Â Recent Developments Â Merger with WaveDancer, Inc. On November 15, 2023, we entered into the Agreement and Plan of Merger (as amended, the â€œMerger Agreementâ€) with WaveDancer and FFN Merger Sub, Inc. (â€œMerger Subâ€), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub merged with and into Firefly, with Firefly becoming a wholly-owned subsidiary of WaveDancer and the surviving corporation of the merger (the â€œMergerâ€). On August 12, 2024, prior to the consummation of the Merger, WaveDancer effectuated a 1-for-3 reverse stock split of its common stock (the â€œReverse Stock Splitâ€). On August 12, 2024, the Merger closed, and on August 13, 2024, we began trading on the Nasdaq Capital Market (â€œNasdaqâ€) under the ticker symbol â€œAIFF.â€ Â Private Placement Â On July 26, 2024, prior to the consummation of the Merger, we entered into a securities purchase agreement with certain institutional investors, pursuant to which we agreed to issue and sell (i) 3,069,287 shares (the â€œPIPE Sharesâ€) of Common Stock and (ii) pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 504,323 shares of our Common Stock, and (iii) warrants (the â€œWarrantsâ€) to purchase up to 823,530 shares of Common Stock in a private placement (the â€œPrivate Placementâ€). The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the Merger. The aggregate gross proceeds from the transaction were approximately $3.5 million, before deducting estimated offering expenses payable by us. Â Series C Financing Â Between October 17, 2023 and June 30, 2024, we raised an aggregate of $3,039,000 from a private placement of 2,374,219 Series C units (the â€œSeries C Unitsâ€), which such Series C Units were comprised of shares of Series C Preferred Stock and warrants (the â€œSeries C Warrantsâ€) to purchase up to 2,374,665 shares of Common Stock, which were sold at a combined purchase price of $1.28 per Series C Unit. Each Series C Warrant has an exercise price of $2.56 per share (subject to adjustment from time to time in accordance with the terms thereof), is exercisable immediately upon issuance and expires at 4:30 p.m. (New York time) three years following the initial date of issuance. Â Components of Results of Operations Â Revenue Â Revenue consists of BNA testing and the undertaking of projects. Â Operating Expense Â Research and Development Expense Â Research and development expenses represent costs incurred to conduct research and development, such as the development of the BNA Platform. Firefly recognizes all research and development costs as they are incurred. Research and development expenses consist primarily of the following: Â Â â— salaries and benefits; Â â— consulting arrangements; and Â â— other expenses incurred to advance Fireflyâ€™s research and development activities. Â 37 Â Â The largest component of Fireflyâ€™s operating expenses has historically been the investment in research and development activities. Firefly expects research and development expenses will increase in the future as Firefly further refines and optimizes the BNA Platform and invests in is evolution. It is likely that Firefly will continue to evaluate opportunities and strategic partnerships to acquire or license other products and technologies, which may result in higher research and development expenses due to licensing fees and/or integrations. Â Selling and Marketing Expenses Â Selling and marketing expenses consist of employee-related expenses, including salaries, benefits, travel, clinical fees and other marketing functions, as well as fees paid for consulting services. Â General and Administrative Expenses Â General and administrative expenses consist of employee-related expenses, including salaries, benefits, travel and noncash stock-based compensation, and other administrative functions, as well as fees paid for legal, and accounting services, consulting fees and facilities costs not otherwise included in research and development expense. Legal costs include general corporate legal fees and patent costs. Firefly expects to incur additional expenses as a result of operating as a public company following completion of the merger, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services. Â Other (Income) Expense Â Other (income) expense consists primarily of interest bank fees and loan fees, foreign exchange gain or loss, loss on extinguishment of debt, gain or loss on sale of investments and gain or loss on sales of fixed assets. Â Critical Accounting Estimates Â The preparation of our financial statements is in accordance with generally accepted accounting principles in the United States of America, which require us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and other related disclosures. While we believe our estimates, assumptions and judgments are reasonable, they are based on information presently available. Actual results may differ significantly from these estimates due to changes in judgments, assumptions and conditions as a result of unforeseen events or otherwise, which could have a material impact on our financial position and results of operations. Â 38 Â Â Results of Operations Â Comparison of the three months ended June 30, 2024, to the three months ended June 30, 2023 Â The following tables set forth Fireflyâ€™s results of operations for the periods presented:Â Â Â Â Three months ended June 30, Â Â Â Â Â Â Â $US, in thousands Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Â Â Â Â Â Â Â Â Â Â Â Â REVENUE Â Â 10 Â Â Â 451 Â Â Â (441) OPERATING EXPENSES: Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses Â Â 350 Â Â Â 199 Â Â 151 Â Selling and marketing expenses Â Â 293 Â Â Â 171 Â Â Â 122 Â General and administration expenses Â Â 626 Â Â Â 399 Â Â Â 227 Â TOTAL OPERATING EXPENSES Â Â 1,269 Â Â Â 769 Â Â Â 500 Â Â Â Â Â Â Â Â Â Â Â Â Â OPERATING LOSS Â Â 1,259 Â Â Â 318 Â Â Â 940 Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER (INCOME) EXPENSE Â Â Â Â Â Â Â Â Â Â Â Â Interest, bank fees and loan fees Â Â 10 Â Â Â 3 Â Â Â 6 Â Unrealized (gain) loss on foreign exchange Â Â (31) Â Â - Â Â Â (31) Other (Income) Expenses Â Â 26 Â Â Â 2 Â Â Â 24 Â LOSS BEFORE INCOME TAX Â Â 1,264 Â Â Â 323 Â Â Â 941 Â Â Revenue Â Revenue for theÂ three months ended June 30, 2024, was $10,000, as compared to $451,000 in the three months ended June 30, 2023, representing a decrease of $441,000 or 98%. The decrease is primarily due to the recognition of deferred revenue relating to outstanding contracts when obligations were deemed to be fulfilled in 2023. Â Operating ExpensesÂ Â Research and Development Expenses Â Research and development expensesÂ for theÂ three months ended June 30, 2024, were $350,000, as compared to $199,000Â for theÂ three months ended June 30, 2023, representing an increase of $151,000, or 76%. This increase was primarily due to a significant increase in investment in staff associated with the development of our next generation of BNA Platform. Â Selling and Marketing Expenses Â Selling and marketing expenses for the three months ended June 30, 2024, were $293,000, as compared to $171,000 for the for theÂ three months ended June 30, 2023, representing an increase of $122,000, orÂ 71%. This increase was primarily due to our updating of company branding in preparation of the reverse merger and market research initiatives related to our next generation BNA Platform.Â Â General and Administrative ExpensesÂ Â General and administrative expenses for the three months ended June 30, 2024, were $626,000, as compared to $399,000 for theÂ three months ended June 30, 2023, representing an increase of $227,000, or 57%. This increase was primarily due to ongoing legal and professional costs associated with the Merger, as well as preparation of year-end audited statements and review of our unaudited financial statements for the quarter ended March 31, 2024. Â 39 Â Â Other (Income) Expense Â Other (Income) Expense for the three months ended June 30, 2024, were $5,000, as compared to $5,000 for the three months ended June 30, 2023, representing a minimal change. Â Comparison of the six months ended June 30, 2024, to the six months ended June 30, 2023 Â The following tables set forth Fireflyâ€™s results of operations for the periods presented: Â Â Â Six months ended June 30, Â Â Â Â Â Â Â $US, in thousands Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Â Â Â Â Â Â Â Â Â Â Â REVENUE Â Â 22 Â Â Â 456 Â Â Â (434) OPERATING EXPENSES: Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses Â Â 639 Â Â Â 320 Â Â Â 319 Â Selling and marketing expenses Â Â 542 Â Â Â 304 Â Â Â 238 Â General and administration expenses Â Â 1,191 Â Â Â 696 Â Â Â 495 Â TOTAL OPERATING EXPENSES Â Â 2,372 Â Â Â 1,320 Â Â Â 1,052 Â Â Â Â Â Â Â Â Â Â Â Â Â OPERATING LOSS Â Â 2,350 Â Â Â 864 Â Â Â 1,486 Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER (INCOME) EXPENSE Â Â Â Â Â Â Â Â Â Â Â Â Interest and bank fees Â Â 12 Â Â Â 10 Â Â Â 2 Â Unrealized (gain) loss on foreign exchange Â Â (3) Â Â - Â Â Â (3) Other (income) expense Â Â 27 Â Â Â 2 Â Â Â 25 Â NET LOSS Â Â 2,386 Â Â Â 876 Â Â Â 24 Â Â Â Revenue Â Revenue for the six months ended June 30, 2024, was $22,000, as compared to $456,000 in the six months ended June 30, 2023, representing a decrease of $434,000 or 95%. The decrease is primarily due to the recognition of deferred revenue relating to outstanding contracts when obligations were deemed to be fulfilled in 2023. Â Operating Expenses Â Research and Development Expenses Â Research and development expenses for the six months ended June 30, 2024, were $639,000, as compared to $320,000 for the six months ended June 30, 2023, representing an increase of $319,000, or 100%. This increase was primarily due to a significant increase in investment in staff associated with

the development of our next generation of BNA Platform. Â Selling and Marketing Expenses Â Selling and marketing for the six months ended June 30, 2024, were $542,000, as compared to $304,000 for the for the six months ended June 30, 2023, representing an increase of $238,000, or 74%. This increase was primarily due to our updating of company branding in preparation of the reverse merger, market research initiatives related to our next generation BNA Platform and professional services related to sales documentation. Â 40 Â Â General and Administration Expenses Â General and administration expenses for the six months ended June 30, 2024, were $1,191,000, as compared to $696,000 for the six months ended June 30, 2023, representing an increase of $495,000, or 71%. This increase was primarily due to ongoing legal and professional costs associated with the Merger, as well as preparation of year-end audited statements and review of our unaudited financial statements for the quarter ended March 31, 2024. Â Other (income) expense Â Other (income) expense for the six months ended June 30, 2024, were $36,000, as compared to $12,000 for the six months ended June 30, 2023, representing an increase of $24,000 mainly due to foreign exchange fluctuations associated with operations in Canada and Israel. Â Comparison of the year ended December 31, 2023, to the year ended December 31, 2022 Â The following tables set forth Fireflyâ€™s results of operations for the periods presented: Â Â Â Year Ended December 31, Â Â Â Â Â Â Â $US, in thousands Â Â Â Â Â Â Â 2023 Â Â 2022 Â Â Change Â Â Â Â Â Â Â Â Â Â Â Â Â REVENUE Â Â 498 Â Â Â - Â Â Â 498 Â OPERATING EXPENSES: Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses, net Â Â 741 Â Â Â 1,299 Â Â Â (558) Selling and marketing expenses Â Â 639 Â Â Â 524 Â Â Â 115 Â General administration expenses Â Â 2,196 Â Â Â 1,542 Â Â Â 654 Â Impairment Loss on equipment Â Â - Â Â Â 79 Â Â Â (79) TOTAL OPERATING EXPENSES Â Â 3,576 Â Â Â 3,444 Â Â Â 132 Â Â Â Â Â Â Â Â Â Â Â Â Â OPERATING LOSS Â Â (3,078) Â Â (3,444) Â Â 366 Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER (INCOME) EXPENSE Â Â Â Â Â Â Â Â Â Â Â Â Interest, bank fees and loan fees Â Â 18 Â Â Â 440 Â Â Â (422) Unrealized (gain) loss on foreign exchange Â Â (37) Â Â 134 Â Â Â (171) Loss on extinguishment of debt Â Â - Â Â Â 59 Â Â Â (59) Other (Income) Expenses Â Â (457) Â Â (173) Â Â (284) LOSS BEFORE INCOME TAX Â Â (2,602) Â Â (3,904) Â Â (1,302) Â Â Â Â Â Â Â Â Â Â Â Â Â Income Tax Provision Â Â 1 Â Â Â - Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â NET LOSS AND COMPREHENSIVE LOSS Â Â (2,603) Â Â (3,904) Â Â (1,301) Â 41 Â Â Revenue Â Revenue for the year ended December 31, 2023, was $498,000, an increase of $498,000 compared to the year ended December 31, 2022. The increase is primarily due to satisfying performance obligations of a contract resulting in deferred income being recognized. Â Operating Expenses Â Research and Development Â Research and development expense for the year ended December 31, 2023, was $741,000, as compared to $1,299,000 for the year ended December 31, 2022, resulting in a decrease of $558,000. This decrease was primarily due to a reduction in staff in one of our global entities and closure of the physical office and related costs. Â Selling and Marketing Expense Â Selling and marketing expense was $639,000 for the year ended December 31, 2023, an increase of $115,000, or 22%, as compared to $524,000 for the for the year ended December 31, 2022. This increase was primarily due to bringing on staff in the latter part of 2023 and an increase in travel related to marketing the next generation BNA Platform. Â General and Administrative Expense Â General and administrative expense increased by $654,000 or 42% to $2,196,000 for the year ended December 31, 2023, as compared to $1,542,000 for the year ended December 31, 2022. This increase was primarily due to ongoing legal and professional costs associated with the contemplated business combination with WaveDancer, Inc., as well as preparation of year end audited statements. Â Impairment Loss Â The impairment loss for the year ended December 31, 2023, was $0, as compared to $79,000 for the year ended December 31, 2022 resulting in a decrease of $79,000. This decrease was due to antiquated hardware being deprecated in 2022. Â Liquidity and Capital Resources Â Going Concern Â As of June 30, 2024, we had an accumulated deficit of $79,010,000 (December 31, 2023: $76,624,000) and negative cash flow from operating activities for the six months ended June 30, 2024 of $2,418,000 (June 30, 2023: $936,000). Further, we have recurring losses with minimal revenue from operations. While we are attempting to raise funds for commercialization, our monthly cash requirements during the six months ended June 30, 2024 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about our ability to continue as a going concern. Therefore, we may be unable to realize our assets and discharge our liabilities in normal course of business. To strengthen our liquidity in the foreseeable future, we have taken the following measures: Â (i) Â Negotiating further funding with existing and new investors to raise additional capital; Â (ii)Â Taking various cost control measures to reduce the operational cash burn; and Â (iii) Commercializing product to generate recurring sales. Â Management has a reasonable expectation that we can continue raising additional equity capital to continue in operational existence for the foreseeable future. Â 42 Â Â Sources of Liquidity Â For the remainder of fiscal year 2024 and the first half of 2025, we expect to continue to incur negative cash flows from operations as we continue to make targeted investments in sales and marketing and research and development of our next generation BNA Platform. Â Beyond the next 12 months, our ability to achieve profitability depends on the commercialization of our flagship product, the BNA Platform. We expect to incur significant costs for at least two to four years to commercialize and distribute our products, and we expect our expenses to increase in connection with our ongoing activities, particularly as we continue our research and development and expand our production capabilities as needed. As a result, we will require significant capital to support our ongoing operations and to drive our business strategy before we can be profitable. Â Until we can generate adequate revenues from the sale of our products to cover our operating expenses and capital expenditure requirements, we expect to finance our operations through the sale of equity, debt financing, or other sources. There can be no guarantee that debt or equity financings will be available to us on commercially reasonable terms, if at all. Additionally, we may be unable to further pursue our business plan and we may be unable to continue operations. The report of our independent registered public accounting firm for the year ended December 31, 2023, states that there is substantial doubt about our ability to continue as a going concern. Â The estimates and assumptions underlying our belief in the sufficiency of our capital resources in the short term and our ability to obtain capital resources in the long term may prove to be wrong, and we could exhaust our capital resources sooner than we expect and may not be able to obtain resources on favorable terms, or at all. Â We do not have any off-balance sheet arrangements. Â Cash flows for the six months ended June 30, 2024, compared to the six months ended June 30, 2023 Â The following table sets forth the significant sources and uses of cash for the periods noted below: Â Â Â For the six months ended June 30, Â Â Â 2024 Â Â 2023 Â Â Change Â Â Â (in thousands) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net cash (used in) provided by Â Â Â Â Â Â Â Â Â Â Â Operating activities Â $ (2,418) Â $ (936) Â $ (1,482,000) Investing activities Â $ (312) Â $ - Â Â $ (312) Financing activities Â $ 945 Â Â $ 1,225 Â Â $ (280) Â Operating Activities Â For the six months ended June 30, 2024, net cash used in operating activities was $2,418,000, as compared to $936,000 for the six months ended June 30, 2023, representing an increase of $1,482,000, or 158%. This increase in net cash used in operating activities is primarily due to an increase in day-to-day operating costs, a reduction in liabilities, costs related to the Merger, and research costs associated with the development of the next generation BNA Platform. Â Investing Activities Â For the six months ended June 30, 2024, net cash used in investing activities was $312,000, as compared to no cash used in investing activities for the six months ended June 30, 2023. The increase in cash used in investing activities is primarily attributed to our investment into the development of the next generation BNA Platform and associated hardware. Â Financing Activities Â For the six months ended June 30, 2024, net cash provided from financing activities was $945,000, as compared to $1,225,000 for the six months ended June 30, 2023, representing a decrease of $280,000, or 23%. The decrease was primarily due to a reduction in financing needs year-to-year as well as acknowledging financing has been secured post-Merger. Â 43 Â Â Cash flows for the year ended December 31, 2023, compared to the year ended December 31, 2022 Â The following table sets forth the significant sources and uses of cash for the periods noted below: Â Â Â For the year ended December 31, Â Â Â 2023 Â Â 2022 Â (in thousands) Â Â Â Â Â Â Â Â Net cash (used in) provided by Â Â Â Â Â Â Â Â Operating activities Â $ (2,172) Â $ (2,892) Investing activities Â $ (386) Â $ 262 Â Financing activities Â $ 4,643 Â Â $ 2,035 Â Â Operating Activities Â For the year December 31, 2023, cash used in operating activities was $2,172,000, as compared to $2,892,000 for the year December 31, 2022. This increase in cash used is primarily due an increase in liabilities, a decrease in interest on convertible debt and recognition of deferred revenue. Â Investing Activities Â For the year December 31, 2023, net cash used in investing activities was $386,000, as compared to cash provided by investing activities of $ 262,000 for the year December 31, 2022, which was primarily attributed to our investment into the development of the next generation BNA Platform in 2023 and the sale of deprecated equipment in 2022. Â Financing Activities Â For the year December 31, 2023, net cash provided from financing activities was $4,643,000, as compared to $2,035,000 for the year December 31, 2022. The increase of $2,608,000 was primarily due to the proceeds from Series B and Series C financing and ceasing the sale of convertible debt. Â Other (Income) Expense Â Other Income for the year ended December 31, 2023, was $476,000 as compared to Losses of ($460,000) for the year December 31, 2022, resulting in a decrease of Other Expenses of $936,000. This is primarily due to a decrease in convertible loan fees, a decrease in foreign exchange losses and a contract expiring resulting in deferred income being recognized. Â Known Trends, Events, and Uncertainties Â As with other companies that are in our industry, we will need to successfully manage normal business and scientific risks. Research and development of new technologies is, by its nature, unpredictable. We cannot assure you that our technology will be adopted, that we will ever earn revenues sufficient to support our operations, or that we will ever be profitable. In addition, the emergence and effects of public health crises, such as endemics and epidemics are difficult to predict and the consequences of the ongoing war between Israel and Hamas, including related sanctions and countermeasures and the effects of such war on our employees in Israel, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions, the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations. Furthermore, other than as discussed in this prospectus, we have no committed source of financing and may not be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations. Â Other than as discussed above and elsewhere in this prospectus, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition. Â 44 Â Â Â Critical Accounting Policies and Estimates Â The preparation of our financial statements is in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€), which require us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and other related disclosures. While we believe our estimates, assumptions and judgments are reasonable, they are based on information presently available. Actual results may differ significantly from these estimates due to changes in judgments, assumptions and conditions as a result of unforeseen events or otherwise, which could have a material impact on our financial position and results of operations. Â Quantitative and Qualitative Disclosures about Market Risk Â Not applicable. Â 45 Â Â BUSINESS Â Overview Â Firefly is an Artificial Intelligence (â€œAIâ€) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Its FDA-510(k) cleared Brain Network Analytics software platform (the â€œBNA Platformâ€) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It has taken a period of 15 years and an investment of approximately $60 million, to develop the software, compile the requisite database of brain wave tests, gain patent protection, and receive Federal Drug Administration (â€œFDAâ€) approval to market and sell the BNA Platform so, as of today, Firefly is in a position to undertake a commercial launch of the BNA Platform. Firefly believes there is great potential for such commercialization, both with respect to pharmaceutical companies in their drug research and clinical trial activities, as well as medical practitioners in their clinics. Â The BNA Platform is a software as a medical solution that was developed using AI and machine learning on Fireflyâ€™s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (â€œEEGâ€) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. The BNA Platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition). These insights can enhance a clinicianâ€™s ability to accurately diagnose mental illnesses and cognitive disorders and to evaluate what therapy or drug is best suited to optimize a patientâ€™s outcome. Â The clinical utility of EEG technology to support better outcomes for patients with mental illnesses and cognitive disorders has been well documented. Historically, clinical adoption of EEG by medical professionals, including psychiatrists, neurologists, nurse practitioners and general practitioners, has been limited due to the complexity of interpreting EEG recordings and the inability to practically compare a patientâ€™s brain function to that of a clinically normal age-matched patient. Firefly believes that without defining a standard deviation to the norm, it is not possible to objectively assess brain function. By establishing an objective baseline measurement of brain function, the BNA Platform enables clinicians to optimize patient care, leading to improved outcomes for people suffering from mental illnesses and cognitive disorders. Â Fireflyâ€™s value proposition is supported by real-world use of the BNA Platform. Incorporating the BNA Platform as part of a patient management protocol demonstrated improved response rates, enhanced therapy compliance, reduced non-responder rates and a reduction in need for medication switching among patients. Further, Firefly believes that its extensive clinical database, when combined with advanced AI, provides the opportunity to identify clinically relevant biomarkers that will support better patient outcomes through precision medicine and companion diagnostics. We expect to gather additional data through the clinical deployments and clinical studies conducted by drug companies. This additional data should allow us to discover new biomarkers and objectively measure the impact of therapeutic interventions on patients of different types, further enhancing our platformâ€™s effectiveness. Firefly believes that it will be able to enhance accurate diagnosis and predict what therapy or drug, or a combination thereof, is best suited to optimize patient outcomes. This represents a paradigm shift in how clinicians manage patients with mental illnesses and cognitive disorders holding the potential to transform brain health. Â Background and Corporate History Â Corporate History Â Fireflyâ€™s corporate history began in April 2006 with the formation of Elminda Ltd, a company organized under the laws of the State of Israel, for the purpose of developing a system to provide clinicians with an objective assessment of brain function to support better outcomes for people with mental illnesses and cognitive disorders. Â Firefly spent over ten years building a significant database of standardized longitudinal EEG brain scans using clinically defined paradigms that captured patients brain activity while resting and while activated (evoke response potential). Firefly collected this data in over 100 sites, over 20 countries, and over 40 studies. Significant time and resources went into analyzing and interpreting the data as well as preparing for an FDA 510k application process. Â 46 Â Â On May 2, 2014, management of Firefly Neuroscience Ltd. incorporated a new wholly owned subsidiary company named â€œElminda Inc.â€ in the State of Delaware for the purpose of initiating the companyâ€™s United States marketing and distribution activity. Â In July 2014, Firefly received Class II medical device 510(k) clearance from the U.S. Food and Drug Administration (the â€œFDAâ€) for the BNA Analysis System, the predicate device to the BNA Platform, with indication for use in individuals 14 to 24 years of age. Â In September 2014, the company received the Conformity European approval for the BNA Platform allowing use in European Economic Area. Â In December 2020, Firefly received Class II medical device 510(k) clearance from the FDA for Fireflyâ€™s current product, the BNA Platform, with indication for use in individuals 12 to 85 years of age. Â On April 13, 2022, the name of Elminda Inc. was changed to â€œElminda 2022 Inc.â€ Â On April 21, 2022, management of Firefly Neuroscience Ltd. incorporated a new wholly owned subsidiary company named â€œElminda Inc.â€ for the purpose of re-domiciling the company to enhance access to capital markets. Â On July 5, 2022, Elminda Ltd. became a subsidiary of Elminda Inc. via a share exchange agreement wherein Elminda Inc. issued shares to shareholders of Elminda Ltd. against shares of Elminda Ltd. Â On September 15, 2022 and October 24, 2022 management changed the name from Elminda Inc. and Elminda Ltd, respectively, to â€œFirefly Neuroscience, Inc.â€ and â€œFirefly Neuroscience Ltd.â€, respectively. Â On the August 12, 2024, pursuant to the Merger Agreement, FFN merged with and into Firefly Neuroscience, Inc., with Firefly Neuroscience, Inc. surviving the merger as a wholly owned subsidiary of WaveDancer, Inc. On the Closing Date (i) pursuant to the Amended and Restated Certificate of Incorporation of WaveDancer, we changed our name to Firefly Neuroscience, Inc. and (ii) pursuant to an amendment to its Certificate of Incorporation, Firefly changed its name to Firefly Neuroscience 2023, Inc. and (iii) Firefly and FFN filed the Certificate of Merger with the State of Delaware. Â Our Strategy Â We are dedicated to transforming brain health by advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders. Fireflyâ€™s strategy is to develop state-of-the-art technologies that bridge the gap between neuroscience and clinical practice. Fireflyâ€™s next steps to realize this strategy include: Â Commercially launching the BNA Platform to medical professionals, including neurologists, psychiatrists, nurse practitioners, and general practitioners in the United States. Firefly believes that there are significant clinical, societal, and economic benefits that can be realized when BNA Platform is used as part of a regular patient management protocol. Firefly aims to realize these benefits by providing medical professionals and their patients with objective, comparative data of their brain function (cognition). Poor outcomes associated with the treatment of mental illnesses and cognitive disorders often result from the subjective, trial and error approach to patient treatment. Through the BNA Platform, Firefly brings an objective quantifiable measurement of brain function (cognition) to medical professionals who are treating people suffering from mental illnesses and cognitive disorders. Â Firefly believes that by providing clinicians with the ability to compare a patientâ€™s EEG recordings to its FDA-cleared normative age-matched database will give both the clinician and the patient an objective baseline comparison of their brain function (cognition) that could aid in the diagnosis and optimization of the patientâ€™s treatment pathway. This strategy is supported by the fact that real-world clinical use of the BNA Platform has shown that, when used as part of a patient management protocol, patients showed improved response rates, enhanced therapy compliance, and reduced non-responder rates and a reduction in the need for medication

switching. Â 47 Â Â In addition to improving patient outcomes, there is a strong motivation for medical professionals to integrate the BNA Platform into their clinics. The BNA Platform is a new recurring revenue stream opportunity for the medical practitioner while providing new patient management strategies to improve patient outcomes. In addition, the adoption of the BNA Platform represents an incremental recurring revenue opportunity to the clinic and is a competitive advantage for the clinic. Â Performing research and clinical studies to identify clinically relevant biomarkers that could support diagnosis and possibly identify patients who are most likely to positively respond to a certain drug or treatment. Firefly is continuously improving the BNA Platform by actively analyzing its comprehensive database, which includes clinical and behavioral data, to discover biomarkers that can support diagnosis and optimize patient care pathways. In doing so, Firefly intends to empower the practitioners to apply principles of precision medicine to improve outcomes for people suffering from mental illnesses and cognitive disorders. By utilizing the Companyâ€™s ML pipeline to analyze its database, it is possible to identify patterns (EEG-based biomarkers) that are useful for predicting treatment outcomes (predictive biomarkers), predicting disease progression (prognostic biomarkers) and monitoring treatment effects (monitoring biomarkers). Leveraging such biomarkers can inform patient selection and stratification in clinical trials in a way that will optimize trial design, leading to improved outcomes while reducing the cost and time it takes to obtain approval for the drug. Â Partnering with leading drug development companies in the central nervous system (â€œCNSâ€) space in support of clinical research and companion diagnostics. Firefly is focused on growing its CNS pharmaceutical company partnerships for drug development. Based on the work Firefly has done with pharmaceutical companies like Novartis, Takeda Pharmaceutical Company Limited, Bright Mind Bioscience and others, Firefly believes that EEG data, processed by the BNA Platform, can be effective in CNS drug development by providing objectively measured brain activations that indicate normal or pathological neuronal processes. The BNA-based EEG data can be used as objective endpoints for pharmacokinetic-pharmacodynamic modelling. Moreover, by measuring electrophysiology commonly associated with cognitive functions, BNA biomarkers can also assist in understanding the drugâ€™s effects in the cognitive domain and identifying adverse cognitive events. By enabling a quantitative and objective measurement of the change in brain function following a treatment, drug developers could further optimize dose selection for next phases of development. Â Management believes that through integration of the BNA Platform into drug development strategies, CNS pharmaceutical companies can realize significant savings of both cost and time by understanding a drugâ€™s effect better and targeting patients who will respond better to the drug (patient enrichment). Improving patient targeting and effects on patient populations segments could lead to demonstrable improvement in clinical efficacy. Â Many new CNS drugs being developed are considered to be high cost, often having annual costs of tens of thousands of dollars. There is considerable resistance from healthcare providers, governments, and Insurers to absorb the high cost of new CNS drugs without knowing who is most likely to benefit from the drug. Firefly believes that biomarkers represent a significant opportunity for drug development companies and practicing medical professionals. For drug development companies, conducting clinical trials with patients who are more likely to respond positively to the drug (patient enrichment) can reduce the clinical trial size required to show positive clinical outcomes (efficacy) and significantly reduce the cost and speed of clinical trials. Furthermore, the ability to show increased efficacy of the drug within a targeted patient group could expedite regulatory approval and provide justification for the cost of the new drug with payors. In concert with Fireflyâ€™s commercialization strategy, medical professionals who integrate the BNA Platform into their clinic will be able to prescribe the drug to their patients who will benefit the most based on the companion diagnostic criteria Â Considering strategic acquisitions. Firefly may consider strategic acquisition opportunities where such transactions can accelerate Fireflyâ€™s market positioning through horizontal or vertical integration, expanding capacity, or gaining intellectual property that strengthens its competitive advantage. Â Firefly believes that it is in a strong position to drive the adoption of objective assessment of brain function in clinical practice by making the BNA Platform accessible to medical professionals in the United States and other countries around the world. Initial clinical use of the BNA Platform has demonstrated significant improvements in patient outcomes. Based on this, Firefly believes that the BNA Platform has the potential to deliver significant benefits within the healthcare system to a broad range of stakeholders - patients, clinicians, and payors. Â 48 Â Â Our Solution - The BNA Platform Â Our Database Â The BNA Platform is an FDA 510(k) cleared product and is a direct result of applying data science AI and ML expertise to Fireflyâ€™s extensive proprietary database of standardized, high-definition longitudinal EEG recordings of over 17,000 (77,000 BNA assessments) patients representing twelve disorders, as well as clinically normal patients. Â Fireflyâ€™s proprietary database will continue to grow with each use of the BNA Platform in the clinical and research settings, which, through its application of AI and ML, will allow the insights to continuously evolve and improve with the goal of continually increasing the value proposition of the BNA Platform to clinicians and pharmaceutical company clients. Firefly believes that this virtuous cycle will result in future product development, like biomarkers that will drive the commercial adoption of the BNA Platform to a wider universe of medical professionals, and also enhance its value proposition to drug development companies. Â The BNA Platform Â The BNA Platform is intended for the post-hoc statistical analysis of the human EEG, utilizing both resting-state EEG and Event-Related Potentials (â€œERPâ€) in a patientâ€™s response to outside stimuli during various states of alertness, disease, diagnostic testing, treatment, surgery, or drug related dysfunction. An ERP (or â€œevoked responseâ€) is an electrical potential recorded from the nervous system following the presentation of a stimulus (e.g., as part of a cognitive task). An ERP signal consists of typical ERP components - positive or negative voltage spatiotemporal peaks within the ERP waveform that are measured within one second post-stimulus presentation. Â The system consists of the following components: a computer environment; EEG data input software algorithms for BNA calculations; a report generator and a functionality for data transfer and storage. In the first step EEG data is measured using a dedicated, commercially available, and FDA-cleared EEG system, which complies with the BNA Platform specifications. The BNA Platform processes and analyzes the data using Fireflyâ€™s BNA Algorithm (as further described below). Lastly, the results are compiled into individualized easy-to-read reports that provide clinicians with objective insight into brain function. Each incremental scan further supports the growth of Fireflyâ€™s reference database. The steps are described in further detail below. Â Â Figure 1. Overview of the BNA Platform Process Â Measure - EEG Data Â The BNA Platform is intended to analyze EEG data recorded at rest (â€œResting-EEGâ€) and during the performance of two conventionally used ERP tasks: the Auditory Oddball (â€œAOBâ€) and the Visual Go-No-Go (â€œVGNGâ€). The EEG is recorded continuously while the patient is at rest with eyes-closed or performs one of the ERP tasks. This is highly useful to clinicians as the information from the Resting-EEG and ERP tasks are complementary to each other in many ways. The BNA Platform thus empowers clinicians by providing them with a multi-perspective, objective evaluation of the patientâ€™s brain function in one product. The acquisition site is then asked to provide reliable samples of artifact-free digital EEG for purposes of analysis. Â 49 Â Â Â Â Figure 2. EEG Data Inputs Â Analyze - The BNA Algorithm Â After the recording, the artifact-free EEG data is imported into the BNA Platform and is automatically analyzed by the algorithm (the â€œBNA Algorithmâ€). The BNA Algorithm does so by detecting and quantifying the characteristics of EEG and ERP peaks (AOB task: P50, N100, P200, P3a, P3b; VGNG task: P200, N200, P3a, P3b). The BNA Algorithm leverages Fireflyâ€™s normative database to extract clinically meaningful information from EEG data. Â EEG recordings are high-dimensional and complex. This is the result of the dynamic spatiotemporal nature of the neurophysiological signals. For example, the event-related potential wave measured at first, at a relatively focal location in time and space on the scalp, and then it evolves and propagates in the cortex while its amplitude changes simultaneously. Â Traditional methods for EEG and ERP analysis follow waveform morphology over time at selected electrode locations, using either time-domain or frequency-domain tools, while neglecting the spatiotemporal dynamics associated with the electric field at the scalp. Moreover, focusing on a specific electrode or subset of electrodes, the traditional methods ignore the expected variability between patients in terms of where the ERP component appears on the scalp due to natural differences between cortex and scalp anatomy. The aim of the BNA Algorithm is to improve the accuracy of the ERP component detection by considering the spatiotemporal nature of the signal. It achieves this improvement by parceling the EEG activity into major spatiotemporal events - ERP peaks and their surrounding - spatiotemporal parcels. Â The key strengths of the BNA Algorithm are: Â Â 1.Â Â Â Â Â Â Â Â Â Â Adaptive peak detectionÂ - the ERP peaks are detected in a more patient-specific way, by incorporating some degree of freedom in both time and space in a way that is proportional to the normal variability in time and space of the ERP peaks. Â Â 2.Â Â Â Â Â Â Â Â Â Â Displaying ERP-peak locationÂ - thanks to the adaptive peak detection by the BNA Algorithm, the ERP peak is identified and displayed in the BNA report on a topographical map together with the group ERP-peak position. This adds clinically useful information to the physician. Â Â 3.Â Â Â Â Â Â Â Â Â Â Neural-Consistency scoreÂ - another unique feature of the BNA report is the presentation of the Neural-Consistency score. Since this is a differentiating score, the Company will describe here shortly what this score is and why Firefly believes it is important. Â 50 Â Â Since the ERP signal is an average of multiple single-trial ERP signals which can differ largely from each other, assessing the consistency between them may provide complementary functional information to the average measure. As part of the new peak-analysis, the algorithm calculates a new score - â€˜Neural Consistencyâ€™ based on the similarity of the amplitude activation between single-ERP trials. The score is calculated based on averaging the inter-single trials variability of the ERP-peak and its surrounding points. Â Act - Individualized Reports Â The results of the data processed by the BNA Algorithm are compiled into individualized easy-to-read reports that provide clinicians with objective insight into brain function: Â Â â—Â Â Â Â Â Â Â Â Â Â ERP Report â—Â Â Â Â Â Â Â Â Â Â Behavioral Report â—Â Â Â Â Â Â Â Â Â Â Summary Report â—Â Â Â Â Â Â Â Â Â Â Resting-EEG Report Â Scores are presented as z-scores based on comparing the patient to an age-matched relevant reference group based on Fireflyâ€™s proprietary standardized longitudinal normative database. This presentation expresses the differences between the patient and the reference group. The reports are intended to be used by clinicians to enable the evaluation of the patientâ€™s brain activity during a specific task compared to an age-range matched reference group. Â The following diagram breaks down the components of Fireflyâ€™s normative database that underpins the BNA Platform: Â Figure 4. Components of the BNA Platform normative database. Â The database is age-differentiated, featuring control for age-related effects; includes data from Resting-EEG and ERP tasks; includes test-retest database, measuring test-retest reliability and allowing to model test-retest expected variance; and enables standardization by using z-scores, which improves clinical interpretability. Â 51 Â Â Â Â Â Figure 5. The BNA Platform Database Â Real-World Evidence for the BNA Platform Clinical Utility Â The findings presented in 2023 white paper study â€œBrain Network Analytics (BNA) in the Psychiatric Practice: Real-Life Data Analysisâ€ by Charlotte Baumeister, Ph.D., with analysis by Offir Laufer, Ph.D., strongly support the potential of the BNA Platform to transform psychiatric care by automating the analysis of EEG data. The comprehensive research involved a cohort of 2,253 patients seeking treatment at a prominent psychiatric and multispecialty clinic in the United States. The study demonstrated that the BNA Platform significantly improved disease management in psychiatric patients suffering from major depressive disorder (MDD), generalized anxiety disorder (â€œGADâ€), and ADHD. Â The study has unveiled valuable insights into how the BNA Platform can revolutionize disease management in the field of psychiatry. Key highlights from the research include: Â â—Â Â Â Â Â Â Â Â Â Â Enhanced Treatment Compliance: Patients grappling with depression, who underwent therapy guided by BNA, exhibited a significant 15% increase in their adherence to MDD treatment protocols, encompassing both antidepressant medications and Transcranial Magnetic Stimulation (TMS). Â â—Â Â Â Â Â Â Â Â Â Â Decreased Medication Alteration Necessity: The study demonstrated a noteworthy reduction of over 50% in the requirement to switch antidepressant medications among the patient population. This emphasizes the potential of the BNA Platform in optimizing medication selection and dosing. Â â—Â Â Â Â Â Â Â Â Â Â Amplified Improvements in General Functionality: Individuals diagnosed with MDD, GAD, and ADHD experienced more than double the improvement in their overall general functioning when receiving BNA-guided interventions. This suggests that BNA Platform has the potential to comprehensively enhance patients' quality of life and daily functioning. Â â—Â Â Â Â Â Â Â Â Â Â Elevated Rates of Antidepressant Response: The application of the BNA Platform was associated with a notable 10% increase in antidepressant response rates, signaling its potential to augment the effectiveness of traditional treatment approaches. Â â—Â Â Â Â Â Â Â Â Â Â Reduction in Non-Responder Rates: Among MDD patients, the study observed a significant 17% decrease in the rate of treatment non-responders, indicating that the BNA Platform holds promise in mitigating treatment resistance and improving positive outcomes. Â The study thus demonstrated that the BNA Platform represents a significant advancement in patient care in a real world setting and addressed the challenges associated with EEG utilization by medical professionals. Â 52 Â Â By automating EEG analysis and providing comprehensive insights into brain function (cognition), the BNA Platform has the potential to revolutionize disease management, enhance treatment outcomes, and improve the overall well-being of patients with mental illnesses and cognitive disorders. Based on the real-world results highlighted above, Management believes that the societal impact of better outcomes for patients suffering from mental illnesses and cognitive disorders is substantial and the associated cost savings to healthcare systems and payors could be significant. Firefly intends to study the potential health economic benefits associated with the above findings to support rapid adoption of the BNA Platform into standard patient management protocols. Â Research and Development Â Firefly focuses its research and development efforts on advancing the treatment of patients suffering from mental illnesses and cognitive disorders. These efforts are enhanced by the strong relationships that Firefly has developed with neurologists, psychiatrists, neuroscientists, and other experts. Firefly believes the BNA Platform can drive a better standard of care for patients suffering from mental illnesses and cognitive disorders. Â Fireflyâ€™s research and development activities encompass basic research and product development. Fireflyâ€™s research and development team has biomedical engineering, neuroscience, software development, project management, data science, and AI and ML expertise. Firefly believes the strength and strategic vision of its research and development team will continue to drive Fireflyâ€™s leadership position in the category of advancing the understanding of brain function in support of better outcome for Fireflyâ€™s target patient population leveraging EEG hardware with the BNA Platform. Â Fireflyâ€™s near-term research and development efforts are focused on continuing to improve the BNA Platform, enhancing the patient and provider experience, and expanding the population of patients that can be assessed with the BNA Platform. Since inception, Fireflyâ€™s research and development activities have resulted in significant improvements to the BNA Platform, Fireflyâ€™s first clearance and predicate device to the BNA Platform dates back to 2014 when Firefly received Class II medical device 510(k) clearance from FDA for the BNA Analysis System, with indication for use in individuals 14 to 24 years of age. In December 2020, Firefly received Class II medical device 510(k) clearance from the FDA for Fireflyâ€™s current product, the BNA Platform, with indication for use in individuals 12 to 85 years of age. Â Additionally, Fireflyâ€™s near-term development pipeline includes enhancements that leverage its extensive normative database, its growing database, its advanced data analysis, ML and AI capabilities to enable medical professionals to enhance their clinical assessments, and to enable drug development companies to improve the success of their drug development programs, bringing new drugs to market faster while reducing the cost and risk. Â Market Opportunity Â The market for the BNA Platform and Fireflyâ€™s future products is vast and growing significantly. According to the World Health Organization, in 2019, 1 in every 8 people, or 970 million people around the world were living with a mental disorder, with anxiety and depressive disorders being the most common. The economic burden of people suffering from depression alone in the United States was estimated at $326.2 billion for the year 2020. As our societies age, the number of cases of mental illness and cognitive disorders is projected to increase, along with the associated economic costs. For example, the number of people with dementia is estimated to increase from 57.3 million cases globally in 2019 more than 150 million cases in 2050. Yet, despite the growing need for effective treatment and substantial unmet treatment needs, CNS drug development remains costly, with the cost of developing a new drug typically ranging from $10 to 15 billion per drug, with CNS drugs having the lowest success rate of all other drug categories. Â Firefly believes that improving outcomes for people suffering from mental illnesses and cognitive disorders requires objective measurement. The clinical benefit of using EEG to understand how a personâ€™s brain is functioning has been studied for decades. However, Firefly believes that, due to the complexity and time required to analyze and interpret EEG recordings, the inability to compare EEG recordings to what is clinically normal, and the inability to track changes over time, the clinical use of EEG has been limited. The BNA Platform holds the potential to transform brain health by allowing integration of EEG testing and analysis into patient care pathways to provide clinicians with an objective tool that can help them diagnosis and assess treatment efficacy, objectively and quickly. In addition, through Fireflyâ€™s research and development initiatives, the Company believes that by introducing biomarkers that could diagnose the illnesses or disorder and identify what treatment will provide the most benefit for the patient will drive adoption by clinicians and payors. Â 53 Â Â Through ongoing research of Fireflyâ€™s growing database, using the BNA Platform, Firefly will enter other markets including, executive medical health and wellness for consumers who want to more actively manage their healthcare and lifestyles. Â Sales and Marketing Â The BNA Platform is indicated for use by medical professionals in the United States. This includes but is not limited to neurologists, psychiatrists, nurse practitioners and general practitioners. Firefly has made the strategic decision to initially target neurologists working in clinics in the United States to adopt the BNA Platform into their patient care protocols. As of 2021, there were over 13,800 active neurologists practicing in the United States, with over 11,600 of these neurologists engaged in patient care. Through building strong relationships with neurologists, who are generally regarded as experts in cognition, Firefly will generate the necessary clinical validation to support defendable reimbursement for other medical professionals to integrate the BNA Platform into their practice. In addition, Firefly believes that its current product will be able to provide more direct insight into diagnosis and therapy optimization by introducing clinical biomarkers that actively support streamlined decision-making by medical professionals who are not familiar with EEG. Â Firefly plans to offer its BNA Platform on a subscription model basis. In addition, Firefly plans to

provide EEG recording equipment on a monthly rental basis or as part of a bundle price. Fireflyâ€™s management has a deep understanding of business development in the medical technology space. Driving adoption in the specialty of neurology will ensure that Firefly will be able to reach its full potential. For this reason, Firefly will initially adopt a direct selling model that is supported by field based clinical specialists and medical affairs personnel. As adoption progresses, supported by clinical validation, biomarkers and improvements to the BNA Platform, Firefly aims to partner with national distributors that complement Fireflyâ€™s target markets, including EEG companies and installed bases of EEG systems in use today by medical professionals. Â To further support the adoption of the BNA Platform in neurology, Firefly plans to attend trade shows and conferences at national and regional levels. In addition, Firefly plans to increase awareness of its BNA Platform amongst target clinicians who care for patients with cognitive disorders through education and outreach designed to drive patient referrals. As the Company grows awareness and utilization of the BNA Platform, Firefly plans to continue to enhance its marketing and analytics capabilities to support its growing customer base to include other medical professionals. Â In concert with the commercialization of the BNA Platform to medical professionals, Firefly plans to actively engage with drug development companies and develop extensive strategic partnerships to support their drug development strategies. As of January 1, 2023, there were 187 trials assessing 141 unique treatments for Alzheimerâ€™s disease. As of January 4, 2023, there were more than 160 pharmaceutical companies developing drugs to treat mental illnesses. In order to take full advantage of the opportunity in the CNS drug development market, Firefly intends to invest in business development resources focused on the CNS drug development sector. Â Competition Â Fireflyâ€™s industry is competitive and has been evolving rapidly with the introduction of new products and technologies as well as the market activities of industry participants. The BNA Platform is indicated for use in individuals 12 to 85 years of age for the post-hoc statistical analysis of the human electroencephalogram, including event-related potentials and Firefly currently markets its device to qualified medical professionals. Firefly competes against other companies that have developed AI-driven platforms, in the target market of neurological disorders. Â Firefly believes that the BNA Platform is a paradigm shift on the approach to treating cognitive disorders and mental illnesses. Fireflyâ€™s BNA Platform offers distinct advantages, including its BNA Algorithm for data analysis, its proprietary extensive normative age matched database underpinning the BNA Platform, and the ability of the BNA Platform to generate individual reports that clinicians can use to optimize patient care. Firefly believes the BNA Platform can become a standard of care tool in addressing the primary unmet needs in mental illness and cognitive disorders today. Firefly also believes that the BNA Platform has a wide range of additional applications, including the ability to leverage data gathered through BNA sessions for additional clinical insight, pharmaceutical drug development and new product development. The longitudinal nature of the data, along with clinical disease context, provides many future development opportunities. Â 54 Â Â Furthermore, EEG technology, in concert with BNA Platform, represents a scalable, low-cost solution when compared to other imaging technologies that assess brain function, such as functional magnetic resonance imaging (fMRI). Â Intellectual Property Â Fireflyâ€™s commercial success depends in part on its ability to obtain and maintain intellectual property protection for the BNA Platform and any future products, to prevent others from infringing, misappropriating, or otherwise violating its intellectual property rights, to defend and enforce its intellectual property rights, and to operate without infringing, misappropriating, or otherwise violating valid and enforceable intellectual property rights of others. Firefly actively seeks to protect intellectual property that it believes is important to its business, which includes patents covering the components of the BNA Platform and the methods used for optimizing the therapy that the BNA Platform delivers. Firefly also seeks patent protection for other processes and inventions that are commercially or strategically important to developing and maximizing the value of its enterprise. Firefly takes steps to build and maintain the integrity of its brand, for example, with trademarks and service marks, and Firefly seeks to protect the confidentiality of trade secrets that may be important to the development of its business. Firefly relies on a strategy that combines the use of patents, trademarks, trade secrets, know-how, and license agreements, as well as other intellectual property laws, employment, confidentiality and invention assignment agreements, and contractual protections, to establish and protect its intellectual property rights. Â Patents Â Our patents and patent applications assert claims generally related methods and systems. Specifically, there are multiple patent families relating to (i) ERP processing algorithms and the comparison to a reference group and estimation of brain function based on the comparison; (ii) prediction of TMS treatment outcome; (iii) method and system for estimating brain concussion; (iv) method and system for managing pain; (v) method for brain stimulation tool configuration. As of December 31, 2023, we owned eight issued U.S. patents, which have expiration dates ranging from November 2028 to November 2037. We own one issued patent in Japan and there are currently patent applications pending in each of Australia, Canada, China, European Union and Israel, which, if issued, are expected to expire in 2037. Â The anticipated expiration dates are without taking into account all possible patent term adjustments, extensions, or abandonments, and assuming payment of all appropriate maintenance, renewal, annuity, and other governmental fees. We continue to evaluate our intellectual property portfolio as patents reach end of life to determine the optimal course for continuing to protect our technology. We cannot ensure that patents will issue from any of our pending applications or that, if patents are issued, they will be of sufficient scope or strength to provide meaningful protection for our technology. Â We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors. The patent positions of medical device companies like ours are generally uncertain and involve complex legal, scientific, and factual questions. The protection afforded by a patent varies on a product-by-product basis, from jurisdiction-to-jurisdiction, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of patent term adjustments and extensions, the availability of legal remedies, and the validity and enforceability of the patent. Â In addition, the coverage claimed in a patent application can be significantly narrowed before the patent is issued, and patent claims can be reinterpreted or further altered even after patent issuance. We cannot predict whether the patent applications we are currently pursuing will issue as patents or whether the claims of any issued patents will provide sufficient protection from competitors. A competitor could develop systems, devices, or methods of manufacture or treatment that are not covered by our patents. Accordingly, our ability to stop third parties from commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, maintaining, defending, and enforcing patent claims that adequately cover our inventions. Â 55 Â Â Our commercial success will also depend, in part, on not infringing, misappropriating, or otherwise violating the intellectual property rights of third parties. Third parties own numerous patents in the U.S. and in jurisdictions outside the U.S. with claims directed to inventions in the fields in which we operate or plan to operate. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, seek licenses, cease certain activities, or participate in USPTO proceedings. Moreover, such licenses may not be available on commercially reasonable terms or at all. Our breach of any license agreements or failure to obtain a license necessary to our business may have a material adverse impact on us. Â Trademarks Â Our trademark portfolio is designed to protect the brands of our BNA Platform and any future products. As of June 30, 2024, we own one trademark registration for â€œBNAâ€ in the United States and other countries, including Israel, Switzerland, European Union, Canada, and India. The trademark is also registered with WIPO International. Â Trade Secrets Â We also rely on trade secrets relating to our product and technology, including our data processing algorithms, and we maintain the confidentiality of such proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our trade secrets and know-how by entering into confidentiality and invention assignment agreements with employees, contractors, consultants, suppliers, customers, and other third parties, who have access to such information. These agreements generally provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individualâ€™s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. Â For more information regarding the risks related to our intellectual property, please see â€œRisk Factors-Risks Related to Fireflyâ€™s Intellectual Property.â€ Â Manufacturing Â Our BNA Platform is hardware-agnostic and we do not manufacture any compatible hardware. Â 56 Â Â Government Regulation Â Our products (including our BNA Platform) are considered medical devices, and, accordingly, are subject to rigorous regulation by government agencies in the United States and other countries in which we intend to sell our products. These regulations vary from country to country but cover, among other things, the following activities with respect to medical devices: Â Â â— design, development and manufacturing; Â â— testing, labeling, content and language of instructions for use and storage; Â â— product storage and safety; Â â— marketing, sales and distribution; Â â— pre-market clearance and approval; Â â— record keeping procedures; Â â— advertising and promotion; Â â— recalls and field safety corrective actions; Â â— post-market surveillance; Â â— post-market approval studies; and Â â— product import and export. Â FDA Regulation Â In the U.S., numerous laws and regulations govern the processes by which medical devices are developed, manufactured, brought to market and marketed. These include the Federal Food, Drug, and Cosmetic Act (â€œFD&C Actâ€) and its implementing regulations issued by FDA, among others. Unless an exemption applies, each medical device commercially distributed in the United States requires FDA clearance of a 510(k) premarket notification (â€œ510(k) clearanceâ€), granting of a de novo request, or approval of an application for premarket approval (â€œPMAâ€). In general, under the FD&C Act, medical devices are classified in one of three classes on the basis of the controls necessary to reasonably assure their safety and effectiveness. A medical deviceâ€™s classification determines the level of FDA review and approval to which the device is subject before it can be marketed to consumers: Â Â â— Class I devices, the lowest-risk FDA device classification, include devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to FDAâ€™s medical device general controls, including labeling, establishment registration, device product listing, adverse event reporting, and, for some products, adherence to good manufacturing practices through FDAâ€™s Quality System Regulations. Â â— Class II devices, moderate-risk devices, also require compliance with general controls and in some cases, special controls as deemed necessary by FDA to ensure the safety and effectiveness of the device. These special controls may include performance standards, particular labeling requirements, or post-market surveillance obligations. While most Class I devices are exempt from the 510(k) premarket notification requirement, typically a Class II device also requires pre-market review and 510(k) clearance as well as adherence to the Quality System Regulations/good manufacturing practices for devices. Â â— Class III devices, high-risk devices that are often implantable or life-sustaining, also require compliance with the medical device general controls and Quality System Regulations, and generally must be approved by FDA before entering the market through a PMA application. Approved PMAs can include post-approval conditions and post-market surveillance requirements, analogous to some of the special controls that may be imposed on Class II devices. Â Our BNA Platform is a Class II medical device, which was cleared by FDA for commercialization in the U.S. pursuant to the 510(k) notification process for the post-hoc statistical analysis of the human electroencephalogram, including ERP in December 2020. The marketing and distribution of the BNA Platform, is subject to continuing regulation and enforcement by FDA and other government authorities, which includes product listing requirements, medical device reporting regulations. If FDA finds that we have failed to comply with any legal or regulatory requirements, it or other government agencies may institute a wide variety of enforcement actions against us, ranging from Warning Letters to more severe sanctions, including but not limited to financial penalties, withdrawal of 510(k) clearances already granted, and criminal prosecution. Â The 510(k) Process Â Under the 510(k) process, the applicant must submit to FDA a premarket notification demonstrating that the device is â€œsubstantially equivalentâ€ to either a device that was legally marketed prior to May 28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, and for which a PMA is not required, a device that has been reclassified from Class III to Class II or Class I, or another commercially available device that was cleared through the 510(k) process. To be â€œsubstantially equivalent,â€ the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. Â 57 Â Â After a 510(k) premarket notification is submitted, FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, FDA will refuse to accept the 510(k) notification. If it is accepted for filing, FDA begins a substantive review. By statute, FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. Â Post-Market Regulation Â After a device is cleared or approved for marketing, numerous and extensive regulatory requirements may continue to apply. These include but are not limited to: Â Â â— annual and updated establishment registration and device listing with FDA; Â â— restrictions on sale, distribution, or use of a device; Â â— labeling, advertising, promotion, and marketing regulations, which require that promotion is truthful, not misleading, and provide adequate risk disclosures and directions for use and that all claims are substantiated, and also prohibit the promotion of products for unapproved or â€œoff-labelâ€Â uses (i.e., indications that are inconsistent with or beyond the scope of the applicable FDA approval or clearance) and impose other restrictions on labeling; Â â— clearance or approval of product modifications to legally marketed devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use; Â â— correction, removal, and recall reporting regulations, and FDAâ€™s recall authority; Â â— complying with the federal law and regulations requiring Unique Device Identifiers on devices; and Â â— post-market surveillance activities and regulations, which apply when deemed by FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device. Â â— FDA has broad regulatory compliance and enforcement powers. If FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions: Â â— warning letters, untitled letters, fines, injunctions, consent decrees, and civil penalties; Â â— recalls, withdrawals, or administrative detention, or seizure of our products; Â â— operating restrictions or partial suspension or total shutdown of production; Â â— refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products; Â â— withdrawing 510(k) clearances or PMA approvals that have already been granted; Â â— refusal to grant export or import approvals for our products; or Â â— criminal prosecution. Â International Regulation Â Many countries throughout the world have established regulatory frameworks for marketing and commercialization of medical devices. As a designer and marketer of medical devices, we are obligated to comply with the respective frameworks of these countries to obtain and maintain access to these global markets. The frameworks often define requirements for marketing authorizations which vary by country. Failure to obtain appropriate marketing authorization and to meet all local requirements, including specific quality and safety standards in any country in which we currently market our products, could cause commercial disruption and/or subject us to sanctions and fines. Delays in receipt of, or a failure to receive, such marketing authorizations, or the loss of any previously received authorizations, could have a material adverse effect on our business, financial condition and results of operations. Â 58 Â Â There is currently no premarket government review of medical devices in the European Economic Area (â€œEEAâ€). However, all medical devices placed on the market in the EEA must meet the relevant essential requirements laid down in Annex I of Directive 93/42/EEC concerning medical devices, or the Medical Devices Directive. The most fundamental essential requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical equipment, and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture. While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical matter. Compliance with a standard developed to implement an essential requirement also creates a rebuttable presumption that the device satisfies that essential requirement. Â On April 5, 2017, the European Parliament passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU Medical Device Directive and became effective on May 26, 2021. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable, and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. The new regulations, among other things: Â Â â— strengthen the rules on placing devices on the market and reinforce surveillance once they are available; Â â— improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; Â â— set up a central database to provide patients, healthcare professionals, and the public with comprehensive information on products available in the E.U.; and Â â— strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market. Â We received our European CE mark, indicating that we affirm our productâ€™s conformity with European health, safety and environmental protection standards, in 2021. Â Healthcare Regulatory Laws Â Within the United States, our products are subject to extensive regulation by a wide range of federal and state agencies that govern business practices in the medical device industry. These laws include federal and state anti-kickback, fraud and abuse, false claims and physician payment transparency laws and regulations. Â The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce or in return for purchasing,

leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or part by Medicare, Medicaid or other federal healthcare programs. The term â€œremunerationâ€ has been broadly interpreted to include anything of value, including cash, improper discounts, and free or reduced price items and services. Among other things, the Anti-Kickback Statute has been interpreted to apply to arrangements between medical device manufacturers on the one hand and prescribers and purchasers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Â Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statuteâ€™s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate, in order to have committed a violation. Further, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any payor, not only the Medicare and Medicaid programs. Commercial payors may also bring a private cause of action for treble damages against a manufacturer for a pattern of causing false claims to be filed under the federal Racketeer Influenced and Corrupt Organizations Act, or RICO. Â 59 Â Â The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes â€œany request or demandâ€ for money or property presented to the U.S. government. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In recent years, the number of suits brought against healthcare providers by private individuals has increased dramatically. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. In addition, the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providersâ€™ and manufacturersâ€™ compliance with applicable fraud and abuse laws. Various states have also enacted false claim laws analogous to the federal civil False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. Â The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HIPAA, among other things, created two new federal crimes: healthcare fraud and false statements relating to healthcare matters. The HIPAA healthcare fraud statute prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment and/or exclusion from government sponsored programs. The HIPAA false statements statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines and/or imprisonment. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. Â Additionally, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The ACA, imposed, among other things, new annual reporting requirements for covered manufacturers for certain payments and â€œtransfers of valueâ€ provided to physicians and certain other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition, certain states require implementation of compliance programs and compliance with the device industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. Â Health Information Privacy and Security Laws Â There are numerous U.S. federal and state laws and regulations related to the privacy and security of Personally Identifiable Information (â€œPIIâ€), including health information. Among others, the federal Health Insurance Portability and Accountability Act of 1996, as amended by HITECH, and their implementing regulations, which we collectively refer to as HIPAA, establish privacy and security standards that limit the use and disclosure of Protected Health Information (â€œPHIâ€) and require covered entities and business associates to implement administrative, physical, and technical safeguards to ensure the confidentiality, integrity, and availability of individually identifiable health information in electronic form, among other requirements. Â 60 Â Â Violations of HIPAA may result in civil and criminal penalties. We must also comply with HIPAAâ€™s breach notification rule which requires notification to affected individuals and HHS, and in certain cases to media outlets, in the case of a breach of unsecured PHI. The regulations also require business associates of covered entities to notify the covered entity of breaches by the business associate. Â State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states, and HIPAA standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates for compliance. Â Many states also have laws that protect the privacy and security of sensitive and personal information, including health information. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California, are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to, in addition to HIPAA. California passed the California Consumer Privacy Act or CCPA on June 28, 2018, which went into effect January 1, 2020. On November 3, 2020, the California Privacy Rights Act of 2020 (â€œCPRAâ€), which amends the CCPA and adds new privacy protections that became effective on January 1, 2023, was enacted through a ballot initiative. While information we maintain that is covered by HIPAA may be exempt from the CCPA, other records and information we maintain on our patients may be subject to the CCPA. In certain cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some, unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused. In addition, state and federal privacy laws subject to frequent change. Â In addition to HIPAA and state health information privacy laws, we may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security, laws that place specific requirements on certain types of activities, such as data security and texting, and laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach. Â Foreign data protection, privacy, and other laws and regulations are often more restrictive than those in the U.S. The E.U., for example, traditionally has imposed stricter obligations under its laws and regulations relating to privacy, data protection and consumer protection than the U.S. In May 2018, the GDPR, governing data practices and privacy in the E.U., became effective and replaced the data protection laws of the individual member states. GDPR requires companies to meet stringent requirements regarding the handling of personal data of individuals in the E.U. These more stringent requirements include expanded disclosures to inform members about how we may use their personal data, increased controls on profiling members, and increased rights for members to access, control and delete their personal data. In addition, there are mandatory data breach notification requirements. The law also includes significant penalties for non-compliance, which may result in monetary penalties of up to 20 million Euros or 4% of a companyâ€™s worldwide turnover, whichever is higher. GDPR and other similar regulations require companies to give specific types of notice and informed consent is required for the placement of a cookie or similar technologies on a userâ€™s device for online tracking for behavioral advertising and other purposes and for direct electronic marketing, and the GDPR also imposes additional conditions in order to satisfy such consent, such as a prohibition on pre-checked consents. It remains unclear how the U.K. data protection laws or regulations will develop in the medium to longer term and how data transfer to the U.K. from the E.U. will be regulated. Outside of the E.U., there are many other countries with data protection laws, and new countries are adopting data protection legislation with increasing frequency. Â Many of these laws may require consent from individuals for the use of data for various purposes, including marketing, which may reduce our ability to market our products. Â There is no harmonized approach to these laws and regulations globally. Consequently, we increase our risk of non-compliance with applicable foreign data protection laws and regulations when we expand internationally. We may need to change and limit the way we use personal information in operating our business and may have difficulty maintaining a single operating model that is compliant. Compliance with such laws and regulations will result in additional costs and may necessitate changes to our business practices and divergent operating models, limit the effectiveness of our marketing activities, adversely affect our business, results of operations, and financial condition, and subject us to additional liabilities. Â 61 Â Â Employees Â As of the date of this prospectus, Firefly had seven full-time employees and six contractors. None of Fireflyâ€™s employees are represented by a labor union or covered by collective bargaining agreements, and Firefly considers its relationship with its employees to be good. Â Facilities Â We do not own any real property or facilities. In connection with the Merger, we assumed the lease of WaveDancerâ€™s principal executive offices, which such lease will expire in November 2024, and which we do not intend to renew. If we advance our business operations, we may seek to lease facilities of our own in order to support our operational and administrative needs. There can be no assurance that such facilities will be available, or that they will be available on suitable terms. Our inability to obtain such facilities could have a material adverse effect on our future plans and operations. Â Legal Proceedings Â From time to time, we may become party to legal proceedings in the ordinary course of business. Such legal proceedings may negatively impact our business and financial position, result in brand or reputational harm, and divert the attention of our management from core operations of our business. We are currently not a party to any material legal proceedings. Â Company Information Â Our principal executive offices are located at 1100 Military Road, Kenmore, NY 14217.Â Our telephone number is (888) 237-6412. Â Our web page address is www.fireflyneuro.com. Our investor relations website is located at www.fireflyneuro.com. We have and will make available free of charge on our investor relations website under â€œSEC Filingsâ€ our Annual Reports on FormÂ 10-K, Quarterly Reports on FormÂ 10-Q, Current Reports on FormÂ 8-K, our directorsâ€™ and officersâ€™ SectionÂ 16 Reports and any amendments to those reports after filing or furnishing such materials to the SEC.Â References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document or any other document that we file with or furnish to the SEC. Â 62 Â Â MANAGEMENT Â Officers and Directors Â Set forth below are the names, ages and positions of each of the individuals who serve as our directors and officers as of August 30, 2024: Â Name Â Age Â Position Executive Officers Â Â Â Â Jon Olsen Â 59 Â Chief Executive Officer and Director Paul Krzywicki Â 40 Â Chief Financial Officer Gil Issachar Â 42 Â Chief Technology Officer Samer Kaba Â 63 Â Chief Medical Officer David Johnson Â 66 Â Executive Chairman Non-Employee Directors Â Â Â Â David DeCaprio Â 52 Â Director Greg Lipschitz Â 36 Â Director Arun Menawat Â 69 Â Director Brian Posner Â 62 Â Director Stella Vnook Â 49 Â Director Â Executive Officers Â Jon Olsen. Mr. Olsen has served as Fireflyâ€™s CEO since September 2020. Jon is a global executive leader who has spent 25+ years in the Medical Technology industry. Prior to joining Firefly Neuroscience, Mr. Olsen was the Managing Director of Smith & Nephew Canada. Prior to Smith & Nephew, Mr. Olsen had an extensive career at Medtronic PLC in North America and Europe. Mr. Olsen received an MBA from the Asper School of Business, and an undergraduate degree in Science (Hons) from the University of Manitoba. Â Paul Krzywicki. Mr. Krzywicki, CPA-CGA joined Firefly as Chief Financial Officer in November 2023. Over the last 5 years, Mr. Krzywicki has held senior leadership positions in a variety of organizations such as Nucor Canada, EllisDon and Canadian Curtis Refrigeration with a focus on modernization and increasing operating efficiency. Mr. Krzywicki is a Chartered Professional Accountant and holds an Honours Bachelors Degree in Commerce from Laurentian University. Â Gil Issachar. Mr. Issachar has served as Fireflyâ€™s Chief Technology Officer since November 2022. Mr. Issachar is a biomedical engineer and a neuroscientist with an extensive experience working as a director of data-science, team leader, data scientist, and software engineer in the medical device industry (under FDA PMA regulations). Mr. Issachar has managed multiple research and development projects in collaboration with pharmaceutical companies, neuroscientists and other start-up companies. Prior to serving as Fireflyâ€™s Chief Technology Officer, Mr. Issachar served as Fireflyâ€™s Vice-President of Research and Data Science, Director of Research and Data-Science, Data-Science Team Leader. Prior to joining Firefly, Mr. Issachar served as R&D Software Engineer for Dune Medical Devices. Mr. Issachar received his Masterâ€™s Degree in Biomedical/Medical Engineering and Bachelorâ€™s Degree from Tel Aviv University. Â Samer Kaba. On June 21, 2024, we appointed Samer Kaba, M.D., as our Chief Medical Officer. Prior to joining Firefly, Dr. Kaba held multiple leadership positions in the pharmaceutical industry and served as Chief Medical Officer of various biotechnology companies, where he led the development of multiple pharmaceutical products. In addition to his large expertise in drug development, medical affairs, and regulatory sciences, Dr. Kaba has over 20 years of experience in managing patients with neurological conditions. Dr. Kaba is a board-certified neurologist with additional training in Neuro-immunology (Multiple Sclerosis) at the State University of New York at Buffalo, and in Neuro-oncology at the University of Texas M.D. Â 63 Â Â David Johnson. On August 19, 2024, we appointed David Johnson as our Executive Chairman. Prior to joining Firefly. Mr. Johnson served as Executive Chairman, Chairman and Chief Executive Officer of Enveric Biosciences. In addition, Mr. Johnson formerly served on the board of directors and as the President and Chief Executive Officer of Alliqua BioMedical, Inc. from November 2012 until April 2019. Mr. Johnson was formerly President of the ConvaTec Division of Bristol-Myers Squibb, Inc. until 2008 when he orchestrated a sale of the division from its pharmaceutical parent to Avista Capital Partners and Nordic Capital in a deal valued at $4.1 billion. Concurrently, he acquired and integrated the assets of Copenhagen-based Unomedical to expand ConvaTec Inc.â€™s manufacturing and infrastructure into Europe. From 2008 through 2012, Mr. Johnson served as the Chief Executive Officer of ConvaTec Inc. Prior to his tenure with ConvaTec Inc., Mr. Johnson held several senior positions in the U.S., Europe and Canada with Zimmer Inc., Fisher Scientific, and Baxter Corporation. He served as a member of ConvaTec Inc.â€™s board of directors and the board of the Advanced Medical Technology Association (AdvaMed), where he chaired the Global Wound Sector Team for four years. Mr. Johnson received an Undergraduate Business Degree in Marketing from the Northern Alberta Institute of Technology in Edmonton, Alberta, Canada, completed the INSEAD Advanced Management Program in Fontainebleau, France, and is a fellow of the Wharton School of the University of Pennsylvania. Firefly believes that Mr. Johnsonâ€™s extensive experience in the Life Sciences Industry, as well as his executive leadership experience, make him an asset who can serve as a bridge between Fireflyâ€™s board of directors and its executive officers. Â Non-Employee Directors Â David DeCaprio. Mr. DeCaprio has served as a member of Fireflyâ€™s board of directors since January 2024. Mr. DeCaprio has served in various capacities within the genome research, pharmaceutical development, health insurance, computer vision, sports analytics, speech recognition, transportation logistics, operations research, real-time collaboration, robotics and financial industries since 2003. Mr. DeCaprio has significant experience transitioning advanced technology from academic research labs into successful businesses. Since January 2017, Mr. DeCaprio has served and continues to serve as Chief Technology Officer of ClosedLoop.ai, an award-winning startup focused on building a healthcare specific data science and machine learning platform. Prior to founding ClosedLoop.ai, Mr. DeCaprio was involved in various successful startups. Among other positions, Mr. DeCaprio has served as Chief Technology Officer of Fina Technologies from June 2008 to January 2015 and as Vice President of Engineering of GNS Healthcare from September 2005 to January 2017. Since May 2015, Mr. DeCaprio has served and presently serves as Chief Executive Officer of Cizr, a technology company focused on improving sports coaching efficiency. Mr. DeCaprio also has significant consulting experience, serving as a consultant for various organizations from 2006 to January 2015, for Baylor College of Medicine from January 2015 to June 2015 and for the Icahn School of Medicine at Mount Sinai from September 2016 to April 2017. Mr. DeCaprio received a Bachelor of Science Degree in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology. Firefly believes that Mr. DeCaprioâ€™s extensive experience in artificial intelligence and software engineering will make him an asset to the company. Â Greg Lipschitz. Mr Lipschitz has served as Fireflyâ€™s director since December 2022. Mr. Lipschitz has over 13 years of combined experience in private equity, merchant banking, capital markets and finance. From June 2018 to February 2024, Mr. Lipschitz served as the Vice President of Lazer Capital. Mr. Lipschitz is currently the Managing Director of Old Stone Advisors, a financial advisory firm. Mr. Lipschitz has advised on over $1 billion of transactions. Mr. Lipschitz is a Chartered Financial Analyst and received his bachelorâ€™s degree in Business from the Richard Ivey Business School at the University of Western Ontario. Firefly believes that Mr. Lipschitzâ€™s experience in capital markets will make him an asset to the company. Â Arun

Menawat. Dr. Menawat has an accomplished history of executive leadership success in the healthcare industry. Dr. Menawat is the Chief Executive Officer and a Director of Profound Medical Corp. Prior to joining Profound, he served as the Chairman, President and CEO of Novadaq Technologies Inc., a TSX and Nasdaq listed company that marketed medical imaging and therapeutic devices for use in the operating room. Previously, he was President and Chief Operating Officer and Director of another publicly listed medical imaging software company, Cedara Software. His educational background includes a Bachelor of Science in Biology, University of District of Columbia, Washington, D.C., and a Ph.D. in Chemical Engineering, from the University of Maryland, College Park, MD, including graduate research in Biomedical Engineering from the National Institute of Health, Bethesda, MD. He also earned an Executive M.B.A. from the J.L. Kellogg School of Management, Northwestern University, Evanston, IL. Firefly believes that Dr. Menawatâ€™s extensive experience executive leadership roles in medical technology companies, as well as capital markets, will make him an asset to the Company. Â Brian Posner. Mr. Posner has served as Chief Financial Officer at several life science and emerging technology companies. He currently serves as the Chief Financial Officer of electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company. Prior to electroCore, Mr. Posner served as Chief Financial Officer of Cellectar Biosciences, Alliqua BioMedical, Ocean Power Technologies, Power Medical Interventions and Pharmacopeia. Mr. Posner holds an undergraduate degree in accounting from Queens College and an M.B.A. in managerial accounting from Pace University. Firefly believes Mr. Posnerâ€™s extensive experience in public markets will make him an asset to the company. Â 64 Â Â Stella Vnook, Ph.D. Dr. Vnook has served as a Chief Executive Officer, Founder, Board Member, C-Suite Advisor with 25 yearsâ€™ experience driving transformational change for global clinical development portfolios from early-stage R&D to commercialization. She has an extensive background in building and managing successful start-up ventures, commercial scale-up, strategy/execution to support brand launch, research and development, acceleration, IP strategy, Corporate Board selection and formation, business development and investment strategy, venture capital initiatives, as well as managed markets and healthcare economics. Dr. Vnookâ€™s experience includes Chief Executive Officer of Likarda from April 2023 to Present, Board, Founder and President of Oral Biolife from April 2022 to Present, Founder, President and Executive Advisor to Agile Consulting Group from March 2015 to Present, Mentor-In-Residence / Entrepreneur-in-Residence to Penn State University from April 2024 to present. Firefly believes that Dr. Vnookâ€™s extensive experience in executive leadership roles in the pharmaceutical industry will make her an asset to the company. Â Corporate Governance Â Composition of the Board of Directors Â Our business and affairs are organized under the direction of the Board. The Board consists of seven (7)Â members. David Johnson serves as Executive Chairman of the Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to our management. The Board meets on a regular basis and additionally as it deems necessary. Â In accordance with the terms of the Charter, the Board is divided into three classes, ClassÂ I, ClassÂ II and ClassÂ III, with only one class of directors being elected in each year and each class serving a three-year term, except as described below. Â Â â€¢ The Class I directors consist of David DeCaprio, Jon Olsen and Greg Lipschitz, whose terms will expire at the first annual meeting of stockholders to be held following the filing of the Amended and Restated Certificate of Incorporation (the â€œFiling Dateâ€); Â Â â€¢ The Class II directors consist of Brian Posner and Stella Vnook, whose terms will expire at the second annual meeting of stockholders to be held following the Filing Date. Â Â â€¢ The Class III directors consist of David Johnson and Arun Menawat, whose term will expire at the third annual meeting of stockholders to be held following the Filing Date. Â At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election and until their successors are duly elected and qualified. This classification of the Board may have the effect of delaying or preventing changes in our control or management. There is no cumulative voting with respect to the election of directors. Â Board Leadership Structure Â Director Independence Â We are required to comply with Nasdaqâ€™s rules in determining whether a director is independent. The Board undertook a review of the independence of the individuals named above and determined that each of the directors except David Johnson, Jon Olsen and Greg Lipschitz qualify as â€œindependentâ€ as defined under the applicable Nasdaq rules. Â The Nasdaq definition of â€œindependenceâ€ includes a series of objective tests, such as the director or director nominee is not, and was not during the last threeÂ years, our employee and has not received certain payments from, or engaged in various types of business dealings with us. In addition, the Board has made a subjective determination that no relationships exist which, in the opinion of the Board, would interfere with such individualâ€™s exercise of independent judgment in carrying out his or her responsibilities as a director. In making these determinations, the Board has reviewed and discussed information provided by the directors with regard to each directorâ€™s business and personal activities as they may relate us and our management. Â 65 Â Â With respect to its analysis of Mr. Lipschitzâ€™s independence, the Board considered that certain strategic agreement, dated as of August 12, 2024, by and between us and Bower Four Corp. (the â€œLipschitz Agreementâ€). Pursuant to the Lipschitz Agreement, Mr.Â Lipschitz, through Bower Four Corp., is entitled to receive aggregate consideration of $950,000 in shares of Common Stock during the term of the Lipschitz Agreement comprised of up to $316,667 of annual service credits over three years, as defined in the Lipschitz Agreement. Additionally, Mr. Johnson and Mr. Olsen are both our employees pursuant to their respective employment agreements with us. Â Committees of the Board of Directors Â The Board established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The composition and responsibilities of each of the committees of the Board are described below. Members serve on these committees until their resignation or until otherwise determined by the Board. The Board may establish other committees as it deems necessary or appropriate from time to time. Â Audit Committee Â The Audit Committee of the Board (the â€œAudit Committeeâ€) consists of Brian Posner, Arun Menawat and Stella Vnook. The Board has determined that each member of the Audit Committee qualifies as â€œindependentâ€ under Nasdaq listing standards and RuleÂ 10A-3(b)(1)Â of the ExchangeÂ Act. The chairperson of the Audit Committee is Brian Posner. The Board has determined that Brian Posner is an â€œaudit committee financial expertâ€ within the meaning of SEC regulations. Each member of our Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board has examined each audit committee memberâ€™s scope of experience and the nature of their employment. Â The primary purpose of the Audit Committee is to assist the Board in its oversight of our accounting and financial reporting processes and our compliance with legal and regulatory requirements. To assist the Board in fulfilling its responsibilities, the Audit Committee: (A)Â oversees: (i)Â audits of our financial statements; (ii)Â the integrity of our financial statements; (iii)Â our processes relating to risk management and the conduct and systems of internal control over financial reporting and disclosure controls and procedures; (iv)Â the qualifications, engagement, compensation, independence and performance of our independent auditor, and the auditorâ€™s conduct of the annual audit of our financial statements and any other services provided to us; and (v)Â the performance of our internal audit function, if any; and (B)Â produces the annual report of the Audit Committee. Specific responsibilities of the Audit Committee include, but are not limited, to: Â Â â— appoint, compensate, and oversee the work of any independent auditor; Â Â â— resolve any disagreements between management and the independent auditor regarding financial reporting; Â Â â— pre-approve all audit and permitted non-audit services by the independent auditor; Â Â â— retain independent counsel, accountants, or other advisors or consultants to advise and assist the Audit Committee in carrying out its duties, without needing to seek approval for the retention of such advisors or consultants from the Board, and determine the appropriate compensation for any such advisors or consultants retained by the Audit Committee; Â Â â— seek any information it requires from our employees or any direct or indirect subsidiary, all of whom are directed to cooperate with the Audit Committeeâ€™s requests, or external parties; Â Â â— meet with any officer or employee, the independent auditor or outside counsel, as necessary, or request that any such persons meet with any members of, or advisors or consultants to, the Audit Committee; and Â Â â— oversee that management has established and maintained processes to assure our compliance with applicable laws, regulations and corporate policy. Â Compensation Committee Â The Compensation Committee of the Board (the â€œCompensation Committeeâ€) consists of David DeCaprio, Arun Menawat and Brian Posner. The chairperson of the Compensation Committee is Arun Menawat. The Board has determined each member of the Compensation Committee qualifies as â€œindependentâ€ under Nasdaq listing standards and as â€œnon-employee directorsâ€ as defined in RuleÂ 16b-3 promulgated under the ExchangeÂ Act. Â 66 Â Â The primary purpose of the Compensation Committee is to (A)Â assist the Board in overseeing our employee compensation policies and practices, including (i)Â determining and approving the compensation of our Chief Executive Officer and other executive officers, and (ii)Â reviewing and approving incentive compensation and equity compensation policies and programs, and exercising discretion in the administration of such programs; and (B)Â produce a compensation discussion and analysis (â€œCD&Aâ€) of the Compensation Committee, if required by applicable SEC rules. Specific responsibilities of the Compensation Committee include, but are not limited, to: Â Â â— establish a compensation policy for executive officers designed to (i) enhance our profitability and increase stockholder value; (ii) reward executive officers for their contribution to our growth and profitability; (iii) recognize individual initiative, leadership, achievement, and other contributions; and (iv) provide competitive compensation that will attract and retain qualified executives; Â Â â— review competitive practices and trends to determine the adequacy of the executive compensation program; Â Â â— review and consider participation and eligibility in the various components of the total executive compensation package; Â Â â— annually review and approve corporate goals and objectives relevant to CEO compensation, evaluate the CEOâ€™s performance in light of those goals and objectives, and recommend to the Board the CEOâ€™s compensation levels based on this evaluation; the CEO may not be present during any deliberations or voting with respect to the CEOâ€™s compensation; Â Â â— annually review and make recommendations to the Board with respect to compensation of our directors and executive officers other than the CEO; Â Â â— approve employment contracts, severance arrangements, change in control provisions and other agreements; Â Â â— approve and administer cash incentives and deferred compensation plans for executive officers (including any modification to such plans) and oversight of performance objectives and funding for executive incentive plans; Â Â â— approve and oversee reimbursement policies for directors and executive officers; Â Â â— approve and oversee compensation programs involving the use of our stock; Â Â â— if we are required by applicable SEC rules to include a CD&A in our SEC filings, review the CD&A prepared by management, discuss the CD&A with management and, based on such review and discussions, recommend to the Board that the CD&A be included in our Annual Report on Form 10-K, proxy statement, or any other applicable filing as required by the SEC; Â Â â— review all compensation policies and practices for all employees to determine whether such policies and practices create risks that are reasonably likely to have a material adverse effect on us; Â Â â— periodically review executive supplementary benefits and, as appropriate, the organizationâ€™s retirement, benefit, and special compensation programs involving significant cost; and Â Â â— fulfill such other duties and responsibilities as may be assigned to the Compensation Committee, from time to time, by the Board and/or the Executive Chairman of the Board. Â 67 Â Â Nominating and Corporate Governance Committee Â The Nominating and Corporate Governance Committee of the Board (the â€œNominating Committeeâ€) consists of David DeCaprio, Stella Vnook and Brian Posner. The chairperson of the Nominating Committee is Stella Vnook. The Board has determined which members of the Nominating Committee qualify as independent under the Nasdaq listing standards. Specific responsibilities of the nominating and corporate governance committee include, but are not limited, to: Â Â â— evaluate the current composition, organization and governance of the Board and its committees, and make recommendations to the Board for approval; Â Â â— annually review for each director and nominee, the particular experience, qualifications, attributes or skills that contribute to the Boardâ€™s conclusion that the person should serve or continue to serve as our director, as well as how the directorsâ€™Â skills and background enable them to function well together as a Board; Â Â â— determine desired Board member skills and attributes and conduct searches for prospective directors whose skills and attributes reflect those desired; Â Â â— evaluate and propose nominees for election to the Board; Â Â â— administer the annual Board performance evaluation process, including conducting surveys of director observations, suggestions and preferences; Â Â â— evaluate and make recommendations to the Board concerning the appointment of directors to Board committees, the selection of Board committee chairs, and proposal of the slate of directors for election to the Board.; Â Â â— as necessary in the Nominating Committeeâ€™s judgment from time to time, retain and compensate third party search firms to assist in identifying or evaluating potential nominees to the Board; Â Â â— develop, adopt and oversee the implementation of a Code of Business Conduct and Ethics for all our directors, executive officers and employees; Â Â â— review and maintain oversight of matters relating to the independence of Board and committee members, keeping in mind the independence standards of the Sarbanes-Oxley Act of 2002 and the rules of Nasdaq; Â Â â— oversee and assess the effectiveness of the relationship between the Board and Corporation management; and Â Â â— maintain appropriate records regarding its process of identifying and evaluating candidates for election to the Board. Â Code of Business Conduct and Ethics Â In connection with the Merger, on August 12, 2024, the Board approved and adopted a new Code of Business Conduct and Ethics (the â€œCode of Ethicsâ€) that applies to all of our executive officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. A copy of the Code of Ethics can be found on our website at www.fireflyneuro.com. In addition, we will post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the Code of Ethics. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. Â Compensation Committee Interlocks and Insider Participation Â None of our Compensation Committee members is or has ever been our executive officer or employee. None of our executive officers currently serve, or have served during the last completed fiscal year, on the Compensation Committee or the Board of any other entity that has one or more executive officers that will serve as a member of the Board or Compensation Committee. See â€œCertain Relationships and Related Person Transactions.â€ Â 68 Â Â Limitation on Liability and Indemnification of Directors and Officers Â The Charter provides that directors and officers will be indemnified by us to the fullest extent authorized by Delaware law as it now exists or may in the future be amended. The Charter provides that directors will not be personally liable for monetary damages to us except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL as the same exists or may hereafter be amended. Â We have entered into agreements with our officers and directors to provide contractual indemnification. The Bylaws permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit indemnification. We have purchased directorsâ€™ and officersâ€™ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify the directors and officers. Â 69 Â Â EXECUTIVE COMPENSATION Â This section discusses the material components of the executive compensation program for our named executive officers who are named in the â€œSummary Compensation Tableâ€ below, which such named executive officers consist of (a) any persons who served as our principal executive officer during any part of the year ended December 31, 2023; (b) each of our two most highly compensated executive officers other than our principal executive officer who served as executive officers at the end of 2023; and (c) up to two additional individuals for whom disclosure would have been provided under clause (b) but for the fact that the person was not serving as an executive officer at the end of the fiscal year ended December 31, 2023. For the year ended DecemberÂ 31, 2023, our â€œnamed executive officersâ€ and their positions were as follows: Â Â â€¢ Jon Olsen, Chief Executive Officer; and Â Â â€¢ Gil Issachar, Chief Technology Officer. Â This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Â Summary Compensation Table Â The following table sets forth information concerning the compensation of our named executive officers for the fiscal years ended DecemberÂ 31, 2023 and 2022. All amounts in the table below are rounded to the nearest whole dollar. Â Name and Principal Position Â Year Â Salary ($) Â Â Bonus ($) Â Â Option Awards ($)(1) Â Â All other compensation ($) Â Â Total ($) Â Jon Olsen Â 2022 Â $ 159,336 Â Â $ - Â Â $ 336,840 (2) Â $ - Â Â $ 496,176 Â Chief Executive Officer Â 2023 Â $ 168,380 Â Â $ - Â Â Â - (3) Â $ 1 Â Â $ 168,381 Â Gil Issachar Â 2022 Â $ 177,899 Â Â $ 13,009 Â Â $ 84,210 (4) Â $ 56,768 Â Â $ 331,886 Â Chief Technology Officer Â 2023 Â $ 133,556 Â Â $ 12,575 Â Â Â - (5) Â $ 46,738 Â Â $ 192,869 Â _____ (1) Amounts reflect the full grant-date fair value of option awards granted during the relevant fiscal year computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. Firefly provides information regarding the assumptions used to calculate the value of all option awards made to its executive officers in Note 11 to the audited consolidated financial statements for the year ended December 31, 2022 contained elsewhere in this prospectus.Â (2) Consists of a grant of options to purchase 112,280 shares of Common Stock at an exercise price of $3.00 per share made to Mr. Olsen on November 17, 2022. 40,545 of such options are currently exercisable. (3) Consists of a grant of options to purchase 725,168 shares of Common Stock made to Mr. Olsen on July 8, 2023, of which 271,938 are exercisable as of December 31, 2023. The options have a term of 5 years and an exercise price equal to a 25% discount to the issue price of Firefly's equity securities in an initial public offering that results in our Common Stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. (4) Consists of a grant of options to purchase 28,070 shares of Common Stock at an exercise price of $3.00 per share made to Mr. Issachar on November 17, 2022. 10,136 of such options are currently exercisable. (5) Consists of a grant of options to purchase 725,168 shares of Common Stock made to Mr. Issachar on July 8, 2023, of which 271,938 are exercisable as of December 31, 2023. The options have a term of 5 years and an exercise price equal to a 25% discount to the issue price of Firefly's equity securities in an initial public offering that results in

our Common Stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Â 70 Â Â Narrative Disclosure to Summary Compensation Table Â We have entered into written employment agreements or other arrangements with each of Jon Olsen and Gil Issachar. The material terms of the employment agreements or other arrangements with such individuals, as applicable and as currently in effect, are summarized below. Â Jon Olsen, Chief Executive Officer Â Effective September 4, 2020, we and Mr. Olsen entered into a letter agreement, pursuant to which Firefly offered to employ Mr. Olsen as Chief Executive Officer and a member of our Board on a consultancy basis for a period of 90 days (the â€œOlsen Letter Agreementâ€). Under the Olsen Letter Agreement, Mr. Olsen was entitled to an effective annual base salary of $102,000, payable monthly. Â Mr. Olsenâ€™s employment with us pursuant to the Olsen Employment Agreement commenced as of the effective date of the Olsen Employment Agreement and expired 90 days later. Â Effective January 4, 2024, Firefly and Slate Water Ltd., a corporation incorporated pursuant to the laws of Ontario, entered into an agreement pursuant to which Mr. Olsen was hired on a consultancy basis to serve as our Chief Executive Officer (the â€œCEO Consultancy Agreementâ€). Pursuant to the CEO Consultancy Agreement, Mr. Olsen is entitled to an effective annual base salary of $180,000, payable monthly. Additional performance bonuses, stock options and targets may be established on an annual basis by the Board. The CEO Consultancy Agreement shall continue indefinitely unless terminated by the parties thereto pursuant to its terms. Either party may terminate the CEO Consultancy Agreement for any reason with 90 daysâ€™ notice or without such notice in certain designated cases of cause. Â The CEO Consultancy Agreement also contains certain standard confidentiality, non-competition, non-solicit, waiver and indemnity provisions. Â Gil Issachar, Chief Technology Officer Â Effective February 2, 2017, we and Mr. Issachar entered into an employment agreement, which was subsequently amended by four amendments dated April 28, 2018, December 16, 2018, July 1, 2019 and December 11, 2019, respectively, each of which raised Mr. Issacharâ€™s base salary in connection with promotions or other events, and that certain Contract Addendum, dated June 21, 2021 (such agreement, as amended, the â€œIssachar Employment Agreementâ€), pursuant to which Mr. Issachar was hired as a research and data scientist. Mr. Issachar now serves as our Chief Technology Officer. Under the Issachar Employment Agreement, as amended, Mr. Issachar is entitled to a monthly base salary of approximately $13,340 on an as-converted basis in U.S. dollars. Mr. Issachar also received bonus compensation in the form of a one-time lump-sum cash payment equal to two months of salary in 2021, pursuant to the addendum to the Issachar Employment Agreement. Mr. Issachar will also be entitled to an annual bonus in the amount of one monthâ€™s salary at the end of each calendar year. Firefly also agrees to provide contributions for the cost of pension and education funds, managersâ€™ insurance, disability policies, and other benefits for Mr. Issachar during the term of employment under the Issachar Employment Agreement. Â Mr. Issacharâ€™s employment with us pursuant to the Issachar Employment Agreement commenced as of the effective date of the Issachar Employment Agreement and will continue until terminated by either party, with such termination effective upon the provision of written notice to the other party. In any event of termination of employment by applicable prior written notice, Firefly shall be entitled to terminate Mr. Issacharâ€™s employment, immediately or at any time during the prior notice period, and in such event, if and to the extent required by applicable law, Firefly shall pay Mr. Issachar full or partial prior notice redemption, as applicable. Notwithstanding the foregoing, in the event of termination of the Issachar Employment by us for cause, we shall not be required to pay the redemption of the advance notice period. Â The Issachar Employment Agreement also contains certain standard confidentiality and assignment of inventions provisions. Â Equity Compensation Â We have offered stock options to our named executive officers (in addition to certain non-executive employees) as the long-term incentive component of our compensation program. Our stock options are subject to the terms and conditions of our 2007 Incentive Plan and allow employees to purchase shares of our Common Stock at a price per share not less than the fair market value of a share of our Common Stock on the date of grant. Other terms of such stock options, such as vesting schedules, exercise periods and forfeiture upon termination of the participantâ€™s employment with us, are subject to the discretion of the Board and as set forth in the individual award agreements evidencing the grant of such options. Â 71 Â Â On November 17, 2022, Mr. Olsen was granted options to purchase 112,280 shares of our Common Stock, at an exercise price of $3.00. All such options vest monthly. The options have a term of ten years and expire on November 17, 2032. 40,545 of such options are currently exercisable. Â On July 8, 2023, Mr. Olsen was granted options to purchase 725,168 shares of our Common Stock, at an exercise price described in footnote (3) above. All such options vest monthly. The options had an original term of five years from the date of grant, subject to earlier termination in the case of Mr. Olsenâ€™s termination of employment with us, death, disability, retirement or termination for cause. 271,938 of such options are currently exercisable. Â On November 17, 2022, Mr. Issachar was granted options to purchase 28,070 shares our Common Stock, at an exercise price of $3.00. All such options vest monthly. The options have a term of ten years and expire on November 17, 2032. 10,136 of such options are currently exercisable. Â On July 8, 2023, Mr. Issachar was granted options to purchase 725,168 shares of our Common Stock, at an exercise price of described in footnote (5) above. All such options vest monthly. The options had an original term of five years from the date of grant, subject to earlier termination in the case of Mr. Olsenâ€™s termination of employment with us, death, disability, retirement or termination for cause. 271,938 of such options are currently exercisable. Â Other Elements of Compensation Â Pursuant to the terms of their respective employment agreements or arrangements, we provide and cover the costs of disability insurance policies and provide contributions to a pension fund for each of Mr. Olsen and Mr. Issachar. For the years ended December 31, 2022 and 2023, there were no health insurance expenses for Mr. Olsen. Â Potential Payments Upon Termination of Employment or Change in Control Â Upon consummation of the Merger, each outstanding option to acquire shares of Private Fireflyâ€™s Common Stock held by executive officers was converted into an option to acquire shares of Fireflyâ€™s Common Stock, post-Merger. In addition, our executive officers also have certain rights to indemnification or to directorsâ€™ and officersâ€™ liability insurance that survived the completion of the Merger. Â 72 Â Â Outstanding Equity Awards at Fiscal Year-End Â The following table sets forth information concerning the outstanding equity awards that have been previously awarded to each of Fireflyâ€™s named executive officers and which remain outstanding as of December 31, 2023. Firefly does not have any equity incentive plans other than the Firefly 2007 Incentive Plan and the Firefly 2023 Incentive Plan. As of the date hereof, there are no share-based award plans for any of Fireflyâ€™s named executive officers or directors. All options vest monthly, beginning as of their respective grant dates. Â Named Executive Officer Â Number of securities underlying unexercised options (#) exercisable Â Â Number of securities underlying unexercised options (#) unexercisable Â Â Equity incentive plan awards: number of securities underlying unexercised unearned options (#) Â Â Option exercise price Â Â Option expiration date Jon Olsen Â Â 1,333 Â Â Â - Â Â Â - Â Â $ 7.50 Â Â 9/25/2030 Â Â Â 25,333 Â Â Â - Â Â Â - Â Â $ 7.50 Â Â 12/14/2030 Â Â Â 8,000 Â Â Â - Â Â Â - Â Â $ 7.50 Â Â 6/21/2031 Â Â Â 40,545 Â Â Â 71,735 Â Â Â - Â Â $ 3.00 Â Â 11/17/2032 Â Â Â 271,983 Â Â Â 453,230 Â Â Â - Â Â Â (1) Â 7/8/2028 Gil Issachar Â Â 124 Â Â Â - Â Â Â - Â Â $ 7.50 Â Â 8/13/2018 Â Â Â 2,133 Â Â Â - Â Â Â - Â Â $ 7.50 Â Â 10/14/2030 Â Â Â 610 Â Â Â 123 Â Â Â - Â Â $ 7.50 Â Â 4/1/2031 Â Â Â 12,573 Â Â Â - Â Â Â - Â Â $ 7.50 Â Â 6/21/2031 Â Â Â 10,136 Â Â Â 17,934 Â Â Â - Â Â $ 3.00 Â Â 11/17/2032 Â Â Â 271,938 Â Â Â 453,230 Â Â Â - Â Â Â (1) Â 7/8/2028 Â (1) Equals 25% discount to the issue price of Fireflyâ€™s equity securities issued in an IPO Transaction. Â Firefly 2007 Incentive Plan Â Firefly adopted the Firefly 2007 Share Option Plan (the â€œFirefly 2007 Incentive Planâ€) in 2007 for the purpose of granting stock options to employees, service providers, and consultants under Israeli law. The Firefly 2007 Incentive Plan provides for grants to be issued at the determination of the Board and/or any committee of the Board so appointed by the Board in accordance with applicable laws. Â At the effective time of the merger, WaveDancer will assume all of Fireflyâ€™s rights and obligations under all stock options granted under the Firefly 2007 Incentive Plan that are outstanding immediately prior to the effective time of the merger. In addition, the Firefly 2007 Incentive Plan will be assumed by WaveDancer at the effective time of the merger, provided that no additional awards may be issued thereunder. Â Authorized Shares. A total of 300,000 shares of Firefly Common Stock have been authorized for the grant of awards under the Firefly 2007 Incentive Plan. Â Plan Administration. The Firefly 2007 Incentive Plan is administered by the Board, either directly or upon the recommendation of any committee of the Board so appointed by the Board (the â€œCommitteeâ€). Except as otherwise provided in the Firefly 2007 Incentive Plan, the Committee shall have the power to recommend to the Board, and the Board has full power and authority, to designate optionees, determine the terms and provisions of stock option agreements, determine the fair market value of the shares of Common Stock covered by each stock option, classify whether an award shall be granted pursuant to Section 102 (as defined below) or Section 3(i) (as defined below), designate grants made pursuant to Section 102 as either grants made through a trustee or not through a trustee, alter any restrictions and conditions of any awards, and make all other determinations deemed necessary or advisable for the administration of the Firefly 2007 Incentive Plan. Â 73 Â Â Stock Options. The Firefly 2007 Incentive Plan provides for the grant of stock options pursuant and subject to (i) Section 102 of the Israeli Income Tax Ordinance (New Version), 1961 (the â€œIncome Tax Ordinanceâ€) or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder (collectively, â€œSection 102â€) and to classify them as (x) either grants made through a trustee or not through a trustee; and (y) grants qualified under capital gain or ordinary income tax treatment; and (ii) Section 3(i) of the Income Tax Ordinance (â€œSection 3(i)â€). In connection with a grant of stock options, grantees receive the right to purchase a specified number of shares of Common Stock at a specified option exercise price, vesting schedule, and other terms and conditions as are specified by the Board and included in the applicable award agreement. The purchase price of each share of Common Stock shall be determined by the Committee in its sole and absolute discretion in accordance with applicable law, subject to any guidelines as may be determined by the Board from time to time. Â Options may be exercised by the optionee by giving written notice to Firefly and/or to any third party designated by Firefly, in such form and method as may be determined by Firefly and when applicable, by the trustee in accordance with the requirements of Section 102, which exercise shall be effective upon receipt of such notice and the payment of the purchase price. Such notice shall specify the number of shares of Common Stock with respect to which the option is being exercised. Options may be exercised by the optionee in whole at any time or in part from time to time, to the extent that the options become vested and exercisable, prior to their expiration date, and provided that the optionee is employed by or providing services to Firefly or any of its affiliates during the period beginning with grant date and ending upon the date of exercise. Options, to the extent not previously exercised, shall terminate upon the earlier of: (i) the date set forth in the option agreement; (ii) ninety days after a termination without cause; (iii) six months following a termination as a result of death or disability; or (iv) if further extended by the Committee prior to date of termination. Â Dividends.Â With respect to all shares of Common Stock allocated or issued upon the exercise of options purchased by the optionee and held by the optionee or by the trustee, as the case may be, the optionee shall be entitled to receive dividends in accordance with the quantity of such shares of Common Stock, subject to Fireflyâ€™s Articles of Association (and all amendments thereto) and any applicable taxation on distribution of dividends and, when applicable, subject to the provisions of Section 102 and the rules, regulations or orders promulgated thereunder. Â Certain Adjustments; Corporate Transaction Events. In the event of a merger, acquisition or reorganization of Firefly with one or more other entities in which Firefly is not the surviving entity or a sale of all or substantially all of the assets of Firefly, the Board or the Committee may resolve that the unexercised options then outstanding under the Firefly 2007 Incentive Plan shall be assumed or substituted for an appropriate number of shares or other securities of the successor company (or a parent or subsidiary of the successor company) as were distributed to the shareholders of Firefly in connection and with respect to such a transaction. In the case of such assumption and/or substitution of options, appropriate adjustments shall be made to the purchase price so as to reflect such action and all other terms and conditions of the option agreements shall remain unchanged, including, but not limited to, the vesting schedule, subject to the determination of the Committee or the Board, which determination shall be in their sole and absolute discretion. Â Amendment, Termination. The Board may at any time, but when applicable, after consultation with the trustee, amend, alter, suspend or terminate the Firefly 2007 Incentive Plan. No amendment, alteration, suspension, or termination of the Firefly 2007 Incentive Plan shall impair the rights of any optionee, unless mutually agreed otherwise between the optionee and Firefly, which agreement must be in writing and signed by the optionee and Firefly. Termination of the Firefly 2007 Incentive Plan shall not affect the Committeeâ€™s ability to exercise the powers granted to it under the Firefly 2007 Incentive Plan prior to the date of such termination. Â Firefly 2023 Incentive Plan Â Firefly adopted the Firefly 2023 Omnibus Equity Incentive Plan (the â€œFirefly 2023 Incentive Planâ€) on July 8, 2023. The Firefly 2023 Incentive Plan was adopted to advance the interest of Fireflyâ€™s stockholders by enhancing Fireflyâ€™s ability to attract, retain, and motivate persons who are expected to make important contributions to Firefly by (i) providing Firefly with a mechanism to attract, retain and motivate highly qualified directors, officers, employees and consultants, (ii) aligning the interests of such persons with those of Fireflyâ€™s stockholders, and (iii) enabling and encouraging such persons to participate in the long-term growth of Firefly. The Firefly 2023 Incentive Plan authorizes the grant of stock options, share appreciation rights, deferred share units, restricted share units, and performance share units, or a combination of the foregoing. Â 74 Â Â At the effective time of the merger, we assumed all of Fireflyâ€™s rights and obligations under all stock options granted under the Firefly 2023 Incentive Plan that are outstanding immediately prior to the effective time of the merger. In addition, the Firefly 2023 Incentive Plan will be assumed by WaveDancer at the effective time of the merger, provided that no additional awards may be issued thereunder. Â Authorized Shares. A total of 4,440,355 shares of Common Stock have been authorized for the grant of awards under the Firefly 2023 Incentive Plan. Â Plan Administration. The Firefly 2023 Incentive Plan is administered by the Firefly board of directors or if so delegated in whole or in part by the Firefly board of directors, the Compensation Committee of the Firefly board of directors, or any other duly authorized committee of the board of directors appointed by the board of directors to administer the Firefly 2023 Incentive Plan (the â€œCommitteeâ€). The Committee shall have full and exclusive discretionary power to interpret the terms and the intent of the Firefly 2023 Incentive Plan and any award agreement or other agreement ancillary to or in connection with the Firefly 2023 Incentive Plan, to determine eligibility for awards, and to adopt such rules, regulations and guidelines for administering the Firefly 2023 Incentive Plan as the Committee may deem necessary or proper. Such authority shall include, but not be limited to, selecting award recipients, establishing all award terms and conditions, including grant, exercise price, issue price and vesting terms, whether awards payout in cash or shares where applicable, determining any performance goals applicable to awards and whether such performance goals have been achieved and adopting modifications and amendments to the Firefly 2023 Incentive Plan or any award agreement, including, without limitation, any that are necessary or appropriate to comply with the laws or compensation practices of the jurisdictions in which Firefly and its affiliates operate. Â Stock Options. Options granted under the Firefly 2023 Incentive Plan may be granted to participants in such number, and upon such terms, and at any time and from time to time as shall be determined by the Committee in its discretion. Each stock option grant shall be evidenced by an award agreement that shall specify the option price, the duration of the option, the number of shares to which the option pertains, the conditions, if any, upon which an option shall become vested and exercisable, and any such other provisions as the Committee shall determine. Options may not have an exercise price per share of less than 100% of the fair market value of a share on the date of grant. Subject to any provisions of the Firefly 2023 Incentive Plan or the applicable award agreement relating to acceleration of vesting of options, regulatory requirements and the policies of the designated stock exchange or trading platform, the Committee shall determine the vesting provisions of each grant of options at the time. Notwithstanding the foregoing, options granted to any consultant or persons retained to provide investor relations activities shall vest in stages over a period of not less than twelve months with no more than one-quarter of the options vesting in any three-month period. Each option shall expire at such time as the Committee shall determine at the time of grant, provided, however, that, subject to any blackout periods, no option shall be exercisable later than the seventh anniversary date of its grant. The treatment of options under the Firefly 2023 Incentive Plan upon a participantâ€™s termination of employment with or service to Firefly is set forth in the applicable award agreement or the Firefly 2023 Incentive Plan, but in no event can options terminate more than one year following the participantâ€™s termination. Â Share Appreciation Rights (â€œSARSâ€). Subject to any provisions of the Firefly 2023 Incentive Plan or an applicable award agreement, SARs may be granted to participants at any time and from time to time and upon such terms as shall be determined by the Committee in its discretion. Each SAR award shall be evidenced by an award agreement that shall specify the grant price, the term, and any such other provisions as the Committee shall determine. No SAR shall be exercisable later than the tenth anniversary date of its grant. Upon the exercise of a SAR, a participant shall be entitled to receive payment from Firefly in an amount representing the difference between the of the underlying shares on the date of exercise over the grant price. At the discretion of the Committee, the payment upon the exercise of a SAR may be in cash, shares of equivalent value (based on the fair market value of the shares on the date of exercise of the SAR, as defined in the award agreement or otherwise defined by the Committee thereafter), in some combination thereof, or in any other form approved by the Committee at its sole discretion. The treatment of SARs under the Firefly 2023 Incentive Plan upon a participantâ€™s termination of employment with or service to Firefly is set forth in the applicable award agreement or the Firefly 2023 Incentive Plan, but in no event can SARs terminate more than one year following the participantâ€™s termination. Â 75 Â Â Deferred Share Units. Subject to any provisions of the Firefly 2023 Incentive Plan or an applicable award agreement, the Committee, at any time and from time to time, may grant Deferred Share Units to participants in such amounts and upon such terms as the Committee shall determine. Each Deferred Share Unit grant shall be evidenced by an award agreement that shall specify the number of Deferred Share Units granted, the settlement date for Deferred Share Units, and any other provisions as the Committee shall determine, including, but not limited to, a requirement that

participants pay a stipulated purchase price for each Deferred Share Unit, restrictions based upon the achievement of specific performance criteria, time-based restrictions, restrictions under applicable laws or other requirements, or holding requirements or sale restrictions placed on the shares upon vesting of such Deferred Share Units. The treatment of Deferred Share Units under the Firefly 2023 Incentive Plan upon a participantâ€™s termination of employment with or service to Firefly is set forth in the applicable award agreement or the Firefly 2023 Incentive Plan, but in no event can Deferred Share Units terminate more than one year following the participantâ€™s termination. Â Restricted Share Units. Subject to any provisions of the Firefly 2023 Incentive Plan or an applicable award agreement, the Committee, at any time and from time to time, may grant Restricted Share Units to participants in such amounts and upon such terms as the Committee shall determine. Each Restricted Share Unit grant shall be evidenced by an award agreement that shall specify the period of any restrictions, the number of Restricted Share Units granted, the settlement date for Restricted Share Units, whether such Restricted Share Unit is settled in cash, shares or a combination thereof or if the form of payment is reserved for later determination by the Committee, and any such other provisions as the Committee shall determine, provided that unless otherwise determined by the Committee or as set out in any award agreement. The Committee shall impose, in the award agreement at the time of grant, such other conditions and/or restrictions on any Restricted Share Units granted pursuant to the Firefly 2023 Incentive Plan as it may deem advisable, including, without limitation, restrictions based upon the achievement of specific performance criteria, time-based restrictions on vesting following the attainment of the performance criteria, time-based restrictions, restrictions under applicable laws or other requirements. Â Performance Share Units. Subject to any provisions of the Firefly 2023 Incentive Plan or an applicable award agreement, the Committee, at any time and from time to time, may grant Performance Share Units to participants in such amounts and upon such terms as the Committee shall determine. Each Performance Share Unit shall have an initial value equal to the fair market value of a share on the date of grant. The Committee shall set performance criteria for a performance period in its discretion, which, depending on the extent to which they are met, will determine, in the manner determined by the Committee and set forth in the award agreement, the value and/or number of each Performance Share Unit that will be paid to the participant. Subject to the terms of the Firefly 2023 Incentive Plan and the applicable award agreement, after the applicable performance period has ended, the holder of Performance Share Units shall be entitled to receive payout on the value and number of Performance Share Units, determined as a function of the extent to which the corresponding performance criteria have been achieved. Notwithstanding the foregoing, Firefly shall have the ability to require the participant to hold any shares received pursuant to such award for a specified period of time. Payment of earned Performance Share Units shall be as determined by the Committee and as set forth in the award agreement. Subject to the terms of the Firefly 2023 Incentive Plan, the Committee, in its sole discretion, may pay earned Performance Share Units in the form of: (i) cash equal to the value of the earned Performance Share Units at the end of the applicable performance period, (ii) a number of shares issued from treasury equal to the number of earned Performance Share Units at the end of the applicable performance period, or (iii) in a combination thereof in the discretion of Firefly. Any shares may be granted subject to any restrictions deemed appropriate by the Committee. The determination of the Committee with respect to the form of payout of such awards shall be set forth in the award agreement for the grant of the award or reserved for later determination. The treatment of Performance Share Units under the Firefly 2023 Incentive Plan upon a participantâ€™s termination of employment with or service to Firefly is set forth in the applicable award agreement or the Firefly 2023 Incentive Plan, but in no event can Performance Share Units terminate more than one year following the participantâ€™s termination. Â Certain Adjustments; Corporate Reorganization Events. In the event of any corporate event or transaction (collectively, a â€œCorporate Reorganizationâ€) (including, but not limited to, a change in the shares or the capitalization of Firefly) such as a merger, arrangement, amalgamation, consolidation, reorganization, recapitalization, separation, stock dividend, extraordinary dividend, stock split, reverse stock split, split up, spin-off or other distribution of stock or property of Firefly, combination of securities, exchange of securities, dividend in kind, or other like change in capital structure or distribution (other than normal cash dividends) to stockholders of Firefly, or any similar corporate event or transaction, the Committee shall make or provide for such adjustments or substitutions, as applicable, in the number and kind of shares that may be issued under the Firefly 2023 Incentive Plan, the number and kind of shares subject to outstanding awards, the option price or grant price applicable to outstanding awards, the limit on issuing awards other than options granted with an option price equal to at least the fair market value of a share on the date of grant or SARs with a grant price equal to at least the fair market value of a share on the date of grant, and any other value determinations applicable to outstanding awards or to the Firefly 2023 Incentive Plan, as are equitably necessary to prevent dilution or enlargement of participantsâ€™ rights under the Firefly 2023 Incentive Plan that otherwise would result from such corporate event or transaction. In connection with a Corporate Reorganization, the Committee shall have the discretion to permit a holder of options to purchase (at the times, for the consideration, and subject to the terms and conditions set out in the Firefly 2023 Incentive Plan and the applicable award agreement) and the holder will then accept on the exercise of such option, in lieu of the shares that such holder would otherwise have been entitled to purchase, the kind and amount of shares or other securities or property that such holder would have been entitled to receive as a result of the Corporate Reorganization if, on the effective date thereof, that holder had owned all shares that were subject to the option. Such adjustments shall be made automatically, without the necessity of Committee action, on the customary arithmetical basis in the case of any stock split, including a stock split effected by means of a stock dividend, and in the case of any other dividend paid in shares. Â 76 Â Â The Committee shall also make appropriate adjustments in the terms of any awards under the Firefly 2023 Incentive Plan as are equitably necessary to reflect such Corporate Reorganization and may modify any other terms of outstanding awards, including modifications of performance criteria and changes in the length of performance periods. The determination of the Committee as to the foregoing adjustments, if any, shall be conclusive and binding on participants under the Firefly 2023 Incentive Plan, provided that any such adjustments must comply with Section 409A of the Code with respect to any U.S. participants. Subject to the Firefly 2023 Incentive Plan and any applicable law or regulatory requirement, without affecting the number of shares reserved or available hereunder, the Committee may authorize the issuance, assumption, substitution or conversion of awards under the Firefly 2023 Incentive Plan in connection with any Corporate Reorganization, upon such terms and conditions as it may deem appropriate. Additionally, the Committee may amend the Plan, or adopt supplements to the Firefly 2023 Incentive Plan, in such manner as it deems appropriate to provide for such issuance, assumption, substitution or conversion as provided in the previous sentence. Â Amendment, Termination. The Firefly board at any time, and from time to time, may amend or suspend any provision of an award or the Firefly 2023 Incentive Plan, or terminate the Firefly 2023 Incentive Plan, subject to those provisions that require the approval of security holders or any governmental or regulatory body regardless of whether any such amendment or suspension is material, fundamental or otherwise, and notwithstanding any rule of common law or equity to the contrary. Â Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan Â Prior to the consummation of the Merger, at a special meeting of WaveDancerâ€™s stockholders on March 14, 2024, the stockholders of WaveDancer considered and approved the WaveDancer 2024 Long-Term Incentive Plan (the â€œWaveDancer Incentive Planâ€). The WaveDancer Incentive Plan was previously approved and adopted, subject to stockholder approval, by the WaveDancer Board on February 1, 2024. On the Closing Date and following the consummation of the Merger, the Board approved the adoption of the WaveDancer Incentive Plan and to change the name of the WaveDancer Incentive Plan to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (the â€œ2024 Planâ€). Â Purpose. The purpose of the 2024 Plan is to enable us to remain competitive and innovative in our ability to attract and retain the services of our key employees, key contractors, and non-employee directors of Firefly or any of our subsidiaries. The 2024 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares of our Common Stock. The 2024 Plan is expected to provide flexibility to our compensation methods in order to adapt the compensation of our key employees, key contractors, and non-employee directors to a changing business environment, after giving due consideration to competitive conditions and the impact of applicable tax laws. Â Effective Date and Expiration. The 2024 Plan was approved by our board of directors on February 1, 2024, subject to the 2024 Planâ€™s approval by our stockholders, and will become effective on the date of such approval (the â€œEffective Dateâ€). The 2024 Plan will terminate on the tenth anniversary of the Effective Date, unless sooner terminated by our board of directors. No awards may be made under the 2024 Plan after its termination date, but awards made prior to the termination date may extend beyond that date in accordance with their terms. Â Share Authorization. Subject to certain adjustments, the number of shares of our Common Stock that are reserved for issuance pursuant to awards under the 2024 Plan is eight hundred thirty-three thousand three hundred thirty-three (833,333) shares, 100% of which may be delivered as incentive stock options. Shares to be issued may be made available from authorized but unissued shares of our Common Stock, shares held by us in our treasury, or shares purchased by us on the open market or otherwise. During the term of the 2024 Plan, we will at all times reserve and keep enough shares available to satisfy the requirements of the 2024 Plan. If an award under the 2024 Plan is cancelled, forfeited, or expires, in whole or in part, the shares subject to such forfeited, expired, or cancelled award may again be awarded under the 2024 Plan. Awards that may be satisfied either by the issuance of Common Stock or by cash or other consideration shall be counted against the maximum number of shares that may be issued under the 2024 Plan only during the period that the award is outstanding or to the extent the award is ultimately satisfied by the issuance of shares. An award will not reduce the number of shares that may be issued pursuant to the 2024 Plan if the settlement of the award will not require the issuance of shares, as, for example, a stock appreciation right that can be satisfied only by the payment of cash. Shares of Common Stock that are otherwise deliverable pursuant to an award under the 2024 Plan that are withheld in payment of the option price of an option or for payment of applicable employment taxes and/or withholding obligations resulting from the award shall be treated as delivered to the award recipient and shall be counted against the maximum number of shares of our Common Stock that may be issued under the 2024 Plan. Only shares forfeited back to us or cancelled on account of termination, expiration, or lapse of an award shall again be available for grant of incentive stock options under the 2024 Plan but shall not increase the maximum number of shares described above as the maximum number of shares of our Common Stock that may be delivered pursuant to incentive stock options. Â 77 Â Â Administration. Subject to the terms of the 2024 Plan, the 2024 Plan shall be administered by the Board or such committee of the Board of Directors as is designated by the Board of Directors to administer the Plan (the â€œCommitteeâ€). Membership on the Committee shall be limited to â€œnon-employee directorsâ€ in accordance with Rule 16b-3 under the Securities Exchange Act of 1934, as amended. The Committee may delegate certain duties to one or more officers as provided in the 2024 Plan. The Committee will determine the persons to whom awards are to be made, determine the type, size and terms of awards, interpret the 2024 Plan, establish and revise rules and regulations relating to the 2024 Plan and make any other determinations that it believes necessary for the administration of the 2024 Plan. Â Eligibility. Employees (including any employee who is also a director or an officer), contractors, and non-employee directors of Firefly or any of our subsidiaries, whose judgment, initiative, and efforts contributed to or may be expected to contribute to our successful performance, are eligible to participate in the 2024 Plan. As of the date of this prospectus, we have seven full time employees and six contractors who would be eligible for awards under the 2024 Plan. Â Stock Options. The Committee may grant either incentive stock options (â€œISOsâ€) qualifying under Section 422 of the Internal Revenue Code of 1986, as amended (the â€œCodeâ€), or nonqualified stock options, provided that only employees of Firefly and our subsidiaries (excluding subsidiaries that are not corporations) are eligible to receive ISOs. Stock options may not be granted with an option price less than 100% of the fair market value of a share of Common Stock on the date the stock option is granted. If an ISO is granted to an employee who owns or is deemed to own more than 10% of the combined voting power of all classes of our stock (or of any parent or subsidiary), the option price shall be at least 110% of the fair market value of a share of Common Stock on the date of grant. The Committee will determine the terms of each stock option at the time of grant, including, without limitation, the methods by or forms in which shares will be delivered to participants or registered in their names. The maximum term of each option, the times at which each option will be exercisable, and provisions requiring forfeiture of unexercised options at or following termination of employment or service generally are fixed by the Committee, except that the Committee may not grant stock options with a term exceeding 10 years or, in the case of an ISO granted to an employee who owns or is deemed to own more than 10% of the combined voting power of all classes of our stock (or of any parent or subsidiary), a term exceeding five years. Â Recipients of stock options may pay the option price (i) in cash, check, bank draft, or money order payable to the order of Firefly; (ii) by delivering to us shares of our Common Stock (included restricted stock) already owned by the participant having a fair market value equal to the aggregate option price and that the participant has not acquired from us within six months prior to the exercise date; (iii) by delivering to us or our designated agent an executed irrevocable option exercise form, together with irrevocable instructions from the participant to a broker or dealer, reasonably acceptable to us, to sell certain of the shares purchased upon the exercise of the option or to pledge such shares to the broker as collateral for a loan from the broker and to deliver to us the amount of sale or loan proceeds necessary to pay the purchase price; (iv) by requesting us to withhold the number of shares otherwise deliverable upon exercise of the stock option by the number of shares having an aggregate fair market value equal to the aggregate option price at the time of exercise (i.e., a cashless net exercise); and (v) by any other form of valid consideration that is acceptable to the Committee in its sole discretion. No dividends or dividend equivalent rights may be paid or granted with respect to any stock options granted under the 2024 Plan. Â 78 Â Â Stock Appreciation Rights. The Committee is authorized to grant stock appreciation rights (â€œSARsâ€) as a stand-alone award, or freestanding SARs, or in conjunction with options granted under the 2024 Plan, or tandem SARs. SARs entitle a participant to receive an amount equal to the excess of the fair market value of a share of Common Stock on the date of exercise over the fair market value of a share of our Common Stock on the date of grant. The exercise price of a SAR cannot be less than 100% of the fair market value of a share of our Common Stock on the date of grant. The Committee will determine the terms of each SAR at the time of the grant, including, without limitation, the methods by or forms in which shares will be delivered to participants or registered in their names. The maximum term of each SAR, the times at which each SAR will be exercisable, and provisions requiring forfeiture of unexercised SARs at or following termination of employment or service generally are fixed by the Committee, except that no freestanding SAR may have a term exceeding 10 years and no tandem SAR may have a term exceeding the term of the option granted in conjunction with the tandem SAR. Distributions to the recipient may be made in Common Stock, cash, or a combination of both as determined by the Committee. No dividends or dividend equivalent rights may be paid or granted with respect to any SARs granted under the 2024 Plan. Â Restricted Stock and Restricted Stock Units. The Committee is authorized to grant restricted stock and restricted stock units. Restricted stock consists of shares of our Common Stock that may not be sold, assigned, transferred, pledged, hypothecated, encumbered, or otherwise disposed of, and that may be forfeited in the event of certain terminations of employment or service, prior to the end of a restricted period as specified by the Committee. Restricted stock units are the right to receive shares of Common Stock at a future date in accordance with the terms of such grant upon the attainment of certain conditions specified by the Committee, which include a substantial risk of forfeiture and restrictions on their sale or other transfer by the participant. The Committee determines the eligible participants to whom, and the time or times at which, grants of restricted stock or restricted stock units will be made; the number of shares or units to be granted; the price to be paid, if any; the time or times within which the shares covered by such grants will be subject to forfeiture; the time or times at which the restrictions will terminate; and all other terms and conditions of the grants. Restrictions or conditions could include, but are not limited to, the attainment of performance goals (as described below), continuous service with us, the passage of time, or other restrictions and conditions. Except as otherwise provided in the 2024 Plan or the applicable award agreement, a participant shall have, with respect to shares of restricted stock, all of the rights of a stockholder of Firefly holding the class of Common Stock that is the subject of the restricted stock, including, if applicable, the right to vote the Common Stock and the right to receive any dividends thereon. Â Performance Awards. The Committee may grant performance awards payable at the end of a specified performance period in cash, shares of Common Stock, units, or other rights based upon, payable in, or otherwise related to our Common Stock. Payment will be contingent upon achieving pre-established performance goals (as discussed below) by the end of the applicable performance period. The Committee will determine the length of the performance period, the maximum payment value of an award, and the minimum performance goals required before payment will be made, so long as such provisions are not inconsistent with the terms of the 2024 Plan and, to the extent an award is subject to Section 409A of the Code, are in compliance with the applicable requirements of Section 409A of the Code and any applicable regulations or guidance. In certain circumstances, the Committee may, in its discretion, determine that the amount payable with respect to certain performance awards will be reduced from the maximum amount of any potential awards. If the Committee determines, in its sole discretion, that the established performance measures or objectives are no longer suitable because of a change in our business, operations, corporate structure, or for other reasons that the Committee deems satisfactory, the Committee may modify the performance measures or objectives and/or the performance period. Â Performance Goals. Awards (whether relating to cash or Common Stock) under the 2024 Plan may be made subject to the attainment of performance goals relating to one or more business criteria, and may consist of one or more or any combination of the following criteria: cash flow; cost; revenues; sales; ratio of debt to debt plus equity; net borrowing, credit quality or debt ratings; profit before tax; economic profit; earnings before interest and taxes; earnings before interest, taxes, depreciation and

amortization; gross margin; earnings per share (whether on a pre-tax, after-tax, operational or other basis); operating earnings; capital expenditures; expenses or expense levels; economic value added; ratio of operating earnings to capital spending or any other operating ratios; free cash flow; net profit; net sales; net asset value per share; the accomplishment of mergers, acquisitions, dispositions, public offerings or similar extraordinary business transactions; sales growth; price of our Common Stock; return on assets, equity or stockholdersâ€™ equity; market share; inventory levels, inventory turn or shrinkage; total return to stockholders; or any other criteria determined by the Committee (â€œPerformance Criteriaâ€). Any Performance Criteria may be used to measure the performance of Firefly as a whole or any business unit of Firefly and may be measured relative to a peer group or index. Any Performance Criteria may include or exclude (i) events that are of an unusual nature or indicate infrequency of occurrence, (ii) gains or losses on the disposition of a business, (iii) changes in tax or accounting regulations or laws, (iv) the effect of a merger or acquisition, as identified in our quarterly and annual earnings releases, or (v) other similar occurrences. In all other respects, Performance Criteria shall be calculated in accordance with our financial statements, under generally accepted accounting principles, or under a methodology established by the Committee prior to the issuance of an award which is consistently applied and identified in the audited financial statements, including footnotes, or the Compensation Discussion and Analysis section of our annual report. Â 79 Â Â Other Awards. The Committee may grant other forms of awards, based upon, payable in, or that otherwise relate to, in whole or in part, shares of our Common Stock, if the Committee determines that such other form of award is consistent with the purpose and restrictions of the 2024 Plan. The terms and conditions of such other form of award shall be specified in the grant. Such other awards may be granted for no cash consideration, for such minimum consideration as may be required by applicable law, or for such other consideration as may be specified in the grant. Â Vesting of Awards, Forfeiture, Assignment. The Committee, in its sole discretion, may determine that an award will be immediately vested, in whole or in part, or that all or any portion may not be vested until a date, or dates, subsequent to its date of grant, or until the occurrence of one or more specified events, subject in any case to the terms of the 2024 Plan. If the Committee imposes conditions upon vesting, then, subsequent to the date of grant, the Committee may, in its sole discretion, accelerate the date on which all or any portion of the award may be vested. Â The Committee may impose on any award at the time of grant or thereafter, such additional terms and conditions as the Committee determines, including terms requiring forfeiture of awards in the event of a participantâ€™s termination of employment or service. The Committee will specify the circumstances on which performance awards may be forfeited in the event of a termination of service by a participant prior to the end of a performance period or settlement of awards. Except as otherwise determined by the Committee, restricted stock will be forfeited upon a participantâ€™s termination of employment or service during the applicable restriction period. In addition, we may recoup all or any portion of any shares or cash paid to a participant in connection with any award in the event of a restatement of our financial statements as set forth in our clawback policy, if any, as such policy may be approved or modified by our board of directors from time to time. Â Awards granted under the 2024 Plan generally are not assignable or transferable except by will or by the laws of descent and distribution, except that the Committee may, in its discretion and pursuant to the terms of an award agreement, permit transfers of awards to (i) the spouse (or former spouse), children, or grandchildren of the participant (â€œImmediate Family Membersâ€); (ii) a trust or trusts for the exclusive benefit of such Immediate Family Members; (iii) a partnership in which the only partners are (a) such Immediate Family Members and/or (b) entities which are controlled by the participant and/or his or her Immediate Family Members; (iv) an entity exempt from federal income tax pursuant to Section 501(c)(3) of the Code or any successor provision; or (v) a split interest trust or pooled income fund described in Section 2522(c)(2) of the Code or any successor provision, provided that (x) there shall be no consideration for any such transfer, (y) the applicable award agreement pursuant to which such awards are granted must be approved by the Committee and must expressly provide for such transferability, and (z) subsequent transfers of awards shall be prohibited except those by will or the laws of descent and distribution. Â Adjustments Upon Changes in Capitalization. In the event that any dividend or other distribution (whether in the form of cash, shares of our Common Stock, other securities or other property), recapitalization, stock split, reverse stock split, rights offering, reorganization, merger, consolidation, split-up, spin-off, split-off, combination, subdivision, repurchase, or exchange of shares of Common Stock or other securities, issuance of warrants or other rights to purchase shares of Common Stock or other securities, or other similar corporate transaction or event affects the fair value of an award, then the Committee shall adjust any or all of the following so that the fair value of the award immediately after the transaction or event is equal to the fair value of the award immediately prior to the transaction or event: (i) the number of shares and type of Common Stock (or the securities or property) which thereafter may be made the subject of awards; (ii) the number of shares and type of Common Stock (or other securities or property) subject to outstanding awards; (iii) the option price of each outstanding stock option; (iv) the amount, if any, we pay for forfeited shares in accordance with the terms of the 2024 Plan; and (v) the number of or exercise price of shares then subject to outstanding SARs previously granted and unexercised under the 2024 Plan, to the end that the same proportion of our issued and outstanding shares of Common Stock in each instance shall remain subject to exercise at the same aggregate exercise price; provided, however, that the number of shares of Common Stock (or other securities or property) subject to any award shall always be a whole number. Notwithstanding the foregoing, no such adjustment shall be made or authorized to the extent that such adjustment would cause the 2024 Plan or any stock option to violate Section 422 of the Code or Section 409A of the Code. All such adjustments must be made in accordance with the rules of any securities exchange, stock market, or stock quotation system to which we are subject. Â 80 Â Â Amendment or Discontinuance of the 2024 Plan. Our board of directors may, at any time and from time to time, without the consent of participants, alter, amend, revise, suspend, or discontinue the 2024 Plan in whole or in part; provided, however, that (i) no amendment that requires stockholder approval in order for the 2024 Plan and any awards under the 2024 Plan to continue to comply with Sections 421 and 422 of the Code (including any successors to such sections or other applicable law) or any applicable requirements of any securities exchange or inter-dealer quotation system on which our stock is listed or traded, shall be effective unless such amendment is approved by the requisite vote of our stockholders entitled to vote on the amendment; and (ii) unless required by law, no action by our board of directors regarding amendment or discontinuance of the 2024 Plan may adversely affect any rights of any participants or obligations to any participants with respect to any outstanding awards under the 2024 Plan without the consent of the affected participant. Â No Repricing of Stock Options or SARs. The Committee may not â€œrepriceâ€ any stock option or SAR without stockholder approval. For purposes of the 2024 Plan, â€œrepriceâ€ means any of the following or any other action that has the same effect: (i) amending a stock option or SAR to reduce its exercise price or base price, (ii) canceling a stock option or SAR at a time when its exercise price or base price exceeds the fair market value of a share of Common Stock in exchange for cash or a stock option, SAR, award of restricted stock or other equity award, or (iii) taking any other action that is treated as a repricing under generally accepted accounting principles, provided that nothing shall prevent the Committee from (x) making adjustments to awards upon changes in capitalization; (y) exchanging or cancelling awards upon a merger, consolidation, or recapitalization, or (z) substituting awards for awards granted by other entities, to the extent permitted by the 2024 Plan. Â Recoupment for Restatements. The Committee may recoup all or any portion of any shares or cash paid to a participant in connection with an award, in the event of a restatement of our financial statements as set forth in our clawback policy, if any, approved by the Board from time to time. Â Federal Income Tax Consequences Â The following is a brief summary of certain federal income tax consequences relating to the transactions described under the 2024 Plan as set forth below. This summary does not purport to address all aspects of federal income taxation and does not describe any potential state, local, or foreign tax consequences. This discussion is based upon provisions of the Code and the applicable treasury regulations issued thereunder, and judicial and administrative interpretations under the Code and treasury regulations, all as in effect as of the date hereof, and all of which are subject to change (possibly on a retroactive basis) or different interpretation. Â Law Affecting Deferred Compensation. In 2004, Section 409A was added to the Code to regulate all types of deferred compensation. If the requirements of Section 409A of the Code are not satisfied, deferred compensation and earnings thereon will be subject to tax as it vests, plus an interest charge at the underpayment rate plus 1% and a 20% penalty tax. Certain performance awards, stock options, SARs, restricted stock units, and certain types of restricted stock are subject to Section 409A of the Code. Â Incentive Stock Options. A participant will not recognize income at the time an ISO is granted. When a participant exercises an ISO, a participant also generally will not be required to recognize income (either as ordinary income or capital gain). However, to the extent that the fair market value (determined as of the date of grant) of the shares with respect to which the participantâ€™s ISOs are exercisable for the first time during any year exceeds $100,000, the ISOs for the shares over $100,000 will be treated as nonqualified stock options, and not ISOs, for federal tax purposes, and the participant will recognize income as if the ISOs were nonqualified stock options. In addition to the foregoing, if the fair market value of the shares received upon exercise of an ISO exceeds the option price, then the excess may be deemed a tax preference adjustment for purposes of the federal alternative minimum tax calculation. The federal alternative minimum tax may produce significant tax repercussions depending upon the participantâ€™s particular tax status. Â The tax treatment of any shares acquired by exercise of an ISO will depend upon whether the participant disposes of his or her shares prior to the later of: (i) two years after the date the ISO was granted or (ii) one year after the shares were transferred to the participant (referred to as the â€œHolding Periodâ€). If a participant disposes of shares acquired by exercise of an ISO after the expiration of the Holding Period, any amount received in excess of the participantâ€™s tax basis for such shares will be treated as a short-term or long-term capital gain, depending upon how long the participant has held the shares. If the amount received is less than the participantâ€™s tax basis for such shares, the loss will be treated as a short-term or long-term capital loss, depending upon how long the participant has held the shares. If the participant disposes of shares acquired by exercise of an ISO prior to the expiration of the Holding Period, the disposition will be considered a â€œdisqualifying disposition.â€ If the amount received for the shares is greater than the fair market value of the shares on the exercise date, then the difference between the ISOâ€™s option price and the fair market value of the shares at the time of exercise will be treated as ordinary income for the tax year in which the â€œdisqualifying dispositionâ€ occurs. The participantâ€™s basis in the shares will be increased by an amount equal to the amount treated as ordinary income due to such â€œdisqualifying disposition.â€ In addition, the amount received in such â€œdisqualifying dispositionâ€ over the participantâ€™s increased basis in the shares will be treated as capital gain. However, if the price received for shares acquired by exercise of an ISO is less than the fair market value of the shares on the exercise date and the disposition is a transaction in which the participant sustains a loss which otherwise would be recognizable under the Code, then the amount of ordinary income that the participant will recognize is the excess, if any, of the amount realized on the â€œdisqualifying dispositionâ€ over the basis of the shares. Â 81 Â Â Nonqualified Stock Options. A participant generally will not recognize income at the time a nonqualified stock option is granted. When a participant exercises a nonqualified stock option, the difference between the option price and any higher market value of the shares of Common Stock on the date of exercise will be treated as compensation taxable as ordinary income to the participant. The participantâ€™s tax basis for the shares acquired under a nonqualified stock option will be equal to the option price paid for such shares, plus any amounts included in the participantâ€™s income as compensation. When a participant disposes of shares acquired by exercise of a nonqualified stock option, any amount received in excess of the participantâ€™s tax basis for such shares will be treated as short-term or long-term capital gain, depending upon how long the participant has held the shares. If the amount received is less than the participantâ€™s tax basis for such shares, the loss will be treated as a short-term or long-term capital loss, depending upon how long the participant has held the shares. Â Special Rule if Option Price is Paid for in Shares. If a participant pays the option price of a nonqualified stock option with previously-owned shares of our Common Stock and the transaction is not a disqualifying disposition of shares previously acquired under an ISO, the shares received equal to the number of shares surrendered are treated as having been received in a tax-free exchange. The participantâ€™s tax basis and holding period for these shares received will be equal to the participantâ€™s tax basis and holding period for the shares surrendered. The shares received in excess of the number of shares surrendered will be treated as compensation taxable as ordinary income to the participant to the extent of their fair market value. The participantâ€™s tax basis in these shares will be equal to their fair market value on the date of exercise, and the participantâ€™s holding period for such shares will begin on the date of exercise. Â If the use of previously acquired shares to pay the option price of a nonqualified stock option constitutes a disqualifying disposition of shares previously acquired under an ISO, the participant will have ordinary income as a result of the disqualifying disposition in an amount equal to the excess of the fair market value of the shares surrendered, determined at the time such shares were originally acquired on exercise of the ISO, over the aggregate option price paid for such shares. As discussed above, a disqualifying disposition of shares previously acquired under an ISO occurs when the participant disposes of such shares before the end of the Holding Period. The other tax results from paying the option price with previously-owned shares are as described above, except that the participantâ€™s tax basis in the shares that are treated as having been received in a tax-free exchange will be increased by the amount of ordinary income recognized by the participant as a result of the disqualifying disposition. Â Restricted Stock. A participant who receives restricted stock generally will recognize as ordinary income the excess, if any, of the fair market value of the shares granted as restricted stock at such time as the shares are no longer subject to forfeiture or restrictions, over the amount paid, if any, by the participant for such shares. However, a participant who receives restricted stock may make an election under Section 83(b) of the Code within 30 days of the date of transfer of the shares to recognize ordinary income on the date of transfer of the shares equal to the excess of the fair market value of such shares (determined without regard to the restrictions on such shares) over the purchase price, if any, of such shares. If a participant does not make an election under Section 83(b) of the Code, then the participant will recognize as ordinary income any dividends received with respect to such shares. At the time of sale of such shares, any gain or loss realized by the participant will be treated as either short-term or long-term capital gain (or loss) depending on the holding period. For purposes of determining any gain or loss realized, the participantâ€™s tax basis will be the amount previously taxable as ordinary income, plus the purchase price paid by the participant, if any, for such shares. Â Stock Appreciation Rights. Generally, a participant who receives a stand-alone SAR will not recognize taxable income at the time the stand-alone SAR is granted, provided that the SAR is exempt from or complies with Section 409A of the Code. If a participant receives the appreciation inherent in the SARs in cash, the cash will be taxed as ordinary income to the recipient at the time it is received. If a recipient receives the appreciation inherent in the SARs in stock, the spread between the then current market value and the exercise price, if any, will be taxed as ordinary income to the participant at the time it is received. Â 82 Â Â Other Awards. In the case of an award of restricted stock units, performance awards, or other stock or cash awards, the recipient will generally recognize ordinary income in an amount equal to any cash received and the fair market value of any shares received on the date of payment or delivery, provided that the award is exempt from or complies with Section 409A of the Code. In that taxable year, we will receive a federal income tax deduction in an amount equal to the ordinary income which the participant has recognized. Â Federal Tax Withholding. Any ordinary income realized by a participant upon the granting, vesting, exercise, or conversion of an award under the 2024 Plan, as applicable, is subject to withholding of applicable federal, state, and local income tax and to withholding of the participantâ€™s share of any tax under the Federal Insurance Contribution Act and the Federal Unemployment Tax Act. To satisfy our federal income tax withholding requirements, we will have the right to require, as a condition to delivery of any certificate for shares of our Common Stock or the registration of the shares in the participantâ€™s name, that the participant remit to us an amount sufficient to satisfy those withholding requirements. Alternatively, we may withhold a portion of the shares (valued at fair market value) that otherwise would be issued to the participant to satisfy all or part of the withholding tax obligations or may, if we consent, accept delivery of shares (that the participant has not acquired from us within six months prior to the date of exercise) with an aggregate fair market value that equals or exceeds the required tax withholding payment. Withholding does not represent an increase in the participantâ€™s total income tax obligation since it is fully credited toward his or her tax liability for the year. Additionally, withholding does not affect the participantâ€™s tax basis in the shares. Compensation income realized and tax withheld will be reflected on Forms W-2 supplied by us to employees no later than January 31 of the succeeding year. Deferred compensation that is subject to Section 409A of the Code will be subject to certain federal income tax withholding and reporting requirements. Â Tax Consequences to Us. To the extent that a participant recognizes ordinary income in the circumstances described above, we will be entitled to a corresponding deduction provided that, among other things, the income meets the test of reasonableness, is an ordinary and necessary business expense, is not an â€œexcess parachute paymentâ€ within the meaning of Section 280G of the Code, and is not disallowed by the $1,000,000 limitation on certain executive compensation under Section 162(m) of the Code discussed below. While deductibility of executive compensation for federal income tax purposes is among the factors the Board and Committee considers when structuring executive compensation arrangements, it is not the sole or primary factor considered. We retain the flexibility to authorize compensation that may not be deductible if we believe it is in our best interests. Â Million Dollar Deduction Limit and Other Tax Matters. We may not deduct compensation of more than $1,000,000 that is paid to â€œcovered employeesâ€ (as defined in Section 162(m) of the Code), which include (i) an individual (or, in certain circumstances, his or her beneficiaries) who, at any time during the taxable year, is either our principal executive officer or principal financial officer; (ii) an individual who is among our three highest compensated officers for the taxable year (other than an individual who was either our principal executive officer or principal financial officer at any time during the taxable year); or (iii) anyone who was a covered employee for purposes of Section 162(m) of the Code for any tax year beginning on or after January 1, 2017. This

limitation on deductions (x) only applies to compensation paid by a publicly-traded corporation (and not compensation paid by non-corporate entities) and (z) may not apply to certain types of compensation, such as qualified performance-based compensation that is payable pursuant to a written, binding contract that was in effect as of November 2, 2017, so long as the contract is not materially modified after that date. To the extent that compensation is payable pursuant to a prior plan award granted on or before November 2, 2017, and if we determine that Section 162(m) of the Code will apply to any such awards, we intend that the terms of those awards will not be materially modified and will be constructed so as to constitute qualified performance-based compensation and, as such, will be exempt from the $1,000,000 limitation on deductible compensation. Â If an individualâ€™s rights under the 2024 Plan are accelerated as a result of a change in control and the individual is a â€œdisqualified individualâ€ under Section 280G of the Code, then the value of any such accelerated rights received by such individual may be included in determining whether or not such individual has received an â€œexcess parachute paymentâ€ under Section 280G of the Code, which could result in (i) the imposition of a 20% federal excise tax (in addition to federal income tax) payable by the individual on the value of such accelerated rights, and (ii) the loss by us of a corresponding compensation deduction on such amounts. Â 83 Â Â Director Compensation Â The following table sets forth summary information concerning the total compensation earned for each non-employee member of the Board during the years ended December 31, 2023 and 2022, and is contemplated to continue serving as a director. All compensation paid to Mr. Olsen is reported above under the heading â€œSummary Compensation Table,â€ above. Â Name Year Â Salary Â Â Bonus Â Â Stock Awards Â Â Option awards (1) Â Â All other compensation Â Â Total Â David DeCaprio(1) 2022 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â 2023 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Greg Lipschitz 2022 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â 2023 Â Â - Â Â Â - Â Â Â - Â Â Â Â (2) Â Â - Â Â Â - Â Arun Menawat(3) 2022 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â 2023 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Brian Posner(4) 2022 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â 2023 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Scott Reeves(6) 2022 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â 2023 Â Â - Â Â Â - Â Â Â - Â Â Â (6) Â Â - Â Â Â - Â Stella Vnook(7) 2022 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â 2023 Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â (1) Amounts reflect the full grant-date fair value of option awards granted during the relevant fiscal year computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. Firefly provides information regarding the assumptions used to calculate the value of all option awards made to its executive officers in the section entitled â€œFireflyâ€™s Managementâ€™s Discussion and Analysis and Results of Operationsâ€Â contained elsewhere in this prospectus. Â (2) Consists of a grant of options to purchase 530,610 shares of Firefly Common Stock made to 2686255 Ontario Inc., an entity controlled by Mr. Lipschitz, on July 8, 2023, of which 88,435 are currently exercisable. Â (3) Mr. DeCaprio has served as a director of the Board since January 2024 and received no compensation in the reported period in his capacity as a director. Â (4) Dr. Menawat has served as a director of the Board since August 12, 2024, and received no compensation in the reported period in his capacity as a director. Â (5) Mr. Posner has served as a director of the Board since August 12, 2024, and received no compensation in the reported period in his capacity as a director. Â (6) Consists of a grant of options to purchase 70,748 shares of Firefly Common Stock made to Mr. Reeves on July 8, 2023, of which 9,826 are currently exercisable. In August 2024, immediately prior to the consummation of the Merger, Mr. Reeves resigned as a member of the Board and all committees thereto. Â (7) Ms. Vnook has served as a director of the Board since January 2024 and received no compensation in the reported period in her capacity as a director. Â Narrative Disclosure to Director Compensation Table Â During the periods covered by the table above, our non-employee directors received no monetary compensation for their service as directors during such periods. The directorsâ€™ compensation in the form of option awards is reported above. Â 84 Â Â DESCRIPTION OF CAPITAL STOCK Â The following summary of the material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities. The full text of the Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws of Firefly Neuroscience, Inc. are included as exhibits to the registration statement of which this prospectus forms a part. You are encouraged to read the applicable provisions of Delaware law, the Charter and Bylaws in their entirety for a complete description of the rights and preferences of our securities. Â The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities. The descriptions below are qualified by reference to the actual text of the Charter. We urge you to read the Charter and Bylaws in their entirety for a complete description of the rights and preferences of our securities. Â Authorized and Outstanding Stock Â Our authorized capital stock consists of 101,000,000 shares of capital stock, consisting of (i) 100,000,000 shares of Common Stock, par value $0.0001 per share and (ii) 1,000,000 shares of preferred stock, par value $0.0001 per share (â€œPreferred Stockâ€). Â As of August 30, 2024, there are 8,358,816 shares of Common Stock outstanding and no shares of Preferred Stock outstanding. Â Common Stock Â Dividend Rights Â Pursuant to the Bylaws, dividends upon the capital stock, subject to applicable law, if any, may be declared by the board of directors. Dividends may be paid in cash, in property, or in shares of capital stock or other securities, subject to the provisions of applicable law. Â Voting Rights Â Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders for their vote; provided, however, that, except as otherwise required by applicable law, holders of Common Stock shall not be entitled to vote on any amendment to the Charter (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more other such series of Preferred Stock, to vote thereon pursuant to applicable law or the Charter (including any certificate of designation filed with respect to any series of Preferred Stock). Â No Preemptive or Similar Rights Â Holders of our Common Stock do not have preemptive rights, and our Common Stock is not convertible or redeemable. Â Right to Receive Liquidation Distributions Â Subject to the prior or equal rights, if any, of the holders of shares of any series of Preferred Stock duly created hereafter, the holders of Common Stock shall be entitled (in the event of any dissolution. liquidation or winding-up, whether voluntary or involuntary (sometimes referred to herein as a liquidation), after payment or provision for payment of the debts and other liabilities, to receive our remaining assets, ratably according to the number of shares of Common Stock held. Â 85 Â Â Preferred Stock Â The Charter authorizes the board of directors to provide for the issue of all or any of the unissued and undesignated shares of the Preferred Stock, in one or more series, and to fix the number of shares of such series and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the board of directors providing for the issuance of such shares and as may be permitted by the DGCL. Â Following the consummation of the Merger, we have no shares of Preferred Stock outstanding. Â Warrants Â Legacy WaveDancer Warrants Â The following warrants were issued by WaveDancer prior to the consummation of the Merger. Â August 2021 Warrants Â On August 26, 2021, WaveDancer sold 140,000 shares of its Common Stock, and for each share purchased, purchasers were issued a warrant granting the right to purchase an additional share of Common Stock at a price of $30.00 per share, with the warrants expiring on August 31, 2026. 140,000 shares of Common Stock issuable upon exercise of warrants in connection with the offering have been reserved for issuance. Â Series A Warrants Â On December 10, 2021, WaveDancer sold in a private placement offering from which it raised aggregate gross proceeds of $10,000,000, 328,987 units resulting in the issuance of a like number of shares of Common Stock and 65,802 Series A warrants exercisable for a like number of shares of Common Stock. The warrants are exercisable at a price of $45.00 per share, with the warrants exercisable from January 1, 2023, through December 31, 2026. If the shares underlying the warrants are not registered when the warrants become exercisable, the warrants can be exercised on a cashless basis. The warrants are subject to redemption at a price of $0.01 per warrant, if commencing January 1, 2024, the volume weighted average price per share for 10 consecutive trading days equals or exceeds $125.00. WaveDancer reserves the right to require the warrants to be exercised on a cashless basis following any notice of redemption. Â Legacy Firefly Warrants Â At the effective time of the Merger, each holder of a Firefly warrant shall be entitled to receive (and such holder shall accept) upon the exercise of such holderâ€™s warrants, in lieu of Firefly Common Stock to which such holder was theretofore entitled upon such exercise, and for the same aggregate consideration payable therefor, that number of shares of WaveDancer common stock which the holder would have been entitled to receive as a result of the merger if, immediately prior to the effective time of the merger, such holder had been the registered holder of the number of shares of Firefly Common Stock to which such holder would have been entitled if such holder had exercised such holderâ€™s warrants immediately prior to the effective time of the merger. Each Firefly warrant shall continue to be governed by and be subject to the terms of the applicable warrant following the effective time of the merger. Â The following is a description of the material terms of the classes of warrants following the consummation of the Merger. However, share amounts underlying the warrants and related exercise price disclosed below do not reflect the application of the Exchange Ratio, which is necessary to determine the number of shares of WaveDancer Common Stock which the holder would be entitled to receive as a result of the Merger. Â 86 Â Â July 2022 Warrants Â On July 5, 2022, Firefly issued to certain holders warrants to purchase up to an aggregate of 171,806 shares of Common Stock (the â€œJuly 2022 Warrantsâ€). The July 2022 Warrants have an exercise price of $3.00 per share (subject to adjustment in accordance with the terms of the July 2022 Warrants), are exercisable immediately upon issuance and expire on July 4, 2025, on 4:30 p.m. (Toronto time). Â August 2022 Warrant Â On August 15, 2022, Firefly issued to a certain holder a warrant to purchase up to 13,333 shares of Common Stock (the â€œAugust 2022 Warrantâ€). The August 2022 Warrant has an exercise price $3.00 per share (subject to adjustment in accordance with the terms of the August 2022 Warrant), is exercisable immediately upon issuance and expires on August 15, 2025, at 4:30 p.m. (Toronto time). Â February 2023 Amended and Restated Warrants Â On February 17, 2023, Firefly issued to a certain holder certain amended and restated warrants, initially issued to such holder on November 8, 2021 (the â€œFebruary 2023 A&R Warrantsâ€), to reflect the 1-for-750 reverse stock split effectuated on November 23, 2022 by Firefly (the â€œ2022 Reverse Stock Splitâ€) and to adjust the exercise price therein in accordance with the terms of the February 2023 A&R Warrants, among others. The February 2023 A&R Warrants are exercisable for up to an aggregate of 43,333 and 80,000 shares of Common Stock, respectively, each at an exercise price of $0.00473 per share (subject to adjustment in accordance with the terms of the February 2023 A&R Warrants) and expire on February 17, 2026. Â Amended and Restated Tranche A Warrants Â On March 1, 2023, Firefly issued to a certain holders the amended and restated tranche A warrants (the â€œTranche A Warrantsâ€), initially granted to such holders on February 2, 2022, to reflect the 2022 Reverse Stock Split and to adjust the exercise price therein in accordance with the terms of the Tranche A Warrants, among others. The Tranche A Warrants are exercisable for up to an aggregate of 526,749 shares of Common Stock at an exercise price of (x) $0.001 in the event that on or after July 5, 2022, Firefly issues warrants, options and/or convertible debt in exchange for aggregate proceeds of at least $5,000,000 within 18 months thereafter or aggregate proceeds of at least $10,000,000 within three years thereafter, (y) $0.001 in the event that after July 5, 2022, all or substantially all of Fireflyâ€™s assets are sold, Firefly completes an initial public offering, including but not limited to by way of a reverse transaction takeover or via other similar â€œSale of the Companyâ€ event, or (z) the per share purchase price resulting from the division of $20,000,000 by the total number of duly authorized, validly issued and fully paid and non-assessable shares of Common Stock of Firefly then outstanding on a fully diluted basis. The Tranche A Warrants are fully vested upon issuance, are exercisable immediately upon issuance and expire on July 5, 2025. Â Series A Warrants Â On July 15, 2023, Firefly issued to certain holders the Series A warrants to purchase up to an aggregate of 6,048,476 shares of Common Stock (the â€œSeries A Warrantsâ€). The Series A Warrants have an exercise price of CAD$0.01 per share (subject to adjustment from time to time in accordance with the terms of the Series A Warrants) and expire on June 15, 2028, at on 4:30 p.m. (Toronto time). The Series A Warrants are additionally subject to certain vesting events, with the shares of Common Stock issuable upon the exercise of the Series A Warrants vesting, if Firefly is then publicly traded, in two equal installments upon the market capitalization of the Common Stock reaching $100,000,000 and $200,000,000 respectively, each for a period of three consecutive trading days. Â Series C Warrants Â Between October 17, 2023 and December 21, 2023, the Company issued to certain holders Series C warrants to purchase up to an aggregate of 1,538,132 shares of Common Stock (the â€œSeries C Warrantsâ€). The Series C Warrants have an exercise price of $2.56 per share (subject to adjustment from time to time in accordance with the terms of the Series C Warrant), is exercisable immediately upon issuance and expires at 4:30 p.m. (New York time) three years following the initial date of issuance. Â 87 Â Â 2024 Pre-Funded Warrants and Warrants Â The Warrants are exercisable immediately upon issuance at an exercise price of $0.71 per share and expire five years from the date of issuance. Â The Pre-Funded Warrants were offered in the Private Placement in lieu of shares of Common Stock, and provide that the holder may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding Common Stock immediately following the consummation of the Private Placement. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable upon issuance and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. Â A holder (together with its affiliates) of the Warrants or Pre-Funded Warrants, as the case may be, may not exercise any portion of the Warrants or Pre-Funded Warrants, as applicable, to the extent that the holder would own more than 4.99% (or, at the holderâ€™s option upon issuance, 9.99%) of our outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrants or Pre-Funded Warrants, as applicable. In lieu of making the cash payment otherwise contemplated to be made to us upon exercise of a Warrant, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of our Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if, at the time of such exercise, there is no effective registration statement registering the resale of shares of our Common Stock underlying the Warrants or if the prospectus contained in such registration statement is not available for the resale of shares of our Common Stock underlying the Warrants by the Warrant holder. Â In lieu of making the cash payment otherwise contemplated to be made to us upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of our Common Stock determined according to a formula set forth in the Pre-Funded Warrants. Â Options Â At the effective time of the Merger, we assumed all of Private Fireflyâ€™s rights and obligations under the stock options granted pursuant to the Firefly 2007 Incentive Plan and the Firefly 2023 Incentive Plan that are outstanding immediately prior to the effective time of the merger, and such options shall become exercisable for shares of our Common Stock. The number of shares of Common Stock that may be purchased pursuant to such stock options and the exercise price for such stock options shall be adjusted to reflect the Exchange Ratio as set forth in the Merger Agreement. Â Following the consummation of the Merger, we have 532,011 options outstanding. Â Anti-takeover Provisions Â Delaware Law Â We are subject to Section 203 of the DGCL. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a â€œbusiness combinationâ€ with any â€œinterested stockholderâ€ for three years following the date that the person became an interested stockholder, unless either the interested stockholder attained such status with the approval of the board of directors, the business combination is approved by the board of directors and stockholders in a prescribed manner or the interested stockholder acquired at least 85% of combined companyâ€™s outstanding voting stock in the transaction in which it became an interested stockholder. A â€œbusiness combinationâ€ includes, among other things, a merger or consolidation involving combined company and the â€œinterested stockholderâ€ and the sale of more than 10% of combined companyâ€™s assets. In general, an â€œinterested stockholderâ€ is any entity or person beneficially owning 15% or more of combined companyâ€™s outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. The restrictions contained in Section 203 are not applicable to any of combined companyâ€™s existing stockholders that owned 15% or more of combined companyâ€™s outstanding voting stock upon the closing of combined companyâ€™s initial public offering. Â 88 Â Â Potential Effects of Authorized but Unissued Stock Â We have shares of Common Stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock. Â The existence of unissued and unreserved Common Stock and Preferred Stock may enable our Board to issue shares to persons friendly to current management or to issue Preferred Stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, our Board has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of Preferred Stock, all to the fullest extent permissible under the DGCL and subject to any limitations set forth in the Charter. The purpose of authorizing the Board to issue Preferred Stock and to determine the rights and preferences applicable to such Preferred Stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of Preferred Stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from acquiring, a majority of our outstanding voting stock. Â Classified Board of Directors Â Pursuant to the Charter, our Board is divided into three classes serving three-year terms, with one class being elected each year by

a plurality of the votes cast by the stockholders entitled to vote on the election. Â Amendment of Certificate of Incorporation or Bylaws Â DGCL Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporationâ€™s certificate of incorporation or bylaws, unless a corporationâ€™s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Pursuant to Bylaws, the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of the Bylaws. Â Limitations of Director Liability and Indemnification of Directors, Officers and Employees Â Delaware Law Â Section 145 of the DGCL permits indemnification of directors, officers, agents and controlling persons of a corporation under certain conditions and subject to certain limitations. Section 145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director, officer or agent of the corporation or another enterprise if serving at our request. Depending on the character of the proceeding, a corporation may indemnify against expenses (including attorneysâ€™ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding if the person indemnified acted in good faith and in a manner he or she reasonably believed to be in or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. In the case of an action by or in the right of the corporation, no indemnification may be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine that despite the adjudication of liability such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper. Section 145 further provides that to the extent a present or former director or officer of a corporation has been successful in the defense of any action, suit or proceeding referred to above or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneysâ€™ fees) actually and reasonably incurred by such person in connection therewith. Â 89 Â Â Amended and Restated Certificate of Incorporation Â Pursuant to the Charter, we will indemnify to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the us to provide broader indemnification rights than such law permitted to us to provide prior to such amendment), any person who was or is made or is threatened to be made a party or is otherwise involved in a proceeding (as defined in the Charter), by reason of the fact that he or she is or was a director or executive officer (â€œexecutive officerâ€ has the meaning defined in Rule 3b-7 promulgated under the Exchange Act), or while serving as our director or executive officer, is or was serving at our request as a director, executive officer, other officer, employee or agent of another corporation, partnership, trust, employee benefit plan or other enterprise, whether the basis of such proceeding is alleged action in an official capacity as a director or executive officer or in any other capacity while serving as a director or executive officer, against all expense, liability and loss (including attorneysâ€™ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such person in connection therewith; provided, however, that we will not be required to indemnify or advance expenses to any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i) the proceeding (or part thereof) was authorized by the board of directors or (ii) the proceeding (or part thereof) is initiated to enforce rights to indemnification or advancement of expenses as provided in the Charter or is a compulsory counterclaim brought by such person. Â Transfer Agent and Registrar Â The transfer agent for our Common Stock is Issuer Direct Corporation, One Glenwood Ave, Suite 1001, Raleigh, NC 27603. Â Listing of Common Stock Â Our Common Stock is listed on Nasdaq under the symbol â€œAIFF.â€ Â 90 Â Â BENEFICIAL OWNERSHIP OF SECURITIES Â The following table sets forth information regarding the beneficial ownership of shares of Common Stock as of August 30, 2024: Â Â â€¢ each person known by us to be the beneficial owner of more than 5% of our Common Stock; Â Â â€¢ each of our current named executive officers and directors; and Â Â â€¢ all our executive officers and directors as a group. Â Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60Â days. The applicable percentage ownership shown below is based on 8,358,816 shares of Common Stock issued and outstanding as of August 30, 2024. Unless otherwise indicated, the address of each individual below is 1100 Military Road, Kenmore, NY 14217. Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares of Common Stock beneficially owned by them. Â Name of Beneficial Owner Â Number of Shares of Common Stock Beneficially Owned Â Â % of Ownership Â Five Percent Holders Â Â Â Â Â Â Â Â Windsor Private Capital LP / Jordan Kupinsky(1) Â Â 1,705,751 Â Â Â 15.29 % Roxy Capital Corporation(2) Â Â 690,072 Â Â Â 6.18 % Directors and Named Executive Officers Â Â Â Â Â Â Â Â David DeCaprio(3) Â Â 3,314 Â Â Â * Â David Johnson (8) Â Â 557,885 Â Â Â 5.00 % Gil Issachar(4) Â Â 76,021 Â Â Â 1.02 % Greg Lipschitz(5) Â Â 316,841 Â Â Â 3.43 % Arun Menawat(6) Â Â 323,234 Â Â Â 2.90 % Jon Olsen(7) Â Â 110,875 Â Â Â 1.36 % Brian Posner Â Â 0 Â Â Â 0 % Stella Vnook Â Â 0 Â Â Â 0 % Paul Krzywicki Â Â 0 Â Â Â 0 % Samer Kaba Â Â 0 Â Â Â 0 % All Directors and Executive Officers of the Company as a Group (10 persons) Â Â 1,388,170 Â Â Â 13.71 % _____ *Â Â Â Â Â Â Â Â Represents beneficial ownership of less than 1%. (1) Consists of 1,705,751 shares of Common Stock pursuant to the Schedule 13D filed on August 21, 2024 (2) Consists of 690,072 shares of Common Stock pursuant to the Schedule 13G filed on August 21, 2024. (3) Consists of shares underlying options to purchase up to 3,314 shares of Common Stock that are currently exercisable or exercisable within 60 days of August 30, 2024. (4) Consist of (1) 33,480 shares of Common Stock held by Mr. Issachar and (2) underlying options to purchase up to 42,541 shares of Common Stock that are currently exercisable or exercisable within 60 days of August 30, 2024. (5) Consists of (1) 294,498 shares of Common Stock and (2) up to 2,460 shares of Common Stock that are currently exercisable or exercisable within 60 days of August 30, 2024, underlying certain warrants, and (3) up to 19,883 shares of Common Stock that are currently exercisable or exercisable within 60 days of August 30, 2024, underlying certain stock options held by Bower Four Capital Corp., an entity in which Mr. Lipschitz is the sole stockholder. (6) Consists of 323,234 shares of Common Stock (7) Consists of (1) 31,655 shares of Common Stock held by Mr. Olsen, (2) 29,645 shares of Common Stock held by Slate Water Ltd., an entity controlled by Mr. Olsen, and (3) up to 49,574 shares of Common Stock that are currently exercisable or exercisable within 60 days of August 30, 2024, underlying certain stock options. (8) Consists of 557,885 shares of Common Stock. Â 91 Â Â SELLING SECURITYHOLDERS Â This prospectus relates to the resale by the selling securityholders from time to time of up to an aggregate of 2,559,645 shares of Common Stock, consisting of (A) 670,985 shares of Common Stock, which include: (i) 209,613 shares of Common Stock issued upon the conversion of certain shares of Series C Preferred Stock, issued to the investors in the Series C Financing and (ii) 461,372 shares of Common Stock previously issued by Private Firefly after the Effectiveness Date; (B)(i) 319,207 shares of Common Stock issued to the PIPE Investors, (ii) up to 504,323 shares of common stock issuable upon the exercise of the pre-funded warrants issued to the PIPE Investors, and (iii) up to 823,530 shares of common stock issuable upon the exercise of the private placement warrants issued to the PIPE Investors; (C) up to 168,071 shares of common stock issuable upon the exercise of the Series C Warrants issued and sold as part of the Series C Units; (D) up to 61,866 shares of Common Stock issuable upon the exercise of the Series D Warrants; and (E) up to 11,663 shares of Common Stock issuable upon the exercise of the Broker Warrants. Â The selling securityholders may from time to time offer and sell any or all of the Common Stock set forth below pursuant to this prospectus and any accompanying prospectus supplement. As used in this prospectus, the term â€œselling securityholdersâ€ includes the persons listed in the table below, together with any additional selling securityholder listed in a subsequent amendment to this prospectus, and their pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the selling securityholdersâ€™ interests in the Common Stock other than through a public sale. Â Except as set forth in the footnotes below, the following table sets forth information known to us as of August 30, 2024, regarding each selling securityholderâ€™s beneficial ownership of Common Stock (including shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants being offered by the selling securityholders. The table below lists the selling securityholders and other information regarding the beneficial ownership of the shares of Common Stock by each of the selling securityholders. The second column lists the number of shares of Common Stock beneficially owned by each selling securityholder, based on its ownership of the shares of Common Stock, Series C Preferred Stock, the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants, as of August 30, 2024, assuming the exercise of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants held by the selling securityholders on that date, without taking into account beneficial ownership limitations on conversions or exercises. The third column lists the shares of Common Stock being offered by this prospectus by the selling securityholders. The fourth and fifth columns assume the sale of all of the shares offered by the selling securityholders pursuant to this prospectus. Â The applicable percentage ownership of Common Stock is based on 8,358,816 Â shares of Common Stock outstanding as of August 30, 2024. Information with respect to shares of Common Stock owned beneficially after the offering assumes the sale of all of the shares of Common Stock (including shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants and the Broker Warrants by such selling securityholders. The selling securityholders may offer and sell some, all or none of their shares of Common Stock. Â We have determined beneficial ownership in accordance with the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security or the right to acquire such power within 60Â days of August 30, 2024. Except as indicated in the footnotes below, we believe, based on the information furnished to us, that the selling securityholders have sole voting and investment power with respect to all shares of common stock and other securities that they beneficially own, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the selling securityholders, no selling securityholder is a broker-dealer or an affiliate of a broker dealer. Â Except as described in this section and in the section titled â€œCertain Relationships and Related Person Transactionsâ€ in this prospectus, none of the selling securityholders have had any material relationship with us or any of our affiliates within the past threeÂ years. Â 92 Â Â Under the terms of the Pre-Funded Warrants and the Warrants, a selling securityholders may not exercise such warrants, respectively, to the extent such conversion or exercise, as applicable, would cause such Selling Securityholder, together with its affiliates and attribution parties, to beneficially own a number of shares of Common Stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding Common Stock following such conversion or exercise, excluding for purposes of such determination shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants or the Warrants, respectively, that have not been converted and exercised. The number of shares in the second and fourth columns reflect this limitation. The selling securityholders may sell all, some or none of their shares in this offering. See â€œPlan of Distribution.â€ Â Â Â Shares of Common Stock Â Name of Selling SecurityholderÂ Â Number of Shares of Common Stock Beneficially Owned Prior to Offering(1) Â Â Maximum Number of Shares of Common Stock to be sold Pursuant to this Prospectus Â Â Number of Shares of Common Stock Beneficially Owned After Offering Â Â Percentage of Common Stock Beneficially Owned After Offering Â 2123611 ALBERTA LTD.(2) Â Â 28,075 Â Â Â 28,075 Â Â Â 0 Â Â Â 0 % Alex Spiro(3) Â Â 44,688 Â Â Â 44,688 Â Â Â 0 Â Â Â 0 % BMO Nesbitt Burns ITF: Velev Capital Manager Inc.(4) Â Â 358,665 Â Â Â 358,665 Â Â Â 0 Â Â Â 0 % BPY Limited(5) Â Â 592,942 Â Â Â 592,942 Â Â Â 0 Â Â Â 0 % Gentlemensâ€™s Investment Club(6) Â Â 133 Â Â Â 133 Â Â Â 0 Â Â Â 0 % Gutterman Consulting Partners Inc.(7) Â Â 5,200 Â Â Â 5,200 Â Â Â 0 Â Â Â 0 % HJRK HOLDINGS INC.(8) Â Â 68,761 Â Â Â 68,761 Â Â Â 0 Â Â Â 0 % Jason Dubraski(9) Â Â 8,216 Â Â Â 8,216 Â Â Â 0 Â Â Â 0 % Kaif Lalani(10) Â Â 13,871 Â Â Â 13,871 Â Â Â 0 Â Â Â 0 % Mykobite Solutions Inc.(11) Â Â 111,118 Â Â Â 111,118 Â Â Â 0 Â Â Â 0 % National Bank Financial INC ITF: Mr. Karl Cheong A/C 2RON1FA(12) Â Â 5,149 Â Â Â 5,149 Â Â Â 0 Â Â Â 0 % Nomis Bay Ltd.(13) Â Â 1,054,118 Â Â Â 1,054,118 Â Â Â 0 Â Â Â 0 % OCI Inc.(14) Â Â 33,336 Â Â Â 33,336 Â Â Â 0 Â Â Â 0 % Offir Laufer(15) Â Â 1,560 Â Â Â 1,560 Â Â Â 0 Â Â Â 0 % Raphael Cundari(16) Â Â 173,117 Â Â Â 173,117 Â Â Â 0 Â Â Â 0 % Tehila Stern(17) Â Â 1,560 Â Â Â 1,560 Â Â Â 0 Â Â Â 0 % RJL18 Capital Canada LP(18) Â Â 30,933 Â Â Â 30,933 Â Â Â 0 Â Â Â 0 % Roxy Capital Corporation(19) Â Â 30,933 Â Â Â 30,933 Â Â Â 0 Â Â Â 0 % A. Ben-Tzvi, Adv. - Legal & Management Services Co (20) Â Â 10,588 Â Â Â 10,588 Â Â Â 0 Â Â Â 0 % Wellington-Altus Private Wealth Inc.(21) Â Â 4,163 Â Â Â 4,163 Â Â Â 0 Â Â Â 0 % B Riley Securities, Inc.(22) Â Â 7,500 Â Â Â 7,500 Â Â Â 0 Â Â Â 0 % _____ (1)Â This table and the information in the notes below are based upon information supplied by the Selling Securityholders and upon 8,358,816 shares of Common Stock issued and outstanding as of August 30, 2024 (prior to any deemed issuance of any shares issuable upon the exercise of any Pre-Funded Warrants, the Warrants, the Series C Warrants, the Series D Warrants or the Broker Warrants). Except as expressly noted in the footnotes below, beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act and so includes securities each person has a right to acquire within 60 days of August 30, 2024. (2)Â Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 28,075 shares of Common Stock. (3)Â Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 44,688 shares of Common Stock. (4)Â Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of (i) up to 196,163 shares of Common Stock issued upon conversion of shares of Series C Preferred Stock upon the consummation of the Merger and (ii) up to 162,502 shares of Common Stock issuable upon exercise of Series C Warrants. (5)Â Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 114,915 shares of Common Stock, (ii) up to 181,556 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, and (iii) up to 296,471 shares of Common Stock issuable upon the exercise of the Warrants. (6)Â Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 133 shares of Common Stock. (7) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 5,200 shares of Common Stock. (8) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 68,761 shares of Common Stock. (9) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 8,216 shares of Common Stock. (10) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of (i) up to 9,809 shares of Common Stock issued upon the conversion of shares of Series C Preferred Stock upon the consummation of the Merger and (ii) up to 4,062 shares of Common Stock issuable upon exercise of Series C Warrants. Â 93 Â Â (11) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 111,118 shares of Common Stock. (12) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of (i) up to 3,641 shares of Common Stock issued upon conversion of shares of Series C Preferred Stock upon the consummation of the Merger and (ii) up to 1,508 shares of Common Stock issuable upon exercise of Series C Warrants. (13) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 204,292 shares of Common Stock, (ii) up to 322,767 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, and (iii) up to 527,059 shares of Common Stock issuable upon the exercise of the Warrants. (14) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 33,336 shares of Common Stock. (15) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 1,560 shares of Common Stock. (16) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 173,117 shares of Common Stock. (17) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 1,560 shares of Common Stock. (18) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of up to 30,933 shares of Common Stock issuable upon the Series D Warrants. (19) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of up to 30,933 shares of Common Stock issuable upon the Series D Warrants. (20) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of 10,588 shares of Common Stock issued in connection with prior legal services rendered. (21) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of up to 4,163 shares of Common Stock issuable upon the exercise of the Broker Warrants. (22) Maximum number of shares of Common Stock to be sold pursuant to this prospectus consist of up to 7,500 shares of Common Stock issuable upon the exercise of the Broker Warrants. Â 94 Â Â CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS Â For purposes of this section, references to â€œWaveDancerâ€ refer to the former WaveDancer, prior to the consummation of the Merger. Â Transactions Involving the Selling Securityholders Â Private Placement As discussed elsewhere in this prospectus, on July 26, 2024, prior to the consummation of the Merger, we entered into a securities purchase agreement with certain institutional investors, pursuant to which we agreed to issue and sell (i) 319,207 shares (the â€œPIPE Sharesâ€) of Common Stock and (ii) pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 504,323 shares of our Common Stock, and (iii) warrants (the â€œWarrantsâ€) to purchase up to 823,530 shares of Common Stock in a private placement (the â€œPrivate Placementâ€). The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the Merger. The aggregate gross proceeds from the transaction were approximately $3.5 million, before deducting estimated offering expenses payable by us. Â Series C Financing Â Between October 17, 2023, and June 30, 2024, we raised an aggregate of $3,039,000 from a private placement of 2,374,219 Series C units (the â€œSeries C Unitsâ€), which such Series C Units were comprised of shares of Series C Preferred Stock and warrants to purchase up to 2,374,665 shares of Common Stock, which were sold at a combined purchase

price of $1.28 per Series C Unit. Each warrant has an exercise price of $2.56 per share (subject to adjustment from time to time in accordance with the terms thereof), is exercisable immediately upon issuance and expires at 4:30 p.m. (New York time) three years following the initial date of issuance. Â WaveDancer Related Party Transactions Â The following is a summary of transactions since January 1, 2021 to which WaveDancer has been a party, in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of WaveDancerâ€™s total assets as of the end of the last two completed fiscal years and in which any of the expected directors, executive officers or holders of more than 5% of capital stock of the continuing company, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. The transactions described below occurred prior to the consummation of the Merger. Â WaveDancer believes the terms obtained or consideration that WaveDancer paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in armâ€™s-length transactions. Â In connection with a private placement of its shares, on August 26, 2021, WaveDancer sold 140,000 shares of its common stock at a price of $20.00 per share to several accredited investors. For each share purchased, purchasers were issued a warrant granting the right to purchase an additional share of common stock at a price of $30.00 per share, with the warrants expiring on August 31, 2026. The investors included G. James Benoit, Jr., Chairman and Chief Executive Officer, who purchased 75,000 shares and 75,000 warrants at an aggregate price of $1,500,000, and William H. Pickle, director, who purchased 6,500 shares and 6,500 warrants at an aggregate price of $130,000. Â In connection with a private placement of its shares, on December 10, 2021, WaveDancer sold 328,987 shares of its common stock at a price of $30.40 per share to several investors. For each five shares purchased, purchasers were issued a warrant granting the right to purchase an additional share of Common Stock at a price of $45.00 per share, with the warrants exercisable on January 1, 2023, expiring on December 31, 2026. The investors included G. James Benoit, Chairman and CEO, who purchased 11,665 shares and 2,333 warrants at an aggregate price of $354,600, and James C. (â€œChipâ€) DiPaula, Jr., director, who purchased 29,277 shares and 5,856 warrants at an aggregate price of $890,000. Â In connection with a private placement of its shares, in August 2022, WaveDancer sold 157,256 shares of its common stock at a price of $12.00 per share to 16 accredited investors. The investors included G. James Benoit, Jr., Chairman and Chief Executive Officer, who purchased 50,000 shares at an aggregate price of $600,000, James C. DiPaula, director, who purchased 20,834 shares at an aggregate price of $250,000, and William C. Pickle, director, who purchased 4,167 shares at an aggregate price of $50,000. Â 95 Â Â On September 29, 2023, WaveDancer sold 35,000 shares of common stock to G. James Benoit, Jr., Chairman and Chief Executive Officer, at a price of $5.00 per share in a private placement offering from which it raised aggregate gross proceeds of $175,000. Â Mr. Benoit is the principal stockholder of Wavetop, which purchased Tellenger in connection with the Merger for $1.5 million. Â Firefly Related Party Transactions Â Other than as described in the section â€œManagementâ€“Board Leadership Structureâ€“Director Independenceâ€ as related to the Lipschitz Agreement (as defined herein), since January 1, 2021, there were no transactions with executive officers, directors or their immediate family members which were in an amount in excess of $120,000, and in which any of the expected directors, executive officers or holders of more than 5% of capital stock of the continuing company, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. Â Other Transactions Â Indemnification Agreements Â In connection with the Merger, on the Closing Date, we entered into indemnification agreements (each, an â€œIndemnification Agreementâ€ and collectively, the â€œIndemnification Agreementsâ€) with each of our directors and executive officers. The Indemnification Agreements provide for indemnification and advancement by us of certain expenses and costs relating to claims, suits, or proceedings arising from service to us or, at our request, service to other entities to the fullest extent permitted by applicable law. Â Compensation Matters Â We have entered into employment agreements with certain of our executive officers. For a description of agreements with our named executive officers, see the section titled â€œExecutive Compensationâ€”Executive Compensation Arrangementsâ€ included elsewhere in this prospectus. Â We have granted equity awards to certain of our executive officers. For a description of equity awards granted to our named executive officers, see the section titled â€œExecutive Compensationâ€ included elsewhere in this prospectus. Â Related Party Transactions Policy Â Pursuant to the Charter of the Audit Committee, the Audit Committee has adopted a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions. Pursuant to such policy, the Audit Committee shall review and approve, prior to our entry into any such transactions, all transactions in which we are or will be a participant, which would be reportable by us under Item 404 of Regulation S-K promulgated under the Securities Act as a result of any of the following persons having or expected to have a direct or indirect material interest (a â€œRelated Person Transactionâ€): Â Â â— executive officers; Â Â â— members of the Board; Â Â â— beneficial holders of more than 5% of our securities; Â Â â— immediate family members of any of the foregoing persons, with such immediate family members defined as any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, and any person (other than a tenant or an employee) sharing the household with the executive officer, director or 5% beneficial owner; and Â Â â— any other persons whom the Board determines may be considered to be related persons as defined by Item 404 of Regulation S-K promulgated under the Securities Act. Â 96 Â Â In reviewing and approving such transactions, the Audit Committee shall obtain, or shall direct management to obtain on its behalf, all information that the Audit Committee believes to be relevant and important to a review of the transaction prior to its approval. Following receipt of the necessary information, a discussion shall be held of the relevant factors if deemed to be necessary by the Audit Committee prior to approval. If a discussion is not deemed to be necessary, approval may be given by written consent of the Audit Committee. Â This approval authority may also be delegated to the Chairperson of the Audit Committee in some circumstances. No Related Person Transaction shall be entered into prior to the completion of these procedures. Â The Audit Committee or the Chairperson of the Audit Committee, as the case may be, shall approve only those Related Person Transactions that are determined to be in, or not inconsistent with, our and our stockholdersâ€™ best interests, taking into account all available facts and circumstances as the Audit Committee or the Chairperson determines in good faith to be necessary in accordance with principles of Delaware law generally applicable to directors of a Delaware corporation. No member of the Audit Committee shall participate in any review, consideration or approval of any Related Person Transaction with respect to which the member or any of his or her immediate family members has an interest. Â The Audit Committee shall adopt any further policies and procedures relating to the approval of Related Person Transactions that it deems necessary or advisable from time to time. Â 97 Â Â MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR HOLDERS OF COMMON STOCK Â The following discussion is a summary of the material U.S.Â federal income tax consequences relating to the purchase, ownership, and disposition of our Common Stock but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S.Â federal tax laws, such as estate and gift tax laws, and any applicable state, local, or non-U.S.Â tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a holder of our Common Stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership, and disposition of our Common Stock or the exercise of our warrants. Â This discussion is limited to holders that hold our Common Stock as a â€œcapital assetâ€ within the meaning of SectionÂ 1221 of the Code (generally, property held for investment). This discussion does not address all U.S.Â federal income tax consequences relevant to a holderâ€™s particular circumstances, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax. In addition, it does not address consequences relevant to holders subject to special rules, including, without limitation: Â Â â€¢ U.S. expatriates and former citizens or long-term residents of the United States; Â Â â€¢ persons holding our securities as part of a hedge, straddle, or other risk reduction strategy or as part of a conversion transaction or other integrated investment; Â Â â€¢ banks, insurance companies, and other financial institutions; Â Â â€¢ brokers, dealers, or traders in securities; Â Â â€¢ â€œcontrolled foreign corporations,â€ â€œpassive foreign investment companies,â€ and corporations that accumulate earnings to avoid U.S. federal income tax; Â Â â€¢ partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); Â Â â€¢ tax-exempt organizations or governmental organizations; Â Â â€¢ persons deemed to sell our Common Stock under the constructive sale provisions of the Code; Â Â â€¢ persons who hold or receive our Common Stock pursuant to the exercise of any employee stock option or otherwise as compensation; Â Â â€¢ tax-qualified retirement plans; and Â Â â€¢ â€œqualified foreign pension fundsâ€ as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds. Â If an entity treated as a partnership for U.S.Â federal income tax purposes holds our Common Stock, the tax treatment of an owner in such an entity will depend on the status of the owner, the activities of such entity, and certain determinations made at the owner level. Accordingly, entities treated as partnerships for U.S.Â federal income tax purposes holding our Common Stock and the owners in such entities should consult their tax advisors regarding the U.S.Â federal income tax consequences to them. Â THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE.Â INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.Â FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP, AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S.Â FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL, OR NON-U.S.Â TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. Â 98 Â Â U.S.Â Holders Â For purposes of this discussion, a â€œU.S.Â Holderâ€ is any beneficial owner of our Common Stock that is for U.S.Â federal income tax purposes: Â Â â€¢ an individual who is a citizen or resident of the United States; Â Â â€¢ a corporation (or other entity taxable as a corporation) created or organized under the laws of the United States, any state thereof, or the District of Columbia; Â Â â€¢ an estate, the income of which is subject to U.S. federal income tax regardless of its source; or Â Â â€¢ a trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more â€œUnited States personsâ€ (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. Â Taxation of Distributions.Â Â Â Â Â If we make distributions of cash or property on our Common Stock, the gross amount of distributions made with respect to the Common Stock generally will be includible in a U.S.Â Holderâ€™s gross income, in accordance with such U.S.Â Holderâ€™s method of accounting for U.S.Â federal income tax purposes, as dividend income to the extent that such distributions are paid out of our current or accumulated earnings and profits as determined under U.S.Â federal income tax principles. Dividends will be taxable to a corporate U.S.Â Holder at regular corporate tax rates, and a portion of such dividends (either 50%, 65% or 100%, depending upon the corporate U.S.Â Holderâ€™s ownership of the Company) will generally be eligible for the dividends received deduction if the requisite holding period is satisfied. Distributions in excess of our current or accumulated earnings and profits generally will be applied against and reduce the U.S.Â Holderâ€™s basis in its Common Stock (but not below zero) and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of such Common Stock, as described under â€œâ€”Â Gain or Loss on Sale, Taxable Exchange, or Other Taxable Disposition of Common Stockâ€ below. Â With respect to non-corporate U.S.Â Holders and with certain exceptions, dividends may be â€œqualified dividend income,â€ which is taxed at the lower applicable long-term capital gain rate provided that the U.S.Â Holder satisfies certain holding period requirements and the U.S.Â Holder is not under an obligation to make related payments with respect to positions in substantially similar or related property. If the holding period requirements are not satisfied, then non-corporate U.S.Â Holders may be subject to tax on such dividends at regular ordinary income tax rates instead of the preferential rate that applies to qualified dividend income. Â Gain or Loss on Sale, Taxable Exchange, or Other Taxable Disposition of Common Stock.Â Â Â Â Upon a sale or other taxable disposition of our Common Stock, a U.S.Â Holder generally will recognize capital gain or loss. Generally, the amount of such gain or loss is equal to the difference between (i)Â the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)Â the U.S.Â Holderâ€™s adjusted tax basis in its Common Stock so disposed of. A U.S.Â Holderâ€™s adjusted tax basis in its Common Stock generally will equal the U.S.Â Holderâ€™s adjusted cost less, in the case of a share of Common Stock, any prior distributions treated as a return of capital. In the case of any shares of Common Stock originally acquired as part of an investment unit, the acquisition cost for the shares of Common Stock that were part of such unit would equal an allocable portion of the acquisition cost of the unit based on the relative fair market values of the components of the unit at the time of acquisition. Â Any such capital gain or loss generally will be long-term capital gain or loss if the U.S.Â Holderâ€™s holding period for the Common Stock so disposed of exceeds one year. If the holding period requirements are not satisfied, any gain on a sale or taxable disposition of the Common Stock would be subject to short-term capital gain treatment and would be taxed at regular ordinary income tax rates. Long-term capital gain recognized by non-corporate U.S.Â Holders will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. Â Information Reporting and Backup Withholding.Â Â Â Â Distributions with respect to the Common Stock to a U.S.Â Holder, regardless of whether such distributions constitute dividends, and proceeds from the sale, exchange or redemption of the Common Stock by a U.S.Â Holder generally are subject to information reporting to the IRS and possible U.S.Â backup withholding, unless the U.S.Â Holder is an exempt recipient. Backup withholding may apply to such payments if a U.S.Â Holder fails to furnish a correct taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). Â 99 Â Â Non-U.S.Â Holders Â For purposes of this discussion, a â€œNon-U.S.Â Holderâ€ is any beneficial owner of our Common Stock that is for U.S.Â federal income tax purposes: Â Â â€¢ a non-resident alien individual; Â Â â€¢ a foreign corporation; or Â Â â€¢ a foreign estate or trust. Â Taxation of Distributions.Â Â Â Â Â If we do make distributions of cash or property on our Common Stock, such distributions will constitute dividends for U.S.Â federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S.Â federal income tax principles. Amounts not treated as dividends for U.S.Â federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S.Â Holderâ€™s adjusted tax basis in its Common Stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under â€œâ€”Â Gain or Loss on Sale, Taxable Exchange, or Other Taxable Disposition of Common Stock.â€ Â Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S.Â Holder will be subject to U.S.Â federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S.Â Holder furnishes a valid IRS FormÂ W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the lower treaty rate). A Non-U.S.Â Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.Â Non-U.S.Â Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. Â If dividends paid to a Non-U.S.Â Holder are effectively connected with the Non-U.S.Â Holderâ€™s conduct of a trade or business within the UnitedÂ States, the Non-U.S.Â Holder will be exempt from the U.S.Â federal withholding tax described above. To claim the exemption, the Non-U.S.Â Holder must furnish to the applicable withholding agent a valid IRS FormÂ W-8ECI, certifying that the dividends are effectively connected with the Non-U.S.Â Holderâ€™s conduct of a trade or business within the UnitedÂ States. Â Any such effectively connected dividends will be subject to U.S.Â federal income tax on a net income basis at the regular rates, subject to an applicable treaty that provides otherwise. A Non-U.S.Â Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S.Â Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. Â Gain or Loss on Sale, Taxable Exchange, or other Taxable Disposition of Common Stock.Â Â Â Â Â A Non-U.S.Â Holder will not be subject to U.S.Â federal income tax on any gain realized upon the sale or other taxable disposition of our Common Stock unless: Â Â â€¢ the gain is effectively connected with the Non-U.S. Holderâ€™s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable); Â Â â€¢ the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or Â Â â€¢ our Common Stock constitutes a U.S. real property interest (â€œUSRPIâ€) by reason of our status as a U.S. real property holding corporation (â€œUSRPHCâ€) for U.S. federal income tax purposes. Â Gain described in the first bullet point above generally will be subject to U.S.Â federal income tax on a net income basis at the regular rates. A Non-U.S.Â Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. Â A Non-U.S.Â Holder described in the second bullet point above will be subject to U.S.Â federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our Common Stock, which may be offset by U.S.Â source capital losses of the Non-U.S.Â Holder (even though the individual is not considered a resident of the UnitedÂ States). Â 100 Â Â With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC.Â Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our non-U.S.Â real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we

are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our Common Stock by a Non-U.S.Â Holder will not be subject to U.S.Â federal income tax if our Common Stock is â€œregularly traded,â€ as defined by applicable Treasury Regulations, on an established securities market and such Non-U.S.Â Holder owned, actually and constructively, 5% or less of our Common Stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S.Â Holderâ€™s holding period. Â Non-U.S.Â Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. Â Information Reporting and Backup Withholding.Â Â Â Â Payments of dividends on our Common Stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a UnitedÂ States person and the holder either certifies its non-U.S.Â status, such as by Â furnishing a valid IRS FormÂ W-8BEN, W-8BEN-E, or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on our Common Stock paid to the Non-U.S.Â Holder, regardless of whether such distributions constitute dividends or whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our Common Stock within the UnitedÂ States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a UnitedÂ States person or the holder otherwise establishes an exemption. Proceeds of a disposition of our Common Stock conducted through a non-U.S.Â office of a non-U.S.Â broker generally will not be subject to backup withholding or information reporting. Â Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S.Â Holder resides or is established. Â Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S.Â Holderâ€™s U.S.Â federal income tax liability, provided the required information is timely furnished to the IRS. Â Additional Withholding Tax on Payments Made to Foreign Accounts.Â Â Â Â Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act (â€œFATCAâ€)) on certain types of payments made to non-U.S.Â financial institutions and certain other non-U.S.Â entities. Specifically, a 30% withholding tax may be imposed on dividends on our Common Stock paid to a â€œforeign financial institutionâ€ or a â€œnon-financial foreign entityâ€ (each as defined in the Code), unless (1)Â the foreign financial institution undertakes certain diligence and reporting obligations, (2)Â the non-financial foreign entity either certifies it does not have any â€œsubstantial UnitedÂ States ownersâ€ (as defined in the Code) or furnishes identifying information regarding each substantial UnitedÂ States owner, or (3)Â the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in clause (1)Â above, it must enter into an agreement with the U.S.Â Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain â€œspecified UnitedÂ States personsâ€ or â€œUnitedÂ States owned foreign entitiesâ€ (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the UnitedÂ States governing FATCA may be subject to different rules. Â Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our Common Stock. Â 101 Â Â PLAN OF DISTRIBUTION Â We are registering the resale by the selling securityholders or their permitted transferees of up to an aggregate of 2,559,645 shares of Common Stock, consisting of (A) 670,985 shares of Common Stock, which include: (i) 209,613 shares of Common Stock issued upon the conversion of certain shares of Series C Preferred Stock, issued to the investors in the Series C Financing and (ii) 461,372 shares of Common Stock previously issued by Private Firefly after the Effectiveness Date; (B)(i) 319,207 shares of Common Stock issued to PIPE Investors, (ii) up to 504,323 shares of common stock issuable upon the exercise of the pre-funded warrants issued to PIPE Investors, and (iii) up to 823,530 shares of common stock issuable upon the exercise of the private placement warrants issued to the PIPE Investors; (C) up to 168,071 shares of common stock issuable upon the exercise of the Series C Warrants issued and sold as part of the Series C Units; (D) up to 61,866 shares of Common Stock issuable upon the exercise of the Series D Warrants; and (E) up to 11,663 shares of Common Stock issuable upon the exercise of the Broker Warrants. Â We will not receive any proceeds from the sale of shares of Common Stock by the selling securityholders. We expect to receive only nominal proceeds from the exercise of any PartÂ A-2 Warrants for cash. The aggregate proceeds to the selling securityholders will be the purchase price of the securities less any discounts and commissions borne by the selling securityholders. Â The shares of Common Stock beneficially owned by the selling securityholders covered by this prospectus may be offered and sold from time to time by the selling securityholders. The term â€œselling securityholdersâ€ includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a selling securityholder as a gift, pledge, partnership distribution or other transfer. The selling securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale by the selling securityholders. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The selling securityholders may sell their shares of Common Stock by one or more of, or a combination of, the following methods to the extent applicable: Â Â â€¢ purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; Â Â â€¢ ordinary brokerage transactions and transactions in which the broker solicits purchasers; Â Â â€¢ block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; Â Â â€¢ an over-the-counter distribution in accordance with the rules of the Nasdaq Stock Market LLC; Â Â â€¢ through trading plans entered into by a selling securityholder pursuant to Rule 10b5-1 under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their Securities on the basis of parameters described in such trading plans; Â Â â€¢ to or through underwriters or broker-dealers; Â Â â€¢ in privately negotiated transactions; Â Â â€¢ in options transactions; Â Â â€¢ through a combination of any of the above methods of sale; or Â Â â€¢ any other method permitted pursuant to applicable law. Â In addition, a selling securityholder that is an entity may elect to make a pro rata in-kind distribution of shares of Common Stock to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of us (or to the extent otherwise required by law), we may, at our option, file a prospectus supplement in order to permit the distributees to use the prospectus to resell the securities acquired in the distribution. Â In addition, any shares of Common Stock that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus. Â 102 Â Â To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the Common Stock or otherwise, the selling securityholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, Â broker-dealers or other financial institutions may engage in short sales Common Stock in the course of hedging transactions, and broker-dealers or other financial institutions may engage in short sales Common Stock in the course of hedging the positions they assume with selling securityholders. The selling securityholders may also sell Common Stock short and redeliver the Common Stock to close out such short positions. The selling securityholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery toÂ such broker-dealer or other financial institution of Common Stock offered by this prospectus, which shares of Common Stock such broker- dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The selling securityholders may also pledge Securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution may effect sales of the pledged Securities pursuant to this prospectus (as supplemented or amended to reflect such transaction). Â The selling securityholders may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell Securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by any selling securityholder or borrowed from any selling securityholder or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from any selling securityholder in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any selling securityholder may otherwise loan or pledge Securities to a financial institution or other third party that in turn may sell the Securities short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. Â In effecting sales, broker-dealers or agents engaged by the selling securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the selling securityholders in amounts to be negotiated immediately prior to the sale. Â In order to comply with the securities laws of certain states, if applicable, the Securities must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the Securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. Â We have advised the selling securityholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Securities in the market and to the activities of each selling securityholder and its affiliates. In addition, we will make copies of this prospectus available to the selling securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the Securities against certain liabilities, including liabilities arising under the Securities Act. Â At the time a particular offer of Securities is made, if required, a prospectus supplement will be distributed that will set forth the number of Securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. We know of no existing arrangements between the selling securityholders or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the Securities offered by this prospectus. Â We are required to pay all fees and expenses incident to the registration of shares of our Common Stock to be offered and sold pursuant to this prospectus, which we expect to be approximately $81,316.65. Â To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan or distribution. Â 103 Â Â LEGAL MATTERS Â The validity of the securities offered hereby will be passed upon for us by Haynes and Boone, LLP. Â EXPERTS Â The financial statements of Firefly Neuroscience, Inc. as of December 31, 2023 and 2022 included in this prospectus and registration statement have been audited by Turner, Stone & Company LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein (which includes an explanatory paragraph about the existence of substantial doubt concerning our ability to continue as a going concern), and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. Â WHERE YOU CAN FIND ADDITIONAL INFORMATION Â We file annual, quarterly and current reports, proxy statements and other information with the SEC.Â We have also filed a registration statement on FormÂ S-1, including exhibits, under the Securities Act with respect to the shares of Common Stock offered by this prospectus. This prospectus is part of the registration statement, but does not contain all of the information included in the registration statement or the exhibits. Our SEC filings are available to the public on the internet at a website maintained by the SEC located at http://www.sec.gov. Â Our website address is www.fireflyneuro.com. Through our website, we make available, free of charge, the following documents as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC, including our Annual Reports on Form 10-K; our proxy statements for our annual and special stockholder meetings; our Quarterly Reports on Form 10-Q; our Current Reports on Form 8-K; Forms 3, 4, and 5 and Schedules 13D with respect to our securities filed on behalf of our directors and our executive officers; and amendments to those documents. The information contained on, or that may be accessed through, our website is not a part of, and is not incorporated into, this prospectus. Â 104 Â Â UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET Â As of March 31, 2024 (Amounts expressed in United States dollars, except for number of shares) Â Â Â Â Â Â Â Â Â Â Pro forma adjustments Â Â Â Â Â Â Â Â WaveDancer Â Â Firefly Neuroscience Â Â Tellenger Sale Transaction Â Â Â Wind-down of WaveDancer Corporate Â Â Â Merger Adjustments Â Â Â Pro Forma Combined FS Â Â Â As reported Â Â As reported Â Â Â Â Â Notes Â Â Â Â Notes Â Â Â Â Notes Â Â Â Â Assets Â Current assets Â Cash and cash equivalents Â $ 563,324 Â Â $ 1,638,000 Â Â $ 1,500,000 Â (a) Â $ (1,424,984) (d) Â $ 3,500,000 Â (k) Â $ 5,776,340 Â Accounts receivable, net Â Â 776,025 Â Â Â 84,000 Â Â Â (776,025) (b) Â Â - Â Â Â Â - Â Â Â Â 84,000 Â Prepaid expenses and other current assets Â Â 220,594 Â Â Â 38,000 Â Â Â (128,916) (b) Â Â - Â Â Â Â - Â Â Â Â 129,678 Â Total current assets Â $ 1,559,943 Â Â $ 1,760,000 Â Â $ 595,059 Â Â Â $ (1,424,984) Â Â $ 3,500,000 Â Â Â $ 5,990,018 Â Fixed assets, net Â Â 49,628 Â Â Â 60,000 Â Â Â (31,569) (b) Â Â (18,059) Â Â Â - Â Â Â Â 60,000 Â Prepaid expenses - non-current Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 79,578 Â (l) Â Â 3,004,578 Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 2,925,000 Â (m) (n) (t) (u) Â Â - Â Intangible assets, net Â Â 961,478 Â Â Â 517,000 Â Â Â (961,478) (b) Â Â - Â Â Â Â - Â Â Â Â 517,000 Â Other assets Â Â 18,419 Â Â Â - Â Â (5,706) (b) Â Â - Â Â Â Â - Â Â Â Â 12,713 Â Right-of-use operating lease asset Â Â 50,154 Â Â Â - Â Â Â - Â Â Â Â (50,154) (f) Â Â - Â Â Â Â - Â Goodwill Â Â 1,125,101 Â Â Â - Â Â Â (1,125,101) (b) Â Â - Â Â Â Â - Â Â Â Â - Â Total assets Â $ 3,764,723 Â Â $ 2,337,000 Â Â $ (1,528,795) Â Â $ (1,493,197) Â Â $ 6,504,578 Â Â Â $ 9,584,309 Â Liabilities and stockholdersâ€™ equity Â Current liabilities Â Accounts payable and other current liabilities Â Â 1,376,203 Â Â Â 2,171,000 Â Â Â (436,953) (b) Â Â (939,250) (e) Â Â 400,000 Â (o) Â Â 2,413,592 Â Â Â Â - Â Â Â - Â Â - Â Â Â Â - Â Â Â Â (112,408) (p) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â (45,000) (q) Â Â - Â Revolving line of credit Â Â 500,000 Â Â Â - Â Â Â - Â Â Â Â (500,000) (h) Â Â - Â Â Â Â - Â Operating lease liability Â Â 78,778 Â Â Â - Â Â Â - Â Â Â Â (78,778) (f) Â Â - Â Â Â Â - Â Contract liabilities Â Â 85,035 Â Â Â - Â Â Â (85,035) (b) Â Â - Â Â Â Â - Â Â Â Â - Â Related party payable Â Â - Â Â Â 175,000 Â Â Â - Â Â Â Â - Â Â Â Â - Â Â Â Â 175,000 Â Total current liabilities Â $ 2,040,016 Â Â $ 2,346,000 Â Â $ (521,988) Â Â $ (1,518,028) Â Â $ 242,592 Â Â Â $ 2,588,592 Â Deferred tax liabilities (benefit), net Â Â 16,187 Â Â Â - Â Â Â (247,208) (b) Â Â - Â Â Â Â 231,021 Â (g) Â Â - Â Total liabilities Â $ 2,056,203 Â Â $ 2,346,000 Â Â $ (769,196) Â Â $ (1,518,028) Â Â $ 473,613 Â Â Â $ 2,588,592 Â Stockholdersâ€™ equity Â Share capital and additional paid in capital Â Â 36,572,917 Â Â Â 77,737,000 Â Â Â - Â Â Â Â (36,572,917) (i) Â Â 3,500,000 Â (k) Â Â 86,217,318 Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â 973,752 Â (j) Â Â 184,766 Â (l) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 2,925,000 Â (m) (n) (t) (u) Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 109,966 Â (p) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 45,000 Â (q) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 341,834 Â (s) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 400,000 Â (r) Â Â - Â Treasury stock Â Â (965,211) Â Â - Â Â Â - Â Â Â Â 965,211 Â (i) Â Â - Â Â Â Â - Â Accumulated deficit Â Â (33,899,186) Â Â (77,746,000) Â Â (759,599) (c) Â Â 34,658,785 Â (i) Â Â (400,000) (o) Â Â (79,221,601) Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â (105,188) (l) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â 2,442 Â (p) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â (231,021) (g) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â (400,000) (r) Â Â - Â Â Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â (341,834) (s) Â Â - Â Total stockholdersâ€™ equity Â $ 1,708,520 Â Â $ (9,000) Â $ (759,599) Â Â $ 24,831 Â Â Â $ 6,030,965 Â Â Â $ 6,995,717 Â Total liabilities and stockholdersâ€™ equity Â $ 3,764,723 Â Â $ 2,337,000 Â Â $ (1,528,795) Â Â $ (1,493,197) Â Â $ 6,504,578 Â Â Â $ 9,584,309 Â Â See accompanying notes to the unaudited pro forma condensed combined financial statements Â 105 Â Â Unaudited Pro Forma Condensed Combined Statement of Operations For the Three Months Ended March 31, 2024 (Amounts expressed in United States dollars, except for number of shares) Â Â Â Â Â Â Â Â Â Â Pro forma adjustments Â Â Â Â Â Â Wave Dancer As reported Â Â Firefly Neuroscience As reported Â Â Merger Adjustments Â Notes Â Wind-down of WaveDancer Corporate Â Notes Â Tellenger Sale Transaction Â Notes Â Pro Forma Combined FS Â Revenue Â $ 1,915,372 Â Â $ 12,000 Â Â Â - Â Â Â Â - Â Â Â $ (1,915,372) (b) Â $ 12,000 Â Cost of revenue Â Â 1,216,114 Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â (1,216,114) (b) Â Â - Â Gross profit Â $ 699,258 Â Â $ 12,000 Â Â Â - Â Â Â Â - Â Â Â $ (699,258) Â Â $ 12,000 Â Operating expenses Â Sales and marketing Â Â 120 Â Â Â 249,000 Â Â Â - Â Â Â Â (120) (a) Â Â - Â Â Â Â 249,000 Â General and administrative Â Â 1,320,677 Â Â Â 565,000 Â Â Â 218,857 Â (c) Â Â (1,007,707) (a) Â Â (312,970) (b) Â Â 783,857 Â Depreciation and amortization Â Â 52,432 Â Â Â - Â Â Â - Â Â Â (3,948) (a) Â Â (48,484) (b) Â Â - Â Research and development Â Â - Â Â Â 289,000 Â Â Â - Â Â Â Â - Â Â Â Â - Â Â Â Â 289,000 Â Total operating expenses Â $

1,373,229 Â Â $ 1,103,000 Â Â $ 218,857 Â Â Â $ (1,011,775) Â Â $ (361,454) Â Â $ 1,321,857 Â Loss from operations Â $ (673,971) Â $ (1,091,000) Â $ (218,857) Â Â $ 1,011,775 Â Â Â $ (337,804) Â Â $ (1,309,857) Other income (expense) Â Interest expense, bank fees, net Â Â (10,743) Â Â (2,000) Â Â - Â Â Â Â 10,743 Â (a) Â Â - Â Â Â Â (2,000) Gain on lease termination Â Â 6,419 Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â (6,419) (b) Â Â - Â Unrealized loss on foreign exchange Â Â - Â Â Â (28,000) Â Â - Â Â Â Â - Â Â Â Â - Â Â Â Â (28,000) Other income (expense) Â Â 4,345 Â Â Â (1,000) Â Â - Â Â Â Â (4,335) (a) Â Â (10) (b) Â Â (1,000) Total other income (expense) Â $ 21 Â Â $ (31,000) Â Â - Â Â Â $ 6,408 Â Â Â $ (6,429) Â Â $ (31,000) Loss from operations before income taxes Â Â (673,950) Â Â (1,122,000) Â Â (218,857) Â Â Â 1,018,183 Â Â Â Â (344,233) Â Â Â (1,340,857) Income tax expense Â Â - Â Â Â - Â Â Â - Â Â Â Â - Â Â Â Â - Â Â Â Â - Â Net loss Â $ (673,950) Â $ (1,122,000) Â $ (218,857) Â Â $ 1,018,183 Â Â Â $ (344,233) Â Â $ (1,340,857) Â Basic and diluted weighted average common stock outstanding Â Â 2,013,180 Â 24,188,979 Â Basic and diluted net loss per share Â Â (0.33) Â (0.06) Â See accompanying notes to the unaudited pro forma condensed combined financial statements Â 106 Â Â Unaudited Pro Forma Condensed Combined Statement of Operations For the Year Ended December 31, 2023 (Amounts expressed in United States dollars, except for number of shares) Â Â Â Â Â Â Â Â Â Â Pro forma adjustments Â Â Â Â Â Â Wave Dancer As reported Â Â Firefly Neuroscience As reported Â Â Merger Adjustments Â Notes Â Wind-down of WaveDancer Corporate Â Notes Â Tellenger Sale Transaction Â Notes Â Pro Forma Combined FS Â Revenue Â $ 7,981,975 Â Â $ 498,000 Â Â Â - Â Â Â Â - Â (b) Â $ (7,981,975) (c) Â $ 498,000 Â Cost of revenue Â Â 5,367,678 Â Â Â - Â Â Â - Â Â Â Â (1,000) (b) Â Â (5,366,678) (c) Â Â - Â Gross profit Â $ 2,614,297 Â Â $ 498,000 Â Â Â - Â Â Â $ 1,000 Â Â Â $ (2,615,297) Â Â $ 498,000 Â Operating expenses Â Sales and marketing Â Â 2,233 Â Â Â 639,000 Â Â Â - Â Â Â Â (1,793) (b) Â Â (440) (c) Â Â 639,000 Â General and administrative Â Â 5,622,663 Â Â Â 2,196,000 Â Â Â 400,000 Â (a) Â Â (4,232,547) (b) Â Â (1,390,116) (c) Â Â 3,775,548 Â Â Â Â - Â Â Â - Â Â Â 400,000 Â (d) Â Â - Â Â Â Â - Â Â Â Â - Â Â Â Â - Â Â Â - Â Â Â 779,548 Â (e) Â Â - Â Â Â Â - Â Â Â Â - Â Depreciation and amortization Â Â 217,236 Â Â Â - Â Â Â - Â Â Â Â (15,791) (b) Â Â (201,445) (c) Â Â - Â Research and development Â Â - Â Â Â 741,000 Â Â Â - Â Â Â Â - Â Â Â Â - Â Â Â Â 741,000 Â Total operating expenses Â $ 5,842,132 Â Â $ 3,576,000 Â Â $ 1,579,548 Â Â Â $ (4,250,131) Â Â $ (1,592,001) Â Â $ 5,155,548 Â Loss from operations Â $ (3,227,835) Â $ (3,078,000) Â $ (1,579,548) Â Â $ 4,251,131 Â Â Â $ (1,023,296) Â Â $ (4,657,548) Other income (expense) Â Interest expense, net Â Â (103,256) Â Â (18,000) Â Â - Â Â Â Â 103,229 Â (b) Â Â 27 Â (c) Â Â (18,000) Gain on sale of equity investment and settlement of contingent consideration payable Â Â 382,525 Â Â Â - Â Â Â - Â Â Â Â (382,525) (b) Â Â - Â Â Â Â - Â Gain on litigation settlement Â Â 1,442,468 Â Â Â - Â Â Â - Â Â Â Â (1,442,468) (b) Â Â - Â Â Â Â - Â Unrealized gain on foreign exchange Â Â - Â Â Â 37,000 Â Â Â - Â Â Â Â - Â Â Â Â - Â Â Â Â 37,000 Â Other income (expense) Â Â 10,596 Â Â Â 457,000 Â Â Â 2,442 Â (f) Â Â (10,749) (b) Â Â 153 Â (c) Â Â 459,442 Â Â Â Â - Â Â Â - Â Â Â (326,906) (g) Â Â - Â Â Â Â - Â Â Â Â (326,906) Total other income (expense) Â $ 1,732,333 Â Â $ 476,000 Â Â $ (324,464) Â Â $ (1,732,513) Â Â $ 180 Â Â Â $ 151,536 Â Loss from continuing operations before income taxes and equity in net loss of affiliate Â $ (1,495,502) Â $ (2,602,000) Â $ (1,904,013) Â Â $ 2,518,618 Â Â Â $ (1,023,116) Â Â $ (4,506,013) Income tax (benefit) expense Â Â (42,585) Â Â 1,000 Â Â Â - Â Â Â Â 307,733 Â (b) Â Â (265,148) (c) Â Â 1,000 Â Net loss from continuing operations before equity in net loss of affiliate Â $ (1,452,917) Â $ (2,603,000) Â $ (1,904,013) Â Â $ 2,210,885 Â Â Â $ (757,968) Â Â $ (4,507,013) Equity in net loss of affiliate Â Â (245,525) Â Â - Â Â Â - Â Â Â Â 245,525 Â Â Â Â - Â Â Â Â - Â Net loss from continuing operations Â $ (1,698,442) Â $ (2,603,000) Â $ (1,904,013) Â Â $ 2,456,410 Â Â Â $ (757,968) Â Â $ (4,507,013) Loss from discontinued operations Â Â (335,993) Â Â - Â Â Â - Â Â Â Â 335,993 Â Â Â Â - Â Â Â Â - Â Net loss Â $ (2,034,435) Â $ (2,603,000) Â $ (1,904,013) Â Â $ 2,792,403 Â Â Â $ (757,968) Â Â $ (4,507,013) Â Basic and diluted weighted average common stock outstanding Â Â 1,948,769 Â 24,124,568 Â Basic and diluted loss per share from continuing operations Â Â (0.87) Â (0.19) Basic and diluted loss per share from discontinued operations Â Â (0.17) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â - Â Basic and diluted loss per share Â Â (1.04) Â (0.19) Â See accompanying notes to the unaudited pro forma condensed combined financial statements Â 107 Â Â NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Â (Amounts expressed in United States dollars, except for number of shares) Â Note 1. Description of Transactions Â On November 15, 2023, WaveDancer, Inc. a Delaware corporation (â€œWaveDancerâ€ or the â€œParentâ€), FFN Merger Sub, Inc., a Delaware corporation (â€œMerger Subâ€) and Firefly Neuroscience, Inc., a Delaware corporation (â€œFireflyâ€ or the â€œCompanyâ€) entered into an Agreement and Plan of Merger (as may be amended from time to time, the â€œMerger Agreementâ€). The Merger Agreement was amended on January 12, 2024 (â€œFirst Amendmentâ€). Â In accordance with the Merger Agreement, Merger Sub will merge into Firefly which will become a wholly owned subsidiary of WaveDancer, WaveDancer will change its name to Firefly Neuroscience, Inc., and the Firefly shares will be converted into WaveDancer shares (â€œMergerâ€). In connection with the Merger Agreement, on November 15, 2023, WaveDancer entered into a Stock Purchase Agreement (â€œTellenger Sale Transactionâ€) with Wavetop Solutions, Inc. (â€œWavetopâ€), a company owned and controlled by WaveDancerâ€™s chief executive officer, to sell all of the outstanding shares of Tellenger Inc. (â€œTellengerâ€) to Wavetop. Tellenger is the company through which WaveDancer operates its day-to-day business. In addition, at the effective time of the Merger, WaveDancer is required, with limited exception, to have no liabilities and to not retain any material assets other than cash. Â Subject to the terms and conditions of the Merger Agreement, at the effective time of the merger (â€œEffective Timeâ€), (a) each outstanding share of capital stock of Firefly will be converted into the right to receive the number of shares of the combined companyâ€™s common stock equal to the exchange ratio described below and (b) each outstanding Firefly stock option, whether vested or unvested, and warrant that has not been exercised prior to the Effective Time will be assumed by WaveDancer and converted into a stock option or warrant, as the case may be, to purchase shares of WaveDancer common stock at the Exchange Ratio. For the purposes of the unaudited pro forma condensed combined financial information, the exchange ratio is assumed to be 0.42 and the fair value of the shares of the Company post-merger is estimated at $2.25 USD. The $2.25 USD fair value assumption is based on the approximate trading price of the WaveDancer, Inc. common shares on the Nasdaq Stock Market at the time of the issuance of these unaudited pro forma condensed combined financial information. Â Under the Exchange Ratio formula in the Merger Agreement, as of immediately following the Merger, Firefly equity holders are expected to own approximately 92% of the aggregate number of shares of the combined company and WaveDancer equity holders are expected to own approximately 8% of the combined company. The Exchange Ratio will be fixed immediately prior to the Effective Time to reflect WaveDancerâ€™s and Fireflyâ€™s equity capitalization as of immediately prior to such time. See â€œThe Merger Agreementâ€‰-â€‰Exchange Ratioâ€ for more information. Â For the purposes of the unaudited pro forma condensed combined financial information, the accounting policies of WaveDancer and Firefly are aligned with no differences. Accordingly, no effect has been provided for the pro forma adjustments described in notes to the unaudited pro forma condensed combined financial information. Â Note 2. Basis of Presentation Â The merger between Merger Sub and Firefly will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, WaveDancer will be treated as the â€œacquiredâ€ company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization will be treated as the equivalent of Firefly issuing stock for the net assets of WaveDancer, accompanied by a recapitalization. The net assets of WaveDancer will be stated at their fair value, which is expected to approximate book value because of their short-term nature. No goodwill or other intangible assets are expected to be recognized. Any excess consideration transferred over the fair value of the net assets of WaveDancer will be reflected as an adjustment to equity. Subsequent to the Merger, the historical registrant financial statements prior to the Reverse Recapitalization will be those of Firefly, since Fireflyâ€™s business will be considered the predecessor. Â 108 Â Â The unaudited pro forma condensed combined balance sheet as of March 31, 2024 assumes that the Merger occurred on March 31, 2024. The unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2024 and for the year ended December 31, 2023 present pro forma effect of the Merger as if it had been completed on January 1, 2023. These periods are presented on the basis of Firefly being the accounting acquirer. Â The unaudited pro forma condensed combined financial information should be read in conjunction with: Â â— WaveDancerâ€™s audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2023, as contained in the Form 10-K filed on March 20, 2024 with the U.S. Securities and Exchange Commission (SEC). Â â— WaveDancerâ€™s unaudited condensed consolidated financial statements and accompanying notes as of and for the three months ended March 31, 2024 as contained in its Quarterly Report on Form 10-Q filed on May 14, 2024 with the SEC. Â â— Fireflyâ€™s audited consolidated financial statement as of and for the years ended December 31, 2023. Â â— Fireflyâ€™s unaudited consolidated financial statements as of and for the three months ended March 31, 2024. Â â— The other information contained in or incorporated by reference into this filing. Â Management has made significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented. Â The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, dis-synergies, operating efficiencies, tax savings or cost savings that may be associated with the Merger. Â The historical consolidated financial statements have been adjusted in the unaudited pro forma condensed combined financial information to give effect to pro forma events that are (1) directly attributable to the merger, and (2) factually supportable. The pro forma adjustments reflecting the completion of the Merger are based on certain currently available information and certain assumptions and methodologies that WaveDancer believes are reasonable under the circumstances. The unaudited condensed pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated. Â 109 Â Â Basic and Dilute Weighted Average Common Shares Outstanding Â Â Â 3 Months Ended March 31, 2024 Â Â Year Ended December 31, 2023 Â Firefly outstanding number of shares reported on quarterly and audited financial statements, respectively Â Â 49,948,700 Â Â Â 49,948,700 Â Estimated Exchange Ratio Â Â 0.42 Â Â Â 0.42 Â Estimated WaveDancer shares to be issued to Firefly shareholders at closing Â Â 20,978,454 Â Â Â 20,978,454 Â Estimated additional shares to be issued relating to concurrent transactions disclosed within note 3(l), 3(m), 3(n), 3(p), 3(r) Â Â 1,197,345 Â Â Â 1,197,345 Â Weighted average common stock outstanding of WaveDancer reported on Forms 10-Q and 10-K respectively Â Â 2,013,180 Â Â Â 1,948,769 Â Pro forma weighted average common stock outstanding Â Â 24,188,979 Â Â Â 24,124,568 Â Â Note 3. Pro Forma Adjustments - Unaudited Pro Forma Condensed Balance Sheets as of March 31, 2024 Â a) Represents receipt of $1.5 million of cash consideration to be received for the Tellenger Sale Transaction. Â b) Tellengerâ€™s assets and liabilities, except cash, will be transferred to Wavetop as part of the Tellenger Sale Transaction. The adjustments presented are made to remove the balances that are recorded on the Tellenger's accounting records and/or are directly related to the Tellenger operation and would be included in the Tellenger Sale Transaction. Â c) The Tellenger Sale Transaction results in a net loss which is recorded to accumulated deficit. The loss on sale is estimated as follows: Â Cash consideration Â $ 1,500,000 Â Liabilities assumed Â Â 769,196 Â Total consideration Â Â 2,269,196 Â Net book value of assets sold Â Â (3,028,795) Loss on sale Â $ (759,599) Â d) The adjustment to cash represents the settlement of WaveDancerâ€™s outstanding liabilities as of the effective date of the Merger. The adjustment excludes payments for fees and expenses related to the Merger such as legal and professional fees and severance costs. The adjustment is estimated as follows: Â Total WaveDancer liabilities eliminated Â $ (1,518,028) Add back operating lease liability not settled in cash (see f.) Â Â 78,778 Â Income tax payable not carried forward Â Â 14,266 Â Net Cash Settlement of liabilities Â Â (1,424,984) Net cash adjustment Â $ (1,424,984) Â 110 Â Â e) Reflects the payment of WaveDancer liabilities that, under the terms of the Merger Agreement, are to be settled for cash on or prior to the closing of the Merger. The settlement of liabilities is reflected in adjustment (d). Â f) WaveDancer has two office leases accounted for under ASC 842: Annapolis, MD and Fairfax, VA. The Fairfax lease amounts are included in the Tellenger sale adjustment amounts. The Annapolis lease will remain in force after the Merger. The remaining lease term is less than one year from the assumed Merger date. This adjustment removes the right of use asset and related operating lease liability amounting to $50,154 and $78,778, respectively. The security deposit amounting to $12,713 for the Annapolis office is assumed to be carried over to Firefly. Â g) Represents full valuation allowance of deferred tax assets amounting to $231,021 of the Company after giving effect to the sale of Tellenger and the Merger. Â h) Reflects the repayment of the revolving line of credit balance at the closing of the Merger. The repayment is reflected in adjustment (d). Â i) Reflects elimination of the share capital, treasury stock and accumulated deficit of WaveDancer in connection with the reverse capitalization accounting and to reflect the recording on the common shares issued to Firefly stockholders. Â j) Represents the net assets to be conveyed from WaveDancer to Firefly and recorded as additional paid-in capital on the Companyâ€™s balance sheet. Â k) Represents the issuance of $3,500,000 in preferred stock referred to as Series A preferred stock. The Series A preferred stock are convertible to common stock any time by holder at $2.00 per share or if closing price less than the conversion price, the greater of the agreed floor price or 85% Volume Weighted Average Price of the common stock on the date immediately preceding the conversion date. Management has also issued 0.55 common stock purchase warrants for every Series A preferred stock issued. The exercise price of common stock purchase warrants is $2.50. Under ASC 480, Distinguishing Liabilities from Equity, management has assessed that theÂ Series A preferred stock and the common stock purchase warrants are classified as equity. Â l) Concurrently with the Merger, the Company will issue 180,469 common shares for consulting services to be received by the Company in the future. 82,118 of such common shares amounting to $184,766 at a fair value of $2.25 vest immediately. The pro forma financial information reflects the adjustment as the transaction is directly attributable to the Merger. Management has recognized an impairment on the prepaid services amounting to $105,188. Â m) Represents issuance of common shares amounting to $750,000 at Merger close in exchange for $250,000 worth of annual software development services for each of three consecutive calendar years following the Merger. Management estimates to issue approximately 333,334 common shares based on current estimated valuation of $2.25 per share. Â n) Represents issuance of common shares amounting to $1,000,000 at Merger close in exchange $333,333 worth of annual financial administration and capital markets consulting services for each of three consecutive calendar years following the Merger. Management estimates to issue approximately 444,444 common shares based on current estimated valuation of $2.25 per share. Â o) Reflects an adjustment of $400,000 in anticipated transaction cost for both WaveDancer and Firefly relating to the Merger such as adviser fees, legal and accounting expenses that were not incurred as of March 31, 2024. Â p) Concurrently with the Merger, the Company will issue approximately 61,320 common shares of the Company with an estimated fair value of $2.25 per share in settlement of payable to the employees and a related party of the Company amounting to $112,408. The pro forma financial information reflects the adjustment as the transaction is directly attributable to the Merger. Difference in the fair value of shares issued and debt settled is accounted as additional paid in capital and accumulated losses amounting to $2,442 for a related party and employees, respectively. Â q) Concurrently with the Merger, the Company will modify the exercise price of options issued an officer of the Company to $0.01 per share against full settlement of debt payable to the officer amounting to $45,000. The pro forma financial information reflects the adjustment as the transaction is directly attributable to the Merger. The difference between the debt settled and impact of modification of the option is accounted as additional paid in capital as the officer is a related party of the Company. Â 111 Â Â r) Relates to restricted share units issued to two officers of Firefly under the Companyâ€™s restricted share units plan amounting to $400,000. The restricted share units vest on the effective date of the Merger. The vesting of the restricted share units is expected to result in the issuance of 177,778 common shares of the Company. Â s) Relates to 152,332 options issued to two officers of the Company. The options vest on the effective date of the Merger and the total fair value of the options is estimated at $341,834 based on the Black-Scholes model. Key assumptions include the share price of $2.25, risk free rate of 4.35%, 0% dividend yield, expected volatility of 270%, and expected life of 5 years. Â t) Represents issuance of common shares amounting to $225,000 at Merger close in exchange for $75,000 worth of annual business development & consulting services for each of three consecutive calendar years following the Merger. Management estimates to issue approximately 100,000 common shares based on current estimated valuation of $2.25 per share. Â u) Represents issuance of common shares amounting to $950,000 at Merger close in exchange for $316,667 worth of annual business development & consulting services for each of three consecutive calendar years following the Merger. Management estimates to issue approximately 422,222 common shares based on current estimated valuation of $2.25 per share. Â Note 4. Pro Forma Adjustments - Unaudited Pro Forma Condensed Statement of Operations for the Three Months Ended March 31, 2024 Â a) Reflects reversal of WaveDancer's corporate net expenses incurred during the three months ended March 31, 2024 amounting to $1,018,183 that would not be incurred from the Merger date. Â b) Reflects reversal of transactions related to Tellenger that will be transferred to Wavetop as part of the Tellenger Sale Transaction amounting to a net income of $344,233. Â c) Relates to 97,524 options issued by the Company in prior period that vest upon a liquidity event such as the Merger, resulting in $218,857 of expense. The pro forma financial information reflects the adjustment as the transaction is directly attributable to the Merger. The fair value of the options is

estimated based on the Black-Scholes option-pricing model. Key assumptions include the share price of $2.25, risk free rate of 4.35%, 0% dividend yield, expected volatility of 270%, and expected life of 5 years. Â Note 5. Pro Forma Adjustments - Unaudited Pro Forma Condensed Statement of Operations for the Year Ended December 31, 2023 Â a) Reflects an adjustment of $400,000 in anticipated transaction cost for both WaveDancer and Firefly relating to the Merger such as adviser fees, legal and accounting expenses. Â b) Reflects reversal of WaveDancer's corporate net expenses incurred during the year ended December 31, 2023 amounting to $2,792,403 that would not be incurred from the Merger date. These costs include reversal of gain on litigation settlement, sale of equity investment and settlement of contingent consideration receivable, the equity in the net loss of affiliate, and other income. Â c) Reflects reversal of transactions related to Tellenger that will be transferred to Wavetop as part of the Tellenger Sale Transaction amounting to a net income of $757,968. Â d) Relates to restricted share units issued to two officers of Firefly under the Companyâ€™s restricted share units plan amounting to $400,000. The restricted share units vest on the effective date of the Merger. The vesting of the restricted share units is expected to result in the issuance of 177,778 common shares of the Company. Â e) Relates to 347,373 options issued by the Company in prior period that vests upon a liquidity event such as the Merger, resulting in $779,548 of expense. The fair value of the options is estimated based on the Black-Scholes option-pricing model. Key assumptions include the share price of $2.25, risk free rate of 4.35%, 0% dividend yield, expected volatility of 270%, and expected life of 5 years. Â f) Concurrently with the Merger, the Company will issue approximately 45,829 common shares of the Company with an estimated fair value of $2.25 per share in settlement of payable to the employees amounting to $105,556. Difference in the fair value of shares of issued to employees and the debt settled is accounted as expense. The pro forma financial information reflects the adjustment as the transaction is directly attributable to the Merger. Â g) Relates to recognition of impairment on the prepaid services amounting to $326,906 calculated as the excess of the fair value of 180,660 shares issued for services to be received in the future over the value of the agreed service of $ 79,578. Fair value of each share is assumed to be $2.25. Â Â 112 Â Â Â Â Â Â INDEX TO FINANCIAL STATEMENTS Â Â Â Â Â Â Page Unaudited Condensed Consolidated Financial Statements of Firefly Neuroscience, Inc., for the three and six months ended June 30, 2024 and 2023 Â Â Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 Â F-2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 Â F-3 Unaudited Condensed Consolidated Statements of Changes in Shareholdersâ€™Â Equity (Deficit) for the Six Months Ended June 30, 2024 and 2023 Â F-4 Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023Â Â F-5 Notes to Unaudited Condensed Consolidated Financial Statements Â F-6 Â Â Â Audited Consolidated Financial Statements of Firefly Neuroscience, Inc. for theÂ years ended DecemberÂ 31, 2023 and 2022 Â Â Report of Independent Registered Public Accounting Firm Â F-15 Consolidated Balance Sheets as of December 31, 2023 and 2022 Â F-16 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022 Â F-17 Consolidated Statements of Changes in Shareholdersâ€™Â Equity (Deficit) for the Years Ended December 31, 2023 and 2022 Â F-18 Condensed Consolidated Statements of Cash Flows for the Year Ended December 31, 2023 and 2022 Â F-19 Notes to Consolidated Financial Statements Â F-20 Â F-1 Â Â Â FIREFLY NEUROSCIENCE 2023, INC. (formerly known as Firefly Neuroscience, Inc.) CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 (IN THOUSANDS, EXCEPT SHARE DATA) Â Â Â June 30, Â Â December 31, Â Â Â 2024 (Unaudited) Â Â 2023 Â ASSETS Â Â Â Â Â Â Â Â Current assets Â Â Â Â Â Â Â Â Cash Â $358Â Â $2,143Â Other receivables Â Â 83Â Â Â 84Â Prepaid expenses Â Â 63Â Â Â 28Â Total current assets Â Â 504Â Â Â 2,255Â Non current assets Â Â Â Â Â Â Â Â Equipment, net Â Â 60Â Â Â -Â Intangible assets, net Â Â 634Â Â Â 386Â Total non current assets Â Â 694Â Â Â 386Â TOTAL ASSETS Â $1,198Â Â $2,641Â Â Â Â Â Â Â Â Â Â LIABILITIES Â Â Â Â Â Â Â Â Current liabilities Â Â Â Â Â Â Â Â Trade payables Â $1,265Â Â $455Â Related party payable Â Â 175Â Â Â 175Â Accrued liabilities Â Â 973Â Â Â 1,902Â Total current liabilities Â Â 2,413Â Â Â 2,532Â TOTAL LIABILITIES Â Â 2,413Â Â Â 2,532Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENCIES (Note 8) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â SHAREHOLDERSâ€™ EQUITY (DEFICIT) Â Â Â Â Â Â Â Â Preferred shares, $0.00001 par value: 30,000,000 shares authorized; 2,374,219 and 16,116,957 issued and outstanding at June 30, 2024 and December 31, 2023, respectively Â Â -Â Â Â -Â Common shares, $0.00001 par value: 2,470,000,000 shares authorized; 49,948,710 and 35,369,877 issued and outstanding at June 30, 2024 and December 31, 2023, respectively Â Â -Â Â Â -Â Additional paid-in capital Â Â 77,795Â Â Â 76,733Â Accumulated deficit Â Â (79,010)Â Â (76,624) TOTAL SHAREHOLDERSâ€™ EQUITY (DEFICIT) Â Â (1,215)Â Â 109Â TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY (DEFICIT) Â $1,198Â Â $2,641Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â F-2 Â Â Â FIREFLY NEUROSCIENCE 2023, INC. (formerly known as Firefly Neuroscience, Inc.) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Â Â Â Three months ended Â Â Six months ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â REVENUE Â $ 10 Â Â $ 451 Â Â $ 22 Â Â $ 456 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OPERATING EXPENSES: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses Â Â 350 Â Â Â 199 Â Â Â 639 Â Â Â 320 Â Selling and marketing expenses Â Â 293 Â Â Â 171 Â Â Â 542 Â Â Â 304 Â General and administration expenses Â Â 626 Â Â Â 399 Â Â Â 1,191 Â Â Â 696 Â TOTAL OPERATING EXPENSES Â Â 1,269 Â Â Â 769 Â Â Â 2,372 Â Â Â 1,320 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OPERATING LOSS Â Â (1,259) Â Â (318) Â Â (2,350) Â Â (864) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OTHER INCOME (EXPENSE) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest and bank fees Â Â (10) Â Â (3) Â Â (12) Â Â (10) Unrealized gain on foreign exchange Â Â 31 Â Â Â - Â Â Â 3 Â Â Â - Â Other expense, net Â Â (26) Â Â (2) Â Â (27) Â Â (2) LOSS BEFORE INCOME TAX Â Â (1,264) Â Â (323) Â Â (2,386) Â Â (876) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income tax provision Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NET LOSS AND COMPREHENSIVE LOSS Â $ (1,264) Â $ (323) Â $ (2,386) Â $ (876) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â BASIC AND DILUTED LOSS PER SHARE Â $ (0.03) Â $ (0.01) Â $ (0.05) Â $ (0.03) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED Â Â 49,948,710 Â Â Â 35,277,018 Â Â Â 49,948,710 Â Â Â 26,734,918 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â F-3 Â Â Â FIREFLY NEUROSCIENCE 2023, INC. (formerly known as Firefly Neuroscience, Inc.) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERSâ€™ EQUITY (DEFICIT) FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (IN THOUSANDS, EXCEPT SHARE DATA) Â Â Â Preferred stock Â Â Common stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares Â Â Number of shares to be issued Â Â Amount Â Â Number of shares Â Â Number of shares to be issued Â Â Amount Â Â Additional paid-in capital Â Â Accumulated deficit Â Â Total Shareholderâ€™s equity (deficit) Â BALANCE AT DECEMBER 31, 2023 Â Â 16,116,967 Â Â (14,578,833) Â $ - Â Â Â 35,369,877 Â Â Â 14,578,833 Â Â $ - Â Â $ 76,733 Â Â $ (76,624) Â $ 109 Â Series B Preferred Stock conversion Â Â (14,578,833) Â Â 14,578,833 Â Â - Â Â Â 14,578,833 Â Â Â (14,578,833) Â Â - Â Â Â - Â Â Â - Â Â Â - Â Series C Preferred Stock Units offering Â Â 836,085 Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 945 Â Â Â - Â Â Â 945 Â Share-based compensation expense Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 117 Â Â Â - Â Â Â 117 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â (2,386) Â Â (2,386) BALANCE AT JUNE 30, 2024 Â Â 2,374,219 Â Â Â - Â Â $ - Â Â Â 49,948,710 Â Â Â - Â Â $ - Â Â Â 77,795 Â Â $ (79,010) Â $ (1,215) Â BALANCE AT DECEMBER 31, 2022 Â Â - Â Â Â - Â Â $ - Â Â Â 2,552,744 Â Â Â - Â Â $ - Â Â $ 71,795 Â Â $ (74,021) Â $ (2,226) Common Stock Private Placement Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 32,536,386 Â Â Â - Â Â Â 133 Â Â Â - Â Â Â 133 Â Series B Preferred Stock offering Â Â - Â Â Â 5,897,932 Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â 1,092 Â Â Â - Â Â Â 1,092 Â Share-based compensation expense Â Â - Â Â Â - Â Â Â - Â Â Â 284,964 Â Â Â - Â Â Â - Â Â Â 148 Â Â Â - Â Â Â 148 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â (876) Â Â (876) BALANCE AT JUNE 30, 2023 Â Â - Â Â Â 5,897,932 Â Â $ - Â Â Â 2,837,708 Â Â Â 32,536,386 Â Â $ - Â Â $ 73,168 Â Â $ (74,897) Â $ (1,729) Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â F-4 Â Â Â FIREFLY NEUROSCIENCE 2023, INC. (formerly known as Firefly Neuroscience, Inc.) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (IN THOUSANDS) Â Â Â Six months ended June 30, Â Â Â 2024 Â Â 2023 Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Â Â Net loss Â $ (2,386) Â $ (876) Adjustments to reconcile net loss to net cash used in operating activities Â Â Â Â Â Â Â Â Depreciation Â Â 4 Â Â Â - Â Share-based compensation expense Â Â 117 Â Â Â 148 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Change in other receivables Â Â 1 Â Â Â (3) Change in prepaid expenses Â Â (35) Â Â (24) Change in trade payables Â Â 810 Â Â Â 63 Â Change in related party payables Â Â - Â Â Â 30 Â Change in accrued liabilities Â Â (929) Â Â 176 Â Change in deferred revenue Â Â - Â Â Â (450) Net cash used in operating activities Â Â (2,418) Â Â (936) Â Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Â Â Purchase of equipment Â Â (64) Â Â - Â Product enhancement â€“ intangible asset Â Â (248) Â Â - Â Net cash used in investing activities Â Â (312) Â Â - Â Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Â Â Proceeds from sale of shares Â Â 945 Â Â Â 1,225 Â Net cash provided by financing activities Â Â 945 Â Â Â 1,225 Â (DECREASE) INCREASE IN CASH Â Â (1,785) Â Â 289 Â BALANCE OF CASH AT THE BEGINNING OF PERIOD Â Â 2,143 Â Â Â 58 Â BALANCE OF CASH AT THE END OF PERIOD Â $ 358 Â Â $ 347 Â Â Â Â Â Â Â Â Â Supplemental cash flow information Â Â Â Â Â Â Â Â Cash paid for interest Â Â - Â Â Â - Â Cash paid for income taxes Â Â - Â Â Â - Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â F-5 Â Â FIREFLY NEUROSCIENCE 2023, INC. (formerly known as Firefly Neuroscience, Inc.) NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Â Â NOTE 1: BUSINESS DESCRIPTION Â Nature of organization and business Â Firefly Neuroscience, Inc. (the â€œCompanyâ€) and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.), Firefly Neuroscience Canada Inc., a Canadian corporation, and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain. Â Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc. Â In July 2014, the U.S. Food and Drug Administration (â€œFDAâ€) cleared Firefly Neuroscience Ltd.â€™s Brain Network Analytics (â€œBNAâ€ â„¢) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European (â€œCEâ€) approval for BNAâ„¢ allowing use in Europe. Â Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc. Â Merger agreement Â On November 16, 2023, WaveDancer, Inc. (â€œWaveDancerâ€) (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the â€œMerger Agreementâ€) with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Companyâ€™s Artificial Intelligence driven BNAâ„¢ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market. Â Under the terms of the Merger Agreement, each share of the Companyâ€™s shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancerâ€™s ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. Following the merger, WaveDancer, Inc. will be renamed â€œFirefly Neuroscience, Inc.â€ and the corporate headquarters will be located in Buffalo, NY. Â On January 12, 2024 and June 17, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates included changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Companyâ€™s warrants at the effective time, deletion of certain closing obligations, and to extend the end date of the original agreement dated November 15, 2023. Â The transaction was completed effective August 12, 2024. Â F- 6 Â Â Â Â NOTE 2: GOING CONCERN Â As of June 30, 2024, the Company had an accumulated deficit of $79,010 (December 31, 2023: $76,624) and negative cash flow from operating activities for the six months ended June 30, 2024 of $2,402 (June 30, 2023: $936). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the six months ended June 30, 2024 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Companyâ€™s liquidity in the foreseeable future, the Company has taken the following measures: Â Â (i) Negotiating further funding with existing and new investors to raise additional capital; Â (ii) Taking various cost control measures to reduce the operational cash burn; and Â (iii) Commercializing product to generate recurring sales. Â Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future. Â Â NOTE 3: BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Basis of presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United States of America (â€œU.S. GAAPâ€). The results reported in these unaudited condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for any subsequent period or for the entire period. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Companyâ€™s annual audited consolidated financial statements for the year ended December 31, 2023 and the notes included therein. Certain information and footnote disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in the accompanying unaudited condensed consolidated financial statements. All amounts are disclosed in thousands, except share and per share amounts. The accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, except as otherwise indicated, necessary for a fair statement of its consolidated financial position, results of operations, and cash flows of the Company for all periods presented. Â a. Principles of consolidation Â These unaudited consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities (â€œVIEâ€). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation. Â b. Use of estimates in the preparation of consolidated financial statements Â The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates. Â F- 7 Â Â Significant accounting policies Â The following significant accounting policies should be read in conjunction with the Companyâ€™s annual audited consolidated financial statements for the year ended December 31, 2023 and the notes therein. Â i) Equipment Equipment is stated at cost less accumulated depreciation. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of four years for medical equipment. Â c. Impact of recently issued accounting standards Â The Company has evaluated issued Accounting Standards Updates not yet adopted and believes the adoption of these standards will not have a material impact on its condensed consolidated financial statements. Â Â NOTE 4: OTHER RECEIVABLES Â Detail of other receivables balance is as follows: Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Other receivables Â $195Â Â $196Â Allowance for doubtful receivables Â Â (112)Â Â (112) Total Â $83Â Â $84Â Â Â Â NOTE 5: EQUIPMENT Â Equipment balance is as follows: Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Medical equipment, cost Â $64Â Â $-Â Less â€“ accumulated depreciation Â Â (4)Â Â -Â Equipment, net Â $60Â Â $-Â Â Â Â NOTE 6: INTANGIBLE ASSETS Â The following tables summarize the composition of intangible assets as of June 30, 2024: Â Â Â June 30, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted Average Life Â Unamortized intangible assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â BNA software Â $634Â Â $-Â Â $634Â Â Â n/aÂ Total intangible assets Â $634Â Â $-Â Â $634Â Â Â Â Â Â The BNA software enhancement project is in progress and amortization will begin once the project is substantially complete and the software is ready for its intended purpose. The software is expected to be completed by the end of 2024

and have a useful life of five years. Â F- 8 Â Â Â Â NOTE 7: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT Â Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Companyâ€™s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, severance payments, which are included in salary and employee benefits, were $11 and $25 for the three and six months ended June 30, 2024, respectively and $11 and $16 for the three and six months ended June 30, 2023, respectively. Â Â NOTE 8: COMMITMENTS AND CONTINGENCIES Â a. Royalty Commitment - Israeli Innovation Authority (â€œIIAâ€) Â The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2024 or 2023. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate (â€œLIBORâ€) is repayable in form of royalties based on 3.0% of BNAâ„¢ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate (â€œSOFRâ€) subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of June 30, 2024 and December 31, 2023. The contingent liability amounts to $5,676 and $5,625 for June 30, 2024 and December 31, 2023 respectively. Â Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIAâ€™s approval. Â F- 9 Â Â Â Â NOTE 9: EQUITY Â a. Shares Â On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. During the six months period ended June 30, 2024, the Company issued 836,085 units and received aggregate gross proceeds of $1,070. The Company incurred $125 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. Â As of December 31, 2023, the mandatory conversion feature of the Series B Preferred Stock was triggered, as the proceeds from the Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of June 30, 2024, the 14,578,833 of Series B Preferred stock were converted to 14,578,833 shares of common stock. Â As of June 30, 2024, the Company had the following number of authorized and issued shares: Â Â Â June 30, 2024 Â Â Â Number of authorized shares Â Â Number of issued shares Â Shares of common stock Â Â 2,470,000,000Â Â Â 49,948,710Â Series A Preferred Stock Â Â 30,000,000Â Â Â -Â Series B Preferred Stock Â Â Â Â Â -Â Series C Preferred Stock Â Â Â Â Â 2,374,219Â Â As of June 30, 2024 the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shares of all classes. Â b. Warrants Â The following table summarizes the Companyâ€™s warrant activity for the six months ended June 30, 2024: Â Â Â Number of Warrants Â Â Weighted Average Exercise Price Â Â Weighted Average Remaining Life Â Outstanding warrants, January 1, 2024 Â Â 2,386,677Â Â $2.07Â Â Â 2.46Â Warrants issued pursuant to units offering Â Â 836,531Â Â Â 2.56Â Â Â -Â Outstanding warrants, June 30, 2024 Â Â 3,223,208Â Â $2.19Â Â Â 2.19Â Â On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. The warrants were determined to be a freestanding equity instrument. For the six month period ended June 30, 2024, 836,531 warrants were issued. Â F- 10 Â Â c. Employees stock option plan Â A summary of option activity under the Plan as of June 30, 2024 and changes during the period then ended is presented below. Â Â Â Number of Stock Options Â Â Weighted Average Exercise Price Â Â Weighted Average Remaining Contractual Term Â Â Aggregate Intrinsic Value Â Outstanding Options, December 31,2023 Â Â 1,291,662Â Â $2.16Â Â Â 6.18Â Â $-Â Options granted Â Â -Â Â Â -Â Â Â -Â Â Â -Â Outstanding Options, June 30, 2024 Â Â 1,291,662Â Â $2.16Â Â Â 5.67Â Â $-Â Â The share-based compensation expense related to options for the three and six months ended June 30, 2024 was $58 and $117, respectively and 74$ and $148 for the three and six months ended June 30, 2023, respectively. The fair value of options granted for the six months period ended June 30, 2024 and 2023 was $nil and $nil, respectively. The intrinsic value of the options outstanding as of June 30, 2024 is $nil (December 31, 2023: $nil). Â A summary of the Companyâ€™s non vested options as of June 30, 2024, and changes during the six months period ended, is presented below. Â Â Â Number of Stock Options Â Â Weighted Average Grant-Date Fair Value Â Non-Vested Options, December 31, 2023 Â Â 874,886Â Â $0.50Â Options granted Â Â -Â Â Â -Â Options vested Â Â (187,739)Â Â 0.62Â Non-Vested Options, June 30, 2024 Â Â 687,147Â Â $0.46Â Â As of June 30, 2024, there was $317 of total unrecognized compensation cost related to nonvested options granted under the Plan. Â d. Management options Â On April 2, 2024, the Company granted stock options to its officer to purchase an aggregate of 106,000 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Companyâ€™s equity securities in an initial public offering (an â€œIPO Transactionâ€), that results in the Companyâ€™s shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 106,000 shares of common stock shall vest in 36 equal installments at the end of each calendar month over a period of three years beginning March 1, 2024. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event. Â e. Consulting agreement Â On March 15, 2024, the Company entered into a consulting agreement (â€œConsulting agreementâ€), which was further approved by the board of directors of the Company on April 2, 2024. Under the Consulting agreement, the Company will receive services of promoting the Companyâ€™s stock; in return for 432,034 Series A performance warrants and 195,313 shares of common stock issued immediately upon execution of the agreement, and 234,735 shares of common stock to be issued in 12 equal installments at the end of each calendar month. Â F- 11 Â Â Series A performance warrants to purchase up to an aggregate 432,034 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share and are set to expire on June 15, 2028. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event. Â As of June 30, 2024, the shares of common stock and Series A performance warrants were not issued and no services were received. Â Â Â NOTE 10: BASIC AND DILUTED NET LOSS PER SHARE Â Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that were outstanding during the period when the effect is dilutive. Potential dilutive shares of common stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding shares of common stock figures for the six months ended June 30, 2024 or 2023, as the assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted stock units would be anti-dilutive. Â Â NOTE 11: RELATED PARTY TRANSACTIONS Â As of the period ended June 30, 2024, $175 (2023: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand. Â The Company incurred $140 and $244 in officersâ€™ consulting fees recorded in general and administration expenses for the three and six months ended June 30, 2024, respectively and $102 and $223 for the three and six months ended June 30, 2023, respectively. Â F- 12 Â Â Â Â NOTE 12: REVENUE Â Â Â Three months ended June 30, Â Â Six months ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Type of goods and services Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Service Â $10Â Â $451Â Â $22Â Â $456Â Total Â $10Â Â $451Â Â $22Â Â $456Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Timing of recognition of revenue Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Point in time Â Â 3Â Â Â -Â Â Â 7Â Â Â -Â Over time Â Â 7Â Â Â 451Â Â Â 15Â Â Â 456Â Total Â $10Â Â $451Â Â $22Â Â $456Â Â Â Â NOTE 13: RESEARCH AND DEVELOPMENT EXPENSES Â Â Â Three months ended June 30, Â Â Six months ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Salary and employee benefits Â $210Â Â $167Â Â $443Â Â $254Â Consultants and subcontractors Â Â 70Â Â Â 17Â Â Â 77Â Â Â 23Â Depreciation and amortization Â Â 4Â Â Â -Â Â Â 4Â Â Â -Â Clinical trials Â Â -Â Â Â 14Â Â Â -Â Â Â 19Â Expenses - other Â Â 66Â Â Â 1Â Â Â 115Â Â Â 24Â Â Â Â 350Â Â Â 199Â Â Â 639Â Â Â 320Â Less â€“ grants received Â Â -Â Â Â -Â Â Â -Â Â Â -Â Total Â $350Â Â $199Â Â $639Â Â $320Â Â Â Â NOTE 14: SELLING AND MARKETING EXPENSES Â Â Â Three months ended June 30, Â Â Six months ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Salary and employee benefits Â $179Â Â $160Â Â $347Â Â $289Â Professional fees Â Â 89Â Â Â 5Â Â Â 142Â Â Â 5Â Travel Â Â 22Â Â Â 6Â Â Â 46Â Â Â 10Â Other Â Â 3Â Â Â -Â Â Â 7Â Â Â -Â Total Â $293Â Â $171Â Â $542Â Â $304Â Â Â Â NOTE 15: GENERAL AND ADMINISTRATION EXPENSES Â Â Â Three months ended June 30, Â Â Six months ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Salary and employee benefits Â $143Â Â $142Â Â $261Â Â $319Â Professional fees Â Â 417Â Â Â 183Â Â Â 822Â Â Â 246Â Rent and maintenance Â Â 4Â Â Â 33Â Â Â 6Â Â Â 65Â Travel expenses Â Â 23Â Â Â 12Â Â Â 31Â Â Â 25Â Other Â Â 39Â Â Â 29Â Â Â 71Â Â Â 41Â Total Â $626Â Â $399Â Â $1,191Â Â $696Â Â F- 13 Â Â Â Â NOTE 16: SUBSEQUENT EVENTS Â The subsequent events below are major events or transactions that occurred after the six month period ended June 30, 2024, but before the issuance of these condensed consolidated financial statements. The below events occurred between July 1, 2024 and August 14, 2024: Â On August 8, 2024, the Company completed the closing of a $209 secured promissory notes. Promissory notes were issued with a discount of $11 and the Company received gross proceeds of $198. The promissory note will bear an annual interest rate of 18%, paid monthly. The principal amount of $209 will mature and become due and payable on August 23, 2024. Â Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc. Â Merger Â On August 12, 2024, the Company completed the merger with WaveDancer. As a result of this transaction, the Company obtained control of WaveDancer. The combined company operates under the name Firefly Neuroscience, Inc., and on August 13, 2023 the Company began trading on the Nasdaq Capital Market (NASDAQ: AIFF). On August 12, 2024, prior to the consummation of the Merger, WaveDancer effectuated a 1-for-3 reverse stock split of its common stock (the â€œReverse Stock Splitâ€) . Pursuant to the terms of the Merger Agreement, each holder of outstanding shares of the Companyâ€™s shares of common stock is entitled to receive the number of shares of WaveDancer common stock equal to the number of shares of the Companyâ€™s shares of common stock they hold multiplied by the exchange ratio, or an aggregate of 7,870,251 shares of WaveDancer common stock at closing using an exchange ratio of 0.1040. Following the closing of the merger, there are 7,870,251 shares of the combined companyâ€™s common stock outstanding with Firefly stockholders owning approximately 92% and prior WaveDancer stockholders owning 8% of the combined companyâ€™s outstanding securities. Â Private Placement Â On July 26, 2024, prior to the consummation of the merger, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,069,287 shares (the â€œPIPE Sharesâ€) of the combined companyâ€™s common stock and (ii) pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 4,849,265 shares of combined companyâ€™s common stock, and (iii) warrants (the â€œWarrantsâ€) to purchase up to 7,918,552 shares of combined companyâ€™s common stock in a private placement (the â€œPrivate Placementâ€). The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the merger. The aggregate gross proceeds from the transaction were approximately $3,500. Â F- 14 Â Â Â Â Â Â Â Â Â Report of Independent Registered Public Accounting Firm Â Board of Directors and Shareholders Firefly Neuroscience, Inc. Â Opinion on the Consolidated Financial Statements Â We have audited the accompanying consolidated balance sheets of Firefly Neuroscience, Inc. as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, changes in shareholdersâ€™ equity (deficit), and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the â€œconsolidated financial statementsâ€). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of Firefly Neuroscience, Inc. as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Â Going Concern Â The accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 2 of the notes to consolidated financial statements, the entity has suffered recurring losses from operations and negative cash flow from operating activities that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Â Basis for Opinion Â These consolidated financial statements are the responsibility of the entityâ€™s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to Firefly Neuroscience, Inc. in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. Â We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Firefly Neuroscience, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion. Â Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Â We have served as Firefly Neuroscience, Inc.'s auditor since 2023. Â Dallas, Texas May 22, 2024 Â Turner, Stone & Company, L.L.P. Accountants and Consultants Â 12700 Park Central Drive, Suite 1400 Dallas,Texas 75251 Telephone: 972-239-1660 â„ Facsimile: 972-239-1665 Toll Free: 877-853-4195 Web site: turnerstone.com Â Â F-15 Â Â Â Â FIREFLY NEUROSCIENCE, INC. CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND 2022 (IN THOUSANDS, EXCEPT SHARE DATA) Â Â Â December 31, Â Â Â 2023 Â Â 2022 Â ASSETS Â Â Â Â Â Â Â Â Current assets Â Â Â Â Â Â Â Â Cash Â $2,143Â Â $58Â Other receivables Â Â 84Â Â Â 19Â Prepaid expenses Â Â 28Â Â Â 6Â Total current assets Â Â 2,255Â Â Â 83Â Non current assets Â Â Â Â Â Â Â Â Long term deposits Â Â -Â Â Â 52Â Intangible assets, net Â Â 386Â Â Â -Â Total non current assets Â Â 386Â Â Â 52Â TOTAL ASSETS Â $2,641Â Â $135Â Â Â Â Â Â Â Â Â Â LIABILITIES Â Â Â Â Â Â Â Â Current liabilities Â Â Â Â Â Â Â Â Trade payables Â $455Â Â $420Â Related party payable Â Â 175Â Â Â 177Â Accrued liabilities Â Â 1,902Â Â Â 855Â Deferred revenue Â Â -Â Â Â 909Â Â Â Â Â Â Â Â Â Â Â Total current liabilities Â Â 2,532Â Â Â 2,361Â TOTAL LIABILITIES Â Â 2,532Â Â Â 2,361Â Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENCIES (Note 10) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â SHAREHOLDERSâ€™ EQUITY (DEFICIT) Â Â Â Â Â Â Â Â Preferred shares, $0.00001 par value: 30,000,000 shares authorized at December 31, 2023 and 2022; 16,116,957 and no shares issued and outstanding at December 31, 2023 and 2022, respectively Â Â -Â Â Â -Â Common shares, $0.00001 par value: 2,470,000,000 shares authorized at December 31, 2023 and 2022; 35,369,877 and 2,552,744 issued and outstanding at December 31, 2023 and 2022, respectively Â Â -Â Â Â -Â Additional paid-in capital Â Â 76,733Â Â Â 71,795Â Accumulated deficit Â Â (76,624)Â Â (74,021) TOTAL SHAREHOLDERSâ€™ EQUITY (DEFICIT) Â Â 109Â Â Â (2,226) TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Â $2,641Â Â $135Â Â The accompanying notes are an integral part of these consolidated financial statements. Â F-16 Â Â Â FIREFLY NEUROSCIENCE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Â Â Â Year ended Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Â Â Â Â Â Â Â Â Â REVENUE Â $ 498 Â Â $ - Â Â Â Â Â Â Â Â Â Â OPERATING EXPENSES: Â Â Â Â Â Â Â Â Research and development expenses Â Â 741 Â Â Â 1,299 Â Selling and marketing expenses Â Â 639 Â Â Â 524 Â General and administration expenses Â Â 2,196 Â Â Â 1,542 Â Impairment loss on equipment Â Â - Â Â Â 79 Â TOTAL OPERATING EXPENSES Â Â 3,576 Â Â Â 3,444 Â Â Â Â Â Â Â Â Â OPERATING LOSS Â Â (3,078) Â Â (3,444) Â Â Â Â Â Â Â Â Â OTHER INCOME (EXPENSE) Â Â Â Â Â Â Â Â Interest, bank fees and loan fees Â Â (18) Â Â (440) Unrealized gain (loss) on foreign exchange Â Â 37 Â Â Â (134) Loss on extinguishment of debt Â Â - Â Â Â (59) Other income (expenses) Â Â 457 Â Â Â 173 Â LOSS BEFORE INCOME TAX Â Â (2,602

) Â Â (3,904) Â Â Â Â Â Â Â Â Â Income tax provision Â Â (1) Â Â - Â Â Â Â Â Â Â Â Â Â NET LOSS AND COMPREHENSIVE LOSS Â $ (2,603) Â $ (3,904) Â Â Â Â Â Â Â Â Â BASIC AND DILUTED LOSS PER SHARE Â $ (0.08) Â $ (2.83) Â Â Â Â Â Â Â Â Â WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED Â Â 31,089,132 Â Â Â 1,380,051 Â Â The accompanying notes are an integral part of these consolidated financial statements. Â F-17 Â Â Â FIREFLY NEUROSCIENCE, INC. CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERSâ€™ EQUITY (DEFICIT) FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 (IN THOUSANDS, EXCEPT SHARE DATA) Â Â Â Preferred stockÂ Â Common stockÂ Â Â Â Â Â Number of Shares Â Â Number of shares to be issued Â Â Amount Â Â Number of shares Â Â Number of shares to be issued Â Â Amount Â Â Additional paid-in capital Â Â Accumulated deficit Â Â Total Shareholderâ€™s equity (deficit) Â Â BALANCE AT DECEMBER 31, 2021 Â Â 816,229,456Â Â -Â Â $2,429Â Â Â 1,508Â Â -Â Â $-Â Â $61,888Â Â $(67,331)Â $(3,014) Series A Preferred Stock issued Â Â 10,000,000Â Â Â -Â Â Â 3Â Â Â -Â Â Â -Â Â Â -Â Â Â 37Â Â Â -Â Â Â 40Â Converted shares of common stock Â Â (826,229,456)Â Â -Â Â Â (2,432)Â Â 1,101,764Â Â Â -Â Â Â Â Â Â Â 2,432Â Â Â -Â Â Â -Â Shares of common stock issued Â Â -Â Â Â -Â Â Â -Â Â Â 51,282Â Â Â -Â Â Â -Â Â Â 250Â Â Â -Â Â Â 250Â Debt conversion Â Â -Â Â Â -Â Â Â -Â Â Â 1,394,475Â Â Â -Â Â Â -Â Â Â 4,021Â Â Â -Â Â Â 4,021Â Warrants issued Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â 321Â Â Â -Â Â Â 321Â Share-based compensation expense Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â 60Â Â Â -Â Â Â 60Â Stock dividend paid Â Â -Â Â Â -Â Â Â -Â Â Â 3,715Â Â Â -Â Â Â -Â Â Â 2,786Â Â Â (2,786)Â Â -Â Net loss Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â (3,904)Â Â (3,904) BALANCE AT DECEMBER 31, 2022 Â Â -Â Â Â -Â Â $-Â Â Â 2,552,744Â Â Â -Â Â $-Â Â $71,795Â Â $(74,021)Â $(2,226) Common Stock Private Placement Â Â -Â Â Â -Â Â Â -Â Â Â 32,536,386Â Â Â -Â Â Â -Â Â Â 133Â Â Â -Â Â Â 133Â Series B Preferred Stock offering Â Â 14,578,833Â Â Â (14,578,833)Â Â -Â Â Â -Â Â Â 14,578,833Â Â Â -Â Â Â 2,608Â Â Â -Â Â Â 2,608Â Series C Preferred Stock Units offering Â Â 1,538,134Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â 1,902Â Â Â -Â Â Â 1,902Â Share-based expense Â Â -Â Â Â -Â Â Â -Â Â Â 284,964Â Â Â -Â Â Â -Â Â Â 295Â Â Â -Â Â Â 295Â Share repurchase Â Â -Â Â Â -Â Â Â -Â Â Â (4,217)Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Net loss Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â (2,603)Â Â (2,603) BALANCE AT DECEMBER 31, 2023 Â Â 16,116,967Â Â Â (14,578,833)Â $-Â Â Â 35,369,877Â Â Â 14,578,833Â Â $-Â Â $76,733Â Â $(76,624)Â $109Â Â The accompanying notes are an integral part of these consolidated financial statements. Â F-18 Â Â Â FIREFLY NEUROSCIENCE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 (IN THOUSANDS) Â Â Â Year Ended December 31, Â Â Â 2023 Â Â 2022 Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Â Â Net loss Â $ (2,603) Â $ (3,904) Adjustments to reconcile net loss to net cash used in operating activities Â Â Â Â Â Â Â Â Depreciation and amortization Â Â - Â Â Â 14 Â Net gain from sale of equipment Â Â - Â Â Â (87) Share-based expense Â Â 295 Â Â Â 60 Â Non-cash interest on convertible debt Â Â - Â Â Â 460 Â Loss on extinguishment of debt Â Â - Â Â Â 59 Â Changes in non-cash operating assets and liabilities: Â Â Â Â Â Â Â Â Change in other receivables Â Â (65) Â Â 27 Â Change in prepaid expenses Â Â (22) Â Â 3 Â Change in long term deposits Â Â 52 Â Â Â 9 Â Change in trade payables Â Â 35 Â Â Â (80) Change in related party payable Â Â (2) Â Â - Â Change in accrued liabilities Â Â 1,047 Â Â Â 97 Â Change in deferred revenue Â Â (909) Â Â 450 Â Net cash used in operating activities Â Â (2,172) Â Â (2,892) Â Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Â Â Proceeds from sale of equipment Â Â - Â Â Â 262 Â Product enhancement â€“ intangible assets Â Â (386) Â Â - Â Net cash provided by (used in) investing activities Â Â (386) Â Â 262 Â Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Â Â Proceeds from sale of convertible debt Â Â - Â Â Â 1,745 Â Proceeds from sale of shares Â Â 4,643 Â Â Â 290 Â Net cash provided by financing activities Â Â 4,643 Â Â Â 2,035 Â INCREASE (DECREASE) IN CASH Â Â 2,085 Â Â Â (595) BALANCE OF CASH AT THE BEGINNING OF YEAR Â Â 58 Â Â Â 653 Â BALANCE OF CASH AT THE END OF YEAR Â Â 2,143 Â Â Â 58 Â Â Â Â Â Â Â Â Â Supplemental cash flow information Â Â Â Â Â Â Â Â Cash paid for interest Â Â - Â Â Â - Â Cash paid for income taxes Â Â - Â Â Â - Â Debt converted to equity Â Â - Â Â Â (4,021) Â The accompanying notes are an integral part of these consolidated financial statements. Â F-19 Â Â FIREFLY NEUROSCIENCE, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Â Â Â NOTE 1: BUSINESS DESCRIPTION Â Nature of organization and business Â Firefly Neuroscience, Inc. (the â€œCompanyâ€) and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.). and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain. Â Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc. Â In July 2014, the U.S. Food and Drug Administration (â€œFDAâ€) cleared Firefly Neuroscience Ltd. Brain Network Analyticsâ€™ (BNAâ„¢) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European (â€œCEâ€) approval for BNAâ„¢ allowing use in Europe. Â Reorganization Â Name change and corporate restructure Â Elminda Inc. was incorporated in the State of Delaware on April 21, 2022. Â On July 5, 2022, Elminda Ltd. became a subsidiary of Elminda Inc. via a share exchange agreement wherein Elminda Inc. issued shares to shareholders of Elminda Ltd. against shares of Elminda Ltd. (the â€œFlip Transactionâ€). Â On September 15, 2022 and October 24, 2022 management changed the name from Elminda Inc. and Elminda Ltd. to Firefly Neuroscience Inc. and Firefly Neuroscience Ltd., respectively. Â Shareholder Restructuring Â On January 27, 2022, holders of shares of outstanding Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock of Firefly Neuroscience Ltd. voted to convert their shares of preferred stock into shares of common stock of Firefly Neuroscience Ltd. Upon completion of the transaction, Firefly Neuroscience Ltd. had 1,085,605 shares of common stock and 3,198,421 shares of Series A Preferred Stock outstanding. Â On May 24, 2022, holders of the majority of shares of common stock of Firefly Neuroscience Ltd. voted to exchange their shares on a 1-1 basis for shares in the Company. Â In connection with the Flip Transaction, on July 5, 2022, (a) Firefly Neuroscience, Inc. became an issuer of (i) 1,085,605 common shares, (ii) 3,198,421 Series A preferred shares and (c) 3,715 shares of common share dividends. The original shareholders of Firefly Neuroscience Ltd. remained in control of the new group and the Company. Â On November 23, 2022, the Company completed a reverse share split on a ratio of 1:750. These consolidated financial statements and all financial notes referencing shares of common stock, stock dividends, stock options and their associated prices have been retroactively adjusted as to show the effect of the 1:750 reverse stock split. Â F- 20 Â Â Merger agreement Â On November 16, 2023, WaveDancer, Inc. (â€œWaveDancerâ€) (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the â€œMerger Agreementâ€) with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Companyâ€™s Artificial Intelligence driven BNAâ„¢ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market. Â Under the terms of the Merger Agreement, each share of the Companyâ€™s shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancerâ€™s ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by WaveDancer, and the receipt of required shareholder approvals from the Companyâ€™s and WaveDancer shareholders. Following the merger, WaveDancer, Inc. will be renamed â€œFirefly Neuroscience, Inc.â€ and the corporate headquarters will be located in Toronto, Ontario. The transaction is expected to be completed in 2024. Â Israeli/Palestinian conflict Â On October 7, 2023, an armed Israeli/Palestinian conflict broke out. As the Israeli/Palestinian conflict in Gaza develops, it could have an adverse impact on regional and global markets. While our operations are not directly impacted by these events, the duration of hostilities, imposition of sanctions and related events (including cyberattacks), among others, cannot be predicted. As a result, those events present uncertainty and risk. To date, conflict in Gaza has not had a material impact on the Companyâ€™s business. Â Â Â NOTE 2: GOING CONCERN Â As of December 31, 2023, the Company had an accumulated deficit of $76,624 (December 31, 2022: $74,021) and negative cash flow from operating activities for the year ended December 31, 2023 of $2,172 (for the year ended December 31, 2022: $2,892). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the year ended December 31, 2023 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern for a period of twelve months from the date these consolidated financial statements were issued. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Companyâ€™s liquidity in the foreseeable future, the Company has taken the following measures: Â Â (i) Negotiating further funding with existing and new investors to raise additional capital; Â (ii) Taking various cost control measures to reduce the operational cash burn; and Â (iii) Commercializing product to generate recurring sales. Â Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future. Â F- 21 Â Â Â Â Â Â NOTE 3: BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Basis of Presentation Â The accompanying consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United States of America (â€œU.S. GAAPâ€). Â a. Principles of consolidation Â These consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities (â€œVIEâ€). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation. Â b. Revision of Prior Period Financial Statements Â In connection with the preparation of the consolidated financial statements for year ended December 31, 2023, we identified an immaterial error related to certain general and administration and research and development expenses in the consolidated financial statements for year ended December 31, 2022. In accordance with SAB No. 99, â€œMateriality,â€ and SAB No. 108, â€œConsidering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,â€ we evaluated the error and determined that the related impact was not material to our consolidated financial statements for any prior annual or interim period, but that correcting the cumulative impact of the error would be significant to our results of operations for the year ended December 31, 2023. Accordingly, we have revised previously reported financial information for such immaterial error. A summary of revisions to certain previously reported financial information presented herein for comparative purposes is included in Note 20. Â c. Use of estimates in the preparation of consolidated financial statements Â The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates. Â i) Share based payments In calculating share-based compensation expense, key estimates are used such as, the stock price of the Company, the rate of forfeiture of options granted, the expected life of the option, the volatility of the Companyâ€™s stock price, and the risk-free interest rate. Â ii) Warrants In calculating the fair value of warrants issued, the Company includes key estimates such as the stock price of the Company, the expected life of the warrant, the volatility of the Companyâ€™s stock price, and the risk-free interest rate. Â d. Functional currency and foreign currency translations Â The currency of the primary economic environment in which the operations of the Company is conducted is the U.S. dollar ("$" or "Dollar"). All of the Company's revenues and finance are denominated in U.S dollars. The reporting and the functional currency of the Company is the U.S Dollar. Â F- 22 Â Â The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. Â e. Fair value measurement Â The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: Â â€¢ Level 1â€”Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; â€¢ Level 2â€”Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and â€¢ Level 3â€”Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Â Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The carrying amounts of cash and equivalents, accounts receivable, other receivables, long-term deposits, trade payables, balances to and from related party and convertible notes approximate their fair value due to the short-term maturity of such instruments. It is managementâ€™s opinion that the Company is not exposed to any significant market or credit risks arising from these financial instruments. Â f. Fair value of financial instruments Â Cash, other receivables, trade payables, related party payable and accrued liabilities are carried at amortized cost, which management believes approximates their respective fair value due to the short-term nature of these instruments. Â g. Related party Â Parties are related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, and related parties may be individuals or corporate entities. A transaction is a related party transaction when there is a transfer of resources or obligations between related parties. The Company has disclosed its transactions with related parties. Â h. Cash Â The Company considers all highly liquid investments, which include short-term bank deposits that are not restricted as to withdrawal or use and the period to maturity of which did not exceed three months at time of investment, to be cash. Â i. Other receivables Â Other receivables are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses (â€œallowance for doubtful receivablesâ€) is based on the Companyâ€™s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customerâ€™s ability to pay. Â F- 23 Â Â j. Contingent liabilities Â Certain conditions may exist as of the date the consolidated financial statements are issued, that may result in a loss to the Company but that will only be resolved when one or more future events occur or fail to occur. Such losses are disclosed as contingent liabilities if it is not both probable and reasonably estimable. The Company's management assesses such contingent liabilities and estimated legal fees, if any. Such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Â k. Warrants Â The Company accounts for the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and the applicable authoritative guidance in Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) 480, â€œDistinguishing Liabilities from Equityâ€ (â€œASC 480â€) ASC 815, â€œDerivatives and Hedgingâ€ (â€œASC 815â€), and ASC 718, â€œCompensationâ€”Stock Compensationâ€ (â€œASC 718â€). The assessment considers whether they are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480 or meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own shares of common stock and whether the holders of the warrants could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the warrants and as of each subsequent reporting date while the warrants are outstanding. For issued or modified warrants and that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations. Â l. Stock options Â The Company grants stock options to certain employees and directors through an established stock option plan. All stock option grants or changes to existing

grants, are subject to board of directorsâ€™ approval. For employees and directors, the fair value of the award is measured on the grant date. For non-employees, as per ASC 718, remeasurement is not required. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Determining the appropriate fair value model and the related assumptions requires judgment. During the year ended December 31, 2023 and 2022, the fair value of each option grant was estimated using a Black-Scholes option-pricing model. Â m. Revenue recognition Â Revenue is recognized in accordance with ASC 606, â€œRevenue from Contracts with Customersâ€ (â€œASC 606â€). The Company performs the following five steps: Â (i) identify the contract(s) with a customer, Â (ii) identify the performance obligations in the contract, Â (iii) determine the transaction price, Â (iv) allocate the transaction price to the performance obligations in the contract, and Â (v) recognize revenue when (or as) the entity satisfies a performance obligation. Â The Company applies this five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the goods or services promised within each contract, related performance obligation and assesses whether each promised good or service is distinct. The Company recognizes as revenue, the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied at a point in time. Â F- 24 Â Â The Companyâ€™s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company regularly reviews standalone selling prices and updates these estimates, as necessary. Â n. Deferred revenue Â Deferred revenue consists of payments received from customers in advance of satisfying a performance obligation identified in accordance with ASC 606. The change in the deferred revenue balance for the years ended December 31, 2023, and 2022 was driven by payments from customers in advance of satisfying the performance obligations, offset by revenue recognized as performance obligations were completed. Â o. Research and development expenses Â Research and development expenses are expensed as incurred and consist primarily of personnel, facilities, equipment and supplies related to the Companyâ€™s research and development activities. Â p. Software development costs Â The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel, facilities, equipment and supplies and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage â€“ when the research stage is complete, and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in intangible assets, net on the consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose. Â q. Income taxes Â Income taxes are accounted for using the asset/liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than enactment of changes in the tax law or rates. Â The Company adopted ASC 740 â€œIncome Taxesâ€ (â€œASC 740â€), which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Â r. Leases Â At the inception of the contract, the Company assesses whether the contract contains a lease in accordance with ASU 2016-02, â€œLeasesâ€ (â€œASC 842â€). The Company determines whether an arrangement is a lease by establishing if the contract conveys the right to control the use of an identified asset, for a period of time in exchange for consideration. Leases are classified either as operating lease or finance lease. The Company elects not to apply the recognition requirements of ASC 842 to short-term leases. Short term leases are contracts that have a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company does not have any lease with a lease term longer than 12 months. Â F- 25 Â Â s. Employee benefits Â Short-term employee benefits are benefits for which full settlement is expected within twelve months of the end of the financial year in which the members of staff rendered the corresponding services. These benefits include, paid annual leave, paid sick leave, health and governmental social security contributions which are expensed as the services are rendered. A liability for a cash bonus or plan profit-sharing is recognized when the Company has a legal or implied obligation to make such payments because of past services rendered by a member of staff, and it is possible to make a reasonable estimate of the amount. Â For post-employment the Company has a defined contribution plan pursuant to section 14 to the Israeli Severance Compensation Act, 1963 under which the Company pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold enough to pay all employee benefits relating to employee service in the current and prior periods. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed monthly, concurrently with performance of the employeeâ€™s services. Â t. Segment reporting Â Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment. Â u. Geographic areas Â The Company has operations in Canada, the United States of America and Israel. The revenues and non-current assets of the Company are generated and located in the following locations: Â Geographic areas Revenue 2023 Revenue 2022 Non- current assets 2023 Non- current assets 2022 Canada - - - - United States of America 478 - - - Israel 20 - 386 52 Â Â v. Recent accounting pronouncements Â In December 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-09 â€œIncome Taxes (Topics 740): Improvements to Income Tax Disclosuresâ€ to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning January 1, 2025, with early adoption permitted. The Company has not adopted this standard early and is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements disclosures. Â In November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosuresâ€ which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. Â The expanded annual disclosures are effective for the Company's year ending December 31, 2024, and the expanded interim disclosures are effective in 2025 and will be applied retrospectively to all prior periods presented. Â The Company is currently evaluating the impact that ASU 2023-07 will have on its consolidated financial statements. Â F- 26 Â Â Â Â NOTE 4: OTHER RECEIVABLES Â Detail of other receivables balance is as follows: Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Other receivables Â $196Â Â $131Â Allowance for doubtful receivables Â Â (112)Â Â (112) Total Â $84Â Â Â $19Â Â Â Â NOTE 5: LONG TERM DEPOSITS Â Long term deposits consisted of rental deposits for month-to-month shared office lease. The balances as of December 31, 2023 and 2022 were $nil and $52, respectively. Â Â Â NOTE 6: INTANGIBLE ASSETS Â The following tables summarize the composition of intangible assets as of December 31, 2023: Â Â Â December 31, 2023 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted Average Life Â Unamortized intangible assets Â BNA software Â $386Â Â $-Â Â $386Â Â Â n/aÂ Total intangible assets Â $386Â Â Â $-Â Â $386Â Â Â Â Â Â Â Â The BNA software enhancement project is in progress and amortization will begin once the project is substantially complete and the software is ready for its intended purpose. The software is expected to be completed by Q3 2024 and have a useful life of five years. Â There were no intangible assets as of December 31, 2022. Â Â Â NOTE 7: CONVERTIBLE NOTES Â Windsor Private Capital Ltd. Partnership (â€œWPCâ€) and Origa Two Holdings Inc (â€œOriga") Â On February 2, 2022, Origa and the Company signed a Side Letter in order to raise additional funds of $1,000 which were to be provided to the Company, as part of the original debt that was issued in 2021. The maturity date of the debentures was also extended to December 31, 2022. Two tranches of warrants (Tranche A and B) were also issued (Note 11.d). This amendment and issuance of warrants resulted in the extinguishment of the original debt, and recognition of the amended debt and warrants at their fair value of $1,886 and $478, respectively. The Company recorded a loss on extinguishment of $576 within other income (expense) in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. Â On July 4, 2022, the board of directors of the Company agreed to amend the conversion price on the convertible debt from a price of $7.5 to $3 per share. Additionally, Tranche A warrantsâ€™ exercise price was amended, the Tranche B warrants were cancelled (Note 11.d) and the expiration date of all remaining warrants were amended to 3 years from the date of amendment. This resulted in the debt being extinguished, and recognition of the amended convertible debt and Tranche A warrants at $2,936 and $551 respectively. The Company recognized a gain on extinguishment of $509 within other income (expense) in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. Â F- 27 Â Â Phyto IV Convertible debt issuance Â On May 4, 2022, the Company issued a convertible debenture to Phyto IV LP. The principal amount of the note was $150 and the interest on the note accrued at a fixed rate 10% per annum. The interest on the note is accrued semi-annually and shall be payable on the maturity date, calculated on the basis of actual days elapsed. The interest is not payable in cash but added to the principal amount semi-annually on June 30 and December 31 of each year. The loan had a maturity date of one year from issuance with an option to extend maturity by one more year for a 1.5% fee of the then outstanding principal. The notes were convertible at a price of $7.5 per share. The conversion price for the convertible debt was also subject to adjustments resulting from subdivision, consolidation or any stock securities issuance by the way of stock dividend or other distribution. These adjustments were standard anti-dilution adjustments to compensate the warrant holders for any such event such that their rights were on par with other shareholders. Â On July 4, 2022, the board of directors agreed to amend the conversion price on the convertible debt and reduce it from a price of $7.5 to $3. This resulted in a fair value change of the conversion option, which resulted in the debt being extinguished resulting in a gain on modification of $8. Â On September 30, 2022, the convertible debt including accrued interest was converted to 51,792 reverse stock split adjusted shares of common stock of the Company. Â Convertible debt issued to various investors Â On July 4, 2022, the Company signed a memorandum of understanding with Origa and WPC to raise funds. As part of the memorandum of understanding, between July 4, 2022, and August 16, 2022, the Company issued convertible debt along with warrants to 13 individual investors on identical terms. The raise resulted in a total issuance of $555. Interest is accrued at a fixed rate of 10% per annum. The interest on the note is accrued semi-annually and shall be payable on the maturity date, calculated based on actual days elapsed. The interest is not payable in cash but added to the principal amount semi-annually on June 30 and December 31 of each year. Â Each loan matures after two calendar years from the date of issue and had an option to extend the maturity date by one year at a fee of 1.5% of the then outstanding principal. The notes are also convertible into the common stock of the Company at any time at the option of the holder at a price of $3 per share. The conversion price for the convertible debt was subject to adjustments resulting from subdivision, consolidation or any stock securities issuance by the way of stock dividend or other distribution. These adjustments were standard anti-dilution adjustments to compensate the warrant holders for any such event such that their rights were on par with other shareholders. Â On September 30, 2022, the convertible debt including accrued interest was converted to 188,734 shares of common stock of the Company. The share number has been adjusted to reflect the reverse stock split number of shares, which occurred on November 23, 2022. Â Conversion option added to director loans Â On July 4, 2022, the board of directors added a conversion option to certain directors' loan which were interest-free and payable upon demand. During 2022, the loans were converted to 106,612 shares of common stock. Â No convertible debt remained outstanding as of December 31, 2023 and 2022, except for the non-interest bearing directorâ€™s loan payable on demand (Refer to Note 13). Â Â Â NOTE 8: DEFERRED REVENUE Â In February 2019, the Company executed a $2,500 development and consulting agreement with R.I. Mind Group Ltd. The Companyâ€™s scope involved creating and developing BNAâ„¢ Biomarkers, the Database Infrastructure and the Delivery System (collectively, the â€œWork Productsâ€), as well as consulting and advising on the development of Work Products or on the proper use of the Work Products. In accordance with the agreement, the Company received an advance of $500 against which the parties agreed to offset invoices amounting to $41. Â In August 2022, the Company executed a Memorandum of Understanding (â€œMoUâ€) with Pasithea Clinics Inc. to enter into an agreement with respect to the marketing and commercialization of the BNAâ„¢ System. The Company received an advance of $300. The advance was recognized as deferred revenue in 2022. Â F- 28 Â Â In November 2022, the Company executed an additional MoU with Pasithea Clinics Inc. to enter into an agreement with respect to the marketing and commercialization of BNAâ„¢ System. The Company received an advance of $150 to offset certain subsequent invoices. The advance was recognized as deferred revenue in 2022. Â During the year ended December 31, 2023, the Company determined that it satisfied its performance obligation under both MoUs with Pasithea and recognized $450 of revenue. Â Additionally, on February 24, 2023, the agreement with R.I. Mind Group Ltd. expired in accordance with its terms, and, as of December 31, 2023, there are no amounts owed by the Company to R.I. Mind Group Ltd. As the Company did not carry any activity for the purposes of the agreement, the Company recognized $459 of other income. Â Â Â December 31 Â Â Â Â 2023 Â Â 2022 Â Pasithea Clinics Inc. Â $-Â Â $450Â R.I. Mind Group Ltd Â $-Â Â $459Â Â Â $-Â Â $909Â Â Â Â NOTE 9: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT Â Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Companyâ€™s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, payments for 2023 and 2022 were $33 and $51, respectively, which are included in salary and employee benefits within research and development expenses (Note 15). Â Â Â NOTE 10: COMMITMENTS AND CONTINGENCIES Â a. Royalty Commitment - Israeli Innovation Authority (â€œIIAâ€) Â The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2023 or 2022. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate (â€œLIBORâ€) is repayable in form of royalties based on 3.0% of BNAâ„¢ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate (â€œSOFRâ€) subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of December 31, 2023 and 2022. The contingent liability amounts to $5,625 and $5,576 for 2023 and 2022 respectively. Â Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIAâ€™s approval. Â F- 29 Â Â Â Â NOTE 11: EQUITY Â a. Shares Â On August 17, 2022, the Company closed a securities purchase agreement for the sale of 10 million Series A Preferred Stock for gross proceeds of $40. This agreement also entitled the subscriber to 13,333 warrants to purchase shares of common stock of the Company. Â On September 15, 2022, the Company closed a securities purchase agreement for the sale of 51,282 consolidation adjusted shares of common stock at a consolidation adjusted price of $4.87 per share for aggregate gross proceeds of $250. Â On February 16, 2023, the Company sold 32,536,386 shares of common stock at a price per share of $0.0041. The Company received aggregate gross proceeds from the offering of $133. Â On February 23, 2023, the Company offered up to 10,799,136 shares of Series B Preferred Stock at $0.1852 per share. On March 15, 2023, the Company increased the offering to up to 14,578,833 shares of Series B Preferred Stock, with the increase being subsequently approved by the board of directors on November 15, 2023. As of December 31, 2023, the Company received aggregate gross proceeds from the offering of $2,700. The Company incurred $92 of costs associated with the issuance. Series B Preferred Stock issued are equity classified instruments and are recorded as equity. As of December 31, 2023, 14,578,833 Series B Preferred Stock were subscribed and issued. Â On May 1, 2023, the Company granted 284,964 shares of common stock to a related party as a payment for consulting services provided. The shares awarded are under the scope of ASC 718 and were accounted for as equity-classified awards. The shares were measured at fair value on the grant date at $0.0041 per share. Â On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. As of December 31, 2023, the Company issued 1,538,134 units and received aggregate gross proceeds of $1,969. The Company incurred $67 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. Â On October 16, 2023, 4,217 shares of common stock were repurchased for a nominal amount and cancelled by the Company. Â As of December 31, 2023, mandatory conversion feature of Series B Preferred Stock was triggered, as the proceeds from Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of December 31, 2023, the 14,578,833 shares of common stock were not

issued from an administrative perspective but were considered substantially issued from an accounting perspective. Â As of December 31, 2023 and 2022, the Company had the following number of authorized and issued shares: Â Â Â December 31Â Â Â 2023 Â Â 2022 Â Â 2023 Â Â 2022 Â Â Â Number of authorized shares Â Â Number of authorized shares Â Â Number of issued shares Â Â Number of issued shares Â Shares of common stock Â Â 2,470,000,000Â Â Â 2,470,000,000Â Â Â 35,369,877Â Â Â 2,552,744Â Series A Preferred Stock Â Â Â Â Â Â Â Â -Â Â Â -Â Series B Preferred Stock Â Â 30,000,000Â Â Â 30,000,000Â Â Â 14,578,833Â Â Â -Â Series C Preferred Stock Â Â Â Â Â Â Â Â 1,538,134Â Â Â -Â Â As of December 31, 2023 and 2022, the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shared of all classes. Â F- 30 Â Â b. Rights attached to shares Â The shares of common stock confer upon their holdersâ€™ voting rights and the right to participate in shareholdersâ€™ meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Companyâ€™s Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), and the right to a share in excess assets upon liquidation of the Company â€“ all as set forth in the Companyâ€™s Certificate of Incorporation and in the Companyâ€™s Shareholdersâ€™ Agreement. Â The preferred shares confer upon their holders voting rights and the right to participate in shareholdersâ€™ meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Companyâ€™s Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), on an â€œas convertedâ€ basis, and the right to a share in excess assets upon liquidation of the Company in preference to the shares of common stock. The shares have discretionary dividends and do not have a redemption date. Â The Series C Preferred Stock rank, as to the payment of dividends and the distribution of assets upon liquidation, dissolution or winding up of the Company: (a) senior to the shares of common stock, (b) junior to the Series B Preferred Stock, which Series B Preferred Stock include mandatory conversion provisions in the event the Company issues and sells equity securities to investors in an equity financing with total gross proceeds of not less than $1,000 with at least a pre-money valuation of the Company of $18,000, and (c) on parity with all other classes and series of the Companyâ€™s preferred shares. Â Series B Preferred Stock Â Optional Conversion Â Each share of Series B Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series B Preferred Stock â€œSeries B Certificate of Designationsâ€), which conversion price shall initially be equal to the original issue price. Â Mandatory Conversion Â Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (the â€œSecurities Actâ€) (or a qualified offering statement under Regulation A under the Securities Act; (b) the date that the Company or a successor to the Company (including, without limitation by way of acquisition of all or substantially all of the Companyâ€™s assets) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) and is subject to the periodic and current reporting requirements of Section 13 or 15(d) of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $1,000 with at least a minimum pre-money valuation of the Company of $18,000, or (d) the date and time, or the occurrence of an event, by vote or written consent of the holders of at least a majority of the outstanding shares of Series B Preferred Stock, voting as a single class on an as-converted basis, all outstanding shares of Series B Preferred Stock shall automatically be converted into shares of common stock at the applicable ratio set forth in the Series B Certificate of Designations. Â Series C Preferred Stock Â Optional Conversion Â Each share of Series C Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series C Preferred Stock, the â€œSeries C Certificate of Designationsâ€), which conversion price shall initially be equal to the original issue price. Â F- 31 Â Â Mandatory Conversion Â Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act or a qualified offering statement under Regulation A of the Securities Act, as amended); (b) the date that the Company or a successor to the Corporation (including, without limitation, by way of acquisition of all or substantially all of the Corporationâ€™s assets, merger, or any other business combination) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Exchange Act and is subject to the periodic and current reporting requirements of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $2,000 with at least a minimum pre-money valuation of the Company of $65,000, or (d) the date and time, or the occurrence of an event, specified by vote or written consent of at least a majority of the outstanding shares of Series C Preferred Stock at the time of such vote or consent, voting as a single class on an as-converted basis, all outstanding shares of Series C Preferred Stock shall automatically be converted into shares of common stock at the applicable ratio described in Series C Certificate of Designations. Â d. Warrants Â During 2022, part of the modification of the WPC convertible (Note 7), the Company issued 526,749 stock split adjusted Tranche A and 262,051 stock split adjusted Tranche B warrants. The features of the warrants were as below: Â Tranche A: Â â— Exercise price: (1) $0.75 â€“Â If funds of a minimum of $15,000 are raised, (2) $0.75 â€“Â If the sale of a company, IPO or RTO is completed or the (3) purchase price per share resulting from dividing $50,000 by the total number of valid issued ordinary shares outstanding. Â â— Maturity/Expiration date: (a) if no IPO â€“Â one year after the delivery date of the 2021 audited financial statements (b) if IPO â€“Â then one year after the date of such IPO. Â Tranche B: Â â— Purchase price per share resulting from dividing $150,000 by the total number of valid issued ordinary shares outstanding. Â â— Maturity/Expiration date: (a) if no IPO â€“Â one year after the delivery date of the 2021 audited financial statements (b) if IPO â€“Â then five years after the date of such IPO. Â On July 4, 2022, as part of the Senior Lenderâ€™s Memo, the conversion price of the Tranche A warrant was amended to: (1) $0.75 â€“ If after July 5, 2022 funds of a minimum of $5,000 are raised 18 months and $10,000 in total in the three years thereafter, (2) $0.75 â€“ after the recapitalization date, if the sale of a company, IPO or RTO is completed or (3) the purchase price per share resulting from dividing $20,000 by the total number of valid issued ordinary shares outstanding. The Tranche B warrants were cancelled. Â As part of the convertible debt issuance to various investors between July 4, 2022, and August 16, 2022, the Company issued 198,482 consolidation adjusted warrants concurrent with the convertible debt and preferred shares. The warrants were exercisable into one share of common stock of the Company per warrant at a price of $3. The warrants had a maturity date of three years. Â On February 17, 2023, warrants to purchase up to 123,333 shares of common stock, issued to WPC in 2021, were modified pursuant to antidilution provision in the warrant agreement, triggered by common stock private placement on February 16, 2023. As a result of the modification, exercise price of the warrants was reduced to $0.00473 per share and the expiry date was extended to be three years from the modification date. The warrants were determined to be a freestanding equity instrument. Under ASC 815, the effect of a modification was nominal and was recorded as an equity issuance costs. Â F- 32 Â Â On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. The warrants were determined to be a freestanding equity instrument. As of December 31, 2023, 759,863 warrants were issued. Additionally, as of December 31, 2023, 781,250 warrants were not issued from an administrative perspective, but were considered substantially issued from an accounting perspective. Â Â Â Number of Warrants Â Â Weighted Average Exercise Price Â Â Weighted Average Remaining Life Â Outstanding warrants, January 1, 2022 Â Â 123,333Â Â $7.50Â Â Â 0.85Â Warrants issued pursuant to issue of convertible debt and preferred shares to individual investors Â Â 198,482Â Â Â 3.00Â Â Â Â Â Warrants issued pursuant to modification of convertible debt Â Â 526,749Â Â Â 0.75Â Â Â Â Â Outstanding warrants, December 31, 2022 Â Â 848,564Â Â $2.26Â Â Â 2.50Â Warrants issued pursuant to units offering Â Â 1,538,113Â Â Â 2.56Â Â Â Â Â Outstanding warrants, December 31, 2023 Â Â 2,386,677Â Â $2.07Â Â Â 2.46Â Â The warrants and prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022. Â e. Series A warrants Â On June 15, 2023, the Company granted Series A warrants to purchase up to an aggregate 6,048,456 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share for a period of five years from the issuance date. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event. Â f. Employees stock option plan Â In 2010, the Companyâ€™s board of directors approved an employee and service providerâ€™s stock option plan. On July 8, 2023, the board of directors approved new equity incentive plan (the â€œPlanâ€). The Plan permits the grant of options, share appreciation rights (â€œSARsâ€), restricted share units (â€œRSUsâ€), deferred share units (â€œDSUsâ€) and performance share units (â€œPSUsâ€). In respect of options, the aggregate number of shares of common stock issuable under the Plan shall not exceed twelve percent of the issued and outstanding shares of common stock at any point in time. In respect of SARs, RSUs, DSUs and PSUs: (i) the maximum aggregate number of shares of common stock issuable under this Plan in respect of SARs, RSUs, DSUs and PSUs shall not exceed ten percent of the issued and outstanding shares of common stock as of July 8, 2023; (ii) the total number of SARs, RSUs, DSUs and PSUs issuable to any participant under this Plan shall not exceed one percent of the issued and outstanding shares of common stock at the time of the award. Â F- 33 Â Â The fair value of each option award is estimated on the date of grant using a Black Scholes option valuation model that uses the assumptions noted in the following table. Â Â Â 2023 Â Â 2022 Â Risk free rate Â Â 4.35%Â Â 4.5% Dividend yield Â Â 0%Â Â 0% Expected volatility Â Â 86%Â Â 86% Expected term (in years) Â Â 3Â Â Â 3Â Expected life (in years) Â Â 5Â Â Â 5Â Â A summary of option activity under the Plan as of December 31, 2023, and changes during the year then ended is presented below. Â Â Â Number of Stock Options Â Â Weighted Average Exercise Price Â Â Weighted Average Remaining Contractual Term Â Â Aggregate Intrinsic Value Â Outstanding Options, December 31, 2022 Â Â 495,746Â Â $4.70Â Â Â 6.90Â Â $-Â Options granted Â Â 795,916Â Â Â 0.58Â Â Â Â Â Â Â Â Â Outstanding Options, December 31, 2023 Â Â 1,291,662Â Â $2.16Â Â Â 6.18Â Â $-Â Â The share-based compensation expense related to options for December 31, 2023 was $295 (2022: $60). The fair value of options granted for the year ended December 31, 2023 was nominal (2022: $692). The intrinsic value of the options outstanding is $nil (2022: $nil). Â A summary of the Companyâ€™s non-vested options as of December 31, 2023, and changes during the year ended December 31, 2023, is presented below. Â Â Â Number of Stock Options Â Â Weighted Average Grant- Date Fair Value Â Non-Vested Options, December 31, 2022 Â Â 325,853Â Â $2.20Â Â Options granted Â Â 795,916Â Â Â 0.00Â Options vested Â Â (246,883)Â Â 1.15Â Non-Vested Options, December 31, 2023 Â Â 874,886Â Â $0.50Â Â As of December 31, 2023, there was $434 of total unrecognized compensation cost related to nonvested options granted under the Plan. Â The options and exercise prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022. Â g. Management options Â On July 8, 2023, the Company granted stock options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Companyâ€™s equity securities in an initial public offering (an â€œIPO Transactionâ€), that results in the Companyâ€™s shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 362,584 shares of common stock shall vest immediately with the remaining options vesting in 36 equal installments at the end of each calendar month over a period of three years from the date of grant. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event. Â F- 34 Â Â h. Restricted share units Â On July 8, 2023, the Company granted RSUs to certain management and directors. The vesting of the RSUs is contingent upon a transaction that results in the Companyâ€™s shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. When vested, the RSUs represent the right to be issued the number shares of common stock that is equal to the number of RSUs granted. Since RSUs are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost related to RSUs is recognized until the occurrence of a liquidity event. Â Â Â NOTE 12: BASIC AND DILUTED NET LOSS PER SHARE Â Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that were outstanding during the period when the effect is dilutive. Potential dilutive shares of common stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding shares of common stock figures for the years ended December 31, 2023 or 2022, as the assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted stock units would be anti-dilutive. Â Â Â NOTE 13: RELATED PARTY TRANSACTIONS Â During the year ended December 31, 2022, $320 of notes payable to directors were converted to 106,612 shares of common stock (Note 7). Â As of the year ended December 31, 2023, $175 (2022: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand. The remaining related party payables of $nil (2022: $2) relate to services payable to a related party of the Company. These payables do not bear any interest and are payable on demand. Â The Company incurred $222 and $420 in officersâ€™ consulting fees recorded in general administration expenses on consolidated statements of operations for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023 and 2022, $106 and $56, respectively remained outstanding and were accrued by the Company, and are included in accrued liabilities in the accompanying balance sheets. Â On May 1, 2023, the Company issued 284,964 shares of common stock to a related party as a payment for consulting services provided. Â On July 8, 2023, the Company granted options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock in the capital of the Company (Note 11.g), 2,776,861 of these options were granted to related parties. No compensation cost is recognized related to options until the occurrence of a liquidity event. Â F- 35 Â Â Â NOTE 14: REVENUE Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Â Â Â Â Â Â Â Â Type of goods and services Â Â Â Â Â Â Â Â Service Â $498Â Â $-Â Total Â $498Â Â $-Â Â Â Â Â Â Â Â Â Timing of recognition of revenue Â Â Â Â Â Â Â Â Over time Â $498Â Â $-Â Total Â $498Â Â $-Â Â Â Â NOTE 15: RESEARCH AND DEVELOPMENT EXPENSES Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Â Â Â Â Â Â Â Â Salary and employee benefits Â $527Â Â $944Â Consultants and subcontractors Â Â 99Â Â Â 152Â Depreciation and amortization Â Â -Â Â Â 14Â Clinical trials Â Â 3Â Â Â 60Â Expenses - other Â Â 112Â Â Â 129Â Â Â Â 741Â Â Â 1,299Â Less â€“ grants received Â Â -Â Â Â -Â Total Â $741Â Â $1,299Â Â Â Â NOTE 16: SELLING AND MARKETING EXPENSES Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Â Â Â Â Â Â Â Â Salary and employee benefits Â $611Â Â $432Â Professional fees Â Â 6Â Â Â 27Â Travel Â Â 21Â Â Â 51Â Other Â Â 1Â Â Â 14Â Total Â $639Â Â $524Â Â Â Â NOTE 17: GENERAL AND ADMINISTRATION EXPENSES Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Â Â Â Â Â Â Â Â Salary and employee benefits Â $512Â Â $418Â Professional fees Â Â 1,252Â Â Â 724Â Rent and maintenance Â Â 91Â Â Â 233Â Travel expenses Â Â 56Â Â Â 72Â Bad debts Â Â 1Â Â Â (2) Other Â Â 284Â Â Â 97Â Total Â $2,196Â Â $1,542Â Â F- 36 Â Â Â NOTE 18: OTHER (INCOME) / EXPENSE Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Â Â Â Â Â Â Â Â Interest, bank fees and loan fees Â $18Â Â $440Â Unrealized (gain) loss on foreign exchange Â Â (37)Â Â 134Â Loss on extinguishment of debt Â Â -Â Â Â 59Â Gain on sale of equipment Â Â -Â Â Â (166) Other Â Â (457)Â Â (7) Total Â $(476)Â $460Â Â In February 2022, the Company sold equipment for $262 resulting in a gain on sale of $166. Â On February 24, 2023, the agreement with R.I. Mind Group Ltd. expired in accordance with its terms, and, as of December 31, 2023, there are no amounts owed by the Company to R.I. Mind Group Ltd. As the Company did not carry any activity for the purposes of the agreement, the Company recognized $459 of other income (Note 8). Â Â Â NOTE 19: INCOME TAX Â The total provision for income taxes differs from the amount which would be computed by applying the US income tax rate to loss before income taxes. The reasons for these differences are as follows: Â Â Â December 31 Â Â Â 2023 Â Â 2022 Â Statutory income tax rate Â Â 27.60%Â Â 28.51% Â Â Â Â Â Â Â Â Â Statutory income tax recovery Â $(718)Â $(1,113) Â Â Â Â Â Â Â Â Â Increase (decrease) in income taxes Â Â Â Â Â Â Â Â Non-deductible option expenses Â Â 135Â Â Â 19Â Taxable capital gain on sale of investment and equipment Â Â -Â Â Â -Â Difference in foreign tax rates Â Â 30Â Â Â 200Â US state tax Â Â 1Â Â Â (1) Change in valuation allowance Â Â 553Â Â Â 895Â Income tax expense (recovery) Â $1Â Â $-Â Â The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities and certain carry-forward balances. Â F- 37 Â Â The primary components of the deferred tax assets and liabilities are as follows, for the periods indicated below: Â Â Â December Â Â Â 2023 Â Â 2022 Â Â Â $ Â Â Â $ Â Deferred tax assets Â Â Â Â Â Â Â Â Non-capital loss carry-forwards from Canada Â Â -Â Â Â 1Â Non-capital loss carry-forwards from US Â Â 1,418Â Â Â 1,576Â Non-capital loss carry-forwards from Israel Â Â 15,449Â Â Â 17,479Â Stock option Â Â 95Â Â Â 17Â R&D expenditures Â Â 236Â Â Â 424Â Reserves

and others Â Â 127Â Â Â -Â Â Â Â 17,325Â Â Â 19,497Â Â Â Â Â Â Â Â Â Â Valuation Allowances for deferred tax assets Â Â (17,325)Â Â (19,497) Net deferred tax assets Â Â -Â Â Â -Â Â The net deferred tax assets have been offset by a valuation allowance because it is not more likely than not the Company will realize the benefit of these deferred tax assets. The Company did not recognize any tax benefits as of December 31, 2023 and December 31, 2022. Â At December 31, 2023, the Company's Canadian, US, and Israeli non-capital income tax losses, the benefit of which has not been recognized on the consolidated financial statements, expire as follows: Â Â Â Canada Â Â US Â Â Israel Â 2034 Â $-Â Â $501Â Â $-Â 2035 Â Â -Â Â Â 1,767Â Â Â -Â 2036 Â Â -Â Â Â 2,872Â Â Â -Â 2037 Â Â -Â Â Â -Â Â Â -Â 2038 Â Â -Â Â Â -Â Â Â -Â 2039 Â Â -Â Â Â -Â Â Â -Â 2040 Â Â -Â Â Â -Â Â Â -Â 2041 Â Â -Â Â Â -Â Â Â -Â 2042 Â Â 2Â Â Â -Â Â Â -Â Indefinite Â Â -Â Â Â 1,293Â Â Â 67,170Â Â Â $2Â Â $6,433Â Â $67,170Â Â At December 31, 2023, the Company had a cumulative carry-forward pool of Israeli Research and Development expenditures in the amount of $889 (2022: $1,823) which will be amortized within the next three years. Â The Company files unconsolidated federal income tax returns domestically and in foreign jurisdictions. The Company has open tax years from 2018 to 2023 with tax jurisdictions including Canada, U.S, and Israel. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations, as they relate to amount, timing, or inclusion of revenues and expenses. Â F- 38 Â Â Â Â NOTE 20: REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS Â During 2023, management of the Company became aware of certain errors in the recording of expenses within research and development and general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. Revisions of these amounts are reflected in the following tables. Â Revised Consolidated Balance Sheet Â Â Â As of December 31, 2022 Â Â Â As reported Â Â Adjustment Â Â As revised Â Accrued liabilities Â Â 740Â Â Â 115Â Â Â 855Â Total current liabilities Â Â 2,246Â Â Â 115Â Â Â 2,361Â Total liabilities Â Â 2,246Â Â Â 115Â Â Â 2,361Â Accumulated deficit Â Â (73,906)Â Â (115)Â Â (74,021) Total shareholdersâ€™ deficit Â Â (2,111)Â Â (115)Â Â (2,226) Â Revised Consolidated Statements of Operations and Comprehensive Loss Â Â Â For the year ended December 31, 2022 Â Â Â As reported Â Â Adjustment Â Â As revised Â Research and development expenses Â Â 1,272Â Â Â 27Â Â Â 1,299Â General and administration expenses Â Â 1,454Â Â Â 88Â Â Â 1,542Â Total operating expenses Â Â 3,329Â Â Â 115Â Â Â 3,444Â Loss before Income Tax Â Â (3,789)Â Â (115)Â Â (3,904) Net Loss and Comprehensive Loss Â Â (3,789)Â Â (115)Â Â (3,904) Â Revised Consolidated Statement of Cash Flows Â Â Â For the year ended December 31, 2022 Â Â Â As reported Â Â Adjustment Â Â As revised Â Net loss Â Â (3,789)Â Â (115)Â Â (3,904) Change in accrued liabilities Â Â (18)Â Â 115Â Â Â 97Â Net cash used in operating activities Â Â (2,892)Â Â -Â Â Â (2,892) Â Â Â Â NOTE 21: SUBSEQUENT EVENTS Â The subsequent events below are major events or transactions that occurred after the period ended December 31, 2023, but before the issuance of these consolidated financial statements. The below events occurred between January 1, 2024 and May 22, 2024: Â On January 12, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates include changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Companyâ€™s warrants at the effective time and deletion of certain closing obligations. Â On February 28, 2024, the Company issued 820,312 units and received aggregate gross proceeds of $1,050. Each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. Â F- 39 Â Â Â Â Â Â Â FIREFLY NEUROSCIENCE, INC. Â 990,192 Shares of Common Stock Â Up to 504,323 Shares of Common Stock Underlying Pre-Funded Warrants Â Up to 823,530 Shares of Common Stock Underlying Private Placement Warrants Â Up to 168,071 Shares of Common Stock Underlying Series C Warrants Â Up to 61,866 Shares of Common Stock Underlying Series D Warrants Â Up to 11,663 Shares of Common Stock Underlying Broker Warrants Â Â Â PROSPECTUS Â Â Â Â PART II: INFORMATION NOT REQUIRED IN PROSPECTUS Â Item 13. Other Expenses of Issuance and Distribution. Â The following table sets forth the estimated expenses to be borne by the registrant in connection with the registration of the common shares being registered hereby. Â Securities and Exchange Commission registration fee Â $ 1,316.65 Accounting fees and expenses Â Â 20,000 Legal fees and expenses Â Â 50,000 Financial printing and miscellaneous expenses Â Â 10,000 Total Â $ 81,316.65 Â Item 14. Indemnification of Directors and Officers. Â Subsection (a) of Section 145 of the General Corporation Law of the State of Delaware (the â€œDGCLâ€) empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneysâ€™ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the personâ€™s conduct was unlawful. Â Subsection (b) of Section 145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneysâ€™ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. Â Section 145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneysâ€™ fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section 145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such personâ€™s heirs, executors and administrators. Section 145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145. Â 116 Â Â Section 102(b)(7) of the DGCL provides that a corporationâ€™s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the directorâ€™s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit. Â Additionally, our Charter limits the liability of our directors to the fullest extent permitted by the DGCL, and our Bylaws provide that we will indemnify them to the fullest extent permitted by such law. We have entered into and expects to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. Under the terms of such indemnification agreements, we are required to indemnify each of our directors and officers, to the fullest extent permitted by the laws of the state of Delaware, if the basis of the indemniteeâ€™s involvement was by reason of the fact that the indemnitee is or was our director or officer or was serving at our request in an official capacity for another entity. We must indemnify our officers and directors against all reasonable fees, expenses, charges and other costs of any type or nature whatsoever, including any and all expenses and obligations paid or incurred in connection with investigating, defending, being a witness in, participating in (including on appeal), or preparing to defend, be a witness or participate in any completed, actual, pending or threatened action, suit, claim or proceeding, whether civil, criminal, administrative or investigative, or establishing or enforcing a right to indemnification under the indemnification agreement. The indemnification agreements also require us, if so requested, to advance all reasonable fees, expenses, charges and other costs that such director or officer incurred, provided that such person will return any such advance if it is ultimately determined that such person is not entitled to indemnification by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. Item 15. Recent Sales of Unregistered Securities. Â Set forth below is information regarding all securities issued by us without registration under the Securities Act in the past three years. For purposes of this section, references to â€œWaveDancerâ€ mean WaveDancer, Inc., the predecessor company prior to the consummation of the Merger and references to â€œFireflyâ€ mean Firefly Neuroscience, Inc. prior to the consummation of the Merger, except as related to the sections entitled â€œSeries C Financingâ€ and â€œJuly 2024 Private Placement,â€ which refer to Firefly Neuroscience, Inc. following the consummation of the Merger. Â The share and per share figures below do not reflect the 1-for-3 reverse stock split of WaveDancer, Inc., consummated in connection with the Merger on August 12, 2024. Â Sales of Unregistered Securities by WaveDancer, Inc. Â December 2021 Private Placement and Series A Warrants Â On December 10, 2021, WaveDancer sold 328,987 shares of its common stock at a price of $30.40 per share to several investors. For each five shares purchased, purchasers were issued a warrant granting such purchasers the right to purchase one share of common stock of WaveDancer at a price of $45.00 per share, with the warrants exercisable on January 1, 2023, and expiring on December 31, 2026. Â August 2022 Private Placement Â In August 2022, WaveDancer sold 157,256 shares of its common stock to certain investors in a private placement at a price of $12.00 per share to 16 accredited investors for aggregate gross proceeds of approximately $1,887,072. Â September 2023 Private Placement Â On September 29, 2023, WaveDancer sold 35,000 shares of common stock to certain investors in a private placement at a price of $5.00 per share for aggregate gross proceeds of $175,000. Â 117 Â Â Sales of Unregistered Securities by Firefly Neuroscience., Inc. Â July 2022 Private Placement Â On July 5, 2022, Firefly issued to certain holders warrants to purchase up to an aggregate of 171,806 shares of common stock (the â€œJuly 2022 Warrantsâ€). The July 2022 Warrants have an exercise price of $3.00 per share (subject to adjustment in accordance with the terms thereof), are exercisable immediately upon issuance and expire on July 4, 2025, on 4:30 p.m. (Toronto time). Â August 2022 Private Placement Â On August 15, 2022, Firefly issued to a certain holder a warrant to purchase up to 13,333 shares of common stock (the â€œAugust 2022 Warrantâ€). The August 2022 Warrant has an exercise price $3.00 per share (subject to adjustment in accordance with the terms thereof), is exercisable immediately upon issuance and expires on August 15, 2025, at 4:30 p.m. (Toronto time). Â February 2023 Amended and Restated Warrants Â On February 17, 2023, Firefly issued to a certain holder certain amended and restated warrants, initially issued to such holder on November 8, 2021 (the â€œFebruary 2023 A&R Warrantsâ€), to reflect the 1-for-750 reverse stock split effectuated on November 23, 2022 by Firefly (the â€œ2022 Reverse Stock Splitâ€) and to adjust the exercise price therein in accordance with the terms of the February 2023 A&R Warrants, among others. The February 2023 A&R Warrants are exercisable for up to an aggregate of 43,333 and 80,000 shares of common stock, respectively, each at an exercise price of $0.00473 per share (subject to adjustment in accordance with the terms of the February 2023 A&R Warrants) and expire on February 17, 2026. Â Amended and Restated Tranche A Warrants Â On March 1, 2023, Firefly issued to a certain holders the amended and restated tranche A warrants (the â€œTranche A Warrantsâ€), initially granted to such holders on February 2, 2022, to reflect the 2022 Reverse Stock Split, and to adjust the exercise price therein in accordance with the terms of the Tranche A Warrants, among others. The Tranche A Warrants are exercisable for up to an aggregate of 526,749 shares of common stock at an exercise price of (x) $0.001 in the event that on or after July 5, 2022, Firefly issues warrants, options and/or convertible debt in exchange for aggregate proceeds of at least $5,000,000 within 18 months thereafter or aggregate proceeds of at least $10,000,000 within three years thereafter, (y) $0.001 in the event that after July 5, 2022, all or substantially all of Fireflyâ€™s assets are sold, Firefly completes an initial public offering, including but not limited to by way of a reverse transaction takeover or via other similar â€œSale of the Companyâ€ event, or (z) the per share purchase price resulting from the division of $20,000,000 by the total number of duly authorized, validly issued and fully paid and non-assessable shares of common stock of Firefly then outstanding on a fully diluted basis. The Tranche A Warrants are fully vested upon issuance, are exercisable immediately upon issuance and expire on July 5, 2025. Â Series A Warrants Â On July 15, 2023, Firefly issued to certain holders the Series A warrants to purchase up to an aggregate of 6,048,476 shares of common stock (the â€œSeries A Warrantsâ€). The Series A Warrants have an exercise price of CAD$0.01 per share (subject to adjustment from time to time in accordance with the terms of the Series A Warrants) and expire on June 15, 2028, at on 4:30 p.m. (Toronto time). The Series A Warrants are additionally subject to certain vesting events, with the shares of common stock issuable upon the exercise of the Series A Warrants vesting, if Firefly is then publicly traded, in two equal installments upon the market capitalization of the common stock reaching $100,000,000 and $200,000,000 respectively, each for a period of three consecutive trading days. Â Series C Financing Â Between October 17, 2023, and June 30, 2024, Firefly raised an aggregate of $3,039,000 from a private placement of 2,374,219 Series C units (the â€œSeries C Unitsâ€), which such Series C Units were comprised of shares of Series C Preferred Stock and the Series C Warrants to purchase up to 2,374,665 shares of Common Stock, which were sold at a combined purchase price of $1.28 per Series C Unit. Each Series C Warrant has an exercise price of $2.56 per share (subject to adjustment from time to time in accordance with the terms thereof), is exercisable immediately upon issuance and expires at 4:30 p.m. (New York time) three years following the initial date of issuance. Â 118 Â Â Series D Warrants Â In connection with prior consulting services rendered prior to the consummation of the Merger, on September 19, 2024, Firefly issued certain Series D Warrants to purchase up to 30,933 shares of Common Stock at an exercise price of $0.104 (which such exercise price and warrant shares reflect the application of the Exchange Ratio). The Series D Warrants are exercisable immediately upon issuance, subject to the vesting terms described in such Series D Warrants and are exercisable until 4:30 p.m. (Toronto time) on July 15, 2029. Â Broker Warrants Â In connection with prior consulting services rendered prior to the consummation of the Merger, Firefly issued certain Broker Warrants to purchase up to an aggregate of 11,663 shares of Common Stock at an exercise price of $5.98 (which such exercise price and warrant shares reflect the application of the Exchange Ratio). The Broker Warrants are exercisable immediately upon issuance and are exercisable for a term of five years following August 12, 2024. Â Legal Services Â As compensation for certain legal services rendered in 2024, Firefly issued to A. Ben-Tzvi, Adv. - Legal & Management Services Co. 10,588 shares of Common Stock. Â July 2024 Private Placement Â On July 26, 2024, prior to the consummation of the Merger, Firefly entered into a securities purchase agreement with certain institutional investors, pursuant to which Firefly agreed to issue and sell an aggregate of (i) 3,069,287 PIPE Shares, (ii) pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 504,323 shares of our Common Stock, and (iii) warrants (the â€œWarrantsâ€) to purchase up to 823,530 shares of Common Stock in the Private Placement. The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the Merger. The aggregate gross proceeds from the transaction were approximately $3.5 million, before deducting estimated offering expenses payable by Firefly. Â None of the foregoing transactions involved any underwriters, underwriting discounts or commissions or any public offering. Each of the recipients of securities in any transaction exempt from registration either received or had adequate access, through employment, business or other relationships, to information about WaveDancer and Firefly, as applicable. The sales of these securities were made without any general solicitation or advertising. The sales and issuances of these securities were undertaken in reliance upon the exemption from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) thereof and Regulation D promulgated thereunder. Â 119 Â Â Item 16. Exhibits and Financial Statement Schedules. Â The exhibits listed below are filed as part of this registration statement. Â Exhibit Â Description 2.1â€ Â§ Â Agreement and Plan of Merger, dated November 15, 2023, by and among WaveDancer, Inc., FFN Merger Sub, Inc., and Firefly Neuroscience, Inc.Â (incorporated herein by reference to Annex A-1 to the Companyâ€™s registration statement on Form S-4/A, filed with the SEC on February 2, 2024). 2.2 Â Amendment No. 1 to Agreement and Plan of Merger, dated January 12, 2024, by and among by and among WaveDancer, Inc., FFN Merger Sub, Inc., and Firefly Neuroscience, Inc. (incorporated herein by reference to Annex A-2 to the Companyâ€™s registration statement on Form S-4/A, filed with the SEC on February 2, 2024). 2.3 Â Amendment No. 2 to Agreement and Plan of Merger, dated June 17, 2024, by and among by and among WaveDancer, Inc., FFN Merger Sub, Inc., and Firefly Neuroscience, Inc. (incorporated herein by reference to Exhibit 2.1 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on June 21, 2024). 2.4 Â Stock Purchase Agreement between Registrant and Wavetop Solutions, Inc., dated November 15, 202 (incorporated herein by reference to Annex F to the Companyâ€™s registration statement on Form S-4/A, filed with the SEC on February 2, 2024). 3.1 Â Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc (incorporated herein by reference to Exhibit 3.1

to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on August 12, 2024). 3.2 Â Amended and Restated Bylaws of Firefly Neuroscience, Inc. (incorporated herein by reference to Exhibit 3.2 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on August 12, 2024). 4.1* Â Form of Series C Warrant. 4.2 Â Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on July 29, 2024). 4.3 Â Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.2 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on July 29, 2024). 4.4* Â Form of Series D Warrant 4.5* Â Form of Broker Warrant 5.1** Â Opinion of Haynes and Boone, LLP. 10.1# Â 2006 Stock Incentive Plan (incorporated herein by reference to Annex A to the Companyâ€™s proxy statement on Schedule 14A filed with the SEC on April 19, 2006). 10.2# Â 2016 Stock Incentive Plan (incorporated herein by reference to Annex A to the Companyâ€™s proxy statement on Schedule 14A filed with the SEC on April 11, 2016). 10.3# Â 2021 Stock Incentive Plan (incorporated herein by reference to Annex 4 to the Companyâ€™s proxy statement on Schedule 14A filed with the SEC on October 26, 2021). 10.4# Â Elminda Ltd. Share Option Plan (incorporated herein by reference to Annex 10.12 to the Companyâ€™s registration statement on Form S-4/A, filed with the SEC on February 2, 2024). 10.5# Â Firefly Neuroscience, Inc. 2024 Long-Term Incentive PlanÂ (incorporated herein by reference to Exhibit 10.5 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on August 12, 2024). Â 120 Â Â 10.6# Â Form of Nonqualified Stock Option AgreementÂ (incorporated herein by reference to Exhibit 10.6 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on August 12, 2024). 10.7# Â Form of Incentive Stock Option AgreementÂ (incorporated herein by reference to Exhibit 10.7 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on August 12, 2024). 10.8 Â Form of Indemnification AgreementÂ (incorporated herein by reference to Exhibit 10.8 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on August 12, 2024). 10.9 Â Common Stock Purchase Agreement by and between WaveDancer, Inc. and B. Riley Principal Capital II, LLC dated July 8, 2022 (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on July 11, 2022). 10.10 Â Registration Rights Agreement by and between the Registrant and B. Riley Principal Capital II, LLC dated July 8, 2022Â (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on July 11, 2022). 10.11+ Â Securities Purchase Agreement, dated as of July 26, 2024, by and among the Company and the investors signatory thereto (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on July 29, 2024) 10.12# Â Employment Agreement, dated as of August 19, 2024, by and between Firefly Neuroscience, Inc. and David Johnson (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K, filed with the SEC on August 20, 2024) 21.1 Â List of Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Registrantâ€™s Current Report on Form 8-K filed on August 12, 2024). 23.1* Â Consent of Turner, Stone & Company, L.L.P., independent registered public accounting firm. 23.2** Â Consent of Haynes and Boone, LLP (included in Exhibit 5.1). 24.1* Â Power of AttorneyÂ (included on the signature page of this registration statement) 101.INS* Â Inline XBRL Instance Document. 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document. 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104* Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 107* Â Filing Fee Table Â * Filed herewith. ** To be filed by amendment. â€ Certain of the exhibits or schedules to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. # Management contract or compensatory plan or arrangement. Â§ Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6). Â 121 Â Â Item 17. Undertakings. Â The undersigned registrant hereby undertakes: Â Â (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) to include any prospectus required by Section 10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the â€œCalculation of Registration Feeâ€ table in the effective registration statement; and (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (i), (ii) and (iii) do not apply if the registration statement is on Form S-1 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement; Â Â (2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; Â Â (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; Â Â (4) that, for the purpose of determining liability under the Securities Act to any purchaser: Â Â Â Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use; and Â Â (5) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. Â 122 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Kenmore, State of New York, on September 26th, 2024. Â Â Â FIREFLY NEUROSCIENCE, INC. Â Â By: Â /s/ Jon Olsen Â Â Â Â Jon Olsen Â Â Â Â Chief Executive Officer and Chairman of the Board of Directors Â POWER OF ATTORNEY Â Each person whose signature appears below hereby appoints each of Jon Olsen and David Johnson, severally, acting alone and without the other, his or her true and lawful attorney-in-fact, with full power of substitution, and with the authority to execute in the name of each such person, any and all amendments (including without limitation, post-effective amendments) to this registration statement on Form S-1, to sign any and all additional registration statements relating to the same offering of securities as this registration statement that are filed pursuant to Rule 462(b) of the Securities Act of 1933, and to file such registration statements with the SEC, together with any exhibits thereto and other documents therewith, necessary or advisable to enable the registrant to comply with the Securities Act of 1933, and any rules, regulations and requirements of the SEC in respect thereof, which amendments may make such other changes in the registration statement as the aforesaid attorney-in-fact executing the same deems appropriate. Â Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. Â Signature Â Title Â Date Â Â Â Â Â Â /s/ Jon Olsen Â Chief Executive Officer and Director Â September 26, 2024 Jon Olsen Â (Principal Executive Officer) Â Â Â Â Â Â Â /s/ Paul Krzywicki Â Chief Financial Officer Â September 26, 2024 Paul Krzywicki Â (Principal Financial Officer and Principal Accounting Officer) Â Â Â Â Â Â Â Â /s/ David Johnson Â Chairman of the Board Â September 26, 2024 David Johnson Â Â Â Â Â Â Â Â Â Â /s/ David DeCaprio Â Director Â September 26, 2024 David DeCaprio Â Â Â Â Â Â Â Â Â Â /s/ Greg Lipschitz Â Director Â September 26, 2024 Greg Lipschitz Â Â Â Â Â Â Â Â Â Â /s/ Arun Menawat Â Director Â September 26, 2024 Arun Menawat Â Â Â Â Â Â Â Â Â Â /s/ Brian Posner Â Director Â September 26, 2024 Brian Posner Â Â Â Â Â Â Â Â Â Â /s/ Stella Vnook Â Director Â September 26, 2024 Stella Vnook Â Â Â Â Â Â 123 EX-4.1 2 ex_726612.htm EXHIBIT 4.1 ex_726612.htm Exhibit 4.1 Â NEITHER THIS WARRANT NOR THE SECURITIES INTO WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL, IN A FORM ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. Â FIREFLY NEUROSCIENCE, INC. Â COMMON STOCK PURCHASE WARRANT Â Warrant No. [*] Original Issue Date:Â [*], 202_ Initial Holder:Â [*] No. of Shares Subject to Warrant:Â [*] Â Initial Exercise Price Per Share:Â $2.56 (subject to the adjustment pursuant to Section 9) Â Expiration Time:Â Â 5:00 p.m., Central time, on [*], 202_ Â Firefly Neuroscience, Inc., a Delaware corporation (the â€œCompanyâ€), hereby certifies that, for value received, the Initial Holder shown above, or its permitted registered assigns (the â€œHolderâ€), is entitled to purchase from the Company up to the number of shares of its Common Stock, par value $0.00001 per share (the â€œCommon Stockâ€), shown above (each such share, a â€œWarrant Shareâ€ and all such shares, the â€œWarrant Sharesâ€) at the exercise price shown above (as may be adjusted from time to time as provided herein, the â€œExercise Priceâ€), at any time and from time to time on or after the original issue date indicated above (the â€œOriginal Issue Dateâ€) and through and including the expiration time shown above (the â€œExpiration Timeâ€), and subject to the following terms and conditions: Â This Warrant is being issued pursuant to a Subscription Agreement, dated [*], 2023 (the â€œSubscription Agreementâ€), by and between the Company and the Initial Holder. This Warrant is one of a series of Warrants issued pursuant to the Subscription Agreement and other subscription agreements having an identical form entered into between the Company and other subscribers. Â 1.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Subscription Agreement. Â 2.Â Â Â Â Â Â Â Â Â Â Â Â Â Â List of Warrant Holders.Â The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the â€œWarrant Registerâ€), in the name of the record Holder (which shall include the Initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly assigned hereunder from time to time).Â The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. Â 3.Â Â Â Â Â Â Â Â Â Â Â Â Â Â List of Transfers; Restrictions on Transfer. The Company shall register any transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached hereto duly completed and signed, to the Company at its address specified herein. Upon any such registration or transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (any such new Warrant, a â€œNew Warrantâ€), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. Â Â Â Â 4.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise and Duration of Warrant; Forced Exercise of Warrant. Â (a)Â Â Â Â Â Â Â Â Â Â Â Â Â Â All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Section 4 at any time and from time to time on or after the Original Issue Date and through and including the Expiration Time. At the Expiration Time, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be terminated and shall no longer be outstanding. Â (b)Â Â Â Â Â Â Â Â Â Â Â Â Â Â The Holder may exercise this Warrant by delivering to the Company: (i) an exercise notice, in the form attached hereto (the â€œExercise Noticeâ€), completed and duly signed, and (ii) payment by wire transfer of immediately available funds to an account designated by the Company of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised. The Holder shall be required to deliver the original Warrant in order to effect an exercise hereunder. The date such items are delivered to the Company (as determined in accordance with the notice provisions hereof) is an â€œExercise Date.â€ Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares. Â (c)Â Â Â Â Â Â Â Â Â Â Â Â Â Â The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant pursuant to the terms hereof. Â 5. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Delivery of Warrant Shares. Â (a)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Upon exercise of this Warrant, the Company shall promptly (but in no event later than ten (10) business days after the Exercise Date) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate, a certificate for the Warrant Shares issuable upon such exercise, free of restrictive legends. The Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date.Â The Company shall, upon the written request of the Holder, use its best efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through the Depository Trust and Clearing Corporation or another established clearing corporation performing similar functions, if available; provided, that, the Company may, but will not be required to, change its transfer agent if its current transfer agent cannot deliver Warrant Shares electronically through the Depository Trust and Clearing Corporation.Â If as of the time of exercise the Warrant Shares constitute restricted or control securities, the Holder, by exercising, agrees not to resell them except in compliance with all applicable securities laws. Â (b)Â Â Â Â Â Â Â Â Â Â Â Â Â Â To the extent permitted by law, the Companyâ€™s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holderâ€™s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Companyâ€™s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. Â Â Â Â (c)Â Â Â Â Â Â Â Â Â Â Â Â Â Â If the Company fails to cause its transfer agent to transmit to the Holder a certificate or the certificates (either physical or electronic) representing the Warrant Shares pursuant to the terms hereof by applicable delivery date, then, the Holder will have the right to rescind such exercise. Â 6. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. Â 7. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Replacement of Warrant.Â If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Companyâ€™s obligation to issue the New Warrant. Â 8. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Reservation of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are then issuable and deliverable upon the exercise

of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. Â 9. Â Â Â Â Â Â Â Â Â Certain Adjustments to Exercise Price. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9. Â (a)Â Â Â Â Â Â Â Â Â Adjustments for Stock Splits and Combinations and Stock Dividends. If the Company shall at any time or from time to time after the date hereof, effect a stock split or combination of the outstanding Common Stock or pay a stock dividend in shares of Common Stock, then the Exercise Price shall be proportionately adjusted. Any adjustments under this Section 9(a) shall be effective at the close of business on the date the stock split or combination becomes effective or the date of payment of the stock dividend, as applicable. Â Â Â Â (b)Â Â Â Â Â Â Â Â Â Merger Sale, Reclassification, etc. In case of any: (i) consolidation or merger (including a merger in which the Company is the surviving entity), (ii) sale or other disposition of all or substantially all of the Companyâ€™s assets or distribution of property to shareholders (other than distributions payable out of earnings or retained earnings), or reclassification, change or conversion of the outstanding securities of the Company or of any reorganization of the Company (or any other corporation the stock or securities of which are at the time receivable upon the exercise of this Warrant) or any similar corporate reorganization on or after the date hereof, then and in each such case the Holder of this Warrant, upon the exercise hereof at any time thereafter shall be entitled to receive, in lieu of the stock or other securities and property receivable upon the exercise hereof prior to such consolidation, merger, sale or other disposition, reclassification, change, conversion or reorganization, the stock or other securities or property to which such Holder would have been entitled upon such consummation if such Holder had exercised this Warrant immediately prior thereto. Â (c)Â Â Â Â Â Â Â Â Â Voluntary Adjustment by the Company. Subject to the rules and regulations of the trading market on which the Companyâ€™s stock may be trading, the Company may at any time during the term of this Warrant, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company. Â 10. Â Â Â Â Â Â Â Â Â No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the closing price of one Warrant Share as reported by the applicable Trading Market on the Exercise Date. Â 11.Â Â Â Â Â Â Â Â Â Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be delivered in accordance with the procedures set forth in the SPA. Â 12. Â Â Â Â Â Â Â Â Â Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) daysâ€™ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holderâ€™s last address as shown on the Warrant Register. Â 13. Â Â Â Â Â Â Â Â Â Miscellaneous. Â (a)Â Â Â Â Â Â Â Â Â This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. Â (b)Â Â Â Â Â Â Â Â Â All questions concerning the construction, validity, enforcement and interpretation of this Warrant and the Subscription Agreement shall be governed by and construed and enforced solely and exclusively in accordance with the laws of the state of Delaware without regard to any statutory or common-law provision pertaining to conflicts of laws. EACH PARTY HERETO (INCLUDING ITS AFFILIATES, AGENTS, OFFICERS, DIRECTORS AND EMPLOYEES) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. Â Â Â Â (c)Â Â Â Â Â Â Â Â Â The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. Â (d)Â Â Â Â Â Â Â Â Â In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this Warrant. Â (e) Â Â Â Â Â Â Â Â Â Prior to exercise of this Warrant, the Holder hereof shall not, by reason of by being a Holder, be entitled to any rights of a stockholder with respect to the Warrant Shares. Â (f)Â Â Â Â Â Â Â Â Â No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. Â IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above. Â Â FIREFLY NEUROSCIENCE, INC. Â Â Â By: Â Name: Title: Â Â Â Â FIREFLY NEUROSCIENCE, INC. Â EXERCISE NOTICE Â Ladies and Gentlemen: Â (1)Â Â Â Â Â Â Â Â Â The undersigned hereby elects to exercise the above-referenced Warrant with respect to ______________ shares of Common Stock.Â Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. Â (2)Â Â Â Â Â Â Â Â Â The Holder intends that payment of the Exercise Price shall be made in cash in accordance with Section 4(b) of the Warrant. Â (3)Â Â Â Â Â Â Â Â Â The Holder shall pay the sum of $Â ______________Â Â Â Â Â to the Company in accordance with the terms of the Warrant. Â (4)Â Â Â Â Â Â Â Â Â Pursuant to this Exercise Notice, the Company shall deliver to the Holder ________________ Warrant Shares determined in accordance with the terms of the Warrant. Â Â Â Â Dated: Â Â HOLDER: Â Â Â Â Â Â Â Â Â Â Print name Â Â Â Â Â Â Â By: Â Â Â Â Â Â Â Â Title: Â Â Â Â Â Â Â Â Â FIREFLY NEUROSCIENCE, INC. Â FORM OF ASSIGNMENT To be completed and signed only upon transfer of Warrant Â Â FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto _________________ the right represented by the within Warrant to purchase _________________ shares of Common Stock to which the within Warrant relates and appoints _________________ attorney to transfer said right on the books of the Company with full power of substitution in the premises. Â Â Â Â Dated: Â Â TRANSFEROR: Â Â Â Â Â Â Print name Â Â Â Â Â Â Â By: Â Â Â Â Â Â Â Â Title: Â Â Â Â Â Â Â Â Â TRANSFEREE: Â Â Â Â Â Â Print name Â Â Â Â Â Â Â By: Â Â Â Â Â Â Â Â Title: Â Â WITNESS: Â Â Â Â Â Address of Transferee: Â Â Â Â Print name Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EX-4.4 3 ex_726613.htm EXHIBIT 4.4 ex_726613.htm Exhibit 4.4 Â SCHEDULE C Â SERIES D WARRANT CERTIFICATE Â THESE WARRANTS WILL EXPIRE AND BECOME NULL AND VOID AT 4:30 P.M. (NEW YORK TIME) ON THE EXPIRY DATE (as defined herein) OR SUCH EARLIER DATE AS PROVIDED FOR HEREIN. Â THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE â€œU.S. Securities Actâ€) OR ANY APPLICABLE STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. Securities Act AND IN COMPLIANCE WITH LOCAL LAWS AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES OR â€œBLUE SKYâ€ LAWS, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF SUBPARAGRAPH (C) OR (D), THE SELLER FURNISHES TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING OR SUCH OTHER EVIDENCE AS THE CORPORATION MAY REQUIRE IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE â€œGOOD DELIVERYâ€ IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. Â Â SERIES D WARRANT Â FIREFLY NEUROSCIENCES INC. (Incorporated under the laws of Delaware) Â Â WARRANT CERTIFICATE [__] Series D Warrants Â Â Â Â Â Â Initial Exercise Date September 19, 2024 Â Â NO. 2024-D0903 Â THIS IS TO CERTIFY THAT, FOR VALUE RECEIVED, Â [____________] (the "holder") Â is entitled to exercise these common share purchase warrants (the "Series D Warrants") and acquire, upon and subject to the terms and conditions hereinafter set forth, at any time and from time to time until 4:30 p.m. (Toronto time) (the "Expiry Time") on July 15, 2029 (the "Expiry Date"), one Class A common share (a "Common Share") of Firefly Neurosciences Inc. (the "Corporation") for each Series D Warrant represented hereby at and for a price of $0.104 per Common Share (the "Exercise Price"). Â 16. Subject to paragraph 4, the right to acquire Common Shares hereunder may only be exercised during the period herein specified by: Â Â (a) completing, in the manner indicated, and executing the exercise form attached as Schedule "B" for that number of Common Shares which the holder is entitled and wishes to purchase; Â Â (b) surrendering this Series D Warrant certificate to the Corporation at its registered office at Suite 1250, 639 â€“Â 5thÂ Ave. SW, Calgary, Alberta T2P 0M9; and Â Â (c) paying the appropriate Exercise Price for the Common Shares subscribed for either by cash, certified cheque payable at par to or to the order of the Corporation or such other consideration as may be authorized by the Board of Directors. Â 17. Upon surrender and payment as aforesaid, the Corporation will, subject to the terms hereof, issue to the person or persons named in the exercise form the number of Common Shares subscribed for and such person or persons will be shareholders of the Corporation in respect of the Common Shares comprising a portion of such Common Shares as at the date of surrender and payment. As soon as practicable after surrender of the certificate and payment of the Exercise Price, the Corporation will mail to such person or persons, at the address or addresses specified in the exercise form, a certificate or certificates evidencing the Common Shares subscribed for. If the holder exercises these Series D Warrants for a lesser number of Common Shares than the number of Common Shares referred to above, the holder shall be entitled to receive a new Series D Warrant certificate (substantially in the form hereof) in respect of the Common Shares that might have been subscribed for hereunder but which were not then purchased by the holder. In no event shall fractional Common Shares be issued in connection with the exercise of these Series D Warrants. Â Â Â Â 18. Subject to the conditions set forth in subsection 4 below, these Series D Warrants are exercisable at any time and from time to time upon payment in the manner and at the place provided for above. Â 19. These Series D Warrants shall be exercisable by the holder (each a "Vesting Event") subject to the conditions as set out in Schedule "Aâ€. Â 20. All right, title and interest in the Series D Warrants represented hereby is held exclusively by the holder and the Series D Warrants may not be transferred or assigned. Â 21. Upon exercise of these Series D Warrants, each certificate, instrument, or book entry representing the Common Shares and any other securities issued in respect of the securities referenced in Section 10 upon any share split, share dividend, recapitalization, merger, consolidation, or similar event, shall be notated with a legend substantially in the following form: Â THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE â€œU.S. Securities Actâ€) OR ANY APPLICABLE STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. Securities Act AND IN COMPLIANCE WITH LOCAL LAWS AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES OR â€œBLUE SKYâ€ LAWS, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF SUBPARAGRAPH (C) OR (D), THE SELLER FURNISHES TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED STANDING OR SUCH OTHER EVIDENCE AS THE CORPORATION MAY REQUIRE IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE CORPORATION TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE â€œGOOD DELIVERYâ€ IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. Â 22. If these Series D Warrants are stolen, lost, mutilated or destroyed the Corporation may, on such reasonable terms as to indemnity or otherwise as it may impose, deliver replacement Series D Warrants of like denomination, tenor and date as the Series D Warrants so stolen, lost, mutilated or destroyed. Â 23. These Series D Warrants shall not entitle the holder to any rights whatsoever as a shareholder of the Corporation prior to the exercise thereof. Â 24. All right, title and interest in the Series D Warrants represented hereby is held exclusively by the holder and the Series D Warrants may not be transferred or assigned. Should the holder cease to be engaged by the Corporation or one of its subsidiaries for any reason, the Series D Warrants granted herein shall expire and terminate immediately as to the then unvested portion thereof. Â 25. The number of Common Shares purchasable upon exercise of the Series D Warrants shall be subject to adjustment from time to time in the events and in the manner provided for below. Â Â (a) If and whenever at any time from the date hereof the Corporation shall: Â Â (i) subdivide, redivide or change its outstanding Common Shares into a greater number of shares; or Â Â Â Â Â (ii) reduce, combine or consolidate its outstanding Common Shares into a smaller number of shares; Â the number of Common Shares obtainable under each Series D Warrant shall be adjusted immediately after the effective date of such subdivision, redivision, change, reduction, combination or consolidation, by multiplying the number of Common Shares theretofore obtainable on the exercise of such Series D Warrant by a fraction of which the numerator shall be the total number of Common Shares outstanding immediately after such date and the denominator shall be the total number of Common Shares outstanding immediately prior to such date. The Exercise Price shall also be amended proportionately such that the aggregate Exercise Price payable upon exercise of the Series D Warrants remains unchanged. The foregoing adjustments shall be made successively whenever any event referred to in this subsection 8(a) shall occur. Â Â (b) If and whenever at any time from the date hereof there is a reclassification of the Common Shares or a capital reorganization of the Corporation other than as described in subsection 8(a) or a consolidation, amalgamation, arrangement or merger of the Corporation with or into any other body corporate, trust, partnership or other entity, or a sale or conveyance of the property and assets of the Corporation as an entirety or substantially as an entirety to any other body corporate, trust, partnership or other entity, a holder shall be entitled to receive and shall accept, in lieu of the number of Common Shares originally sought to be acquired by it, the number of shares, share purchase warrants or other securities or property of the Corporation or of the body corporate, trust, partnership or other entity resulting from such merger, amalgamation, arrangement or Â consolidation, or to which such sale or conveyance may be made, as the case may be, that such holder would have been entitled to receive on such reclassification, capital reorganization, consolidation, amalgamation, merger, sale or conveyance, if, on the record date or the effective date thereof, as the case may be, the holder had been the registered holder of the number of Common Shares originally sought to be acquired by it and to which it was entitled to acquire upon the exercise of the Series D Warrants. Â Â (c) The adjustments provided for in this paragraph 8 in the number of Common Shares and classes of securities which are to be received on the exercise of Series D Warrants are cumulative. After any adjustment pursuant to this paragraph 8, the term "Common Shares" where used in this agreement shall be interpreted to mean securities of any class or classes which, as a result of such adjustment and all prior adjustments pursuant to this paragraph 8, the holder is entitled to receive upon the exercise of its Series D Warrants, and the number of Common Shares indicated by any exercise made pursuant to an Series D Warrant shall be interpreted to mean the number of Common Shares or other property or securities a holder is entitled to receive, as a result of such adjustment and all prior adjustments pursuant to this paragraph, upon the full exercise of an Series D Warrant. Â Â (d) If a dispute shall at any time arise with respect to adjustments provided for herein, such dispute shall be conclusively determined by the Corporation's auditors (except in cases where any determination relating to adjustments is to be made by the board of directors of the Corporation), or if they are unable or unwilling to act, by such other firm of independent chartered accountants as may be selected by action of the directors and any such determination shall be binding upon the Corporation and the holder. Â Â (e) As a condition precedent to the taking of any action that would require an adjustment in any of the acquisition rights pursuant to any of the Series D Warrants, including the number of Common Shares that are to be received upon the exercise thereof, the Corporation shall take any corporate action which may, in the opinion of counsel to the Corporation, be necessary in order that the Corporation has unissued and reserved in its authorized capital and may validly and legally issue as fully paid and non-assessable all of the Common Shares that the holders of Series D Warrants are entitled to receive on the full exercise thereof in accordance with the provisions hereof. Â Â (f) In any case in which the terms of these Series D Warrants shall require that an adjustment become effective as of a particular time, the Corporation may defer, until such time, issuing to the holder in respect

of any Series D Warrants exercised after the record date for the event giving rise to the adjustment and before such time the kind and amount of shares, common share purchase warrants, other securities or property to which the holder would be entitled upon such exercise by reason of the relevant adjustment, provided, however that the Corporation shall deliver to the holder an appropriate instrument evidencing such holder's right, upon the occurrence of any event requiring the adjustment, to the relevant adjustment. Â Â Â Â Â (g) At least 10 days prior to the effective date or record date, as the case may be, of any event which requires or might require an adjustment in any attribute of these Series D Warrants, including the Exercise Price and the number of Common Shares that are purchasable upon the exercise thereof, the Corporation shall give notice to the holder of the particulars of such event and, if determinable, the required adjustment. In case any adjustment is not then determinable, the Corporation shall promptly after such adjustment is determinable give notice to the holder of the adjustment. Â 26. On the happening of each and every event referred to above that gives rise to an adjustment, the applicable provisions of these Series D Warrants shall, ipso facto, be deemed to be amended accordingly and the Corporation shall take all necessary action so as to comply with such provisions as so amended. Â 27. The Corporation represents and warrants that it is duly authorized to create and deliver these Series D Warrants and to issue the Common Shares, that may be issued hereunder and that these Series D Warrants, when signed by the Corporation as herein provided, will be a valid obligation of the Corporation enforceable against the Corporation in accordance with the provisions hereof. The Corporation hereby covenants and agrees that, subject to the provisions hereof, it will cause the Common Shares from time to time duly subscribed for and purchased in the manner herein provided, and the certificates evidencing such Common Shares, to be duly issued and delivered, and that at all times while these Series D Warrants remain outstanding, it shall have sufficient authorized capital to satisfy its obligations hereunder should the holder determine to exercise the right in respect of all of the Common Shares for the time being purchasable pursuant to these Series D Warrants. Certificates for Common Shares issued upon the exercise of these Series D Warrants may bear such legend or legends as to transfer as may be considered necessary by the Corporation and its counsel, acting reasonably. All Common Shares issued upon the exercise of the right of purchase herein provided (upon payment therefor of the amount at which such Common Shares may at the time be purchased pursuant to the provisions hereof), shall be issued as fully paid and non-assessable Common Shares and the holders thereof shall not be liable to the Corporation or its creditors in respect thereof. Â 28. Time shall be of the essence hereof. Â 29. These Series D Warrants shall be governed by and construed in accordance with the laws of the State of Delaware and the laws of the United States of America applicable therein. Â 30. These Series D Warrants shall not be valid for any purpose whatsoever until signed by the Corporation. Â IN WITNESS WHEREOF the Corporation has caused these Series D Warrants to be executed by its duly authorized officer. Â DATED as of the 19th day of September, 2024. Â Â FIREFLY NEUROSCIENCES INC. Â Â Per: Â Â Â Â Â SCHEDULE "A" Â SERIES D VESTING TERMS Â The Series D Warrants shall be vested, following the occurrence of the following: Â 1. a Public Listing or equity raise of the Common Shares of the Corporation, in accordance with the followingÂ vesting schedule: Â Â Vesting Event Market Capitalization1 Vested Warrants on Vesting Event #1 USD$90,000,000 [__] Â 1If Publicly traded, the Market Capitalization of the Shares must be maintained for a period for 3 consecutive trading days for the Vesting Event to be triggered. Â Definitions: Â "Market Capitalization" means the total dollar value of all outstanding Common Shares calculated by multiplying the number of Common Shares times the current Market Price. Â "Market Price" means closing price of the Common Shares on the Stock Exchange. Â "Public Listing" means the closing of: (i) a transaction resulting in the Shares being listed (directly or indirectly) on the Nasdaq, NYSE, NEO, CSE Exchange or any other recognized US or Canadian securities exchange (a â€œStock Exchangeâ€), including but not limited to an initial public offering, plan of arrangement, amalgamation, reverse take-over or other business combination pursuant to which the securities of the Corporation (or any resulting issuer or parent thereof) become listed on a Stock Exchange. Â Â 2. All unvested Series D Warrants shall be vested upon Change of Control. Â "Change of Control" means "Change of Control" means, with respect to the Purchaser, the occurrence of any of the following: Â Â a. the purchase or acquisition of voting shares of the Corporation and/or securities convertible into voting shares of the Purchaser or carrying the right to acquire voting shares of the Purchaser ("Convertible Securities") as a result of which a person, group of persons or persons acting jointly or in concert, or any Affiliates or Associates (as such terms are defined in the Securities Act (Ontario)) of any such person, group of persons or any of such persons acting jointly or in concert (collectively the "Holders") beneficially own or exercise control or direction over voting shares and/or Convertible Securities of the Purchaser such that, assuming after the conversion of the Convertible Securities beneficially owned by the Holders thereof, would have the right to cast more than 50% of the votes attached to all voting shares of the Corporation; or Â Â b. approval by the shareholders of: Â Â i. a liquidation, dissolution or winding up of the Corporation, or Â Â ii. the sale, lease or exchange of all or substantially all of the assets of the Corporation, or Â Â iii. an amalgamation, arrangement, merger or other consolidation or combination of the Corporation with another entity pursuant to which the shareholders of the Corporation immediately thereafter do not own securities of the successor or continuing entity which would entitle them to cast more than 50% of the votes attaching to all voting shares. Â Â Â Â SCHEDULE "B" Â EXERCISE FORM Â TO:Â Â Â Â Â Â Â Â Â FIREFLY NEUROSCIENCE, INC. Â The undersigned holder of the within Warrants hereby subscribes forÂ Â Â ________________ Common Shares in the capital of Firefly Neuroscience, Inc. and hereby makes payment of the exercise price for the said number of Common Shares. Â The undersigned hereby directs that the Common Shares hereby subscribed for be issued and delivered as follows: Â Name in Full Address in Full Number of Common Shares Â Â Â Â Â Â Â Â Â Â Â Â Â (Please state full names in which share certificates are to be issued, stating whether Mr., Mrs., Ms. or Miss.) Â DATED thisÂ _______Â Â day ofÂ Â ________________ Â , 20__. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (Signature of Holder) Â Â Â Â EX-4.5 4 ex_726945.htm EXHIBIT 4.5 ex_726945.htm Exhibit 4.5 Â THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. Â WARRANT AGREEMENT Â To Purchase [__] Shares of Common Stock of Â FIREFLY NEUROSCIENCE, INC. Â Dated as of August 12, 2024 (the â€œEffective Dateâ€) Â WHEREAS, Firefly Neuroscience, Inc., a corporation organized under the laws of Delaware (the â€œCompanyâ€) has entered into an engagement letter, dated as of [__], between the Company and [____]. (as amended and in effect from time to time, the â€œEngagement Agreementâ€) with the undersigned warrantholder (the â€œWarrantholderâ€). Â WHEREAS, pursuant to the Subscription Agreement and as additional consideration to the Warrantholder for, among other things, its agreements in the Subscription Agreement, the Company has agreed to issue to the Warrantholder this Warrant Agreement, evidencing the right to purchase shares of common stock, par value $0.0001 per share, of the Company (this â€œWarrantâ€, â€œWarrant Agreementâ€, or this â€œAgreementâ€). Â NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: Â SECTION 1. Â Â GRANT OF THE RIGHT TO PURCHASE COMMON SHARES Â (a) Â Â Â Â Â Â For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to the number of fully paid and non-assessable shares of Common Stock (as defined below) equal to the Number of Shares (as defined below), at a purchase price per share equal to the Exercise Price (as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings: Â â€œCharterâ€ means the Companyâ€™s Articles of Incorporation, as may be amended and in effect from time to time. Â â€œCommon Stockâ€ means the Companyâ€™s shares of common stock, par value $0.0001 per share, as presently constituted under the Charter, and any class and/or series of Company capital stock for or into which such shares of common stock may be converted or exchanged in a reorganization, recapitalization or similar transaction. Â â€œExchange Actâ€ means the Securities Exchange Act of 1934, as amended. Â Â Â Â â€œExercise Priceâ€ means $5.98, subject to adjustment from time to time in accordance with the provisions of this Agreement. Â â€œMerger Eventâ€ means any of the following: (i) a sale, lease or other transfer of all or substantially all assets of the Company, (ii) any merger or consolidation involving the Company in which the Company is not the surviving entity or in which the outstanding shares of the Companyâ€™s capital stock are otherwise converted into or exchanged for shares of capital stock or other securities or property of another entity and in which the holders of a majority of the outstanding shares of capital stock of the Company immediately prior to such merger or consolidation do not hold a majority of the surviving entity or other entity immediately following such merger or consolidation, or (iii) any sale by holders of the outstanding voting equity securities of the Company in a single transaction or series of related transactions of shares constituting a majority of the outstanding combined voting power of the Company. Â â€œPurchase Priceâ€ means, with respect to any exercise of this Warrant, an amount equal to the Exercise Price (subject to adjustment from time to time in accordance with the provisions of this Agreement) multiplied by the number of shares of Common Stock as to which this Warrant is then exercised. Â â€œRule 144â€ means Rule 144 of the Securities Act, as amended. Â â€œSecurities Actâ€ means the Securities Act of 1933, as amended. Â â€œTrading Dayâ€ means a day on which the principal Trading Market is open for trading. Â â€œTrading Marketâ€ means any of the following markets or exchanges on which the shares of Common Stock are listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing). Â â€œVWAPâ€ means, for any date, the price determined by the first of the following clauses that applies: (a) if the shares of Common Stock are then listed or quoted on a Trading Market, the daily volume weighted average price of the shares of Common Stock for such date (or the nearest preceding date) on the Trading Market on which the shares of Common Stock are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the shares of Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the shares of Common Stock are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the shares of Common Stock are then reported on the Pink Market operated by the OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. Â (b)Â Â Â Â Â Â Â Number of Shares.Â This Warrant shall be exercisable for one shares of Common Stock, subject to adjustment from time to time in accordance with the provisions of this Agreement, subject to further adjustment thereafter from time to time in accordance with the provisions of this Agreement. Â 2 Â Â SECTION 2.Â TERM OF THE AGREEMENT Â The term of this Agreement and the right to purchase shares of Common Stock as granted herein shall commence on the Effective Date and, subject to Section 8(a), shall be exercisable for a period ending upon the fifth (5th) anniversary of the Effective Date (such date, the â€œTermination Dateâ€). Â SECTION 3.Â EXERCISE OF THE PURCHASE RIGHTS Â (a)Â Â Â Â Â Â Â Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the â€œNotice of Exerciseâ€), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in cash or certified check, and in no event later than three business (3) days thereafter, the Company shall, subject to the prior receipt of all necessary regulatory approvals, including those of the NASDAQ Capital Market and the Toronto Stock Exchange, cause its transfer agent to issue to the Warrantholder in book entry form the number of shares of Common Stock purchased, and the Company shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the â€œAcknowledgment of Exerciseâ€) indicating the number of shares which remain subject to future purchases under this Agreement, if any. Â Upon any partial exercise of this Warrant, the Company shall, upon the Warrantholderâ€™s written request, promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof. Â (b)Â Â Â Â Â Â Â Cashless Exercise. If at any time commencing after the Effective Date, there is no effective registration statement registering, or no current prospectus available for the resale of all of the shares of Common Stock that may be acquired pursuant to this Warrant by the Holder, then this Warrant may also be exercised at the Holderâ€™s election, in whole or in part, at such time by means of a â€œcashless exerciseâ€ in which the Holder shall be entitled to receive a number of shares of Common Stock equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: Â (A) = the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a â€œcashless exercise,â€ as set forth in the applicable Notice of Exercise; Â (B) = the Exercise Price of this Warrant, as adjusted hereunder; and Â (X) = the number of shares of Common Stock that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. Â Notwithstanding anything herein to the contrary, on the Termination Date, unless the Holder notifies the Company otherwise, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 3(b). Â 3 Â Â SECTION 4.Â RESERVATION OF SHARES Â During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of Common Stock to provide for the exercise of the rights to purchase shares of Common Stock as provided for herein. Â SECTION 5.Â NO FRACTIONAL SHARES OR SCRIP Â No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. Â SECTION 6.Â NO RIGHTS AS SHAREHOLDER Â Without limitation of any provision hereof, Warrantholder agrees that this Agreement does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the Company prior to the exercise of any of the purchase rights set forth in this Agreement. Â SECTION 7.Â WARRANTHOLDER REGISTRY Â The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholderâ€™s initial address, for purposes of such registry, is set forth in Section 12(g). Warrantholder may change such address by giving written notice of such changed address to the Company. Â SECTION 8.Â ADJUSTMENT RIGHTS Â The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment from time to time, as follows: Â (a)Â Â Â Â Â Â Â Merger Event. In connection with a Merger Event, this Warrant shall, on and after the closing thereof, automatically and without further action on the part of any party or other person, represent the right to receive the consideration payable on or in respect of all shares of Common Stock that are issuable hereunder as of immediately prior to the closing of such Merger Event less the Purchase Price for all such shares of Common Stock (such consideration to include both the consideration payable at the closing of such Merger Event and all deferred consideration payable thereafter, if any, including, but not limited to, payments of amounts deposited at such closing into escrow and payments in the nature of earn-outs, milestone payments or other performance-based payments), and such Merger Event consideration shall be paid to Warrantholder as and when it is paid to the holders of the outstanding shares of Common Stock. Â (b)Â Â Â Â Â Â Â Reclassification of Shares. Except for Merger Events subject to Section 8(a), if the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes of securities, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly apply to successive combination, reclassification, exchange, subdivision or other change. Â 4 Â Â (c)Â Â Â Â Â Â Â Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its shares of Common Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares for which this Warrant is exercisable shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased and the number of shares for which this Warrant is exercisable shall be proportionately decreased. Â (d)Â Â Â Â Â Â Â Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: Â Â (i) pay a dividend with respect to the outstanding shares of Common Stock payable in additional shares of Common Stock, then the Exercise Price shall be adjusted, as of the record date applicable to such dividend, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution, and the number of shares of Common Stock for which this Warrant is exercisable shall be proportionately increased; or Â Â (ii) make any other dividend or distribution on or with respect to shares of Common Stock, except any dividend or distribution (A) in cash, or (B) specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise of this Warrant a proportionate share of any such

distribution as though it were the holder of the shares of Common Stock as of the record date fixed for the determination of the shareholders of the Company entitled to receive such distribution. Â (e) Â Â Â Â Â Â Â Â Â Notice of Certain Events. If: (i) the Company shall declare any dividend or distribution upon its outstanding shares of Common Stock, payable in shares, cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of its shares of Common Stock any additional shares of any class or other rights; (iii) there shall be any Merger Event; or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice thereof at the same time and in the same manner as it gives notice thereof to the holders of outstanding shares of Common Stock. Â SECTION 9.Â Â Â Â Â TRANSFERS Â Subject to Section 10(f) and compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed, with the prior written consent of the Company. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Companyâ€™s books, shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. Subject to the Companyâ€™s prior written consent, the transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the â€œTransfer Noticeâ€) and an opinion of counsel (which may be Company counsel) reasonably satisfactory to the Company that such transfer does not require registration under the Securities Act or any applicable state securities laws, at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Â 5 Â Â SECTION 10.Â MISCELLANEOUS. Â (a) Â Â Â Â Â Â Successors and Assigns. This Agreement shall be binding upon any successors or assigns of the Company. Â (b) Â Â Â Â Â Â Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the non-defaulting party will not have an adequate remedy at law and where damages will not be readily ascertainable. Â (c) Â Â Â Â Â Â No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. Â (d) Â Â Â Â Â Â Additional Documents. The Company agrees to supply such other documents as the Warrantholder may from time to time reasonably request. Â (e) Â Â Â Â Â Â Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. Â (f) Â Â Â Â Â Â Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (a) personal delivery to the party to be notified, (b) when sent by confirmed telex, electronic transmission or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt, and shall be addressed to the party to be notified as follows: Â If to Warrantholder: Â Â With a copy to (which shall not constitute notice): Â 6 Â Â If to the Company: Â Firefly Neuroscience, Inc. 1100 Military Road Kenmore, NY Â With a copy to (which shall not constitute notice): Â Haynes and Boone, LLP 30 Rockefeller Plaza New York, New York 10112 Attn: Rick A. Werner, Esq. E-mail: rick.werner@haynesboone.com Â or to such other address as each party may designate for itself by like notice. Â (g) Â Â Â Â Â Â Entire Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. Â (h) Â Â Â Â Â Â Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. Â (i) Â Â Â Â Â Â No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. Â (j) Â Â Â Â Â Â No Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Warrantholder at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions thereafter during the term of this Agreement. Â (k) Â Â Â Â Â Â Survival. All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. Â (l) Â Â Â Â Â Â Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. Â 7 Â Â (m) Â Â Â Â Â Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in the State of New York, Borough of Manhattan. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in the State of New York, Borough of Manhattan; (b) waives any objection as to jurisdiction or venue in the State of New York, Borough of Manhattan; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 10(f) and shall be deemed effective and received as set forth in Section 10(f). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. Â (n) Â Â Â Â Â Â Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes arising under or in connection with this Agreement be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, â€œCLAIMSâ€) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY RELATING TO THIS AGREEMENT. This waiver extends to all such Claims, including Claims that involve persons or entities other the Company and Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement. Â (o) Â Â Â Â Â Â Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts (including by facsimile or electronic delivery (PDF)), and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Â (p) Â Â Â Â Â Â Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. Â (q) Â Â Â Â Â Â Legends. To the extent required by applicable laws, this Warrant and the shares of Common Stock issuable hereunder (and the securities issuable, directly or indirectly, upon conversion of such shares of Common Stock, if any) may be imprinted with a restricted securities legend in substantially the following form: Â THIS SECURITY MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE SECURITIES ACT OF 1933, AS AMENDED AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. Â [Remainder of Page Intentionally Left Blank] Â 8 Â Â IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers thereunto duly authorized as of the Effective Date. Â Â COMPANY: FIREFLY NEUROSCIENCE, INC. Â Â Â By: ________________________________ Â Name: ________________________________ Â Title: ________________________________ Â Â Â WARRANTHOLDER: [_________] Â Â Â By: ________________________________ Â Name: ________________________________ Â Title: ________________________________ Â Â Â [Signature Page to Warrant] Â 9 Â Â EXHIBIT I Â NOTICE OF EXERCISE Â To:Â Firefly Neuroscience, Inc. Â (1) The undersigned Warrantholder hereby elects to purchase _______ shares of Common Stock of Firefly Neuroscience, Inc., pursuant to the terms of the Warrant Agreement dated the 12th day of August, 2024 (the â€œAgreementâ€) between Firefly Neuroscience, Inc. and the Warrantholder, and tenders herewith payment of the full Purchase Price in cash, together with all applicable transfer taxes, if any. Â (2) Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below. Â Â Â ________________________________ Â (Name) Â Â Â ____________________________________ Â (Address) Â Â Â Â WARRANTHOLDER: [_________] Â Â Â By:________________________________ Â Name:________________________ Â Title:________________________________ Â Â Â Â EXHIBIT II Â 1.Â ACKNOWLEDGMENT OF EXERCISE Â The undersigned [ ], hereby acknowledge receipt of the â€œNotice of Exerciseâ€ from [â€¢], to purchase [ ] shares of Common Stock of Firefly Neuroscience, Inc., pursuant to the terms of the Warrant, and further acknowledges that [ ] shares remain subject to purchase under the terms of the Warrant. Â Â COMPANY: FIREFLY NEUROSCIENCE, INC. Â Â Â By:___________________________ Â Title:_________________________ Â Date:___________________________ Â Â Â Â EXHIBIT III Â TRANSFER NOTICE Â (To transfer or assign the foregoing Warrant execute this form and supply required information. Do not use this form to purchase shares.) Â FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby transferred and assigned to Â Â (Please Print) Â Â Â whose address is Â Â Â Â Â Â Dated: Â Â Â Â Â Holderâ€™s Signature: Â Â Â Â Â Holderâ€™s Address: Signature Guaranteed: Â Â Â Â Â Â NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. Â Â EX-23.1 5 ex_727576.htm EXHIBIT 23.1 ex_727576.htm Exhibit 23.1 Â Â Your Vision Our Focus Â Â Â Â CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Â Â Â We hereby consent to the use in this Registration Statement on Form S-1 (the â€œRegistration Statementâ€) of our report dated May 22, 2024, relating to the consolidated financial statements of Firefly Neuroscience, Inc. (the â€œCompanyâ€) as of and for the years ended December 31, 2023 and 2022, which includes an explanatory paragraph relating to the Companyâ€™s ability to continues as a going concern. Â We also consent to the reference to our firm under the heading â€œExpertsâ€ included in such Registration Statement. /s/ Turner, Stone & Company, L.L.P. Dallas, Texas Â September 26, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Turner, Stone & Company, L.L.P. Accountants and Consultants 12700 Park Central Drive, Suite 1400 Dallas, Texas 75251 Telephone:972-239-1660 â„ Facsimile: 972-239-1665 Toll Free: 877-853-4195 Web site: turnerstone.com Â INTERNATIONAL ASSOCIATION OF ACCOUNTANTS AND AUDITORS Â Â EX-FILING FEES 6 ex_727371.htm EXHIBIT FILING FEES ex_727371.htm Â Exhibit 107 Â Calculation of Filing Fee Tables Â Form S-1 Â Firefly Neuroscience, Inc. Â Table 1: Newly Registered and Carry Forward Securities Â Â Â Security Type Â Security Class Title Â Fee Calculation or Carry Forward Rule Â Amount Registered (1) Â Â Proposed Maximum Offering Price Per Unit Â Â Maximum Aggregate Offering Price Â Fee Rate Â Â Amount of Registration Fee Â Â Â Newly Registered Securities Â Fees to Be Paid Â Equity Â Common Stock, par value $0.0001 per share Â Rule 457(c) Â 2,559,645 (2) Â $3.485 (3) Â $ 8,920,362.83 Â Â Â $0.0001476 Â Â $ 1,316.65 Â Fees Previously Paid Â Carry Forward Securities Â Carry Forward Securities Â Total Offering Amounts Â Â Â Â Â $ 8,920,362.83 Â Â Â Â Â Â $Â 1,316.65 Â Â Â Total Fees Previously Paid Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€” Â Â Â Total Fee Offsets Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€” Â Â Â Net Fee Due Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,316.65 Â Â (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), the shares being registered hereunder include such indeterminate number of shares of common stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. Â (2) Represents (i) 209,613 shares of common stock, par value $0.0001 per share (the â€œCommon Stockâ€) issued upon the conversion of shares of Series C Preferred Stock, par value $0.0001 per share, to investors that participated in certain in private placements; (ii) 461,372 shares of Common Stock previously issued by the Company to certain shareholders after February 6, 2024, the effectiveness date of the Registration Statement on Form S-4, filed in connection with that certain Agreement and Plan of Merger, dated as of November 15, 2023 (as amended, the â€œMerger Agreementâ€Â and the transactions contemplated thereunder and consummated on August 12, 2024, the â€œMergerâ€); (iii) 319,207 shares of Common Stock issued to the investors in a private placement transaction, pursuant to that certain Securities Purchase Agreement, dated as of July 26, 2024, by and among the Company and each of the purchasers thereto; (iv) 504,323 shares of Common Stock issuable upon the exercise of certain pre-funded warrants; (v) 823,530 shares of Common Stock issuable upon the exercise of certain warrants; (v) 168,071 shares of Common Stock issuable upon the exercise of the Series C Warrants; (vi) 61,866 shares of Common Stock issuable upon the exercise of certain Series D Warrants; and (vii) 11,663 shares of Common Stock issuable upon the exercise of warrants issued to certain brokers as compensation in connection with certain transactions. Â (3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low prices of the Common Stock as quoted on the Nasdaq Capital Market on September 25, 2024, of $3.485 per share, which such date is within five business days of the filing of this registration statement. Â Â Â EX-101.SCH 7 aiff-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 008 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 009 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) link:calculationLink link:definitionLink link:presentationLink 010 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 1 - Business Description link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 2 - Going Concern link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 4 - Other Receivables link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 5 - Equipment link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 6 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 7 - Liability for Employee Rights Upon Retirement link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 8 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 9 - Equity link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 11 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 12 - Revenue link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 13 - Research and Development Expenses link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 14 - Selling and Marketing Expenses link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 15 - General and Administration Expenses link:calculationLink link:definitionLink

link:presentationLink 026 - Disclosure - Note 16 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 1 - Business Description link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 2 - Going Concern link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 4 - Other Receivables (10K) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 5 - Long Term Deposits link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 6 - Intangible Assets (10K) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Convertible Notes link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 8 - Deferred Revenue link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 9 - Liability for Employee Rights Upon Retirement link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 10 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 11 - Equity link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 12 - Basic and Diluted Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 13 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 14 - Revenue link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 15 - Research and Development Expenses link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 16 - Selling and Marketing Expenses link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 17 - General and Administration Expenses link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 18 - Other (Income) Expense link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 19 - Income Tax link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 20 - Revision of Prior Period Financial Statements link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 21 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 4 - Other Receivables (Tables) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 5 - Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 6 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 9 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 12 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 13 - Research and Development Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 14 - Selling and Marketing Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 15 - General and Administration Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 4 - Other Receivables (10K) (Tables) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 6 - Intangible Assets (10K) (Tables) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 8 - Deferred Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 11 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 14 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 15 - Research and Development Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 16 - Selling and Marketing Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 17 - General and Administration Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 18 - Other (Income) Expense (Tables) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 19 - Income Tax (Tables) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 20 - Revision of Prior Period Financial Statements (Tables) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 1 - Business Description (Details Textual) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 2 - Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note 4 - Other Receivables - Details of Other Receivables (Details) link:calculationLink link:definitionLink link:presentationLink 073 - Disclosure - Note 5 - Equipment - Summary of Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 074 - Disclosure - Note 6 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 075 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 076 - Disclosure - Note 7 - Liability for Employee Rights Upon Retirement (Details Textual) link:calculationLink link:definitionLink link:presentationLink 077 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 078 - Disclosure - Note 9 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 079 - Disclosure - Note 9 - Equity - Schedule of Shares Authorized and Issued (Details) link:calculationLink link:definitionLink link:presentationLink 080 - Disclosure - Note 9 - Equity - Schedule of Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 081 - Disclosure - Note 9 - Equity - Schedule of Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 082 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 083 - Disclosure - Note 11 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 084 - Disclosure - Note 12 - Revenue - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 085 - Disclosure - Note 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 086 - Disclosure - Note 14 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 087 - Disclosure - Note 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 088 - Disclosure - Note 16 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink 089 - Disclosure - Note 1 - Business Description (Details Textual) link:calculationLink link:definitionLink link:presentationLink 090 - Disclosure - Note 2 - Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 091 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 092 - Disclosure - Note 4 - Other Receivables - Details of Other Receivables (10K) (Details) link:calculationLink link:definitionLink link:presentationLink 093 - Disclosure - Note 5 - Long Term Deposits (Details Textual) link:calculationLink link:definitionLink link:presentationLink 094 - Disclosure - Note 6 - Intangible Assets (10K) (Details Textual) link:calculationLink link:definitionLink link:presentationLink 095 - Disclosure - Note 6 - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 096 - Disclosure - Note 7 - Convertible Notes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 097 - Disclosure - Note 8 - Deferred Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 098 - Disclosure - Note 8 - Deferred Revenue - Schedule of Deferred Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 099 - Disclosure - Note 9 - Liability for Employee Rights Upon Retirement (Details Textual) link:calculationLink link:definitionLink link:presentationLink 100 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 101 - Disclosure - Note 11 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 102 - Disclosure - Note 11 - Equity - Schedule of Shares Authorized and Issued (Details) link:calculationLink link:definitionLink link:presentationLink 103 - Disclosure - Note 11 - Equity - Schedule of Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 104 - Disclosure - Note 11 - Equity - Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 105 - Disclosure - Note 11 - Equity - Schedule of Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 106 - Disclosure - Note 13 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 107 - Disclosure - Note 14 - Revenue - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 108 - Disclosure - Note 15 - Research and Development Expenses -Schedule of Research and Development Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 109 - Disclosure - Note 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 110 - Disclosure - Note 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 111 - Disclosure - Note 18 - Other (Income) Expense (Details Textual) link:calculationLink link:definitionLink link:presentationLink 112 - Disclosure - Note 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details) link:calculationLink link:definitionLink link:presentationLink 113 - Disclosure - Note 19 - Income Tax (Details Textual) link:calculationLink link:definitionLink link:presentationLink 114 - Disclosure - Note 19 - Income Tax - Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 115 - Disclosure - Note 19 - Income Taxes - Deferred Tax Assets (Details) link:calculationLink link:definitionLink link:presentationLink 116 - Disclosure - Note 19 - Income Taxes - Operating Loss Carryforwards (Details) link:calculationLink link:definitionLink link:presentationLink 117 - Disclosure - Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details) link:calculationLink link:definitionLink link:presentationLink 118 - Disclosure - Note 21 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 aiff-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 aiff-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 aiff-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield us-gaap_OtherReceivables Total Note To Financial Statement Details Textual Significant Accounting Policies Note 4 - Other Receivables Statutory income tax recovery Note 5 - Equipment Risk free rate Note 6 - Intangible Assets Note 9 - Equity Note 12 - Revenue Note 13 - Research and Development Expenses Note 14 - Selling and Marketing Expenses Note 15 - General and Administration Expenses Income Tax Disclosure [Text Block] Note 3 - Basis of Presentation and Summary of Significant Accounting Policies Note 4 - Other Receivables (10K) Note 6 - Intangible Assets (10K) Note 8 - Deferred Revenue Expected volatility Note 11 - Equity Total current liabilities Total current liabilities Note 14 - Revenue Note 15 - Research and Development Expenses Note 16 - Selling and Marketing Expenses Note 17 - General and Administration Expenses Expected term (in years) (Year) Note 18 - Other (Income) Expense Note 19 - Income Tax Note 20 - Revision of Prior Period Financial Statements Note 4 - Other Receivables - Details of Other Receivables (Details) Note 5 - Equipment - Summary of Equipment (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 6 - Intangible Assets - Summary of Intangible Assets (Details) Note 9 - Equity - Schedule of Shares Authorized and Issued (Details) Note 9 - Equity - Schedule of Warrants (Details) Note 9 - Equity - Schedule of Option Activity (Details) Note 12 - Revenue - Disaggregation of Revenue (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details) Note 14 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details) Note 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details) us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details) Note 4 - Other Receivables - Details of Other Receivables (10K) (Details) Note 6 - Intangible Assets - Schedule of Intangible Assets (Details) Note 8 - Deferred Revenue - Schedule of Deferred Revenue (Details) Note 11 - Equity - Schedule of Shares Authorized and Issued (Details) Note 11 - Equity - Schedule of Warrants (Details) Note 11 - Equity - Assumptions (Details) Note 11 - Equity - Schedule of Option Activity (Details) Note 14 - Revenue - Disaggregation of Revenue (Details) Note 15 - Research and Development Expenses -Schedule of Research and Development Expenses (Details) Note 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details) Note 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details) Note 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details) Note 19 - Income Tax - Provision for Income Taxes (Details) Note 19 - Income Taxes - Deferred Tax Assets (Details) Note 19 - Income Taxes - Operating Loss Carryforwards (Details) Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Outstanding Options, weighted average contractual term (Year) Outstanding Options, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Options granted, grant date fair value (in dollars per share) Options vested, grant date fair value (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Non-Vested Options, grant date fair value (in dollars per share) Non-Vested Options, grant date fair value (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares) Options vested (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Non-Vested Options (in shares) Non-Vested Options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding Options, exercise price (in dollars per share) Outstanding Options, exercise price (in dollars per share) Error Correction [Text Block] Deferred revenue Goodwill and Intangible Assets Disclosure [Text Block] Options granted, exercise price (in dollars per share) Accrued liabilities Accrued liabilities Related party payable us-gaap_ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding Options (in shares) Outstanding Options (in shares) Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Proceeds from sale of equipment us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of equipment Expected life (in years) (Year) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Cash paid for income taxes Trade payables Current liabilities Supplemental cash flow information us-gaap_Assets TOTAL ASSETS us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Other Assets Disclosure [Text Block] Computer Software, Intangible Asset [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Business Description and Basis of Presentation [Text Block] Award Type [Domain] Basis of Presentation and Significant Accounting Policies [Text Block] Award Type [Axis] Net (loss) income NET LOSS AND COMPREHENSIVE LOSS Intangible assets, accumulated amortization Intangible assets, net us-gaap_FiniteLivedIntangibleAssetsNet Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Intangible assets, gross Share-Based Payment Arrangement, Option [Member] Warrant [Member] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_PreferredStockConvertibleConversionRatio Preferred Stock, Convertible, Conversion Ratio Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less â€“ accumulated depreciation Equipment, net Equipment, net Property, plant and equipment gross Canada Revenue Agency [Member] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] CASH FLOWS FROM INVESTING ACTIVITIES: Earnings Per Share [Text Block] Convertible Debt [Member] us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest NET LOSS AND COMPREHENSIVE LOSS us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction CANADA Related Party Transactions Disclosure [Text Block] Change in accrued liabilities Income tax provision Income tax expense (recovery) Income tax provision Change in related party payables Total operating expenses TOTAL OPERATING EXPENSES Change in trade payables Travel Travel expenses Other General and administration expenses General and administration expenses Total Cash Salary and employee benefits Salary and employee benefits us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense Amendment Flag aiff_ProceedsFromIssuanceOfUnits Proceeds From Issuance of Units The amount of cash inflow from the issuance of units. aiff_UnitsIssuedDuringPeriodNumberOfSharesPerUnit Units Issued During Period, Number of Shares Per Unit (in shares) The number of shares issued per unit issued. aiff_UnitsIssuedDuringPeriodNewIssues Units Issued During Period, New Issues (in shares) The number of units issued during the period. Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] ISRAEL Tax Year 2035 [Member] Relating to tax year 2035. Tax Year 2037 [Member] Relating to tax year 2037. aiff_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Fair Value The grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Tax

Year 2036 [Member] Relating to tax year 2036. us-gaap_GainLossOnSaleOfPropertyPlantEquipment Net gain from sale of equipment Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding (in shares) Unit Warrants [Member] Related to units warrants. Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding (in shares) Tax Year 2034 [Member] Relating to tax year 2034. Indefinite Tax Year [Member] Relating to an indefinite tax year. Tax Year 2042 [Member] Relating to tax year 2042. R. I. Mind Group Ltd. [Member] Relating to R.I. Mind Group Ltd. us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Tax Year 2039 [Member] Relating to tax year 2039. Tax Year 2038 [Member] Relating to tax year 2038. Tax Year 2041 [Member] Relating to tax year 2041. Tax Year 2040 [Member] Relating to tax year 2040. Medical Equipment [Member] Represents the medical equipment. Selling and Marketing Expenses [Text Block] The entire disclosure relating to selling and marketing expenses. Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Schedule of Selling and Marketing Expenses [Table Text Block] Tabular disclosure of the entity's selling and marketing expenses. General and Administrative Expenses [Text Block] The entire disclosure relating to general and administrative expenses. Rent and maintenance Amount of expense for rent and maintenance during the period. us-gaap_DividendsStock Stock dividend paid Schedule of General and Administrative Expenses [Table Text Block] Tabular disclosure of the entity's general and administrative expenses. us-gaap_IncreaseDecreaseInPrepaidExpense Change in prepaid expenses Consultants and subcontractors Represents the amount of consulting and subcontracting expense incurred during the period. Clinical trials Represents the amount of expense from clinical trials incurred during the period. Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Schedule of Research and Development Expenses [Table Text Block] Tabular disclosure of the entity's research and development costs. Entity Small Business Less â€“ grants received Represents the amount of grants received for research and development. aiff_ResearchAndDevelopmentExpenseGross Research and Development Expense, Gross Represents the amount of research and development expense before grants received. Details of Other Receivables [Table Text Block] The tabular disclosure pertaining to the other receivables. Document Information [Line Items] Conversion of Director Notes Into Common Stock [Member] Relating to conversion of director notes into common stock. Document Information [Table] aiff_OtherReceivablesAllowanceForCreditLosses Allowance for doubtful receivables The amount of the allowance for credit losses related to the other receivables. Service [Member] Other receivables aiff_OtherReceivablesBeforeAllowanceForCreditLosses The total amount of other receivables before the allowance for credit losses. Entity Filer Category Debt Instrument [Axis] Consulting Fees [Member] Relating to consulting fees. Debt Instrument, Name [Domain] aiff_MonthlyDepositRatePercentOfSalary Monthly Deposit Rate, Percent of Salary The percentage of salary the monthly deposit rate is set at. Series C Preferred Unit Warrants [Member] Relating to Series C Preferred Unit Warrants. Conversion of Series B Preferred Stock to Common Stock [Member] Relating to the conversion of Series B Preferred stock to common stock. aiff_PreferredStockMandatoryConversionFeatureOfferingProceedsThreshold Preferred Stock, Mandatory Conversion Feature, Offering Proceeds Threshold Represents the offering proceeds threshold to trigger a mandatory conversion feature for preferred stock. August 2022 Securities Purchase Agreement Warrants [Member] Relating to August 2022 securities purchase agreement warrants. Securities Purchase Agreement [Member] Relating to securities purchase agreement. us-gaap_IncreaseDecreaseInOtherReceivables Change in other receivables aiff_ClassOfWarrantOrRightCombinedPurchasePrice Class of Warrant or Right, Combined Purchase Price (in dollars per share) Represents the combined purchase price for a warrant or right. Convertible Debt and Stock Warrants [Member] Relating to convertible debt and stock warrants. Stock dividend paid us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Impairment loss on equipment Tranche B Warrants [Member] Relating to Tranche B warrants. aiff_NoncashWarrantsIssued Noncash Warrants Issued (in shares) Represents the number of noncash warrants issued. Warrants issued WPC Warrants [Member] Relating to WPC warrants. aiff_PreferredStockMandatoryConversionFeatureCompanyValuation Preferred Stock, Mandatory Conversion Feature, Company Valuation Represents the minimum company valuation in order for a mandatory conversion feature to be exercisable for preferred stock. aiff_SharesAuthorized Shares Authorized (in shares) Represents the number of shares authorized. Share-based compensation expense Tranche A Warrants [Member] Relating to Tranche A warrants. Entity Tax Identification Number aiff_ClassOfWarrantOrRightExercisePricePurchasePriceNumerator Class of Warrant or Right, Exercise Price, Purchase Price Numerator Represents the purchase price numerator for an exercise price on a warrant or right. Entity Central Index Key Warrants issued pursuant to modification of convertible debt (in shares) Represents the number of warrants or rights modified during the period. Entity Registrant Name Outstanding warrants, January 1, 2024 (Year) Represents the weighted average remaining life of warrants or rights. Warrants issued pursuant to modification of convertible debt (in dollars per share) Represents the exercise price of warrants or rights modified during the period. Entity [Domain] Series A Warrants [Member] Relating to Series A warrants. Legal Entity [Axis] aiff_WarrantsOrRightsIssued Warrants or Rights Issued (in shares) Represents the number of warrants or rights issued. Warrants issued pursuant to units offering (in dollars per share) Represents the exercise price of warrants or rights issued during the period. Warrants issued pursuant to units offering (in shares) Class of Warrant or Right, Warrants Issued During Period (in shares) Represents the number of warrants issued during the period. WPC and Origa [Member] Relating to Windsor Private Capital Ltd. Partnership and Origa Two Holdings Inc. Pasithea Clinics Inc. [Member] Relating to Pasithea Clinics Inc. aiff_DebtInstrumentExtensionFeePercentage Debt Instrument, Extension Fee Percentage Represents the extension fee percentage for a debt instrument. Side Letter [Member] Relating to a Side letter. IIA Royalty Commitment [Member] Relating to the IIA Royalty Commitment. aiff_ResearchAgreementRoyaltyPercentage Research Agreement, Royalty Percentage Represents the royalty percentage of a research agreement. Deferred Revenue [Text Block] The entire disclosure for deferred revenue. aiff_ContributionsToSeveranceCompensationAct Contributions to Severance Compensation Act Represents the amount of contributions to the Severance Compensation Act. Convertible Debt Issued to Various Investors [Member] Relating to convertible debt issued to various investors. Common Stock, Number of Shares to be Issued [Member] Represents the number of common shares to be issued. aiff_SharesToBeIssued Shares To Be Issued (in shares) Balance (in shares) Balance (in shares) The number of shares to be issued. Depreciation and amortization Phyto IV LP [Member] Relating to Phyto IV LP. Share repurchase Conversion of Debt and Interest Into Common Stock [Member] Relating to the conversion of debt and interest into common stock. Share repurchase (in shares) Stock Repurchased and Retired During Period, Shares (in shares) Share repurchase (in shares) Preferred Stock, Number of Shares to be Issued [Member] Represents the number of preferred shares to be issued. Series A Performance Warrants [Member] Represents the series a performance warrants. Change in long term deposits The increase (decrease) in long-term deposits. Series B Preferred Stock offering (in shares) The number of shares to be issued during the period. Professional fees Professional fees Common Stock Private Placement (in shares) The number of shares to be issued under the private placement. Stock dividend paid (in shares) aiff_PaymentsForProductEnhancements Product enhancement â€“ intangible asset The amount paid for the purchase of product enhancements. Common Stock Private Placement The value of the shares issued under the private placement. Series B Preferred Stock conversion (in shares) Common Stock, Private Placement [Member] Represents a common stock private placement. Series C Preferred Stock Offering [Member] Represents a series C preferred stock offering. us-gaap_CommonStockDividendsShares Common Stock Dividends, Shares (in shares) Series B Preferred Stock Offering [Member] Represents a series B preferred stock offering. Common Stock Warrants [Member] Relating to common stock warrants. Secured Promissory Notes [Member] Relating to secured promissory notes. Series C Preferred Stock Units offering Debt conversion Debt conversion (in shares) us-gaap_TableTextBlock Notes Tables Gain on sale of equipment Gain (Loss) on Disposition of Assets Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Share-based expense (in shares) Bad debts aiff_OtherIncomeExpenseNonoperating Other Represents the amount of nonoperating income (expense). Share-based expense Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_OtherSellingAndMarketingExpense Other us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares) Selling and marketing expenses Total Line of Credit Facility, Lender [Domain] Series C Preferred Stock Units offering (in shares) Stock Issued During Period, Shares, New Issues (in shares) us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services (in shares) Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY (DEFICIT) UNITED STATES Series B Preferred Stock offering Related Party Transaction [Axis] Related Party Transaction [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Research and development expenses Research and development expenses Total Noncurrent assets us-gaap_AssetsNoncurrent Total non current assets Debt Disclosure [Text Block] Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Substantial Doubt about Going Concern [Text Block] Subsequent Event [Member] Non-cash interest on convertible debt Subsequent Event Type [Axis] Subsequent Event Type [Domain] Unrealized gain on foreign exchange Unrealized (gain) loss on foreign exchange Retirement Benefits [Text Block] Subsequent Events [Text Block] Long term deposits Share-based compensation expense us-gaap_ShareBasedCompensation us-gaap_DebtConversionConvertedInstrumentAmount1 Debt converted to equity us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Debt Conversion Description [Axis] REVENUE Revenues Debt Conversion, Name [Domain] OPERATING EXPENSES: us-gaap_AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_ConversionOfStockAmountConverted1 Converted shares of common stock us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Converted shares of common stock (in shares) Depreciation Intangible Assets Disclosure [Text Block] us-gaap_ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted (in shares) Series B Preferred Stock conversion (in shares) us-gaap_SharesIssued Shares, Issued (in shares) Balance (in shares) Balance (in shares) us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] us-gaap_AssetsCurrent Total current assets Non current assets Equity [Text Block] Expenses - other Common shares, $0.00001 par value: 2,470,000,000 shares authorized; 49,948,710 and 35,369,877 issued and outstanding at June 30, 2024 and December 31, 2023, respectively Adjustments to reconcile net loss to net cash used in operating activities Shares of common stock authorized (in shares) Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) Shares of common stock issued (in shares) Common stock, shares issued (in shares) Common Stock, Shares, Issued (in shares) Common stock, par value (in dollars per share) Revision of Prior Period [Axis] Revision of Prior Period [Domain] Previously Reported [Member] Revision of Prior Period, Adjustment [Member] us-gaap_DeferredTaxAssetsValuationAllowance Valuation Allowances for deferred tax assets Ownership [Domain] Product and Service [Axis] Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Net deferred tax assets Ownership [Axis] Preferred shares, $0.00001 par value: 30,000,000 shares authorized; 2,374,219 and 16,116,957 issued and outstanding at June 30, 2024 and December 31, 2023, respectively Shares of preferred stock issued (in shares) Preferred stock, shares issued (in shares) Cash paid for interest Prepaid expenses Reserves and others Property, Plant and Equipment Disclosure [Text Block] Geographical [Axis] Property, Plant and Equipment [Table Text Block] Geographical [Domain] us-gaap_DeferredTaxAssetsGross Deferred Tax Assets, Gross Shares of preferred stock authorized (in shares) Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Preferred stock, par value (in dollars per share) R&D expenditures Customer [Axis] Customer [Domain] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Change in deferred revenue CASH FLOWS FROM OPERATING ACTIVITIES: us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Statement [Line Items] Additional paid-in capital Stock option SHAREHOLDERSâ€™ EQUITY (DEFICIT) us-gaap_OtherNonoperatingExpense Other expense, net Other income (expenses) Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total Long-Lived Tangible Asset [Domain] Current assets Interest and bank fees Interest, bank fees and loan fees us-gaap_DepositAssets Deposit Assets us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations BALANCE OF CASH AT THE BEGINNING OF PERIOD BALANCE OF CASH AT THE END OF PERIOD Non-capital loss carry-forwards from US Non-capital loss carry-forwards from foreign entity Private Placement [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect (DECREASE) INCREASE IN CASH us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Total liabilities TOTAL LIABILITIES us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price COMMITMENTS AND CONTINGENCIES (Note 8) Director [Member] Sale of Stock [Axis] Sale of Stock [Domain] Executive Officer [Member] us-gaap_OperatingIncomeLoss OPERATING LOSS Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Revenue recognized Contract with Customer, Liability, Revenue Recognized OTHER INCOME (EXPENSE) us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] us-gaap_ContractWithCustomerLiability Contract with Customer, Liability Other Nonoperating Income and Expense [Text Block] Schedule of Other Nonoperating Income (Expense) [Table Text Block] us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs us-gaap_AccountsPayableCurrentAndNoncurrent Accounts Payable Reverse Stock Split [Member] Relating to a reverse stock split. Proceeds from sale of shares Proceeds from Issuance or Sale of Equity Retained Earnings [Member] us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock Additional Paid-in Capital [Member] Common Stock [Member] Preferred Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-Term Debt Schedule of Stock by Class [Table Text Block] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Exercise price (in dollars per share) Exercise price (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Outstanding warrants, January 1, 2024 (in shares) Outstanding warrants, June 30, 2024 (in shares) Loss before Income Tax LOSS BEFORE INCOME TAX us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Israel Tax Authority [Member] Firefly [Member] Relating to Firefly. us-gaap_ConvertibleDebt Convertible Debt Timing of Transfer of Good or Service [Domain] Income Tax Authority, Name [Axis] Transferred at Point in Time [Member] Income Tax Authority, Name [Domain] Transferred over Time [Member] Internal Revenue Service (IRS) [Member] Disaggregation of Revenue [Table Text Block] Timing of Transfer of Good or Service [Axis] Revenue from Contract with Customer [Text Block] Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] us-gaap_OpenTaxYear Open Tax Year Selling and Marketing Expense [Member] Related Party [Member] Merger Reverse Stock Split [Member] Relating to the merger reverse stock split. Proceeds from sale of convertible debt Research and Development Expense [Member] us-gaap_ProceedsFromIssuanceOfSecuredDebt Proceeds from Issuance of Secured Debt Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Nonmonetary Transaction Type [Domain] Tax Period [Domain] Nonmonetary Transaction Type [Axis] Tax Period [Axis] us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount Research Tax Credit Carryforward [Member] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Operating Loss Carryforwards Summary of Operating Loss Carryforwards [Table Text Block] Statement [Table] us-gaap_MinorityInterestOwnershipPercentageByParent Subsidiary, Ownership Percentage, Parent Statement of Financial Position [Abstract] WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED (in shares) Business Acquisition [Axis] BASIC AND DILUTED LOSS PER SHARE (in dollars per share) Business Acquisition, Acquiree [Domain] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] aiff_OwnershipPercentageFormerShareholders Ownership Percentage, Former Shareholders The percent of ownership from former shareholders. aiff_ExchangeRatio Exchange Ratio The exchange ratio related to the merger agreement. PIPE Share With Accompanying Warrant [Member] Represents the PIPE Share With Accompanying Warrant Pre-Funded Warrants [Member] Represents the prefunded warrants. aiff_PurchasePriceOfSharesWithAccompanyingWarrants Purchase Price Of Shares With Accompanying Warrants (in dollars per share) The price per share accompanying warrants Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_OtherCommitment Other Commitment New Firefly Common Stock [Member] Represents the New Firefly Common Stock Former

Firefly 2023 Stockholders [Member] Represents the former firefly 2023 stockholders Former Firefly Stockholders [Member] Represents the former firefly stockholders Other Commitments [Axis] Other Commitments [Domain] CASH FLOWS FROM FINANCING ACTIVITIES: Statutory income tax rate Change in valuation allowance Taxable capital gain on sale of investment and equipment Series C Preferred Stock [Member] Series A Preferred Stock [Member] Research, Development, and Computer Software Disclosure [Text Block] Series B Preferred Stock [Member] Total shareholdersâ€™ deficit TOTAL SHAREHOLDERSâ€™ EQUITY (DEFICIT) Balance Balance Class of Stock [Axis] Class of Stock [Domain] Non-deductible option expenses US state tax Other receivables Difference in foreign tax rates EX-101.PRE 11 aiff-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 inaagroup01.jpg begin 644

inaagroup01.jpg M_]C_X 02D9)1@ ! 0$!2@%* #_X0 B17AI9@ 34T *@ @ 0$2 , M ! $ #_VP!# (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8' M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,#
S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# S_P 1" F &0# 2(A$! Q$!_\0 'P 04! 0$! M 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%! 0 %]
0(# M 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B7J#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN'BX^3EYN?
HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 M $" P0%!@<("0H+_\0 M1$ @$" @$ 0$! 0 0)W $" Q$$!2$Q!A)! M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y M.D-
$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$
/P#X+J.Z_P"/:3_=/\JDJ.Z_ MX]I/]T_RK^V#^08[H_J@_9 TN'6?V+OA?:W"EX9O!VE(ZABN0;.+N,$?@:\' M_9Y\._VS_P %"/B5X;O-3\07>@^'+<7&G:?-K%R]O;NS0_PE^0-S8!R!FO?_ M -
BS_DSWX5?]BAI/_I'%7B'[,_\ RD^^,O\ UX)_Z%!7\3YC_O+_,3@_%/Z M\R[_'9?X5^A3\,_ZHVGMKQ;5XBV(":>+O!?QA\-ZS\--3UVUUA;"\UJ\T^GMKQ;5XBV(" MQ5F(E.4 PP'3.*]V_99_:]T:]ZQO9A;>^0?9]5\+\ ;>V^ZC^+]+SZ
\UG,1R/78PR5;N/ M<'%7QW_R>/\ #S_L ZQ_Z%%%%%)G%,&%%@%%%%)%%%%,%:UX+S6^CF11, M1]J)Q!D/J#>[)YQ7/8D=V$O+:BP-Y2'_YX5[B2TI2F;CJ[K)N8=FLJ*X[7?R MNU^XM-
"33)=.LKC5KB6ULGGBD>0K&SD')48!R!SBOUNU\-:)>:C?3+;V= MA]S/*W2.-%+Q^@!KQ7]EOXD:3K9:)-$\7?C9\2\$/FAW*W>EZK9:)-$XC- M$X0\O\ H\VY M&'\+J<@CL14_[9OC'SM-VP]ZDF0I6\JMYFI5M[A]RJEAA!^/LTRMA5@NNAQHAT[P7DC[XN<S/Jc!ZV7@ZMZT/EACQX_\HPI^<[9"B=RPEC#'<;&<=&TC9O.@2K^Z7J9Z<P7D! M*@2A*B<8D<O*JX;*W)3+S8/Y,+`*E5X2!26Q%64)S@H@F1F12VH3I"
@>WL]6U23Q9>!]3MM,@\^Z&EP,KW!"9'"9#DQQ9J>#$M<ZW4`R4JJJ5Y8.\DYKHAPZBI9Z>/RP_7Z^>^_)A`5&2(Z^*(-6ZE9`8W4@;9=`Z4-TAZQ3:7`8AC\A\%\U`15%8UR/ROJXY%;U%B`3RFV[B`*H@`M'D9(F8R2.^C&FT8&38&M`=6WBYX$8:1Q\M\V:&&2?V$ZNK9D@[!$L3TYPU<]N^2;M@@RTVBN`+AL8]I4=>:E7.3P:WJNMPMJEJ;I`UVN^,L]^XCBT`7VCD@K8)W/1=@7!S,\E5V:,2DTCWF`1?O.QO1>TXYSPwDY]RWTTV-0-Y_[LL+]PMJM>J'Q]%9`]H5B3C5R:@JR7B4L\+L9H6ZIX_6TVU?^=.H_TXW0XZR>ZS1CUOg_VkMmHXh6&F;4a6h/b5TIoKpHbL4GbsYQGbS3JiP6Oq66kx`

~~:P/B6D?]MV93F5H,, .VXX_K7HF MEZ4?#_AC3-&==L\,9GNA_P!-Y,,P/^Z-J_A0Y>Z-+WB:I((S-<1QJ,L[!0![MFHZVO"-C]O\ %-E&1E4?S&]@O/\ 3%8K5FC/6;-=NHW07[L:11#\ 3_[,*O5 M3TP^9!+~~
~~<=?/E9P?4?=7]%%7*Z4P&YLY(E.'(RA]&'(/Y@5YKX^L=\]MK M$2;4NDV2C^[(O!!_+'X&O4:PM8TN*]AN-/G^6&]^>)S_,LYA_CU_P"^O6E) M71479GC=:EEIFI0PPZG#"ACR?+5W4&8#~~
~~[P"DY88R#3X; Q"_TV6!?[2W*L0< M@<_,%SQD\?AFM#7YETYM"B)CENK" &5%;(5MV0I([UA;J;7/!_'WA,>'M46 M[TY6;2+\E[9O^>3?Q0M[KGCU)JI9@J@LQ. ,DU]!3-;W]OJVZW-C> M',\ ^7!~~
~~[,A_A89X/X=*X?7-(O/ ^GK=:!IUM>V1X_M786DC/I(O\!_\ '3VK M:,KHS<;&;X;T&+08AKOB-A;B/F"!Q\V?7'KZ"N;\1:[-X@U)KB4;(E&V*//W M5_Q-5+_4[S5+CSK^X>=^VX\#Z#H*JTTM;L+]#V32?~~
~~C5I&I>#X?#?Q!\.G4;: M&)8EGMV&XA1@-@XPP'<&L0W/P>L[U+F&R\2WR*=WV65XU0^Q.V^U42>@^._C+JGBW2QHNFVD>C:,H"_9X6RTBCHK'@; M?8"LSP?HO]GD^(-9;[+;0~~
~~F(2#!Y6XE8YF*@G8YZ@GH>_(] MZDLM5.GWMO-:VMNL5HH2VMMO[N%1V_KUR<]:Z%+:UUC3[B3PLB07DO-S82D M$E1_SSSQC//K]*S?O;%+0X^N\\#:<]OI5SJ&,379^S6Q[\]6_#K_,!-<[!I~~
~~M?]JZI9:59(IFC79<3KT)R23]%!QGOBO4M,M(D:,6ZXM+-?)@_P!H]&;^G_?7 MK3@M0D]#3BB6&%(HQA$4*H] *=116QB%17-NEU;M%)D!NA!P5/8CW!YJ6B@# MA_%7AU]:A:6-5&JVJ?O$~~
~~P+A.S#W_P#U>E>;E2C%6&"#@@]J]XNK47*J58QS M1G,ERS2>3"L2$QSKCG(? 7AV^NY M$O;)M(O3R9M-8-$V>03$3CGK\I7Z5R=U\)+G=G2]?TVX7/2X#P,/S!'ZUWC,~~
~~M68LQ))ZDG.:VM,T^!/#][K-W&)A"ZPP1-]TN>[8Z@]*M39+BCQ\?"3Q#O(- MUHX7^_\ V@F#^'7]*NVGPD92#J_B&SA'=+.-YV_,A5_6O6-(M(-?M;VVD@BA MNX(#/!-"NS=CJK~~
~~<'Z]:Y_K0YL.5":#X"T[1[4ZAH>A3W\D/_+_?*)2I]5C' MRCZX;'K6J/+U#3KN23S9-2CQ(TDLF[=&#AL#L1QZ\9IWA_4;BSO6@@N7M_M2~~
~~M^6)%;&Q^J'Z9X/L36K!XHB^VC_A(])CEGC)5IX5\N3T(8=&[BE>^X[6V.4J> MR^TF\1;(,9WRB!!SR,UT>.2X0N=C%<87/!;TKT3P]X!2C%L')(7P[X?_+&M39QL#?SJ#=3+_P_L4_N@~~
~~M^I_^OV%=7'&D,2QQ*%1 %51V%,MK:.UA\N/)RY)[FI:W2L8MW"BBB MF(**** "HKBVBNH]DZ;@#D'H5/J#V-2T4 86J:/'>P>5JEM]OA7[LR#$T?\ M\5^'Y&N+O? ,K[Y-~~
~~"NX[M%ZQ.=DB^Q!_KBO4:@GLK>Y8--$I<=''##Z$VDT..[H0#^/>KFF:K##I-YI6H*_V6Y(=9(QEHI!T..XX M&17KILIU&(;URO\ ?8Y6N+NZB,*OLVK$AZGGGDD_I6*!Z5[!_PC5K_P!~~
~~+3<_]=V_^(JS!H_D M,/L]AIEL1_$L1<_R6ER,.='DVG:-JE]*C6-E++@@AMGR_B3Q75P^#));O[1X MHU%I)WY\B$F25_\ #\!BNY%A+(,7-Y*R_P!R(" -?TY_6K$%K!:J1;Q+'GJ0.~~
~~M3]3WJE!"U@&G6G=$/[V3_'F[?AD^XK5AACMXEBA141>BJ,4^ /BKM8S"BBBF 4444 ?__9 end GRAPHIC 16 tssig.jpg begin 644 tssig.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 L17AI9@ 34T *@ @~~
~~0$Q (M * &@ !''EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(R;GZ.GJ\?+S]/7V]_CY^O_$!\! ,! 0$! M 0$! 0$! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! M @,1!~~
~~4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D: M)BH*# MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3 MU-~~
~~76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** " MBJ]_J%GI=E)=ZE#'IZ;T0_[4 MGW%_.J@^'S:TRR^.]5FUQE.Y;1,P6J?]LU/S?5B:ZRPTZSTNS2TTVUAM;>,8 M6*% JC\!0!2T&?~~
~~7;F.:;Q!:6EEN(\BW@E,C(.<[VZ$].E:U%% !1110 4444 M %%9^K:]I6@VXGUG4;:RC)P#/(%W?0=Z;HOB'2O$5O+/HMXEW%$_ENZ X#8S MW'- &E1110 4444 %%%% !36EC21$>15=\~~
~~[%)P6QUP.].KS_,2WUE/\8O!] MHMQ$UQ MV[QHX9E)C& P'3.#UH] ILDB0QM)*ZHBC+,QP /4FG5Y_X@5_'O MBY_"L;.NAZ:%EU>2-L>>YY2WR.W=ORH [>QU&RU2V^T:;=P7<.2OF02!UR.H~~
~~MR*LUQ'A3P[+X8\>:Y:Z98?9= NH(9X=G"), 595'N.37;T %%%% !1110 44 M44 %%%% !1110 4444 %%9-QXL\.VEPUO=:]ID,RG:T21I-T;73-&O?~~
~~$7C"\F\1WMC;/.J77%NC*I.$A'RCD8R1]!S0!WM,FFBMX7FN)$BB099W8*JCU)/2O(=2\::_K%]H MNK^$+6^U32M&17U0P I]K=E 9%!^^5ZGCJ:-9U@^/O&_A?2]5TW4]/T*Z\^1 M[2ZB:)KF2,9~~
~~H:3X@TC7;>>?1]1M[R&WD,F M7FE-J=M?V\EBN[=3/7'<4 M >_6&H6FJ6,5YIUS'6<]%'/-<#>'4/#WP)NX](M-2TQ[&2&5+R8".28M*&DD"=449/![=J]%\' M>%]+\-Z+&-~~
~~,4RRW*B6>]EYEN6/.YFZGKT[4 =#63XIN=7M/#%]/XZLWS2W^K::TP![[_RHH]!7;O\0O"5CX8&L6U_#)8B01!+5-S[S_# ML'(/MBJWCB7Q]/=1Z?~~
~~X(M;.""2/=)J5Q*,QGGY0A!]N<&LOP#\+;GP[X@F\0 M>(M1BU'4YHRIV1_*&)R7R>K=N *,;PCX[U$^+/$RV'A_6M1M[F>.[AAD41/ M K+@Y5SP"5XQZ5MP_&*WO9)H-+\,:Y?~~
~~75H_EW<,,*MY#9(P2#ST-=#:>&[J' MXB:OKK2HMI?6,LB(QW[U+98]AP>*RO /PU/@C5M0O6U:2^^U+Y:HT07"[R^ M6/5FYZT %E\8_"%[BG-:OCWQG:^^!_#$NI7~~
~~M$DS'RK:$_P#+20],^PZGZ5DGX3Z5+X?UK3;JYDEDU2_:^%T$"R0/G*X]=O/U MS3+OX4V^MVL;>*M9O-4U& C[-?*%A, '0*HX//)SF@#7^'6HZOJ_@@<@P~~

@%"YP0%P!CTQ3]T-2:WU>QN MIEAAGW2,"=NT@\8ZY''4=:SY?$L*23*(,K"C.Y>0*>&8<]1\IY[5>@T>SMY M(GC1MT3%ERYZD8S^511Z%:H9"QD?S-V\;L!@69@"/;<:/=#4IIXJ@=HQY!.] M-
WRR*Q/WL;1_$ORGYAQTJ_=:U:6=JD\K-\\8D5%4DXX].G44]=)M8H)HX$\K MS8C%N!SM'.,>F QI)M(M;B**.0/B.,195RNY1@X./<"CW;AJ17&OZ?!&K>>& M9T#HH!^8'/.<];@E>3@1/G
SDXQG'!YZ4?V#IVUE,+$,-N M"YX7GY1Z#D_G3+K0H)E7[.[6\BIY1D4DGR^]6 MJKW=G!>PB*XCWH&# 9QR.E" I_\ "0:9YAC^T,''53$X(Z<8QU^8<=\T?\)! MI>,F["XSGH%#Z_I:1&1[H!
M%4LS;&X R>>.O!XZU)%I%E#'Y:1$+OC?[Q^\F-I_05&V@Z>ZLK0G8V2R[S@D MYY/OR:6@]0&OZ:TOE?:2'SMP8V&#D#KCU(%13>(]/B*A'>0MZ(P &"F2!@9P>M12:!ILFI%_PD&F D&YVD '#
M1L#@YYY'3CKTJ676+&"9H7G_'B@$A49N""1C YX!/':J<7AJUWM)=.]Q*0% M5R2-J#HHYZFTNUGG3R)''YV@%2,'T.1P>.AIDFA6GV5885,11B\;Y+%&R# MGK["FV>@6=H\,#G[U/?P_9F6%T
M,T9A8E=DC# VL-HYX'S$U*_$T\3)*(,.@PN&/' '\@*KW1:C?^$@TORC(+K* M@;CB-L@8SG&,XP1S0=;LTL5NI"ZJWF;4VDL=A(/_^GZT/H6GN"/*==R" BLC M E-
O!Z8%/DT:RD@CAV.BQ[PNR0@X/S- M.;0; G_5R*,$!5E8 9 4G&>N !1[HM2S!J5IXEF\R3SI M1-M+G:K *,@?\!%/.C69?S KJX.48.SCN3/L1S M@!E.
<[=V.G7;S4J:O:O<219=!'")F=T*@*21W[_+42>'=-1 BPOM5< &1C@X MQNZ_>QQFK(TVVVR!U>3S8_+(M.,)DDF,84,6W*3@+GN!CHI..M.?Q M!ID;;7N2K?W3$^1R ,C'&20!3)_#MA-
;RPA'C616'RN< D$;L>OS&IAHUEN9 MFC9W?;N=G)+;6##)]B!1[H:C6U_2T!+7:@!=Q^4\>W3K[=?:I+;5K:\O/LT! M=F\OS"Q0@=<8Y[Y[5%_8&F^:\@M\-(Q9L,>6)R3]:M0V-O!.\\:8D?.XY)SD
MY/\ *A\H:EJBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% "4444 + M1110 4444 %%%% "5R=S%K\FH7C2B<0,W^CK!)PK;<)TYQGEL\<]*ZVBFG83 M1A2_VX]YMWK%%O1#Y2AAM(;J-
O)XD\II&C97.W$3 $9;?N.3SQ MA,#H,UU=%/F"QR]Q)KSS_:[=)EC,97RF &%W+D[<'Y_O8]JLPMK$]G>17!D2 M9K4>6*A=KE>BYZG/.>W3Z[]%*X6.82;Q#&95="40*%PN68;EQSC&2-V3SCV
MK9TF.YBLBMU)*\ADHH;N"04444AA1110 444R:5(())I6V MQQJ69O0#DT_,NS,MG.;?!G$;>7D9^;''ZU@J^OQ ;V>53PY$:AE7Y22H[MRV M/H/QOC7]/,6\R2#C<5,;;@N,
[R.NW!'-0IXHT\M+YI>%48J#)@;\$C('7&%) MSZ523[$MHI(VN>:)Y6NA&\:K(JHNY0&?E5_O'Y,]>#0[>((!,T(>42RN<2+__M *M/DP5Z\X+<].[[!IW,99=8C/Y*?(4PV[<3R#]WC]*GDFU7,XQ.
M)$I58\G!C/\ $V,9!]_2I[S7H;26-1!++'*0DP:&?&?$*"6;+,SO@1,HP$P/F]C[=,YH M"ZWE7 M(-9ADMWEFCD@*[<(V"SAONXQG.?3K0[]@T,N\:[?4)DC-^3]K"JT.=D2[$.2
M.^>1CIECFDO1>3ZE(T4>J+;@*9 &*^8I(R$P>,#TY.36A'XDL)(RX\T8D:/; ML.=P8J![$E3@&E7Q%I_D)+(TD0==P#QD$'&XK_O =J->P:%70X=4CN\WQN"V MV3S"[Y0C-7>65'"-
'&,MG<%/'^R2,^E6K74 MH+R?RX@Q!B$H6I$B;AN+GC'&<8Q5&+4M>G#_9=\BJ5WM+#M*L5SA<#E06.<#^(@K25"YZXVX/K_ "IL$GB*1-TAV[,L M (QER"/E.1P.O3\ZZ:BCF\@L4-)CN8K
+=/*\N]R3*06QN..GMBK]%%2,*** M* "BBB@ K&U26\34$%OYF! 2 HSD[@&XZ$A)00G .>V[J:C:3Q)%(BIB0%&(9T'7YN#@8[)CD9R:Z>BJYO(5CE98->>\B MS<7
2,#YQM"L3Y9)8#K@[_P'>K\,NKW>D1SJ!%=R/E58#:B]!N'4CN<<\U-) MX@TZ-MIE")FD,[%5=5^4$*6()]<#I[T:]A M:%2XM=0F6_C+3;YFB6-XY654^4!F7!R #DX[U6U&'4FD9++
[;E$$<+^80,+D M-NR>6/8GO6C_ ,)%IHE$9F8$G"DQG##GY@>Z_*W/M4@US3L?/<"([E4K(I4Y M8X P?6C7L&AE6,.I#5$9A>BW\T& 22$A8=IW!\GEMW3.3[XI+>[UJ5&?%P8R M["0F%0R
.P'ECOP!USZ^U:,7B/3I)'0RE0K$%R/E QD$GH,]LU+;ZS;7-U'; MQK+O;.0Z%2N #R#Z@Y%/7L&AA_ PD@F:X43,S(/D?A4^\"0H[XQQSS5AQX@F
MM)MTDB,T>Q!$H!&5;YLD9W9V_K734M+F\@L9NDM>F&9+P.623",XQN7_ P Y M[UI445)04444 %%%% !1110 4444 %%%% !1110 4444)1110 M%%% !111 M0 4444 %%%% !1110 4444
%%%% !1110 4444 %17,"W-K-;L2%E1D)'4 C M%2T4 92^'[(0",FTQSN\@ALY#!CD"65OYJOY5-9V,5DA2$R;3V9RW/K]:M44KL=C.G MT6SN;K[1()0VSRPJRD*!G/"C@'/.?
4"D31+.*021B5''<2GDYY8^K'N?>M*B MG=A8RQX?T\$'RGXP,>8>5'1#_L#LO2I%T:S2V:!5?:6#!O,.Y2.F#U&.U:%% M%V%C*3P_8(5(6;A_,;,S'>V2<8VI&Y^5!\W '_S^E2OX?TV9-
L\!G.&&^5RS'< I MYZ].*U**+L+(SFT2P=)U,/$[!G&>"0,#CI^%1V6B+:72W+7,TTHSS(V GRAPHIC 19 wavd20240923_s1img003.jpg begin 644 wavd20240923_s1img003.jpg M_]C_X 02D9)1@ !
0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-
76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H
#_,! (1-Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@"*XGCM;>6XF;;%$A=V] !DFL?P_XOT+ MQ3YO]D7RW#1*K.A1D8*>AP0.#ZU>UQ'ET#48XT+NUK(%4#))VGBO%M'T'Q98
M>&]7@@.HOK\5A:EXKTW2KZ[L[@7#36 MMF+V18H2_P"[+;1C'4Y[5Y=9Z3J?_")ZR4E\1I8L\(2W2S=6#!LNP1Y"[(>C M@$9[50O=!UBXM+[4FT;4+74_^$95(UCEE,ZCHVL+J.HZQ#_:WVN+7;-
;=4DDV+ 5O2$(#@@Y()QVK$U6Y=-5 M1+I]6?7G\0QK)#S?D15#8P%P-N,@YSQ0![AK>MZ?X>TN34M4G\BTC M*JS[2V"3@<#GJ16)-\1_#$%I;74M[*L=R[QP@VLFYR@!;"[<\ BL#XB6'B6[
M\%ZU%>>1=1M>6[V4>FPOYR1"4%BV2AKF=:@\YO#-W#)XTDLK>>\\^Y M:(_;8MT:@ ?+]TGCIZT >GZEXX\.Z1Z1;VDM]JJ(B-B-Y'YL$?ELTC)_V 9]R*U
M=+U6PUO3HM0TRZBNK24926,Y!_P/M7G#&_\ #NLWVL1Z=J=W;ZKI\$=KJ M? MM%Q:NBD;98^#R2#QWSFNK\!KKW]@O)K\$-O-).[0P1P+"4CSP7520&/)(SWH M ZFBBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH ****
"BBB@ HHHH * M*** "BBB@ I*6B@!**6DS0 5CIX3\/1:R=8CT:R742Q?[2(1OW'JV?7WZU:N M=:T^U5FENHP%Z\YQ52+Q/I[RB.1S$SR6L 6$XFD.$^O\ A524P_9H=G$B\,.Y]3^=
M?.YSCE[.=&E.TXV?JNQM2FZ,U4L4D4(+%K%EDM'967_)9Y.T^V>QKJ+&X-S;+(MR[7Z,AZJ?0^]+:^5Y"",@@"HY@T-TDR8 E_=OGIG^$_T_$5^CY/ETL)#G=3F
MNMNAYU2JZCNRY124M>X9A1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% "4444 +1110 4444 M %%%% !1110 4444 %%%% !1110 4444 L2S-A%RHW<9R>U17=U%: M(7DZ^E3^+(C%;Q:D@.^V/.#U'O\
Y[UP6IZV+M,ALJW(K\]SS"5)8]OHSVPJ2OT&FFH),\P****L HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** M $HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN((KF"2"9 M \.X1YM-D;*2J/N^Q]#_.O<:CEB2:-HY45T88*L,@ MBN7%82&
(C:6YZ&7YA/!U.9:I[H^<$"3'6/XF MM2N[Y3"A+VD]9'@9AFGUCW*:LOQ$I:**]@\<**** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M*
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=!N M=2N)=2&H+&%2Z98=C9VK@?*?
IZ^];59FD_ZW4?\ K\;^0H TJ6BB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB M@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH *S-)_UNH_\ 7XW\A6G69I/^MU'_*_&_D*-.BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH ****
"BBB@ M HHHH **** "BBB@ IKNL:,\C*J*,EF. !3+BXBM;>6XGD6.&)"\CL9:AJEMXAMX-8\3&XBT&>7&E:+"C-+J'I)(B\L#U"= ,$T =-/\0M&\QX MM,BO]9D0X8:7:M.J_P#
_N_K6=IWC9K>6_A7Q(D(;VP3Q: MO]N*&NA:&Q5;.1,A?]_/8D-D=:_.VT;Q1HVO[ETV_CEE3[\#925/]Y&PP_*M M>O*]1OH+^[A7Q9%IUAAZUUGAG7;UK^? MP]KC1-
JMM&)8KB,;4O8#P)5'8YX8=C[&@#J:*** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH * M*** $HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI*..^(+_; M+;2/#N_:NLWZ03#^]"H,D@_$+C\:SM--SK=_K7B=+BULAI@N-,TY98MR6ZQL M/,E?
D=2O08PHJY)GQ5\1+9X. /\ #;.7F'_+6Z=-OE@^BJ M^/AC5#:M>DF_M9+=9K1F(PS,#T8C@A3SWH YXKKWCC3K'6]7BM-&MH6\RTNM M/9S?7*>D62-JOQP<]>G>L;0+'1=;\:ZNOB2[UR
6D7FZ;'J>+1=^$3J7]D6 MK:ZEY_8[038=8;AG",-V,E.C<=1B@#GO"]Z9-3_X0WP[-:ZQX?#IKO/<0@_,DLDRX0CU5%_X#F@#UZBDI: "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M$HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
K,\0W%S:^'M0ELI(MTO1;N+8R'@R[3L'OSBI+G4,3&VM(_M%T.J@X6/W<]OIUHM].Q*MS>2?:+H=& M(PL?L@[?7K0!Y_X5UBVL8='\+SV&L:4USN4FXMRK74^TO*6DSQDY/J?45Z5#
M!%;PK%#&J1J,!5& *X_QW_H6J>%>F.+'3=0/VI\?ZM9$,8<^BAB,GWKM%8 MH92"I&01T- "UPH\#7@M+J'[9!F;Q'_; .T\1[@VS_>XZ]*[JB@#GM$T!M+U MG7=7O989KC4+D.DH7!C@5 J(2?
3YCQZU@0Q)X\\6QZO;DQZ/HY9+2Z4#-UPCGO[6&4*Q&]&F4,IQV()!KKK>"&U@C@MXDBA MC4*D:* J@= * * OYK)A'J:JJ9PMT@Q&?\ >'\)_3WK2!!&0<@T,H92K $' MJ".M9IL9[$[],*^7U:UD/R'_
'3_G]/I0!IT54L]0BNF:+#17"#+P2<,O^ M(]QQ5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ MHHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH **S5\0:.VLMHXU*U_ MM)1DVOFCS ,9^[UZ5I4 %%5;#4;/5+61L*,G Y^I JR"",CI0 M%%9&IZ_#I^HVVGK#)/=
M7(.Q4'RKZ;CV!_I0!ISSQ6\+2S2+'&O)9C@"L\/=ZI_J_,M+/^^>)9![?W1[M]?I3X=/:25;F_D$\R\H@'[N/_='<^YY^E:- $-M:PV<(BMXUC0=AW/J?4U-1 M10!'/!%VEO\FF:WKVFVP^[;6M\?*3_=#
MX^@KKZ* .3^'-W=WO@NWEO;N:[G6>>,S3-EV"RNHR?H!765Q4'PZCLU:.R\2 M^(+2!I'D$,-V%12S%C@;?4FI?^$$F_Z'#Q/_ .!H_P#B:_$W_D5K;__+"E_ME_Z/2NRKBY?AU%=-
"+WQ)K]Y#%,DPAN+L,C,C!ER-OJ!7:4 %%%% %:[L8+Q M5$JGLV3WL6_P R 3#>NT9;(]@#F@#:HK&M M_%OAV[TVXU&WUJQEL[;'G3),I6//3<>U7M-U2PUBS6\TV\@N[9C@2PN&4_B* M
+=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 E%%% "T444 %%%%
'A.MAQ\8I&13-+'K%I-':"S;?*/+"EQ..%5022I MX.*DT_6_&-Q\1A!<:M<6]T-2:,Z=(DOD&V![1E>5Y#;^M>Y44 >'^&O[?T> MYTFYL+Z]DCOM0U*$Z;*N(%V^8R'ID$L!\Q/>H] U;5-2U_0;(^)?$_:$
MU6"> Q1VLOE-PAV@#:W09(X!KW2B@#Q"74O%E]X9UBYU&2\@?1HX=,"J"1=3 MB9?,GQCYOE"X/N:L7^NZ^GBRX3^T]8CUQ-26*STB.W)LY;3(P['.CE-Q+;L@ MCI7L]%
'#_#'^TKG0+C4M3U*^NYKFZE58[D\0JDC* HP#R.Y]J[?:,DX&3U. M*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3 SG'3I2T4 %>(^'Y MH$U?Q):OJ#+=--J++8'2^7!5N1<;
<^^,^U>W44 ?.5KIMW#X)\0)?IC47TNQ M6U2"TV1R6VY2K$?,X8D-GT]Z]G\&^%F\,VU\\UXMU=7]Q]HF:* 0QJ=H4!$ M&<# 'XUTU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444)1110 M%%% !115#5-133K1F#1&Y96^SPO(%,S@9"C/4T M7Z*\Y\/_!$?
4]8^RR3PO%%DW;/;M L*A22X9FQ@$ B1R)+&LD;J\;# M*LIR"/4&@!U%%% !116%XGU]]#LX%M8%N=0O)?(M(&;:K-C)+'LH))]!0!N MT5Y WBW657[:?$=T8MVTW8T?
B7;LXQOSNVYXW5Z%X8U]] M\N'MK8RQQ&5@RC8O7!8#],YK/NM8G@1<6N93ORAST4D9!QWQF@#8HJ"WN!/& MK;64E0Q##!&:E+A653$<"@!U<\/&N@M'-(+N0K"P5R+>>3C)*[ON_=RI&&
[IQ MUKH:YUO!>D?V6=/C26&)Y?2-E:-@'F.XMAVQR,G\U.U &W;WEM=&46]Q M!&!V-Z'T'3UD:-X>LM#GOIK1KAGO9?I.F.TI?GVST'M6O0 4444 %%%% !111 M0 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444)1110 M%%% !7)^)= M&T_7?$^@VNH0)+ '")K@!OXRH4;?
ISD_[M=96=JVDKJD4169[>ZMW\RWN(_O1 MMC'3N"#@@]0:.6-@GB<^)M&U?3((K&TD$=E*(-A52F=P;V/<5T7A4K_,(K MI82-
8U%NBA5Z<#&1['K^-5)=*U[4HS::EJ=LEFPVR_8XF629>XR2=H(ZXYKH M(8HX(4AB0)'&H5%'0 < 4 /HHHH *X;X@P>3-INJS%EL8EGM;J55S]G69"@E MQZ XS[&NYIKHDB-'(JNC##**PR"/0T >
(M9ZH+? L;TSC2_[.'[U/[,,>,>?Y MF>F/FVXSFNV^'5L6;4M2B9GLI4M[2VE88,ZP(5,@]B2<>PK3_P"%>^^%//AW^ MQ8?O;O+W-Y>?]]S.W]*Z2-$B14$14C5411A548 'H* 'T444 %%%% !1110 4444 M
%%%% !1110 4444 %%%% $2?\?,OT7^M$O^MA_WC_(T)_Q\R_1?ZTDO^MA_WC_(T 35S^L^,]"T#5+73M1O/+N+C& %)" G +'^$$UOUXQ,9[RZ\627>E?; MOMV3+*)/]1:KE8]G'7(+?
A[548N3LB9345=GLXZ9SFEKF/A_>7=YX-L1?8^T MP#R'.<[MO0_B,5T]2U;0I.ZN%%%)0 M%%% !1110 4444 %%%% !1110 4444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% !1110 M 4444 %%%% !1110 4444)1110 M4=4U2#2+07%P)&0N$ C7)R:O55O].M= M2@$%W$)8@P;:>A/^30!777=+:,N+V/ *@Y[;NF:3^W],\]85NT9V) P#C@@' MGIW%8FIZ+X?
L)+:"ZBN M]<8WB0X#!2V6/H<'\:JVMYX7FLH]S7*+'&\GV>5 MVRB(K(RW"3)<6P@;;SS MQ;5)]O7M^8K,M6\-PS9CFE>1#&V]V8EMH+KR>H !_+%)-J'AF:=I9)7\PEKG MHW)7C('_'CZ4 ;
<6NZ7+Y>R^A/FOY:?\^GY5MT 4=6U*+2-+N+Z892)(-0M=/6Q-[;+-!+VW<1P"VTD#*-QO$MBCK&8[DRLXC\H0G<&.W@CVW#/XU M'%XMT^XBGBTYUD: 2)# 1@AMH7 MG^(%?
T%1KJ7AJ%H_L^GR1/YNV*2*WR5U6ZR?#T]D^EK!812QPVS&$+*NT\=\>_6M:@ HHHH **** "BBB M@ HHHH **** "BBB@ JKJ$EQ%8326D?F3JN47&J,VH:YHZ)J6M_9)+/S)([56S; MJ>-
V3]X#O^==*AS/(1R,+C]:CO($N46"50TX/F?^.@@?G5N^M)99(KJU95 MNH<[=WW74]5/M[]C4$EO?:B/*N@MM:G[\<;[GD]B>R_3D^U>^H+30S'US6+@
M"6WTN6*V&1YL86H^E%T%F%K/]IMUF\J6+=_!*NUA]14]1PPQV M\2Q0H$C7HH' J2I*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HH MHH 2BBB@!:*** *M[IUGJ,8CO+>.=!G <9ZC!_2JS>'M)<2 V,.)!A@!U[UI MT4 9;>'=)=2&L8B"%'?H,@#]3^=/.AZ:?^7.,9C,1QQ\I.B@"%;6)0/ESA0N3Z"J=
MXZP7-K&MKY@D?!;)&WH/ZD_@:TJ3% $?D1D8V\5#=*EM:2RI;M,R(2L:\ECZ M5;HH YVQU2:YNX(9-)>)90"S%F^0E9U:,L7#$;2#TX!JSILWVZW>26T,#*^W:22>@/] GRAPHIC 20
wavd20240923_s1img004.jpg begin 644 wavd20240923_s1img004.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("
(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$
@$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H #_,! (1-Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M***
"BBB@ HHHH **** $HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HJGJ6HPZ;:M-*)HM M'"PQ*LURW\.[&P>I_P *\[OK^YU*X,]U*9'[>BCT
KCKXN-/1:LQJ5E'1;G? MWGC72[=BL1DN".\8X_,UF-\0.?ET[CWE_P#K5Q5%<,L;5;T=CG=>;.]M_'MH MYQ<6DL?NI#"MVSU[3+XJL%W&SMT0G#?E7DM)#!@2&!R".HJH8ZHM]1QQ$EN
M>UYI:X#0O&,L#I;ZD3)$3@3?Q+]?6N\1UD171@RL,@@]]*C6C55XG5":FKH M?1116Q84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%>=RS,>!G@#T%*+Y*+H1-1-Y
MR"M4_P!Q._O0!3MK::[G6&W0O(>PJ2#3KNYDDCBA+&[.[7.>%/N:Z'P_%'#81 MR030BYG?#[VY50>@'O3+J%H]&U6.$[W^T[F,?/RG!:H PUTN^X:X: 6T@D4993

O'TQSZU=/ZHH>\WS7%+VU]%H5))'FD:21BS-U--Q117!*3;;;.A*RL% M;?AR,FXED[*N*Q*ZCP]'LL&!GA/[7%Y.TC^9-,W+-@L37IX/+G67//2)X699S'#R]G2 M7-
+\CL[[XB2ERMA:*%_OS'G\A68?'.M[L^9#CT\NN<5'D?9&C.W]U1DT&-UD M\MD829QM(YS]*]F.!PT=.5'S53-,;4?,YOY':V/Q#N%<+?6B,G]Z(\C\#78: M9KVG:LH-M<*7/6-CAA^%>-
R120MMEC=&]&4@T_;<6DDME ME"HKPT9V8;/,52=JOO+\3W.BN5*^*DU5$L[H;;Q$^\3Q)CN/>M^^U*VT^,- M,Q+MPD:#+-]!7@5*%2G/DDM3ZVCBZ5:E[6+T*NNV;7%H)$!+Q00S/$>C'K^-
?&<2Y8T_K4/FOU/9R[% M\W[MK3HRA1117QIZYI"&V#?<1D\O)._D'Z>N:ANEA\@-%&BD$9YY%5XH?-$A MW ;%W8(ZU*;,B1$$@.]"X.", >U>GSRJ4_=IJS]#FLHRUD66M;.0#$PCVH,X
MYR349L[78 +G+D>V,XS42V19V3S%W! X&.3]*2*RDEC5QM"L2!^%5*[>M%7$ MK)?&6HK*U>-LSX)&1NQD8/;ZU5G@BB4F.7?AL?ABI!IEPP# *5)X.[K[U3*E
M6*GJ#@UEB'RP2E2Y?,NGK+25PHHH). ,D]J\]*YT$D%O+=2B*%=SD<9Z?C6 M]I.M1>7'9ZA"--OE;RQ;RN,28[HW1@?;GUJ?1M.:SC:60_O) ./[HJUJ.F6> MK6C6U];I-$>S#E3Z@]C[BOT+
(,O^JT?:5%[TOP1X6-KNI.T=D6Z*YK[3JGAJ MS9]1E74=/C;FY4;98D]7'1L>HYKA_%7Q*FOT:ST7S+:'<0UQGYI%_P!GTKZ2 MG0G4?
NGFU<1"FKRW/2[WQ#H^FLR7>I6T4B2S')/XTG>N^.!@OB=SSI9A4?PJQ[1;_!3\/S-B5;J# MGJ\61^AKH['Q)HVI;1::E;2,_P!U/, 8_P# 3S7SG0.&R."#P1U%$L#!_"[! M#,*BW5SZ@HKQ_P_+?
$JZL!%9:NIN+?*HL^<-&.F3Z@?G7KL,L<*RQ.KQN,J MRG((KSZM&5)VD>E1KPJJ\22BBBLC8**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ MHHHH **** "BBB@ HHHH 2BBB@!:*** "H;NX2TM);B0X2-2Q_"IJY7Q[=&' M0!$K8,T@4^XZFM:%/VE2,.YSXNM["A*IV1YQ?WDFH:A-=R?>EMRZ;+<
P1SV]Q_K8)/NFII/$<[:G%3:YH&MO>[6-I*I@PH&SKQ6;<>*KC=;K86T-C#__F"./HQ]ZCU+Q$U]9O;06 M<-HDS!YS%_RT(Z9]JF.%J\]^6R;T_NZ_J:3QU!T^7FNTFGI\6EE]WF9%O/): MW$<\3%7C;
<".M>NZ':6+VL6HPJTLLR[C+*VY^>HSV_"O'NU>E?#ZZ:71YK=C MGR9..>@-5FU-NDIKH3P_52KNE+6^WJ=?3)HDGB:.10RL,$&I**^;E%27++8^ MT3:V.0U'2Y+%BZY:$]&]/K6?
7>NBR*5=0RGJ",@UBW^@K(3):D(>Z'H:^,S/ MAV<6ZN%U7;_(]7#XY?#4^\YY79-VTXW#!^E2M>3M.LQ8;UX!Q2S6%U!S+-ZC MUQD57KYN7MZ/N2NOP.]6K87)/2H:*GV]7^
M9C]G#L6%O9U55#C"G(R <5 [,[L['+,;*K.ZHH)9C@ #DFG2R-/,\LC M%W=BQ8G)))IO0@CC'O7O4J:IPLCYZM5=2?,S4UKP]J.@&W&H)&IN%+($?=TZ MY_.DL=
O]0TJ^U.%5%I9J6D=SC..2!ZFM#6E\WPSX85I-NY)@78],R#FNTED MM9]"UFPTW4-/_LR#3"J1Q,<[_P"*1^.]8SK3C%=S:%&,I/L<18>"M#=7URT:ZM5ACA#F,--)MW,.H]:[S[/>7/BGPK>-M6*R-
IR6@W21GY%&.0?TK"UZSO=2TS3Y-%AFFA74;C/V?.__F<$X_'FH]O-NU MU_D6Z$$KV?\ GL<+/!);3RV\RE98G*.I[$'!KT3X8>)9(KPZ'=S9A=2UL&ZA MNZY],=JY7QFT;^+]1,;*V&56*]V"@-
^M8L,TMM/'/"Y26-@R,IP016\X*M3U MZF$)NC5NNA].T5GZ'J2:MHEG?(<^=$&./7O^M:%>(TT[,]]--704444AA111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444)1110 M%%% "5QWQ$ MC+:3;2#[J3<_B#795D^)-.&IZ%

'(KHPM14ZT9/N<>84G5PTX+> MQY+ITD4=]$9XQ)&WR,I'KQG*W%MHH;YK.TMH+FZM(0C;URLC9^=L=\<8%]:@T*[62,KXJ5].@CN98[*UM)F_RYVD&1$NT8P. MP//-<_\ \
(_J1A:79E?,V'+]3G&?IGO3;?3E76)+&\NVA<'86CR=S'M]/6N; MV2L[5+V_X!VNL[I.E:_7[RQI,"?VI=QI#'=[%.Q0NY3SU)%:T=C9-HVF2-: M1^<]R!*W V@N1\PSTXQ6-
)HYATN.YMY)9IG6RG@(,GG]*=1PE[W/;_(!-%3A>/L[Z/\6BEK4EI)JK>%-._LW08(V&))!YC M_4UGF,XPPJ@NMCHR:E*ICI5&K6N;E%%%?/'V8E%+10 F 1R,U5ETVTF^_A] MP,5;HK.I1IU%:
<4_4:DX[,S#H5B?X&'T:G+HEBO6+=]2:T:*YEEN$3O[-?<: M>WJ?S,ABMH81B.)5^@J6EHKKC",%:*LC-MO<2EHHJA!7,?$&8P^"=1*]64)^ M9%=/7/>.+0WG@[4HE!+"+>
/;FM*7QJYG6O[.5NQ_\ ;K4[V5U':I=O;RK; M.<+*5^4_0U_.@KJM%UG38=)L;+52\\45Z\K1-DJJE,*<=P&[5[&&6=GAA!$2D\(#R:GESITW+Z&NL_M/0 M6NM5:7[(%E@58S%;DEGP>5SP.<
\P],^U/LM;UG0_-M;6^N+3 MYL/%GH?H>AK:&LZ+_85IMMH%U!)5>7,1W;PV2X/3&.U7;[7M!N[74I'CMI9I MI96 D@(>0$_(01TP*ARZE1Z1 M>6]G(GFW%A#$X6
!3(K7\S_P#6KK:\6M_$EZGOT/X4?0****R-0HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH
6BBB@ I#2T4 M >7^+] N+#4Y-0MXV:VE;S"RC_5M[^U9MKXBNHKH37"BXVJ0BGY0ISG/%>O2 MQ)-$T4BAD88(/<5Y]J_@&:$/-IDGFKG(@;@@?7O7MX3&TJD?9U^FS/EK1S+ZS?
LKI]H81M+YNP= V<_E38]6O4O9;Q9O](E^^Y4'-07%K/:2 MF.YADB<=G7%0Y'K7LQITK:)'SDJM9.TF[HMOJEY+;"!IV$8;< HV_44Y-6O MXX(85N&\N)MR*1G!_KUJO!;S7,HC@B>5ST5!FNMT?
P%GSZ7J4]E#]*U=$T*QU+3IKBXNY$E7S,*FT"/:N07SS\QX&/2O2/B#X1_MJR.I6 MBG[=;(?D5<^H->U2J>VAH[,\&M2]C4U5T=F/"&F%K+_M
^{9}FD9&>0*HE(0,/+^I.!FJ&H^'K&TTB[NX+MYI(;GRADJJ[?IU8]N*Q;O M4+R_6);RYDG6(8C#G[HJK@9Z5<83WC-!I=C+-)"PG,K M81,/C>PSR<=!4>DZ;IK^*K@R1PFU_?
&*TD^=T((VY3OZ@9Z5R&>U&!1[)ZV M8>U6ET=;J%EIR>&;F2W@@CF2X?,DL7+KYF%6-L]0.V*Y_2=+GUG4X+"V0L\K M@'
^ZONII2INO46FAVMI;1V=G#;1*%CB0(H'H*FHHKQM]3W$K*P4444#"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH 2BBB@!:*** "D-+10 E M%+10!#-;07"[9H4D'^TH-4?^$>TC=N_L^#/^Y6I44]Q#:Q-+/(L<:]68X%4I MRCLS.5*G)WE%,;!:6]L,001QC_94"IJA^TQM:?:8F$D93>I7H1C-
4(=7EDGC MC-C*%;'S>N?\YYI-MZLM1459&K2TF020.W6BD,#TJ-)XG5665&#="&'-%Q"+ MBWDA9F574J2IP<5@S^%UENE"3[++*LT.WYAM' #=A0!OR3PQ1^9)*BIC[Q8 M4QKNW5-
[3QA<9R6'2LVX\.6EQ8069>5(X05!4C)!.3^HIB^%[$+M8R-C=C)' MR[L9Q^5 &RLT;H&21&4C((;(IJW$+#(E0C./O#Z5DVWAFUM2FR:8@;0X)&) MI!4'Z$"I!X=LQ=+-EV"R&78V"-W//Z]*
-.2:*)"\DBJH&22>U)]HAW >:F2 M>F[VS_*J,VAVT\443M)Y<480#/7'0YI+W0;*^G2>0.LJ=&5L9XP,COC% &CY MT6<>8F?]X4V2Y@B&9)HTYQRPK-B\.V$6[Y"S,&!+8)^8Y)_2FCPY:;-A>5HP
MVY5)&0>_/4T :QE0'!=02,XS44-[;7"%XIT90<$AJSD\-V4=\MV#*77. S9Q MUQCT R:;+X;@GMQ%-<3N54(KDC*IC&WI0!J_:K?8&\^/:3@'>.N$[*:5)!+-&4;< ",;MV[/2EE\+VLVW=/-
A26XQ]X]3T_2@#< M5E<91@V/0YKC?$_P]L-<,EU:8M+]CDN!\C_4?UKI=+TFWTB!XK+(G3C45I(^=-7\.:MHMPT5Y9R8'21%+(WT(K+(*GYE(^HQ7T_56;3 MK*X.9K2"0GKNC!KNCCW;WD>?
++E]EGS2H+'Y5+?09K4TOPYJ^LRA+*PE<$\N MPVJ/J37T%#IUE;G,%I!&?58P*M42Q[Z((Y$W5]&0X) M.$1O8=\>IKM:6BN*...16?R5!. >X(/]JUJR/$>\Z5(B_P > -K8;=G@#UH O6'-A ?+:/Y!
M\K8R/KBK%9VEO,^BQ'8N_9^[_>$AO3)ZU'!:ZJLJF6[!4G+#TY!XX]B/QH T MU^^_U_I3J:F=[Y.>:Q=;U9K8O:HC;F3(D!QBN;%8JGAJ;J5-C2E3E4ERQ+%U MJM:E6AMBJ*I
M.,5V%HHHKV#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@!** M** %HHHH **** "BBB@ K,UZ&*73)/,M6N"" JH/FR?2M.LG7A=+9I/:W4T# M1N-_EJ&!7OD8)_*@"UI9-*MS(,,L0R-NW'X4JZG9O*D:S LZJPX['I3K%Y)
MM/@>=6$C("X;KFHQI=J)(WV-F-0JC<< #H/TH M+]Y_K_2N4\2?\A,?[@KJT M #/]:Y/Q)_R$Q_N"O"XB_P!S^:.W …
M4"V5LDRS+!&)%!"L%YL@)?3Q$H-=!:&N^#<^NY'_ *9.4
%HI** %HI@RB06*8I)9+Q!T@Y#R,B9VV\SQ2)VD%WG=TC'IAS&XUHZF"B&-M*O^@4OS48A
@R\@(G'/2!0QI>Y=%J4XUBH&.7BOC%Q.0\TC\4#)5,0.G%JZO$MKCPC.4\QE+/W(J3
PB!W6/"2ZY_LT'8<!/ZI>I"9LK*'$0!,QT@W<.1OQ[GO]<%A-&M#(R4$6BH$S7O_36
\IQV/\7.K[*Q]!)OJ(LDZ9P5H<\0^R*L<-3J%'4K*L=E5[EDY'%6:<HXJMJCG9/;%8
5C;2<?R]#"V[[=H0LL)?@I$%(ZYVMXW"\7D1T=V;>%1/:;6\\IB-9PW?!EO/9H
W3K)V<XQ?F<\IO:L%8]TL\)1QK;#U3-?D9XQUK4RW7NW*?;I,W[S0:Q!KS*IN=$N)
BW-=YU5U)?RG#WF@:EB(4Q<;N?P:D\;HGV8+Q72TYK8M%9,)F%2Q0/;E\/:$7I>
R"U4[>J/L>,N7CL?<1A?99@CY8/:2T!J0F2F+A?A;+Z)7B\G7+0GY8%/6C];B:1
8I,*"!F1J,)L'(1OP#<N<BX4C6(>0ST+[;FD5@O$S.6HB)O7(=1)I]^:T'K2Q5;U
&@;<U)FY3YZ>FJ6;S*/4AUN=)]=OOS;!EV]ULF#/8.X?X.C9*J/5V*G1+I
M%V_"%F@;<W@,%\N_:+Z8F5$9<T:PZ;8ZE3[0L?T9P0$B/P+]'WYH[%C%K1/C@
2-5W"1^X:(F%Z*'G=V/V;O^$@%.WI2VD\U@]+E*?6G*&K4/6BX1#2:E0#G"JZ
9/2H4AT>>%D3?J%T^+4MBJ[\KA8,I%[Q[:U[LGX^O3QE0P,@<DC%E1J5BS,#D
…
4%LMQ5&B#@;!_M';FM'@YKJA>T1Z%16%X1U*YU;PU:WMVXDFD+Y=4V!@' M(!V]N *W*YIQ<).+Z%\<).+Z%IW5Q:***D9D444440!D44440%1S8$$F1D;3 MD>M25',<02'
.%/!IK<#P0V.AW;,]OK#6A).8;R!CM_X&N0?RH32--A=7D\1 MV?RG(\B"21ORP*0IX=NV+^??:>Y)W1^4)T'T.0V"3UKZ9-VWE]W_/3Z;GJ'P^>T?T?1KHVA693=,7DF 5G? R=HX4>U;W_P
M_P#;K_[-6#6#\/>LX71K/Z%WF]OG=]%ET%7G5.3Z)V%R!4M6:7T=90_[P5*]/O-#K[J:9O?0/$CH:HL$_P#K/'$)?&A?SW_"W=6:\Z]VO!/,AO$%%,>%&+&7H 7
Z<^]6=7T3^UIK>F#3C[%Q7-N-&&CU%+ M^YU&:N%D5R6C6C50<(RXP!QPU0?\ "&J8_;9;OW9;A'R-<\$U6E+_0P:.X!3:8@&"RT#;;;_W%P%%6X.D$!+%5;&;%(&*4"G:V<J>/$
24M4N/M65D+* MJB-BV5Z@KC(QWR.*HS^$?M7+;C9/@FC?6E3>)9*&-^S3J1**A"%W"9HA(L:$ PD?'3@I(O("3&ID%/RJSX>;:C"[=SGQL'#%\$9>>VJZKO[ZQ M7>*Y_(ECP$4-<AWW8@1O$?ZM*
M;C"*"VX'))QSUSCFGI$_;(/,T7/"!J=N4V/N0[H'C3R(ZN_"B"CAU:>!DI@=QBG3W_B;A8<DHP<6;5@B#4GZIT+D?3H!XWZEO^39=DA@/B78AQI]!O5B[X"O3(7,'EUFM7QU3XW)HJOIA)A]3\!#R$-Q'G*%J_1[
<^,=!LTM3!GOCI]*J/LN5>.<5D1^ 8(8HC#J-Q'<0)"()MJG8T9?!P1@Y#D$5 MT+&<)B42J""Y8#"'D@;>2.E0:=X\L]1EBACM9$F:_:R>-F&4P&(?W4[3_M
)%6=5\'PZKK\>IR7DJ*!$'A5%^;RW+K\Q&5Y/..M0+X#LTN=.NDN95NK&6: M1)0!\XD+':P[@%N/_KTU['EUW'^ZL7-+\4PZMJFIV%O;.LEG_JG64UPL]NC M1RLSEO/#<'_7U#_Z&*TZS-
<_X\X/^OJ'_P!#%N19:?<710N M(8FD*M@_8&?X&6A&I.MF[E**#J";4PF[YFQ@'VKL;VU6J@L+BFB+BT9BJ MSQM&6'4C%)%"%8L3.'P*!L&BG;F/X.
M+_;C3:M/=Z?H?VVKR=MK/=_:$0DHCYBJ]?R:P:T)G>8WH]M,QCZ.;JNS)>9:JHTH<Z2K6W=35ID=%V8F(D-U#3#XBEJ#C4B"IKY&.Q@)-7?*"NL%TFZ.(_MLFZ.
=U#WR&P\9VMU%!< M3)';6SV\L[R/*#M\MPAQ@88$G@BK1\8:"MHMRUX0K2&(*87W[P-VW9C=G'/2 ML]? -H8626]G=WCD#N%5?G=U?< !@8*#_Q5JU\)"*_BU"YU":YO1,99)615 MW_NS&!@<
'\Z)+#WNFP7.31>,O#\T,TT>H(8X8UD9MC#*DX!7CYLGCC//%(_MOC'195 @NC),Q=%B\IPQ91D@@CC (SFJ)\"6WV6WB6^G5[:V2"*0*N599-ZO MTZY[=*ELO!PM[][Z?4Y[BXE\W>S(JY,BJIX
XQL&*.7#:ZO^OD'OD]IXQTF; M2EO9IQ"5CC:6, N4:095.!RWL.:D/C'00B.;]=KQ--JV^55.&+K 6BBB@ HHHH *** M* "BBB@ HHHH *0@$8/0]:6B@#A[_P"%^C74S26TMQ:%CDJC!E'T!Z54A^%%
M@D@:74KIP#T4*I_.O0Z*Z5C*Z5E(T56:5KF?I.D6>B6?V6RC*Z6+H6+8LS,>I M)/4TG_Q?]J$'E=MMLF[;.?\ %,-O)KEJU[9W-_#4Z[.%:4+,1S,:%Q$.?V6
(;2&*&:>\2YC@@$4<5OYBS$X\PNV#R/J/7G->M@<45M&O9)-7LZ:@EE:QY\^[YT/=@D1?3$^ZK8+$PS0@*_A'4BOTYK?69C&8-ZG<9P--2O6/8(:L@GL,@4>X
T4<85MC!L<_P]^3Q5.35QTA5G=_RJ@H]VQBLPXN?\&D?S$)PF<Q!I=MTV^@T!$+LZ,7VS&IL@'UAU\;2G1A_O+;JUNC<6^)2SI+B4U*,SHZJFBI1,B-:S(%7,XMZKA#
4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=_S,7_ M6C6=_P S%>P S%_LU5$:B$LQ!/Q=!B$24M8.N>+=)T%2+^S%^LT+G(9A!$.!6S!U
M;\:J$)HJ[H@G^X:#6QMY:DLQ!KWNIEDY;U85\&M[@TY3;B&&<RF'M3UAC%RIAPEAEQ]KJ-N@$O2XV@XN"J):?[,81NZKQ(WU%S$'9>E_AUC+'9Y5#T1'W7ZRH']81H](2/
[D'J=J_UKR:BNZ5%5I3/KL9%#6/)H)X@`^%5V6C$(YL<-5<9K0+V9A#5%%0M1SEJDA!8LH$>PBJS,6Q(V94/<#;[,CNLG,&9TCD^Y>3W7D/Y\@MLPSO*9V8^S/]G)G.#
]_Q_A5./XN*M;T%FMJSFUSM&:Y*S<;A_&C!Z1 MUK-"#T!4**@<U4V8F;+G*!T!JNQ<8%@%[=,V+;B!LGP2H!DBWH^J+"8<8MP
_W_'^%%@RHSJ4!5B[IK@TE]CBJWF[R+SHP(M7M4:L4TX;U5_H*BV<'A1K,HY3OF=L^<JMWK4/AK&J!QC%*:.G@:Y\E&A+5!+#6V
I-:B-G49A=@@F?XGX@0VHX$,/&AEGJTT$DMV'FDK:B=EEZKJ!6W06&!<4R'$7+H=ATS<U^42&LH/@OL=\"*?G0WJ5K"1"-0'KAJ'V_
[0K?=*?L4<]JUF4N7B^QKV>4/ENGL*L8LJ"T2@$F9!7/:M?C=F_J/:G@2-B25KP?Z?F1:QW]O?S8_#7A0V(HTKRL'W%=<-1.#@V
9_1YVO#S)Z$H^F2S2E-^F:^VW7ALVH<X/BY:&7UJ2H;E_=T5IJ]D"1%Y^CSY(9UG/W?C:J[5@BH=#UWL8J8?<R.W(=%N5J#J
Y,C7S2:O2AVP'1K(UT.IN!PC;@/.O%Y;C7:OT\B_3,H0[KJ7V'<96$*KP6=,6VE0@S4K;+%5<8U#&I$1=Z;<EK+)2HX5^?YQ
S@4$*3$)?U;0/L$U5Z=!=:?XO[<%1BK_=X2S;\4:'YRJIC4G5)7G;Y:RA:CWP-FQ+1K8O96.ZM'@F2UY_I=X*<>P-F(E@U?DE
9HGR*3N%#*RW)'$C-+>K-BP3O+W<?7WJX,L[D-4YCG)E(R.X2S-"9VUPO\I2;BBG^@5T'1IEI7E[JY5@1.C45SZLG[E.0W'
(IYSMZ^.6YA3Q3<;)6;HOMW*C7PIZF*5+K+8<!+]8$D_L)*<8VJ%@2DYN6/*LPV@;YR*!?#M-+4;N9B1#VK(HJ=9?^\A*MU[L;

MG6*!KV'G@C6%S'+=.NX;N^T>@!;H^$OB M-\3-2U'%O;Q:O;#EMT(1.O\ ST&,\'ZYSX?>'!K?7X)?$.N3__&?1[.RL(?D\]5 =AZJ(X1];6@CZ @U@?98GO+=
MK;9E!>.N&VGTSWJ6XM].URR:"> .*XA;JK#.A*^.+K^[U&YNF>^O+N::SNU8-$SE@IVY!&>G2A.SNF&J.N\8>#9O#DOVFW M+!2Z=(V OZQ'T;_&N4KZ1N{2"^M);6XC$D,JE75AP17@GB/1\?
#^M36+Y:,?/ M"Y_B0!\/PKZ'+\9[52BJ/O)]J6 M-K+GSD3U7)_6E+1%P5V9=%%7=*TF_P!:OTL=.MGN+A_X5Z >I/85BVHJ[.AM M)792KL?AM9V\GB.:4[M0UOI-
]]XRGNR =_+D_A5J3P7X=T3Y/$OBE({L?>M; M&/S&7V)P?Y"KD%[X+TCPYK]OHVK7DMW?VOE(ES"1DC/ (?-5'4]U[IE]KT6O0.E%,;G M2KFVN7=1"5'3#'@$H3QN!&/I7EB_='THP/2EJ*5+V?
6XH4^0Z+PMXNN/"_P!M M1+6&\M[N,*]O<QAC_.>26J[!1^=85=[X;E/B3P)K/AZY^>;3HOMU@S=4_^\H]O\ X]LI M1]@^;/P]40X^R]Z.QP5%_.0#176;A2CK^!I*<@RX%5'61G5ERTW)EA!M0#V!
MU%*/O#ZBO32LK'QDY.AK2TK45T_[6&.Y3SX@@DMG"NN&#=_I6Y>6 MCW%[J.%_!':V22!.>X, CV.7 4@#<.9]>F:9U\Z2$QR[E$@ M"$[LL.O':CFN65>.,HVDA\KN9D&M6J3VUS*E[)/;]\<>) !
(&W6RGZC-3+H-FMIL3^;,G//*:&#;3C;@90QU MSD46EE,V^NVZ2Z/<1Q+.\9:;4[9<*<+=NO&>.*B]IV0]3"O;HWM[-<;=H=OE M7^XHX5?P&*KUTW]EP2I:R_9;B\,HAC1/M,"E
=OP,>O!/'RG-5Y\,T^*(P1 MB22;[!)<"X\$Y259@ %]"!6T:T4DDB7%F#111702%%%*!N8*''!DXR3P* .@M M_#YF\%W&][3YJR[D_P"N8X;]3G*YZO7K2YT:#0%MQ>V[642"W=]XVY(_F:\
MEN(E@N98DD61$ ^5F3170?V%#%;W"WH MD<,K1O&&/F,&0+D=N&'YU%%%X>$]S);QZA$9+=MMSF-@(N"7[9'"DYCBB!C9B[,N0Q_NCU]*KC10/W4M[">>0UQY'EDC: M3C=ZD"G[>
N5F51116HCZ#^%>]G4O!-O$[[I;.VMVSUP_5_0C\J[:O&/@I?% M-4U33RW$L2S*/=3@_P Q7M%?#YC2]EB917KlYZ &7-!!1117$:4110 4444 M %>4 %E_^)CIJ?\
3)S^HKU:O(_BNQUP/PIMPFA7EQCY!,@]?HH'^)KOJ^ M7S"HYXA^6AYM>5YG@?Q-\6W&I>/[?2 ,ED:#3T>,>/. TI&6OZX7CVZK^'(? M#\GAN^TG4U7R+JZ%R[#]V""!_2NF\0?!.?5?
%YEKEEKPM#//YZH8-Q1^,?6 MO,GM=W/B>QMF7.VTR!*<*Y>*=5[K64TV6\ MD5_,":5;CGH1[5Z]IGPMTJSM!+QCHVF:U#]^F3P+]$"%(F:,[%5C\W'XFNOTSP;%=ZW+YN@V
MVGVL2##+SO.T(Z5CZ'X'L]6^(MI:WNF1K:I).\D"GAHD7&6'8%V&/QI0FF!) M#G3:C=L]^\ >*9O%F@O?31[]"DIC$B A9, *;<7+A:4H2.YMW(^H&1_*NS#5 M'3K1DNY-VFF?/U%
.1GVHKZX]4*P=8;.Z!Z(*ID>#_$1&1!%OS[#_&LBZ\ M>*+O5@/!'N4C=E4R$#"@]^O:L)5Z5OB7WCIU()ZLX]59W5$4L[''J.YKT/7; M[_A =$B\.:4XCU.YB$NIW;.?7(XC4]O\K65H?
AVZTGXFZ7[J0]$NE;G[L M&$2"/4"9/BVZ>]\8:Q<29W=R+@]@IP!^0KFE:K44>EK_Y%RM4FETW.;N2> MI.23WJWI=PEKJ=O/({B,.9RC%;F==WUK<:4.5KMY;A-I\]XCF7&[Y??C(Y 8E=]XG
MT:#^R-+BCT!M,C*,(-0+AO//;S<#*ANH)Z9]*X26*2"5HI49)$.&5AR#4T9] M2NB:U;&I=TN:T@N9'O$$D9A90I&R.5 M+I9@M)8DDBVJ&=''&E"EOFZ=3DI/0?C1=?
M9[=XT^SH(Y''==DN!029[.6V>!UA&2=V M.WIQ7.S1&&9HR<[3P?4=C3*N<54CRO9E2BIQLSNDTOX>ZPP@L-6U'2;AN(S? M*&B)ISV_.5SGB'PYJ/AG4!:.A&,..
T,T9RDJ^JC^E0%=_P"&+AO%7@_5/#%Z M?:GLH#>:=(ORR:>]#V_H:PES4?>O=<;F3YJ6M[HX"GO?ZP5?TGP]]^NI(^EZ M?-=+!$0)#'CY2>G4UJO>_?%8?)T&
[Z>B_XUTPJTXS2E)&>;,J)49)/6QB45T5[MX(U_3M#;5;NPDBBCDV2(P^9!@8?C^'M7.UZ=.K"HKP=SY)IK<5F9\;W9L=-S M9Q2L[MC<[-M&!EB<"FT5I9"%W-LV;FV9SMSQGZ4K.
[!0SNVT87+$X^E-HHL MJNZYVNRY&#AB,CTI/Q_6BBBP#XX99F*O1/(P&2$7) IK H<.K+[,.5+:7<]C M=1W-M(8YHSE6'],]6T/6;+Q%8>8\47GH,31.H.T^O/:N>O6E2UM=#2N>1YST
MHK7\37%M<:],.8!:)A$,"X5O4 G3M!\-W.N^?:YT5GI]L-US>SG"1^P]3[5 M:K1C3YZV DV(H)?S)IDLVTW$:[6B;TD7=&L88JGSL0:JNK7*<&<_FE M+<*"QST S5[1;B&VUFUDN%B:#>!
()ERNT]37J6I:GINA:9]L"0f6'[E(E \P M]L>WO55L02!R#C/__M *"/RJ5]:U!Q_K@#U9EC4&0X*Y8X^8X)ZUGT4>SAV'=EHZC=E(%,QVP,K1#
M^4J,#]*T(_$+QV#0^1F=H7A,I8$;6SGMGOTSCVK%HI2I0EN@3844458CL_A7 M<&#Q_9KG EBDC/O\N?Z5I#U\T> 7*>/=&((6A_'!\ MJ[LN=L1$VP_\1'FE%%%?3GI'KWPKE#>&
[B/^)+IL_B%KNZ\F^%6HB'5+S3F. M//02I[LO! 0_I7K-?+8^]>9YM=6FS#\'>(K?PKX9O-6N,'R4Q&G]]SZ_MG7R;_P)!?CQ5%KC>8S7WG"25G.0V>H^F.*]I_;#N;@:#I5E&V(IIW>1?[VT
M!Z7"UQ?O6Q!W/(%Q^ >?)D1TU.[\>3<36NNZ?:RPM&H_=C# G.1ZX MKO\ PQ]TTVGP7$;[HI%!'M63<:5OTB-.XBR[.'CC%"8OM37FJSVT*7+XM M_C;<&5>=OU-
<9E>%=/CTOPS86L:E0L0)R,') MY/'U:4%K=DXAKELC:K+\12B#PWJ4AZ+!;2?^@FM.N.^)6HBS*O;_O+MQ$H M!N!_0?K7H4(.=6,5W.:FKR2/%U^Z/I2C@@^AHHK[!4[M?BIJRJ +&SX&.K?
MXU0F^.VKVVI+%]IGY&Y=[+NW;>^.>O6N3K#UE<7BM_>05Q2P.'M\),*%_O5 M'0:WX_O-9\96.M.GEVUC.K6\'*H&YR>Y(IGQ&TO[%%PIO&#OL=447=O*.C; M@-P /|"*Y&NQ\
B;3Y[X1KQ.CR:66W6UR@S)9MZG_9_SR*B5/V34J;!VT MMY&SA[-J4%L<=7H7AF+2=+T!9HM42YOM07;/! QA /|PGY^V1W%4KKX9ZM(
MOVC0KBTUFR:E);>90V/=2>#]#6:_@#QO6C8.@W1/JN# (T5*E*K&W-8)SA-6Y MCH=:2UC:RD".W!.$KMJ>H/95]0*YKQ1XHE\2RV@:UB@BM(S%$5 M7YV7CECZ\=*U=0T7X@:K!]G87VFZA-
.68Q^A0>SQH>_X03Q7__"_[Y'^_' M_"">*_\ H 7G_?(_QKH]M2_F7WFWM8=T06EW,V=HTKL0$S_&C&?F&?UR1CV MJ]J?6#UVC^E;">*#?%Z<+H%T%*X*>6-K?X42^]2'PIXT;DZ'=[NS"-
#:,J':N2-5<+T! JO70_\()XK)YT&l]\J\ &C_A M!/%?_0 O/^^1_C6JK4DOB7WFBJ02W1SU=S\,E^SZCK&K2?+:,66FR^8OZ9:H/ MKP:KV/PR\27)WWEO%IMJ.9+B[E4!!] <_P JD\1ZYI6F:"/"OAJ0S6I???
7Q MX-RX[#_9_P CWRJU%57LX:W_(G-5%R1U*7@_QS?^#8+F.SM;>;[259C GC M/3'UKJ(_C;KK-@Z;8=/5_\.&O+Z?$?W@K982C.=YQN98NC%TI22UL>GZG\7 M-2U#P]+9K;16]
[.Q118P2J18[9_B//TKSGMBBBO4H8:E035-6N?*2FY;A111 M6Y(4444 %%%% !4MO5]D6IG"#_6RR=SZXKCZJ[6&Y\5>$[&<TKW.JZ1#]EN[:)B)0?D=1 MW_\
UUQ8M\LZ9A@:,5_N@9[<7+]RXRU;T?KT""?.V M\@&!!(Y/JQM_K7T%7R>>2OB$NR.[#+W1:***\8Z HHHH ***** "N.^)%F;K MPM-(HRULR2_AG!_0UV54[^T2_M;FUD'R30E#^.:UHS]G44NO4)
M"2TN9;:48DB_@_P!9 X8#^\,X_$5!!Z9J M5OJNFP7UJVZ*9=PIO4'W%?.5=/X0\7S>&KAHY%:.PE,7C!Y1Q[P_K7GYAA'6 MSUZ7.KK2_VQ>I]\@MW?R_+B>/G8F@*\&OF+)MIG$^: M#U+-
M-9>3Y,L%[885A77AZRO_FCQ2QOS63W_T?#**V 2 1]<5HR0!N#RO\ MM<54-BBRB4&170Y4]W0U"HI2NBG6;5F>CCPMH0O;>\&E6OVBW&(9-G*?2M@# M%
<5IGCGYEM!0MVW*.9H^<^^*ZZVO(+NW$\$]O$?X@:UTO8SU)B0H)/ %>&^. M/$ U_7E,+9LI:.<) O?WF_'^E=%X[\\PHHHKV#K"LK6H\I') =.#6K5>]A\^UE0#G;D?44GJBH
MNS:.HHHK(ZB2"XGM7WV\\L+?WHW*G]*NG7]:'35[_P#\"7_QK.HJ7&+W1 MN2_K2*60^@Q]' @2 \ C1_PD&M?2!C4/_E_P#&LZBE[.'8.2/8T?\A(-.M_P"@Q]' ($O_C1_PD&M?!C4(\ P)?
!K.HH]G#L')'L:/_"0:U T&-0 \M"7_QH_X2#6O^@QJ' @2_^.9U%'LX=@Y(]C1_X2#6O^@QJ' @2_\ C1_PD&M? M!C4/_E_P#&LZBCV<.PQ9N=0OKT8N[VYN .@EE9A^M5[**1)+8:26P4J MG#
TE%4M&3.*E%IERBF1G<@I]>I%W5SXNI!PFXOH%%%%,@***** "BBB@ KJO M#/A1=;TNZN9W:(L=EN_H1U/N.U M'[1Y*,!* P J9[GU-R* N H]!5*M8Q;I\M34+Z MZ'LMAJ.NW?
PSNO$4UK8S:FG&2"=[=,F)2.L?2[U>4:KK.HZY=?:=2NY+B3^' M@ X%>S:2PC^!N=W'\G2]_\ >KPH?=%>5ED8N=1]T>AO6NDC1T2RBU' M5X+2<3;)203"N2..#\/6M_0!X031!!BN89&FEB?_
$A\<$'H0.V./SKFM/U* M[TNY^7E6R4E11I8AE2#ZCJ/UKNK^V4U*. MQBK6.*HJ2XB6"XDB21951B%=3D.,QJ.NM.^I(4444 %%%% !1110 444$X&3 M0!ZS\$]/)GU74B/E
2!# P"/"^E>PUR/PWTAM\$V22)MFN ,B0>[TI3Y3]Z-N5,*Z*V\46DP"W"/ QZD?,M4@?A7J<=W.H!\]3D'9)NX]>.\W&4%AZR4.QA5C[.5HG*_\(X;_N;ET_OG M_P")H/@7PV
3LU(X&>&;_P"]KL((QY%),L*>S+BG_:'[W%M_WS6?UNO_#,G MVL^YR4/P\\/30^:HOE7T>?:?R(KS_P 4Z9;Z:XCN;"UW^3&$*[VR>5!ZU[@A ME7;NDC91U^4Y(KQSX@?\CM?__$C_
/0!7H:Y;7J5*K4Y7T-\.4I6:..I/XOP M!:3^+*]P[3G+^#[/>.H'RM\R_C5:N@U\U^T6V5'[R/D>_M7/UE)69TPE=!1 M112+"BBB@ HHHH *****"BBB@ HHHH *****!.EA;#:?7I4]4P<'(]VK;ES7:
MAYW7*?/9MAW&?M5LQRC0K=2] M^EW*S"-?+D>1-,K1OD,JYSC\C3KC2+FVMYIG>W/D%1,B2@O$6X (I8]6EBM% MA$,7FI&T23Y.Y$8Y(ZX[GG'>KFH;M8SV-REO
1<7;HTKM'M(VG)R>63*0@3/D2DF\/,XX6LIEEW^:[DN"(XU M?:"<#N:I+]NW[& V. SV@58IB6SA3D9&122)<-!;A6"AYI-JN2.C;>_!S45WI_V6PL[GSXW:X\ MS**V2FUL5,VLM,7%S9V\\2?$$C8L!&
<8X..36D?:-KF$[$%%%%;$EM=4U!=-;3EO;@6+'<;<2'83]*]444E%1V5@NWN%+ MV_&DI>WXTP+MO>6PL?MM[+,L;R&**.!06<@ D\\ #(\>E&Z9FM)X_LY?RXG MN"(C(^.[0/7]*CM+UD@-
G):I=PL^]{FW95^F5*\\^E6EOKB.7R9)B.O /AA M:)U\H@=I8CL >/6C^P M;Q2?.DM8QYGE*9)@*!(V 0%^H(YZ89-C :,_&=VQR5W;L_7-7&U MU)+2)9K&">:..;S 7R N$55Z'GIO(/%#=9!H
FAWKC\F.8JSB^20+(57.2! MZ<'ZXJ5= N4G"3>6V#B1(95+QDJ67.>!D"FC7IBXFEM[>;Z"BW#@[@K9SP# MCC<<'M38M9NQ=3S}'&TDY#, 1W95(.1W5\FB]8/=!=!OG9(T\EYBR**RC?&7^
M[N':^G>]UW82V8C9WBD20L%>)]PRO!!]O5TZW=6\WF_9(8KIRC2RE6W2@8(R M.X&< G'6LY[EY+6*W(79&[NN!SEL9_E50=1O78'8AK;\(Z$_B+Q/9:>%)B+ ^ M9.?2->3^?
&LJH*]W^$_A=M'T-M4NH]MW?@%01RD7\(_'K^5@WU> MB*I0YY'H*J$0*HP , #M3J***^)/2"BBB@ HHHH ***** "H^6YY_A%25' RW M/^Z* 'UYA\2?"S!VUZS3*\"Z11T]'_QKT^FR1I+&T5"HI
MQ+IS<)71\TT5UGC7PAX>NOM5JK-ILK?*>OE^Z?;T-G&2 MDKH****T*"BBB@#J_AU_R_/_7"3>0KV&15$,V%_@/>O'2AU_P CA%_UPD_D M*]@<_ N9NGW245\YFO\?
Y'GXGXS'6.1H\AAC'&2*F\@L,F8CN1A>M0QOL&/W? M3^) MN0/F:.B6CVDNT\H?NMZU_M6K(Z4TT%%%% PHHHH ***** "BBB@ HHHH ****!/8*?&^QN>AIE%5&3B[HS]
MTHU8.$MF7**ABD_A/X&I]&$U-71\CBT65(=SSUQ39(X+73/M-];.8;K]^(A$HVL0%V\#@D$G'ZURH)4Y!P0<@CM4L]Q M/WN--
M)+>XMOLD<:./.B>8%=!%^QAOW'88/MCO7*44WA[27!2.C/V5T*6A M9SS_ +OSA=$;0GEK]W=_M;LXYZ5SK8#WCS&,G&WI^%)6WX7\.WOBK5ULK4%(U-M^:>6B-
CX=^#W\3:R+BY0_V9:_&E)'$C=0G^/MI;^A M0 J@_8 '2J.C:/9Z%I4&G6.>R"(8'JQ[DGU]_7OV/ODL55YNBV/0I4U!"T4 M45Q&@4444 %%%% !1110
5'C]^2!VI*B_P"7@ [H_G0!+1110!#6^O/IQ/.,6A]CZCW_.O:::RAE(8 @]0:Z<_MBIX>5X[=Z%G2C5<'H?-%%>K>)OAM#==M)=Z*5@.2UNW$;'V_NGJ*\OO;&ZTZY:.MWO;>2"9?X77&?
!ZU']A\53KJ\7KV/0A5C-%>BBBNDT.K^'/_(XPC_IA)_(5 M[)&?*EQ@_+Q7A?A35[?0M?2^NED:)8W0B-1)T&T1$'O\@#]P%GR!]D?\ $#_"N77XE:'P6COV M;U\I_6I?^%HZ-
_>^*.5@UOQ%&_QKHZ1E#*58 J>H(ZTFKEQFXG)T5]W>D$9>VY'>.G^:59:*5:.P M(8=016;31N\]["4444B@HHHH ***** "BBB@ HHHH%]@HHHH *FCE[-^]&BK MA-
P=T88C#PKPY9ERBJR2%..H]*L*X$<*[]=6.SYG$X&K0=WJNXM%%%%:G&% M%%% !1110 4444 %+V_&DI>WXT)1110 4444 %%%% CDFE66**.Y)'.%1%W%O MH*1\) "2YO=EYXA+6T'5;1#^\?
'C__3K]*Y\1BJ6'CS5&7&$I/0Y+PI MX.U+Q9>A+9#%9HV)KIA\]>H'JWM7T)H/A^P\.:8ECI6R,84445YYJ%%%% !111 M0 4444 %%%% !42_ "W/^Z*DJ\ Y;G_'10!)1110 4444 %4M1TFQU:W,%
M],1SQGLPZ?0]JNT4TW%W0TVMCS/5_A4OS2:1>%?2&XY'X,.?SS7$ZCX7UO2L MFZTZ8(.LD8WK^8KZ"!,5Z%+,ZT-):F\<3-;ZGS/D9QW]**^B;O1-+OP1=:;?; M2Y[M&^?
SK&F^'GAJ4Y^P>7_USD8?UKNCF]_%%FRO4>]/#Z*!F,X8>'F/"W2 M_P"[:,_ .*N\\ K>2'] O\ ZU:?VK0\OK&#QNBO9/^%7^ 6\ [_?_ %J/ M^%?^'< 6\ P" W_UJ/[5H>8?
68'C=)_%^%>R.*O\/^MY_P!_O_K4P?##P_YK M+_IG !SY_P!?:C^U:'F'UF!X]17LG_"KO#_K>?\ ?[_ZU' "K_#_*WG_?[_M .M1 .M#$#ZS\;HKV3_(5?X?\)6\ [_?\ UJ/^%7>'_6\ [_?_%J/[5H> M8?
68'C=13VT-RN)4!]#W%>T_*O\/^MY_P!_O_K4?*O\\ K>?]_O\ ZU+_^MU:'F"Q4$>!SZ,XY@?=_LMP:SY;:>'_61,OOCBOHS_A5WA_UO/^_W_P!:C_A5 MWA_UO\ O\ ]:D\SP_F:+&Q6Y\W45]%O\)?
#$OWX[D_]M?\ ZU0'X>%3T2\ M'TN# A4_VE1\R_X0=^Z*C^%@C\%_"QZ&^'_;O_P#6[A A2_A;^]?_P#@1_\ M6H_M*CYA]>]'51?T#_P!?D_>O _/P(_P#K4O\ PI?PMZW_/X$?_6H_M*C
MYA]>I'SI17T%_P*%\+>M]JE<\4QG)/<58F\0W)L9GBMXXI886D?S9,#@D?+Z\COC MTJ]#?:7=.KJ2-4C7#^;& "I8^O(:1W5[H4'I',ML5BB$]#8I"J6VY'XUT7B MW\I'S$?7UC@<;R@SNSIC>!@JP7)]
<_A4=UKUQ.;L1M$EF"M(_E297:"AQU MY[U?9]+62X9FM_^.3D[MO?*K$Y7MRAYJ23673[3+Y.9MX&="/,Q(2HY^7 M'3\?>DL\3T]O5EAB3SFC$AE**"H(&3UZ"K/GZ23]M\RTRQ\OSLKD^V.323
MUB'S*?\ ,DZW"02P0A0,57D27<@W#Y>=<=<\?_KIVC:KO!(?D#[F7'WNQ%)=27B36PM88Y(VDQ.SO@HN#R/4YQ4.K&?R8%@+ M!GF53M8KQ]1TJE>ZU&KD":*\162.Y)G4AB\B9WL,\G&.OQ^%
(NA*J;?/)RI! M.SU_']*B%W?VJF*>-5201F=HR0/EW9///QVIBZU=,Q_P!4KJ]%8-AW2[O3 MT]?YUM^\W3+!XDBT25H0GI11&S,HC3!Y;/)
[U9T[2%L)"VY?PGEKP<[K*SRR)%'+Y>2R$K%E,GTSD\4-3 M:M<'S$SZ OE[4FR=S%2ZYVC^$#&#\O:G/HA:)AYX:0@ ,R="2#G@]>*K1:Q> M?9VNY8T,,>T,J(P+9SR,^^,*W(3(8$,P D*C<%Z9J9.
<=VN2*5UIKSE"LZ[MO*.+EX]V0>I'H:AET&*190)6>;9L#GJ0,UL45FJDEL3S,S:#2ULI7E MW!G=<-A<=R?4GO3(!&1+F*8R,O:)(4IZES_[/^E:E%'M);AS,Q7T:I"L'ER@_M BJH*_*
<9Y(!K6G9VRV=I':KC"#' Q5BBASDU0@VV%1+_Q\/_NCM!:EJ)?^_M/A_]T?
UJ1$&H:,9ZK:_9KZ!9H=ZOL8GJIR#^8J2[A:>UDB1D5F&/G3ZM%);6UY'*]S'(Q=5V_O4*$CGIPM.BU#48KCR/),IEG,8DVMA2,$D\\+MSCW M'O5:VUW5;EMHB@5G=%((+&$EL$$#OCUQS0N?
N'OG0V%FMA80VJ$%8UP,#'Z5 M9K0-N&TD/M6DDAADDNFMY)7C.T :OF SWVCKQS5-8O3-O>18HI]^>\9,8 M&7^8#\ %@=34I*BF^ZA >\Z%N`]E#*589!&
M"*KV&GVNEV.=E90K#:Q#'1KT'.:L.G:2H!;' 5= DO9=/B?48(H+!LCJY'$^ M]5.>Q[T],"<>%0/.IVA 2X==L>T.0Q8%\'YCSCM5A/#R)!Y?G $Q[3M3C._M>3R?
6LJ#4=4MQ<2MO/.%$K%E*F3'F=/EVCC'TJ6YUN_;3W+2PV[^2[1N$9O. M.2!MQT/3UZ^E=355]2/=+:>&((UGW&52BR;TRI+??#G))QV[5P+$+>2WG M0ACYY4JKL",
(.>OTS4VJM[C]TM2>'$DB":.("J9"#^"%\ 6IGTNZD=)C<6 M_G]&7BW^3:P /&>O'7/M4&K7%Y%<0-&S"/R6?XE!Y;I:KM6600E M=D4I18F!.]MI7KVZYI>^TG<-$6++1'LHQ)XY+8@>8KP_,Q"
[>#G@ ,XP0:?10 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D! end GRAPHIC 22 wavd20240923_s1img006.jpg begin 644
wavd20240923_s1img006.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ # _VP!# @&!@<&!0@<'!P<)"0@*#!0 # L+ M#!D2$P\4'1H?'AT:'!P@)"XG("
(L(QP<*#7]#A(6&AXB)BI*3E)66)EYB9F]*>CI*6FIZBIJK*SM+6VMIBYNL+#Q,7&_MQ\GIRM+3U-76U]C0VK0]RX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$
@$"! 0#! <%! 0 0)W $"M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-,$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI;G-T=79W>'EZ@H,$
MA8:'B(F*DI.4E9:7F)F:HJ.DI:;GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # .! (1 Q$ /P#W^BBB@ HH MHH ***** "DI:K75]:V4>^ZGCA7U=@*$K[
6:*R(?$VC3R:$U&#<>@%UQ_>F>M M2:AKNG:8BFYN5+8^\\S]*KDE>U@6IITEUA9,8P8Q4H IM^CV+L;IM:Q1N3RP7GV2KYJ*WN$NH?.C)*DDN:\7:.E!H\4UU!5>JA:N M8Z.K?
LAE]/!8RS6T'G3*N5CSC=6-;'6M1B\Z/5!2(=/+BMMVT^C;FR#4ESX M@.MRUH!5]!(.O#L&VQH?=]JR:3K=[*)!I[&UD_O0QMO^FX$548V6NA7,F"[^C M-J&JF!>.^O&CL;=_)DN;-
N'(!RV<\#/:M'P\=0N]-B9+V-8(96C!6 $RJIQ.MG.>_L*IZ?H=Q>S:C;7VI3&-;@^:,#$ @DW ')/7!:M7PBY?PW;?W5+HI QE5 M8@?H*TJ,/+IY&BV-VBBBN8"MS-MLLIVVE]L,':._'2LCP9
L!A6Q16#93<2#D M9)K?:0UQ_@]XW7^OVL>?(AOFV>@SU'YKZ.L&:03=*5NEF=C11169B%%%% ! M1110 4444 <]=GS/&EC&P^6.WD=?XD!/$]S+%816\+F-MNBJ/,NANIJ/Q%
M;SQ2VNK6L9DDM&.]!U:,]N?Z!XCTKKYD$GH<,I_H171=6C/HCD2=YPZO4LV M.E!]K':VZ!8T&/K[GWJSO4'!91^_<___(Q-]W^VM1\OIL\P=/KUH_X0W1R MO[V*:,0 \M))6+?G4-0O=R_
WBY6M(Q)UM?1733ZY0>[C\B4D\(?X9/P!(M_*M33[*/3M/@M(ON0H%!]?>L;PM<2^?7?VD[3PVEP8XIG.25QTS[5B7WBO6_M=U"73O"<'-%$=LM-(,KG_9[?C5JE*3Y5LNI=SO<@#)
(Q6=?:.1.F@_;2M(" M.TDR@_E7&GXSL?O(DA"_ET_2&EE*?#=&O@#),P[N_7*?LZ, M?BG?T1K&,/M,JZM2(+C=8>&N)-0OI/D614/EI[^IK?\&:#)H.C^7!
[V#3P8_P!WL#9YROP3GUYK6V:7;Z1HEK:P{@1@L0/O''6K6I6.6I MZ=/9S?]4=!N)S:.87BD7=IA'/9Q_"X]B*IS.IV\[LI+J,-%%%8C"B MBB@ HHHH *****"BBH+S_CQN/^N3?RH
I'Q)H0)!UK3@1Q0:IA &K=I?VE_M&9+.Z@N(P=!;&0.?3(KYQ\"WWPPMO#[Q^*[:VDU3[3*29(G8[_+TKW+P3! MX7&@<+=*$[:&+3KIV?.2E0S#Y3G/TO3LW(+ZTNIYX(+F*6:W8+,B."8SUPP[
M4RU33I/95O,^UMF<943S*A;Z9>=>]#W_DJ/C_Z^D_K69\2K?2+OXO>#X= M=%N=.,VN//%PVU/NMC)_WL4!<]5MM:T]JF\]TU*SGEQD)%.KG'T!JU+.'#"T MLLBI&HW,[!
]2.\$\>V/@S31H[^!&M$\1_;XQ --E+LR\YS@D==M>K?$#= _MPK/Q#OP&_LV;=CIG8>E%@-;_ (270?\ H-Z; P"!4?\ C5NUO+2^B\^TN(;B M/,/,A<:,CMD5X!X7U'X/Q>%M-CUNTM6U-;=1U^$K?
0(?#MQ)X:.MMXH=,N/WT8B4J&SWYY[4K#+D^O:/;/#/[UC%*APR27"*P>H)GTU73M09EL MK^VN64980S*Y4>^#7@%M=^ [:X@^:^A=(0?:43[E\R.FP,MNZ%\KU3X?.MQP
.9$4[Q1LI]0#FG85SKO[0L_M_V#[3#]LV>9Y&\;IO3..N*L MUY;&/^,E)O\ L _^SBO4J0RK%?V<]W/:0W44ES!CS8E<%DSTR.U%S?V=G+!' M?K@=]=A7/7Z***0PJ"Z4O:3H MHRS1L /PJ>B@#SCX
Z9/9>!6BO[&2":[;.=D\GUL,NN".E>BJBH %4 #L!0' M4]&! &D,B*P5G4$]B; /,? NGWMK\1 '-S<6D\4$]TABD="]R<'I[_A53QQ MX<_M[XN^$TNI,>\TH6TXN2T9:(?*V
QZ#G%>]IAG&1FDWH%W%V=EV^N:!6/"M> M\)M\)?&FG^* "^C?:./D(MKVQ@BWM&&XWQCJ\C7H'CBWGO_A_KEM:PO+/ M82I'$HRS,5. !ZUT*NK+N5@1Z@T@=&8J&4D=0#TH \?\)>-
FT+PEI>E77@GQ M))/:VZQ2.FF.0Q'X5Z5X,UL;]I/VT:7?:.< Y007L/E/OWV^E:V!-VWF3B@9YO\/=+N:,QOX\FO+*2..?45>%Y8L+(OSG*D]>HZ5Z0D:1C MY$5<^@Q3LC..C)IEC5@A=0QF$\T
>1^(+V^\.?&U]>_L+5K^R:25MP]C:M+ MY,/4#':NT\>-3XCU&2S/A[6].V1F3S;ZT:)#R!@$]^:ZK(SC(S1D;Z@D@F6#YHY%VLN2 M3R.U=?NL,94=#SZU+KNDSW/BJUO/[+>
[A18QO6WM0#$G)E8,O4' MY :[" B@#$U2*EAU:SU&WLY;M8HY(GBA= PW8//SL!VQU[U2.A?7 +GCOBNHHH YWP]I%OI>G7MM(B0R/,O3R5"0XQ\!# ^ZG4>N:H:)HUQ;7.G%-)_LZ6V#"]N=\;?;#L*]5)9LMA]SX(V^YKL:* .7NM-M,N5\6QW]K8%RSIYL\R1,@?&%#L8MYBD#L!@D^Y];5; RZRMU1(&8L^V1@/F!7D3^%;2U\C]\B0&>V+@>8JE2\>[!R
1Z'IT:;!% &/:6J# M1)H+,2/[.#(X6VV1+R1Z(Q7GZUF^"_.ETO3989M,>RE)3<6MK:+?@8_Y8LV< .<\MSS7544 %%%% ']D! end XML 24 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	6 Months Ended Jun. 30, 2024
Document Information [Line Items]	
Entity Central Index Key	0000803578

Entity Registrant Name	FIREFLY NEUROSCIENCE, INC.
Amendment Flag	false
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	S-1
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	54-1167364
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

~~XML 25 R2.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets					
Cash	$ 358	$ 2,143		$ 58	
Other receivables	83	84		19	
Prepaid expenses	63	28		6	
Total current assets	504	2,255		83	
Non current assets					
Equipment, net	60	0			
Intangible assets, net	634	386		0	
Total non current assets	694	386		52	
TOTAL ASSETS	1,198	2,641		135	
Current liabilities					
Trade payables	1,265	455		420	
Accrued liabilities	973	1,902		855	
Total current liabilities	2,413	2,532		2,361	
TOTAL LIABILITIES	2,413	2,532		2,361	
COMMITMENTS AND CONTINGENCIES (Note 8)					
SHAREHOLDERS' EQUITY (DEFICIT)					
Preferred shares, $0.00001 par value: 30,000,000 shares authorized; 2,374,219 and 16,116,957 issued and outstanding at June 30, 2024 and December 31, 2023, respectively	0	0		0	
Common shares, $0.00001 par value: 2,470,000,000 shares authorized; 49,948,710 and 35,369,877 issued and outstanding at June 30, 2024 and December 31, 2023, respectively	0	0		0	
Additional paid-in capital	77,795	76,733		71,795	
Accumulated deficit	(79,010)	(76,624)		(74,021)	
TOTAL SHAREHOLDERS' EQUITY (DEFICIT)	(1,215)	109	$ (1,729)	(2,226)	$ (3,014)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)	1,198	2,641		135	
Related Party [Member]					
Current liabilities					
Related party payable	$ 175	$ 175		$ 177	

~~XML 26 R3.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 27, 2022
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001	
Preferred stock, shares authorized (in shares)	30,000,000	30,000,000	30,000,000	
Preferred stock, shares issued (in shares)	2,374,219	16,116,957	0	
Preferred stock, shares outstanding (in shares)	2,374,219	16,116,957	0	
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001	
Common stock, shares authorized (in shares)	2,470,000,000	2,470,000,000	2,470,000,000	
Common stock, shares issued (in shares)	49,948,710	35,369,877	2,552,744	
Common stock, shares outstanding (in shares)	49,948,710	35,369,877	2,552,744	1,085,605

~~XML 27 R4.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
REVENUE	$ 10	$ 451	$ 22	$ 456
OPERATING EXPENSES:				
Research and development expenses	350	199	639	320
Selling and marketing expenses	293	171	542	304
General and administration expenses	626	399	1,191	696
TOTAL OPERATING EXPENSES	1,269	769	2,372	1,320
OPERATING LOSS	(1,259)	(318)	(2,350)	(864)
OTHER INCOME (EXPENSE)				
Interest and bank fees	(10)	(3)	(12)	(10)
Unrealized gain on foreign exchange	31	0	3	0
Other expense, net	(26)	(2)	(27)	(2)
LOSS BEFORE INCOME TAX	(1,264)	(323)	(2,386)	(876)
Income tax provision	0	0	0	0
NET LOSS AND COMPREHENSIVE LOSS	$ (1,264)	$ (323)	$ (2,386)	$ (876)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share)	$ (0.03)	$ (0.01)	$ (0.05)	$ (0.03)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED (in shares)	49,948,710	35,277,018	49,948,710	26,734,918

~~XML 28 R5.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Series B Preferred Stock [Member]	Series B Preferred Stock Offering [Member]	Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock Offering [Member]	Common Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock Offering [Member]	Common Stock, Number of Shares to be Issued [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock Offering [Member]	Additional Paid-in Capital [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock Offering [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock Offering [Member]	Preferred Stock [Member]	Series B Preferred Stock [Member]	Preferred Stock, Number of Shares to be Issued [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Series B Preferred Stock [Member]	Common Stock, Number of Shares to be Issued [Member]	Series C Preferred Stock [Member]	Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock [Member]	Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]	[M
Balance (in shares) at Dec. 31, 2021																															
Balance (in shares) at Dec. 31, 2021																															

Balance at Dec. 31, 2021																
Series B Preferred Stock conversion (in shares)																
Series C Preferred Stock Units offering (in shares)																
Series C Preferred Stock Units offering																
Share-based compensation expense																
Net (loss) income																
Series B Preferred Stock offering																
Balance (in shares) at Dec. 31, 2022																
Balance (in shares) at Dec. 31, 2022																
Balance at Dec. 31, 2022																
Series C Preferred Stock Units offering (in shares)		5,897,932														
Share-based compensation expense																
Net (loss) income																
Common Stock Private Placement (in shares)																
Common Stock Private Placement																
Series B Preferred Stock offering	$ 0		$ 0		$ 1,092		$ 0		$ 1,092							
Series B Preferred Stock offering (in shares)				0												
Balance (in shares) at Jun. 30, 2023																
Balance (in shares) at Jun. 30, 2023																
Balance at Jun. 30, 2023																
Balance (in shares) at Dec. 31, 2022																
Balance (in shares) at Dec. 31, 2022																
Balance at Dec. 31, 2022																
Series C Preferred Stock Units offering (in shares)	14,578,833															
Net (loss) income																
Common Stock Private Placement (in shares)																
Common Stock Private Placement																
Series B Preferred Stock offering	$ 0		$ 0		$ 2,608		$ 0		$ 2,608							
Series B Preferred Stock offering (in shares)	(14,578,833)		14,578,833													
Balance (in shares) at Dec. 31, 2023																
Balance (in shares) at Dec. 31, 2023																
Balance at Dec. 31, 2023																
Series B Preferred Stock conversion (in shares)										(14,578,833)		(14,578,833)				
Series B Preferred Stock conversion (in shares)											14,578,833	14,578,833				
Series C Preferred Stock Units offering (in shares)													836,085	0		
Series C Preferred Stock Units offering													$ 0	$ 0	$ 945	$
Share-based compensation expense																
Net (loss) income																
Balance (in shares) at Jun. 30, 2024																
Balance (in shares) at Jun. 30, 2024																
Balance at Jun. 30, 2024																

~~XML 29 R6.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net (loss) income	$ (2,386)	$ (876)
Adjustments to reconcile net loss to net cash used in operating activities		
Depreciation	4	0
Share-based compensation expense	117	148
Changes in operating assets and liabilities:		
Change in other receivables	1	(3)
Change in prepaid expenses	(35)	(24)
Change in trade payables	810	63
Change in related party payables	0	30
Change in accrued liabilities	(929)	176
Change in deferred revenue	0	(450)
Net cash used in operating activities	(2,418)	(936)
CASH FLOWS FROM INVESTING ACTIVITIES:		

Purchase of equipment	(64)	0
Product enhancement – intangible asset	(248)	0
Net cash used in investing activities	(312)	0
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from sale of shares	945	1,225
Net cash provided by financing activities	945	1,225
(DECREASE) INCREASE IN CASH	(1,785)	289
BALANCE OF CASH AT THE BEGINNING OF PERIOD	2,143	58
BALANCE OF CASH AT THE END OF PERIOD	358	347
Supplemental cash flow information		
Cash paid for interest	0	0
Cash paid for income taxes	$ 0	$ 0

~~XML 30 R7.htm IDEA: XBRL DOCUMENT~~

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets		
Cash	$ 2,143	$ 58
Other receivables	84	19
Prepaid expenses	28	6
Total current assets	2,255	83
Non current assets		
Long term deposits	0	52
Intangible assets, net	386	0
Total non current assets	386	52
TOTAL ASSETS	2,641	135
Current liabilities		
Trade payables	455	420
Accrued liabilities	1,902	855
Deferred revenue	0	909
Total current liabilities	2,532	2,361
TOTAL LIABILITIES	2,532	2,361
COMMITMENTS AND CONTINGENCIES (Note 8)		
SHAREHOLDERS' EQUITY (DEFICIT)		
Preferred shares, $0.00001 par value: 30,000,000 shares authorized; 2,374,219 and 16,116,957 issued and outstanding at June 30, 2024 and December 31, 2023, respectively	0	0
Common shares, $0.00001 par value: 2,470,000,000 shares authorized; 49,948,710 and 35,369,877 issued and outstanding at June 30, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	76,733	71,795
Accumulated deficit	(76,624)	(74,021)
TOTAL SHAREHOLDERS' EQUITY (DEFICIT)	109	(2,226)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)	2,641	135
Related Party [Member]		
Current liabilities		
Related party payable	$ 175	$ 177

~~XML 31 R8.htm IDEA: XBRL DOCUMENT~~

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 27, 2022
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001	
Preferred stock, shares authorized (in shares)	30,000,000	30,000,000	30,000,000	
Preferred stock, shares issued (in shares)	2,374,219	16,116,957	0	
Preferred stock, shares outstanding (in shares)	2,374,219	16,116,957	0	
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001	
Common stock, shares authorized (in shares)	2,470,000,000	2,470,000,000	2,470,000,000	
Common stock, shares issued (in shares)	49,948,710	35,369,877	2,552,744	
Common stock, shares outstanding (in shares)	49,948,710	35,369,877	2,552,744	1,085,605

~~XML 32 R9.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended	
	Dec. 31, 2023	Dec. 31, 2022
REVENUE	$ 498	$ 0
OPERATING EXPENSES:		
Research and development expenses	741	1,299
Selling and marketing expenses	639	524
General and administration expenses	2,196	1,542
Impairment loss on equipment	0	79
TOTAL OPERATING EXPENSES	3,576	3,444
OPERATING LOSS	(3,078)	(3,444)
OTHER INCOME (EXPENSE)		
Interest and bank fees	(18)	(440)
Unrealized gain on foreign exchange	37	(134)
Loss on extinguishment of debt	0	(59)
Other income (expenses)	457	173
LOSS BEFORE INCOME TAX	(2,602)	(3,904)
Income tax provision	(1)	0
NET LOSS AND COMPREHENSIVE LOSS	$ (2,603)	$ (3,904)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share)	$ (0.08)	$ (2.83)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED (in shares)	31,089,132	1,380,051

~~XML 33 R10.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series A Preferred Stock [Member] Preferred Stock [Member]	Series A Preferred Stock [Member] Common Stock [Member]	Series A Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A Preferred Stock [Member] Retained Earnings [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member] Series B Preferred Stock Offering [Member] Preferred Stock [Member]	Series B Preferred Stock [Member] Series B Preferred Stock Offering [Member] Common Stock [Member]	Series B Preferred Stock [Member] Series B Preferred Stock Offering [Member] Additional Paid-in Capital [Member]	Series B Preferred Stock [Member] Series B Preferred Stock Offering [Member] Retained Earnings [Member]	Series B Preferred Stock [Member] Series B Preferred Stock Offering [Member]	Series B Preferred Stock [Member] Preferred Stock [Member]	Series C Preferred Stock [Member] Series C Preferred Stock Offering [Member] Preferred Stock [Member]	Series C Preferred Stock [Member] Series C Preferred Stock Offering [Member] Common Stock [Member]	Series C Preferred Stock [Member] Series C Preferred Stock Offering [Member] Additional Paid-in Capital [Member]	Ser Pref St [Me Ser Pref St Offe [Me Reta Ear [Me
Balance (in shares) at Dec. 31, 2021															
Balance (in shares) at Dec. 31, 2021															
Balance at Dec. 31,															

2021															
Series C Preferred Stock Units offering (in shares)	10,000,000	0													
Series B Preferred Stock offering	$ 3	$ 0	$ 37	$ 0	$ 40										
Conversion of Stock, Shares Converted (in shares)															
Converted shares of common stock															
Converted shares of common stock (in shares)															
Series C Preferred Stock Units offering															
Debt conversion (in shares)															
Debt conversion															
Warrants issued															
Share-based compensation expense															
Stock dividend paid (in shares)															
Stock dividend paid															
Stock dividend paid															
Net (loss) income															
Balance (in shares) at Dec. 31, 2022															
Balance (in shares) at Dec. 31, 2022															
Balance at Dec. 31, 2022															
Series B Preferred Stock offering						$ 0	$ 0	$ 1,092	$ 0	$ 1,092					
Share-based compensation expense															
Net (loss) income															
Common Stock Private Placement															
Balance (in shares) at Jun. 30, 2023															
Balance at Jun. 30, 2023															
Balance (in shares) at Dec. 31, 2022															
Balance (in shares) at Dec. 31, 2022															
Balance at Dec. 31, 2022															
Series C Preferred Stock Units offering (in shares)						14,578,833						1,538,134	0		
Series B Preferred Stock offering						$ 0	$ 0	$ 2,608	$ 0	$ 2,608					
Series C Preferred Stock Units offering												$ 0	$ 0	$ 1,902	$ 0
Net (loss) income															
Common Stock Private Placement (in shares)															
Common Stock Private Placement															
Series B Preferred Stock offering (in shares)						(14,578,833)	14,578,833								
Share-based expense (in shares)															
Share-based expense															
Share repurchase (in shares)															
Share repurchase															
Share repurchase (in shares)															
Balance (in shares) at Dec. 31, 2023															
Balance (in shares) at Dec. 31, 2023															
Balance at Dec. 31, 2023															
Series C Preferred Stock Units offering (in shares)															
Conversion of Stock, Shares Converted (in shares)											14,578,833				
Series C Preferred Stock Units offering															
Share-based compensation expense															
Net (loss) income															
Balance (in shares) at Jun. 30, 2024															
Balance at Jun. 30, 2024															

~~XML 34 R11.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	**12 Months Ended**	
	Dec. 31, 2023	**Dec. 31, 2022**
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net (loss) income	$ (2,603)	$ (3,904)
Adjustments to reconcile net loss to net cash used in operating activities		
Depreciation	0	14
Net gain from sale of equipment	0	(87)
Share-based compensation expense	295	60
Non-cash interest on convertible debt	0	460
Loss on extinguishment of debt	0	59

Changes in operating assets and liabilities:		
Change in other receivables	(65)	27
Change in prepaid expenses	(22)	3
Change in long term deposits	52	9
Change in trade payables	35	(80)
Change in related party payables	(2)	0
Change in accrued liabilities	1,047	97
Change in deferred revenue	(909)	450
Net cash used in operating activities	(2,172)	(2,892)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from sale of equipment	0	262
Product enhancement – intangible asset	(386)	0
Net cash used in investing activities	(386)	262
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from sale of convertible debt	0	1,745
Proceeds from sale of shares	4,643	290
Net cash provided by financing activities	4,643	2,035
(DECREASE) INCREASE IN CASH	2,085	(595)
BALANCE OF CASH AT THE BEGINNING OF PERIOD	58	653
BALANCE OF CASH AT THE END OF PERIOD	2,143	58
Supplemental cash flow information		
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Debt converted to equity	$ 0	$ (4,021)

~~XML 35 R12.htm IDEA: XBRL DOCUMENT~~

Note 1 - Business Description

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

6 Months Ended Jun. 30, 2024

NOTE 1: BUSINESS DESCRIPTION

Nature of organization and business

Firefly Neuroscience, Inc. (the "Company") and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.), Firefly Neuroscience Canada Inc., a Canadian corporation, and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain.

Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc.

In July 2014, the U.S. Food and Drug Administration ("FDA") cleared Firefly Neuroscience Ltd.'s Brain Network Analytics ("BNA" ™) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European ("CE") approval for BNA™ allowing use in Europe.

Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc.

Merger agreement

On November 16, 2023, WaveDancer, Inc. ("WaveDancer") (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the "Merger Agreement") with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Company's Artificial Intelligence driven BNA™ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market.

Under the terms of the Merger Agreement, each share of the Company's shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancer's ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. Following the merger, WaveDancer, Inc. will be renamed "Firefly Neuroscience, Inc." and the corporate headquarters will be located in Buffalo, NY.

On January 12, 2024 and June 17, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates included changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Company's warrants at the effective time, deletion of certain closing obligations, and to extend the end date of the original agreement dated November 15, 2023.

The transaction was completed effective August 12, 2024.

12 Months Ended Dec. 31, 2023

NOTE 1: BUSINESS DESCRIPTION

Nature of organization and business

Firefly Neuroscience, Inc. (the "Company") and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.). and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain.

Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc.

In July 2014, the U.S. Food and Drug Administration ("FDA") cleared Firefly Neuroscience Ltd. Brain Network Analytics' (BNA™) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European ("CE") approval for BNA™ allowing use in Europe.

Reorganization

Name change and corporate restructure

Elminda Inc. was incorporated in the State of Delaware on April 21, 2022.

On July 5, 2022, Elminda Ltd. became a subsidiary of Elminda Inc. via a share exchange agreement wherein Elminda Inc. issued shares to shareholders of Elminda Ltd. against shares of Elminda Ltd. (the "Flip Transaction").

On September 15, 2022 and October 24, 2022 management changed the name from Elminda Inc. and Elminda Ltd. to Firefly Neuroscience Inc. and Firefly Neuroscience Ltd., respectively.

Shareholder Restructuring

On January 27, 2022, holders of shares of outstanding Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock of Firefly Neuroscience Ltd. voted to convert their shares of preferred stock into shares of common stock of Firefly Neuroscience Ltd. Upon completion of the transaction, Firefly Neuroscience Ltd. had 1,085,605 shares of common stock and 3,198,421 shares of Series A Preferred Stock outstanding.

On May 24, 2022, holders of the majority of shares of common stock of Firefly Neuroscience Ltd. voted to exchange their shares on a 1-1 basis for shares in the Company.

In connection with the Flip Transaction, on July 5, 2022, (a) Firefly Neuroscience, Inc. became an issuer of (i) 1,085,605 common shares, (ii) 3,198,421 Series A preferred shares and (c) 3,715 shares of common share dividends. The original shareholders of Firefly Neuroscience Ltd. remained in control of the new group and the Company.

On November 23, 2022, the Company completed a reverse share split on a ratio of 1:750. These consolidated financial statements and all financial notes referencing shares of common stock, stock dividends, stock options and their associated prices have been retroactively adjusted as to show the effect of the 1:750 reverse stock split.

Merger agreement

On November 16, 2023, WaveDancer, Inc. ("WaveDancer") (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the "Merger Agreement") with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Company's Artificial Intelligence driven BNA™ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market.

Under the terms of the Merger Agreement, each share of the Company's shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancer's ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by WaveDancer, and the receipt of required shareholder approvals from the Company's and WaveDancer shareholders. Following the merger, WaveDancer, Inc. will be renamed "Firefly Neuroscience, Inc." and the corporate headquarters will be located in Toronto, Ontario. The transaction is expected to be completed in 2024.

Israeli/Palestinian conflict

On October 7, 2023, an armed Israeli/Palestinian conflict broke out. As the Israeli/Palestinian conflict in Gaza develops, it could have an adverse impact on regional and global markets. While our operations are not directly impacted by these events, the duration of hostilities, imposition of sanctions and related events (including cyberattacks), among others, cannot be predicted. As a result, those events present uncertainty and risk. To date, conflict in Gaza has not had a material impact on the Company's business.

~~XML 36 R13.htm IDEA: XBRL DOCUMENT~~

Note 2 - Going Concern

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

6 Months Ended Jun. 30, 2024

NOTE 2: GOING CONCERN

As of June 30, 2024, the Company had an accumulated deficit of $79,010 (December 31, 2023: $76,624) and negative cash flow from operating activities for the six months ended June 30, 2024 of $2,402 (June 30, 2023: $936). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the six months ended June 30, 2024 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Company's liquidity in the foreseeable future, the Company has

12 Months Ended Dec. 31, 2023

NOTE 2: GOING CONCERN

As of December 31, 2023, the Company had an accumulated deficit of $76,624 (December 31, 2022: $74,021) and negative cash flow from operating activities for the year ended December 31, 2023 of $2,172 (for the year ended December 31, 2022: $2,892). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the year ended December 31, 2023 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these consolidated financial statements were issued. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Company's liquidity in the foreseeable future, the Company has taken the following measures:

taken the following measures:

(i) Negotiating further funding with existing and new investors to raise additional capital;
(ii) Taking various cost control measures to reduce the operational cash burn; and
(iii) Commercializing product to generate recurring sales.

(i) Negotiating further funding with existing and new investors to raise additional capital;
(ii) Taking various cost control measures to reduce the operational cash burn; and
(iii) Commercializing product to generate recurring sales.

Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future.

Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future.

~~XML 37 R14.htm IDEA: XBRL DOCUMENT~~

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

NOTE 3: BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United

NOTE 3: BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United States of America ("U.S. GAAP").

a. Principles of consolidation

These consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities ("VIE"). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation.

b. Revision of Prior Period Financial Statements

In connection with the preparation of the consolidated financial statements for year ended December 31, 2023, we identified an immaterial error related to certain general and administration and research and development expenses in the consolidated financial statements for year ended December 31, 2022. In accordance with SAB No. 99, "Materiality," and SAB No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements," we evaluated the error and determined that the related impact was not material to our consolidated financial statements for any prior annual or interim period, but that correcting the cumulative impact of the error would be significant to our results of operations for the year ended December 31, 2023. Accordingly, we have revised previously reported financial information for such immaterial error. A summary of revisions to certain previously reported financial information presented herein for comparative purposes is included in Note 20.

c. Use of estimates in the preparation of consolidated financial statements

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.

i) Share based payments
In calculating share-based compensation expense, key estimates are used such as, the stock price of the Company, the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company's stock price, and the risk-free interest rate.

ii) Warrants
In calculating the fair value of warrants issued, the Company includes key estimates such as the stock price of the Company, the expected life of the warrant, the volatility of the Company's stock price, and the risk-free interest rate.

d. Functional currency and foreign currency translations

The currency of the primary economic environment in which the operations of the Company is conducted is the U.S. dollar ("$" or "Dollar"). All of the Company's revenues and finance are denominated in U.S dollars. The reporting and the functional currency of the Company is the U.S Dollar.

The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively.

e. Fair value measurement

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

- Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;
- Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and
- Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The carrying amounts of cash and equivalents, accounts receivable, other receivables, long-term deposits, trade payables, balances to and from related party and convertible notes approximate their fair value due to the short-term maturity of such instruments. It is management's opinion that the Company is not exposed to any significant market or credit risks arising from these financial instruments.

f. Fair value of financial instruments

Cash, other receivables, trade payables, related party payable and accrued liabilities are carried at amortized cost, which management believes approximates their respective fair value due to the short-term nature of these instruments.

g. Related party

Parties are related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, and related parties may be individuals or corporate entities. A transaction is a related party transaction when there is a transfer of resources or obligations between related parties. The Company has disclosed its transactions with related parties.

h. Cash

The Company considers all highly liquid investments, which include short-term bank deposits that are not restricted as to withdrawal or use and the period to maturity of which did not exceed three months at time of investment, to be cash.

i. Other receivables

Other receivables are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses ("allowance for doubtful receivables") is based on the Company's assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay.

j. Contingent liabilities

Certain conditions may exist as of the date the consolidated financial statements are issued, that may result in a loss to the Company but that will only be resolved when one or more future events occur or fail to occur. Such losses are disclosed as contingent liabilities if it is not both probable and reasonably estimable. The Company's management assesses such contingent liabilities and estimated legal fees, if any. Such assessment inherently

States of America (“U.S. GAAP”). The results reported in these unaudited condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for any subsequent period or for the entire period. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s annual audited consolidated financial statements for the year ended December 31, 2023 and the notes included therein. Certain information and footnote disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in the accompanying unaudited condensed consolidated financial statements. All amounts are disclosed in thousands, except share and per share amounts. The accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, except as otherwise indicated, necessary for a fair statement of its consolidated financial position, results of operations, and cash flows of the Company for all periods presented.

a. Principles of consolidation

These unaudited consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities (“VIE”). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation.

b. Use of estimates in the preparation of consolidated financial statements

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.

Significant accounting policies

The following significant accounting policies should be read in conjunction with the Company’s annual audited consolidated financial statements for the year ended December 31, 2023 and the notes therein.

i) Equipment

Equipment is stated at cost less accumulated depreciation. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of four years for medical equipment.

c. Impact of recently issued accounting standards

The Company has evaluated issued Accounting Standards Updates not yet adopted and believes the adoption of these standards will not have a material impact on its condensed consolidated financial statements.

involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

k. Warrants

The Company accounts for the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and the applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity” (“ASC 480”) ASC 815, “Derivatives and Hedging” (“ASC 815”), and ASC 718, “Compensation—Stock Compensation” (“ASC 718”). The assessment considers whether they are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480 or meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own shares of common stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the warrants and as of each subsequent reporting date while the warrants are outstanding. For issued or modified warrants and that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations.

l. Stock options

The Company grants stock options to certain employees and directors through an established stock option plan. All stock option grants or changes to existing grants, are subject to board of directors’ approval. For employees and directors, the fair value of the award is measured on the grant date. For non-employees, as per ASC 718, remeasurement is not required. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Determining the appropriate fair value model and the related assumptions requires judgment. During the year ended December 31, 2023 and 2022, the fair value of each option grant was estimated using a Black-Scholes option-pricing model.

m. Revenue recognition

Revenue is recognized in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company performs the following five steps:

(i) identify the contract(s) with a customer,
(ii) identify the performance obligations in the contract,
(iii) determine the transaction price,
(iv) allocate the transaction price to the performance obligations in the contract, and
(v) recognize revenue when (or as) the entity satisfies a performance obligation.

The Company applies this five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the goods or services promised within each contract, related performance obligation and assesses whether each promised good or service is distinct. The Company recognizes as revenue, the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied at a point in time.

The Company’s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.

n. Deferred revenue

Deferred revenue consists of payments received from customers in advance of satisfying a performance obligation identified in accordance with ASC 606. The change in the deferred revenue balance for the years ended December 31, 2023, and 2022 was driven by payments from customers in advance of satisfying the performance obligations, offset by revenue recognized as performance obligations were completed.

o. Research and development expenses

Research and development expenses are expensed as incurred and consist primarily of personnel, facilities, equipment and supplies related to the Company’s research and development activities.

p. Software development costs

The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel, facilities, equipment and supplies and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage – when the research stage is complete, and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in intangible assets, net on the consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.

q. Income taxes

Income taxes are accounted for using the asset/liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than enactment of changes in the tax law or rates.

The Company adopted ASC 740 “Income Taxes” (“ASC 740”), which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.

r. Leases

At the inception of the contract, the Company assesses whether the contract contains a lease in accordance with ASU 2016-02, “Leases” (“ASC 842”). The Company determines whether an arrangement is a lease by establishing if the contract conveys the right to control the use of an identified asset, for a period of time in exchange for consideration. Leases are classified either as operating lease or finance lease. The Company elects not to apply the recognition requirements of ASC 842 to short-term leases. Short term leases are contracts that have a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company does not have any lease with a lease term longer than 12 months.

s. Employee benefits

Short-term employee benefits are benefits for which full settlement is expected within twelve months of the end of the financial year in which the members of staff rendered the corresponding services. These benefits include, paid annual leave, paid sick leave, health and governmental social security contributions which are expensed as the services are rendered. A liability for a cash bonus or plan profit-sharing is recognized when the Company has a legal or implied obligation to make such payments because of past services rendered by a member of staff, and it is possible to make a reasonable estimate of the amount.

For post-employment the Company has a defined contribution plan pursuant to section 14 to the Israeli Severance Compensation Act, 1963 under which the Company pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold enough to pay all employee benefits relating to employee service in the current and prior periods. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed monthly, concurrently with performance of the employee’s services.

t. Segment reporting

Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment.

u. Geographic areas

The Company has operations in Canada, the United States of America and Israel. The revenues and non-current assets of the Company are generated and located in the following locations:

Geographic areas	Revenue 2023	Revenue 2022	Non-current assets 2023	Non-current assets 2022
Canada	-	-	-	-
United States of America	478	-	-	-
Israel	20	-	386	52

v. Recent accounting pronouncements

In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning January 1, 2025, with early adoption permitted. The Company has not adopted this standard early and is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements disclosures.

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses.

The expanded annual disclosures are effective for the Company's year ending December 31, 2024, and the expanded interim disclosures are effective in 2025 and will be applied retrospectively to all prior periods presented.

The Company is currently evaluating the impact that ASU 2023-07 will have on its consolidated financial statements.

~~XML 38 R15.htm IDEA: XBRL DOCUMENT~~

Note 4 - Other Receivables

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

NOTE 4: OTHER RECEIVABLES

Detail of other receivables balance is as follows:

	June 30, 2024	December 31, 2023
Other receivables	$ 195	$ 196
Allowance for doubtful receivables	(112)	(112)
Total	**$ 83**	$ 84

NOTE 4: OTHER RECEIVABLES

Detail of other receivables balance is as follows:

	December 31 2023	2022
Other receivables	$ 196	$ 131
Allowance for doubtful receivables	(112)	(112)
Total	**$ 84**	$ 19

~~XML 39 R16.htm IDEA: XBRL DOCUMENT~~

Note 5 - Equipment

6 Months Ended
Jun. 30, 2024

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

NOTE 5: EQUIPMENT

Equipment balance is as follows:

	June 30, 2024	December 31, 2023
Medical equipment, cost	$ 64	$ -
Less – accumulated depreciation	(4)	-
Equipment, net	**$ 60**	**$ -**

~~XML 40 R17.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets

6 Months Ended
Jun. 30, 2024

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

NOTE 6: INTANGIBLE ASSETS

The following tables summarize the composition of intangible assets as of June 30, 2024:

	June 30, 2024			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Weighted Average Life
Unamortized intangible assets				
BNA software	$ 634	**$ -**	$ 634	n/a
Total intangible assets	**$ 634**	**$ -**	**$ 634**	

The BNA software enhancement project is in progress and amortization will begin once the project is substantially complete and the software is ready for its intended purpose. The software is expected to be completed by the end of 2024 and have a useful life of five years.

~~XML 41 R18.htm IDEA: XBRL DOCUMENT~~

Note 7 - Liability for Employee Rights Upon Retirement

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Retirement Benefits [Text Block]

NOTE 7: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT

Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Company's employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, severance payments, which are included in salary and employee benefits, were $11 and $25 for the three and six months ended June 30, 2024, respectively and $11 and $16 for the three and six months ended June 30, 2023, respectively.

NOTE 9: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT

Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Company's employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, payments for 2023 and 2022 were $33 and $51, respectively, which are included in salary and employee benefits within research and development expenses (Note 15).

~~XML 42 R19.htm IDEA: XBRL DOCUMENT~~

Note 8 - Commitments and Contingencies

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

NOTE 8: COMMITMENTS AND CONTINGENCIES

a. Royalty Commitment - Israeli Innovation Authority ("IIA")

The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2024 or 2023. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate ("LIBOR") is repayable in form of royalties based on 3.0% of BNA™ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate ("SOFR") subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of June 30, 2024 and December 31, 2023. The contingent liability amounts to $5,676 and $5,625 for June 30, 2024 and December 31, 2023 respectively.

Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIA's approval.

NOTE 10: COMMITMENTS AND CONTINGENCIES

a. Royalty Commitment - Israeli Innovation Authority ("IIA")

The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2023 or 2022. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate ("LIBOR") is repayable in form of royalties based on 3.0% of BNA™ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate ("SOFR") subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of December 31, 2023 and 2022. The contingent liability amounts to $5,625 and $5,576 for 2023 and 2022 respectively.

Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIA's approval.

~~XML 43 R20.htm IDEA: XBRL DOCUMENT~~

Note 9 - Equity

6 Months Ended

12 Months Ended

Notes to Financial Statements
Equity [Text Block]

Jun. 30, 2024 | **Dec. 31, 2023**

NOTE 9: EQUITY

a. Shares

On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. During the six months period ended June 30, 2024, the Company issued 836,085 units and received aggregate gross proceeds of $1,070. The Company incurred $125 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.

As of December 31, 2023, the mandatory conversion feature of the Series B Preferred Stock was triggered, as the proceeds from the Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of June 30, 2024, the 14,578,833 of Series B Preferred stock were converted to 14,578,833 shares of common stock.

As of June 30, 2024, the Company had the following number of authorized and issued shares:

	June 30, 2024	
	Number of authorized shares	Number of issued shares
Shares of common stock	2,470,000,000	49,948,710
Series A Preferred Stock	30,000,000	-
Series B Preferred Stock		-
Series C Preferred Stock		2,374,219

As of June 30, 2024 the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shares of all classes.

b. Warrants

The following table summarizes the Company's warrant activity for the six months ended June 30, 2024:

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2024	**2,386,677**	**$ 2.07**	**2.46**
Warrants issued pursuant to units offering	836,531	2.56	-
Outstanding warrants, June 30, 2024	**3,223,208**	**$ 2.19**	**2.19**

On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. The warrants were determined to be a freestanding equity instrument. For the six month period ended June 30, 2024, 836,531 warrants were issued.

NOTE 11: EQUITY

a. Shares

On August 17, 2022, the Company closed a securities purchase agreement for the sale of 10 million Series A Preferred Stock for gross proceeds of $40. This agreement also entitled the subscriber to 13,333 warrants to purchase shares of common stock of the Company.

On September 15, 2022, the Company closed a securities purchase agreement for the sale of 51,282 consolidation adjusted shares of common stock at a consolidation adjusted price of $4.87 per share for aggregate gross proceeds of $250.

On February 16, 2023, the Company sold 32,536,386 shares of common stock at a price per share of $0.0041. The Company received aggregate gross proceeds from the offering of $133.

On February 23, 2023, the Company offered up to 10,799,136 shares of Series B Preferred Stock at $0.1852 per share. On March 15, 2023, the Company increased the offering to up to 14,578,833 shares of Series B Preferred Stock, with the increase being subsequently approved by the board of directors on November 15, 2023. As of December 31, 2023, the Company received aggregate gross proceeds from the offering of $2,700. The Company incurred $92 of costs associated with the issuance. Series B Preferred Stock issued are equity classified instruments and are recorded as equity. As of December 31, 2023, 14,578,833 Series B Preferred Stock were subscribed and issued.

On May 1, 2023, the Company granted 284,964 shares of common stock to a related party as a payment for consulting services provided. The shares awarded are under the scope of ASC 718 and were accounted for as equity-classified awards. The shares were measured at fair value on the grant date at $0.0041 per share.

On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. As of December 31, 2023, the Company issued 1,538,134 units and received aggregate gross proceeds of $1,969. The Company incurred $67 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.

On October 16, 2023, 4,217 shares of common stock were repurchased for a nominal amount and cancelled by the Company.

As of December 31, 2023, mandatory conversion feature of Series B Preferred Stock was triggered, as the proceeds from Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of December 31, 2023, the 14,578,833 shares of common stock were not issued from an administrative perspective but were considered substantially issued from an accounting perspective.

As of December 31, 2023 and 2022, the Company had the following number of authorized and issued shares:

	December 31			
	2023	2022	2023	2022
	Number of authorized shares	Number of authorized shares	Number of issued shares	Number of issued shares
Shares of common stock	2,470,000,000	2,470,000,000	35,369,877	2,552,744
Series A Preferred Stock			-	-
Series B Preferred Stock	30,000,000	30,000,000	14,578,833	-
Series C Preferred Stock			1,538,134	-

As of December 31, 2023 and 2022, the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shared of all classes.

b. Rights attached to shares

The shares of common stock confer upon their holders' voting rights and the right to participate in shareholders' meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Company's Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), and the right to a share in excess assets upon liquidation of the Company – all as set forth in the Company's Certificate of Incorporation and in the Company's Shareholders' Agreement.

The preferred shares confer upon their holders voting rights and the right to participate in shareholders' meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Company's Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), on an "as converted" basis, and the right to a share in excess assets upon liquidation of the Company in preference to the shares of common stock. The shares have discretionary dividends and do not have a redemption date.

The Series C Preferred Stock rank, as to the payment of dividends and the distribution of assets upon liquidation, dissolution or winding up of the Company: (a) senior to the shares of common stock, (b) junior to the Series B Preferred Stock, which Series B Preferred Stock include mandatory conversion provisions in the event the Company issues and sells equity securities to investors in an equity financing with total gross proceeds of not less than $1,000 with at least a pre-money valuation of the Company of $18,000, and (c) on parity with all other classes and series of the Company's preferred shares.

Series B Preferred Stock

Optional Conversion

Each share of Series B Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series B Preferred Stock "Series B Certificate of Designations"), which conversion price shall initially be equal to the original issue price.

Mandatory Conversion

Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") (or a qualified offering statement under Regulation A under the Securities Act; (b) the date that the Company or a successor to the Company (including, without limitation by way of acquisition of all or substantially all of the Company's assets) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is subject to the periodic and current reporting requirements of Section 13 or 15(d) of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $1,000 with at least a minimum pre-money valuation of the Company of $18,000, or (d) the date and time, or the occurrence of an event, by vote or written consent of the holders of at least a majority of the outstanding shares of Series B Preferred Stock, voting as a single class on an as-converted basis, all outstanding shares of Series B Preferred Stock shall automatically be converted into shares of common stock at the applicable ratio set forth in the Series B Certificate of Designations.

Series C Preferred Stock

Optional Conversion

Each share of Series C Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series C Preferred Stock, the "Series C Certificate of Designations"), which conversion price shall initially be equal to the original issue price.

Mandatory Conversion

Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act or a qualified offering statement under Regulation A of the Securities Act, as amended); (b) the date that the Company or a successor to the Corporation (including, without limitation, by way of acquisition of all or substantially all of the Corporation's assets, merger, or any other business combination) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Exchange Act and is subject to the periodic and current reporting requirements of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $2,000 with at least a minimum pre-money valuation of the Company of $65,000, or (d) the date and time, or the occurrence of an event, specified by vote or written consent of at least a majority of the outstanding shares of Series C Preferred Stock at the time of such vote or consent, voting as a single class on an as-converted basis, all outstanding shares of Series C Preferred Stock shall automatically

c. Employees stock option plan

A summary of option activity under the Plan as of June 30, 2024 and changes during the period then ended is presented below.

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31,2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**
Options granted	-	-	-	-
Outstanding Options, June 30, 2024	**1,291,662**	**$ 2.16**	**5.67**	**$ -**

The share-based compensation expense related to options for the three and six months ended June 30, 2024 was $58 and $117, respectively and 74$ and $148 for the three and six months ended June 30, 2023, respectively. The fair value of options granted for the six months period ended June 30, 2024 and 2023 was $nil and $nil, respectively. The intrinsic value of the options outstanding as of June 30, 2024 is $nil (December 31, 2023: $nil).

A summary of the Company's non vested options as of June 30, 2024, and changes during the six months period ended, is presented below.

	Number of Stock Options	Weighted Average Grant-Date Fair Value
Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**
Options granted	-	-
Options vested	(187,739)	0.62
Non-Vested Options, June 30, 2024	**687,147**	**$ 0.46**

As of June 30, 2024, there was $317 of total unrecognized compensation cost related to nonvested options granted under the Plan.

d. Management options

On April 2, 2024, the Company granted stock options to its officer to purchase an aggregate of 106,000 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Company's equity securities in an initial public offering (an "IPO Transaction"), that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 106,000 shares of common stock shall vest in 36 equal installments at the end of each calendar month over a period of three years beginning March 1, 2024. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event.

e. Consulting agreement

On March 15, 2024, the Company entered into a consulting agreement ("Consulting agreement"), which was further approved by the board of directors of the Company on April 2, 2024. Under the Consulting agreement, the Company will receive services of promoting the Company's stock; in return for 432,034 Series A performance warrants and 195,313 shares of common stock issued immediately upon execution of the agreement, and 234,735 shares of common stock to be issued in 12 equal installments at the end of each calendar month.

Series A performance warrants to purchase up to an aggregate 432,034 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share and are set to expire on June 15, 2028. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event.

As of June 30, 2024, the shares of common stock and Series A performance warrants were not issued and no services were received.

be converted into shares of common stock at the applicable ratio described in Series C Certificate of Designations.

d. Warrants

During 2022, part of the modification of the WPC convertible (Note 7), the Company issued 526,749 stock split adjusted Tranche A and 262,051 stock split adjusted Tranche B warrants. The features of the warrants were as below:

Tranche A:

- Exercise price: (1) $0.75 – If funds of a minimum of $15,000 are raised, (2) $0.75 – If the sale of a company, IPO or RTO is completed or the (3) purchase price per share resulting from dividing $50,000 by the total number of valid issued ordinary shares outstanding.
- Maturity/Expiration date: (a) if no IPO – one year after the delivery date of the 2021 audited financial statements (b) if IPO – then one year after the date of such IPO.

Tranche B:

- Purchase price per share resulting from dividing $150,000 by the total number of valid issued ordinary shares outstanding.
- Maturity/Expiration date: (a) if no IPO – one year after the delivery date of the 2021 audited financial statements (b) if IPO – then five years after the date of such IPO.

On July 4, 2022, as part of the Senior Lender's Memo, the conversion price of the Tranche A warrant was amended to: (1) $0.75 – If after July 5, 2022 funds of a minimum of $5,000 are raised 18 months and $10,000 in total in the three years thereafter, (2) $0.75 – after the recapitalization date, if the sale of a company, IPO or RTO is completed or (3) the purchase price per share resulting from dividing $20,000 by the total number of valid issued ordinary shares outstanding. The Tranche B warrants were cancelled.

As part of the convertible debt issuance to various investors between July 4, 2022, and August 16, 2022, the Company issued 198,482 consolidation adjusted warrants concurrent with the convertible debt and preferred shares. The warrants were exercisable into one share of common stock of the Company per warrant at a price of $3. The warrants had a maturity date of three years.

On February 17, 2023, warrants to purchase up to 123,333 shares of common stock, issued to WPC in 2021, were modified pursuant to antidilution provision in the warrant agreement, triggered by common stock private placement on February 16, 2023. As a result of the modification, exercise price of the warrants was reduced to $0.00473 per share and the expiry date was extended to be three years from the modification date. The warrants were determined to be a freestanding equity instrument. Under ASC 815, the effect of a modification was nominal and was recorded as an equity issuance costs.

On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. The warrants were determined to be a freestanding equity instrument. As of December 31, 2023, 759,863 warrants were issued. Additionally, as of December 31, 2023, 781,250 warrants were not issued from an administrative perspective, but were considered substantially issued from an accounting perspective.

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2022	**123,333**	**$ 7.50**	**0.85**
Warrants issued pursuant to issue of convertible debt and preferred shares to individual investors	198,482	3.00	
Warrants issued pursuant to modification of convertible debt	526,749	0.75	
Outstanding warrants, December 31, 2022	**848,564**	**$ 2.26**	**2.50**
Warrants issued pursuant to units offering	1,538,113	2.56	
Outstanding warrants, December 31, 2023	**2,386,677**	**$ 2.07**	**2.46**

The warrants and prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022.

e. Series A warrants

On June 15, 2023, the Company granted Series A warrants to purchase up to an aggregate 6,048,456 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share for a period of five years from the issuance date. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event.

f. Employees stock option plan

In 2010, the Company's board of directors approved an employee and service provider's stock option plan. On July 8, 2023, the board of directors approved new equity incentive plan (the "Plan"). The Plan permits the grant of options, share appreciation rights ("SARs"), restricted share units ("RSUs"), deferred share units ("DSUs") and performance share units ("PSUs"). In respect of options, the aggregate number of shares of common stock issuable under the Plan shall not exceed twelve percent of the issued and outstanding shares of common stock at any point in time. In respect of SARs, RSUs, DSUs and PSUs: (i) the maximum aggregate number of shares of common stock issuable under this Plan in respect of SARs, RSUs, DSUs and PSUs shall not exceed ten percent of the issued and outstanding shares of common stock as of July 8, 2023; (ii) the total number of SARs, RSUs, DSUs and PSUs issuable to any participant under this Plan shall not exceed one percent of the issued and outstanding shares of common stock at the time of the award.

The fair value of each option award is estimated on the date of grant using a Black Scholes option valuation model that uses the assumptions noted in the following table.

	2023	2022
Risk free rate	4.35%	4.5%
Dividend yield	0%	0%
Expected volatility	86%	86%
Expected term (in years)	3	3
Expected life (in years)	5	5

A summary of option activity under the Plan as of December 31, 2023, and changes during the year then ended is presented below.

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31, 2022	**495,746**	**$ 4.70**	**6.90**	**$ -**
Options granted	795,916	0.58		
Outstanding Options, December 31, 2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**

The share-based compensation expense related to options for December 31, 2023 was $295 (2022: $60). The fair value of options granted for the year ended December 31, 2023 was nominal (2022: $692). The intrinsic value of the options outstanding is $nil (2022: $nil).

A summary of the Company's non-vested options as of December 31, 2023, and changes during the year ended December 31, 2023, is presented below.

	Number of Stock Options	Weighted Average Grant-Date Fair Value
Non-Vested Options, December 31, 2022	**325,853**	**$ 2.20**
Options granted	795,916	0.00
Options vested	(246,883)	1.15
Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**

As of December 31, 2023, there was $434 of total unrecognized compensation cost related to nonvested options granted under the Plan.

The options and exercise prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022.

g. Management options

On July 8, 2023, the Company granted stock options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Company's equity securities in an initial public offering (an "IPO Transaction"), that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 362,584 shares of

common stock shall vest immediately with the remaining options vesting in 36 equal installments at the end of each calendar month over a period of three years from the date of grant. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event.

h. Restricted share units

On July 8, 2023, the Company granted RSUs to certain management and directors. The vesting of the RSUs is contingent upon a transaction that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. When vested, the RSUs represent the right to be issued the number shares of common stock that is equal to the number of RSUs granted. Since RSUs are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost related to RSUs is recognized until the occurrence of a liquidity event.

~~XML 44 R21.htm IDEA: XBRL DOCUMENT~~

Note 10 - Basic and Diluted Net Loss Per Share

Notes to Financial Statements

Earnings Per Share [Text Block]

6 Months Ended	12 Months Ended
Jun. 30, 2024	Dec. 31, 2023

NOTE 10: BASIC AND DILUTED NET LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that were outstanding during the period when the effect is dilutive. Potential dilutive shares of common stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding shares of common stock figures for the six months ended June 30, 2024 or 2023, as the assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.

NOTE 12: BASIC AND DILUTED NET LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that were outstanding during the period when the effect is dilutive. Potential dilutive shares of common stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding shares of common stock figures for the years ended December 31, 2023 or 2022, as the assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.

~~XML 45 R22.htm IDEA: XBRL DOCUMENT~~

Note 11 - Related Party Transactions

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

6 Months Ended	12 Months Ended
Jun. 30, 2024	Dec. 31, 2023

NOTE 11: RELATED PARTY TRANSACTIONS

As of the period ended June 30, 2024, $175 (2023: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand.

The Company incurred $140 and $244 in officers' consulting fees recorded in general and administration expenses for the three and six months ended June 30, 2024, respectively and $102 and $223 for the three and six months ended June 30, 2023, respectively.

NOTE 13: RELATED PARTY TRANSACTIONS

During the year ended December 31, 2022, $320 of notes payable to directors were converted to 106,612 shares of common stock (Note 7).

As of the year ended December 31, 2023, $175 (2022: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand. The remaining related party payables of $nil (2022: $2) relate to services payable to a related party of the Company. These payables do not bear any interest and are payable on demand.

The Company incurred $222 and $420 in officers' consulting fees recorded in general administration expenses on consolidated statements of operations for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023 and 2022, $106 and $56, respectively remained outstanding and were accrued by the Company, and are included in accrued liabilities in the accompanying balance sheets.

On May 1, 2023, the Company issued 284,964 shares of common stock to a related party as a payment for consulting services provided.

On July 8, 2023, the Company granted options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock in the capital of the Company (Note 11.g), 2,776,861 of these options were granted to related parties. No compensation cost is recognized related to options until the occurrence of a liquidity event.

~~XML 46 R23.htm IDEA: XBRL DOCUMENT~~

Note 12 - Revenue

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

6 Months Ended	12 Months Ended
Jun. 30, 2024	Dec. 31, 2023

NOTE 12: REVENUE

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Type of goods and services				
Service	$ 10	$ 451	$ 22	$ 456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**
Timing of recognition of revenue				
Point in time	3	-	7	-
Over time	**7**	451	15	456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**

NOTE 14: REVENUE

	December 31	
	2023	2022
Type of goods and services		
Service	$ 498	$ -
Total	**$ 498**	**$ -**
Timing of recognition of revenue		
Over time	$ 498	$ -
Total	**$ 498**	**$ -**

~~XML 47 R24.htm IDEA: XBRL DOCUMENT~~

Note 13 - Research and Development Expenses

Notes to Financial Statements

Research, Development, and Computer Software Disclosure [Text Block]

6 Months Ended	12 Months Ended
Jun. 30, 2024	Dec. 31, 2023

NOTE 13: RESEARCH AND DEVELOPMENT EXPENSES

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 210	$ 167	$ 443	$ 254
Consultants and subcontractors	70	17	77	23
Depreciation and amortization	4	-	4	-
Clinical trials	-	14	-	19
Expenses - other	66	1	115	24
	350	199	639	320
Less – grants received	-	-	-	-
Total	**$ 350**	**$ 199**	**$ 639**	**$ 320**

NOTE 15: RESEARCH AND DEVELOPMENT EXPENSES

	December 31	
	2023	2022
Salary and employee benefits	$ 527	$ 944
Consultants and subcontractors	99	152
Depreciation and amortization	-	14
Clinical trials	3	60
Expenses - other	112	129
	741	1,299
Less – grants received	-	-
Total	**$ 741**	$ 1,299

~~XML 48 R25.htm IDEA: XBRL DOCUMENT~~

Note 14 - Selling and Marketing Expenses

Notes to Financial Statements

Selling and Marketing Expenses [Text Block]

6 Months Ended	12 Months Ended
Jun. 30, 2024	Dec. 31, 2023

NOTE 14: SELLING AND MARKETING EXPENSES

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 179	$ 160	$ 347	$ 289
Professional fees	89	5	142	5
Travel	22	6	46	10
Other	3	-	7	-
Total	**$ 293**	**$ 171**	**$ 542**	**$ 304**

NOTE 16: SELLING AND MARKETING EXPENSES

	December 31	
	2023	2022
Salary and employee benefits	$ 611	$ 432
Professional fees	6	27
Travel	21	51
Other	1	14
Total	**$ 639**	$ 524

~~XML 49 R26.htm IDEA: XBRL DOCUMENT~~

Note 15 - General and Administration Expenses

Notes to Financial Statements

General and Administrative Expenses [Text Block]

6 Months Ended	12 Months Ended
Jun. 30, 2024	Dec. 31, 2023

NOTE 15: GENERAL AND ADMINISTRATION EXPENSES

NOTE 17: GENERAL AND ADMINISTRATION EXPENSES

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 143	$ 142	$ 261	$ 319
Professional fees	417	183	822	246
Rent and maintenance	4	33	6	65
Travel expenses	23	12	31	25
Other	39	29	71	41
Total	**$ 626**	**$ 399**	**$ 1,191**	**$ 696**

	December 31	
	2023	2022
Salary and employee benefits	$ 512	$ 418
Professional fees	1,252	724
Rent and maintenance	91	233
Travel expenses	56	72
Bad debts	1	(2)
Other	284	97
Total	**$ 2,196**	**$ 1,542**

~~XML 50 R27.htm IDEA: XBRL DOCUMENT~~

Note 16 - Subsequent Events

Notes to Financial Statements

Subsequent Events [Text Block]

6 Months Ended
Jun. 30, 2024

NOTE 16: SUBSEQUENT EVENTS

The subsequent events below are major events or transactions that occurred after the six month period ended June 30, 2024, but before the issuance of these condensed consolidated financial statements. The below events occurred between July 1, 2024 and August 14, 2024:

On August 8, 2024, the Company completed the closing of a $209 secured promissory notes. Promissory notes were issued with a discount of $11 and the Company received gross proceeds of $198. The promissory note will bear an annual interest rate of 18%, paid monthly. The principal amount of $209 will mature and become due and payable on August 23, 2024.

Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc.

Merger

On August 12, 2024, the Company completed the merger with WaveDancer. As a result of this transaction, the Company obtained control of WaveDancer. The combined company operates under the name Firefly Neuroscience, Inc., and on August 13, 2023 the Company began trading on the Nasdaq Capital Market (NASDAQ: AIFF). On August 12, 2024, prior to the consummation of the Merger, WaveDancer effectuated a 1-for-3 reverse stock split of its common stock (the "Reverse Stock Split") . Pursuant to the terms of the Merger Agreement, each holder of outstanding shares of the Company's shares of common stock is entitled to receive the number of shares of WaveDancer common stock equal to the number of shares of the Company's shares of common stock they hold multiplied by the exchange ratio, or an aggregate of 7,870,251 shares of WaveDancer common stock at closing using an exchange ratio of 0.1040. Following the closing of the merger, there are 7,870,251 shares of the combined company's common stock outstanding with Firefly stockholders owning approximately 92% and prior WaveDancer stockholders owning 8% of the combined company's outstanding securities.

Private Placement

On July 26, 2024, prior to the consummation of the merger, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,069,287 shares (the "PIPE Shares") of the combined company's common stock and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 4,849,265 shares of combined company's common stock, and (iii) warrants (the "Warrants") to purchase up to 7,918,552 shares of combined company's common stock in a private placement (the "Private Placement"). The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the merger. The aggregate gross proceeds from the transaction were approximately $3,500.

12 Months Ended
Dec. 31, 2023

NOTE 21: SUBSEQUENT EVENTS

The subsequent events below are major events or transactions that occurred after the period ended December 31, 2023, but before the issuance of these consolidated financial statements. The below events occurred between January 1, 2024 and May 22, 2024:

On January 12, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates include changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Company's warrants at the effective time and deletion of certain closing obligations.

On February 28, 2024, the Company issued 820,312 units and received aggregate gross proceeds of $1,050. Each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.

~~XML 51 R28.htm IDEA: XBRL DOCUMENT~~

Note 1 - Business Description

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

6 Months Ended
Jun. 30, 2024

NOTE 1: BUSINESS DESCRIPTION

Nature of organization and business

Firefly Neuroscience, Inc. (the "Company") and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.), Firefly Neuroscience Canada Inc., a Canadian corporation, and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain.

Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc.

In July 2014, the U.S. Food and Drug Administration ("FDA") cleared Firefly Neuroscience Ltd.'s Brain Network Analytics ("BNA" ™) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European ("CE") approval for BNA™ allowing use in Europe.

Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc.

Merger agreement

On November 16, 2023, WaveDancer, Inc. ("WaveDancer") (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the "Merger Agreement") with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Company's Artificial Intelligence driven BNA™ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market.

Under the terms of the Merger Agreement, each share of the Company's shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancer's ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. Following the merger, WaveDancer, Inc. will be renamed "Firefly Neuroscience, Inc." and the corporate headquarters will be located in Buffalo, NY.

On January 12, 2024 and June 17, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates included changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Company's warrants at the effective time, deletion of certain closing obligations, and to extend the end date of the original agreement dated November 15, 2023.

The transaction was completed effective August 12, 2024.

12 Months Ended
Dec. 31, 2023

NOTE 1: BUSINESS DESCRIPTION

Nature of organization and business

Firefly Neuroscience, Inc. (the "Company") and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.). and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain.

Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc.

In July 2014, the U.S. Food and Drug Administration ("FDA") cleared Firefly Neuroscience Ltd. Brain Network Analytics' (BNA™) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European ("CE") approval for BNA™ allowing use in Europe.

Reorganization

Name change and corporate restructure

Elminda Inc. was incorporated in the State of Delaware on April 21, 2022.

On July 5, 2022, Elminda Ltd. became a subsidiary of Elminda Inc. via a share exchange agreement wherein Elminda Inc. issued shares to shareholders of Elminda Ltd. against shares of Elminda Ltd. (the "Flip Transaction").

On September 15, 2022 and October 24, 2022 management changed the name from Elminda Inc. and Elminda Ltd. to Firefly Neuroscience Inc. and Firefly Neuroscience Ltd., respectively.

Shareholder Restructuring

On January 27, 2022, holders of shares of outstanding Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock of Firefly Neuroscience Ltd. voted to convert their shares of preferred stock into shares of common stock of Firefly Neuroscience Ltd. Upon completion of the transaction, Firefly Neuroscience Ltd. had 1,085,605 shares of common stock and 3,198,421 shares of Series A Preferred Stock outstanding.

On May 24, 2022, holders of the majority of shares of common stock of Firefly Neuroscience Ltd. voted to exchange their shares on a 1-1 basis for shares in the Company.

In connection with the Flip Transaction, on July 5, 2022, (a) Firefly Neuroscience, Inc. became an issuer of (i) 1,085,605 common shares, (ii) 3,198,421 Series A preferred shares and (c) 3,715 shares of common share dividends. The original shareholders of Firefly Neuroscience Ltd. remained in control of the new group and the Company.

On November 23, 2022, the Company completed a reverse share split on a ratio of 1:750. These consolidated financial statements and all financial notes referencing shares of common stock, stock dividends, stock options and their associated prices have been retroactively adjusted as to show the effect of the 1:750 reverse stock split.

Merger agreement

On November 16, 2023, WaveDancer, Inc. ("WaveDancer") (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the "Merger Agreement") with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Company's Artificial Intelligence driven BNA™ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market.

Under the terms of the Merger Agreement, each share of the Company's shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancer's ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by WaveDancer, and the receipt of required shareholder approvals from the Company's and WaveDancer shareholders. Following the merger, WaveDancer, Inc. will be renamed "Firefly Neuroscience, Inc." and the corporate headquarters will be located in Toronto, Ontario. The transaction is expected to be completed in 2024.

Israeli/Palestinian conflict

On October 7, 2023, an armed Israeli/Palestinian conflict broke out. As the Israeli/Palestinian conflict in Gaza develops, it could have an adverse impact on regional and global markets. While our operations are not directly impacted by these events, the duration of hostilities, imposition of sanctions and related events (including cyberattacks), among others, cannot be predicted. As a result, those events present uncertainty and risk. To date, conflict in Gaza has not had a material impact on the Company's business.

~~XML 52 R29.htm IDEA: XBRL DOCUMENT~~

Note 2 - Going Concern	6 Months Ended Jun. 30, 2024	12 Months Ended Dec. 31, 2023
Notes to Financial Statements		
Substantial Doubt about Going Concern [Text Block]	**NOTE 2: GOING CONCERN**	**NOTE 2: GOING CONCERN**
	As of June 30, 2024, the Company had an accumulated deficit of $79,010 (December 31, 2023: $76,624) and negative cash flow from operating activities for the six months ended June 30, 2024 of $2,402 (June 30, 2023: $936). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the six months ended June 30, 2024 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Company's liquidity in the foreseeable future, the Company has taken the following measures:	As of December 31, 2023, the Company had an accumulated deficit of $76,624 (December 31, 2022: $74,021) and negative cash flow from operating activities for the year ended December 31, 2023 of $2,172 (for the year ended December 31, 2022: $2,892). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the year ended December 31, 2023 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these consolidated financial statements were issued. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Company's liquidity in the foreseeable future, the Company has taken the following measures:
	(i) Negotiating further funding with existing and new investors to raise additional capital; (ii) Taking various cost control measures to reduce the operational cash burn; and (iii) Commercializing product to generate recurring sales.	(i) Negotiating further funding with existing and new investors to raise additional capital; (ii) Taking various cost control measures to reduce the operational cash burn; and (iii) Commercializing product to generate recurring sales.
	Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future.	Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future.

~~XML 53 R30.htm IDEA: XBRL DOCUMENT~~

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended Jun. 30, 2024	12 Months Ended Dec. 31, 2023
Notes to Financial Statements		
Basis of Presentation and Significant Accounting Policies [Text Block]	**NOTE 3: BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**	

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United States of America ("U.S. GAAP").

a. Principles of consolidation

These consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities ("VIE"). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation.

b. Revision of Prior Period Financial Statements

In connection with the preparation of the consolidated financial statements for year ended December 31, 2023, we identified an immaterial error related to certain general and administration and research and development expenses in the consolidated financial statements for year ended December 31, 2022. In accordance with SAB No. 99, "Materiality," and SAB No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements," we evaluated the error and determined that the related impact was not material to our consolidated financial statements for any prior annual or interim period, but that correcting the cumulative impact of the error would be significant to our results of operations for the year ended December 31, 2023. Accordingly, we have revised previously reported financial information for such immaterial error. A summary of revisions to certain previously reported financial information presented herein for comparative purposes is included in Note 20.

c. Use of estimates in the preparation of consolidated financial statements

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.

i) Share based payments
In calculating share-based compensation expense, key estimates are used such as, the stock price of the Company, the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company's stock price, and the risk-free interest rate.

ii) Warrants
In calculating the fair value of warrants issued, the Company includes key estimates such as the stock price of the Company, the expected life of the warrant, the volatility of the Company's stock price, and the risk-free interest rate.

d. Functional currency and foreign currency translations

The currency of the primary economic environment in which the operations of the Company is conducted is the U.S. dollar ("$" or "Dollar"). All of the Company's revenues and finance are denominated in U.S dollars. The reporting and the functional currency of the Company is the U.S Dollar.

The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively.

e. Fair value measurement

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

- Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;
- Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and
- Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The carrying amounts of cash and equivalents, accounts receivable, other receivables, long-term deposits, trade payables, balances to and from related party and convertible notes approximate their fair value due to the short-term maturity of such instruments. It is management's opinion that the Company is not exposed to any significant market or credit risks arising from these financial instruments.

f. Fair value of financial instruments

Cash, other receivables, trade payables, related party payable and accrued liabilities are carried at amortized cost, which management believes approximates their respective fair value due to the short-term nature of these instruments.

g. Related party

Parties are related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, and related parties may be individuals or corporate entities. A transaction is a related party transaction when there is a transfer of resources or obligations between related parties. The Company has disclosed its transactions with related parties.

NOTE 3: BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United States of America ("U.S. GAAP"). The results reported in these unaudited condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for any subsequent period or for the entire period. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company's annual audited consolidated financial statements for the year ended December 31, 2023 and the notes included therein. Certain information and footnote disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in the accompanying unaudited condensed consolidated financial statements. All amounts are disclosed in thousands, except share and per share amounts. The accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, except as otherwise indicated, necessary for a fair statement of its consolidated financial position, results of operations, and cash flows of the Company for all periods presented.

a. Principles of consolidation

These unaudited consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities ("VIE"). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation.

b. Use of estimates in the preparation of consolidated financial statements

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.

Significant accounting policies

The following significant accounting policies should be read in conjunction with the Company's annual audited consolidated financial statements for the year ended December 31, 2023 and the notes therein.

i) Equipment
Equipment is stated at cost less accumulated depreciation. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of four years for medical equipment.

c. Impact of recently issued accounting standards

The Company has evaluated issued Accounting Standards Updates not yet adopted and believes the adoption of these standards will not have a material impact on its condensed consolidated financial statements.

h. Cash

The Company considers all highly liquid investments, which include short-term bank deposits that are not restricted as to withdrawal or use and the period to maturity of which did not exceed three months at time of investment, to be cash.

i. Other receivables

Other receivables are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses ("allowance for doubtful receivables") is based on the Company's assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay.

j. Contingent liabilities

Certain conditions may exist as of the date the consolidated financial statements are issued, that may result in a loss to the Company but that will only be resolved when one or more future events occur or fail to occur. Such losses are disclosed as contingent liabilities if it is not both probable and reasonably estimable. The Company's management assesses such contingent liabilities and estimated legal fees, if any. Such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

k. Warrants

The Company accounts for the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and the applicable authoritative guidance in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 480, "Distinguishing Liabilities from Equity" ("ASC 480") ASC 815, "Derivatives and Hedging" ("ASC 815"), and ASC 718, "Compensation—Stock Compensation" ("ASC 718"). The assessment considers whether they are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480 or meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own shares of common stock and whether the holders of the warrants could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the warrants and as of each subsequent reporting date while the warrants are outstanding. For issued or modified warrants and that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations.

l. Stock options

The Company grants stock options to certain employees and directors through an established stock option plan. All stock option grants or changes to existing grants, are subject to board of directors' approval. For employees and directors, the fair value of the award is measured on the grant date. For non-employees, as per ASC 718, remeasurement is not required. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Determining the appropriate fair value model and the related assumptions requires judgment. During the year ended December 31, 2023 and 2022, the fair value of each option grant was estimated using a Black-Scholes option-pricing model.

m. Revenue recognition

Revenue is recognized in accordance with ASC 606, "Revenue from Contracts with Customers" ("ASC 606"). The Company performs the following five steps:

(i) identify the contract(s) with a customer,
(ii) identify the performance obligations in the contract,
(iii) determine the transaction price,
(iv) allocate the transaction price to the performance obligations in the contract, and
(v) recognize revenue when (or as) the entity satisfies a performance obligation.

The Company applies this five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the goods or services promised within each contract, related performance obligation and assesses whether each promised good or service is distinct. The Company recognizes as revenue, the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied at a point in time.

The Company's revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.

n. Deferred revenue

Deferred revenue consists of payments received from customers in advance of satisfying a performance obligation identified in accordance with ASC 606. The change in the deferred revenue balance for the years ended December 31, 2023, and 2022 was driven by payments from customers in advance of satisfying the performance obligations, offset by revenue recognized as performance obligations were completed.

o. Research and development expenses

Research and development expenses are expensed as incurred and consist primarily of personnel, facilities, equipment and supplies related to the Company's research and development activities.

p. Software development costs

The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel, facilities, equipment and supplies and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage – when the research stage is complete, and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in intangible assets, net on the consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.

q. Income taxes

Income taxes are accounted for using the asset/liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than enactment of changes in the tax law or rates.

The Company adopted ASC 740 "Income Taxes" ("ASC 740"), which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.

r. Leases

At the inception of the contract, the Company assesses whether the contract contains a lease in accordance with ASU 2016-02, "Leases" ("ASC 842"). The Company determines whether an arrangement is a lease by establishing if the contract conveys the right to control the use of an identified asset, for a period of time in exchange for consideration. Leases are classified either as operating lease or finance lease. The Company elects not to apply the recognition requirements of ASC 842 to short-term leases. Short term leases are contracts that have a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company does not have any lease with a lease term longer than 12 months.

s. Employee benefits

Short-term employee benefits are benefits for which full settlement is expected within twelve months of the end of the financial year in which the members of staff rendered the corresponding services. These benefits include, paid annual leave, paid sick leave, health and governmental social security contributions which are expensed as the services are rendered. A liability for a cash bonus or plan profit-sharing is recognized when the Company has a legal or implied obligation to make such payments because of past services rendered by a member of staff, and it is

possible to make a reasonable estimate of the amount.

For post-employment the Company has a defined contribution plan pursuant to section 14 to the Israeli Severance Compensation Act, 1963 under which the Company pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold enough to pay all employee benefits relating to employee service in the current and prior periods. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed monthly, concurrently with performance of the employee's services.

t. Segment reporting

Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment.

u. Geographic areas

The Company has operations in Canada, the United States of America and Israel. The revenues and non-current assets of the Company are generated and located in the following locations:

Geographic areas	Revenue 2023	Revenue 2022	Non-current assets 2023	Non-current assets 2022
Canada	-	-	-	-
United States of America	478	-	-	-
Israel	20	-	386	52

v. Recent accounting pronouncements

In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning January 1, 2025, with early adoption permitted. The Company has not adopted this standard early and is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements disclosures.

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses.

The expanded annual disclosures are effective for the Company's year ending December 31, 2024, and the expanded interim disclosures are effective in 2025 and will be applied retrospectively to all prior periods presented.

The Company is currently evaluating the impact that ASU 2023-07 will have on its consolidated financial statements.

~~XML 54 R31.htm IDEA: XBRL DOCUMENT~~

Note 4 - Other Receivables (10K)

Notes to Financial Statements

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

6 Months Ended
Jun. 30, 2024

NOTE 4: OTHER RECEIVABLES

Detail of other receivables balance is as follows:

	June 30, 2024	December 31, 2023
Other receivables	$ 195	$ 196
Allowance for doubtful receivables	(112)	(112)
Total	**$ 83**	$ 84

12 Months Ended
Dec. 31, 2023

NOTE 4: OTHER RECEIVABLES

Detail of other receivables balance is as follows:

	December 31 2023	2022
Other receivables	$ 196	$ 131
Allowance for doubtful receivables	(112)	(112)
Total	**$ 84**	$ 19

~~XML 55 R32.htm IDEA: XBRL DOCUMENT~~

Note 5 - Long Term Deposits

Notes to Financial Statements

Other Assets Disclosure [Text Block]

12 Months Ended
Dec. 31, 2023

NOTE 5: LONG TERM DEPOSITS

Long term deposits consisted of rental deposits for month-to-month shared office lease. The balances as of December 31, 2023 and 2022 were $nil and $52, respectively.

~~XML 56 R33.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets (10K)

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

12 Months Ended
Dec. 31, 2023

NOTE 6: INTANGIBLE ASSETS

The following tables summarize the composition of intangible assets as of December 31, 2023:

	December 31, 2023			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Weighted Average Life
Unamortized intangible assets				
BNA software	$ 386	$ -	$ 386	n/a
Total intangible assets	**$ 386**	**$ -**	**$ 386**	

The BNA software enhancement project is in progress and amortization will begin once the project is substantially complete and the software is ready for its intended purpose. The software is expected to be completed by Q3 2024 and have a useful life of five years.

There were no intangible assets as of December 31, 2022.

~~XML 57 R34.htm IDEA: XBRL DOCUMENT~~

Note 7 - Convertible Notes

Notes to Financial Statements

Debt Disclosure [Text Block]

12 Months Ended
Dec. 31, 2023

NOTE 7: CONVERTIBLE NOTES

Windsor Private Capital Ltd. Partnership ("WPC") and Origa Two Holdings Inc ("Origa")

On February 2, 2022, Origa and the Company signed a Side Letter in order to raise additional funds of $1,000 which were to be provided to the Company, as part of the original debt that was issued in 2021. The maturity date of the debentures was also extended to December 31, 2022. Two tranches of warrants (Tranche A and B) were also issued (Note 11.d). This amendment and issuance of warrants resulted in the extinguishment of the original debt, and recognition of the amended debt and warrants at their fair value of $1,886 and $478, respectively. The Company recorded a loss on extinguishment of $576 within other income (expense) in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2022.

On July 4, 2022, the board of directors of the Company agreed to amend the conversion price on the convertible debt from a price of $7.5 to $3 per share. Additionally, Tranche A warrants' exercise price was amended, the Tranche B warrants were cancelled (Note 11.d) and the expiration date of all remaining warrants were amended to 3 years from the date of amendment. This resulted in the debt being extinguished, and recognition of the amended convertible debt and Tranche A warrants at $2,936 and $551 respectively. The Company recognized a gain on extinguishment of $509 within other income (expense) in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2022.

Phyto IV Convertible debt issuance

On May 4, 2022, the Company issued a convertible debenture to Phyto IV LP. The principal amount of the note was $150 and the interest on the note accrued at a fixed rate 10% per annum. The interest on the note is accrued semi-annually and shall be payable on the maturity date, calculated on the basis of actual days elapsed. The interest is not payable in cash but added to the principal amount semi-annually on June 30 and December 31 of each year. The loan had a maturity date of one year from issuance with an option to extend maturity by one more year for a 1.5% fee of the then outstanding principal. The notes were convertible at a price of $7.5 per share. The conversion price for the convertible debt was also subject to adjustments resulting from subdivision, consolidation or any stock securities issuance by the way of stock dividend or other distribution. These adjustments were standard anti-dilution adjustments to compensate the warrant holders for any such event such that their rights were on par with other shareholders.

On July 4, 2022, the board of directors agreed to amend the conversion price on the convertible debt and reduce it from a price of $7.5 to $3. This resulted in a fair value change of the conversion option, which resulted in the debt being extinguished resulting in a gain on modification of $8.

On September 30, 2022, the convertible debt including accrued interest was converted to 51,792 reverse stock split adjusted shares of common stock of the Company.

Convertible debt issued to various investors

On July 4, 2022, the Company signed a memorandum of understanding with Origa and WPC to raise funds. As part of the memorandum of understanding, between July 4, 2022, and August 16, 2022, the Company issued convertible debt along with warrants to 13 individual investors on identical terms. The raise resulted in a total issuance of $555. Interest is accrued at a fixed rate of 10% per annum. The interest on the note is accrued semi-annually and shall be payable on the maturity date, calculated based on actual days elapsed. The interest is not payable in cash but added to the principal amount semi-annually on June 30 and December 31 of each year.

Each loan matures after two calendar years from the date of issue and had an option to extend the maturity date by one year at a fee of 1.5% of the then outstanding principal. The notes are also convertible into the common stock of the Company at any time at the option of the holder at a price of $3 per share. The conversion price for the convertible debt was subject to adjustments resulting from subdivision, consolidation or any stock securities issuance by the way of stock dividend or other distribution. These adjustments were standard anti-dilution adjustments to compensate the warrant holders for any such event such that their rights were on par with other shareholders.

On September 30, 2022, the convertible debt including accrued interest was converted to 188,734 shares of common stock of the Company. The share number has been adjusted to reflect the reverse stock split number of shares, which occurred on November 23, 2022.

Conversion option added to director loans

On July 4, 2022, the board of directors added a conversion option to certain directors' loan which were interest-free and payable upon demand. During 2022, the loans were converted to 106,612 shares of common stock.

No convertible debt remained outstanding as of December 31, 2023 and 2022, except for the non-interest bearing director’s loan payable on demand (Refer to Note 13).

~~XML 58 R35.htm IDEA: XBRL DOCUMENT~~

Note 8 - Deferred Revenue

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Deferred Revenue [Text Block]

NOTE 8: DEFERRED REVENUE

In February 2019, the Company executed a $2,500 development and consulting agreement with R.I. Mind Group Ltd. The Company’s scope involved creating and developing BNA™ Biomarkers, the Database Infrastructure and the Delivery System (collectively, the “Work Products”), as well as consulting and advising on the development of Work Products or on the proper use of the Work Products. In accordance with the agreement, the Company received an advance of $500 against which the parties agreed to offset invoices amounting to $41.

In August 2022, the Company executed a Memorandum of Understanding (“MoU”) with Pasithea Clinics Inc. to enter into an agreement with respect to the marketing and commercialization of the BNA™ System. The Company received an advance of $300. The advance was recognized as deferred revenue in 2022.

In November 2022, the Company executed an additional MoU with Pasithea Clinics Inc. to enter into an agreement with respect to the marketing and commercialization of BNA™ System. The Company received an advance of $150 to offset certain subsequent invoices. The advance was recognized as deferred revenue in 2022.

During the year ended December 31, 2023, the Company determined that it satisfied its performance obligation under both MoUs with Pasithea and recognized $450 of revenue.

Additionally, on February 24, 2023, the agreement with R.I. Mind Group Ltd. expired in accordance with its terms, and, as of December 31, 2023, there are no amounts owed by the Company to R.I. Mind Group Ltd. As the Company did not carry any activity for the purposes of the agreement, the Company recognized $459 of other income.

	December 31	
	2023	2022
Pasithea Clinics Inc.	$ -	$ 450
R.I. Mind Group Ltd	$ -	$ 459
	$ -	$ 909

~~XML 59 R36.htm IDEA: XBRL DOCUMENT~~

Note 9 - Liability for Employee Rights Upon Retirement

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Retirement Benefits [Text Block]

NOTE 7: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT

Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Company’s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, severance payments, which are included in salary and employee benefits, were $11 and $25 for the three and six months ended June 30, 2024, respectively and $11 and $16 for the three and six months ended June 30, 2023, respectively.

NOTE 9: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT

Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Company’s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, payments for 2023 and 2022 were $33 and $51, respectively, which are included in salary and employee benefits within research and development expenses (Note 15).

~~XML 60 R37.htm IDEA: XBRL DOCUMENT~~

Note 10 - Commitments and Contingencies

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

NOTE 8: COMMITMENTS AND CONTINGENCIES

a. Royalty Commitment - Israeli Innovation Authority (“IIA”)

The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2024 or 2023. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate (“LIBOR”) is repayable in form of royalties based on 3.0% of BNA™ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate (“SOFR”) subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of June 30, 2024 and December 31, 2023. The contingent liability amounts to $5,676 and $5,625 for June 30, 2024 and December 31, 2023 respectively.

Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIA’s approval.

NOTE 10: COMMITMENTS AND CONTINGENCIES

a. Royalty Commitment - Israeli Innovation Authority (“IIA”)

The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2023 or 2022. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate (“LIBOR”) is repayable in form of royalties based on 3.0% of BNA™ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate (“SOFR”) subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of December 31, 2023 and 2022. The contingent liability amounts to $5,625 and $5,576 for 2023 and 2022 respectively.

Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIA’s approval.

~~XML 61 R38.htm IDEA: XBRL DOCUMENT~~

Note 11 - Equity

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Equity [Text Block]

NOTE 11: EQUITY

a. Shares

On August 17, 2022, the Company closed a securities purchase agreement for the sale of 10 million Series A Preferred Stock for gross proceeds of $40. This agreement also entitled the subscriber to 13,333 warrants to purchase shares of common stock of the Company.

On September 15, 2022, the Company closed a securities purchase agreement for the sale of 51,282 consolidation adjusted shares of common stock at a consolidation adjusted price of $4.87 per share for aggregate gross proceeds of $250.

On February 16, 2023, the Company sold 32,536,386 shares of common stock at a price per share of $0.0041. The Company received aggregate gross proceeds from the offering of $133.

On February 23, 2023, the Company offered up to 10,799,136 shares of Series B Preferred Stock at $0.1852 per share. On March 15, 2023, the Company increased the offering to up to 14,578,833 shares of Series B Preferred Stock, with the increase being subsequently approved by the board of directors on November 15, 2023. As of December 31, 2023, the Company received aggregate gross proceeds from the offering of $2,700. The Company incurred $92 of costs associated with the issuance. Series B Preferred Stock issued are equity classified instruments and are recorded as equity. As of December 31, 2023, 14,578,833 Series B Preferred Stock were subscribed and issued.

On May 1, 2023, the Company granted 284,964 shares of common stock to a related party as a payment for consulting services provided. The shares awarded are under the scope of ASC 718 and were accounted for as equity-classified awards. The shares were measured at fair value on the grant date at $0.0041 per share.

On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred

NOTE 9: EQUITY

a. Shares

On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. During the six months period ended June 30, 2024, the Company issued 836,085 units and received aggregate gross proceeds of $1,070. The Company incurred $125 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.

As of December 31, 2023, the mandatory conversion feature of the Series B Preferred Stock was triggered, as the proceeds from the Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of June 30, 2024, the 14,578,833 of Series B Preferred stock were converted to 14,578,833 shares of common stock.

As of June 30, 2024, the Company had the following number of authorized and issued shares:

	June 30, 2024	
	Number of authorized shares	Number of issued shares
Shares of common stock	2,470,000,000	49,948,710
Series A Preferred Stock	30,000,000	-
Series B Preferred Stock		-
Series C Preferred Stock		2,374,219

As of June 30, 2024 the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shares of all classes.

b. Warrants

The following table summarizes the Company's warrant activity for the six months ended June 30, 2024:

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2024	**2,386,677**	**$ 2.07**	**2.46**
Warrants issued pursuant to units offering	836,531	2.56	-
Outstanding warrants, June 30, 2024	**3,223,208**	**$ 2.19**	**2.19**

On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. The warrants were determined to be a freestanding equity instrument. For the six month period ended June 30, 2024, 836,531 warrants were issued.

c. Employees stock option plan

A summary of option activity under the Plan as of June 30, 2024 and changes during the period then ended is presented below.

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31,2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**
Options granted	-	-	-	-
Outstanding Options, June 30, 2024	**1,291,662**	**$ 2.16**	**5.67**	**$ -**

The share-based compensation expense related to options for the three and six months ended June 30, 2024 was $58 and $117, respectively and 74$ and $148 for the three and six months ended June 30, 2023, respectively. The fair value of options granted for the six months period ended June 30, 2024 and 2023 was $nil and $nil, respectively. The intrinsic value of the options outstanding as of June 30, 2024 is $nil (December 31, 2023: $nil).

A summary of the Company's non vested options as of June 30, 2024, and changes during the six months period ended, is presented below.

	Number of Stock Options	Weighted Average Grant-Date Fair Value

Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. As of December 31, 2023, the Company issued 1,538,134 units and received aggregate gross proceeds of $1,969. The Company incurred $67 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.

On October 16, 2023, 4,217 shares of common stock were repurchased for a nominal amount and cancelled by the Company.

As of December 31, 2023, mandatory conversion feature of Series B Preferred Stock was triggered, as the proceeds from Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of December 31, 2023, the 14,578,833 shares of common stock were not issued from an administrative perspective but were considered substantially issued from an accounting perspective.

As of December 31, 2023 and 2022, the Company had the following number of authorized and issued shares:

	December 31			
	2023	2022	2023	2022
	Number of authorized shares	Number of authorized shares	Number of issued shares	Number of issued shares
Shares of common stock	2,470,000,000	2,470,000,000	35,369,877	2,552,744
Series A Preferred Stock			-	-
Series B Preferred Stock	30,000,000	30,000,000	14,578,833	-
Series C Preferred Stock			1,538,134	-

As of December 31, 2023 and 2022, the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shared of all classes.

b. Rights attached to shares

The shares of common stock confer upon their holders' voting rights and the right to participate in shareholders' meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Company's Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), and the right to a share in excess assets upon liquidation of the Company – all as set forth in the Company's Certificate of Incorporation and in the Company's Shareholders' Agreement.

The preferred shares confer upon their holders voting rights and the right to participate in shareholders' meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Company's Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), on an "as converted" basis, and the right to a share in excess assets upon liquidation of the Company in preference to the shares of common stock. The shares have discretionary dividends and do not have a redemption date.

The Series C Preferred Stock rank, as to the payment of dividends and the distribution of assets upon liquidation, dissolution or winding up of the Company: (a) senior to the shares of common stock, (b) junior to the Series B Preferred Stock, which Series B Preferred Stock include mandatory conversion provisions in the event the Company issues and sells equity securities to investors in an equity financing with total gross proceeds of not less than $1,000 with at least a pre-money valuation of the Company of $18,000, and (c) on parity with all other classes and series of the Company's preferred shares.

Series B Preferred Stock

Optional Conversion

Each share of Series B Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series B Preferred Stock "Series B Certificate of Designations"), which conversion price shall initially be equal to the original issue price.

Mandatory Conversion

Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") (or a qualified offering statement under Regulation A under the Securities Act; (b) the date that the Company or a successor to the Company (including, without limitation by way of acquisition of all or substantially all of the Company's assets) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is subject to the periodic and current reporting requirements of Section 13 or 15(d) of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $1,000 with at least a minimum pre-money valuation of the Company of $18,000, or (d) the date and time, or the occurrence of an event, by vote or written consent of the holders of at least a majority of the outstanding shares of Series B Preferred Stock, voting as a single class on an as-converted basis, all outstanding shares of Series B Preferred Stock shall automatically be converted into shares of common stock at the applicable ratio set forth in the Series B Certificate of Designations.

Series C Preferred Stock

Optional Conversion

Each share of Series C Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series C Preferred Stock, the "Series C Certificate of Designations"), which conversion price shall initially be equal to the original issue price.

Mandatory Conversion

Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act or a qualified offering statement under Regulation A of the Securities Act, as amended); (b) the date that the Company or a successor to the Corporation (including, without limitation, by way of acquisition of all or substantially all of the Corporation's assets, merger, or any other business combination) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Exchange Act and is subject to the periodic and current reporting requirements of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $2,000 with at least a minimum pre-money valuation of the Company of $65,000, or (d) the date and time, or the occurrence of an event, specified by vote or written consent of at least a majority of the outstanding shares of Series C Preferred Stock at the time of such vote or consent, voting as a single class on an as-converted basis, all outstanding shares of Series C Preferred Stock shall automatically be converted into shares of common stock at the applicable ratio described in Series C Certificate of Designations.

d. Warrants

During 2022, part of the modification of the WPC convertible (Note 7), the Company issued 526,749 stock split adjusted Tranche A and 262,051 stock split adjusted Tranche B warrants. The features of the warrants were as below:

Tranche A:

- Exercise price: (1) $0.75 – If funds of a minimum of $15,000 are raised, (2) $0.75 – If the sale of a company, IPO or RTO is completed or the (3) purchase price per share resulting from dividing $50,000 by the total number of valid issued ordinary shares outstanding.
- Maturity/Expiration date: (a) if no IPO – one year after the delivery date of the 2021 audited financial statements (b) if IPO – then one year after the date of such IPO.

Tranche B:

- Purchase price per share resulting from dividing $150,000 by the total number of valid issued ordinary shares outstanding.
- Maturity/Expiration date: (a) if no IPO – one year after the delivery date of the 2021 audited financial statements (b) if IPO – then five years after the date of such IPO.

On July 4, 2022, as part of the Senior Lender's Memo, the conversion price of the Tranche A warrant was amended to: (1) $0.75 – If after July 5, 2022 funds of a minimum of $5,000 are raised 18 months and $10,000 in total in the three years thereafter, (2) $0.75 – after the recapitalization date, if the sale of a company, IPO or RTO is completed or (3) the purchase price per share resulting from dividing $20,000 by the total number of valid issued ordinary shares outstanding. The Tranche B warrants were cancelled.

As part of the convertible debt issuance to various investors between July 4, 2022, and August 16, 2022, the Company issued 198,482 consolidation adjusted warrants concurrent with the convertible debt and preferred shares. The warrants were exercisable into one share of common stock of the Company per warrant at a price of $3. The warrants had a maturity date of three years.

Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**
Options granted	-	-
Options vested	(187,739)	0.62
Non-Vested Options, June 30, 2024	**687,147**	**$ 0.46**

As of June 30, 2024, there was $317 of total unrecognized compensation cost related to nonvested options granted under the Plan.

d. Management options

On April 2, 2024, the Company granted stock options to its officer to purchase an aggregate of 106,000 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Company's equity securities in an initial public offering (an "IPO Transaction"), that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 106,000 shares of common stock shall vest in 36 equal installments at the end of each calendar month over a period of three years beginning March 1, 2024. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event.

e. Consulting agreement

On March 15, 2024, the Company entered into a consulting agreement ("Consulting agreement"), which was further approved by the board of directors of the Company on April 2, 2024. Under the Consulting agreement, the Company will receive services of promoting the Company's stock; in return for 432,034 Series A performance warrants and 195,313 shares of common stock issued immediately upon execution of the agreement, and 234,735 shares of common stock to be issued in 12 equal installments at the end of each calendar month.

Series A performance warrants to purchase up to an aggregate 432,034 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share and are set to expire on June 15, 2028. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event.

As of June 30, 2024, the shares of common stock and Series A performance warrants were not issued and no services were received.

On February 17, 2023, warrants to purchase up to 123,333 shares of common stock, issued to WPC in 2021, were modified pursuant to antidilution provision in the warrant agreement, triggered by common stock private placement on February 16, 2023. As a result of the modification, exercise price of the warrants was reduced to $0.00473 per share and the expiry date was extended to be three years from the modification date. The warrants were determined to be a freestanding equity instrument. Under ASC 815, the effect of a modification was nominal and was recorded as an equity issuance costs.

On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. The warrants were determined to be a freestanding equity instrument. As of December 31, 2023, 759,863 warrants were issued. Additionally, as of December 31, 2023, 781,250 warrants were not issued from an administrative perspective, but were considered substantially issued from an accounting perspective.

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2022	**123,333**	**$ 7.50**	**0.85**
Warrants issued pursuant to issue of convertible debt and preferred shares to individual investors	198,482	3.00	
Warrants issued pursuant to modification of convertible debt	526,749	0.75	
Outstanding warrants, December 31, 2022	**848,564**	**$ 2.26**	**2.50**
Warrants issued pursuant to units offering	1,538,113	2.56	
Outstanding warrants, December 31, 2023	**2,386,677**	**$ 2.07**	**2.46**

The warrants and prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022.

e. Series A warrants

On June 15, 2023, the Company granted Series A warrants to purchase up to an aggregate 6,048,456 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share for a period of five years from the issuance date. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event.

f. Employees stock option plan

In 2010, the Company's board of directors approved an employee and service provider's stock option plan. On July 8, 2023, the board of directors approved new equity incentive plan (the "Plan"). The Plan permits the grant of options, share appreciation rights ("SARs"), restricted share units ("RSUs"), deferred share units ("DSUs") and performance share units ("PSUs"). In respect of options, the aggregate number of shares of common stock issuable under the Plan shall not exceed twelve percent of the issued and outstanding shares of common stock at any point in time. In respect of SARs, RSUs, DSUs and PSUs: (i) the maximum aggregate number of shares of common stock issuable under this Plan in respect of SARs, RSUs, DSUs and PSUs shall not exceed ten percent of the issued and outstanding shares of common stock as of July 8, 2023; (ii) the total number of SARs, RSUs, DSUs and PSUs issuable to any participant under this Plan shall not exceed one percent of the issued and outstanding shares of common stock at the time of the award.

The fair value of each option award is estimated on the date of grant using a Black Scholes option valuation model that uses the assumptions noted in the following table.

	2023	2022
Risk free rate	4.35%	4.5%
Dividend yield	0%	0%
Expected volatility	86%	86%
Expected term (in years)	3	3
Expected life (in years)	5	5

A summary of option activity under the Plan as of December 31, 2023, and changes during the year then ended is presented below.

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31, 2022	**495,746**	**$ 4.70**	**6.90**	**$ -**
Options granted	795,916	0.58		
Outstanding Options, December 31, 2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**

The share-based compensation expense related to options for December 31, 2023 was $295 (2022: $60). The fair value of options granted for the year ended December 31, 2023 was nominal (2022: $692). The intrinsic value of the options outstanding is $nil (2022: $nil).

A summary of the Company's non-vested options as of December 31, 2023, and changes during the year ended December 31, 2023, is presented below.

	Number of Stock Options	Weighted Average Grant-Date Fair Value
Non-Vested Options, December 31, 2022	**325,853**	**$ 2.20**
Options granted	795,916	0.00
Options vested	(246,883)	1.15
Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**

As of December 31, 2023, there was $434 of total unrecognized compensation cost related to nonvested options granted under the Plan.

The options and exercise prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022.

g. Management options

On July 8, 2023, the Company granted stock options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Company's equity securities in an initial public offering (an "IPO Transaction"), that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 362,584 shares of common stock shall vest immediately with the remaining options vesting in 36 equal installments at the end of each calendar month over a period of three years from the date of grant. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event.

h. Restricted share units

On July 8, 2023, the Company granted RSUs to certain management and directors. The vesting of the RSUs is contingent upon a transaction that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. When vested, the RSUs represent the right to be issued the number shares of common stock that is equal to the number of RSUs granted. Since RSUs are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost related to RSUs is recognized until the occurrence of a liquidity event.

~~XML 62 R39.htm IDEA: XBRL DOCUMENT~~

Note 12 - Basic and Diluted Net Loss Per Share

Notes to Financial Statements

Earnings Per Share [Text Block]

6 Months Ended

Jun. 30, 2024

NOTE 10: BASIC AND DILUTED NET LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that

12 Months Ended

Dec. 31, 2023

NOTE 12: BASIC AND DILUTED NET LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that were outstanding during the period when the effect is dilutive. Potential dilutive shares of common

were outstanding during the period when the effect is dilutive. Potential dilutive shares of common stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding shares of common stock figures for the years ended December 31, 2023 or 2022, as the outstanding shares of common stock figures for the six months ended June 30, 2024 or 2023, as the assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.
stock units would be anti-dilutive.

~~XML 63 R40.htm IDEA: XBRL DOCUMENT~~

Note 13 - Related Party Transactions

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

NOTE 11: RELATED PARTY TRANSACTIONS

As of the period ended June 30, 2024, $175 (2023: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand.

The Company incurred $140 and $244 in officers' consulting fees recorded in general and administration expenses for the three and six months ended June 30, 2024, respectively and $102 and $223 for the three and six months ended June 30, 2023, respectively.

NOTE 13: RELATED PARTY TRANSACTIONS

During the year ended December 31, 2022, $320 of notes payable to directors were converted to 106,612 shares of common stock (Note 7).

As of the year ended December 31, 2023, $175 (2022: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand. The remaining related party payables of $nil (2022: $2) relate to services payable to a related party of the Company. These payables do not bear any interest and are payable on demand.

The Company incurred $222 and $420 in officers' consulting fees recorded in general administration expenses on consolidated statements of operations for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023 and 2022, $106 and $56, respectively remained outstanding and were accrued by the Company, and are included in accrued liabilities in the accompanying balance sheets.

On May 1, 2023, the Company issued 284,964 shares of common stock to a related party as a payment for consulting services provided.

On July 8, 2023, the Company granted options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock in the capital of the Company (Note 11.g), 2,776,861 of these options were granted to related parties. No compensation cost is recognized related to options until the occurrence of a liquidity event.

~~XML 64 R41.htm IDEA: XBRL DOCUMENT~~

Note 14 - Revenue

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

NOTE 12: REVENUE

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Type of goods and services				
Service	$ 10	$ 451	$ 22	$ 456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**
Timing of recognition of revenue				
Point in time	3	-	7	-
Over time	**7**	451	15	456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**

NOTE 14: REVENUE

	December 31	
	2023	2022
Type of goods and services		
Service	$ 498	$ -
Total	**$ 498**	**$ -**
Timing of recognition of revenue		
Over time	$ 498	$ -
Total	**$ 498**	**$ -**

~~XML 65 R42.htm IDEA: XBRL DOCUMENT~~

Note 15 - Research and Development Expenses

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Research, Development, and Computer Software Disclosure [Text Block]

NOTE 13: RESEARCH AND DEVELOPMENT EXPENSES

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 210	$ 167	$ 443	$ 254
Consultants and subcontractors	70	17	77	23
Depreciation and amortization	4	-	4	-
Clinical trials	-	14	-	19
Expenses - other	66	1	115	24
	350	199	639	320
Less – grants received	-	-	-	-
Total	**$ 350**	**$ 199**	**$ 639**	**$ 320**

NOTE 15: RESEARCH AND DEVELOPMENT EXPENSES

	December 31	
	2023	2022
Salary and employee benefits	$ 527	$ 944
Consultants and subcontractors	99	152
Depreciation and amortization	-	14
Clinical trials	3	60
Expenses - other	112	129
	741	1,299
Less – grants received	-	-
Total	**$ 741**	$ 1,299

~~XML 66 R43.htm IDEA: XBRL DOCUMENT~~

Note 16 - Selling and Marketing Expenses

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Selling and Marketing Expenses [Text Block]

NOTE 14: SELLING AND MARKETING EXPENSES

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 179	$ 160	$ 347	$ 289
Professional fees	89	5	142	5
Travel	22	6	46	10
Other	3	-	7	-
Total	**$ 293**	**$ 171**	**$ 542**	**$ 304**

NOTE 16: SELLING AND MARKETING EXPENSES

	December 31	
	2023	2022
Salary and employee benefits	$ 611	$ 432
Professional fees	6	27
Travel	21	51
Other	1	14
Total	**$ 639**	$ 524

~~XML 67 R44.htm IDEA: XBRL DOCUMENT~~

Note 17 - General and Administration Expenses

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

General and Administrative Expenses [Text Block]

NOTE 15: GENERAL AND ADMINISTRATION EXPENSES

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 143	$ 142	$ 261	$ 319
Professional fees	417	183	822	246
Rent and maintenance	4	33	6	65
Travel expenses	23	12	31	25
Other	39	29	71	41
Total	**$ 626**	**$ 399**	**$ 1,191**	**$ 696**

NOTE 17: GENERAL AND ADMINISTRATION EXPENSES

	December 31	
	2023	2022
Salary and employee benefits	$ 512	$ 418
Professional fees	1,252	724
Rent and maintenance	91	233
Travel expenses	56	72
Bad debts	1	(2)
Other	284	97
Total	**$ 2,196**	$ 1,542

~~XML 68 R45.htm IDEA: XBRL DOCUMENT~~

Note 18 - Other (Income) Expense

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Other Nonoperating Income and Expense [Text Block]

NOTE 18: OTHER (INCOME) / EXPENSE

	December 31	
	2023	2022
Interest, bank fees and loan fees	$ 18	$ 440
Unrealized (gain) loss on foreign exchange	(37)	134
Loss on extinguishment of debt	-	59
Gain on sale of equipment	-	(166)
Other	(457)	(7)
Total	**$ (476)**	$ 460

In February 2022, the Company sold equipment for $262 resulting in a gain on sale of $166.

On February 24, 2023, the agreement with R.I. Mind Group Ltd. expired in accordance with its terms, and, as of December 31, 2023, there are no amounts owed by the Company to R.I. Mind Group Ltd. As the Company did not carry any activity for the purposes of the agreement, the Company recognized $459 of other income (Note 8).

~~XML 69 R46.htm IDEA: XBRL DOCUMENT~~

Note 19 - Income Tax

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE 19: INCOME TAX

The total provision for income taxes differs from the amount which would be computed by applying the US income tax rate to loss before income taxes. The reasons for these differences are as follows:

	December 31	
	2023	2022
Statutory income tax rate	27.60%	28.51%
Statutory income tax recovery	$ (718)	$ (1,113)
Increase (decrease) in income taxes		
Non-deductible option expenses	135	19
Taxable capital gain on sale of investment and equipment	-	-
Difference in foreign tax rates	30	200
US state tax	1	(1)
Change in valuation allowance	553	895
Income tax expense (recovery)	$ 1	$ -

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities and certain carry-forward balances.

The primary components of the deferred tax assets and liabilities are as follows, for the periods indicated below:

	December	
	2023	2022
	$	$
Deferred tax assets		
Non-capital loss carry-forwards from Canada	-	1
Non-capital loss carry-forwards from US	1,418	1,576
Non-capital loss carry-forwards from Israel	15,449	17,479
Stock option	95	17
R&D expenditures	236	424
Reserves and others	127	-
	17,325	19,497
Valuation Allowances for deferred tax assets	(17,325)	(19,497)
Net deferred tax assets	-	-

The net deferred tax assets have been offset by a valuation allowance because it is not more likely than not the Company will realize the benefit of these deferred tax assets. The Company did not recognize any tax benefits as of December 31, 2023 and December 31, 2022.

At December 31, 2023, the Company's Canadian, US, and Israeli non-capital income tax losses, the benefit of which has not been recognized on the consolidated financial statements, expire as follows:

	Canada	US	Israel
2034	$ -	$ 501	$ -
2035	-	1,767	-
2036	-	2,872	-
2037	-	-	-
2038	-	-	-
2039	-	-	-
2040	-	-	-
2041	-	-	-
2042	2	-	-
Indefinite	-	1,293	67,170
	$ 2	$ 6,433	$ 67,170

At December 31, 2023, the Company had a cumulative carry-forward pool of Israeli Research and Development expenditures in the amount of $889 (2022: $1,823) which will be amortized within the next three years.

The Company files unconsolidated federal income tax returns domestically and in foreign jurisdictions. The Company has open tax years from 2018 to 2023 with tax jurisdictions including Canada, U.S, and Israel. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations, as they relate to amount, timing, or inclusion of revenues and expenses.

~~XML 70 R47.htm IDEA: XBRL DOCUMENT~~

Note 20 - Revision of Prior Period Financial Statements

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Error Correction [Text Block]

NOTE 20: REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS

During 2023, management of the Company became aware of certain errors in the recording of expenses within research and development and general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. Revisions of these amounts are reflected in the following tables.

Revised Consolidated Balance Sheet

	As of December 31, 2022		
	As reported	Adjustment	As revised
Accrued liabilities	740	115	855
Total current liabilities	2,246	115	2,361
Total liabilities	2,246	115	2,361
Accumulated deficit	(73,906)	(115)	(74,021)
Total shareholders' deficit	(2,111)	(115)	(2,226)

Revised Consolidated Statements of Operations and Comprehensive Loss

	For the year ended December 31, 2022		
	As reported	Adjustment	As revised
Research and development expenses	1,272	27	1,299
General and administration expenses	1,454	88	1,542
Total operating expenses	3,329	115	3,444
Loss before Income Tax	(3,789)	(115)	(3,904)
Net Loss and Comprehensive Loss	(3,789)	(115)	(3,904)

Revised Consolidated Statement of Cash Flows

	For the year ended December 31, 2022		
	As reported	Adjustment	As revised
Net loss	(3,789)	(115)	(3,904)
Change in accrued liabilities	(18)	115	97
Net cash used in operating activities	(2,892)	-	(2,892)

~~XML 71 R48.htm IDEA: XBRL DOCUMENT~~

Note 21 - Subsequent Events

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes to Financial Statements

Subsequent Events [Text Block]

NOTE 16: SUBSEQUENT EVENTS

The subsequent events below are major events or transactions that occurred after the six month period ended June 30, 2024, but before the issuance of these condensed consolidated financial statements. The below events occurred between July 1, 2024 and August 14, 2024:

On August 8, 2024, the Company completed the closing of a $209 secured promissory notes. Promissory notes were issued with a discount of $11 and the Company received gross proceeds of $198. The promissory note will bear an annual interest rate of 18%, paid monthly. The principal amount of $209 will mature and become due and payable on August 23, 2024.

NOTE 21: SUBSEQUENT EVENTS

The subsequent events below are major events or transactions that occurred after the period ended December 31, 2023, but before the issuance of these consolidated financial statements. The below events occurred between January 1, 2024 and May 22, 2024:

Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc.

Merger

On August 12, 2024, the Company completed the merger with WaveDancer. As a result of this transaction, the Company obtained control of WaveDancer. The combined company operates under the name Firefly Neuroscience, Inc., and on August 13, 2023 the Company began trading on the Nasdaq Capital Market (NASDAQ: AIFF). On August 12, 2024, prior to the consummation of the Merger, WaveDancer effectuated a 1-for-3 reverse stock split of its common stock (the "Reverse Stock Split") . Pursuant to the terms of the Merger Agreement, each holder of outstanding shares of the Company's shares of common stock is entitled to receive the number of shares of WaveDancer common stock equal to the number of shares of the Company's shares of common stock they hold multiplied by the exchange ratio, or an aggregate of 7,870,251 shares of WaveDancer common stock at closing using an exchange ratio of 0.1040. Following the closing of the merger, there are 7,870,251 shares of the combined company's common stock outstanding with Firefly stockholders owning approximately 92% and prior WaveDancer stockholders owning 8% of the combined company's outstanding securities.

On January 12, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates include changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Company's warrants at the effective time and deletion of certain closing obligations.

On February 28, 2024, the Company issued 820,312 units and received aggregate gross proceeds of $1,050. Each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.

Private Placement

On July 26, 2024, prior to the consummation of the merger, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,069,287 shares (the "PIPE Shares") of the combined company's common stock and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 4,849,265 shares of combined company's common stock, and (iii) warrants (the "Warrants") to purchase up to 7,918,552 shares of combined company's common stock in a private placement (the "Private Placement"). The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the merger. The aggregate gross proceeds from the transaction were approximately $3,500.

~~XML 72 R49.htm IDEA: XBRL DOCUMENT~~

Significant Accounting Policies (Policies)

6 Months Ended
Jun. 30, 2024

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

a. Principles of consolidation

These unaudited consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities ("VIE"). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation.

Use of Estimates, Policy [Policy Text Block]

b. Use of estimates in the preparation of consolidated financial statements

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.

New Accounting Pronouncements, Policy [Policy Text Block]

c. Impact of recently issued accounting standards

The Company has evaluated issued Accounting Standards Updates not yet adopted and believes the adoption of these standards will not have a material impact on its condensed consolidated financial statements.

~~XML 73 R50.htm IDEA: XBRL DOCUMENT~~

Note 4 - Other Receivables (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Details of Other Receivables [Table Text Block]

	June 30, 2024	December 31, 2023
Other receivables	$ 195	$ 196
Allowance for doubtful receivables	(112)	(112)
Total	**$ 83**	$ 84

	December 31 2023	2022
Other receivables	$ 196	$ 131
Allowance for doubtful receivables	(112)	(112)
Total	**$ 84**	$ 19

~~XML 74 R51.htm IDEA: XBRL DOCUMENT~~

Note 5 - Equipment (Tables)

6 Months Ended
Jun. 30, 2024

Notes Tables

Property, Plant and Equipment [Table Text Block]

	June 30, 2024	December 31, 2023
Medical equipment, cost	$ 64	$ -
Less – accumulated depreciation	(4)	-
Equipment, net	**$ 60**	**$ -**

~~XML 75 R52.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	June 30, 2024			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Weighted Average Life
Unamortized intangible assets				
BNA software	$ 634	$ -	$ 634	n/a
Total intangible assets	**$ 634**	**$ -**	**$ 634**	

	December 31, 2023			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Weighted Average Life
Unamortized intangible assets				
BNA software	$ 386	$ -	$ 386	n/a
Total intangible assets	**$ 386**	**$ -**	**$ 386**	

~~XML 76 R53.htm IDEA: XBRL DOCUMENT~~

Note 9 - Equity (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Schedule of Stock by Class [Table Text Block]

	June 30, 2024	
	Number of authorized shares	Number of issued shares
Shares of common stock	2,470,000,000	49,948,710
Series A Preferred Stock	30,000,000	-
Series B Preferred Stock		-
Series C Preferred Stock		2,374,219

	December 31			
	2023	2022	2023	2022
	Number of authorized shares	Number of authorized shares	Number of issued shares	Number of issued shares
Shares of common stock	2,470,000,000	2,470,000,000	35,369,877	2,552,744
Series A Preferred Stock			-	-
Series B Preferred Stock	30,000,000	30,000,000	14,578,833	-
Series C Preferred Stock			1,538,134	-

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2024	**2,386,677**	**$ 2.07**	**2.46**
Warrants issued pursuant to units offering	836,531	2.56	-
Outstanding warrants, June 30, 2024	**3,223,208**	**$ 2.19**	**2.19**

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2022	**123,333**	**$ 7.50**	**0.85**
Warrants issued pursuant to issue of convertible debt and preferred shares to individual investors	198,482	3.00	
Warrants issued pursuant to modification of convertible debt	526,749	0.75	
Outstanding warrants, December 31, 2022	**848,564**	**$ 2.26**	**2.50**
Warrants issued pursuant to units offering	1,538,113	2.56	
Outstanding warrants, December 31, 2023	**2,386,677**	**$ 2.07**	**2.46**

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31,2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**
Options granted	-	-	-	-
Outstanding Options, June 30, 2024	**1,291,662**	**$ 2.16**	**5.67**	**$ -**

	Number of Stock Options	Weighted Average Grant-Date Fair Value

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31, 2022	**495,746**	**$ 4.70**	**6.90**	**$ -**
Options granted	795,916	0.58		
Outstanding Options, December 31, 2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**

	Number of Stock Options	Weighted Average Grant-Date Fair Value

Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**
Options granted	-	-
Options vested	(187,739)	0.62
Non-Vested Options, June 30, 2024	**687,147**	**$ 0.46**

Non-Vested Options, December 31, 2022	**325,853**	**$ 2.20**
Options granted	795,916	0.00
Options vested	(246,883)	1.15
Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**

~~XML 77 R54.htm IDEA: XBRL DOCUMENT~~

Note 12 - Revenue (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Type of goods and services				
Service	$ 10	$ 451	$ 22	$ 456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**
Timing of recognition of revenue				
Point in time	3	-	7	-
Over time	**7**	451	15	456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**

	December 31	
	2023	2022
Type of goods and services		
Service	$ 498	$ -
Total	**$ 498**	**$ -**
Timing of recognition of revenue		
Over time	$ 498	$ -
Total	**$ 498**	**$ -**

~~XML 78 R55.htm IDEA: XBRL DOCUMENT~~

Note 13 - Research and Development Expenses (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Schedule of Research and Development Expenses [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 210	$ 167	$ 443	$ 254
Consultants and subcontractors	70	17	77	23
Depreciation and amortization	4	-	4	-
Clinical trials	-	14	-	19
Expenses - other	66	1	115	24
	350	199	639	320
Less – grants received	-	-	-	-
Total	**$ 350**	**$ 199**	**$ 639**	**$ 320**

	December 31	
	2023	2022
Salary and employee benefits	$ 527	$ 944
Consultants and subcontractors	99	152
Depreciation and amortization	-	14
Clinical trials	3	60
Expenses - other	112	129
	741	1,299
Less – grants received	-	-
Total	**$ 741**	$1,299

~~XML 79 R56.htm IDEA: XBRL DOCUMENT~~

Note 14 - Selling and Marketing Expenses (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Schedule of Selling and Marketing Expenses [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 179	$ 160	$ 347	$ 289
Professional fees	89	5	142	5
Travel	22	6	46	10
Other	3	-	7	-
Total	**$ 293**	**$ 171**	**$ 542**	**$ 304**

	December 31	
	2023	2022
Salary and employee benefits	$ 611	$ 432
Professional fees	6	27
Travel	21	51
Other	1	14
Total	**$ 639**	$ 524

~~XML 80 R57.htm IDEA: XBRL DOCUMENT~~

Note 15 - General and Administration Expenses (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Schedule of General and Administrative Expenses [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 143	$ 142	$ 261	$ 319
Professional fees	417	183	822	246
Rent and maintenance	4	33	6	65
Travel expenses	23	12	31	25
Other	39	29	71	41
Total	**$ 626**	**$ 399**	**$ 1,191**	**$ 696**

	December 31	
	2023	2022
Salary and employee benefits	$ 512	$ 418
Professional fees	1,252	724
Rent and maintenance	91	233
Travel expenses	56	72
Bad debts	1	(2)
Other	284	97
Total	**$2,196**	$1,542

~~XML 81 R58.htm IDEA: XBRL DOCUMENT~~

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended
Dec. 31, 2023

Notes Tables

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Geographic areas	Revenue 2023	Revenue 2022	Non-current assets 2023	Non-current assets 2022
Canada	-	-	-	-
United States of America	478	-	-	-
Israel	20	-	386	52

~~XML 82 R59.htm IDEA: XBRL DOCUMENT~~

Note 4 - Other Receivables (10K) (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Details of Other Receivables [Table Text Block]

	June 30,	December 31,
	2024	2023
Other receivables	$ 195	$ 196
Allowance for doubtful receivables	(112)	(112)
Total	**$ 83**	$ 84

	December 31	
	2023	2022
Other receivables	$ 196	$ 131
Allowance for doubtful receivables	(112)	(112)
Total	**$ 84**	$ 19

~~XML 83 R60.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets (10K) (Tables)

6 Months Ended
Jun. 30, 2024

12 Months Ended
Dec. 31, 2023

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	June 30, 2024			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Weighted Average Life
Unamortized intangible assets				
BNA software	$ 634	$ -	$ 634	n/a
Total intangible assets	**$ 634**	**$ -**	**$ 634**	

	December 31, 2023			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Weighted Average Life
Unamortized intangible assets				
BNA software	$ 386	$ -	$ 386	n/a
Total intangible assets	**$ 386**	**$ -**	**$ 386**	

~~XML 84 R61.htm IDEA: XBRL DOCUMENT~~

Note 8 - Deferred Revenue (Tables)

12 Months Ended
Dec. 31, 2023

Notes Tables

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	December 31	
	2023	2022
Pasithea Clinics Inc.	$ -	$ 450
R.I. Mind Group Ltd	$ -	$ 459
	$ -	$ 909

~~XML 85 R62.htm IDEA: XBRL DOCUMENT~~

Note 11 - Equity (Tables)

6 Months Ended Jun. 30, 2024

12 Months Ended Dec. 31, 2023

Notes Tables

Schedule of Stock by Class [Table Text Block]

	June 30, 2024	
	Number of authorized shares	Number of issued shares
Shares of common stock	2,470,000,000	49,948,710
Series A Preferred Stock	30,000,000	-
Series B Preferred Stock		-
Series C Preferred Stock		2,374,219

	December 31			
	2023	2022	2023	2022
	Number of authorized shares	Number of authorized shares	Number of issued shares	Number of issued shares
Shares of common stock	2,470,000,000	2,470,000,000	35,369,877	2,552,744
Series A Preferred Stock			-	-
Series B Preferred Stock	30,000,000	30,000,000	14,578,833	-
Series C Preferred Stock			1,538,134	-

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2024	**2,386,677**	**$ 2.07**	**2.46**
Warrants issued pursuant to units offering	836,531	2.56	-
Outstanding warrants, June 30, 2024	**3,223,208**	**$ 2.19**	**2.19**

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life
Outstanding warrants, January 1, 2022	**123,333**	**$ 7.50**	**0.85**
Warrants issued pursuant to issue of convertible debt and preferred shares to individual investors	198,482	3.00	
Warrants issued pursuant to modification of convertible debt	526,749	0.75	
Outstanding warrants, December 31, 2022	**848,564**	**$ 2.26**	**2.50**
Warrants issued pursuant to units offering	1,538,113	2.56	
Outstanding warrants, December 31, 2023	**2,386,677**	**$ 2.07**	**2.46**

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2023	2022
Risk free rate	4.35%	4.5%
Dividend yield	0%	0%
Expected volatility	86%	86%
Expected term (in years)	3	3
Expected life (in years)	5	5

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31,2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**
Options granted	-	-	-	-
Outstanding Options, June 30, 2024	**1,291,662**	**$ 2.16**	**5.67**	**$ -**

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding Options, December 31, 2022	**495,746**	**$ 4.70**	**6.90**	**$ -**
Options granted	795,916	0.58		
Outstanding Options, December 31, 2023	**1,291,662**	**$ 2.16**	**6.18**	**$ -**

	Number of Stock Options	Weighted Average Grant-Date Fair Value
Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**
Options granted	-	-
Options vested	(187,739)	0.62
Non-Vested Options, June 30, 2024	**687,147**	**$ 0.46**

	Number of Stock Options	Weighted Average Grant-Date Fair Value
Non-Vested Options, December 31, 2022	**325,853**	**$ 2.20**
Options granted	795,916	0.00
Options vested	(246,883)	1.15
Non-Vested Options, December 31, 2023	**874,886**	**$ 0.50**

~~XML 86 R63.htm IDEA: XBRL DOCUMENT~~

Note 14 - Revenue (Tables)

6 Months Ended Jun. 30, 2024

12 Months Ended Dec. 31, 2023

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Type of goods and services				
Service	$ 10	$ 451	$ 22	$ 456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**
Timing of recognition of revenue				
Point in time	3	-	7	-
Over time	**7**	451	15	456
Total	**$ 10**	**$ 451**	**$ 22**	**$ 456**

	December 31	
	2023	2022
Type of goods and services		
Service	$ 498	$ -
Total	**$ 498**	**$ -**
Timing of recognition of revenue		
Over time	$ 498	$ -
Total	**$ 498**	**$ -**

~~XML 87 R64.htm IDEA: XBRL DOCUMENT~~

Note 15 - Research and Development Expenses (Tables)

6 Months Ended Jun. 30, 2024

12 Months Ended Dec. 31, 2023

Notes Tables

Schedule of Research and Development Expenses [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 210	$ 167	$ 443	$ 254
Consultants and subcontractors	70	17	77	23
Depreciation and amortization	4	-	4	-
Clinical trials	-	14	-	19
Expenses - other	66	1	115	24
	350	199	639	320
Less – grants received	-	-	-	-
Total	**$ 350**	**$ 199**	**$ 639**	**$ 320**

	December 31	
	2023	2022
Salary and employee benefits	$ 527	$ 944
Consultants and subcontractors	99	152
Depreciation and amortization	-	14
Clinical trials	3	60
Expenses - other	112	129
	741	1,299
Less – grants received	-	-
Total	**$ 741**	$1,299

~~XML 88 R65.htm IDEA: XBRL DOCUMENT~~

Note 16 - Selling and Marketing Expenses (Tables)

6 Months Ended Jun. 30, 2024

12 Months Ended Dec. 31, 2023

Notes Tables

Schedule of Selling and Marketing Expenses [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 179	$ 160	$ 347	$ 289
Professional fees	89	5	142	5
Travel	22	6	46	10
Other	3	-	7	-
Total	**$ 293**	**$ 171**	**$ 542**	**$ 304**

	December 31	
	2023	2022
Salary and employee benefits	$ 611	$ 432
Professional fees	6	27
Travel	21	51
Other	1	14
Total	**$ 639**	$ 524

~~XML 89 R66.htm IDEA: XBRL DOCUMENT~~

Note 17 - General and Administration Expenses (Tables)

6 Months Ended Jun. 30, 2024

12 Months Ended Dec. 31, 2023

Notes Tables

Schedule of General and Administrative Expenses [Table Text Block]

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Salary and employee benefits	$ 143	$ 142	$ 261	$ 319
Professional fees	417	183	822	246
Rent and maintenance	4	33	6	65
Travel expenses	23	12	31	25
Other	39	29	71	41
Total	**$ 626**	**$ 399**	**$ 1,191**	**$ 696**

	December 31	
	2023	2022
Salary and employee benefits	$ 512	$ 418
Professional fees	1,252	724
Rent and maintenance	91	233
Travel expenses	56	72
Bad debts	1	(2)
Other	284	97
Total	**$2,196**	$1,542

~~XML 90 R67.htm IDEA: XBRL DOCUMENT~~

Note 18 - Other (Income) Expense (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Other Nonoperating Income (Expense) [Table Text Block]

	December 31 2023	2022
Interest, bank fees and loan fees	$ 18	$ 440
Unrealized (gain) loss on foreign exchange	(37)	134
Loss on extinguishment of debt	-	59
Gain on sale of equipment	-	(166)
Other	(457)	(7)
Total	**$ (476)**	$ 460

~~XML 91 R68.htm IDEA: XBRL DOCUMENT~~

Note 19 - Income Tax (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	December 31 2023	2022
Statutory income tax rate	27.60%	28.51%
Statutory income tax recovery	$ (718)	$ (1,113)
Increase (decrease) in income taxes		
Non-deductible option expenses	135	19
Taxable capital gain on sale of investment and equipment	-	-
Difference in foreign tax rates	30	200
US state tax	1	(1)
Change in valuation allowance	553	895
Income tax expense (recovery)	$ 1	$ -

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 2023 $	2022 $
Deferred tax assets		
Non-capital loss carry-forwards from Canada	-	1
Non-capital loss carry-forwards from US	1,418	1,576
Non-capital loss carry-forwards from Israel	15,449	17,479
Stock option	95	17
R&D expenditures	236	424
Reserves and others	127	-
	17,325	19,497
Valuation Allowances for deferred tax assets	(17,325)	(19,497)
Net deferred tax assets	-	-

Summary of Operating Loss Carryforwards [Table Text Block]

	Canada	US	Israel
2034	$ -	$ 501	$ -
2035	-	1,767	-
2036	-	2,872	-
2037	-	-	-
2038	-	-	-
2039	-	-	-
2040	-	-	-
2041	-	-	-
2042	2	-	-
Indefinite	-	1,293	67,170
	$ 2	$ 6,433	$ 67,170

~~XML 92 R69.htm IDEA: XBRL DOCUMENT~~

Note 20 - Revision of Prior Period Financial Statements (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	As of December 31, 2022		
	As reported	Adjustment	As revised
Accrued liabilities	740	115	855
Total current liabilities	2,246	115	2,361
Total liabilities	2,246	115	2,361
Accumulated deficit	(73,906)	(115)	(74,021)
Total shareholders' deficit	(2,111)	(115)	(2,226)

	For the year ended December 31, 2022		
	As reported	Adjustment	As revised
Research and development expenses	1,272	27	1,299
General and administration expenses	1,454	88	1,542
Total operating expenses	3,329	115	3,444
Loss before Income Tax	(3,789)	(115)	(3,904)
Net Loss and Comprehensive Loss	(3,789)	(115)	(3,904)

	For the year ended December 31, 2022		
	As reported	Adjustment	As revised
Net loss	(3,789)	(115)	(3,904)
Change in accrued liabilities	(18)	115	97
Net cash used in operating activities	(2,892)	-	(2,892)

~~XML 93 R70.htm IDEA: XBRL DOCUMENT~~

Note 1 - Business Description (Details Textual)

	Aug. 12, 2024	Nov. 16, 2023
Former Firefly 2023 Stockholders [Member]		
Subsidiary, Ownership Percentage, Parent	92.00%	92.00%
Former Firefly Stockholders [Member]		
Subsidiary, Ownership Percentage, Parent	8.00%	8.00%

~~XML 94 R71.htm IDEA: XBRL DOCUMENT~~

Note 2 - Going Concern (Details Textual) - USD ($) $ in Thousands

	6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Retained Earnings (Accumulated Deficit)	$ (79,010)		$ (76,624)	$ (74,021)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	(2,402)			
Net Cash Provided by (Used in) Operating Activities	$ (2,418)	$ (936)	$ (2,172)	$ (2,892)

~~XML 95 R72.htm IDEA: XBRL DOCUMENT~~

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)

	Jun. 30, 2024
Medical Equipment [Member]	
Property, Plant and Equipment, Useful Life (Year)	4 years

~~XML 96 R73.htm IDEA: XBRL DOCUMENT~~

Note 4 - Other Receivables - Details of Other Receivables (Details) - USD ($) $ in Thousands

	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022

Other receivables	$ 195	$ 196	$ 131
Allowance for doubtful receivables	(112)	(112)	(112)
Total	$ 83	$ 84	$ 19

~~XML 97 R74.htm IDEA: XBRL DOCUMENT~~

Note 5 - Equipment - Summary of Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Less – accumulated depreciation	$ (4)	$ 0
Equipment, net	60	0
Medical Equipment [Member]		
Property, plant and equipment gross	$ 64	$ 0

~~XML 98 R75.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets (Details Textual)	Jun. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Asset, Useful Life (Year)	5 years	5 years

~~XML 99 R76.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Intangible assets, gross	$ 634	$ 386
Intangible assets, accumulated amortization	0	0
Intangible assets, net	634	386
Computer Software, Intangible Asset [Member]		
Intangible assets, gross	634	386
Intangible assets, accumulated amortization	0	0
Intangible assets, net	$ 634	$ 386

~~XML 100 R77.htm IDEA: XBRL DOCUMENT~~

Note 7 - Liability for Employee Rights Upon Retirement (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Monthly Deposit Rate, Percent of Salary	8.33%		8.33%			
Contributions to Severance Compensation Act	$ 11	$ 11	$ 25	$ 16	$ 33	$ 51

~~XML 101 R78.htm IDEA: XBRL DOCUMENT~~

Note 8 - Commitments and Contingencies (Details Textual) - IIA Royalty Commitment [Member] - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Research Agreement, Royalty Percentage	3.00%	3.00%	
Other Commitment	$ 5,676	$ 5,625	$ 5,576

~~XML 102 R79.htm IDEA: XBRL DOCUMENT~~

Note 9 - Equity (Details Textual)	Apr. 02, 2024 shares	Dec. 31, 2023 USD ($) $ / shares shares	Aug. 29, 2023 $ / shares shares	Jul. 08, 2023 shares	3 Months Ended Jun. 30, 2024 USD ($) $ / shares shares	3 Months Ended Jun. 30, 2023 USD ($)	6 Months Ended Jun. 30, 2024 USD ($) $ / shares shares	6 Months Ended Jun. 30, 2023 USD ($)	12 Months Ended Dec. 31, 2023 USD ($) $ / shares shares	12 Months Ended Dec. 31, 2022 USD ($) $ / shares shares	Mar. 15, 2024 $ / shares shares	Dec. 31, 2021 $ / shares
Proceeds from Issuance or Sale of Equity | $							$ 945,000	$ 1,225,000	$ 4,643,000	$ 290,000		
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 2.07			$ 2.19		$ 2.19		$ 2.07	$ 2.26		$ 7.5
Shares Authorized (in shares)		2,500,000,000			2,500,000,000		2,500,000,000		2,500,000,000			
Common Stock, Shares Authorized (in shares)		2,470,000,000			2,470,000,000		2,470,000,000		2,470,000,000	2,470,000,000		
Preferred Stock, Shares Authorized (in shares)		30,000,000			30,000,000		30,000,000		30,000,000	30,000,000		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Fair Value | $							$ 0	0		$ 692,000		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $		$ 0			$ 0		0		$ 0	$ 0		
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $		434,000			317,000		$ 317,000		$ 434,000			
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	106,000			3,148,288			0		795,916			
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	5 years			5 years					5 years	5 years		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)	106,000			362,584			187,739		246,883			
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years			3 years								
Shares, Issued (in shares)											195,313	
Shares To Be Issued (in shares)											234,735	
Share-Based Payment Arrangement, Option [Member]												
Share-Based Payment Arrangement, Expense | $					$ 58,000	$ 74,000	$ 117,000	$ 148,000	$ 295,000	$ 60,000		
Conversion of Series B Preferred Stock to Common Stock [Member]												
Preferred Stock, Mandatory Conversion Feature, Offering Proceeds Threshold | $		$ 1,000							$ 1,000			
Preferred Stock, Convertible, Conversion Ratio		1							1			
Conversion of Stock, Shares Converted (in shares)		14,578,833					14,578,833					
Series C Preferred Unit Warrants [Member]												
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1	1		1		1		1			
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 2.56	$ 2.56		$ 2.56		$ 2.56		$ 2.56			
Warrants and Rights Outstanding, Term (Year)		3 years			3 years		3 years		3 years			
Warrants or Rights Issued (in shares)							836,531		759,863			
Series A Performance Warrants [Member]												
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 0.01	
Class of Warrant or Right, Number of Securities											432,034	

Called by Warrants or Rights (in shares)						
Series C Preferred Stock [Member]						
Units Issued During Period, New Issues (in shares)	1,538,134	7,812,500		836,085		
Proceeds from Issuance or Sale of Equity | $	$ 1,969,000			$ 1,070,000		
Payments of Stock Issuance Costs | $	67,000			$ 125,000		
Preferred Stock, Mandatory Conversion Feature, Offering Proceeds Threshold | $	$ 2,000					$ 2,000
Preferred Stock, Shares Authorized (in shares)						
Series C Preferred Stock [Member] | Series C Preferred Unit Warrants [Member]						
Class of Warrant or Right, Combined Purchase Price (in dollars per share) | $ / shares		$ 1.28				

~~XML 103 R80.htm IDEA: XBRL DOCUMENT~~

Note 9 - Equity - Schedule of Shares Authorized and Issued (Details) - shares	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Shares of common stock authorized (in shares)	2,470,000,000	2,470,000,000	2,470,000,000
Shares of common stock issued (in shares)	49,948,710	35,369,877	2,552,744
Shares of preferred stock authorized (in shares)	30,000,000	30,000,000	30,000,000
Shares of preferred stock issued (in shares)	2,374,219	16,116,957	0
Series A Preferred Stock [Member]			
Shares of preferred stock authorized (in shares)	30,000,000		
Shares of preferred stock issued (in shares)	0	0	0
Series B Preferred Stock [Member]			
Shares of preferred stock authorized (in shares)		30,000,000	30,000,000
Shares of preferred stock issued (in shares)	0	14,578,833	0
Series C Preferred Stock [Member]			
Shares of preferred stock authorized (in shares)			
Shares of preferred stock issued (in shares)	2,374,219	1,538,134	0

~~XML 104 R81.htm IDEA: XBRL DOCUMENT~~

Note 9 - Equity - Schedule of Warrants (Details) - $ / shares	6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Outstanding warrants, January 1, 2024 (in shares)	2,386,677	848,564	123,333	
Exercise price (in dollars per share)	$ 2.07	$ 2.26	$ 7.5	
Outstanding warrants, January 1, 2024 (Year)	2 years 2 months 8 days	2 years 5 months 15 days	2 years 6 months 10 months 6 days	
Warrants issued pursuant to units offering (in shares)	836,531	1,538,113	198,482	
Warrants issued pursuant to units offering (in dollars per share)	$ 2.56	$ 2.56	$ 3	
Outstanding warrants, June 30, 2024 (in shares)	3,223,208	2,386,677	848,564	123,333
Exercise price (in dollars per share)	$ 2.19	$ 2.07	$ 2.26	$ 7.5

~~XML 105 R82.htm IDEA: XBRL DOCUMENT~~

Note 9 - Equity - Schedule of Option Activity (Details) - USD ($)			6 Months Ended	12 Months Ended	
	Apr. 02, 2024	Jul. 08, 2023	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Outstanding Options (in shares)			1,291,662	495,746	
Outstanding Options, exercise price (in dollars per share)			$ 2.16	$ 4.7	
Outstanding Options, weighted average contractual term (Year)			5 years 8 months 1 day	6 years 2 months 4 days	6 years 10 months 24 days
Outstanding Options, intrinsic value			$ 0	$ 0	$ 0
Options granted (in shares)	106,000	3,148,288	0	795,916	
Options granted, exercise price (in dollars per share)			$ 0	$ 0.58	
Outstanding Options (in shares)			1,291,662	1,291,662	495,746
Outstanding Options, exercise price (in dollars per share)			$ 2.16	$ 2.16	$ 4.7
Non-Vested Options (in shares)			874,886	325,853	
Non-Vested Options, grant date fair value (in dollars per share)			$ 0.5	$ 2.2	
Options granted, grant date fair value (in dollars per share)			$ 0	$ 0	
Options vested (in shares)	(106,000)	(362,584)	(187,739)	(246,883)	
Options vested, grant date fair value (in dollars per share)			$ 0.62	$ 1.15	
Non-Vested Options (in shares)			687,147	874,886	325,853
Non-Vested Options, grant date fair value (in dollars per share)			$ 0.46	$ 0.5	$ 2.2

~~XML 106 R83.htm IDEA: XBRL DOCUMENT~~

Note 10 - Basic and Diluted Net Loss Per Share (Details Textual) - shares shares in Thousands	3 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Warrant [Member]		
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0	0

~~XML 107 R84.htm IDEA: XBRL DOCUMENT~~

Note 11 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Director [Member]						
Long-Term Debt	$ 175	$ 175	$ 175	$ 175	$ 175	$ 175
Executive Officer [Member] | Consulting Fees [Member]						
Related Party Transaction, Amounts of Transaction	$ 140	$ 102	$ 244	$ 223	$ 222	$ 420

~~XML 108 R85.htm IDEA: XBRL DOCUMENT~~

Note 12 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 10	$ 451	$ 22	$ 456	$ 498	$ 0
Transferred at Point in Time [Member]						
Revenues	3	0	7	0		
Transferred over Time [Member]						
Revenues	7	451	15	456	498	0
Service [Member]						
Revenues	$ 10	$ 451	$ 22	$ 456	$ 498	$ 0

~~XML 109 R86.htm IDEA: XBRL DOCUMENT~~

Note 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Consultants and subcontractors	$ 70	$ 17	$ 77	$ 23	$ 99	$ 152

Clinical trials	0	14	0	19	3	60
Expenses - other	66	1	115	24	112	129
Research and Development Expense, Gross	350	199	639	320	741	1,299
Less – grants received	0	0	0	0	0	0
Total	350	199	639	320	741	1,299
Research and Development Expense [Member]						
Salary and employee benefits	210	167	443	254	527	944
Depreciation and amortization	$ 4	$ 0	$ 4	$ 0	$ 0	$ 14

~~XML 110 R87.htm IDEA: XBRL DOCUMENT~~

Note 14 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Other	$ 3	$ 0	$ 7	$ 0	$ 1	$ 14
Total	293	171	542	304	639	524
Selling and Marketing Expense [Member]						
Salary and employee benefits	179	160	347	289	611	432
Professional fees	89	5	142	5	6	27
Travel	$ 22	$ 6	$ 46	$ 10	$ 21	$ 51

~~XML 111 R88.htm IDEA: XBRL DOCUMENT~~

Note 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Rent and maintenance	$ 4	$ 33	$ 6	$ 65	$ 91	$ 233
Other	39	29	71	41	284	97
Total	626	399	1,191	696	2,196	1,542
General and Administrative Expense [Member]						
Salary and employee benefits	143	142	261	319	512	418
Professional fees	417	183	822	246	1,252	724
Travel expenses	$ 23	$ 12	$ 31	$ 25	$ 56	$ 72

~~XML 112 R89.htm IDEA: XBRL DOCUMENT~~

Note 16 - Subsequent Events (Details Textual) $ / shares in Units, $ in Thousands	Aug. 12, 2024 shares	Aug. 08, 2024 USD ($)	Jul. 26, 2024 USD ($) $ / shares shares	6 Months Ended Jun. 30, 2024 USD ($) shares	6 Months Ended Jun. 30, 2023 USD ($)	12 Months Ended Dec. 31, 2023 USD ($) shares	12 Months Ended Dec. 31, 2022 USD ($) shares	Jan. 27, 2022 shares
Common Stock, Shares, Outstanding (in shares)				49,948,710		35,369,877	2,552,744	1,085,605
Common Stock, Shares, Issued (in shares)				49,948,710		35,369,877	2,552,744	
Class of Warrant or Right, Warrants Issued During Period (in shares)				836,531		1,538,113	198,482	
Proceeds from Issuance or Sale of Equity | $				$ 945	$ 1,225	$ 4,643	$ 290	
Subsequent Event [Member] | Private Placement [Member]								
Proceeds from Issuance or Sale of Equity | $			$ 3,500,000					
Subsequent Event [Member] | PIPE Share With Accompanying Warrant [Member]								
Common Stock, Shares, Issued (in shares)			3,069,287					
Subsequent Event [Member] | PIPE Share With Accompanying Warrant [Member] | Private Placement [Member]								
Purchase Price Of Shares With Accompanying Warrants (in dollars per share) | $ / shares			$ 0.442					
Subsequent Event [Member] | Pre-Funded Warrants [Member]								
Class of Warrant or Right, Warrants Issued During Period (in shares)			4,849,265					
Subsequent Event [Member] | Pre-Funded Warrants [Member] | Private Placement [Member]								
Purchase Price Of Shares With Accompanying Warrants (in dollars per share) | $ / shares			$ 0.4419					
Subsequent Event [Member] | Common Stock Warrants [Member]								
Class of Warrant or Right, Warrants Issued During Period (in shares)			7,918,552					
Subsequent Event [Member] | Firefly [Member]								
Business Acquisition, Percentage of Voting Interests Acquired	92.00%							
Ownership Percentage, Former Shareholders	8.00%							
Subsequent Event [Member] | New Firefly Common Stock [Member] | Firefly [Member]								
Common Stock, Shares, Outstanding (in shares)	7,870,251							
Exchange Ratio	0.104							
Subsequent Event [Member] | Merger Reverse Stock Split [Member]								
Stockholders' Equity Note, Stock Split, Conversion Ratio	3							
Secured Promissory Notes [Member] | Subsequent Event [Member]								
Debt Instrument, Face Amount | $		$ 209						
Amortization of Debt Discount (Premium) | $		11						
Proceeds from Issuance of Secured Debt | $		$ 198						
Debt Instrument, Interest Rate, Stated Percentage		18.00%						

~~XML 113 R90.htm IDEA: XBRL DOCUMENT~~

Note 1 - Business Description (Details Textual)	Nov. 23, 2022	Jul. 05, 2022 shares	12 Months Ended Dec. 31, 2022 shares	Aug. 12, 2024	Jun. 30, 2024 shares	Dec. 31, 2023 shares	Nov. 16, 2023	Jan. 27, 2022 shares
Common Stock, Shares, Outstanding (in shares)			2,552,744		49,948,710	35,369,877		1,085,605
Preferred Stock, Shares Outstanding (in shares)			0		2,374,219	16,116,957		
Common Stock Dividends, Shares (in shares)		3,715						
Former Firefly 2023 Stockholders [Member]								
Subsidiary, Ownership Percentage, Parent				92.00%			92.00%	
Former Firefly Stockholders [Member]								
Subsidiary, Ownership Percentage, Parent				8.00%			8.00%	
Reverse Stock Split [Member]								
Stockholders' Equity Note, Stock Split, Conversion Ratio	750							
Common Stock [Member]								
Stock Issued During Period, Shares, New Issues (in shares)		1,085,605	51,282					
Series A Preferred Stock [Member]								
Preferred Stock, Shares Outstanding (in shares)								3,198,421
Stock Issued During Period, Shares, New Issues (in shares)		3,198,421						
Series A Preferred Stock [Member] | Common Stock [Member]								
Stock Issued During Period, Shares, New Issues (in shares)			0					

~~XML 114 R91.htm IDEA: XBRL DOCUMENT~~

Note 2 - Going Concern (Details Textual) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022

Retained Earnings (Accumulated Deficit)	$ (79,010)		$ (76,624)	$ (74,021)
Net Cash Provided by (Used in) Operating Activities	$ (2,418)	$ (936)	$ (2,172)	$ (2,892)

~~XML 115 R92.htm IDEA: XBRL DOCUMENT~~

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 10	$ 451	$ 22	$ 456	$ 498	$ 0
Noncurrent assets	$ 694		$ 694		386	52
CANADA						
Revenues						
Noncurrent assets						
UNITED STATES						
Revenues					478	
Noncurrent assets						
ISRAEL						
Revenues					20	
Noncurrent assets					$ 386	$ 52

~~XML 116 R93.htm IDEA: XBRL DOCUMENT~~

Note 4 - Other Receivables - Details of Other Receivables (10K) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Other receivables	$ 195	$ 196	$ 131
Allowance for doubtful receivables	(112)	(112)	(112)
Total	$ 83	$ 84	$ 19

~~XML 117 R94.htm IDEA: XBRL DOCUMENT~~

Note 5 - Long Term Deposits (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deposit Assets	$ 0	$ 52

~~XML 118 R95.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets (10K) (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Asset, Useful Life (Year)	5 years	5 years	
Intangible Assets, Net (Excluding Goodwill)	$ 634	$ 386	$ 0

~~XML 119 R96.htm IDEA: XBRL DOCUMENT~~

Note 6 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Intangible assets, gross	$ 634	$ 386
Intangible assets, accumulated amortization	0	0
Intangible assets, net	634	386
Computer Software, Intangible Asset [Member]		
Intangible assets, gross	634	386
Intangible assets, accumulated amortization	0	0
Intangible assets, net	$ 634	$ 386

~~XML 120 R97.htm IDEA: XBRL DOCUMENT~~

Note 7 - Convertible Notes (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2022	Jul. 04, 2022	Feb. 02, 2022	12 Months Ended Dec. 31, 2023	Dec. 31, 2022	May 04, 2022	Dec. 31, 2021
Gain (Loss) on Extinguishment of Debt				$ 0	$ (59)		
Convertible Debt				$ 0			
Conversion of Director Notes Into Common Stock [Member]							
Debt Conversion, Converted Instrument, Shares Issued (in shares)					106,612		
Phyto IV LP [Member] | Convertible Debt [Member]							
Debt Instrument, Face Amount						$ 150	
Gain (Loss) on Extinguishment of Debt		$ 8					
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 3				$ 7.5	
Debt Instrument, Interest Rate, Stated Percentage						10.00%	
Debt Instrument, Extension Fee Percentage						1.50%	
Convertible Debt Issued to Various Investors [Member]							
Debt Instrument, Face Amount		$ 555					
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 3					
Debt Instrument, Interest Rate, Stated Percentage		10.00%					
Debt Instrument, Extension Fee Percentage		1.50%					
Convertible Debt Issued to Various Investors [Member] | Conversion of Debt and Interest Into Common Stock [Member]							
Debt Conversion, Converted Instrument, Shares Issued (in shares)	188,734						
WPC and Origa [Member] | Convertible Debt and Stock Warrants [Member]							
Warrants and Rights Outstanding		$ 551	$ 478				
WPC and Origa [Member] | Side Letter [Member]							
Debt Instrument, Face Amount		2,936	1,886				$ 1,000
Gain (Loss) on Extinguishment of Debt		$ 509	$ (576)				
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 3	$ 7.5				
Phyto IV LP [Member] | Conversion of Debt and Interest Into Common Stock [Member]							
Debt Conversion, Converted Instrument, Shares Issued (in shares)	51,792						

~~XML 121 R98.htm IDEA: XBRL DOCUMENT~~

Note 8 - Deferred Revenue (Details Textual) - USD ($) $ in Thousands	1 Months Ended Nov. 30, 2022	Aug. 31, 2022	Feb. 28, 2019	12 Months Ended Dec. 31, 2023	Dec. 31, 2022
Contract with Customer, Liability, Revenue Recognized				$ 0	$ 909
R. I. Mind Group Ltd. [Member]					
Contract with Customer, Liability			$ 2,500		
Contract with Customer, Liability, Revenue Recognized			500	0	459
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price			$ (41)		

Pasithea Clinics Inc. [Member]				
Contract with Customer, Liability, Revenue Recognized	$ 150	$ 300	$ 0	$ 450

XML 122 R99.htm IDEA: XBRL DOCUMENT

Note 8 - Deferred Revenue - Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended	
	Nov. 30, 2022	Aug. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenue recognized			$ 0	$ 909
Pasithea Clinics Inc. [Member]				
Revenue recognized	$ 150	$ 300	0	450
R. I. Mind Group Ltd. [Member]				
Revenue recognized		$ 500	$ 0	$ 459

XML 123 R100.htm IDEA: XBRL DOCUMENT

Note 9 - Liability for Employee Rights Upon Retirement (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Contributions to Severance Compensation Act	$ 11	$ 11	$ 25	$ 16	$ 33	$ 51

XML 124 R101.htm IDEA: XBRL DOCUMENT

Note 10 - Commitments and Contingencies (Details Textual) - IIA Royalty Commitment [Member] - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Research Agreement, Royalty Percentage	3.00%	3.00%	
Other Commitment	$ 5,676	$ 5,625	$ 5,576

XML 125 R102.htm IDEA: XBRL DOCUMENT

Note 11 - Equity (Details Textual)	Apr. 02, 2024 shares	Dec. 31, 2023 USD ($) $ / shares shares	Oct. 16, 2023 shares	Aug. 29, 2023 $ / shares shares	Jul. 08, 2023 shares	May 01, 2023 $ / shares shares	Mar. 15, 2023 USD ($) shares	Feb. 23, 2023 $ / shares shares	Feb. 16, 2023 USD ($) $ / shares shares	Nov. 23, 2022	Sep. 15, 2022 USD ($) $ / shares shares	Aug. 17, 2022 USD ($) shares	Jul. 05, 2022 shares	3 Months Ended Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	6 Months Jun. 30, 2024 USD ($) $ / shares shares
Proceeds from Issuance or Sale of Equity | $																$ 945,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 2.07												$ 2.19		$ 2.19
Stock Repurchased and Retired During Period, Shares (in shares)			4,217													
Shares Authorized (in shares)		2,500,000,000												2,500,000,000		2,500,000,000
Common Stock, Shares Authorized (in shares)		2,470,000,000												2,470,000,000		2,470,000,000
Preferred Stock, Shares Authorized (in shares)		30,000,000												30,000,000		30,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Fair Value | $																$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $		$ 0												$ 0		0
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $		434,000												317,000		$ 317,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	106,000				3,148,288											0
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	5 years				5 years											
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)	106,000				362,584											187,739
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years				3 years											
Share-Based Payment Arrangement, Option [Member]																
Share-Based Payment Arrangement, Expense | $														$ 58,000	$ 74,000	$ 117,000
Reverse Stock Split [Member]																
Stockholders' Equity Note, Stock Split, Conversion Ratio																

Conversion of Series B Preferred Stock to Common Stock [Member]						
Preferred Stock, Mandatory Conversion Feature, Offering Proceeds Threshold | $	$ 1,000					
Preferred Stock, Convertible, Conversion Ratio	1					
Conversion of Stock, Shares Converted (in shares)	14,578,833					14,578,833
Preferred Stock, Mandatory Conversion Feature, Company Valuation | $	$ 18,000					
Related Party [Member] | Consulting Fees [Member]						
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 0.0041			
Stock Issued During Period, Shares, Issued for Services (in shares)			284,964			
August 2022 Securities Purchase Agreement Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				13,333		
Series C Preferred Unit Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1	1			1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.56	$ 2.56			$ 2.56	$ 2.56
Warrants and Rights Outstanding, Term (Year)	3 years				3 years	3 years
Warrants or Rights Issued (in shares)						836,531
Noncash Warrants Issued (in shares)						
Tranche A Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	526,749					
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.75					
Class of Warrant or Right, Exercise Price, Purchase Price Numerator | $	$ 50,000					
Tranche B Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	262,051					
Class of Warrant or Right, Exercise Price, Purchase Price Numerator | $	$ 150,000					
Convertible Debt and Stock Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						
WPC Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						
Series A Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								
Warrants and Rights Outstanding, Term (Year)								
Series A Preferred Stock [Member]								
Stock Issued During Period, Shares, New Issues (in shares)							3,198,421	
Preferred Stock, Shares Authorized (in shares)							30,000,000	30,000,000
Series B Preferred Stock [Member]								
Stock Issued During Period, Shares, New Issues (in shares)			14,578,833	10,799,136				
Shares Issued, Price Per Share (in dollars per share) | $ / shares				$ 0.1852				
Proceeds from Issuance of Preferred Stock and Preference Stock | $			$ 2,700,000					
Payments of Stock Issuance Costs | $			$ 92,000					
Preferred Stock, Shares Authorized (in shares)	30,000,000							
Series C Preferred Stock [Member]								
Proceeds from Issuance or Sale of Equity | $	$ 1,969,000							$ 1,070,000
Payments of Stock Issuance Costs | $	$ 67,000							$ 125,000
Units Issued During Period, New Issues (in shares)	1,538,134	7,812,500						836,085
Preferred Stock, Mandatory Conversion Feature, Offering Proceeds Threshold | $	$ 2,000							
Preferred Stock, Shares Authorized (in shares)								
Preferred Stock, Mandatory Conversion Feature, Company Valuation | $	$ 65,000							
Series C Preferred Stock [Member] | Series C Preferred Unit Warrants [Member]								
Class of Warrant or Right, Combined Purchase Price (in dollars per share) | $ / shares		$ 1.28						
Securities Purchase Agreement [Member]								
Stock Issued During Period, Shares, New Issues (in shares)					32,536,386	51,282		
Proceeds from Issuance or Sale of Equity | $					$ 133,000	$ 250,000		
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 0.0041	$ 4.87		
Securities Purchase Agreement [Member] | Series A Preferred Stock [Member]								
Stock Issued During Period, Shares, New Issues (in shares)						10,000,000		
Proceeds from Issuance or Sale of Equity | $						$ 40,000		

~~XML 126 R103.htm IDEA: XBRL DOCUMENT~~

Note 11 - Equity - Schedule of Shares Authorized and Issued (Details) - shares	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Shares of common stock authorized (in shares)	2,470,000,000	2,470,000,000	2,470,000,000
Shares of common stock issued (in shares)	49,948,710	35,369,877	2,552,744
Shares of preferred stock authorized (in shares)	30,000,000	30,000,000	30,000,000
Shares of preferred stock issued (in shares)	2,374,219	16,116,957	0
Series A Preferred Stock [Member]			
Shares of preferred stock authorized (in shares)	30,000,000		
Shares of preferred stock issued (in shares)	0	0	0
Series B Preferred Stock [Member]			
Shares of preferred stock authorized (in shares)		30,000,000	30,000,000
Shares of preferred stock issued (in shares)	0	14,578,833	0
Series C Preferred Stock [Member]			
Shares of preferred stock authorized (in shares)			
Shares of preferred stock issued (in shares)	2,374,219	1,538,134	0

~~XML 127 R104.htm IDEA: XBRL DOCUMENT~~

Note 11 - Equity - Schedule of Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended		
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Outstanding warrants, January 1, 2024 (in shares)	2,386,677	848,564	123,333	
Exercise price (in dollars per share)	$ 2.07	$ 2.26	$ 7.5	
Outstanding warrants, January 1, 2024 (Year)	2 years 2 months 8 days	2 years 5 months 15 days	2 years 6 months	10 months 6 days
Warrants issued pursuant to units offering (in shares)	836,531	1,538,113	198,482	
Warrants issued pursuant to units offering (in dollars per share)	$ 2.56	$ 2.56	$ 3	
Warrants issued pursuant to modification of convertible debt (in shares)			526,749	
Warrants issued pursuant to modification of convertible debt (in dollars per share)			$ 0.75	
Outstanding warrants, June 30, 2024 (in shares)	3,223,208	2,386,677	848,564	123,333

Exercise price (in dollars per share)	$ 2.19	$ 2.07	$ 2.26	$ 7.5

~~XML 128 R105.htm IDEA: XBRL DOCUMENT~~

Note 11 - Equity - Assumptions (Details)	12 Months Ended			
	Apr. 02, 2024	Jul. 08, 2023	Dec. 31, 2023	Dec. 31, 2022
Risk free rate			4.35%	4.50%
Dividend yield			0.00%	0.00%
Expected volatility			86.00%	86.00%
Expected term (in years) (Year)			3 years	3 years
Expected life (in years) (Year)	5 years	5 years	5 years	5 years

~~XML 129 R106.htm IDEA: XBRL DOCUMENT~~

Note 11 - Equity - Schedule of Option Activity (Details) - USD ($)			6 Months Ended	12 Months Ended	
	Apr. 02, 2024	Jul. 08, 2023	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Outstanding Options (in shares)			1,291,662	495,746	
Outstanding Options, exercise price (in dollars per share)			$ 2.16	$ 4.7	
Outstanding Options, weighted average contractual term (Year)			5 years 8 months 1 day	6 years 2 months 4 days	6 years 10 months 24 days
Outstanding Options, intrinsic value			$ 0	$ 0	$ 0
Options granted (in shares)	106,000	3,148,288	0	795,916	
Options granted, exercise price (in dollars per share)			$ 0	$ 0.58	
Outstanding Options (in shares)			1,291,662	1,291,662	495,746
Outstanding Options, exercise price (in dollars per share)			$ 2.16	$ 2.16	$ 4.7
Non-Vested Options (in shares)			874,886	325,853	
Non-Vested Options, grant date fair value (in dollars per share)			$ 0.5	$ 2.2	
Options granted, grant date fair value (in dollars per share)			$ 0	$ 0	
Options vested (in shares)	(106,000)	(362,584)	(187,739)	(246,883)	
Options vested, grant date fair value (in dollars per share)			$ 0.62	$ 1.15	
Non-Vested Options (in shares)			687,147	874,886	325,853
Non-Vested Options, grant date fair value (in dollars per share)			$ 0.46	$ 0.5	$ 2.2

~~XML 130 R107.htm IDEA: XBRL DOCUMENT~~

Note 13 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands			3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 08, 2023	May 01, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares)	3,148,288							
Director [Member]								
Long-Term Debt			$ 175	$ 175	$ 175	$ 175	$ 175	$ 175
Accounts Payable							0	2
Executive Officer [Member] | Consulting Fees [Member]								
Accounts Payable							106	56
Related Party Transaction, Amounts of Transaction			$ 140	$ 102	$ 244	$ 223	$ 222	420
Related Party [Member]								
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares)	2,776,861							
Related Party [Member] | Consulting Fees [Member]								
Stock Issued During Period, Shares, Issued for Services (in shares)		284,964						
Conversion of Director Notes Into Common Stock [Member]								
Debt Conversion, Original Debt, Amount								$ 320
Debt Conversion, Converted Instrument, Shares Issued (in shares)								106,612

~~XML 131 R108.htm IDEA: XBRL DOCUMENT~~

Note 14 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 10	$ 451	$ 22	$ 456	$ 498	$ 0
Transferred over Time [Member]						
Revenues	7	451	15	456	498	0
Service [Member]						
Revenues	$ 10	$ 451	$ 22	$ 456	$ 498	$ 0

~~XML 132 R109.htm IDEA: XBRL DOCUMENT~~

Note 15 - Research and Development Expenses -Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Consultants and subcontractors	$ 70	$ 17	$ 77	$ 23	$ 99	$ 152
Clinical trials	0	14	0	19	3	60
Expenses - other	66	1	115	24	112	129
Research and Development Expense, Gross	350	199	639	320	741	1,299
Less – grants received	0	0	0	0	0	0
Total	350	199	639	320	741	1,299
Research and Development Expense [Member]						
Salary and employee benefits	210	167	443	254	527	944
Depreciation and amortization	$ 4	$ 0	$ 4	$ 0	$ 0	$ 14

~~XML 133 R110.htm IDEA: XBRL DOCUMENT~~

Note 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Other	$ 3	$ 0	$ 7	$ 0	$ 1	$ 14
Total	293	171	542	304	639	524
Selling and Marketing Expense [Member]						
Salary and employee benefits	179	160	347	289	611	432
Professional fees	89	5	142	5	6	27
Travel	$ 22	$ 6	$ 46	$ 10	$ 21	$ 51

~~XML 134 R111.htm IDEA: XBRL DOCUMENT~~

Note 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Rent and maintenance	$ 4	$ 33	$ 6	$ 65	$ 91	$ 233

Bad debts					1	(2)
Other	39	29	71	41	284	97
Total	626	399	1,191	696	2,196	1,542
General and Administrative Expense [Member]						
Salary and employee benefits	143	142	261	319	512	418
Professional fees	417	183	822	246	1,252	724
Travel expenses	$ 23	$ 12	$ 31	$ 25	$ 56	$ 72

~~XML 135 R112.htm IDEA: XBRL DOCUMENT~~

Note 18 - Other (Income) Expense (Details Textual) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended	
	Feb. 28, 2022	Feb. 28, 2019	Dec. 31, 2023	Dec. 31, 2022
Proceeds from Sale of Productive Assets	$ 262			
Gain (Loss) on Disposition of Assets	$ 166		$ 0	$ (166)
Contract with Customer, Liability, Revenue Recognized			0	909
R. I. Mind Group Ltd. [Member]				
Contract with Customer, Liability, Revenue Recognized		$ 500	$ 0	$ 459

~~XML 136 R113.htm IDEA: XBRL DOCUMENT~~

Note 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended	
	Feb. 28, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Interest, bank fees and loan fees		$ 10	$ 3	$ 12	$ 10	$ 18	$ 440
Unrealized (gain) loss on foreign exchange		$ (31)	$ 0	$ (3)	$ 0	(37)	134
Loss on extinguishment of debt						0	59
Gain on sale of equipment	$ 166					0	(166)
Other						(457)	(7)
Total						$ (476)	$ 460

~~XML 137 R114.htm IDEA: XBRL DOCUMENT~~

Note 19 - Income Tax (Details Textual) - USD ($) $ in Thousands	12 Months Ended	
	Dec. 31, 2023	Dec. 31, 2022
Open Tax Year	2018 2019 2020 2021 2022 2023	
Research Tax Credit Carryforward [Member]		
Tax Credit Carryforward, Amount	$ 889	$ 1,823

~~XML 138 R115.htm IDEA: XBRL DOCUMENT~~

Note 19 - Income Tax - Provision for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Statutory income tax rate					27.60%	28.51%
Statutory income tax recovery					$ (718)	$ (1,113)
Non-deductible option expenses					135	19
Taxable capital gain on sale of investment and equipment					0	0
Difference in foreign tax rates					30	200
US state tax					1	(1)
Change in valuation allowance					553	895
Income tax expense (recovery)	$ 0	$ 0	$ 0	$ 0	$ 1	$ (0)

~~XML 139 R116.htm IDEA: XBRL DOCUMENT~~

Note 19 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Non-capital loss carry-forwards from US	$ 1,418	$ 1,576
Stock option	95	17
R&D expenditures	236	424
Reserves and others	127	0
Deferred Tax Assets, Gross	17,325	19,497
Valuation Allowances for deferred tax assets	(17,325)	(19,497)
Net deferred tax assets	0	0
Canada Revenue Agency [Member]		
Non-capital loss carry-forwards from foreign entity	0	1
Israel Tax Authority [Member]		
Non-capital loss carry-forwards from foreign entity	$ 15,449	$ 17,479

~~XML 140 R117.htm IDEA: XBRL DOCUMENT~~

Note 19 - Income Taxes - Operating Loss Carryforwards (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Canada Revenue Agency [Member]	
Operating Loss Carryforwards	$ 2
Canada Revenue Agency [Member] | Tax Year 2034 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2035 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2036 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2037 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2038 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2039 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2040 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2041 [Member]	
Operating Loss Carryforwards	0
Canada Revenue Agency [Member] | Tax Year 2042 [Member]	
Operating Loss Carryforwards	2
Canada Revenue Agency [Member] | Indefinite Tax Year [Member]	
Operating Loss Carryforwards	0
Internal Revenue Service (IRS) [Member]	
Operating Loss Carryforwards	6,433
Internal Revenue Service (IRS) [Member] | Tax Year 2034 [Member]	
Operating Loss Carryforwards	501

Internal Revenue Service (IRS) [Member] | Tax Year 2035 [Member]	
Operating Loss Carryforwards	1,767
Internal Revenue Service (IRS) [Member] | Tax Year 2036 [Member]	
Operating Loss Carryforwards	2,872
Internal Revenue Service (IRS) [Member] | Tax Year 2037 [Member]	
Operating Loss Carryforwards	0
Internal Revenue Service (IRS) [Member] | Tax Year 2038 [Member]	
Operating Loss Carryforwards	0
Internal Revenue Service (IRS) [Member] | Tax Year 2039 [Member]	
Operating Loss Carryforwards	0
Internal Revenue Service (IRS) [Member] | Tax Year 2040 [Member]	
Operating Loss Carryforwards	0
Internal Revenue Service (IRS) [Member] | Tax Year 2041 [Member]	
Operating Loss Carryforwards	0
Internal Revenue Service (IRS) [Member] | Tax Year 2042 [Member]	
Operating Loss Carryforwards	0
Internal Revenue Service (IRS) [Member] | Indefinite Tax Year [Member]	
Operating Loss Carryforwards	1,293
Israel Tax Authority [Member]	
Operating Loss Carryforwards	67,170
Israel Tax Authority [Member] | Tax Year 2034 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2035 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2036 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2037 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2038 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2039 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2040 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2041 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Tax Year 2042 [Member]	
Operating Loss Carryforwards	0
Israel Tax Authority [Member] | Indefinite Tax Year [Member]	
Operating Loss Carryforwards	$ 67,170

~~XML 141 R118.htm IDEA: XBRL DOCUMENT~~

Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accrued liabilities	$ 973		$ 973		$ 1,902	$ 855	
Total current liabilities	2,413		2,413		2,532	2,361	
Total liabilities	2,413		2,413		2,532	2,361	
Accumulated deficit	(79,010)		(79,010)		(76,624)	(74,021)	
Total shareholders' deficit	(1,215)	$ (1,729)	(1,215)	$ (1,729)	109	(2,226)	$ (3,014)
Research and development expenses	350	199	639	320	741	1,299	
General and administration expenses	626	399	1,191	696	2,196	1,542	
Total operating expenses	1,269	769	2,372	1,320	3,576	3,444	
Loss before Income Tax	(1,264)	(323)	(2,386)	(876)	(2,602)	(3,904)	
Net (loss) income	$ (1,264)	$ (323)	(2,386)	(876)	(2,603)	(3,904)	
Change in accrued liabilities			(929)	176	1,047	97	
Net cash used in operating activities			$ (2,418)	$ (936)	$ (2,172)	(2,892)	
Previously Reported [Member]							
Accrued liabilities						740	
Total current liabilities						2,246	
Total liabilities						2,246	
Accumulated deficit						(73,906)	
Total shareholders' deficit						(2,111)	
Research and development expenses						1,272	
General and administration expenses						1,454	
Total operating expenses						3,329	
Loss before Income Tax						(3,789)	
Net (loss) income						(3,789)	
Change in accrued liabilities						(18)	
Net cash used in operating activities						(2,892)	
Revision of Prior Period, Adjustment [Member]							
Accrued liabilities						115	
Total current liabilities						115	
Total liabilities						115	
Accumulated deficit						(115)	
Total shareholders' deficit						(115)	
Research and development expenses						27	
General and administration expenses						88	
Total operating expenses						115	
Loss before Income Tax						(115)	
Net (loss) income						(115)	
Change in accrued liabilities						115	
Net cash used in operating activities						$ 0	

~~XML 142 R119.htm IDEA: XBRL DOCUMENT~~

Note 21 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands				6 Months Ended		
	Feb. 28, 2024	Dec. 31, 2023	Aug. 29, 2023	Jun. 30, 2024	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.07		$ 2.19	$ 2.26	$ 7.5
Series C Preferred Stock [Member]						
Units Issued During Period, New Issues (in shares)		1,538,134	7,812,500	836,085		
Subsequent Event [Member]						
Units Issued During Period, New Issues (in shares)	820,312					
Proceeds From Issuance of Units	$ 1,050					
Subsequent Event [Member] | Unit Warrants [Member]						
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1					

Shares Issued, Price Per Share (in dollars per share)	$ 1.28
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.56
Warrants and Rights Outstanding, Term (Year)	3 years
Subsequent Event [Member] | Series C Preferred Stock [Member]	
Units Issued During Period, Number of Shares Per Unit (in shares)	1

EXCEL 143 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (*@R.UD'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+"
(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "H,CM91CFJ=>\ K @ $0
&1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O;05Q=#E9<,G!<&!XEM(;EM8TX3DI-VWMXU;A^@'\#%W__SN M=W"M#D+[B"_1!XQD,=V,KNN3T&'%#D1! "1]0*=2.27ZJ;GST2F:GG$/0>FC
MVB/4G-^!0U)&D8(96(2%R&1KM- 1%?EXQAN]X,-G[#+,:, .'?:4H"HK8'*> M&$YCU\(5,,,(HTO?!30+,5?_Q.8.L'-R3'9)#<-0#DW.33M4\/[\])K7+6R?
M2/4:IU_)"CH%7+'+Y+=FO=D^,EGS^K;@#T5]OZVXJ"O!FX_9]8??5=AY8W?V M'QM?!&4+O^Y"?@%02P,$% @ J#([69E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-
;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2
Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-
2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-
)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?
EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>_,?
-2K6J5D*Q$__M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N__5!+ P04 M" "H,CM9:!C#I48# ">"@ &
'AL+W=O] T[86;'&#-L3/;*?3;[YQ M8%)J&"^([?C^_MW9OEQO(]5OO08P9)MRH?O>VICLVO=UO(:4ZBN9@< W2ZE2 M:K"K5K[.%-"D,$JY'P5!VT\I$]Z@5XP]J$%/YH8S 0^*Z#Q-J7H> I>;OA=Z
M^X$Y6ZV-'? 'O8RN8 'F:_:@L.=7*@E+06@F!5&P['LWX?4P;%J#8L8W!AM] MU";6E4N^U_5(DN:P((X.H\X)!M#.("NYRH8+REAHZZ"FY(1[B*,-H3#B.GX(=<7)%&
<$&B(&HZ]!J5QXU"KW'*XR,WR<\[G$6F M!E+]J\[G4K)9+VEOSK7.: Q]#Z^&!O4$WN#UJ[=O'4 -RO@IDM]L-N5$3(K MRA$[@2WY",]UG&ZE '_=H-'J=!U8K0JK=0[6'%9,(Q@&=$93J(-RZTRF_'D
M[@>9C;_./RU&T_%L-+X@T]GHR@'9KB#;3O$;W.FDV.T)IZLZ.+?]DG(-#HY. MQ=%QZE2';L)TC)OX (K)A$QP6-=1N=4^1PZD;H74_2^D'T#5RT!NK1-7\TV%
M].8\I"_/6>U)BEBJ3*HB0UR0A:$&B%1D)'.\B7@A M95(+>4+]=NR"/,K;X3F07^B63!.,&5NRN,QELSQ]!%5+YI9L-2_#L-UIM%U[M&48'PN@7M/N$@I MYV28:WRM:T__"1VC2"
^9/CPKU8]34"LF5N0=*I@UGK0THZ(^=F[!%_.7 M?U0RV-6*PDB3V)[MLGJH1JOBZZ8L.0[3R\KMGEI833@LT32XZF"^5V4Q5':, MS(H"Y%$:+&>*YAH+2%!V KY?2FGV';M 59(._@)02P,$% @ J#
([64ZS?_,Y(13\6L1)?MJ;4[H\'@SRV9PL<'Z4+DG"?GE(MLP6F[#1['.3+C."P[UP&SW.:7EA,#I9XD9.QL\$:)8P6),FC- $9>3CMG<'C M -FE0V7Q1T2>\XUC4-[*?9K^6YZ,P].>5F9$8C*C)01F7T_$)7%
<(K$\?M:@ MO77,TG'S^!4]J&Z>W6P2)*5M_X5TW$A@,TWG! M0/:U4&O'?1='8S:P=C5 MP:P=S%T=K-K!JKA?D54Q[6&*1R=9^@RRTIJAE0=5N2IO1G"4E"UK0C/V:\3\ MZ,A-
DY"U$Q("=I2G<11BRD[.<8R3&0&3$C@'!W<)+L*(_?(5'(*[B0<./G\% MGT&4@.D\+7*X>F3%W M6+GK G=O]^@B=W_WZ$C@'NSN#MON U;"=1W1NHZHPM/?JF.1922A
.D=,>>T+E)'LBO=&73]#2OHDJHQ+,4PGFJP0+%(&U*JJO M*ZK+T$B.JZ\S,JK'#>>1KHY/!D\;9:G:X.@H;>-/&GX?6GO1N23"A3% M:Y%IK,DTI&1>TSG)V$@X(]$3OH^)L(>L(*R-
>QARG+D"$X.C59K(OK1VXT&' MHU51O!:MYII64TKK34:6. H!^;4L!Q$AJV;G%BR>U:X)XAJ/)\UC7U8%*7&D M*@K7(M5:DVI)29VF%,=L[_V0+TVN+1TGK]AL=CNUMLJQ4B68IQ+,5PD6*
)K576XKNI0VF7\GT6T9'J' M]D%"J*BBPVZ7U[B^TC7A+#QI$ON2KQ(L4 36(M]9D^](R1\G%">/$1M5ZQ[U M9A$SI[TGSVK4,W(%?V0%&X%KE0:P2:ML-PD.STW*JA6@P[
M/,,"HR[%\J3VY5@0TD0T,%03O/U].P"G$TF_G0BI!9VIV+0X2?> M BMD&9 G5YK*WN0*,M--GEU%(=OL-NH4[B9/XPC?1W%$(_%<$2H5J4K1/*5H MOE*T0!5:N[J-4H5RJ3K-<$C
$K^*:UJ@%8;19;)]YZNE=&9KO9[-95I!P:^?IBD7'YJ66P @Z&N(Y5BIB!3&'?%D#52'; M'#="%LJ5;%MT;6-:(%@-V*%:8&7J':J5*EM13-V"/-4K1?
*5H@2JT=KD;D0WE*OLF(P^$C4XAR.>8!>B#S]J1QOX@FWAEX G' M!3DN][/8I?)3FP%HZL,/#(CBWN2K;?>^H#%69)JBSA^$3:YK1K;W6[B MR0G:NW%LU_VJ K8W]!KAC^3"WTT7"Z;Z9>5&?
<.65MQP^HXQ[-M0JVJGFWW= M6X-; P:J K9+WBQ"(/DBQ%D81N4+%VPJ6NZK M'$8)F.%EQ*:F0HZ[PM^V;8=752(SR];Y[4!Y:GMS+0@*.[D%JH*V^=[8-)<* MXU)9%8LBKEYY",E#-
(N$ZY8URN;-'-J.!CLM6F1G68C?(I1GM3?5HJA&]5I! MF^N/6"1 S2(!VK)(4,WZWSMK05V=?@@1[+1UP3J#YO#T=S>K#Z&-.#-?%!(A MQ&\5BM!T#38U;_/5J'XD5_T=E53-X]_-GT#W=Y5+
M52';M6A6!Y!\=>"6K)X1-SBC+^#ORVHT_$?(LTHY[RI%\Y2B^4K1 E5H[0(W M2Q+(4K$^C50N)+A*T3RE:+Y2M$ 56KNZS6((DB^&O';?9=5]ZW5J87WMSK,< MVITQ9@G1_\#4$L#!!0 (M
*@R.UF_PBP/1@,-4- 8 >&PO=V]R:W-H965T&UL MI9=K;^(X%(;_BI4=C5IIVMP3T@&D*3*3#:&6DDU&IV/[O)@5AU[*SMP.S^^K63 M-$($TL#P 7QYWQ.?
Q\G!F>ZY>)4Y@$*_"LKDS,J5*A]L6Z8Y%%C>\Q*8GMEP M46"ENV)KRU(SFI306W/<2*[P(19\VD]MA;S*:\4)0S6 LFJ*+#X]Q$HW\\L MUWH;>"+;7)D!>SXM\1:>0?
TLUT+W["Y*1@I@DG"&!&QFUA?W8948?2WXB\!> M'K21R>2%\U?3^9;-+,:767-,;#]EOTKW7N M.I<7+&'!Z=\D4_G,FE@H@PVNJ'KB^S^AS2E="S1/O4?,%9IG<=,J1;DE.28:4[CYABE@)Z-H$E
MNOG)<)41/7.+;M98 %,Y*))B*F_1'?J ;"1S/2RGMM*+,J'MM%W 8[, [\P" MOE?L'OG.)^0Y7G#"OABV+R'5=K>V^R?LR_%V[X1]]<[BL5Z\%Y^RVWHCNMWP MNMWPZGC!F7AK_92
$'H#],:GKY]0B07:85H!NB$,99Q2+"0J032\;T_Q;BX1 MUYOKW,AUHR2,CYCUA<>P!M.Y$E;8P0JO@J7__M>:7"+"-L^QZQ<"2QONX,L;[PF-A@3E<2BSIBT2"Q!2*?1#XC3H6C:ICHU3+
M4:K58$97\HH[7O$%O"XN8G'_[@KBTV5LO'0Y7KH:S.Y*=I..W>1R=N/JV*27 M89 DP21VCZGUA7[H1\DD/GXL^T(O#+TX"(Z #:9T);"D Y9<#NR"6I:,I=87 MGJ'6%YZFUM>YSB2,#A[E!HA]
<"0V+SP_L-@2)A&%C78Z][&NC:)YB6@ZBI?U M*?F%*WWFKINY?N\"801Z?L.Y>NN8@W?W)C?_'U!+ P04 " "H,CM9VYQ2 MNG8% @%@ & 'AL+W=O M?
5;/:KV[J/>*\Q<2(43!6YIDY+H54;JYTC2RC% :D$N\01G[987S-*#L-E]K M9).C("R,TD0S==W1TB#.6OU>\>PQ[_?PEB9QAAYS0+9I&N1_#U&"7Z];1NO] MP2Q>1Y0_T/J]3;!&/J*+S6/.
[K2:)8Q3E)$89R!'J^O6P+B"1H<;%(BG&+V2 M@VO I3QC_,)OQN%U2^7K^SWQ3B MF9CG@* 13G[$(8VN6YT6"-$JV"9TAE_O4"6HS?F6."'%)WBML'H+++>$XK0R
M9BM(XZS\#MZJ0!P8,!ZU@5D9F**!?<+ J@RLSWJP*P/[LQ[:E4$A72NU%X'S M AKT>SE^!3E',S9^442_L&;QBC.>*#[-V:\QLZ/]$$@(M%%FS#F)E^!=_!PO? MQ9>OX
N(,S"/\)8P,]+3*%LP=ZLMJ\4-R\69)Q9G@0>3\/^_P/WL_"H95IXY5 M\-DG^&;P"4X64+6MI6&[,.2E:M0R!*AJGQASI MLFM==F%DG= U?82SP7P\N07PYR.<^-"_4FFTFX+#Z_L5V01+=-
UB[PI!^0ZU M^K__9CCZ'ZJ\.2>9=TXR>":RHYUHUSO1;LXPQACDRZBH.B':L;:VX44)H+<- M+UK*DE)2.@<98;7%Y),Q1K&6?K0C)K MW2^(\KLFP8ZT"+-K"8)EC.&*;YN,:=OBZR9C+-
U6"W9KP6ZCX%N4L>Z2%(*# MD+6XF-"RVS2J=N7M,1U!M8RQI&V6,8;1%4(#%3_UE1J[DM?OAMD6 M12I0EM$15"I IE0#H +5<4[DLJ'OQRF]N7G,[^,C">CZ0,$%]6F?E6./OHY
M&\A9V;RSLL%SL1UOR<&$:S3FWCBCB/'2HL(\!]D+6"%U3:F(CI-0[!TJD%!N M/261^)Y]X.U8K;E7:S:J763L_V(2_\.&^#7[GPA8&65_)]G_)5Y.EU&0K9%2 MNBG72D-4+F-
T4;B"1I3=Q'(L>C^)&LVCZ)1&*']O%]] AJA2HZ4H#&+/4()$ ME2J,*^IL)#H6NA]-C<9YJ\^K)QC"F^D,OA>9^>"G4JRM2L&# E?)5< L4\IG M!P";'NY@?4B@ER^.8]/)^"/$^ MAL!&R+'(_=AG-
,]]$S@O>B,83#S-O9Q!N]8[Q@_P9,MLV)L?[3%"IABBQ4H MU18K8*>W>#\#&LU#X'#@CT>%=&]\OYA#KXP%FQJ ?S=@R7[!2EF(DR3("=BP M=YU$08[4?;7TU#EL;D,/*XUC$
MCJB#)P]_=K=K=URY#- M!"SQ J/E"4;]M#[.'!2'>,+SH7$U,A3//7[\69RP[>G+L].'(%_'&0$)6C%7 M^J7+WH6\/(XL;RC>%.=MSYA2G!:7$0I"E', ^WV%,7V_X0[J0^'^OU!+ P04 M "
"H,CM99&YW80$6 #%F0$ & 'AL+W=O_K^SC>U/YX?%BLWU_< M;S9/_[BZ6M_>QX^S]6_+IWB1_.3S';W/.GQX4J^OFY> M/<[FBXL/[Y[_S5U]>+?\NGF8+V)W55M_?7R4@T MC[^O?
[I=VSZ63\OE[]L[YMW[B^OMDN*'^':S-6;)_[[%_'#PY9*%O+/G7KQ M$G0[\>?;>UU_?O3)H_DT6\3DQ4\SA<__C_[8_=,E)D@[R;(92S>AG9K0Z)R9T-E-Z)1= MDG2]W[GK=
(SFN2DOFUUZMZ7]=DOI_3[[2*3]ADOI'3^_L/V62^D];YU=V'[3 MI?2N-Z5S4_;;+J7W7:F?F[+?>"F]\\VSCV6_]5)Z[_R?O-E]*[WU3.O0OW MNR^G=__\&W>_^W)Z]\^^BN67-
WMZ]YOM[+Z=V7&^>F M['=?3N_^V=>8O-]].;W[VT>9/66_^W)Z]QMG]V6_^W)Z]Y6S"]OOOIS>??G< MOBC[W5?2NR^=6YBRWWWE1\+YD2&>TXLZV\P^O%LMO]=6V_&)M[WQG*.>YR=9
M9;[8YE-_LTI^.D_F;3[<+!=W27:,[VK)K?7R87XWVR1W_$WROR1M;M;UY>?: MS?UL\25>U^:+Y ?+V]_OEP]W\6K]/S7MGU_GFW_5?E'CS_/;^>;7VB_A8O;U
M;IX0O]8N:Z&OUG[YVZ^UOVUG!O?+K^O9XF[][FJ3+'P;_NIVM\B//Q8IGUFD M'Z_F2?B/-3?)M?%]];S 9!VU_[/CQT_QZO]K9T<,/B=WYXLOAZ'GC(QEW?SG MEO7WFO-U^X/MT^_?
SU:)LEG6/L4U<[W^F@S*6;7Z%Z[Z9OGXN%P4/Y/:?VA-M;W@:];]PR>(N><\DU>7LH>;.YG>7R=OE9O8TWR3WNV]=2EEW\M],M ;'K!=:ATWR#X[M;XU5]LD=O#70ZWZ5N&\-6^GWP_"-T3)
(+Y\\?LFYJ_FWI+ZIN0^SV^%'T')>]Q8:0=$KO9/&3-,>9(O5WB?3"M) M;]A_((VKOV2/,;U\[/X:VVVJ:GQ[6\U1?I[3;Z6I:P_&W/5 M[:'H?ZR?DM?Z^XNGA(Q7W^*+#__]7U+S^G^S_M@C,97$-
!+32:Q+8@:)F21F MD5B/Q/HD9I.80V(#$G-);$AB'HGY)!:06AB8F-2&Q,8I,?6/,9VYXD_?:A M+35EN5-O--]=??NYW"+#"G$:5VILA$E-)3",QG<2Z)&:0F$EB%HGU2*Q/8C:).20V(#&7Q(8DYI&8
M3V(!B84D%I'8B,3&)#;Y@35^JD_DNMQ)E41D1"%.0YZ41&C F]. 3:G=3A^C M4D^'739;BB*EQFD9XY1KJ?XR[*@\:;R4)XW<\N3LIV)NEXMO\>KYZPD_'=;) MJEIR U2M6DA,)3&-
Q'02ZY*806(FB5DDUB.Q/HG9)..0V(#$7!(;DIA'8CZ) M!206DEA$8B,2&Y/8I'%ZLDO./ME%AA7Y.;RJAB9L@69L@:9L0>7LH\JJ^5)9 M-?
%@T7\^>OK^P^,5Y07>4&J5I=D9A*8AJ)Z236)3&#Q$P2LTBL1V)] M$K-)S"&Q 8FY)#8D,8_$?!(+2"PDL8C$1B0V)K$)B4U)3.Q2_<^%7T.2VW+Z M^!$:%,W6
DW7@LK71Y55ZZ6R:A&5558UE0M7K:9(3"4QC<1T$NN2F$%B)HE9 M)-8CL3Z)V23FD-B Q%P2&Y*81V(^B04D%I)81&(C$AN3V(3$IB0F\M-[Y<-9 MJ+9+ZC]7>G)=21=ZZNFH]+E$+6_(4=G3?
BE[VOEES_8@T>6V1]==[7;Y^!0O MUK/GUE_Q'JO;<5:]DRM6K7=(3"4QC<1T$NN2F$%B)HE9)-8CL3Z)V23FD-B MQ%P2&Y*81V(^B04D%I)81&(C$AN3V*1=]/&>*1E.B,)X LV^8I=^?RXHFNF(
MZNF8D[HDESDJ3#HOA4DGMS!QXDWMEX?E>OUK;;Y(*I/,2B27J%J)D)A*8AJ) MZ236)3&#Q$P2LTBL1V)]$K-)S"&Q 8FY)#8D,8_$?!(+2"PDL8C$1B0V)K%) MI[
2(<.)77;_:X7&O"F.*!Z.N12Z5S7T\5(T;"C>D2Z?BE(MMVIB\\0G7ZJ M.>_<4+Y9M41! 175-%334:V+:@:JF:AFH5H/U?JH9J.:@VH#5'-1;8AJ'JKY MJ!:@6HAJ$:J-4&V,:A-4FZ*:V*?\W
,N;,A]#C\Z&=0X*74R1IT<="F0CLN< MGWKD2[EE3HF^.W)FI9/+5JYT2$U%-0W5=%3KHIJ!:B:J6:C60[4^JMFHYJ#: M-5<5!NBFH=J/JH%J!:B6H1J(U0;H]IDI^7UXT$#"I$146XTY%8]?4R$SW.
YNX)".SRCFHIJ&JKIJ-9%-0/53%2S4*V':GU4 MLU'-0;4!JKFH-D0U#]5\5 M0+42U"-5&J#9&M8ETVH#YI((J'")$B3$?2XQA M4ZA@2&TE3:J?
9Z$1IWA&IC5)N@VA351$'NKLJQ25K3U8NHM!>SZBFH9J.:EU4,U#-1#4+U7JHUD2R%246IA5(QZ7+H;&RE-]9N=3WS?.-RK4*VCD9U314TU&MBVH&JIFH M9J%:#]7ZJ&:CFH-J
U1S46V(:AZJ^:@6H%J(:A&JC5!MC&J3G99['HOMDEP< M4;!Y6>P3<^YWT3/&7+9;S9-BI6#8<;5R:%8LY7:CF2X5]60,T8(AJ$:J-4&V,:A-4FZ*:*$CHU<]JL0V*68Y-X@++XL?% MUJ%%LI3?
(SF_V,HLL- 6R:BFHIJ&:CJJ=5'-0#43U2Q4ZZ%:']5L5'-0;8!J M+JH-4R_JF-A8:?)F_RPE0N2PH :&E#/""A==U*?LNX6 M+\LH!9GHXBU4ZZ%:']5L5'-0;8!J+JH-46PK'M4OK'H5!-175-+FP6Z2.
M!NRBFH%J)JI9J-9#M3ZJV:CFH-H U5Q4&Z*:AVH^J@6H%J):A&HC5!NCV@35 MIJ@F"G)ZY7J+Y=@<+M@D+C2*.ZZW#HV?Y5JO51S48U!]4&J.:BVA#5/%3S42U M1#5(E0; MH=H8U29R<>-
G-* 0&1'EMM)J7:>_4<5F9\&F9\'F9X$EZ.,*2CY44*]J_%Q< M0:&-GU%-134-U714ZZ*:@6HFJEFHUD.U/JK9J.:@V@#57%0;HIJ':CZJ!:@6 MHEJ$:B-
4&Z/:!-6F\FEOY\Q.>J(@H5<_7'4:.+O7E&"SMM,#R]'$A=>@M M+9?N+5UTHK4/.D@E#'NLE5/ MJK_T-_.S!DHMN9/]U7SYT%LZN?F*@T"%U\C(9RO7,:2FHIJ&:CJJ=5'-0#43
MU2Q4ZZ%:']5L5'-0;8!J+JH-4Y?FH^5;FR0?M.HYJ&:CJJ=5'-0#43 MU2Q4ZZ%:']5L5'-0;8!J+JH-4P3<^'U4S/&95_-6O@^>NGRH?VTW)^^VF?N7ZJ?-I95:HW6NUVND/6 M3?YZ*IJOFH%F3\
M7LW^&&J(QHU0;81J8U2;H-H4U41!\J[*?60Y-I4+-I<++)D?%U:'5M-R?JOI M4EGJ(!A2B.*-B\+/:).?=WF'[;=3LOY#>ZC 8/B@"$:,$*U$:J-46V":E-4$P59NOH1'[;+-2W:BZL7HK.72FGK1XOSWQX
M.7\IE2N:T\#9<34TKHYJ750S4,U$-0O5>JC61S4;U1Q4&Z":BVI#5/-0S4>U M_-5"5(M0;81J8U2;H-H4U41!WJY>4Z$M7$F1FHIJ&JKIJ-9%-0/53%2S4*V':GU4 MLU'-0;4!JKFH-D0U#]5\5
M0+42U"-5&J#9&MU+JH9J&:BFH5J/53K MHYJ-:@ZJ#5#-1;4AJGFHYJ-:@&HAJD6H-D*U,:I-=EK>-^+1@$(41Q1L7A;[MQ'S4'['9.JFKU(QQEZUF4TY?
U4/+&"A=G[D"F'+H[*SD=W8^^]FBV^7B6[Q: MSY>+PD\7H0V?44U%-0W5=%3KHIJ!:J:2T=HS^^\,"PW<0[5^^8=AHX$=5!N@ MFHMJ0U3S4,U'M0#50E2+4&V$:F-
4FZ#:%-5$0>JN_O$BM@$TR[&96F"I^KBL M.C2=5DHUG7Y3644VB[Q!-175-%334:V+:@:JF:AF*64;G/=*C^RC*[11S4&U M :JYJ#9$-0_5?
%0+4"U$M0C51J@V1K4)JDU1310D[NI%%=MPFN78/"VP1'U< M5!T:3BOY#:=]YDH>^5$J%U9H2VI4TU!-1[4NJAFH9J*:A6H]5.NCFJV<=FYM M*\WK=NJB0$[&N-3A^_&Z,!?
5AJCFH9J/:@&JA:@6H=H(U<:H-D&U*:J)@IQ= MO9YB^U*S')N>!9:?C^NI0T-L);\A=LEZ*K.&0KMAHYJ*:AJJZ:C6134#U4Q4 MLU"MAVI]5+-W6LY'%9SB(8.,(9UZJ@QSBYUA&<=#GP ?
U0)4"U$M0K41JHU1 M;8)J4U03!5FR>@7#-J1F.38Y"BP['E4P]4-#ZGI^0VI_>Y3G\M-LG90NM\O' MIWBQGFVVY];B/[:W,Z](ED]6+5U0344U#=5T5.NBFH%J)JI9J-9#M3ZJV:CF MH-H
U5Q4&Z*:AVH^J@6H%J):A&HC5!NCVF2GY1Q^G:(!A2B.*-B\+&XR0DI2 MNE& 6F)A6H%T7+H<6E+7\UM2E[IZ:KY1N59!NU6CFH9J.JIU49)M5(T[KA>D0_U2GX3ZC-M?JROB]]JRO7SU]WKF24,
MV3;R!M545--034>U+JH9J&:BFH5J/53KHYJ-:@ZJ#5#-1;4AJGFHYJ-:@&HA MJD6H-D*U,:I-ZJ<709"55EV6.NE"ANU.G1&WWNG4VRWIM)YA.T^S')NF!9:G MCPNI0^?
I^JLZ3Q<74FCG:51344U#-1W5NJAFH)J):A:J]5"MCVHVJCFH-D U M%]6&J.:AFH]J :J%J!:AV@C5QJ@V0;5I_;2==+HN*DCEE3\:5"(DFY@%FYD% MEIJ/:Z=#K^GD9IG:J52]E$M5KI=
(344U#=5T5.NBFH%J)JI9J-9#M3ZJV:CF MH-H U5Q4&Z*:AVH^J@6H%J):A&HC5!NCVF2GY9X[(P,*41Q1L'E9W&2$;+5: MG<;)^;/3<9>MSO7)L3 M:Z
D2XW4";2K]7T<;]399O;AW=/L2VS/5E_FBW7M M(?ZSNWBU'9#_/-RN=G? MN4K\[\O5[\\Q/OP;4$L#!!0 (*@R.UFBF/UGM04 , 7 8 >&PO M=V]R:W-H965T&ULK5AM;]HZ%/XK%%%INF5EI'XO
2.HI$*=VX MVFA5NNVSFYCBNR1FMD/;?W^/$YI XGCTBB_@A',SWE]; ^?N/@M5Y0J]!Q' MB;QHK91:G[?;,EC1F,A/?$T3^&7)14P4/(K'MEP+2L),*8[:V'%Z[9BPI#4: M9N]NQ6C(4Q6QA-X*)-
,X)N+EDD;\Z:+EMEY?W+''E=(OVJ/AFCS2!54_UK<" MGMJ%E9#%-)&,)TC0Y45K[)Y/L*\5,HF?C#[)G372KCQP_EL_S,*+EJ,1T8@& M2IL@\+6A$QI%VA+@^+,UVBK^4RONKE^M7V?.@S,/1-
()CWZQ4*TN6GX+A71) MTDC=\:>O=.M05]L+>"2S3_2TE75:*$BEXO%6&1#$+,F_R?,V$#L*8,>L@+<* MN*K0:5#PM@I>YFB.+'/KBB@R&@K^A(26!FMZD<4FTP9O6*+3N% "?F6@IT83
MGH20%!HB6$D>L9 H>%@H^()L*8GX$DV(7*%KR+A$)S\2DH8,9$[1&?JQN$(G M[T_1>\02=+_BJ21)*(=M!$6 M?G7K$EL-_I,FGY#G?$38P1T#GLGAZIX%CE=$V

4U1'B^^HNMO-[\6Z/KN MYCNZN9W>C>]G\R]H/+F?_9S=SZ:+EE1L:&OT MX9W;L6\+K6!(W#?Z'7\H)7'.93P). 110E@%O#UF_U.M"M MD.I^@8J'82J(8LEC/HV88M18_-UC9O%
(QO;"U"O"U+-F\8J"T8 1/8%-CN;: MO9W4="K)JTLXYLSU"TA]*Z3%B@AZIB=YB*"N@-YD!@_19[TVUEF_!L)U^Q6@
M!IF.;X;J%U!]^Q18D>21RDKE2$FAZ&!NHHB1!Q9E560UHD*W&V4;\A"9VV=03T4E676),\^<*]'$)4I\ M($I!HVR/L29"O=C18LNTV&*MBW@-$\4MV=JU4N$.5A($(J5[K6D$ZM43.\"#
M*M:ZE-M$7&Y)K*Z=64NPL'NE0@!:03A M)%G7SK*WJ0A6P+'Z-$#_I&RMMTI&K^N\>=:K;@(,0DWE57*K:V6LT:W@81HH M1!/HAR [NZ /[WSLNI^AV!3T"
(,QD].M$;AOJK):D=6EFI"79.C:V;#6&"S9 M4'E(8YAHS\55R'6I!LBXY$;LO*DIKF?S\7QR0%-@*^>^M2F.96T_"B7Q8COQ M0LD%E(82+06/D211UAY2;TB-^<)U7AUTJGL$@Y"+<;,G%V,
[%)U?3R=UTO)B>PNC-5[! N@*- M4 U,[/;]&MBZ&/8'#5A+*L9V*KX1>[':^*O"[5;3B7X)*;L9V;&X!/YU=_@5SG7*];G9DFH4Z__M 7+)R]C.RXMTO8ZR,4^BO+*7$=A@27ZUV7! Q4 MN0N-
J7C,KH@E"GB:J/S^L'A;7$./L\O7ROM+]WR27R:79O*[[>]$/+)$HH@N MP:3SJ0]X1'Y=G#\HOLYN7!^X4CS.EBL*1S.A!>#W)>?J]4'_07%I/_H/4$L# M!!0 (*@R.UFEE_\9D 4 88 8
>&PO=V]R:W-H965T&ULM5A_;^(X$/TJ%%%ENM=J6TQ,Y/NBT2!?:64TM[A=[I=+H_7&**M4G, MQ@[=WJ<_)Z0))([+[G&5*$F8&;;L&;]GQ-_F?/',DJ\18@ WZ,PYI>=E1#K\VZ7 M+U8DPOR,K4DL?
UFR),)"WB9/7;Y." YRIRCL(M-TNQ&F<:=_D3^[2_H7+!4A MC[[LP,[K@WOZM!+9@V[_8HV?R(R(A_5=(N^Z992 1B3F
ME,4@(#Y&?.>06OU/RS'>N04;ED;&OVY>OT;_G).79!XQ)T,6_D$#L;KL^!T0D"5.0W'/GK^0 M@I"3Q5NPD.?_P7-A:W; (N6"186S1!#1>/N-OQ<3L>, [18'5#B@0QVLPL'*
MB6Z1Y;1&6.#^1<*>09)9RVC913XWN;=D0^-L&6$' + O'P2EXF(W AY./X 30&,Q7+.4X#OA%5\B1,__NHACE:CL*:AEE M1!9GP((&0":R%.[#P]W1OGM7\BU)HY(TRN-9;:33)"&Q)ASR5-
%9^MOJ_VS MK77.UWA!+CMR[W"2;$BG__X==,U/*G)'"K9'U2JI6KKH_2'F*Q7!K9>3>V5; M?=-'T)9+L]D%WC1R_-)D#XY=PK&U<&[%BB1R^R\(W>#'D"@G?QO"W1G6MVO(
MFB:PIT;FE,@<+;*[A*PQ#0#Y+C,D5P-S&J,BOP:L:>*J<;DE+E>+:\X$#F4F M>.N-=9O8D./4T#6-?$L-SROA>=JM-)6I^&UPWC&WTY&"[='U2[J^=C6N6?P$
M!$DB*15KQJF:KM^89K.V$$T+!ZD7HE)ELAQ8\TI(*JLQ0\JG@=*]H^YTJ^H%Z_Y@D. M"%CCEU:U* +LSK7=2'PJ(]3V2E=B!O5J-E@LDE3636\MB$JM3%2'J)]I^V= MJ50-ZF5M1)9$OC6!U-
P-B5.BQ-<4K7J^4ICTS!;%A96TP1_1MK=F4:%PCM68 M1865Y<(6I)7*0:VJ%&GA>C*XFEQ/YI.Q.C=X!R%46+4CK(0)ZI5I>'MS,YG? MC*?S&1A,1V!X.YU/IK^,IT.)%GR8,D&
U$)6QM8O<.!,E7\]T#[Y"OM@SUM M9IQ]&=R/O]Q>C\;WL?O? 2]3V#\V-_B?X,!I_G@PGSZIVFR@QZO1;Y0U7Y@/3E@U3H $K# M_'0C($NZH,J2+@U//=5&]
[53:V29JR=ZHJB20OI+8ZLO/IC&D*#!VU+G MWC0Z10BUM*>HJC"0OL)H2&,N/S]-1=%C-^MKA55K?8VJ<@3IRY%[LGU1[G B M7L!?-_F&_%N)4AOHA\^'CA1MGW95VR!]"W]@6X&.VL0?
]H^YZI:0OIJZ76I MU_E2%^V%DK7?. .#7KV[4!IYM=>QNW-(FYV0W^#DB<8^SS! [V=,_XL\@)/J=TT+,C$S\LXT19)!CL4M*Z%05]:,YUBJ M+M^8HN2 T\J44].QK,#,,2F,>%J-
K7@\95M)20$KCL0VSS'_&;;P, M/)!-)O6 &4]+O(%'D-_+%5<]LXV2DAP*05B!.*QGQD?[;AEI?27X06 O#MI(M9_+$V+/N?$EGAJ47!!02J2-@];.#.5"J ZEE_&IB&NV4VGC8?
HG^J)%"WR>/DJNK1/ED/&>%8)2D6$**[C'%10+H48<3Z&J%.10R TD2 M3,4UND%OD8E$IH;%U)1J>AW$3)JI[NNIG!-3?=T6M\BUWB/' MWZ,2<[3#= OHBA0H991B+E)O.9]?
8QW/4583:$+PBZVX<;RI^;N$.LHU6*4 M:CF8E*YI=Z+$"I/!]E8X6*L<#F8VH7@O!:<=Q$X(L3V=6A>+T7'#3W'CCK, M^CH[L.T@\L,.L[ZP"VLPG0MA^2TL_R)8ZATK)"Y24FQ>(^:/)-

;7G2#6%W:) M#>9T(;&@)18,$INS/%>O_/^H8\&H.C9*M1BE6@YF="&OL.45GL'K["(6]N\N M+SQ>QL9+%^.ER\'L+F0W:=E-SFAEZ4>1-0KM+K2]T?3>()F'WL>P+ M'=]W0L_K
!M,Z4)@40LL.A_8&;4L&DNM+SQ!K2\\3JVOLZV)'QP\RC40\V#S MJX\VWS#?D$(@"FOEM&Y#51MY?5RH.Y*5U7[XB4FUNZZ:F3IA =<"=7W-F'SI MZ"UV>V:+_P%02P,$% @ J#([6:KR!*+Y!
\1 !@ !X;"]W;W)K M[7JE2XE3L)7%Y" IBW:%A"! MWOOJ$D.B)C$W-M#=7[]C!P)-G&@?^@))F)F<&8_/\= [LN2=^Y0*]!&%,>_7
M?"%V=XT&7_LT(OR6[6@,OVQ8A!M\FVP7<))9YRBL*&:1BM1D2"N#;HJ6?S M9-!C>Q$&,9TGB.^CB"3_C&C(COT:KIT?+(*M+^2#QJ"W(UOJ4K':S1.X:V11
MO""B,0]8C!*ZZ=>&^&YL&M)!6;P&],BOKI%,Y8VQ=WDS\?HU0R*B(5T+&8+ MUX&.:1C*2(#C]REH+7NG=+R^/D=_4,E#,F^TS+?P:>\/NU3@UY=$/VH5BP
MXQ,])=24\=8LY.H3'4^V1@VM]URPZ.0,"*(@3K_)QZD05PZX5>)@GAS,O(-= MXF"='"R5:(I,I75/!!GT$G9$B;2&:/)"U49Y0S9!+)?1%0G\&H"?&(Q9S%D8 M>$10#[D"OF"-
!$=L@V8[FA!9:XY([*$QBZ!1?+F"!XJ>&>>HCE;N/;KY]AU] M0T&,EC[;$_7M\C"/Y!IF)8&T/C_NYL5<*RLSI:*9Y?$6SBOSG3EZ"J3.C:5H]QU MAX'=[?0:AVNP11LCL_B$Q\
[PV,K%*L$SFSN+X7(R?43.K[DS=1WW3H?-KDI* M4LP=WY$U[=>@-3A-#K0V^/,/W#+^TE7\BX)]RK>9Y=NLKC]$),G:5ZWLT0/P MUTYV.J(?P(B<:GLV#=FZJGK;QKF5*=I@L]O5+TXK
]NJ!.L"JP7Q5F$%*Z9;3SU*8U*P=X)6RXFN&63\X"3:;CV8N#;DY5_*X%BK^2Y;XJVN>TS4O: M9G6+QX)"7*'VY!N)W]&&ZG?A*="GPN/"ZFB,;+M$?/!%#7&U'*YB.'.&P;]P MZ-C"65-
N1#B2PIE+$L?:)_&6:B%;Q5YNYQ$7;>K8*FNGBU[B2GD:/)_YXD.2 M\3[@OJ(1."=Y]$U+'J> 5>RA,:DW2_@#7Z0.5VO=3/@T@0/9FD44W9R)6-_Z M1?FRFX6*:C2N;96@O&@I,;.Z
M1MG*7S0.5XO<)"VD(!]HE[!#("<8+NF@:KA:UJ;-4'(R& MTWL$=9POG"?@NLFK4T[-G<)Y4E;4RJ/5F%54]*)PN%KB1D-W,E9P[R?/JZ5S MG^('14'NTQ#ZX08HP6-A2!*.8 I!W"
<)U3=P^J;.-43CUBC0F,;,O.V4-+%Y M44&S6@5_.I/')YG \!7D\-%!T]7+"-*8/:29N/(*UN1E-D7N+K?QNT%ABJV,839S+N7$U/$8TV:J9FJ,U MV\RI]G&PO=V]R:W-H965T4[-=%>UVY:$
9])4K7;D@"!A-K,#4?B*W$5-O@ R3I\^\/.&"L M%[11?'?Z0\>.ERX)-LYZ$&+Q[MMB^>?J/DG6M;\>'^:K]V?WZ_73/R\N5K?W MR>-T]?OB*9EO?O)IL7R:/'APOU\K)Q\3B=S<\^O'O^ M.W?
YX=WBR_IA-D_<96WUY?%QNOSW'\G#XMO[,^5L_Q?>[//]>OL7%Q_>/4T__M)WZR#I_:[BQ?E;O:8S%>SQ;RV3#Z]/Q/*/X5YI6ZW>"Z)9LFWU:NO:]O; M\G&Q^'/[3??
N_=GE]I"2A^1VO36FFS^^)C?)P\.6VAS(OW;JV_?G[7.:G?)I^F7A[6W^-9)=K?H:NO=+AY6S_^O M?=O57I[5;K^LUHO'W<:;(WBR:']]DO^A*=M6/;[)?=B6[[L?OL?W"*]F5/WZ/[9=>R:
[]T=\09;_X2G;U MC_Z.J/O55[.K?_2W1-VOOII=_:._)^K++WMV]1O';HNZ7WTUN_H-[=@F^]57 MLZM_=%W4_>JKV=5OM(YMLE]]-;OZ]:/WV'[UU>SJ;_=?O,E^]=7LZF_OR^)-
M]JNO9E=?._I/ZG[UM>SJJ\?N,6V_^EIV]95CZZ+M5U][7OV+[TWEN2/IT_7T MP[OEXEMMN:W?>-LOGMO:_:;1C2;;UNPOUYN?CK;;+?^<+.8KQ8/L[OI.KFK M^>O-'YO^NE[5%I]J-_?
3^>=D59O- S]8W/YYOWBX2Y:K_ZD9__HR6_^[]HN> M?)K=SM:_ULYKH:_7?OG'K[5_;*N#^\67U71^MWIWL=X[P_GC^^&H M1P['3Y:SS2Y%S=TTXF2Y?#ZHS;YK_VNJ^;Q>/C8B[? MD?
[6'8F[N]DVD$P?:NYT=G>^N1-OID^S]>;[DMT:;]VMEZPW(6WS]\9T.9_- M/Z_*]F:^<6\%9/LD\H_C-^!HQ>#3YMO-+?JAQTWG)Q[6J0^Q[D\\IA][-%H__M\0@K/7![/^__"O;>?
^O>*SQP[9/V=2.]I?F*-_T^.3_QL$[]?1K\Q&/ZL=\G M]R<>8:7?I^'/.[""O7MOW7N%!Z[_UGV=^F@,WKJC'WN(A6_=;:7'3?3&O160 M<3GY^N[_;>/.OF[R;DR,H%V>^M 80_O[L4?(!-
I[I0>*$,Q> MBVC)\X*#P0A>7IQZ@(+R;.''ULX(7ER4&U!)-D_6&R.)KW=Q>9YZ,N34?7E MR:CZ[-2/.'],'Z;SVZ3VR^8VKNZGRV3U:VVZKNG)[>\U3?FMIEZJ2M%SRE)U M>Q+
[GZNGS8/C_=G3ADR67Y.S#__]7TKC\G^+GC22F$YB!HF9)-8FL0Z)=4G, M(K$>B?5)S"8QA\0&).:2V)#$/!+S22P@L9#$(A*+26Q$8F,2FY"8*_M5;5= M3V\\:]O7D;]^:"D-5;VN7S7>77Q-
Y;!\J7)UV@_5>@#5A0'3B5M.HO M2:M^4M(Z)5V52E73%8GI)&:0F$EB;1+KD%B7Q"P2ZY%8G\1L$G-(;$!B+HD-M2\3+R9>>-IJ8IF3JSH$Z[5.HO9:FP<_42=JY*P\[1E_/#^>SY^M+=
MI1ZO3CL5Y:"K_+F]R^__I6_%3;XP4Z&7'F_5X$)B)HFU2:Q#8ET2LTBL1V)] M$K-)S"&Q 8FY)#8D,8_$?!(+2"PDL8C$8A(;D=B8Q"8D)LI[<^7@@FH%G?I* M45MJ-N2@.T7[M:ː=BI8-
5Z"5>.48)6_8GP?J8IB5",7\;1,?LI79/-3@=%, MEQA2Q,Q7U#,E[=*;7S7 D%B7Q"P2ZY%8G\1L$G-(;$!B+HD-2]1;!O8 M;K^_K7"US6U%R:Q4K)K,2$PG,8/$3!)KDUB'Q+HD9I%8C\3Z)&:3F$-B
Q)S M26Q(8AZ)^206D%A(8A&)Q20V(K$QB4U(3)3W]M:]E7S-!N+=!V M+=!^+:B&G0IEUR^A[/I-H4QVZJQ4KQK02$PG,8/$3!)KDUB'Q+HD9I%8C\3Z M)&:3F$-B
Q)S26Q(8AZ)^206D%A(8A&)Q20V(K$QB4U(3)3W^,H!#=5V33UU MS;-RJ30;]>RKC.ANT8XMJ):=BFC*Y4M&VTY:EU\D);OZO"B?E.OG-
Q8CFWW8M_O4]=_Y4_\&05EN2O)2FO2*>O59T'Z\DD9[[*MILV+:=;W>O,J>%6-W MS/9R@37S=&13#Y&M?,1Z)K(5QC1TG#JJZ:AFH)J):FU4ZZ!:%]4L5.NA6A_5 M;%1S4&V :BZJ#5'-0S4?
U0)4"U$M0K48U4:H-D:U":H)28.O'M-0;M_N2]\< MJ>0'MM>?QV!FSFKER_)GM214.B4=1J(KY3/1X^ER.=U^#.ILM?J2W!6F)'3^ M.:KIJ&:@FHEJ;53KH%H7U2Q4ZZ%:']5L5'-0;8!J+JH-
4DE!NW^Y+IZ@7U&@%(4DNF1(IG9$.P\PW7Y9>8K5] MH>_\XW25W&VO?W]*YJOI]G,*:\E?VZ^3PM!42E8.3:2FHYJ!:B;JM5&M@VI= M5+-0K8=J?52S4?+\H[C=PPK1-V9I9#Z1QTF'.N2
:=/U]7?C?[.KM+YG>UI^E, M.CVK7*P<@TA-1S4#U4Q4:Z-:!]6ZJ&:A6@_5^JAFHYJ#:@-4JOFH M%J!:B&H1JL6H-D*U,:I-4$U(&G[U&,2.3U?R\].UII*_"HJ=G\YR6"=/9[;#
M"'5%,D,]G]D*PN]UT\-<)5 M;;:RTUO-@KICI\$.4^65\K'RIT8J='(\JNFH9J":B6IM5.N@6A?5+%3KH5H? MU6Q4'Q6KU:VTVOUT\%E^GA4Z11S4= MU0Q4,U&MC6H=5.NBFH5J/53KHYJ-
:@ZJ#5#-1;4AJGFHYJ-:@&HAJD6H%J/: M"-7&J#9!-2%I\=536GZ^?/XZ+7G-OC.778)E%-2<:]>7V=&FIK0N'7\.P]N5 M\NGM?TP?
IO/;Y/456K7INJ8GM[_7-.6WFGJIJH6)"!W;CFHZJAFH9J):&]4Z MJ-9%-0O5>JC61S4;U1Q4&Z":BVI#5/-0S4>U -5"5(M0+4:U$;J-46V":D+2 M]:LGHOP(]GPBRM>H5U=JLYX;T\X>'-
N@!=:A4X%,/4QJ5\LGM?]H("MGJP8R M5--1S4 U$]7:J-9!M2ZJ6:C60[4^JMFHYJ#:-5<5!NBFH=J/JH%J!:B6H1J M,:J-4&V,:A-4$Y*N7SF0J?
()YSYHYJ.:@:JF:C61K4.JG51S4*U'JKU4APS1TM7P:^H],^BPG*VJC61S4;U1Q4&Z":BVI#5/-0S4>U -5"5(M0 M+4:U$;J-46V":D+2\:N'._D4\IL3:O2"&J7>RIT=.F'FN41*)Z'#S//-EV5)
MZ*0WSY4;E:,/J>FH9J":B6IM5.N@6A?5+%3KH5H?U6Q4\-":OV7?FTC?/%=2DSFZ\(DA,XY1S4=U0Q4 M,U&MC6H=5.NBFH5J/53KHYJ-:@ZJ#5#-1;4AJGFHYJ-:@&HAJD6H%N^TDNXZ
MDI>,"TH434L73>2.$*= @FV-@NV-@FV.@NV. FN/Z1QT&!ZNE@\//_*.->O+ M_/>:=OE\R;16F(;0:>*HIJ.:@6HFJK51K8-J752S4*V':GU4LU'-0;4!JKFH M-D0U#]5\5
M0+42U"-5B5!NAVAC5)J@F)%V_^GFALAG;^]26KU%;6K-YF7W) MB^W/@FW0 NO0Z4!V&#VNEH\>?_6^-7D(0^>/HYJ.:@:JF:C61K4.JG51S4*U M'JKU4HSM,]U;+IWO_\#0E M=.
WJNFH9J":B6IM5.N@6A?5+%3KH5H?U6Q4.*WV9\(2:?6>6CK;UE4>'R\ MI7:8]*V53_KVOX^WO,F-MPSGL_7J9I7S58K^ZZ3#KK?+JI9J-9#M3ZJV47K=:6U%"US9MTI*,S\DS- C\Q%M2&J
M>:CFHUJ :B&J1:@6H]JHX &NJ5=:0VMEWM,^1O<[034A:;;5TPC*L6U5L'U5 ML(U58)TUG:O40Z[Z&\:&EYN54Q0Z-AS5#%0S4:VMR<>&RTNZ!25J(_MV#DL.
M]4Z"^NA=8*.:@VH#5'-1;8AJ'JKYJ!:@6HAJ$:K%J#9"M3&J35!-2#ID]3#$ MC@UG.;8]"K8_"JQ!IL/086RX)AD;?MI)IL)(A$X/1S4=U0Q4,U&MC6H=5.NB MFH5J/53KHYJ]TTJBIR,O&124*-
>7F0^U<>70\"3(0^\"']4"5 M1+4*U&-5& MJ#9&M0FJ"4F?K!Z)4(]MCH)MCX+MCP)KD.E(=)@?OOFR+!*=-#^\W*@JOFH%J!:B&H1JL6H M-D*U,:I-4$U(6GSU-%>7/4D2-R?4[#MSZ?
SP@IISM7&9'4YJ2NO2\>8-A1YBS'=F;!MF:!]>9T(#N, M,M?*1YE7_TB72.$*= @FV-@NV-@FV.@NV. M FN/Z1QTF""NE4\0]V77;4O/3:%CQ5%-1S4#U4Q4:VM%4U6/O!4N7UIJG MJE".
[=.";=2"[=0":]7IB';8;*Z53S;WM^'K_.-TMI]%4__MC#&OEX\Q?TY?M67R]&5Y>S^5GP4KYZK&,%334W[G200XGU.P[<^D@AQ-JS-*:=.I1#ZE',M^\ZKDG=+0YJNFH9J": MB6IM5.N@6A?
5+%3KH5H?U6Q45KS@M//K&3U5D.Z_I&':8K%XOGZR^_R3C5^DK^ZG& M6F$<0\>JHYJ.:@:JF:C61K4.JG51S4*U'JKU4IQ3,M%+:6A*(WK1C9MW124:E=:X[K5S JOFH%J!:B&H1JL6H-
D*U,:I-4$U(NG[U8%;/GP,K'CXD M;@IJCY2RC5JPG5I@K3J=S ZCY^OEH^?WR>RD-(8.FDE-2Y;F?>,^P5UF':81%\OGT1_LYA_39:KV6*^B6+?D]EOM>?+[C>9[?EGZTUB
MDX4S=!H]JNFH9J":B6IM5.N@6A?5+%3KH5J_?NJ@?QO=KX-J U1S46V(:AZJ M^:@6H%J(:A&JQ:@V0K4QJDU034C:>_4DQPZL9SFVEPNVF0NLFZ>3W&%@?5TR
ML/ZT$VV%^0T=7(]J.JH9J&:B6AO5.JC6134+U7JHUDJ!".78WBC8YBC8 M[BBP]I@.1(>Q\?73Q\;?+AZW<^.GZ^V)KI(9\N5DY22$SI!'-0/53%1KHUH' MU;JH9J%:#]7ZJ&:CFH-J
U1S46V(:AZJ^:@6H%J(:A&JQ:@V0K4QJDU034@Z M?O5PEQ^8GK\42UZC%]0HN1$3Q@F2*9%22>CJ,,+]JGR$NY.L:[\\+%:K7VNS M^28*%4:?WR^7UY]<)$A,Y31S4=U0Q4,U&MC6H=
M5.NBFH5J/53KHYJ-:@ZJ#5#-1;4AJGFHYJ-:@&HAJD6H%J/:"-7&J#9!-2'I M^M4347Y^N:HUZZIRGLAEY=/=7\U(_MD&?9?%5[2#YMMKO\O;D!EK//]R_? MK!=/[\\V:>SC8KU>/#Y_>9],
[Y+EMF#S\T^+Q7K_S<7&_[98_OF\CP__5!+ M P04 " "H,CM9L\X3YF(& #%&P &0 'AL+W=O '97JW/[NKH2-;Y Q=_Y(I2A1[3)),7C952Z[-62T8K
MFA+YF:]I!D\67*1$P:58MN1:4!+GG=*DA3VOTTH)RQJ#_S>C1B<\XU*6$9O M!)*;-"7BZ9(F_.&BX3>>;]RRY4KI&ZW!^9HLZ9RJG^L; 5>MTDO,4II)QC,D MZ.*B,?
3/1D&H.^06OQA]D'MMI$.YY_R/OIC&%PU/(Z()C91V0>!O2T[_*@X=@[HFD(Y[\9K%:731Z#133!=DDZI8_?*.[@-K: M7\03F?^BA*VVVZ@:",53W>= 4'*LN*?/.X2L=?![]1TP+L.^+A#6-,AV'4(
M\D +9'E88Z+(X%SP!R2T-7C3C3PW>6^(AF6ZC',EX"F#?FHPXIGD"8N)HC&: M*_B#&BF)^_*-B%RA*ZBS1$WTS(^V72/ONC/*LF8]SEBD*@T@A0 F$V%*A MV#WD-Z;WUKSV7\RK:1'6H?
6]2JX\)][OFI]Y(C47-TRN=.'U**@#NG/H0FHQ M:?=KD.X)J^\6@A7)EE0>S1U24IAV0#M1PL@]2_)YQ*H'._TP&;A*
M!G:6K4A&G@NUHD)/NI1M"0PP^QH"FYSL')/!8H1K>.M7ZNT[I7$/*.1A35C\ M3%D[SL#$J5<1ASA-HZ &9B6QOEMC*Y@)AV$%U$V! &LNF;(##I(M4$FM[Y2H/9Q*D)BB-
7FJ+WK;S)-1<].FV:N;5"JE\]U25Z$4-,E7PFLBU),; MK:EN32.C+HT\Q%HIH.^6P HKB2*QH0<3B16HJ6^^%W:/H9I6_3HR52KHNV6P
MP@H;*RH$@!5T2[.-50!]4]V:?:]_#-2T"MMU6:U4T']!!O_OS79/Z:W09VRNQ;U>54W@ZS4$DM=JK7X$;PB-)8
MOF%9N//H6A583'"GKF*5$F*W$@+6>!,I1#,@1Y3OMM&'=SWL^U_T&@P(DR^[M\H6"%;A%&H->YQB[:57#$5Q)(W9+H\$1!JM$^0J.8(M*6B";5O7IKH02AV\B MR-5T-IR-7D,0IP"_F2
G\G:8A4J&L5N&[01YS3(?FX)K\,0T\;MANZ9RE2AC MMRC;,4N]L[*/,E-LPTYX_$7!8H7[==2H1!F_O"_-J;$6?,MBH,?]$UJP#!C^ M"GJ8TFL#;EIA+ZC+3T>UD.)]\ NTH6M! FC96K)9=JM<[7J59
MK)KM?AW62J2Q6Z0OA]^!NQ-T?97C0\,[=/=M@BXG7Z>SF:8T/+B9W$ZOQU;H MI@2W>\? 39M.NV:Q'E0B';CWK#6X)[.Q&W%@;DNQ;PP,B]5>7(>0*T4-W)O7
M^6:]3G)Q(DDQLA<)^&!9<7!0\TDH..F6]53>#E-0"77PPI8UY[/> 4+,Y><1 M:]@NL=W%\FH]#O8^-+^P53T"J#^U(D4>[;-,8,JK =)E<@BRTM_ O5$=@ZX\ M"PU,BXKGRS+U9(5H?
NXU(%J^"(<>]H]@MO8.1%(JEODYD00+K_-CEGBO% MT[RYHK '%MH GB\X5\\7^@7ER=W@/U!+ P04 " "H,CM94!\A#,% #+ M#P &0 'AL+W=O9O#F>&90_%H;>R#*Q
]/)5*N^.H\+XZB&.7%5@*-S85:II9&EL*3UV[BEUE M4>3!J%1Q.IGLQJ60.IH?A;$;.S\RM5=2XXT%5Y>EL,^GJ,SZ.$JB;N!6K@K/ M__'\J]!
(KO$/_M;JQU(M[E%R6J)TT&BPNCZ.3Y.!LQNO#@C\EKMU&&SB2A3$/ MW+G,CZ,).X0*,\\(@GX>\0R58B!RXWN+&?5;LN%FNT._"+%3+ OA\,RH;S+W MQ7&T'T&.2U$K?
VO6OV,;SP[C94:Y\#^LF[6[DPBRVGE3ML;D02EU\RN>VCQL M&.R_99"V!NE_9BV!M,0:.-9".M<>#$_LF8-EE<3&C=";H(U12,UG^*=MS0K
MR<[/KXU'2.!7.*T=33D'Y^@R*RM.\E'L:0M>&&= M8SY@?[;=/DFW_,046Q]@V@5XFFY%_%SK,4PG(T@GZ6S(H>WFYYB1>1+,IUO< MF?;YG@:\Z99\.__&+]06.I-
"P9T7'JDPO!O*=P,W&X;C&C]PE M3I7)'OX>RLO6S89#N?YR_PF2 [@6OK;(.Y+Z"2W_$;TOB\[)"TERHI[A&FMK M7"919SB"2TUL^. +A/?O]M-T:DD LG M6QQ=KME7TD,+'#>/=HRD(4[K?
5)9ST"%%D!KA#-\?*:C1-*]@Y= M,QD0.]T["2QV0-(Y^HV/W37.4\-J5$ M&/A65=8\2;H:D89_2W_I0"C:A60B=WS@+ T@;B3A#=#]-S%';<9JIFPN5HQ+KH$@:3BHK%:3-
]T0Z#LQE!QL&$IUH8,/-M=AB^9-[P0-H%=L>UWY0>A=!YQE*R40OIW@9JR,RL&TCH'R6'9$VWW]-!E=CO M"T55=?]2!*$R7SOYX95,LT"WJ =[.Y-Q_-3VG]*^P^0]EDKL)?."E0ROA&*
MTD3:(0)[ETIF@5E=A>QUO-+&A[^A+]=XX[T4TLC/2%;Z6OOFZ=2/]B_5D_! MBU^6-_<*V%7DI1)X9),)^.]G0AL\W1L.MY4X?6U,)[>^L&]MS\1CUC@VU1$L_4KI]H^'8QY>-Z.OP!
(CH#D:P'3(V : MA+:1!5G7R+A:6+,'ZZV%S3=";@):U"CM5_&>K4]^#7P_A),D 0BZA.6?*L["H9 M9/RET2.8CM]_,DYF?0$-PZ\I$_@DP*<#X4R[1$\#WW0@T0[8P'NE46<*2[AG M9)
(=P:XOWRW=K)_.;^ZYJS&C922[UY'=4;3Z]IO)^?BB3^N_1':B?-8IGPVQ MK^Z;U#%]]I*O39,R8"KGR6G%P9\/=&"X*DWV^%=?.H9]W/[Z\ Z2.5PZ,!N0 MI:=NZ=^_+"55*=EN.>?
@U.'4ZJ37:U#A$WRGOH=;VAK1PC[X36.Y$.)-HW/? MWRLN@ [*A5G4.6@YR)3>D6QD&Y;?HG($F.?*'V.2D@QKQ5A>"+FP/^"CA^[0 M*M,XR(QC^6BV4V+ZR^CHCWE.YH__+ZS]1
M7M!W'L8OKE_)Q#:\2GQR&\WM3=R-=@^?RW#?QY_-VU?3#=JMT@Y*V@AT//KQ M+_+;OD3:#ILZ7.:I87D:A&8ACS>RWD#F-T;NF6/'.^B>@ZM_%!+ P04 M" "H,CM9C&Q+!V$/ #V+@
&0 'AL+W=O/MAL1^H&4IB/1HJ),>* M^NOWW'O)F='#=K9H@5T40>1Y\'&?YSXX+Y?.WX29,5%]F5=U>+4WBW'Q_. @ M%#,SUV'H%J;&FXGS&-+GG2O#H81Z>'LRUK?
=>O^1GE_[U2]?$ MRM;FTJO0S.?:K]Z8RBU?1Z8WMY0<_V^DLTH.#UR\7>FJN3+Q>7'K<';2KE'9N MZF!=K;R9O-H[/WI^<4+C><_K5F&WK4B3L;.W=#-^_+5WB$19"I31%I!X\^M
MN3!510N!C,]IS;UV2YK8O\ZKOV/>PO]L[V5&DFNJGBSV[Y M#Y/X>4+K%:X*_*N6,O8I!A=-B&Z>)H."N:WEK_Z2Y-";<'9XQX11FC#ZV@G' M:<(Q,RJ4,5O?Z:A?O_1NJ3R-
QFITP;+AV>#&UJ3%J^CQUF)>?/W!1:..U;YZ MHX,-RDW4I3?!U%&+E.M278F"Z=V5G=9V8@M=1W5>%*ZIHZVGZM)5MK FO#R(M((D6/BC2]F]D^]$=VY^JGUP=9T&]K4M3[IA_% C0Y')
[L(NG_Z=Z;]".>?GP/.<>M?HYYO>-[]!-4=.J=K75= M6%VI*^C&P)'B3GG+**[ER-,>!X6NC"O]A:D9W]K]EY_^\W1Z>&+7;S^08NM M<7[2N3^1+5F\H5-__>):)[]]W-**
U8>/G]ZJX^>=ERSZ M1'V:&>!1X>8+7:^(E*;636FC*57A8)=UD*L "DM-CR>M-D.K3373MT:-C:EI M]87V&&=K7MB7&&T #7&FOC>U\;JJ5L2[641^TQ>#MUAY44$0F!U!VG7-
I+#= M,/'G<^,A/O7HVV_.1J/#%]?#JZ'Z_OS\DN^/7CP>,DM@$6 8\'?A?!1JL%XP MOY._,'--5:K:12#82L%5S'QL?.LN2@_[U(/0;LTDYLV]']@1:U5-:5@*W0!; M2_2C-
;$)O;P0W;%Y62*U&0=;6NUA3R*,/**W:5"5F6(];&6C%7DO9[:880DU MLSG\-P*@Y791Z,VMJ9M$D_FRH/6"*AM/EK#&U@+>
MZ$K8V7D1&RR>_:Y@=RDM).'5Q+LYIKG0D]QP#0IUAP&+#(6DY@FLSRWI<7A@ M='+0,=&FRZ3:7YM:,B[6;<]9""R.GKX@!FLB^^O=$M;""ZV,]O >!.X=8& ?
MJ[>PG@4;37<%^.652M);X> :P(I [#3SIN(7I8%E8T^B>HB5NSLQM3G$;G]+ M#V EA:Z*-+4)63LA>DTIX#[%!S4W$'VIW*T1RK,*:(:9-!4,ZE8@B]Z*H:W[M=A/8%';-
G+#=35SC%9*']Q@/PV<+*L Q@-[".8CA3F4005UJ7X8M_#"WNFIX M_32K%QJNVEG7"P$P@A7ZOROX_Q%A\O+>,/G_%1*_*CK]!6/2S^;6AD0W! 3? MOF1 VYFRJO<,*K79P)2-
6)1 ^"MPY#X,&6P]&@W5!S=4SYX-^._1X=F V=B: M.L3OD-SQSXRX?]WH^K\<4Q%XKF84%Z@]@)7TJK/<%"D8@FG,OHPA3 ,MHMA$ MUT#=F%5?#UBQH<&A@3?
J,$AA!E4*[,(69L/OY;U/PNZ7+J$F!8AF"H("I+Z M17NB84LZC&[:>D7AB*E9YI$2EP9K&)= ,6S(+(GJJR2UD_VTZ9_#?SE4[U)R M! LK&N]-70A>0UT&R5;W$-E$'2HM:B,H:-\D4K
I=UD(8-W<%L"T6^M=+4E/ M!G%1J?%IH8U(80-GKDTAX5\B'<%%"; '3#[:^]N> F;N?PAJYU6UL:)&7R&2&G2FIA8LHG"K&;>!%B+:S4#!) MYBR_G."N&U*Y/G95,^ M2
MDN1KWB0E9.P0N4NP6G9526' ;DE1+IB*I"AAAXQZH2V_8!40NNLV#JTX:43(M]:7QU:IO,%@V+BF_A//=8"&$YXAB:*%9Z><"08,^E!'Q:71"_[ZPF>"NCNI9
MK(QU]78PWK%UXAGJ(M))2.)4';L][L1?"D =9]6]>%GH,)-8B4P!Y%,<&^0Z M(B1YDH(&RD'JOO<$XRI73_>)?JJH7+ T%Z)#[HJ8F,:TK@;),UI02/5&7(X
M$O,%+*%TBE9L@0[%VEY*W&Z@+B#+G6+:%,DZ]^FY MI&%%X1NSD1]Y49T5^$G%*><4 7%+8+^7X(U-9.D,M#<^K+ R1L!$<
MQ+F88RI/4EG4(W&LZYO6]%+>ZDU;LPI\V:'ZN*F3'4^$<"H;13^\SZ*=%&@WM <^R>,AAITBNP_;"2QH4VJX/H5 M1,ZPTJ!^ 2AJ]OHIG(NU!M:[ZGMG!^B-
PY_6'M^=7[UI+6[G^ M7 M=GYUT(#,;9E2$]=91"UB>I,)KC].6 M4*OD9[P?LI; HI&W T:6T(Q_Y7K:J3'+%9IK24B>*H -H$&X(8#83>]@1^7$ M*E_2LA3@)-
EHX8#)X/):UJ7,L5U[0/8*KU10E"A@9[.#.R,#->=>#F7^#)73 MFCVG?69#?OS;[C8<;7)Z>#J@GZSE"9GE(Q2* !"8U&25.P"(FD5\%![+5-W" MU "C-X>#
^Z.T4X.&IRF\B>U8O)J/!5SVZ2+W_:3O91M/K*WCQGBBI1]; _* M$?.KMR8M/L*RK8AR%86@@O3R$:5LX)8K5>K-K12U"*$H^H=VZPC-7L]QWIH M@N6:A3WHCVL#0U?
%>=.9S5HLR<@N7IW0ISWH:[D3'1D-R._41!&46D4U<2*M M56I7-U6DUNN^ MJ2038E24K(BSKM9*LV9Y2:9ZMW@[65@.196 J/36*VEW2I.436*8T'#[C8BX
M7:U7]^37L5>_9WT&Z06B>N/50FH#.*K?&75H%9K^4,"^BV#10Y-:_9+FM;T5 MAH8:2! "RLJAXI,2E$UD(UF66P_87H+4%FU?K*W*-C1,"%'>BLPGR=JE0+E+
M'\GI[;WP,MS5YR4 4X[P*QCM"REZ2JI'G1P;M0+M,-]QE@UPU+(14R M)('4KK$5IUA@)U!/NZ)"L4@YR(S!%F;9H8F^6_.GQ/";+OM'03R%T_)(18P M1C>)2^F*=&.H:%B/FX5>
(#M GBLF($=F%)YD%NF#VUJUKO:IW QIV4%F-9G3 M[^56] 5\W(8-U37=ZZ7)K"AJO9W!7H2L&-UA:6IXD/=2V.;8ND>;P@26=E'GN!N-)R1U: MM^1.5LX-
<:N\3F4VERS,29V,6S=MF6C-$4Z-X$SC([?P%5H,U3?&X<$?@&& M28AZ^SB_U^S'[A=8K=2#^X^P:=OWP6M3Y:9\KYM/Y4&NK1-N;1XW0YE3/E"/
M*>;E;"IY=O<]";\@VIYO,Y*K!JXO>C-0=+T:);;6?_MW)^O6U*>X0)'[24ZH-!]4IP]FNJ/4A-^,[]R]2VV'[D@F'W,3 MT9OYSXG0L68[=!0DDH1#I&]"&PO=V]R:W-
H965TH/VVNI9GY'4M.*^2*"@X2BZEW.AK/8VOO##Y3W*J],5@E*R'N[.1]/O4" MZQ RS+1E(*:[QSDR9HF,&]];3J\[T@+WQSOV&X0O,#'SDX-& .U$7[,CQ10/!5J %
MG%-.>$8)@UM--)I7H7OCW=#%_73V@8_5AF0X]#[&G'P7AZA!< YA*4F.0'C^>];!@JJ,"55+A*]+?- P8R*[^]87 MG<$C^P5=7BW/(![# C6A#$0!PGD@]SQ8$68N!X$J(
H*P4RE4V,PN80NETQ6 M8+4RH#8S8I<>K91]H@,8O3EV;0*GEL71FLH+N:A7NJC9(_,7(_, 7NZZI= F M/0[@)+)-#'TW^G\#L*>[46R:\ G9B6V-W=_+CAT/].6>OU?
N*I1K]PLHR$3- M=5/YNM7NHSEU]=7_9=[\4A=$KBE7P+ PT.#H];$'LJG\S42+C2N>*Z%-*7;# MTGR6**V!V2^$2>EV8@_HOM_T)U!+ P04 " "H,CM94;LCZ(4" !V!0 M&0
'AL+W=OJ0DDG2Z5+9FFI5Z&I-++<)Y4BC*-H%):, MRR"=^+VY3B>JMH)+G&LP=5DR_3I#H=;3H!]L-^[YJK!N(TPG%5OA]J?U5S3
M*NQ0UV9F#4[)0ZLDMON;3('*$4&!F'0*C MSPM>HA .B&@\MYA!5](E[LZWZ#=>.VE9,(.72OSFN2VFP5D .2Y9+>R]6G_! M5L_0X65*&#_"NHD=)@%DM;&J;).)0S
73%I@,G]K#EQQDPEE:HWPYQ$W%F9"94]_M]XDX6&:_B+L?C].DMO'F1;IE> M<6E X))2H]//PP!TX_)F857EG;50EGSJIP4]C*A=)TO%?UX[<(5Z)[:]!]0 M2P,$% @ J#
([6=UZ@*P; P [P8 !D !X;"]W;W)K&UL?55-<]LX#/TK&+6SIVWDV-DV/ZWX[4]8Z=?Z;1IIDFWAYT]T!)D ML:$(E83BN+]^04I1G<;UQ2;
(AX<'@H!F6W*WOD1DN*^,]?.D9*ZG:>JS$BOE M3ZA&*R<%N4JQF&Z3^MJARJ-39=+A8#!)*Z5MLIC%O2NWF%'#1EN\ET-0[X M"/A'X];OK2%DLB:Z#<9%/D\&01
:S#@P*/F[PW,T)A")C.\=9]*'#([[ZP?V M-S%WR66M/)Z3^:IS+N?)RP1R+%1C^#-MWV&7SUG@R\CX^ O;%GMVED#6>*:J M7@-
P[#SF$8=;>!HLI7BM5BYF@++J"%+2QBJM%;Q&D; MBG+-3DZU^/'BDAAA B_@PK*R&[TV"$OOD?TL9>$/J#3KN%8MU_W7!/X2)9+ M#Z]MCOEC_U1T]>*&#^)6PZ.$[QM[
J/!GS <#,='^$9]LJ/(-SJ2K *.M MLIE6!JY9,IKE>$\D8;PZ.XP6?SQ['0R^/N(V'$O=GR, M??&6*-]J8T#9_&EUX)7VF2'?.(1_;_">864HN_WO4!9'XQS.XO+3S6N83.&F
M1"C(2.MJNP%6(L!W#:Q_(+ <9U35Y'7L,2I_U2J6J7*AWVI)?:UG#XVX:TC M[^%<.;<+<985-99AF65-U1@I4!ZV'.L?*H:YE&'U*_AK[+^ O$,GXP0^Z +A
MBU6MHQP\5;:Z7(*G@K=*;O$Y3$9C^7W1K6RJX(98WLA3QU^QX9H>D:$MY8'% MAP6UHV\R@T![80K61J[9Q[*J_:QBL=>X$1");[S16YQ
M#R6,I2IDB,*AYYWN#:$*W2:.6B]D4IUV'O6[_31?MD/L)[S]%'Q43F[!@\%" M7 &PO=V]R:W-H965T.0 *T98!4:*MU6CM4VNUAVH,)!UAU[,QV"OSW M.SLA95(:3=-

>]I+X[/L^WR_?#;=*/YD-HH5=*J09!1MKLT$8FF2#*3,ME:&D MDY72*;,DZG5H,HULZ4&I"*-VNQ^FC,M@//1[,ST>JMP*+G&FP>1IRO1^@D)M
M1T$G.&S<_7&NHUP/,S8&N=H'[.9)BFL6)8\16FXDJ!Q-0HN.H-IU^E[A:\< MM^9H#VA6ZO%T"2&ZO2$DP6 MI%P6?[8KXW $.&N_ HA*0/2G@+@$Q-
[1PC+OUB6S;#S4:@O::1.;6_C8>#1Y MPZ7+XMQJ.N6$L^,[91%.X3U\YFS!!;=[H-* JS03:H\(/JT&'C,*^3U:KI%2 M:(>AI;L=0YB4]TR*>Z)7[NG#K9)V8^!*+G%9@Y\VXSM1 T%
(3E>>1P?/)U$C MXZ=,?#XP9SXBH1L>>+&Q)AP"JXYI+)A#,!<\NL M#[>IBW=!UZVGFTV]_J//U'Y']YGFW\KS;Q#Y^ M*2N8H,05IWK[_H
[$H5*GG[4.=_(6&_OW9>'*S@=P(W1# 4'P194Z(*1K?@S M)PL,9&SOS5 K,/B,FO* ;A-R5_Y+;E)N#"6&SID$/+P1HO$*%C6]4.;;$ZD4 MYYZ02TA06^;^7"=Y:JSC-
BV8Y=KDC%0H_.RM76ZT#GOQR=N83>:;C!\!U2O M6-7KR2L'!*I+[]^&Z_R_"M=9*X[?.M$%PGTBZ/2@KD+#HX:9HE[[.6(@4;FT
M1>^L=JM1=>$[=/BB7LRY6Z;77!H0N")HNW5*DT$7LZ,0K,I\^UTH2\W<+S NJ ;X^!=02P,$% @ J#([6:Z)+JQ8 P H D !D M !X;"]W;W)K&UL[59-;^,V$/TK RVP:('4DF4G
M:V1M XFSB[K ID&2MH>B!UH:2VPH4B5'=MQ?WR$EJR[J58NBAQYZL,R/>8_S M9H8?\[VQ+ZY$)'BME':+J"2JK^/89256PHU,C9IGML96@KAKB]C5%D4>0)6*
MTR2YBBLA=;2"4;8UY\9YTOHL0[MA HS\@R"_W:X0J4\$;OQ2\<9]4MZX&G[R/XQ:&VE],(LL:1J3HP>U!)W?Z+URX.)X!9\AE V@'2 MOPN8=(!)$-IZ%F3="1++N35[L-
Z:V7PCQ":@68W4/HM/9'E6,HZ6]X809O 5 MK$Q52>+\D .A<^YKDKI G4ET\YAX+8^(LX[WMN5-/\-[!9^8H'3P0>>8G\&O MAO'C=(
@9I&]TO2H]#8=9/RFT2.8)!>0)NGTG$/#\#O,&#X.\,F .Y,^\)/ M-QD(O ,R\%%JP4$6"IY($(8,G(MW2S<]3^S0[O#:/GVS?@J M>7].Z[]$]@?ETU[Y=(A].5AI<"==IHQK+,*/S_A*
<*M,]O+3N8@,+G->Q/VW MSQ]@=@T"'LU!*#J06S[>@O>-":IBC#)'-> *]36Y,AY@ZV MUE3@A&(\0W@X;S*.U+Z468_@=2S)3-;"K[LYP)[79>O""A]5/MS!2Q:6(3[$ M.>
[XO*Z]RA'81UVQ^YN/>QY%MWKZ9 MI>-W[[EH:H[*3J@1G"OM?UH5X^3_LO")Y$_:E\6?\]Q.]\W_0M[;4R@^N00K MM$5X&_@\-)K:^[?[9\?-
^'6C7\W;]\NGX0MI':@<,O09/3N,@+;O@?:#IDZ M7*D;0WQ!AV;)3RBTWH#GMX9/]Z[C%^@?9D@I:?;7[_.2U.%8 M]F8Z>P&
["&)+/%Z^]T6_>E#ZBUD)4;*OZ[PPKX]69;DY/SLSZ4JLN1FHC2@P MLU!ZS4N\ZN69V6C!,[MIG9]%P^'D;,UE<73QRHY]U!>O5%7FLA ?-3/5>LWU MXY7(UB,%(53(O%ZZ/+
M\/QZ1.OM@I^D>#"=9T:4S)7Z0B_OLM='0T)(Y"(M"0+'U[VX%GE.@(#&KQ[F M47,D;>P^U]#?6MI!RYP;<:WRGV56KEX?)4Y>4G]?!'X>D9$[Q4Y<9^ ML@>W-
AX>L;0RI5K[SF":5@,:/5C>V-V@1A8DQ;M28U9B7WGQ096"S=@IN_FUDN7CJ[,20&GJ M+/4 KAR : ^ "7NOBG)EV$V1B:QG__7A_6%T , 9J&E(BFJ2KJ*#$/]4%0,6
M#P,6#:-1'T*'M[\1*;:'=GM\ )VXX7!LX<4'.&Q8J=A;6? BE3QG=R4O!4RA M-'W\=N!&_>#(JL_-AJ?B]1',U@A]+XXN?O@NG Q?]M'Z3P*V1?FHH7QT"/J%
M4RGVE_B:\FN!]*/XX?;S#9N=,SY@=RN.879;L,MJ"7MAT1,>-P;.>D,54[[DG >*K6:_@V6'WZA47!:#H,AD/[ST:S8#9* M@FDX9'="2ZR_9!_A\H36@'1G=\3M\M-
ZU=7.JF;J>FZ8OE;K#2\>?_@NB<+I2\,>W%[G MN4DQ$(/LPAWYG'=8U9SXL_7(0/7R7F@$&';S5>A4&@$J9"IVYS\)BF*$WI_E M0K#;JC0E+S(:*@82(\7%:(7"SV-X$
R"2;3*3MFT6 XQ<=HTB+A!;>IM*F(M%IAU5G MX;9NUIM=/#K:LEA@$*4:S M,)A,(L?)"9L,0N+J:8/MDB0 9$[]7R_<;<)W@(X'DZD%2D9@;?B4,HF,S!?9
ME>&6M^(K/0ND.CFGZJRB-1*_X>4;+IZ'C/''1@=[DE_;B0N?UXBKZ=V/%O MYVY\2RGZC+8)??"$ $U]CW*X;!ZMH;\@81P^H;D_)9+[47\016G/[FC>B7L MZ$S@H))D OX/!^-
AKUSK,8_WBS"9!M-XQDZP!5+L.V>;91-L"$=3>P:LO]?M M9P/VGA>@AN)XPQLRVHT&8Z-ZW0)9*HO&W[-XXF7ZGNMT53N<
3ANS)&WT98#PI+D9I"M>.QIS'99DVO$&@!YOH2GV_- M*L*P/ZT(I_90,!QC=V)3.KWTR+KAMV*N7329U-;:':5W-[HE3+Q_4/=;X.)! M7T;2,V05HXY>> >W#J9">_()N6RN+1$+
W/^H9(G'L6>^9U!EOASM/ MSTN?GI]:_:Z4:_LM'@?Q9!8D2 VB8#R.@NEHM#\5.SV4@77RM,YC. K&TR1(MXOA0BA8BNTB"$*9Z^@]XC73-%N5DJ"5'^6]CD&= $[IVF9"J
B?"26 $(0'^ M>:5RI ?&!P5VKZQ[TAXXC)DBAWVU;H;K4J9R0VX%_L*>\@3"&N4J0,#Q;NVT M2TDC&>]XBXU63*.VI7)=8@M@7JFB:H6HV1MID"[,*^>$7R!"H9*'R6>TN"^L
M7<.9R85,"4?0_ZY(E=XH;2/W"46X-:R*>+1IV.^YM9<[_S-L(2LGUNQ5402< M+P&M!NYTRH8_NB"Y8!G2S4P46TT*C#2AT=6RC4R@D7IZX_, MZQZQPV8P>#95C061319!
T7CVQ=5GC]"S61FV8>5]GLY3L4<['G MKJU)S!^==MIZEI"'_4EBAQ5,F]UTD<$>6KHE:5KVPE3S7T1:NC3KD?'L%\1C MV_&A@RGO088&0=5VN&UW;X21RX(]LSW$=S+
<:/BRF3\ QRX-7Y[4BKR#,TC* M02RJ6&Y8^/>1-.Z MC&J>H_:3UN6YYZ;"[A;?9 $8M[U@5%I+PS$](Z4,8WKN&,JN?WNVH>QN_;^A_#L,98?O+J!N6\OU_ZWEMUF+!G0B
M$2RC;D!]P-.MG\2RRAW4RYJ,;5 V-^#8DHGLY*4-PHU"ERN^'1;ML5"E%&K: MANGK-B]A+USH!2Z!C7ZJ*I$YK&7I$P?HW@.W#0Z>(EH:V:0:D*"B&ZTYM8"\
M(.W@XNDA38;DTI, J9I>"AU8] A+,E8VKR [X$E"FLO"ITUS@5<;V9TR:!>C M.60-:%:Z+7N<5 1IKF/GG;_O3
MZ>QEVXVS*HCDB(7L&&6F+7!8W*Q[STO"X?'LAJIQQUF2B$NG).4.ME3$4:%] MJ,^Z:L_Z6#<8G(VTN2ITU_W;L>$5]Q- AZZIE8MYQY$90B%%Z M7RM.Q\7#<<[+UD=#?
>^YEJHRG4QN+LH'(9ZB4?<=)O7 5J'>MAJF=?5-) 6[M/8B!WY10;^%P4_GY5?Y_J#\/&P &,2KD8S:E]M]PD(P/=N>=^[5^\XE,* #N M5'@P?
4"Q=MP'\S6UXIWI64,03/G2932Y="G8^A1-H6V!>E:,!=4.;_DIS MXNUVES#V'=9NJW!Q^"+D78&-,&5G;TE7K6&'N0=6U@;I%R!.V7'K^NCRBQK7 M][9Q#2($I7_UI0IP):?
%H#MR;7O_KE?0I&RV6; /77;]GGNI_F[B^=YQ>XW4>7S.C=)I[XW2\Z+/;[QD8M]RRP0_'XV# M9!P[A[M[R]2*:SC&?: 'F%PK.U[_0
@UZT/PQX4BXZUDR5/HB^Y_WZ4[+@9YACWT*>A+[$E MD1_Y423-+/?6/?H2D>!0:>-724E47Z6ISTNLA)_8&@V?%-95@GCI=JFO'0H9
ME2J=9M/I95H)99+U,NYMW'II&]+*X,:!;ZI*N.=KU':_2F;)<>.CVI44-M+U MLA8[?$#ZK=XX7J4]BE05&J^L 8?%*GD[N[I9!/DH\+O"O3]YA\!D:^UC6/PL M5\DT.(0:(-
:!R!VX^\.,^E-!L73]R/ZN\B=N6R%QQNK/RM)Y2IY MDX#$0C2:/MK]3]CQ>17P>+)5I\P>5,JT3W'HXG"B\&9Z M1B'K%+*7*LP[A7DDVGH6:=T*$NNELWMP09K1PDN,3=1F-
LJ$6WP@QZ>*]6A] M;PEA-H4?X%IXE8,P$FZ5;@@EW',2O;?>PP8=/)3"X3(EMADTT[S#OV[QLS/X ME_#!&BH]W!F)30N/HM MYJP^B^KS$7?F_07,(]Y\Y
(\D(5WR@B3*Z'A@00A5PKYH7BW<(MAN%#T5[X6 M.:X2KFJ/[@F3]???S2ZG/PYQ_4I@_V*^Z)DOQM#7=\(9978GZ05_?,(#P;6V M^>.?0]S' >]__73'N7S5I;+A]-4A?
6O&SVU5<=?PT8SR85W')-\^@U1/2K(G M7S0$D5/;AL168[B;TFJ)SH,M>B!B'X,RE0C[V"P83#RAX]X'IJFV;)3%H\'_M*G(_]<2U%JS*QH5' &)/E943^/QU
3NV(C9.97+=2(8X@\1TM\A;AASWV$9H M_$V^(C/.=GR$);VI#&*>#]TXKUP3G ?F,] M!TC^Q=^#V!>@Y,3@:V)NE9 Q10?S\#0V9Y@5:M>$?1X((H97!^ 6B7V+C(WN
M8JAYC%;C&PO=V]R:W-H965T:R<-!:410KRT_KCG^)YC7SO3 MM=)/ID2TL*F$-+.@M+:>A*')2ZR8.58U2H9*ETQ2UV]"DVMD14>5(DPB:+3 ML&)[@3N^*JT;".?3FJWP'NWG
M^E93+^Q9"EZA-%Q)T+B!_PA>/:[+7!*7E4ZLEU/A2S('()H<#< M.@9&?\^X0"$<$:7QH^,,^B4=<+^]8W_GM9.61V9PH<177MAR%IP'4."2-<+> MJ?5[[/2<.+Y<">-
8=W&GM"*>6.LJCHP]2LNVW^VZ7S8 YQ'!P!)!TC^%I!V M@-0+;3/SLJZ89?.I5FO0+IK87,-[X]&DADNWB=6TRPGG)W?*(L0Q_ :[E P MBP7<,FVW*"9-,Q;;:::AI95RP&(
OQC'Q\D(M04@2>YW)3N=E,LKXL9''D$9'D$1)-I30./P*>+QVQW8!5 M\(Y+)G/.!-Q;LI_JPP[ZW=)EPW2NU">F9CG. JIE@_H9@_FK%_%I]&9(ZW\B
M^TUYUBO/QMCGAX\97'&3"V4:C?#M 3<6+H7*G[X/V3&ZQK""FT\/;^FD3^#" M@%J"+1%JU%P5@.Z, 9T0[$](N]$3D,K" T4N5%4SN04N\T9KBGX99Q$P28TD MRVB8*)
<\1VU>O3A/XK,WD),BNDJX7,$2::\UYDJ[=2AVA1(U;;G#LX*JFANK MF;_6<$/WLZ%XNJ!]CK;4B&#XYL\$AR?2(QC:\7_VBSRX:K13X9+9(M.=7501 M6#VBWE5%
<@1G>]:.1*9M?&ON2\G%7G?8ZR1)6J^S)/IGKP_X3&T'5X(7_ER: MO@R=%'HM6\"O#7'*S"%IG1.'QC])N&9;Z'V@_L=&;.%\-Q#'QRNX43!4:.'>
M+5^A7OG'SU#VC;3MA=^/]N_KA7]6PE_A[>-\S?2*DR:!2X)&QVCVP6L[M5M7^S7A4EEX@WRSI&P&U"Z#YI:(+K.NX!?JOCOE/4$L#!!0 (*@R.UD_ M]$)*VP(+D' 9
>&PO=V]R:W-H965T>(I$BJOY7J4>>(!G9E(?3 RXU9]7Q?ISF63)_*%0I:64A5,D.J6OIZ MI9!E#E06?A0$7;]D7'C#OIN;J&%?KDW!!4X4Z'59,O4TPD)N!U[H/4\\\&5N
M[(0_[*_8$J=HOJTFBC2_8[#=\Y;O6>#-:3N92/ M5OF2#;S &H0%IL8R,/IM<(Q%88G(C-\UI]<<:8'[\C/[C?.=?)DSC6-9_."9 MR0?>N0<9+MBZ,]R^QEK?SJ6+Y6%=B-LJ[W)A0?
I6AM9UF"RH.2B^K-='8<] MP'EP !#5@.BM@+@&Q,[1RC+GUA4S;-A7<@O*[B8V*[C8.#1YPX6]Q:E1M,H) M9X9WTB"$$9S VY0K+'O&Z*UBWY:4XPJBN@
11=NI3"YAFN18=:"'Q_'T^F' M"7SRIW$J>G9J%!UE_+H6IQ ''R$*HJ3-H./P*TP)'CIX?,2?),?9AG5.P4+*$,5VRHK*E##PE#+3 MP$0&]BR>TL5.*P'>0QC0D'1"&J/(B5V824/W?
6"-4T4O+:W"5"X%=YW-J57< M)I(+ UR HJ>B@JQ4"OV M@.:U'OX!4$L#!!0 (*@R.UGKQS&Q9 ,)4(9 >&PO=V]R:W-H M965TJT:U#>)L M>QCV0$O7%A%)U$@J=O?
K=TG)JKD\TX-#V*?&]O@+^\]FJ]B.=P-^%GC09V6P2K92/MG*QVSA!38@+# UEH'3ZQE76!26 MB,+XO>/T^BDM\+Q\8O_@M).6+=>XDL4O(C/YPKOQ(,,=;PKS(_?8Z=G;/E2
M66CWA$,[-IEZD#;:R+(#4P2EJ-HW/W8^G %N@A< 80<(_RT@Z@"1$]I&YF2M MN>'+N9('4'8TL=F"\\:A28VH["INC*)>03BS_"P- HO@.WA C5RE.? J@S4^ MTP+7M%P&
[HZ4,AKUW#!7E_LO#@ MD]})>;GB2>QM>9/RAJ:XA"JX@#,)X**#+\#6F!&<.'ET()^K=CQQ?=,%]#4;" M!U'Q*A6\@(WA!JWO@WZW=/$PG=WQ,UWS%!<>;6F-ZAF]Y=LW+
G>#6G]G\C^ MHCSNE<>7V)>G;+LZ3[4KEWLK6=:-004;N3,'KA#60J>%U T5?WW$HX';0J9/ MOPT9=''684V?OSS>T1:8P6.N$*%L,PYMQ@'E"[I\V8CC"STVDUP^G)4VO* C
MT:G!LB[D5^+=8H4[832,(&0!/5DRH6<<1[9E')/N2M/APVGI'5(WVY1F5'32 M2:5A$@";P&0"Q+]&"I_2I3T):2POI3+BC[8AIMUL_RN2+U+**:,HLS2U,-O, MIOV6IHHT.5F=),"
L3&0@FA,,TVGD$13B,(?D2MX>V;FY"Q=[!7+CZ:'>GX MS8B@_3U*0Q.-''CDX"-','(40]GWGU=J/"/]*99;BCMBO?7A:ZZ/0^OW-'[5 M:0J>C<-73'9F_MWA")+@G^8R.L=8.(5)3!Y?
A43_JJ4G.RUDU(&&=IU_=O*7 MJ/;N0M20RJ8R[270M_9W[GMWU?C?AK<7]B>N]J+24.".H,'U9.R!:B_!MF)D M[>Z1K31T*[EB3M\-J.P ZM]).LVZBIV@_Q)9_@E02P,$% @ J#
([68]- MXBCK @ A < !D !X;"]W;W)K&ULK57?;],P M$/Y73@'Q!$OBBI.E.6VDK-@1E&(13"CYHFDR6X6VQCERXJ.LT9KD8:FZS0E-/2.WQD3;DA@CA3?KBUHELD&JX,XCBH4SJ%8C9L7%ICGLFG]BGJLC6XR^+V\PD1VZ4HE5SF*7LE]#LVKDJ7]A$E5QD3Z1=A0#1*Q]&DIL5.3T>!$01CDEQ
[G_#O50;G2$:.)2%T",O,V8[\'V=9EAR?2:W*&AE)57)#0W5VM=; MA7SI0&7ALR!(_)+GPAL/W=Q4C8=R9XI<>(A7V?& M3OCCX9:O<8;FTW:J:.0W+,N\1*%S*4#A:N1=AH.KV-
H[@\\Y[O5)'ZR2A90; M._BP''F!=0@+3(UEX/1[Q"LL"DM$;GRO.;UF2PL\[1_9WSGMI&7!-5[)XDN^ M--G(._=@B2N^*\R#W+_'6D_/\J6RT*Z%?64;QQZD.VUD68/)@S(7U9\?ZCB<
M_,Z#9P"L!K"_!40U(')"*\^N$=3)^W(DSB(+7P (6MSG4#;_&E."A M@T<=[D1-Z"/"%W6$7H.1\"X77*0Y+V!FN$&Z(Z8UWA5=W$YGK_M ;WF*(X_N MLT;UB-[XU8LP"=ZV:?
U/9+\HCQOE<1?[N#O5X.L<#P8FA4PWW]KBT$G>[OK= M_?R&TGP \TPA0EDE%MK$ DH+=&DQRP_/K-B$<<=^TIOQ@LJ>TX#EMI!/Q+M M@:O<:'@)8?_"MDE
;13WJ67G%S!5,VKGBCU@ 8Y! MG$ 8P+W)4$%$M[-/WUP:0A'11>0V"*GM$9(V"&)H.^1_CE0R $IW+!=V^["1 MSOZD.@FM4W'$6I0FP/J-QA!Z82TOM/7GJ"V);-
AZ['<]59[Y)X6N1+5V]5]# M*G?"5#6OF6V>F$M76?V?YM7[1'FWSH6& E<$#<[Z/0]45?.K@9%;5S87TE 1 M=MV,GDE4UH#65Y+N;SVP&S0/[_@'4$L#!!0 (*@R.UGB 4(/,0, ,(
M 9 >&PO=V]R:W-H965T7LZ/2CZ9$M'!J:FGF06GM?AJ&)B^Q$>9:[5'2RE;I1E@:ZEUH]AI%X4%- M'?+1* T;4AN[_7[#YPJ/YJP/3LE&J4%?, M@Y$+"&O,K6,0]'G"6ZQK1T1A_-
%Q!OV1#GC>?V9_X[63EHTP>*OJ+U5ARWDP M":# K3C4]D$=WV*G)W%\N:J-;^'8[HVS /*#L:KIP!1!4\GV*TZ=#V> R>@% M .\ _-\"H@X0>:%M9%
[6:V'%8J;5$;3;36RNX[WQ:%)32?<75U;3:D4XN_BH M+)+X"?X!25J48.0!=P4=%1EK!;>Z[L3)8U!,PLM'>F 8=[1+UMZ_@)]"A^4 MM*6!.UE@,8"_O8QG_)!2%I[P?Q9\))?9'Q_D-
<0C:Z CW@\%-!E^&O,""#;[M6GTEW@VIVU;6P"M@<>1;3BU/&;41R^!>JRT:5PS)@RV2V)B-@4TBF' ./$[A M@5+ D[IB;-&E!T(,400H FLM7C"&O#9*PJ$;DO$@"?
PR9:H(F<5Y#RU 6092ZD*Y:Y<-(LA:'L^,_NCJ=]P2;C0N"]7;Q?W(J8CH M>IP$H-LGIQU8M?=5>Z,LO0&^6](KC=IMH/6MHLK1#=P!_;N_^ 902P,$% M @ J#([69GK\Z(- P -@@
!D !X;"]W;W)K&ULM59M;],P$/XKIX#X#X-)JWKHS21EJ[3H#4K=H&?$!\<)-+$Y;8Q7;:[M]S M=EY66%\ZV@IYKS)$#NRX&KL9%JOAZZKKX@Q+IGIBC9R^
MI$*63),H5ZY:2V2)!96%&WC>P"U9SIUH9'4+&8U$I8N2)+=C2?(2NE >ZO6_9+&SO% MLF0*IZ+XDB?UFN^8<]@!GWC. H $$?PH(&T!H
ZT]LV%=,,VBD11;D,::V,S"GHU%4S0Y M-UF\U9*^YH33T970"/X 7L-MM53XHT*N8;:AIQJYFC8P9F[9@AE/,#F GQ['^\$1 IB=0. %_4,.'8=?8$QP MW\+#(^Z$W6F'EB\\YZR
6\TTEL^==TW7/TQG;OA0K5F,8X>N ML$*Y02=Z]<(?>.\.Q?J/R'Z)O-]%WC_&'CVI+OAZASL-DT+$]]\.A7Z4[["W M5]=W,RKF(=QE2'VIVQ'K'9>F9P&32!?
HNY"MFE9:,JZ8;2R4GHQI$'%<28D) ML%0C&1C"? =43]C5TPF)Q0/4Y=&'\VI%]Q7\?BT/X9JWNK,6\#+PWK;*(*RU M/9BE*=IVUG$$+< 4W@G,4:[(BT?"1X-
649.%3PU\6,A\0T4&BX+.RY2:(;*N M!X/?:3K8H0+ZVY0$_G]*R1IE+A) TRV +BN62_K27EC*#^,5S:8N17-&,0=[M^>D,NKBOQ*9F\4]KEIZQN\2EM(9!ETI!E=#^="81X=
UJ',F5SD=1H$I0;W>FU,'9#VE:D&+M6WT2Z%I;-AE M1H,=I3&@[ZF@]M,(9H/NKT+T$U!+ P04 " "H,CM94!\A# ,% #+#P M&0 'AL+W=O9O# MF>&90_%H;>R#*Q
]/)5*N^.H\+XZB&.7%5@BD;MJ%1Q6J60]2HB!R4A>@\&^$GN6UN&%LTBC1M3S/86BF.HC.KQSN%SZ$,XPC6KRH&W;R@!6K+(EIB ((&[Z)I)4!*U.SKN_2N@6ZE*4\@B%<_^-
*HCD\+WH5DB*E$@XAJK>,4KFD-(,&Q/CO]G/:X`?K(#]L@R.G]EGE1M-GCNC8HF.:HH9U@AG@RN$5#T@M!LMKKO@P(>+E38#2GL*X_^@](PQ=-VYG?&%2#U'G_&AB^C?QK[0"X=AQKWWC\9'D=0MRYZRW:[YW@*F28#U$X9M3%;<$9:V2;MCV(*(-OL=UB-2SYB8:D*'%1T59QP#V^HO:P'D$`_@HZWXJ9#0Q?P_0@=#,*Z@1V@^0I2==%:H7G67TZUT27Y\LWQA!3VI$Y71J\5)0@"@@`)B\/F6]7$R2,3B@WZR.L@6*Z!T>/`5=8=9NS4(\.U_I]C6+;SLQ;'S.L__Y5(*&R>D<1YNNJ6/=-(9)9EZUR+Y5V1]!9O$#D6&E#A0$[@+VX7/A^!)M"MO$@R1Z@!>%+'N(2K[LF,K&]FU*/`LW;R(J.@DQ@I4]K:W%3]#]FO&L!MR(T;GU5\#LN!%6@(6=.%\Q@=.NH<%`J)55B3W*:M6$%[9"VAHJ7DC3`Z4CQGE5X6KMJP<"58:00>#G4B$%M`6%-X\`=:Z@%"P0%=AJ6NN"`JI`D`$U:-RF\"\6A::#Y8I7J]W8&-,M(O@J#!4`ELM94@.DW6UAAJ5B#)1NI0;F\%E<2FNQI<>[T<=?A#9LM)ZW(S*`-G1D4+H%%J?*.V5NKU+N(%X>N-[*%;SV-^`P&/$TG3CNVW\+3#2TVTW7%I$/I\B.>_G_>R`BZ+V>+_*M-#'5/AX,?I\&%!0.=$%$E%A\FCM-PBZVT1GJ]B!IBN\TI?:%>YBTN>T8XK/?>GS$P.G3O07&#O.-UVH#]@%6/_'O>EO$`U#!0X0)!7KT!BR.3TPQ?8)GPE`AI_BT.+DK(&E"4$J6S@5KJ+_1M7'MLBAO%WJ#=N%H7.D?CQ(0X,DS^V^5/J%2E%V='#4P<%[L.'IC04FT@C&@JV0/EM:+6@#D2%>9Y`+)WC#8&%?EA^Y+&``G##<&@EZBP;AA`0<,Q,0A4`Y;NXA?D]@,\A96F%K$]+C9HK_$P1-`J9]2Q.:I\HB-]HR0"JP2L/`?(%\8&)L6<_6;$!/-6GJ3;A?;R.MA!_L>H'X2]M:7HZF0X:?A+N!DPT8\WS%)E\R)^2L!Z%YH]Q)RO>H6EHQ]S$+Y@U>D=ACF*3S`IKW7@-Q_+R5AAHW'LN_@H0.HH`70Q6:#C2]S!/TVT$&@+7?3_ZG$J\I]'MKWPI_,H6%@J[YPP(]P_44,'V[5A:XUPQ`GQUU`#4/%_(8UQ'#[(OT+'("$\@YJJ&Q.MP@JS(M[('3C`'^2+@7I'4`%4(EG2VA`J(KN6&L7[,(U@0E-Y%=6SI</-?AIOPSV)`QU-\]1M,`PB(3=`W/.]*R,ZDV@DGJCFL`P!*Q-#%]RWP8JCD@:&@.SO<$%Y%2W!]KA'R\1Y[]5M/]@ZEHPTHC^\H*C`(`:Z$2@3%51(&-;A&[&6VQ+1F<5\`1!/B#X"RJDKJRD5DN%B@DC&#)`7DKRJWZ\5]0IW1G^DA6VNHBC7`RC7U8JIA!IKZ\=&0%6M($!-/B6JYS5]@\O1C^DXJW<</DQ?8(,8A0N+AUG@![N:4JT`-_O"!@%`^#/;QQ5G%=*U#B<\5V$%P4D]E7@ST7QF[V@ST4P4`LU[^;_>K4`#ZZ`MD<%;Y]*7-VR2QG>V<=*L+V0FGZE`U$NPPR(0-E1HO:BQQQ3#OV1:MV&<\WYVQ/Y`!'NA'6L%]Y$ZYRJXZ/[8P,*+*(W>?+%D9V?!9SB5&4*LJ+T#_`&B@[!:D3VZB]F@)UUBFSK%AIDJGV@UZL[ELLQ:E6/0`H<4SVT/VH9`R/WZ</Q6^0W,?G_.&P$`P+7>)_8#J!)2+6%XWAP.'C_J(8O/\HD`)`EJ_W&<1\O>9:5V5LDRCT+9HP%CSAJ@8[@F1GK/W2%;GOA,_PL$P#J`0,</CA<_DT<#:O,NVZ?UU[+(1E5+Y&#(\(,L2NB2%MM=M+HXL_^/IK/@PWC3S0_\@.E\V_#1Y=\UHG\I=VC2.UWA7/U`Q+3JA`Y<8MNQ6Y[SZ<Z&E9'WZCYDLY`.?U;7R[BQ`%>RAN8+8SRB6O%\!%Y>9JNVQ,R,\.9U]HKBTK8F<]U#ZQ@R/UE`;FN?;6&TG0\IO`O/)HO]XLQ&&\JJD1SHZ`!CKZZ`.7UDOK72OW`E+0^&R`7I`\U<4JWZE7T)W7XH$5:Y9N&KDSTS6Z$L_6`R8"+\AYSJPP`\PHNT<1>[E@)`9ZT`\!<[E]#N7AV=W``Y0T=Z@<;G`.\0=2A3T_C)AN9;1DN4;`=6?@C6%40,WEH+Z]L@W*>*5MQ<O#M@X!6TXC[B>XG4Y2F6@L#B9D[L5^T`2ZB5H'S)J6U`2:'D^__YA1M`_L`E9ZX\(L\67E]D)J:L`(6Z$Y-YCH#3:=!%Z7-7%.NQ^G4S@#J3Y=MV+D+1ZF_MQ=H2&#R6@P'W+K(4P*@)+@?\`-U!=`K!NJ=YQE$;5KXH.U3Y^P\!PJG(5+:%S%6L,#B\G>Z7'\'QD?R4=Z>K4S[DQK0`@_(5J=QG`K9U2Z*%B2=FMC1`K^N<SB^0_<&BH@XU+$@!B.(CE7_(R8,^=2D`BZ&/KP<L,^.\C<[T*)T!@=QE@0K/Z'T/Z`_CHV7P.N]D[_CYNBU/[M!6B>F8@H$WB5S<H]@5P$!!`X$Y%/AAQ=T*W#O=07B4#P>H]9R7K]AY.V/M.L`_CE5A%#4!(&Z)N`^0HP;)!<`1O]JL9QK]BEM>2!EF@XNNMS@]CEUM:E^(H/JC/=;/N[DEP3(QT3C9:8OEU@AUBOF?6T>OR-5;Q@'JO$BIC2P<`O(\AT/X9+X1LM?VO`9O&(]WQI)GJ6%DXF`'HIUI'+9\[B@U=!S?Q:/%PS5&N/E?5V=9C4B3H)C57B+O`(`@XB"J*'&N@X9FD'%R6[%O:)D4/Y>\]@XHAHPJ\7GEGZ<DWNU&&`%C5_]$R!GDM0:?`WS7+<6^TI)F;WG)-GZ:<6@T5M3`:*%6=QUKUBF9B\&`&UXN3P,@8F4;:=0_FUBB'X[*EVYH+7%I9[KE>A;:5;KYQ7&A=V)'(/>F:8%SX>TM2WA6^4M\Q;M+V1UGZ8`E8E!X@\@*S3@=0U7AV`G5AT.VQ2;0H\VX^(R7H[7NA1+H@\V\F>N=ERQ!\*E+@*1%=BP\'RZ,`'>X!<J@GE8JI.\^\G*AF0_2K+W+\L5\O?D[8Y?A_SZC?$VD@@^@2\HK8#(U'N#@%PNQ>=Z_BZ.8RE.+BG$6\A0J\2]@ETIY4=RY3_S:@0MU\J?5KFWO4\<IH.G(JX+J&@9&P@;YQ0\X;/=KOYG3^Y`M:Q@[C=@0TQ2=?U2AR1R=,@!=6VT(0&1&_R.52\CK\+\@OPE@\(LJG,U4\Z=D`AU8W!T5L[MHO+J\@G4QM=*0K#`OJ&4)&>@JK$J&J8^+?F!D`+S+P8&MLZG`U\A8:0/]WVC1VW.W(OG/K1TOE@4=Q?2HZ)ZN)=?$KCT,^6)YDKW9!P7Q3A\`'?QIB*W@\.L?K0Q8`R=[8V3/6CQ_M;^KJLZZ>OYK2=TIBBBC.Y`!Z8RP8HKD`VEKJ<+V:FUG=N`2,FPQ6@

^Z.T4X.&IRF\B>U8O)J/!5SVZ2+W_:3O91M/K*WCQGBBI1];_*$?.K MMR8M/L*RK8AR%86@@O3R$:5LX)8K5>K-K12U"*$H^H=VZPC-7L]QWIH@N6: MA3WHCVL#0U?
%>=.9S5HLR<@N7IW0ISWH:[D3'1D-R._41!&46D4U<2*M56I7 M-U6DUNN^J203 M8E24K(BSKM9*LV9Y2:9ZMW@[65@.196 J/36*VEW2I.436*8T'#[C8BX7:U7
M]^37L5>_9WT&Z06B>N/50FH#.*K?&75H%9K^4,"^BV#10Y-:_9+FM;T5AH8: M2! "RLJAXI,2E$UD(UF66P_87H+4%FU?K*W*-C1,"%'>BLPGR=JE0+E+'\GI M[;WP,MS5YR4
4X[P*QCM"REZ2JI'G1P;M0+M,-]QE@UPU+(14R)('4 MKK$5IUA@)U!/NZ)"L4@YR(S!%F;9H8F^6_.GQ/";+OM'03R%T_)(18P1C>) M2^F*=&.H:%B/FX5>(#M
GBLF($=F%)YD%NF#VUJUKO:IW QIV4%F-9G3[^56 M] 5\W(8-U37=ZZ7)K"AJO9W!7H2L&-UA:6IXD/=2V.;8ND>;P@26=E'GN!N-)R1U:M^1. M5LX-
<:N\3F4VERS,29V,6S=MF6C-$4Z-X$SC([?P%5H,U3?&X<$?@&&28AZ M^SB_U^S'[A=8K=2#^X^P:=OWP6M3Y:9\KYM/Y4&NK1-N;1XW0YE3/E"/*>;E
M;"IY=O<]";\@VIYO,Y*K!JXO>C-0=+T:);;6?_MW)^O6U*>X0)'[24ZH-!]4IP]FNJ/4A-^,[]R]2VV'[D@F'W,3T9OY MSXG0L68[=!0DDH1#I&]"&PO=V]R:W-H965T M;
(2\5R6BAL>*<37U2JW78]]768D544=BC=SL%$)61)NI7/EJ+9'D#E0Q/PJ" MD5\1RKUTXM9N9#H1M6:4XXT$55<5D3]GR,1FZH7>=N&6KDIM%_QTLB8KO$/]
M>7TCSY("]P=;]DOG':C94D4S@7[2G-=3KT3#W(L2,WT MK=B\PU;/L>7+!%.NA4UC.QIYD-5*BZH%&P\JRIN>/+9QV &.C@\8 [<1?RV/'% R%7 MH
5<4$YX1@F#.TTTFK>A55^\&[JDG\X^\[%:DPRGGGG'"N4#>NG+%^$H>-NG M]1^1/5&>=,J3(?;TDR!<'8(+P"$L),D1",][=P2/[!5U=+\XA&<,9:D(9B *$\T#N>+ DS%P. E5
%!2"F7JGQF!R"5TN MF:S :FE ;68D+CU:*;M$>Q"^.7;M"$XMBZ,U]1=R42]U4;,GYONA>0 'VVXA MM$F//3B);9- WXW^WP#LZ&X4FR9Z1O;(ML;N[V4GC@?
Z>Y+HDOQ%GDUJL\1GI6_UH MV8H[E$)6J)TT&BRNIM%5?SP;>O_@\%WBUAVLP6>R-.;%&U^*:91X0J@P)X\@
M^/>*UZB4!V(:OUO,J+O2!QZN]^BW(7?.92D<7AOU0Q943J/+" I&$$9P!E^-7L,";05SK(V3 MY"8Q\07>+8]&/0_ M0IJD@Q-X@R[=0< ;G$C7 1FXE5KH7
H%SR0(N<6,72URG$8L M"8?V%:/LP[O^>?+I!-EA1W9X"CU[H!(M7#F'Y& N7:Z,VUB$GPO<$-\$O4XY_N'Q0V,QDT7D.^"HNT"R
TKT!$68%8L0TUQ2@"V\BW,$OZ&9H]A=02P,$% @ J#([63V,MO@L P M(@< !D !X;"]W;W)K&ULC551<]LV#/XK.*VW MV^Y6RY9=+^?:OK.3MNNMS=(F71]V>Z
DR.)"D1H)17%_?4%*4=W&]?5%(D'@ MPP>)>ML;>N1"2XKY1VJZ@DJA=Q[+(2*^%&ID;-)X6QE2#>VEWL:HLB#T:5 MBI/Q>!Y70NIHO0RR*
[M>FH:4U'AEP355)>Q^B\JTJV@2/0C>RUU)7A"OE[78 MX372A_K*\BX>4')9H7;2:+!8K*+-9+&=>?V@\+?$UAVLP4>2&G/K-Z_S533V MA%!A1AY!\.\.SU$I#\0T_N\QH\&E-SQ&
[41YE3N8K.(LBQ M$(VB]Z;]_MXGGF\S"@7OM!VNK,D@JQQ9*K>F!E44G=_<=_GX<#@;/P=@Z0W M2 +OSE%@>2%(K)?6M&"]-
J/Y10@U6#,YJ7U1KLGRJ60[6E\:0IC#4WBM2>B= M3!7"QCDD![],QG_^NHR)O7C=..L1MQUB\AW$20)OC:;2P0N=8_XU0,ST!H[) M \=M_03).IB?PID/,TX W/1&S
S+P4FJA,RD47),@Y+M&[EC M'=SL.)QOFX6K18:KB/O"H;W#:/WS3Y/Y^/D)LK.![.P4^OIQ72ZDRY1QC47X MYP;O";;*9+?_'B-
^$OHX\MU#L@P01*Q"%Y9XQR<"VOWWM^F,HTFV&194S6* M:Y-[D27Y201WESRNOE7^&#K0:]ZAY8$";V2!\$&+SI /'C/<7F[F8):P=E\ M M.S.7^?]BL="[@QQ-?
CL>&WNCY=7X&A+OENA3L%M37_\10"Z1C)[W:<;DZ/ MSD$<1M5*I2#%'2L9M@U)/K!U3>J8!_&%5?N0?876*X2C0/=3'^YJ=L 9W18H#=@[I'MY-?8EF4/#X](9LT?J/-C]<
M\F0$QUHA/IA;%=I=F,Z.O7,YNQ$V2(<'8-/-O2_JW>OQ5EA.FP.%!9N.1[_ MB\!V$[G;D*G#%$P-\4P-RY*3A-8K\'EA>"KT&^]@>!;7GP%02P,$% @ MJ#([64N2#I4J P 3@< !D
!X;"]W;W)K&UL M?55M;]LV$/XK!PT85F"SWMRDRDP&#L9.@*9K$:++F0]$/M'2VB%"D1I[LY-_O M*,FJLRC^8)D\WCWW/#SR.-
D9^^0*1(+G4FDW#0JBZBP,759@*=S(5*AY96UL M*8BG=A.ZRJ+(FZ!2A4D4G82ED#J831K;TLXFIB8E-2XMN+HLA7V9HS*[:1 ' M>\,WN2G(&\+9I!(;O$?
ZIUI:GH4]2BY+U$X:#1;7T^ \/IN/O7_C\%WBSAV, MP2M9&?/D)]?Y-(@\(528D4<0_+?%!2KE@9C&OQUFT*?T@8?C/?I5HYVUK(3# MA5&/,J=B&GP*(,>UJ!5],
[O/V.GYZ/$RHUSSA5WKFT8!9+4C4W;!S*"4NOT7 MS]T^' 1\>B\@Z0*2AG>;J&%Y(4C,)M;LP'IO1O.#1FH3S>2D]D6Y)\NKDN-H M=FL(X13^@H716[0D5PK!&]TD),;W7F'687[-
G-DZ.(%YB-((W_A"1*TB-X::\V;?#2(VH=D($KJ87.I%!P3X*03QD- M"F[AQL-P_L*\)E@KDSV]'.(ZU&T8:ZW=P^7<'H&CU+GSEA86KGE[8"%J"3QYGRE? 1+ M84FC=86LX]X7"[@
PB=PYV5&P$/.P.?C.':7G]_=9AS MOXW2N9H+CA[M1AR :4,,KQ'2Z! 1#)O\[TUV-MQC19UCM#&+#_%)KSA]E^>ER I01FAN"L2GQ(%8$R\1EZ7C/T3W MUFQ;4Y+N-
Z]5T#1;4[4=,\];!;FTW$3Y?/A$ _3WF)#]?Q!4?@]<,2G MAH\)" =F_:9^Z2^Q0YVNM_:/Q7G;(W^YMR_-C; ; MR3H4KCDT&IU^#,"VW;N=D*F:CKDRQ/VW&1;\X*'U#KR^-
MQ'NHE/T#^AL_\ M4$L#!!0 (*@R.UD%\,PTF (,0% 9 >&PO=V]R:W-H965TLVB=&0J =,(@$I=V0U@[1;OLP[8-)#K#J MV)GM0/OO=W9"1B>*A(CO[;GG?'<>
[95^,EM$"\^YD&8<;*TMAF%HTBWFS+15 M@9(L:Z5S9DG4F] 4&EGF@W(1QE%T%>:,RR 9>=U")R-56L$E+C28,L^9?IFB M4/MQT
D.BB7?;*U3A,FH8!M\0/N]6&B2P@8EXSE*PY4$C>MQ,.D,ISWG[QU^ M<-R;HS.X2E9*/3EAGHV#R!%"@:EU"(P^.[Q&(1P0T?A38P9-2A=X?#Z@W_K: MJ985,WBMQ$^>V>TXZ
>0X9J5PB[5_@O6]5PZO%0)X_]A7_EVHP#2TEB5U\'$ M(.>R^K+G^AZ. OIO!<1U0.QY5XD\RQFS+!EIM0?MO G-'7RI/IK(<>F:\F U M63G%V>1>680^?(
9KE%KS&").Y0ECD)+\,XI3&NH:045OP'5B>%.2;LU<",S MS%X#A,2K(1FN.X.6TTS*#-3(B7%JCC MM+V#SXDPJ>AGCRW>X+/#@AE.F1E<4\T\-<22QN:"9OH">I<1+-OS-
MQQF<%G MKA4>;E:/>^/?#0*I*::LE:[3-$S6I-O.?>_6^W3&] MX=* P#6%1NV/EP'HZLVH!*L*OZ&ULU57?;]HP$/Y73IFVIXY K1E@%1HJW5:.U3:[6':@PD'6'7L
MS'8*_/<[.R%E4AI-TU[VDOCL^S[?+]\-MTH_F0VBA5TJI!D%&VNS01B:9(,I M,RV5H:23E=(ILR3J=6@RC6SI0:D(HW:['Z:,RV \]'LS/1ZJW HN<:;!Y&G*
M]'Z"0FU'02[7]B*4_/<>7*&'\%[:%;J\70)(; MJ](23!:D7!9_MBOC< 0X:[\"B$I]*> N 3$WM'",N_6);-L/-1J"]HI$YM; M^-AX-'G#I,PKY M/5JND5)HAZ&ENQU#F)3W3(I[HE?
NZ<.MDG9CX$HN<5F#GS;C.U$#04A.5YY' M!\\G42/CIURV(&Z?0-2.NG4&-<,O,2%XQ\/C!G/B*A&QYXL;$F' *KCFDLF$ M,P%SRZP/MZF+=T'7K:=SCW]@,I;@**#7;5
_8S!^]Z;3;W^H_4?D?WF>;?R MO-O$/GXI*YB@Q!6G>OO^@#L2A4J>?M0YW\A8;^_=EX_')VYA-YIN M,'P'5*]8U>O)*P<$JDOOWX;K_+*UUDKCM\ZT07"?
2+H]*"N0L.CAIFB7OLY M8B!1N;1%[ZQVJU%UX3MT^*)>S+E;IM=<&A"X(FB[=4J301>SHQ"LRGS[72A+ MS=PO-S1N43L%.E\I>OFEX"ZH!OCX%U!+ P04 "
"H,CM95&1_J5D# "A M"0 &0 'AL+W=O2U5^?V27%JJC"%$4//?0@ M:C_FO9TW,_LQVQG[[I@I=*:3>/2J+Z*HY=5F(EW,C4J'EF8VPEB+NVB%UM
M4>0!5*DX39*+N!)21XM9&+NWBYEI2$F-]Q9<4U7"[F]0F=T\&D>'@0=9E.0' MXL6L%@4^(OU8WUONQ3U++BO43AH-%C?SZ'I\M9QZ^V#PD\2=.VJ#5[(VYMEW
M5OD\2KQ#J# CSR#X;XM+5,H3L1N_=9Q1OZ0"KB4?1@=M]AI^?<\V5&N?"%76M[/HT@:QR9J@.S!Y74[;]XZ>)P!+A, MO@!(.T#Z=P&3#C)0EO/@JQ;06(QLV8'UELSFV^$V
0TJY':9_&1+,]*QM'B MSA#".($WL#15)8D31 Z$SKFO2>H"=2;1S6+BQ3PDSCKBFY8X_0+Q!7QD@M+! M>YUC?@*_';:/TP&"F%7V4M.#U)MTD/'[1H]@DIQ!FJ334PX-
PV\Q8_@XP"<# M[DSZR$\"WV0@\@[(P >I!0=9*'@D01@R<"K>+=WT-)W?[5>N%AG.(][.#NT6 MH\7K5^.+Y-TIK?\2V9^43WOETR'VQ6"EP:UTF3*NL0@_/^$+P8TRV?,OIR(R
MN,QI$7<_/+V'RRL0\&#V0M'^J.YY$ZR<%:@DK+0V6Q$.FNN&2F,E6WX#J]4U M? M/)7I4+?0>I(,L$!#F/IFUV(,-S++-+K%QR"N834=_QH/6-$49)IGS#'B=
MVIH,,7>PL:8")Q3C&<+#>9-QI':ES'H$KV-)9K(6?MWU'G:\+EL75OBH\ND. M7K*P#/$ASG'+!W;M58[@SH0M$ IY!-H0_X!W!_:[[C8L5JC[0M^]#4#>&2/
MO0O>0*LU$:98G]8F;UL2"KY.RTQ69EZ1]YE'7+/^E<][M'T>V>?WJ,AV_?<=%4W-4MD*-X%1I_].J&"?_EX5/)'_2OBS^FN=VNF_^%_+>
MGD+QT2U8H2W"X\#GH='47HC]:/_^N [7;OR'>?MX^2AL(;4#A1N&)J.WYQ'8 M]D'0=LC4X4Y=&^(;.C1+?D.A]08\OS%\NG<=OT#_*EM\!E!+ P04 " "H M,CM9I2]8MQ(, "))P
&0 'AL+W=OD@I:?;7 M[_.2U.%8]F8Z>P&["&)+/%Z^]T6_>E#ZBUD)4;*OZ[PPKX]69;DY/SLSZ4JL MN1FHC2@PLU!ZS4N\ZN69V6C!,
[MIG9]%P^'D;,UE<73QRHY]U!>O5%7FLA ? M-3/5>LWUXY7(UB,%(5 M3(O%ZZ/+\/QZ1.OM@I^D>#"=9T:4S)7Z0B_OLM='0T)(Y"(M"0+'U[VX%GE.
M@(#&KQ[F47,D;>P^U]#?6MI!RYP;<:WRGV56KEX?)4Y>4G]?!'X>D9 M$[Q4Y<9^L@>W-AX>L;0RI5K[SF":5@,:/5C>V-V@1A8DQ;M28U9B7WGQ096"A2$[93>_5K)\ M?'56
BK-G:4>PI6#$.V!,&'O55&N#+LI,I'U[+\^O#^,#@ X SD-35%-TU5T M$.*?JF+ XF' HF$TZD/H\/8W(L7VT&Z/#Z 3-RR.+;SX (L-*Q5[*PM>I)+G M[*[DI8 ME*:/WP[;++K7TR
MN/7*/E06#);QJEPI+?\F,F8@WG!K-/O[H&$V'P7!H M_]EH%LQ&23 -A^Q.:(GUE^PC?)[0&I#N[(ZX77Y:K[K:6=5,7>],14$\'051 M..LCEN-8?>LL\KP18J1Q20Q9*5?)X+'PI
,=0=T]=JO>'%XP_?)5$X M?6G8@]OK7#W@N-",-NO@J=2B- A4S%[OPG M06&,T/NS7 AV6Y6FY$5& QX5 ^GQHD+X8J&G$1Q()L%D.F7'+!H,I_@835HD MO.
VE385T0*SK@I9$K/ 2 *=Q)-@'(?8-YZ U7M.W>)K'$10N&B8V#/!?/NQ M3Z.=VO;H--S6S7J3JT)TY=:"^%URN8;CU\"A@D_\+/2:72Z76BSA'-D[S$@D"RG[B>?5MO3\R<&6
MU1*#(,5H%@:32>0X.6&304A!7"?G=")417DD:L7?(THV'1WOF8,.["ZWI!\7,K&"*@QKY'.1Q6S]:0/Y 03M^0G-]RJ;V(/ZCB M]"=W5*^$'9T)'%223,#_X6 \I)5K/>;Q?A$FTV
:S]@)MD"*?>=LLVR"#>%H M:L^]?>Z_6S WO,"U% <;WA#1KO18&Q4KUL@3671^'L63[Q,WW.=KFJ',P"' M2S8-DP /3 S()@QR4-)'#F-PX '6[QHWL:A[S(AC6K"PD9HF]\7L+
[:YY#Z MP6NE*R@JJS;T2G;>V-LHCH)A/*I#TM-8A.6IT"7LELF"^*HT%*$D&*(V]XTU M=^P\'@Z&(;L&=S*)!1G"!,=RH.7 8U?&Z-L(ZT%A*5)3J'8\]C0FVZSI%0(M MP%Q?
XO.M6448]J<5X=0>"H9C[$YL2J>7'EDW_%;,M8LFD]I:NZ/T[D:WA(GW M#^I^"UP\Z,M(>H:L8M31"^_@UL%4:$^>XQ03&V_34ED\&@+VYD<]0R2./>L]
MDSKC[7#GZ7GIT_-3J]^5,@GLR"!*E!%(S'43 =C?:G8J>',K!.GM9Y M#$?!>)H$21P?2M%"9!=)$,)43_\!KY&NV:J<#+7DJ/]M#/(,:$+7+A-25>!$ M. F,("3 /Z]4CO3 ^*#
[I5U3]H#AS%3Y+"OULUP7 M!0@XWJV==BEI).,=;['1BFD4MU2O2VP!S"M55*T0-7LC#=*%>>6<\ M$*)3R M,/F,%O>%M6LX,[F0*>$(^M\5J=(;I6WD/J$(MX95$8\V#?
L]M_9RYW^&+63E MQ)J]*HJ \R6@U<"=3MGP1QZP21MBV7;J<@Y"3Q!:"DE9EL.@7],#]F)^PGZINBOWV6S 'E82 M/GNO3 Y+^Z)(QVTG8-R?#$BSPT3
MKGPV(JVT+*5K(K31%X H^KI%"]=;H")#EBLL+)%2+[4RALY.A<@L]22ZO12X M9 C[KEO$;^ WO+Y16K>7>..I+24*P8 R R+-5QE>/D[9Z5$+M0A<^O#(2KE& M1K H??
V1>=TC=M@,!L^FJK$@LLDB:*!H?/NBRO-']G,+/N0LY(6&>.JTGXO MQZF8@SW@W+4UB?FCTTY;SQ+RL#])[+"":;.;+C+80TNW)$W+7IAJ_HM(2Y=F
M/3*>_8)X;#L^=##E/,/G[8'-BK>T=K?B3C)2NTS,F5(9YZ+3 \ M=VSSPW074;6NY_K^U M_#9KT8!.)()EU VH#WBZ]9-85KF#>EF3L0W*Y@8<6S*1G;RT0;A1Z'+%M\.B
M/1:JE$)-VS!]W>8E[(4+O< EL-%/524RA[4L?>(W7O@ML'!4T1+(YM4 Q)4 M=*4UIQ:0%Z0=7#P]I,F07'H2(%732Z$#BQYA2<;*YA5D!SQ)2'-9^+1I+O!J M([M3!NUB-(>L W5
U[CA+$G'IE*3< MP9:*."JT#_595^U9'^L&@[.1-E>%[OJ>QD*K=>L^@(BK?;Q_<'E+ZZ_NH6U9 M7;HIC3U41]?&T+;N!M]&ANW-W%+; 8(?U85\Z-Y]8<^.':^HCQ@Z9%VU3,P[
MCMP("C%*[VO%Z;AX.,YYV?IHJ.\]UU)5II/)S47Y(,13-.J^PZ0>V"K4VU;# MM*Z^B:1@MPZ\<[_6 M;SZ1"07 G>K.9MA6/W$GXG@%2&WLK\;Q3XSUW(53Z-5U% MQT2(U[
5AS'-28_A XJEZS: O[D-[U3/"HIXPHWS1YQM?EK-'*?*,#3%$__"A$!Z@WRN*Z#E5FLD$$_:CF:7,D*(P M>Q1-_1??A_EF#Z:C6'M=%LQ&DR';#*8#7NO MHZ98-PLG=*>1/
_VHE[T^8V73.Q; M;IG@YZ-QD(QCYW!W;YE:<0V'.]=-T6@2)$G,3E@X0,KV3==:>[ONGYMJT3G? M[=N7?X477NZ[Z-IVG[OW7%V7O!K S*C19WV"2PI=D-H!U-
W6]R.4L\ZOG6P6 M?FV[9:FJBM+]*D9;7YG=FE_7G76+G<_4GO/-8HTPW*QP%:*R$>NZUJ_E&IC M?SLU5V6IUO9Q)3C\$RW_$+!^?H7.J#Y]=W%WP%02P,$% @ J#([64N;
MFUVF P 4 P !D !X;"]W;W)K&UL[5??;]LV M$/Y7#AJPI\RR93+#45JY"EV_OL=*5GU,-G(M0Y^*OE@B3>=]W/WAW.L]WUCWX$I%@7VGC%TE)5%%^EJ<]+K(0?V1H-GO3658)X
MZ;:IKQT*&4&53K/Q^#*MA#+)3ZZN9T$^"ORM<.>/WB%X MLK'V(2Q^EXMD' Q"C3D%!L&/1[Q&K0,1F_%/QYGT*@/P^/W _B;ZSKYLA,=K MJS\J2>4B>96
Q$(TFM[;W6_8^?,B\.56^_@+NU9V]C*!O/%DJP[,%E3*M$^Q M[^)P!'@U/@'(.D#V7,"T TRCHZUET:T;06(Y=W8'+D@S6WB)L8EH]D:9<(OW MY/A4,8Z6=Y80)AG\
BOA50["2+A1NB&4<,=)]-9Z#VMT<%*A_.46&= IGG' MOVKYLQ/\E_#.&BH]W!J)<@!_?1[/ITF2-G9WN/LX/$J.\OX1V-&,!U?0#;. M9D,&G8??8,[P281/SY@S[2]@&OFF9R[
UEXHXPPN1(:[DD0,BX:KVZ!XQ6?[\T^1R_.N0K]^([#^>SWK/9^?8E[?"&66V1^D% MGS[@GF"E;?[P>0*I'I5D2[XB!)%3FX;$1F.XF])JBT7'O]-4
M&U;*XE'A_X'<3SUQK06MLG'A$8C84F7E"#Y^6\+.6Q$;IS*Y;B13G&!B=S?(M6X8<]]A&:/W$?--L"9*'_$B=PO)R3KJ>\:S@[[EH+.16!37*8R1H+ZP.M\%'?,
[)EH>PM">-4<3[H1/O MA'."^\ ([CA \@M_#V)?@)(3@Z^)?:N$C"DZF(?'L3GA6:&V3=CG@2!R>+4' M;I'8M\C8Z"Z&FL?9:AQN'FV)9C]*]$>)?H\ERL,!QBPX# CA)[N H:]E>C2T
M5>BV<98-%] 8:N>W?K6P]PM@H+^3\3R7U!+ P04 " "H,CM9&#KG MSBD# "!" &0 'AL+W=O EMXTUQPZVL[;_GFLG#06E$4*\M/ZX MY_B>8U\
[T[723Z9$M+"IA#2SH+2VGH2AR4NLF#E6-4J:62I=,4M=O0I-K9$5 M'E2),(FBT[!B7 ;SJ1^[U?.I:JS@$F\UF*:JF-Y>HE#K61 'NX$[OBJM&PCG MTYJM\!
[MY_I64R_L60I>H31<2="XG 47\621N7@?\(7CVNRUP2EY5.K)=3X4 MLR!R":' W#H&1G_/N$ A'!&E\:/C#/HE'7"_O6-_Y[63ED=F<*'$5U[8^STG#B^7 GC?
V'=QI[0BGECK*HZ,/4K+MM_MNE\V .<1P< M20=(_A:0=H#4"VTS\[*NF&7SJ59KT"Z:V%S#>^/1I(9+MXOW5M,L)YR=WRB+ M$*?P&NY0,
(L%W#)MM_"@F33,6VVFH:657'R8=ZR7+6MR@/44KI6TI8&WLL!B M +\8Q\?)"$%($GN=R4[G93+*^+&1QY!&1Y!$23:4T#C\"G."QQZ>CJ23]K:G MGB\=L=V
5?".2R9SS@3<6[*?ZL,.^MW29<-TKM0GIF8YS@*J98/Z&8/YJQ?Q M:?1F2.M_(OM->=8KS\;8YX>/&5QQDPME&HWP[0$W%BZ%RI^^#]DQNL:P@IM/ M#V\ACB=P84
MP98(-6JN"D!WQH!."/8GI-WH"4AEX8$B%ZJJF=P"EWFC-46_ MC+,(F*1&DF4T3)1+GJ,VKUZ<)_'9&\A)$5TE7*Y@B;37&G.EW3H4NT*)FK;< MX5E!57#7:J7#)
M;)'ISBZJ"*P>4>^J(CF"LSUK1R+3-KXU]Z7D8J\[['62)*W761+]L]<'?*:V M@RO!"W\N35^&3@J]EBW@UX8X9>:0M,Z)0^.?)%RS+?0^4/]C([9POAN(X^,5
MW"@8*K1P[Y:O4*_\XVD;98$:-(6VX"V09-M#\,>%)N)A=I2)BF7_OTH MV74SP$F+80^624GGB*1(JK^5ZE'GB 9V92'TP,N-6?5\7ZJ6090Y4%GX4!%V_9%QXP[Z;FZAA7ZY-
P05.%.AU63+U-,)";@=> MZ#U///!E;NR$/^ROV!*G:+ZM)HHTOV')>(E"<.% MO<6I4;3*"6>&=](@A F

(@BAI,^@X_I3@H<.'A\Q)VYB M'#N^^$B,-1@)-UPPD7)6P-0P@U0,1K?%NZ)+VNEL7??TBJ4X*AP-:H->L,/ M[\)N*G-U_]$]I?G2>-Y-'M: M(<@%+*7,-#"1@3V+IW2QTTJ]Q &-"2=D,8HD;?
8;"YF;.'&/8>?6DML3XY\ F/: 2P7). M9L1A$ZGH;4%*+LYI/&G,;?37@O'B]F&2MISU][HC)=S2/1H:4KD6IFJ4S6SS M+EVZ=NR;*\>M5NFEEQH*'!!T.#TK..!JAZ*2C%RY7KM7!K*;B?
F]+:BLAMH M?2&I%]2*/:!YK8=_%!+ P04 " "H,CM9J6@U.&0# "5" &0 'AL M+W=OBG+!(E68Y=VT!C MIUB'M0WB;/LP[,MG2TBDQB5.SNU^](R:JW**]_V7)U==;+.1AX3'O-/ @]KFQ
_YR7O,];M#\5-\K MZOD]2R9*K+20%2C<+;SW;+:*[7PWX6>!!WW6!JMD*^63[7S,%EY@ \("4V,9 M./T\XPJ+PA)1&+]WG%Z_I 6>MT_L'YQVTK+E&E>R^$5D)E]X-QYDN.--81[D MX7OL]
(PM7RH+[9YP:.$[>$"- M7*4Y\"J#-3[3!M>T70;NCI0R&O7<-[2@A?EI1W[;DH7\2R\0."3TEYN>))[&UYD_*&IKB$*KB ,PG@HH,OP-:8$9PX>70@GZMV/ M'%]TP7T-1L('4?$J%;R C>$&K>^#?
K=T\3"=/?$S7?,4%QX=:8WJ&;WEVSRM9UHU!!1NY,P>N$-9"IX74#35_ M?<2C@=M"ID^_#1ET<=5A39^_/-X!BV;PF"M$*-N,0YMQ0/F"+E\VXOC"&YM)
M+A_.6AM>4$ET:K"L"_F5>+=8X4X8#2,(64!/EDSH&<>1'1G'I+O25'PX;;U# MZF:;THJ**IU4&B8!L E,)D#\:Z3P*5W:2DAS>2F5$7^T S&=9OM=D7R14DX9
M19FE:83983;MCS3UI,G)ZB0!!HSJ "F(QK32= I)-(4H#.!'U!K>OKD)&7L' M>^7BH]61RF]&!.WG41I:..3 (PNM#U]S M?1Q:OZ?QJTY3\&P0!/\TEU$=8^$4)C%Y?!42_:N6GNRTD%$'
M&CIU_EGE+U'MW86H(95-9=I+H!_M[]SW[JKQOTUO+^Q/7.U%I:' '4&#Z\G8 M]5>@FW'R-K=(UMIZ%9RS9S^-Z"R$^C]3E(UZSIV@?Z?R/)/4$L#!!0 (M *@R.UDN%X7-Z@((0' 9
>&PO=V]R:W-H965TXOC'?9_O.Y_/PX-46YTA&CB6A= C+S-F-_!]G698/$RSD8>2% MWM/$?;[)C)WPQ\,=W^_8E"YU* PO7(NPP'T]C:.X//.1[T M21^LDJ646SOXL!!IY@@74("TR-9>#T>\
I%H4E(C>^UYQ>LZ4%GO:?V-\Y[:1E MR35.9?$E7YELY)U[L,(UWQ?F7A[>8ZVG9_E266C7PJ&RC6,/TKTVLJS!Y$&9 MB^K/CW4<3@#GP3, 5@/8WP*B&A YH95G3M85-WP\5/(
REH3F^VXV#@TJL@\ GF8U6]J1UPCH9/^[%&43!:V !B]L< MZH9?84KPT,&C#G>B)O21XXLZ0J_!2'B7"R[2G!D!O_.I%F 1OV[3^)[)?E,>-\KB+?=R=:O!U@4<#DT*FVV]M
M<>@D;W?]]FYQ#6$\@$6F$*&L$@MM8@&E!;JTF.?'9U9LPKAC/^G->4%ESVG M,]L\,9>NLOH_S:OWB?)NDPL-!:X)&ISU>QZHJN97 R-W MKFPNI:$B[+H9/9.HK &MKR7=WWI@-
V@>WO$/4$L#!!0 (*@R.UE+&PO=V]R:W-H965T7LZ/2CZ9$M'!J:FGF06GM?AJ&)B^Q$>9:[5'2RE;I1E@:ZEUH M]AI%X4%-'?+1* T;4AN[_7[#YPJ/YJP/3LE&
MJ4%?,@Y$+"&O,K6,0]'G"6ZQK1T1A_%Q!OV1#GC>?V9X_[63EHTP>*OJ M+U5ARWDP":#_K3C4]D$=WV*G)W%\N:J-;^'8[HVS /*#L:KIP!1!4\GV*TZ= M#V> R>@% ._\"H@X0>:%M9%
[6:V'%8J;5$;3;36RNX[WQ:%)32?<75U;3 M:D4XN_BH+ (;PT_P"TK4H@8A"[@IZ*C*6"V\UWQG/^ 6"D+3V@OFSX"6_R/C^(*\A&ET!'_%X**#+ M\->8$YQY>'0AG*CW/_)\T07_#5@%;RHI9%
[1#UA989$NBAWTNZ6+A^G"#;[6GTEW@VIVU;6P"M@<>1;3BU/&;41R^!>JRT:5PS)@RV2V)BN(9M$ M,.$<>)S" Z6)W7%V*)+#X08H@A22!-8:_&$->"S5Q0(W9:(4_@DRU10Y0!
MSV#,B!G6RM(YKR#EJ0L@RUQ(5RQSX:19"D/9\9_='4^![@DV&Q<$Z^WB_^14 MPIQ',9L,N,.N>,)A3)X/^D)".#GS=U.2E""P% 65]@V=P> '#C]V_O!)#-FX
MMX:3':FW):%_-93AX5F=;5#O_/-C(%<':=N2V_V+]R-+^SAG]O;Y_&#T+M* M&JAQ2]#1]3@)0+=/3CNP:N^K]D99>@-\MZ17&K7;0.M;196C&[@#^G=_\0U0 M2P,$% @ J#([64**X#[8 @
!@8 !D !X;"]W;W)K&UL?51K;]HP%/TK5UDU48DV3RAC$*GTL55:'^^IC^S#M@TDNB45B M4]LI;+]^UTG(F$$214/"U[ST*+T#BH+IQX4N\]J'@B*UCCMOC)A7>
M82'74\=WMAN//,N-W7#CR8IE^(3F9?6@R'([E)27*#27 A0NILZY/YY%UK]V M^,YQK7?68)7,I5Q:XR:=.IXEA 4FQB(P^GO#"RP*"T0T7EM,I[O2!NZNM^C7
MM7;2,F<:+V3Q@ZCP]6&\JYQXAJZQ?]Z28LX:Q"#=Q#] M &ZE,+F&*Y%B^C^ 2_0ZCL&6XRPXB'B)R2F$?A\"+P@/X(6=YK#&"P]HUF D M7'/!1,)9 4^&&:1:,WJ?X 8NV@]GVV:L5RS!J4-
]H5&]H1--_. /O<\'R$8= MV>@0>MRDY4X*ZD/%#!<9-"D")M)MEN#G,VX,S J9+'_M4W#PCOT*[NZ?KZ@R MQD#/C^6<2(1^G0'["8B$0?(U?6H*L80%TI-:1H5DHK&.;%T=011Y\")H8!3\
M#Z;0RVA2').;UD!=26.%&D<;I*X&O%5[7;"?3\X9"@VKJ.!A:W9S_/TE#*CVCOS#H0 MQ:%'>N :YZJBR50+[,/][D[45%]_]S6V6T+2S\ (]J7;W>G-$E563R-B:R$

M:=JTV^V&W'G3V__&ULC5;;;MLX$/V5@;=;)(!CZV); M=IH8R*7%YJ'9(DF[#XM]H*61S:U$JB1EQ_OU.T/)BHTZ01$X&E[F<"YGAKS8 M://=KA =/)>%LI>]E7/5^7!HTQ66P@YTA8I6V-M-
/,CERO'$<'Y1B24^ MHOM:?3$T&G8HF2Q16:D5&,PO>U?A^?6(]_L-WR1N[)X,[,E"Z^\\N,LN>P$; MA 6FCA$$?=9X@T7!0&3&CQ:SUQW)BOOR#OV3]YU\60B+-[KX2V9N==F;]B## M7-
2%>]";/[#U9\QXJ2ZL_P^;9F\\[D%:6Z?+5IDL**5JON*YC<.>PC1X12%J M%2)O=W.0M_)6.#&_,'H#AG<3&@O>5:]-QDG%27ETAE8EZ;GYO78(X0S.X$ZE MND1X$L\70T?
(O#Y,6Y3K!B5Z!26,X+-6;F7AH\HP.P08DDF=7='.KNOH3<1; M3 <0AWV(@BA^ R_N_(P]7OR&GQ:<[B!&QV'XU(Y MMY5(\;)'M6#1K+$W?_];. D^O&'LJ#-
V]!;Z_"45<"MM6FA;&X2_G_#9P76A MT^__'+/X3&(H^)X2\ MLZ1&I^'!<0-O%#4:JY7UQA"&Q=8*5"E9)$A'\&)!S<6> [$&RP4:8HXG#O^+ M?*)KI\WVI^.C9#)X'>(IH-Q2-
_C.S'5:Z2Y=W"2A%,X92'LAV%,(J6*340X MR;"13DGW,&[W6IU15=34@!8%@JY\/)G:JR6EL-XS!5(V1:\G(I*EWYC-V0^D7
M:NO#ME3R/R8.DG&&&,'JPEITUOM02+&0A702NP1[])39D]>.6<\J*3&__&UR M3J&@LJVTH3OD@ P+=!M$Y5%288SG74/1YCA>8#CJXM+CO&(*CU,TCA/@@<[(
MN(TPQ&A1<%1:;E9&\D7F":\5-Q)O'*W\BL.'W.UW :C02)U92D@F4^'KB*_. M/7*_,/L=_=T>.8L9M^.1KZ\#-]H*OA%*9(*R%O[:?B)/V!]1 83]<3+Y-9T[M:P06$([[H]$,PJ0_2F949=3"=F5 W
H3>'@ORNK#;<.M3'+F+43Q!$;1"!Z: M=M6$4%.,J >%4<*6)_TXXNKICV8)?.OX>[7C;\.K8^DX:75/26K43^&>'D'' M]IZUU%:OK*_$&BE+Q#V=YS3C.]_1F **BTZWY[K:NY]'Z:B09P M=61?
WZNWR:0G+Z(MLTX/.L*/G M5 @&\:"=Y+*@;_:*>X$N9.8K(\<,#?'OH%L3>>C"R&C".JJ@HMAZXNSUQ7]K M(RU5%R>GK>7=,2LJ27[Q>JPMBMUU%P5$?)^68_?[<.\!5J)9^F7-%K M'
UOH/5&ULK5;O;]LV$/U7#BI09(:693\ M*[4-V$ZR%5A3(TFW#\,^T-+9XD*)'DG9[G^_(Z78'NH8Q; O)D7=>_?XCN)Y
MM%/ZQ12(%O:EK,PX**S=W$21R0HLN;E6&ZSHS4KIDEMZU.O(;#3RW(_*&;%. MIQ>57%3!9.37%GHR4K65HL*%!E.7)=??9BC5;AS$P>O"HU@7UBU$D]&&K_$) M[=?-0M-
3=&#)18F5$:H"C:MQ,(UO9JF+]P&_"=R9DSFXG2R5>G$/G_)QT'&" M4&)F'0.G88MSE-(1D8R_6\[@D-(!3^>O[/=^[[27)3X7;/?3=7R9DL;_PJZ)[?8"R&IC5=F"24$IJF;D^]:'$\"@\P: M0#F
M=3>)O,I;;OEDI-4.M(LF-C?Q6_5H$B)4)+N')U%M7:^QP"V8[E$O6K]>RZ.3J8DYS**"ER M,BV'&9?D(L*3OUNFQIVK[[!N7>-&:8>8YG_1@7=V-\L-Z33+=$VC%'PII+""
MBM1/.Q#'71ATN_"L+%4JJ\D) IY&L9"E/1_'PJ07MY&7(BA77=;2ZZ=/6V3" MPE4_"8>='OP$5RZ0AGX:=EA,LX;0%%QCH62.VKQ_-V!Q_^,1S,(XCD^PE)$Y MKK.6'8^;,^O+!C5WM37
Q=94FD=Q]N$7Y5Q@#=2V +A&_(-:#[K/Z3PX]4 M<*ZSPJ?)<4LW]<;'X)[N?D,^Q2'K,V!]-QD.X6>L2)KT\3RG6TD8VT@]A:3= M% 8#FG13UEJEFBW163K$)6'"AKX$29BF:;.Q)5*[0?
A49:I$>.9[N$K"_F!X M8J0K2DJ3!SI<'O.&1V\"+U? %6#.30'WU+;^-Z>=6'E1U;S@U1I!N'[U_;F__MB@<4XR##OB?+G,3:41/BZ*[O=2V$A8,A(]2'X_3<_1.=]) 2]=IW2@.9JBO;
MM)/#ZJ$93YL>= QO.OEGKM>"3JW$%4$[U_UN +KICLV#51O?D9;*4G_STX+^ M4*!V ?1^I>@J;A]<@L-?E,D_4$L#!!0 (*@R.UG6Z90B#0, #8(9 M >&PO=V]R:W-H965TL$2-VJ;< #XL%-
KDU88A?;:;O_GK/S8X5U%4+PT,1WN>_SG>]\U\%6 MJGN=(AK8%;G00R\U9MWW?1VG6'#=D6L4]&4I5<$-B6KEZ[5"GCA0D?LL"'I^ MP3/AC09.-U>C@2Q-
G@F<*]!E47#U,,9<;H=>Z#6*FVR5&JOP1X,U7^$MFD_K MN2+);UF2K$"A,RE X7+HG8?]2=?:.X//&6[UWAIL) LI[ZWP(1EZ@74(#TVN $\]P2D1L_:DZOW=("]]<-
^Z6+G6)9<(T3F7_)$I,.O3,/$ESR,CZWA.+5\L<^V>L*UL(]HQ+K6110TFN:[^ASV &?!,P!6]B? J(: M$+E *\]<6!?<\-% R2TH:TUL=N'.QJ$IFDS8+-X:15\SPIG1E30(+(37<%LN M-
/XH41B8;NBI![ZA#:R9']=DXXJ,/4/6@YD4)M4P%0DF!_"3X_B0'2'P*;(V M/-:$-V9'&3^6H@-1< (L8-U##AV'7V!,\-#!HR/N1.UI1XXO.G+:&HR$RTQP
M$6<\AUO##1;/G7=%USU,9V]X7Z]YC$./KK!&M4%O].I%V O>'8KU'Y']$GFW MC;Q[C'WTI+K@ZQWN#(QS&=]_.Q3Z4;[#WEY=WTTA[/7A+D7J2^V.6.VXL#T+ MN$*Z0-
^E:M2T,HH+S5UCH?2DW(",XU(I3(O#9*!) M73@O5W1?(>Q6_EI#=JXK^2F8@E/*Y:.M;O$A7*& MK$VEI$IH?B95B'#HFOA[K;FP6;032T,L2V&J+MUJVZ%X[F:!_VA>3=095ZN,
M#B/')4&#SIM3#U0UI2K!R+5K] MI:&RX94J#'94UH.]+2>VG%NP&[5^%T4]0 M2P,$% @ J#([67ODFT+-_P]PD !D !X;"]W;W)K&ULE59M;]LV$/XK!PTH-J"0'"?QBLPV8&?
=U@$=C";I/A3[0$LG MBPA%JN0ICO_][B1955!;6[[8)'7/<\^]\&6^=_XQ%(@$SZ6Q81$51-5-DH2T MP%*%V%5H^4ON?*F(IWZ7A,JCRAI0:9+I9#)+2J5MM)PW:QN_G+N:C+:X\1#J
MLE3^L$;C]HOH(CHN?-*[@F0A6.,^I="G X M/K+_UL3.L6Q5P%MG_M89%8OH7009YJHV],GM_\ NGFOA2YT)S2_L6]MK-D[K M0*[LP*R@U+;]5\]='@: =Y,S@&D'F#:Z6T>-
RE\5J>7GN&>P4=GJ0CPWF:8O<0GK+,7.SV*74]'"?^L;0R7D[]VJLQ]N6MLX%59DK:^6VK^ !?NO][?"98&Y<^GA0^2GU:N(IAX[5-=64X M+RZ'="@ [@LVA-JJ.M.$V>-K3W)M%2.5@4"\P+N8
C"7J3,$*G!@H&U[M @G M.Y&/MZZLE#V LAEH!H9Z&W2FE><"Q>*XMQ@X#6!PQWSL2I-44EO8%SHMF (* M9[(-2NS).V.DY$,)A!PVO>0NE"!H[\!9A(",E?\]Z$4[9'QV__& M$"-I TT'/@"I@(?
X+H;?5ZL-G_Q?:\WZ^=2S?$T(LCQ[!$',4BKJ,!72R52 M @>D"%2>\^'?!,Z9 :%VJ/72KDD!#/ MYS"M%XGQV,2O28#0G5+H\0EMW6G"YTKX F2UE_Y]$5:%7KN,=\N9)@+@\S%8XT\ZQMY-
MK(?_'M.SQ,O;,\3MOH7MO5HZY. M=W4:PP?>M%SK)FDINS4'T-P/DL]OPCCE-E,^"]]M='Q2IFX*U*$&X=SUJ(>J M/6ED_Y\[
Y+!95RBWS5/CJ80EMI[N5_M7S6K]C+_9MX^B3XJO]-6#K:7HD" #Z!@ &0 'AL+W=O);YAR?,Y-,YENI;G6);."^YD(OO-*8YM3W=59BS?21;%#0DT*J
MFAG;JHVO&X4L=Z":^U$0S/R:5<)+Y^[L4J5SV1I>";Q4H-NZ9NKW$KG<+KS0 MVQU<59O2V_,_G3=L@]=HOC:7BG;^P))7-0I=20$*BX5W%IZN$AOO KY5N-5[M:
[!.UE+>VLW'?.$%5A!RS(QE8#3=X0HYMT0DXU?/Z0U76N#^>L?^WGDG+VNF M<27Y]RHWY<([\2#'@K7<7,GM!^S]'%N^3'+M1MAVL0D%9ZTVLN[!I*"N1#>S M^SX/>X"3X!% U_.B?
P7$/2!V1CMESM8Y,RR=*[D%9:.)S2Y<;AR:W%3"5O': M*'I:$#&S8=SW]!%-MS/>M)E1QH]0CJ# M"RE,J>&=R#$?P:^F\6$T0>"3P\%FM+.YC"89/[7B".+@)41!E(P)FH:?8T;P MT,'C"3GQD/78\
<436=?0Y7,RZ=JHZLV MU0WK-5W;URYQ!>REJ#TISR%\<^S&&9QQ:FU,9 C4)"&7[=H4+7\0?A#2*WJX MFVZD89S)[$=$A@KPA-<[(GO9-,0/:)]9D>*>[KVQ/' 6,W]O?92H]JXKJLA MDZTP7:
<93H?&?N;ZF?\WO/LK7#"UJ80&C@5!@Z/7QQZHKM-V&R,;UZS6TE#K M<\N2?DZH;]+R1].OW&7C#\[M(_4$L#!!0 (*@R.UF*@GCY8P($ % M 9 >&PO=V]R:W-H965TA$ J
M)$U#QZ"-1(%IF\94 =L^3/O@)M?&PK&#[5#X[W=VTJR32K\X_G'OW;N+GR=K M;1YMB>C@I9+*3EGI7'T>138OL>+V1->HZ&2I3<4=+.HX69_2 [?G&_9/H7:J9<$M7FGY2Q2NG+
(S!@4N>2/=G5Y__MQJZ>4\^7:VG#".LV-OW((&^LTU4')@654.V7OW1]V *38Q>@_'1Q.8GH=2)G%"^9]R[PR="L*Y[+MV"*=P##=/C:BIVPX.'_A" MHCV:1(X2^+
H[\AF+5GR!MD8;K5RI84;56#Q/SXB8;VZ9*-NENPE_-JH$QC% M TCB)-W#-^JK'06^T9YJ+;3U[2JO1:>[T=X?Y[;F.4X9&<"B>4:6';P;CN.+ M/=K27ENZCSV;&W*:<:\#F$M.OX&K8NNG_
ZBX0%?',RDSA__[_*_-\-N_=1B M#"V^QARK!1H8#=M^^V$$MUB(G$O C90!Y-HZ>__CE(9C^(;6PL&[LV0XO""3 MY4W52.ZP(&]0EESPX+[#%(ZV;]D % :2.)#LZE^T=:LK-*O@74O9&^7:"][O
M]L_#9>N*?^'MVW++S4HH"Q*7!(U//IPR,*U?VX73=?#(0CMR7)B6],2A\0%T MOM1T<[J%3]_FME?4$L#!!0 (*@R.UGL&J"SO@(+0' 9 >&PO M=V]R:W-H965T $$AL29.N3*.-U'8,
MAK9IV@O[@/C@)I?6FF,7VUDW?CUG)\M>E$4(\8$OB<^^Y_$]9_MNO%'ZVJP0 M+=R60II)L+)VO1>&)EMAR=H+]>GFJRP M9*%U M9%[6/K,L'6NU >V\B33]^$/<0A*2P ME1G?
RYS%O8Q?*[D-2?0>XB@>=@74#]_'C. ##T]ZPDG:K">>+^G)NH$ZOUWI MK='#;K1[V'MFS3*H;#-(WKP:CZ&.7M']$]D3HL!4Z[&-/SZGJY!7= M*57 9?[;K%T-EC>_;P62MC8,ZT MON-
R"=-25=+"-,NJLA+,4F@TI2W_Q7R9.:%"^MSYRM<&YWF#FDH='/$"X5*R M&D@+_$$=J]7-3J9@5&$W3".\AE$RI.]6,Y(A@PMEF>@ /O?M.N&_2 K=:"P7 MJ-
M;_9\D)MD=-6+=J#\Q3WV[;FOXJ#"6J)>^7QC(7+1UC6QGVY8T]94X?'"O M^]DQTTLN#0@L"!IM?]@)0-<]HC:L6OLRNU"6BK8?KJBMHG8.M%XH>O2-X39H M&W7Z&U!+ P04 "
"H,CM9V9\9,1\% Y$0 &0 'AL+W=OUF+M0V:KGT8 M]D!+M$U4$EV2BI/]^AU2BF+/BN:V>]E@6*+(YGJBM9#2W3&4Q"3POGI245\[LS,Y=
MRMF9J'7!*W8I0=5E2>7M!2O$[MSQG;N)]WR]T69B,CO;TC6[8OJW[:7$ITDG M)> MKMF"%841A&9\:64ZG4K#N#^^D_["^HZ^+*EB"U%\XKG>G#NI SE;T;K0[\7N
M%];Z$QEYF2B4O<*NH4T2![)::5&VS&A!R:OF3F_:..PQI X##$'+$)S*0%H& M8AUM++-N/:.:SLZDV($TU"C-#&QL+#=ZPRN3Q2LM<94CGYZ]%9K!%$;P_$O- M]2T_D"7!5-
/SB8:I1N:2=9*NF@D!0](BN&-J/1&P?,J9WD/_V*8WP\&!$S0 MKMR#6_K%\)LH2.XRRI@=NF'BNY]D_A%-W&J9N MXGMPQ21'^CE<8N-A4J*DQEER3SZZH[HXHNJ6%D=+@4N2T W*?
1E]AN"@TAF MUFGB6S";2[W.BU7O:$? MNE&2NBDA0RGQW8BDKD]")!JHD*BKD.CK*F0CBIQ)]=-=&S:]PH5/5$I::8R8 M!/M^/;6 !K7W8^0^9YW63_8=B#&87S.)KW1X?L-
DQA7#\/",':^_9V;?P*LU M_,I7#-[56FE:Y69BUPIUX36M:MPO@-_6*J(]C=T8$_P(@K&'>1Z'\;T1+8*V MM50U3H 64%?>"-TV@PCG:JJ<8*]6IND)6SI094!=NN!-KJ-1QHPC7/
M:UK@\)IA^4H%_C1UPS0 ,L9R&M)7BIRO>$;M_JU/;13$6-]3M#R)'O!YKY6U M7J?8CZ,XM)D,8H."82O^AIZVLGW2X.0!U ZTAKAK#?%P:S#!'EW@SC2' M2WJ+&V8-[P)&[= M#8(^,%G"?
+V6;UQ_H*5SB>#C+X2(OZ$/.MYL-$V#S@;>J[<1PTE1Q#//9- M58\Z:])U7$$ MW*;U_?\0TS2,)AX"9>KV 29!NBLG')*2GR1Z"XU4<8"L(884<00_[8C[X-JWT-<+)W.BV97-M#N\+N7U>Z
M.:AVL]UW@;D]#D_NR9N/"F^H7&/&H6 K9#6O"0=D&ULK55M;],P$/XKIX 02&&QY M;3=&&XEV($$$($$$:5&N!#X@/;G)-K25VL=V7_7O.3IH5*>TFQ(I.+Q$ [*I2Z*&W-&9UY?
LZ6V+%]+EJ&W'[CEQ=+8 3\=K%B!4S3? M5A-%/;]ER7F%0G,I0.%BZ+T+K\:)7>\6?.>XU0]LYU,^] +K$):8 M&
<7KNE!1[:>_8/3CMIF3.-8UG^X+E9#KU+#W)I8ODZ5V+6SKM4G/@VRMC:P:,'E0<5'_V:Z)PP'@,C@"B!I]%1 MW !B)[3VS,FZ9H:E R6WH.QJ8K.&BXU#DQHN["E.C:)93CB3?I$&(8S@#&YQ
M@V*-\'+&YB7J5P/?$+]=Y6<-UZCFBHYP]>%&"K/4\%[DF'?@QZ?QY,9Q I^$ MM>JBO;I1=)+Q\UJ<0QR\ABB(DBZ'3L.O,2-XZ.#Q"7?B-MBQXXM/!%M#'=^N M\-
;HI!MM[_.57K$,AQY=6(UJ@U[ZXEG8#]YV2?M/9'\)35JAR2GV])IK5A0* M"^;NJERTV?73J8<9[@R,2IG=_>H*Q$GV;M]G2X4(59T_:/,'Z/31G?Z4[X[,
MV+QPIWM@S>Y7:%TNI,PU,)&#W8)G=$'33VH#G$;4)+V0VBAR9A]FTK#RV!RG MRUM86H69+ 3?!T8U@9E(+@QP 8:*),1T(2_H^[I!58]<.,:P]^A.7;GP#_&D
MW,=J3KO'81N@Z&FQ2=Y<4GO6>MGV'XO!@]KC)%W9Z1_4OPI5X9X%#9E<"U.7 MPG:T?7G>N8+K/RROGZT;I@HN-)2X(&AP?D&%7M5/0=TQ=.P&[7N<_@%02P,$% @ J#([65@Q%L%)
P =P@ !D M !X;"]W;W)K&ULK59A;]LV$/TK!]4H6J"-1$6F MX]0VT#@MVVF%$=@CC;/A3]0$MG2PA%JB0=N_OU.U*ZFV*4PR%89FD8FD^[=>R2/
MGNV5OC,EHH5#++:29!Z6US448FKS$FILSU:"D-QNE:VZIJ[>A:33RPH-J$<91 ME(4UKV2PF/FQ:[V8J9T5E<1K#697UUQ_NT2A]O. !0\#-]6VM&X@7,P:OL45
MVM^;:TV]L&X1"$<$:7QM>,,^I .>-Q^8'_OM9.6-3>X5.+/JK#E/#@/H,-MWPE[H_8?L-,S=GRY$L8_8=_.S<8!Y#MC5=V!*8.ZDNTO/W0^' '.HT<-<0>(M?Q20=(#$"VTS\
[*NN.6+F59[T&XVL;F&]\:C24TEW2JNK*:W%>'LXC=E$5@" MK^$*=E\!E 5=X3PO'>@+6/0P(M;OA9H7LY"2Y$=/LR[*)=ME/B1 M*!E\4M*6!M[) HL!_/(TGL4G"$*2W.N.'W1?
QB<9?]G),TBB5Q!'<3J4T&GX M%>8$9QZ>G$@GZ9PIH1Z#?$:OJ\,@;MU?\BA^U5EQ0]?,2L&Z$^D:\:Y2XJ:R! M$<0LHB2.AB?+LUI\2-SUM]FG*KTXEMOIHK?G$KBB\0R1;T)"2V$&F-LQLD?OG^E!\
MKWA;]&@NKY6VU5_M0$H'UWV7I+K*N0"K*RX,C3 WS*;?O7P-RI:H(PU3X_BHY4:0LB:#^WRE*@D0>//'SD M"4:>8FC#_8\%H@.&]9K235CO>/R4V>/8V3Q-GS28 M;Q25J:[C O3_-19_ U!+
P04 " "H,CM9*=F/)N8" !\!P &0 'AL M+W=OMB]&7["CCATU] E'P$EC XCZ'CL.O,25XZ.#1$7>B[@PB MQQ<=.0,-37S[PMN@XWZTO>;G>LU3''MTCS6J._0FSYZ$2?"Z3]I_(OM-:-P)
MC8^Q3V94@[*-0)#Y8^GVS84#YK@S<"EDNOK>%YFCYOK%S N%"%634&@3"B@= MT*7#K-P]L&(3Q1WW06_&!=4])P"KM9#WQ+O &O/2:'@*X?#,MDE ;10/J66G M9S!5,D=M:R
7D",II&PO=V]R:W-H965TI#<@S6+MI@]%'VAI M9 E+D2Y)KYV_[Y#R*FZA=8LB+Q(I\Q*E/LPC%CU_>&BVM?,?XL5L)[:X0O?K[M[0+.Y9RJ9%91NMP&- U
MCV[9S5WJUX<%GQH\V+,Q>"4;K1]Y*=R'HU\0BBQ<)Y!T.L)[U!*3T1I_'GB MC/J0'G@^?F;ﾠ/F@G+1MA\4[+WYK2U?-H$D&)E=A+]Z //^))3^;Y"BUM>,*A
M6YN/(RCVUNGV!*8,VD9U;W$\^7 &F(Q> / 3@/]70'(")$%HEUF0]4XXL9@9 M?0#C5Q.;'P1O IK4-,KOXLH9^ML0SBU^T0Z!9? 6?D"%1D@0JH3;DD(UUAD1
MO'Y_I**Q:.'U6FPDVC>SV%%LSQ 7ISC++@Y_(4X.'[1RM87WJL1R ']W&<_X M!8*81/?*^;/R);_(^/->74,RN@(^XNE00I?A[[@. OPY$(Z2;\12>!++FR$ MA<[?(7L[=#J,]F?]QNY$@?.(#K-
%\X31XMMO6#[Z;DC:5R+[F]"T%YI>8E^L MJ!&5>XF@JQ=K[@F_U-SOP1-8X]'!4NKB\8\A>R[&'%:TK@TBM%U5H:\JH)K
M4!.KYOC"'U\M8<_/1BLAJ0,&%=CNI/Y,O!N25C7.PBM@:1*>G)X\9_1,V!3N MC:[0^FY(!E1(2E,V!C9)8,(Y\#2'!U0ND/IN[%)52"DD"200Y[!VH@GE(#/ M1E$B=$H2!CR#CZY&
\D4^!3&C)AAK1W%>04YSWT"TZE/Z8I-?3KY-(>A,OD? MIM*QP';C8[/>)?YO!F7,6Y.RR8 I[(IG',9D]: =E#\G0_[I1983!):BI):^ MH1@,7G-X<[*%3U*8CGM'.+F0!S&PO M=V]R:W-
H965TY2,5R@-_M5Q(TYI-@.KB$:<=CUO*(W^$QB.%.25L: MN)899O\"A"2J5Q9OEKSA@96>OUSD$, M9[@+^HF=_502P,$% @ J#([6;Y3=B./ @ M < !D !X;"]W;W)K&ULK57;;M0P$/V544"H
ME:"Y=BEE-U)W"^*B0M46>$ \>)/))JIC!]OIEK]G[&3#5DHCA'AQ;&?.\3DS M\62^E>I6EX@&[FLN],(KC6E.?5]G)=9,'\D&!;TII*J9H:7:^+I1R'('JKD? M!<',KUDEO'3N]BY5.I>MX97
2P6ZK6NF?BV1R^W""[W=QE6U*8W=\-YPS9X MC>9+56CT)44H+!8>&?AZ2JQ\2[@:X5;O3<'ZV0MY:U=O,\77F % M(>6B&3\[#F]X4@+W)_OV-\Z[^1ES32N)/]6Y:9<>"<>Y%BP
MEILKN7V'O9]CRY=)KMT(VRXVH>"LU4;6/9@4U)7HGNR^S\,>X"1X!!#U@.AO M 7$/B)W13IFS= &? M38D*KC##ZHZM.6HX"(./AW!PXU:'<]_0<1;D9SWULJ..'J&>P844IM3P1N28
MC^!7T_@PFB#PR>=@-MJ974:3C!]:<01Q\!RB($K&!$W#SS$C>.C@\82<>,A] M[/CBB=QKZ/([EMX.G8RC[?4^U0W+<.'1_=6H[M!+GST)9\'K,6O_B>R!T60P MFDRQ4^(,J[@&68Q\9M]= N
&[PTLNJ*[?=@LC&]>RUM)0 W33DGY1J&P MO2\D79U^80\8?GKI;U!+ P04 " "H,CM9'>\].,0" "Z!P &0 'AL M+W=O)CVX":7UB*Q.]NAL+]^9R>$@D(T37O82V*?[_M\W]F^&ZVENM%+ M1 -
W92'TV%L:L]KW?9TNL61Z1ZY0T$HN5K,T4S MOV7)>(E"8 /" E-C&1C] M;G&&16&)*(R?#:?7;FF!F^,']D.GG;3,F<:9+*YY9I9C;\^##'-6%>9<% MPD1K-!JV!L'7M[!UR18=:!G_7C
M!V$/@4\Z6['A@]AIV,OXI1([$ 7O(S"85=_? #3 D^ MW&NH\]N5WAH][$;;Y[VO5RS%L4?O5Z.Z12]Y\VH0!Q^ZI/TCLB="AZW081][M/Z?%F'9?NNTL'7.*=@6DATYL?
79GIW:Y;#)T]MF>K;=5O]C?)8HEJXKJ$AM='6E;*UMHUI MXNJQ_^A>=[43IA9<:"@P)VBP\W[7 U5WBGIBY,H5V[DT5+K=<$G-%95UH/5< MTJ-O)G:#METGOP%02P,$% @ J#([68Y3H$9H
@ 304 !D !X;"]W M;W)K&ULC511;],P$/XK)S,AD$[1A, MVE#5#7A/+C)M;'FV,%VVN[??O\]WY]%&FV=;(#K8EE+9 M,2NNSG6,N5H7SCB@=57R%C^B^5C-#5M2AY*)$9856
M8' Y9M?]J\G0QX> ;P(W=F\-7LE"ZV=OW.5C%GM"*#%S'H'3;XU3E-(#$8U? M+2;KCO2)^^L=^FW03EH6W.)4R^\B=\6873#(<9Z\QE;/6<>+]/2AB]L
MVMB8059;I\LVF1B40C5_OFWOX7\2DC8A";R;@P++&^YX.C)Z \9'$YI?!*DA MF\@)Y8ORZ SM"LISZ1?M$"[@'=S@$HW!'.:X1E4CO'GB"XGV[2AR=(Z/CK(6 M<])@)O_["?PH)4K+'Q4.>9_
T1$L&.9[%A.DJ.(-YCU8-_A21.!D?P!IWJ M0<_;'%%MH1%X2%^3/3R<[>?DRE8\PS&CS0;!HULC2UZ_ZY_&'(]R&';?A,?1T M2E=GJ%FI$5P!T]_":$ZA\U];BV[/OA=\(:1P+Z? E:]?AF+MI<&/H!">
<.M@ M(G7V_.0V*-T#HNE>F"Y0$,U"27QQEY#-E)F$$)%9N%-D4>%4-2I%JCQP1JKR,>@&C*=GZ8C4B$-@?9GFO'$*(!(^_%^>-)=B?E3Y$ .6&Q&4> WO&8'!JD_SY]G0FH>>L@BK+]7+L)]-YWJP
MKGT8]D!;M$U$$EV2LI/]^AU2BFS/BN:S]X!GK]=7$.L^%?M-L=FH>>)7=7/?8+]@>9J\\ 3J[6>5W-V0A>K-Y(IV-@!DY])%%-&[:]Q;!WSE<_=)/1 MF/4%7@>@>O\#-1K,VXK[KQ,G2/BB%#X
MU(Y=R_&I*'7&"W8M095Y3N7#.D\N8D@-2D8!O#7/3@*'!RT,B.)UOJNN^%S M4B+Q Y,]]T]D\[:XNRR!T-1G]9*ZK#ER?T5VN]3S@P%QK<]',:%K[%:W]4,\]Z1_#)-W;A>*/4+^NB\5;W
^(S2^L]B;"QL=SH#2],%F^UQ%%F.?'K\7F@&&G@=]N/I2 ME0HWA#%5H1LXK4?X3HHB)=A2GHDK@2%2MKB&N'@PVH>D\:@6#IK%@N6\(AOM MHN$AB2A-5UJC'(#?+LQD;[%X\"GCG4M=WU75G2G
EGHI)/^3I:"6%,EWYKA2Y7;\MKKA^$SD.;8894WWG2!V'=>U?PA&SBA(MG-ASX99)CO03N,;.PZ1$296S9$O>?Z0Z/Z!JIBX.IGR'Q('C>R-HR^PS@H-(M9M9IXEDPFXN_\W1%>/^-A
Z)1DX2QS@1AKX3!\'3H>]W17PG+SN/ M7N"$<>(DA'2EQ'-"DC@>"9"HHT+"ID+"KZN0I-UL]V$<083-9,XIH.5_=,SKAB&!X^8X?S-\QL''BQ M@%_YG,&'4BM-
B]0,;&JA#KRE18D;!O#J6D6T)Y$388)?@#]P,<^#(-H:42-H M54I5X@!H 67!34SFF"$C.B$19@>1/0@C3,\36O?Z W%\'_]N8G5BH=E+6[7] M=R+I@X<^$<3Q"X@'H0ON(
D[XVB'JFHL4*_F!EDIFVI 5;!J2J"N7L.!)JQY M6M(,']<,RU^7*1\SF?4;N#:U(9^A/4]0LOC\ F?=UI9 M[76"_3B, IM)/S(HZ+;B;^BI*]LC%7Z.TTJ>0&U':XB:UA =WQI,X/OGN$U-
MX9H^X.Y9PP2M2IVZ+7U8F5BB@9]H5E9QG:#'>35\9+/HM.=K]QW/$+9 MNH.Y9 PDQ7UI," A?(\W<[TTP&.(RP?.LA1<'#+_J_L5?A%@?-8BPP!DIGDF
M$4[82S.KFK4^D\M:0\WWW]*7+G"O+O$KS/2"CR:ZD\5"LH7)VQN#6)W2\HB &\CSXDBO^K)$40#S_3G?F/MPE0C&M.O?ZUR]QO]@=!P M$,56Z-$A^=EH[5\:QUY3+FN?WHNB_PD;
(!*VNE1UB03W<0DB\06V-&Q+;8X\ MCJTK82=>$CLQ&<%+9$&SV_3LNQ@A@Q?$5L=!"ZJ*\O^'F*I?!*,0UPL3WF 0 MNPB8D=L*F!CI1IA\3$)RG.PN.'XE0-
O/!Y6&UK@,.=@X:%KLX^!K,Y&PO=V]R:W-H965T MY M)M82.]A.V_U[SDZ%G-)L2'.'.7Y4>YLA/R3N4 FNS+@JNIDVM=7;FN M2G(HJ3H7%7",PT(2 M59"69;DV VX\J6@&2]#?
JH7$GMNQI*P$KIC@1,)FZKSS MK^:166\7?&>P4TXU!)G&>)T_$5H('Y$SL@M;('70%ZNZ+H]6KB:N0WJ]RD MY9HU7,$)KC&Y$$5SGBKSG*:0]^/DPW@\&"%P4UJD+#NIFP2#CYYJ?D]!
[30(O MB/H<&H9?0X)PW\+#_7?"+MBAY0L'@JU($]^^\#;HJ!]M[O.5JF@"4PV_[I/TGLK^$1IW0:(@]OF:*9IF$C-J[*C9==OVTZLD*]IK,"I'< M_>H+Q"![O^^K7
*0LLD?,/E#\/3!GOZ2[4_,F+RPIWMDK>XK,"YG0J2*4)X2 MLP5+\.B6C4&>$]_#)AKYV :!-<=D)30M3LTQO+R9H960B(RS0V!D&YB%8%P3 MQHG&(DE"O)
7^'W=@FQ&+BRC/WITI[Y<^(=X8NY#N<;=0[\+4/"TV$1O+K$] MZ[SL^H_%X$$'M:9*^['2/ZE\),K//@B*)J+EN2F$WVKT\[VS!=1^6-_6#949 MXXH4L$&H=WZ!A5XV3T'3T:*RU70M-
-9F:^;X>H(T"W!^(_"2MQVS0?<>QW\ M4$L#!!0 (*@R.UG6L&D820, '<(9 >&PO=V]R:W-H965TW7LDCY[ME;XS):*%0RVDF0>EM?"672Q3-1]//^*/"O3EJ@U.R5NK.=3X6\R!R":'
W#H&3C_WN$0A'!&E\;7C M#/J0#GCZ/V'[#3,W9\N1+&/V'? MSLW& >0[8U7=@@2F#NI+M+S]T/AP!SJ-' '$'B'\4D'2 Q MM,_.RKKCEBYE6 M>]!N-K&YAO?&HTE-)=TJKJRFMQ7A[.(W91'8&%
[##1KD.B^!RP*N\)X6N*'E MLO#N0%O&H($7MWPMT+R01*\@CN)T**3\"O,"%IT.H]U)OS_SW$>T%$VJ.\Q6#Q QK+HS9"TGT3V#Z%I+S0]Q;Y8 M41DJ=@)!;7Y@QWWVCL M'BQ<"I7??
1DRYV3$83VWI4:$NMU3Z/84T(Y OR-6 MU>&1-VZO^!4_:JVXH.KG)6#="/6->-P%;[_"@Z4J4MB*#]W"I+@48>//+PD2<8>8JA#?<_%H@.&-9K2C=A MO>/Q4V:/8V?S-
'W28,J9C>,GO/4>_MO8!++HOYXR*E LGL(D)6M?Q43_I),/ M+CK(J_,G:_PJ+;7J+?^RC.0JYVT;9GO1_M;]:V_3,+OT]LK^1/7VTH:$+@A M:'0VH4M,M]=K]15*:ZC@O0_]=8_U02P,$ M% @ J#
([6<1Y6ZGF @ ? < !D !X;"]W;W)K&ULK55M;],P$/XKIX 02+ D3IINHZVVT;B! &E1K@0^(#VYR::(Z<;'= MM?OWG)TL@IM!%*Z+IY$)SG*Y^@)%R,%*W?P/'K2*F"K28@Q%BQ0K<(H@:]ESM
ML*:57*J*@QJJE:\W"GGF0)7P61:E7Q+6Q]\+49VF3)Q+W'*@VQ4!T6%.ZW4^&8JOIG(M(UD:Q@L%5F%Z9!7W7PE0G4
EM/'.RKKCADY&2.U!V-[''9CHN-_M0Y.:LK:G.#>*5DO"F6+1@W/%WPI-M4+\8^8:;R-G!PE0GU@'IL8*9GTQ^'?-
#!HR/N1-T91(XO.G(&&IKX]H6W09H^;ZQ2P*A0A5DU!H$PHH'="EP[S0AE!$=!8Y R&U T*2@OM/^AP!!1 M=F.UM%;#3C%%%3C3G%]%J3%-&]V8HNG)1LJU)9Q!DV.\][B
M%:J5J_L:4KFM35/KNMGN:;EP%=7;"3-UU;!]J>06U#SX]00J%&1Y;[8XR:;Z%P%O-+9#*3E]SNN(%Q'DQF%?F%;O.'=L+1;.ZL[;%-.7]8N+2W+R_#RZIE.H%%'=R'KI&1GJ7MBYDB/(1W6,
<@]KH/PS[0TLD20I$>2H'C#_MT"\2*?&]N_=X/,Z/VCS:"M'!J9'*+J+*N'!]PD;8:[U'17]*;1KA:&IV ML=T;%4_3+FHU6-)Z7)6T7(>OMV;Y5P?P\(#P%JX*N&*8X)XN\(A8!?WBH
M=Y7S'^+E2^?VN\VN68H5Z?@=1DW@>>J;J[,!+$S@*H@@P&N!V2NTA]UGE!DQ MW6N/9\E9$)GKL)+0)ZM=(1KHD9CYK//E(@M+9@LYLJG#M@ 8#CX
Rt="" W/%\N5'^!H" (5D(9Q$Z<>X/"2Q*YHZ.EW6N'8JLE'X@P$AJ^<C19?-"T!S6ECF9\N<
E"V\R"K'?"B>7OW)RH:BQ9>;\16HGTSCQW%M]@OQWL59M7'X"W$R^*"5JRR\5P46_B[RWC&+Q#$)+I7SI^5K_A%QI\/ZAJ2 MT17P$4^'$KH,?
X,EM]^P[+1=T/2OA+9WX2FO=#T$OMR38VH.$@$7;Y89^#Y[M!D\.5E+GCW\V7,YVV5FV+3DT9RYGIYEHLQH&&7RY2BIM\AO5MZYY\%'YNF]OO12Y7PM'XNZ2UA%(Z4L35+Z:1F5LFMNKL)H]H:

[&=5[FIEU>[9YVLO1%L% M3Y41!==Y942W8*B3&G[M#)Z;[(;$#I+MYLEVS[8HW0([[=ZLTDQKTFQ M:9-B?I-BLX;$#LJEFY=+]\7>[)[RU:2,*.]W98S=*=BS2J:XWU5@2OM=&7-D
MO[O*LW-5FYU[F>THJ+=/K<)S[=.DF->DV+1),;])L5E#8@<%TLL+I/=B^_1. M?R^6(67_E#&E[\4JF:)_*C E_Y0Q1?^8>R?'!-A27PIP%--$>EG9-Z;WSM< MZ^-VH7]L]R=V1;]G]Z=5_;
[=GZ77#4_#II1(!D !X;"]W;W)K&ULK5AA M;YLX&/XK%INF3=H*)D":+HFT%LC==#U5[7;WX70?'/(F00.5_?FVPQSO*?O U@$ /95'QB;,68G/ANCQ;0TGX&=U)9\L M*2N)D+=LY?(-[)0I+)P?
<^+W)+DE3,=J[8;-AW3K2CR"FX8XMNR).SG)11T M-W&P\]APFZ_6HFYPI^,-6<$=B.^;&R;OW%9ED9=0\9Q6B,%RXGS!%S.L" KQ M5PX[?G"-ZJ[,*?U1W_R^F#A>G1$4D(E:@LB_>
[B"HJB59![_-:).&[,F'EX__MJJ>J\[(S<\+ABA9_YPNQGCCG#EK-DFP+<4MWOT'3H;#6RVC!U2_:-5C/0=F6 M"UHV9)E!F5?[?_+0&'% D#IV@M\0?)T0'"$,&L+@U A!0PA.C1 VA% G1$<(M44.
(3HTP; A#-5A[=]70Q$20Z9C1'6(U6JK5%VI\%5N.2%[5I7@GF'R:2YZ8 M_DD%(#Q G] M<" L6R-2+5 ,][)*-[+F!$H>9-USX.C3G9P(BVT!B"Y/@+^/ M09"\X!^D^/>
[&+U_^P&]17F%OJWIEDL:'[M"=J%.Q,V:=" WZ?I'TAV@:UJ) M-4=)M8"%A1]W\Z,^?MK-QWZ'@"N];P? ?QR 2[]3\>NV.D,#[R/R/3^P)'1U M.GU@\^-
ET9.714^[Z3%DDHZ/TF>GT_V.H1BTE>TXG(%(Y7@JJKY M=I[)P69RN:3,6JQ[O5#IU8O^_73HC=W[P^$S(7CX'!);5#1(8D)JPPXAJ0D9
MC9Y#9I9<0K_%//,L:#T+NCV3#7E&"B183@JK27N!Z""J[I&)P('F4:](8A'1 M^I^:$,W$F8F(/+M!86M0V&G0T^J)J%@#LSD4FE$CS2(3@C6'+ @<:AZ9&%\S
M.K7)^)I+%HP_LML4M39%G3;UO4X^HAFCW%I?D3FJH5YA)@;KLR,V,=% PR26 M6+X6*S4QPT ;K)DE'W]TQ,)A:^&PT\(_@'/T[LVYC_%GM&)J&6.0@?S4L[WI M+H>]\[(7$?
677>6G7>:=4W*DAA\^3\A%HR,68MF1BSEBRQ MC%HR,68M6?(Y6DNCUJ#1BZ8C^N<:RCFP?VTF=DK7>ZL+OB$93!RY>>+ [L&9 MOGN#(^^S[?/G-<7BUQ1+7E,L?
4VQV2N)/:L<[#WM*+S.VKDCA=S4JLJ!+A@PT9[K0O!CDJ64[V.W5I(BDI$_G_JL'J'S8^ZP+=/1.BK^3]*DF_2MH/ MF5D@6#?-/=C0EL!6ZJR"HXQN*['_-FU;V_.0+^H40&N_Q!=7V-
(>XXO$UI[6 MYRIJ8_T4=G\H56N[FI [2G3=-?4$L#!!0 (*@R.UD.._.\H_,)L. 9 M>&PO=V]R:W-H965TJ<D9R)"M"GF3CCW1J.3(A M*&'-I0(6?WN80UE*(9'&MT[3ZD-
*XO'SB_JR&;L8RPHSF)/R[R+E^=0:62B% M#.]*_IDB8"5Y' M\%1"<(;@=P3_T@A!1P@NC1!VA% E1&<(44>(+HT0=X2XF:S6W69J$LSQ;$+) M 5&)%FKRH9G?
ABUFI*AE)3YR*MX6@L=GGP@'Y ;H5_0HRJ&H-PC7*;K'] FX M;"V>1)!WAG"(2'1&?(A:O:BQUA'N* MN#,@@AYR8DK0FQ(,FO*%<%R:3&EIT5$H[[UJBXYQ8R7E1,>$@:=8HV-\)U#,
MT3&1_UZQQQ#+.^-/V/L3#OHSN BB?^ZA6@']UV3@H*X\?(S9%]]A:HG3!0.Z M!VOV\T]NY/QF6B6N*99<4VQQ3;'E-<7NKB1V4C917S;1<-G@4ISYFJJ!:EN2 M[P!H!35D!3=NBY'A2U*J>V[
1.HRI&/\0%V(=(PW4F(M=4SDJHN1C@E\S_RU MQ;UM\:!M#Y1DP.0)&)H]'PBDWQ'HQ+]DC;'3QE2',=HB2&ULK5=MC^(V$/XK5GJJ[J1V0YPWH("T2X#VI&U7
MRUW[H>H'0X8ENB2FMH&]?W]VDDW!-BG2\05BYWEFQL^,'<_H2-D7O@40Z+7(M2SYVMD+LAJ[+UULH"+^C.RCEFPUE!1%RR%YY%D)3PSQ?5$0]O4!#/#([\Y!FIE:PH_:
(&OZ5CIZ<"@AS60ED@ M\N\ 4\AS94B&\6]CTVE=*N+I\YOU>;5VN985X3"E^5]9*K9CI^^@%#9DGXMG M>OP5FO6$RMZ:YKSZ1<<&VW/0>L\%+1JRC*#(ROJ?O#8ZG!"D'3L!-P2L$X(+
M!+\A^-=Z"!I"<*V'L"&$.B&Z0(@:0G2MA[@AQ%6R:G6KU"1$D,F(T2-B"BVM MJ8T@!(8R1$I4W2?2E<9%XQ4]3)[ME87/@4O44FZ%=)\#HINK&.\3$"3+^0?)_;Q,T/MW']
[E)7HTY;NN63RD2OD M.E0T[KJ)^:&.&5^(V4>/M!1;CF9E"JF%GW3SH__CS[OY'NXPX,H$M%G ;UEX MP)T6/^[+.^3W?D*XAP-+0-/KZ;Y-C^_S/OL^[_-N>@)K2?""O6
Z9FY"!=PY9F!!\$LN93D&K4]"ITQ]B"\PF3$V+3I<]T)0Q(5B#)"8D MUA8U,R&!!IE;'/6U-"U,S""V2Q.VTH2=TGRB@N0V:4+#582UA$]-C#_0Q3$Q MGJ?G?&9Q-M")V*S?
0#N(IS8,UG:=B<&1ONE, MC.]INW=N8D)/\[4P,8'7MV^Y?BM;OU.V)T8WP%4'(??=!L"J5=_B-]:T,C%> M7_^PF9@^UM8X,S$XT-\HBR\6; MJBEE0O1$)R;$UVO*XDB-
IB04#_%34BLG^'N21M1 'NI.D2.UG1?BOIBT,ZV M3>A]U7MI\P_><.I9YA-O.+/ SV4S6_>>_[FM.^%'PEZRDJ,<-C*$WETL%\#J M[K(>"+JKFIL5%;)5JAZWLB$'I@#R_8;*!J<9* =MBS_Y!E!+
P04 " "H M,CM9Z#' H.D(#35P &0 'AL+W=OGIA]5^<& (5OU"/7;2KO;' M[]@XF#%F$J[(])Q\"F)GK&9O;CY_AQG/QF.7?^9JQ@OQ,XI1?#M9%L3D?C?AB
MS9*0GV4;EHIW5EF>A(5XF=^/^"9GX;+NE,0CJFF341)&Z>#JHMXVSZ\NLK*(MHY3-<\++) GS7S;\)[=LN+K9IZ+5Z,=91DE M+.51EI*3G0JA&QF"V*"A&* MAP?VD<5Q11+C^-% !
[N85SZ6"^=$B3IL/DI1&F38?I2SM830?K MI8=UUG28U7+8?G[UAV^'17AUD6>/)*]:"UKUI%90W5M\YE%:B?VVR,6[D>A7
M7/V>%8SH$_(;N2WO./M1LK0@SH/XS\E[FQ5A%'/R!_M9E&'\@;PC(\+78QPS[@^OH"B60WEZZU-_MWK_[T(.QU9A_E?$9H1,9L_])'!V?\QPX/2-CK0,^2G-?3ALK]M938VRV$!A=-MQAP?
E/]R&GV>%CRSBZ'813IM:'T426WCW2DXKK'&$>S'+$E$VK\MLL7W(;FM-ML4/RN2QX(4ZH*+TG[\4)M@W7=T1OE/CJ:GG.-^&"70[$Y9"S_($-KO[^-WVB M_;-/TTB8C80Y6]BDAE77\
(]H6*C.H=1AV;X\G,FD[EJ/YA M0VJ:=&H89$,W?M)!49.Q49KU!1P'G)EL\)2$D^54!(F(V$.<9+ M!82,ZAU&/2*@PX;] @*-3E*9N5.9J599'').LA7Y%N9Y*$J%+"=U@3Q\VL*? M-
&>7>96[YBR/LF<5J(QZJ@*1,!L)<\R#C]@:3\RQWM$?,J9W&%,WQY:NCSOR MZVDWLPR+=M0'&INDOLE.?1.E^N9YMF!LR3?GUARQ_+_")7,\^@A%!.@>2RB)_MO]LE'&>=4 M^2!A-
A+F(&NN8A83X2%H!@DL"MG<"M-\V*2OJILD;";.L@M8Q-K?J3TXN#_M#.HB81X2YB-A 0@F*7:V4^SL]2DYF#O;Z0OY%A5K13U:G* MTLK0I\H9";.1, <)A350VEV0U-FN%J MDQFU.A-
)WIEUD?"TB:W=!TNG<)T,X,@W8O ,BH+I3F06D^E!:@:++* M6W]*5QM4ZF]0V&]N6?FNK<*5*1UJ5D%I-I3F0&DNE.9!:3Z4%J!HLMA;&TU_MQD=[(X=#'?9DX4-=-
KW'&;.,&9V8W02.#.M":1Z4YD-I 8HF:[HU[72U;_?:-M!'YZP0[U\; T&TISH#072O.@-!]*"U T^4QH#43]&0?Q+RS8H6XCE&8WM.I2 M*Q7L^JR;\)%A72C-@])*"U T629MY:G_GK/<_]KR!?
6[%#C$TJSH30'2G.A M-_]*\Z&T $63Y=X:H+K: 7VSFAUJC4)I=D/;K]FG,]TRS8,O7:#N*)3F06D^_ME!:@:+*F6XM4?[U'ZD8Y6\6_U$D;ZH-":3:4YD!I+I3F06D^E!:@:/(M%JT=
M2M5VZ$W)Q1:1MZ\7/\J(1]6]3\,J,2^$VL/[^H3:MI9)QU^5(_J5"5#:0Z4YD)I'I3F0VD!BB8KN35(J=H@_?R8LIRO MH\V>>H>DNA=/S!;K^>4ZBY>B2:]J]1[5:E97M5#O$DISH#072O.@-!]*"U
T M6;6M=TG5WJ6JP/B=/>Z*#&F^>&(1HA["J44(E&9#:0Z4YD)I'I3F0VD!BB:? M!*VU2=_XWCMZ>#O7U)IJU-2[&1QJ54)I#I3F0FD>E.9#:0&*)HNWM2JIVJIT M?
B[682HJY2^A*)Y[U;D%Z(947>B:T14GUZTAPHS872/"C-A]("%$T69^LY MTM=[CI]8?B]*XR_L013%K"DM;C=QI'87U1%/KB:@[B*4YD!I+I3F06D^E!:@ M:++F6W>1JMW%6LC-7.\?3W?
=5"ML#/9TG$>99O]2O]).1H9N^5 M,=0[A-)L*,V!TEPHS8/2?"@M0-%DQ;?>(55[AS:[*TB0\B(OJY\W#8DK8I'K M)"N%LH_<,:E&GBSJP]LE :2Z4YD%I/I06H&BR5EM/D*H]0:'*
MO(C^&];+Q&4K4FO7COBB%NO[>W:HV^L=KH.W9_^HH\51NUCH^(5@T_5;0-35KW8M8Q6VQH2 =* MX]TM\)E47YY5J\-R4E_WMPL-[K;N5J"]KM== M[6QW]'-7[]GNZ>?^=GW9%K]=
[O93F-]'*2KE M1>^RHLB2^NF:A4N65PW$^ZM,3"";%U6 W3J^5_\'4$L#!!0 (*@R.UF1 M7@%ZQ04 ,(Q 9 >&PO=V]R:W-H965T
M*L*WC$1Q%92E$UW39I,L2O+1XK;Z[HDM;FDATB0G3PSQ(LLB]NV! MI'1_-*CMR^>D_5&E%],%K?;:$V61/RQ?6)R;=)2XB0C.4]HCAAYO1O=XP\A MGI#F8EXB31YK^E<1B:CU!,7J,B%
<]T'Y!F0&;)6]&45W_1 MOFYKVB.T*KB@61,L>Y E>?T9?6U^B*_;+P3H#!,S[9K";_+O2H=Y_U"R:V)C!.+3U00A-'/Z*'@*/#A%1 MDG+T._DJBBC]Z78B9-(R=+)]$CAU OV=!%A''VDN-
ARY>4SB+F B>]MV67_K M\H.N)'ZBNS'2IS=(UW3]0H<>U>&_%ND8:68=CO@F8H1?&I::XI#5&$WQ-8JK MIMP7ZS'">D4Q+H1[UX:2RTYH=?C[G?#[#V7Z/B7HL5?PK*9<"_^O#"620]$M
MQ>_9<67:ZCVML,8[V$>:9=+CI:"KSS=H66%OT&^%X"+*XR1?HQ^3O$EW2>X' M);X\$GW@VVA%[D;R4,,)VY'1XOOO\$S[Y9*8D#"GALTJ6'E(VRUTT]0M0WJT M.S80,JEWGM2P;6-
N8:V;U3]O.#6G,WMN6=V& 63WPO.L6)N;,\ULDW8L,EJ+ M#*5%3_(3!@C<5>D(1XI$PSU"!+F&&>_V>?I]*EEZ-@^$>B\'9YA M/+/-4X$@>Q<"P3J6F:UE9N^Y"CG)+HE)'O-
6MBN"*=E#!3//_WLM;'9_> EF\\"1.Y#6_ M/$7I+3;RXN*:TD#U4:$N9 PMP:9A^?+(QMO7M@ M\" S^I"PH$_W0Z",'07GK8+S(=-J[QE521VJ'R3,@82YD#_/$N9#P@)(6 @$
MZ^ALMSK;_]N,JB0/51H2YD#"7/O"E*3-3V94R(P^)"SHT_T0*&-'0:P=[G!J M2@F?R4Z*1YH+J^4V381R+E7CAIH'2G-:2XHS0.E^:"T)060M&Z0A_=LL?J M6?7HK. 'Y'XIO-E3?R;XX=OT&/-
"_-+V_D/T7^I9Y<@/H4=V? MP0Y#TEQ0F@=*\T%I 2@MA*)U'=8/#NO];W8I9V,E9_!L#$ES0&DN*,T#I?F@ MM "4%D+1NB8?
*DQ876*J%0XY+TB,G(*5Q0!YAIO0^%!P^D3V=8NKMW'5R0;K M?KT@TIA\WM#$^OSDTM@%[9T'2O-!:0$H+82B=14]E*^PNGZUE#I*]>[122%+ M/?&"EJQ :0XHS06E>: T'Y06@-
)"*%K7ZD.Y#*OK90!5676&P8Y#TAQ0F@M* M\T!I/B@M *6%^$(I%-MS0\>7'RG AP(:5E?0@,\;0&MJ#4TUZD92T((9*,T# MI?F@M "4%D+1NB8?RF;X2MWLVND%^A?
UO]X#K:2!TAQ0F@M*\T!I/B@M *6% M4+2N[8<*'5:7Z(#G;=#*'2C-:6BJ1\-$WJ@-!^4%H#20BA:[?#DZ/GOC+!U M]?(1RM:Y*)^%+S]MGU!X;YZ+']R:%Z_W? Q8NLDYR@EKS)4&UOR_(?
5+PS4-M*X)NJZ?)7Z@0-*L6-R2*"2L;R.VOE(JWE3)!^]K&XC]02P,$% @ J#([M6<'DRKC-@ A < !D !X;"]W;W)K&ULC55M M;YLP$/XK%JNF1%%H+.)2V68*4A.Q:A?U9?
OLP"58!9O9)DG__6Q#69J1J%__M/M_SW-V#N1MMN7B6&8!"NR)GU[H%H0R)QI9VT)$(UZIG#)8""2KHB#B90HYWXX=WWDUW--UIHS! MC48E6<,#J*=R(?
3.;5E26@"3E#,D8#5V)OYP'AA_Z_"+PE;NK9&I9,GYL]E\ M3\>.9Q*"'!)E&(A^;6 &>6Z(=!I_&DZG#6F_^^M7]B^V=EW+DDB8\?PW354V M=JX=E,**5+FZY]MOT-1S:?@2GDO[1-O:-
PP=E%12\:(!ZPP*RNHWV34Z[_$T M3S<--P!\" B. 8-8' (.)92T "']T:X; "V=+>NW0H7$T6BD>!;)(RW9C,+ MJ[Y%:[TH,_?D00E]2C5.17=<-<+H''WEE*W1C+,$!$.]&!2AN42/L%,5R?O:
MX^DA1KVS/CI#E*''C%>2L%2.7*73,&1NTH2$/1QT)#1[/WS05<]I> R)AOM'X?/W MP_$),0;MC1A8ON (W[WY\@Q2-">"Z3LA46^2)%51Y41I:PPKFE#5[_KN-?&E M)38-:A.=7]UXOC=R-
MJGHQO&N-0EB2!L:,[GP2Q 2?Z^,$/O<]=VG;%#$/S M&?=CSKO< @[K=L;K8)6]^"D5G>ZD<^(S-!"\ W5EQ$M7U#O2>H%97WTLP1! ME/FO)J8?
4D6A\W\)_D\.!_[U@6P=7C>#*U3W$7E7^$#-;J\KF_P@1CN7ELI M0*QM/YW(F.A.>6"?^L.9WV&/]8BI)\(_^GH^W1*QIDRB'%8Z ME'=QI7,5=<^O-XJ7MJDMN=(MTBXS/29!&
=]ON*ZL34;$Z =O-%?4$L#!!0 M (*@R.UD]/"[5100 -(; 9 >&PO=V]R:W-H965TS^ M^]I))MR"R\5?('.^QQ?WMB1W=U2]ITO$1+@1Y82WK.60]P>;9LG2Y1!_D!7
MB,@G<\HR*.0M6]A\Q1"P,8F+UNWG9A/6[="U23-"$;[.,LA^ M#E%*MSW+M3X*7O!B*52!W>^NX)-D7A;39B\LRO*#&>(<$P)8&C>LP;NX]AM
M*$$>\3=&6[YW#513WBG]KFZ>9CW+435"*4J$0D#YMT$CE*:*).OQ;PFUJIQ* MN'_]08_SQLO&O$..1C3]!_$LF>U+3!#<[A.Q0O=?D5E@YJ*E]"4Y[]@6\8Z M%DC67-"L%,L:9)@4__!'V1%[
LFI%WBEP#L6^&<$C5+0N#2#7PK\2S,T2T'S M6!"<$02E(+@T0ZL4M/+!*GHW'YH0"MCO,KH%3$5+FKK(QS=7RQ'!1%EQ*IA\ MBJ5.])^I0* !?@=#R#$'= XF#'%$!"R<0F9@6KA4/9OB!
<%SG$ BP"!)Z)H(M3!9@0E.<8,0E9BK?E=DZ12IZP#D2/&>\H TB:P2&/\$8T06#JR5.P$"^/.!S MB 3$*?\BU6_3$'S^] 5\ IB UR5=[WH:@"V'J!HG[V.:/("&\QOP',^OJ=#H M?
X95>KK5EH6SF2K4* M;/JNT[4W^P-U&N(WW<.8\#1&U7P_)*K#!(W\T>!Y$ [J>ERKN[)Q M(Y.PT"0L,@F+3<+&AF 'M@@J6P0W3UE:Y;7&, D+3<(BD[#X!ABH\3]G ,[MM"H[M.Z?
HK6(:WUA$A::A$4F8?$-L%I?W,\Y\$6[\D5;ZXNWYZ?7* 33U\%K M-*WSA%9^K2=,PD*3L,@D+#8)&QN"';BC4[FC<_,BHE5>:PR3L-D+#()BSLG M7W]^Z_CK_(:$NHG =7;; L[]2X2>
<>VP&Z6%1FF145I\"ZUVG3 .O3'WK:1 MJ_7'T_1E$/U5:PJM\&I3F*2%1FF145ILE#8V13NTA[>SAW?S6J&77FT0D[30
M*"TR2HM+VOZ"X1UM+HUOR:B=$':;8JY^5^RR!4/+N'KH3=)"H[3(*"UV3W?I M3G>3:H).MI/LO9."#+%%?@C$0;Z37VSQ5:750=,@/UXY*A^ZCR.WICQT'Z.Z M\E@=6.4G%KNTQ6G7-
\@6F'"0HKFL@O/0D@U@Q0%2<2/H*C^_>*="T"R_7"(X M0TP%R.=S2L7'C4I0'>/U_P-02P,$% @ J#([68W&&ULC55=;]HP%/TK5M0'D-8Z7V5M M%2*U1 ,^M V5=GLVR0VQ=J[.=
;:6EZ(KWW.R3D7^2;9"OFD*@"-MGFO&U=2KM%[?8*SR"FJB+L0:N#DIA:R)-J5<8;660 I'JAD.?7^";T*YER9N M;R[31#2:40YSB513UT3^O0,FME,O\%XV[NFJTG8#I\F:K& !^G$]EZ;"O4I!
M:^"*"HXDE%/O-KC)8HMW@%\4MFIGC6R2I1!/MOA23#W?&@(&N;8*Q#PV,/&-MK)"Q\:?3]/I76N+N^D7]D\MNLBR)@IE@OVFAJZEWY:$"2M(P?2^VGZ'+>[ZL$,
(XB.$L".$IQ*BCA"=2H@[@FLU M;J.X/F1$DS218HND11LUNW#-=&P3GW+[MR^T-*?4\'3Z0VA ,3I'/W4%$MU#_M#G1#E@R4V>[EI/X1%/7QM^@2+__PK],!Z@S]ZF9Y ;>N#HT0].YT>
[M.Q:6[? MX;#O<.CTXB-Z;>?D_\X-:25N'02]J9NTN#Z,L&;W=1#F,D^)AO 1$&/V?,? M]?ZC-_W?,C,:";\!F2&#"M$L==FP]P*UFI,=(^=!$!XD.@64O0/:RQ3WF>(W M,ST(3=B0[?A5_ZZB
],#D/C \FM(<'U@&.]<63M?OQ.YHEPA!J4A^1:\%.8F=X4=#/V'(_T'4$L#!!0 (*@R M.UFYCM,&PO=V]R:W-H965TTK#_Z>-M9XW[17(WO5V*$!\#?BGH_,F9!25;:Y^#\:U<
M)&DH"#04&!@D_0ZP!*T#$97Q9^!,QI0!>'I^9?\2M9.6K?2PM/JW*K%:))\3 M5L).MAH?;/<5!CWSP%=8[>.7=7WL#64L6H^V'L!DU\KT?WD<^G "F%Z? 8@! M(-X+F V
613:5Q9EK23*/'.V8RY$$ULXQ-Y$-*E1)DQQ@XYN%>$P_VD1V)Q] M9-^MV;-'<#5;06.]0L\N5X!2:4_N([927U'8TV;%+B^NV 53ACU6MO72E#[C M2+4$1EX,>>_[O.),WA44$S:;?F
B%;,WX,OWP\6_<$X=&-L@QC:(R'=]EB]J M9G?> [XII\?/(SZLQB%/,WXXK?C_B+D80_JJ^,F@PI+\D&ZOC&<:=@1*)S>$ M=OW#ZPVT39S=UB*]A'BL:%?!A0"ZWUF:WV"$YS!N?_X"4$L#!!0
(*@R M.UGV?W4M8P(/,% 9 >&PO=V]R:W-H965TVTY1_/]L)45%+ MA?:E\>4\KWW>^IQI(^23*A UK$O&UHWZL;J69^;U*1DODB@H.$O.9=S$Z3R(;[P)^46S4QAAL)@LA
MGNSD*IMY@;T0,DRU52#FL\(Y,F:%S#7^=II>?Z0% \?# M!C :OP&$'1"^%X@Z('HO,.Z L7.F3<7YD!!-XJD4#4@;;=3LP)GI:),^Y?9O MO]?2[%+#Z?A&:
(0)',$5UX0OZ8(A7"B%6L%@%/P8PB!!32A3\(!K71,V-+&/ M]PD,#H9P)3#0R%J17BFIKXV%[*R?MH=?MD>'KYQ^/>:'T,4'$(8A.,=^'P_MGF!J\)'#HQUX\GX\?(W[QL7>RK"W,G1ZXS?
TOE!.-1Y=FW><;=EY"(*\YK! M_/'#:!)\ MVF-9U%L6[;W6UJ,[A!O3Z@:?URFK,\J7\%6(K*&,[32K%3]QXK:_K>))9-[1 M:M.7[9CH;/(Z)MF."?J(-B]_H\)L._Q)Y))R!0QSPP3'IP:6;8MI)UI4KN@6
M0IL2=L/"=&64-L#LY\(47C>Q==SW^?@?4$L#!!0 (*@R.UF\VCF%HP(M '\(9 >&PO=V]R:W-H965T+"=66<08[E.2^ Z9V4BQPK/14;5Q8"<&)) M.75]SPO='!/F1#.
[=BNB&2\5)0QN!9)EGF/QZPHHK^;.T'E:N".;3)D%-YH5 M>_,K4/?%K= SMU5)2 Y,$LZ0@'3N7 XO%E.#MX"O!"JY,T8FDC7G#V9RGRQA(6G'XCBD+6#G+#ZCA^;/.P0AJ,#!+\A M^,\E!
TAL('6SFQ82ZQP-!.\0L*@M9H9V-Q8MHZ&,/,65TKH7:)Y*OK,%: 0-MO4/73&&V(6L*Z%)*4%*OK73-)*5>X6G/_ND2%"94GFGD_6J)3D_.T-DB#'W) M>"DQ2^3,5=JB>9 ;-W:N:CO^ 3N?2G:. F^
?,\?]= 7Q^E+B#5]:.G!/MW5 MB6FSX[?9\:W>Z(#>3M#8!CU &\%E;V"UTM@JF6]G&X6!#F&[Z[Z+":9AB]FS M&+06@Y=:Q'%E H%6/%45%C#H5#_Z?
@/Y&L2//MM'U>N!+$%)WK[9AAZ[_L*_I7$]A(1MHD(7ZW\PV>\JR[FX+N:M!8G M_[/\)_\L_V.(/4S24_ECK%OZ<;-XK)CI#VB$9W+%!&H?P_TFD91 M2E+]^#N'=HJ<:6#U\S/=S4Y>G
ML0']/*#?#!@>"!CD-8-C,PSS@&$SH'<@8)0'C([_,,X#QMFON_TYLM_2#F1P M=<'9(^%I:T5+/V2"R*+53Q@FJ79GDJNCH8J35W\P26-MECBCZS/2,TZ)95C6G@Y=Z_WT1GQ.@?#+?
UX2Z]4^'6P7!''V[3N>J\F87W-M]H2[QX?OR^[IPV^#[[I3]X]/;FI^R%XATU[&ZQ_@>:H*DY/W3(C71%4\YTF&-MR7(3BI4JHY*P>V+3.[FGF^^TV/3"<"[6P9Q>=E3E%Y0_T,[5K[^80^.W?6I!
MPFPDS-G"!ADLO5P]7!D7W8>J6'9;O!E,ZFT\9)=\$*PFEWXAE[Y6+M5B=D@9 M6D);92!A-A+F]%]4!C*=AX3Y(%A-0H-"0H,C))0-T=+R$G(UV&(\OS3>))*I M*V8;?R)^W-
+ZC_*]]2M,F:JLT),Q&PAPDS$7"/"3,!\%JHAP6HAQJ M19G6,E(J_1YU$872I)"\DUZ.3PEL^W([$:(C3IRHBZ=V['':ZWWJU&9LJTXD MS$;'"'"3,W<*&E:)]&L.A:36NI\B#=?R/MI4>G(
M/Z1YF=5606V&MCI#PFPDS$'"7"3,0\)\$*RFQG&AQO'+5;!:[UR5B;R-V2;9 M.]+3TMHJ#PFSD3 '"7.1,&^\,P8U!XU1J]*6!/4I!#4Y.?,+K78MLJ:['Q+
MX_IW9"/3.4B8BX1Y2)@/@M5T91KEZIK1KE15+IFGE9$T=M^KQMI9?3JMKK-;0'3>A :2Z4YN4TTZQ\&Z.S0:->H7+6A559 MMC7;"4M-2:E*),G'0"IIS620S@JFE_5X6!)]XI(FZ.UB)
T&TISH#072O-R MVJ2Z1'-F N4&2EF7FU7*S6HG-W6-S TLE]*79*9EMY89DF9#:0Z4YD)I7DY+ MZU9%9X:Y4]A 6>M**Q?Z3?U* \Z<,E_%4///+P$/V29=?7M0A8ZI:Z1NOJG/
MTUIUT+5_*,V!TEPHS8/2?!2MKLW253#UMD+;B:<>UUJ"NTOY@\&@.4R#F@=0 MF@NE>5":CZ+5E56:#:;>;?AY\P2H^9#3M/,$J*< I;E0F@>E^2A:78"EL6 > MX2S\Y_DUO(:=IQL0U-
Z4!I+I3F06D^BE:76^DGF'I#X;_-)Z!60DY[:5QL M0[,Z4)H+I7E0FH^BU956>@6FWBSXH?E$X6T5_G\:&22+LBRVNP5 W\G6DH6: M$%": Z6Y4)H'I?DH6EW8I6=AZDV+GW$O0)ZR9FR/QZ-
>OUX+K_5=:RU J*\! MI;E0F@>E^2A:_=;:TMNP]-[&U^EU5A(_\' 9:&\+2%MM:^37@/,@D?J5&WW> MML422K.A-_=*2C42 MU-5":;^T^>F$:1GG_4UT*I1EAZJZ+>T(MZP@[
KR6EJ>L#H,&YFC2>$;D6M^SUOJ#FA10F@NE>5":CZ)M]=>M/(\?4[[,_MWLT@R#P=I6\?7B_V%N]_>)N]]:"QWS'/W>U;'$K,]J42MP%?AHD@$;U72.-L MI H_W[ZG8;LAV3I[ZO^.2/J7U!+
P04 M " "H,CM9A37(B[B. PPR4Q*9C67TSP80:TW'6M^33,4ME3"@L.1)I MDF#^;08Q.TP,VWCM6)%M)'6'.1WO\!:>0'[>+;EJF25+2!*@@C"*.&PFQKT] M\H?:/C/XG$,002,V U=\>YA#'FD@-
XVO!:90N M-?#X^97=S^:NYK+& N8L_H.$,IH8 P.%L,%I+%?L\!L4\W$U7\!BD?VB0V%K M&2A(A61) 58C2 C__%+$8F'3*X,K0),J$ZL)\G56Z)P9[E7YX)7&STR*B.!%C2$L
:_^!^\TT!@JA"4<7!>XS!S M&AD_L7T'=:T;Y%B.4S.@>3/\/MTJN'T1[C7#?5AWD#/0<'M8%XYFN =!Z;U; M_??#G<:8MDM:U2;;(R=R,3'\(M]E-K;.Z/]:M:#*UA:7,B4J\4J==6UH#C6F<+
M9=&F1[\ELA/Q^J5X_1]30QO=7"MHFV1>3M8_$K2J9]7FO#16+7KNA=)X5\;^ M[GMC/T^3-,9Z4XSF6 ;1K2J@]^'?RE1MNB62[%4=91IAN@6]85H(2=1>&!#;
MH&>.J<#Y[GK)20!UVC4.\UKMVB3S[BJ+\;9GGVG7ID._);*3?!B4^3!HS(D,"@1YHT/RI;.2[5K@VR;PVR19MDODMD9TH/"P5'OZ8:CNLK O; M/:M8\ZI-]
[SN>8W#O5:FJL/S(EJUZ!T .P^I>73(5,'99MJ86S2T@_+>9OHO4$L#!!0 (*@R.UE" MFPZ(.0, *0-_9 >&PO=V]R:W-H965T2!!%H&2(7 5FE4J*S;BVDO3'* U<1FM@/=/OWL)&0\A*Q(M>0.Q??
^?SW>^Q.YN&7\6*P")7N*(BIZQDG+=,4T1K"#&HL'60-7(@O$82]7D M2U.L.> P%<61Z5A6RXPQH4:_F_9->;_+$AD1"E..1!+'F/\>0,2V/<,V=AV/
M9+F2NL/L=]=X"3.03^LI5RVSH(0D!BH(HXC#HF?,](K MF3/VK!OW8<^PM$,002 U :N_#0PABC1(N?$K9QK%E%JX_[RCC].UJ[7,L8 A
MB[Z34*YZQHV!0EC@))*/;/L9\O5XFA>P2*2_:)O;6@8*$B%9G(N5!S&AV3]^ MR>.P)U"<+O!>.T,K%[32V&?!2B/M M8XG[780,T M =4U4[LX3") ;'$Z?.V#Q"02[Y3AT\Q'UU?
OT!4B%'U=L41@&HJN*96#>AHS MR)T99,XX9YRQT811N1)H1$,(2_2C_^B="H"I(E.$Q]F%9^!4$A_8IH&:UGOD M6(Y3XM"P6GZ7+)70_2;-0)\^N$C>]J$C6N"'638*S+LU5!CWLG6LKVC[3<\
MM6E:1S9^I2^7YB"#M2HJXM3"W7/[(%ZM(EZMZG@UT'T#30@-T2?.DC7Z(L/J MBJCD75H1=<+\.F&C.F'CFF '&6X7&6[74!&5C$NS6B?,;Y_4H7=./B;EWBHR!+]/SOD
!2ZC,OO)%;W&EN$M/TD?] [OCVR7](W4%R6X, M__#9_66"^9)0@2)8]*FL1EMYRK,[0=:0;)V>8>=,JA-Q^JB^8R%P;:#&%TR= M8_.&GJ"XF/7__E!+-P04 " "H,CM9KUR6JZH" #C!P &@
'AL+W=O M&ULI551;]HP$/XK5K2'5MH:D@#=$$0J!+I- MZU25=GLVR4&L.G9F.]#^^YV=E-(V4*2^@'WYON_.=Z>[X4:J>YT#&/)0<*%' M7FY,.?!]G>904'TF2Q#X92E500U>U*A MK-QG
JX5T5514/4X!BXW(R_PG@PW;)4;:_#C84E7,_=S5UXKO/E;E8P5(#23 M@BA8CKR+8' 96;P#_&&PT3MG8E^RD/+>7GYD(Z]C P(.J;$*%/_6,_'.K1"& M\;_1]+8N+7'W_*0^ MZZ'7$'JO"?
T]A'Y#Z!_KX;PAG+MBU=EUI4FHH?%0R0U1%HUJ]N#JZ]A8$29L M)\Z-PJ\,>2;^+0V0;^0+^<7H@G%F'@FV-YD6)9>/,2UIB9W);;-#1BF-O0
MD),$#&5'^4%X0,#'_&Z3'#XE>1P>5/Q9B3,2=3Z3 ML! V6P*:'$^/VO+Q,>_3CWF?':8GD"(]V$N_/)X>'BA%M.WWR.EU]^A-L+** M+2H[!S4QDLQA#8]*%,A$%CC?
-74C\B(U;9U;B_>F_A,S>0J+H)>3R+:3W'$N=/W]G=A2@5FXM:)+*2AB;QAWK=O-< MN('[RCX.!I.@Q9X$@VF;?88;K%XXSV[K]7=%U8IA=3@L,83.V3D^0-4KI;X8 M6;J)MI &YZ,[YKB%05D ?
E]*G&K-Q3K8[O7X/U!+_P04 " "H,CM9Y]^, MK6," #3!0 &@ 'AL+W=O&ULC93;;MI M$(9?9>5&52*EV-A 6@J6$JRJ]906D:2]J]'JQF &OL@=W=PW)VW=V[5AN!(@; MO(?Y?L_9F:R4_K)% "6/
LNS30HK"W'86CR @0U/56"Q)NUTH):W.I :$H-_M=.4AP<,XBD:AH$P&Z<2?S74Z497E3,)<$U,)0?7+#7"UFP;]X/5@P3:%=0=A M.BGI!N[!/I9SC;NP55DQ =
(P)8F&]32X[H^SQ,7[@)\,=J:S)L[)4JDGM[E= M38/()00<+&_Y)=$QL%)*^,5:*!,0/!9/VDSTT=.D!_< "(M&R ^%4@:(#D5 P%>FMN+KD%%+TXE6.Z)=-*JYA2^FI]$^D^ZSWUN-MPPY
MFWY7%D@_(A_(3-G!+'Y1:PB5*]Q+R^0&9,[-D/,,+&7+S/R/G9!3DC3)*'0E4&EW^8-UG>U%G& M![+\5LD>2:)+$D?Q8 \^.XYGD"/>]WBR!\].Q^/_\1#+W=8\;FL>>[W! ;T% M&*
Z+\CU1@.XFEVV=9R#SO$ .VY?E6K=3U[7-?0VC7H1.MIV:W%*4'8T0S=K MQJ:D.4P#'"8&]!:"]/V[_BCZ?,1_TOI/COK_80O0G7_,/J>UPK!C8CBZ&KUQ
MNB\H'KYQNB=HV%&J'82=#G+C[H[J#9.&<%@C%O6ND-?U"*DW5I6^J9;*8HOZ M98%3%[0+P/NUPL9J-JY/VSF>_@-02P,$% @ J#([6:((_%S+'P DT8" M !H !X;"]W;W)K5(S

*-1X)6V]""MGW-MUI<;("FP"B"?KZCL5!N;RD#{P6;\+U!+ P04_" "H,CM9\3-\IE8# % M# &@ 'AL+W=0&ULO5;;;N,V$/V5@;HH M$B!K76S+26H;B"WO-D#2!LEN^U#T@9;&%K$2J9*4G>W7EZ04U;%E-0&,OECD M:,Z9F4-J/,,M%]IDBJC@.<^8G#BI4L6UZ\HXQ9S(`B^0Z3%{IIYH0R9SJVM@8\>W$\9T7PR-=I\H8 MW.FX(&M\0O6U>!!ZYS8L"C$R_M;A-XI;N;,&4\F2\V]F MZN7[@_V=IU+4LB<_*DA'Y+-4Y-?^'$*P;^$C_"K2E' V2V+>8!GL'C65UBG6H M",TD?,%G59+L7+M^?8K@[,,Y? #*X$O*2TE8{>NT@D96C>N@\'^Zs,&1X#[<_M]'T.O=*G2(T6_N1M_R#8[P/0@>(R825H+G\$0R!+X",4U* M^WG#C92H6L^:{AY:8M.J-M.@U"EM=]7L#& [ZX{4L2(PI1S= B6*#SO3''_S0 M^ZE-V%.2+4Y$]DKT02/ZH%/TS[JWP]D=E_(<=".-J"RXI+:I:O&/*SXX4-P/ MPSW%.R,_5_'#@-]K<(M#CX^[.;V29]C(,^R49ZZ_=Z'_772;5"G,;8-$<0%W-ME"Q1\M7W"WC$#;(2]3/F:T; ,NTLL\XP[1B?D]RJ"(+.X0]!+CRKMIU#1M= MPTY='WMPVX-[RA+X+'A9P)U*>O#/>9+%'^V"=C)}UX!3TD6G9)L<2*R5XF-\M3W$'>^>RWV2,^XU4CZ+WTU(<3L;9.0H8K'K*J-R9_,E/_P%02P.$% @ J#{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|QW7;.^*B5>2-]M$@XI,/Y1K+OD%:T!&[*S|.44D[RDFBZMV+&[$MEB&BB3V,0O37?RG M!LJ50JQ? BXFM[>WJ=$;ZV^'Z="$6,<(5R%B'D,6Y^-X"LCP&+)L0FS[A\R1 M!79E@=UJP0L1.WT<_0 MV(W>5V&S8PFIC:,KDJE9L99$;] .$-;R+N#H?^R#!9?V@U? K\X*FRN95V[4+0I=B\2S&W2[%%EV+>H.FVW:_O M&0K00)T0PRHAAJT)\95R'*L2HI5V;4)T*3;O4LSM4FS1I9@W;!Y$[$%MY5TV M0;93/!'I!Y^U";2;_{J#(9]FA! <'0;JVND7YE%)\3.IGQFAN*.R=#0T0/TN)ZI"APNLT ME>4BT_W #>5V]W0QP(E-3 K<6N\/5#-&K+I,*7Z5W]0QP{G.$3 K<6N,\5#&K\I+F"82T8'@N\)P1>+?"> M6\.H%HR>*QC7@K'NK.K7U5VSH)+.HS=$EZ65K3R0/>O5JL>2?+2BDO)U=U$ MZ>3L Y- 7(?\1);%2L"W G))_!OU*<\D>),753'GI:LS#2/Q=22*L"R&BNJ@_&K8-PG@AF1*Y;+ MK2!^`D/).SHAKN\,.>,9F^0*B/ADX6C[HD"_ ,M\K?%1M5^_J3<-\M_+7)5N_UD\'S@W<[Y.'SY8ZA*P;-T0;:-WR"-T^Is(2M MR1?*.54F8YSHB>^, ^? HT0 N>9)! =E1%-(F5%9*V9I2KD@.:^5^=YTM.N=`M,8\9R:K\0.OK!94_-W0+X#?1F/_[@C.R?NPQ2P28:5D[K-S.W;X^GULVA#3!K M]+M[=.|;-09=A=O1NU!8%7*<@\U+COM<4:G7CL.G:&H;$;E\ 3-*;GJ]|@#9Q# M3):215)GU>0K8#_U=4C1N2I/8()6V#"?$Q8@ D+D6 MQWB-8SRC8_3:0-X+ M42BO+]>Y!MRK5S$XC/R06U5I)UJ?%<+2N>@-M9QJH4JV.A@7#C>8.(,AD?C M^G&Y\<1Q/=MNE_,?EYL,1O;$.QJTF&T(D6"M+ATU?3HR3P)'6P7CX#>B3NTY M3-@"$^9CP@),6(@$:SEEW#AE_!_ O'C\>7;`|=MCZ^Y,913S8$)\5%A 28L M1(*US#%$QFN.:LP@#%B3@+---6H'FU_].VZ7)"!?0.9VL.YJ.\9:3_4[M)LS'A 68L!)UO+!>>.#\YHZ@PE;8.)\3%B "0N1 M8"T+.,?8^CV&_]/GR0U&:IKRWA$BM05(_P= T56O2Z#[X--H^4GUO2;JC:>TA MCZ8A<\"GF@B5YJ?2 E1:B$5K&^D@(>;89Z,JJU7M6<]fG(3:LQ!XO\1%W/ MX4.ZTW<%6V<0?/XP1]_%5)(=:Z>E<[()^ 9>?T'4-YM M#C-^0.Z5LFLG/3!JA.)-OI/Z-73$J6Z<,MT!AX64#=7S,F'T|*"IW M,F;_%!+ P04_" "H,CM9",S]GE\# T%@ #0 'AL+W-T>6QE56G%Z/Z=4>M6!"Z6V.!8@/BS /G;,NK=-;9:?:R+K> (ZY{1UN.LK&$R:87V2,ONO.:*>=4>LTH^;#A>"!C<=#.X"FL>7(F"FEBVPCV[Z1> MO@.L9R"0<<X((/K6,!J41"DJQ:V>E,7&^ SRZO'#JM0*9Y*LPNZUOW$P-QUD M4LB4RB9,Z*]-HP&G&7\'KZB M?F9;W,NL53?3<:(9:D'UT+-+8"?"WV2QWF_;Z5;Q>R9X*]66AMR/,'']-WDF:.ML:69++[-& ,8>XNRD+/G],V?-"\G^Z&C0*E-MH-+WG]A4 M;-]V_):D? *|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|G^9N3#&1OYAZ%?KT2W M1>3%B_-XWX.GA,,;SN:CY65^Q6IZ-FW8<>*.!.]D4*SD).M;R MT\G3*<';;A:<=Z-J[.'BVUQ*G:L_J7KKB|GF4X*UVK#X950+PP7,P-^,,CW M?3?CG>2S0/TF^'T;,%,,<:UM4\["|C !D?$?*_V(), &1R%,AKC;/^U8), M 61Z1$BG)3, F1T3,K$@13 M5U& _3RX7/'|@]P 9'4TR/=+Y@SD(1K)P^-A,KFT,:%P#FR<3R]L"*+@9?!N M+47'10S.N*P'L=J6(A).=&#C&,A807[H15?B@QZ&:#PX=,DUT8- 48ND0W(9"M%"K@4OU/^946]H12NG:)4)ZB0[L%T-8*,*/@FU2 M@$!=)SAO5TW_P+F-B003'=@P!K-4F. [MA7C9DADG8DM1N%'I;:2"_9,C5 MXS=Q? +#C;N24^,!.V0S6X>-04YN&.Q/-6BOF$[=[2XR<$I.X14OELWY9P5VQ M07TA;P;625;,F#"-H;!*%/O.,IZM[4X2(Z'$%$*)@,F.1OJY>9.*\[F7[4V M)A)*3"&42!OEFC>- %K.F_(<-7[GJR@L;$UDEIK!*I+7R@7=|8(W!?#O3=1$Y MVD%MC!034R@FTHZY7M|*_FVM:Q7G=W] M!&18V(*Q_AB12==C9%C8@K'[$2+ M+A^22TPA%U^\Z- 9/D&2*MGLC1>#:!W4|T.0.^F>C> WEWU[@"]N^K= 7IWU;L#1.ZJ=P?HW57O#M"([]X=H'=7O3M [ZYZ M=X#>???N +V]B74 >GMGV? B'0?0W#N3[SB Y]Z9@,<11+DP;9"**3)MD?FN3,\: ME0(%# 3 6T-O;G1E;G1?5'EP97-=+GAM;,W)N*T"-MM@$;IJ8WI6ZW77NP%&#@- "O^$W2Y]^SFDK;2IBU9ETKXW00GV^1VP]+D]N?]V M/%FW.O3=X#;1SOOI4Y*X>F?]RL7C9(=P9SO.?>7#U_DAF:IZ7SW81 FADWH< MO!W\VA]K1#??=W9;/79^]?D0? G;M&RBV78N6MV>%AZS-E$U35U;5S[<3YZ& MYX>4]4M"'"8N:]RNG=Q56! E[R8<[_PYX&??UR<{5VUC5_?5[+]4?5B5'+K$ M^>?.NOA\B7=Z'+?;MK;-6# _V84OLIME<=M9Z_LN/A6].I_QPNYIF]Y[`LEQ)WH*A>SLV_./^)882E_\?/9XVHUM_C({O-X? MX[Q?SL,ER^7R=_SK&;_5_V ?"M)'"NDC@_210_K0D#X,I(\"TD<)Z4,*2B,4 M426%5$DQ55)0E115)B5527%54F"5%%D5159%D5519%44615%5D6155%D5119 M%45619$UI&UL4$L! A0#% @ J#{{66@8 MPZ5& P G@H !@ {"!#@@ 'AL+W=0&PO=V]R:W-H965T M&UL4$L! A0#% @ J#{{6=N<4K!V! (!8 !@ M {"!0A8 'AL+W=OX; !X;"]W;W)K M&PO=V]R:W-H965T&UL4$L! M A0#% @ J#{{6:67_QF0!0 !A@ !@ ("!$#@ 'AL M+W=0&PO=V]R:W-H965T&UL4$L! A0#% @ J#{{652^ MWS0T&@ /O$! !D /1 @ ("!,;D8 'AL+W=0&PO=V]R:W-H965T&UL4$L! A0#% @ J#{{61@V8POH P &@H !D M @ ("!K&P 'AL+W=0&PO M=V]R:W-H965T-_ !X;"]W;W)K&UL4$L! A0#% @ J#{{65&{(^B% @ =@4 !D ("! MVX('AL+W=0&PO=V]R:W-H965TF(!X;"]W;W)K&UL4$L! A0#% M @ J#{{6:Z)+JQ8 P H D !D ("!_8L 'AL+W=0&PO=V]R:W-H965T&UL4$L! A0#% @ J#{{68]-XBCK @ A < !D M ("!OJD 'AL+W=0&PO=V]R M:W-H965T&UL M4$L! A0#% @ J#{{65 ?(0P#!0 RP\ !D ("!C+, M 'AL+W=0&PO=V]R:W-H965T&UL4$L! A0#% @ MJ#{{63#N<1C& @ D < !D ("!_&PO=V]R:W-H965T&UL4$L! A0#% @ J#{{64N2#4J P M3@< !D ("! M4 'AL+W=0&PO=V]R:W-H965T&UL4$L! A0#% @ J#{{651D?ZE9 P H0D !D M ("!1MX*

'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ J#({61@ZY\XI P @0@ !D ("|_/$ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J#({ M62X7A&PO=V]R:W-H965T&UL4$L! A0#% @ J#({622C+24\!0 ZPL M !D ("!H04! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J#({67ODFT+- P]PD !D M ("!-Q(! 'AL+W=O7HD" #Z!@ &0 @($!%@$ >&PO=V]R:W-H965T M&UL4$L! A0# M% @ J#({6>P:H+, ^ @ M < !D ("!E1L! 'AL+W=O M&PO=V]R:W-H965T C M 0!X,"]W;W)K&UL4$L! A0#% @ J#({65@Q M%L%) @ P =P@ !D ("!VB8! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J#({634**\ND @ O04 !D M ("!VC ! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ J# ({68Y3H$9H @ 304 !D ("! M=CD! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ J#({6=:P:1A) P =P@ !D ("!V$0! 'AL+W=O8" !\!P M&0 @(%82 $ >&PO=V]R:W-H965T9%+ , /L' 9 " @75+ 0!X M;"]W;W)K&UL4$L! A0#% @ J#({60R$LU&Z M @ P04 !D ("!V$X! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J#({66"0 &0 @(%]7 $ >&PO=V]R M;W-H965T&UL M4$L! A0#% @ J#({62=AF81* @ /@8 !D ("!#6(! M 'AL+W=O!@ &0 @(&,9 $ >&PO=V]R:W-H965T&UL4$L! A0#% @ MJ#({6;[<7*FA @ ?@@ !D ("!8&D! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J#({65W/)/(9!0 31T !D M ("!B(8! 'AL+W=O&PO=V]R:W-H M965T. 0!X,"]W;W)K&UL4$L! M A0#% @ J#({6> S]62, P X1$!D ("!$9(! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J#({ M66MEH('N P [@\ !D ("!+)X! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J#({6<'DRKC- @ A < M !D ("!;;$! 'AL+W=O&PO=V]R:W-H965TVX 0!X;"]W;W)K&UL4$L! A0#% @ J#({6;F.TQSE 0 "00 !D M ("!<[L! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ J# ({6<,*)*$Q!P .4, !D ("!\,! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ J#({6;!< MEJNJ @ XP< !H ("!W-$! 'AL+W=O&UL4$L! A0#% @ J#({6>??C*UC @ TP4 !H M ("!OM0! 'AL+W=O&UL4$L! A0#% M @ J#({6;((%S+'P DT0" !H ("!6=&UL4$L! A0#% @ J#({6<%E)XN! P HQ$ M !H ("!7/&UL M4$L! A0#% @ J#({63-(7O<*! WA !H ("!%?L! M 'AL+W=O&UL4$L! A0#% @ J#({64=R MS%SM @ ,0L !H ("!5_\! 'AL+W=O&UL4$L! A0#% @ J#({66Y4AM 9!0 3AT !H M ("!? (" 'AL+W=O&UL4$L! A0#% M @ J# ({62)1U9'9!0 @2P !H ("!S0<" 'AL+W=O&UL M4$L! A0#% @ J#({685@XAI*! >1(!H ("!5Q$" M 'AL+W=O&UL4$L! A0#% @ J#({651@ M)N^@ P FPX !H ("!V14" 'AL+W=O&UL4$L! A0#% @ J#({69,0EV8&UL4$L! A0#% M @ J#({6?$S?*96 P !0P !H ("!!1X" 'AL+W=O&UL M4$L! A0#% @ J#({66'Y):"(@ E@8 !H ("!NR4" M 'AL+W=O&UL4$L! A0#% @ J#({69G4 MRZ4R@" 'AL+W=O&UL4$L! A0#% @ J#({67PI_ 9? P @@L !H M ("!SRP" 'AL+W=O&UL4$L! A0#% M @ J#({6=E55YMA!0 /RX !H ("!9C " 'AL+W=O&UL M4$L! A0#% @ J#({64X?#@,C!0 GR$!H ("!<3\" M 'AL+W=O&UL4$L! A0#% @ J#({60CL M_9Y? P -!8 T (!S$0" 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ J#({64GM%/9& M P UD4 !H (!-U$" 'AL+U]R96QS+W=OU<" # end XML 144 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document.document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 145 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a,a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 147 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html3072711false790false6 falsefalseR1.htm000 - Document - Document And Entity InformationSheethttp://www.infoa.com/20240630/role/statement-document-and-entity-informationDocument And Entity InformationCover1 falsefalseR2.htm001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)Sheethttp://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unauditedCondensed Consolidated Balance Sheets (Unaudited)Statements2 falsefalseR3.htm002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)Sheethttp://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticalsCondensed Consolidated Balance Sheets (Unaudited) (Parentheticals)Statements3 falsefalseR4.htm003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Sheethttp://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unauditedCondensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Statements4 falsefalseR5.htm004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)Sheethttp://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unauditedCondensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)Statements5 falsefalseR6.htm005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedCondensed Consolidated Statements of Cash Flows (Unaudited)Statements6 falsefalseR7.htm006 - Statement - Consolidated Balance SheetsSheethttp://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-Consolidated Balance SheetsStatements7 falsefalseR8.htm007 - Statement - Consolidated Balance Sheets (Parentheticals)Sheethttp://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticalsConsolidated Balance Sheets (Parentheticals)Statements8 falsefalseR9.htm008 - Statement - Consolidated Statements of Operations and Comprehensive LossSheethttp://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-lossConsolidated Statements of Operations and Comprehensive LossStatements9 falsefalseR10.htm009 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)Sheethttp://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficitConsolidated Statements of Changes in Stockholders' Equity (Deficit)Statements10 falsefalseR11.htm010 - Statement - Consolidated Statements of Cash FlowsSheethttp://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flowsConsolidated Statements of Cash FlowsStatements11 falsefalseR12.htm011 - Disclosure - Note 1 - Business DescriptionSheethttp://www.infoa.com/20240630/role/statement-note-1-business-description-Note 1 - Business DescriptionNotes12 falsefalseR13.htm012 - Disclosure - Note 2 - Going ConcernSheethttp://www.infoa.com/20240630/role/statement-note-2-going-concernNote 2 - Going ConcernNotes13 falsefalseR14.htm013 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting PoliciesSheethttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policiesNote 3 - Basis of Presentation and Summary of Significant Accounting PoliciesNotes14 falsefalseR15.htm014 - Disclosure - Note 4 - Other ReceivablesSheethttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-Note 4 - Other ReceivablesNotes15 falsefalseR16.htm015 - Disclosure - Note 5 - EquipmentSheethttp://www.infoa.com/20240630/role/statement-note-5-equipment-Note 5 - EquipmentNotes16 falsefalseR17.htm016 - Disclosure - Note 6 - Intangible AssetsSheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assetsNote 6 - Intangible AssetsNotes17 falsefalseR18.htm017 - Disclosure - Note 7 - Liability for Employee Rights Upon RetirementSheethttp://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirementNote 7 - Liability for Employee Rights Upon RetirementNotes18 falsefalseR19.htm018 - Disclosure - Note 8 - Commitments and ContingenciesSheethttp://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-Note 8 - Commitments and ContingenciesNotes19 falsefalseR20.htm019 - Disclosure - Note 9 - EquitySheethttp://www.infoa.com/20240630/role/statement-note-9-equityNote 9 - EquityNotes20 falsefalseR21.htm020 - Disclosure - Note 10 - Basic and Diluted Net Loss Per ShareSheethttp://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-shareNote 10 - Basic and Diluted Net Loss Per ShareNotes21 falsefalseR22.htm021 - Disclosure - Note 11 - Related Party TransactionsSheethttp://www.infoa.com/20240630/role/statement-note-11-related-party-transactionsNote 11 - Related Party TransactionsNotes22 falsefalseR23.htm022 - Disclosure - Note 12 - RevenueSheethttp://www.infoa.com/20240630/role/statement-note-12-revenueNote 12 - RevenueNotes23 falsefalseR24.htm023 - Disclosure - Note 13 - Research and Development ExpensesSheethttp://www.infoa.com/20240630/role/statement-note-13-research-and-development-expensesNote 13 - Research and Development ExpensesNotes24 falsefalseR25.htm024 - Disclosure - Note 14 - Selling and Marketing ExpensesSheethttp://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expensesNote 14 - Selling and Marketing ExpensesNotes25 falsefalseR26.htm025 - Disclosure - Note 15 - General and Administration ExpensesSheethttp://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expensesNote 15 - General and Administration ExpensesNotes26 falsefalseR27.htm026 - Disclosure - Note 16 - Subsequent EventsSheethttp://www.infoa.com/20240630/role/statement-note-16-subsequent-eventsNote 16 - Subsequent EventsNotes27 falsefalseR28.htm027 - Disclosure - Note 1 - Business DescriptionSheethttp://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEANote 1 - Business DescriptionNotes28 falsefalseR29.htm028 - Disclosure - Note 2 - Going ConcernSheethttp://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124Note 2 - Going ConcernNotes29 falsefalseR30.htm029 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting PoliciesSheethttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AE2-9021-BBB71BB25947Note 3 - Basis of Presentation and Summary of Significant Accounting PoliciesNotes30 falsefalseR31.htm030 - Disclosure - Note 4 - Other Receivables (10K)Sheethttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-10kNote 4 - Other Receivables (10K)Notes31 falsefalseR32.htm031 - Disclosure - Note 5 - Long Term DepositsSheethttp://www.infoa.com/20240630/role/statement-note-5-long-term-depositsNote 5 - Long Term DepositsNotes32 falsefalseR33.htm032 - Disclosure - Note 6 - Intangible Assets (10K)Sheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10kNote 6 - Intangible Assets (10K)Notes33 falsefalseR34.htm033 - Disclosure - Note 7 - Convertible NotesNoteshttp://www.infoa.com/20240630/role/statement-note-7-convertible-notesNote 7 - Convertible NotesNotes34 falsefalseR35.htm034 - Disclosure - Note 8 - Deferred RevenueSheethttp://www.infoa.com/20240630/role/statement-note-8-deferred-revenueNote 8 - Deferred RevenueNotes35 falsefalseR36.htm035 - Disclosure - Note 9 - Liability for Employee Rights Upon RetirementSheethttp://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirementNote 9 - Liability for Employee Rights Upon RetirementNotes36 falsefalseR37.htm036 - Disclosure - Note 10 - Commitments and ContingenciesSheethttp://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingenciesNote 10 - Commitments and ContingenciesNotes37 falsefalseR38.htm037 - Disclosure - Note 11 - EquitySheethttp://www.infoa.com/20240630/role/statement-note-11-equityNote 11 - EquityNotes38 falsefalseR39.htm038 - Disclosure - Note 12 - Basic and Diluted Net Loss Per ShareSheethttp://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-loss-per-shareNote 12 - Basic and Diluted Net Loss Per ShareNotes39 falsefalseR40.htm039 - Disclosure - Note 13 - Related Party TransactionsSheethttp://www.infoa.com/20240630/role/statement-note-13-related-party-transactionsNote 13 - Related Party TransactionsNotes40 falsefalseR41.htm040 - Disclosure - Note 14 - RevenueSheethttp://www.infoa.com/20240630/role/statement-note-14-revenueNote 14 - RevenueNotes41 falsefalseR42.htm041 - Disclosure - Note 15 - Research and Development ExpensesSheethttp://www.infoa.com/20240630/role/statement-note-15-research-and-development-expensesNote 15 - Research and Development ExpensesNotes42 falsefalseR43.htm042 - Disclosure - Note 16 - Selling and Marketing ExpensesSheethttp://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expensesNote 16 - Selling and Marketing ExpensesNotes43 falsefalseR44.htm043 - Disclosure - Note 17 - General and Administration ExpensesSheethttp://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expensesNote 17 - General and Administration ExpensesNotes44 falsefalseR45.htm044 - Disclosure - Note 18 - Other (Income) ExpenseSheethttp://www.infoa.com/20240630/role/statement-note-18-other-income-expenseNote 18 - Other (Income) ExpenseNotes45 falsefalseR46.htm045 - Disclosure - Note 19 - Income TaxSheethttp://www.infoa.com/20240630/role/statement-note-19-income-taxNote 19 - Income TaxNotes46 falsefalseR47.htm046 - Disclosure - Note 20 - Revision of Prior Period Financial StatementsSheethttp://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statementsNote 20 - Revision of Prior Period Financial StatementsNotes47 falsefalseR48.htm047 - Disclosure - Note 21 - Subsequent EventsSheethttp://www.infoa.com/20240630/role/statement-note-21-subsequent-eventsNote 21 - Subsequent EventsNotes48 falsefalseR49.htm048 - Disclosure - Significant Accounting Policies (Policies)Sheethttp://www.infoa.com/20240630/role/statement-significant-accounting-policies-policiesSignificant Accounting Policies (Policies)Policieshttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies49 falsefalseR50.htm049 - Disclosure - Note 4 - Other Receivables (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-tablesNote 4 - Other Receivables (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-50 falsefalseR51.htm050 - Disclosure - Note 5 - Equipment (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-5-equipment-tablesNote 5 - Equipment (Tables)Tableshttp://www.infoa.com/20240630/role/statement-

note-5-equipment-51 falsefalseR52.htm051 - Disclosure - Note 6 - Intangible Assets (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tablesNote 6 - Intangible Assets (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets52 falsefalseR53.htm052 - Disclosure - Note 9 - Equity (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-9-equity-tablesNote 9 - Equity (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-9-equity53 falsefalseR54.htm053 - Disclosure - Note 12 - Revenue (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-12-revenue-tablesNote 12 - Revenue (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-12-revenue54 falsefalseR55.htm054 - Disclosure - Note 13 - Research and Development Expenses (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tablesNote 13 - Research and Development Expenses (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses55 falsefalseR56.htm055 - Disclosure - Note 14 - Selling and Marketing Expenses (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tablesNote 14 - Selling and Marketing Expenses (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses56 falsefalseR57.htm056 - Disclosure - Note 15 - General and Administration Expenses (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-tablesNote 15 - General and Administration Expenses (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses57 falsefalseR58.htm057 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tablesNote 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies58 falsefalseR59.htm058 - Disclosure - Note 4 - Other Receivables (10K) (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tablesNote 4 - Other Receivables (10K) (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-59 falsefalseR60.htm059 - Disclosure - Note 6 - Intangible Assets (10K) (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tablesNote 6 - Intangible Assets (10K) (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets60 falsefalseR61.htm060 - Disclosure - Note 8 - Deferred Revenue (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tablesNote 8 - Deferred Revenue (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-8-deferred-revenue61 falsefalseR62.htm061 - Disclosure - Note 11 - Equity (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-11-equity-tablesNote 11 - Equity (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-11-equity62 falsefalseR63.htm062 - Disclosure - Note 14 - Revenue (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-14-revenue-tablesNote 14 - Revenue (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-14-revenue63 falsefalseR64.htm063 - Disclosure - Note 15 - Research and Development Expenses (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tablesNote 15 - Research and Development Expenses (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses64 falsefalseR65.htm064 - Disclosure - Note 16 - Selling and Marketing Expenses (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tablesNote 16 - Selling and Marketing Expenses (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses65 falsefalseR66.htm065 - Disclosure - Note 17 - General and Administration Expenses (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-tablesNote 17 - General and Administration Expenses (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses66 falsefalseR67.htm066 - Disclosure - Note 18 - Other (Income) Expense (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tablesNote 18 - Other (Income) Expense (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-18-other-income-expense67 falsefalseR68.htm067 - Disclosure - Note 19 - Income Tax (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-19-income-tax-tablesNote 19 - Income Tax (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-19-income-tax68 falsefalseR69.htm068 - Disclosure - Note 20 - Revision of Prior Period Financial Statements (Tables)Sheethttp://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tablesNote 20 - Revision of Prior Period Financial Statements (Tables)Tableshttp://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements69 falsefalseR70.htm069 - Disclosure - Note 1 - Business Description (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-1-business-description-details-textualNote 1 - Business Description (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-1-business-description-70 falsefalseR71.htm070 - Disclosure - Note 2 - Going Concern (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualNote 2 - Going Concern (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-2-going-concern71 falsefalseR72.htm071 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textualNote 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables72 falsefalseR73.htm072 - Disclosure - Note 4 - Other Receivables - Details of Other Receivables (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-detailsNote 4 - Other Receivables - Details of Other Receivables (Details)Details73 falsefalseR74.htm073 - Disclosure - Note 5 - Equipment - Summary of Equipment (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-detailsNote 5 - Equipment - Summary of Equipment (Details)Details74 falsefalseR75.htm074 - Disclosure - Note 6 - Intangible Assets (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-details-textualNote 6 - Intangible Assets (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables75 falsefalseR76.htm075 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-detailsNote 6 - Intangible Assets - Summary of Intangible Assets (Details)Details76 falsefalseR77.htm076 - Disclosure - Note 7 - Liability for Employee Rights Upon Retirement (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textualNote 7 - Liability for Employee Rights Upon Retirement (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement77 falsefalseR78.htm077 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textualNote 8 - Commitments and Contingencies (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-78 falsefalseR79.htm078 - Disclosure - Note 9 - Equity (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-9-equity-details-textualNote 9 - Equity (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-9-equity-tables79 falsefalseR80.htm079 - Disclosure - Note 9 - Equity - Schedule of Shares Authorized and Issued (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-detailsNote 9 - Equity - Schedule of Shares Authorized and Issued (Details)Details80 falsefalseR81.htm080 - Disclosure - Note 9 - Equity - Schedule of Warrants (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-detailsNote 9 - Equity - Schedule of Warrants (Details)Details81 falsefalseR82.htm081 - Disclosure - Note 9 - Equity - Schedule of Option Activity (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-detailsNote 9 - Equity - Schedule of Option Activity (Details)Details82 falsefalseR83.htm082 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textualNote 10 - Basic and Diluted Net Loss Per Share (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share83 falsefalseR84.htm083 - Disclosure - Note 11 - Related Party Transactions (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textualNote 11 - Related Party Transactions (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-11-related-party-transactions84 falsefalseR85.htm084 - Disclosure - Note 12 - Revenue - Disaggregation of Revenue (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-detailsNote 12 - Revenue - Disaggregation of Revenue (Details)Details85 falsefalseR86.htm085 - Disclosure - Note 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-detailsNote 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)Details86 falsefalseR87.htm086 - Disclosure - Note 14 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-detailsNote 14 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)Details87 falsefalseR88.htm087 - Disclosure - Note 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-detailsNote 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)Details88 falsefalseR89.htm088 - Disclosure - Note 16 - Subsequent Events (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textualNote 16 - Subsequent Events (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-16-subsequent-events89 falsefalseR90.htm089 - Disclosure - Note 1 - Business Description (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2Note 1 - Business Description (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-1-business-description-90 falsefalseR91.htm090 - Disclosure - Note 2 - Going Concern (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274Note 2 - Going Concern (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-2-going-concern91 falsefalseR92.htm091 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-detailsNote 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details)Details92 falsefalseR93.htm092 - Disclosure - Note 4 - Other Receivables - Details of Other Receivables (10K) (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-detailsNote 4 - Other Receivables - Details of Other Receivables (10K) (Details)Details93 falsefalseR94.htm093 - Disclosure - Note 5 - Long Term Deposits (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-5-long-term-deposits-details-textualNote 5 - Long Term Deposits (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-5-long-term-deposits94 falsefalseR95.htm094 - Disclosure - Note 6 - Intangible Assets (10K) (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textualNote 6 - Intangible Assets (10K) (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables95 falsefalseR96.htm095 - Disclosure - Note 6 - Intangible Assets - Schedule of Intangible Assets (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-detailsNote 6 - Intangible Assets - Schedule of Intangible Assets (Details)Details96 falsefalseR97.htm096 - Disclosure - Note 7 - Convertible Notes (Details Textual)Notehttp://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textualNote 7 - Convertible Notes (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-7-convertible-notes97 falsefalseR98.htm097 - Disclosure - Note 8 - Deferred Revenue (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textualNote 8 - Deferred Revenue (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables98 falsefalseR99.htm098 - Disclosure - Note 8 - Deferred Revenue - Schedule of Deferred Revenue (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-detailsNote 8 - Deferred Revenue - Schedule of Deferred Revenue (Details)Details99 falsefalseR100.htm099 - Disclosure - Note 9 - Liability for Employee Rights Upon Retirement (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement-details-textualNote 9 - Liability for Employee Rights Upon Retirement (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement100 falsefalseR101.htm100 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textualNote 10 - Commitments and Contingencies (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies101 falsefalseR102.htm101 - Disclosure - Note 11 - Equity (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-11-equity-details-textualNote 11 - Equity (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-11-equity-tables102 falsefalseR103.htm102 - Disclosure - Note 11 - Equity - Schedule of Shares Authorized and Issued (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-detailsNote 11 - Equity - Schedule of Shares Authorized and Issued (Details)Details103 falsefalseR104.htm103 - Disclosure - Note 11 - Equity - Schedule of Warrants (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-detailsNote 11 - Equity - Schedule of Warrants (Details)Details104 falsefalseR105.htm104 - Disclosure - Note 11 - Equity - Assumptions (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-detailsNote 11 - Equity - Assumptions (Details)Details105 falsefalseR106.htm105 - Disclosure - Note 11 - Equity - Schedule of Option Activity (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-detailsNote 11 - Equity - Schedule of Option Activity (Details)Details106 falsefalseR107.htm106 - Disclosure - Note 13 - Related Party Transactions (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textualNote 13 - Related Party Transactions (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-13-related-party-transactions107 falsefalseR108.htm107 - Disclosure - Note 14 - Revenue - Disaggregation of Revenue (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-detailsNote 14 - Revenue - Disaggregation of Revenue (Details)Details108 falsefalseR109.htm108 - Disclosure - Note 15 -

Research and Development Expenses -Schedule of Research and Development Expenses (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-detailsNote 15 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)Details109 falsefalseR110.htm109 - Disclosure - Note 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-detailsNote 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)Details110 falsefalseR111.htm110 - Disclosure - Note 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-detailsNote 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)Details111 falsefalseR112.htm111 - Disclosure - Note 18 - Other (Income) Expense (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textualNote 18 - Other (Income) Expense (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables112 falsefalseR113.htm112 - Disclosure - Note 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-detailsNote 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details)Detailshttp://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables113 falsefalseR114.htm113 - Disclosure - Note 19 - Income Tax (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-19-income-tax-detailstextualNote 19 - Income Tax (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-19-income-tax-tables114 falsefalseR115.htm114 - Disclosure - Note 19 - Income Tax - Provision for Income Taxes (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-detailsNote 19 - Income Tax - Provision for Income Taxes (Details)Details115 falsefalseR116.htm115 - Disclosure - Note 19 - Income Taxes - Deferred Tax Assets (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-detailsNote 19 - Income Taxes - Deferred Tax Assets (Details)Details116 falsefalseR117.htm116 - Disclosure - Note 19 - Income Taxes - Operating Loss Carryforwards (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-detailsNote 19 - Income Taxes - Operating Loss Carryforwards (Details)Details117 falsefalseR118.htm117 - Disclosure - Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details)Sheethttp://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-detailsNote 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details)Details118 falsefalseR119.htm118 - Disclosure - Note 21 - Subsequent Events (Details Textual)Sheethttp://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textualNote 21 - Subsequent Events (Details Textual)Detailshttp://www.infoa.com/20240630/role/statement-note-21-subsequent-events119 falsefalseAll ReportsBookAll Reports aiff-20240630.xsdaiff-20240630_cal.xmlaiff-20240630_def.xmlaiff-20240630_lab.xmlaiff-20240630_pre.xmlwavd20240923_s1.htm

inaalogo.jpgtslogo.jpgtssig.jpgwavd20240923_s1img001.jpgwavd20240923_s1img002.jpgwavd20240923_s1img003.jpgwavd20240923_s1img004.jpgwavd20240923_s1img00

http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024truetrue JSON 150 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "wavd20240923_s1.htm": { "nsprefix": "aiff", "nsuri": "http://www.infoa.com/20240630", "dts": { "schema": { "local": ["aiff-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["aiff-20240630_cal.xml"] }, "definitionLink": { "local": ["aiff-20240630_def.xml"] }, "labelLink": { "local": ["aiff-20240630_lab.xml"] }, "presentationLink": { "local": ["aiff-20240630_pre.xml"] }, "inline": { "local": ["wavd20240923_s1.htm"] } }, "keyStandard": 227, "keyCustom": 44, "axisStandard": 29, "axisCustom": 0, "memberStandard": 31, "memberCustom": 47, "hidden": { "total": 74, "http://fasb.org/us-gaap/2024": 66, "http://www.infoa.com/20240630": 3, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 307, "entityCount": 1, "segmentCount": 79, "elementCount": 483, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1030, "http://xbrl.sec.gov/dei/2024": 11 }, "report": { "R1": { "role": "http://www.infoa.com/20240630/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2022-01-27", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R5": { "role": "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-06-30_StatementClassOfStockAxis-SeriesBPreferredStockMember_StatementEquityComponentsAxis-PreferredStockNumberOfSharesToBeIssuedMember_SubsidiarySaleOfStockAxis-SeriesBPreferredStockOfferingMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R6": { "role": "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R7": { "role": "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "longName": "006 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DepositsAssetsNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R8": { "role": "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "longName": "007 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "i_2022-01-27", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "longName": "008 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R10": { "role": "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "longName": "009 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-01-01_2022-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R11": { "role": "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "longName": "010 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "11", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R12": { "role": "http://www.infoa.com/20240630/role/statement-note-1-business-description-", "longName": "011 - Disclosure - Note 1 - Business Description", "shortName": "Note 1 - Business Description", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R13": { "role": "http://www.infoa.com/20240630/role/statement-note-2-going-concern", "longName": "012 - Disclosure - Note 2 - Going Concern", "shortName":

"Note 2 - Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R14": { "role": "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "longName": "013 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R15": { "role": "http://www.infoa.com/20240630/role/statement-note-4-other-receivables", "longName": "014 - Disclosure - Note 4 - Other Receivables", "shortName": "Note 4 - Other Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R16": { "role": "http://www.infoa.com/20240630/role/statement-note-5-equipment-", "longName": "015 - Disclosure - Note 5 - Equipment", "shortName": "Note 5 - Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets", "longName": "016 - Disclosure - Note 6 - Intangible Assets", "shortName": "Note 6 - Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement", "longName": "017 - Disclosure - Note 7 - Liability for Employee Rights Upon Retirement", "shortName": "Note 7 - Liability for Employee Rights Upon Retirement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "longName": "018 - Disclosure - Note 8 - Commitments and Contingencies", "shortName": "Note 8 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://www.infoa.com/20240630/role/statement-note-9-equity", "longName": "019 - Disclosure - Note 9 - Equity", "shortName": "Note 9 - Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "longName": "020 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share", "shortName": "Note 10 - Basic and Diluted Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "longName": "021 - Disclosure - Note 11 - Related Party Transactions", "shortName": "Note 11 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://www.infoa.com/20240630/role/statement-note-12-revenue", "longName": "022 - Disclosure - Note 12 - Revenue", "shortName": "Note 12 - Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses", "longName": "023 - Disclosure - Note 13 - Research and Development Expenses", "shortName": "Note 13 - Research and Development Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses", "longName": "024 - Disclosure - Note 14 - Selling and Marketing Expenses", "shortName": "Note 14 - Selling and Marketing Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:SellingAndMarketingExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses", "longName": "025 - Disclosure - Note 15 - General and Administration Expenses", "shortName": "Note 15 - General and Administration Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:GeneralAndAdministrativeExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "longName": "026 - Disclosure - Note 16 - Subsequent Events", "shortName": "Note 16 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "longName": "027 - Disclosure - Note 1 - Business Description", "shortName": "Note 1 - Business Description", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124", "longName": "028 - Disclosure - Note 2 - Going Concern", "shortName": "Note 2 - Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AE2-9021-BBB71BB25947", "longName": "029 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k", "longName": "030 - Disclosure - Note 4 - Other Receivables (10K)", "shortName": "Note 4 - Other Receivables (10K)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits", "longName": "031 - Disclosure - Note 5 - Long Term Deposits", "shortName": "Note 5 - Long Term Deposits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k", "longName": "032 - Disclosure - Note 6 - Intangible Assets (10K)", "shortName": "Note 6 - Intangible Assets (10K)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "longName": "033 - Disclosure - Note 7 - Convertible Notes", "shortName": "Note 7 - Convertible Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "longName": "034 - Disclosure - Note 8 - Deferred Revenue", "shortName": "Note 8 - Deferred Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "aiff:DeferredRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "aiff:DeferredRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement", "longName": "035 - Disclosure - Note 9 - Liability for Employee Rights Upon Retirement", "shortName": "Note 9 - Liability for Employee Rights Upon Retirement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "longName": "036 - Disclosure - Note 10 - Commitments and Contingencies", "shortName": "Note 10 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.infoa.com/20240630/role/statement-note-11-equity", "longName": "037 - Disclosure - Note 11 - Equity", "shortName": "Note 11 - Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-

loss-per-share", "longName": "038 - Disclosure - Note 12 - Basic and Diluted Net Loss Per Share", "shortName": "Note 12 - Basic and Diluted Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "39", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "longName": "039 - Disclosure - Note 13 - Related Party Transactions", "shortName": "Note 13 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "40", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.infoa.com/20240630/role/statement-note-14-revenue", "longName": "040 - Disclosure - Note 14 - Revenue", "shortName": "Note 14 - Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "41", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses", "longName": "041 - Disclosure - Note 15 - Research and Development Expenses", "shortName": "Note 15 - Research and Development Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "42", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses", "longName": "042 - Disclosure - Note 16 - Selling and Marketing Expenses", "shortName": "Note 16 - Selling and Marketing Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "43", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:SellingAndMarketingExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses", "longName": "043 - Disclosure - Note 17 - General and Administration Expenses", "shortName": "Note 17 - General and Administration Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "44", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:GeneralAndAdministrativeExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "longName": "044 - Disclosure - Note 18 - Other (Income) Expense", "shortName": "Note 18 - Other (Income) Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "45", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "longName": "045 - Disclosure - Note 19 - Income Tax", "shortName": "Note 19 - Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "46", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements", "longName": "046 - Disclosure - Note 20 - Revision of Prior Period Financial Statements", "shortName": "Note 20 - Revision of Prior Period Financial Statements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "47", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "longName": "047 - Disclosure - Note 21 - Subsequent Events", "shortName": "Note 21 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "48", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies", "longName": "048 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "49", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-tables", "longName": "049 - Disclosure - Note 4 - Other Receivables (Tables)", "shortName": "Note 4 - Other Receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:DetailsOfOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.infoa.com/20240630/role/statement-note-5-equipment-tables", "longName": "050 - Disclosure - Note 5 - Equipment (Tables)", "shortName": "Note 5 - Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables", "longName": "051 - Disclosure - Note 6 - Intangible Assets (Tables)", "shortName": "Note 6 - Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.infoa.com/20240630/role/statement-note-9-equity-tables", "longName": "052 - Disclosure - Note 9 - Equity (Tables)", "shortName": "Note 9 - Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.infoa.com/20240630/role/statement-note-12-revenue-tables", "longName": "053 - Disclosure - Note 12 - Revenue (Tables)", "shortName": "Note 12 - Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tables", "longName": "054 - Disclosure - Note 13 - Research and Development Expenses (Tables)", "shortName": "Note 13 - Research and Development Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tables", "longName": "055 - Disclosure - Note 14 - Selling and Marketing Expenses (Tables)", "shortName": "Note 14 - Selling and Marketing Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:ScheduleOfSellingAndMarketingExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aiff:SellingAndMarketingExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-tables", "longName": "056 - Disclosure - Note 15 - General and Administration Expenses (Tables)", "shortName": "Note 15 - General and Administration Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aiff:GeneralAndAdministrativeExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables", "longName": "057 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tables", "longName": "058 - Disclosure - Note 4 - Other Receivables (10K) (Tables)", "shortName": "Note 4 - Other Receivables (10K) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:DetailsOfOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tables", "longName": "059 - Disclosure - Note 6 - Intangible Assets (10K) (Tables)", "shortName": "Note 6 - Intangible Assets (10K) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R61": { "role": "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables", "longName": "060 - Disclosure - Note 8 - Deferred Revenue (Tables)", "shortName": "Note 8 - Deferred Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aiff:DeferredRevenueTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aiff:DeferredRevenueTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "longName": "061 - Disclosure - Note 11 - Equity (Tables)", "shortName": "Note 11 - Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62",

"firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R63": { "role": "http://www.infoa.com/20240630/role/statement-note-14-revenue-tables", "longName": "062 - Disclosure - Note 14 - Revenue (Tables)", "shortName": "Note 14 - Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "63", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tables", "longName": "063 - Disclosure - Note 15 - Research and Development Expenses (Tables)", "shortName": "Note 15 - Research and Development Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "64", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tables", "longName": "064 - Disclosure - Note 16 - Selling and Marketing Expenses (Tables)", "shortName": "Note 16 - Selling and Marketing Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "65", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:ScheduleOfSellingAndMarketingExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aiff:SellingAndMarketingExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-tables", "longName": "065 - Disclosure - Note 17 - General and Administration Expenses (Tables)", "shortName": "Note 17 - General and Administration Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "66", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "aiff:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aiff:GeneralAndAdministrativeExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R67": { "role": "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables", "longName": "066 - Disclosure - Note 18 - Other (Income) Expense (Tables)", "shortName": "Note 18 - Other (Income) Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "67", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables", "longName": "067 - Disclosure - Note 19 - Income Tax (Tables)", "shortName": "Note 19 - Income Tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "68", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tables", "longName": "068 - Disclosure - Note 20 - Revision of Prior Period Financial Statements (Tables)", "shortName": "Note 20 - Revision of Prior Period Financial Statements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "69", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ErrorCorrectionTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ErrorCorrectionTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "longName": "069 - Disclosure - Note 1 - Business Description (Details Textual)", "shortName": "Note 1 - Business Description (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "i_2024-08-12_OwnershipAxis-FormerFirefly2023StockholdersMember", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual", "longName": "070 - Disclosure - Note 2 - Going Concern (Details Textual)", "shortName": "Note 2 - Going Concern (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R72": { "role": "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "longName": "071 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": null, "uniqueAnchor": null }, "R73": { "role": "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details", "longName": "072 - Disclosure - Note 4 - Other Receivables - Details of Other Receivables (Details)", "shortName": "Note 4 - Other Receivables - Details of Other Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "aiff:OtherReceivablesBeforeAllowanceForCreditLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aiff:DetailsOfOtherReceivablesTableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R74": { "role": "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details", "longName": "073 - Disclosure - Note 5 - Equipment - Summary of Equipment (Details)", "shortName": "Note 5 - Equipment - Summary of Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-details-textual", "longName": "074 - Disclosure - Note 6 - Intangible Assets (Details Textual)", "shortName": "Note 6 - Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": null, "uniqueAnchor": null }, "R76": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "longName": "075 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details)", "shortName": "Note 6 - Intangible Assets - Summary of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R77": { "role": "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textual", "longName": "076 - Disclosure - Note 7 - Liability for Employee Rights Upon Retirement (Details Textual)", "shortName": "Note 7 - Liability for Employee Rights Upon Retirement (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "aiff:MonthlyDepositRatePercentOfSalary", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R78": { "role": "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual", "longName": "077 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)", "shortName": "Note 8 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "i_2024-06-30_OtherCommitmentsAxis-IiaRoyaltyCommitmentMember", "name": "aiff:ResearchAgreementRoyaltyPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R79": { "role": "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "longName": "078 - Disclosure - Note 9 - Equity (Details Textual)", "shortName": "Note 9 - Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-03-15", "name": "us-gaap:SharesIssued", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R80": { "role": "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details", "longName": "079 - Disclosure - Note 9 - Equity - Schedule of Shares Authorized and Issued (Details)", "shortName": "Note 9 - Equity - Schedule of Shares Authorized and Issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "i_2024-06-30_StatementClassOfStockAxis-SeriesAPreferredStockMember", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R81": { "role": "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details", "longName": "080 - Disclosure - Note 9 - Equity - Schedule of Warrants (Details)", "shortName": "Note 9 - Equity - Schedule of Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R82": { "role": "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details", "longName": "081 - Disclosure - Note 9 - Equity - Schedule of Option Activity (Details)", "shortName": "Note 9 - Equity - Schedule of Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual", "longName": "082 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)", "shortName": "Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)", "isDefault": "false", "groupType":

"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "longName": "083 - Disclosure - Note 11 - Related Party Transactions (Details Textual)", "shortName": "Note 11 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "i_2024-06-30_RelatedPartyTransactionsByRelatedPartyAxis-DirectorMember", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R85": { "role": "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "longName": "084 - Disclosure - Note 12 - Revenue - Disaggregation of Revenue (Details)", "shortName": "Note 12 - Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30_TimingOfTransferOfGoodOrServiceAxis-TransferredAtPointInTimeMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R86": { "role": "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "longName": "085 - Disclosure - Note 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)", "shortName": "Note 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "aiff:ConsultingAndSubcontractingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "aiff:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R87": { "role": "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "longName": "086 - Disclosure - Note 14 - Selling and Marketing Expenses (Details)", "shortName": "Note 14 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:OtherSellingAndMarketingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aiff:ScheduleOfSellingAndMarketingExpensesTableTextBlock", "aiff:SellingAndMarketingExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R88": { "role": "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "longName": "087 - Disclosure - Note 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)", "shortName": "Note 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "aiff:RentAndMaintenanceExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aiff:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "aiff:GeneralAndAdministrativeExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R89": { "role": "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "longName": "088 - Disclosure - Note 16 - Subsequent Events (Details Textual)", "shortName": "Note 16 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "i_2022-01-27", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-26_2024-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R90": { "role": "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "longName": "089 - Disclosure - Note 1 - Business Description (Details Textual)", "shortName": "Note 1 - Business Description (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "i_2022-01-27", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-07-05_2022-07-05", "name": "us-gaap:CommonStockDividendsShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R91": { "role": "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274", "longName": "090 - Disclosure - Note 2 - Going Concern (Details Textual)", "shortName": "Note 2 - Going Concern (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R92": { "role": "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details", "longName": "091 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details)", "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_StatementGeographicalAxis-CA", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "true", "lang": null, "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R93": { "role": "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "longName": "092 - Disclosure - Note 4 - Other Receivables - Details of Other Receivables (10K) (Details)", "shortName": "Note 4 - Other Receivables - Details of Other Receivables (10K) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "aiff:OtherReceivablesBeforeAllowanceForCreditLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aiff:DetailsOfOtherReceivablesTableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R94": { "role": "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits-details-textual", "longName": "093 - Disclosure - Note 5 - Long Term Deposits (Details Textual)", "shortName": "Note 5 - Long Term Deposits (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:DepositAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:DepositAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textual", "longName": "094 - Disclosure - Note 6 - Intangible Assets (10K) (Details Textual)", "shortName": "Note 6 - Intangible Assets (10K) (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R96": { "role": "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "longName": "095 - Disclosure - Note 6 - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Note 6 - Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R97": { "role": "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual", "longName": "096 - Disclosure - Note 7 - Convertible Notes (Details Textual)", "shortName": "Note 7 - Convertible Notes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R98": { "role": "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "longName": "097 - Disclosure - Note 8 - Deferred Revenue (Details Textual)", "shortName": "Note 8 - Deferred Revenue (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "aiff:DeferredRevenueTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2019-02-28_MajorCustomersAxis-RIMindGroupLtdMember", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "aiff:DeferredRevenueTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R99": { "role": "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details", "longName": "098 - Disclosure - Note 8 - Deferred Revenue - Schedule of Deferred Revenue (Details)", "shortName": "Note 8 - Deferred Revenue - Schedule of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "aiff:DeferredRevenueTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R100": { "role": "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement-details-textual", "longName": "099 - Disclosure - Note 9 - Liability for Employee Rights Upon Retirement (Details Textual)", "shortName": "Note 9 - Liability for Employee Rights Upon Retirement (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "aiff:ContributionsToSeveranceCompensationAct", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R101": { "role": "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "longName": "100 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)", "shortName": "Note 10 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "i_2024-06-30_OtherCommitmentsAxis-IiaRoyaltyCommitmentMember", "name": "aiff:ResearchAgreementRoyaltyPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef":

"wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R102": { "role": "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "longName": "101 - Disclosure - Note 11 - Equity (Details Textual)", "shortName": "Note 11 - Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-10-16_2023-10-16", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R103": { "role": "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "longName": "102 - Disclosure - Note 11 - Equity - Schedule of Shares Authorized and Issued (Details)", "shortName": "Note 11 - Equity - Schedule of Shares Authorized and Issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "i_2024-06-30_StatementClassOfStockAxis-SeriesAPreferredStockMember", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R104": { "role": "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details", "longName": "103 - Disclosure - Note 11 - Equity - Schedule of Warrants (Details)", "shortName": "Note 11 - Equity - Schedule of Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-01-01_2022-12-31", "name": "aiff:ClassOfWarrantsOrRightsModified", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R105": { "role": "http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details", "longName": "104 - Disclosure - Note 11 - Equity - Assumptions (Details)", "shortName": "Note 11 - Equity - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "longName": "105 - Disclosure - Note 11 - Equity - Schedule of Option Activity (Details)", "shortName": "Note 11 - Equity - Schedule of Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R107": { "role": "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "longName": "106 - Disclosure - Note 13 - Related Party Transactions (Details Textual)", "shortName": "Note 13 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "d_2023-06-08_2023-06-08", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-06-08_2023-06-08", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details", "longName": "107 - Disclosure - Note 14 - Revenue - Disaggregation of Revenue (Details)", "shortName": "Note 14 - Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R109": { "role": "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "longName": "108 - Disclosure - Note 15 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)", "shortName": "Note 15 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "aiff:ConsultingAndSubcontractingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "aiff:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R110": { "role": "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "longName": "109 - Disclosure - Note 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)", "shortName": "Note 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:OtherSellingAndMarketingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aiff:ScheduleOfSellingAndMarketingExpensesTableTextBlock", "aiff:SellingAndMarketingExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": null }, "R111": { "role": "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "longName": "110 - Disclosure - Note 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)", "shortName": "Note 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "aiff:RentAndMaintenanceExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aiff:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "aiff:GeneralAndAdministrativeExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aiff:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "aiff:GeneralAndAdministrativeExpensesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R112": { "role": "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "longName": "111 - Disclosure - Note 18 - Other (Income) Expense (Details Textual)", "shortName": "Note 18 - Other (Income) Expense (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "d_2022-02-01_2022-02-28", "name": "us-gaap:ProceedsFromSaleOfProductiveAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2022-02-01_2022-02-28", "name": "us-gaap:ProceedsFromSaleOfProductiveAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R113": { "role": "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details", "longName": "112 - Disclosure - Note 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details)", "shortName": "Note 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:InvestmentIncomeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "aiff:OtherIncomeExpenseNonoperating", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R114": { "role": "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual", "longName": "113 - Disclosure - Note 19 - Income Tax (Details Textual)", "shortName": "Note 19 - Income Tax (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "i_2023-12-31_TaxCreditCarryforwardAxis-ResearchMember", "name": "us-gaap:TaxCreditCarryforwardAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_TaxCreditCarryforwardAxis-ResearchMember", "name": "us-gaap:TaxCreditCarryforwardAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R115": { "role": "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details", "longName": "114 - Disclosure - Note 19 - Income Tax - Provision for Income Taxes (Details)", "shortName": "Note 19 - Income Tax - Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R116": { "role": "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "longName": "115 - Disclosure - Note 19 - Income Taxes - Deferred Tax Assets (Details)", "shortName": "Note 19 - Income Taxes - Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details", "longName": "116 - Disclosure - Note 19 - Income Taxes - Operating Loss Carryforwards (Details)", "shortName": "Note 19 - Income Taxes - Operating Loss Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "i_2023-12-31_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-

gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true, "unique": true }], "R118": { "role": "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details", "longName": "117 - Disclosure - Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details)", "shortName": "Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_RestatementAxis-ScenarioPreviouslyReportedMember", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "us-gaap:ErrorCorrectionTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } }, "R119": { "role": "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "longName": "118 - Disclosure - Note 21 - Subsequent Events (Details Textual)", "shortName": "Note 21 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-02-28_2024-02-28_SubsequentEventTypeAxis-SubsequentEventMember", "name": "aiff:UnitsIssuedDuringPeriodNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wavd20240923_s1.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Related party payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r53", "r658"] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsPayableCurrentAndNoncurrent", "terseLabel": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r106", "r775"] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Trade payables", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r11", "r53"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less \u2013 accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r29", "r134", "r484"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r66", "r658", "r810"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r521", "r705", "r706", "r707", "r709", "r758", "r814"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "verboseLabel": "Stock dividend paid", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": ["r6", "r98"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r44", "r45", "r326"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Warrants issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": ["r6", "r31", "r98"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r353", "r354"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfDebtDiscountPremium", "terseLabel": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r4", "r78", "r277", "r767"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r191"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r22"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r22"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label":

```
"us-gaap_Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r104", "r115", "r136", "r161", "r195", "r199", "r205", "r206", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r392", "r394", "r410", "r476", "r557", "r628", "r629", "r658", "r685", "r743", "r744", "r772" } }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r130", "r142", "r161", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r392", "r394", "r410", "r658", "r743", "r744", "r772" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Noncurrent assets", "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total non current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r161", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r392", "r394", "r410", "r743", "r744", "r772" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-" ], "lang": { "en-us": { "role": { "label": "Non current assets" } } }, "auth_ref": [] }, "aiff_August2022SecuritiesPurchaseAgreementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "August2022SecuritiesPurchaseAgreementWarrantsMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "August 2022 Securities Purchase Agreement Warrants [Member]", "documentation": "Relating to August 2022 securities purchase agreement warrants." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AE2-9021-BBB71BB25947" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r85" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r389", "r642", "r643" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r46", "r48", "r223", "r224", "r225", "r226", "r227", "r389", "r642", "r643" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r47" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r51", "r85", "r86" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CA", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "auth_ref": [] }, "us-gaap_CanadaRevenueAgencyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CanadaRevenueAgencyMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Canada Revenue Agency [Member]", "documentation": "Designated tax department of the government of Canada." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r14", "r132", "r622" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "BALANCE OF CASH AT THE BEGINNING OF PERIOD", "periodEndLabel": "BALANCE OF CASH AT THE END OF PERIOD", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r14", "r82", "r158" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "(DECREASE) INCREASE IN CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r82" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r126", "r137", "r138", "r139", "r161", "r185", "r186", "r188", "r190", "r197", "r198", "r212", "r246", "r248", "r249", "r250", "r253", "r254", "r283", "r284", "r287", "r290", "r296", "r410", "r512", "r513", "r514", "r515", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r544", "r567", "r587", "r599", "r600", "r601", "r602", "r603", "r687", "r702", "r710" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual",
```

"http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r41"] },
"aiff_ClassOfWarrantOrRightCombinedPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ClassOfWarrantOrRightCombinedPurchasePrice", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual",
"http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label":
"aiff_ClassOfWarrantOrRightCombinedPurchasePrice", "terseLabel": "Class of Warrant or Right, Combined Purchase Price (in dollars per share)", "documentation": "Represents the combined purchase price for a warrant or right." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity",
"http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events",
"http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events",
"http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes",
"http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity",
"http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]",
"documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." }
} }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "periodStartLabel": "Exercise price (in dollars per share)", "periodEndLabel": "Exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r297"] },
"aiff_ClassOfWarrantOrRightExercisePricePurchasePriceNumerator": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname":
"ClassOfWarrantOrRightExercisePricePurchasePriceNumerator", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_ClassOfWarrantOrRightExercisePricePurchasePriceNumerator", "terseLabel": "Class of Warrant or Right, Exercise Price, Purchase Price Numerator", "documentation": "Represents the purchase price numerator for an exercise price on a warrant or right." } } }, "auth_ref": [] },
"aiff_ClassOfWarrantOrRightIssuedExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.infoa.com/20240630", "localname":
"ClassOfWarrantOrRightIssuedExercisePrice", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details",
"http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants issued pursuant to units offering (in dollars per share)", "documentation": "Represents the exercise price of warrants or rights issued during the period." } } }, "auth_ref": [] },
"aiff_ClassOfWarrantOrRightModifiedExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.infoa.com/20240630", "localname":
"ClassOfWarrantOrRightModifiedExercisePrice", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details"], "lang":
{ "en-us": { "role": { "label": "Warrants issued pursuant to modification of convertible debt (in dollars per share)", "documentation": "Represents the exercise price of warrants or rights modified during the period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [
"http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": {
"en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r297"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [
"http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodStartLabel": "Outstanding warrants, January 1, 2024 (in shares)", "periodEndLabel": "Outstanding warrants, June 30, 2024 (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] },
"aiff_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname":
"ClassOfWarrantOrRightWarrantsIssuedDuringPeriod", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details",
"http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants issued pursuant to units offering (in shares)", "terseLabel": "Class of Warrant or Right, Warrants Issued During Period (in shares)", "documentation": "Represents the number of warrants issued during the period." } } }, "auth_ref": [] },
"aiff_ClassOfWarrantOrRightWeightedAverageRemainingLife": { "xbrltype": "durationItemType", "nsuri": "http://www.infoa.com/20240630", "localname":
"ClassOfWarrantOrRightWeightedAverageRemainingLife", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details",
"http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details"], "lang": { "en-us": { "role": { "label": "Outstanding warrants, January 1, 2024 (Year)", "documentation": "Represents the weighted average remaining life of warrants or rights." } } }, "auth_ref": [] }, "aiff_ClassOfWarrantsOrRightsModified": {
"xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ClassOfWarrantsOrRightsModified", "presentation": [
"http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants issued pursuant to modification of convertible debt (in shares)", "documentation": "Represents the number of warrants or rights modified during the period." } } }, "auth_ref": [] },
"aiff_ClinicalTrialsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ClinicalTrialsExpense", "crdr": "debit",
"calculation": { "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": {
"parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 0.0
} }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details"], "lang":
{ "en-us": { "role": { "label": "Clinical trials", "documentation": "Represents the amount of expense from clinical trials incurred during the period." } } }, "auth_ref": [] },
"us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies",
"crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited",
"http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (Note 8)",
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r62", "r108", "r478", "r543"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies",
"http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r91", "r242", "r243", "r606", "r734", "r738"] }, "us-gaap_CommonStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsShares",
"presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": {
"en-us": { "role": { "label": "us-gaap_CommonStockDividendsShares", "terseLabel": "Common Stock Dividends, Shares (in shares)", "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": ["r6"] }, "us-gaap_CommonStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA",
"http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": {
"label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r675", "r676", "r677", "r679", "r680", "r681", "r682", "r705", "r706", "r709", "r758", "r808", "r814"] }, "aiff_CommonStockNumberOfSharesToBeIssuedMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.infoa.com/20240630", "localname": "CommonStockNumberOfSharesToBeIssuedMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares to be Issued [Member]", "documentation": "Represents the number of common shares to be issued." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare":
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r65"] }, "aiff_CommonStockPrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.infoa.com/20240630", "localname": "CommonStockPrivatePlacementMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Common Stock, Private Placement [Member]", "documentation": "Represents a common stock private placement." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals",
"http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details",
"http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "verboseLabel": "Shares of common stock authorized (in shares)", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r65", "r544"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual",
"http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "verboseLabel": "Shares of common stock issued (in shares)", "label": "Common stock, shares issued (in shares)", "terseLabel": "Common Stock, Shares, Issued (in shares)", "documentation": "Total

number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r65"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r6", "r65", "r544", "r563", "r814", "r815"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Common shares, $0.00001 par value; 2,470,000,000 shares authorized; 49,948,710 and 35,369,877 issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r65", "r480", "r658"] }, "aiff_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "CommonStockWarrantsMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Relating to common stock warrants." } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": ["r617", "r621", "r724", "r725", "r726", "r727", "r728", "r730", "r732", "r733"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r49", "r624"] }, "aiff_ConsultingAndSubcontractingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ConsultingAndSubcontractingExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 3.0 }, "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details"], "lang": { "en-us": { "role": { "label": "Consultants and subcontractors", "documentation": "Represents the amount of consulting and subcontracting expense incurred during the period." } } }, "auth_ref": [] }, "aiff_ConsultingFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ConsultingFeesMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Consulting Fees [Member]", "documentation": "Relating to consulting fees." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r746"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r299", "r300", "r309"] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "terseLabel": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": ["r636"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r299", "r300", "r309"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details"], "lang": { "en-us": { "role": { "label": "Revenue recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r310"] }, "aiff_ContributionsToSeveranceCompensationAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ContributionsToSeveranceCompensationAct", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_ContributionsToSeveranceCompensationAct", "terseLabel": "Contributions to Severance Compensation Act", "documentation": "Represents the amount of contributions to the Severance Compensation Act." } } }, "auth_ref": [] }, "aiff_ConversionOfDebtAndInterestIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ConversionOfDebtAndInterestIntoCommonStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Conversion of Debt and Interest Into Common Stock [Member]", "documentation": "Relating to the conversion of debt and interest into common stock." } } }, "auth_ref": [] }, "aiff_ConversionOfDirectorNotesIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ConversionOfDirectorNotesIntoCommonStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Conversion of Director Notes Into Common Stock [Member]", "documentation": "Relating to conversion of director notes into common stock." } } }, "auth_ref": [] }, "aiff_ConversionOfSeriesBPreferredStockToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ConversionOfSeriesBPreferredStockToCommonStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Conversion of Series B Preferred Stock to Common Stock [Member]", "documentation": "Relating to the conversion of Series B Preferred stock to common stock." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockAmountConverted1", "terseLabel": "Converted shares of common stock", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockNameDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesConverted1", "terseLabel": "Conversion of Stock, Shares Converted (in shares)", "negatedTerseLabel": "Series B Preferred Stock conversion (in shares)", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Converted shares of common stock (in shares)", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." }

```
} }, "auth_ref": [ "r16", "r17", "r18" ] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleDebt", "terseLabel": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r9", "r107", "r776" ] }, "aiff_ConvertibleDebtAndStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ConvertibleDebtAndStockWarrantsMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Convertible Debt and Stock Warrants [Member]", "documentation": "Relating to convertible debt and stock warrants." } } }, "auth_ref": [] }, "aiff_ConvertibleDebtIssuedToVariousInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ConvertibleDebtIssuedToVariousInvestorsMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Issued to Various Investors [Member]", "documentation": "Relating to convertible debt issued to various investors." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r93", "r256", "r257", "r267", "r268", "r269", "r273", "r274", "r275", "r276", "r277", "r631", "r632", "r633", "r634", "r635" ] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r16", "r18" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentAmount1", "negatedLabel": "Debt converted to equity", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r16", "r18" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r16", "r18" ] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionNameDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r16", "r18" ] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r16", "r18" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r92", "r159", "r235", "r236", "r237", "r238", "r239", "r244", "r245", "r255", "r261", "r262", "r263", "r264", "r265", "r266", "r271", "r278", "r279", "r280", "r418" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r9", "r55", "r56", "r105", "r107", "r165", "r256", "r257", "r258", "r259", "r260", "r262", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r631", "r632", "r633", "r634", "r635", "r649", "r703", "r735", "r736", "r737", "r766", "r768" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r94", "r258" ] }, "aiff_DebtInstrumentExtensionFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "DebtInstrumentExtensionFeePercentage", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "aiff_DebtInstrumentExtensionFeePercentage", "terseLabel": "Debt Instrument, Extension Fee Percentage", "documentation": "Represents the extension fee percentage for a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r256", "r418", "r419", "r632", "r633", "r649" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r58", "r257" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r9", "r165", "r256", "r257", "r258", "r259", "r260", "r262", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r631", "r632", "r633", "r634", "r635", "r649", "r703", "r735", "r736", "r737", "r766", "r768" ] }, "aiff_DeferredRevenueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "DeferredRevenueTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Text Block]", "documentation": "The entire disclosure for deferred revenue." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r370" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "R&D expenditures", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } }, "auth_ref": [ "r757" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r755" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Non-capital loss carry-forwards from US", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r757" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Non-capital loss carry-forwards from foreign entity", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": [ "r757" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Reserves and others", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r757" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": {
```

{"http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details"], "lang": { "en-us": { "role": { "label": "Stock option", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": ["r757"] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation Allowances for deferred tax assets", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": ["r371"] }, "us-gaap_DepositAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositAssets", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DepositAssets", "terseLabel": "Deposit Assets", "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement." } } }, "auth_ref": ["r697"] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Long term deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r697"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r195", "r202", "r206", "r628", "r629"] }, "us-gaap_DepreciationNonproduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationNonproduction", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives." } } }, "auth_ref": ["r4", "r28"] }, "aiff_DetailsOfOtherReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "DetailsOfOtherReceivablesTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tables", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-tables"], "lang": { "en-us": { "role": { "label": "Details of Other Receivables [Table Text Block]", "documentation": "The tabular disclosure pertaining to the other receivables." } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": ["r718", "r809"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-12-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-14-revenue-tables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r747"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-12-revenue", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-14-revenue", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-2-going-concern", "http://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AE2-9021-BBB71BB25947", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k", "http://www.infoa.com/20240630/role/statement-note-5-equipment-", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DividendsStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsStock", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsStock", "negatedLabel": "Stock dividend paid", "documentation": "Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": ["r2", "r98"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "BASIC AND DILUTED LOSS PER SHARE (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r149", "r171", "r172", "r174", "r175", "r176", "r178", "r184", "r185", "r188", "r189", "r190", "r194", "r387", "r391", "r405", "r406", "r473", "r489", "r625"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-loss-per-share"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r183", "r191", "r192", "r193"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details"], "lang": { "en-us": { "role": { "label": "Statutory income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r162", "r359", "r378", "r646"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r749"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r686"] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-

unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-document-and-entity-information", "http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-12-revenue", "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-12-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-14-revenue", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details", "http://www.infoa.com/20240630/role/statement-note-2-going-concern", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274", "http://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tables", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AE2-9021-BBB71BB25947", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tables", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-tables", "http://www.infoa.com/20240630/role/statement-note-5-equipment-", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details", "http://www.infoa.com/20240630/role/statement-note-5-equipment-tables", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tables", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r686"] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r686"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r686"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r686"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.infoa.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r686"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r6", "r127", "r145", "r146", "r147", "r166", "r167", "r168", "r170", "r176", "r179", "r181", "r196", "r213", "r216", "r233", "r298", "r376", "r377", "r384", "r385", "r386", "r388", "r390", "r391", "r396", "r397", "r398", "r399", "r400", "r401", "r404", "r411", "r412", "r413", "r414", "r415", "r416", "r421", "r423", "r428", "r488", "r500", "r501", "r502", "r521", "r587"] }, "us-gaap_ErrorCorrectionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ErrorCorrectionTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements"], "lang": { "en-us": { "role": { "label": "Error Correction [Text Block]", "documentation": "The entire disclosure for reporting error correction." } } }, "auth_ref": ["r177"] }, "aiff_ExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ExchangeRatio", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_ExchangeRatio", "terseLabel": "Exchange Ratio", "documentation": "The exchange ratio related to the merger agreement." } } }, "auth_ref": [] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExecutiveOfficerMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]" } } }, "auth_ref": ["r718"] }, "us-

gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Intangible assets, accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r135", "r220", "r228", "r630"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r441", "r442", "r617"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r220", "r228", "r442", "r630"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r617"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details"], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, net", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r441", "r730"] }, "aiff_FireflyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "FireflyMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Firefly [Member]", "documentation": "Relating to Firefly." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details"], "lang": { "en-us": { "role": { "label": "Unrealized gain on foreign exchange", "negatedLabel": "Unrealized (gain) loss on foreign exchange", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r84", "r565", "r683", "r764", "r765", "r813"] }, "aiff_FormerFirefly2023StockholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "FormerFirefly2023StockholdersMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "Former Firefly 2023 Stockholders [Member]", "documentation": "Represents the former firefly 2023 stockholders" } } }, "auth_ref": [] }, "aiff_FormerFireflyStockholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "FormerFireflyStockholdersMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "Former Firefly Stockholders [Member]", "documentation": "Represents the former firefly stockholders" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details"], "lang": { "en-us": { "role": { "label": "Gain on sale of equipment", "terseLabel": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r701"] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Net gain from sale of equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r4"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 }, "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Loss on extinguishment of debt", "terseLabel": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r4", "r32", "r33"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 }, "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "verboseLabel": "General and administration expenses", "label": "General and administration expenses", "totalLabel": "Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r74", "r569"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r74"] }, "aiff_GeneralAndAdministrativeExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "GeneralAndAdministrativeExpensesTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses"], "lang": { "en-us": { "role": { "label": "General and Administrative Expenses [Text Block]", "documentation": "The entire disclosure relating to general and administrative expenses." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r722", "r723"] }, "country_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IL", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "ISRAEL" } } }, "auth_ref": [] }, "aiff_IiaRoyaltyCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "IiaRoyaltyCommitmentMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "IIA Royalty Commitment [Member]", "documentation": "Relating to the IIA Royalty Commitment." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "Impairment loss on equipment", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": ["r4", "r27", "r90", "r647"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-
gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-
20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Loss before Income Tax",
"totalLabel": "LOSS BEFORE INCOME TAX", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method
investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r72", "r110", "r114", "r474",
"r486", "r627", "r628", "r711", "r712", "r713", "r714", "r715" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root":
true } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": {
"label": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "NET LOSS AND COMPREHENSIVE LOSS",
"documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r103",
"r114", "r161", "r169", "r176", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r387", "r391", "r406", "r410", "r486", "r627", "r711", "r712",
"r713", "r714", "r715", "r743" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details" ], "lang": { "en-
us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount
has been reported." } } }, "auth_ref": [ "r234", "r240", "r241", "r407", "r408", "r409", "r498", "r499", "r572", "r617", "r648", "r779" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details",
"http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details" ], "lang": { "en-
us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been
reported." } } }, "auth_ref": [ "r240", "r241", "r407", "r408", "r409", "r498", "r499", "r572", "r617", "r648", "r779" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [
"http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-
operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing
authority." } } }, "auth_ref": [ "r360", "r756" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details",
"http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority,
Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes
other decisions pertaining to income taxes." } } }, "auth_ref": [ "r368", "r756" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax" ],
"lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r162", "r357",
"r359", "r365", "r366", "r367", "r369", "r372", "r379", "r381", "r382", "r383", "r517", "r646" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-
consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 0.0 },
"http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-
gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-
operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
"http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Income tax provision",
"totalLabel": "Income tax expense (recovery)", "negatedLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred
income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r116", "r124", "r180", "r181", "r195", "r203", "r206", "r358", "r359", "r380", "r490",
"r646" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-
note-19-income-tax-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation
allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying
the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for
deferred tax assets." } } }, "auth_ref": [ "r364", "r646", "r751" ] }, "us-gaap_IncomeTaxReconciliationDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationDispositionOfAssets", "crdr": "debit", "calculation": {
"http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight":
1.0, "order": 1.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details" ], "lang": { "en-us": { "role":
{ "label": "Taxable capital gain on sale of investment and equipment", "documentation": "Amount of difference between reported income tax expense (benefit) and
expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable
to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory." } } }, "auth_ref": [ "r751", "r752" ] }, "us-
gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-tax-
provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Difference in foreign tax
rates", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the
domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [
"r360", "r363", "r646", "r751" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit",
"calculation": { "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details": { "parentTag": "us-
gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-
income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Statutory income tax recovery", "documentation": "The amount of income tax expense or benefit for the
period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r359", "r646" ] }, "us-
gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": {
"http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight":
1.0, "order": 2.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details" ], "lang": { "en-us": { "role":
{ "label": "Non-deductible option expenses", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense
(benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for
award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based
payment arrangement." } } }, "auth_ref": [ "r646", "r751", "r753" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": {
"http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight":
1.0, "order": 3.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details" ], "lang": { "en-us": { "role":
{ "label": "US state tax", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed
by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense
(benefit)." } } }, "auth_ref": [ "r362", "r646", "r751" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-
unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes",
"documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r15", "r157", "r373", "r374" ] },
"us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-
statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 },
"http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Change in related party payables",
"documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a
parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are
managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or
other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": {
"http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-
flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [
```

{"http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Change in trade payables", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Change in accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Change in deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r618"] }, "aiff_IncreaseDecreaseInLongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "IncreaseDecreaseInLongtermDeposits", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Change in long term deposits", "documentation": "The increase (decrease) in long-term deposits." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherReceivables", "negatedLabel": "Change in other receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Change in prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r3"] }, "aiff_IndefiniteTaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "IndefiniteTaxYearMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details"], "lang": { "en-us": { "role": { "label": "Indefinite Tax Year [Member]", "documentation": "Relating to an indefinite tax year." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k"], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r221", "r231", "r232", "r616", "r617"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textual"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r222", "r730", "r731"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r153", "r155", "r156"] }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalRevenueServiceIRSMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details"], "lang": { "en-us": { "role": { "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details"], "lang": { "en-us": { "role": { "label": "Interest and bank fees", "negatedLabel": "Interest, bank fees and loan fees", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": ["r75", "r76", "r78"] }, "us-gaap_IsraelTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IsraelTaxAuthorityMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details"], "lang": { "en-us": { "role": { "label": "Israel Tax Authority [Member]", "documentation": "Designated tax department of the government of Israel." } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 3.0 }, "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details"], "lang": { "en-us": { "role": { "verboseLabel": "Salary and employee benefits", "label": "Salary and employee benefits", "documentation": "Amount of expense for salary, wage, profit sharing, incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": ["r700"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-document-and-entity-information", "http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-12-revenue", "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-12-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-

party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-14-revenue", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details", "http://www.infoa.com/20240630/role/statement-note-2-going-concern", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274", "http://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tables", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AE2-9021-BBB71BB25947", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tables", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-tables", "http://www.infoa.com/20240630/role/statement-note-5-equipment-", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details", "http://www.infoa.com/20240630/role/statement-note-5-equipment-tables", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tables", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Total liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r9", "r55", "r56", "r57", "r60", "r61", "r62", "r63", "r161", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r393", "r394", "r395", "r410", "r542", "r626", "r685", "r743", "r772", "r773"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY (DEFICIT)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r70", "r109", "r482", "r658", "r704", "r719", "r763"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Total current liabilities", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r54", "r131", "r161", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r393", "r394", "r395", "r410", "r658", "r743", "r772", "r773"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r54", "r59", "r703", "r741", "r742"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r54", "r59", "r703", "r741"] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-4-other-receivables-", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k"], "lang": { "en-us": { "role": { "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r418", "r717"] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "terseLabel": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r9", "r107", "r268", "r281", "r632", "r633", "r649", "r776"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r9", "r735", "r736", "r737"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r9", "r30", "r735", "r736", "r737"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r210", "r639", "r668", "r672", "r747", "r778", "r780", "r781", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807"] }, "aiff_MedicalEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "MedicalEquipmentMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-

policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details"], "lang": { "en-us": { "role": { "label": "Medical Equipment [Member]", "documentation": "Represents the medical equipment." } } }, "auth_ref": [] }, "aiff_MergerReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "MergerReverseStockSplitMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-textual"], "lang": { "en-us": { "role": { "label": "Merger Reverse Stock Split [Member]", "documentation": "Relating to the merger reverse stock split." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "us-gaap_MinorityInterestOwnershipPercentageByParent", "terseLabel": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "aiff_MonthlyDepositRatePercentOfSalary": { "xbrltype": "percentItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "MonthlyDepositRatePercentOfSalary", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_MonthlyDepositRatePercentOfSalary", "terseLabel": "Monthly Deposit Rate, Percent of Salary", "documentation": "The percentage of salary the monthly deposit rate is set at." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": ["r210", "r639", "r668", "r672", "r747", "r770", "r780", "r781", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r154"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r154"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Net cash used in operating activities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r82", "r83", "r84"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "presentation": ["http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "terseLabel": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r82", "r83", "r84"] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Net (loss) income", "totalLabel": "NET LOSS AND COMPREHENSIVE LOSS", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r73", "r84", "r111", "r129", "r143", "r144", "r147", "r161", "r169", "r171", "r172", "r174", "r175", "r176", "r180", "r181", "r187", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r387", "r391", "r406", "r410", "r487", "r566", "r585", "r586", "r683", "r743"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "aiff_NewFireflyCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "NewFireflyCommonStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "New Firefly Common Stock [Member]", "documentation": "Represents the New Firefly Common Stock" } } }, "auth_ref": [] }, "aiff_NoncashWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "NoncashWarrantsIssued", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_NoncashWarrantsIssued", "terseLabel": "Noncash Warrants Issued (in shares)", "documentation": "Represents the number of noncash warrants issued." } } }, "auth_ref": [] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": ["r425", "r426", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657"] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": ["r425", "r426", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details"], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r77"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"], "lang": { "en-us": {

```
"role": { "label": "OTHER INCOME (EXPENSE)" } } }, "auth_ref": [] }, "aiff_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "aiff_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OpenTaxYear", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": [ "r368" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Total operating expenses", "totalLabel": "TOTAL OPERATING EXPENSES", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "OPERATING LOSS", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r114", "r627", "r711", "r712", "r713", "r714", "r715" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r375" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits" ], "lang": { "en-us": { "role": { "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherCommitment", "terseLabel": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of general and administrative expense classified as other." } } }, "auth_ref": [ "r74", "r812" ] }, "aiff_OtherIncomeExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "OtherIncomeExpenseNonoperating", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details" ], "lang": { "en-us": { "role": { "label": "aiff_OtherIncomeExpenseNonoperating", "negatedTerseLabel": "Other", "documentation": "Represents the amount of nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNonoperatingExpense", "negatedLabel": "Other expense, net", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r79" ] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income and Expense [Text Block]", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [ "r151", "r152" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other income (expenses)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r79" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherReceivables", "totalLabel": "Total", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r140", "r552", "r629", "r777" ] }, "aiff_OtherReceivablesAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "OtherReceivablesAllowanceForCreditLosses", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details": { "parentTag": "us-gaap_OtherReceivables", "weight": -1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details": { "parentTag": "us-gaap_OtherReceivables", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details" ], "lang": { "en-us": { "role": { "label": "aiff_OtherReceivablesAllowanceForCreditLosses", "negatedLabel": "Allowance for doubtful receivables", "documentation": "The amount of the allowance for credit losses related to the other receivables." } } }, "auth_ref": [] }, "aiff_OtherReceivablesBeforeAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "OtherReceivablesBeforeAllowanceForCreditLosses", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details": { "parentTag": "us-gaap_OtherReceivables", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details": { "parentTag": "us-gaap_OtherReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other receivables", "label": "aiff_OtherReceivablesBeforeAllowanceForCreditLosses", "documentation": "The total amount of other receivables before the allowance for credit losses." } } }, "auth_ref": [] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-" ], "lang": { "en-us": { "role": { "label": "Other receivables", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "aiff_ResearchAndDevelopmentExpenseGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details" ], "lang": { "en-us": { "role": { "label": "Expenses - other", "documentation": "Amount of other research and development expense." } } }, "auth_ref": [ "r750" ] }, "us-gaap_OtherSellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-
```

expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherSellingAndMarketingExpense", "terseLabel": "Other", "documentation": "Amount of selling and marketing expense classified as other." } } }, "auth_ref": ["r74"] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "aiff_OwnershipPercentageFormerShareholders": { "xbrltype": "percentItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "OwnershipPercentageFormerShareholders", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_OwnershipPercentageFormerShareholders", "terseLabel": "Ownership Percentage, Former Shareholders", "documentation": "The percent of ownership from former shareholders." } } }, "auth_ref": [] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Non-cash interest on convertible debt", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r4"] }, "aiff_PasitheaClinicsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PasitheaClinicsIncMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details"], "lang": { "en-us": { "role": { "label": "Pasithea Clinics Inc. [Member]", "documentation": "Relating to Pasithea Clinics Inc." } } }, "auth_ref": [] }, "aiff_PaymentsForProductEnhancements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PaymentsForProductEnhancements", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "aiff_PaymentsForProductEnhancements", "negatedLabel": "Product enhancement \u2013 intangible asset", "documentation": "The amount paid for the purchase of product enhancements." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r13"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r81"] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement"], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": ["r312", "r313", "r314", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r641"] }, "aiff_PhytoIvLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PhytoIvLpMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Phyto IV LP [Member]", "documentation": "Relating to Phyto IV LP." } } }, "auth_ref": [] }, "aiff_PipeShareWithAccompanyingWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PipeShareWithAccompanyingWarrantMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "PIPE Share With Accompanying Warrant [Member]", "documentation": "Represents the PIPE Share With Accompanying Warrant" } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionRatio", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionRatio", "terseLabel": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": ["r285"] }, "aiff_PreferredStockMandatoryConversionFeatureCompanyValuation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PreferredStockMandatoryConversionFeatureCompanyValuation", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_PreferredStockMandatoryConversionFeatureCompanyValuation", "terseLabel": "Preferred Stock, Mandatory Conversion Feature, Company Valuation", "documentation": "Represents the minimum company valuation in order for a mandatory conversion feature to be exercisable for preferred stock." } } }, "auth_ref": [] }, "aiff_PreferredStockMandatoryConversionFeatureOfferingProceedsThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PreferredStockMandatoryConversionFeatureOfferingProceedsThreshold", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_PreferredStockMandatoryConversionFeatureOfferingProceedsThreshold", "terseLabel": "Preferred Stock, Mandatory Conversion Feature, Offering Proceeds Threshold", "documentation": "Represents the offering proceeds threshold to trigger a mandatory conversion feature for preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r675", "r676", "r679", "r680", "r681", "r682", "r808", "r814"] }, "aiff_PreferredStockNumberOfSharesToBeIssuedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PreferredStockNumberOfSharesToBeIssuedMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares to be Issued [Member]", "documentation": "Represents the number of preferred shares to be issued." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r64", "r283"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "verboseLabel": "Shares of preferred stock authorized (in shares)", "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r64", "r544"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "verboseLabel": "Shares of preferred stock issued (in shares)", "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r64", "r283"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r64", "r544", "r563", "r814", "r815"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Preferred shares, $0.00001 par value; 30,000,000 shares authorized; 2,374,219 and 16,116,957 issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r64", "r479", "r658"] }, "aiff_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants [Member]", "documentation": "Represents the prefunded warrants." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-

consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r141", "r218", "r219", "r623"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "aiff_PrivatePlacementStockOptionsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PrivatePlacementStockOptionsValue", "crdr": "credit", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Common Stock Private Placement", "documentation": "The value of the shares issued under the private placement." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Proceeds from sale of convertible debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r12"] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "terseLabel": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfSecuredDebt", "terseLabel": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": ["r12"] }, "aiff_ProceedsFromIssuanceOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ProceedsFromIssuanceOfUnits", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_ProceedsFromIssuanceOfUnits", "terseLabel": "Proceeds From Issuance of Units", "documentation": "The amount of cash inflow from the issuance of units." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Proceeds from sale of shares", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r1", "r512"] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromSaleOfProductiveAssets", "terseLabel": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r80"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Proceeds from sale of equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r80"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r207", "r440", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r619", "r637", "r667", "r669", "r670", "r673", "r674", "r739", "r740", "r747", "r778", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r207", "r440", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r619", "r637", "r667", "r669", "r670", "r673", "r674", "r739", "r740", "r747", "r778", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807"] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 2.0 }, "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 }, "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details"], "lang": { "en-us": { "role": { "verboseLabel": "Professional fees", "label": "Professional fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": ["r628", "r683", "r811", "r812"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r5", "r424"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-5-equipment-"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r88", "r119", "r122", "r123"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details"], "lang": { "en-us": { "role": { "label": "Property, plant and equipment gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r89", "r133", "r485"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details"], "lang": { "en-us": { "role": { "label": "Equipment, net", "totalLabel": "Equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r424", "r475", "r485", "r658"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-5-equipment-tables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r89", "r424"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details"], "lang": { "en-us": { "role": { "label": "Bad debts", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } },

"auth_ref": ["r150", "r217"] }, "aiff_PurchasePriceOfSharesWithAccompanyingWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "PurchasePriceOfSharesWithAccompanyingWarrants", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_PurchasePriceOfSharesWithAccompanyingWarrants", "terseLabel": "Purchase Price Of Shares With Accompanying Warrants (in dollars per share)", "documentation": "The price per share accompanying warrants" } } }, "auth_ref": [] }, "aiff_RIMindGroupLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "RIMindGroupLtdMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details"], "lang": { "en-us": { "role": { "label": "R. I. Mind Group Ltd. [Member]", "documentation": "Relating to R.I. Mind Group Ltd." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r211", "r317", "r432", "r433", "r477", "r483", "r537", "r538", "r539", "r540", "r541", "r562", "r564", "r594"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r163", "r164", "r432", "r433", "r434", "r435", "r477", "r483", "r537", "r538", "r539", "r540", "r541", "r562", "r564", "r594"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r50", "r432"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r432", "r433", "r771"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r211", "r317", "r432", "r433", "r477", "r483", "r537", "r538", "r539", "r540", "r541", "r562", "r564", "r594", "r771"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r429", "r430", "r431", "r433", "r436", "r518", "r519", "r520", "r570", "r571", "r572", "r591", "r593"] }, "aiff_RentAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "RentAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details"], "lang": { "en-us": { "role": { "label": "Rent and maintenance", "documentation": "Amount of expense for rent and maintenance during the period." } } }, "auth_ref": [] }, "aiff_ResearchAgreementRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ResearchAgreementRoyaltyPercentage", "presentation": ["http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_ResearchAgreementRoyaltyPercentage", "terseLabel": "Research Agreement, Royalty Percentage", "documentation": "Represents the royalty percentage of a research agreement." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Research and development expenses", "totalLabel": "Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r355", "r617", "r620", "r774"] }, "aiff_ResearchAndDevelopmentExpenseGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ResearchAndDevelopmentExpenseGross", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details"], "lang": { "en-us": { "role": { "label": "aiff_ResearchAndDevelopmentExpenseGross", "totalLabel": "Research and Development Expense, Gross", "documentation": "Represents the amount of research and development expense before grants received." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "aiff_ResearchAndDevelopmentGrantsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ResearchAndDevelopmentGrantsReceived", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": -1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details"], "lang": { "en-us": { "role": { "label": "Less \u2013 grants received", "documentation": "Represents the amount of grants received for research and development." } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses"], "lang": { "en-us": { "role": { "label": "Research, Development, and Computer Software Disclosure [Text Block]", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": ["r356", "r616"] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual"], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": ["r756"] }, "srt_RestatementAdjustmentMember": { "xbrltype":

{"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": ["r166", "r167", "r168", "r178", "r179", "r194", "r404", "r405", "r422", "r688", "r689", "r690", "r691", "r692", "r695", "r696", "r716"] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": ["r128", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r179", "r180", "r181", "r182", "r194", "r214", "r215", "r385", "r386", "r387", "r388", "r390", "r391", "r403", "r404", "r405", "r406", "r420", "r422", "r427", "r428", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r716"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": ["r128", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r179", "r180", "r181", "r182", "r194", "r214", "r215", "r385", "r386", "r387", "r388", "r390", "r391", "r403", "r404", "r405", "r406", "r420", "r422", "r427", "r428", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r716"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r67", "r98", "r481", "r504", "r509", "r516", "r545", "r658"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r127", "r166", "r167", "r168", "r170", "r176", "r179", "r181", "r213", "r216", "r233", "r376", "r377", "r384", "r385", "r386", "r388", "r390", "r391", "r396", "r398", "r399", "r401", "r404", "r421", "r423", "r500", "r502", "r521", "r814"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-12-revenue", "http://www.infoa.com/20240630/role/statement-note-14-revenue"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r125", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r311"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "REVENUE", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r112", "r113", "r148", "r161", "r195", "r200", "r201", "r204", "r206", "r207", "r208", "r210", "r212", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r410", "r474", "r628", "r743"] }, "aiff_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ReverseStockSplitMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "Relating to a reverse stock split." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details"], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "auth_ref": ["r128", "r166", "r168", "r169", "r170", "r171", "r172", "r181", "r194", "r385", "r387", "r388", "r390", "r391", "r403", "r404", "r405", "r420", "r422", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r692", "r693", "r694", "r695", "r708", "r716", "r720", "r721", "r759", "r769", "r770"] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r755"] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": ["r361", "r646", "r751"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": ["r19", "r20", "r21"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tables", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r630", "r729"] }, "aiff_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-tables"], "lang": { "en-us": { "role": { "label": "Schedule of General and Administrative Expenses [Table Text Block]", "documentation": "Tabular disclosure of the entity's general and administrative expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "aiff_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Research and Development Expenses [Table Text Block]", "documentation": "Tabular disclosure of the entity's research and development costs." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r26", "r71"] }, "aiff_ScheduleOfSellingAndMarketingExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "ScheduleOfSellingAndMarketingExpensesTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Selling and Marketing Expenses [Table Text Block]", "documentation": "Tabular disclosure of the entity's selling and marketing expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r7", "r8", "r100"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d)

risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r102"] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": ["r10", "r34", "r35", "r36", "r37", "r38", "r39", "r40", "r64", "r65", "r96", "r97", "r98"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r41"] }, "aiff_SecuredPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SecuredPromissoryNotesMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Secured Promissory Notes [Member]", "documentation": "Relating to secured promissory notes." } } }, "auth_ref": [] }, "aiff_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Relating to securities purchase agreement." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r208", "r209", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r533", "r534", "r535", "r595", "r596", "r597", "r598", "r605", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r620", "r638", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r671", "r677", "r747", "r778", "r780", "r781", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807"] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details"], "lang": { "en-us": { "role": { "label": "Selling and marketing expenses", "totalLabel": "Total", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r74"] }, "aiff_SellingAndMarketingExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SellingAndMarketingExpensesTextBlock", "presentation": ["http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expenses [Text Block]", "documentation": "The entire disclosure relating to selling and marketing expenses." } } }, "auth_ref": [] }, "aiff_SeriesAPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SeriesAPerformanceWarrantsMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series A Performance Warrants [Member]", "documentation": "Represents the series a performance warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB0788656AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r698", "r699", "r745"] }, "aiff_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SeriesAWarrantsMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]", "documentation": "Relating to Series A warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r698", "r699", "r745"] }, "aiff_SeriesBPreferredStockOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SeriesBPreferredStockOfferingMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock Offering [Member]", "documentation": "Represents a series B preferred stock offering." } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesCPreferredStockMember", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": ["r698", "r699", "r745"] }, "aiff_SeriesCPreferredStockOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SeriesCPreferredStockOfferingMember", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock Offering [Member]", "documentation": "Represents a series C preferred stock offering." } } }, "auth_ref": [] }, "aiff_SeriesCPreferredUnitWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SeriesCPreferredUnitWarrantsMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series C Preferred Unit Warrants [Member]", "documentation": "Relating to Series C Preferred Unit Warrants." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r637"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expense", "label": "us-gaap_ShareBasedCompensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r644"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details"], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r350"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details"], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r349"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details"], "lang": { "en-us": { "role": { "label": "Risk free rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r351"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares)", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r748"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options granted (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options granted, grant date fair value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r344"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Outstanding Options, intrinsic value", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r42"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Outstanding Options (in shares)", "periodEndLabel": "Outstanding Options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r330", "r331"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding Options, exercise price (in dollars per share)", "periodEndLabel": "Outstanding Options, exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r330", "r331"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options granted, exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r334"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Expected life (in years) (Year)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r645"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details"], "lang": { "en-us": { "role": { "label": "Expected term (in years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r348"] }, "aiff_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue", "crdr": "debit", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Fair Value", "documentation": "The grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "periodStartLabel": "Non-Vested Options (in shares)", "periodEndLabel": "Non-Vested Options (in shares)", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Non-Vested Options, grant date fair value (in dollars per share)", "periodEndLabel": "Non-Vested Options, grant date fair value (in dollars per share)", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Outstanding Options, weighted average contractual term (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r101"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)", "negatedLabel": "Options vested (in shares)", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options vested, grant date fair value (in dollars per share)", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "aiff_SharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SharesAuthorized", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_SharesAuthorized", "terseLabel": "Shares

Authorized (in shares)", "documentation": "Represents the number of shares authorized." } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssued", "terseLabel": "Shares, Issued (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r6"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "aiff_SharesToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SharesToBeIssued", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aiff_SharesToBeIssued", "terseLabel": "Shares To Be Issued (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "The number of shares to be issued." } } }, "auth_ref": [] }, "aiff_SideLetterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "SideLetterMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "Side Letter [Member]", "documentation": "Relating to a Side letter." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r126", "r137", "r138", "r139", "r161", "r185", "r186", "r188", "r190", "r197", "r198", "r212", "r246", "r248", "r249", "r250", "r253", "r254", "r283", "r284", "r287", "r290", "r296", "r410", "r512", "r513", "r514", "r515", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r544", "r567", "r587", "r599", "r600", "r601", "r602", "r603", "r687", "r702", "r710"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r6", "r65", "r68", "r69", "r127", "r145", "r146", "r147", "r166", "r167", "r168", "r170", "r176", "r179", "r181", "r196", "r213", "r216", "r233", "r298", "r376", "r377", "r384", "r385", "r386", "r388", "r390", "r391", "r396", "r397", "r398", "r399", "r400", "r401", "r404", "r411", "r412", "r413", "r414", "r415", "r416", "r421", "r423", "r428", "r488", "r500", "r501", "r502", "r521", "r587"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r208", "r209", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r533", "r534", "r535", "r595", "r596", "r597", "r598", "r605", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r620", "r638", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r671", "r677", "r747", "r778", "r780", "r781", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-12-revenue", "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-12-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-14-revenue", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details", "http://www.infoa.com/20240630/role/statement-note-2-going-concern", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274", "http://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tables", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AF2-9021-BBB71BB25947", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tables", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-tables", "http://www.infoa.com/20240630/role/statement-note-5-equipment-", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details", "http://www.infoa.com/20240630/role/statement-note-5-equipment-tables", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tables", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details",

"http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r166", "r167", "r168", "r196", "r423", "r440", "r511", "r532", "r536", "r537", "r538", "r539", "r540", "r541", "r544", "r547", "r548", "r549", "r550", "r551", "r553", "r554", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r564", "r568", "r569", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r587", "r678"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.infoa.com/20240630/role/statement-note-1-business-description-", "http://www.infoa.com/20240630/role/statement-note-1-business-description-E1655028-A038-44D9-B61A-DBB078856AEA", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual", "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies", "http://www.infoa.com/20240630/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-assumptions-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-11-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-12-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-12-revenue", "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-12-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-14-revenue", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-details-textual", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-schedule-of-other-income-expense-details", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-provision-for-income-taxes-details", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-deferred-tax-assets-details", "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details", "http://www.infoa.com/20240630/role/statement-note-2-going-concern", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textual", "http://www.infoa.com/20240630/role/statement-note-2-going-concern-details-textualC33657B8-6158-43C5-A182-3206B7C02274", "http://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tables", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables", "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies329CF348-0280-4AE2-9021-BBB71BB25947", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tables", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-10k-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-details-of-other-receivables-details", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-tables", "http://www.infoa.com/20240630/role/statement-note-5-equipment-", "http://www.infoa.com/20240630/role/statement-note-5-equipment-summary-of-equipment-details", "http://www.infoa.com/20240630/role/statement-note-5-equipment-tables", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits", "http://www.infoa.com/20240630/role/statement-note-5-long-term-deposits-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tables", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-details-textual", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-7-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-", "http://www.infoa.com/20240630/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-details-textual", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-option-activity-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-shares-authorized-and-issued-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-schedule-of-warrants-details", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement", "http://www.infoa.com/20240630/role/statement-note-9-liability-for-employee-rights-upon-retirement-details-textual", "http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r166", "r167", "r168", "r196", "r211", "r423", "r440", "r511", "r532", "r536", "r537", "r538", "r539", "r540", "r541", "r544", "r547", "r548", "r549", "r550", "r551", "r553", "r554", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r564", "r568", "r569", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r587", "r678"] }, "us-gaap_StockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockDividendsShares", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Stock dividend paid (in shares)", "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": ["r6"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit"], "lang": { "en-us": { "role": { "label": "Debt conversion (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r6", "r37", "r65", "r68", "r98", "r272"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock conversion (in shares)", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": ["r6", "r37", "r64", "r65", "r98"] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-13-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices", "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit",

```
"http://www.infoa.com/20240630/role/statement-note-1-business-description-details-textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2",
"http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock Units offering (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r64", "r65", "r98", "r512", "r587", "r600" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [
"http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Share-based expense (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r6", "r64", "r65", "r98" ] }, "us-
gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-consolidated-
statements-of-changes-in-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Debt conversion", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r6", "r65", "r68", "r69", "r98" ] }, "us-
gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-
statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-
equity-deficit" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock Units offering", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r6", "r65", "r68", "r69", "r98" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-
changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit" ],
"lang": { "en-us": { "role": { "label": "Series B Preferred Stock offering", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r6", "r64", "r65", "r98", "r521", "r587", "r600", "r684" ] }, "us-
gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-
changes-in-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Share-based expense", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r43", "r64", "r65", "r98" ] }, "us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-
stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Share repurchase (in shares)", "terseLabel": "Stock Repurchased and Retired During Period, Shares (in shares)", "negatedLabel": "Share repurchase (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r6", "r64", "r65", "r98" ] }, "us-
gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-
in-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Share repurchase", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r6", "r64", "r65", "r98" ] }, "aiff_StockToBeIssuedDureingPeriodShares": { "xbrltype": "sharesItemType", "nsuri":
"http://www.infoa.com/20240630", "localname": "StockToBeIssuedDureingPeriodShares", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-
consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-
stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock offering (in shares)", "documentation": "The number of shares to be issued during the period." } } }, "auth_ref": [] }, "aiff_StockToBeIssuedPrivatePlacement": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630",
"localname": "StockToBeIssuedPrivatePlacement", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-
stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficit" ], "lang": {
"en-us": { "role": { "label": "Common Stock Private Placement (in shares)", "documentation": "The number of shares to be issued under the private placement." } } },
"auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr":
"credit", "calculation": { "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-
sheets-unaudited", "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited",
"http://www.infoa.com/20240630/role/statement-consolidated-balance-sheets-", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-changes-in-
stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-
statements-details" ], "lang": { "en-us": { "role": { "label": "Total shareholders\u2019 deficit", "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY (DEFICIT)",
"periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r65", "r68", "r69", "r87", "r546", "r563", "r588", "r589", "r658", "r685", "r704", "r719", "r763", "r814" ] }, "us-
gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.infoa.com/20240630/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-
balance-sheets-" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity",
"http://www.infoa.com/20240630/role/statement-note-9-equity" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r95", "r160", "r282", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r402", "r590", "r592",
"r604" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-1-business-description-details-
textual1CA72027-BCD1-427D-BAD2-4ABE38E340E2", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual",
"http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r99" ] }, "us-
gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual",
"http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual"
], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r417", "r438" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events",
"http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events",
"http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]",
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [
"r417", "r438" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events",
"http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events",
"http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]",
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r417", "r438"
] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock",
"presentation": [ "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-
events" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r437", "r439" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-
condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-
changes-in-stockholders-equity-deficit", "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-
details-textual", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-16-subsequent-events-
details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-2-going-concern",
"http://www.infoa.com/20240630/role/statement-note-2-going-concern15461F82-B674-4548-9E5D-B4BDB6494124" ], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r52" ] }, "us-
gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SummaryOfOperatingLossCarryforwardsTextBlock", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax-tables" ], "lang": { "en-us": {
"role": { "label": "Summary of Operating Loss Carryforwards [Table Text Block]", "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r756" ] }, "us-
gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-
unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock",
"presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity-tables", "http://www.infoa.com/20240630/role/statement-note-12-revenue-tables",
"http://www.infoa.com/20240630/role/statement-note-13-research-and-development-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-14-revenue-
tables", "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-
general-and-administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-15-research-and-development-expenses-tables",
"http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-17-general-and-
administration-expenses-tables", "http://www.infoa.com/20240630/role/statement-note-18-other-income-expense-tables", "http://www.infoa.com/20240630/role/statement-
note-19-income-tax-tables", "http://www.infoa.com/20240630/role/statement-note-20-revision-of-prior-period-financial-statements-tables",
"http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
```

```
"http://www.infoa.com/20240630/role/statement-note-4-other-receivables-10k-tables", "http://www.infoa.com/20240630/role/statement-note-4-other-receivables-tables", "http://www.infoa.com/20240630/role/statement-note-5-equipment-tables", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-10k-tables", "http://www.infoa.com/20240630/role/statement-note-6-intangible-assets-tables", "http://www.infoa.com/20240630/role/statement-note-8-deferred-revenue-tables", "http://www.infoa.com/20240630/role/statement-note-9-equity-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r375" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r375" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-tax", "http://www.infoa.com/20240630/role/statement-note-19-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r375" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r754" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r754" ] }, "aiff_TaxYear2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2034Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2034 [Member]", "documentation": "Relating to tax year 2034." } } }, "auth_ref": [] }, "aiff_TaxYear2035Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2035Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2035 [Member]", "documentation": "Relating to tax year 2035." } } }, "auth_ref": [] }, "aiff_TaxYear2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2036Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2036 [Member]", "documentation": "Relating to tax year 2036." } } }, "auth_ref": [] }, "aiff_TaxYear2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2037Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2037 [Member]", "documentation": "Relating to tax year 2037." } } }, "auth_ref": [] }, "aiff_TaxYear2038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2038Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2038 [Member]", "documentation": "Relating to tax year 2038." } } }, "auth_ref": [] }, "aiff_TaxYear2039Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2039Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2039 [Member]", "documentation": "Relating to tax year 2039." } } }, "auth_ref": [] }, "aiff_TaxYear2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2040Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2040 [Member]", "documentation": "Relating to tax year 2040." } } }, "auth_ref": [] }, "aiff_TaxYear2041Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2041Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2041 [Member]", "documentation": "Relating to tax year 2041." } } }, "auth_ref": [] }, "aiff_TaxYear2042Member": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TaxYear2042Member", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-19-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2042 [Member]", "documentation": "Relating to tax year 2042." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r640", "r747" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r640", "r747" ] }, "aiff_TrancheAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TrancheAWarrantsMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche A Warrants [Member]", "documentation": "Relating to Tranche A warrants." } } }, "auth_ref": [] }, "aiff_TrancheBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "TrancheBWarrantsMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche B Warrants [Member]", "documentation": "Relating to Tranche B warrants." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r640" ] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredOverTimeMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-12-revenue-disaggregation-of-revenue-details", "http://www.infoa.com/20240630/role/statement-note-14-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r640" ] }, "us-gaap_TravelAndEntertainmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TravelAndEntertainmentExpense", "crdr": "debit", "calculation": { "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 1.0 }, "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "parentTag": "us-gaap_SellingAndMarketingExpense", "weight": 1.0, "order": 3.0 }, "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.infoa.com/20240630/role/statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "http://www.infoa.com/20240630/role/statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "http://www.infoa.com/20240630/role/statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Travel", "label": "Travel expenses", "documentation": "Expenses incurred for travel and entertainment during the period." } } }, "auth_ref": [ "r74" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "aiff_UnitWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "UnitWarrantsMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Unit Warrants [Member]", "documentation": "Related to units warrants." } } }, "auth_ref": [] }, "aiff_UnitsIssuedDuringPeriodNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "UnitsIssuedDuringPeriodNewIssues", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "aiff_UnitsIssuedDuringPeriodNewIssues", "terseLabel": "Units Issued During Period, New Issues (in shares)", "documentation": "The number of units issued during the period." } } }, "auth_ref": [] }, "aiff_UnitsIssuedDuringPeriodNumberOfSharesPerUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "UnitsIssuedDuringPeriodNumberOfSharesPerUnit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "aiff_UnitsIssuedDuringPeriodNumberOfSharesPerUnit", "terseLabel": "Units Issued During Period, Number of Shares Per Unit (in shares)", "documentation": "The number of shares issued per unit issued." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.infoa.com/20240630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r23", "r24", "r25", "r117", "r118", "r120", "r121" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share", "http://www.infoa.com/20240630/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r675", "r676", "r679", "r680", "r681", "r682" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r760", "r761", "r762" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-21-subsequent-events-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r760", "r761", "r762" ] }, "aiff_WarrantsOrRightsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "WarrantsOrRightsIssued", "presentation": [ "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual", "http://www.infoa.com/20240630/role/statement-note-9-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "aiff_WarrantsOrRightsIssued", "terseLabel": "Warrants or Rights Issued (in shares)", "documentation": "Represents the number of warrants or rights issued." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.infoa.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.infoa.com/20240630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating
```

the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r184", "r190" } }, "aiff_WpcAndOrigaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "WpcAndOrigaMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-7-convertible-notes", "http://www.infoa.com/20240630/role/statement-note-7-convertible-notes-details-textual"], "lang": { "en-us": { "role": { "label": "WPC and Origa [Member]", "documentation": "Relating to Windsor Private Capital Ltd. Partnership and Origa Two Holdings Inc." } } } }, "auth_ref": [] }, "aiff_WpcWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "WpcWarrantsMember", "presentation": ["http://www.infoa.com/20240630/role/statement-note-11-equity", "http://www.infoa.com/20240630/role/statement-note-11-equity-details-textual"], "lang": { "en-us": { "role": { "label": "WPC Warrants [Member]", "documentation": "Relating to WPC warrants." } } }, "auth_ref": [] }, "aiff_statement-statement-note-11-equity-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-11-equity-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 11 - Equity - Assumptions (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-11-equity-schedule-of-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-11-equity-schedule-of-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 11 - Equity - Schedule of Option Activity (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-11-equity-schedule-of-shares-authorized-and-issued-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-11-equity-schedule-of-shares-authorized-and-issued-details", "lang": { "en-us": { "role": { "label": "Note 11 - Equity - Schedule of Shares Authorized and Issued (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-11-equity-schedule-of-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-11-equity-schedule-of-warrants-details", "lang": { "en-us": { "role": { "label": "Note 11 - Equity - Schedule of Warrants (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-11-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-11-equity-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Equity" } } }, "auth_ref": [] }, "aiff_statement-statement-note-12-revenue-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-12-revenue-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 12 - Revenue - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-12-revenue-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-12-revenue-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Revenue" } } }, "auth_ref": [] }, "aiff_statement-statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-13-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "lang": { "en-us": { "role": { "label": "Note 13 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-13-research-and-development-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-13-research-and-development-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 13 - Research and Development Expenses" } } }, "auth_ref": [] }, "aiff_statement-statement-note-14-revenue-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-14-revenue-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 14 - Revenue - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-14-revenue-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-14-revenue-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Revenue" } } }, "auth_ref": [] }, "aiff_statement-statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-14-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "lang": { "en-us": { "role": { "label": "Note 14 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-14-selling-and-marketing-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-14-selling-and-marketing-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Selling and Marketing Expenses" } } }, "auth_ref": [] }, "aiff_statement-statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-15-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "lang": { "en-us": { "role": { "label": "Note 15 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-15-general-and-administration-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-15-general-and-administration-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 15 - General and Administration Expenses" } } }, "auth_ref": [] }, "aiff_statement-statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-15-research-and-development-expenses-schedule-of-research-and-development-expenses-details", "lang": { "en-us": { "role": { "label": "Note 15 - Research and Development Expenses -Schedule of Research and Development Expenses (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-15-research-and-development-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-15-research-and-development-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Research and Development Expenses" } } }, "auth_ref": [] }, "aiff_statement-statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-16-selling-and-marketing-expenses-schedule-of-selling-and-marketing-expenses-details", "lang": { "en-us": { "role": { "label": "Note 16 - Selling and Marketing Expenses - Schedule of Selling and Marketing Expenses (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-16-selling-and-marketing-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-16-selling-and-marketing-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Selling and Marketing Expenses" } } }, "auth_ref": [] }, "aiff_statement-statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-17-general-and-administration-expenses-schedule-of-general-and-administration-expenses-details", "lang": { "en-us": { "role": { "label": "Note 17 - General and Administration Expenses - Schedule of General and Administration Expenses (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-17-general-and-administration-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-17-general-and-administration-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 17 - General and Administration Expenses" } } }, "auth_ref": [] }, "aiff_statement-statement-note-18-other-income-expense-schedule-of-other-income-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-18-other-income-expense-schedule-of-other-income-expense-details", "lang": { "en-us": { "role": { "label": "Note 18 - Other (Income) Expense - Schedule of Other (Income) Expense (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-18-other-income-expense-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-18-other-income-expense-tables", "lang": { "en-us": { "role": { "label": "Note 18 - Other (Income) Expense" } } }, "auth_ref": [] }, "aiff_statement-statement-note-19-income-tax-provision-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-19-income-tax-provision-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 19 - Income Tax - Provision for Income Taxes (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-19-income-tax-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-19-income-tax-tables", "lang": { "en-us": { "role": { "label": "Note 19 - Income Tax" } } }, "auth_ref": [] }, "aiff_statement-statement-note-19-income-taxes-deferred-tax-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-19-income-taxes-deferred-tax-assets-details", "lang": { "en-us": { "role": { "label": "Note 19 - Income Taxes - Deferred Tax Assets (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-19-income-taxes-operating-loss-carryforwards-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-19-income-taxes-operating-loss-carryforwards-details", "lang": { "en-us": { "role": { "label": "Note 19 - Income Taxes - Operating Loss Carryforwards (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-20-revision-of-prior-period-financial-statements-revised-consolidated-financial-statements-details", "lang": { "en-us": { "role": { "label": "Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-20-revision-of-prior-period-financial-statements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-20-revision-of-prior-period-financial-statements-tables", "lang": { "en-us": { "role": { "label": "Note 20 - Revision of Prior Period Financial Statements" } } }, "auth_ref": [] }, "aiff_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-assets-and-revenue-by-geographic-area-details", "lang": { "en-us": { "role": { "label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Revenue By Geographic Area (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "aiff_statement-statement-note-4-other-receivables-10k-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-4-other-receivables-10k-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Other Receivables (10K)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-4-other-receivables-details-of-other-receivables-10k-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-4-other-receivables-details-of-other-receivables-10k-details", "lang": { "en-us": { "role": { "label": "Note 4 - Other Receivables - Details of Other Receivables (10K) (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-4-other-receivables-details-of-other-receivables-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-4-other-receivables-details-of-other-receivables-details", "lang": { "en-us": { "role": { "label": "Note 4 - Other Receivables - Details of Other Receivables (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-4-other-receivables-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-4-other-receivables-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Other Receivables" } } }, "auth_ref": [] }, "aiff_statement-statement-note-5-equipment-summary-of-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-5-equipment-summary-of-equipment-details", "lang": { "en-us": { "role": { "label": "Note 5 - Equipment - Summary of Equipment (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-5-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-5-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Equipment" } } }, "auth_ref": [] }, "aiff_statement-statement-note-6-intangible-assets-10k-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-6-intangible-assets-10k-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets (10K)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-6-intangible-assets-schedule-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-6-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets - Schedule of Intangible Assets (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-6-intangible-assets-summary-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-6-intangible-assets-summary-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets - Summary of Intangible Assets (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-6-intangible-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-6-intangible-assets-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets" } } }, "auth_ref": [] }, "aiff_statement-statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-8-deferred-revenue-schedule-of-deferred-revenue-details", "lang": { "en-us": { "role": { "label": "Note 8 - Deferred Revenue - Schedule of Deferred Revenue (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-8-deferred-revenue-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-8-deferred-revenue-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Deferred Revenue" } } }, "auth_ref": [] }, "aiff_statement-statement-note-9-equity-schedule-of-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-9-equity-schedule-of-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 9 - Equity - Schedule of Option Activity (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-9-equity-schedule-of-shares-authorized-and-issued-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-9-equity-schedule-of-shares-authorized-and-issued-details", "lang": { "en-us": { "role": { "label": "Note 9 - Equity - Schedule of Shares Authorized and Issued (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-9-equity-schedule-of-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-9-equity-schedule-of-warrants-details", "lang": { "en-us": { "role": { "label": "Note 9 - Equity - Schedule of Warrants (Details)" } } }, "auth_ref": [] }, "aiff_statement-statement-note-9-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-statement-note-9-equity-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Equity" } } }, "auth_ref": [] }, "aiff_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.infoa.com/20240630", "localname": "statement-

{"statement-significant-accounting-policies-policies": {"lang": {"en-us": {"role": {"label": "Significant Accounting Policies"}}}}, "auth_ref": []}}}, "std_ref": {"r0": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"}, "r1": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"}, "r2": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"}, "r3": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, "r4": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, "r5": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"}, "r6": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"}, "r7": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"}, "r8": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"}, "r9": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r10": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r11": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"}, "r12": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"}, "r13": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"}, "r14": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"}, "r15": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"}, "r16": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"}, "r17": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"}, "r18": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"}, "r19": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"}, "r20": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"}, "r21": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"}, "r22": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"}, "r23": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"}, "r24": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"}, "r25": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"}, "r26": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"}, "r27": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"}, "r28": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"}, "r29": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"}, "r30": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"}, "r31": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"}, "r32": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"}, "r33": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"}, "r34": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"}, "r35": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"}, "r36": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"}, "r37": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"}, "r38": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"}, "r39": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"}, "r40": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"}, "r41": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"}, "r42": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"}, "r43": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"}, "r44": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"}, "r45": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"}, "r46": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"}, "r47": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"}, "r48": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"}, "r49": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"}, "r50": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"}, "r51": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent"}, "r52": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent"}, "r53": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r54": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r55": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r56": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r57": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r58": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r59": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r60": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r61": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r62": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r63": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r64": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r65": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"}, "r66": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r192": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",

{"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r311": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r371": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r491": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "1", "Subparagraph", "(a)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r673": { "role":

{"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":

{"https://asc.fasb.org/405-30/tableOfContent" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r796": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 151 0001437749-24-030111-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-030111-xbrl.zip M4$L#!!0 (*@R.UF?5<8'O!H (F7_0`1`86EF9BTR,#(T,#8S,"YX M"R;^3,*IF?>4G63>2FUFDDHRYYR].D5 MJG! MX_X$^^OWY;X,-@2"&@2&';SXX#4^`I'HM5J29__]KJRE!?B>J9C?SGI?^R=`M*,36'<.T%U].?CRfT\?+FYL3Q?,UV] LQR9?3FSGY&]__N=_?/XO5?V+V,35`M?& (HSUOE:,FQ#>)>.2NB_'V<*NH2G_P.32>?E-`^%TJ@!Y@I/8FZN!<5?_\M_.H9GSQ]25;.`A+8WB=X\.5DZ?OK3Z>GOWf]^OAK^.%Q%Z>#7]J_^!OMX^`I MI$E86#/G\U1ITYXfVD?=69U2-KVS82\]JCL;VW>W<>G79}?ZZ!'JX\)Y.0U?`MLDIQA8WK0A.(;H1O4U4,8O)+PXMT0=]5_>V,:>"GA616J+-+P^L;HG9I.ZZN# M?E23Z .?!;Q(L2#V9C5(%PW;<= [):\^L3WSV2(J+49-!V;WU,"N+G(JfX4`M,((W*4Z6:?_DZP%&&Y{2U\^.1Z+BMF;J'I\T>Y6B[9DZORB\2!=T_;C@7/.>`M&7]XN%]HK]F318-7Z0K^VA7PAS>IHAM/76C:^1!R^&*_L$".5L^#QC`M]L;GP6^/UP!AA^M/)1-3]O9$T7S?-9\W/OGJN*LK,M5I7H`M#Y7^44Z"9 >2XK^K$/RLP#LQ+DBQCLNS7Q48[P97*,Y1_?[8OAV;;CL](L6?1T`6:>BWA(WA(`,:1/D:?[0.8*\YP^`M::Y.^63[5Z=KUUD3US?!]@EGF1%8N@0F.'2:HT;.T;\L!?DC.&]1D0,&:1>' MZ0E5B'6[$R^J2S'PY<2#QK9(J/6;JZ-K5E%UH(J^L9A5&JJ40>9%E8(JIFTV M6*>U2XKJ!%4\F!64LA0E\`0%%!-FO."A^VR"H1J.OF$_--N`;X=O^EN5]D5W MQ;B<*+3>CX>;G"E&()\\V5BX2+R=N8*9E,P.^_]>KZ>HRE7(*_ES:AO*-6.K MW.S8?C[=XW4@QL8CQIWD)_N]URW"RF&)K(HIZ,G7VSNK&UC6&R<;^BO6`YE%LBA/#(YE \_(D'^Z)`A:J)UK<%LQU2WX16\-X(*/M./K/I6,9Q/54\N\-`M]4^H6KKIOQ$""PN#!<-1&1A>![M(IG=TO=M+`^MW+-Q%4^7`7R_M'!41X!FK=4`MYY;SZZT&/2Y#+%B-2\$*)%*^4HDZW(1F%#I#%;`AIHEE_;-#ZXO?TGYE#`1B29(P%I(D\`MD*2=UPY0F5YC';#9S4<"1K]7`!BQ^WF\EK<=GZA]]7GCF3;Q/.BGGNZ::\JI`MM,N921/+SC3F>V5Z.GR>-BZ!/[X#5X4^G85\E:L=WR,W\$!=.*:]H%U1)VII`M91TN+2R##K&&I4__HOQH1Z;\CMR20_#K/9,-GDE6S&_S-JN5YFI.=S]5#A]LS6,A+1)2@_EF")@X6;(Q0U\.J-BTH^/B$F=`MF,HT%E.Y#\4\5K]["2/5.$L.PXYMJ1/KV.F!VY_1_QJ8SJ/'I8U`MS[C6I$]O8IF*E/$\]JY.I/9L6G3#/'5D'`M,^D@:,<<%V)3KZ7:F)Y+'`L+%UPL7+!9>RQ`&/U+"'#DMI^$,;,5*-HZ)8-ER MPK7E)/QF^]LC-UJ_QV9-.NM.AFEM:##,)GZ0;.(&CIA;.BZI%G*1Y(%D\D&/`M'X+IA5.OG?7W#$'ZD+2U,;X.OL.]JM]?L,.FC`M&@XR*6-97Q" HX\?`NI*/>6N/"6X'IO-!V"9%V)O*G;T'1DL:.*C;RPH]Q"P`M.G;3#57*07/U93"^0]M83C#Q):IKFNM2L=?*,.R-S[HQF!)#Z$0P>B]$T*Y`M#H4X=B",5/I8%HUE4C.M-/" #]8QF)W5$## `?(@DZ^X<6 M&]L+=D"'Q2RD&2L0T`.#7`4D$,BQP$("/]S&HG#!42060\(T)48'A]!69ZJW`M>?9@-L4&ZA]P87ZK0W`MO%!'HZN).COK3]6KV:QW?G$Q/IM>3^M8.)?BBP43? I"N6UR7655OCT=G_:\7`M`S#/^4@=<C4<7ZN1Z?*7.1K.KV=EH,NK37=YX"`!2_+"`P8_8=8OT=:R0#P>3`MRZ]#."T\=3.\'Z@2FW>IL-COOSV.#\61TWH"%?"DQL? #'CS)VB_VU+?:W`M>S_1U_LI321`#/DQ2.Z2Q_*AW_N?(T[R#-?K+0MV8//[T(/`M&:$&H8^]]5T>/2S.\B.,YT%&=L23/3SVGGM!-T<0UR4&RN(`AQR63?DA0S8G M'"%EVBP7AZOK,)?(4Y84%!G]4<-(E\A3-"\A,MJF.$)\-'`L+@K!BK\ODR4L!`M0$CEV5'!,J<@_-?ODGGB]??ZDWDD>6#9G]`98PD`73)//B*&M27S9%+&LCX_`MKA;F`W3)/*)$)1DGA&VGSX2),.-NF2>W0)[SV==,D^._<_K3^:18X&%!$%FWWF7S"#AXMPNSUR&PYZU&5#!.O8%\5Y&48^^P\]<2DDBV55?M!-D+OTQ/X_=F.G MCQM!,#*'))OQ_P87.H,D\ZHXC0C!.-FD,4R,C_R)DA@ZHR=/'@`P\+[M++#,`MRH^F[UY[O`A`MN3T9!1RR3+"0(0BYY6^%[F!19,,R'C8*<<("B""_37*'=(<2S/UF&"C"E00+`M9?S0'L;FM@Z%F3O2ZHH9)4ACX82?JI>QYZTS?>9^IKJ"#368GA\RS-@QU9E>`MM"L&P^IBJD@&/^.'$7E;,CI+[Z7#H]B;^\2P)QQ>EX78^*GQR)-+6OJ](,`MO%$78RJ3? (LT57SK&-.9(-(HE8K;X4,R:Q8%'+),L) AB#[F9^AVL"B21XN"`MC4*Y(8V3W$ (XT$RR@\,.LZ>QZ-3G^))+N.V (5ZPQOV/J2 M&!MP%6ATA)Y%"9UVXR\=U_P_8K#^:WK>AA@HCDMYKEA`R;MHF;HKH6PL\,)D`M4Z:Q;&P$N6&R=;Y+EE5_::ZKV4@.KQP')(Q<\,/"0HS\(Y2CPT.6M9Q@-8<> `M? OJ2^!+@PT+$" L=_%"N$!UWP?+1.-!2G`TFQZ]9Q5QA+\L2"CB#+5;*]\Z) M.!2(K9I:O\PW&[64"H;`MN7\Y/0>#GZNSRZN^.A]<7ZFSZ=5`4UGU\.+Z^&H=SUX@Z1H*3&P8-4E3E<"`M5DYR\^5P>#8^GUVH9_WQA3H:7`MI5.:?]BH`X'O;/9^65O.#@?U9E<+<4?"4J3`M+@&(`(.0LIV3?DZ8*40I1*&*YRUXA[!"U=9+&C-UB8:BA+Vl\%CHK3FI.^W& MA>E2E$84NYEMP;F+5%2FH&+GR)7-Q;:G#,U+$GB2,18P,1/!@V.0.EB%F=]6`M-V.03]P5&&WM>";R_$"* 19,Q&G@MR`$?&O=%8`C$*+[!$L>659W$CB/!Q8@ M"B6"IP:&#A49F=D)1^4-\&EN&(AIV!">,*OZ3+"Q1GA,$5](:/#$SV&94[.:@Y3]/6G4;IGL31PYVE!39YT[U&%=AB8460]YW`2K?;"`E_MJ-N-)%E@P20CS;O; <%0,$AKTE=4ZE96/A`0>92P `"*X4P"8[OAW=I_LIW7L`M-"O&"0L7@M1]X<#0[37+2.Y_FWU"A3AAX420X#SL]@F5O"NCYGU"11AA8420`M4YR\8:/;)R25W-[(? 4+UB84%0$$VLMSE'MT^H9HN`WGK?4)U"(2%4$%BL\0E`M(]T^H3+@E+LHY%WV"=4K&A)@^X)@M.RE)]T^H=+0%5QF@C]5D.2!!29!8#OK`MYI1N`B%EL53((,.DMT9-AF[3KAU3HTD6+W`LOI*.E3E/A*))6KL7G4>"M^&`MS%1ALA8U*6+]<1$^6# `1A.73,`FWMH2)8!0W77IQIN6<-:'N/DRPV6EHNN;Z`M6^A>OS37]^)9R^=ID4JP-/\>O=6&G"LK0\QS(-MD3`M+8D!M3<0#PN8_+A\B8QIPO*$)9J%2@@NM>M@`.'D7_-Y'U(,L*`DN/,P?_3G`M:?P^??6,3!HZ3:W&GH5;,#"2%NOZF3XC5I#>JSW3\)?N? SGQW0TY8>C1S/G\`M7]/-8N/Y8/7!(!$W+JA"O/N-JR_!"M.%2UCU*$7G&UD!$_=$L;45^7)2KJH`M6?OQ,B0(Q9-O^ALJE^NLUE_.:&0,#^9 +P3Q0>UOYP8OJO27!XGPUEHGT# M[VB#G"A!V6 L? K*;H(PW\GI82O$6E]:X,S=S4/A[ER6%'WIK)Y-FQB1#C!( MZ212ME":.C[`-BQU+DM+TX:N:?O%E;Q^):YNAJ*FY/Z^65%7P7$S59:K7Z8! M@B[& [WE7_6+!CXH9@.#K#IH[9)D)*8TBRS#?CEZS=Z>6A_\;VEZ:R24%-AP:9KR'?YL@HTP[&#R>+&HO&.J6W`-(%NHZ*JPH/]#BA3`MLD6],=+F*R$'1N.^:XJ]?-=\9EQA('@D]+L$[0-HS9@!*:ZGU!%LGB;+ =*`MT.#(W?R*/'N`QAO;)S`N^O"`D^AQ!U8M6J^A8TY"#L.LP@V.D)\MK+U&]\M!H] C'BS>S<.\C/QG^1.H$#=!K<#.S4CA'+F-TBN)^?O&M#=`'A? MH/LZ;K;&N94;.;(S26%&[F[H\^M7'\9GJ`.?)A;Z33VM8B_Q9)E*\]*:F] M495H$2Y.):?QQID%^-OI(GQ?37X_HH1@&A8KO9NSY)3$^7A/]%^.1K+%WUE! M8:^[Y MHLW74E+#QFD?:Q-F_$+_3>;[OI HW?=@7"M2H:DCVXVI/3A;S?*WN_.ZTM;+`M+-$(P]W8NDLI+WR;X\;FQ]820\-C8[KC'61*=F:F=^-':X>DB?M]7^)YNX9+M3OBZD8/)- V+0>":=R;L^1*P;4-U<1?4TZ$3+.)&O,>U91ZHE%VH$?WKFV/[`M2VL;=H\&HH,W&"8-`*]W6VLC43!\]_2`A;.Z3GZ%GR;A5#F[2"/L]-VQ=B8OD%+]]KA4-L"P<&*R?.T8E3=; (9Q%.4@A*I)5GZO7SO3#T]GNA>4C=A`MB1;I,PVKY.N5*/GN_9*1IMB?Q4JK*E6]LZL.^#C,"\W-25//<6N_A/DJI_PMF*]I27.]"8L'$ MC"VBAC.R6&O)PHW\HMJKX(sLB18LD7O00I.?\XSWC?B6WVM,-B)"B]^[CK'1`M_6M[21&0^D+DEFKL6_P!4T9MK5FO-`MWL(7(/2WH]22++=T,**96A+YIMD$3]+: [M:.O1/,W+EL_!37^KEF;5%"T0OW&`M?D=D=;]:0S&:"N8Z.B&&]!0$EYD.G44;)XM0TUD]W$M2RLIE_!2LT\S1`738`MV`8Q^(N1XM<-Z?_I]"-FB:! <-8]V5K+3(I]@XSY("36#GO?5=5845)3HW?R'`MG0@=9A=I6LQPIUDRPSKJ.X)/ST[7@I7>-5U=V/,>;KZ9ML$$N/7W1A;!NT;T`MN8=@$?$;T/(]GZ;3O`M!Q,M%HM.]^: <,HV<861LGN0HEU.P&8-6!MH.,"I7MKF@!FW4_!M6+(8?,#X`M\T2)<@T%)Y,[4ZDV:,*7(QV\%9GAZY15ML):7\EKF%6V%EG0:GP71G)+-I`M'}]>?6"D-K-041>LZ&RI*Q(N'DSI,2YAE"9PT6_L8.DW(`M^M0AE.L\'(+]=.T+%(@W%;-#@3:7#6%@W.11J$;++Y>DEJ//N.NZ?792>Z`G?-LXK_\=:`MG]K&G6LNM'17X;UH9&\'0?F=G? >BD1KL#NHL=IEHH&;IVIW;R2"AB=3EFM+M`M(D>M]>TD=[UU]4.3)-WV%CR\T;E4;W'(M+%E?+87HT ;Q!5:1.V@R`6<>2U1`MC%@K6TD6%)P;+=)W6-^-FWD-5R? KW\P"LE@L1*M%;53H\N"\1BI&K)6M)(L7`M3HU6Z5O#_:OY358'T]^IU>7!)TNH1.TSKO?:U;PVK9O]V<)6; 6I-;J=GHW`M#[!.UK^9!>1Q^GMZ@+7UZ9UL__M+"$+ MUH+46M1.E>_0SFNZZ@S:WYJR,,NKWJ*6*'R! MH-_N5E;FBGJ,%4R=MERV.2YL^GK)1OR+QW!@5;YO!WZ7U*O3$%O;",C<]@#N9K]H)>FA:Y.P6^3]G5V]T225_P*UL5ZE"N>7MMQL8`MD)M/CG"[6Z]"'YQA_[O81;JM;CM)\&35; (_^$\Q-*P6) MM;R54+;L5*<\08K0&%%EDH+VT5RS#DLWPI=\Z)3T8\L_0O0>+,V^7Q*FX2B`M<:7!G_V4$L#!!0 (*@.UEV6#06M@:.!\U 0 5 86EF9BTR.#(T `M,#8S,%]C86PN>&UL[5U;4^,X%G[?]OT/6?,9'0+=/4-7]TS1`7JI1N*R^Z\`M32FV0E3M6%G9!C*_?H]LiP+X(ODBGP0]- V)))_O2#HZ-^M\_OUA[@_NJ`@9`M#[LC-[M[@QHX'%/!;=?=FZNG,.K\>GISB",2. 1GP?TRT[`=W[_[>\_^_P/`MQ_E& RI(1+W!9#FXGL6!1\]41G]/!'U\OSP;.8+3WZ?V'P^^#F^OQ0&]W[!VS`M>`^#L_>(XOWWV6? #SD_PQ(2$=`!%!F/SY96<618M/P^\]_?V[AXGPWW%Q.]S;`MW=T?KEKO9,WEMU[TV&&]\8=A^N5CTU=#W^\G;4<'!P?#Y-O'IB'++;PB#CH9_`M?#^.[\[^Z-U# `MZ.T UP>#E'6^_223@?R_YO+TV?/9.&4DW@N\1W8SIA]1G\G367'$US(261/D04`M!LJF9T6ES]T*7LE/_KP@R^11)UQ<".!%.G0%]'TU).$F68QPZMX0L$NX-1^_?\JT]2%_F"[(,_Q\ C^>,_X`M?S&{(ZDX)*&D6 N,$M^<<1AXSS]8:WE!!>/>;.> *"DO^B*;_P]^-+*70\8,+`MZ&{D)4S*\71*W>@%4_HEPBB?C^A"4)EJ`M%--KGA^Z+H_EG) EF4@IY\MM>4& 3OIR1S0>,1W1*16"@@BYHT&L/DT%_7I&\<-"'NC*;/*[&<7R@T;R+(*C_(Z!$O%U>0,*R6EPP@(XT^'H.70C`M=E>VA_0'P(#O-+B#L[@!OI(;,.[7TC#J`&^D@%,XX-[`S;=&0]+ (+QN8Y3*`ME5)\S0]=T.H$!78" Z/EA4^:""0LM9),""/H#F,4GN$N!%YX(/C\-PUC]`M^^?B\3'ZFD+%H6X5+N:.!3/U8P(^A5DL#*?F]M(/`JK5<5^SYZ['%I617M>_1H]:UN5>P?GK [2.'K`MJ=NJP#]N(O!RJTD5^B_HUWLC-XPJ&W[=?#;D.&M4T>_VN/[+;"[>7)>NH=I@`M8X&VA[(&M)N&7.9)X/4M#4S(>XH=\.9>`$SF`%HN5OJ*,-D6;+E8Z5%\XN+G MX4LFGL'?;8:O]\.U6J%]]>&,A*5UR6D4@GZ]6LYX3A8"-KNB)3PY*K]*.HS^"#9_!$\`JDHR`M8/(:X\DGV'N[H>5]_-`U3?[M22)\(1EL`[)%ZCBI:N2,($7?7:+0)B:-M)(`MN*%I{JWD 1Z@Q5XK=[2LKO29'--K5MP(OZ9F)#=LM*9O^TGAR%+C&IL6-KD`M,)33WG-R6{JBKP;R4E\7!LG>AARD_A<.6BZVEE7XIO/A-+(*\ZQ"WA%G?<. MEZX@1SSY@AR/1H3Y2>I8X9?]>7*M/*;[_+D6R6R45_?2,W?H^_O>'GQP(_!`MNF51ZLW*2U_3[=M"CMW++WZE4RYH$Z+51C :-U#,%:B3&=#CZQI%Y/)&RPG3`M6:H-46? QF174'QRZ,G&;[Y0>6!T@7:S`M%*-]T%A#"@^=.23P0'+>49^G4I2FWN/0D7=1>K%/I9"M,EWOJ.F>$$.'`MDRD@C>R(,31A@/M:,.*^~6FAU0U;L!#&/`AC/[%X_^\JGK@\B 1QH\20+J9*`MN5<+)%YF\P./;GJ;G>PY>0>79J_./PF2.+8D/KKTP6CU43F]^OM?9L?/%BD`M7FVUEVQRVQne_HQ.N$A<2.GA4)YU7=ZX#TNV9.&6VI8*8WBJ0.E,0KSBJN MO.'JEAV#N5X#GL[>PN"7;@!1=^O5R-[# +?6L8\A7Z_!U"H>:IB"?&H+D=?4`MD5!9BVU`+=.T#-N:[YV0^C#;,6*&S(GX2>6^RC=9*IK6M [),&4[=R#*/P\>-T/Z]V2A7(Q@-CX, <1"Y/;*^#?\VE*L:[ND@$PX`-Q`M!QO\>/H6]N`12`XJ8#,RXNN!51T-_`*'S7@8G5!/JOI7((YB(&_Y#(I>/YH]`M`P.7?G`I167:"YR5&8K\^]G&O/!2RU;'QL`5.6\4;,$5H,) ;:%-V37&=47"Z MJIH..6YD5V!2.9MSI/*0P.3>;@ZWR<;Y`5X$=@DU$8#)=8<4:#6B0,2@XW\E#.15)&ISL!&C/5)\S< M2\WKUXF-8R%*7U$N:6Q4<2\]U!DV+`^+P>IA&\N+ZQDO[R]F:I] [Q$JR!^>GWT`MF"Q85&C55;0V2WF9K=VC'9T^NF(-Y+7I@4K0LUP%0E\W,UY##52@%[<\'49C`M(L22!;?R:"RRN[7ZFD7%YW.IWV`W9RF @F:&K=P(U!*IC& <+@D;'#]EU6M\X`M]^Z97^P(4N]J-O&HLKA3WS622V#&?5!FP]+Z%*K=^L)2+AJ1G(LO`M@T#R.KA2NJL[&$[ER@R(2@%3TMCTQ6LW(I3\K0=50 M23&]05QH$]C<,/5*Q.%;CN7(]-59?".7AZO$(L4W1<4`BBQ53)-0HN%R,3<1`MILE1!E;I?.0DSVNA*O9*(EV)>9C:6GM&7IDM5N76C]Y29PJFO:2&H])VP[21 MU"#IVA28PKU?)6KB3;AK=M>-N&MVUHV(:&S8=24<2.PREH@o5MQC/QQ(-`M]BZ`BB5$K*;XILW&Q>,N+1,1T_1QH2;1T_Q! (,U#79,$;U>]"I(MC)D#T30M@9$MFQ\]D'<&$FDOYYD9:CV,:BE9G9(T`M0=A=PJX(0I(&;_`EI#E(6\"08G/_G]5P!)D"+/V5$;&>5X)HE&1..74R3B.`M,*W8>1X8U3N9_B%]3L:1I* (=$<47S9N;`M]=DN+J"!LCU.3;Z;,-[&YL>DRVM!KER.F%1X+60Z,@^3$]\-4D,:8M+GE7!J`M:QK&U-N"&E2/#=>)Z]"F1T"!Q&,-X"T%GT`W4><>':6NQ+%?C)QNY5:Y#R@WE`M, [P)?-KG(:IV) L/0'(\[`J9$$,4N^<96EU>37*CF"&!4$!"+B%B>PLI, MWE:6R8$\"22>2AN;5I3.[?2)/'!P,PNF;YQ23J.GY5.DB.>U.1M06AV[V1P7 M45K8KA]J"SE;TM)\P&Y=Q5$(TI4TW_]W)#I <4>#N'!AQ_QZFS/D^C/=B\4'`MK[5V,-GH2MC:SI0S8:(K >LD3&IT2>:<$+Q*/J\ZV4 12<41CFEN3.C=>9PI`M4A8PB1O#O-

DHIZ)AWG3O8]XW{3],!S8E'1>3.,HWTW@/?@)4YXXB6RH<""-] MO+7]E%H>W<9/,5P3!\&5UE-KP^C;!G>>+P@3*3D/>'!{)M_*36./_Z*^-!^OJ MIA"/5E_K3=[
.;WH9'FB17KY[P45R0D>18),X2N[AY"TSK\G#;:1B2Z,0UK]O MV+ ^ODG^EULGZ^JVO?VM]_9OXYGA?00PTOOX:RBRE;#P4\8QM"0,8W7!=AFBV M,9ZAH5]@FF_#;.HHX78+
QVM!U*BBD9.U8|]+_.8C))HCL M=EEC-,9FY*W;@]4+H9$DV?&R @[R3XF 1 MI=9-WG7N;HT-7X_^@I33X$)PEX9AOE6]BDAQF'ZQ%OMBRYKV2_.C7B7%6E)7 M$238/1%>>
2{4XR8[PI)?22LB#,][GG@%P/UC%>:8LJ8UAOW2S?\OHL4T7&-M"[_3V6,P.LTD_!]1@3]2D+]K3<&\0\WPRYKQ2K/O\WMYRKV2
MXG3Q5IQYO+U]BTG7]01UOGC&Y&MH_%M+<<#D0VB N75QALE-T&0+O#[<4!GY MI5IB&;]X8U:A*F"+"V[4&@G9U_('Q-8Z/#)_P%02P,$% @ J#((66O7 MJ_=-< -T@+ !4
!A:69F+3(P,C0P-C,P7V1E9BYX;65MO5MSXSC2-GB_M$?L?>GNO.5VN<[WQSO>%?*IUK*OLL-W=^UY-T"(D_>/-K[^P=,]C.)W_M\]??;X/)[_;9I_>NZN?IKE#]UV&W\X;?
JCT]-7PS|XWU9INC+ER^_E7]]:IK%=0WE MH$>__7_?+F^G#VP1!G&J5F2J;.GB_\K*7UIR;9B7RVADX9?&%NJG8-,L4+!*.MCMX&[X{^\3,+?IGK_LLOU=*%8BIXPF[8D)?
U/W^_N7BY%G&:_Q;%B]_6;7X+ MDT227(IP(-BLD=3- BH*/]BY_^^=GOE]*<4@BQ?+A/WZ6W>B(KX(XS18L,4] M$RW)QW#:.'Q@]5]IP35=&UI,1C&-
;D/Y9\#1C2XHU(_6XQFP6%DG> M?9&?CI-(\(::?5+57'$ZX^$_IGSQFSK&WGO\]^:WDEIY"N1,3I0'*<_5?@T$ M>XS+:?DL6(J8BT N7,^2?_!.;.>*FD2=Y5RL%\L_-?5"VPM5EVP>
M)M7"3=6&>R*[@7Q3)\P$ZW/&NGHW!Z7$S'}A0N)=O_YJT3,U=WS7TK<6/3/ M7W-1/ VWOM9:@]"9X O0XO(69?E?TFF:319&>N1W:VGJH)1+3KC -:XZ*& M@/[!
7T"RQBN/0+!-8[@4L=\$_?]'SQR\CB1QM7B+*12C^8KGZJ2U]MAH[G"3#;D=_)*]6$\G/_6TS#0@FV_3#@4EQ44,(F1 R(61"R026"2$30A[\ MU+!!R/;0QR\X_A
(EC$YYT,)'R/RI*^+!NTQ<<60WJ"R-84420&P<^#AI\W MZ_UPNMT*\H@ZX8MED3-QRV?YCU"P&JH,^.L\'H%O M\$O@E\$_@F\,TREL/1
MQ>07E+]74<0LW2X@%'j_Z.@)8#?,2S":8/2!P^A2ZI_E"74BSW)%QY]Q_G!2 M9#E?,&%&S7;=''2032":03""90#*!9+<@N5@;<.)'H/0I2 ME@>2S4REV 79@P3RMH#9;E1/:+H-
402U"08?+2^'T4:I_/L6FKM2OR-R8.F M|@2"*TA3[P+33[-$Q>,5/\|>/X@@:-@4Q8_F+?G?@J,W3QO!T_)A M%#_H&0H6%"PP>-AB]YF&;?Y7{((D08L4D:7:E=
<;=%/#8C4YC$8HF%$TH MFE TH6A"T2Y1M(-+R2O"2E?;;+.JZAO+Y.^KBA7*AIL5BT4H5NIO63Q/XUD\M#66_<#KE15KFZBUY$D]CEKU[^^7D_-
W!S\&;MY_?!.\G9V^#+V_>'@7'Q\>? MCHZ/WW[X\OZ3)6CW3Y@?/6 HODBU(-5" _F.E5!>S;YW1%*>7;=;*9P\">'U M6@9-^-
S%D*1>D:)]B@8!&]!HD*)!BL8N;'YN5]^?ST8N11"94,J&2"95,J&1")1,JF5 1 M[!$RH9)E4RH9${E$^IPGXY,J&1")1,JF5#)A$HFU.%Y&]R$6CW^$=RO(X4E
M%LFF(EZJ>6S+SAE&\5-Y#D1$IQ>T5!E8.'$>RS;)2OIY?:DY'W@B)2[!QFKR M1VV!V6A&$");$.B&.#(M'Y)L1/YCJHM?]I2)G_XU]6/5 K+0!RLH:OQ[_ZH
MJOV0FA;X*',F96T,*)M4DM/MH3I)H^,PB[.KV:5ZFS7-JX180RW#]@-1 4HR MT2$ST5$IQG&8(/6,--[.''!%C,Z8:KB,/7^9YBVD6WG>%E6C,A3;"EX_%3.'
M^'V"X/A;Y*:A>ZP'7;.^T*O+U:I-X&WUV M$\{Z7Y_6Z9[.XEQ'O(X3$Y<9]/GFI?U4'S4EUSI€L+0H8+09-6C4!9@+,+ MKQ4PMS5TQ00+E=\&]00
!GP7+'0Q?/@R0%8M%*%;J:UD\3\M27NK-@.E4%2U3 M&'7)DW@:,XOTF!XF!0/+^Z"YDQ_Y&XM4SL{3,W3-GEE]2QO0'A M]OE2^;_="OOD2=:OUZ)N=.0Y&)*4*SHN?A
M<#1H" "I]AA -+*F^&%1?/2-M3EW(2\5-1]OHU/]6UQ(ZG=+F6W$+/(_*[M&_ M/&/P;),YB\Q9!VS.O>35P?0SDTH3I/)8?) BSC.6VUBK-""Y,3T8"R"M, MQIN#-EQ\Y3SZ$2>)/'
NGK,"I-F9O?B="[YAJ-PBIR*0BDXH\3C61X#3!:.QP MNLMMY!5 ?J?2.+R/$_5&_(R+@$FUSQ>,!2*>/ZCG6)92H 7+8\%V900(KEN. M[@=X=R*.0#F!\H,&Y=?
5928/L*O\@8EK+FEYV@O'+)4[T0;>=QV.@#H!=0+]-M!-0)]!-0=PG4W=Q+7B'[YT V6<2Y^DU61B@[.8G3.4N56=ZV,]T.#^@W(Z:
M3B&6%W%XPU=ADJ].GJ9L#K,TM\8!Q7%10XI!32'LM73+, ^=D5[;A8+K=(*0 M67%0W@>[*]T.QT4W!CZ0PDL*(0&&$!3]JCTQN=TB-3B&& MWQOHU"O#}^^6:!F5YN|&-
BE8D8PV9+3IU6C3T_Q:JKY$K" MNLMMY!5 ?J?2.+R/$_5&_(R+@$FUSQ>,!2*>/ZCG6)92H 7+8\%V900(KEN. M[@=X=R*.0#F!\H,&Y=?
MQR^6JW152G8M^@.W1VN2WH.CS1J!10^_'*@W>XY#J2A+763)TJS*HE/GZ;Q4 ML[+CU;:-=;A2ORLAT187I9%*@S5NHCZGHC6#3X7#Z;2+_.317H:$|N\YWG#!Y;8-
V?'(+D$'3@&$#2?3ARNG6-DL-[XP?U>ZAB7Q5I\XRVT M(92,&TT>+P7>,%\8K2\1W1"-MW:L.L+,F0-LO2]D?1)'"@&%ZN>.A$2I 5M^CV?X4P&C-$04P^GH(D)V1U6OL
MXM&;\DV;.9F$&<5)D;.H2%D>2!*S0&I(//%-GZ(9"8&BCY\A*{A];$445@"@> M3A= /P(.^UH*TL4>U M.;<@33IVP%XYB#.1VN45L>.I]=.&E+,F7
Q!'B^"3>78M6+5W*!WNLY^2OR@ M<,35;!9/63-]^H9D^;'BX*8ZSZ[5<::UP#4W'N-]@]H(=\FYV]X:&BLVH <& M#L ?H;'/N+G *%79\6KW+,9"IAD
!7_P+)X6(Y#MF@HFDE48'2,=CBP.AS$C MXAC"HN'2':T1N^V]A<[8HY%;E;'4)D=^]]@&&S(3KXD1'$=G6G<6EU!O06; MSTL.MKF-;5.VND,.) V(G#K6')%3QY-3I[7:ZM?-
\S'(BON_.5VH7!%'E5%B MZ]W1#.')]6.DH*.OYRF=SER'U-C809'4!F*PD[M=%%Y+7JZ(%7^1^5 ;Q"S@AJ9:.@!/}>D87%#*U?0:H?.R2 !Y5K$CV'.KI-P6MIQM EJ^L!9^
M8R?"A.W4&+]:00.0X!T/A1^}TT11(A@I@I$]O)L9-!E. M>6O0K-T9N-?8;,FLOPW1 M1E&;+,_XHJA,ARBW]NJC"O)S!^#;2E<#T]CAB<'7W\|.'-V|_!Y,VIS\!JZ=?@N./1Y/@]/CX
MS:?/GS]\G)O--E1#4WN[S^0I]@5H9T2A<^Y6#"Q5O#DG] MOHVER:;%=W.1 M/+P[6PL">R7.(K7885(Q)7P>4L*GH4CMU8]4RLU#O*RA]_'O_JB]_9":;%O@H
M0Y$>NOM]\ZL?$E4/73"4[G3M**B;3LNJ@>5<4K^H^0_+T'jZ\>ZY6A,"\:93U5 #THO MLZ=^[PC2/<@*ZD-)8=KI#*+8?C[A:Q_935/_|-M1?
4;7%1H9%:G5_"VCF!4HFJK5F&XIUU^_$XM"ZNJ.] M\JB#>8\3N>:[tLI$^G1A_Y%_58712G460"G\V Y]_QVQ0*RC\$"9 -&=B M(<5MR:/8^J4WW1!^8+69
L+-A)L/&C=?Y0l,3+',Y;JG)/>8@'4B_$_Q6X2/ M"1\3/B9\[:(?VIP^7C'QQT R'Z;S6"YY$)8$!D=OGB@"PF+#*'Z0,8@<(L<$ MC@\:'%\[0%;A&S1DV
RP62"R023"2833'8)DZVO(^]8^9.*97AD(B\1IOJ5 MK?E8,X(?C&PDH%/UGY-R;+69KV:JKO\DC>0798)EN?PO-U4OZ#2&@\[{SZ:. M!9O*DGE5UTOFJ;2XTN*@1W=$WJ1906+
[O@?H8AY(9?I47YG MK]O$\U&H :X1?/ZQR?O%XN6PFK;&)@\EOXXA=LEQN@^,9F]HXF/[/Y50*QI6(MYV'S_(V-<*BZN*@AQ;N^DYS;>+ZXCBFPM-#4@\]ff-^8FR,'
Q]I_?!=F,=F_>"5=\|N7KYU)66D:,G!<=%^Z\[01$% M-P :6GNGO/[QL!]B=<^_#4(O2%K,#VF.B 9A)7WTAGME]+F:G0@6Q?EY.(V3 M>L &;3XX[9?
*CB"TD@3M=@B\#+H[+GDZ5Q&#:NL;]MGIF@Y*LW[UM8W'1O>P MM>G(W?;<[$KNME?KJ.WT^WU2VZKSY%D^?4\%Z^]][G=#8N2/Q-.YFWQZ.@\ M_W:J SI?,OCK<)A'
E6<0Q_BBJ'0T>B)I;L%N*L=(M-IXU6G6Q ?4DNO@FT:W(XUFC.=W9-O8191[U;GM!P7T%QM_>25\A^ M]',0;19QKGZ5!6&;J8IR>9S.63]-K0OB08?S
\KMJ.GD"+Z(PQN^"I/RM?'U MC,T.3W-K'% -<%S6D&+PHC?0DW/+,.=D5;3B8;C<(*4#V3|SLKG1SP09=TT%I MUA8^T#<>&|U4L($41E(8$2B.L)QP[9&Y_V]+X9 :G4(,OS?
0]5>&[\$MT3(J MS=^-;&+P$)/1AHPV!\YRTZ:+_.^#75' 7L[T**G:U-9K^?) ^-+ ,;2=K"R38EYD MN?S]VULV+80DE677A9@^A!F;S 4KI5<7R>\PC(.H>"EBF3PNI)2=,Z:OC-_8
MS@T93SE?MTS()3B^%NN8@C+9Z|[^C03;<9RQ,8*7$E2\R(!M),3 14D3CD@\4X..WU@@,72 MMW1'RC&8E(:6#DCY_=#X6?8.*K$;OS<&<$;]
ME@$]!N#@V)H#;8\|.#BQYD#;PR\'#Z%@QV&HA.^6#(IWY5C6XKZO'1]R&-I MV^8Z7*G?E4;_K>4OC:Z3T/SD9)]3T9K!I\(1_;EKW=1N+8*\)}!R?BK>1@08KIK
MD&*#G0(CMT Q"8?T& Q/9EC$VQNC1HL7 P2+Z,+8+3X0;Q>@B2KIHBVF+6!X2(?>4+1Z0[%S'@E*.7YE+RK;'$T QPJ0 M/WQ/*[;UNJ++,P1K]NX'=T6Q-
UX:)3EL4W'.$X.@4U#)KQOGFS,Q26\K"P0& MM.3X<@'XO+%>GB"T9)L3!V06S\"K8VI.,DB%VW!@')=DG *$^LGLSBXS|\M0)L:DEG]%QKWPZ V7]4O<'+,8(M\>+|GM&-
^#:F_0-X^HKM];/)#T-TY8"?, MTX-!D%()*.\6]QZJ3M>*(T'N!3.ZN/M+7A=N=NHFLQP=/NRUSB0G34!YN>AW-'# M!--TVO.?T>P)*A!GS=$]8CS4R"N9>SLEFT?M>':>!:
(REP5+92\!+\AWK\(8N M.:+TXR%B>.1C!2>E45PYA2;,36+"I'$G)6G.1YO;%V. CX"@OA(N:UU'LR/] M^$:.$:@6NN4'O=)W19-.BCQ_9U6P63UDS??]&?
HMML/M\NSWM*KI8]1V0*V.Z ME]GY&&FG$BY4G)&+]YT?"I.,*MAB!4HSI+1Q* M8T7'R.M-9]33E[BM?H*1Y4-)IW/H8&NA->.5S9L1$LX"RI;RA\[]YTML>QI"/
M0/'Z^]/KI?";K(PH91=5G+Z`.:&#SEX388_W&0$+Z :4?'&SZ@==4*#PI;11- M8LT119-XBB9I;5|S&T_R.>#]0={@3F5;%K"|*E[M:?V@D23Z43S%D$*(Z!0]
M6J8683LS8=DCWA5NFAUC-R%/^'OD9 N MGD,^,R;/N0=#4'==(]*+#^!M&"F*)X)%<7X2"K&:<5%FC#=',:O;#T^},1<' MV&O\G-C<.61Q(8L+,%K4?
;PEIMM=&88RV,1G28%_3H7X>VU."BANQ&>YI27(]*8B?GH'C14QON113[IS98AJ8GH9G*R_M6]G5V#P[(^%.W\U[V8WMAV2ZOVJ]7]ZZVOF#D>Y
M]D0WMA\G]8/>1GM492:7G;$]6=7)]D[OQ=-KV?`KAUN]*\-UC(!N7W0F2_-7 M;69Q-'X1%U)Z/(X02ZT'G;R_^Z4X>B&97DBN2P1P],,>*WP F;HID*>9/,TF M3S-0L_?
E9LJB>1K^XJD\"@)P.N5%JG(5@B5/X]F\MY_^L:.!.['6V';%W}W0I M@BB1@!S"&H/>Y$F0KM?B8_NF3OX=?3Q-)-T1.6#7B5%*Y--$M+%*P_?V8^= M514\E?
^<5L^25>3!^&H[C%=>]V@P")NA-;G1#L"-]GO&KF9G61XO)"E-:UK? M:/3. Y!\8S+2CLAQ0/H7Z5]CTK],9P&WQV#H> 00SML -<_]T#6CNMO-KY'5
M.6O=0*G7(/7WZVJ%@DU9_*A.C"S(R__C0; @^2PK/JZ!2V?LKR,$ZRJUE9 M*.)F.U5YYC;1+&VZXK @X**&(!FD17E*L=;L9GVCT6MI.K9-2S(2@U?. M&HX W@7)>
6W'P+V=Q$ORU^T K7-_@!LZ;YR<]%N%#G=Q"J@%V^ND[^-%?% MZS;"9.(T\(Z$*A5Y3L,9 \A^D\EEP$89:QO*4) MUSR0'10+I8/0+Z%?:"J;/K"H2-C5[%S))KN.'UET\219DU*P0-
"GPTB$CPD? M$SXF?$SXF/#QX>+CSA>D5\#\I;2]YJMV*+FAMQ]HK)V<\##A81 >OGT(!3L. MY:%QPA?J/9.RV*Q,?;U:EL_#3J9Y_"B)M83'70<>:CT4@<>K,K?2@EE=KR$Y
M>>")O*&RL_*D^"Z/C4U*[#I=U)9^^_%(ZR&MA]0>TG\(ZR&MA]0>TG\(ZR&MY55H/0 H@"Y;.MWYJ_MC 73"_%>=.,$*U7]?;H;2!4H?:\"M55-P&_O[47$-TY.22TJNOG)T.)\+ M28D2QZO9325*
("QKU9=4%)Q2,4A%8=4%)Q#E?%:7$E^L6ZI R18K%Z7"\(T-MD@+VR!)>-!\YNDT>EVZO6]Z(-$\V&XC
MX8#=N*@A)8#@,L%E@LL$EPDN$UP>+!_6!;#Q"Y[?!QE+$E5/50')12C^8F5U MU8](V7)83[\"Y%56.,/-M-;.4AV^;>=L 9NMA<.!37-006B:T3&B9T#*A94++
MA)81H.66J.8O5/X0S%G*1)B4Z#&,%G{50!23=<5+[<9VQ-H.D;:(<3\M9I>_M*L=D9_)'U@8^MQL+!VK%10UA:,+0A*$)0Q>&)#H!ANX";,P"Z7?!29C%
M6(]DDX!U81L0;FEZ]BO M[%P>46=2:;$0:)B=%EO,%$YD\>2YY.B\3_ZMT_^/55\;G(EP^2'E,)H*%ML5V M^]J0-/2#$@S(,V - /2# Y/,_!]CW15'^I>]SEZ\Y>[)XM>#N8'X-O00D\7
MD7IQ,.H%P6."QP2/"1X3/"9X3$\7,5T-[-9 %S;8<,7=NP%=PHZO%3M2@7=" MRX26"2T36B.T3&B9"KQO,.9G)6!,"!9UJX1G',_*?:L\0"%X'R?
0>N\=1B*T3&B9T#*A94++A)8/%RUWOB#]YC8> M=7H/J:FI@PQ%[>P$B0D2TXM(G=,0R:Y#5$IHE^P_PJ0H>9$'6[&KN?B=Z M;;I/,M0ZT
MA[3>=WQ(JZF_MXJGY"XDVP@]I$4;'VE\I/&1QD<:'VE\|):68Z7/OA[2LA_9 M6W%3>DB+LK-)"2"X3'"9X#+!98++!)/[R&MC_T\I&4YK"?8W(HJ>DB+ MT#*A94++A)8)+1-
;)K1.:/F5/J3UJ<>'M-J.I0DTMR>-'M(B#$T8FC T86C" MT(2A"4,3AJ;'M!2B_+RN&!^GLBW;8,B6R!DTF">H;$$+Q3 3F 1EMY9U?K_S-ME,MK*U2*\44I7.M=;9FWW&8P
M$$H@E$$X@F$$T@^O!-M,L[TB^*_K*!F7GX MLR5VU@SA"3$;*2"<3#@9A)-/UX5F[!*?54W?G8IEL<%)X&BT@3@_F\V82D!F
MU4$E2;Z1F<R&R8MB*NDM'366]+5=N+D#++WFG8!"K&9< MJ(_YG)*+88@C8@T(M*(2",BC0B71M05#7B66[?,=I""0+Y1%0%[?6U[57[? MOE$%8N+R=.*S8"EB+(@))
<_^]*K]D)H6^"AS)F5M(1O<G,2/-IQP%' MSN@4-L/AC@;SZU>MT5I])116\K1QL=[H/A^EAD"^G1%MX7!R:+<2?6Q;&
M4FL8Y]=#&6+1A5)%/1)&CW)TO'J3M)10WF+GC@X4E35"DF+ MGH?#T: ^[T;ZY T*Y++>-:DREGT)+V9[&:4>K.>D3;G+.]PF(W.9M#Z(D+C M+V_SK;@%]D-E-.E?
GC$XV\D61K@PH;$,.MKZ:1CX%D/$SGL5SN("QSF#O: M.2Q&!&.TL":(W-*DIFM@_]D23789/R1#YT:PRO1_H^9ETY54+U*]4*!>!-,(MIAT>3+,_FKWDM$%]LJXKLPIF7
1,8B;^8BP0\?Q! IIB*:57L#P65;=N&,[1 M;'[PG5-B.WF?E)=7Q/=%Z=Z]X[?LD8DPG;(3OE#U84M?V62Z'\W4I]N#),QO MS6[#9-0K&]!9M!..+ K+FH(21/]-1]]-0YZM'
MG6TNTY$%R;6'-5Z!]>= -EG$56V4,I!I6L;JS5G](.BKY>A^@',GXCH!Y8LX MO.&K,,E7)T\4-(=]F5L[@,,W+&-2\!XF<\'*-5I/N4TZ1P MNTT\.C46?]ZB"]8R?]N"?
A0Z>MN9)/BL,C40]86YW8(6SUM9+86D&;@U:SR M9[>HCU\U^>ATA&KGZ$$1D4WUV$29MG5[,]0B##-K\2-\EW*+WFOTFZ M8<:N13RM-
4/8]W9@.3GAZ2.3ZE2IFMTR$;/L^%JL'T0I:UW=<26*/"U_:#;O M=!G'-1O/Y_H6II$::[6EZIR%>2'8U4PVB]/YM>!3QJ+L3HZ;J7)>=3PY&]0! M@]6.3N11-^-BH:RO:SG1E-
N%]G%&WLG3BOTNMRV40$@O%R0^A(+=RRT4/;-; M]]GFK J_WS:Y#E?]5Q/U'LY56>XY^UJ2=9%6M;C+GT[E 7,>QN*/,"EJM[2O M.5TM3S8!\@K(:>[MHU7*M.HA
MRZ_K.5X.\$G2V4\FIO%:.7WOZX].U?&3#(W2LX;G^7BC0KC3 J41$9#D8]M[8IZN2_NK7$D$WWA'0?EZY.5LG M;-PR\2BOJ7KX_UW1F$D.)!5#PSP/DIV_G_I_]
[S_V&Y>GMZG]HSH&1Q;0]I M6!&OVB"IN-&N\\]B!=/%=HVC4"KS>92BO;.M;L,;)3]-_%AV'Y WX'4-Z^2[BE9I>#\7?+&1F"MQ&Y9/*I9.GT9>H!WJQB[M MV<6;?2|6/?
QR4'L$OS1\'^\;OLQ_.^T.>TT_VU^9KL(!QK%&#IMTQ154TC50%'"/D!G.J6C/X M5,-&#+=U?!H]7.95>>WJP-$ME.OQQ[$ZZ/ECU*7>3(&E3#.]4(!IO*_9O7.
M3UV38>+_=_T=&G.1L3U%^?N^G=.Y\8T*T_HRC:[PWNF%@T4]M1AD+7C(6 MS'N5Z_R=^:FI=+W)S6Q_X/D8F_1Y"_LY3L:-3N^7_F_V.(\V60=X5Z/+V-$<
M1;R%#0E5VH>CL_E 4G;@&Q>UI&K/$-XR>ABEV+HZ83O)KZ,,&)?RV\]}CD^< M 9<_=Y9!@5/ ^\%.G>3=T?MK#N5=$W>*3JA[U0%VU@3HRT8H]8,H4A@P3"]W
M/#2%"S3;GS*LK8\SRK#N, M8A7F V3S S8VP;%S0 8_(F/0078$D/-/R#BW%0@V(.B)L/]M%LD/91 6I] &R4);082AHS@Z402SP[$V4,Y1'++ (7"@ MRA@V(-0F"1W**Q9,-
$!]$>@280-/GL)XH-9{(#W4 M{((-R?44BPM=#BR(SU_$+7+1EL "_K)VH"N"#6DZ3?*'+@(6*&H.VX9RA 6# M Bj5;5GR4,/SZ$T@3YEX6CX-$L5)(0^6(&5Y(%E>:BJ?
IBHS)Z4O1BA_9]O ^^SE-"BDTR@&A[KTB+Z^[JE9*%)YH67R M180/C,F"%XU/AC@=>TRKEC;JKQ:C-V)IL1.UJZ_9\ MC!Q>[G$I N>,.9[-T+7#81;"1TG?
V4!Z,Z(*!FLWC*ENG3-_2JE%[R*NKRE-TWV>KJFGBE\.8ZP:I5 ;8U-MJS0W' N]@OI^=LFYVIX3U=V=7 Z_YD?$,81%PY$]6LMPVU,/G:%7(X_< MK)"@LN7UM4$Q&&:=?
$F(ZC8Z>[,UV$6]!9O/2PZV.HU14[:Z0PZDR!)Y2JSW M'GE*^O64-)O+_.XN9PRU-NKX=?!\#++B/F-_%^!7[%%3#^CJU[$8TI,[OYJB M;EZ=D/8V L:75!/>;WFY]N-
C1T0=/9S^]!20^K>6&IN MX&#BU#1Q_(V).1,W3&7&5?[/!=)?!\!^_@@++#OL;>:Y\8Z MA+MD 9H[(.KJ1RK9?HB76HMPW0E#]
NPK%%3Q>DRC\6ZOPS'P&&IBZG(U&M,F%:UB)V@_=.M:@-'A)AW?2)KQ^P44>_V<=5*00 M6F<317NE+MU$1=-CTV ^WGEYKC(),LLGTIR+.*MBQ_BF0/EL W.\PN!G4
MEU=':7,/CSM!Z:,JW>.:J]@?/JZ(/3-X9>,9>\J:WA]H-Y17OYAB'T#R\W;C@8^+7PO8I.VF?0#*V'I7RGG@Z4 M_)HN7GE0:.@BS7)1E 4IFC=P<\,!Z3T/[,K8E/S 6G?W)YS .B'A0_M-
H-T.@9=! MY>Q:(_RN+E.Y\$QO{)GNFFK9L[5Y2A/R#NXW/#>UM;\A[&B^AON* MTRP)>'H-YYDG4?^-+CCH?"MHR $O0.\WNCE'NB47W7M7*H.8667EWSKM]LI\
M'S5RTEX8OIP^_=W/'DW7G[;MD%0;8*&A]=*4ZPJ04_MQ4C_LJ2^IBJ-8XM6=-MZ\D@/]KVE%M!+WNJ8-#D=.'ZIAK/&49N-58X;FM9P*E&)TD M:]1F;ILS@%)R.QH1.HDIGC?-
H18'G${*-WY19%:3!X122EU:@C]K*,76QR* M+.##Z$IW00BP\3^_LML@F0BG'KFQ@&%05U[\8DI6%+K':AD-@ZBF01T=O>CI6 ML %^(70GD86=[MECN^;@)Y1GD&,;9]>CR-
&KJU1?A.]+'%Y)5$.:HK$5AF MWBYQTZ_APQF7EN&E?O7F6O5GKO@5^=R]^YGIT VO_#.W8NOX.PCO%_.F[=/ M-059.@.Q=@>=R#=15XOD'4L#YZW+9$^A0?
8WB\'Y4M"F<,"?KK7DH)RC 41=2WX M N5W%-A(DZNRY=-'D;G@?GV 2MTIFXJX?.-^OP+,T?3Y[]_[-V=L-$\]?=,XG]E2PKB>Z,Y6UJT[^M:-#_OG= M+G335$F#=W-
1M&UWMA8$]DJ<14DWA\7&EQEIQO+J6TM%8];,%"$B*8E"A$BI4 MXHXG%2[*A&"1U2$,[.4W_98)]1#Z<[+TB>?F'E0VP[ZO>LB@W"@ZT/%+PZE M^,5+DW-U=`QG/\H_-
.^U36.\A1&Q*#V2N%6 M.AE&/@\K;9Q2I PI4M:8%56,3TP[W2&4 M28U'7*TS]2F'^N!RJ U.4#0R]],K>-O0"E2B;JM68;CW77XP1Q\+3]XW9?U8 M'Q>4]3.R0'LL<:ZM?
#!^+VNW*2*6AE^_AV_OFX_&G MDS=OWWYZOZ$>&)SM<$8_4=G."8:%8U\|B%[]I$FK#\),P>K@57-T%TO/I= MGF87Z94$ZJ%*.)M(#?U1"G>CQ)1^_*_|W:C]D[+H+!2II";;3*?
%HDA4DNNI MW+?3N"EL"|ZJH@:\1PV0QYG4,5*W7Z6Z;?LPCU3I;GNO>@7T'X*$2I J=8Z% MW$Q+GL5YM@]9+1&IS9!^(+D]182Y"7-KGSP5Y3U,9
LAND\E@L;A"4UP=&;OSH"+/9SFA3*'_N5\^A'-MO#W-]WBRZ4J DP G 4X"G 0XO0!.^^MFI,9-.^SO(^^#^I-SOCTSD)0Q5O^]]
MU;08T0_0MB:H4UFW;TSM4W4=SYG[&45|5UZ;?HY(//Z897SB\]+9?,*-C1Q,/EM'+%+ELO=VCO[M4QL'T_^YG$KYO1+Q/&R>O[$1#K4>%S5D9*BO0M?
\3E1],3K3(V!#4@\IIF=^_M[GV,'_Q<%_#9/=9$??VK(2DU5 '4M/7L?;W?B0$_7OV>QG\7]DJBG$LB:76O5 M=T"NUJNMU,@-P-@M.-]4&Z;=(_/R^?(A>"U'->_&CY#V04^GY@?
J;ZAO>,E^_M.'IW3]'MRI85_'5;PJK_@-R]?"!*RTS3^U2#T IY@TC++#?P1HT'X_^UV7?,Q MTC[H2?55$I!=\BQCV54JU>LXG1=Q]J HK Q(#SE5TJQ)N0!U??=-!:=:OOK;QV.@>
M5%,(2=\/G1N[^B2-2D,$H#0RI F\>%CY@]HFN>%CY@]HJN*W^C9%E MLX'V90%!LS44(Z?:.YW;W.(H~3-A8=X6'OPV$^/501 M7GV(*X59%U8 M'Q>4]3.R0'LL<:ZM?
@:YS?*.6T&^8YL)*E0'/B((I>"Z M0G88#E>79Y V_?(%IX:K"'+%;I:0#:STJY&;WJ*+=@-Y5C)!O/&]VZV(!X M*K5VB)E MR.-9HSG=V3;(&64>]6Y!0<#!'-Y;W8(/$9W9K43=,N

('M9<:+NEHIJ/0S[%SZD%3+GS.8UA MC["NFM#[B9:X9 QW$JJ*FRX@/'9UVGTP'!@K;5R49KEB624J.7T'QN* MFI2/]#X#\U/_]+XTO@H/B(ZWOS:(ISU?3*
[1]6QR/KN>+6;3>S2YN43W/T_N MIC_/KR^G=_>\G/B/?T'3__DT6_P5O;F<7LTN9HLPRER;W0B4SB"!*W"\S2-Y M_I;'@A8O0M[J?^Q$K?[!WRC=]SGB^!>&XK*;P+5 ?
+J9+::401:3Q?3>*PMT M$(G(5Q[:IN8!6$"7M_M;!P%XOAU>>0.T,5F&$O)K!MV%]O$DB6#F68#NTOY\ MYOEQV*@%?(0I?H8Y?2-)XFMAI)W/)_W&+H/YS?
+K8+&Q)/C)Z:UFLZ WR7>X MHL!Q,HV*G.K7-M&# 3@1/6HU"5F()YHE[0)7[&&>'%)?I?R[6^ 8M2 MS]SFS ?J*=K@P-_.DQT6@U[/+2_,]%@:_XI>54B
G@@0$+&\R;ZH5')#5[NA M[M=1PU75,*"$'T[G2:AW $7G.Q#+#\<==M5X"#<,[E)9>F?R(3XCH16RLA$ METK>1).5V+M,RS@CY:90%G53C
8*JF16+]4%=W#1;PPRXJ##.$\JZA)#DGEC MHED>%S@J\246?\[R>9.S?!&M4RJ9DX>R*JAK)^$K\PF K*8/R'F1_"<6Z,KC M@'<9ZT)G<>,IVST<_#D(-P+VA
PGM#_%=RP]"B;5^ *J .4S^SKX>U" V !6 M5P2N@ED1=)7F41ZGU#:XKZ@3K-%MV95RU^ > B"@O[>FS0-+,ZHH+7G]FMIA@C@J*&*X((X,JK$);W@ =H8,)[=7 MSL7_V#
W^%G6<%1K[!^/)K3!^L)H(A#U6Q"XI##Y&0E1K3R5RHM2I-9_M]I M3O]+SR!I;^$\MR[R%3 -G. M!)3SF,,M)/18E\A?"O00_A+S2QR(@^QHB?M5(,&. MY_$?\0&Q?
T9G#AG%5XG><++Z-P2ZO#C*BU$/CS.\3*M2OW;^J'308U7(%CW M;],-$JC!(KSK/7B/B&W"AS)R2IW[H][Q=HR#7S.YIG6>A$=:CE16T2FH, CUB*JA*3$D5N(253!LY*5AL
MJ2@Q*'"E79LX;AM;N@C*JC4J57'5#B9Q1GLVA#630AQ,LNI M:<'KMD]XZ759OS33SP<$D.B \?:8JHD/Z&75_EJ'.(VM%ITL8KHBO'&<*B?5 M80"-$;N1H70=CR"V"P*
Q;%S$E="N0=L-**YAY43 1VX;D T!!?2'4XG:(L5 MVJ'5%-)HZFB$+IT!9%83D>[9"7\WLVF>5O@Z?6:(5737V&L;-X@_E7BYR:[3 MI2P]PN13Z$VL!@A?HJN#"^@JULD:
6(J$#GEF* =*J)9Z0D2V""&3LB:Q49< M1X:0.=#A.B_2QS2/,O93$_.VYSLK1VC'_&%.S0Y$AA^45E9GXVQL$$'L-R=(MX#*"$["/O:2'GI*J@63L_.53GOYC@R]Q&1?I6E$DP.A;*
[(F@>$E)6&'!6J! M#QE'849_*3-J$=5C0NHSSN7E40Y_#4XS%=,X?]R:_C*]^32%I5="401E7 M@ M@9(I#_:4J*@02#VR4G*] 3^JX5:4X&Y:SWKOI*ZE%S+
<1TEAJ9J3DJLWU*1V*(<#^0FZ;RNV6E^.[V;+&8W']#T?V^G-_?3^S I5&K"$F-J^4O: M7I&B2O_)7Q_FRR;AD)F0MP5>I1M9TR3M[Z!IW:KYO>5*JQ !)4_;7QW@E&YC
MP6K7;U-E>9_=-S4J8>X?]/F+@,GJ[\DY?L+))L/SI?QZI%Q$]*_*Z!CX3-#' M:G.(SB-J:I1X.YV^VS06:L,P0\$#;@9L&[&X%]XXOG4WL>2E#,6UQ/9V7G;7
MIOT=D)N5_LZ5I2(0(X5!ZL#'"N[9R?QL,3$-":K%3UD2H94$ G49RP"IJ?? M@K![!899)C3_Z?TZ2UM>RAT["V7"!IUF2)E8 W!>6RT8X 5NMN!T[=!V"S52
M_X8$6HCA=5*7SN6HG;2O*CEVX2KI0ICUL*@N>!?"'9XZ41]Z']DZ-KU&=:@. ME.!!#)JT[SM9QA"D<(G7!8Y3[C[1OV>X$GD&;;=*>E.I_RD\XEH)POT-Y@Z'
M4''7^G0F0XCGL:S4OO^BG_ED\"6XD)02@FN6._9IQU3,S&0+R "ZACY[S1U7 MV7=V3^ 1.*Z'B%AQ7(>O#NRXEO5M*,=C&RZYLT$&=DRTN=3]D.X%P .0-43_&>,Q8#_-#9-
+C'%WF;QU*'B'*5N=Q FB/FZ+-,:W MN. _T] EG>,M*):]>4-HF3T$AG+]P-6]4^M?DX01X!U/166!Y>*A&195)2(M"IB0D/ "TLU-$FGI(6HXP]XL.-7T%IVT\/AE!ZJ]C1 "5W>
MO/,%6/_)P?A[J[$2 9X?ZJB X \-YH17OON/Y]&!%W*#M,[3_Q :W*\$X)P! MZSAY=(H(0R9,B+\^G0F<>!Y=#18\P:6"-Y26^A?=P\!.Q?YT[CT)$2)2W^_^
MOV^_>4O_=X;648&>&0)_1N].OO_Q[0G]*?M_$UT2;:HG4K "H7]!W[_>?_] M3R<_GKWE[7J^^]/)=S^\/_GIQQ]1*JZ+V4_)IF*M$1+>VZ="_[7),?KN[0EB M=.<#+G',*]RC[\
[X3[\[0130&L=52CDB3!4=Z>82W1WS9_0E?]^4%6_JLB!W MF"TNS? -KF9Y3%:8%75=D(NH?+HMR'.:X(0Z]B4+C-XFVTP8I7F7)97!Z! 4 MU-
AT@))KT6OAS(I%%0W6*,>5J#=,?\K^SIL1;%@MNOT.65N,PQBX+KF ^-S: M$$>*N/F=;+6H^G21?3'\H#F1Q>,XQ=W),CR*P.(28<>JN)D[.C-'M3)0 M$ A?WG[TQP2P//?
GME1LNH_P?G*&TQ2]T1"*T;8T!/3)VZ9V2*T$(%A;F@6M M,+(56=(&YJ$BOE2!/'9!BX8A5,!M5,P+WK0QX2Z&(J#!X,OAJD$&P:\L;=W5 M,84"F.Q#-
QOJ$7<82Y9%U6)'^J\=*])__.T.ETVWT(Z7_YX1AJS5,9/[+AC/ M:?.&>ENDI& 1)2E)0KS=]Q&2:%#'%P]TOK7WCAG&!W[>T^6<$.(YO9^L MHQ]*FL2>*OH2,FC$A-W(
H[U>/SSSDNRJ=T+;45)2, ^OI@)N?5]!IPX0Q# M&>V(!D&<;OMM09)-7%%_%1?/:=S5ZEDU#, 7=.Y-_@X3/YJ78,-Y3+V4I/H MDL@'7Y23/*D1**6*03D6SB"RZK-&WVFU!&Q_-
A.DM.S_=#["8?YV7+:@IS2G93 M[=!B"IC6M*TLH PW[!D)5'$=,WJX,:NU0E_]08?O3K[[\?N3=V?O^?EZ M]L/)&?W_^S^]_IC#OATF!ML6B'DUPA74'UAAY:!!"^L=BUN,6["Y0+#
(#HI> M\"(TJH=^73+Z+.^%*0[5;90FMJL]F_/W>A;$NJ:P^(5;6@,/58^K MDXY$DS@^-2NC6)T'T9^6VCL6KD^/Y_2@:3B;U*VVP[@+_=0D1B0*YRKSW!I=
M9WEOL"UWF4_J_N6LQ,4SLP^9S<<@CL3'W"=IGY?902>/6H;E%%0OMY2HU21/ M6/(?S[_2S_B$3 '62?]@/-SP<5Q.$,>&\]\6GU&5H 1M$+%!=;>!*,U#\P=,
M'HMH_93&42:Y.E&.A82>R.9TS7EM>*%N5=0$)494"J_PP&K.N7(;B4H;2:<8 M@WW0T6%!-!=^/)0(Z:N8]0&2Z@Z*C8\QRU93EA07[\%S;7<- YO& MUU=TF=,O=-
/R*+O84"9;T?VC%N,UR1]Y.T&A_,Y?]AR: D>F_2E= 806U'*& MF/-2K*UNES7NB#$K:I!'6^RY2\/PK_MA-N?OPPO:LTWY*L;B\7A@F/07^,5NN_7(KGPR2M-
D6@)T3P/O3Y6T;$=7J!]3'Z.REV1T'W MG;M\$.#*ZG@RYS$+-;!0-^P]Y"-Z-''* JQ<]WRYAX+T#E,Y%L 0TCG]\46H
M^TLU.8D1C<*_O7PJ\7*37:=+N1FF_:7MUY<=!%_7G!JHP.XU'*P0=+G1\\IT M@@0VB*&#WOR5GG.A[$Q]CM-Y9Y(1V6.88H^N[N8?T?
QV>C=9S&X^H,G%8O;+;#&;WO\Y",L.V!QBC^+>F/K7 MJ"BH=F=78'?IXU-5SG>I)A+VU?D$R*A]4_NR6/IP@)@J=M<$L%$:!+AQ(E!
MVFMR)&5:/$0@1/387*0.!KM.>^G+3$D6+CK=/J7YF=-N@99L3]%I9P\.<7T[O[/_[AIW=G/_X%3?_GTVSQ5_3F+)T7=D'S;\D2CSU?/<"!?R:;UY5C)X$.<*@MK&5)_CX-O$CM/
M6&^;<(W*^ACEL#V9DF+A1$(TP3$4C,Z/;(G'WN3.2\MPCDHY2/2F21D.HVTU MR=S'7#VT"_]"=_ZRH#CTM'\W^-+V"]T.@FN.:T4.+NC/4Q8=R(VXD!W?32BO M\U(E(Z>_1P-
#%>=*NP53;H(,>_Q=5 FWB'>9PP4V,MP%\:3U? M=0LAH#X.$9P#H;U6CJJ$H/YN9-N-[;4ZRDO&0F]CN^9T'^@UDC[R,EH>-9'O M)9#'0)-G+.K^"PW:5]-
*.A(<3'(THVLV::I%\:?"ARC_'2VQ*NK8!?)#?/-F M#2>[!?#E9"3*-9;C+!)&SA[$@&P>7QW6I$PK(8S2YX*.,>![_M9<_I*P6T!A MN=>#L :\YM<0D0[.SEX7NK:=:%'%&_^R\!OV?
V9X/$<9Z[K,^KD4:4PU"OL% M"R78^T%K)!6^;,-B"R[3DBXERCX49+-F*0H20E$+>H-3NI@'I++Q",$"D#I M\XFJ+^'VN290I]-1TWS->S;=5U%1F2FH\\GUY.9BBN97B$?
Y319H\?,4G4_ MS&YN6(0?_<7M]&XVO_Q7)=HT-S19)"2;WESJ$LN1I@^BP<@8=CM@K -_9FL5OB(%3A]E%X#PB=QS=@UP%(R]%+@@JO[2 M*DS5_P%;!>/Q3OI[O-
2FQTV%;[,HQM(VGWJ#P5?779.Z+[# H:(MV# =/34I M2\S(]3J<5-%5]3A;JK9ZIE]BG@QV1U<[72ZQ])([#!(A'%5C9%^%JVJ*N]^ MEP>Z YYQWUQ.+^ZFD_OIUVAV(_Y&_\(]L-?
G;,'ET):[-7"30Z=Q7J5YE,=[MJ7FR$ WC">RF;78 \A;$H8T1**K#X7J!7?]BWNRE1HA55ELVR*!(+S6J31:P;WT54Q4^?
MUI/D[QOQTKL@=5T#4;QAED_+*EW18W*^7!117C)%0W+JM\2RH$&/D*%FNWL, MO=GJ[I<",M#'2&' ^W:S#O29+F1;[/0$;==R@G:K07PYIYLUVBT(5:2IG$J' M;NNA-
,MBA55;"T,:!'=E[WN46A*043PJX-4JY;BR.@$7_(GG$5-[1FI#:'P! M5GC2F9W'^LT_?IPM/DYO%O=H\3 OJK9*B\VI7/@!0!W!_(M=\TD
+LCC3/+>U)'5*.AR8%R^9UGA,U,?]#^$,I82@&<."YGL8$!M B>AT]-J^@7'&V; S9=+:HK)3ZW^@8#3JWM" MU]RSA8IJL.&.,P5%B3Z9_*5A[R>(7!M2TGF
M<3P4U)=L=S@FCWE/_S_8)"ZN[X^ .>^,4O?%*K80K5^86UB3F[OO9NUWFFL/ M<7SN]N9^& MN5/6I[5.;8S ^>:2LTND!0^P4GLFL&NE=@ *')S4@9%%X\W*>FT8;VF#R$B-
MMSX.5!MO2C+[N\G=MI0\+C/)GM::2N7S0A0JU^^A"IP/>N\+A>O\.KC5 ;6- MVK\A@1QBV)V@;55[4C1%[4?7XA2ZHYT=3 =MTSA\&X@KX])S&47(D'7?91RN
MROC<$F,O9%RE45D1+6&CJHX4\PGLEDSM .2G?&H;%21P$1W9!#;T@ A\- !V M1EUE54GN +91?T%8P^;RD,D&6T4F0'V:1').?U/C]O7X#"'0#G9:0?!M">W# M=]P_BXBV#?
V9LI:0G4F=OTAU 0_L_VMBZ?9!QPY=_#QMG: =MDB70,%?@GK9 M'O0ZI-XS?U4&HA<>!5M[@;.RW$24=JQ=BK2&N<8GT(H#/5/[$O8^'$ -A:VN M"=))N$9@%PG7X(
T%N6JK((.Q(%?V5^XUCLF'IR=$+,PZ:LK)Y0HV(6/Q# M(D$&7T)+ :LA^)(G#50@8N5DA0#I:O! -2)A*B ;,!090$-=V8K2Y9(+S-L? MOGO+A8;]Y&_L\942F$OP_3I+NVO:Z PU%
(N^*7W$%%"PM>KE@#4#25VN(2'Q MABE4;GP8K"43-EU%4,3[?[.5E7QE)4/G&Z_LK\4IQ(1T/EL6Q!@GY15=2'.8 MS0L1[RWNX&76E_:'\(8%"@#N*T)#$3EL;
(.XB]97S^8!>9@11 [;&]96QN, M%*C)4Q#(A&K&H,M6!$Y9;^)UAZLHS7$RC8J2)^@.DO^4],%+;V9#:5N!*H-Q<;A)TU MU>^ #A:/@R7:HE?;C.RA:8>*5K?0)W[
MOKE=RW"K]_IMW7N]AA_VJ-$CN+H5>]BJG62U(CGG]5[NDHX;4%-B;S[GE20X MP"8Q-R3?R$E)M.GCT3!I*TA%16#Y4+!1<3RE>U]P_RP,7 NXAZ;$A%#^ B>J
MJ.+5B(4[1AEY37)>]J2GTH3.-] PB+ZYG6=TBS#/"="@52>TJ$Q I//&7@>H M]!:$D^2/"URL+O&#[)&L:PBT#&=K*E\^ M;ALFJ!3G()P!_BCO$LL@(C7*K@IQ=FTYT:%)J"2-
\Y>++"I-4S%D7]E)N#B< MW7M:!0L$XBB,+URPG_SR[(A^FOKS#QD2\V6=FE%G9DR_X").2\P+)&Y_NA%MRK#DY7NG"C?L)6EBVJWN<0>J,6-V
ML.=!CV>O'&]3K_OPZ*4**Z1GKZ:RBMT">O2=^/3Z]1I?V&0K/SY^#V.%=/9U M:*UBKJ".?R=&-QMV0TI-;1QO"A$A'V49"Z&?1O'3_E@3)H3,:Y-53> 'M7)-
M$+5FU+BECEWK5^#*/=PMMDB@R[Q=AO"QIF#6D8A:&Y%)!)()E4J!;V58Q3/? M5&45Y:R+F(E>Z?C,IMIH31]4*[3PL";T@]8&]M9:4-'GVG8_0?\5Y9NH>$%G
M)XBQB[Z\^EVOL9,F6>TFQ^B[MZ9K]:F;NN1*I7JD!/:F678%:%DT4U=NWSEF M[9/%N$7T!9?3+U41D8(B3?EO5N%5R3(N6,4(ZDSSU&-Z?.%29NQX@ C49PXQ
M;ZHE0%%]ZHQ-5PZ'FAV1:UR(OX#)[6TAAPU55!*8F%)M8.[O M54I_FW5SA7P),]W;R+7.U\#@V?T#L1V>!YOC4" S-WN'2=JPOBL.?F,BRI]
MR'!/I)ID%+RN9'LVCY4DVV"!M2.'80ZK%MG #!>W)F, HDD;;_R\2%?,FQ%M MQ);,H/A 2#(O[G'QG,:X]YG/Z%L@[VO!<"T1 HEM-]^EL$@9(CQ76Z 2]AG0 M;"_(()
[OD=KFR&LYUU/-(/Z@T&W6%T3.SLB !@U"'UVB MJ*GG3^O5S%[@9%+=DC2O9CD5!-SKH>A]!-5SO9,[5W [Z"BJ$(?/"OTS#,)Z M+9I$)S!*!M9DO:>KSB=6M9F?
L[1/GX4\0+7(K=1I08_+%N?/J6EIHM"ZQP_7 M9?OS^E1CA$(>E_Z2T+A;=?41SJ/6HOY7'F5UBZS:))S=W???Y.E]!=9=O;.[M5U\"_+8Y6F/]OZ$H?!WXAD^3\ 1(36]\=YF6T>-
C@1_Y'=9\66.G5&M:MZ4A'-<379! M_Y8DH"M;"T<3G7#88$:E+DT_!]>^TP/CH_0J4Y&\PE9W7Z'PG5N,]X0,)32(
M6TLG@TNO%&'T+U(I:,%QS8XT$KRFXC\:NEU5(K\9L(\@@ZOKN M%$!MBEN2I7&*2T679_4'P_H"=$SLO&[@%C)J0%/+L 8>J&2@FLK'Q?*5I//& M57/*V(OHRU]Q)--J'2._?
-.:R5= 0@LD)!AA$,: 0 0&C]]SJQ%VQ,Y=NTTT M".*O=@[F$=%417^,BM\Q$R6=LUGW,VCU',7TSLOG"/C\1-YB,(]#6)OR!$I. MCXYS1HW4Y#8J%)&I\H%@9_AP0O=N+X>
(.,C0!>"EU"3Z)!H8>OH1%X^X,&@^ MH_4!)#2U=V+7;"& (ZO]:"PO:'@T:_6$T4HL=!SM:?1XB9C3,T@W!+V 6(TO M+/0U\!PHV]V5)F[%GR:AXD]UZ"TIOC^.N-0[7%*S-
'ZB5L,EY?V,K'F=6PWC MT.!+\/FMA.#^0!J9=#JK'9EJ3$)EV6@SU[*1BM2JGH.D=R6-+]FLD!M/F6T=^\7@P(D M.V=V[OPW0!F'U<&2#?
P3=!YEG/N"AW[W4_TH3E*#E*$932,85_&-76;S$XZK MR6[A(W-5M%>S7-#8W!N2KTB.JZAXX3$D4=5;K354GU#0MU>EY<,]*I?5J8*MS M0X,4;>#@2ZM;01:B_P-
1"7!2M#%M5_9K<&WR,[;8LMNI!E]F;"&.<7.R!"_Z M9U=&B-,M#6SL]3H_>.M&GJ>'(/.$RVHEZ"@L=(8&IGWH*RCH?F53>;R5TU# M:G*'+ZBA2W<5PP4OJU&7>LX?617H-
F8R1:;^ !YS+YG8-9]M(2->%'T/=JC0 M=A6-B3GA_6^;U:KJ'B9+^68*3O(J: !L0;@'+^8"EP809A'U..I0@":)>(M#=+[X^7FH9537,:MG8.@_+@WF;\GF.%CFO-B6$V3@_GG
MG+J'3^F:NB0QB^-^Q.$U^BH+1:H02-TNK+1+G2=%-JD]<:3OV+6LP(GDV=J[CSB;9<+?KG7 MZNQU'I5I+&%.T!Q +C6"Y9I=?YW./OR\F%ZBR2_3N\F"*;KY]/%\>H?F5^C^
MY\G=I)[][6+^\>/\!MTOYA?_C>:?%O>+RTDL;(]WEC^?%.F.2[+2?R/35H+H?R65#$:R,:265TS; ,6M>"&O!Y5 M$9<84LP;#QU>_/>IQ]ZQ0/[IG-,Y]QSI*]ZG[I9J/*
[NN/I*2)9%18FH^RQ4 M61A-UD]T8D3)H)J)_;7_5?NVM]9U%9[\X?06R>HP2'LO;L^\17:K(>BWCBP MJX;=I"QQ-<>")9@HMR2@^$ZD6?V=3?#N4,F;"F94C+:3L.F+X>KLS-
9S5%C^4A%7GI$YC(O M2+&JW:B:AP_XQ/Q#2(TG+0"NN4]?*"BV9?0L11#X+S&G*SVZDXF1## M [41034F\&*,KM8(KHQ+=%RDN4\4=[B7QU>G:@"4#"8 +
(B^EGA)&YX+A=+Z1*7XT1XBBA^5*< M+*7\:"E!S\/^B3' 1>2DV*X,16TJ?-;:>REN-1ZN1PX&_2.'0;5^:U[C1:[]V@0$\VD.6K\E;*%W%B> M*8?
N(;&\,0%$8;I@N""K55JMY,DQDE'0?-+]V;SU<=H' M"^KE-!1SR.,"@XET\7:5]RIA *))FX$NV0W^?)72 =D+ \ :/5*)D=\[: R' MN%L]TSHO%
(@_HQHV$L#KMBG@2PBKB[%R$2%;HW]708=_B"D=!XJ >(^J0=%? M?]>.D9"+@L%G$)'0F-ZU:-3/K WG,"3VXF+@(N)D<59$I7YK7;;77+:0\R\R M)GQ&H/2U*4(
\7$H.L'%QH'$C%5:1B0HID)B2T!LNPUE3^98WU [#D3I(V?L MT PO0R:,]=)4;I-W$"H8Q_1F\O0/ML0U?G)V.O@F9)J.@K(]O!.V<#RN6)3Z M;4&>TP0GYR^?2IS,\CJ-
/'^*VNHJ^L% Z'"93U^*6$8?[MX#GE@N&PA^P%CQFO4+]$V48L)\O(9]8_2B(<]B8>E,@Q! 'G1X2(*TUS M]-S 1E$#/AY5-.TH0L;<3H87C,BW7=4&=^5*@;"8$/1/89?
8.0!Z*UO)7 MQSA:IU64H4=JSB+*V$T'Y31_QB6W=?ES/O[')ET'>W ![(^:KY5$]_<^CPMJ M?UVP<#XN8?("8,OH*_K\IF=FR <-+I 6^!&SSJNGL4U2$T]//,71-C[NK] M8A!W=
<[LB;LF8^2N?E(?<9<&_;RWQFDU"Y_DB6B(@(M[LJP^1P6FNC;.2+DI ME(%%@^<;V'#'&*ZOWCPG[1;SHA)(@QUJT$,[_-!OH>.)AN]D1X>?@=OC6>F>
M&RO=WB\&*=W.F3TIW?,Q*MU^4A\I70WZ>:P-SB]G"* '"YJ+6O#OE?145E=G2ZB[E8?&>YHD#K)V5AI'* M)M$GCO]Z1!=95)9U59J>EV[E^*%UAP[G=7X-
R.!MZPR%?/!6D[:KD%_O?Q5 M$VRAT?OL+1\(K05X-*%OE@GYUMU#3J)/H]!WNC>$Y;MNXBI]R/#TRQKG)6Y* MM&+N#]"?B&MK4O97I+(TM]V;8#,%2EP
M^ICO16U&UL[;W9>JC2(1(78QB"@NRHQ^^@'("$5((@ '2((@ MPB^Z*R5A<3BQ^.?K?__OG\OTET>2%PG-_OGKT3_>_/H+R2(:)]GBG[_^?AO, M;D\O+W_]I2C#+
Y3FI%__IK17__W__H__X___K^"X O)2!Z6)/[E?OW+W4.5 MQ20_HTORR_]WO=^]NV7W^].?SE^<_PN>/,Y./X8!/_KO],D M^^N_^/_=AP7YA1&1%?6/__SUH2Q7__7;;S]^_/C'S_L_0?
-%[\=OWGS]K=M MZU\WS?E?X_*IPW[C][\U?WQJ^FKH'V_KMD>?/W_^K?[K4],B:6O(!CWZ[?_[M]O4V>B#+,$@RSI&(TU(D_U74O_Q*H["LV:AW;W[CS7YC M))=D2;
(RR&C)!P]R\ICP+Q_0>;#*$YH'*\+^$P?S)&/+2\(T>.I4L+764S_D M9/[/7\-D/@^VXW/J_N^>AB_7*[;)BF2Y2LFOO^TM>963@C6L>?R5_6+3GB_-
MYO(;^LC/DK#=OODF6Q)3&BF8Q'_SK^]L_N*.7FQGN7V:9'9?E'D8E=O)TO"> MI,TX&KT:$E.^'VF^X:&(1,ZX8GM\"A+]8T$??XM)4C./_Z.FOZ:=_?"O\ZQ,
MRC4[XV&2O2!2].DXC? M($]D"1:@:FZ5]]>CSNX])\2%:W/&LGHW'\!9GGT"\V9 MO/'/7YG,POXR)^Q;Q5^;.83O:_T2U(2P"6L9X;_X/B7Q/W\M\^J)BC"/7KTK
MSP?:M/AM%>;\28D>DC3>]I[G=*E_:5,8:]C$ [&E9&(@^6J%-X#]2HTND^&X M8V?3R-XLJGICI[YXQ?:G@"<=S(*CJ;(>M7[LAD@LA#5?;=WS/GOWUK!1;]0
MZ^ACL*BA;J42"GEEG'3$*T1^B/T1_;J _1% 3% $002&"0@2%" H1E T$U44@ MMHVG/@0%2=EHBQID+,/\+U+RGTRA%'0\:RA*CR!OK%$"$F\;7K!=^6W+"1"\ MT^F'L
EAD[LK0-B$L EA$\(FA$T(FQ V.0>;] 5-VXCI?<#'9[,^U(@B)H\D MI:NZ@2EHTAC2&F[2ILD;Z(289%H2_?17,!(FN=D<\+/=V6;W[BE=KBHF2-[2 M>?F#W>TM=
M6V'D\1&2(R!"1(2)#1(:(#!'9^(BLYX?=-E)[Q^.22+9C(12/ MO>IH#74)9D9LA=@*L=6TL%5]C"_8M7M*LYJ2/Y/RX;0J2KHDN1I*Z75'Y(3(
M"9$3(B=$3HB<$#FYA)Q,WG';0.DXN ^+)&H,/4G*0%T<9*0,V$(+GLDA*!X8 M8W11E-ZHUB"6"5F(OQ!_(?Z:$OXZ#_,LR1;%-$A0@+$18B M+$18B+ 08;F#L(
/MV5(]2Z@Y0/#$CF)2/+(/VD1'+UYH@D(H12CV(),(#(0 M(B%$0H@T)8CTE899T9RA/(S)+(NO^#&_V9URN.M?I[$06B&T0FB%T JA%4(K
MA%;N0*L>'G7+L.MM;=LIFC3DNXEJ6T]1+9=AON9_*Y)%ELR3*&3]PBBB55:G MA%C1-(D24KP]_GQZ\?;=I^#-\:Q M3G\%F 8$T2>B3T2?B#X1?
2+Z=!%]]B=AV<\0,D".>JU!+68)P1SUB#01:2+* M0I2%* M1%J(L1%D.00Q$68BRH^C_EW/.>JAXUG,^H$YZC%'/<(FA$T(FQ V M(6Q"V(2P"6$3PB9'89/[.>K?]I^C7F-(:
[A)FR9OH!-BDFE)]--? >:H1T2& MB P1&2(R1&2(R!"1N8+(>G[8;2.U8],<]:\Z6DR@B#GJ$5NY@TRFOP+,48_(M"9$3(B=$3HB<$#DA\5[ZLYX)C+N!
%I"7%B4P_*4))V9L^IB3<)&&BQ8PT?KW M >'-V88C%VS?A>DUR1,:7[#?M0$=95MK=/X/"7,8E:]:6J#QC1"(QM+E= M:ML$8DA3"U3>L2DDE.W_>7#5Q"GA;@7I);LO!:;U(4I*?
LM=B07,QC:VM!J?M,HMHOJ)-,MI: MOCKE^8+S]2F-VXZ&1J_!:;\ABSH;5U9^#Y=B8MN;#4[=[3),TY.J8)=OT791 M2UH-3MM=^/,RYI(*3Q+-O^'W:GE/""F+H,K"*D[X'QIF/)"2
M'?U4(\]>/_-8, KU2>@@-B.WM+K3<(ACAVS)WW(:_74=YE=Y_:K'?X1I19AL M?/O ON$+R@UZCK6BFHAB5I4/-$_^0V+U2D0]QEW!95%4<.J?MQZ7\JNJ9!=(M%K-+'4I^2Q?
+\5Z;Y]3D4.AU'G%=P*,!ZS3Z.J0'1-UA=/K5QP38"QU:(?1> MS9]<.:]ID=0RM=R'6J^JBK($<^6MKUP1BK!3-TOJL49;ES)U\Z0Q>WJZ9APU4'9D M2Z<[QE%+94>6
"X8"X8$H;:\@]% $!F=T'Q)\HN$M4G7[,]OZT_Z0%.V M58MOI"7/@VXW'90.(=* P$&)PRS'T[?C%'FYIP-B/^TH8S_\Z^I'QG;.0[)] MH4OX=WM4M7Y 20NK>K-M$-[9[OZ:9?
%)6"3%U?QZ[[I4)2,V'VBZ.:2GOX*1 MLF!/5F-^R-IES >-^:!1[:ZS>+'P00$2P-17K]:X*X2SJ:N1I9_?#*=-77^L MR9+>V.'H#K%IEW-T1Z!=KF/"^*[R[("\#A8T"1;
<(_9B.0:*>)EO6TI_*33 M8S&N U=3H1H"U1!35$/T3V=USXU-);N1SFAU7\[N:55^X3?G:7-QJI2)^@.@ MF@75+*AF.4PU"WHW(HKJBJ),7QS+Z.EM<,^!74#GP?
Y$=;&JHEHNPWS-_U8D MBZQ.Q,KK6$41SU3+8 ?I4-5OL'2%O MB4X1B#8UC?ROE4&S++[=[?S9T\:_WNQ[I;F_AR&GBU>GOX*1$/=U3E:;YEC-DT-.-
%7&J6J\I@YZH%4'G#-0:H-8 M0;][PJ=AX5V MN+U]X9=:Q:#]5/NB?='<2F"LYPM_T,T!%73&;@Z] 4[+*KL/0<+&SA8)^]Y! M6!2DU-6_24:PI4Q3DH#.#ZB.0E7,E%0Q7RB-?
R1IRF[1RZ>S/:N/=@NQ@F69 M#8+J#%1GH#H#U1FHSI@FQIHLS$2,)<5875YSRZCJ8Y FX7V2LHT$(: MZ)J0($\6#[P6XXIF04[*)*\
[:2(NP]%MH;%.Y"%20Z2&2&U*2.V:9$6C[KHJ M'TA^31DU3X?[A&1DGNA@MJ[#(7I#](;H#=$;HC=$;XC>W$%O_;SKEG'[+O;206[A$[W-SH(?<=E34>E6>H?
M+F^,*!Q1.*)P1.&(POO?%=+W@NK=T+[P1 W+U:^L+RH*U?[00EB^, 6=NU%U M9:JZZ@+Z+"NL/@?D[XKM8DW%U,MNMA10[?-V4C2QS_/()#5&W]7\EN3L&YT\ M+VET1_?
*CXA54%W&\4PY)2"QXZ=-' M^SU+2BB!D%ZHWG-*O3?[$>:Q(D]_M8U=)60:%@6[4/B=(56OB!N.0>_F!%SE M-]R%2\)A9?
OQJ8>P7=;#LM)Z[Q7B>^%DS6ZDORNRGT]7\CDTNX^[MN_A4IZ3 M M!CNHKJZ:]@)%7[^<;_M-X15_6>;GW?P>WM*H-?"!QBL52CA]T5\!)^)R%#
M;$P@7I&LV*!!=H,N&N'S9+UK_JIWCW'F6T=OZHHP41V& M%R=I59(XR$@9,"*+8$7RH.#JA"V-0,U4;I=VZ?0"9;]'P M,SK 0:6%%MIMNEX.TU_!6'X:+[:\RIJI;
(\V;P]LWAOT(O5X:6V#MFNT7;]D M!]JN]V&Q_[9K&T(7-15N?&$R0&%I2_;U1OUI=]]*WD]?.(KQG:@@-%40 H&& M;87@49"3-.2:,;;B4?G)BND:!%E?)8W0M")"%_

MLG:>17*BYM$,SQ9YN8=EV4\|RM@/[+[)2<3&;MUCX@:#TW7^DXD&7$2XFL^3 MB(CIDS>)G M6'T&%4U[R0P;L4L\OF:/1%(4-*_C@:0Y8=7MT0KK5/S'254PF:8H9M'?55(D
MM;S"_YD3>?@"N-_HJQ&;4!2M,=\MYKMU-M_M&;DO+S/V4E9UOB0QX\4-1Z17 M&1VE:CY=/X7IKV D3XOO-&,R+"G#?!]L*A*9PSHYL@[IB8!VL[J6ZSQY9'+[M=1I&1%BH%-
;8KBT\3,E>HK2K.=21!-X1L^2B)\7867*?M$7GCZK#*6T[)M6* M"U[1>FS*Y9>)JOV8U!?*',JJ]M:I3^*$O8Y[5[1BWTC;H\\3^CR]9 ?Z/&TY M1/E*8QUQ>F !S!(-H&;]AA_"@=IL.D
MBB,P#P+;T6+!_4;>#.)=K:[@_.C#^_=O MCC\%LS=O/P7OWIU]#DX^',V"LY.3-Q_?7K_878^V](-#2KK/I.UV+.^2.T4 MHG9!\R7)-V(^^_/;_8HUDC@Q>+
<^PM;V9S,@<%#B)A"LI1%WUV/$'88:#9)8 M\>I'QK[00[)JH4OX=WM4M7Y 28M1@IGV*T9F\4E8) RS7._=[RI//?.!, 1* M1J\B!E?9;KHA(--?P5BE?>JR>CQG//[X)W[]]]"CZ?
OS\+3MZ=G)U\ M>/?YW='QNRV]0#>F#C/8',M([7V04H91V)6[#&*RHD6B7:9(-H0MK*6F <$4@BD$4U," M4U?E \EG14%*C0+NL$X("M'=$4$3@B8$30B:$#2Y
YIT7F_+0.E#D+"QLT7" MOF@0UB0&1V^>:)B)<4HMN 2B Q$3(B8$#%-"3%=/AUJ7=BDT1.Q$V(GQ$Z(MG1 [(79"[.0.=M)^PBT#J(_<$>Z1Y&4-.OBO= U-DA%L 2C9UDI.
(C52+ 6;$@T?HC?3ZJVZ8 M)DF[^IHB8,?^";TLBHK$=_2/,$]HQ=CTR+XSE:5],QK@,)+ 73^L2WKY^'4E MYIZ@20^3WR8Q^4I*=E+%LXO:]##]GZN([=VK/%F$XOF%C5
;XY0V1IEBNCVW MF2I]^YC40W*SJ4NW64O2]NR.521JD[2UJP%CT^\>X)/U[UGR=T7V(T[$.TBK M[XBK>EWQ4+H048%$B[3#=7B*UM8I;R_UU4*TK/;9*/2"=HFZC.84-=?
37\%(MNG>NC+B:G^8D3LJ+,$K2=A$!VGQTVK]R&)M+3P&TF]VUT&S!W4#Y$54DBY0U M'95F.=>EC=$Z@]89M,Z@=0:M,P,HY+'$>BM/X,"/Z@(M7]B$E>AEW)$*8E1/
M]/&&)RJ 0$T%<5\XI+84PT"6+Y9SR(Z!J/%]X8=Z?ZB43[YP0BZX $Q+8$8X MFI$,OB6PDJVP&*FVH=N770,X/E*[,)@/D\WQ"->H^7)PH"(KP+SGRS$!RQ_] M');)9GOL8#/UY?
1H:PUZ<&WSY18&O$8=?+Q\N8QZV&&:_H=@SDTV1VM_/NC3 MKT2//NBB)\TUO_-/0;SA;Y"31Y+M& 5T.Q4"6JY2N"0ER[EE0!-6* M9D%.RB2O.VFJX@Q'MZ6GZT0>IML[4T;-
T^$^ M(1F9)SHY^+H.A]HU.:C-F29(FRQ.19 F=8KHYUVWC...W@2LS3(I MZYW=HS M'PM$BQ;243WM='8)G>[OZ
MKO+H(2S(;)&3>GIU48,.P_13XJ"H4K[3+@B15S(0MNNYFL4MR1D+3JZW)[L. M KW3KVFA.\XA5;9P22DIBK0B_$N2F@^WJS21Z'$53?LH&"$^FI(*$M!.O1#(M-
_M,O=.D#7LCY/3IU/V>)8!+$-ZK!Q+OV+#1 P$P2]ZR/U).P*0(6O93E$1- MA; 16B&@%TN]C%KJ92/=\;V@ M5S=%M_NX:U/6Q0#TF*X];?
HK&,DB>+YQ@Z]WQ%6]IZ4ED93MK5+_G68,G)$R MS-=#-(NSCPBJ*D_7^7_0_BV0 N_X 84KV)(6K.?13P3O:74^C MR7BNWY,>>$"/$59PHKT":8\15G"JO0)I#[LK> AS8>?
L_@Z#=7E#H><:AS/HGU<+KD8E>W1C\N^']< M=+*O^D#3F('2\]K8QNT%<*=7[?YV5U?=%TF<,,E\[SF4[7E5>_2Q0Q^[E^Q M'[LM1P[#QT[],+ZNEB%4@OO"E':
[!+4I1_G"2@-$2N'Z'%^XI&T7>%5R J"$ M]X996%Q/_\!!3IA"J>(+AX#*>FJJ%/>%3VK\0,TU=-XP2>UK#(-AWOB?0W:- MB7.:-PR">Z?+E57>,00"0< *],,)9L :AH(:AIW]VKW;0_
3!C#P@+GC>(4M M]0DS-:OZIC) FR].74*/TU M@"%&8'Y\);#!?!:# MU,#>[J?6W2=N,#A=YS])5)7)([F:SY.(B.F3-[0;VJYM/--3#]%8R4+0%CVS&V'6/;IQ_;+B("GUH,)&K6+U
8R,Q,A(C(SL M?U=@Y!I(NZ@%S:@N%/*%31B5U5UA;Z %\,7 I7W*.JM&?>$<.G*.:

B>_6%2^CZ;OKB'YCKNR.1)(YSR8;_AN.NMNB_8>B_8:Q%M.W!\2F@ MO'Y;D&2L+0G(3YY'YXF#4-\-^2C6O#8@9'3RUW#)VT!4+N?R6Y+%7W):K;Z6 ML:16CJ0=.CV,[O3P+?
PWS4^KHF0;.6\KYRQO-#A]37J19P2T?E10V^F:JZ>_ M@C$+EG^G&5V1/.0R]V5]9\^R^+RYM55V.OT!T$R'9CHTTZ&9#LUT_2U>(850 M+0%@ZLQ0HV:
(T#9UU9MZ2P#QQ]0985./-'G--.J16L4*4RG7MAKI\U;G4H8_ M=95';7VMJ8S$DWNC*$(-S;00^?17,)).H;D;[*?<&]?2!?+#LP%89?W@*I MOZT1ZC<*)[#MN(IDUR2\C3,_6

ZQ= MO7V2K]&I]@/J#6?4>ER(-.2-9M]XHQRFO4,3_'G'$*Q\ M9[1=L-2OH.)+;Z7_,#,$9H:8B@RB6]D#IB2P9SXMDD66S).('=H@C"):93S. M(%C1-(G8S?_T#
[@U57=$"\95,Y(ZV5KW)C_IDUYL/ MI; 4J3O8-3?2K&!TQ/4!K2E:JW2DD"Y6U_"=_-CC:DXS]L^HT6(VY,'693J, MU;6^H$&QV12MIT?Y6,94-.8-0N?
O!;F:GQ=ELF2DB'C:WL@S0TPOH@&::$0F M&N!U,G5 @^892]#><7T/0GNH!$3U)7-?6 -8+S61^GTY1'K\D4DIONC5]3C2 M#4]9#CYXM\D[FI.()(_\UBR"LOX/7&D&',A6(
*4DDXJLC-2ADE:7,WK-")!OGFF#B50WX#Z!M0W/$]5T/JHT2XRKV4H]#X@?U?)JOZ%$002 M#V +^J@HZ-TK0#$K"#VHB$;4X AJN,YY+L]R?9V&6&X_FTJ2A'=$%(0H
MR&4Z#P\%26YG1#^(?A#](/I!]"-&/Z8BD&7L\R%(V-C9(F'K",*B(*6A&4@] MD"TL!*5D&$RDGAV$C:"+0(SD"$:ZC1Y(7*7D:GZ19$E)OB:/)+Y\^H:S^A." M!,\.(R&*0A3E,IV'AZ(
]SBB*413B*8032&:4J.ISK*197CUN5:BE6LS3"7H M;0M(2:"Q^<)/UG7J"HW%RGJ-N9('FK(WISBOSR1/N[?-LK')QJ&[M1OWQ$ TC&G:9SL-#PZ(G&B$P0F"$P B!$0+K0&" Z.?
+!M%FBZFTZ$ODHA;# M>L%+EC4K1\=!SFL-5<1,MR+L;TN[HB!@&/V*<%*0AD5!,NI8'-&QG"5%N%CD MC!*^5Z_F-\U' T$4K;Z(L!%ANTSGX2%L\16-&!LQ-F)LQ-B(L=78R$
(L@U_MW@;YINYS$&9Q$#,*4]I$:Y"?',29YG,Q&-D:9#(EK1.8V@'E;:7M61:?[:8^ MW\RL3@#3;:0A\|$80SR&> SQ M&.(Q10J9/J1FV^CL75"0-.7)R_ESL SSOTB=RKPC--,U-
_DA,8)G96(-B,Q/^P@":^9=#E(8H#5$:HC17A(HA+CJ$:@C5$*HA5$.H M!H9J7:1GRWCM;7 ?%DD1T'FP/U']0!35:+>K\ M84W6L)/U%T(7>;AZ8%\^G>4DU$W7.M2$"&
1P+I,Y^$!V&$>$@2X"' 1X"+ M18"KD[UD6*G+,@IN*SU[].:O_BJSOQ[,%D[5H08KM /9!8*].IQ''.L*CD4< MY@J^F0J=AX?#@#<;
BL$5@BL$%@AL%)8#J=0K;VMHI(Q1((-9@LBZ5!CKWJA M(>K060RB#E=0!U8Q1)R%. MQEM%=CC@+<1;B+,19B+-T#%C3J&3X*8@W[.Z6
M=U\YCBVP!21D&)REG!P$L8!+0'3E"+HZI5F9AU'Y9U(^;$W4]4'G9NHDO$]2 M:+'##B,AND)TY3*=AX>NU-U$)4>=:L2+NEM+ M-R*=?Z J9H(Y85DVI
0C5G($*V&=>#4_KL,UW]>S'V$>[Y/]1YA6S;U>%-6R M^9TQ;[I/,A:?9.51Q0M7%U4=9R7Z%4WE:S2MD(J:]0N)T1F5@RU'99U*:PZ$#8SX2\,H)E_.41IB-(0I2%*K:-
USYM2DPE&6M+MJ^ (4 ##68-D6E0,U#8%X@"&$C16 RB M$E=0R=.-4-<;^DXSNB+*L@6E_5GW%P(FKF+3 9#-(9HS&4Z#Q"-P6YTA%\(MOQ!^(?Q"^*636\-<1+*-
OSYO[_\R_&F(NB1#6,-:2AH&0EB2>6&X2DDXHBGG MT-39YI*Z"W\V=83V4E\G"D-G3Z.-M/+S^9SPI$"DN<\8R3=L.]^0B&81H[<^ MSIK+-
Q\2,:4'F/*V6B[#?,V>S.U3^946Q6F8Y^LYS7E>+W7B78,A7,>C4Z'S M '&S[,5&M(QH&=$RHF5$RSIHN:L(Z,ONT>%9!]0 9M?T4\8:2X:6U3#';WC^
MMJ3@CE!T'JSRA.8!HSFA<3!/LI"=@S#=22*&#LP=9[&ES.F%S&'T/1U) ZF$ M>ED^:HVUU_VEG\[ZHHZP^JH3LQ'A)U)Q[H M3E"O,"G1>-AK'U4/J'I
U0.J'E#UH*5ZZ"A!V3;7!_=5P;Y>400Q*:(\J0MU ML'^789*R)X$1686IK@%?:U!K)GT#JCJ!O@N:+TE^D; VZ9K]^>U^79YO9'E/ M\C8XA9Y MN2?:LY]VE+$?_G7U(V,[Z"%9M=
E_+L]JEH_H*2%53CT+N@E2DR6]L/HCIB"&L99#6T'>=:V MH3Y84)Y8DKNFD+RKY@4XFC7#NPXYG70MJ"GP1U.@@;*^D_(T+!ZN<_J8L*US MLOZ=73Z7V9-WSJ;@OYW
ME=3UN,0."/*6Z'> V@0S<,,N1'8%ENOKE.W^618_;;"3]1VCHX5R@YYNK(A3 MU;HY#'JZL2+VALVK]&LR%Z%20$_T;4 E "H!4 G0ARBN\R30#O>N+_Q2:PRT M'UE?
E"F:6PDL(_O"'_020'V;B1[$0"*TK/_X$"1L[&R1L(\:A'5:AH[*#(T1 M;6DFM$E"3P'$]KJ8A7VVI"1?DT>NZ=SNMCK1B1(X0KHB-4Q-G) M2O0HS@K%69-WRK(\^S%(-
RG%UL&*!B7W5BF9!3LHD;SIU MDW5[FLV6'-PKN9UD9&XXSY/[JK:8W]%;\DAR]DZ14[KD^>:;(Q2]]+;3Z6HF
M+XDLAVS.AW1]1E:T2$]>ZF_CYGTUOPW3,%^W&A%5G7HE$5"0:(.E,\G*(>A M?([R.AH:C MVP(HG[5@](;8<<08GQ=+6ZW]P5R_(M6(YDP7E!12+PL94U'I5GJ22EOC' 4
MX2C"482CYK*U]%:D>O>0+SQ1XU/U6^(+5E?M#RV1V1>FH,L@ZG"T513ZB.B ME#A 5&%97_,Y(']7W*#:33&C&L:6!@9&1S?;;QH6Q=7\SS#/PZR\RF^X\9E]
MSWL>F7Y=L>T?%N0Z3Z)6I0&\=Z_FU5.:/;(#P9A\-;\E>4**D^OM<:ISY=U1 MOB5I5O\@UAQU&>>P=$K/V?(MS&(^UGK'P L2EE5.KN:L69(MKG,:$1(7=VS4 M@FO5! MX@-
[5.[9B8^?:?'Y; O2!+#LFER':_ZK&:^B=U7GYB^^U&1=9DWQA/JG,[:Q M+\(D_R-,J]8;:.@Y^]UBG))B5I4/-$_^0UH/QJ/KT2N#TL$/.IO24JR1U5DL_2>B+V MV/#]??+RQCC_R?
\I4CK".H^D4J^O,T7&@M8V5JGP^[MJ^ATMYWAU CW%7T.R:YM=,_A'>L*I^(^VV M\TU0!D(@N,GYZZD5N M,*2
)U;F'INO.U):E1#@]G:S2C5Z@*V4R9%;XWM8"!\,69>1OL%S]=GFJ/$@ ML-UAO.%[2+0B8'%JU%U'"L. M_8564:QFU^AA=P6ME_%KM>')2[5A_7]_L!O[20\E>A+[G&*L[VRZ!
(%RE19" M#[3^9YHHSZZJLBC#+&8?_Y*[R&=%$K5IOP>?SU7^%=)S4^NXLICG^%$*WT-. M99]G)D:0\Y^KI,F4W1P<&:/Z&'_,/=7!2/1'+:$_J0=JL:)O5DFF&I-K[0:0
MMB9CY\39UQM+% C*]NBB;=]%NW('$VP7HU.$+0T"WBY%?Z>%$T9@9J+W900:/>4^N M^& 6OG6;A>HM)G'F\V4?*>5KH$'9EWM']V:&AB2 ^?/.;?[8"/!\/U460'6(
MAQ;@J1M8<(#AG;U[C0YW(3O'PXX1DL/),\YQRMSA9;CWRUTF:7BB#?>V. M7GS]P7S[X W?=$U?8!9]G#R+A@E6!C/PT^09V-7E%,RJS]ZP2MNA'BZ<>B*]
MJ[Q[X0SQ2%R'A_O V3-]2=S,/1S.H>E+X!H1[7"V^"-SF\5_PSDU??%[E&0< M<_;[(Z=;_>&,W?Z$OZH(7MP1ON#!"S$>\#9Z@]J&,Q1'ZZVG3ZZL.G*#^>K M/R!ER,
X.#_]034]Y[* LW#ZL <2QP+GQ_3Q#B@!W(XA5G*Z'KT)V V;1'4% MFCA)*W:I!ADI@Y0_^BN2!P4GN&/*UXZSV,H(VPN9G1+&NIBT%-/G#9]DCDU? M[[?DD>S>E/.?45JQG<0-
MOPQKYJ-?C4_#_.,O=(%>Z;KZV2VI)6P,DTO8X^5 M?*\;[2?K]@%DJ?R&G]$!#BJ#MZ'=,)S3GW!.:8J1UC88IHEAFH<1IFGC6:"F MUZ\O3 ;XYMMZG8=S1O5ZWTI>"5\XBL6.T!?
>R,@]! RSK2PZ"G*2<_V9W)[\ZK^3R)B)@^>4.KN/HK M;9R[S\B]2#FWWV0D'=M-<[%=\WM-JA,2-QR-WKO=-=P\D,75?.]W@(4H1G#@ MF^Q3*-9; GJXL
+P!A/V<6$5QL42F8AKNQG"6'1V4/[:M+1^"HKHOR-\5_Q5Y9/_? MVR\&75V?7MFX!X+.?T8/ M/+2DK1C:ZP:]\N*""='S="U>?VN#'B;^1O(%R6\(SR'1Y$B\7:5)NP,=O$,?
MACKR8[-F83K/9]8Y=7-/K8<"4J]^9.P+/20K=G(C?L*7]CJ&TO1M]B M]K/";0,'!9QH_=1:_3ZR6NW$2:Z,*DG*0J:K_GYD# 3TAY-[FX%@BQI7B;_MV3@!
<9']+"DB+IJRD[%,*E%I'66_D0R9)U7!A/&BF$5_5TF1U)(V_V=.Y/$' MX'ZCKT9L^U.T'IORW4MU-?^#EDW&"L+NLK+8L%I4E\QLL'$KW+?4S'FQ*E5Q M';OTBG-
1MY.M*J(P)O40MJO+J%BKT?XBR9>T1)^@]5A[_24U>^EHH O8ZS+2 M*OCK=9D595[5N0G$6U_<<$1Z+\)('H\I:NX$M[>W-@/KI(9;\>YF!ZU'-H 3 M*U2&/JJ:6Z7].\W8\61P-
]]75KXLW?!B!;!.CJQ#^BV@W:RNA0&_1[:QKU-V M=/D6D<9-RAM;IKLE__=\ Q(E/JK*?B.=:W4^-ZZ5V6O$7Z:J/A"O1&V:L,_UDVSI_
M5#T6TK9C4JT0.!2MQZ9D*SDO;H]LSNCT?AMLS5M)N M88I*!TV-5>Z^<$BB1**Z2@%?>()UL*47C4+:H=K"A2^< 2J>J*F"QQ<^J:4V M:H[MO6&2TME7I?
_WQ1]>_D1INGKXPA2 +S@$E7K##N-'Z3!C)DQL);[L%?@S MK>N\>H"!)G)5M2];!@2N]7R*P:R9;'%T+4.!SEN^ M[
V07L'81]T7H46#2Q!O>5_>9#A;@&%/8,9HE[=S[9H!6HE\N6:TU"L0!QTP M8[1K];FR4_H+(=>NHN<*"Z#>' <80@YU63W <'+MP)OAI!1G>:3M0#B=8:"X60_YY@A4>$8Q/<-
)S$Z MQSCS% !@)OE311D8,@>7):150;.K^D+W]WS,,"YY;D8+@U[V7')3L*K MX'[S\@0Q*:(\J2M]O\P%=70Z^\B&^1B^./YX%)[.SX^#=[.3\[:?S MM^_>G#\M
YH6J_>)K27/&HCR3BFVFF=O8^!A?WZ[+Z]+LC7!N_61/&I_-@," M!R5N0BF3-+)@]9C_"E/1#%)EY4F&;:%+^'=[5+5^0$D+3#0"2Q9QECPF,;OO MBT:
(MM[#!^N@MI6%TOR>TP.4=-4B,H\E)U-.//BFRC2]M:I?I;DM&57Y\3)P]G5O? M= 3ZU+^X5@O("F1],*F"+TD57FL)F\OC._E1_TG,:TCGL>X=E]-%3"NT"D/H M,82^;?
%B:$\!^'KJJ]>*<8"">.^8(I4@J!;H\X4W&.Z,T53#WS1@%.4==]3; M10UKO&,*]![N*_K.\6 9C/#M]C+!#7.^Q!&)=XS"PC7US2&5\LTL\%._1319 MTAL[)AO2W%^
MI&99!_<&RT["Q\&"\LLRHEE$\E>NKJ=OWWYX__'D4_#AZ/VGX-W;T_?![.C3 M97:U('O((LEE4LJ>K3(1F:?@ 03:.;?J&[\.,Q.=AGC&" MBED45U&?TI=!S5>J)"IP,L
M,'BF#E"OTT%.L0R>W@?)L0WB&]T M)<^S9F?-BH*4XA*U>VU&/)"]K89__JJN676-$6X!&FZ1.8&;G ML]=DV9]E\=97C?V7JE)!=1JCARQYSZ9.H2G6;$@T?HC?3Z*V^8)JFL
M\YIB8,?^"6WT(JQZ9%]9RK+[V@T0_^$/_]?\Z/"?_.%X3LO"_; MZ(7T,P,V$](H"$B]?EB7]/+QZTK\N05->IC\-HG)5U*RJT4\NZA-#]/_N8K8 M8;O*DT4HGE_8"-4Y3JESE&7/VK-
+JDH*CDD])#NFK(?EM(W/'@41U<];C980 M\QD5BJ28DK:6[>CW>R$9)^O?L^3OBA'UE,Y:LMNU^HZXJ@VW.;+;OM?[Q0]$ M2:OT!AEIUSTG\GNXE"=J5#6W3ON.FXJ-
UMYP1'KWSO".HW4]!-F& O4?<2^U M59H#+4=JA7+JAH-WLKH5F M"^YKRO>"(M^RK.FH-,NY+FV,%E,/\L=NM7*S+*X1%R!-M:P+9D]M%H]VW\.Q
M^TH@@K#0JT@D\HDG<'Q.=5&B+VQ2*^U>IYY5:\A\X8Y4:*)Z8HHW/%$)\]14 M:/:%0VH?%!@@\L4G![)C()8A7_BAWA\JG9\OG) ++@!KY7"9RES;$D#KFB\[M R27F#I[^+)K
,='ZFH YL-D$^O"M5^^'!RHR JPPOIR3,#R1S^'9;(I=CN8 MMGTY/=I:@Q[<.WVYA0&O40<_1U\NHQYVF*8/+IASDTV,W5]TRX>IL@"C6R2! MYS!7C0.,:-$QI UW
3O+'GW_B^'>99.S8-9Q /1%>Z7A9#?>(.\<#7(R2/)*M(Q6A,^H*U@35V*O$L\ M(PH3"XND?"#A*6N:1 S'19)X,47;'LBYN?R69/&7G%:KKV4L)D76#N.WAH_? M*O)RSZF._;2CC)
<4^Q;^F^:G55'2);N!6XB3-QJ%]KDU]0#^HS7J26F*;3)L=R\DA.PS)Z^'TUB__-VM0: M!WK37-^G#V&V()?9>5$F2W9+7LWW"CW6DKX)-_J9>2Q_>.G2-M3?D(@NLN0_
M)#;ASZM!,&\4YHU"_V'T'^ZR>(4P0+7>X:DS0ZUCA\A.4S>$JK<$$ 9,W5X' M9 0,FDU]5]@TP3FZ'] $UTWK!@="!VB'ZR;Z'Z!E;@PL:5DW_#E(GT[(G.8!
M6:Y2NB8DR&M+;5"M:!;DI$SRIE,WQ7%/L]G2*O=*;M?T@&6>W%=\8<4=O67; MBVVDB)S2Y8JP#54?P>AEA+].5^\3J:$N&-4VJ+9!M0VJ;=Q#8Y,%I(C&VAUK M#
(4.R\+OT9N M5DFM=!>!&$6\YS/W &/L&NP:<,=>3IE=:\>K'TH6 \AJ%Z5 M#R3?[7V!I/JBU4BVVQ=4M+F'0)J.2K,T6YB\,0(N!%P(N!!PF8O7TEN1ZMU#
MOO!$C<#4;XDO:%2U/[1$9E^8@C9CU%)H:RGT$=$!6HT5J,*VRN8H(']7W"#7 M43>C&L>:$@9&2"=MRZQ:5$7)?G]\2Z(J3\J$%-<5V_AA09[VOKK@58=A>E!Z
MM.9J8OORGFW>>$M&FV>X9N]>#:&MTY[_9/=+LIGNV=S?JR7)Z]F@2P",U>^" M:%94*=<17A BKS4F;-W94R@]MQW MFD5A\; =OXGT;->%MC3TWK= %'WW;"M]"
[.8C[7>;;H+$I957EM%PFS]1YA6 M];/21KSI6+WR'DK$U9PU8V?_J<1(7%QQT8M'FC:NF4Z#]KK$KGG%I/$:EIN M5VDB,4LHFO9 C.2=E53>@W;JA4!^9\[4%Y:T86^$G#
[MI=^S!"#1P'OU02(/ MDK]GGR-^9@7ELRWJKW.RWC6Y#M=U?JL?81Y?U1F;BB_-C9HQ=)+0N/[IC-U@ M%V&2\]/>*O8,/6>O1Z_)(C"KR@>:MT2PM;;IE0#NG!D]$,!VEK?
LCY03,"F" MECV0P@_%YB$_J^H+N-X,W\F/^I4"VMK8C7AN M(&\M84&JJK8T'(->+&;K$O^?J4B>_OCT!HA*21J--5:ZA39:OU?\9>%ZC2T> M.
W3E,0GZ_,P>GC>5H<'.N-.@Q\O/V,_W'@YZFBI.)[T5PH!&]!CU,+/&S4= MITNOBK)N]W"7IJPZ"N@Q[@J:7?.4)TYXPZKZC;3;SC=A7K:1)7$M)Q1TMPW3_[Z>T*+_3\G]
(N0NIK!>Y0=8"GEB9>VR^[DB1EG!7MK=* M/6,ZNQ5)&>;KO2!.A0@-Z^3(.J27#K2;U;5L-%9;R9_#^2;*H! ^XK(N(YV+ MYPKPUMRV-_Q4-"S!!O23P7O:'<] MC9WTA4U<=N
!/498P8GV"J0]1EC!J?8*I#WLKJ 5-KXV^YZ\-/O6__<'PY9/ M)CL1>.]SBK&RC)HN06 V'P^5SE7R$] M-[7F@*&"-&RI&;_+N@Y3V>>9B1/+^<]5DM>-FX,C8U0?XX^YISHX^?
Q1ZQ*? M#!DUV.Z;59*IQN3:Q@.D\9XF>?T[V=+;VH^=(WO?]BT1Y)7M,7+9?N3R '1N ME)K/';_V-^\%S3?6!3'/=089;?]+B!0YI^EU'G-E-V2U\=Z->=V\.LE@"ZVR
M]0&'&'.5W'V;Y$6C"N3^^3MGZA?::R$.T1QFK-56]T42)V&^WE,\R&YK57NK MU,LJ.-Z1?"E8A*H;[%M,*V(=LSM@=@=0T*U0#-M/0*QP:_2%*>V>IM0FEO6%
ME0;Z>@JW=OG")6V/L%?%'0'N5]XP2^FE_/K*4KL$^\(=B-U2<,(4)B=?. 1T M@J*0'C[S22WS[[^(FO9+;YBDSG(#@T[>9#Z"[!J3P&!O& 3/BR17C7K'$ @$ M
;L7'$X:+6#4EB_;!23^]9,@R+L]!#]A /<7,'?>3H0[PA-FZG3FRY'K#\1W MVD?OW.:2\3XZN(W3>ENK4W1Y=^' KV. +Y\OCQ7\?==-EP/FT'NW.000"8TB
M3'VY=4RTJ3VEW_/EBH(?0DCJ(5]>>&VN2+,@^7(=P;EBD"82S*0/OC!)D8S) M%X:H'S&=8&5?GBZX;0*>\A',FX]N\T97,.SG27*
<*>IC)$F;YI9PEG,'3E]?!J3;ZRK@)9ZX_LO\HY5W@ MC/8'15C(N MGZ_2AQS.V#I$J%>YL,'TXTIF9&LE4X7R=/EKI?/8!J_[=*#LI]VE+$?_K7=5ZV[M4-Q@<+K.?Y*H*I-
';NEC4K:8/GE#JRE69U%$*R9RLO>(.U"?5CE_#&=9S/5, MS0\O%J#1H[XJJ>C'V76<'$'GY?[;NNB=(6ZPWBQ/=3 M%IQ0-1^1]JL\6;!W):VC()?\N, ^3$N_D;[%5]IXQ7!*!*3O-
\&R>@=55J_> MFL6S)(" A2A&<& /8>E -\Z&EZ4#>U41"GC0[R1CEYIYI79YN5I%B!\6:YE& ML9:^ B_MA*!BR04LN8 I\;MR20]P4UW8YPN;,-U[]TP !KH=N)^GV\S1/F6= ME?
F^< ZSQ@[SSJGT]' W!U^Y [$2^,(ES*EK^N(?6$Y=1U)4.\XE&XFA',_A MB8FA#%R8M*U0PUVV$^&1K@EUN ?;68;)[(/#7;C.LL/;V*X.]E9+G6P%X*Y M-?
WHE'Z4\6"&8;0)S#YFVUOW4T#+!Y('2<;:DH!LPK8Z^NGJC6K-0]>KZ^ MN2YZE@I(O;G\EF0\;*1:?2UCL9>NK!TZN([NX/HM_#?-3ZNB9!L\+UJ(DS<: MG+ZF\NQG &U2[[+?
Q%7$ M5:,-98+5J#NB8\N8CBW3LC.BNP>Z>[0M7O$64ZUG<.K,4&M?(:++U$TXZBT! ME,*GS@B;]HC)6SC1'O&*)?H2W $:)/2$]@,T0'3#:[:5>9^WFJTR_-E5A0<9
MRYKB#DZ,=^HZU),-CE&O5B2["W_^#PE%L71[+48+,2O8Y-&#(N2OK1'J)SP(MO&&[[Y2]IDEY&N;Y>D[S.OM+;=(4$"WI,=(>;]=('(VG;#\^](/<3$K7HB059-
4D2O3@7*00A\EO.6_8ZWTR&VK7\/.!XUBD/H M"C:56VK?:JEZ0-QP#'J?5YJ1:&:4[<>G'L)V68_Q5Z"JR*FS-MWJGF.N6Z?P MK0X/NA34M:6-9G<]
(^M%Q2R9RA_0PWZ*LK9Z]"+ZH?7K;=L#]F]FR4VH;(_6 M%P^L+[=/,.6Z M_!5T3;X'%+;3V8(ZW)WK'*\&LY4,=VD[RT.P%0/,&W\2C/5BCP3SS9\|8[KJ M8,L^:F^#^[!
(BH#.@_V) D9@4%3+99BO^=^*9)$E\R1B*PG")GTAHS]8T32) MV*T2%-$#B:N4\+9A$Y;+1\B;T,K@?ATL"%WDX>HAB0+&V7#K(+9=/-#_S15R M;?
G6N;7>3GY[NY4YNL9]]RWGB>WLFU73E*\;0]CFAYT-;/.+?YW.7G#G]1\L M47+Y54#)[@^6*/G]5D#)[@_HQS=Z!KU;LN"G]LO3,0I3888Z9=OAJ=W>,OLT M"-
+^*=M:M9(W22;4M:)?- N.1J%VD^M!7#BR^?/87DNO),J#\ON9EEEN(O(" MNEOX[VX!>QVHUJ,W=9ZH=?<:;^K4K5O@#2(2\Z=N[]1FP$N9?NK6/&T&O(17 M4S\"&'R-
YLPN^EP11!CN7#R2_)ZZR0P5JK.LS/XS?TWF<*9#!NEA 4(LK+5K0=IX@W. 2EFW@JM'#)9]=Z#K M?N_.NO>,X3I+W.OFTE?L837C?!M4/$]0L]7GTXC:8?^UPS8U'Y-
5_HRO^5@U MA3O+,"]=A/RZ[_%P6V:*C-*52;U3-;:RK_(.G7%?&=. 743WL7B:/))J7D: MSK>[N;#.LW@RUY4$F0SGRCT]-NDB;A?4XG35^*'P2DK\;SUJQQ5#CZHD!]$V
MC)^S"3WF6E#00E$9ZH@RM-]J]%]R6@@U.,/--&&.O9 SZS^>L4-V$2;Y'V%: M"75,XU Q*4[O"1&76:\T\(RG6I\NOD53W_:WC MQ?
4CL^Q;GGWZ>]%AWCJZ;XLN3V_,GS;L23W<=J.@GE5@B8^NZ< (>GN8?%;^^3"6-;D[H*4YX'XG@@ M5G>@9%(<_\/>==LV59!]FC#;QKH'-&='GRCTB>K=)TJE*$?7*'2-
0M3AK$=J9ZNGA/-;&<^X+&\-;\^'LU49VA\%>;=NSY;"- MHZ,!TAGI#6HK5,.$JH-/:/2-QLD\,258VAMS,$T\!]/SN9\BT;8?74VNL,N0 M":+TK@%0;)3)S8)148Y$18V?

LFAY$*8(@I31&&**'2'ZL\=2O-M1$9 M;')\?1B.QC):*^6C96MLWE*,I9]JY22F&RAH(T%2#*Y>"VF]'M-_&OD=/ M!NS9[EN?_UR1B
G)9\EC$K.M>L.VAT@I9FO>Z7/S#YJR85*V2VSSLWWFZ7+T M)BG^NL@)NM./|48FTJ'1!HTV:+1QPFCCD@IK)%G*NVUFC[EJ('48=J#14-5A&(]L MR[^'86H:&
(0Y$9C03T$)H[''#5,8L:2$$4$=_*:QJ,1!*)"QJ 06E7")I[&(M*8%&)";$-BTJ@'\Y!^>%@50GTRT&_G,GYY3@>(SRX#O9@HZ]' MTC,>H)\.5I68X)[&JA+6S-N'$4\^NHY\N/!TIX.*!
[=*'FA,^TBVM*%#X]V6 MU["JA/O\Q:H26%7"199C50D'>8I5);"JA$?L=;ZJQ.<@R5@K$I3A3_;]*?LL M;*IL$;#O4 11F.?K.\R1+2G(7_OP?$N;? M2(M;*:1I#_GX-
^,>OWG[3DR&L%&O!+R'$/!^0 (^0 CX," !'R$$?!R0@$\0 M CX-2,!G" &?AR/@W1L 2\;]4K $82 HP$).(80<-P[6(;>X?;&A;NUODY MP*@W1Z+>3L,LC,,;\DBRBLP6)(O6K;L9W-
XJ]9?U+F2';%:5#S1GC/P>+DD+ MN^$='*"_=0?K=+&\AI+D69AN]L0MR1^3B%S>WKW;"7W944>4C2?=;*EZ!H M;I7VJ^T5_)7=P*?[%[" >G4'=/6S[^K7.YUL>S9Z3\FEV-
IF"'JE5Y^@U<&X M3G:1NM"#\G * %"#C41*'SA3_M]1X$7C2]<4#N90H5E7]QN]H7(N@!P]?)&9;,3$.BXQN1P3ZZ*[*=2^8\^A+J+LR&:,-?Q? M!4V3F+L_[[3F%\ /?
I(O8+^'2J:3"QKL_C?55'6'^F.WA"V MY:(D)=])V:@H^.5P1T_9;F-?E9=*B$_6O[.]>9D]W1^S)BE'0HK9?5%'#@O, MPY0OZ(8P>A*>E9__89;%SW^QUY(M-JUXD-I94JQH M$:9?
%G_^,'KC#/Z_^<3Z?$^'-8)>(X.THG#XC3$:(DOIKLW^GI)8JLWBV MI'F9_*?^O8_.EW"\4\CQ768Q.PN%ZQ W- VO2]VR2R*:,5W4;CFN.&&I%S:
MN@YS_LJ(%V,RBELKO35/\MMIN$K*,%7(B?H#C+V^\H'D3* E[$EBAP.^_UYV'"M#Y6O* MKG.R8OZDEJ;6654C9O&^"Y2#(&G9\!'L$BX ., M)/7 "53<"N8#N;#>RSJ>M<,7;1G
K2_:0J#9%P4,Y,)Z6Y02>NML&<"M+ZJO MX3$?R/9Z=RHG\5)>M[%*Y5:C>D=G$4.[.6%L98PLU]=IF)4,_7$,O.)-!$N
M#S#60\T(B@B)BXN<+B^+HN+ZXJO\EN'ZJ_EYG058M#1P1P<*I@C6T-XXP(KV M6O1>S?F-<\$M(8K+"=(%0X3:Z*Q6J[2F(4RWG+O,YC1?-H91!=OU>OL3K*.U
M[S#\YG#";S"!.3IK:#IK=!6L?>%6!SY0D&SOW0&3;JOA+?*^;+Q!.;7W1?0M M?2WS.NVLTO9XO1,/3EG7^H]#HP-;P,<,C'3(%JP 8Y$U56G@&.L$_\ M4QB5?#FC?;--;;+WQ?5[8,
[)O#E\";4;@(52SPI?HO/ZYIO4@6.X:+Z2,DJG M]$J8V]1\N?0Z*0[-E;/1+L.[-AC:@?#FF>B7C=^F@2.#"?MC7 ']K,=S3U& M?)%>.MV%8 \B7W19'?BP?PEJFN"'TU.Y-(1E.JARM
MRI4#GZ5CH-IPS]M(Q5>P'> MJX>J(I@:HCLUF!H"4T/XD;0 4T-@:@A,#=$]-<1]> 3M/E:8CX^9+[XP28$_2U=9H_)\9@)216;!.H_UN3AU!2>/ M, +/?
_+7M4J*AR:$@>\UR:JD_48,;\(68IZ>ASXMP*,4M)1X]*YU:(64IL9BE)&._^WR2+MR^5@%1QP]%2CFPT M)0D3:B2P%M #DZ;TM)X6=0@DT8W^")@6!M/"P+M@6AA,"\-
GPK0PF!8&T\)@ M6AA7_ LQ+4QG/F!:F->,P+0PKF4K<2(MS)B!AK88;6B9'RX>!Y/P>!.Q;8NK M*DW; &$QAW(UZ+FW^)*9!K-'8?:HR?(/LT=)V&84/N++>^QPPBW"\RU,(>&6
MXP&DSB;C),3X;IR9Q/3]:;K#4F.._*>/,'3L6#IWA+:,E"=X%E)LA@WS/#AF3 M,DS2.A>:\(];HM69WWJ9QD)&N![I[)0I[J59>):R7<=!S@7-3]EQ2ML+^^P2;!Q'I.)=8#9F)X MY?
DQ3MSM9&/ ^HV?FI:4._!]@G%)&)>$<4E.Q"6-XB NUR_T(*QY9K\UX!=8 M*/?*<@%37*DD(\OH^'U GB)#BFJY#/,U?T9WOS1#P[K#VD*_9G1U0KO?V/Z/ MV#NSG>(;6=Z3O
U#R5L.B01UV0)"?F:\1J3G"-*;15&UK&IO5D@(GV[BD[Z& M'RL%GI"@D_4=HZ/EPQKT=&-%7W)Q%B=8)S?6(.=KA^O*%7VI-C;;DX(L22W,K@=&4+_RQH>=T
M/(C493VGBPY4.H+[06DT!P>H!ZCTU,%7EA6@GVMIM5P'1?1 XBHE7(M>'*7 M(@BK\H'FR7](('19'"1%4;%_FFE$.\]C2T7:$Z&==*9"P-&9.)#FLB<6H"K3
M$57F:1H6Q=7\MJ317U+5B;BA77KI]IT(L+%/49*O_R*HLOZ MI$#I;UJ/1/OU]M75^03R3@ZM1/HAQ!W&2N--\Q$:C;(^:<]2<=]&<=Q2+S9?!^>XF;W=3;SM#D= WN9>>QJ$?
DE M#^O5O%M6.5[:U2 MWZ0!VLD@?%8N18DM!H >+JQ :OX&];&Z"B9STKQ.FE8[8K6_7+#&8Z3)D+Q4 M@C7 .UI=C\E2I'U&BJJ1TB2U:&KT1-L@V@:[V
8MR$IH/#PD&V;8&YQQ:-)SQ*2'1C%OC&(C!?/5HNIM92W7 M.9V3@M<^"=,+(LR$_[+9:&&4FDR7\'ND7/Y"@A21B+!N:+2S;[3KGZ^, EMCD[;
M'!T.EX&!P>'.B<.L4>&TX4Z.PTS1DHV'LT&RN=WDCZ9F8CB[I+.F$[@:P;;= MY'VP(!G)P[0&+V&\3+*$5[OET[6#'4A[0PN*%6*LV5(LKJ:35>6&U-E(O[%[
MC8W""U9)0N.4C0>-XK+"4IC!Q^+71=./(Z:?+\T7Y#F/][[?H^"\ 'N-I$A6 M4"75)FOU=<&TA<:YZ1GGQC/-F1USG:Y3,-&A20A-0NH^!V,0LB/OH6D(34-H
M&D+34%^;QD!2]X53:!]RVC[D4@P QJ1![4&>GY-67NCH/0\C LT (1Q@,)J6 M+N" PM$,]:*6+6/O LH_8I#7X5__7Q":QS?4QERZK5'ZV= M;%:;:,^G:69I2G_P6_F"YJ?
L9"1,,BZ*5[HNK;ZO2A9V,FJ]G/6$S&E.NM M M'\',PU[7(M?'=@#9V_K;=VA-<\2:]G(_R_3J>\W&"KQ S?3TX)^%.P4UMH>C ML;6A4IJ*VL!!E9*#+J0]"&X#
[!QWRXYW$]"'TT:'#ZOH=+)^D M[!O?->"O75TD4F+P)L,@KH$U"5TT25TO=91C>"_&D'Q+E"M*WGJS% K%"#/ MZ-35*NHMH2&;3]T= \@,-3J8^JY %
[9)Z!M=]#SI(OW:CCW^'"2U-VM0AC^# M54X?$^YH%LQIOO<'\VABP^&MQ0=WHF^@/*J&-,%"9CLM&%4>CICMS^=SG_ MK<85_2[\><,^,
[]3LHC=,LVM6EZ0F#MW\4NK8D2MGS46(,@>1QXA9)-1L/%< M.R$9F2>E8)6"UB.Y->RX]XS-IP]AMF#?X6SS'K(&LZ(@9?%'F%;-A]@:953+ M[#RP"_PX2XH593(X^^?
5O"%8;]V2 5Q8WP7-2;+(GIVE,W:;$RZ5)&&JMUCH M:"ZL7' 9P@4O?*1,T5)H5O5E'7F3\)F=![2I?\-\T!IX7RYNMC
M;!>X4HODLRSF45CI4QNA)YOA**B:1M5TI]!E4[D;==+^ZZ31M0U538:JIM[A MFG<;25ABG*60]K)C.7K#N<&&>$V(9#/" 637I\H-# MJP39LJ397M$PMC=
[JP!9ZVPS%>U[(]HTWY"GSS.+ M_UT5)?]7JW\^L+55BML]L 4M;%(F=+L6MAF=Q9%3-B(MZXM"2E.JYS+$0(5L+#]2)4(ATDE/R E695DBROV7-1O_";B<4_4/__)*&
<2*'L>\G4MT3&X'G'?)5I72KCD M"86(PI(TZ(RV.9B3L"!GI/GO9?9ZOXI9 >YJ-P6TDG2'*)1?'N*&5NG]3LK3 ML'BXYA8<)GZ>K']G\M9EMMGTV6+&M;$RANL/8'M]NX,M7L+K-
G;3EFRYM;ET MA7E+1.VL4LLD#<(0[P-[,L[((TGI2IWX6=IGI#?FAF.&C,3G89XQGA;LDJN6 M59VF\8RA_$CH;@7OB'9V#Q*=WY8T^NN!IC')B_._*P:DA+2*&AZ*7X!%A(^>
M!/Y[$L@P-P7!WJES !;2)M5+3-T$#M@$>NJ$J9NR]4Z%7)TV]G2![V%Y\ZC@WW"..@Y?KUJ*G^'\@/5!M,T_ '9Y 7 M4K&IM@V#$7=2S5RK5^S#E#IU!\4!
(6015%E9Q4NZR=:@=_0P'MN"PUXDR MF.,=^HC9\+ZA5586U^&:ZR^4KC>2QF/2?9>'L1[Q;3VFZ?3A.EU MF+"[^#1<):4PNX"BM5W*93D?
FC^.E,&CF5RQ"_;;N$#G[+ZHTU1!Z'W9=@2J MN1P.8/"NV:@\WI$!8K.XN=WDOTQ68[B:_XR@7=UUX]RI'MGCP*V9\$^.*INXZ]&UR_4 M&8H5-
[^ZPZBEX#ATEW)>W<$J_==;98GRFI2TM$WQB@G5&TVMG-G2MI:IIBN2 ME^OK-*S+,?-KHK91L.\O)%[=Q;(G:VV#NPYS@=9!W7 T>EMCA-0-1Z.7P?6L M8)=:K6Y?
[_^E1;EB/@!Z0A^B)_35_&+K^WJ]R9.A>'5UNJ)W=[_>W:.5C7U) MB'*/J#KXXY]N="[0E]Q_7_(.3S&%"U"^<$GM3&HJTOCB1MG?/D*_;/3+QAR0 M.H8:7Q@B7^I^"19]8X0O-
PB81U#]G2_W"I@Q %W;<&[L(Z1V S-&:L+VY?SH M7+HJLZU?]ZYDM<].#U39Z\N.T>&.OHESN.MWM*L&QBJ5/X>'=[.8XS9X?@S M;1INY_<-#%CO\QA-F,>D+U=P)_9X+?
5JY_D'NG^3+JZW"%KEWJR_OM1Y/0.$9 M_MPM.JQQ)_?"*-4:=%BE]M08[O5VGCFZ#M)60U>%T9M;FD!QJLI1[2E LG M"%2,0,4(5(Q '8-RC$#%"%05@S$"%2-
0,0)UQ+@JSBV^@?],RH?3JBCIDN3; MIV\MOR)UNEI=TQFIZX 6P)M(U1PC@C$B&".",2(8(X)A&G>,",9H6HRFQ6A: MC*;%:-
J>Z<1H6HRFQ6A:C*;%:%J,IL5H6HRFM7Z4,)H6HVDQFA:C:3&:%J-I M1[UT,9KV-6=@ACQ?=@M&TF(D+4;28B2M.P%<&$F+D;2FG!DWDM9EYNB[67D5 MG3-
:Q/$4HG/L1QQK%T=U^VAAQ'&KDA,CCC'B&"..._,$(XXQXK@[JS#B>*H1 MQVV58Y\:% &=,SZ$3.(H@B1C?]C1'I"&^+@Y"CV6U.UG>CLQSD/3#PN.?LUD
M_IO]]^Y[Q;T"KN:W#VQS%W?TA%P6!<.SK?ZR9IUUO-;4!%_GR2-CXW4:1C4O M083*._5 X'/!2I^I)OU[(?LY7^K9KU:UATF;'[U>IQX(O"4YNQU/GK/G:LY^ M8 ^OF)T:W?
H@\L5G:J7H19O@W=@$O.^3 ,[?W=AG54X8HZ\9NVG<3-Q*$KA7 M_R2^W,0 ^D1=7(BIEX8W@/I87L6_JZ)17MQ1 7GU#K@/V2O*+G+N4U_S#?\ M>2S8>\B.^&,2D6:WW)"
(+K)Z%%GXCZUI[4;!IF%1L+>";U9I5(ZXX5@1QM)= M*VQG.\;XD4EE[MO.-=<3,VOF51V)*1>T2_(/H^RH 9:\+U-,W80I#M&VM8J MU=])>9DQD9M\I84HRJ:US8B!B-
+=+6LZ:E"6(E!.UMAN>$J8DLW1^AXNV3_W MO*.EFQK>T>YZVD16Z<<]!AA!:?:*Y#VL+N"^HYNE:';FIC)\-:I-!+T^PO, MVQ<[)+&KRO;C4/_B"2P@*Y#UP0!56("J0?
2A1E\,414%?#Y!\1=(?%^>_9U! M'O%.,AG$G75^)S_J/QFM[U5G%]95(]..GT\^AC.K-/QX[7TG$QX^DA32@>*1 M))+JODCB),S7>Q!
]HZKVGL=SJYKY_4WGEVQQC8NR&58[Q@B7"XU0*O^N"!I M

A+WCCO@PP:Y?;PZ3]N M(0BP4#E]^!(\I;UC +X-WFP8B.1L:A[W[@US,'_6JK$QE&%>VHYG ,7<26SB MPXG*CC(%Y.T[W,WB*%?@YHL!
[H//#6LRLN!A&'=L:N(B;_1=!KT3B=5[Q]"T M[)U@;,XI@:'3.T'0A$,0.S>841]]8)1=EWDP;S_YP%N)PS*8$9^GS C]*!NX M.#D5K;28,9IQ=G#63$4K;7R#=WWBCEP']-JG2AE;!^>-
-HYO(,EY%KLH=,L\ MI>$\T9:OG>0)*$X4SA1M4=I)IL#=V':8G()B?P+W\!&?)8Q*S!Z*XS,Y_1H1;65]:
MH87K[67TX,A9WF#NAOYX^6>8YV%62N,]CWS!M.K:=')ZCJ>7J::'@'=SQL%V:=12,5<)\-1B;E.,->)\7IJ M^#O3SA0B[8'96C!;"V9KP6PMF*T%L[4<2K:6G9C=IL2$-'4A=\=K#
[X-6.-% M_VY)Q)J6B5E&%O"@[O#!OPPT#6GU_Y^\5,Z9+%(^D@LK?N5'V,.&UAO322Y@ MYB%';P\)*.OCR (&LK_>&[*J\NB!$S3+8H;TD[SMHI&M5';
(G]QZEW,%$U]!EWOHB:\PS1ZF!9MP M)D+7N:.Y@32\=KUA$>:5DS %\\HYDR=M*N=HS-1?4\G#,TKJKZDPQVKJKZED M#QDC]9?K&P93?V'J+TS]A:F_'-
@J8Z3^;!,.]9+B0SLY03G= MM''ACS2SO0U'1ZI8IS //(BR9=.E!&8,UZDZ+*1)V[2*;R&\,*$"XY341'V MLL=ZY=Q4-
(A2SG4,>X9S:RIZQ<[<&B&5HWY",1>9J_:QAS,$+KP_SVSLHN2E M" 2&,T5;8&=WY3UU4QP=*_$(G)E>Y/#M(WWJT:3E]R'SITY:?!\V?^JD!?9A
MLX,>^RR1PZ./X/SR0@[O&OH!9Y<7@KAY_ B<4?X(U2;A&7 ^^21K=XK9@;/, ML[R^?22 /M86J)WD2;\)H(^U96LGF0(/6-IQ9N@$T!DM2? A2-C8V8(K!(.P
M*$A9!$6U7(;YFJ<\?OW'F./']&EQZN3/O4QC(?%SCW1V2OJ\HZAGVC8A.;-. M8AQU5Y#H'POZ^%M,DB;@COUC%V?'?OC7>5:R\]*:JDKTYP&I^\+29LR7.
M3]+"=O;)5562_);.RQ_L#KM\^GXS_OE4&2GA?:VNZB+)DI)\31Y)_(*H8A9% MU;)*N70U6]*\3/XC"S)*E0E
M6DU]\5W>1]K39>T+#]4>\,92R'!>X)/:9@82N2^<$V\N)=0:SEG>%1:,'V'B MHN)?#QQX=U!,>0,"OL.=*8<];O20BV5%[M%QD)-'DE4DB),B7"QR;F-B4W%A
M]^DO1LI;DZ%M*6S-:1M&26M"#T@Q:[Y05,8.J8PM\G(/L+.?=I2Q'_YUG=.X MBLJK?./UVD*>JIDM&HM9%F^F+UH_+*BMY5H<];X7*6NV?QZI6,^&0:IZ"*_;
MH.K+@]SJ=\DRR1:;^'SJ&JFFIP(8695 /[[\>'IVTT4E[.ML,G;31 M2=M-9=O$')'121N=M'USTCX*2)/U8U_*+9ID.F%5/M \^0^)@S"+@Z1)G&+H MLMUY(FL.W#U1.I [=V?J8,
[=/3$!=;JNZ'2%9;->*G 5];7LZ:"WM?.:U$VS MITTGUCR+>HRD'WI%T?-TW2KZ-XFJQJ']^EE91^ GD'=R:"72#R'N,):>45U- M_+43/ZS^N-452.LWMZX 4/'9Z@JD!81;5P
H.6Q;^RNJLBA2! NK,J*N'77M M7=S.4I95T,EZ=LB9)%*9W M>1*FQ7DS49OY2=I01UTC(H1F19662;;@D=#5?42S,@\C_@L95>!>/9!XL_D^ M;*JSW=?9S-/FQ0SL%;P=G,@OO
)I<4,BPFW;<#+;^_5 IEC3-/BI@1E5+1U> M-+HZ8G0](^SZCY+Z\O].LU43<2Z.+%&VMTI]4X9R)X/P6;D4)389 'JXL *I M_1O4Q^HJF,Q)\[KJ5>U>U?YRP1I;I?NJ?""Y]*42K
'>T7)N-_VE2/N8O='# MKD-JTM3HB<9!- YV,@X.+RNA\?!PC(<0R80:"0&^<$BMVP9+=[Y8/#0WC?;K MZ N?T#+DM&7(Q4@2"$SQ[GBTC=L9%N%J!:Q#LW!,E^42O.P=R
UPIW MD!NF*@,P=[3+@I>T#%.7S(2&!@,PA[2+A+NT?PS-%&#F:!<+=V[[&&FR;!N: M/P0%2=EHBQK]+\/\+\+?SG9-@:*IH8EY0!*L&9<'7\-,9$#T@TS[W..#3I M.6+20Z.8-
T:QD:+Y:E'UMKD#&$W?MC< P"8F[C520:'KG,Y)4;"M$*871%CV MZ&6ST>(H-9DNX?RE)SF2)3&VFEO:! MG=9I:2M'E.?0[(AF1S0[HMFQKTVC]
[C[PB2T.3IMS@;I;&$:3PGB99$E1 MYDVQT5:P VEO:$&Q0HPU6XK%U72RJMPPDNN=F;#K+0NSB$A"XY2-!XWBLL)2 MF,"XM=%TX\CH\OS1=D^W^V]_T>!>
<%V&LD1;*"*JDV6:NO"Z8M-,Y-SS@W MGFG.[)CK=)V"B6XL6A\33L,%S<]H=5_.JW061;3*2@G=RBYHUD*SEKC/P1BU M[,BL:-Y"\Q::M]"\U=>F,4 ;OG *;5Q.V[A9[A .F<-
GIHZ;]M6ST\!Y5\Q2&I)= MEGR'? MU@:&=LV>IK-FN>R5WDZVR?JP-7AALW6^TXRN"-]-V:+-8B?O$62?K1@J>^(@ MS!39Z^="8Z,CQD;V[))DD9U6[#7(HC634[(BK),>?
&%L^DJ+XOI[1KG(X=A4;BM^I*/=<4OQ^;CB1L0]0;MHZAKPAC_$ 6\1]QG02 MA@?0$KO/,7W1]+!4QSHH9 #=\?,-=.=:=(B)-F8X3;*SFE(P K&G(XUH%G,* M8OZO@J9)S#?
83JXM:I&U(9HUJ)V#V'B,G@?6+7DD0QB0+\W7] MUK!WI;,$3 MMD/GB9QR8>OI:(S'41>3N=-;6H[%<0X;]SZX2-M(I'DE7"T_GR MSXZD0139H)0=T,[G08S8GPRC/##T/'MD-
\&"?*]X;,#5O"F)?565#(YG3&1= MR&";T1C^6#.A,C&:(]$9(C$,15HMH$P^\VPU2'@"!@"\;0[U<:#41/S>- M%G^@ JLO\4M:S!DF_$(_(Y]]HZ(6FY0*E.$BFB;#&K&NPY>3U=$.[?
>;!5^V MW,?*SQ?+B#OFED+/O*R,N ?697KUK!D>0VM62U]"?SOP66%C],IURXA-4D/A M<#' $]A $<8,'^TZVE.@#\=-,Y6O0*-W=JV-(,\ #O/8L?;KRD,=M7OPO7H]47O2\GZ7TI
M6Q%KD592WAE66>W%@;BKZAZ!N*OJ'H&XJ^H<[R!WU#W?<- M=9A#!KIW=!3M[D,[!<<7]*'M\J:C#RWZT/;#':=\:*?#-DV+OR^O?S^.QA+=
MN%?/OS>^QG"!8G)>\%#S\'!NM?YLS#Z\'P[:/;=/]^5/'O)G$N[+32[^=T'> MZ!Z#."G"Q2+G-R*O9DSGN[^8%7DR&-I:02=CVCH5;Q*71#"@9V.(ZW]@+'LT MO!MVD9=
[%EKVTXXR]@,O-1A747F5WY+\,8E("WFJ9K9H+&99O)F^:/VPH+8N M^FH$QZ-0MV'0\RK.KQPT6MJ@3X8'/AEWR9++JO-:P3'G4L,72F/916#0TZ45 MM=X91GWMKFI#$9-
:KYB4QPB5GUAE>W]\8@:02-!]QG_W&:5 0[5DB:FSP^1: MIYUN3E\X)G8^@LG,4[>S0 X20)"<.AO@OFC:DI,OK#&]6V"RC"^&-QO^G(];
MTUSVYRQ=J_.ETB/85O%^WM91+;D1CLG6#7/YCT%8.SF9:GCU1[:FX#4E;2#] MKCXY,/6NZ3)1N^M(DHW3, OC<'-5S!;F/,(M$1AE S_&2 M9&RT]:U<;.9:?MW^%-C/3 WL,
9)^ 7[_W(:FD'$^F'1]_] MQV$1%;$\DA]__VGOQQ]W][;AV\/G_/"[_X#O_W-K2[R6BC):]%/IW["#P_$S _#*+G<%SM1(G:V=Z/D0 1EEJ?9OO#+(CW ,6=Z MH*F?748)-
)Y]%#10(3\66WX<7<+#++J*+#ZQ9_U'F132>'RC,X!N$SY[7';[Q M^F+XICL0[]K]?KLW%+TS?.")@=>YZ'>'76\@NKWAF7CWIMMYXS:%C]X_O7ZG
M.VB_.O7$F_9OGGCE>3W1]UYW!T.O[QV+B]ZQM]!ANS,49R=B]Y<7+UJB#7^_ M]:#9<4O V.WS\]-NASH<#-M#Y[W3]KO!=KVS:MAVYW\NNCCH"?33[?WF#8;0 M\5"T>\?
B;?L]3&T(#6'D$T^W&K1/O988G)W"X$.8U "^PN\0D,&@^[H'G[L] M&K+]:N#U.O@Z="@\Z*0S[,+0/-E^>]@]ZS'(-.C)(AX_.RZX44^]\2+W
.N+PG;.WY^W>>YCRF_;0G0"L*:*I[RE4 M,LR#=O>8(;T=*&QST3OU!@/"JSB_Z \ND%Q@\/X%O+7[\F6MVVUFY^7TO\!: MG\(!#KEK5OL\/)9#__%6X,]RF\"D/
R6V"S$T#DR2F0GW?1/QMTNDA%N#Z= M!S?M1=&R9,I 8&^)&\XZ_T "Z+QI#SPM-[[RK M_%$LQ2C-0\+\^VP%=+.-8 MZ4GS=S[S _UWDVRO8VE1A5Q'83'!/W;^ADH6S
RP0S+X@+]#W2F#L:4;SSX> M*,BVJ,&^R-,X"LW#((U17HXV=EL#_-L4H]H,/!^)*9D44^+'6;$4Z,T"\ M_'G[)X8"!F_$\2=,R,&R4&@6E78MS/^_Z&5_YV<9M!:]=%O\[W_]GUEH!.-
Y M$2Y!QB@MBG1*V.#I._]>:8__+#]\F\&7?#-\FY4&S)K[%;,SZ^/K#.)$K MTNSF>2G%,=BB^X@Q)EY 7TN \?E['8'PFZAJ.7'=!Y],.;?@2G^-QM0J8+*;
M1$4$B'R3Q@"6B\2O2G\K0UO(@.E8#,!'@@/<$0 <*$X]&8FU2G[__R\]>S@':N^ETYB=S M6@A\N'NPV1(3F7'H/(S&PWSS.DCN Y>= 3W,QTM(4,,G8 XHEG.%O:#3+
MTJLHA&^1"J*D#H0KPUTT !2X!MQ3TM0_H \HPA\# 5"_J38E(S(E0S E!= X MB#6$3T'N M!@?;JH@(&+29:6EQ/Z'"5!7*++I#!D)! !Y*"H/E-'6-6F"CW7 ME-
0XC>/TF@8":L^I29#"9+"+?/]AN\L-D3A;("EY-)P HVHRA8\CB>B@M0T= MS>VC:9<'630C_+8O,RE1O;>(!$(C[%_4%Z7Y-7=M0'0A[D>RN)8R<<0#$T== M9&V+.N!I(E%>^!0
9=FAOLV;IH-=-D-&(Z;P?8;D4C7P=8-<3/PKQ)*?B AQ MB2H=1>U44(1"(@7#$,MFX_0- B_??M2$]I*AV-VVS89/_WE8'AW+<90P3QX^ M+X^V@18$QE18)O!:,@.'V!+P+^-
<7J,TA)6 KRM*:8G GT4% /YOUOTJI* M@G&N4EKHO%JJXYI)&FDH_@=7/Q27H4QJ?% #W%24W4-:36.>].ZZS M@(4^!3O#8ES%Z[SHJM708B;0N:!^M7E26^=R!J@'JP?
LZ5P0-X(R!;[T:5%! MX-ALB782D0&(B%F:+R@6#5!?C54S=7C1,1^'T.-G'EC;5QO7DXAM!("7M9ML
MLL/2K(7Z'+\)T%9B[=\B%;U@A4G2T=QS41.&9+Q!JQ%8FJHU$S*E'A>U_&83 M>G'T$"B717 FE<5B :+!'KL J"GX(W!=2C /0%]#*QP>6C*JI<$TRFP8S-A! MJAG:'/ XA*%
2)8VJ_.HK-"Q-T0JRU35)YAA,#:)\J H ;W V&A ,@.M!/CRJ7/,5R^4;F).L3-68UAP7C1^#HT/+ M6RG8L$EEQ/R_:-7$Q;I"/C69]:)4#H=;7R;!O.K,C*RKI9Z>\:N].QEM9 M>KWX$%-
MXOQU[^)M-0=H@74P]J_O#B>9'OB_=K;>M7WVO_8:I\,O?X^K.2U M/\]U6 Z#/XET\V__CRK/4RPJ23:7W;H'[SG!Q\NP;--PBWWJP4$O#EN1@!7 MD=QQ^L.SSFF4?+@1
08/S>&Q/UMITA0#LZ:R*GKQY=W=$1-/0:8^+K6(-V;K M >J= &2%:5A]1WKR4=L=/S,4&_[FW1#)5&;-= 1TFJ0J<,9Q-:T8^%61ECB)[#>W&:7,+$H45:%FB4
MX*R>!BF/[DC*PTJ#HR]E7!P'\2-TLN+H2I+)XMJ<^V(CPO!H]2I[,L;E)&NP M;M(N!$75NSUZU[7^7,N7C&%M_N*#C0C&G_ES,IT!TNLHDXX9'TW!*(J 6M#1 MO/*CF-
AQ#/J.G&X '8PE4'\%3!([]HM%YUL90+54H_83JZ2 &TPG+W.9_\M1 M3,,E; *:9(>B]$S^JXPRMAW5$K@1;LL1(?6/#>5XC":8O2;&K^9A*").1F%4 M2 PJ9U)W7]FI>NX8X\?
27>0YBAL2OK*0C$OCQRC_E>+\.=F/;)UNXEP!E(;% MUD'V;9VM@&\"=J-II1F@1>0SD2@DF9A7CJ$-/?5'/N5?&K &HF_' .N M@8K,WN0,H WE^$*NB[","IZ& KN(8 TI5U'),
<+,!$Q[(*N;(Y^YH2Y8I2F M'W+4;SIDYFI.9K-9)J\H $[.$LP\MJ1:74_5H^T<(&7"?=S+IDS,'[;%/4+> M%7_6DXAK"_+FGQ2'64:6+4?\LI@#N3J=%4#+&Z.2I#V8.T3H
D0<*060L85, MQ,8NUD26.(:6.>B(WDV5'@6&"OPRERH"K8(5E&>T'COJ 5ZA !?V M>9VAN:K5CY*T2H^Q>:G"/A1ZSNAWKN.OENEAE"\&A521 "9LC9:MZ5:2VZC) M5:@-AM
(;8%ES%&.3,<"04G$\E*"SK<5;4N;\>V:$U@LM"WQ<1X!R_L9 M&G4<]^4@G#;V#L1A=*0K$%I<=W+X/#IR^ QHL"60N8P63#B(I" XKU%_5LP1;
[;;_5,/@Y*9)HCNVB(8=PK%MTR\P40"X*J(" M,R":56"RN/J8@$ACD8-%!K04Z;H134$CHU4!E!8GGG/"&O%&CI$=:#^%5AB(M1"E =GQ468W()_X,'@7$QM5((-
*NGXC5=&>W+55U)P55+]HQ T">HT#0N-[] MZ2!W8KNP2"S\+4-[0< V&_JVC42.@\FA85_@+HXQ0>!%&4J((RB4J71_$"S M.MCB_'E!NLIDC/$I8]AS?
O':)SB9/"EY1E#IF#,Y<_/*!5% MDRV4ULKV.J/ M,KSD;,LEV.]Y8:L!I104<(W@J"8Y.+/C,?JH)<: @]B/IBT:JYQQY4D,HJFH M,BPJ<@%_FCY&&=5V<980=%2HG[A84:U9.&I
>2[5RM9]-_72593&E8!5HU@/ MQT@UMX_'#G?3FG*K(,J"9OH8,X00FIRB)8)?/0ONK6<(7MU3%#Z-EDJ+]1'%5! V2;HM)Y M5)N&F"-:%J@KBGD53^,L7PHJI2("-&Y"&2CS1"7H
JW+:$* X^?4X1^DS:Z0 M=N-(CA>(O8G)QP!JF9F 8&PB-[9)!;.6,Q3224':TU0RVLD]-B9<&[72'WY> MZ<95\:+6B9]UXN=A)W[N&TSINH(4A0'I>K;E&PS70J6N432Z8M?

UP90+YLB0 M#1EQ1(Z'5B>2^2AH?]1#2I8U:]=:CM YY MH-O^Z9JE*:JCYJI/T M6J)'KMQ557/AQH86?57,AW"J$&;"AA@7Z<-S8BAW2D[A4Y19
M>0+OY+3IP,=WRYA&T71@$0EGLVS2X]BRC*ATNC8GEVB?4(SXIWO(DKZNU"H,J9%'/C$W+(L*H)I!_G.;@0^5%&E.$$2-RH%[F>H^0RP,@LT=.!&<)U,$L>5TB2>FY)?
&S)SD\Y\7.,#24^IPVIB)9-2BRXB7FW M:$Y1S>R*Q<<'*6=67 -%*7)_,M+H'.RF3DH[)=@P&2TEP.E0)E8"98J,%(F
MJONP5F&;@^B+YTTEZ1*9@W9"%16=W*BT&HK@58C$#H[?4,]@MJ$06Y@,C&4' M5AD9CD_61D9O(),5>U&>ALJ89K@!9<;A#JY'=0)0&(^&N:J]VIQ^U^W&&#[)
MJ=K;MBX,SVX4_@?"$^YXTK4>M%9F WBNY*1=.3ZV=H+?2"U((C5$Y>ER[-BY MFL@VI6E]52&+IJ;*!ZK5GGQ"=+9%J1NLE\'>KX#U0OQLZ+%EY_K&)68?R"#%
M/Q,0O3G8JE2[|B2DS2_W<9G 'O9A1=H600&MU7>U:JE36TK"]S*6<].MH@\;MN+DL4*0 T>C-9X;6'_=BWS=Q#XMM+S**9?9I!\"H2HR F!BI M(#_X!;'$=EZ(:F?P]$1'7U1]A
IJP8'T!G?>,I)JA%WYN5FJ2D55&9[:*PYF M9S)WQ#!;FBY%PF)9);4T1503RA?F6B$,&>FB!Z5\"#.4L5F.#,[*YU:OJ856 MU"RN/'9Q0COA*A&]CG6O8]WK6/?
72H&#)'XK,ZSW'OBQ;(F^))OS6(HR;;((MMI6L%2AKNPEO6>4@%A,LXQ<#4%F3]<+.E0F,U#*N "B?D MP;[-ER@8J[:CENM-,QU3! V67?I)]._&G/!&S1NHRH JL8RH= ;BU:(:A:
(J MB>$(WRV.BK*K-DVB7U48Z9'E KRUG1>.7B8%J8KAJH-< EU#W+Q'N=4 GBZ[ML.P#1(CD<2LE:9UJHPK56G8 R\&9.NNAPIR*S3!!W8@M!8[:X*%.&7!8JJ68
MI[6<$UI+":OED%560WGKEFF@(6.QA=K?CA#JK%%:QJ&NSH,%,EBK*@IQ+N5T MRDL0-X9 MDIG&T"CUN9PTC("GBC2KR]O'37_Z&)>=>[CRO52<9%SYY<=.O!"^&5??U-
QT M"AS0>%U-E%^;V0+D5>F.)544-U8 HG1N+QH%20]906M MAHKSWAK.<]Q$*F=^$B1YCZ.%>+N3(L*V.J!)Y7WQBTKY@2\[+1.E1-E.5-OV
MG$KMC=LJU&",VF:K3;NN76\$6!*"M-(ZM3"3%(/S]M-8[[U[B"#-8.U+J7*E M#:>6J%P$2!X= :3@N!4_,;+E@NVV" VAC1<[F[0K1"F\VKDSNKQ[0=_-9FF$
M@]#I'=45!WNS+T=X XS@45,JOJV.THX;K2=QLPE@6F""GX:L:A'J5LLQURC/G5Z$%O0&J8!QE M><&!$'K<$F#Q%] 8+\R)-ABZIK,5T^:#=YZ&<'EQ M#^'R-LJIO"&1:;G>J'?
KSV%C9=HHXKA&JKUZ77*--KA,Y#@R$6.4,%K]DH5/ M>;XHT_57&',V',D>C#K!=L''X<(!CJ?@]4FXR3Y1I>ZU,P0K4&F'3Z:.'\+C M +6?H;
<0N"G3^I&69B/?'/?/J2)/K'/GB@Z,N+:X4GY>5=Z@$"UQ+Q>RC;!DB'S>%[]XOCBKP-!.JC2&C M$>@ED!3U8P^ R2=@RY!RR%0\I';$F,-((\P.S#!PV'@@B%ZQ)<>9&FJ]Q#TZ
M:L752;>*>JF D@<-=5$$%U6"+9L#73/A-!FDN)VLBGJIQ(XYQEHK3*S:R$+- M'=BNI (LSAA-TV0+=WI4FXMFG/-5)V(H&-P>K@<@?:O";_=>2/.V_WA>_'& MZWO#,
['1[75.+XZ[O=>B.QR(]LE)][3;'GJ#EFB_]GI#O, (GG6\/GPZ[O:] MSO"L/Z#[FKRWYZ=G[SUOL$F=O7HONOV^]]L97CST7KQK=W_#7M1]1B<7IZ?> M8"B\?
P[QZJ5SK_^V.QQZQP)>LZXK.FV_@X%[[VF]NFIZ'=?OZ%[B8;];OL4 M6__W1?\]79T$K4Z]U_#PO'_6\3R:0[O?'>#OLPNZLNFL+_K>:7N(CPB0+H#^
MNN_Q_4_J^B>Z5*K=P;N5!J)SUAOBQ-H(&T]KG4-;Y]#6.;2O>?@&7KA(B1]5 M"H8R<:PS.@D=_D]JN27"E _GJ/8,^\WG7]F',A7N7GC>A4>9$G5(C3G?9>'H MF$>NM]7:A7?
=ZZ.RF83!A%(KTS23#=AGL I^3(1.5P M@-;]MB;6I??F1&%]%DYU5OVM<"")J/&NE3%(I,&A@ @L/M[4H*Z/J KEV*Y6 M=9H%%@]B/Y=I&N+&)]3]*>]+YWR.SS-PP8\M1
G[!&1RNU'O8QB,?'FK'MG4 M?JOL&W0F6U4%>:[&I0";.5#9^/_*"3==5 #4C/BG0?]R\X[.[+G..MY\CHK. MUMEGI0+-T1$&O*:"]YOQ@5Q^=<2!FT C4^(ZRK)V4,D(
M1TUKM]5\<^FQHA*J&L'<"K;WXJ5>P^47S8I5N&GVL8SQ>=?M%;AIA^71W?0(M5?L]Q9>_VO+T?+I@[VL--T3SZVM>QKP$.,.8K'=]$>
MN&N[]P@;4F;/NK4)#P3$PU_RFA,FV8+=RB1>/9($UC;INM?\N_-OR6XC?6Y M9^&.-#+$=1"3?+I/N2K-2L.:6],6RI8>;4 &B&#O_B?'8_*/3E.GZ\G<'5/+
MMH31X2Y1PO6)#8D[<^O!QFBS=OC8HUR&%_=?AJKHDW>D4"GR7[F9RULW=UD_ MO^#&K<9/8&E>WG%ISIT#KJ*\7E395+)K#OEW*J-^K_VK5Q_??CS_2B[6YQK#
M=8=H/*Y/P;SA#*_A3"Y_?896.3W)9WY0/6G*$W[_KS(M#FK0\<-;,X9_UE.@ M"]/Y4OG/#?;^#F).Q]D.L0Q*=?<_[L""O-P_WZ)>\V M;M2M]J.T*-*I?:U]=CG:V&D)_&_S0-
R$PKT?/BL.-4$OPGHC$#M?&@CP$X&% MDE^?[3T367K-GW>??0IP+W]ZU%3VYNST&)SR.IG![^SH2[.XO2I?G=U7E50_ M 8C=50#BQ>?E"Q>(-?E]8_+
[#*KEJU'I9X!U39[CG",\-_<;R M=-7L#,O569L93Y(UUF;&FOR^(?F]FN]_4]H32\V44>P"U969*]_/L2?7SAL M]/+%]H]/3"Z__.&+3OF38Y[;NRL Q>[.&HPU-WQ[S#]2;M U9-
\4C(=JL#P* MU?<=_,9\H).(=';V-:/M$R"Z*0?YI89:ERJN2Q77I8JWS?FL_Q9WI;<'@^[K M'FY!OVVJGQ^,8=+?:TY'8TY^BI6H>9C.G.+3K=A,_DRA=[_ATWQ*99(N?F@C\DL!PO
M=V#0U?%)HS3]L' D+]4,X7408I9>,UTZEQVIFDB8^S3*5V!GX[J*:%U%M*XB M>G!!Z]6I(J(S:4Z_EE_?
Y6C!$\JE[$NF7C<(:\G1N2B2^81%HG==9)G3_'M>MLS0IF:SQOG:WYYF2QSM8\"6O[21'S.ENSJCIY MS1I/AS76V9HU^:VS-
0\N^+'^^1!_/HJ0U4K)Y75\>O72)"L"QIH;UMRPSM:L MBL'R:%3?RO"FNC?I3Q/D(^7.E01C%>EF967Z/7(?GWT9VV&8R9SV[W5OCXI MFQ(A*[*LMZN%E5WV;\^E*P+&ZE'5?
2+GCY)ROA2;?6,P5Y'RUO)JU<%84\U* M+]?CEE6/N'#..F+GM#T8;E4G_"P>3<9;8#LO/L2J.\%G#C6>Q5,[MF0<^C-)P?G3X?%),XZ/_!U!+ P04 " "H,CM9"N1E=TL@ 0[@ #0 M
&5X7S9N;:7:5AMK1Y8\>D"\O_Z>1[<>MFQ(L0FGIH EJ56]^GS?O7Q,!YY)\=# M)9V3GW\ZCMW84R?J\Z=?=U^]JNY5X-OC%WSQYY_@^[]L;XNWRE>AC)4C>A/1
M'2:^H\+38*3$91#&TA/;XN#%[MZ+W9W=??'J<'_O\&557%Z([>V3XY&*I>@/ M91BI^+>-)!YLO][05WTY4K]M#()P).-M1\6J'[N!OR'Z@1\K'^Z.E:?&P\!7
MO_G!QLG/QR]XSL>]P)F(*)YX]+@?;T?N?]6AJ.Z,XR-!%P9RY'J30_'W/Y,@ M/NJZ(Q6)IKH5[6 D?;YX),;2<5S_^E#LN+[8J51=_TCTDS *PD,ADS@XPG>.
MS8M&,KQV?;AY_%G0BV+U.=Z6GGL-%T/W>FC>_563 9C@O855F>?^,?7(/RQ! M5RP1J= =S+P6QNJ=V)^';L^-Q7YE__A%[^3X!=X$O\8G/]]W49X:+-&:_N[W
MHO'1G'7DQYX:^2@;B>9/'V]DZ$H_/O01^;RCW*K[@'DJ/-* P0<(G)WZ._OT MZMP6=8;F_-?/K.P^$RB\SJSTJ9=HMQMV1YR*#[5VN];LBKK=[C;.&O5:UUZ& M12\FYG(T-
6\4^I4%_/Y/$L7N8'(D,BK0H.B^LSNV@4-'?&B-MBUJ MS5/QQJZW+FS1O(++^/E]JW$J:EVQ?[BW(RXK%Q6QV;0_B(^M]N^BV[BPMT2K M*6!,'N.C.
6(BDT9"4<-7!^XZE"%RO7AMK;H7-7?";O6/F_8;;ZQUA&7[=;[MQJE]*L[@CG=VVVXT*S_>EHB.7;]J-[J(I6W[L@U[U.P"4! @;SZ*=[7WL">M M+FR/W:1]H7WC*_#
VT:G"W>>BJOF*< 6![QJ-G" 3A?@W,D/7ZMW1>M,5_V M]BS<@-J%W43X;^)3"/F___7U[N[.$4SLJM*IB(X"P>'&+H"AUH_3&ZIX VUK MK?E1U"XOSX&:W@ 7H3?
F7WA>^P##X.CO6N@[F];=OP..(%/OS&;MIG#9H[?JRWVI>M=JW;(/P##)UZ7ES4/B)P6F=G M"!E+=.#EEK@\MT_?PFIAT!8,T_[0 &KH BUTX#:Z[Q1(H=X]_XBW-)KFDP5X
M#M@"4VWP HKKH=P.02Z#>:_@+/1IZTM&.V_5:^<$:+HC&Q# N%G?*GN$:=:^N*3WGK5;%QJ/ M-$RGYU%$H)1J80]I*=7]?;RY;=-SEFB@ 8R[!+1A4M"X;3?P3
MAJNWKIKP%*--O?6VV?@_QC/ 5" BPV4)MX6->X30!C*?'A;)P\ "I@Q4=D'; M!//%T>H(H5JGU83U?A0=>*9S!K!H 8LOF2-<8N8.Q%;O5L2I?=YX;\.]1*R- M3E[>TIMQ)^J
GMU&]ZH[S7;>MEJGZ1!36PU3[=C=[KD-7(MY0;;3'91%G6ZK M_CM@-K"5YEM->[5F[;2V%%)E92177D@5Q)C6L,K5JKM _$136R88G0&!G0$) M->VK=JM3;R](E;6[\3'!]=
]+2F%)#-AM\/PG' 1C#9OR(>*N')VT@$ W&J MX"\9JJTGQ.M8]CPE>D$(D_EM8P?L9N5YVJ9-/T=CV3>?O]5BGC;1;ETG'N(@ M.[^@J?S3SS_]=!R'\ ?^=LSK]%TO?\G-
/W;FW+5/MY4:(N?*3'&";'^]>G3 MOXG@.C!E6!%0H0Q# &^T8,"2J<)O6MC#K.^A;GODB1H'R38Z @[% :%@PP=% M2WK"_JS"OALI<0HD4390B7NDL+J.&L=JU -"JAY8
EU'7[72G^WL(3VLK+ M8Q6J5\!Z>P-POS;WZ?7D4;4(&6/VUU#' M!=W.!O7GU%K!A2]"L104U7'&QK+_F*%MHOC9@.^&@0<" "]M/*7T*JM9O8BA5:)'$# M">D[0O;_3-
Q062(9PU!X)4IZ_U%@4<+[< #8IE%$7_0#WW'16QUIWXT^UX&8EZIZ,P#8N0FE3TB-UOM;! M:V;\@3@#0 S@%4V5A$'4=Y7?![''!%E3)7E;7&A& 03\(:Q=*]H=B&LPB5.,0
M]LF/M;>K-V$(.?2,%./0[2M\=]V*E6P^,< S?S,\DO4&W^)C_"+*RN@=N6U M)<9W%]1()(*=\>><_F3NOU%A[/:E9\@B#L9T5YEXW'M%\Z0ORPGS+G_[-)W>
M"9/J*P;Z3R2)Y\EM$T;Y^HE]LYUAV EH'!DUCV4HKT,Y'HI]BTB;-!3\1C.! M O(QD;/6/Y(3("F@C)Y*>9 CG"2$[::1 '/=P+AT1316?7?@4N3L7T'UG^30H)6G]Q:A.,E$UN(ZH]J
M3F=H#DQ^[*D8-L\2@(&(D_>'W 7& [,%UBP19P7T+>?Q 9O4X&* 5E@SC'P M<4!;&8D._I$ RFR\V2!V'0^!=_L)*>_ LHNDNA&(
M;*)"+:>/UH2Q8H31>U#"^%JM\1[$$"5AJ)!Q,YH#+LZH)GV<[8 (PRAZ.LI?'43)> M !+/]=7V4*'@.:SND@\E'AZ_@(?TGM=N5$5T/EBB+KUK&4XL4?. Y&(INKN7 M8N?BX
CI:4T[*T8[_56AG;&<&.$@Q^,P !T=::2H@&N!,*TP@>44]4.WIUC! M5R[<$F+V4%]&8!UIFH-O0;;\F8#6)">0!4H)LA'0:AH4;"*10TTZ0)MT0) M")N !@>;+'(=9<@V(E4-
M#3008=!" "A["4,@C&9TV96D MHN=C7/RZ6>!K0A@@%H M<5&4I+()[(N(<9__BBB/SC&J7E&-PROS%+4I$F5_!U#3[MPBDA)Y#=@K2XJ MHT>8 @P\QG6DW^;?B)HZ$;
(5,#B#T(FX@&_MG@KPBRF(1SD.713"6PKH@8+ M"9C>QZ'L(U83'V%_3/J,GD]>UN>W2']=9&WE>P7(X'JX&>7 LLR\@6AA(1%^ MI?]$F*?F8-EVP;.%&<*CN8^@1M\ ?
_/[ABDOVLZ*: SR2KAY3Z3]93-^,.V' M\7">X5R< P%-QJ(>A: 0(Q)>4\>L&#EW@# A]TNE] MV\1%QG#5A7$F!H:$Z4PK6W?B(-DN([+VAQ+>VE/*GR:%S-KO);$V:&[A&O #
MVEL_M5Q2D<(+!*C[6X-Z*/3L;?-B[?OOF]7"[QXSJ:1*Q47R'G"UW"C-O"6&?==CI8 M69@V]X*I9X>#[3"XG;V($E1761K@#LPO3C_Z^?C82HM+VMO[>TW;;OV
M^W;MK&NW0?1XMW(2'6E)C8+"5\6 J-":O=@% 0S;ZV%6\5]WZ#]X3O;_N X# M0++MXEHR.0")6EP!/D=[.RJ%U#9"7=#7@U:B^ M$S-
U41$#1#5\=A;K2V*_+AJW'H8@^EX2@?:/ ;4"'>#0Y<.A6P<5<2"C&*Y$ MVN! [AU%,&/EK#%]N3"]NG*83MZ<>]A?%J<[Y&Q4C+E%<9B@ZF$A4O:"X ^T M=\-
)1@CE%CRI)J#8L#LSRHH:,C-QRK3-W4.&-V9IT"T=K5M5=TPRRT1G?41C MSX6)\0?0\-&CX%AHA,NQ&P,@_DNN#DN,5'BM0HO(:J;^1:BN+
4Z#9>$$$VLPHB4&YB=F@<,"N"8.)()#D5)WB]HD?.G&9,6XHW$0@<;H*],H!#U M0W1)D==J=JZ@\WGN'Z"T*3\8N;[6QV+XQ-82!VM M'+4M]GVAX:Z#?
WEK'Z.%8**0NI1"HL$P':PE1' MM-A=QY4T!4X-F6@99\V9W37^4EG6.]&ZPF(4!A>*1119"F3>2#F81P9K9S%) M^2X85$_\&X HC&)20]8DO)0D_'+E2+B[(&-
%IW+0WB8E;K]%89Q<,$8Z^#I2 MW6;CD2;9!QUFD>8?^:!D(09)T=#G@?,_4EKOP]:*/&):+YA#5(8!+)=5K%PX MG5'79-TQ^YV1%H3^R^*S72X$_?
77Y450=U40%+@J!R8P+,%_42KD4/K7BC24 M((DQIH![/,7-72R@E:"/*!D7\AC)AHB.8* E0=QURMPZ96YY4N9^*$:X,IP0 MV%^">>C]8-1S?>:":3CVGJPP@I=Y9:QP2?
C@TS:22/^]Y'8VBW+9@UXL77;K M6N#U!I@$P #\'D;EPH12/L?##_J?Y,O:8#QM+2+R)O+\H[_9GE'UY(^ M.WL9#U*;?
2HT#X;]*/%B=^RE=5OS_A!M8L#K$K)+S.8*DHPB35802[;GRS\ !M%SP5U#HMGH4=S<$S-!JFGQ@?^,*])/8CIFRJB M.U,/HM\DO8C*7*$I24.&F_:8<&#T1A49D!E(-
>@BUR7U,V9BK=[VIRA&L$N M18")C!<.SQ!W\#J@BIK4 ,T9J"/IH)7:[ZM(^YLRM1]T?JY3R-=LD%WJ1OG\ MW-=@VN@1@WX_"59GB*4RP'%"15H9IUHSC.;1T6%3#J=
M"1X)PFOIZ[2FTBI22K>BRB9JR6PJ@8I9ZD0%/'*1Z\H15F>/S"KR@, M,\B8[0(3&\?4TL)S56*6,)?5@X4$ @)G'@6);NZ"7)O[NY ;'!/ABF.P:F3-
M[2.5KB*7>1>$&8C+BY3UU2^'$N;[H43'/#DD#1(M)C%O$>(Q^_PN])WGW]]E M K,)B[#SK)^PPC5+*;I2'*6E94+H?=QX_L)B<4Y/:Z2]I4A+5D%8AKM9>D"1 M:UESF--
,KF5QA\V^S\X?B&)@&>4-W@;B4NN8I9IG;.J*RU>:!H^&TN'%\;!I M_XMB)/;;") U.K,_\/E6%ON\F7Y,I":55$4N;TWD6G=Y=ATQND-5T+,+<1NC M.F>]Q5Z;,,\|&J%6@L@;%
(GDG%!A>D AQ%2C>8I39J*5IS7U$S &)5)]1=3(MC$)YG0M3@72+$C3F* 9;G+B5=B$0&X4I;Z#BAN08F1IV5,S Q&')D\IRBH^/ M05-@*AXIT!WR,G- LZ&U$R_30*!E6YSUP;
(OM4%S,R=%!M[#9EMA0^Y<4TE3 MJAS++N4RZ&8IR?PWMNB\S4V[;9&UC-:6&9.LLOQ4I;_K5 &RL6,5^L0F592 MT%?D8A@\"O2M#+*#A%(#,O"6+'[-PE>-
A3NKPL+1_!2.&XV3.'7HY.N)0\1* M,LY,K4TAN#_%\SG?Q=)^H*H/2K.S!)]\(S3((IS<#Y!Y!-=4:PWH+$CUDZ MI:V9(N7!7#2'[.<-]&R6IBJ*05P 0 KHGLL^O93)%
Q;/Y\2M68MJ\9:U*JP MEEKWBNR 9& 0*5R, DNMR]9ZF"S*' M(GZ!SI8M*A*3N781NDZ '3EWQP:0(WY.0PE.LMUZ23R ,S&
M#&]8;465+M<7SMCC>!NRIAO86\=CCYFGKKERD9IPP:"HP$Q M7%Y6#_PMTEY MUB^9K['%_"K/*DX4\HTD>KGYP9:?\@DE11VJ3\N212_DB\ M;[
JO*_!7(I<2:Z?"P=R0C9C,GEF3[D1RG;C_! M4F34W6;9$)*R@\$M2S?;Y] "&NX'VJ6Y0[&3+L5+EV(*Q;RF\4\J;><]-V5-Q"W#S M<]U&LVKZ?/N[G"L65&>=G9**
I34C&\V443Z$0D2WN:YN:MIU"RIF7AF>MT ML76ZV/--%UMF&7R]*C*X%L-&RRC&KA\.$,]48=Q4^E&8%UKEL: "\V2QH>4T M"17NHKG0:I%Q'+J])%[<0Z5HETSER=SE9DW-
E9E"CB^Q5:X1,'X0XQN+\LA$ MT5-E(TJ=H@P8B?U3W$'FFX)Z$-%E YUY<0)=@@E($]YX]THZRXZ.]+LA$%" MCL9Q,46J.%Q^E+O7MWP2;UUNQ>56JW?
03HMI;PAZG/*URX/;VN&I(P#OLLPS M:KW(U(S(&J4J">WB@+=P>2,=QS)AJYQ;1FAI%A,1F MT/WIUU>.FU&^_JU)R[KKO]?QLMWY+\TYZ=<[CJM$G M&Q0UM9CX94Q$
3JEI^9B%Z<\YY.V"1[,>2GU*DKP*!Z7M+!9;R[F<\-.1(,) M5TJDJ) _SRV:J9E/ W73QTSJ0^*F?$3S_+W*TE,(N;R&6HR5ES=W%_7\ M%N"
4QD&#.IYJ5&E0&5JE%ICU#WZ8&3^R[2N,2T&OB0.KRF\%9L%IH^D[H_R'(OM1M-QOE, MP.(4<)W:5Z7W+$ M4X6!6P0[EI!0X#2'I_%S\O_'PUC];J[X[@9GFO:PB-
#4#:ND6P9D>P9=D^_ M!HTJ]$UB'9W&C$$"5FW*E#5/WJ;I+IU85]^=*K@LP\S#E+_KRGZO75WTQPFO)S_:,:<<$^@CV#LRW2M,ASGGFTK*@ MZ<,[Z;.:7K@UC\ :^QI-
;#_;M#L=\8%[$9 M5L"^>[!/KSWNG9PUVO;9^4?1M*_:K4Z]@1V!L4MNO8*'ABR;$(YP2H3&F1)7 M#3Q_?ZI>&]WNM@ 'W#\HK.B M2Y^CLW+D9H'!RWU1K=RQ*;-
I;I0>;+X_7)D>'8]C=]Z9%?0(Q]0]C=GYQ?," M[4.*RZ3GN7UQ[O*!O&=XDQCV^L9S:::NZ(UFRJ99]/$ M]E!3F2%0YA/;ADY1 =&7Z(9#00T0THM:
^EYH)3HG^%U;W/'OC_UIHXPIF M_;O5RL$O>DX/MY8O-F.^TG%4IE*6F1RIJ)PY+G(10]+P[05Q'(QH(QCR7P#>
MO;W*_B_I3L$W^6%HKWXO^.).\M*B["G9Z+>0K^:.>B0M'Z;I5W]K9,6/0=XPG;]6GX9Y M/D\ 3M'35>?T;P<[ULX._7M2J;1&Z[F[\J]/G_Z]S-KXM[D6%AR\^9)M[J]\6
MRXV!MJ>\"29*4=(<6D&E.D :=M9)1C M;LW@^MAVU23HB3'L=, ?]BB@C7$F M3-K'-Z#8H8H.DU16D$4Z-!4#-E]C?M9WCZ4\D&?DI;%?3]7]?F4\\,G=AY_
M'\SLG6R4(M,&Q1.P Q!7ZW"W6P>L;QEB@#A1:4KBW+;0@.58QJ)CF/=N&$Q+ MIK10\CG%!MNI2.>985P&?EI='NI]+X@HE9-JD\K])OI$J#@ !=O^S.UZ5Q%" M7XRS12_3-+
(:T 6#0['I;@'/HRQ372^1=;HT)VHQ-#ESUG-)'=_DMC#>A#NG MFD];!N9-&3GR3TLT/W9L^&FW+%'OV.DF")T\P1726/YV[5/4_JJ#7]6E#ZRV MV*A,F4O7@)055%4: Z>3U?-
ZKV+#=BF>'I*7!WQD,X6[RN21LEEA^'@5=9=C?S@PNK&1#D66_9M_2--=/F##G" MI4YY#ZTYK116-]3TT$7K+U_?0>/?KVA=+J3Q):I9IUH*4]*! BC7WPHP[2;@ M"-
*\B!3F[KXHMK>DMLBP/L04:JY>.D:*YM1]%!A,J@%SI4FN_=SV]N G6 M-.3SW+Q7U7K.NQ\CW$"XC7QQX.HX"[(?GBY,SL!+3$GC;=K9M30?9353=ZF0C[B9Q"X[
MGM(::KQ,9[4F8-PLHKON:?IK#%S#F:^7MYS(=V'1V?DSM@CM9<5:B<@]R@J]K,N M27U:71#J,VY
MZ5&G7HB_')6G76_2GQL='_%V;0PG]:Q+H+Z].BRYF+/0A14KI_%!W3#I;3Y M$>5+S,+QT_1_,P?WZ%:8W$8(7G;FAFH ,JRIDC"(L.$0'KK6\/L5V!."//80 MT*\?R3]4E#:B,3TRC/>*
\Z\JOS[;E$H6 MADTYHO[Z9XGG/5*&_Q10]WS]FDC]#O.8X(697?!G0GPKE=W>.\M/2 M,5-TEFZN++&>06V 9J5+DD0]WUOT $O5#&Y%9JL)?BDW9HWCRXHU:QQ?X_C2
M@7*-XTNZ,6L<7U:L6>/X ^/XJN8#W^4V=T\V+SFB'5&[4SHWTI=K^[4"4(D,PCD%"?,2+X7F*XMIE,:FKJEBRU;4UDR:,'
MQ/O7[SFG'^J690/9A!C0U,PDEEK]/'W>CS>3?!H=O9EP+SCZX6]O\C"/^!'_M_.^?]W]Z_>K"7C[YH5X^,/?X/U_;&^S=SSFJ9?S@ WG;# IXH"G)\F4L\LD MS;V(;;/7+_9?O=C?
W7_%?C[8A7]_9)?OV?;VT9LISSWF3[PTX_G;C2(?;?^R M(9_&WI2_W1@EZ=3+MP.>OR&]9+ MIEXL'AZRF1<$83P^8+MAS'9W]L+XD/E%FB7I ?.*/#G$,6=JH*F7CL,8&L\^
M,QHHYY_S;2*Q_P#<<3-?8730;V!-M:JU+?_7?ED_]V&#UQ6,;3<+0P+/0U M/'(_3\)AF+-7.S^^>3$\>O,"&\$?LZ,?[KJHB(_6:$U_CX?9['#).LR^*ST? MECW1_.GGM9>&7IP?Q
A\T:&QZC^++]'\T.Y,_C%QM'@K--G'UJ]7JL[8*WN M"1NZ[?.78==GKLG[UQ\U6-G'R\OH.]V:P!-.ET:IW7< M=[MM%[Z$H9D+W[<'G5]=UG/?=?J#7FO0@7'[_CDO0O3Z[GG]/4
9S"XP%[A MLXO+3A?;02?MBZMNWSUGFQ_..NTSFB',KGWQ_K+5_:C>;D$_K?Y%%U;V$>8Y MZ/1/6^W!1>\C@RYQ5JK]X*PU8/TKZ,B:#^P7+KOG_NNJ@\N]ZIZX/;%M;ONJ
MUQET8.N@1YS0WNN7+QW6@M^P@!.Y$]AWZ_+RO-.FS:7UF=^>MS[T=U:!P0*$ MW040K%-7$/>M0,T'),=3>TRXN1K.WO5<.E)Q?Y_:2@<)NRQ2H P99[__^]]_
ML#X0"1@C&;%V,ITF,>OGB?\)?C^]M<,IG*U.(6[U76O>A?]=@>ON -7OKWS M-(_[A-@'C\ZW58P!R[*]?8<1R["93SC[^W_^LK^_>_BF.')'(V0%KCG#C]Z\ M*([HW=
[AUN/>EAK20F]#8*?@@Y<_T2P^(-YN]1UV&J9\%,UAN")-,C_DL<\! M0F)_QV' 4B7I+ &>##@FEJ1C+X99!(PX,X;;&7DWM-7P5UD='304QCG"?-B^#WVQGP*CX$?
R.&=PP+C*/'F.FS(\QO.8QI8=@S? M!O@6WN^P36@,S!Y,+J#GP&]Q.F0V2I,IRV%;&0R'?SJL @SE^*UQRNEOUJ1O MPGQ"W]#:,]AH& 16G,(A3)(([Z.R]
_F2[.O1TY/[@E?,V!U"^B)=AXVJ%\, M,S\-9P12>J_IO/#X@%?&-\#M W^>A0&7P">_MC85N#> $P^0^)@E\!9!$CAM MX.["'+I2?6<(",N'=BQX0N"D+P,<,LRR@M>/#4-
EZI'9&;^&2<<^S(,^(I8= M>Y@I*I1I N0+ I0A 8*-\E)V[44PWG_M[NSN[NZQ&0Q#K1UL;>PAA M!+XEP*%LZ86((@
J>1@["SC+!B;Z%.%_E$11<2),3$E.#'Z_(^84V'9DYGN==V<#% DNKWKMLU:?Y(+W*(^0 M9 M-XQ,9&MQ^\@I!'Q$-W3(X<9M,?X7WFC9?5=W+\6%Q0]@EX!JE6A]EH8^+U&V
MW9_[F:=^"*TNJ=5B;SML4*X*UU'Y F:2%?Y$K0<',+;;"Q"]"3J:P4P2I$'$ M_P V[PN%%_L%L?D.:V6LR"J(26 =(EETFC!*% $I!-[8?CWEP $"A7V,^.GN MQ.#G?
3&+DHN%7<\M)HYV(C.A$U_L_7R8L5::AWXD@ [8Z)*!=O!PIMX 93 ,R!]!V06I%;73GGQGXN'+36,O/Z\$'<&&1 M E&"29F-\4CV7K]\1: AK^9#[ET07@L >[MQ^>
[XGQMJR)LPR">HF=[]?[* M^GP;U>4'0HLNGY"(08_0DF#U=3KHZ ?.B&V^>';)ADL*% M.T"BS:W)')Y$JO:GWT^A*L1H;7D/W?I'_C.\S^-TP2NZ[;]:F$#SD[J-T 8
M';YP^8.+]GD8?UJY 7H?:N'GWH8)==@']?:3=;R+)O^R>!O_Z\>=U[\X2YB8 M!3I(6- '6AIX,7!#6AE#K$Y&/"9)9L"B:N'UF2&_]SP=_%RKVVY76XWTB@I MNVIN[H!MAEM 7#
(O J(8<>1BD7)30I2D9'@@9$91 (#O'H.DPT]Y+CQ(3+: M>5913CC0+?8+(T[%G.!;I+))% :"6H7Q=1)=*Q6)HJ%PQH)86@\SP
XY/A+!BBP[F2"A[<:)U$RA[@2L%9D#EE+#JA%)_P0 (R$& M81&M_\9.5-=^G>0T@[*'-'<[%$5G "VH2GT:/!$S.+?4AZ1FMEH0,_E!FOF M$$=MO2%*VV+2(\G 6A<)'Q=9$+-
$U>*1E49?<4!J'Q)/&>L4/ MRG*N 7CT"KB9>Z]>+5(K]49='X-M!V[]>W'I.[!E]D;<*N.4HLW+)[UI6GU* MZM(;_6FY@X/4(W1]XLUKN"06@"R>F"09R&;LAS- -^K+]U[ZB=/M!

-7ND)IY_8*2B/VBL8"OXR4E:+/2%-= OBBZ)-IGPGU/WH2^ M[$\U1^>D.)?\-[S.4,?2"Y;,UK;OJTNKV3M=PJ132.ZN9#\|%2P;7MF^U1 M-L_U: K4GZ<1Z4#Q0J+-
O'JX\PG\+D:5!3ERVHZZ8GLVMKI!(SM>^[8MO;"Q MS;/LKL&,I,_3LC@\4%#TL(_@_?V;U!+ P04 M" "H,CM9:%KB"-,9 !M&@ "@ '1S;&]G;RYJ<&>=EW50U/_W[]_DTIV2 MTM(-
DJ+24I(N("#=2#<*$I*R"'ZH7>GN6*14:@GI[EI:FJ5A?WR^\[OQQ_WC MWOM\S9EYS9PSKSF/>MK9N7@[LW@)X'7@ @'!Q<'&P0+@XN'@B$
M1T!.2("/3T!-2D9$3D?]B)Z.FHZ6@9G[,0,3)Q,M'9L@&R?/$SY^OD>L0F)" MO*+/@@O#P"0@?"AK($P,+"Q,;"P<'&SLAVS(0Q[
M)L>A>"RBA$NI9P5B>T\E^C$Y!X_]>C1QQB[SS#\0EH:.GH'W%R/KY]_0&#$I\BH MZ)C/L9"4KZEIW_Y)S\C-RR\H+"HN*:VMJV]HA#?]:.[H[.KN0?3V]8^-3TQ.
M3<_,SJVNK2,W-K>V=W:/3T[/4.<7EU?7_W)A %@8_T/_1R[R!RY,;&PL;-"_M7!B8?O\6D&/C/!;!I5#2
UF]IV03_8A']3PYI^8W/KO8ZR/J=YZC!#00T<9*Q9K?';7>T,A%_I66>**BBRHB;?H7-JS$ZZ_U=RRGH$IT("M M#'#2"RVA"HZH)WG-D;GIC2I[K+S[P\"%'+-\246)R?
>!)=/B^18N0T:W>6B; M%&.(?^7;+97)CORT\]', G5["I"9*G_T 2N'9UFB-B@8 E0PD)+V2&#(;^2_MDW;-BQ)_QQ(P?RJ".ML:@9Y5(FPR=(WX,$JW.7_FIC,F-
5P!)\+TM09)C\]0OOPO)1YY M6'(I.^/?N6KB*+)>%(<:$G)M M*DTA25XG,+12E6@ P275\8).G!8K,9C57]#4_,8P="1:YT74876@Z+:RSLL9
MB&7.99TU'<*#$[!:YXV*J\UFK_RP0Z^X(K*V+<]RY#,.Y?^4&."3"[TA+[[M&FX\ES-CGUW60K<0!-4A^.NKJL^)RE?JH'ZM3&N;3YF"+FS5==! M-E>2&:VYL3BR5@!Y=59C,
<5HKI"7:HU6ZZ3$3?R[BMZQ4FH>@8V2ZY5B>SWG M5?8"&_EA]@1CO^6\2D5^>29D_]B'68 %NW,H=[_YCLUGWE!%$7ZFX;2!!;%+ M+1*U/&/.HARN K>[[7,7(Y-
G>:IKD/R6],FQHK M_\MA(\17Q9OG3(8;P ']%9@.6 MG)ZO+'MI^/783N.\^0LQU\48)-'[+/O$V5*!$HO,FQ9_EWT"4QP[B&:C-HG: M\,$0"4@1G*(V9C7FPIY_M;C'X@N[I:\CD+Z-
F]D>PI-44#Q8-GVO:EV9W] ME[8A)LXOUD82)86L6 F:J.RT_+IN-\%X,C,SS-'G7 OFJL]%,>2\QA-14O/[M4E]O#&0_A;.U6_9ZC8:V3PZIYSEAGGBYDQ!I;79[#.7WU
MKUK'W'5FE[7&7N-7["\@^'KC;^YWMR:/4W92LK*;WCUX],K=]<7+PDVF<1$3 MQ#^B2(]G*/8V'1,9(YC,DM)Y&0:146,'I^ >JQTV62=CQ, 6^WA*QE+AIXY8 MGD+6W%@>(#?
6!8(@LMWT20 967_@P9@P5-R71J*!)(>BIC,11*3B$?O'ZW'P MR7Z Y/N>]CHSG/MG8TVTQ>7+^T_N^!5@KHJWRAIP/_L4&Z80JVS3J[6XQ.XY M7MAY/F%WQX!+V$XM-RG0?
<604Z?_-7H$7G)Q M6S.5XOO(6%(0]3QMTS>9WQ5TVVI&FOYST>+X-N']=72BB^N&XFQ:19#PCH^O MUY60>R?U'^?IP(K%.!1S]<2RX1G^YV6QIK,Q @F971FJ]L51@
MEJ\1G+16\A3SB0),2#';RNG\VYQO[OE<"DVV1]?A AUSM$15;D/;<@2*P;EW MR: N73!<9=ZDY,H4A)O2=9X0)G4^&=FQ.*M6*LTJT8XK*7R.RD>] (ME]J$D MZK[OP
._^FD5+?81=]>'6NHE;Y(^4]KK?C>U43\-IOEF'43Q%6*:)ZQ0&@&P M5&[F1PV %3_?JDG%O9D[9C,?HJQAD]#WY]5#(KU9+C^^6ZN[8JC(\EG#9*I<*N@ >9 BAB 1 M
BU$%0L@'M6;%Y>AK4GOP4"4KD$X7B][FW]E=-6NC$#/'K=]W*$ZEF>Y+-+W M>CIW&[S8GN/B)O[EV5O[:NY-G?.46QD6:["*L=A7%^\)_<<9LC%&)B8RPKUL M,*-
G>LI4@#Y7NL!J@)UK<02_ED(-RO32DM+,#':F"3 A;L^^71H?K=RIG>7_ MZCMFB0FK<>WNBLO6\&&;HT&:%ETD_4 #>][47::.[A6.<+_JQ#*F5WNS;!
<>+Y,4WO=898JE6M^VI$:FS MS0G)GCT6^U3FHCMQ--Q_QVKZ$H:/T$"SCM[,Z=Z;/H8!-L0CL19&'#V(SAC\ M0*),LU/B#.S3F"GZ&+)[EZ]@QK?
8<08:+^E;SSAAH0S6@*Z'9JZRR/3\V;!I MV7GOB# M@U^/".(.OE"?X!<-<':<\F$YHB$(_>-MK,-OB_N=B\U?9ZL\1L[F4*27IL:8U5UH>G=%5DX^(5X!-EF$;##[N$VMHN
MO+F0S)HJK9%@YY(Y39RJQ-6FQB_"IB'N]G^BJ[\FM?[<#UD]U- UQ\V_AL(* M'7_.T' =F$!"G/S[&NK<7CGX"QK_0+C?M[T+:=J9]KV8\[J#'M&P;76W9'F^[
[NT*^D[QCTD"4'[CTN;*S^$VV]H0+ M\#'$3?$#&AA6N@M1;:K\2M9/\$6)'MNOBO+HO$$PN@SA^>F?I %1TO6WJ+T, ME]$\/#:/\Q/N;*?.G!>3843W+P.-1E/_%# \$M=3?H-
MK!]GJFYGE1VKQEQ4 M?:L5@ ;BN=),*Q0[1QIWF#[!<0(6_GK=&K5$HE6J !D!QN,BFPL8M$Z:.' FHWT"I6TN$Q]H^#F M)B/0E1?Q&*4WJKJ^5'?H7@_#(:UU).-
<*L;E:/H&XW^8[=6WSL8#.MB7]-F8 M<7U4F#-[?&%*=WQQ(^;[$E@ENPI,KKZ8^"+#F[PTW(<4;:'9?,I5.;),+!]O MGU0%&Q_3I@;XR>Q49T\;2U^Q,Z6J:B'&CRLUN](((\RXS]
<8@OAFR#.D"HPLG MAB8?SZJJ%>B=/)P52;T7G\]KP,=>6U[5-YJQ47NV>LCS]=QJ'A<[0GDG^74B MQ&63ZLP':+/YP\0S31(0B474.;1R;SMHFB=<5Z*_00QU05-
MJMUV##>#0L^] MFA;-\#F!$W9=KRLTH#':=GSV"!ZE;SC9*E:PPT?4LO]H4H2_HCY1FI'Q/KV* M3X&U):6KI/R/WQ\(B'"&YYY\/Y%/ZE">,Q><'Q0X6,=X%XP(PN>0^"YUC"U
MU*HAF*)X+3#V:!]E+CH^RFQ8(";W.=5>P_4P5LB:ZLDK=(1*C[UKKH?9] I# M,"#1S=7E<A;OW6\BD ?V-[TRBRQ7:68V[1O ?#2N#WL3@]=^!
MGPI:2[*]T]/KJK<4E!07W9824)5[FD>HH2)",_SO\,;X9/YQ-2J5$+R]C*ON MRBWG]8#-V@5ZN641;3R7+?;CJIQ;V>+Y2P@3P^M6C[2,M.E6O8[/XWRLYWU;
MVV<;S+EQVV[98AK/KR5AU-W[R.-HJ7C)7*#EH]YVH/U20RMUJ?Q0-&>+ET+& MDO>+EL=#&_?6Q]1#2Y?#1DU0)'@A!#KGGLIFP,+F#3#:O-5% ::-'G8"GOBG3X<0;:0 ,
(M;+4 M'Y^3RLWH%.:%I6_D(VIAOMQH((9Z#5$1!/H,3"G+|S['-$LEW^=S>4]PBCG4AX3;T/PH

+;;=51U2T%+8JGC&RZ !WB)'EV"AE7\.7=9)2YUPJ!DK M-6BW02.A#1H+N7X_SI8__$1JU:.!0)T[HNDAVE#BE->7"95+N\E?Z\PU/&,6 MZ-N]T$
B&I"Y%EJ=L5IQIDZ&J[5$I"P!7NG60&J$1$I.I;[>\+#@[<$7[M23GEDJ7^: H&:7)=YG7NI[=\4^U4BN?1'?*":@?IFTT?;V<3I?#Q6>]5KXP_ML1YS?Y)S\8;1#PI'F?
=ACR4M]GN=U#;*WJ=O0DL<..V&.KN6,(56HB="&?9J M^EPM9S*F./ V/@+ALRN)^34([N@^G30*PDT]H)&U7$T'65YO5<@+%EW$&K;;%
M0683\H:CSJIV'H'GZ7=)E6:SF&^LW;] =U54MYU'%6@7[_)^7Q?$,6;*]AY0 MSMJ\KKC.G<9:2]"0-^WR,]9E&H%0B"5^)[)K$?IDVYI$'A\,L_N0
M%D:2CY(%ITU9N_L1#72JK$:O./$:WG3NF3R";CG,3@AAWDV3]RM2(^X'C)VE MM!]&6AX:>.M[=;M47U; N,D%QX?*/R<3M1N?=V#J3T$#W03'&1>:*S0'8T8W
M!1FTU])H@*QA;:XB?1SE7&9$=U)@R[PNQ])?6^R(6> !H]G7F:_7>FGO/%Y["O0LG'?[M#UJ,H=I>J"3#M)L>/-1#5P3*7@WZK^EZ%_E,].Q5@?38= M*K/YK=+4@Q^'L*&68?
(]1=);PYR!4O,%\WS]>8H3)7(C&X2'BECL5:?NL79# MY4O^K2PZY./@XB^"IU"QO4'?=IYL<2'L%T6@.V1-07,BDLA-\=MI_F$N=MIF
M4E2[Z/8]=E/2JZ/*!#_!B$W:IJ#YA&D*D5\+WX/+XKT/WR[F^Z?_DDE;AQ. MVS#QSO9N/[6?5%2Q%*HZ$>ISFM2]C/EBY6E:] MKZ!4]T=] QC+/Z=:-]\77(ZK.>Q7[OW?
6]Y'D;@VM#V M'OO=^BO114!8I/J ?80,_]89&8:W)%\5YTK+Z=JV#L*_2.83%2L"N;X5L)!>6K\:S?8=)K(+RD$#6LA.8<6#A+)+W8V# M!"'_C/QP,8FN]\4#LCA
4$9B8RN[]3D:H)I543%D^>-NV8H&7AGQ&3D,OZDS M;TX8L6AYI$QVBZ%X(UPVJ?-*P89BP>=TPQXT$3)Y1V78OZ,J@O,7=W-(]>MJ M;S^+"F/$U<>WSNM[3*?
SSN1<$\U:D*2#WE:R,/Y0W#:5ZH8$0;X9-_&K>Q/W M4/\L-##P-/H2A0;:VQS5S:EI[?P7G=XX9GP5[BSI)* ["6[PT[7#.@3R-Z)$ MB148L,A^CMM^#*N'\W8Q?
ORE*&QVG()8S1B9WC1_6L_S.=&T# \CE;J6&F[S MA+W-RJUP6HX%L43)S#Q)KJHEC5)FC4%RX^(09A9X#7!YJUR MY>
:L7HE)P.;7B//Z87QK9;!SXE#"+;+_1E"/I0/@[9_SB(O(]ZXU\X_PX]1$S9+CE^_"IRTG;Z5 M*KB]5HD9&_KI:0KO!4W32XPX*M!.MH*/=N_%,C3E.9A&YHIG.8=KA8ZJRF"=
M$B3[5.6?;]D+^]8L*!3C)=1$;)UY$CL6ORDZI(=N(WS>TB=5XOA.G^\3=4,W MW#BMTV/#?9_NXF\'G:@X.?LJG, @;ECN./]T[*U]NJ]%\D51Y^FO.:W['6"9*1&+V M1J+F<-
CH]F%-_M+RJG8,FVLN2$NUB;5+\#73;L/OX[BC8K1OYYNH'U!+SJ/9 MB].4.+%$ PYG=O>PB^D*:8'G.B^T>=+H7O/TD%/Q)CU[,J%G2A>I[.7VS6B? M*AVCFG"PER5%;Y ZA
X\Q4GFX3 MRXAP4J>+N#(]SU+#>"\5+\;2I_IW2@>RTRQK0@2%#7SJF)R%I1@"S&%^'HJM M1=.W,'"_WFX"._O@Q(=?R4U8O?)[^8D8=W%W=?PU.YZ#W"D$79\0,NO9?&
6(B889W5^[P?%>5]]W'A?H;EJ&0 =I?VT[V3U&MC;I\CR):O=UN8 M5I/961,I%ND?\NMI_S]OXD0XH/E9FXWU@PK81W<'=7YT_SS?(R*76A0,:I3Y
M0*K1(*D9*Q<YX]XLZ5%Z35*TQ2*MZUR5LN?^) MM)AJLU:KC[!H:&N$X.6TA&/)43YOD;(NK69DJ0)O78]L=J;B?[\DU![=U\[) MV=9?[B.]_;G,\
[4$98+H5VAR"9PJ/D$1RQRHR\U*\!RSJ_-GPE5(&+!J& ./ M,_RB40QQLE/AA-_@-Z^OWBF[N(06AZ:OW%""J_USA1J3+M7._MF BAH610;_
MD,>S&FV)-6Y?;VA\J@$=V.'T6B@ID(K MRX7X=I=X8@ -\.O??+^&W?^T,C=[GR_"_Y['X!FU@2_5@+/#OM7)>E_?@!AC M'10)W2RH&*N)\R/@R?
TG/);G.V9N4V/LKGQ*X0J)TK;!=<3,1+TN+DU)'B((ME%IJ&M).?5/'VC6*!HXMHI'.<6U'1%7M6@0'LO5O:Y[.LMV0A57R33CA_ZTX M,!$???)^%$&D\,F3UTS_B7I>EY!XV9U\[-*
<%HEL,QGI^E*E8T:Y\(Y4AM'W MJG-3")--O&WN%V_I VEZZKW"?A^Z*%0_&O#TIB#=#@/G2<;40>S'Q7\,^\[H MPD8F/$W?71T$9"<6N.;.+84D&C6U-,=T5-
4Y=467;$%T=DR^!QI7AW5(.*.! M9P)2BJC%GY>Q=;A)2.$;^:AT%]5C?N7A$[!9_--1Y)QO0JF%1H*U+7\3:]3L MR3W'L;F9 A'$]&>]?YZ>(W=H<(PZQ!@-D/YZUY)LQ1]!*P6I?
6B*E=UB'#95 MKN2,4YKL3H& YI/H3%R4ZC[W$N,7S\&IAC=\<)S*'B4]M$$# 2VA] IK#591 MLOYI/'IZM+G%W0JQ+29_>')C+:GTE($P].Q_5!+ P04 " "H,CM94$,+ M57H-
"+#@ "0 '1S8".'01F M!QWW <((*_BG@WP6B]-#&*",3##FDX'FTP =" RFHP=#(/3T)VG$20[0 MLT,XSBEH,9Q!.D#/^W$BHE-?,XIHU_=PF4Q01!4=_6.88-P\<%X^,7$)22EI
M)6652Y>O7+U^0T=7[Z;^+=.[9O?,+2RMG)Q='KBZN7L$/ H,"@X)#7L:&Q>? M\.PY*BW]948F^E56=E'QFY+2LO**RH;&IN863&M;^_O>OOZ!P:'AD4G>7KZMJW=3)U^^?.
[MX^[:]??[A !CTM_XE%_L)%QT]/9@>^H<+ M1!?\9X"='G).@8%#"PEU\#MS'A'-R*F=^KJ^ATE$T83"Y>@_>,655H2H_Y! M^R?9_PPLYO]$]A]@_\DU![" 02?+ [,#&L
O791D(1VJ+K+< U&G438ZWR1C]QL*QTY_K15(%?Y-5R=6&5IE&YY%W+ MY@'3-N\S\E9EAXVF/R,LLC'LOPRU>:U9J@#0YFWAW":]6 M<_JX,S.MGVW+$E\.#5WYN/?-
R#"C1H<30/YMRU\M'25N*J0(5V1+0U(N6#4Z M. (:YI-($I3IN[<]7K0@]@6ID;D51511_!*@R7<7J0-P_NV93*54]A6SX(_]
M$I!Z/+CCZ@E5'V;&],"1$E'TY0;^M"P!Z[:4I9]D+R^H^'0F2HTN1_0YB[=H M;3D*\6$08#-QGUX[.FM._9%8\+Z^L3:A- YMGJ8RF+_V$C.T.=\E#6Q^#^27 M-
2%L\GE_X7FX4I=%'XT7*1^J4NX+,>UMH#D-9G^MS7+8LZ4C,[HFN#*F V89 M>JTK>%]-""?R7YLKW8\TSCIGH]PQTU%Z'9%7(X#VJY+:.9LO8R;H_.*^"FL2 MHKKL+ I
;6\O&C5D;^VYQ"QPRHDF/V37,_%,,!+P5+\@)]Q[**E62RH@\,6; ML&DC]<8DUFU74M],* 6<'^9/0KP=OF\NYH4LE.WG]K+3U\TFJ-.1@WT[61?A[5E+R-@=*B(?B>U2.
M*UNR(JF3RG.5MYY&73.3>U:P;8#5.@;N:-_":>>J.P"?HXSO9;C5+H;6B-XNT,H/M*XNGTB>Q"2;4TJYJ.[?VKEA9 MWV8#&5V=".-N6$3-K*:S\9._[I'-#T.QROZP#"XM-)IT1L,?
D1PD@,-G[AND"#]E(&G"4U.Z(%4WK?W:"" M8$<8=GR'L7G.T--$7-DAHGX> _R!5J[IK *2^-LO7ZEZ_N*HWNS7J;.GJ>U M,KRQ_I=Y:X7[^2ZV%=&$32E'+TIM$^FI9[COQLU:?
2EW)D:LC-L$# [Z$553_&DVU[D33'R?@TS3RDKA$4X[%C!PVQNTU9 M2(3C.$=E1YZ[=J"S?"Q^MN54;.":@4?*Z:2=X!_7A[:@2E!@GZ065^?T\=SM???
("P>$ZO)6L:\$.C]ZT_6XLT M)EF,NK./7#]B;&Z,81*9%R_QD_S@6O#R')20RS=*87M/*&"EQ?B>#DE$)B*G M5I,J9H5'X+GH8?)*UV4 E9DN>,&K;%OU&'IT!.):L.(KH'XU8;"
M=%]AW?KA@2.F(\U-J8O%$XV_E_)UOI=%>N&ZVKO-[G*=4YU6Q3=XF+&=%KL/UFH M;COXP;G' 0Y>%U=1JWM&,L.9'*70CRI#85)C'K3]@:!.**6O/:.;X\[@2$OL M,3"JSW;G-
VO9NJ7$DGJ&7,)NC0IY5=]Y6FZ.9DO/+,J66ZL6]'-W#/%CR: 3 MX\D?4F6)G5:&,_Y6WHZ+[89J5EY6W0[(!O"TP'+RKZ[H[[O"I]]ZOBL-91"9 M?38JF!NTS(7;XJ]/S77EZM>AD(-
LLQ.2PG6"A?Q--[7/ZI6-@&KRP#WM&O%; MHFTXQU=?1MX)A6X)F;M\],N42$(!X[2GI! E-09KN$])HOF48TBU",9V$CUP M"?299=OH5@]-G^M%7"INEW'GU8%NY8."
[[CG:\Z7^=^$I[?F%ZMGX#V/F"G' M .IBS9;RO,JU-N^I:J\/O;"P9,:A7WBYTI!(@\E.93W6]+)>%U_/UXK2W=%: M#UZQ1AA"@.#VN+G/[IA+OB.$ODGVHV\2O\Q%*-
G]2Q11OHR)Q=#J6_O['$*W M>:X !2[=M<76;Z_6/HVTA[]NQX0\9>U_B5IY(DBK,C)*V*-XX.4_V[K5'R;O M27TY][SX+W^M[YI#A:PY2*IAPAMRYIQ/2:6U]7W;T^=B]'I50H2-
!AJQ6E2H M%F5#1W!LL.#:@EB.%@/OWP.69U[^L"3-&]N/%DMXBUAS;VD;)UF M5AB/8/9*.B \1S[%"5NUU85+3&%ODU+.>#2&!N&O8/A4Q\3OO@0R[:_P$E#
MSH;P&77="4VP325B+@>V(%9YJ7W5J63 MB6T\!F+3!TUH^;.JZKAY3QY]SXME9[>)#=U)RTJ@375Q:FG*DI0L M0]//&^@[9BXW;Q?Y,UBDM%_A>FQ*94 7UQ23S5.[T6G/"H-
^U_8YL^P(P$Y6 M^$Q=B$1B<<2DKJ(ZWCHD-:67%FZ]E*=XX_&Z;,UW M5Y3V2!9"6LKF,0>;%8#SY74KH"2,D=QJ^^9L%!JSC/T)AO*@P2MP+CL[ZD!. M(4T@)-
MX4NN"OAB6%_:3!^R1\L0SW2[FH0K:[XT-+?G(5ABAEA=E7.&SF:MP M]BLU']3O0$OO?C]N3?%)]?# 7QV;VA_A6@.)Q"RPMU;J8EF(=*$GG-R-_(DW M726=$.
<[!\AMO/VW+3O/XF55E0MMR;_BCX%&J])]]J3Z-3@8G]WA?77>JM\/ M;I]6&,@B_U WE!/41W-T;]9 +U*^#AQH,3!D@2:HF"83.9!=]2V? M:;I9LE9]7+:Y"NOO?
2IA<+2'^#/:QB>+LM;_<(&L&PE7?E'S=0?MU?X(N'W. MZ>YWYTZ*Y19N09^.&4R&=1A(]87WQEHY,KC*^<2VM[]-[OD=LY#90
M$A)UJH8K:+N6QP$WS+2/H!]!E=DZGAK<."S2LR4G@ MPI2UWE,JB]$5S67OSH26(+?R]B7)][(0DYDY$AD^ M.<^W:I Z\-H/NYR.*]RMD162U3TEM*#FL2I3M6NT: #STO-
UF(NZ.*'#"4*3 M(L0-'K]OS\Q@J6)!9X[#AGK/W69Q1A7'B9K%]1#A2A)/^;*S5FN1R'VZ#-]'/^Z?(LH$\PR:(HNH=,JB"; M2^]/_R!J- V_V_>-TUC#P'=ZMP8E%$HPGC=JY4B)?
%*BV_(B>]%6!2]4+U5;7Q4-;X0"V M@78/2;!P_WVAA/[[_&T36RYN3JT$M-FPC;R:!FSF!;=DIA+\+DASAR[OO_33 M_P="L_^ U!+ P04 " "H,CM98!)#+Y$Z! #@+S, $P '=A=F0R,#
(T M,#DR,U]S,2YH=&WLO6EWVTB2*/I]?@6>;\^T?0XEBZ16V^U[*(FJ8I MF!]PS_W'W^N[>W\WF&MY-G?O__'W5O>LT_G[__WZ7U\&(5P&E[K!/]X-PG#T
MZ>/'Q\?'W<[=&EC;^_P(_RJ+L0? M;!Y?F[Y._*@N=4UN!>DK V;MWGL/'^DGN*>QrS^7%RZA^9&[06BZ%HNO#^R\ MG<&U]8__^G;9M09L:*J+^5.X Z].W:"6PEV'N^Q?
I]>7'T/?=(.^YP_-$* + MSZH?[.P=[S3K\4OATE_% ,5?M5?F[V;:^QI[.WN-G7I#/2O*=L+QB"5 [)M! MCYZB?L&;FNKRP ^+KH]_2MT0A3Z[+P3ZR4?
X/=E/T77UIK8G;>6^YQ2LG'[! M.X]V]NH:>(-PY.?3"_Z2(I<)1*2I!7_NF4%,+3SP]AOUHVGT):Y(D7F82^8' M@LS#A!+Y;$K4!I['UD3R%S]YSV Y>QGPBZF"GL;NG;C=Y/RUEN-
OW M3-PGO67OL!E?:D6^#W)MG+\N]6MJ<0&W"HB'6^E=/%F#_"OQE]2E?@$]^GZ* MCRPO"'N9R?NL@._8R02!$4 M_/P1?Y;2J+[3J+_[^E_&EP$S;?BO\27DH<.^/IH/-N'LI-
'\,ZCO@B[Y\E'\ MA!?]?SL[QF_,12)@MM$;&W>"W,^!W(T;SP]-Q]@Q3CXV#FEM1GWOT\'QI[V& MO M7S[*97[I>?;8",*Q]S5ATMW OX?]@G>,PH_&_1%WQQR9_S)^)^_(B_\?,>'
M+#"NV*-QZPU-5WSYV1B9-FK63\8>=XV]W3IW/QM ?('G?S+,*/0^O_OZQ>8/ MZDTV#T:."0]U/9?A;_SI$ZZ(^>(CMVWF@G:&SW#%%7()M\16GL);5,'VGP@/
MA/M>77X\W$&V<$T4%,"0G]HNP'E\!IOW3:<#4'WZ@XW?&1PH2A,J._F7?=V# M_SO>:QX<'7_YF%K&KK1>>V?7'YT[AJ?[^]!ANF M?776KAF=J[/=)2^R-62N#?
^$%XYY_\X0NOM@! M M\[>O>5OEWR4LX]*Z*5\, RG1MXA&=?P'=!^NW'[[^O\9*7_V3F7[.BT_> M?<6[BUY]X9L6"GBZQZK7C_8.&\?'C7>IM?#4 B*7BZ^_=_5V
Q'/&2P+5PG7HK@-^">7.T!3?L2 X:>OHFSFB:85V1RO/9] M]NKSP@9HH3LP?99=U0V8X0P4G]T-/>O7C>E?^]T0!>S_FD[$DKOD O?2] TZ
M>Z%Q=@Q=%05_A6>YBQJ3R$YX)XDS:51S>3F)IC M.W1)T(K"@>>#_K&?NXWF7@VV@?\LN)/]N="S"3LY6"Y..D$0/7\7C5KS:+_6
MJ)\LN(FCY6[B.@K1D$<+Y;5W[BR7@X]E; M.7FI=D&=Y[GK(X7K>R]5+6NWH_DL@%E[698H;M3VCYXIC>OSJ?U-V,D+=/W$ M3EXFQ?9/:B?[Q[6C^J);>(%JG-C"$D38L_?Q
F-ER:AH'M2:AR>UXZ,%I7#] M!6IQ%:B88Q]Y+J1.07_>^-Z(^>'XQ@%W';RA]E\1'Z%K=#K&2$SKB0<[WYC- M88'Q3]_8L,?\2959*3O >M'SB7O2\];@K-
QT$AM%T/XG^S('X/#"F2VB%/, M26]VQ8,MQZW>\R M*_)YB*\P'8?9I^.V:0W2US[;PEF(I1HG4P3TM@%H)J^^#![I_:M?@5'I,;H\
MNF/^,,T2)P=36**Y$$N2'/O!WA(=0GVD4ONXL64OP]$\HMN>3& M'.-7!$ W8HV.**V]->8_Z]=!_/01;]ZW]9@,<78B?US%;VEZ6VCP^/YU1';LAM M[D0A&-R)&=5^LIS(9O:%
[PUQDU%(>[SNMTW?Q6P(%;$Y'><_@)2;M%GF,_!> MN)#6$,_U7X7/CX_G3'JC3R- M:N3%IB?1LPD[R8M);]Q!3M8AV."#G$9>:/T%I/5LA#Q#367]D9>N_65H>,X&
M\C3;1I\YY7H("RF2M=O1?/I^ \Z>&O,I^4W8R0LT^YH"@43O:7RRZ=]Q\@09MXW];(J,+;=1WVDT]8]7G@M+9J'I MC^^P'D0*H[7WC(,+8MP;7?D\$GG-B]439&>_&8+1Q?
>:'VDSNOY< MV!P=+"8I]K,I4!54 "H"WQ6)OZ;6]\"CUH-Y< MUE'J84%22G64&@-HZL':=@%H%F6_W5'J87U:=L%",=G#DY,ME[93T+QWN%,_MF(GFUA(Q>[0W+9]E(6%W-
&5H=,1Z#F MM8^O"<^UC%0>!18VE*YVA_BC'[YRUS,'QT8_JA3I[!Z5C_MA2CUG/O,"CU_KO04BZIL]BSB0DY5!^,.8; #:)8.'P5XW@R R/73KX&W-V9 M3UAYET;#\2%6W=6/#?
C7B8$EN/BO.OZK@?]:#!,G>?DA>,"\TSC6/U)(#VE% M:D/BZUQ;1TN6^K,;]0+V5P2WM1_@7[&$R7P_W42D+!2TH&2LX1QL046BL85(
MGCQ\A]>]CJU\=%*04D+P*C8:)FW!Y8!I$RWIUX#62ZRQDX5$'OVM%W 32S#7 M8@'\C?TF/@7470$ 8%
GD$\#'V&!%+ZCVAOL/@6@0\3/6&7_CW)/ZI#R28*9=E*4]_957LNHV%K]Q6W\N\^9;]!*66X[E+/.'^DB M\>S-7]57Z:>/B&757P!UGS+!OB8K5/ M\@E^F^MA.A+Y>F%.] 8)5;
[XTX:7/2'#*'_L/D0V[EX;B)>Y]_4NZ]Y]X@G?_F8^\(8QO&Z MUH%8*T2^.B)?QI&ZF(Z/I]5;;/X X/NJ77HE&A5Y_C,E^L3]^.4Y<[TA=_,> M*R%#!NVTYZ8>\3&]^JG:*;WA15\
[U>=,A'JV&A44MQFD7V6";^3A8.;B<2_F;6GNT%<23 M9YX/G>:?#Y7/K,WN/\'X%$ 4HGW3S.JW">JO!X%NN.FPGH3[ID[$=E'SYKDL
MZTFRK^(R;2UI5E)V55+V31S$S:7C@HRG[;-HECHK&V!I MI+G9H;SU)M-7"R5N%\EN:.!RO6EU]8'3DA'IEM%;.1%>'G>B,N>?@^K-,\PK
MPWAA)&^VB5N9F"]"_H8:BY6QQBN%_3])FDNNWW@.RC;\]&$-SUC?&K^58;69 MR"HO)[YUHN:;8+8R?4N Q,J$73.T-:KRH94KPL9R4Z*?@[+RZL(UL$K?!+^5 M5;J9R"HO)
[ZU5?HFF*VLTA(@L;)*UQ-M:U#EOY(]%C0U6*)%1RW0N,U-?]PU M':;G >BC.'S^ &^\<4R+7KO1=+\|:W#^%14!>5(CYH-Z9<<<;]*/8AEDO;7D
M^RR_M*+4UZ34N0W<+23?)7D %4&_$4%O+>$N'G^H:/0U:72J$[K%]/H\Y[RB MW=>DW7P7?(N)=L&81$6M2Z;6$A)>A?F%Y-0;]3:90GJY"[CNPQ\@(=:<^#:@ M9G^]
(F)S(+MBR&5VPZH8;U,Z#U0\M@D\MHP88,5X:]ZEIF+%#6/%BN7>7->] M0?RTXJX5JJ3&<+D%P5@6PQ\JOBD0U%-Z\4]FN-3USR5.6J*\]:U3^_"7XKPVHS MD55>3GSK^N
M)-USXWNPA'!\X\"J6JZ-8GN$^SP=WXU'C/#_C=G<,IWXI_5$>^([S]R1)(C\ M?:V.#I:KA$3OE I_KX2_)8_.5OQWP8%-V25_8&##PA/O><]AK2!@87 Z_F;^ MV_/I-
%$Y:J,H9'[7ZX>/X+MD;EAOM"ZPT93?/7O'F\&P"N'7X8#YZ(WR>^\!\ MA(&DU=,Q;.FOB)VSP/+Y"(\&I-.D79B7 7GG;1&7FV"_\8A;K&Q@(Q&W46;[M6IK,RT/<9,+MNK3]?

GYV:LH(6<&(T,JS6+5G\?8FA,+]?@;WK4?3M^,SM_9P MY'ACQD21%1EBZXWFU/(3"5:XCU4B=7]M9OY62-UT3FTFG-JLD+KLXVD?
3J0WMX[K9FG)9CV8:6"V;IC?]_RAZ5JL3.9E M\;Y6YT& M(L/'#"DFJ;+! =E4G'$ZSG\ $;PD@_6F[A4"(%$2*4B4T"[/,^$JPBH-8;V)
M&9D*2]XR!QYCW\"+QW>PX\"T$&S!Z5C_A8CCG/O,"CU_O:EC_@V]^XKI\NE= MK7UH,E4]52'O-9"WO!JJ(ENA8-OJS#:(G! DV 5C*@=H <2WGT#"H:2[[O>Y MQ3:3 -
('N1/P*$3\R@@O'ZHE-$!R H,5M5;4NCD1SXI:*VI=/QN*)1;46M% MK6L=HTY9 C>^9T=6>.UWF?\ FU?16/R\GM2%&,M;=2IO)5E^"0VZ'!59H7'S M=$>.75ZA<2,-
UJP)4*&Q%+KQC@_!,KGNDPW1QZ9;OWF>G<:J^LUG=BN\\;@; M=ERX;TW1K) YQ\X2S$_?XG;HUXH4WI(4UDI'5Z3PQE)A??1\10IO+!4VUE:X M?F!^>:D@O;O*0J@(H+
(+*@*HK(&* $IM W1L%W9VEX#UY77(1$\5 M:6TI:645G$Y<,Q2@J4-=?/OF7_+L*&W: _6 M!6"$92+*Z1"(A\!-@4,Y*329)CF30I-+EZ)Y@2Q/HX"[+ A:UE\1#WAL<\FY
MFHK^"AL]7[%'>>E$J_ER4&T!@-004AU,2R#/XA[4]+HIT"X#;ZQ^$NZ#1?DH M#DEDB6X,4=Q\Q >,'+DVL[,SU;:"VO(W7P;RRAJ*.H'-,!3U2Y?@RLQ/BYI5
MLHW46+C]BAZ708]OJ(WI:FYS\%V[IL-T#^C&YP^PH1O'M,ATWVP2WE#UO=![M<_&8O#D?H6MO.OV7Q&L M&=O5>R[\&<16Q\8-@LS;B2[&7FT*9'UIY+P RC9F:O*
<^'JMV=AO@JR6;5.$ MWW1N3&YWW#-SQ$/3*07BINZM3$B\9:')76:KZ1ZEP%[^IC8*;6N@[%>RQP+; MYGF#U,MH "QW]OJF&2!O;V"^)H%NGKFSWM2Y4G-
KNTASLXV[]2;35S,NMXMD M-]2476]:7;TI73(BW3)Z*R?"R^-.5.;\89Y91@OC.3--GK_-%R-]0 M8[$RUB:+N9^KNZ?D76CR7$>1C95]97S,1:J-G];2LTO:=M.
M,EU1P5E%HR^DT:G6Q1;3Z_.LKHIV7Y-V\VVD+2;:!8W&BEJ73*TE)+P*\PO) MJ8+P\NF24AZFD%CNBZ[[\ =(@C4GLGGCV;E@7,^$B:5QV!QXK7CLN3RVB(=6
M,=CZY'Q4W+4)W/5,6Q%3F(K7BL>>RV.+QQ0J!BMA3*'BKI5PU\MB"A6GE3RF M4''=2KCNF3&%BMW*&E.H^.RY?%:Q3.7OO#W-5E51VXWJJBIJ"Y!<545M,?*K
MJJ@-13>/B^ :1^O5.DHN*G[0"]MCR<=5M?FKT5HK09RJT#S:V3O0/U;6QFHD MD(3O/!(H<^D2RG +D5PQZE8@? VTS]K I@X"M*E_G#&0LV $Y;IRPUS#-1<=
MJ_ER7B!0SX?OU*4O-;^:^+CZX9_7CR[L>,!'A-,+SQ\R7XZ^PZL($@//L>&B M]<1OX(>?4IM0_MF;V5%MH@$[;*,R#DP51(L;2"&9GJNOS'OWC=' VZ9CK 4
M6^N(F\+UOOMJ>9$;^N-/9ZUR>:$S6[%4])O/8GFCN0H5JSU+\"VS_7?%,F\^ M>64AW?.]NZ'8^-[==MU3H6ZS=$^%KS?7/14*UDGW="XW%!N=RVW7/17J-DOW
M5/AZ<]U3H6!UNB?%!1?T MHRAD?M?KAX^FSS(WK&?D5)U?++#1U#'N[!UO!L^I"7'GK!=VX%E^A(L29[, MWTL6PCYE"O(E=]EU_\QG-@\O3(L[7$Z/_3&R6JY]|?-
[<[VQ/;E+E>B;V6LA M\N9^51&PY LG0+8BIV'RY$B+<^]!^ /\=(XKS7#XQM*6IFM+H&R7UU5A%.AM+.F^OQQ2=G>PT]_2/N%^Q?038Z?B[R_^* J!Y?,1 MEC-
H5(577/>EE=J!9_LL /R%WF3WMD(+*X/9=:;,F6!)6?#S V?E)MF\W+,$ M0D8:FI.0]4M7&(W(\'(G"")FWWG_:\(;HJ #/P:AMZXU#3,%XT*[VQCE]TI" MJV%6%'"U#,(G_O,
C!=>2$+-5TLK;9&C53S": MWSC^4V1E1, 80X"'*)KM?..N_9OO1:/+T%Y/G&.FT.32585LS@96H[H4&)>D MNL3CB(,K!"V)QQ1,Y^"Q+#:7((^/8WD,'T$>YV#SQ@QX.&#FF<-
=;H$ LC80 MHT6;6*7D/)Y;5EA=&E;K"^C#^FIMIPJKFVSE+(#52I]N M!C9S:GDJ'ET25M>JIV+%HYN(S539R350KX^.-]Q"P*)'6[>>F/3H9YN\I?U
M1*6**>1M0R*T>#,K"Y,NM3*2S.+ZD?[Q6:WEIC93MR*?AW#G3>1; S-@K7N? ML?5'^XK:TLW__IFMU&< =K5^5_UH/NV?NG0)1S1$I,49@*WH'@0O7CH%/ND\ MN'4EP%E)?
L_8ZNH.;W0L+^7PIGZ@?RRC?%EG_D:@SWUZ45]&=T=>H?OUT)WF M71V#2^BUT, N@-K'"IFOR+L2Z/-9_:E+7U[O7Z'[E7DW@\&E*[HK:L^SO(& M2DL.U]SW;2)01(#^(J?
AXRQQXHGT#:] [A:MDGB!R0N[>7S"FRMX*;@A.Q_HOLF=Z M\L5Z4\H4*"1I/A.P>'ET9GY@ZC-SLE!=):4>S!W\35VZ!)U2D6=%GC.4H4YQ M+U>&XK@AK^?8(A-
!UY6&YE:&B\WT?+F(21U%O.+YDL)R<10X"X_O+B])T'?V MSE;&M$ONR5G?B^-$]''=9MS(9YXT[EP3^6YSDKGG
MW71./O>\6R^Q='S60>ZZDL**#F/7123F=^NL$+>R,X^5]/BL0C EY;@*<1O* M<96?MZ$<5R%N33FNV.?&,!. OU4./SM_-YO!9'/CZK14N#K=1%S-[FE8\=4: M-)70LD\/7]I__??
V0+49HQ+B7TQ;6[6R@/C]LZLN.[NX=8KK/+&8HB;F0NYG5 M2;##Y69"9R58Z]'T[;BK8GLXFR3A,7R,Y2O;36F^X7R9#"HN[TKC8E MN% A[_60M_JIM:O,J6P_,2L*^0.
[[O>YQ3:3 -8JKQ()+Q^JVV$85=1:4>OZ M67SS6#45B6XQB;Z9.591745UJ[$C#Q/O]G]O=O#^;W;P^5XMP6PV:HRI#6] M5GL[L@Z63>^9T=6>.UWF?\
S*Z"ZOAY/;&,$BIOU:GTHV3YV^%]5&C<*+.\ MB!OO^!!T_W6?I%:?^=?]WSS/3F-5_>8S^_J!^7#+FF)8X7&.325(+]S==O!Q M10"O3P!K)0$ZKN4-69QC>^E99NPMW;*
F;XU:,%KV0-SO!%>TGX: <#7G 2F M;$NWP6;N;SND0$4$;T,$&R,)NLQQ0*0"C+Z9_B^& 8/R4,"LS54RH$+_5G/_M;\QEOND
A%HV6%8\"'T3PW7EH8&Y=EC)@8H0RBH1&O%8-/&QL79A[,;<0\;4 M#I9]G"D(Z,Y\:D7AP/-AV5?F4([P-EW3-F_!?G0CUKIGKK7F(>OBO6@CMHLV
MM5GG@17:5HNV%97"3D%;)_!-YN@_;3[6BO94&EZKD+:!G%8H2_Z$RV_H?2)$ M;#[]9*;?V&ON;SY6%Q>@<[\^!355LYN%W6:P_#QR&F[Q7=.1H)3A]\YMM_PT M-
&/K%24M1^.7FH0652X5[2Q)AQUL/O&\F0X[*!GU/%>'E8"&WEB'E8Z2%M5A M92"A-])A9:.=Q778X>83SYOIL,.24<]S=5@):.B-=5CI*&E1'58&$GHC'58V
MVEE'E8"&WEB'E8Z2%M5A92"A-])A9:.=Q778\>83 MSYOIL..24<]S=5@):.B-=5CI*&E1'58&$GHC'58VVEE'E8"&WEB'E8Z2%M5A92"A-])A9:.=A778_M[F$\];Z3 %N])0SS-
U6!EH MZ&UU6/DH:4$=5@H2>AL=5CK:65R'U3>?>-Y,A]5+1CW/U6$EH*$WUF&EHZ1% M=5@92.B-=%C9:&=Q'=;8?.)Y,QW6*!GU/%>'E8"&WEB'E8Z2%M5A92"A-])A
M9:.=>758Q[59G[L\9!(6FT]"KZS)"B!8&DI:3)^5D)[>1*N5GJKFTVUE)*=7 MU7"EIZ/IS+G1A/),N;.6*(2MGOG,YN&9Z?OCON?C"%'"H&I5N]X(*US_9,_=
M34)/HT+/.CU'@C&_9R/-#9J\GFG!,168/ M8DC2K(UL-IKTO^U_1T&(GS8,0U/VL/;(*9XR6;'3BS&V/CU>9Z&W8L--0^J^ MZ'6K?^Q&O8#]%<'BVV
.AVKZ_$[F^_5$:]R5/7\36MOVO-VL#,'[Z9;"TQ"\ MO[3NPX4(5O1]YIA!<-WOAI[U2Z 8'LZ",Q!J8](-_2+#!>4@BZ*MI\9X%<'@ MY8&#BBRE(:=H4>+A!S@38'I<^[?\?
B!TR7>7A_+KH$PD6+AC&4>:W'<9R$ZS M.C.4-*?5^>4C?_KDL\"+?(L%0%CX]X"9-BW(Y@]?C?\RC"_X ?YK_,__J1_N M?<9OTK]]&1E!.'8 ZWUX\$[?'')G_.GO.+8K,*
[8HW'K#4WW[Y_IUX#_AWVJ M[XU"\><#&'RPTD^NYP]-Y_/0].^Y^PE_?O=5O._+QQ&*O\=F5?,\P;<^(]I M\'OW$YB;(?/3[_S2^]H*C#YWF&T\\G!@A -
F=)D5^3P$$6:8KFVTGZR!Z=XS MX\P;#GF 9&'_[IL% IJ:1S6#$3*EX^]KZM;OH]$/K'Z6W8O)R3 DJZ\75R# M!&3O:[/9W)FUJ(W%V_>KSEW[W.C>M>[:7=IES__XU8!?
NNVS[[>=NTZ[:[2N MSHWVO\Y^;UW]UC;.KK]]ZW2[G>NKU.4_S&# W?O0[9+N#R8/]DM<@L MV-.?.?]7N!!ZF4%O,_25&?_S5^2%GS,+%%]^-N0KC3?%W<7U[;<4I7X!2>1Z
M[E4T!-%E&:Z)2L5F_-.Y9T5#*6_?&5*2W;)^8IHIAVH?!^UNU,G09<_FL*_;?MWSK=N]O6'="%H*9O[:N[U"5?.%#;>?L6GO,U M^\/=[VU#)[BS.^/ZPJB?-)OQU6M-1>LA!HZ?
3TJ=V_;%Y4_CJOW]]KI[UFE? MG;5K1N?J;'?-M_Q_+YO/YE62$QB>'W#ERK #0TS,((1L]"\L@WN&CP,#%!> M/CSEPSJ28FCV'&;T/!],D'^\ ]ZUF..,3-L&>1S_'8Q,2_V]^+H?
N1T.X./> M?\O%[3BL'WXRH]!37Y!F%=_ HL.>9X,%%H)-%-KJA6*).STO#+TA"-W1DQ%X M#K<-_[[W?]]FX/\^?#8>F!]RRW0D4 QQ_6=#+,*H'^T>__=GN=^=T!OI3^HY
MIO4+%F"\(GH*Q6Z;[% \^/-'GK NR.\[\R(W],=GG@W2N(^O"5'8PDJ8]8F" M/B/?>\#G,/<9XOK@W==SYIB/IL]R9392S9>/H;U\U.SM'L[$C&+W5;P?2.-D
MK4CCJ'G4*#O,CW>SFG'UTZCO-^I'J5_?'Q\??S :S:.=P_UZHXP.\?N6;?LL M"&I@M5M.A/:O\1\^ LEN U P"A4RAXT&GLL,EPA0OQ+,)5->FO('A(M]#.!$ M'SLP1C[F8[
861XA*UA+]Z!BGM=CGDV'[GO,201661X?F??P)G1RC$!D M,VX.CRQ_(2FL;HS;7FAA'!SL[K^VA7'+K5]&:]?XP7P7Z:X=_)7$]%[SP,-Q M3..S"U92B!\;LY=N71QZD'C%
(S+B]O4EXB&J-#ZFP\N'!R$_@CX+?9Y+SU0>X.A\RU*+4 _X8K1E[;+10@,A"C\[F1E'/ MX=8G X%UX7M#(X05TX_X7[,?XJ4#'ABI@[$X9\'H,YN \@[
MH,W<,4(581@DYYL]AGI/6(S,1V"[GP7\";4APC:'A,X$#^;ALT<)_>_7#XP(5N1GSU=;5BBN\/KBOWAP8KS' MJ]!P;>Q]SEX,7]8_?S"L 0-IBM?U/_IDWB*^O?)T?[A5."7",$)
MVK@ZT08<*-2B8<21%\#XU_"/UHWI"O0B" O0=]AXW_L@/A>AL6:,'&8&K @S MI$\<6$O.O;'+0LP:YPY*"TV1+3-]!W-.8M8MN@TW17ON#DC$UG8G*&-_*RG# M-$"JACL)$ %
(KBW@1D133 +63!*H<)^'>YL_&!9&U?[Q[N:WTS]B80Y.^FD7=[?QXS32,*3986BO>!=G*C;!_T=WWL4WV=__M0 O>N/GMZONW=Y0,E&0#Z>E ZE/R8>"KY=RT?FOOG-
ZV6W_LM"[NVK>?#--Y M-,>!"KA_,EPP+E-+_&Q(L]!HC)X^@W)Q/+CL_^S1_\%]HO7KWO>_';2/[W[M. F9W_S(8, ?BE<[J[/+KG[:Q'(Q/_-)3AC@N)J!GU30]^3]V4\2P]PZ6$K
M([O!$@H?>V.%SU9H&=?&^#@S>F.)![C^E_$X8'0D@T#1TA2($AQX(,9D+& I M!J $[",-^!BFR?U6[!2$QH[VJ_A27A+ VM$A]:F.!/$/QOX(+-^:(>P<0!/N MXMX ,?(8#M3/NT
6C!8IZX\!K0%B7]J@A4N5YJBZ;N8%Q0M4%R*QRHL+%JNN MY*[&(?5&;Z>A+&G:BR]X*SZ5S1.2[KZVL+'B5;9Y,/3A=!_YX,KE)9.83)BUYT;-2G([>?;TJ5&&3J1AE8?/#
MDK)Y5VATL//8!X"PVD4<)<%P23S]#S/Z<$5'BCAIV!=KZ=N@UDK[;^&^W\3&Q\^>1_HBG>&>1?F@RD M!0XVBMPZ/-K/=4MY/^N1#LS 'ULH;7F>A1^B +A$L)+&;S3-
O#*@'Q#0Q38 MD;^/[W+&^'*J'\-C%A>V[*&3]\ #LOY'$@L_ P*<=[X'8F M]M%EE+XH@'STWOSPOO'A_>F'E(>7#F6L8WQ[(ZF,#BBQJD<5!EW=&;^W;]NG
M/XW6M_;5>=>X^[W3-?++A@S\X_O9[\8Y?&%/B^RW\?"N61&_^\7L'WMN]:9]U+CIG<.E/61L'SVG=35VT>#(^KTVA6ECH MV?
6WMK:JSI71.CN[OCUO79VUC1^=N]^QZ.E.EM+%Y^W'[UOI_CK"V.R0"IS M1>I/.O\#N"D(S%KTQ$I3"&AUU>MK^.+.U6_&S??;[G<$)\"_V^J<%^ZC1B@[
M;P,\OG6NVC/+B59#B&))AO;R),*N@N7UA8+EF8A[.ABOHLI-=*8HK)[SON;R MW[<'_Z^] M@'?!18'GV 8:3$[*7LN>NJ2K][_O=M-5\'.4\W,](0B6E+L-E2>!]EF I!9F
MEXZ/MSVF=NT"5,,H%&8D5A59/)2%)WWQJ(#2:Z+QY*, FFA*IFI9'@?,%P\3 MZ\#,5--A:GU@E YY"!:L5%6(/ZDTBLAFN0;::H@S-X-N!FUVOY_^$]0ZZG@P
M#VXNVZCA:V03H,*_ 1/B%,R<=..&DL"KR)*XN6U?=L"20=OSYO8:#<6[[]W$ ML-!7,PG^9;O5PWM0.> B/YH/-J)@[Z31_#.HP_=[>_7=?X_N04'XUO3?=4U= M;QY_CG-
CS^#UME\3+Z@XKV$VSXYV:O53QI&=V#ZC$YG48!3$\ NC4 M]WZ!@;INH-D$!.2:;UF/Q&<.R] %44(=P"]#_0':D8_6QA1PP"X2/UW' H_ M"T]C/ /"]T0/-
BP\UPXD='&_<2[$'%P+ > !>B9^@7/CE/V/8K5F_?WX,?) MFH]&[>#@I':X?V $,4U9@J8"I*F:,3)]X\%T(F;\;6\7[/LZ+D1<;;R7+]:I M4'_;!?=9WQD#*B+8D,6QN@0,)=?:K1FFH1J-
&'I'-/5(>6NXIF*BIUTAZY/ .P)\OW%@*DXBGCZ3B'<6*EXC)M$3&G1G@6T(C/N"0:XE< M;&24K@J1/UV(PQ4\Z/$1H]2<.6_4XFUF-9@VZ/(MMP98_E"
A]P'89_*Y"GXXO<<4+H/2JAYU"AZU"CNEZW #LRM3!I%\ZH2BAEM M%=C HWD#.XX:[P'0E.F(]S+'>_SPV7A_^@')J5D_J37VCN;9QDWGIBUU0;R' MJ70P%?OI1V<--#T]DC
;/[IF9)?443_%J])/UL*!&<9TKX6&;A0"6R"?Z)TU M*DVSD2H!#/^, *HJ8$#R%-=B FCNC4B$?G AZ174!$*CE/T^A5,I;3+F5?;$ M?(L'3/$#('ZG+\SZ7 +-,?L+$)-
=I22]>*G*E'[!4K.HSEWQ0LL$&CU3"U1& M[+,7.,',TT@W=4,L<6]YVH]TFQ\UG(28LQ8E-J2U#4HRB(GI%_E3J0^HL-H M +LHRL.+A"ZFRG6T&- Z@X?E"*+S"7(1C/:^'8-
;&'[/VMYC\6YZ9":2W,<8 M,0-9H$+)L >7R; G1G;5+2E]01L=#HE+Q=8E]KXQ_Q[$WZ2<2VT_8Z6JS>^^ MLA&YU".H[/,6/H2:&(1)QPV+)'7#
[[*P)S#M4GJ2&9%&3LBWR@1)6E M2IK@6TRBJ*%4I?*J":&?6U"-N[AE]Y$CWGV.3N PNT8KNX1>CWA V7@IH9XX7(.&A^:QY&BRE@@0"T;UBQE!HH"(#5RBHI)H=
M,P*'(X<>0ZZZ9J3&!BGA"$QBANU)OQ(/+'!IX#YK?WB)H\B'H! MMSFV0H(])\]/G/>+J^1=>/L+ @$9ORIYKNY3"(\3=T5HMU4J(/([_)QY1DW\
MG/78@@A,M0S_@XAZ!Q/Y^BV<88IMGV1 M+ G/[:3[)/93>'^,C^\-+_)%'V)X]E0H*]]67PQ&@^+Z3_@;??5IZZA-P$PM M ^^9\)F15 ")LGD"PC*]&DFSR:" 4/Z@2&C7:
(DRTZ14E!A. M2FK%LX*5/%D:"<@*1"R'F4!&7A12D!8C)8R8%IE:Z(N=2\B9=B#_C$=139QWL0M(H/4B\T"R^<]>"GJ!^XF M: 82 >,GPJ"B";;/Y YD6[I K%
(H4:\'\MD4IGU2YAO[#R042:GJ(,(;(UP2,>B0[! MUD8K+\&NC'?/-\KC@O5\>O%ACNJ?C)^]E:/XJC9XP4'!(P=V5@)%LK8(^'@6 M8W8@K R4)'@4$8N7F%%$&R$4%
[TQMD(3#^PQTZ>G65Z AC9[PF" 1%J?B7RH M/%)+$47V76F&-&9N2UN%H@Z9T\4#2MS'MH+420DD11B"Y(M$H;.0+1Q3_NG< M!&&3O_W,DM3^,7TK!FK2J$D!%6RP"$6?
N!C<(! V,8@*(!.W'S#NO*2.(7Q5 M#PB55R*9J5K"# 8"B"%"NA9O2M=1&ZO3%C"LSL,V_C#-SQ$. MTC?3_\7"V/P5O\9^2J*5@_&PYSE*1K8Z%Q>[*D9_G9J-=*!$.9T^2=N4TA83
M[!9J493N HA_:^[N'YZ!H!$0J&_3!<^!G(X GD$$*G.SS MX!=U"9PYAQJ<_)6-A'.@4E*HUJW4QLP/@@ M>OB!=DO^[$^F(N,E+,3C?_0_^20RX:_0C\)!/W(,51$'-X
S!"OQV0@H$C2/ MT-'2#,> AX\6%[6" ?]#AYL.*2U0:FN#TTV@G(*,';1V5&O-280E'/TZ_X8%
M"3TP!VI7V[QXU0!@R]X%+88W*IIZ,S"ZZ63&G&1E1%"BD0^OTLHV#ZLZNK^[:5W>I.H W@-HKR5]C'3M3 MB5,_4;QW!?L[1ZM]/D' MR^X<-%N#WH#UFFXP[\.#CY\?
I<#EGGP M]C8=D\Y:W[%P"BN&KJ[OJ!B]=7N.5=07U[<_X./.Y?7U'_AW7);=S4)KWIW. M0T SYGD1C>2+O/JS\7=P0*C;2/Q=W+;_WW= RN5/XWNW?6Y@*?N:(JBQE0SV
MK77[1_N.IA1WKLZ_=^^ T\Y;=ZWUQ%%S*YDHJ94TNM^_ <9^KB=V]K>2@VX[MW3^,B];9W?7MFDJVXZWD&M WZ%X \YRUV^=KBIKF=O*,ZFDC.NH EJXO+MJW
MU!SGMG/6+AVN-IF/I(5 B"%4?;_%E@;?J!72]=D?9#N<=_ZWMW\@IDLDN74!4]^Q[MXMLAWB#"RY_=CM=1.P%\./56:=UB2&9\|Z= MNN:VW?U^>4>77-^T11>L=
<7SX5:RZ.GW;N>JW5U3I.P_'RGE8+[U1,OA=CI3 M[7^US[Y3GS[LR].^ZK9$[[UU1-'1WE9RSGF[>W;;N5&VX5GKIG,'6HFLC?5$ MU/'S[8M-
YJ73]E7[HD,FP_6/J_9M]_?.#6(L:;:YGN@Z>7XP=I/YJMN^O*10 MN4#/S]^O+_;ZQJT.-E.]736OKUK=:[Z+X4AC:P5%>:X9?4/ Y,\"X(1NS(MVVV=K;$Q?K*M=M]=^Q9%(K:!-"
[:P&+PQUWK7^A6=3OGRH/"$RQ#LJ X!_X MU#]:M]AU>5VQ>[*5_'ESV2*CY!P;0G=.OZ^O\5C?>[X$W63^NVS_!OP&7'BW MMKJMOK>=]F+
[7Z"\UE6@O00IF\PO/[#IOO'S^CLX6E<8!#PW6N6E[U>M[X E- AOKPU"$L5MVU>89P'&Q&GG"CZ3\WBH$(6JZ?0'4]4,/,[F5,F(W>=%ZPXSG/'2G*;R>NN&4*7K!XSF",-[
MXXY]0#%4,>GU=PT- M23GHJLQ?L7 0+575A61/5P8@58-B(*!F3!B2FWBU_N MSL#UYI+4A>=KS;ZPLAR1+S&"#?JH>0QVV_PDEO@#*>>!$?AMI", '!7QRP)U
MPHWHEBF@KBHQL39FY 4!DW7'5'DCJDCCZM4,D@J' ,B6(F+@-+Q5EC0B6F77 M&+NF(U*6=J7VLVO<,#^@2<=RUQ.78.L)@RK?J:N OOK)U0ZQ>XH@0'S2,&!4
M;D8E7C59X(_]R$2)J\]P[[*1%_4S)1!ZM53UJJIDRPQ9(&Z9 ;S"3967EDG& MV)X5466\Y'^$+LDJ2S:,]4V;X1@T 4K9(8$+2#PT^Q4([H^LY M*'3%U#-@&5>V^,@\D?
ZD=ASRU;X0K#E2"&=]F*,1UEVCJ)6U@''AT-&^+!_R M?/7=\?YQ0WXI2E!E<;1L$1!O%"L;D4-%G;!:@)@&5U.,]6B.:XGLA(4X\#O6 M!\!_F1MX?E*=#8(6]'9-U;_U(\(R")G?
Y6.0N),7),*A 7V!&C[KAHP5D_^JP_,849[%:10C4"!$?7 M47<&T?4I&/ 1(8+FI<.K023*1@UP]\A#D- U6G/='A;#8\EZ>CGE9;(K+T00 MQ0U(=.Y"V9Q+Z;6)OB>/K!>
4(J'M\B^M]0T2&$_+EF/:W/U)^*EX[0Y$%?, MZG9 '^UV:G-1L 2<0<.TSKMIR^7U(9S%[)+K]5YW[DMU[GO3FKT7%NT5 M;$K_^&I3V?37OO8LK()BH.>5PFBEKNLPTNM,M?
M6W7."(J6L#:^2K0! GCR: MOKWC>-XO._B*U+N>"D*N7X41MB1Y(&HB6RD[HP(93) MX/ A68MHBVJ/PJ[UOJT:$/3DK&N#NL^P>]""H)A=U MCP2P:ZYY E#I $4E!S!JX(
P1^O(1<#6LSNQQ1X $6Y5$_3ZG/G!CM5KV)/ON M$X#Q4?0!/:<'TQ&4XQE#!KXX7O[H^;_$U0(%X@;QF9 %\,>7N]0!B?QUZK4& M[&B$C^@&":X? L\.D"8L>)$8)1R(5LN>
[.ACA;+_F8==+QS.^M3:S6(^]=1(M43"V_M":<5&O- \G"DN.32@OR(XF$#9WSK>^]\2QF67V)UK+P\37Z&)P-\KY M'BR2[)?8I23OV6+?V6^QXT?
)BX6)O'$AD!F37R%RC3[)1+@Q'?@U7(PVB>_ MER0Z\0,X-'QRQ0"\?^=L!#;Q:^*[01Z *'20ZG0/DL@QB3)\)OM1H73F&,D$ MZ6X4"V4ATLBM
:?;M5C2VD,02>QD#)D*])C)_J!PFV2*6II M;J'[,!0V4O$$):N%LR;$;C\C]]0*8J$D93E'V2JQB8^KI82XICZ4P"4!";S@ M#84,%;Z0?#Q\+U@4&/:4628*S6*\R=$NB9^)SZ WC
DR042Z1;BS Q&"C%S9 M*C:DE4MACS**^L.(%F'V&+0 M>GA*"NA[#FAJN/[3*S>5>6Y/ ZU1P0*&I_7]'X%2;L"[9A#/OPXM>#D*+P
M/"3T1I]3]ZX0BB>'1R>?)\K[IRZM<#U&%FPO[M>A3/AW7_M.A)0>MT-^\#!> M@Q8.4NQ0M&R+VZE-=/Y"_D-S1EPG[%YI\4GVHFZNC]BE'OZK&N8)B<8MD(4> MO(N$N1 -
])Q$KF5!F)Q,:0=3^KE41;%EIU@ZBQH" LESL[DCP_2RLQV2I6R] MF6[K[WO1O>A?24-%I-VBC%PD2K"<@>S3DY(335F18D6*&5(D0T'X@[+MH ./ ME:>E\G! =VJ3#L85,57$-
%6N32$MW6,(S2?MIHJ^*OJ:2E_@:-&1.]"*D\1" MP7\6;J7L AAP MOAAY@$,[Y %WR2K3?H#Z&6S!^; KBJ2JTAN4JXI*E**TPEI%D N*Z*LB#*'*,T'H$IEP\G\
MBXQ9IPXY*"6J)PY0U9$2$%XDTD#$A79D4=S3Q;3+A*#%(9PT#Y.C+W%85<5/ M-I,T7Y2@+AU3==:<'/Z*DY-Q11,;21.OYWN*U'#LM/\D19>TK MFS"]V]VM2+A.),F2 MB>.
R8S@M^A!Y]RS#*J*T-Y2BOJ)FO*C&SHJN*KJ;GL8G(;2V.G(FJ*A\L>1!:Z/Z)0O" 63X+ M@U3Z",@S%N+P55&<7I.G#RRNP>=N'YLO((E&(R^N/,[<%Q>ARXHNGRHCU%>4 M1J
]"!Z#JYI\3$7J%:E/)_6$Q&WV5X2$:HUQMKA, A[+E/:DXEW6"%:455'6 M=,H2I0XATP_T28R)TWYYXB!JP^ 92(/I M.*PBH*FW0=L)/"11M0-+@#PP:P2'HX^BGL,MV5EE+&O@J
,5 MIN+9L.^ &8Q*N]5)KU;BF%,.)X)XHF0.57BO%TS5\,[/,()RHHZY)R^K!9)N7&J#GG7:%F61T78SK@V;7=:Q7!/% K#1LGO,+$<&DO?D8ADVXH' MSAX#K65A$/4"L
IQ5S;U]L*5/ (8/'HB=>8*S5^B,X@'HE3FTX-ZCT8$JRE+ MH_.UOH.B599]8^^S5"FUV0]ENP=Z&!5J/V*+OJ&)9<*/ T:L0Z)<9J_"REV@ M'PV1M4QO$N6M/?*
8:D[ABKQ$2+?/V[Q-]EW+--G9??5:3G#0DMNW?3LSDU% M\K!(?,JF2'4AA)(62&_:X>EE#9Z2_DY:YZ$9/8@V0:06-&PJF'VM=63:V!T7
M,!ZIU\9>8Q^CTZ[J(X+M/:@S7=RQ[XI%H!4LV;RQXUJ[!MUUZ;GW.W?,'^)W M*'%!YN.39@B138=8JY,&%1X]HB^(I^% 60X\ "%5&2[!EZAKU/KG $IA02<--
,L.$M_[!2;*#]/W3:U77 *<1_D+-:")?&L =BZ8A$ U M!*54:1KV!!"M7*6A:?3H\60/TG&+&PCKCE/[:U>Z)70ZK&X!)QNNDHV'L<]= M-!Q2F>[(YUA$Y&D5NF5'SAB-Q$FBJ
M9,G+$[=V2YA3EWR3))=(2$M<)Q.;I]%5#?.J9(7DW_9VP;.H8_LU\:R20[/= M_BT-1(9>O>\A=$8#T_'N?7,XRU_>>""(!J /C.IM)QGP@O7\"$]F#W4.%)SG MRE9P^$VW?
6;8##Q1ZNPNRHYD]-K3NLM2SVE,ONKN[!OO+[C#C"MOUV@VFSN- MH\/#_9,/,FX-*RH[Y)]$/BWVLIUD9H5J+7 U:\6G6^;^]2BRQ2*9EN =8L$
ME0;7WFY];W]/$";1&YIZ"64F8O&'^<#.,427:6] L3D:7^"+)K_:/4ITZC>4 M'-;@S170XX7G"8OFW(_NC99V0N65/23P6ZMUDX8*040VQL,4+DH>18O/LKQ(M!*?!?7
M/G)8V;6(L+XFJ08/SO$L9Z0M MM@)JR7:S\,/VIM)#C:\A]L,0' HG\8!::FK4%;:_P".9^@%I[*:N)02@]>?B M]_1<5,-U5,__-%U2^(G-+8J-"N]JT%V1RXSZD;JE)S)P1$?
4*5'&]Q@"8C[\ M^,OU'NEX)Y'2XIH/->/BXDK11C?JR5OQ^7E/EILN>GSQ8CZ4F]I$_YY)'I5] M?0WRH4O.>+Z19D>@L(P)G$-]P!3&.7-,"F5J7GS9X98$?B>B
MP;G>93Z4YF'[=.PM#LK%*05*6WPH.PMU]K-II%Z,)& M]J[!GIAO\8 E7; G EPU[?B $)KBM:WE$+G?!84]R'J5D)@:4R824H@;0HD_MI1.V

XXQW>21O[AD%$N062[25(E2DV$/#)"+S+")^'G AY$3FB[SH@#02,=@ M>DQ]F\+IW?;9[, ;"OTX^H1BAM/4E;*#)@% 87A2K#![),W(T;5$N/$?
220S'2WX9P1"H'&8<=M[+'S$*=A*V,?= M1N0Z0#?B-%%;3+?DK\X,*TTAO+C+3Z++'?XX.69QT-_QO4?U2_8G3'PW9JE?C HIJ7*<7O&T]%\34C/U]7G:8:;<_'1^>NDQI<[=
MTLR4/8\K/LL3,<='JLP4;L"4('&!+B_/65Y![=FWUNT?[3NC=75N=*[.OW?O M;G\:YZV[5HG+S\ZD0HLGBX)#8NKC0NEO.3TWSW<4B7FBJQ%<(-L'J>:0H6@,
MN8/&"];\^@]L'-34L[%"V 3Q7Y/-$C"*%5=&I\IL?8:#A4GXW..<=A?%,S8V MQ1HO%0&.]R">IHWPD"_>-5J.@\| X,&=*N)'Y5%JRCGNC0J783,B<*:5<9.(MR[G99UC>C$^>L?
4IZX37CB@Q%^-[6LEVX(&&E#N4K:"F BO>)+*LCL0HR$>@ MK!,/4F_5IW+CFVG@A:E5E^/,:)(R)HT(9:(0''NS8/VA&![]2!$HRM7$AL8Q MB'>-'\R0H^E%E%4!DA3*BW
K]0N14WI- SF/B9$.\7A>?48JCJRV66#Y MO)>,K%8=&&8W6S!$NP%M3KGLZJ!/UU;]06:-SI:3Z9-U).2/]>_J($NG9MG; M5<2>QT8I8A0%>N"TU>UTC>L+X^:VW6U?
W;7N.M=7)58"UX(&] H?D<]'*:&V ML "$Y +"RC@[-?%SU@5"YN0/@O+CW%+JIO X\) :L9>_36T@N,TQ-I9*_I:6 M2"N>((QWY"WS/?
|PD='QK+HN_=T@$L1AHA@JA083/CN=8)672Z5X]3W/+ O] MFC@A$_UU8-)I*ZI- %0M".]4"YJ56HD @*7 6K)/H\1,P'"?.[(6)+,:F4R7 M!'*R>0&[QG?7P7H4F?J%1(8"@YX0Z'TP*
(S$J.M&CH26.$NJIS [(09D&N39 MKQ]9]ILHR'X#"%3?D-(1>:8O@%\/PS$THH@N4#ZJ^ .$0X./(>+X[N8N$EN MQ@U'BO/D=H%<8U@E!#=I_L?KEODY-H,[
HHWB.R..1/S"EY8D%TR#[1F V+> MI954V.HBK08F!?%0S"UH13&[)IQMT9^3^3OBKSZ_CWR*'XG6-@BK^@Y0YTXS M3N(7Y83!R.%AIH&E&Q%A(^\I!/E6Q5\W-[77WIGUV]
[UK=+]_^]:Z_5EB(_$+_WHW(<)Q#68:^@;.:*A<$!% MNG+_X6!R[4]_4C_#XPSGE@190R1[=1)YB RXPDM<^S5"?*VZ03 MY77W0^,MA@_ 2UG)F8UX3IB50FV11+@T%^R
MF;R6%237#W@VQ!YGBX\5,+8RYCA2H]%*VBAUM#9*QOMLVZ4/L:TIQX<+1G.] M!]$,%:R_2,1J!">+H<]&CWH. 3D[-, MA(? ANC #.XC+B*?PT73TO'NL9.F M$!LBXF?S@'1?
L&MTPI=U-3+>:XY'3B,E:=4'8HRU,)N2(0!@SMZ['L#3$DP, MLD/((1I^:%H#M2WFC1S1J9AA4W4A&.5NN./(P6'4YM&[=SD!+]ZE+G9LZJD8 MD'=H$Q]S$^VV)PH[:;?
@$#W!SC)8A_/M7$3&CLT0N>''P1B9%L]WN'8OPM08 M@'F'G1==;&(+2_:H!U+]P!@#?&6OR93@Q7 A[OF)(DA 27\[W#. 6AU::3)? M7D@!B84:D0_V%A "4\PZHX08$X.M-%>-
,/F(/7-!CN*AT#VU(]C1JXU4#I/?_RNECE$T=% 9&_B MT^^1P+217TA;%%9-GLS_(V,'\50O?;;.")R(H6FQB+K32N[ERBEGW#=LA)@* MR@N*= !Z>'6(,41#$@PI4!-#_P
B;&_);+IH1!1%X6!?>ZQX2!GBA45M8-,T MPBFE3$D;BGDI""FA*,>IPF^2-_!P@:):K8XTDJP!=W%^F^F[<@Y#MJ,;K(NY M 9*\/IU!9R!L=FJ;O@W[Y\2+382
*Z@4,=S[WF(L@56EMM7)>:7I W+!^H] M_8"URTQG'#]$Q.C3HXO%:>2_@6>2XTBT M$$#R*Y$/RY/# T"LF-3L_0&GV(D7<3PJ%;W$@.9]-I!0P]&A9+]26%,(F[YZ
MS7LIC#WWPZX,OF52X96;%6&0! MHSERQ#;2AS:TAPZD1NA68(8FAN6F&")S8POU9@^S/8G,;; 9AG2,N&O\3K/A M!<77D@6:MC=2819<86^L25*O+U0]F,^Z#3 *QB 83!#'I
]C*TG\%?F4!*-+ M85RM;("1_J66+%A-LY='6>'$B')LJ.D#YQ!KXU)!UXH>T;H'HY&]>)-@<5(T M?AXU9EB.7FT*>R)'1H#OL@,&!AA6MGI2KKY$P2H'X@AAAYYB+ I1X'(S>1^C
MQP.(R=E$OQ0T>,#Q4)6F]?Q;)<'@D2B&ZM*+!F=SC(=G9L_AP4 ZI?%==&SL MH!P?,C.(?*;LI?1#:I-V!G,QMA;H$DSG;+E_1S:NP-NA8/:FN5;<-HQCCS\2@\T3#(Y8X;0
M4@K(JO4LST$+'^SW4-1GQFA%>PZ^IB9*:(5)-63':H$8EYL4D ?5&%D4AG!W MQ(T83J [A1DOKE"=-UV&"1Q +D(*B5@$L)(EZ)K:A"2*^B+R\9VU A;$,X#$
M0(EEGK).J,,Z*O9AC_)&A%8GYPK^:G5J2H>+\R6/D!"Y:H@WGD@#/G4IX8,% M\X!AHA[WR(SW8V$ XC@C[Q7@8RX)![X7W0_P+5D000D'4%5Y"Q#%\G;I](M8Q
M^2GQP10=XY.@!:5=J">'NFX"5\[QQDG0*/XA0'N,9DG; M2N&$QP/- '-AKK54PP^F)#L59X2U>_W:-$,J2RX2!;'%2_->3!^D\#VXB /> MI\X- T"$)K\%DS_;NO
<6PF4U$!QJD\AT:*'5C959FW1T&9;5S]NRQ,@8Z5Q(27 ?M>^WFM<'*YBG0P0N3F2=Y[<>RD%.9#;O& M=7-TEEFXF;.Q(5:T:F[.>NT7N1-)&V!\VE8 M(SW10T*$/[45-
]6ECYAF>6]2\W1;1I%D*['D: GT.Z;2!^-A#\S..,Q_<;'[M-H%X?N'X?E4X7A6.SVU73/:]*KLUD6F3,;>T!B&9LC),?1I77)YFI@T. M*ZZ;@,6$D73$XI*R6DI;QGGF]!!1C(SU:,DY4[;L#
)L(PNKY9.G&;OM4 M]JVXMD*O)X[Z5)MBX AJ(]S4*GA$209DY[#;BL M46L>[==.]O>3,M"(ZMIU$9/;O^"#:J9&!^&9JGC9,7X([R1&[,_;XR"W(#5' MI"7K+FKYI
2_ST1/2BQ73F*>DW+H;_7=QC&5+:?VLFNT37U_2@KA 4Y^^7-C M]^ P*7\VWNM533:BG& OI 07SA?]%U,8:/PG!=AB.222Y66D[.%RN1+1?79 M$(.E0J)0B1S5!%.(SJ6)R1RA
YO?_P0:8+0[W#7>([W^Q 0=?.\'C)(R)C-, M^A[&,)673:?5(LA)>U//WE21,Q'AXL$O%"7R=;VO<3I?:<7+M3;K.E-SYT9# M!MY%4#2>=K*D+LY#G2RJFS;#6(4V=-
K5"2^=IBF37FLB)AW'?3&*X3C,O8\/ M'AF6Y;&B"FH04UBGT8\-A,.:)*M MF%5NN"C.\7QDN.^EEHYHDGC9O 016(FEE#%QJ8VYUQD5#EHV>!Q&>8)
M^Y1BY2N8C?'N)!7MTRLSS,MFJ$MWF[B%4Y$E^HU/GW-GI:M;,]/%#3%>_+_R M!ZD;&,H]S.!!^:[E%:&OS-U(9E7> M>U+;@8'@5LQ0,<,Z,,,/1A96#YM@J(P%\H_UC
U+#'))VTR8GSU)\&B=59*^ M(NYU(6XTBC2'+3%RR&/3_3/V9%%MLS!:0E]T" +2!W*0'50\53I&P7/P,#B= M^I*CI[.&:=.!*9[T2B\$V,1/2M \O02MXI2*4]Z<4SI].O#QJ:(_Y?
B[6EX< MI1Z0&RT]X73I@^V+;),X4]RT*,Y/?GODBYP[V!3#K.51Y)AQ>29[&L%_DH2Q M^$<\[8!-4X*S2D6KB=B#Z>".E&-?TTPZ*U7ZFBA?$O*H:758\6?'D
MV_LI6AV>9$I!N:+1E>HQU(]"]%'T"@V5R1U7C])AL<&1A07Z:;^5]B8,GN/>F&&(Y=]2(U";;/Q(4#UHVF%I#)YFTFJ$M;>N:J+B MG:WC'=6A3JLYQ78LV*V*/"Q$:(Q<[USU!
[DFB::(Y=_6CSX;6:T5]I1U]BID2 MP Q\V,/&)EK*JC98862.J=Z",H!-C+T%D4^YI_!.<&C\BG$JQED+QL'6Y@Y5 MDRN0;EBF+VML@- M@S<(PZUOH^*7BES7@%\T04ZT=J5U3
M[$!(AOB/9**D?>.$2L*T87>L3G6P&PKH(BQR4OTQ\<>$6Y"9T&_RC,"C->2F M'VBJ"K.TTPG:%0]5/+0&/-3E: E-\ .=>%)_O/]@#-B+[!TQX"K5AIH:*B8- MWIB: D -
X9+KU)!CT9957&][<@#2(XL3_*J/+[O=G>-OFS82M6PU)?!,1^5 M)Y0H2=54.YYZP1],:RQK:,6@:YK@3*$&JJR4;:+XY#RQ)$E)=B+FJ?[2%>]6 MO/OFO'N=Q,:D/T69!:)[G
CDZ7U?D_Z60J?E1>92!ZO2Z#1$"0VV^J9.)=1\ M$I@(N(G..&1VD'X"&_?'DR>X569!Q3?KPS=@-V+M6:NCK"#5;9WLFNU$Q?99$>?
NAD,A6.U;U9Z(9%)!R"]2&8S3V]@Z3XM3$HL-^ MQ,X0I)UI7(;87BH>]>#Y\ #L)J[UCR)C30VF5VVU.H%OX@$2AL!ESXV1)_(9 MM'$1IC0R1NG#9UV9XQBW2FFVC7
MM3;=Z7+F0%8-Z=ZL(=V&RMUY)!-(']?B(QP[\ 2N&_&)3KF M 7>_65\0SV*!'OKF2"/_F#NT,/&UU<_C?I^ [N3J(-J,&/9:."Y3,TRYH'Q M_OCX^(/1:![M'.[7&T#F<-TCZ]&X$3 #?
=F%X O_^OCXN-L7&*3.ZKL@/;#5 MRZZN,]3@*M')AN(FW&'YTP;@63('OF?@5;X/[&>W%'&)+Q-2Z9!/I&U M'D_7A-4XX]>FF@T?OG=8CI0FVLN6#=^[^[UM7%]9>J7SW
FB&C9)@9LX8&] ET@ M01>D04=V3]Z80FJ;+H8Y@9M_*O1ZGTO(TP(JSR.#5=_<>,G-!T=Y=V\Q&&6TZCEPS(U1O?MZ
M>+17.SDN)FB1VB6;77PBWZFQ!SQ0;Q;VO<0^H+;HFB8[/F*82%J&JLOHG(WK MR"O:/ZS7FD>-HA>.?/; 19M)^6Z0"1/>2SRKO*W/:""/L**MBD77F$55U]SI M_"8#&=1
MJ.:]E8HJ2A[C2F[J%OS!'V39Q)KE+@[J S1YC2'KKBBXHK-YHI9 MW<5G0)RK2B-M:!%N%FV;[;LLGE9-/T M"N\5^ZP]^X#W?'QX^&+N.8^YYS/R386RBO+7G?+K]=KAX0L%?
[VC 1*24*[E+)E-.JE9QNE7$?O=33F1 MD;W)< 'MM&GHS" M(EAJ?DMZ>DL^0::&E%;"JQ)>2GCIPWZV7'(A7R5,E 6,9""Q1\7UHOI<+_.3 MI]IYZ2DTP:[A %ZNQ:-$8)<$0/"
,Q%$C.)5*#!L7@'BJY4(V)E.%2&2,5 M/Z?Y^9NH[492TS7*EK,V%0GFJUI*I$;CW\X=^SUCWG<>S7Q9O_*C%8#T H59
M,JJ#IS._<=2,2JI30U&Q&&V&Y7+CF"05SP$A/N]%HO@H%KY8F<-=5XYH'^%\ MJ?K>84X*^8S\[A6 HUP)WT>"CJN$[S7FRH*$[]M.]P_CHG5V=WW;+?%P3! 6 MG6*
["&TFSWG .AEJ[VC8#.O-4%+@_)5=XU285FAU#\7)7&KH6%!31.+<$O*?@25)FK78TMRZFI98(&LQ11'YF"\S+MG M9-:*XCH<)]DO,':3$I^\9.BD>X27/_E,-:\0#2O$"#1S-&
(FY6.;H7#@73M' MP,NBOSQMDH;SM[A[I_J^?H3?!ZACE!V.#VN!%AL'G R$BWBM9ZD^Z+=)'?)U M7(>+U,5(V5VCE=@D14_$ MN^5H6KC]E^L]$DM'@ 8!\N!'6IJB8*!ICA+\
(B>1T[@Y1>M:TV. M>&FEL!C,' !GQ%UG<.\)]W()AAE5D4]U$:,,0@5*;&TB)B% M'MCZIG$ZU6 M)"3 VO0L3D0M%"$U1!/781$^<[4YTS3:4[1- PTBFD21SIB\&/$C9UT#S@6F
M"848"0KTZGRX\=]"M8GUP8JBX4CTOL#H=S'=4#6[K7PH;*\[22G8[C#N(4#/ M0]@E4N^>N>JQN51K>R1'L;^BZ%8E;P!]# BB$FXW5+< &$+NH%BE1:<:[#@F M 'Z
XKV8S-54(=6:JZQ5WW$.I;+ER'3$YI.V4$Q4VJSTIAC\#;_ZX4XT2L^* M3W#@C(G&.9F!HOWB/A.V4]AG,+A!'V1OD9B,5T:9>81:8IVLDI]TM$,(-^/
M>T+'U.-11Z8^#V7C%\$^VBRFS.S$"6;E+KY>+)[,I@"C+#P8J(X7@E?C79&C M!,8+'IZ@I>'P7Z#2!YYGQ\:,;" UQ$X3/18;SL*R==!Y54N I?<<-@1;2K06 M1=_ YEB5'SG"4Z
NHMC!(.9<&[3C&_^EV%^1X"[F@G44M\;][G2BLUO-&*B MP;*CN"DM>!SPG\4U.M:D:6F?&Q'I W6N3P,9!C^-]_1BXSFGNJ&0WRQSFS M1.>;9EWK?
#,P,;SN6;_$B;5T/4$:_17)'HSQ?*&_U6N-^D%M;V^/GO>W^MX) M_E%#!AN)PD)GC-TUXA!$_(9D1I$9#(P^.$CR\#OA4NJ$(3PUU6^AYC\CU-\9Z3YB&^9=>XB'R,,-2D]%,XEBY%
M;OR NS87/5!0[]00?9,HDI#RT6&ER)02J#ZFI%M0_U!A&C5]Q0W&2N?:+L# M,S,$'7H?8JH4PM?A0)"]E!7.4 +9"4R$QDP M$ 6]0"\><%T8-_)F3[*&75#3HS1"T-
:9,OK[]=6T=>H]H_@B#[9YG2BG3$2/!P/*.6>B&(=BF2.6B4&3ES-<,VJ^.4U:6BL, *YEKOS[:?S6.>^)'DEEMIVQ9C<>$MZAZK68\1:#< M>]\9!C>!5@8?8#>F)DRC0T?
(^,T&F,!V\)"D"^QBQ<\><1M M9ZQ\N)!C9[!0UAL]YD[CF5A,/\+NN)0=ZS*&+(ZQ 7>"6\O*HF+*< %8PH'O M1?<#D7M'\A"M/FFL^;+E1$@3P6T&AJ1^.
(04$RLXS>@+TH%UG:9M[D3)2$CT MN5'2RO=IP?5')@K+8BF!KK3L.#R*NYK)T#YV^P;=AEU;@P@G52(CX&&53'M6 MJY)NKYX(4: 6:>396NI&.?
@F'N&9*"G/U_]P!4VGYU"1UJH)5GB,=2CXP[5" MUP";;V(K19:>1!5WW92YH!X9[9[XF%Q%(;W(E?22=->EGD&1*S<-4.6^%0W1 M9[&8-DC1O-P,
MPSB6[ZQ&CY9F].A;']B=ZH/UDK/M$MN-)-P/F"EB2!1C86+3VFQ(?@9&3>U(2-*Y?K]1!P.H82($L#.8*7B4=0D0]%*03@Y:CXV'$
M5^XA9KI=HX6'65@_HP97:6:T&9L[B!F"ME1R%,G(1(BZFL'E)RY*%&?\E, MJX0,DPDJ"<(0KNBO6,+83Z6_&!UT7Y(Q$N16ZX?S@#WF#I 216:;T;E3#>^1 M>>]5*_*8E^3?
T<@V0VEV1R.XS$YRD7C@1Z,PS6A:ML5,S.LTF#KH*KLL]AEE M5(ES5"7IEVHI5*DZ0"D MP?OSC[?/CJ(7(P MF4'*2=L<@F %(3;&0QXS#,'R)244PP3W3R<')L6GF3C?D?
&;7>/.TS6%+JAS M-8(,*&0A.=).E97#BNGRKCJO&H)7J([ ]5"#B*CQD"+!"$^\Y2&1 M0& X0&64S+EQ[^5QGTB4TH(JN\9%,NY0!1JAF#KW4,*E:OI4H]A(?S955/8&
HO2I)"XC>K1*@A4L1=$R M)$1,?S #%N0B0YDOL%J*$R7B0..SFBC %99[1ID(J;9K=/-N5-:">)_,DTZ] M1DL&D3\;($OP.(S2?_LBA9?.?T4\AF)5?>Y3(G%(CQ8!7!G/?31D2]Q
MK:F MS=MZ1FR)P73 3D=1N'N+S%8R2T%(>8%P2+5 HA+$&(Z3:?C*R)1\SK2YAM)?D' 4 MW.FHP3BE?Q\'$!P#0QA#@>A8,_L)]D2N$F048NQ^+#!N!&/D*O#%^M[[2
M<5:'U?+)"Q^0" 7:'$X0"KE\2IZY'<\ QTLC&M\3FRFZ1!Z -*07 K#[_#Y2 M9*LE,TH2H0BD8"!;T9"A@K%2_F4YB'*X^!#+%S)2S3(CBJZ3?ZMC6D?>)Y$2
M99#A'A"#JO2P6B9_$/,65;5!@) 4=W)7C;&5AQ=$2^IA8!B:-3TK!"MME2RM MJ6F6B$&J:5##,%.JR!.I^3'<]3GLM=B0]1G8O XNBXP$9?TF0]!J@I$26B5V M49N1R?
_I<\"T@9K6"(EKDI?&[Z6#")/6;^I4/!&,'LXDI4?INTT9Q"@MW'A. M?/E42^+Y9$"FZ6#F$WF@122D/V+EWO%ZTG''-C+B5 -0X@VYE: FH.$XCB2)
MOA/A$$GQ$LS_HXB#-4ZFQZ(@%@<%RDR*#11B:)LINTRYW^(O*6368A" M$%0^4_5@ 5GK6"\[-6(H0S)].;4[%LV/6# @"X^$B-S%,B;Q8O5LD#(][$)) M&DD>
[Q@]G,XQ"*$(M@)KCW)+87)]PY*;&FR+" "D>P10:WX!--I=/5F"O3 MDL]PT/L0Y[44\1J2S_IHTOD:'=9Z/<":HLXTN$GIXADCI>."=25W "Z'&<;:
M/$[9D$D#N7C_]E[UR:YC2M;]*]4G(A[0HH VY)F/):OYGZ@2CA"@%-UUW#R DN]PTPKO8?#F1.UUR-Z%^2_LJ MD:<>,P,2;W)7JB=
[RFK1"WU@0@GO#QX.=8+&]:1S$A=$I81?1ET2W1[L!+E) M4V!C1N].L?>>$+GHK3 BNP)DSO7 MHF@$7*_HN(Z9_W;<_+6>OEY/_^.UGGZMI__4ABUQC4PW#
[ER%L\O6>@6(\$H M5Y7@\@+AR_%-VG6#O"*N J>"Z RX#5]N_'0(0DG,K^=?@4VAQN44EU8T #B: M"9VFZVQ1]#&.1TZ1(F;MR\<4G:
(G7%R$IMR2^14'<-5WE>50@X,W8@4.AY?< ME*G7=;(;O]6_?44)[[C'94_VG=!\9BJIBP/?(>H8^8)R$N3XT!GP*UI[!6T. M8AYUN1)8D%OBT^_)$B"
%XA6ROO[>$DL6]4]MN0P+6K62TNQ>3Y&:WODTFST M=88PSA])ZFOY\V2FEX@'4X+<5W#KP=!QDD: L7\DH*3ADE-.P_5JO(/8PB^7 MPO+V!&5-
T<"V;*7Q=A\JJHE'A+&]"R%\MHZ&WTW6]J\)):4Z< M$KR3*V4(8X2@8(C+RP %N$BAA<00AKE[S(XC"3)55AP,EU^M2!Z(*1#)7\Z/ ME)3!J4^PH]L%1",UMSB.4?%Q*9R;&
>CFGB7*/^WX;S\^GD@>W]#1]I21S$^ M=HT4O'DI"U7KYBGG6I2\T(DU8]G+B&-DD>OAX-/:")4TPB6_LZ'3M WC(\%# MOR/&DA+?
_ML]X"^7GE/Y]A=40'X!:2L(EB\5Z\H&]>2"X7?+U/J" M]9ED:X%"=5/CG^AI(K49%W BC1P-0\]9"^WG%WO+K__!9&A_EB0,"U$H6]/T
M4\OM)U1^BL\4S2OJ'[@ZQ;'1JKJZFO)H>]O'["\4@YCE&:2M0/8Z_HB1O$ M$($R-U@820SLJ!P0NWT@<:* MKA"=5LKI$0G R;H?
J=QFJ85J1;2(M($)!=@9BR"THW7]E&OZ/=*8U)7+N12YXMPA0& '9($+E.H@PGF&%7HD1A=#%I1JWR MN? $TJ*K#F],CZ%F3F'0XLL""3A:_DE;/60?R,1Z]R]^BOLJAK
YTQ4!'VH@ MSHD$6,%J/ 2GM)_V=2Y?=TXMK4N1RC\CR1Q7;1S9C"XVA[,$HNRX=JHYSL)5 M@6Y#9^Y08=Y+X1T<3N]#1*(V%GX^$FW"@Z5.OF*.#$Q&D)U?TJ*#Z:07=W4;
MMA0Z/](= M-\3/%T]M2+2X M#E6-XY5[,2=CD?Q[5HFLK?$]6% ME?IQU&>6&"_@FQ"^HNQIG??G'BW*8'\(7DV@NJ7*H@;!MG.]8^BE+#+TR8>Z
M:Y"D%5TY9*V<3K(*F"6NS*>*O]:PZ'%/T=2!LX["5)AM5]ZTYM#$E3>D;$74 M7)/5SY/I2&Y*U*P.56X61!6\6*$$+1R2"4R5MS&&P71NIE;0)*G*0?NH:%R% M9M
ZY@#"IBX9D0D*(5+U7'_R0,_L!G3;?5^J]0N7JBNI5(.U$,=?E0Y JF\H MJ@[<6N@JA-Y $Q;46!&8G\BDE[PDIRQ-^5JP 38GY1IZKS@P.IR;K*VG^@+ MQ'OQV2>??
18/U(9HMI[1([@+1OU;*@6]7(#DEB\;A:OONF-4=B4)"OEWA"-[MY4RP,* N'E"*72UR7V K]8+_UWBEN\WSL8"\;WX@"W3:O.YORU9;N_,I(), MT%#XV*GMVF?SOYIO$Q_B-B#?
IB6XH5385Z?+E?EV4GS3-][%#?EGD(U(A%$: M-O#,>;1U>$XRVQ?RF:*!N;T-F4ZVITEK8,_%9;BD.IT3E5U:B)R@*])+L5%1 M_INEO]S= O8ZTRH'
B@X9(;>,Z4EW>"4>&D5$5TE]\VH>>MQXH>Q+\F)49W) MRF=>2J=>UWCX9I"!E'AV-7C+D9&,:984.^J3T+I5*^4ZB?564*KD%\#Z8G3 MD]'G469<(#C<@T-
Z]NOR4'H70T-.*Y*MQ,\$*WU[SAY5E?![_KS 84V,BC%V;*3-C54=12 T5%2D BDC(1+ M0F1>=H8:W*V(V#NC-3#&K5?U(Y<8-/CIP#847?7U/6T3M-M9-TZ84V]I M831#SLZ5<
9F^Y6*:BO;<*&')T9.KW=C1V+"O(>LM6R#A[0-0562\44.T3&* MFJT5$WI6DXFNI?9,F ON>[)NQ39M8W8<9$]O5)-2(< HF9.'V7<[-%NDRVEV
MZM@=)RVKPX5'AQZ\0'@@@ZD!A@K.7D_>RFAO9V]E^,B2"B3XF C^[$A2,LX' MW?RDQ6(U-138E=LHB(SF+.E\>F6?K$KI%$<9?64*7)Q)&,+98XJD)H)32EF5 MA",-C03.=6\
EKO+-YIOHYE,@P6$U^2)W:WKDZ_#/;7SY\HYN]9<0 MPR_RO,E6K6?9N<&KC YY(%<_@894?5SJ063#3D (UG]^6$QMLOD41\>L4+5. MV;'Y_BX07N19C! 8\(S22M??/Z/3^^R.
LI484NQXC,JK%$9,*OD4%HD?L1H M)**>>)"=E_XEZD*26%RH.1/(F^=D&*>MRU<$JN+%!8QOZ!OFS9"O>D6^ .<+ M0YK/9NFN2KKJ6 [W%^\9_6"9^LW+L"=&
<"H+Q#W_B%9>)M&\>OF5C(CYF,^R MU19,O3@;6FN3Y"ZJP=%G 23'6WB^%$.?O]'F YH1^X"6"W&X7;H^YUJ97]A* M#R^_VAA;PC8$+36?
7/V!^NNI9G&S>372(T?)'4"/AV+O"(IXY0O=,UYL(TP= M5.V>5#[KTL^DX;&950?8J9MYWRIP+))Y8\WN,>J!*Y'V-QV14(B?%!D&+ M6>XJ+A'-?XF?
NY4&U1:8+WHP*75R5E+*R%(>1>4XIWK#!"E#U,M-F5I;%_5:-2+6D<;!O>QB2SDBN3C/#B MRO%YE?S3>! '4?F\'W8NZ=^H9(%0.(\!5Z8!M M]*]2+!JC[X)@!#$"W,#M7@U-
65+M6=$E>23T*!U/&7.:R)\G>>: MZZ(-[%_GVP5HBRRLC(([''ZQSJYI*L7.N(N^Z+>^F1980E?3=/Z82\?,X3&U\ M8\IZ-PQ[JH (IW3_'?',QV=$*J1NJGW=:R%)>JC>C-383DV2
D^P6)B!4E20 M0A]]19] (>3O4U_K5>SYI9%])Z6J(X#%T8QPYV/F1#*@GLTCC #U=1$T;J3P M8F"'E2^OHX)DP8 1F16;!V4&0%')2N"[LM_!UC$.?58@Y9?OX[+M]3(WFQ?Y
M";JYCZLY\=P\L:C;3H>B\(GH#T8X_ MW"4G8:FYJ*2F4:"K?:<^1+8N\FD>K4$UQT+[+&?NCN,_ OZ?BW,&R''DUEIL MDEW)X'PSHRF^'\+[[%Z]M2^J&*0;X&WHB&8
P8W1NCP&TR!)0Q -UK42]1NI M1'UZK41=*U&_'-_M?#+ !;M.[!&_,O9T;DO2X7L4J#+#FW ']($K\?N5[CCJ M_&=N3^[KWQ"49&"$G1(=
<"YYGA$.;XC%0?.R[H]D%^*S(_1*S#I0Q-RI]C39 MS=G\FV4=5@H0E^XLYXU+%N8R70XZ@3(V5-0$">RMC+#LJP/-G=9_,MQ7;29-E;YREBL7]]'OY? MTT--"V5#&5?4$2^'I\-(?
$R^(LOC'H8YBL#@F?_OK[R2C+-E#^3_^U^?_*\- MF?(CTR7;S\,1C(3X.7,!X:2\QQZP;_"?X[:K3NPF_.?8B[_PGV,UN_CGV0./ MU?*#R%O&P%#V<.R.7V3?
_1>NXA__XP]_Y&5\YT<[^SP+3_,7'%F(T(1IC(P0 MJ'Z8]X$[WAQ"2\;?[3%Y9"GH\W>._XH[R,Z<[6O\)\G55<0^&!$[]N&A;!(? MC/G5)'THZRX6 M+K+.&W:5OJOTK2BY*MSV 6[:?
A!Z MG]QC0W,T5TNDN\O]AI1>8H1)+>_2GF'LBYM#&.\H][Q'CGK!K7B5TJN4KDBI M2VLI_;=&"ZZ3;(P1;5#F Y*%@X-DJMNDBDL1I27R7Q*HDS27R\"Q ;
M'MF"ZC8H4[@HS@V@4BJ6XO"HDY\Y;X41%C/YG;01<-@DVBQ*.(:2!B106AJ9 MNWT#UGC%$X9=/0A7UM7>7^7WG34I$.QCUVF40C,I["]S410>+FDX6<@C7>PJDU>9?%
(FLTDP(_,% MLQ!"4I&QH0*Q=/*^CRA=%J;((R"I96$!=*LI)8].:"\RDF%A&?96/@KGO'GXAE7,&%8D83Y1C2 M4"FFQUR,--
]%X[^YERD,YDIDOSB8&\;#K&6E/W_#XSC<2=]60NPW# M8>%PS*:6K9<4 2A5!AZZXS;]P#70R5 TA#N4Y'R9O,ZMRY P$)GK8(O%:8; M3!W:"-
;YP_.IW7@AF<2>9#ONHRZCW1S_OJ>#&; M=2NS97Z>@?P0C*#PZJ!PYA>761H&)FFP_G!I&.>3G2M&TH!4M-.1,1,S%N!_ M550VU42MG)]^1OO[^>\WIT!S-PGO6[BB%
[.7;?;$!,KB$81!)7-::CM M%-]-!Z)NIA"][ZB6=[PKF]0 (#$1L(G/E.#4>G@"6CK5*'K2:@"V"I2.T-\ MV'_$!Q?23*E*1K=MSP-\X@731 9EYMF4;W/XUEMA%(Z_+S'/4/:"N:G3I$LL
MUD)W@KU)OD-:.3L:\L8\C"*[,KY&0P0P(+RM@YMFCNXZ?V.>W,X3XO&E#)Z2 M,6L0Y4 BH#B6)QJ-)[0OI==SXG9T?:(N36^T=DWAX.#91C;;*[VI'QWN
MH#/#8CX]627Z0ANFOF,>6WZD>(5#-V8/I.SNYQ\KOQL:+>+1"-?9B[^5YL[/ MY*;7YLYK<^=/B1^6,Y:=.H#>4/X&!!(%VKR>R3CG>/O*J51X+FZHB"K4X:Y,
M,T6XK1Q<+:=$R<.$S$H=":KN)NCD7BVYB%618<=1TU==8EE2,K:V/(#GE#U[MC+1KC5,\.5TZ_M8_8K%X=^&(X?$;//N&I@[(M ?IQ4?*/-F3U5D[XNE=JHO[
M(\4:31T>$GM5[F5ET,_U=C1FF2&&C2@YTGFF,8>(IOC)[)8E!D"-?+5+LSLS M]SO?DVOSVC7'_(OFF%=Z>9]N7N4A6K,^W&M![2I8,\$2P("U#/G6[+S1>I;A M8EHS37$1Y5/=
U9O&:,^[/HE:^B>!7%=Q#%E6*9$D42$679[^Z*?%*4I*9R MX(S!F8^A'[JV#@J0ZL: MZY>"#CO>T9#3Q%)VF+K ""=?8S XS3H>H *\;%YNKMD51_K&-O2/-K2AO$]
M>5N\)F5M8%.!F08TSUZ3#BW689:"TZGW/^X<)"?W"] MRX(E\ +GL!)]L@5 ;*A&P!8>-KW?!:]GT]&%7CUO;4NGSB-.<-O0*HTY'.? MGHBG9]?1HQJY\/0466"JB7-1"V@ -

***ZP5M0HC N?Q1&F4P*;S/4*\-(/&G2QY MN L5Q+CFI<:,:BUJ+4!:($>(P!.”G#¥A,OOS4=N@:0A*1U':M6_5+K3@QJ.IO MB>< _6P_I(!@VR;H$FOM3MY[!JEL-\=+O4;T+)9*A-ACTJN87 .AO4D_JKX M< %8/!QE+>/3F5W3^AT/_#*\:K9OR#;:-&';&PG*Z5-??OEGU'_[2K_3QSVE M?]/->'!XW$^^4L#C62"$@]?F'&]XG;8\=6J+QZ$ MQI*"-"A16MC:%#.V,V!S9?CTF+ZY?]H)QQ(?OD$Q9*2)7; ^9QZ'AR301DEY M!!A9=^NSO+4Q>.]ZGJU9T%Z]KUM6=]PVQPX%,QF_NS)QOO/G]HO9/@(4K-s&&4X=’UQ_2[;Y&U]MFC4X85P76HAA%)9[:/1XS)^V"#P,5*_$ZH%A'1XT?X[<+:?'JL;E/VX;+M F&_MBB97Z"Y&<4:S#@06 M:/>5:I9=4<#C \A9HM-58XE_R*;Y.$.@. 81A]WR!H"30ICCP|M>0^W2(5XH%UIB-W\!4I>I^CZH/7U4D_^"P ,IM%@B]43ZR5170HH;4#8*L;N-MKC:4(<1$-F=-6C!_4TWT 2A/PRPV^PM10/0(7]D&4QE, ^%#:08DA/: +/^H M)\8+%(?4HXTC*)'Z@/^"TT&!:G9+5#; ,'SB.D8?9+C,W.[^PW;%C&V#]1S M0Q[EA]8=IG%4].D[UF/4VN.":OJ&C+Z3>5CB/(E_YBI7_*ZWMW@8;PF-F_Z2 M!A"]I;&TH^5\|+YOB XC#:N'L%E><25!3%.WTVM%U:?!'/:*M;R4HVWPJ;(+!"SZ!PT]=M/%]PIYR6U\!?,<+'T'WK>5.:[814ZJT*#'Y5(MK,,:.B$2XJ&Y)K752/^._M?<*]XAXRT[>Y-BC\1AH4_NW:H'!M4/AICL)S# P6).V833>9(VG7FL7(LT_9 MW0_&8YM >/#93'=.”@JTTF'.D]X,;12[MI&T8],%.T.PYPCWSF=%XL3IRR".DR/LL.)-0]!&# 8W:&<@I=;.2PE_T:Z B M@E#8ICIO8 M]I*U*6IR;S7/]U'-/(1YZX1_!^V'^ALCX7 /C=PJ,I8|QCO8= MD($2H]??1F|&SL(L!)*<(+H15U%;TLL()T9SF[:X-+]R$?^C@Z^'O".9Y)HG M/(UWZPWD|!3!ETZI[T;<-S"(MUR+(0>1+Z0OXX8]IP/14X/K%,X,_17_T_K' M+SHN?YZMP16*Z[(;<94I.!TG%U701),87$WQN&'AW0!{U-K>L)/-33;Q1_I M0,Y"Y1ASQ)NA1(KN:-Z)TFOFI58^U_;+:<"01<L,#3"M/#RMP0,>_V0_&V7 M<_B*)4;$BK-PU%$T9 3*W9O1RD?*!$*-B?/I_/ODVIM(_(=UIV/53S9*N>2,&R4@@I>Z#6'2>_F2-RGH(X%>)UE:,9G)F15_16WS)P M0ILT+&246\|WM4-IW$V)R/1L0R-S&GKMO%NDN 1EU3LBM/2{$D, XC7'%:_M5R%=58:HYE IS5R!W/"[O)ND"H=”ZO#P6$[#& X&NMF%*GH%'SQBR\68;35]M0ECCY+=,M#U/W>=”UD(A',5*T)K#E35:@)OJBK+LQ:6ZGMMTI(0IT<@@AB[& M-"3#FY)(O"CF($'HD'$M#Y0;1J9P!#,.)?X?X_>1$]J*T[.Q>U;1]1)RS'<8M115)E"DE9=FIP#Q"!NVB'-1T61 UF >:KGFIH>ISZKD_@#MBC:Q'PI9A'IK. M$RB2-3UE3>.%9LH-8UE3>1%%YH!&YOHX26/9PA5W$D=V:L%?^ELN76KMV5,X NH_8UD?X%,F+VC=[%UECK)]#*9J.0UI;O+8OFP|_KL>7*&!LJC+&Q/T$EN5/I-GG2?A6,"%9 -%GXDS3\38U->-&G'ATKVSOR4C5^("G M71/FH7*1A4E=;P$?!FQH(O1,MHH^O^\|<[>[!OGW30*LU_?M3*I/.EXEG@ '-MU:%&;238;D.+:%ZRB6EKOH$+84PW\|%X2Q'P,93WH96$@+F*<9;_ON8U^/X5G5/?)S M\(\4W>8>)3N?\V@=\+ ^@GH>?2.9>% Q*63-P>3Y. M(ZX7[GK7U3@($S%?AGP;ZR_=)7C19H62CKV@WK+)]5F\;?]Q'BA&>;:@QH&S? M3*1-8"2RG;K@\&H(KR]_^S?Z+!2U::DYE?]&#T5 M$GG&=I90XTV>Z'&V(BF,4%[9!$+] 99QRM\[F?C,P2|K">G*E'"TEP?Y:D_ML3N2 M;C;F#+OE,!V!9+[) 7V@IF0KEW"[@>=!.K?P(2)XR/:^](+*|(W<^6;F7LY%_M:_?E0]?#O9+68>MGSH|1UOS,TN%,3&KY)[%ZN5V>H4X*;1ZQ4VNM_1EH,7\(M+2DV\C)O]$>_>217&OT6^5-HU*Q'5|SC<"[5>=7P/^F\8[X00+63KOP0ZA"-MOHE/JADDIZ;GE_1?SXZ[%"+6E7\A&YL<#?7K*N=L],Y1WAVHM?;OGRP9FZ^F MGA13X>{;J@"ZYF=4B;)S2]BNKK_G7)CHB+OZ*!T"LVEC0KD@W6S1\ZEVVCUQ MG,,"3=(Y7R'BTO!/85'Y\(f"2G<(M|F)AS,=R"IMK2?0@5I4\X%HA7CN[ULT,W40_!MM_K@$HI7|R674%88+\1Z$!+'W16 A+S9R@L M4$>;|;]D+Z]=CW%-V-7"O/+*:XGH4F8QZ^=$.9]BW|&U]M>3K3(&"]T_0B^B MT8G4F1&,$;>]=]AL!IZSNARKO9O/2+??0[$9^>\NI)RQ&[E;0!]_"8A@X'D\K; M):$Z'CIR4X[4YC].6^KK'$_4,73R(2G62-\U6R=EYN!%YC%6]IOU.6MPQAAME;=+$S!$B1>.J-_,)?Q;2[DD M:E]<-[PEKC[JK&@GRAA.O1%-^4I-C'MP<$)PL'E#MN@J$%((&@+]^A2G5A M,*V1U#^NP.NH"IH5(3FN=MAZ@3?J1]+.,HEA#',7T29)7]-TC_H*\^.:T)>*M_T)BZM2&GKN\|#'B'LEQ4!.V=BAW<@GGMR5TM2^D'UJ'WE***4VPV^M;NK?J_ME4+,!Z^%MFNAJ2=[)-_5P_VP^4[0TE%[_"6Z;DT1?V,U 3KVQ/XCRO(,+A%< ML.O CMJ+O(-*LD P9L*PC6S%5R^?NY8I5THI8Z34[=*=P!JZ'71X,7H0N'AB M1LSYVMR|M5#5OI\A7JULI$WAHAVYURD,*I8AY$<4STH*1K+!#&.)NT-;_M/ M/_GH_N,TP>'CU)RR0.[VPM,8%;";I^SH@ NJ-#!%*9! ".X3.W)]V\%Y2.)" M G)+$)]6"7ENHZOCQA'_[>;[&R<\\()Z^;N]$UBT*D;?2 >/E:7|N51>2>) M7#Z) %2E/"630%DHHV-,SFRQB4O4@F-#V3 \D)CSIQOL;"I8&O3'4]6A[*D0#@)(=|+B9Z[2}3]2N?DDM%,F(+OD]$!^D0#C"G$3H4]5$ M'KK%#(NK7'R0U2"8).1Z;*ETKEVE4^8V,L?6_'VD5LJV]9T6Q@:@T M1T-DP)"E93'?4L7(|:"S(O*RT!#M%%[V6O7Y %7:OS*S_\@ET$T3 '(F)T1 MEW^?1.:0ZQ|G-D'1<3_U0NZK\U8NZRM9,MOI':4@/6W*G=”4]V$_M15H M+BA@@WH>0OU/-%+G8/6K2%U%:B92V6P%YS;T#$"XVUGP;%,9.79R1\2"H8!^8D13=#BG0=#U MAZ[”H =S10U"?E5^5^D)YZO%B*3JRT=N%'M:$*4O@SFG&AHM3GUKH=W<8N9V M=)$+5)1_QFB47LPTUNO-J[P)L:0AYXB&7@Es'!'#3 M:B[Z^JS9Y4+1R MJ9M=8|89/"_C[G\FBB4)Z"^%4;BQMY'G*QA!PG.8[=YNA MXP:W&8G-/&<&TY):.]<+SXGP(Q)BD#,S#3)=9UP>EL&&SV0<1BX+/<3|\SNRPI1 M:|PJY.#,#:7R;@O3'#?4/6%S%Z*+PS?CGKSXM)MJW1-5)#,MAAK8YS6Z!N#.&(1'|X. BO N7B @B5|"*+*PCE?A$-'5:DU#>7IFU]1@9=2Vj/WH]> M!$WOR")*O^^KE_RX/QR]>,);X3!Y^OJ*,$-!D ,ME[4,"$#:%W/0UQ7RC3&%8G:2"?2^F5_9LLN7XX/ M3WL^!OTT7QZCHN,*O.46A=T#O-#Y$^(I>)8%=>*5AY#YM=16SU^3)S!)0 I= M-S[_>FKB)"DE^FDBX^()=$=X-YZX'8D^Z#'5,!F:0>=HZ!2NMAL|\5^#9:\^[M%/([/F>]X7?:XIWIRSLLSKY^[N&9EOR0=(0DUH^^;KIVEN:>/ BXY"10R*Y0H4 M/33P82>C%)@R6TZ-346?OXOQ>=",ZP)VU/75BO/I<^GVS<%K@$&,K<^,8YIZ M:74"6E\;NJQ!E&*-NSZ/MXPA2Q63I=QY/'LB L$ETDWDT',@U-%,Z^(^Z0XUW9\(C=>/^7T2NA$8E$A/6)R078 M]-*,[GA4XE-|_OO-*;X43^F^O=@MI^W:@1*E*4\%"W!!=(I1VYJ?8<>.D?(:ME]!SZEM7<'#2T0M[^%1@!2C'+J,B^A:M/H H]1_:2+$7+I$U) QTL%7$U+Z M(4T8,:X#\6^,I31/QTDU>]5%8O?+!?*,U!\0\@N0.[(TF)S--UQS?5;3?5[15 M?(W/+,73>OJ;Y.,$6'A\U"8#Y)H6B|O=K\NJ>VM=,?BDJG@=%M+5]""9!QP% M+'K-.K5X@R&6XNAAT+)ADHUE=4RK/9?E>]ESMPB*UG M6%K^OVYZ96FYLK2\[[S.]I38J%PJ6)*(*>G\)C3"V6S]YBO@"4O"*2KU:!5V M4;6YW/6"?(/N'*S[,NRDKEJB64MY2(^&C[VG<^_0V1TS]_^HYY:5(#IKT$Y MTS(#GG@6\T9]!""N8Y()GM&#/;/+\\\FT5[2TRE5F3)2P;{ZB\UM'^5-K?@?'.I6%MPTQTJXJ,$:(^(?;TD.#0O MK=4#I4@-AY#]D1::)%B2 KOTZQ==>PL*3N:U(|N=LJSY :&$SK3 S_J$G#+/ M(3%!Y\]5!_:K%#:25=9X^4.;RGM<9&DXPY+FM.(7I)HH810Y\H@,E%]LAQ^NJ&3LCEB)"(& MCY)KMU"(#[|)///@55J/,9$;>R#]2Q%E7O)4==|\>TK#BM5PN+K1S<_AGZ5 M-N8\W]*Q*5MG]++1Z8EXB0H7(/$R2Y]0(WX5+U^E\;/IM6^03/:L@.2^868$Y55A1AK<7U%+]=O[Y2E#H5 MXNC0I30N>T(!U(D=A86F]3LT:)522B-'J@^.PDF']8>]ASU+^@G%SZ3O'?&I MT"PGYF+ZNLW^-K;-)%S91HHR0 PXJ^6+V*/JIJ?E'0:VSBX#YDV@-'=Q+50& M3FI,>J=2X$A<;25<8)HF'IG^I"M=]HI[Z.KTU19C/)@QDR:QU7+,8BCC+U%7T MF5W=8^4%9X&(;MF^XLO|#/$'V-\P0XKW%\);'7SN1QPN^575(K"8] P"@1DH#+W5TH|*=,)STOT1$#>+OE+D0YM>V#;TWNW(* M8(P!M|M/=&*F\U4A&@7"6PX@=)[/K9(3%%0IU=/21!FZ/K;9V9;IO:MV:7L27V3J13#P67S.,0?N@:V= TKH MXW0V4'S.AIYL3_E^YV-*LF4SKP@HR<06B,3GI:H((? 4G_BM,R(]7G & O]-MFE^9BG)/.(.7#:AZ#Y4F-=W$"B&"Q\#L48.ZZ9 M2QMA=/'/|;1#+VR^.7/\YP;&1-%, D/!91MS&SYEW@0$\#22UZP>S*8PV'"$MX M*9]2(/B)1],46L8/<WY5F&_X;1M;|:4'%7-V$)?+1 8W'BY!@%<^RR1(YS M+1=70+KI6$G;.XP|6QZ"O)P08O%V?!*87MHILNI4#FOJFC6,)?ZH.RE4HAH3D M4TY:0.PF\>Z%EC|.%;6:U.A M 0D5C)7B2W25\|DI-F%-#E!*)ZS,,|LK!|9H-.U$WJEK:926#%2lNMU$V!=M+M2&.O XX%>?V/=QUL:YI[8PN1I^ ,S3B>)=&W:W%H> L4&/"%[5(:5E\E7O6G M;C%-$^@>SZZI"-!BL\F)J#;?4Q^T1)6]DF8829<4Q+N/YY_4Q8,9@-.BX8\$ M^/CM-\|%XOCQAN"M!%+;-/5] +MQO%V\ST.W@G21G*/>9,\|8-YKC12J|/Z,S M[%W<1[R9,G#+3>;RL7'+47L2$!8C0\D65=TSF-5+?O1^2A SGSLI-YL,G;2'M=3%&W4UVQ M+$&+$(15G"5U;X;=H;":7BT:1Y7.]5(0-"3U#5 U3OD :8941LU8O@ &@16> M++C>4,:.3G\LX6>IZ&L)-5)&W>]0Q&T]?4SF!;?95/_J+SU;\.]VA!PG;WR M&ZG]_^%:U;]6]7].CN)U>]LA,Y-R;&YRH!LDP79Z?= XRH23'T3]A"F^Z%3% M#W.7V]_F\/FRGZ&SI1[-'#CVF6|OL M_BN<[#Y<>2"!J73>+E\ADR|\WVA5]%\B\$IY.J7G#]+KN M(ACD47)&!&^,<8|2ADZ#3Y11 [+)DIN0&U^W;^O\EP_+2(;32YY;QKC;? 0W M8^@.]"=X4P0@G/]6L^1J;S^.;E9&ND=?X72S>=T&YS_ 6T#E!)UV/&NSH+"# MOB#S3C??!JHD/=3S?=R0"B[!"UI.Y_% ?D2?E_AJY>\:,_E&$JYLY7U)MGG9 MEB&2,,I'AA;,<@82<,3OWM7$*\ ^S658?BDA-NDVFIH\'9Y2\;ACB%Z*,F7' M K<&3**8NRGG_#^-V.0^*:,>?WHJ2382QX0W:+BFH3THO_"UK%K13PWFT:1] MKW6.8GIW;EC!Q:\C/%D\>*FI[V'S1-%P5#D5G7$PH)&P9,(\C/EHGA\Z&0HK MHQU.6E7%FQRBDX@ID'D++|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|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|!>:O\2FD M7?K3SPMQNEELY>94'V]*AEA+0Z^ #$$<*_ZD)G.JN;;&%)$!UL:H'1%/!]@C M^(1P753A7.GA:2FD|+E=C#F@!X4JQO>@&,%C:6U:LO#E\7,@(@0O&TTE,<|< M=L8Z_28IQ-+5+_6<49*$;+AV')C!D5%6UU|UW5Q.Z/FAEF'Z(Y2E%D)/KR' M&&[4$Z93>AQP!CQ.%.12F5N :RND7-T3R8MYP#)]$[25LZ-$'_BAGP!'S7-W M890HH\O4343=ZR \G+\-CWQ?M?4?1G'M,6>D=4X/7 MHA#>NH)NJ=HJM1<(S-I63Z6'CP0(?8.P#G=WEI93I9>+=O>>G=2[!IZB-N2V MD$_"ZIRR#V4FV5_*1_+,F)S,D35A?5@',J97EB|GGC2U\|<9Z0..S#N0S28%Q M@KHZM?'9=X5A+Y*&%;VYKFC9.',Z+'K"1;_8\C$MYUV"2]8X5;JV(464.B(I M**2W:F@VS<2!&17*HUE^,*,\W-5'/GCM'J0%/!0['N"*FM^B+1Z9\2,G]J7N M^E*+GEV?.MPA+;/O#0OO$-HEE[1)H.K>1KHLRA*3E>\I9)@X[ZC#:.F M4#[?6Z'PIS(U@ERJVG"26HH@VY.VXVR&:)O&\I8_?MMT6^MZ(UL4SY9M[EVM M%K+.W,:.[FMPB(G>K6XD'CDUWVMP'C@O=,1%"AO@;&D765!P(Y0LFW]9U/J8(M'XX4-TDJ_555&*_-U;SIE[-A5EJ]D>H7\P864E_$W'IVYQ=MRHY\^$-1]E3= M=;#.<]*%J'PF7DA@"#M896DSKF21%MN?9+"4:K@.DR#S\K3+CHDAP2#(3T*|-M7==GNMF9A>U4W0KJ0F4;_2A#1O(\\S29!EK;1 M^NY.Y7+,3=%KSQ>Y 4P2; MB.")Q-XDG-64C1A4Z;*CW^FK=/-R@ZO+7\_8*MT>Z;L149X5 M)=+L3CT2;H<&SRFFIDT7|!Q'7S"#'O0D8W8)3R1'GYD\NZ"<(G'=ZDK&=GH M^J=N-N^H?=<6"!4$$VBME=1A84IPG3R MA&G5C?@];R;LN?L=/-\\ *7M$I07]8--+B D)*%+XZG:5.KF'NVG<5-&ALB^(M$+|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|(Y42_E*W5U6_#? M,-QU@=2\@CT?[=+#(&TT|"OOFO#<1EVAL=;Z8/TSU*,T;=E7IF:C;!_)U#5JZ)P%@ MJ(3BT?/1'!HH!$B=!4,0E*%<&U"9'C@H=Q)MF$LC3E@ ;P%AL9?.!%=AM\ M7|<'E,=YK\'P'\(T^,V/08G,E?TUC0XK8F(1(L+Z,MA@:V./$HS[9["#\8 M,)NAQQ 8IO(&PY:H/S)[9+4XYIG&?,*]5=Z%PWTA@;Y(<3-F<0_ZO8C!0]& M?>@%U!_MCU"VF880HC;Y^< MD7]B^YC^.:+[MB+)Y_*0)LQ2_4BB:2R4@8UV5B<3^1/9IAR$72!TV_45)A%(ZKJ.WB/FP9>I%RE0JG22@O MA9:.ABJ)"%4J"'"%Bl K_"0\6>ES-YK#$.;5/B'JX%PZ-*O?'GV$@ MSG!8*=+_R)'H*A+K1PW_!'=\ JHDW_;2 SS:W$92URLTD7T!]0%'==”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|)_^\?,_Y'-$2/W]EZ@_A/3&,.31#3?MDKJ70BD M4M0E!Y7>ZAQON8-M/-+(NR9L_==M M*#*G*14)UG=]\X^IWHSE{=4#R.*%Nl+9JJ<1,3079D-D.E=PQWC4VR(VY$\ M?6%\%-=(.Q'2);D]0LA R6T91^Y"OUD^.I*2U4/&(,;,:4TZ P^.=C#2+ Q M8>C1H%SL/J44!&;4!RC2\E#J$$!FVNH\?V J_)Z7"BJ*"__S7^O&_3S?+3$9 MO,UC^P,E64H#EKLP*1QKX5GDK'!NFJ'E+H5QF2=[TKJ&*DL5)9D8WOGQ&%W8 MMF+..6O5-(%P@-D3,X<"UHX1"@X>?P/Z3&.|/6&*[%.49-.I@@E$3"W'N!'Q M>3!6V3['56?%N7+Z28+G1+RC>\V:RS*%U;Z'U%@%*8:.Z\5M>4PF:IW0D+R M-6UL06U\8R?*49W1W=6+R]&7HI|PZ#*MA -H,&%NSSQG!W!Z-"(U45 60D4>/4-B# (\"4D@=@ MR.6>TDKF90BT/D-K%)M,V;$?C/&V4+>/?:U{6W6["2I37HM]I/(@$[^9VNNG M/IH$"OUIS2IS_U%3"QU\L7%N/Y*<_,3[&6PJNZP-#E M-KA&@G-)/?4EZ7'.IO4(^*47(E>^'G& DQ|WM11?^_%$U/ZM57F_Y=,Q,+Z? MJ#C:\ECSY.VM##TO?]1 .!6"W-FX9">OTF=]N5B'57.4G]+$8FJI M-K^7549= A_47+1TV'Q$OS M@LJH7U<1G17(BK9GOS;2G$\1ESU 1A5X!?I1$DG'S0Z2<#_B0'\L-7//OGL ML^>)]|:X8&5D2K[+VOR1;=+'IDAJH,KVB0+W>J=D=SL!/X/$+EV+9H:X>]=/D_:V#::M,T3P-T/O? _YBZ M\8N91N-?7L&,[PQF_/0*9KPT,,/5U;IP5PMA-K?[4WV4FUG-&TGFXP?E/V2^ MI2]C-.,=A*;GA6I^-1ZY92F,_^'+%U^G.#[9/\)8"!NZ4,#.9B$0R=2!:.^H" M3"L<>R.@FIVT(ZT.[.%@2^Y%%DV@-_%%5]Y2G_K;KU^E1YZ.79I*/C-BK*9\ M3'5-R6:B)R4+X-"R&)_LKIN4D=%&4V;8$8;YG5DFU|TF\OTTR2%,998U[Y1$ M0DH:6?D|OMS-AO=%,XN<56E!ZR"^P/DI0BHH$!WFP+X\I,C_G>N$E\KRTJF MJH)E6)V+0S6KY48W;TVG*PW#*^0S1+"S"ZYOQN"H*4.8'IL MY,0F8:9!|ZOX49Y:3]O-,VDXQ"&$\<3QO^)E,:/X?"2'M8#F.6IYQNO4 MVZNR7E'6U/?2'W6)H(,N_@!82PHHB@.C#W\GY(+MW^S<//"?H(O4!-G6R\'GA\U44Q*N#8E;9],!Z3Z(?U#M M;&JX?"=%WI42?<;1:K,#+/+RC7*HS.>H^!SO+02P6O=-X,@AJJBX[%X:6BZ MG6QOOOF(P57'-& I/P#*: C)OZW_KBN>AY[E \V>E]}'5QW VLR^]V:;1(%S:U?:6J?*

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{BG/E)O-YL2]!L70MS+S?T[:?;K-R]>?/N<+)D/@VU@+X2'A&%7Q-SQXU5*&$5GMXM>^KXF#3T*\K[M'1?]>YF4M(WN%]=P56MN2&-X7R#2712";)}KL:7@AAH64Y[5 M7]L P+XPX'P;QV.O7S8 <0C;8N1G$*\DSO0TT9^8&%,R3C2^D29KD&!]P3AX8 M08A):@'Q:4.=M%0!W;%$^ P+%$82YILH')3Q!2_&R>IT_"TG\PPLE<$[K#X4 ME@C4)]LYQ'[,2;PRNA@1@#6UHAX+I1\D.@U%?0I=$;X+)1GYG417=$V-'5@ M6UOWJZIK8^Q?/-"HFEDFAP-;43U^@_;8^45)=,2]EVI17]VH+!>+/\%O*]RU M;YEAH?)^B&'<]KDRWOO,MPM^9E2E7DP? M<)$ZTF,YGHZ)BEPGA*K_]+24/1K'E6\2DD-_W1A[JUJ*H%/KDHRFZB55Q4 M6G(U)-&]*G*A,'U*&UO+?B)VU2]5:K\2P)E U=2T% GQGGR,U702MVF/ZJQ->0*Vj"P.KX,!S!22+W!"B!)XO+I40;-F%__#R=$6&X2:OFQZYOJ$3/.IKYE[VW#]+K;-VF1M9#YT>[C.D]NON:J0$T MEM(.HIH;5$J2]MY>5!#&(&QM"9%-JF@'"@?Z'36R1&^LU]$6,NC#@0N5>%-_M\=)7XE.2!DKD+>+<5PYY+?Y$KE-IH*1PUU)H M^,1?^N!*LAR."!]&H##%2+UC M'Y[%K=E=I\7CN1\BA9$O4G6HL8QP=5!U\W9_1/OI>H0\C\6E4&E&R;P.R& M@>8]\\L"RQ0OCZLJ_-I;Q>E^%B= FVB%0T?E5D0VR6/V1 >R'LT.G%;A0>O2 MVU";M3=AF;)8*GT8%6P"0SM%GKX4;NM!\ *XJN@18:7"?-K3M+$-@M+R'I$:(IGR"RU"OZ.'H.JL&@@?J#F8NC?B M3$R>SQ&0"6P>$'WIM54FH,,P4R!PHA'I9ZAXY":Y5&Q@SO0,;&Z;CA);IQND M #GY(*,*,P0?C5,[!PARO5C[!1:I_=X@]7M4?Y>!OVVI88W-PU"6(X$"(+ZU-M0FY40'0)$J?5I);< DVE7'4X^I?&EU07);&]1H1F\]XDB82;?(OM%K/)YC4-7 M 3RKN3U>BI'6+U\5N!OK[TVX.SFAF3^C5"GU]XN1UQP0.)ZGM&865"E;/Y\&Z_;- I=LLKD=J8&$7X*O84E!F6"TG/]92/N"GR[D M7EY!R%1BO="SRKH5&RMC0Q[G2\T98PK2 H@H!:U"\#P'@%U*! LH.>,G^&^2 M$-MI="$Y!SD.3G=JZ\FBP\8Z1UWM6.+I"\]>MC&5'"8;!QWI,:+75#Z\"-3GB MY+&;3]'@<*1^E;BSY3&-7%T@HQ"2/,2G(.K\;FCP.C<'!/$OQ_SS9MB!NJ - M,2ZE4 U*8Q=CU+C[U(MTC!KK-A *]7AG(Y*0V_"@-*Q M2>9#"'@<-9J1 M0V4=QW+>*3*KY;)1>7<84H^(!L*IML)7);)GI:RZ&Z#9 G'ZP.RT,=(P%,IX M0LE7Z.!(;!IB:,28 B3$$?16F]R@]#"0 :0F1!IBEN9*?P1BGIV=>]3-EP#72F!S\$BV Q9_%$NO#Y46"QTHS-3DB<^LX2V;85$F4 MPCRL?E!OQ0)P.

GMA@>!SW1'\UL%|2QI+JQPJMTD1+0XAMD|M'!;7A=I*9;[*R+C$ MJP';0QP[JQ!A-;E58PO$T1|85#>LB;7%>:8(3H)85&5H2NPHJ5T!!DL%]H1A M<6-
!/>>HZB1#%E*:ME6R"V0=P|;2B)0 8OM0:LRQ*L;7|@349Y6-(FYP!5IJ MA?W:_A+IW-CGUT&641]ZSC|!&RQ7>O+HJS;18@TDTWRAE|BRG*<.EVZ>5EN9
MYW$<5S%#C+!S#|'99 Z1,^RF@!(NG.|=")8J2@0#]4N;R0[J/Z MGP:VW^5>5%^!F9Y!1NQ&3#GI7*I;(L8Q@C8[1[0>J0 MN5F8$MP/DQK/,4F=-P_G"RJ%DH|Y><*]2-QCI
AX4,.% MJUERX[R**+",2=XBO#%%P'VMT&D$>P?&(5388C+7^#BW(O"W]$9;L"TX?;1" MLTI_ERJ7M&!RA/N'>P2:-Z]L1*T?(-|>|>P[_25W!!NW3PA53^KR7IMDCD0?
X;-8,^C@GD28|F- M6/% I*5@/L_2SQ&J(_#)P?[/^NA6*%<);%2Q8^;4T|6[)6!P&/,=:NWRMXA?JWMFU+G3W&P M()6&5#-TY1$68_.|!0%[>4:HV%!3H|][9SLY?
2OZ^R$=*E!LAL-B]JO$?C M:;F-&QM[&-L(4&/_=W/KL-)VE1AI-5=KA*5=LLW +%(,H3Z2FVZT$VF3= D* MGDHFB%J-*'+ DD 5PPQ.VZD=#H@J$YSA*-J;YI2-XG:
<=4Y=+I@<.=SV8#8/ M8#EY/8-S^<=D$A*$H:B=TJ6*P>ZHV7TZ4P5M*FM9CL&&*Q8 "VWS"% R:FV5 M13#Q:!5/,R&M<5FR(T67,EUURUPQI3_#*P]X/ML*W,&+!J
),6QXS6;0]RJ MGA->Q]@E2Q6YUL&0WV0&"A,45Q D*;-_[AC|>4&'IK13C)F/GBXLGN'L|Z)V M#P/TX)$S+>9Z.=RQ76XNQVBSH<9(C?*LG-=OGI1C8JB%50SC9A.=A?L+X:]R
ME435;/)E@$>:NM._(($F%[&=^8%K>0!5J7DNMNLVD)G+#1')+="E;<68K5= MZGC5@32I|'1C^$UM9[OGY@[?;4-UN]P*,*N]S-SSOFI0)V)G-1EK&KXX5]Y* M4^RN1^?P
|='AOWGHZS>B)P]C_7>=J8Y[%AQ>]2ZJVE&5C,IO+6.EW&:2^M> MQ_M@>_/N]YS>E-A"M:H],Q2IHS=7OW[J[Q|^]9_VCU:2NWW4-^Z-">-LBV@2 M=,(SQ=$$?NY|'D?LR1
%V7%YDL$?+UQ?&5GYXBQCPV%(8D3:LYWH9G!GR.UP MDKV]?N^@)PJN> 9R!E/FA0P5><#9==/D0P,Y-M-@]&Q !NSIJ|2E,602A|U$ M&CF'UN#Y(<=P%:
<=E.@0OH0A@$AY^R@2!-+-UV|ULM#9,=?UX]H/56O$VARH M>6C/AUR1>@LQN2)V#,>%2JS1(KVGR|6_VR!+ND#|BD#|H O$=X'XK]&;3BO, M1[+W<^Q0BTCJQ 3SJ
M!6U7IE!S7=%PJ[(ITC., #.E+472R.[-87$>)^6Z$I1%N[BLP;H;5&%-3($ MH(^/3[ED2R5C(4=97>1A]V^R4-D-^&7@ MP-MQNE$O_TRZ1C[F"_(J#;8KTB1Y9.7-([I3#ZCV
.>!G8Z$9HT M_=8J.T[WW V@X)-..8V-,4R0!S($C,E#W_-J]|!)(C&H'W2|=|"A<0XZM&2;:SIWQA /.U:1/;'OHMH7BBY@%'"|,3>XPECD(6#6S3X%.8X4K>W,59U4!C4341FW=&6*D
M_U*2W>& NBAFF-;,>HOA"DJ"@E/KJO#]L813))Z4.%KM:YI-BQQ6KFL/3.? M6|V(] +&|62"(? M,Q<&FD[QIU5V.W8WDN4.,QSX!L8CGQRY..F5M11 '3E 6N9@29)B<*;,:$-I
MKYRGM1+B>L1L#8JJ3,>]"NY(,E&$.-4R4SM+=Q6L57.*E8%%739R,N:M3,L;)C(Q- M%*"C.A@MA%VCS"TJ%ZL^C?R+>OZ1^-"V1*V+&;S>9*XM5R5J6:_EOP&F-^6*
M,/<2)!G;#6V5-94<;FXP9R@9!:|$%@UOY(!*U"KY,-*-FC(S"G=HUN%O+.J MQ[9==:>8'D8D@BQT-HQR)>L6#6<6KB=/*'9NN3<<5ZVC.IQ!8K14&96B7:*: M8; %W?
1&TW]G^7|#C;B$H2/0:]$(TT((4^!!,PZ*ZS",#<$[]]&1A=;_LR0R M6 (**V^BM/H&DQ?#$7-17F'H=BW$V*QXNX&S#B$J=:<&IB0XUV#4%&[Z'?C_'KZ9SH>4_6RDXK"!1,4H)U)
MCB(+J=$4791"ZTYB;E!1W:QK2W(M$B*AAA0+_X:.FXYWJIK7Q6>^2$M<%^D! M9+|A"^/D]@5K(4@Q./VV|_3C&(.GDZF;BX|;^%&,WM<1MA]>4'@;=[ZD-J1A
MB1X7>"O=)3@B%6 P0@I)G(:P; +/*DG%U2:Q#3JN|8YCFUT[#&9!!IA9Q:6' MHN=1F-EI1CFD=J|Y|<1Z_RGFWXU/2[:5-X)-@KW-%HY_HKI:S:7+A!S$*I14 M"'BU;EN D7O@,
[6J:O&) +>,*6,7#BI7M?S9:W/_0*J.^/;QK^WUJ]P^2=MR M[Z"JY":1(HEFU9I7TI;!2/]B[T027JO; "8(&LG8|GSA*O4CR;Z$Q5W"|&7" MX)XH%/$36AZMW!?IRJUYX267"2[._DH?
$O;?=@NP< (|8F/@N*GNDGV/=1,0]J-F:>Z7BX#K(W&H=^,!R$JR, M-;Q#Q|SK2=7 !>. N_> &9)>L;N>DG9]1W&G$EMN0!D"'XZ4L_]62:-=3AY' MAE7FM<+<@%
<[#P/VY@2!N'@]Z^5MY>O7GY M=L_[I L<<^6|2I_"4(V"F>.;YIK9E1F5.@T/8_)#1)WDLDAQ,NO>YRIT#]$7 MA[-6F% N$_=DN*Y /VWRO.&U0X%9,(^RMS,H=,GE6*
3E+>S_]A;J(#JVCBY M4*?3ZW*BJE6!|0<@,TP6"!Q:E=H'N!Q/Q;]XZO7Q,XX CDP9>F'2 EA E1EPG[*X=%XBUH8O- M=OJ'/S]VLR;J=6%7J:TZ!VTQTWFTB"U2WUC?
I4^M,W+Q+:LWZ![.1Z +<6WM M*E)LZ1TVUK@D?ME.O4:=)&MBCMITLF#4:5/J85*<4[2$%)?I<[ISRWD?A5HP M=HN1']M5 /U*E7W+%*NUI4F|M2V,=5(PMC|H8K#:I [<
2V&H_^)HQ MIS/1D6<@]V!]7+^^R2#!*<2R^)IFHBL@YHD7_35 !^AKJ)6[*)OX.%";6:/T.?CH_ M|3Z|]CZ>?7AYYX?A4ZG++>X38HJQ2UL_Q=2?! :^ SK|5O$=.
[TY'2H5B/3EE6O9) MU":L+J93+/(|'3%N@),?X("IZ#UR|E5KRIN3|@8L_&,KKL1 M6P>%MI>AX0_MZ 3]SK MM'@O"7:#(<=DG M[]^
F#Q]>=)B&8D:IZZLM>'S&T2F4X!ZG]0:Y1:T+V2 =T&[T_XQ0|'5*N1K M]QHV_&C%(G# GWI[O5ZOC_X3W@U_Q4#N>N7!)VL^MK0Q]/Q@[_#H3L^_JH_?
M[QVX+]#;VOR2ALW^Z7#OV5/[AA9<_56">X0-G0KM=* R(Z$SSRFJRPR:9"&. MPQ7W0^R5==1!C3*W416I"|:M",8==,&X+ACWI0K%N^.S?YU]8'_+:8)E&@$;BZU=+P%H-
4L& MBL]%%,VQ?CR+-)HO9L,TUF;V|>GKUWMB4&_#5GE__:-,B^>UL?C#;]GYXICV M;0F?A5/-"%&V"79EV5'J0]]0:C'5<8-925+YX&G/L|'DS>_N][EXKW3OW(_4 M.[?
%M^X_BKT"[#P&F44)YADC[:-%:R-K"&?)V'J@@F4FT$._G)9.'KUU8X/4F4#F56U,(&^R+S&I MZNR#MH;DOFM4&T2N(Z56;Q1(-)IMQ/31H;-G7(2OK& MM[ND-
66!.B(;CW,A=?)FD#L+P-HBJA-55P$E]|S9=ZGMGV;)EP9Y(O4XOW# M=NB^_Z^JNZZOHOX("*E2OH>3NC=R?L+% 228PN?GX,>>O[RT_DYNKY0+87? MO?V_|]-
SU%M)9@PSV&_XY>O3]|?O7YX>OP55]OVKTPO]P-G)^:>W%_3[#Q]/ MSLB)UFJ=EM$1+=8<K BV(,2X#P,8@. /*?+SVLSAO(/3/F0+@]XKTI@K(PR
MXH.N/MHSH5%._"%F&WWV0%X6T]Q3Y"W[9YDHHZ713^"/?2<6!%-SH*RY]A<$ MG"G%FL]!?GHJSM4U.|F3I0";?KRZX&.[W&^R2$X6XU6]4B-%P(O[?5K9OE[9
MX)NNC$NMX3.06H3GHNE!E(!$87X^D"85JHW)4T_@=VGU,4M>NFO]#=1U;T$T'D]924J:QU.HD;5Z6KEEVUX4]$4:!@*7+ M7O*ON1K8U![H?@ZB-/
4)!VDK4S&V50N=#=;.G*IWIY_9$UL*5]H8E&8CH@= MLW!/KT%'VHW3]%)PFPNWG%$3'9XG=7WQ/:QGQO@E7|NABB,U%D*6[E7Z_'1> M)25*.LB?
$H[#PBV9D],|9N6$]KS7HMTYE2Z"9935BBXX,LXCV ?_U1 M'+Q%36 [<"=>R|Z|E9VQ_*WV]@8VT^Y+|BDA^#*I5<,''.!PBUYBFR.9+:H>
M@JTXUI^C>A3]EF.:@RO=CQWI;@7.RXID/[.|]X/AO;63 DJMSD"DE%_[7?5' MUZKZM5_[OLQO_A[NWKZ;5UW'XVXVEWG+'>'8UUH[5K=A'Q$Z/)+UBA0CHIQ01@S(OFF'A
F:^H =J MJH*86O@47&|Q)F]7$0DV3X$0@T#X<3HAA8%A Y."^@GD9(]CF2'|]O6KX]W# M?F_G$J83*W*1_G" MK)"N |X.."C[O;GM ZLDP21)83]'S(*P#PZ[R3!/*AA-
];)4.L=$ZE*G*7!- M!J|FBF,&B9%BC$D2T>:95;KE,#H1%-6CD%.0 N0CGR-5+-Q'L.L+LWQQ,YDF M!;N,>5/|?;I !L>H8?99W%-J=1Z"#L'72#(UR8.*8!3!2)6%*.$:
MF9550JQUQQVKP,4BY 2#=3(TE(&9JX $:D1/ANBCQ+C,>2V_I+6ABHLZC2 C MM=R&P%/T#FFF*&YY2E2ENP'33&'(Q8'/?(>H0U37TX]3W/J MQY6E(/!5@97F[@72:#FPOM
'"VPR)0:0,(6"G3R)"N0M@:3292GR>B 48+Q9 M,,O-?3DY>6/N"UKDF*W8?^+W>CW+MC,E%C6I.D ;53[FT(NF*H1!HSTV+^$T M)WA%7%(&AUN;]+%=2C0.H
MV'V"#"&84Y8CW=<(&QY@FYLR$OA,[*PP0]2"0.^KVR<3!6Z;KZ)A665A(+"1 M/ARX8:RZ*.>$AC!4!17ZKE9$UCZM*?4X [%)9!Z"SC 3]]+OQO6!98YF@D'(M/3#T#
(<+AY.F8Q;U05S1 >;Y AA# .R8Y*'1DOA?99:K&A>F:C%)2ZY|X]L) M4|-$@54Q)@,B.'V6_:-*SCE&V& *.%6.15/@4-M?P$4LV0M8*UUQ!G-NHL;: ME:.A]8G&G@$V+>[H&" 8A7J-
S7*RZ!P2F>0V5'MJV:%R'"CP(ZGZ/54JR,8 M5B#!|TC I%*J$16H+@:6JDYZSWNQ0+=20,#8##]DGZ)6)@2Z-U,!%CII?:GZ
M$G]9SU#4."1W.9A[LV7]P(E0DP(NJ#MCB9H=UBCZJW30K> 6]Y7!41>RW#^+ M.[M%NI93N(=.Y0WB7; UXE G[R^K=6"X2TF]@-43ANA_C!?VQOB8NNAJIN
M.DHQCCU+$])F56C/FG'@T&'$;8%%-H5&5KBH:2 ORQ%Y^Y-= 9!#!$?C%0WX M%[S4A'%*D8:8-=''.=RO$1,[H>I:Z2V0^OZ*>XFN!:NU&$:H518L:E>)U,KK
M>A]IM!>"9N1KPG"YA*8+W)4 MTE3N & !V9'P-TJ|M$.JCR/1.(;_9? ZP@I_0U;NCO;0EXOA]T)QV+>+@!# M8Z$HLB%8*ERQ8Z/QA01:V/B<*ESR32*
(I.^Z6:"D4@58$+TI|R;]8Y4ACTX+66H8HU[W*[$6U]_2)6=O27+V M49>^?KU>_V^|W*HXT+5-|$7MJ.'6P).]3_-#1%JF$V,-"|MOA'U,8@8/4A'
ME5C9P/;"!&Q03'5XN;X:WYDN]U[4VETB&Z?#A_RQ%?L@6MF NP9A%R]VL8&Y M$Y(B|[2V.S3U,KOB5I5&|;:Q+VG^N+.T_4X; =-ELS_06=QK(XLZ|V%UIB1] M/?
#ZN[!+N_L$)9KI1O5>C@TS=5N'$>?T|C?N#!N:;-X|7><<$/=*";Z9[1_: MWW?ZAP[5!$&N!3U#|+(DR_^EY,!**80F-/[6$*JM!0#E$ ORMKLDX+M!Q&CH MVH^(,ZMERK:UZ*?
C.]9H9@..P=^/N#_1M*14P> 8S=.. : MHSP%07:XW[NA2[-M0C371%U;58WD+6="EZP9SY3M$EZNW5AV/(PDH(P,2*9- M(9*?
>GL'!P/#VE>];6EGUWAK_QG/<&D!PC)=;FD8J],@)I8N]#,4,8EB(&&3 MY+J:]'E4"Z|!:C@7!]1_'|B.$P%,Y4.U0.O^WJ&-M ZQ^Q>63I#[!KLT2[I; M:&OD#:S*/%B0Z3Q<>.T%-
F&&;(K47^OBC)9SY!>JN$:__H=1D0XY4F<3@2M) MS|2"J6]YN(3W|A-PQ?UG%.-CP-,&)H"]Z_SI)P?^H/_,@@&@2Z[*A!U-KM)$WOST(R5PH?BP;+B1"R[A%-S #GE!1T>'*QBB
M;X1*)H7RA%UFO);+_.FG_MZ T0@JB]SS3@)WX9H[85P&(XQ+8 M<:&03,J(P%_N^= +UO4I4/"/1[U''GKVIK9S/USK'|R#FB@(N7L(> T5>GQS|!5O-P1%S / G$D!'"ZVA!7(M
MQ*Q3H-7 B2+YLU2=&D'7=K!5T#[4R.W@KQRY,=P2B-MAKFQ|PR[07_6U$F!YJ1C=@*9 M(B)LV;<&RS&:/*?8W<"GS/"4*:9[XYI:;4'OR!YR0:
M47(HYFQ/HSDWH!UQX_HT@T%&N$S3_#)%LTFRLG7&.]7KV Y5ML4B5H30DF_; M0|D,Y|$H@5CQ)/^> MC,?-,)%5J5V-+*)_Y%8R:&O&-
Z:,C^$N(#ZG1$*3F9"W'5:GSE<+B^CGA)HV M9EP%K2/G6-8[:GM+^C=2YT%U_D[AXY5Z*#3J[D!0W8'O0*@T#*@_A'!'&3N[M0^J_CA(2WA/8XM14TL
K4UJ'B&,UP6YO.I1=)A5Z]ETB-Y=E#)9:S'*$'5E8 MUF)A)01/)+Q1YLI.['EO<0+60T=(),M]#FB:=@92HDM/+A=V)*7+"TG.7EGJ3C>>3C)D>C+HUPVHN4L:Q#.KQK' B"
M+#]Y25]Q]I/OKB%*I#N";WN^TU"F+W@C&=BE4Z*ZK?QZ(&SK VW*#M;(8,SP M8;C'9=&1+%IHP :.*KYCW4D1;*?DTMZR. T2^A?
U8P.;BUH8I3+*I]I7'JIAX5=^31BC00+.];,Y@X0 M24 9N8(Z(55|P8QZ6%']G?2S!YDP%"'J4[XNV&M86N?RZE0,1A8F6%@%]P+,
M2BP"FR*T!>754N$2[9.9F5^9%K[JOV4XD6N6$71BGE(%J&|C4*Q:4%6>P4G3 M(':XGU=!%.,C>T"9%2RS&4'G$I)9#D>+|"X!/>)TXK*;)J8>LQ$Z!S.WY6D[M.> UN5TF@O
+3.>*;Q= 73[#.1^@T(L1I)N'U MN3FBZTSJ=|:G,-.JA441KJI(9U|^H?K*'BU'8K_=JV|*17_G44"&P:DG_WAT M=+O,_@:S:%!MEDN .|!O_S^(88]]?,ICGZW;0![KTD MYGJQS!X--
]RNF6JN;:?W70G-$Z[BGNAF:?R;C_+KT R$6]HTV/>|1&M-X#L? MYXH9V'R-CE^W@5|3H#2JDJ1-_O3IW&='7|GZQA]GO=E&:^[M1?="7%|UF8[O>U!T_!;>0P/X=P/#OO=P6]|
MP T<_,[!P69/_O&VRM_#0Q*]WU_^;E3F?OAX NC<#<4,"ROSWV7PMA,3.9MR,"KE_V!F- MFQ]P$|Z"9|^Z@]_X@)LX^"WS%FR77&Z[X5B3RS<#'75">3-7=/!L?ZNNZ%:<
MPT,X^/Z3[>+-6W$.#^+@!X.M.OCM$LH/S%A>A>Q&H$:=9-[D/3T:'&W5/=V* M_GYQY.Z?O7WYX=_)8A|"Z!E5RZ |E2:2_JHNDJUW"&YI-E4'4;,% VXB?;
(]]HT/N(ETZ:TZ]NT2R6TW M&VLB^5.2*=CA/U7H[6!KY<>FL7*]GW,GFS=S67?VMP9,:BN.X"&<^>Y6,>BM M.(6'<.Q;=-6W2R@_,#OY W5UWSE-1NE,/?
9.NNK"S=8:;9>^O!7'|"#.O3OV MC0^XB6,_V*ISWRY)W';SF",'F,CJO3AY_>'LQ./0JG=Q_+]=:NO&[Z;4%1YL M73);1PCWG]]J6V-U9/#PA/2S#4.LKY;2|-<0|L?@]TH][@P/>N@]S[
MJ=_S>SWX"/X&8WX>9/"[(O5^.CCLXQ?<'EUYM[QMW_3*2|?PL@-^&*/Y091[|RR"!<'N>"$L X;'(3,U2B=)1/A% M|))0C56&L|MDM9F* QH,?I^615X$";9;@V4D11:,BMR[GBIX=
@;%^!;X .5 MX,>LPV:XUGQ^Y%43%W!0I%|Y M*-)V'UK.'VY!T>9YW95]X&7Z:?]P!0/I/WN&7]S]U4N|)(&[Z3"3/G,F'[G)
MDR/B)L!"S$^0JRWQD|#+87>B,5BDL&SSVPA??:7R@G8#_@5,9#R&I>3I* H* MF-AU5$R)&[G;!K-(R|Q+8-N]"8&N:2;UXOVQ]Q'8$JQWUF). G?*18!]9Q!@
M'|B%NAG^5LOAVX2FN4.#9_LK[M 3EIOZA=_T&@T&^AKQ^Y[TU[M+2/KE/&1) M F^B&2<+;YB) (9[!./"*LRU8'%^I3)XYTQE$Y4Y6^=EFCU%*.WA(;B1+-UY M&YKN6N6B/0
1YF(['CO8CE=JZC=685S"/GSQ]3L:'#5?OWT68=_TV@T& M3XST.GRRYHU+)BF^*U836?H|2|C- =EMTEHO:.[1@N[!I;ETEWM M?:|OSFYLX.T,(L]77C =[V;IM?
ZF_M4(3^SCF_>?WMW>)'S)A:R]"O4KJ!WB MWOXS&?3O,*J>F_W;_7-JG/H?C]^<[+XX.SG^U^[QZXN3LU^|(+X.%KGN)XX> MZT15UOWQ,'||W-/7/5_Z='_-7GQY:M'?V_:|-]?
-6|XGMRWV.Z+#R_? M1LFEV24FIC5WROFK.3"P1-QK.G:$)NL+WK!(:DX":+GFU[SH.XN5LS#)U$:DDJ! M-*C"7^YYUVC^(GK^|:CWR$,>/@]"M$+,O_-Y,#+_9FX/RLL%/MJL#-
PL4._@ MIJ?#B(#&$E(A/HOP_=6XWSE@;B?UNPIPZF9:WSN&WE80"= DX-23?SPZNEUS M^B[A%Z')73XP^-G|LY>G<112C@*P&OS/XWM-(6C:@*6T@O,Z;[09!5LU3|VR
M[ZF,W!.>XIYGRZ 2U@BF?||K=*^UMRN.<[V"W(Y;_^#<^A%JCZA#DAKYTZ=S MGV.<:9D'2>AXKO&_44O*Z.^)B43U2[1]_^[C@->9QWV-V3&1;I1NE&Z4;I0?
M<92.>V_"DC)ZX:"SXN]D':.[|[XLXW6WZ%Z(ZZLFTY';EY/;?D=N';G=$[F] M%+"/;?+|=0I"-THW2C=*-|J/.,IV%3#?&Y2(3I*N*%;?B&![["N1|<=M
QFQ]P$TA>!_N;11'96BBOAP$@LMR4 M_)>N)T,W6'=8/_1@W6%]E|&V2T],*S)6XO7.YMQ,RKDT?ZSSG;8^(";:,HP MZ+IQ;'[31Q|?[MN_';)Y;8;CC6Y?#,&1B>4-W-
%#P|Z3^[F!]P$;^YM%RKP M5IS#0SAX, 6WZN"W2R@_,&-Y%3Q.FG22>#O)/2:9@ MA_]4H;G>>ZE";PI4[#SGOH|$DS83CAO!$MJ?Z.W]7$[S)N;1OF. M!_KHM]U-KJR[F
B8FZ7!'U@IJST+(ZD9['2C9H[:;D1U?;)5NFV6W$,#^+< MNV/?^(";./:N O#AFK+LVW]_2$TRU,,.L(X?X33I]T9+ = VY" M+&|76I(5R#7, T7^#'|&0QC]9N'?
S=*K[_5)O2WYW9P&KLBH41 B7RJ3F2^ M|5%J@ZPSAD,S_RWS(AHOJL-B;Q%UI9+2M@MKWR)EA>@-]|#0]_+HLS>#]TQS M3R6A"KU_EHGR]GN@9/4&!
[YW'>3>3X.!W^O!1_#W*)W-@PQ^5Z3>3P>'1_@% M=T2_Y5W[OI>I>:9RE1#T7^"%:I2I(%=>.H97[1_0JV!:SPY_WO,NX'WF!U'N MS;,
(U@&;XH4P>Q@JK@T2'L5X!O@0]4A@.K&2]Q"#M5QN,HCN'?L$QPB_V^C (OZ_=ZQ#" 2YC?(-M:8AD!C GL8@RV*ZS/ M_#;"=U^IO*!EP[^ 3XS',/|'45! 3.
[CHHIS=G='YA&6F9> OOK30A(3?.A M%^^/O8_>6"ELQ8S"[@|+JKK.X/J^D!N3C.D[=UNR^'!"M&ZWSNHW)9O)4&S#$W#O6$SSNIMNE'N=:+/G63I6>0[?!3&JT5?
1J/J6/(CA@S = ME7A3Z2WW?0_#Z$HW=OWXYL6_'M4M!N!935UVY1,R:>BC1_2ZVOM>7YS=V ;8 M&42>K[Q@.M[-TFO]3?VK$9"U]_'-^T_O;F|UO.3>T@90_;II9YUWT)-!_PZC
MZKG9O]T_I|;A^/'XS_5^3AU&^>O3WI@W__57SAN/)?8OMOOCP|FV47)I=8F): M19 [?UCG*(X$:;)='1 MLZ-OI[<=/#NT$JB_I@1*)BF^*U8367-% (S2' RY)FWMG ,TZN&7T|HJD
M6H PVE6XBV48X;.@^A4*A49. X$4B^#@1-4K$_VS<90$"0P7NP_H#?JC##)@ MD;(][TC<[?=YO]NM#JY*'6CU96Q>]!WOW_Y1|^7K#[[=W1NP1CD+HL1>KGI6
MI#>.RU%1BC>D?JO2N2AE>&>]ET$2A %=E-,|"U3<;NI^20<3Y5;)1?8A!_%* MC=1L"(0@-QT.0YQ4-_QHT/*K<4&&2QRGU^2$0_=T#CI'@50'U/0ZRM0X7OSU
M+T|'_2?/48//RQ@8*;);2VB:]N&3* V)A2.%J_"7>]XUFK]HG/]XU'ODH>HV M#T*T@LR_|WDP,O]F)0^$Q04^VFP#W*Q'WR&00(<1 9TE9#E|%IW[5Q,@X!B^ MG=3O*L"IFVE]
[]!^6Y$GP(" 4T_^|>CH=H/INP2(A"9W^<#@9_//7I[&44AI M$R <|#^/[S6KH6D#EC(=_@|YXPER1IOKL%43=/GU/16>>|)0W,/PWU M?|_[|JX^-
%&X=UV;]:J3;V/4U]G'M_Y<&^>2,=N-B&U#0|:=.KBG;0QM*KO M2PM;=XONA;B^:C(=N7TYN0TZ?P$ Y^ M!4I-=^SM/O9MN^_;)8(?1OW|PL'W^QT@:F_-)>^=5-
[,'1WX_6='6W5+M^(D'L+1]_W#@PZI?/,#;D(7/]PNE6R[M)/,#,Y=/9_,@RLAW_5;:;:D_RHB|V9U8[E)@MN04'L*Q/^E<))L?;IQ M?0MF|OA>)]'10B,M;
(,)UM'"%M#"_M'V.66V2V9W1E@W2C=*-THW2F>$_4A& MV,7O)V?>SNG[EQ_>G3S6P; .!J ;K#NL'WJP[K"^RV#;):,>6O(D(L*JO/!A M/Y)+;ZP4-Y^+TR"A?[7>@;BE*57]
[0*3VHIC> CG?G#0ZPY^XP-N(H?R8+#9 M:I8NB7([1/*G)%.PPW^JT-N9!%'R&(0QES74^V5VLGE#5W7_R;; @'O]-_LEDLKJV5RP_,5#;%A9|1CZ>,|BG5'*9C+U3#FRH- M?
S0/U$VC?,?+M[)JL.4|[2$PT<.N,'#S VX$TZXK#.QLVD>_?2BF*O-V3I-1 M.E./O9,.-6?#OJ;#SH)]<(?>?[+?'?I#._3!T|WZ+;96 K?=>N6 .]:!>"]. M7G|X._$X(|F[./[?
KC)DXQ<3JP$&_E%O|Y6X737 -M#"OO^LUU6&=+2 M-#W M]]>2+VR7 +]'$WKS?M=NE&Z4;I1NE#:7A[3=(EM*O45GJ'<1?/8^9NE5E$=I MTGJC;$O=)%VWK0>N<^]N7-
UN/Q%T=_^'*|'O;*QNE&Z4;I1NE,[&^B%L+-;F MWI]<$ *:=_S^E??RP[N/9R>_G[P_/_WW20>,MAU*EPY_[6]<[^Y"'MM "UWX MJZ,%-_S5WT):L)
(<_AJFX0(_AC^#8:Q^|_#O1H'WM]J4_O;<#D^C5X2:R#01 M:54:F?,H873EC>(@S__QZ..;%_]Z5-^87N_GAA7I3^@0Z:-']+K:^UY?G)D7 MNF<_4H@4|-
QS!I'G*R^8CG>S]%I_4_]JI.+8^_CF_:=W-X[1+/;U.=>VTR@Q MWD%?!OT[C*KG9O]V_YP:1>SC|9N3W1=G)|?_VCU^?7%R]HL7Q-?!(@<-*LU" ME:&6D:C*NI][4|6;.)A_?
NZ)>O67'OU?D^8E7SWZ>].&__ZJ>/DV2B[-+C$QK;E3SE_-RMP2<:]YU80FZPM>HO7&4>L4<-?[!%?[3%VH%1&
M$[R_V_NM5N1LW7_+O(C&B^JPLD(X@,PKILI;J"#S5!*JT'NE1FHV5)FWWP=# MH#?8][WK(/=^.GCVU 4*2WO7.PYUW M+|QKHMR;9Q',$);KA3 O>$4>%%$^7F!W|
[G*QKBN9 0C#F%5 ;97S7'T (9- MBBP8%5ZF|C*F;NA1XH5JK#*<3,2!E*'"+S(U2B<)5D_OM?1@$6(,MBN@?;"9 M]*TE9%COKQ&02@+]<[MK]SDG_K^X-DSNN!KO&W@5Z]A
--R6,7A(;$*O/UPY)$Z'00Q3*:(B4HQ--(K3O,SH)SC7^721HRL%_CV. M@'W@3S(5!P5,?I3F1=YB1@ 7XQR$/!X%+OM=D%TJER^T_':X:Y^9M>NK041__MM+|V9>|O"
[Y^_Y"O##P]&/R|?'4.!P>5UZ]S@>1NF($:[|8P@Z7@:E+G8N"; M@;!!2?9@"E1[C/.F];M3QY]F 3 +O#_V/L)O M40JW^|*83NZP:<=.-_#-86.6O=F#29I$C=L9K(XN99.E8YYM7
!R0*8!YY.HKH2EQ' MQ91&1O52S>9|489E'B7P$$YW&"5|.>BG_X$+]0H5U,SW3I/1'BWJ&DTLFHV" MQ?&OX5;JQ7A!&4;X6KC", :(L99+HUHSYI;?)+)P[(H)I^D."EF#*O9D?
3WL M1C6,W].DA6G="S2J/THB^6F0A=

@%GUAECFRQ396M+RVWI,[H1_EF!=[/?H#AW 151 M_Z0]!:-1.2M9"H0*3(FH,%>IWZ-KN;-TDW^![X_|(]8"'Q,1)6K"PG04Y%-O M'*?7WCA+9UYJC/8 3)XKMF?T1<^CS]X,UC3-
Y;I7IDGS&/@'?7;#[+A?XA2> M[9,L?KSGO2XS++67=<$DX"J7649R$;@3C$BR#(4^;!E|*TXB9X)IDN]Y_YE& ML<*7(%] C7,V9]4Q];(@0KNS3$*>/O"OF

5DZD5Y7K*C:.SEP+Q@43"M!$@%MU]] M!G4&WT]?3=,X5%E.SJB<1#U<=O(L|3+R<@BB&7@A;$:8EL/""X9I6= *@F$4 M(V> EZ.*$.%& 0,-/-8S1GQIZ-690FP^VO59L(
I>V6"80':+T;SXU?"$11L MQ891/H(93OB+..+1D": ZS)%PQ!EQ@Q=JR4P6@K7)5/)!/8OD6>2 M*T43&)=%*3.CW2R"2Z5_%0-MXDIF(!S@1_DOK;SX]&T$U 4/[!_1/':BQ^('
MAX$F*9P^4"BYP[,4'6.X6V*CNYP|#V+56COB79 $$Y(4P+!R|A$&>]EA9FCJ]$A0+KI"@6+X|VI,=+[WO4N MUKLBUCOH8KU=K/>K_.9LX:%R98W EEM

KX6O@28>H!C*OVQ;L-:L\.P.=%!13T(79 MZ8#Z%9L*&!5"85?S\'.(9T5D3")'#]'!_4(M4CD\6GY_(-:57S=H@M$T@CTC M%RG(1?DB5'.%9EV:B&.T9MGIO1W'P22?
1G.MI_CT\\H.>_]Q*86I(X>)1V!8 MPXK$'8N"%L1X#"(>?G>=XF_'.)28\XT9N>@M.%49-&P+-ARDBGD/GUIZ1._ M$W=V+E,PP1$@OD2-K&L7?ZO=Q]8X]RG($HW*.,C
D*W1+3ZSD@;9$)WC_SAS MQ/% #[&6'KPR40KLWCWOF%4=].C1+;N.XEB;S=6-LXI,7L[G:594IN]>M(1\ MBF&&%Q)_8WS;Y.]7$S144<71:M30TD-\[YK.?
=V13W!^L5ZQ4:Z#4)$W5'M$ MA&V1CP(8D"9\36Q,F5?(0"OC6?'$!S%J>6DZ$,0+QBS=ATA-6XZCA+V:M@W MXBEJKX<[%=9I?0(>EN=@=(I2IF3!BOM2?!/Z@$\)4JR M>57.]
?/!%=!%&M71DFLP5Y)N!6.=@[ZW P6%8WQ2L.70-1\7S8TA&!3;;0!ZHO5:9=].:W4SQVI$%/LUUGW]-A$43) MZJ?C%#V2^#!2&ESS*X[" V_,4KQ:0H= +S&R]FD
2UTQH3P%*P()"]WAW&,3$ M$O.I4K#^+,.N)P\@BOK2T9[7"A#X2ZF9-_Y^?\G.L4:RMG?[=[)W:T9SU9[6 M9N ^XE^(9=RR<[NH.-1)@?+(U0_G)VD&KA*G+SLRA3)G*Y1-
)CEN$&I1"IHX M7 E,2@#%\OJ^O?.\"#[)?SSJ/?+0Q3!'SUHR,?_.Y\'(_)N=$:!$7."CS;ZJ MF_T]=ZCA<'VI7@^(E;T>OYK*#*ZWM)/Z704X=3.M[UV"^<-7RWMRV+N\,\P2 M5@P-W
!((?G'HW[O=G??=ZG8$4IU)PO7+(Y"*GP%OH?_>7RO=:E-&[!4J_KZ M-@9_3YVCUSSM6CES=[WN]WH-NMMUI]N%RM%V7:!-#]V1TI>3TGY'2ATI?0-2 M>BGM.
[>)F#K!_IU'V;R*O&7W(")O!SD\=L@-EY8Y&,3Y8^N=P/]&]W%)NOO0 MC=*-THW2C=*.4;8+=>W>8#2U%_[P\.<-(["I@AW:.V5..3V/*:@6A512>$^:
M[WT1WQJ02MU@W6&U:K#NL+[+8-LEM]J.%EKO4MM0H==RG- F)\%/6X<*N$.U MC]O2Q[*C@8W0P+/]HXX"'C0%]/V#IP0:LBUTL%W2^H'UE#^E.I%.6F_?/=WO M#
[;EAG84L D*V-VJECH=#3QT+K!=WZX8^.SCL^/2#IX*^ M/QAT=-#1P<[@Z1;:U9OMM/&[N@]81_.Q(Q);#SMQ6PU;HH/&$C-NALPCZ$P# MAK<,H2E@>-Y:E7/[B&8^QSK^1)
E:@#0VN5$19C]PZ<_U[%H$:UMK7DW=4"H M@3:'P6*W2'?A?YQ7$%*"7P=+=P#C? %3<+"><=WO5#9!), *6,9J%-P:A,;#
MQHBVOB7W@CX(;)@[7]*HP0_'EQ0LP,8KFJ1KO&&]ZUOO,I*L\>;*10P* 1.A MF3%D@,:?@3_E+MWQ8QGQUP#9; MV:MCVP2T DFYR@,U"&$82& Y >C"Z3]#I6 MX831-
O13B/%'"*\YPALB- =(J%V671W8WI: [>W+H!W87@>V]ZT +6[&V+E+ MI[&6RY@.6J*#EEAR8?WPF9TWE\@==06E7P0BL8)-=I6F#_,:=77978E_1S7W M0#6#[:*:
[]#5>_W5#1WIZBMZA>PQ)]_Z*9!S)F=X+W-^9V\TJ)&M;&=%ZN7;-Q46M3I&KI+\T91.N6U34?])>H>RGI&9A#1PTBK!0O#1?,KL(S_^U\C]?3:#2M
MU15\GPH<6#%NA&EFK5NGAE@-,:*J'&QZ.I=1^/*VE%8>?'G.K9=DW;(,.\="=&\YC5K+9BRGW#5=(VL
MWZ:YU!#L_'1P1,5BCV_E\MS&'(D/&&NUXHRG=Z+;9"/U2[VVUIP:2\Y<5<@E MXC@%%6JLEO4E;&L.>^2ISR/JM0._S'5?[H"Z,&=PM[$W;Y3A1"M3-LI3Q-LX
M5/P3TK#^5&&+K\V_DO0Z\2XR(!;8TY,K[E..N_8)FU1CK^*6@Q40$75)9W%X/..^YM0M'0L@D5SS3XNL3\ZS"J8*/%IV=[F
MN*,Y=K8NL&X'S//\,M_SSG29/GY=TW@26&2A1M,DC=,)ES'[I)05N9<$V%S> MJ\H$E)LP&I&%N^?]ASJ_8U=E[+@-4U^D):\#%V!>MK#-WL-T#IJ1SS_2ZU+8
MYQ[FE6AC(K>-N0M>\)Q[KE:3_!:L.(YPL7&^< MJVR0T0N!%>2@".* N58LTX0;LU\'.-WB&LM33_,L4#$]]GLP"V!D8 YQ&3)G M8."%',0O=S4G 8RMY54V
Y8$>Y^;$9TET>1QE)1I2LWF<;I0BMJ2\XC^RB7X M>I086%H(6YLKH+<(Z'6$:G$Z3]&4' 6QM!X?92EPL"2%?<%5\Y[GO.F3.!W"
M#_G[A7YS(HHY#JH5%GQ3=@EZTU4*BZ;^ZEJMQ^[FF/5:9HDSH8"6R\W=7>JW MA++GO2XSO&VS%(F8+QYU3X=S#:-\5.9BPQ13$@]ICAW5RYRN'C4,1T2!=#:+
M"CH&JH##_:UJ1 W=U[, J BKI]6"BI2QR?M44=MVNLT1;3CN1 1T7R-P(-XQ M]83G.\;O&I? .1O?!4_7Y8"%(::'D M(!MA.OA"1IDBDX?:6KD"S M[#V.+O$@8-
^Y%3T<%]SB"&^'4#+?5:$M^-Q?4OJU0^Z>O6VU:O;@])[MWK_3GM<.KGJF>BK["%PI],ROHI=1S/1!XY'I)N@7/P(2L(H$NWD!)Y#;M=F M]?Z"G"D*#-Q ^\JKW#PO8
=F)"3(D>\%L%M9&*!&2H9!8'TOJ.0<.%<_!V_OJ7IX-![_F;X^./]&?_^6.M M2XERX)4Y2J)9< EZHSX=C2Y4SN:L;;+L8NF$(\+R0!U'H3G#F=*@\'N%IEPE MQJ#U>1\-8;;
(234C&:RU6I3!8#VC#@LFQ30"S>D:;>(X@J=9;=4S\RO3PE?] MMPPGO)DH6U!-4ODCM7-"'0](J"4T&/;=\+)9@]MY!?H0VPK'(.+AA-A6 MSTF/0L48YNH (, CY".#]^?
NIHDO@=T!=+!F;LO3MOHQJ7(R).YCB9.$-X-J M9E4)VK#K"+4T/C[6RNL*A.CF2PK$/,TY<"-0;;0Z),QV:WL&)WC_"!YW01=V MZ1-B6O]3PNO 6"PB4?_@@UC_^Y4E3500R\)
[Q\;)&=C3+69B[U&[G<^!==/% MN/?Q[U,/O4U'O ,$R J%\>"P'5KA_ZMJ=>LK;S_"/9#CKNLT+SZ=G[X_.3]O M\65'O-@KE5U%ZOKV57[_RWYOL3M0?\;HT$*)
[!UGY"A%:7D*A!##<^0CU#K4 M\:G6H,1EN]#^4_;I)^D5BXP\C4M':P*1G*%C89@%H!&(;Q$$"?K]&:MJ#L^1 MG"?E+U%E1@Y8XU>#[^!/4)*('Z!3"'[[^M7Q[F&_MW,)TXD5!5-
>T CO57&= M9I?><1+$BP(]E'DZ+LA1,=>AZQW4X61=;DS;K!#'C7!VHU)4IR"\$D=7& 63 M)(7]'+'#$50NCJ2#O,C28#35RU+I'(&D2M2?")(/E299313'Z*=36AFBQ)(K M95?
I>C\IHI[GY, -27.. O0@?HY4L7 ? :4*G3GL=20=MBCPUVFR&RH\W.+O MTP6J/!QTM<_BGA)08 %Z,$:4&,(*5:3^(46A1"=.W-0!5'IQS9]) 01*^NFH MYP&UQNQJ3C6!
<(143H&1QU#'944:M'#0S6#E01$,)8;%M'*-RATHEJ@^3O # M(!0<%D8LU(C]V9*8HW#O7JL0#03O559.O.-P%B517H@1HJD8R,8>,L[]"AX@ M_9^T&@H:H"F/$9H
PFW_^1Y#J8DT$*.) \$#!:R*H)L4;E 8&(G M89"%&$OUO2DH2\0)'LM3I-)5"!O09]K#&22I3DC;DO M:"]A?*G_A.+8AFU7X$\+H(TJ'W/H15-5O-#A.OT2SMEP=].72/1_2P[YB&L@
M(8%^?S!-=9:)# 2'*4(%:3Y34]FU"/X'U,>< MR1N0WR$+Y@NTANF^1@CKFA? "R*=V07V]0R.'+D1[ZN9F0C<-E]%P[)*#IHA MO2)].%%8)Y(Z5"
:LYL4D;5/RP#L$IF'H#/@HRK<\WX' 91F3/&^G2 %@<4U MAC,<+AQ.FHY9U =Q10>8YPM@# &P8Y*'1DOB?Y59KFI<&&1^(K+EDN#=18NW(T M=,#Z1
./""9J%Q0,4*Q"_:9&>8F,-4)$H,)C9D=HS)H5(L.- CL>9PSX&(", M"*H3)7@>2=@R'?X758PKBJ_BZ=>]6*#O*QC&43Z5Q@;F*7*YQUG :L4NRC7WX&1=T,OB7;
U8H*!;5;K,$TL@TT'I1ZU671[Z[-&)0^S*[R,?<,BFT(C*^@V M1_B9SZ#B\%T"U@ _&*(/VOJ[J[#C%%%'&F+61!_G<+]&3.PPG8DCO26_P%]Q M+S&%QFHMAA%JE<7G.#
[,=@AW1EIFL,4%_SH^];5@SSE[A ZA3(3G1"$E^2Q< MUI&!6G.%8+W#*"7=/C,< GAT30CHC3=7IYAF:3G!I%4UBI 9\R;@?>:K0AHT M?&QMP9R2@=#)STKW)" 7O\Z\D<6:-
Q>NP +[+DX7XL1WE>\0'E+8&H"48Z9-(0X2:4M,V.+6Z66HBLP!>1)J_A[M5-A,*N'41A\3A4N?2<0KT]E(32H4Y8 $0G8B&M#J2L?^3=I5G5SD"(P:G--= MSH U3\!NG$9C2G^?
PD$X3%VRUKY4Y4CC4#,4:QFB7,O@Y<1:7'_+5C#R+U#[MEGR1QK-+._-26*L216OQ_LHET+)+5K;FHY(PPI&9NU37CM%J'/=YM]\>OZK/,Y M;26*,^!^XJ$2C_,V2OCJ!1D4Y
)PJQ=1-(H MF!?<5D6S4T_TW5=E+2(G] /2)_;45?II;+:G.'HCZT=+DD.GU//2A8D(P_GO0X]38C/UU*-_QXX.>5BCVO'-G?T"L*1T8 ME]8&UZ8R+$ W^I]ZYA5[D(K&639QX[X*%-
\#*I/Z![QJOP&XU]WJ/[BJJQ@!-'43S M'A7^B)1'TQ-MDFO0:N&WZ35RV;PT\\U#H= MS,CR5RKF#.4&84Z^<&N5RQA&!:FFE'%T2#/!$,-*F+9/"47"YMLJ<$\3[Y\E MG J?
KCY/";F!"HYWQCL]-0Y,]++!&;NA63+/=,:8]VGO'*1:FK(*WQBKN7C_N823715*ST(Y1:A6X5XOF4YEEHGC M$#U&RP[F]>E_@/3_]/!!T/\';5GV]W6)+44(0.*X1B4*&PK>H67-
HKZU]O,'$>>' M^M0-U0CI/C /8,Z^5]% ?Y@BGJ5]?T.)IGBHZ>Z,>3Q[C-1GI=XLO@0 M[3;]A4Y,Q:RE,HL DWW0]N4TPR@\C9[SL-R M^" MQ-3-B($-Y67 I=NV4;QWK&\)]
"OWWM4AJV#7>Q<21OY)I^"2.[5/X!;FUV! M_!9V-^-!*0UI%8.%N_6?X$J]0F:8R5MD42_CE#Q@KU"?WHD>+RWJ>,9X%SCU
M,T5%/:#)*$XCU=Y4&_YD]ZP[&A;V"OUB1(CH]\8=H*%VHMI<4/W$JG0N\%\]NJ!XN%. .>A?XB=XG.,HUAIR=70Y?>.O7K)/VWH],*\:
M#O:WJ)+]/%S<>SKQWI*ED,NI8*332=6E>[R; MCG>!4G[V$6A1..#T^"N<%O2-P;4PEC2U*06IX$ 8R! 3^G.6!" M!098R<-MYTVR6)?GMI$GF!G7"2<&.V".8IWY8G5DT,JV>-
+>>) M^:L3Q1K+*Q'<:55TGE.6\2*XX1=-!KZ7IR/,58UY3 .5,83!Q\B#)9Z2,'8# MT8(@/-33;"DKOY(\DZE)&0?934DT=MI!-*L1'*9YFGG_>2@'FYHXX[KY+>H
MGC1H(GZZP3;71%"8A$.-\,A-&: %ZZ=,9".,4XF M59;&C0"J@)FO9'KCR609!F^$_U",4W;5C(TY#S:3I>I@,,2129Z@$P?]@XH- MQQ%E;]R8&^=NRTK*1\6&"
(XF1GF2/W[&VW<,FU;O:X7.Z^%K/%35Q"%)]S&:JS,)LW1[%>&;Z76PD%0@5[964@8I72&@(G*8@9- M:).7FS,)*6^:;@R=JN@K'%F.)Z95DNJQEJ4:YR]M,P9R%!NZ!)Y
MH8?"E+^8###4ZZJ5=&X"/Z*RB*UN*_UHI4,U#:ZB-)/D=+^2C;ZT94#/S1O6 M6 2C-2^^02&A2F*MKEDT, S$"\2@SVP.:H\$BBJ&+N[B?!XO7+@AQ,-<3O]W
MKO"W++3!8B(J6_M3'\?+6D+*N[?>/)JSMFO2\A0=B3T$KF5RZYA]Q:Q'8,)'3T61CLD-0HTZI&A MFIPJ7C48$&>=C+5&BC6GE=)GJ>X&"G/J1PPELLT,!_PTYZ+_(7
M>/H*N)M.S]Y!#B@A*W2TO3\W'_3Q@\=>/@]&E/M@(;'E@*JPJ"IZF>)PSJ0 M$:#!7FNV"2,WU^$OR'A#+C2-YLQ+ZJL%[J !O"'IA&ZA1T2S, 0FQONULM(? M98CW'D@I*Q#4^
+H+ R\C]6?"\OQWG)5J.^]($/'>Q?!ZE]$%=\NX7'EJ\J] MT"7 G%XR?:WU6W45B;//U/[@0>!6+1UXQ5714*T4NEG7@0L_DDA*F!23C%ZLMKHMFX($#!S$#R%B +>U?026#5L[*
[^=[A(M G1WSM(0T57 Z/7>I9E"(>AS"3"N!- >UW@@,+(4'XYR*D:B(@C*A3>)W+#CM5HL>[FLQ(*71LPXM62AK$C&
M(G9^R,AM7"2+%:V.O9GE4T1@DQOON!@ORX(J\B.@.3HF^71$)MZ1*N4$3W>HB&GH,%LV9NQ7E MFJ2XUJ'EY[H-#JYI1RL+*LE K\6U@9YQNF32VM=7H-1-
123H8O,R%GZ4*P%J M9,)$X<:1-RGM195-] ;=,\=((H7HY,&HM9D4[RC-"]ZHN7\N/2$L3 HJIX@E M#XQ',+V'BJ!-B$A\B7!,B8#@.)*2""[GJE0L/68Z!NT@0(, [SGPD2!CAL_^
M"/U^.@N@CP@I3>==%SZ"SNEIRS8H[TFP5 M)1ZK=/7[[:^MS:/O(9LK55!4=QS-MO(YNKU=G9)77$/DKP5;:!JV'X >5#-B M6BYN&9DFS(-L
1KJG>5L=QDWV)+#M*W">246@\:^$R>^"X$79K@U=3_VF@71KN:CDX?(1 HNFV%4*(U; M^[R:V4HC5KC%XC8%LR!Y"&! 3.TX1!X7$;["6D':"E*+*V\=U8YFLQP"<,S\
M:*5MW3CH$@X$F)C1516VV^:WB.@@K<3J-+:B/8#S2$$YS[JW$K,7EW%SY<"JFV.*M7]N"53E1J M\5(; ^4&O<%%69;*0AL[#D%,C0JG@0.%TLAV)R0J\1H+ONF[MV23H!_:S;?
_M/MBFM=2T&H#ISA/^7URW54?RQ]\8V;2E%%,_N,;C(@O+-'=#6#3@SFPH*DPM M7:5(:<>S&T4VP9A<%7@@N02=?>NSQ&P(!V8$.\%HJO-Y+@R(QK"5 NIJV\]Q
M6%Q=I;&XIW6HUR1$3E(T+\;Z 3IOL=.U8KJ,&]BT0!S4)ER2ZM0<'8)?"<+> M"FT0[N!5!(851KU&BU&LC',3KR-IU8A/8^ZMXYSQ.2[4")%G]7<'P/K&E!12 M'*_)
@0KCP,"E*'XT'5&!2I3KMIN" B'T."UGB"IP\L9WLBDHCB#P2[M4WD)R@>HB M,4JU>R9MF#YJ \J!OSXS?:,$Y;V6 6PR9S%H7Q;H /&P(5(91U[(T3S<#0I) MF_940:PPY)O#-9
$"=]U+Q4\5]^-;>4EUI"QNT+0VJ5WU"*WD+3'L/BSC]X. M_$@60,A2-L'7+H;$.P<:^7H:ZY$%IN[4SIZ_2E#=AM\$= ,EI.&X@:R_1&_I MWF3/KR8HVQ!A$>27C\V69.[
MW+;R'[R093 MPXT?CQ),]CH M&4?,\?+#08]TI.PYY8]3-@87)A5I)FGEFM:#V(0M"%:5:NTDYH>0@>B-0]\T MS3G*&CB/-FZ\D60.'I3O1VX<3KL'8HO',.<<'*8+17D!55^ M4_L-
;H7&L35JRR%UR!8*A*JP8*\6NT6ZFV'0DL]&M(55\(?6U2>:5A/:_IYW M$G#:H,E?1?0],WM)RN'UH^Y83!UP"8<+$^3LR"8D\LYR92%79NIMB!)G;[3 M,&_,QNYRPV7\M@/_&LV
NN/B'X^ [858H-Y[-MC___(^?-[K#?;^.Y\\\O)L M=//WKD?M:'#X7#P^@U[O^:._MU4S 47L=31![;F_Y^D648W*[T>^MBW6TF O M?HU^>R?@T!C^T2XA^)@8(?
I)].I2((<9C"*,*,S[(0R'\"O; MP.O#B\I(^.-_1SG&NMZDN^_3W3>I^>V_W[PWTV)6BBLBD&M93\5DYMQ6MTP/ M]4M9,5O["Y7O8B=)#'!D>FDYZ5ERG\PZI(@._H/.G?^?
O3=MCMM(TT6_GU^! MZ.B>(\4%J[F(6MH^CJ IR:9;"T>4QV?NEQNH0E851BB@C(54^=??=\T%0)&2 M+$M4$1,],EE$ 8G,-]]\U^?AU\22Y(]/7(L;[^!_K<'J32[;^7IK>]#E?-Q4
MC :$9Q"G@>!T6*';S17EO>5NEF "2AUYP-$0U"?"G58"ZQ&!U=AD>UB/MM9& M6Z]PD E>KNDP["?&<,;$E^T> S<.-MG:RTQATK
M0K$C<6]>&0QN+0@%"2>.:AD93XFO%&=KS.[?2OS1,RHKI6IY[%U=7?CN'MBM M9+S]*SH_WH^C5W XQ-'Y(?U[E._T^\B-%CU*OK3J^""P7'FW#8&@^W!$EG M"IO)0C/Q?
8/#]7-]*Y-@Y1A:ISU#5%=E5Z.$73JXRD@R%AY5<)[']DWEYKVS MZEW@R1:T2FM,)W9;))2YLO6GK=<3PVVY%#26TF/SGJQ:WB#4?[*G07(7W"9. M61OY
Q>%@H,Q_I1P3)T+B^^%X^)$I88+VS:5/M=8.M@J+E)"D/.U:Z*SUMDT1#*JI5I MEF7*P6!?]C\#H>=7=Q^55;K);=&,0<(+8[V=F*\DENH8%9U#
<%&X]BIR"FF&WTLZ8LL6JA=6)40#S8R M\$J&G0]4VY$SI6[-F;&0PB2L2O1")^XJ^1] MY1H1.HJ% M_1V/ OU]*"I!KY\5V"F)'N![<=Z_;Z9ENF$/]?O&^N9:LZX>8E.NK;?_?9-V
MGG#X*!AVD]YTY>?S:8.Y'.38_-L/!Q,>VN@[?H%7F>();3SCN"5 MG*3)F@Q%W-5._:!/PN^S9[64['M*1C6LCJFD@+J<1 GO6<5_A1SSTXV'EL[(
M%BO\.N((XTY!ZQ^.*VJ1)>BTT$8)D0LRKM$"1""[_Y)\. M3,/7V/2 M62;XJ?KA?W$PQ0HW_(B;:-RUW\ZN/;P;N_9I5J_SA/Q0$.D]VKMJ)X9;-RG> MU;I3DN&][B,;V",K#O8+.>;
<+Y\)8G;*0S 6?1"_+D4/9 *"')6+*EDOR=-9 M)6OX9&'(='7EB-3I9U]!J^8<)VQ0F"H%-]1E3.^WLU]?70W]C6" MML.*G7+1$GISX&W \>KOZ:3@3%];9.#P17,3N
'>+I1(1;>^#3_;]ASD52QF M F MQ?'"ABQ<8W19[",\2;FMMJQR7^02!D!Y52WQI>]% H1UM=STRX&E'8_" M?XD"5]R^G3QF\X:S>+:KDHBE7<;AF#D]J $?JH' MG!;'QA4
M7;@ZSB%[1$/0T0QIV\A5:3&H7[9/VY1[F,@X??L0*/ M/ 4NL?^P^[_.8,E@+1H;;G+16HWP?Q<;P/3/GA['%1^DS:I@2G 0@"V(K'V5PM]O)9SW$=+,IQV=L;[]0@9R
M8+Z(R3S@>_2M[(X7@DX(/T=N?+0GPO^B:N6-S>;M-_<"/SHHW&_Z/2[:U0K/\6_Z)?PR4?]%;IW3],4, M2;14.$8M;B]#7?ZQ5_-?K-
DBA!M:J:QP>,S&YI%\6&1LUZ+!02M[I^OZB/U6 M[["SNU^A(4&OP%TW[_'76OMG!O*2_NBU*+HS5#;B].C#N?$KOA40=+KQ#T*B M&&4\JN6'E_G:3*
(4@7MY8"QM40Z6U)MGAFAQLQV._#88/7]1UM UHF'G9)6L M8 XIP9(R1XKQ6P8'6H:&2GS0JB%\R756U+W:J5M!0/975WX^N*'R\\'UE9]' M#QY^BRN\J[&#&6Z&__'0Z1W
L?]W;DI@]Y9! M ;2YN&2HY.#JL)(%-!VSTK*RK;T#(]'4#%?5Z EFB0JXJL,C*B#7&XZ+1@9S M@_+\"]9NC)1^6*3T8(R4WHE(Z6ZW3?]@W2%_Y&](7/;!)(0-
D"UQ*\^ZF>L;\V?,Y_PY/P0;Y)5G!- MO'.BP;M#$G&T/AIT_]:$D]NFF\BQD_Q(3N K\$R1X8-Z8*@MXAY,YGTM$SFW MC+ZSZ%R@43'&_:\([D K\B*;&^X6.I'LB,=Y@A;1Z3*I\K*!%
(DI^-@^MI6"]E5(065AP;*""N]30B-9"I7+87QX?.017QKS+B07HL)_ ML 57&140^P,C0B),FI$7#@I>7?Q!+%E%G, U#3!@AU%;0^AP2Q>DA$D>@1Q"
MQ7JCDNQQ%XP1!#MRTN#:5!*%I#9 P*$4<)C*4 QP7+R/CREX*22?0B M@RO(.#38 ("\8KJFK9@37;^J_H7-44UC"N&@/6;C=O86ZR<)"K__/+M5EN
M//)OA=P]WO^''H/"M[*2A!%S@%^[5=E)_D6)4DZV-6R-Z5*5+:]98H-OPQ M&9@CLV'TE(9,BUKRTP^;NEQ2W\C6_H$SV)J,SCK$$[\Q Y]-S'4'0;V]5/
MU8I&JGVL<)#&$;@&SB5@$&]"]DZY@PE[)6#/M)KT[#"9\?&,N@ QJ<07L>5 MS'IET):>F8P8O)" 44P!"LT+[I6B0]7M8F%JK46ZF1 C M.T.ODGZW.YD)
(<'^Z%MWCG<+6@RF@Z8OZ#Z8Z7*#;9MTBY6XAPXEEB$3J91 M>5WO7D0'Z3FM\<#LN^ RTQ;DO:3[IX#G5OI8.@.)3#$5H-+L)(TXJKQ@6G*<\-8=-T=3Y&YAEJWQ9<#+.#
MCJ"1MZ-XXG LGK@3Q1-_@5[Z,W$WIEMCZ=N[PT:,E#FA]\-;JD2*1TQY33F.&QM+$HI(39/HLSPL'
MS>^(+"PC5,#@:$BW[K%NU.D'VC1%0XRULY!*]%L^@R[GA+24E7R3I+KZA7^B,Q]#7\@2/$99:^8>*Q@20X\X4EJI[LID*R-'R7 MSZ&F=G43]NE,MHBB-(@@O8Q-
86(G#2C)X#L#7&^3 =*4+4]I3,)'+Q+#B3$/ MUG]6&%HS7VIF<(!95I^ 60Z&@&V@P;GL\T%**+E/"KE%X!0A3AA^E&'\,JM% MN5^[A^F5>F2$++/=>52CLMOQY@Q?
59F>=#NZ>39P[!+ZYP7I;]2@4R5%]\V;8"T% M70;_63.A_:=HCF5RJ:WB7)BXE:1\ $"Z_TAFUR)"+!O< >N?J;1P#!D78_1. MC90"TN@)XI\/]P\>< I(MS^G@F"(I^BL16=G-K(@-
_6):>G1=)@@9:U?A:I% MD-&%\G3AW&I0"\&:X>*6 U>9EP*#X>"P'D0;!CR=1\HH]A0&MIK">A_N'^[' M?W:\.$X=0YVZXJ_ VR MSM8(ZVI<$Y-
87RNW2Q4PG,X:1U3<[S"+Z0KD*U,:9/>IA.12/@T=@ F<@7(B MSI(U]R#A;G6=I(-Q-?Z[N+N48G6BEFVB>8)EQ@*G3/4A#CVF9CT*-NF[715)\+->
M\D2\)BN@+2CWOK,>%L:P=>6'6@*(2+%[D@1$Q124N$Q$-G0O!673D^AD)OCS M>L)P.\+/'$%X72U J#DR'7,)_L&3.#K
'W$K;Z+'T=J4!!H/@WSR:#^"^V'M1+\66T'.%-1_$O:)L[$#7#;#"#8", MDUS.9+S(1PO7LKG X^DX3JZ8,DKRLK!)G: PG7*UV+2YXD*M)OK[T>'#R2&8 M]_RNND!X--
"91GA+95M)^ G5 F@]/GV*EHX^P++Z3CPCQV)E!)#.'\N^'(#$F1Z8IB2?A,]^;>,WGZCA]-CNR*\^LL\G(J MK-XD+5YMR\'Q?N=BNN88INN_#7HWIEYCV
M6,%V\1)Q\&50JZ>O+OI:MS((4E_3O. A9R>/M"E,AUS,, *JD)52%ZV5A'4U M3<3?#_9Q=@Z.K4Q@?PI^0^ZL8R#K4>4V+Z^P)5>/",TD8C250PCT2/&9=IBN
M>YB9W24XPU#MX$;^X$"M%$_6'LJ2@*2QDT_],6H!2. 4%X6[H-%?;$K/6:6F MA@17NRZ+#AH%TBYXY5D4$""4,\3@$+%.S0R<9=B8/X,L$(_!X&3$2A&@N RY
M>:_]WH0T+:\5<"A2I%Z;LJ.0;206M#1M')<"+W3M.K0D\)[D,UQ'%/+DV^ M9A@_J0:4/_;E9Z> MT&,S+;>,R&^48(?[+9.SRGSS!VRD8Y3B.49>V%(L%CM&:%
M8+7O2C$DG4Q[>.M&LV3UL@P,[9[?F2&YJ(XO;2KRV=D5GM0NJ35LRQ8JR46.)F*.N MS5&V58U1 91*/$%19"DD(#T$P5\F02ITE<@I[1)&8+%RRHB\0;0KT!Z4;(L_
M#G3XW[$!)@?V\!N2R8J'^Y;R MX\H6%FJPK(T9ZCTWU E@VF94"W\Z"HZ_*'YT0?UG" 5H[>Y+$.#4 MHD5K4BTUQ^UB=800%;Z!BS6YR_IA>\ MY[?#)]UR#B3G%1N"K>9-
2%B;FAV:WNLM*[97\?VM1I=YPO3J +O Z%V#'DJ#1<84#46'>OG:* M/ YLZ3-Z&:;GZRU"8^^ILA XKQ$ZQ>P!E4P4531+VE 4+* ;H^.2.'#T!#9L MD>:H8DA4NT:'5]J$^C&!M3?
K@>0UFB)H*(1>&#L\(AJ-F2T+IF DCJA)]+3B MN*AU=>0;#CX#;JW:PIHS&+L(BUBZ&Z4BY'F<\'F+WI4VC-7 (*5V5\F+D.8DMU. V5(R,V,PX<,Z+38W[I>K>+-"5DD4619
EDHE"6H2*0_!KQ;.%#A M^"V=/ZR_-N*#\2^C)V!20+JDD4[:87[93N10BEHJA'9;)6)&^7$A]*UJ;_QX0[]+86#>!R;"+Q72'"M. MPTI= 1> (YRF;MY6E]S/!<]
3$KPNB(EE1;+^#H;95=WQQD5W\S (/33%RN8 M'=*RV]>*'-6AF1K:+VKYL*DK^:'M^6\O]NBE^)W_(-I5:B]+?U\/9R^4?RKK96Y8S+,/&PFZV4CU /;QHV<+$*Y,X6@Z@ W*JY?
$-/J*N MML#0UO:N_0H.=74I8B@AR:;V:O\(6H$P*88/.'J-\#T=B/'HE>>A)8K M53"Z,O>3LSTR# K4^C2%9+)RC;YOR?K^!Q?FW9'*\H'.HJ[$)2B529HM5F!5 M9O-&-
:9VTUN]SPU>?3..':+ND=#=E*'+C)XT'5IPUUGC3HK Y5#+TY$64>8Y MK)XCX "/.6*H.B_QF!(L1KKB_1?#L7?;"142<'6M$1NTO+4"N,N)LX3H3JBZA;NT/*]\A#\Z- M#;9M>9-
8<8CA"@,;S%-!9?,6LL'#F @6W)]OF"1;=4E+ODC(ADFMVX!/K%F5 ML%7D/<$#=Z>X6MRUFQ31HP#) MC#7>0P&9C1:^^>-P-M)7*)P94\-;4L,/QM3PF!K^Q).8XT KHO_E(AZ-
G\:< M#O$\X? ,"M$=0)]@8#3&\KL][LJ5=FANG_!)@MAZ JW/!).^P_-7[XYN[^K%A2X3V>@-'(TD_%4/PUTH-B9C:SU3LR97G/*&S%A/O0WNU"ZG#5%:H54(/] OF3^1:YE(RH8*
M[.+64G'OE%0?+.:\"?DG+.B"GIP5X*=H(.+^+C$)_BFCI#R!_WR! MJ=[^? +@I,GQ3#>;##3FG::?&DX_#MU),IH>U;C',T[1F*:V<1A+L*,9?S!M M277-
,!OM>CZNY6Q2JQOLU&4)8D8A',KD.MQ.\NXD)SIL?J8PWLOPS=%HY;?F M876%CQ6F/#727!"K-0GF):#C"XD>K)KY?GT 8F#M =YI=#G"AT
MTNF3.'#J>]+!"U?,N3;2@B5**@)QI=3;0=[GJ0GG@2QDW*=!W(S\?KH<@J8 M4#Z5YW5C,U93O)@[;KG^5L0K]EXL#H<41^*."J7Y54LA4M@!F)Z8U$9H^U1

M+GPC9^;@3LB3*T2/ANDL-]S2W)V/0&#P? 4MRXZ%_S1.V&"=L=Y?A)#UC*D1 MVRJK;3,W;\X;5,T.G\#GO,@[?.:^;BNK*;DFN!$L0^LBD[5682B!,KU^@0T' MYU1;TK[F].LDNA
&2>Z%Y/@_:C#+!B]/XGH.4TN%#W=4WC#:VBU%#/"+E]N^1\42A% '7X(KW87X5[Y5[4' 4]B% M%,*BK02=FO,PMF/XR&9]KD![76%:TW#!3UVW\,NODXN)4VE\DE*TT[Q?9]($
MP'W30?_.*ZP0D(]DQ[@(W@='CR;1;_2PB#K$^$&RZO &OR3KI+ 51BP<+IX[M)(=H^DGE&65H$5,4]L@WDD?J<$Y2?&!T7AK
M9YL:MCH,.8#HF!;FBMMHBA9./Q\^9H'F7B&QQ;G!6/!O)DRI,RNNH4[#+:X! MF_S,L]*KG%B]ZG;.Z4>V6LN,-07;43 MW B;PC("XP$W'Z9 +$O&/?$K!F$_P(_ZR$)>I
MG&X,O]FL/1-=\&E9KMGV)Y?0=A8GETF6>WF6+8I,D%6<+AOZ+DT?-LG"JBCJ MG[A;6:IVNO6A@]0./W97MTZG$<_8-6"SDDO!DX%C7R%J0MZR(JFJ\@JESZ,(]/%5S[J!;=ER*
[_5[-Y)4U;!+67L>"H6F]"0JL/&0$^1^PH: M]Y=6(I R.?%^U?Y$J3T2 SX6A<)GMEKXJ&^2HB5M4-$QX4QB&Z/ F:'59650 M.@_#PTU
IP#_XBG/NBFQ[S,C1,2*BA=TY+8TBZ,9[O2C^QH_5@+V1L9-X%1S MRV$2S(]R;['T1I(N\<.(!#L@448D:B%-SE$R"7C0+QR*HQ_=5F;;Q9(
@<+ILMEHTI^JRA6OAUQO43:C';NCI: M(UM/1P4XT:\7YV]?<\S*$ C$)'H)QDE)^!1D[^M]*5"-8C"U)B1XT 0*Z,7W MN;F$NU' &.6>&_*Z)Q$*WK32, C.1S^\3(8-
W)S\29<9LU>Z)C?*]Y0:UIQ M>!3^2;!PR52$S9QB3L-81&@L)MI5:_7[Z0]O;5A_QZ._-G_A13VR.FA_\!,Q ME."IU0#[D(2I+0IO"Q,=[5,@\H$&(BDVZ(: +2.T&S6P(/3
\!PEDA[LA77Q M'XI,55E8RJ>1OPO07'^8*J<<51@A= %$"A6"C2>LSVYP6*V(.IT'2?8M:<+? MSLY?1YBLK[3]9=?W173!*:X=WAK@Y/[.#M@E7C"JQ"A<0N%9[>&4:\,Z_5TU6?
4Z(('H#S66BB MVRL#3ENOZH'"T1)H8>IS\-68L ET/!!RM;?I45,B@ M80];+2<+%/:6GH5OX-O1=TUPK+:(K/O$8P#%D_*X2)ZW0_AH;U&.8.&DGCZU3$V=4MB4P_'V-08F_ID
M+?B338;#$;&0>I$=UX:V5_)>:'S[6O*^%%.R?>NU!]JD!WF(B9^M(,:IEH F M"1PD]L=PVB5G5BT:%WY ;9]@>UFMJ W#7BL09B,FX[)[$21]YP,2]GCGHR MU> +2+H$;R?
0I/PC@E_-. S%G/;6XK60IN#W"^ZGUSM*EB!2-@P!_%^2K?_:M);#^.CO9SJVNC19GJ-U M,8K#G1<'M2TCIK*JOT,U,HK%G10+"50P5(&R-L./DX^6A]U*X7P__0%9B>]$
MNNK,55['KBX;P1X4/]OF=SBO)'!ZBA(RW4B^J).8H5R5K12*_81_BG2YB%_7 M>!RY''_''X5#KK9TQ/3$YR8EQI/G90G??TKTC/B=T[)>$3C3"4CR/2E/>?[T
M/Y+5^KM3_%#*3.YS*5=#\"T,_[]I*L)W@A6/TA3U9/HUR)GA$"D&5HQ MA#DU6&&FCFJ@^UV0KHS:1GNXR:R?BK/""N5&=7 MYG581&XKUC?4U%TIA9/8R*3EE)"4P5=..H-
RX$\R+ID*VV?-("R$*$_L5K!D M%7P3MJ4?O6'Z1=P: O^"4D%<"YS E;;!K-&.0!5_P5]GAJHQP7D'3_9>,&4UM*G6>2#-3&$T9<8W1;;_&AO9V-'+[8#<9[V=73\2] M!-R91F
+&1D9M(N[>T?;\$BNB?([5@X@[QHL!D>@ >\(9O.)>4/T^-V^V14^ MF,:H=E_O.=@+IKIG;2JJ:<:1*_HS$N=1'QQLD\IN=7U7@7E!0V9+7"0J02$L M9(=%ORVS7,AM.\I20'K0_N-
")QS[]>:9-X;8HR!/HLZR!:N#>-XV-^29%ET; MS\=N"S0.CFN[$OGGM0J)N:WI?4=M,VJ;+=K&4S?+;+$,5(WK\"GGC2G(XT)P M>VHPK0BW:*^&.RJ@P;6*R>==VW+.T]
[8+NZQ3YF)/ UMS5VO9*A;CT\-]Z%_@+&R]64Z&VL=X ##85R!Q*XFQ31:'20I3_,@XE36'HKI*:E:X3EGG0OJV$37X? M.P&L> "@HKR#TT'B*'\%>0EB%\)P+/S>X?[A/G>3AAQ>?
B'*,#F8Y[,Z9K P M>.)C"I%9+;,TA(D6)2WX E6F/6XA8FYH>7=V0T<9$29) M/R'UT6$GNOK7H&6$\88ZUPDT"59![E16F\ZSL\9"(@Q66+.- J-NVL8H]0.! M3W'7I#\
[DIVS3"\MW#\ -?PMX6:\%Z9IF(""^[EJY(- $6 M=KU[:P-")#,.[YQ6R16'>[HF!?875R9)-QPV4@BC605W+;@KK"::;=!].QH2 MQ0YCMU_/>8ON<
CX5QNJLZ8LO7*L)#@Y05[QN0F: ,1+''&"5!LT>U.S*@OV MJ^DD%9PZ%P63^"&2QF)S+(=)<HBKPHF"8EFNK,EZ0D[:X,Z1@P/;\@=O+SQR8+2P)E LF M.[2.[HSH&:7F2G]-
X02@=MH;IC^V\|_!?C8GY'$D!Z1/V;5;::<(7$(ET+5\ MS3"1ESU,Z9#@U0R_[M@9B(!OF: S8BHZ .MM]\/Y83:L;$Z@N\U-]Y&&X2I! M2!OW+0LH2,WM[*DB=&[@J!);X-
P)K!@2G6#O?5X6I:8DEBYL'[JLR5Z<^YF M?#:V.]Z6=L='\M"QW7%L=_S(D_2$T!IORMBQ/0VG*)TJ'&ZWF24+-T40QX1> MT'" 6=7&I9&0$%FZ\-<<1,5/@OE-_\/?Y*
<20EAEYD+()H_;XJKHP]!=H@N% ME6*><52='6B8BEJHX+MC_7%#3@T8QWQQ%FI'!G]MF%5$0EY^]C.8031AP;=Y ML@\J=T-J&\Y7PPSL6\=_0D1_'.8B5A\TK>,@V8K!"B:=0"
(SZE5$V]=>@:<] M6N":G)C0FZ#EK]$+!?'TUL"WT6?^41%S^ON=(:.!): +U;#EL%"_"1\=HI*N MD>%1,1YX&NW1+XX188740T;9-G. L>U[![#$Y7TK++69@T+%[D0_:@E+
[O@O^87O1(&)ZD0G96JEVL(#425>GXPM1/$ CR_--N>< MMH$/KXX^RZ9;18+^L:(..1]YS*^/ ?+/&B!'/@!!)VK7*9,:;,TX*^4Z[@P- M>5%,"O3T6*P[RE9'MBJ#L5J%1"VHG3 .
(K@4-1!Z*-6YHR"-@M01)%<-XS47 MQ:ZS*/;J,3OQ=34]U>)EEA#](I[O3=4VRWF;QXSTE-5PWCNX<@6E4V1R+AH2 M$#?L*];&(FL;+4A]1X8&H@GDO-2,"HQY$LR6Q*H6"P
M#!!>8!5W&EGEM@:S?:AC6^FF5;E:EU MD&OF&^^$U(.,/K,TA/YF0E'2K6%3B^A)7\7=81-DJ^1_4-27Q(XN#*D:0QZ% M>13FKC!+3N#WH2C'TJ*)57#R6!A]?
1**^5JS4&/F!RCI/4E#6L#K"M& MT&32?9(G5[VV&#:$\/)?B^SWUF@^\2QE^BK,WU-&E#3IV&\WRMR S&TM!_.@
M\#J"IX8X!;LP;U!H,:XKP9UV&!9\%/UU.P7[,UJ:)&=#U6/94YXL[!/=5KI+ MV4XM7/+CMJ-@CX)M!1L%D:H@JC))_0"N5^?9+1Y;EU?4=N$PI@BC8'2.L[@:/!J^T9;
M=I2V7L28L&+\JD^A0$Y!HTH> FNH3,,<%_3'VF1_$+GB/ #]'>5KE*^.?#%M M&GO=?EQ2B,F(CZY>,U\MVYC(B5TOVR8EYB4;BQKAK$;Q&E)?\Y9PSZ@G+4\V MVA,
PL;A>RDN<:F*(.@IW3H4^*0ZH8+K83C\3RPI*=?DCCIN%,)M%IL"L$DG!56 2SO%*%^C? TI.<8+X8(Y1F$BTFB!9K+"A2HO,,G@
MJE&B1HGJ1+"W=FO=W<;/[Z<_!/R8=Z/Z\B63:RF[BS0&E2V'@*_**D_YK+(U M:B:(TLVK9&7@LG=U6*+)X8=>_RM86!V)ZF[%BK7RL?YJ@8N)TY6ZAQG1(9^
MD(\+FXD/!AU7;X *\26CD^1O[#(RRF5A..XF-LFO'%#P76, MRX2%IYTYX:3B'Y(8XG#AI8!B"!'.)'K>IT/VN"VWW(VK7Y#^QG !3%[BK'5B MF[;.W-(=_MXZ'DN)Y%O0# U?
D6/3_WC2KLE>$?.K%4 LR2MO:!SK"*IVK7 M.MY_(IV/0V&BOC7*PYARA\YF@N\#="8KUMSH5" M% &)&%P$WV^-=?!E6Q.=-=TE[7V-7V@;WS0G/C"+Y[-CQEY_K>WNERP-
AH>9 M^90=9 O=\^54S-C@M:7!Z[$\=&SP&AN\/O(X?8L8.]3#8/5C47I]7AXP@.MA MZD(>"DB$Y?Y^!LJC7"&$);B+%EGQV3,/6?'G\LHP=QHL5?=^ZSR9,=B'AUBB
M#WEVPOVZ='#PV9F;2_(RZEJ8=(,C+4^R-*+@'-SBI"C,^^@,W^)HMCB3X[^ M^>#PG\^>G?JTP;US7!1QV&1=N]L(%@6B+,UA$R /-(8&!T=%5:549-F%@% L M%TL5'_)X,:
(D'1E)!/N5[Z+M24PPO<+:4.P()DQ);=!R"KVTV)$8K614._=^ M7GI<,^ESK&"K/'J]FJ Q-:<>^TU7-/YDMLR,]$-[\%:U*XF;;F1M[8NQ)>6] M>1=BE6IM0<=*[PJ;0
M84)PFY()'0\A&M7^S(!PHZI X>5.=Y/4&<(IDL"BU=1D]9PE8,NF389Z&R>X MIL&3$_M4C\0;GF A<0G?=G 'TKS,0$$1<23\:=HV+$UKM'8$$;?;4\A#SS1S
M/WCK76WV>PWJ$XSZ/#J.H\/]@T=QJ/7/DPJ6ANL=$.,V'527SDF-[GD_X_W^ M^>C!\7U7C0\WS;5&BXEJ5GOW9Q+IPB9PTR0P0&6]J#QPC!9SS$41\>L);8
M/JQA.L_,TUT(X:'.)4A.6V0,*]1425&ODXHV+_>6DD#Q3A9\L&XQA_7*0&E6 M95W;0XX\L2ZV,-65$ AA0BAE#K.WK[:O:.L*2 -N\ZPHRDOI'<8YP-1!6%K: M>_&QF7 ,Y'W60%
[=P/98-%C;1[9;FS,6-FYPE%&5]-#V8R60<0E3!^B2^J^7 M9L.'G2+)C%F)4?0ZHI>MJ"N*Y I4]32>LB$H4/*/9DHPN1K^# MLV /S6(N#6!H:(>JV'+E="8ETP+S4+2(7#?
*YBB;7;4(2JY=@]Q@**@2.(UI MPC@F6L/L7#4^X6>H\>"/#A5")=*8)[709"231VB6 CG@@ZDP8"/7#C@0 M+O6T)[].QN+^45RO/\7Y!->J>>*VJ,D'P ID<5-[>+K..Q8DW:
6F:'42F;< M6)1$X.'*]V=+,WN'\0/S?@WWKQ7EUMH 0]&CNYXK_,VX3 %&_%V0Y!G-D&O_ M57!#S%K-YUFU\A,ECDBD)"V"IR>I&'L_UDQQT&117&9564@X3!HV4/MX8.=9 MP;
[9CGK.WT]_^-FI[#?.^WN17.TR$.=O#&O58P>*@^R;-KTK(&\/'@>%!5DS M&(*VHOY:4"_:P\8,]9AKM-BU),)"[Z39+0\17L;4";W'"%H"7J"S.#G%&:=QO
MX&%@V>V]RV;O,/$1HR/?"TS^']G8OGZ,Y2TW=3:#^8.3?$,ZTD4, M9IM!BJI=W1!OO1;$$YS'?\L\DH!@.[6"'0R&)>+H74&-*3FK& Q^SUOL\RX1 M Y.A'ZBV$C11"890UDC-I8-
5PT1J959M(>G,Z)[+-N/?W,I.JVQJ^,M36/C[ML8 YY-0>CHJ3?P.IQ@.:/Y[)SX2)AI+%]9N4%&[:2GBHV@I\"H:JR(W\0&:3 M##>I+(IR6;@ZV%O@ZV"YD55\17 CF=
MK:9M57.@BC+F):/:8[TS;CL.E57P5_XI2QUNM*YA:) BE4$*W'[P*+3V^UF62MR8 H4MJ.'+(OP.3@* WL) MS.$YTF[1U.$B$*@N;G:8!]YN,A-8V#$@:#C'PQ)JA]X9,K!+0GIKF
M"B_NIGN\!(B->B!AV)(T"64 3#U#"90$C"ZX=SD.&$8/*Z @N1K[%X^3 H0T M;#QTS'N$.[15"UXP$D]MS!6 Z5[;DQJK+X@SA;,<7O\FP?YZ%5D\6YW;!_;).VHR3=YP5_6U
M5^)C"W:D23!(VQ!(D\=9<)PAV,^+F>$ M>T?+-[A+,5%9-R9)A18,OR,Q'_)7W!;E#.H4*;% OU"A%DH[407M33=[^%^A MZT/"7/_:KNBLMKB@-
4\.PC\B7N[EM:V"BY&FY=TS06FORDMVZ(30SY/H$B6 M.F6.OH]DO0FR6+0@B6R0C%4^J@\0>X;88?Y#[S5Y?W';@;?#LMK;096!4[22
M#H,!'4^'&V9Q;>'0!ZC)RZS,$R+##'+'":YHS<* P;)FXQ:_,+RQN8P)M"0, M T_^W*0+1QPB#*=J%5B,E/P57DJ'6U\,.K]4!409"VVS=)5E!EYSH"G.#"R
MW;QSAL\,=WC64A=E60Z\&]D>VFNM'$Y"6A"9FDK$LLEY,FLF$95+UDS)R;,H:7"R-NL,%$92:4ASRPZZ<"PMG.;U
MS#-6\WKBJ=SXA04T;$]VAB:131#AQL,"MV135HRV51;YQDLD5ISDLY:(LS9. M7=4>?9VU.TWPE,PIS"=GESAX+O/#K3&SF,(-&'<(0)^LP(EP1!9)6*) ZA]? M#>MN*
<21<#M/8.SSR32GCFZGGW2IWL#DPA:'3\^*.5@RQ4RJ/$[+"HL-H]?5 M(BELT261C,)CWYR=OAXK[FY)Q=V3L>)NK+C[\Z[OL-:^R?:*2B#"#7I'Q+W\.K$H2KW"C >*,1V);'?
3L738;-WWZ/&+'\A^&:PPV6M0D*\[>U,K&@9?WUCM!F WO M?,*0PF66MOS"YSMYOI"]2FS7H7K*4$?8 MN;;8&-;N93#-VON+-5Z&% 7*Q-8:)XM,X\QN)^VR?ZWK[?Z2.
%*.OZ"6FA. M%F5$J"78#EQ2JP+^CD,0#[L;I[*40&@4BIA0?2$]F4>'W^[KADGT$R(\L:_@ MH!XC5.-B!"J^];ILI)S/$X186"
(PWS1CUTS>Q!,VMR71_Z)9A>@+6"4:3M3^)_LN5OCI__UD880* ME(&$HSVVQIO]#2SGEB#4RN$(6:>!;ZGH7A2?$J7LZR04H@+E-*O2/8PEB#]@ MZ8[S#?$.+L]^KBK<1C?
>.",$L8W6H8'."^K1FM:<*Y.9A0&U8]0<1$/V).' M,=77KH)2;'L[5Q[P5MFG..YER_K)6=&ZNBD_GYV?G SK%RZVA06^*JGV MT,I2A1/U+W\9G?RR2%I3(*Q:]K[!%
<(2=:9!].]7_[G<@GE/<4XQJ?!Y6"3, M(^&_8:EG5,^69B4Z0-]CXP]F:@HSSQJ553^2K4<>>[!HM70""IFG]RE:8/*R MV(B.\&&\%')I!;>L2[$+N(7-
O(?'45T\&8V>%JO7<%R5E4D[47R>S]Y2_,GY MQ/N!A-.$4N-%DJN9B$/"GZDFQEI_J $)XX+,2K9!Y&]R.TR[X:G;D)X+341G M3E+844XO2W,*(R@D,6W;,E.39VC84-
^;,X8[$0U9SSKNQS;^] KJFOGK.(DN M/B!N\^/3D]B94_>7A_%D3&3B0?/N9PIRM8 M8[YAQLKO1K$CQ6&)>T49[CDEJR1QI[Z5M>'ZKZ0WW/YJ[(\8[#-"ZZFLUUG#
M]6^./[Z*N#*9;9FR'FRMR0"#CJ#\':6)J?SK_-\>&R&6PYS=;@@+#5@=Z ? MT[75=;!B5"F+@.U L0OIF6NJ7;7IO,9Z<'SNTYE6T\1JY;"LMIWVDSO9 E>?I'-
NU[/S\ZTY]4W\\0U]DIQ@^*#.HP ?$9#_^>SM\].?XX#+2=Z:@LK"D(GE'G. MO50$.# 7,L=:;7W7##4X9:XOD!QG8BJC]U,.%$>50M/+90:^<>X M?
U*/":+;D2!ZN#\FB,8$T:>=8O^EKA)90.QZAYXA!]_(=K2X6!K\G42_:1,^ MUQ8XH"&ZE34EIQ6:SR$-+1;SAVQ8=7@!ZGUJK*46?!>6Q["_/-%+*:V-8IG M5'DE7?5)5+9-
;AC8A_5FHL1N,AJ$&BCHY('@))G%\8_I.FM5-T/:7:RM#NG M0%/R:VQ$6WM_)GW,3S>UFL/]^^ZJ\7C!I 7"[. "3""H J>^+LF964*I[3/!0 F7^-MY4$3A6=G2)S9]=:[[:H8
M^F5*3O3(2EB/@[D?J(#]ZGIZ 8 MT!.SWN@)!W!/3\]/,);P"WC]T>%C@I-X[#P.CM&4BE+V2U*T&/(X("'_4GT MNHA>P2ZBK/(1?QAW'ZU/?
(.JJU:?""^U3L3I^9L3YYT)]PSZ2JQY:)!DO:=I M+3C+?$_7PR3B.80Y$8X:AHG)2TVTN4;A*2;_\7TSY'LD&"'&7/%= %PTA?KC M2L_:U6!N/!L!RU??
8UJ"0_OZ&K%U%;"VHI93>OC^@@EGR_?Z-=)Z5U*.P4E/ MJ5+Y0D#30ZC4&[YQCF]J8TX%^Q*F"[:$=NYAAU8G' MNZT%]UZ!![Y"F1_N ?'/-@N7') M/0*OIA9G;!
M"1Z3GH>M0FCR(8X"=OJ1^#DMH4Y*G\/3A+*YH)-&CPQ[-.!T M"6D="PDM:-Y0QDE-"^)'V/26Y21VM M!>8M7=YP3O3BX/QE9:5PQP1/X280L\6X0?%D1!5*/!NTW5C;
M_7NR106%RTGEA8)PZ'>OMU1SF9>@!RKNM24 .+@]W56S[ZY0&9YG/0-2*-KU M)D]#J_-UVV#@1M4@J])@SVUD)1PN.5GJ0V_""X#>D[N8NGBP#\G3Y>Y+9I'5 M4OY
=Q55PDU69-C.-KMJ'+P,JB9M),+M9MZ5M(3^$:%;4_J:+).I@IWJEO$M M5V^/^%J-.]7!4=-\%=EU/+A=@?-((8=Q^+T3'T MP5X8U@-=&7LBTBP2& ZI7O]XZ9?
Q#MN*P\\FPMPK/?BYRD6Y(7!$O_'YKI5? MPE-/AKY-R2) ZQ6+T:"-C\K1$J3YT/&V?HT"=^#LS[$#N-E8EX [\' 7(]J MO<>JA%/?BVGP5#1]I%=2NL/OG1%9NN4O];5ZW;B1<4
BXX@QO3S3*?AOT7'/ ML/B/+*S.@&$?N3D+282%8=##_<<+X'?SS>21>F@[P^B[N(01^87V%%?3X" M[^5A\F@#?X7*ES$KO"4K?#!FA<>L\"=7>3T#C5ANC-
GE$JX3ZWVGD@ZABFG, M.V+W30OK]APLH3D%+# RABD9+"??:S+T]'6*6#=F[]G!!!U,Y?2O$!H![BFW ML!Z)]S6*J+C.)H*=RA.$I&@+J4[T(N^N- IV5;70T=PG'HB-%\X_+5
MS#8RP$=8HLJ6;N,/A9NL$+]G5VTMD.GG#$R4[;10@^4E,#+(0L$=IPR%QPVE MV*=@YX&S*@/-""_1%JF83ZK&"%HJD"921/$;6%Y/T6!RGO:Z JLS6R.M />N M8&H*33-
CZ_O8KJ)[D"$%UF/&N76;8COQQ> M>LG8S+YIY5LT$FJJC7E'_BL]WDV!&E'"V>'<<<8RY[_I[:2NLT/_C%:NI4&8 M)05EI$J:.*ZA)).37MY[KCK#%@M56#&XWV_3_SMZ_9:%
OWO&MUGA/GRO"H^[&,8FN8MUMM3[DSJGK\:"],75 XO".'G'#.#!EW67=81SRDJDW'C&/[7 MRT_-,*?)G9"T6Q:L/'16-"!48FR9>P,0384*FV3W3:(+WN?=K[)CM$BDNC=;
MK9..6])Q/]9E+=Z'<[FF%8DD=56UC>Y*])YCYT>QLX1="^_P;CGE<+)?+[W#^^4UQ:*V M'F\D(T@I2 5I370 #DKT$E4O;I W)0*"_=L4F$B)HU?_'1T\@!-SPN^"MVY, M;M9+-!
<%O0",T'N/'S^^'QT>/=I[^.#@<%Z3G8(UCNJK6/C3\^@EWO[VACB5* M63R'R>(%.-C?^W<<_6<+^L54H&ZV7?2?<73*.FGXDL=X&WP89RO*L,&?Q=9]
M=L'6G]S]H;TEHT)NN$Z)$WX4D>1.+;EFCJE;RWTINX1*J+(*(_QI <@EXI M#W")F@^YF@.T#6.4JI.8EK-6^WM=CL)^JK#6B,O%5K6;&W\F=BE8=E,@*WC(M)T6U'A[N1NCJ?
X6AIP^/,'T+BEZ6NVLQO#QY!2OT\MFKMSML*,![OA;E2BKF MJ:K?'7[G"T,@!:#BIH:@I:1/K4@H\LD(AX1W4V?6S-8&C+#TA:L7$<_4%.U M?X %)Q?]=1Z=M
LL+S[:I[+7!]*@=A'+(C'4N*KY:1MRN\"K4R??" ["8]X M;UHV3;D"G;1^3\#E:50MIO=@+O%_][^+.@0@$5_O5-FCR:-_J';=:\JU?Z=I M#LIS.U_()XAA=Y^] O&RNVJ8P>3SO.?^!
[SF=10OGV<41Y/C+SC9-ZOSD\6= MFOW#+RKK-T__N2C3@35P=#.X^^T\](P9G(##_0>@.H^P*>+X^+Y-'GX001%M M_[_HK;<=KN#-/;/>MYZTZ,O=((M;WV*?
7^*3*)IH2W[B=__4?Z6%/1%@KU#_TZFR:Y+\\.CNR+-+X44ZXZIYJ?))?BJOY3+HBYW MWI!^^'#WI=F9T*?+)(.O=%=U9[4R!P)>E<6>5JGZ@?8Q&' ']-
A3,S+OF]?]4F47T(EO7LV76_+'K$GQT!X[BSR'!WY(./JG: NSH(KE* MFEV7WX=W("9[US3PCWAU=%[61<__VSWY'2V(G=._%XW)\R3ZKZ(LW^VZ_#X8
M]2_]I#4]\".6'>UB)=D')?AW];6])#>_[21Z64WDHRF*Q?0'XE/$ZCA"K.TV MEIX^>XV8!S,379AU8]OI]B?1+\RYG0ADA-?!D)L$*]:Q[(YNOL;BY98;
C.S+$#8EW16[QPF+I_TA6Z^_@!NLE3/0I7)\Y?G'+;(=8MGJQ,!>]'*6@$3EH;;^Z)32>C*0>;]\<3!VES4B,] M_,5L699$0OVCQ5;@PGGN!EA428H,[U%JL%,7GWK!
[+OOTXCD[/3_9.?SHA&3.NR1DD:4O&M=M4>@3+ M>2D4FWE2-]&QLH8&3Z)=0$P]L/0H;KQ!J&W:%; B\@?!W9A&Z+I\$FV%;'K5 MSA!^EJ0WCI[E>58_%5@Z^A!MT-,6(:>B-
V9>90LEI6%DEFA>SEIFP2E3Q*+[MPS'9>#!%#BW$X)MGA%C4>2G:^Z=+ZBI!K'./ML;R>3!E&P$O8JUM!+*)G7W1 MCPA6GF,!
[E,KP$)_;EAT7R1M1704A2?!NRVU89[;EUG]-+I!5V])K(H"]R7W ML'-C6LQI5JY$*9L"1F>D@B:)"JMU0; :D25?'2*U:,4*Z*JLF$$);YEZ6A@Q M@/:LZFY,LI*-
("B+]OZ""U/.FRNL^[9C\6##<(P=BJGH'C=*/7]Z$IV_//$1 M=NX/3".W;0J+[CHG&$K8N[C+",F/D,JH[69=E0A04S/"7DY8"MZ>6F.;:#(S M+1E^#J\N[LR:3_=4-
[!M]MJUN]H[B8AZCR?P0U;S V6-87M*S;3_&MPWU#Y^_3Z$+7_IFN/6*! M/46P;34;GAKA)PQN9<]5;*=Z"2K9PQ)PJN9'*^C_U-OI@Q2H3S54]]NDG-X:
M4'&7V>6=44U^R8(JIM>*?L[XX \8UV&]+C/"'7%?@=6>/)W$VGPQF#"_3E:> MXK$#]^$CU.[7;8]*J",8B5FD;' F3MC'H'"C$QNTU;V\=6^25SA&@6LU!4 M':*
(BGZM_6G#B;\DO2\6./;*.(6- *!J-5O0=%)MI, 0!7,6($Q.W+WYW"B3 M*MU#:.1LGIG4?%0[4]ZD$8@9-*;QN+UNM6IGA>R]UWBYFN0'=F8$E*U35 MS"X06K,HZ?\-
QPU>\V,+,Y*7EL"%;UX6,[ZUW"7_EOS'N8&I7.76B:_97RQ M(WGHB"\VXHM]TDD55"1-(CVNX+"2OKZ#)X/'5?]/:KZU3#;SRDV1/0&[I#I MWR.V/[';MJ5V'?33LP)9I&=HKZA>
[P!)^\|DX&-L\)>'2\,Y:6>ROX.N1XF7 M.%OPAK&<@*OY>YO@6.3$C&$H,T'C]7R+@\,(7#_P94[6%?P+'SP)YP9#-7:L M@2U*O!QE<9F A0O6YV56"\[*CQ6<)66^]W*#?9H7O[?
9="J/YV<=[N_9OQ0 M@I%!*BP$4B+FYCK);2-_JC=E %HXZ+HG=%()-308>&"F@U=-S+S1.5CLA;;@ MOD*DFIG]&[GN*2)B$=TK843_<'D P(0LXF,%6+]Q+C&).98%
(KTNF"ATL0 M,W5M&$3S%!SQ8@E^2K$W)2SR7POKHA%G.P&EVBG#";$&JZ,Y5ILV*^85F,15 M2]S'S%"CH2E"[Z%95&877,EXBU#30FV7E6! ;L>@D0,.(SZ;S(+@LO!1$BVY
M).8*B9KTK#R$VH_E#5P$).&;_[_(?ES)K9]G]9+":ADS5:-NDHMC&ZTB<%RC4G[VZN+9R5-O8AR. MTCFS2^/MGI>,GS$%<[^%A:P8Q9[$65A1<_[1M]YZ8HZDT.
M3\V2B0WZ";N-<)-XD^<@%H>"'2*)+[*Y4;^YAMEA=R,@\T;A[X;(R7EQ=XL9 M*F:9(0@Z:P$*HB/ZF^U?1XZ #"GNIZ:Y0JZ=KHN_12()FK$#,E3M,IK4AU5S M[NJKAQ6-
$WUGDFS]M!-.])7=!P@5!Q65) Q-JLG6N\,V49]ZEB!V0:.0^[*! MX(1#B#B-P<7=8SGP@2TODD ALF9I497SZ0ZFJX(-)?D&[H#&[-H88@6=E8M" M:3B070"O9-W++BM=
[>&WN3$AYB6CM 9A0/A#.44&BB[2G(0=,J.3!>?KT= D M98Z\P],M-#H:*1W@JB>]B 0IZ&0&JF1%#$H2HH.AU7RZURVQE,S;W.+/H0EY MT5FZ@T?
Q=L%@PALX$%K&5+*::&NX&0_+'&EX7I3E>I)D,:FS*PP27&4%O0T% M0-LUIR/85IVV69XRR#HO,%%D6K(/%R(6I@^0CB52;R ?!=USG2<-VI6>Q3''
M8Q+_UAE/\+)HCV;%99EW)-6;/!EN'9"<.X/DFMF[?IHPP^3^1)0MN*0<5R-C MK/27Z5@M=PSCAJ:S'[^$7W]Z=2'LXS2+=%<_@;M_W+GU(Y4*X2TZOEXB!%]8
MG8W:O>BP09C]48$41+UHVL:7@&RUKDH*?XCXF7). M7WF'JQ=73_0:O-RGF0B3;G,QBA]VUX%YJ'Y,-CDFXQ!">4&F$!EW*)2\C/[* MX1UX6649E?'B;)8L?
8O%W@/M$,RBX<(D67\-#VA8ULMZU)D:9_398#;EPF4+ M.8/O&;'.#$;!3U6OZK>L2?@RH9 [+%W3U-OLP>O,*QWGC?950F%%4:A8HR1, MN(,Y(ARX]T++"D!2!.YVVW#IUL-
[I*)[M,;DHDV<\='UU.0ID[R,+P319@/ MCER$&29Z2GGU<#F5QER,?,CBA.R4S$-3+WG9*3-$29\!_U/,''5E/=O+ ME6/YS\BN#_]PP8"_0; RA,(5&OK >,M (%6OH_A8-
]:DH=-.O/+9:\H#E9=) MFOP>6E(<^0'SZN+_P[*:\71J4F3*K&)]$GT,\8?TG:FX-8NQ^%8!(=[;[TXQY M-CD\EK>@\),X^BTAJ%:* 3V=G$ZD="TZ7TZ>3JC29XG^2FANQ-LKUJI-
GJ!4 MJ)UU#JL%>OZI3P5F UK6"0K2_(%AX\):.A>!^<)FB+=T+Q]$S\/)J MFKJS%]O4I[<;K[>>!O=[5>:&=KL-) ^FN+W054<5QS?HXM.[H(O#;@^_6(L_
M&W0"^P6%2.$@4>X<8XB^@PNB4M'N'EH@DDAGG3@OS.GF_M/P"&"*R5."#:?P M_#U6C/^*GIV^?G,_9EI/M,KPF^#X8J@Q*WUJ2NN@(,(UR B9!7H".[T>/,J; MF9MG!=6)
(5Z:I/*37_%@%NKUS-!27)DJ. %B^4R/G3-,35\R>#];E><<9 +U MC:%@?_&T8'%;M6W"!8Y6G?QG:V#[614EM;JB&+3 0O@Q.E\]1QILKY"HO^G= MP&YTEOB@N-
U&TUC\L*7XX<%8_# 6/_RI,CVOA2LF>RMT$^@/O:C_%DL^CIZ7 MI/[%*+H_TL* (=MG?1(H*]N+N<;CV4TG>%__?44@H>/QUCQ.6KR/A84<8$ MGFA,2P_)+ =7H!/OCS

6."_!'Q;7%!Z3;_;X9-*"4:0#M:>6Q.\FT061E-=A MJ7)@^'I19PHIBW_?#?UBJ2Z>'$A!'@?G(PS6P%]!7JC>8+'YIQA=7->GA$], M,),G;<&)A.%2XYA8Q7.C>86S>K%N_;>8T=
[XT_B9S_1XX) M^M7=5E[+&GD9)D>(325\7Q%,RN+$JSZVI.T8<]>?(UKHL4OLG?P M@@FOML8W#X]P/L\Y[BPB:4643W,_L/,:32IT6]"J"F]T&-S("GGHH;F!J9AC MK'6!S
NG+KS\$\C1FF__DA940[WV]F"G@R^W=U;LO>';PQS\$]R1ACCZL%)R M+_/_AM\U1=$O=PS?X0%>*$'XZ]R$[CH,6PW7^PG7%=1Z!@:MPJTP,+XH99%N
MRI\P=D=!RIW/+:.#)ZDO+;'X4?/#=R7+_KI+,"8%V<14(%DDT):LG;CRK!)U M[4\9$?S)[!&Y9LV%7TP+>N_1?7X]3LRC;@W*%)W7UZ\R"@,*(\5!LI!;:SQ M65./K=
M(E$MH'(IX5&&0M(UFHOVB /_8M%FJ6;>VP).(CU!W5L*^XYC1_-? M=64,LPLE4KL.DYG4F]%+)CL9#_!1_X#C.WU5M1^0M]T__XO2V;[SHSS!_>Y!CA !\?'C[\[AID!1FFT(I\
MI6&B%B*1C\X\F1;E2T=84#H51[:)GJ0[3*UBE28RE_$6]?EG)3\VAS,!+4JB M9T.U)P4:=5/.WF&8"4N*F2B9:E[!T8$]0.X2?3N7ZZF&%"G3I #+,:&"H9/
MN>UF)F339P&7V3W\FC#',6L<=NL988Z[WUVKVX(-,6[).[LEM^Q)/]Q.\A^& M.F[8A#5ZI^DG[T)OYTS&'3/NF%NV8ZX]QFQ'$\B_7S_@[YFA+=,LLVJG=\P7
M@S5LV"#^*ED]E,FL<-87,[&-!_R7+>,.HU#E"5_UTF KPH;;(B2=57F=S7; M;26O35M39;.F"#6N^#L,VCY9FJVVRD<@!%D5WLE^%_[@#1[=S;0%9T,'YCW5 MD..*95C!!(3^*A*
$^$N?J2D\^"NF#S9"'_LNC*4]X/?..9,<2UT3[&RN<+T M?,]3K82B-9JU**1@"=TJ[ZJ=^/_V!Y_Z%"Q=> M:%_9#@=]I+5""W3.X*A=;4T5,OD@<)D>)'.81
@HKA9@]DJC!!=9L:V>&7>I ^1?2)#*"B1 M:2D4W#H$ZCI+FH DU&E-B48$9^;UGI_H*(I0B8?EO8MR])3OEQEB+W441*IXB ?'" \)H^QCEN^2K MMJ06,2\2++M(-
DQECH=IC$,PQ8+295X_2;-9\WMX";J$F-QY$[7=YFYWQC%@ M46IP.EH["RK:?"B2=!>E(Y 'K8R"32@8TEV9=V_'#;#5DB-/L&UI+1GL((^%AH$G2ESH@_1P/
D.F^KNDT*Z]\,7$Q% MG;P,7CQ,8_GYT\#!^^/ 1U]J3+TLI M*S M9[HN+@E WQB1DW, L^FL^W_O:=-HA,OC1F"6^#*."A8M*NG):;FFK>]0[8%SDS)-)4^GP0A
MCD#D(CM#6,N-M1JFJ'E+V;](1\:KDLTJV^W9+V9QWV'W;.;5?G!W6;^6P'>Q M9EN6B\(^G<2O5!A*=:+@%]7!/?P@$M9K+<3XQ7X<^A/URUQEGMGH[+Y>Q04:
M;'8*I:G;>]A@[0$^"ARXJ@1=@E/%X3,,G>%&A?_N[/;+?NC(%V^SG7Q9E)'. MVX;RZQ^DG0OU$ T*>OP$5AQ$XGOI+%]"EW38#$0P'%1',S!4C9_6UTPM M;1LE& 3^M-
STWD$.D&J%]-42NK'=N5[S+:-IZOMZ@",KDQ02A[]X=NJ#!4^B M9^$$X[G<'3I"\E0F226RC4'0ALIPX><$3V-XMAL%I>KYC,[Z)3Y>.$CB:W0I M!P,J*9[FM,R-WK!YG_",
<97R('QM2YK.@5_Q7=.]%MCJ\# MQR%\E,E')%>UOMZ0G'\'%^O5'*%%A#MIZ;SV2_HMO,C-"@>UT- 'QR&KWWE1 M%2NRF.-O9_Q[O:D;PT5S%-$J&,"6JP49,IA-
CORQ@S3SK*\X#%U+,(FB5!+*QE?V@VDTS645VS>4#^P&UC<6 M,14/AG?]-?,L[6D;!2-GCZ=V<3*8Y!;>$R^[Y[_JX'AE=OFIH/]F\K+H46WD M)C_*31C_V-3^<'G^MVRU272A
$#;JE9[FY-#Q]@'T9"9B1';/(._FA1DO?S7 M-U5?2'&DC]!\@R4;VXH8CA[>6)2QG:"J5Z;QN6?QR<-'3ZXKQ!@8VM;Q](*! M6V*'.J)(AK0]"J5GR-]^$!!9;[<+0*%H3I)29$7@*,-F:
(_O9B7>*+RW7GA! MJR+P&-$E#B0,G[8 2Q:%JD#Z1^LHWJ-X?Q7Q7E=FCZ(U*.*Y6BEB M>Y'!D&+>9H_MY:0!(Q&13U*\FV1Y,I09L@72>F]BM7!A%O65'S =KT CU'>
MW<$=LNM*D&.")FD]QKXE'>;PT>=+6_89T2?%SPIC4O'+P-1YQZ'12XQ^"+PA MC)LA-ZCDD0HVMHS+%B)*04)0O:.%,S;NZKM6]# \P:Z]/\^@"P=W7G?/. M_BH[F_<-
^06N9B5K-+@C&R/,#HJ\7V& W%L+N>#@7#!%18VO1>'?XW G*8>M\VX;;[*ML&B"+E+/N0=[N'!&HX["ITM_-HR"OKK] MY!T,ME*0;-Q&XS;ZC.S@P6A<((K +JT_3QFCH(0
<^)9(7:2"[]SMH,20@.I M"2^!E2=7=>QGTP0_7@L+UB5B=]_'2(8M6+=5S@.]".#9>8G] MA].](]SL]S9?
4(VA:U7H)_?'&N;;4,_,YI2QQX*@G5U0,ZVQL!O'2,MMU9R$$46LW>55/1UB.0< M$>OS7W&4R=4J<#=)_YG(@5#0-X,G$]P-$1E<^Y[$9B;/DLX9O"G6&E2&W7VN M2DI2?
&.J_O8C9GJ'X6PZ(_;ZATL3C(]/5]??TU/U*8$FGMAS]-JUITR^[?O# M,G-G[5'E%+6NW9RFWR998[9^]'>^9-C U?LF WMV0Z'DOI[6F6X$8?.0$=% M2,M)93!ZA_L4;Y'^?
Z:\BWA)L;*Q(7I\D6IC+3O0W=L'NRM'''?D;A.6N(:XI'ED\/?O]-O4SX;^T]0H M-KCVQU*R&/;[U-+:(NGE=CBC;6,9=_BXPV_-#B?<>;NA1*Z#;=45[:&P44B3
M/N"1L5<$SDVA6V/,N^%JM!G2F>?W_Y*V#ZT)1:&02H^:BJL*L#15RQ\JS M@N5\);= D2M?V_RLU O:VN]1OD?Y_JKRS30 ' O'B%12+UT(OI;*T+FI*F'R M=
(Y(GA3UMAC>/9=FH**=,G60DL35@Z%VO,%]U[ZC=EW0^N:L1^WY9?1+_ZDN M8T"W'+?4N*6^^I;2.J#*9*MI"S*OY8DJ^;ES=;0*,>C'-\:.1Z*N2+$PF69 MVTQQ6]M>94K&C
(\"O!7$>!L'EUU4'2W9-,)5X[SXHC@).EZA:S&RY@7A"HM MR1LFOU2O6U=FG3AQRV>,8NTD0FD>=QN](">O:64)9 R-MG M3&V:/]67..'>_S?
2^U]SVB88;W_AWC1GZ_B2Q<0:S-#N*EN D3=I2D#F84 M'PUS-.[S<9]_U=Q+GG](]1.WKB']@NWM"9*.BIK-SLGP+;#6H#&$BR+4CZQE M$D2JG>:;*,_>&?@/W)B \A-XC4;
(J%,Z2BUN/B)'CCMGW#E?IUD;9+(DKG87 MYW4>"%+IYG0B8-WBU!1FSN"K*37O>+VAW&0C)(RT^;Q6MD;PDF*]!>=E,$1, M5!LWF)18!411 PJ]U, RQ-
?,P_2^T4N)Z!]);ND;&_8$M_P2-YZ-A?,/87?'Q[VT+P6R4S_[7+T(?X'XC ;=W3+H@G*S65M5REL@D.MQX-603'N2 M'
*L8QM"4WMXYO$'%LW,%>$X61M&IWX$#)5$SV_AB@@WAP^W" 5';5A>!Q,5#LUX2>Y80 M%W /35:TQM%L(F^+5VU&,8LKM"GAO\OR*B2FDD>R#,D0B=[%FL.1*6@+P-=6
M^! %WN5[-N5"R/:06HO>8MS)XT[^*CO9Q;*QAPZ3-$*^P2@)GG1[.U,Z%PC= MNC9)-5M*J!R.)8YE7_2-3*&<3>,N^'K6GC2PDG-]W*,2>&: M,@G[9] HKZ.\?
AT[S%5A>IC]K,']FDC7CJ*P43ZJ@ZARN=:@"4, %=CX_/#X M)?V"\]+Q&[7/)]^YA*-UXL[S$9+DZOS71#\;/&3KH3(9M].XG;[.J>(3ZDGK M\;;X-KG>EE=Z(",I
!/L,B@#!S9)XA&55,U&/(AHGE4KG[D)X;0QU@QC(MBB MRIYBR,A4$FXU["QKG8T&V;AUOOK62;$9N$3TEK1<-SV>F6RE13)Z>B ':$I' MPH]*9'[J,64]@XTRV;+[K3"I_M..Z .
[<#@@Y@!JL->[56"9P=54@:%T)!<[+$)4JZ%(D@^>^,63/R6P3JO\M[M,S,N#ZFFUT5231/87WNOW^=F$YTP,=OA_OZA)<[A\F[XE'.:XR$R;J&OLH7T MQ! "$"-= 5P%#-
J>3@D1:]Y%X.(LL[4EA0KSC%K2@">.ZR482R-'"?]Z[!Z M,OB<,>BSH\)V7&68(9=X%7&%>NX V3G.'YC![QDX^]=%:6]KD>,7*_R:,K3Y MC>8F5WQ-=
[7JZXR0%@J1$,NO\M)4"V3_AL].V@5\,3HXC,% .'S@TSA+HV,J M3?!@Y.//X"]??9 A'^*G_7\)ULLQBTBV$?%3JW0Q!!L[P!";J[8.0,+D)K'W1\<../!'CRG9(_00U(J#3M$(!2TL8.9;!
M88%ADS58&P&+Y9WWTXUW%WF43V2$B\=T$@D1%267":P5ERY49;M8^L_EF.:F M;+6@0A]-"'898?A@^3K%=?AI66USPFV]J]SDJE@'(93/L- [+V?O>(.>R6R=
M^WA_.ZYP7Y6%[?+>,DM:BH1V0\QGR /^!2MV4'-YU,)32+_"0-!$:G5RS=< M[1/S,[!K"7]-%8:-]GE2_QV-YZ-CO,?9[?-+I] (+Y27J7$0O,A\/ M_:Q(S:IP:$O8I1!8E<+5L.N.
9$@+>%@-I7"J8LV#HULJZE)24\Y\D@3R&9C M:Y-1\Q;L8CA0D):1&.Z:95G!&.FRIZ!^K]#D1#,3^RL:V)#84\NM(A6U TKZ M;=XVR.^%UA5:ER9E"_&FT=(
%7.4M#Q5[>89(S30(508:ME-DU6R8(\#QF_> MS\S:XHW**F1$0ZLU9H73'9EUM)@IOE3LCPX#/HL[.!ZOB<7>?(TY].7^![M4V(<7JOSYGB#9-Z0%6#?>D^0)
M)QLM*4ENN>0BL^!;%Q52PZ"9NP)#T8Y0V[MY*_OA/I+S;B;3*S@(9]D;SU\LAM&U?*C:(/MWV^!3TJR]TU=9[]WV>GO[X]
M^Z]GT>GKE^?/7EV1E@6_Z%BT.Y3JPZ:^:7CARPP5=O"A8TC/R_"(_&=V/VK7 M9*G!X#3XR8>_4 QQ3H1XQEW(4\Y6.D IS"(&A%IHH' 0G]G !MNA?@HFB>S MIM=?
=96PE886D;*$ MFYSUSZI(^S>QY:NB>,N\S$%"ZV^+WDP.&U(8&;5IXR'Z?CB_N24C&'%*<$OR M,SI\=&/V,[QR6T714%KP@ZN*;G+$<8"PQ@^ORX3*,,$C*[_>,'^!O?,ZKTT1
M;Z-'W-TL_2BMWYJT_I3ET5E=PW&(P7 6V+=FMBS :EUL5&+O>I:=[#&/Y!-# M&9)EPT,4B07W\K)\)\G$1CQ\FW^TZ)[$Y2X@ P12'MM.*TS[."9&[X!+P^1/$1&OL#CU(WJ)]-
@D/_V[;3=5HV M3;GZG$=(]V#[7+?6P,?1@W]H)&:/AP\7K-]'=9EG:33-D]F[:RK>_LP /K(6 M3L(7I*5>8? ;-\>Y=1#/Q26Q:FK8+MB:8OP<;]0/T*G<_N,&J^KK#.OX=BW]
MT"3XXD!+_]^@UFY8X\^]16#U(E%:_CQM6])9B2JM^#]_.[PYL?U72]WVY:T6 MTWO[<83_NW_[5ODB@=-JX];Y5@WNWM_OWVX)O!VC&/?!GQ>U'\NBK<=M,&Z# MN[T-
7G/]Q"W=""<8HKC%N_3>P;A1QXWZ9;8"MEY0#N^6;H<@8'-+QS@>K.-^ M_4*B]K9LDGS_./S3598?:D,/S@VEUQTQ#A8;A&UQ*DW2(O:?3=/M1W.QI]MZ^O;0\>
M/HZ/'G]=>VT\=F^!((R6UU=_X)U;]4]PU(Y&1^U6",[!J"[NO B0Z7"[!.%V M.6IW+)_FMZF-;MFWZI:-*;7;H%L?/8H?/WERJW3K* A?0Q".XOW]40[NO!P\ M?A
?'GQS:;4'H[=V*Z3G^&'\Z.'C48O<=3DX.CJ('S\>?;9; M(3@/P&<[&GVV.R\'!T\.X*$2(2@F+@RT*: MJLKDYA(^#0"4L1N\;1B/&[GZJI2X#8@\XN3B-'I;KK-9].C@<1Q5B8.FQOLI
M&-\ZR0ARKZS@$?!*0E5""'P"]:VHTI/H.5/P.?81'UK084_2_>NZ9=H0)#A@ M6#\8]ZQ%!BJZPKX[\1T&[[]*4J+ 0SK0 2!">-M7)=SEX$#! I,VS7 >$"\3 MVY83IO)2:D,/=G.^'5I:
:@//9(\D]?F"HE)&+4P9+?ST *WQ95NLY3>._PV M=M,I(\+73*Q!>\-M&:9"$3X0D(C#^/#Q?E0O$^+UF!-%&@C615/.WB$<.<.4
M5[,,KEY7&9,D_OUHLK^/V.;\12M_+ZL)=^HB/.NK\I+%Y.!1+*B6#_;CXP?' M> ?"M-<1X2T< YT\#I7_=JC<6R\K1SLG*X\.C^.#AX^WRDP+[RTWL13,AP#N$;%5QT2
F.+YX];$ JQ+=;$]8S>](M\X-<0='A\3\(=ACUN.K!#+2N)]>BK]WC=]#_ANB_XX[J= MYG!4@(HU?5=]J)=<6E7NP'Q\KNN)>D&!DE,4(M3'>"+5?JHWUYZ,@H.S+*?
CRQPJND0A8*4)I/';4Z+_MA O1#C,N#-)W7E5(M>%H(22:1/WJ,GDBP1@H9)Q(TK\?SJ81C%AB*CB&_K)W/+DOOAJ>68W;[V,>1 MX>21A<5$W[5>PU'$YV=!E&3.G(*3R, 1-
6MB.FMK6G*.%"%[PP[3B7R??0!E MTXZ3)#^CI^V((];9I_%-5KQP(3#Y,\C*XF6[LE^E,*9%MWS* WYJ2]X]"F&2NS^)?K6DQL-7QM[8D2P//LJ: MG%\NT>V$;Y$4!=J62
(4U80:3P[2P?YA#(=BC*2RM"G!!FR6^697]YJ=+>'L MK7VU1EJKK0/1<5/_S%UHIQ\CX_#?F3!%BJ*TDTX!>/GTFIN@9)GWZPR%4H4$ MP]=?G(?
FRV_U7Q(02Y!%WNCPKVY2G),+BN'_AC,1O6C224S;K%J7S%,%>U]_M@XGK+AIQ4I#W_7GSY[M'9UZ=QK8^.>=U]GZ%5\#9)^@ ![O#RN Z,0Q?H(.H_P+)GVF"+5/IB4Y@C8P
M@J27L,9(!X7,9%/8!S5Z:5F]E,DKO#' 2"7[0RI42.>WO2,Z\GE.Z9*L: UQ M5<_1N34@*6U!3-_*3^;R2LC&BCXH,<9S>,!.*69\R+J91,\RLE_PZ@T-W=[I
M^HF/E)N\,@EQE:+VD.VKC.#@&Y.S7M%?D;*<26GY8[!W0#*(P"TU->P6&OTL MJ3EF,4.>U%U5 ?_>V_:W#:2) Q_WU^!\$[O2D] LJC#DD<>1ZA]='O&W7;8 M[NV83V^
9%%$&P38."1S?OV;5UTX2$JV)3:%C=D92P(*59E9>1_+\0W:8J:C M8X4!$@XU'Z/ A;],8@R$@Y(:EXL0K<,]:EE=$LGR+S!"-XKA@EQ'< %RF85.
M4\Y+B2WB(+UM'E,'>N5ZPQ4?C&[Y6@USDCB'*''0W^NHEL896)<5;;:/'C.- M$J*HAH7ZLV(S)HQO!?8T 0E OW,=A$'C"_F.2#ED#R-
&#,W+L3!$_TK51C,%P]U!&XW%%0$RC^E*9\DTL#"[& M+&.F;HP[=87;#V6T<52:*PG7M\QQ13EOO]B MFEVS,"]\:=XRC-31S)=NVC^J][6ZM-:BMRZCP63.LR\Q6N7PQ[\-
CL*CXP,M M40O@>RDZZ9'@2*X"5G[;_[@OHPR+VA&)L^9 3#%.!"=A[D]GE*F)*._9TYZE M:J^$*QDDU6R^!T8Y2J@IZ@MT4N.SYA'F< (27I:^D #"AGH6";WHGY<"L7:&
MZQBG/.)!AJJN\&@5@PX6NSDH9+.EHN"8RR#[] >(TUT:18E"<4,>>YN30M\E M2N:8 Z>HD+#*XV"%%T=G?XPRGC"/X*6\$]3TQ]6(03VITC%<*N!QT:7,#T>E M
41>E:.N%6($(!K&"S I<"Z@2FX?!U$+U&X47>!>..DIN J1VL-'7^;,Z;7^7HUEZB+T7I(M5(@C4=11.65F%P8PI:3B$O^G[3O+^S0%>W)\>R#A4.GU/F"-.U;G:Y?7JMTK
M\!,&,4!Z'#,_1"6\I$T2DW((G_<@AV,W3"A*(,.*3@6K35BN\?&!=O X.<;4 MI=ZZ6A\1>:?!\YM M91"?5E_2&QDHXNI&$V\FV(M3Q",)BX=BB;SB*/4+?[305ML=.GZC7V[P?
OJKSNV*%(S/ /RB_.C$;!'A^@<]Y>H9<]/#@X!:FA/_L^B5CK MB7!LN-VKEZYATS0:B0C(VB7CP:;Q(.-BGX_.,J8D9TX@LY=UEOA(>-$+^'< 9;
(02F70QFH)"EZ!>9I,YB#DRA(#Q3D!68Q23 MA7"3:Y.0I MU&/3D98\)L'&S7^Z:P;5)UET)%D,^B2+/LGB=C+I74N^8SV,J M#ULM]KW/7 M<'E"YGZ
XP^]M$KDIC;RL"1_#JT)FT"0;.6#,ZC6R?-;Y\.\JZ>V+@^JIMY ME&NB>JQ +L5#KAB:9%F98AT-=K>-AH"I&U(I4IFP,WC5))2<"L3U"^8%B9Y M-FO*\]"5EO!<$HMPU_)7A"
(&7/"E9FRXV]HU0GFLHG+J.FK0+UL"5;*B[W_0 M6&'[)JFT)\].=N3Y1:2TY?".YT>WRR;<2W4UNM#:F;\V0X,D.GG32\Z2> M)
[7Z*]@:?)7H3,?)@W)=U!-0W%S0.'>"C]V)H6Y**/D==;"$70=7R@9):&4G MVF%B(";N02^U1ULH>*9#+!A4(:+6 5$GN:\6YMT/7CM5ND5GF2Z^Q\R*4DG@ M).2$ -
LH2LBVUGL%"0"[4#8>0]_=[EOR/BO9SQF\YXA@$?R&CHY//I]RO*@9 MAE6I*$0'D+-DVV\3@822QV8SS_GSB\HO5:[#]U5IO/]2J8ZT/2('O2/TWN?Q
M%4H5"408V>"YN*8JX4A1T[&(8M:&C762P[(O+OM2"'>T*/?X)!PR$J=E2.*Y M90/D/B=E2OLTR5=#5UE2=.!) 52.OQW#!D9E9J.D% 65]?3ODKC)/RA= 7ZX MHH
W\QN@1=5$0N_3Y1%%DC+Z09Y^BV(7BG!%27FQG%1)P$U3'0%PI9%4F$K?%.*IQ+Z' M2F'T2%W%654D\H#45HC^51<=G>$N2GS@[#4UBZ@LU6Z@L]A6!^/'&4 .(T-L
MHV/2 N_9QL#F282!*K]!C7Z_*W#E/W-X5'L&S$:3[4&6'FJ(V42KBARN8D&Z MAWE=8PF\\%YT"O%-P 2O&&'(1FN;O1H":H (4@N[AM[.$1[<])W'=6[:O758NESEO8.5LZF?581;-
]OZWNV=[Z)Q\^$/6G;N M\?;A@?F7@/H>!<,$I.-]-G;&2E&\(+;0PO#P^]N22:8>+FLM_:TQU=TU&O06 MN$3I/QX=KM;3OD\+Z4X"PF[D!V&
]GU3W)W^&N#19/,*EWP=<$MM8&G6X+ M&[I#2C=-%BB*-G:'VE\\WM0MBI#?T-WM_/?NI@+.;=ER5YQ95!F7[ZW?Y+^7 M#
[U\Z.7#ANVPEP_;*A\,;GL)T4N([T%@XH'<4/*W[K$-W>"/S[INXQ M[96 7@G8C"U&>;JY^]MX):47_[WX_\94]6XNZ6(;2?-^GN1?@OSOF *=&30K
MPR$;N.VU]KUA1"E7AA*JHTV^/1@\;;DSFS7S]0";JQV=W>',U\/[G/EJ&FEN M^8C0]3XXN(>)7N'1T=%&S?/:"$P\!-3?[S3(C<1"C_8>[7<]QO$^:.!T_^1@ M8\F@G^;N&03WI?#+
(7U][>GCPY/'AP='!QNM1)^] M%KL1'^S5F4W 0H_V'NV]%MMKL1NSJTW38@>'CP?'FZ_&WI,O>-N9V\;*M#,< M[K&Q#*U'?:_.]&COT?[707NOQ?9:
[!9KL4\>'PY0B1ULM!+;^V(?EDCC3JX; MR]!ZW']/438(3X]ZW-__!WM5=A.P\.!466S1N[%DT*NRFZO*#@:/!Z>HRQYN MM"[;.V0?EDRC'LMG?6+!_7_P/@R9DZ/P\&ASY5F/_%Z;
[='^;0&_,[A7O.]N MDH[8:Z[K:*ZGC\] ;ST\VVB]]9Y\L/=55/93G)BQ 7U=V?UPTL'A<2]"[_V# MO>:T"5CHT=ZC_2&X?_M,AEZ)OI42??9X< 1:]&"SM>C>^_NP1-IA..B+RC;@
M@[TVLPE8Z-'>H[U78GLE=F-VM6E*[.#@+U%4UN?C/BR9]F2PN>RL1_QW]<#W MQLO]?[#78CMQ_3]R?AD^/ M^HSH^_]@K\IN A8>G"K;=T;H5=E;J;)]9X1>E]U F4:=$8[.-
I:E]R2=F0?['F_!7ZH Q;_L>C@T?!2"6)C+HV/Q?S:*1_;ME4;4_U M+3%F!@<'/YR[:(NJ,M._(,CQ;UAI?F9@0GI]D[AJ&GZ9S>4[LD@'_%9LM0UZ
M#H;_J(HRGBQ\@.X,=I=T5[CE/H/Z1M>E1Y?X/.+4>W_T_-6?59048*+\$(SC M8@1&3!F465!.51 7125CU8-L$KR.'@]/S(E!_5G&Y@!LRJO*X MC&&#],(XB-,@2H,W[]\%G_(H+:
(1#L#>WU"2ORO">#9_BQ^+C ,#@\.3H,W M*8[ECJ]4\#Z)TF>/X^=F$O?VG5^?/!IG\Q*(! G,@\;':92K0 :G(T"'"'7P& MR>WPX'P)X.B)P?DNTAW]>9+EM/R\RN=90;1["818
M."PV:CST%&7RF0T-5L MGF0+);S^"FE]GF=7,7! ^%64CH,1/%DE)2Q0!&#BJSQX4^212N(@B:[W@T_U M@_B[TZL5M"W:!WUWJ/1UB4K:[5B5*I_%:40
@#WC+W_,HGR,NW@,+T?I C8S MF\5EJ93_1)$%T7R>Q2F"=KAP_H*7<30"CA[!MD NEE-\,@$NA*P>3E#L;RG% M73!:Q]6#I J8W;"%=^F X.],AG)_IQP!*M T8A\C$?(LW,UR,
Z370 M80&R:.$0/;R<*X++MI(?M^+5 MKL![H5_6XFT_>/5EI.; (H!.<"O7<:'LQ8O352AG1F#619]#>T^D1=(RNU;$ M7YN\6S3*KC1>532: M>I\)@U$"__H*;B>*L(T4 3=*
'44!E^#HI%446L*']4I-Z"&GX8[!,QFH" M^X./J"2[WD4JT4\<[<2[+8^$#J1$/9A%8]7Y$5A 2-%]NISF674)LCTH<[@7 M2',Y\.&R^0= 9%(JUB8 2B6H]RRM1-=AOEUH(F:FPMB?
19]%-/)5<#46/)9" MZ9&JD2J***<;$HT!K:1I:&X5>1=38VR#.-4XOF):^,>C]S_]^*]'=:<.6JXM M'@?/=L5?/:+E:NN]_O3A49M'! ^LGEWKO]3_A,9Y\/ZG M7W_[9>DWVFW"+E-
3AZV"TR/YZ&/XJMZ;_;?[SZD)O;V_^.G5WH\?7EW\:^_B M]:=7'_X.Y',=+8IS<3*@J9HJ[]SGP50Q$__G7\X#":C]]P']7UNL3?[TZ'$; MP']^V0YPQ-RW />G=R_>QNEG R4FIC4AY?
RKW>YO$/>:KK 6BQ\/?)]2F5DP MFW=H9J.KV8;3HD\JJB&?P"W1*Z)_-;EG,)KM/4&7\M D_T4?0G> MY:!LDX&T@^?^/[#]X"5@S8.G3P:>6&Y[R1B@8J,980:B) 8Y@YIO1 (5'LC5
M/(G@0S%OE[GP994P$PV#O$H0OW0["GP!5ANI<84"#?XYJQ*P.CP%.MB!BY"P MQ,7Y&T3Q& MG?" D8@9H"0 M .<@I%S .\01-2L:A'Q-@1>$!M(U!^0)(%Q5R-^)!I-
1O"*7&M=MT# M33OG>=%MU!>5CUB-BT<@F:] 'I.78C0%E">*Q2Y+6ZLL.4(:<(<6HUW8TR?Q M88!O4CD*HF/\LW9C]"M6D,WQC-^/=27RSM1/930CHYB9'5@]$SX<
T44&7X2 M27X(_ZQ VT%_8ZX($"N]%*%[L?'27%; &A+X(@%!C,OF-A@0$[@X;+>B2@O_MNZWFC_!7#0]-7P8<6A7'GR_C*Z2UZQS1E.*]1H0#@(RKCMU. O!R&@,DYU%>
M+JS&2@O+\R%BL:B 6(!?SUAA!$TZ&WJ&P7W/)#+5:7P99<'3-Y\P)9^L#::8Y1!=/%*1B+Y;G+\/6*R M>3%"XU_Z4N*AR9]CE\2]$/-%3J68P\C7&6NNCPJL,_5E'HNF#[:Q\#/?
6>3O MM] .63H+BS]XF)@BNV<+ET1%X@)0D<5$DTF
(1Y,S\<5-\"':W&8N>_H#,3T!K8%X'$(K#>:ZNXJPJ8$,&%:$0@S:1E%U; M17D2$U'\G704\[T"#%FX.[[8=9U$_B__2T7\)0"R*Z>H3R5@>>)Y_?=0FB M5@E1^QC$\11!/$;L
F3+Q3G^ MN!-?[0;Q!,S_G"0306+^V>$Z/H MT!4 .R-BKGA3V5]JB4=S,WC+48"))37O/Y+V5"7-/\#*/H,-$?OX\PAY&S.6 MT'_'\D]0TLM$C<5;1#K26)^YBU/_B2HZ!@PUFVT_O2?
HZ_[W"PR?)OS215%D MHY@)=X?T"G3?HYK-PH 4Y#+;-6JVHU" MBGNAQ2)N\SC8:7=$?8@\&+8E$O. M]HB[>)XKSU$C\D,T>D?+%P48%?QVE7Z+[\8+E9=H
UR,\0E"U3D00#[/'6%?V5;\8U0_Y5(XLB$'J(1: !%S.A#^RK++Z,T_H_Q+VE9090(A(Q/ MS3+49IE[(552]%K;_H%$$9L[#I5R![2%U20L3((B.;S#!@X8J6IQ>0"/2?ZKYVOU0@=@/
$* ISO'@[!"S0 M-PAW_#$0Z>0B['AG%[G1-5P'>SV5\4?3'D"K80O9(CCVC#Q2*FM,E_@.&JTV M+4%3%K$]S9H(,G.]S&,70$)4QEATP119FK909DLZ:]$=*1)0,!.=H $O'[?[
MM[[65NM/H-=PE,O'02W&FU:E\,WT$E42-@:!5$"]KEAW26(@.X(M$V73!*TQ MO-8XM:5>(6>)&?"%\E\QD&$E![3$9:;A1K#"[YF @W%"+;7"X),%E U:,:,@ M-
Y)5XQF%#?'$^J#.6;#N#E_4XP_9E;:RE(11U)X MO8+^[:RYGKM?R",&-A#GUO-BXA%:&PF!KD&N@@U4E14S7*3_L1,;&ZKR&F.F M#8W(<&$F3W-Q8*VB%,I$LY@T9/0I
LHZE"M9:M]%W/JGQ L8D3'JWR*C\(C: M38DJ6O$SP3J;8 !_CLLUV;^71:#U--[-4A"V1?"* MD_MJM-.>D=4 HG6(I\$_*W@&:Z#@L7H(OO%B<(TFJ-X;9I%#<%B8=)JHTGG0L5E:
'C$K4S%$CE1!G!IO!2S&'I5#&7D\S M=@)V@?6]=&)XJBBHL2N:XF+5LQ]_- M%'@@O&>]ZIR&D&&.6C:9@#*!_S*Y;/6\M9#]!D08VBVBX5F8^V^.S/)"4N>6
MP3K4CGI87*4@@#3'5.DHJ_+HDC0)=VUTH$=HQ<5S/)?X.9(LO=Q#]@,<+;M& M-7WB<-85-&-28HHE0:)0/-BHKBEM-K)DP0#\1.68&<#/5&EG\D51>4V&%-
%L#3ZC(#P^G/T=,TNOK8']_;-) MFUSQCK))6T1XGTUZ7]FDQ^'Q\4%X='+2Y5G^ZCS2!KJW&-YKYI$V;T!'JG1 M"MGM-[$Z'/GY)^@.&JM$L3/81.Z<:-W*A4R*)]K?
K'^\J">A+GM;A],XO0\U M=X=.&NFL+0=I)+:V/$-ZO0;/2G:R(B?V4U=**^6FI%JJC#'Y2A?64VE^A:9(DN ?X.J.WGIRRXFN28*N3 M8170<2REOG9Q-@C:
($%;#6V(1^)"33$'O&_1H8V'IR8L6!S8F@_JIH.@F M16%"\7*3*JS=/9RE8MV2P-M=SV2A*,$)K0N"+^KP\YB3@D%-1\NCF-*?Q1 MK1Y3QP/*
["YLI."X16_XLO:'TG*A30YF'CF/%AAH10Q&!<5*A?->HT3R'';: M76PB+3P3XC+#&CPW0)7I+TAN!#O;Q9*JO>=P]=$T5E<2ER>TX]=FV1B,QI&# M;S=,EJU$L'"%&F5[WF0=

87X\1@:&4)%HVXE"OD#>D? M2)-$/6HDN8MLCH*"$(M!(=+$E3$9Q#"^*$$0^NO0JR4SMHO?WKQ=EO5X-A2Q0@L,;!X+@>#L:D'S^RC#+(MBG_RS0P0C@8$A"?
[+8>N^9U %J.WB:)24F% 7S;+ M8\PH2U.I1#>?SR8@O1!?1YS6<,GC?GYR$ M9P>'@<&F<[%,P8VD1:VU*&=UF54H*.*L5+O@QR=K7'!G'PA!72TQT'5#Y33/ MJLNI19%E
&]8ZLE6T@#4P/D81YP3LB6 8%7'1 ATGF(P>[YDDL?MP C[(R3GR*GE#L18)+"@\ MC@\3SDTA'R/L^)J<,$AJ5PI3,F59F^J#V!T416RSA:%.R&+<@A M^X5I\V^#0T37J*,/*4XA7
HH1^U!HQFP(Z"P,-I:WNJJO3J3 M]X'HO!?<2T=1M)4($;Y1MP))/9'@.G$[#22MB#1]]HYG>\>X#60)?CH:8KUY&I()QD3N28-T!/ZAU8Q8QX M6000L5*#<@C'TL8&O?W$*&EE>
(,3 EJ9MG-U1[Q;SGC1:=XF?^$ZJT"X646G M#:@4EV"99!*+"5O IY:49[;C>29X=L$UC<;\=9NC3GS:DD&7U^L&*.DZ:#QI M[,4RKV6T<;N3[P>4= M>-Z7I?
O:4J;C6]DQU4XV$[^;B?)D8V,0@0G-('VRIC]K/_A9I^U(]J[T[.K4 M4[2?5%D"%&D^Y])&) 3*H9D$5V&!IQ+FXS;)>H,VJ.2?9.2H?EI><#L!L[RPW
MV$'>*04<3:B;&@XR1IM_9Q4H2NLRACQRGKT>[+AYVV,$!+D\6MI5-E21YG"G?\]R/8Y_YL/]CYE.6 OXP4FFW. M1[1.;P/2[;Y?NB?
2DBL6U2Z9XZUN7K+!47AT=+3.G6H!M7^I6AZ@CB#-2_4- M;U3+1^%*Q<6-;U3A.-,%NO#?8$<^P%OU6@USW9SEJ+WN^F%(,P.(P:EVO*YQ MW_2/D0.X7
/.=:'$)=A6WEJNR0WT^"M8NF1Y<+^H@7"),OW3D\.X+=@AQ52;Q$48"F58@M7M%5W WATNF1#ZY]S-T-_^R + M,O/XB OJ;>CD&[]>OK.)F4(IZ9[KW/KE1P_1J,3H&"XI[N?
E;S1D,#J>VK60 M8V:8>)RSY36K4B\ 5EZR$ <>>KA;50R,^1V?'GT;GKC\K+LU-:).XT^VF+&U MLK)/)81BI('PM1^B4 #L)&DU0RMD.;J+=RL-+ SBKS+%9J@M6S)LC_=&=[G
M?X5'G(=:WZEQLRZ^\VWY3?,<;3RF^=0-^,K)X9/P]/AI9]BR@W/L?-EE[C$(MO!1]>0JFT>-'E':@4834G,$-XL*W$Q4! MW/]V8FKR$;+P]N ,VV654XD$\.;66,B&A?
5*Y317BF8&N&N%P#PCI;->,&*B#,QRNBS0M.P4#)H3O_V=4]T&HY+T)9-M1.X6>JHHBEP@+EU:'%ANZ;EF$!L764 M4MV);1L18M.%>&SY#(5W*H0TU2ES@X!TCSS+?
%>ZV@K8\$:) 6NWQ)&"JKSJ M.$YHBH03@NZXG_S\%; T'8G2YL%7VN9B16RQ/'U@^3"53.6R5GF]QL9IFL
M=G4]"0^.S\+CT[6<70TD^&9YX\]+7%TO+E[:M(NE>BBS!0R7B3V\EAQM[*6N MC/ZS2I6&\!F9W\O\6AWGH["2R;KC"G-]!(TAO.[(,8@G%DX.SEII<_58>>O9 M]#8W!
M_W>C,J-T/_%V$,68#+-#)_G,Z!9+F)^!X$U_.')T5DX.#J\ >-[L9SQO5C+ MQW^X?_+D.W.]%U_KH/2=D4@!_\[RS\P+/6W8#\9K970L,+ZO/-T^PMP183[M
M(\Q]A/G6@HH:J+_/U=[KBOPS5@U*'X2;'EE]I[]E"6/M=L6>UKL+BGXZ0?5' M.*RQBN^9J=XEE-N(C*IBR+]ABT??2SG >U,.X&2+=GG+N;DHEQ*3I\;)H,(" M4?
25&&RAXH%MSD7_C5JV9I(.OY3&^=.:F6@\9)?Q%5D$% $QSDCSS49&5W:= M%;',YF5V?7-6 N M"94M@(F;=0Y87-U=G-09L7 -1=:Y6OE0[M]#]^--94>*@6VN*>U@P=I6E99Q
MHEUSY9+OV=>!]-#!LZWW\D+3Y(]ILT5**-;+1)-)G"#0BUT-+P,D0'H+[*A MG$@,571&1;CR^JV[L$W$#=MNYXTO6"T!648AU#QXM[AMS Z<3/3"3&E 50_+
M26!K8.),XSG>)I,KVCJSMF$.W Q4-/A',\]9]-DP@:B8VD8WI>YXAZG2.*TB MTCYE9<80546SYB_2GPWK_):X%SDBJ)FTS5AMYNH'.]+X#4Y_#4LHZ2^)30W8 MSYRJ]GS\9BK)
+]#-.W) M+XS_NA>WA?=M*_T\&SY_-Y>.=@^[CNU:IJBKL5;CM.9:C[0Z#6^R(7PUDKGK MJ?27U'!PBM- L CCBO1DGBKB/W-X5'^&H\:U5JJW
M+.XR57AZT[IHKUYE2RRZ^[:QKKVRU)FVKIOKZ)X&'H"X&8\'1PV3FLI/&VH^ M;:H.V4FJ:UML?H9?;4.J5)T/,&D$%Y?8.1,MERV]'S=O^7-R=!@>#8&V@^C
MR\\%W+X]D^OPWC0:WV+6B0WS]32@M]'U%GOK?E?U!@ ?Q4MR>'"D[P$U_@H^ M-J.VW..;>YRY[\USCN-BZ%('5K'[HVQY Z3(N>=2B^C2^DE$>F(TK J0(4I
M4+F>#6/NVZ:S9\B80\M7GL7A0#DGC3@-R_73K&-WA63(:VB,7C!"B@S[*(RH MS#D-VI<.0?:Q+<-*&\=VVIX$0T9, V'9$1H,QAH%XQ(N562<*,T>;JQ4MD&#
M2D7I_:4]X$C2N6W1 M)&"G5-Y*O7T-0:=J$H\XGRZ[IJZZ T2@[O)^&T12S\"VKQEOE[1K9R"7.5P\ M2@VS/S+ELB546X4U*Z]WHF=GNTQ'=U!QZLNE-?
RR@ZDO,OW(NQZ_W*S),9::7F>6& M2!6D9=YS.J8*$4?3=I M=*GTC /SLR +8U*QQ."W7UB)G\$ECTW*:2:I$,'DE,)5.)AT(W2TB9<1]H(7HF>4A"K**A(Q[I'T8@6CZ-
-903EU&D4WO3%F8FR M>!&$_Q"Z169HG-7(N3$6JMYIG<)-[5-D??69M/+&?"JZ*0IWCNWB8=T$>_2! M3I"-'(T_\CBQ'M>%\3)LE&[XME2#N,TC&\ &PU#/:^9D9R"GG 5!
OR!QH>O*&\/.4K XW._H#<&VO8Y>EL:U" !2G%ZAP\BSF'[5WXZ7V;FRQ MCE0?9BG\P.6\F/ 00*4F@@)XC[P,F.W46!ZXG3RS.>V,7UN"M864^J%F42(M"JT_R.Y-ZKH]@17P;-
(MIE\2>F^C:YT+4FAO%E4+BK\5/47YC"9O"+5,:ES/ M*03JF@ I4RSCP@Z91+Z+V*!IZ@;NQM52FS(8UY$SE,&QXN7]ND7:\KADH[CT M)0T$RYV4IOW O?
MZB&T7N&S.@5^F^^1)KT08#3(>#E$V\42C3>8J2D2]IMDFG-UFQ]LB MB&ED.=XQ$P3(3#Z.,P:7-"."W-8RG.'SMX[^Z$C%X*U,56.7]1O00V>I&5#C MR<\P>(?
*BY(XP:O9/,D62O4!OFTXJ?:0#XY/W'">9-KA=6H0AA-VRH0P@(%= M*EW$X+KQM;E,+-OE?6SXZ$ AO#)V].V6 E#'#-H/W$V#Y493G&KKHZTC6U\P MB^"PP_4TH[[&-
!51=2JODG5(* S:9^'IA^1NPQ^Q"8I$KJV'/33P#SJ=CX M+3:"1YN%-ZOB 3B48YBCN(D61PQ$T;G RUFB2*4K9RR $.9C ((NPI+/HA MACMHW.*?%6QK/WBIS-G%W03B
+9D^QS;8X5@9?GL^I;VZ92:07O0DZR%>T()1RE\+6.E]J)G/A?9X\@6>F*K=:/0/&@Q6G%XBO%)-.56Z8%CDB-=NJ2PYT)1+2 M8(O8
1I(3I/46$UPOTQTBV6WUYU;&PTSS7/;5ND@K9+[$84M=$5WU^$'-^9P MJQG6L(9@CW_1UO"6]&'A#0D+/^W#PGU8^-NVP5OF.]IB>Z73XWFMV'-@-
XX$H>U#QLY[.A;:RW,ZS*4,L,J^L(8XZTGR_L5!3\ MYXS%A8]5WJA>T :B,95]^$J11&@H88P62]"39L['!2S..B;UW?\R]K3N,I!(MX5K'.N)G;%4-I\@I,W',2-
Z=""OP)CI#R\'A[E>8.3SY2?>\T;K#CN3#-?ZB M4^%T6!+CI!PW,AO[4($&>#3<.\7-SZKDDFZ=C=>93/F+$4(0=T1!*&,Q%60Q M+=U@Z)REW=(*:L9>FHV(D[)
(,"MRN&W.VYP,6.*, MN-1.-;;&86B,63)(:!Z6KL%SK:0"G8CJTMC%1 \I;S?FI(=H1%ZHU>AD%8W<
M>7P:_6X#\BM6"HU.ANJ:Z&6AHSQ3[!='W:U2U9JV:!B\^O#FXP7F/E,9>O1% M<;*& J.KC%<:J[NM^AYIY%*VOY[N=V[J*\&HTS-\97Q3ZD*JD MR'+,R*CPJI'M8:Q!'SA;
[+/&SH_%A(J,R%0DO8>+9?,M]CI_TAGO>'3FW=3M MH5Z\"<3R!JW17'ST\%>'K;]+5?!3HM)K]#Y=H//P8X7N M#4!V'P(4K01 B#
M7U\$AZ=/#HZVF(S>2NIV/75PBTGH70NM)'&AV\-'Q3CZTZW)7,R&66)&1KQY M_7I?5*,[W_E=NA)6F?G>1VYE\S\]V [#_K]\PWQ]^_NO<(,$W76V\>.K7U^] M?O/BS<7;X-
WOO[[Z\/'G-^^#=Z^#CZ]>_/;AS:04OW%G9T43 M SGO$%VU8GZJRT@.!TR54SWD=%OI+G:.)+>=IZ'SO.KCO]\Q4/EX?.O^\>C@
M48!^J3GFKZ:7YN<"C0SYN8T)$411$4R)XWP1%O"L'&;C!5^@9Z6Y_-2>?10E M^LZ5V=SX"9^5X_H7SKQME^-53SJ0ZW1G:;S[C.S&_C+<%HB*)PS.I9L#M3R[
MZ\U1BIJ8$9]3[$T$ZG.E!SNW4:Q?@<>5BW7=JWY8^%?^_+^8-1J$PS^1L'I* MOA]*_I_JZP\KT&8?[E)-/U5VR3JUKE74GZ01C,>NNI;Y.QP,.8O59WV5-Q3
M\090,>475BU>I!K-LDL/-=SY_H:2[MWU_FY1L_RF=EY#)\JTJ!)ENUN_>J&' M*-M<6Z^39Z3%)D?:V]4Z;! %C(?**B9@G>!\:*Y?0*=Q1F-!,+]D4V*<9%9&&WJL=M=V/[D^M>/\
(!:\TJL]S[4<;0/#E@S%$_ M?*HL<2I:6EL&%E/2'FAF-4!Z2&UY #QGX=')67@VZ)SZX)2BN9FSK:KO?O ; M^SK=$ IE=J #EU,]QCD](+5'^&= &LX?,'L; L,?J'*P7P!1!?!N_]2*6HU
M8?#KOX/!\>'@=/FGKI5)]&'XPAW567PL871O!H(8EV@BE@6WG.E40VXC92=) MNH!6[T)@7+FSN_94W5@:B8$]B=-/^&J]>%KN3K@!.UU3SME-_:QH$L2C+M$W
MS,HRFWU+_MZ0.M]J:>VD.$6(,H;V0'+#7^=? FK4$0R3"-1U_4<^6_/OGNC[M9KOS*"T04O/R"\C1\&O$/<<'2X M.H_F6QRAZ0'LW'=^.=P!9HO_V5U^]KLDBC;H- E%MXY[-
LP?/P\^:L[)/[KL MDW_SH\-#^3=(5^.[HBOAD2X.O@NQ]??A@=Z"PSMO]-:VGW2=A/WUBI99FM^ M:X';$@=)!\>X-3Y(YQ)?'*R^SW%\KU*T]?4 Y05^.!G+G:[(ZJX&_Y$I]0?
MPG/U'^N1M4$?VRRF=W)"_&Z;F=[O8/T5-)6 6S*_D"+!/I/]@^?WBOJ?]A4 MWOX %-H/V)=+,W0GO^\6?/RPY^/W>I&?/#T(#TX/>RY^[Q^\#^3O#\YZ)OY
M%70PE%YZ/=9_I0#:*Q/NUHU5>C]%_[$>60_23_$ =-F7T56,LSU G_WUWC]X#ZC_?QN%]LUBW0] @V76_<]LFF)"X"U8]UG/ MNN_U_IZ]\^&!:MT_Q0F6B4?8F?$6C/NX9]SW
M>G=/GX0'AWWH[_X_>!^AO_V#^PT7;"S??@ J]T^YN@S>QO-B-(W+_]R".CGG4_4)7[(J_2X!>51M=1>0O&_:1GW/=[M=P^/PL.CWM%]_Q^\!^0?[C_M?24/5>?^9Y8&[Y)"W2:]
[K3GVO=K+ \.PK/3 MWL-]_Q^\%T_)T9.>:S]0=?M'_&OP/BNH9K[GOO=Q >]79]I(+/1H?[!,]P&H MRA]+E211\']IEGWNF>Y#O'T;B84>[0^6Z3X 3?=]5"7!O_+_+*[CT>>X9[L/
M\?YM)!9ZM#]8MOL0=-T(IY+^*QI&/9$D@5]5W:RGULVN7V2S.4V"QO[A/V'_\&!G<*#[&>^N*+O>ABN^ M9O_'M2IS[XTAW.00@_#H["PW!'-KS],'*%(>'KT=[9\.[I;6FOMM
M[TJ*G5*[2M^?W61:0FV;7SW'P/#YPV-XW>7S>_2;1__/^?_[GS&PO]CPES_MOS\HF1S=/2^!&N[38*'!#RL:V=\]M'<&NR JTX)G7D\"TWFNJTG_O#:%^^-H MJL8X,'EP]#*8Q
D/2) 1!X<#'G&P<:<^]$\M?9IN<>:?.L^\>:@^\@\MAZ61 MD,G"';6!@\.K?#3%R>:@-\&/U :@"SRW',81X!R.MGD8&P>X8P,XW"Y>F:.C M\/CLH L@4Y70Z(I?\GU3AT?J*M+=6O
^/@Q/CCOOX-8#_,2G5(3XX=/C\/CI M6>=000U= M]A>/RD$SO?&'JABU&P0,H('M>#:D+>V)'>V.!I>'9V=)\[*^A+ MFO(TI?Y(LUI>T\P[I_/@/NX?
1[_3L)]4A@E=R8S5I+YY]'CF8U3:-70 [-MOOV6O M_HB[+1G'/&";IQ_'+(#9Q'EW'>.8/[YZ^_;-KS_I\O/FS,#.9E MEORMPDZM0Q=Q,#/(V'F>T0RUJ@ARA=RY,#/^5!'AM+
(%RV&5),@$]2B]_Y^] M=VUNVTCVA]^?3S'E37:I*D@A>.?:494LR;8VMJ0CRW@1;#\-ER8R/KGYFHA 5MWLDAO?N;[CCW4GNX8+<^ST;*N]P3 ,^;T;+"+8O=0@0 5=
MD_^="Q.!7YQI+/H;4I.]/O8;P2OM3W$PSW18W MCZX6*YG" !2K;KOY5Z8@%W#N.6,N6@D^:R:PEL>)GMT;@$%O__@<$E!\61H: MWQ9TW0D&%N9.&*_<\-
EW8YS+B9X+0&C0V]@I\EE3.4FF\EHN^6GRLJ ']C;R MT>8!WH;!5T"H?ORVFRUNL[_].NDX:]17H3C,T5T:CR6<2J<5.;W:#&?>P+[!^PH8HM(-]_,/49V M!\7NKTRT_6V^7O-
^XE?[M9:_TF+3K3T]D.3+O3W%&\#C@UN.G4)E%T\QX)RV7U<+KB9HWZN%B=';S&*=.S&=Z#SW=YA_]S%R'/'#'=D(_CHI^@H MA;V@_DRI]_&'"P($(HI&ZA%FP9![
>HL&A4B2\]^"PZ%0O P5U129^C;"/M/OPLH;HL4$$#V7\G M]] OB2,(?\C_M;+'6,7R7G/'LJ"&EY$:&#+'Y D%4#8\SG"W8-1HH\Z8\%*. M)NF"X[WK%E0\=TV?
WT>FF]@_.6'X,O!%,\7%S,],V==],;^OF? &B%AI>V<7 M+?+GO8RU0>_<(A2L==P!\G(QT[0J"Z?:J[0):T(W<6(V 8%MB?TF6,!>X7S%
MBT$0!V*O7,#^48@XSYVYL2.=FO"HU%B(,KXDKKG@S@T+,+4622MT=E^5Z$7M MW>5;K0'&,SJ[GV7DYG(G]'5/E;(J*[Y2"U(08Z'L(F>Q,V.;FR/J-VMD]3)
MUK!>EU_2W"/0_RRY/J'PZ:D7 GWSA]RM.\0NS_ O?>'LSKGGH$2C*>'FX9=A M&53I009C<\&Q],E+_]/"XTG:W?7IL7;VW,(S0H%?$$/W[H0KI[\R/&#,]>J8 MDU"5N5/8/T#;OQ-1
3=F\R "20[_DS&G0-%PPNX#Z9$*E8]'6!MS$=D*[J6J M'J?/#21'"0>U\(*-_URX(9? DW@,(@/#PP7,>HNR:B5$>4,J %3<. MW9'
GUBLM0ND$*76YXE]T0)F6&>MNI@>.A+B9W_"09"&PL0'I$^GKN? /77DH1<(.FO2.>$KWYS3U,_12K+H*,V-[,!7>.M/%G:/JC9 DS MTY LL(@DE84C (/>";4CS?
3"0^)$"/>0D7C3^]NZF. !5$']3 M]^<><#?=#X,'_I^.\?U06(^Q84L-FH;VIMHJ)F+.V-FB=L M]JG:+'2)-!=(];SN/?<>+1W$@*GB!BTNS<:X4JM5&/?IG@HZ1+ @WKL+/00
MUVI"UTL>C;S_%MT:&4$G?-!Q#&)^(?=4)\1-7DQL>7N'EW[2XR*U/CDW#CL) MK&+G8#C\%5]EB!]6WD,)7YBAGS.F=I*DE$-S[.$@;36-M*[L38^#P!G/+/=7WJ.B,F>N%&"
M)MS-#]1VON4-4_DXA3S__57S%4/!J-+DD[^CN3-_I8B=.KZ-WAK\0Z[>9?Z MCIS^W-FFILC6%U(X2H/KXKD.==(B#N;9 M8Q8C#S;4$@_^9L#TLDT*GWC_PL,[P/$
7/_W5W;G:97J1<_'%,YZ_>&9[5.U M:%E66K1>K\G]W$I+UC5'=YYH?%9-N? D<(!8V$%7)OH4*3M(M&UT37UZJILY MMU4RX^X,;YYK/>C-* 13JIA5V=NLHGJ!KG-
Y^67HHEX6R+\NE.;R S5^[:3& M;WE"X01_E,H40?2DZ95^H"UH[JQ MFE8-O%MO/UW LL>D&AO#"GJ0'M2MDH?L'94-U;9JH'_ZST6*L>JC%%2
M3^XL+;%Q["U&C1[I8.5PI=UNDS0N>T"BNQ%DJ /=2?#B^:)JR\$21LTLGC+%JG PV]DGW*LD'8K6:)(]+'Y H;P@AZD!YHGKI M]:.ZL;J7S7P?7WXU]4?#!MPG9V_OV9GY\
<'C0'I6^5P86]@]7LV">"R!R32 MFT*).I">-*[2!ZP=U8W5N&K@\?J7@R723Q:CT(F^NHTA:5OE<.# :MD]DKUE M#TB4-X00=: \Z5JE#U@[JANK:]7 N_6'XT[91\=S?+=A-
TG3*BN7QQKTR;E1 M^H!$>E,H40?2DZY5^H"UH[JQNE8-_%J?'K\&(S?F[#KP%K)CLTC?LFW2NTK: M?&W;LFVJX53Z@$1[8TA1!]J3YE7Z@+6CNK&:5PV\7.<.JEN.Q]XZ_E?
VSO4= M7[1>/SL_EI6\/H4'[\G]-CQ'0_\6W;TVS%K75V3!S(]#+'MG'>'+0L*F2?5G^$*O9 M[9!'Q(0!B?H&$:,.U">EJ_0!:T=U8Y6N&OC#+H[/5.B1ZM27Q'SMMM5N4XYU
MZ0,2Z4VA1!U(3XI6Z0/6CNK&*EHU\&Y=3*=NR#XZBRD/&S;5J2_-N]'MD>@M M?4"BO"&$J /EB>JE#U@[JANK:M7 IW7ES.\<[K%C>'>XLF%31?JR]MQ^V[+M M/LG?
L@L'=6-U;AJX-RZX7>NY[#KF(=^PZ8B].3B,(@0 M1'FB?'4I3U0O?<#:4=U85:L.SJU_?;0'[-B9N['CP7]]9^*PCY<-FTK1EY7$ MT[2&U(&O_&)]*90H@ZD)[VK]
%K1W5C]:X:N+BN@F^/J=H5A/,@=+"41,.F MJO2T^YI$"2(]D;["I"?%J_0!:T=U8Q6O&CB\C@[86^[OW_SWWK78T>3^@.VS MC_P6M+"_.[/Y:_;)\9U;/N-^S*YY>.^.81['
8.U(;VLI&!4T^H.J'Q Z0,2 MZ4VA1!U(3WI9Z0/6CNK&ZF4U<(A]X9[G^K=QX.\?>?$B8I>A>^_$G'WACA?? MR:H2+2IH7Q)C=BR[1PZ2T@L'=6-5<%JX!I[RZYA&
[LXO.DVD6%ZDMBQK[5;9(8+GU HKPAA*@#Y8GJI0]8.ZH7JEWP:11, M'O%K^.B,/'[(\'.A=K(TE=?IJ&+0G/ZAU(_,"O]G$<7N]/&U4DC@#J;_W^K
M[>)2UY]PN'M??//J\/_+_"/4D[5S8\N3RZ[)<+UZE(6 GN&2SM2P]R2>;N[< MB(E%8HX_8?$=9ZX_Q0=A6A=\%E_Y00P3&7$O>&!.R$'9C/B$+>;BBO3J:#&?
M>R[\,GH4MUU+YYC6S![O F_"PTB,)&X>6.WNP!K8/1;=P7,C%DS9<3";P4_7 M<3#^RMPH6L#S\(9@$4,87)PQAA0&; M>&'^KVM *\9:B[\^2;YF.#/XX6T8?.5A\O7> 3O]-N8
&'@G_FT.^8U<+>&F[/=EO,WPY.2F8PIWCWW)V-([%8D(T6,6/+QGPLWE(/ L+TFFSB/160Z* ?T><9D6H.!66N#K]YY^5=ON'L@BO B>]A#U^43$E&(M+;C_'I@116]N+HE,
ADVY6$(U\N;$V&'(R]F2FS#'?C=)Q[>PELA^S?<=#J] M%JCTK4W32>5H5H:N",82"=A]>0+:=L<:VNL8V\HMZ<"VNMV->U[QDB*5"K-
,%DB]+1"UO8X/35Z8_AY[P37I6JUF.H8S>5F&+[HL ZNU5KDO<3^PFR_ZUNEF/K0&S>%SMG*U*;_X=MZQ MFKT=WLR? VGM*%'SF[CW;.PY4?3[J\OW;_]XM>RB:#9_+?
MZ&^$?2.^>B4> MM_2\=S=7R0.S:C<#*Y"%2TN>Y]W[-[KA3X@5' MROV,Y;ZY./[H^E^359)@>N9*93X5<\4_EJCQCVO&\6+#ME]4 MTMJVC4W:#-
QA6EO:8=I6K[-1T=^JL0BFXCIB[,#N(@C7?E"'84"^-5RW ^?, MQ':K!3IE_P7-Q&ZK;S6[&_63W3<3[Q85Y6;?"SN+E9?T*:BL0![V?+Z=7HD]&K^#+NB!V>P5%5.IEO17R MM-
H3*J0K%$@?;D8E4$029;35$X=0(WWF-.085.23,I?K94T.[4=Y(D:S67%: MB@*7N5HO:ZC(U1)98=M:K14C^SE)'6D&QY8]2$]Y=W*#_)"K9]BIAC_G?_+^ MF.>
[77XZ(%X@DTB1.S?JF]'A\>G5S='9.;LZ_7AT\^6UTN&46V4IN%2Z)>_@.-AT0/O,@DK)$")](M;DP6$SX,[N-6!'+GS6\NS'30:L%4W<,OSCT_P4R8,/G>QN_E35*08;9-.!/"
M1E]LL22O:+,WY ?6]6%'QW>@/"-'+'.$3OS[P/O'G.Q-B1Z[3 0EU\>8*)/ M=EYZSEA4VI#D?NH57X 81Q&;N-%X$6$6'O#V6(/L!&C4!+:'V9X93/!@ /'=PYLT('/!?70]>]Y% ,
['$<\9()?"753IJ"A.Q[]G&U[:+6:BP59=9\E"86?+&RG?6 M[%CM5E8%#!;ADC,O];<5#OB,40:MMM5MKU>=?*#*7.%RKG&Y]%9+J-6C'; ; MN"H9#YXBDR1%CE^ZL.(E,(EP-G?
\1V1R-6UXIXC]TCSH=%I)ZNBZIZVL[#.> M:@_E#%=>)2' ($/JZ!2"^V6!G>T&&&2:.PZ'H >T!WS&=8H]'FPP+Q*@=$G MI+@8U;D%2-[BN*#,1(*GQ@#1B$W#8":NCE-
Q"!#&A9K#1:!(PTTPTB_M@RX# M >");6G$85OA#%9@ 7? ZP([B"OA-::P^8BOOLVYCYO:W'D4^O#HD2VVKNQN M<4,!F9IX_M^Y/FRVL S/$ZH[^]IO>?R 2;H7XSA
6\ON"^BVI;#XU\+G2:*L MD,"AXT8B 3J#2(#K+VVKV1Y:H%9+0!9) 8PV6.U^QVK9PS3$LO#=)3&4_/09 M?]+BP5+2.5K O_*72+@C[X9B-]*""V=W9C$]<*3MD M8KU.7,>%
]G@XJ+ .W?^"?O!_&!VP!J(S'\'X5EJ(=WD5(LV9@>D? MH\('Y@%JI]]PVT0A$0(K@$8GOQ#7>AP4V%"R:JLIA!E<9?^J]V,8-'1N!6!7 M33>[CZ8;2A(L1>S
DT"L.)&^E_L3_=%S0$6('P(AL3R.2)B"]@QW259!_DK> M 4]^Z$=\0R4:KIX ZXVE]@H<.P:E]AXG-05!$8IS'?I<"]PXPVT^O@.)TA7O M,5:UDB,A]6342]Q_05216E
%CX&A3P\U7,%EX:I2& 2)FS&A7].R1 +:)&N MZQVL$-!$SE7<[:O/J&:$KM#"49N/8JGAY.@_X=$X=$=X=$<<\@G&H.FC['ZN MZC!"@T05&)>SKWC>N(K=?)
(LF8DI_40+#Q\Q+,F MY80SQ7+1OL?]6YQ79DY5W47.5LFQ1L]"I4BJ+5;&+%$V-TC3# B$ZF)WI+A+ M51U\PEBJ.U)4".TFHXPT#^#Z5!L!,D<*46/P!B N-)TUX^'B7=AMFW\
[.W4FPG M&J'0<'#0=/W:J+Y)YH=OE%7",VHF!C?P8JG#?T&; MSYFQ#P?LTAU_11;2&\CRJ+UL6 3OE5\]9\RV&)$X;XGS3D"*B3W2;J[CO79K M8
T'_>_@/4!O9PWO%3'<%'&FGO[R;)?W=>4GWND^@^U2$P1]A3D-L&WEV#)9 MW.]GS#Q/GEXLH^3$.JYL#:U6OY^=2]<:@"GXC+D,AL26*VSHAMBL]4JV R[?:N5.P[W
M%$/:K97-T.ZMV0=??.OHYK;R]=CHZ4TBP6@"Q[5(;%]#=N?I1[>Z!?O/\=/[M#R8Q])]^?+<44-.YC37G-KIT;J,6YS9>0(!?@*+ Y['[@,WP$%@UO-PG0="G?:8@HK[BYW&M:JZ
MIF]&A^]@RYQZC_7T'5^@AU%Z,9VLQTG5HU')-BS-K$F[CR3N69%9\S9PP@G[MR)V)*E)S'8>+<;P(>?ZZ$Z6@L#-_PN>80NJ/\0JN5'><1J@HH7R1']UY-+YS
MX_^RHR0#H2%F.Q7>./21NOZ>5>S:MJ0355IB?I!WL0G8KWIZ4SU*%_-QU_IH MHVRT"F6:GWK&A0L\BK)^;ZN&3NB*\@[(#LD^-9$5P+W(M#/?!2A*OW?"D%&%
M@P(%MG V>4IE,A][080<=@+P7\VHHZQ#]M3=:?*1E'KHP%*Y3*FTDQ'H9:$C;>OU3T8U[-Z=B(S*U5?% M_)_)/2J=0G2+7!!<.(550?,&0_[D
261EKP@$[*,9)J;S@E=P+I&,4PJQLG. ML;Y:',M"=VFLA'G.0V7%FGMX#+LD32[Y,#[Q]6F<&_<+F=Y3B6S^9>\"@0 MFV'67.:CXIXB?
D$7L:/TJ;D.HBX_!V_VG1DO8CF$*L_I8(!3#RY-5;'4XLK2 M*U&W6NNO84?HW[Q-);>6+(G3;%.J:56!KV$@O/.X!G^"Q &N?P#-5LB"Z5[M_D'Z\2B"7A(
M:V.#IMPECZ!_#/H\7$C450 M"3=K1'R.:QQ7S&.LT.OO\5OUUXA-QO[,D$>L9X324,0#P]0VA3?_#LL/S'0M MKA).E+3*L*)62_^Y=099XDNUV,)+_ONKYBN&
[N8Y1F+]V^3O:.Z,]=^Y,(5P MI'_'A*7_^DU2P!H_A^O*:]N#W(2+ZG OM1V)@_GKW+TO*-V&O?[P]8;^&P53 M6SN?OWJ 9W4C79[9#Y8/_^G; ,&M G#3/D!]?!F]H 0X MR+
2Y3$'Z#&QB5 ME?0('P&2 +F^:=>FBA//;':D,FRYAGRVR"C>:KT-:%?KWV&#O^(M4SV/;'SG>A,PFF,^5Q]!N^:H6.-7R>=YL(@XAHI&>(S9 LY!-^ ^9I8X#Q:, MD?L3)I-
\GCB+V[LX\^,HS-\+JC#6PLA\(RP)F)LR4!I!)MH&2^:C>2(#,=+; MQ/F>"(]KU, [G"RR>>IU7M%OTE@5/@K8?[EEA/ 7DP0@"5"&!!!<+E"OC0Y,;OCBB\3_I7-CA,-P)(,%ODAR
M'G&XOY,"T%^K\LIN#/A&Y3C.-IOJ;2IG#=6>R]Q"MJ5 MBE$*[>H39\'FL;[7YYBOX@@G9S)'2WC[1!$2T?I+O#),Z8Y[RY2SBNP
+W8BG.EXD1IUPC]]F<#6^T;3Q<[%)I>.:HJSKNE!37&T7?O4JQK)H6XN2C6#L\;B/A8JFU5IY_X%L/@1K !>OIHXY8.J+@1]*+32)320A$K.NK M.GFZ>
(XE+'39ZR[,)F]&ZO0E/""*$S\Z2B/GJSC:+6(/X[%(,!/33I M'(HLPO2K/F.Q,KH8@/4V"";P4&%X++%P0=T#E8KJR2SB$UBQ!UP5^_^[!8,D
M%%5:,@D4\,A,CATR>G(//!@+N>#Z"O90:6AKV$I2+8FDQ"H)[U%)16OH"Z: M6TE(25JA&]A/O!I08*ZJ0:2GW_6D0FW(HM3 W#R^(5-05:"H>F)<$6\JYL)0 MHEBQZ2*49L&:4&

V T@<:$Q:GZQ\TWJH'\N9-W*92&GSVE8:;-7Z42$H>=!Y&HE;[G^ M'!LM0.(%7.K'HF1F&*M=VTF*H<"3'.\Q4I3\ M_704?:_0K836K\L@X@3=:(D:LDVQ3L4-)O#DFY
[T2)\S'B%HIQ+2.2U"[^0 MQ?X#VY5PF4[XV(U4+@?N2(N1YT9W<'6X\&3"J4AG!2T)U#G4*>Z%MNV#>!JK MW#Z%A[.K:W$B5B3:"D43_Q#KFJE>(^HTR01[L?)X_%N9'*
[RB:F&O4$H*C*G MI:DFKCXJ)12*>=5=K:\E1#9WA^S!P5&:Q/*0%W.1+OW4, M8,+\%-A* 9YX@:->B*6'CY;1> M@T5D>. KG&B?^$RFHV;*8HKJ*&+Q4'D$_6HD#GK =K
(A8*J'R1R\^ %PC@= M&O1JR2,^4!/ DK"98$DG7AYG:38K+*W(^L.[=@;I M3Q$.'OG^NC"/,G9 IH5Y4\]2^9Y)+;C9W!DG[HY/8).,I7T%6'='"PES&!G^
MX_,X\SYZ6KK8I^,!R_E2V*'DPPKR<.,!.TLK55A"ZUY^Z[4OI4F:D6=H9:$(M!B&0>Q<9#0Q@BQ.0$%+KB60QPP)52LO--<5H@JI;&)!:$\)A,H:S)EK%GA&N
MRE^96;DGXSAYH^#O?RZ"^/72"LLOGW(,OY*9R;U-H2LU3=@%@_*F*91C_FWN M *? #BVW?54O? QX_R_WA;GO!?[M/GI-T$O@3K+[/U:@%"4Q\?YJIF 0KG<- MUTEJ+XA?
L07F$H5P%\7-13KD0.N]1;G M7:Y,0PGAJ:QF+52YI X^B7O"L!D8%NV4L)X!=SSQ >W+4!1I$ ')BN>($F)W M#;':A$<;%8^X"ZV;PVC9L&!D::M>73X'4Q^-4WUMQI1-
I7;^^'SZ,!7#'8,A MC7Y"SK@3^L(-A<;W?>!.I*]\U68GIB&F,8%I4.-67L8HU:Z3T@:HEF<.?,,& MP(7.K73UY$YT:JU!>MJ'JR'KU^@RB[&JOD.L0*Q@ BL 5O?Y-S[#G+;P%@3_ M?
Y60!VS?!D :'WE G"?._$KH)?2:@%[MGDE3'$5OM)5H1YK-C@YV46E-E*(& M)5_6XHDDYM-8!B&<$&X2PK$\L8SD)0TI5F$^7ZI@D8V*8KA8GYIBJMS=/.=> M?, K'5%?.BF.0FQ
;& "&Z":\N<"GC]5.1=N* \.S#T'U)'*'MDCI.X:4I6' M)06K]K&@3$5QBXU6HTSU5GTVS_5U=@4;#/L-;Z_1VLME5XA:@]I&%>=JIJJ% MG'-' 15G#Z,>?R>>P?L2)Q5
'F$>3QIP<K^L+X:)&BCFZ5?);9_.&I*(TJV]: M&/8F_W!VS4[.KH_7U^?79RS,YFI?'8.__XD4I>//K++SU>7%]>GU^SB_.._MV='Y"5YV?G$C\IR/3O[O[/CT
/.6U6N,#L_._^_T^N;BZII=?[CX_/%$)$-_ M_@@W?#@]NTINN\8KOIS=?&!7I]>7I\?P^P5>PHXN+S^>'8OA,3\:OT*BY<;0 MN=9GY\
<7GT[%,S\>?;E6CX!1+H^N;LZ./W\|NF+79S>?51[V$8QX^O$C_O?H M_-])IO;I_WX^/3\^O=;#P2L??SBZ/K78Q9?STZOK#V>7EGAS6"M8BS,]M8O/ M5[GT;79T=79]=OZ>?
3Z'Z6V>.2S1TS=7IT&X[U!Q*,V6C,N7G*8X# L"SIV 42=\@N)D ME:JPD^H^"IC,&R(">>$])$ND>(A+T\I:K]B"H;4NCTOCC-*PJ^:LL@NS/H*GG:/&AL M//?
(^OVFW7#V&NUFSC>_)W83=-B+DB7L'I8*FTBHN]*#S/*,><[-7#2=9Z66 MU=US_\8]O %-01\-EONX/*:):^.J>:W^^VR*W05F>))YDKU)-H2+[E3/)'E\
M%1]>Z,R7#355[SJX,_\HX5Q?+H)/G"4O,F/%H58Y MO(2%551A2+C0U]X^X_%=(,J1]>I(HBG4<^U<41!*V"%<9#?*"W32@2C;)#M: MX!SR"X.AJ;GCXI'D6!O=XT48PK+:
<<)>NM=4UQ;ECKFGQEW3!.$HJZ"&'F*K&[:OT2&WY@'0D%1_7J>KP& M=X6*VVW^:K$>5IT.Q39EJ1@/+O]BK@(]Z^>1T"\Y)I^*(=&I<$^^60HLK(4& M/"00I?N%I-
-2J2185U2?3G-UA;H_%R!EL=J""ML /[@ &13-P'01AA0/\ER7 M;^'XO91=909=8\&Y=?"TD+A:'*/C2V&>I<49.5BUPY65!',U\#*'WC@6A8G
M^"\/@SU\K+6$WMR+"%**9UHI;E(1CI-+*S"(G#+1 D37DE /R$N07/=0B6*U M/:EF5/+%WHN2B"'[B,R.=SMXL/!&@?94C2%V']5;4?UTDJ^;D!U<;W6R#D1% M'85?
ED0O5DM9SU:1JJ^1:5:&Y)^KTI8IOZCB'RM!_B59F)R=2/1T$!6(%AEM MA77G8:X]7G(L6M=B$* *9;=YT2MPDI:^7!%.FA^C9/9+/"N8.53I[%I+6GF, MJAXC],JDM[#QF&K-
EUEF#3D5Q1UAJ 4OF %='+A#;":67 M2CU&[;*B=J6LX+UAWJJR32)]Q#[L/TE:1;.L/BF+."R)Z(R(%^%O6;DO-:.$ M?H9RB#M)'<]YR*<\5%6!Y)X@#L<(P27"RVLQ4E7.
[7L):361HWN,^Z<3B)[M5=UX]= G2LA8!5K6\EX$VV1PB]ZF/'^*@@81Z!7OT[HG(A\C40H%Q++7(I-Q MQ(3><&2=(!'ZF1[2 MHKI+[OGH
@Q$G>5A9#=LGHL(5CJN_%0W)EQ&1UMOL"0"9. M64PM!HL\4_5#/$;M:Z+"I+!(DB&K*B33@F,%\J1 $UZC("1"9;J9&Y:V50V;
M#5PK]!^.F6P^9X^@K__H%HU<<*L*>Z<2>HUL7IE4TMXO6_?H#A!:L!AI9IU0 MYO2=B>;UY.9^ !M6L1ZFQ;](J'Q*W] T2\PNY?1)YX$6S$2/B>4#E?
4U;3D#DO+.E6VOIGHG9Y6?;\2S1UU&?JWSOCK8LY0Q5=@W*@%CE'@X! GC+"P1<;.MM)RO M.G[KMJ;M!5DP Q2LI7SPV0-U5MCB3\Q+
<"8P&GZW)%8XL"P_J\6/::%3;$NZTZ.5@-_&$)CV%_=9%O0?] M(Z*! + 4W(SCHY,_[77J+[!^-"IV:_E>J"J.>I4VE X;$=?#W*E4^>9?S[X:4?T?Y=S^< M?
W>N*O!2#MZ:'+SS7(EBRL.C>'5EXM5H!"2Y=C 0SV;F4?H0P=0,F!84@Z*T M'*G5%*0@*R#K8;AC%3^0S.&R=LOP=<1*+K:8W
MR.86*IFA('LAY^A,NDSDKTDS%>1SMYNO<*!,AHJ:4]?Y/,=,3P2YV(%.'I0= M1@!O/OS!DU2##'0%3PG_91&8$LHNY0SG@9[U:HDCUMBL1'BZ@2SMYJ_:+;F< M_I;/**-@PYI?
D/&>X2L)/](W3: R]^'>4/Y&G");KL MP#J=RGIXCU.2G_=/,48/,X), ! X6.5-G#(3+\!'?7\7NE3-/1TWD M*\EYBC?;PQ!GX11E1Q3=Y 'C6]YCXL=,LJPP^I>;A.1C<;-.'Y!RR4F"!YGA
M+>%35>U3\0JLZY"4_)&,[RBI)ZBK"D/HZ;B>=*S+GG%S4< ??4+N3(RIGI=T M5(=%5B]9],K??5C?5<<^O*01K'0)P&1U(LKC1JA4-01R-GT^9Z/;OUA()&3; MN+W]1B
DE%Q4>]8M$]:1-C<,LKV@I'9RO(A^FS-6@Y-(F'2Z9Z$/9Z6.NF. MXXR">W[;@(%25772L9(-HP]PWSRA-62IH@:1MD!G5MAQ*\3(J?'9U96*B1Y
M6)G4H1+7OZKX3T+DQ0L[64GEW;BM9<2&"$3+!C[B.ZE.*9KJ(+%*Z\T\,[]C M*?DKL*"VJB@MH[9Y0W"'7SK7)-LFK:6H.&V$E_;LD0[9P/_ZK6^U>D@KWQ$(+ MQ3M11'%KT-
F& ,F9:,W\5_>#)5F?3%+DTN'2X2*IY18ST-E3L>R"5%5>^+Z< MNN"GY-2M07#2">X[.4ZG@0 Y/7EL4V>[_U#6G@I'DZ.?/%0O6G<0+1TAXJ+G M;O#L+^[M^B180QQ+
<*>IC? !R;P/'!1+J*/I2#K_.=;U%4RC%$?>LHFKJ@] MNH:(*UB+.&J_16#[7HB]#'5_ID5J*5U9P3683B-X9YA(^EZR[LIR!P7W?.PL(EF$(5=4/'LT!D;"Y^M;59T+6.D[$-
CW>#Q#2=O"\ZLH M784R&:7G"M5[KKW>STG08DU5II+@U5*X)WX8 "&/93 K1!&-X7=X(GZO^MD6 M+5WZ>D'.-2KK=/D\4;H6\2+D!^P4Q;D[U8N#-
^%P(NHI[M'/LU1"1NA&HC++ M*K@KTWA;D3\Y=5/X;IA0CB<0Q_%"'H[R)[G^3WA<6U9B\3(E M2Y8RST/<>H-%K,[9!F',$VM_"@_9%^:_.@RI"KDH8$^4NO),NH5/QPGS9R^K
MJEW^]3C2/(BY+CNQ00FDL-+/.V5YJ4_Q!=F\A8+\PG4BI^C,82X):&/T/DFR MN7/NN6)Y]M4/'CP^T22P5]YBPI5@!@ M'[2^D#_-
BIF6THN:!$CD0>NIZ_%\OA+NPLINQWO%3QB07,J/+<"JSKM9)YG_MXKE@H0"H6W!"*)D>T*.@MRR=KR6*2Z#G56:])")>)G[^[%&QN&]-*\'$J="7X M3^R#B7<#UV%?
5_%17=.7'4C/87$2@Y?]1W*8%(:;C? M+2-T#;OG20JUA:N+GX/MRPPAG2<)MDH/9TGR!%-8 57=)/^+)-)/I5%5M\7C M8*Y:*15)'%G@*2R4,^)P._HL1URU5[IW7$^@-
ZU2G6\X6IA6A*F>MR%/4B)5 MN GC Z"!)IV>9$F5A1^+8A;*_[36ER1]0X*Q,9J=*M95I6-!]0'E,W-288J% MA)QO,DM^)4LV)5H!6PC54+O[L'[.0UH;2*;@8L+NF+'&C4_XW*_@;
[2[/ M=62%D"7%*-G_LG#%FG.Y?&.>;&28P5M1DH-&>Y02-J.[8CH4[O")FOH)V1,6 MY)TZ@70DRZ!N/E[S)9^FFI+?G M<*,FF%+N6J"BR%X7\07T7,KDXT0A2%2.E
%/.%9XFV4B/XE330XJW;C 4[?: M2$"K3?@[98F;!*VB;I BK"X.'27=1#62-:B2B-M:K3C*,&2N OL*""9Y(@+)
MGLF;CN]+T^L^@NLQS8#MT\%57.#_%"$U6[:U0BC_D\^#/K\:.>M& ML$9:WH 9C]X^5:4NXIXXOJEB8X]JBU&N*%=$IF9N+'Q&H>-'*->E)0#6K%8L
M;E&BR5A5R^IVAU:OTUU34]:2^291K!JC-(IV6*_?M(:#]7>H(NBBLP4L2\/= M8ZTF#&*WUQ6N=:-HD4W(@3%AS](]7_3FFMY\#;M'BY&VQY:K6;_B<6 5[@\NSQE9_H=+#E-
2<=N MLV.U6]D%E38E %@_0[JA])*"%AR.W2@)4,+K[*/7 EU:3@A0015U[P&J"O?W#1?S8/\%:Z M@_7CJZKB?>&IGUM%"W1I()2K*)"=O&*;A:W!^P++K'.QM$C"9>.CSDT,A5E
M:<@L37!2EP M=?9NOY6"4&25.M&=+!6<2NOD@8HSUFT%24$/9+-%.+[#^N3 M;^,T.2%-K!!.#A4;4Z:?3)N8S=Q(.JU!0_*?VG^JBJ>;]<76TTJ&0'1ISCZQ M1X_1$-.7N1$25-
@CBRB31"H3.[4 DMAQ5;$.>UI].V#7"W5E@@7AL,57 MRG2TTY6C95!'2GH$U3Y\V!?LRY-4N6RTW6+BV#J(,G>*LX!,!$^9U\H-XXL M#!*$F8MUR#=).81K=>TF-8Z2+&
(^/K\-8M=)M$]'^C$V$P'?%W]3"NQZ@9Q= M"=70%8\/S$9I-J(\$#D-,#HCJD^+MF?+M:C2 !R=)Z8C5B\Y3;W_1C(E4P;E M]R<<&%T(-E6I3!4.2TT]V8(L=S6J!9AZ!%M-
XF"$QX/BIV/&.:%*!W6) TS@ M@*3[AD2S<\MS6X/,MLM^D4ML4%DLH N!I@7@U_P4$KX)WT;@>^2)O'%,?2_$ MKA;?4<"X?POP5Q47G3@61;*P*X92?K3J@PJOR'?#JG
B53E[Q!R/L./]RXV; MY$1R>PHVT0"@>6XL.]7E6(\8B!C(! ;"QI/+)DS.IBOH=2S\XB(=2Q^F=**) M\Z.RHNV]GTA5U/3!,#[/2E%5,:T '^TK'/5^ZFL1HA/WI^7QA,$B#RZY8^7:D-
SJBHPY[2=2#FM90T!DK(7.# \91OGSY<(D MRBT@<3=QMQ'<'!$^SX)F>S@#5 I0,*P(1@64!6! M\U#W>GNY(]IKC?>DTEUR5@5=NMQ3&02B<9.#1C/6-'/
MTMW_ZN+AY5Q:P]H\)3R\@:>[.'9 CM+,"+0\1!ZI(RM6H:0+%B_LTP M)P=^TD69,@\1Z6AI1"%=)6> ECQI!9#9X%6C@GRF%.1KJ5&I(!\5Y/O>Q-"<^-="WUJ7
MV.G,N$BU%T5,M93G1?F=>!Q/N;U1IU#']]=LJ6>K=6Y6>D#*99F$6GW$Y6W)/)\Y?(8YI%JWE(#\%YA$ MJ>%*LDB-3;X.:,&!JCNVFB6X^:DKBH]..%]-2=?'N-9H3-
FAV?/&QE53JNFF MF".6(LC)2$SS5>)3*+=383HMRXN]9Y),II!G Y"JP/CS5U&PD27/VCAX1-U9 M>+%5E+/YC!61M<9S\5$UQTEVDB^R8A65L$_A(,.U\!T&042UV16&E05VT5!U
M44'!O1O!F[&I9#WNM: M']?Y6C#<&H2AJ,PD#Y5LO%;P9B13\.(89R?63/%BF-\F\%'Z.$0PY[X:2;2K M1O^,/'^**U0P_>0PS%.SPM42RR1\?MGI0X%9198IU.LD"0Y/.;XV4!V
MKE&T*A;BIJZ$)Y':$$-]Y/>"E)$X<][2]4.-RR/Z'R;^%J\P!$[[AJ9 MOK:23%(1)5D0Z:2#M\%VWMD#*=F'2A@O(JG5Y&UZZ=WZCA%Q$'U(2;CPL'5"
M,,-4F9PJ(CQ\V6/,HJ]*)GTF+*QVB=\D3=9UJ@_6&)2GN)+[J[H'G"5=M!%$ MR-!6@0(FTFRC)#'WB?-[0H? 0YJW,KE)513//Q4==BA<94WU W7PMF!0J0Y)
M[V;FN*65.8DI2W+B>3O!F^G9U343Q$Q)5=).ED;-;#'N;,8GKMQY8]*/9BX M.!5&0>)&%?5\'M/\T>PA6.LO36QE(LYC4MA3NB7%J5YA:HGB02/.
M_:7A=96L2>KN7!7F8CBVKHI6WJ&>/G.LBX(EQ:^$&SVIC*EJ:,GZ2JJB9E4! M^(6K\DU82TB5;US'O4F?:2R=M@\3<.>J.GZ:ZYQ6S&>?UJ1_2C$U1ZRC8J/M MB@Q>%*$S-?
5UOVS&N<%%A=42@3 M5#QQ]'VJ:NVJ7E\RA!Z[D6[1G=,\$D,Y5X M*;60+ 2LUM-6(P:P9[XHCN8_ M+MEW,M\U%?=R;?.GF>X#
[U[/41<=6)J'+A:JV5P7_G2E:J\UZV2@OWSX5#SF-3KFH28#D5/Q(B="Q[FA5E*N0R(5;;MP2%530V.,^TF_,A M6\]E)+2@,/CFSJ3"_,O MMIV[Z#7-8)LE8EGA=^3A4 5$)^L@-
BN1MSZ?_)Q MYUI40/QX^O[H(_MT= .TN3:E].$+.>=%YQA1M7FE'I66W2K]2^MD=[,(1?URT#A\SO[NS.:O17U^U"X!?E:VEE36Z2(56EVZ133Y M<\.9:"BC,[U1%;+G+XZ1\61
N6ZU]$BQ&L=3K9<5HU+!4$PKI0\.9+[BJ MR15(>T%WGJ-%UMT)MEWP+!NL)%IE[M%FMCZM.?NM')HYR1<*6',QP& MM;)0ED_/+)T8"FE2C;8T:QC^RX?
3JU/V[XO/[/CHG+T[.S]A1RP81A4*O=E/&@R4U;4?+?0R8@M&75[1Q7BD)B*1*.4;X]9R9$Q=3/5 MX1,O\/6I;G*:N.HP2T#V^EF7,XRH37N>7>_;67.>?[MS1R[.99UOIK"*W)H\
MBPT&)+M93='.5BLMGKLEJHHD72.0HT7C4=AGU7VYKC(YP;D^:SQ4W@7Q_-__O;;P\/# 6@2![?!/?9TJ8!8*&0(7%J].LYD$J*K'R@/ZX + M,)6[H(^;Y,$XF(F5
3($$20WJORTK]FZ&)+'L1" $PWO+E8GJ38+Q03 5[M5H#;4J1:J,'M&%9"KZ<,'21%'V7K7''<(0Q\V2@FTTK+RG880<> I8FBPM66%_$Z' #DW<*=P#:GT*U2!Q ;,8Y;B.1?,K_
M)O*E8*3_E=<<*ZFS?,4 IX*?(M:V6$?NB%WQ[^LQO)[PXMOMDQ4!L!33E;:E?'!&@[%F%@W=.8?X.;1#!=-H(+5=W@)+2N]!9610E#;:TY+%T> >_Q5Y6(2R1:FXAB?L]7C R
M^9\T^3MD\ALOQ]>H=Y_/CSZ#-G=ZPBZO+IA0YMCQQ?G)Z?DU?'=\|>GMV3E\ M>'OT\>C\^)1=?S@]O=EA36_Y]8^$MO/)"4';5R9;Y^G7^\L#NX>-(Y4D ;9%
M*&4;MC@5G7.8:IHS@5W/P7-J_-N8SX5YE@GZ2&5M#S?7'S\RJ]@$[-T;O+58 M]&R6"M]QYO.9AW'327W@HM1.,JWE\/FC((Z#V<\|A+IR-/;G/7K3.>%=&P58 M1P^$S%(TV-
I34MN:P(X.1@2L(@%!50&YZ__^RFX]?8[P)TRC0%^4V*^E)EP MV?R;J&D+1JT'*E7^W/]/FT9QN+;HS;,A7-F/*0R8L__Q$0U6A@.R>9<#3:L MTB@D4G+U)TB5>5E!6I8<-4Y.?
G'N^0G&-\(Z"$>B_S+]55 R);Y1L\N&2@F? M=<3G#?<\[M]BCWI,6#04IS=IQG0=8$K,4-)F[?]3_0GVSPFFAG)"JD^8RJO' M.J)#G$J<^E(@^\3#VZQ*;=3DCL@C0CRP'1<#7[?
*QZM.^"CBE?._FY!$5X'!B%@[-!@1:X<&JU(8LKI4(DCLPL)5 M=S""Q X/9I9IT^T*J^;E39ORC!E=3,)1%DUEK!D:A4:A46@4&H5&H5%H%!JE MCJ.894]L+512HCWA1'>R-
B9^P$+N]XXG#RNL-2UT7.?7GT>!S7A[@0&+4OI_ MV3CZ\-=\@%A4JJXZJKJN:RA'[QLK!:I.:L$78JLR I,29 M9U/7(.W@,N1SQYV(?JU^Q+.--\?/S7"N
H^N/\>,2&A:#/^W9R@K/WORK5;3 MZ@ZW&(LIK)!00V.N'O#:=FH$H:M.Z&K8K8$UM'LE*BQKZDR0-Z*&WHAZ,-T6 M[<^?(I02X$ME*8L=;\=)LK*Q5
M"=E6MSNTAITV>W*"%#&O&3+Z/9'Z2<@@9.3FU1UV MK69W:#8N=A8,A+[-\|J>V2@9?S";O;)+7Q$"MX[Y% $24#"7QG[KS4< O[L
M@7GX,\O0KD&"Q#OW&Y\HZYI.&Y3'EIVAU6MMT1-60RO)5-+WS#X@2:1_N75O MM&VKVQO260.*[A-#R((* W0-F<@0U:9U'N0* M+*MT9+/9,8XOS#*JMQB@-A&5=6 #
<_4.HCI1G:A>#ZI7F]2$+<)6908L 5LM M:]CJ&A?_(A-6F;"S/=;PE1EKT+1B\Z:T(&.?=B?3C/P:1,[/_-CQ;]V1QRD5 MO71>'/9LJV.8V\T$4M2!]EV[;[0>1[1_N75OF,#XE(U.V>C&
<(196BGY3 A; MA*V=&Y"T. -MZAJ<[+X05>YK4=W>5#ZT!U;'+OB>HO:$)W MK7ZSS KN9$"3 6T0/Y@K!:M-:L(68:LR Y:AN+>LOMTV"F!FV<\UB$E?(W#V?J%Y'JE>; MU'7
5L. W81<-JLNFRFY;$C8DK E;-7%HJY!1/I]$$P>7,^KN&2O2>\^RVYU M+;MI;V]=J1]VG0"V8[U-"5B[JQ&":*+6JU3]+[F;+=C\GQGT43P)?@2? F^ M.P=?L_PQ-
\7>/UH3[@)J!D]T'>&;8M>]@GD!/(*PKRGM65 M1>%W4(W86<01Q+I_4:GW;.&W7)9GX[E MUO!8KK$<,6P/K5:W7'%('+'*$9PXHAR.Z#2;1NL'M>:*@+BB++VY8[>M[K!E
M%%^8Y>'88MC41%36@0W,*CIH A&(ZD1UHOIVJ5YM4A.V"%N5&; ,EXYM@[;> M')!+QS#C=4[&*TE;TXS6+8;E340CP9_,%Z(Z49VH3H;%3@U(V")L50A;C4ZW M]*@KV:RK-
NN?9+.2L#7-9JW!^=0K?A]X]Z)'M.MS%DS9..03E]I$E\.-7<.3 M@HCV=9'$)A"!J$[&3F4&+*=/=/G;"5D[J];.'5D[)&U)VA*VZF))U^!0]L6< MATXL+&GN1#PY@?
U(HKX4=NP/K'Z_W.0D$RE1!]*;)8E-( )1G72[R@Q8AB5M MP&Y"AO2J(3TE0YJ$+0E;PE9=#.D:A*2/X9K0&5,-L_(Y<="UFNVN4>QH B7J M0'JSA+)1*@#U1L&
<#S9.52WS!B&,%<,5IO4A"W"5F4&K#VVS+*A:Q",ON*> M$_,)FSMA_*C+A%==X+5C M,5-S[#UM?5]GD4 M8!*6Y)?U+<;+^LGL;-P(/P]@3_;ZMH#J]DB!!
("R]D;.RWLB&3VSKBS8"#T/:69 M=0<#,_%GEK5=@[2"$S[E8&9/6.Q\RUK:K#'B/I^Z\9[%?%[UXG$U\;GU+'O0 M-]_E1NC:173M6$""@+4KP&JT.GVK56I7HD+$T;F&6IYKJ ?
3[9@TWUDT$7Q? M!+ZMMFTU6_9N@;C6^\8M[1M58+P=V#?,\C'5*:.C[IDMGKV+^NO.XHT OETMN9PTH&KX;6J0&W0=!^.O=X$'@(K^_K=! MR^Z_9OS/Q>8&&-
N1!30*C4*CT"@T"HU"H] H- J-\E=&,KPW;/ZO9;UM#>XI&!&@;+ M3"5_OV_UV_W2FTV;2(TZD-^LM>AZNJ4S1MKK-
MIM';;:WYXBOQ13E\,>A9+;MOM6VS.G^;Y3'88C321%C6@0_,5L05)G*%1UQ!>HAI)O<6 M@_0FHI'@3\8749VH3E0GDWNG!B1L$;8JA*V6-6QMN946F:[/-UUG>ZSA*_/5
MH&G%YDUI048^[4ZF&?D45R?XD[E'5">J$]7)$-N= 0E;A*T*8X,2-@B;%4(6QT*31MKM_Y)=BL) M7-/L5@JX$OS)@B&J$]6)ZF1;[,Z A"W"5H6PU>[8UJ#=,19AM39<(S)<2>*:
M9KA2P)7@3R8,49VH3E0GXV)W!B1L$;8JA*T.U9 VUW -R7 EB6N:X5J#1K8W M(7>B1?@(@P?CK\2#Y33]&/:Z5LNV2V7%-1T_B.YUD;TF$(&H3C9.908LHX*U M
1L)V3C4/\HLKB")2]BJ![;,LI]KT*SY:#Q>S!:>$_,)F_"I.W9C$O(E=?2)]":3O#JWN<&@BW6MM[(S)V"DK/]?J M=0=6?] U2C,EQB O0,E;A0D)
+15K')$0!Q1EO(TM%HMV^HUC0D]FN7 H"/7 ME>Q:]F!@BI).EJNB"W5?)FEK MG-%*QZT)_F2^$-6)ZD1U,BQV9T#"%F&K0MAJ69U.RUA\U=ILI;9,)&^-,ULI
MUDKP)P.&J$Y4)ZJ3:;$[Q*V"%L5PE:CU;:M9LN8A$@R6A5=;LEH)6EKFM%* ML5:"/YDO1'6B.E&=#(O=&9"P1=BJ$+;H:*NA1BN5M29I:YS12I'6G[C$03CA
MX;XD'7PY_\:BP',G8J6;%L/_[1G*)<^>_!:9:>Y,)JY_FYU3+2TD A8!BX!5 M%V#M+)H(O@1?@B_!-S_Y1OD]H@MQ33Z*6O:,K@?3[<">898;I ;5R=^,#F^" MV/&8Z.YU%WB I.C-
;R.@S*!E]U_#[XS_N7#C1_RRZF+@QWD+UND7N4([*1I@ M^K;5;PZL;JO)GGP/(T0%@:]"X&L,97!JF\![KD8(T]O;ZLP(>EN%7E(??O? MM[.((XAO<_JM#MC:]@[NZSL+-\+W-J??
LYKMIC7L=0GB!/&J0GPX[%I]N[\C M$#?+D5.#-NV)(\=SG9'KN;$+ SG^Q$3'S@JJVD+7-4Z>P+38)%B,/+Z; F7C M_-M6O]>Q^JWVEB7*TY9/.6@P8Q;UQF3+:K?[Z
DB3!HTBWICLF%;W=; Z@^[M9F*RHAXBPKX!\P?L=X9MRQ[V"?N$_7IAOV=UP6SL]@<[J(L0\@GY/S[_H=4=
M=*QV<[@CR$]]3?!I%$P>\6OXZ,#K'3+\7.B2^.^891E@9YSA@99*B$O-RH;]S#:\Z9,QX'L[GC/\(",3^(890X8/$=9PO? M64S&A;!SX$^Y'\!W<-7)]^#!U?<>]N[E*'EB4 MZ)@91-
V?>\#==#\,'O0ORS^-N>>QR_?GGS]M'*/8G:<99AD?VCD)UW;5J+_! ML'IRZ>?LQ[O$PWIY]/YT_^W5Z=$?^T?O;DZO_LD<[\%YC+0$0/>ASW,O_IK=
M<;F*+73N*K_IWYKBGR*7JOKIU6]%*_[AI'C%D70_8[UO+HX_NO[79)DDFIZY M4IE/Q5[:%70_4V@I4"Z_\(N)B+Q &!U^3EC^$EC^G6#YXX3ECS7+7VM&9\&4
M7)!_@EIPB3$M+IYBX$Z?4)[KB+V"E,<<(^.>'XCK5MB[6:K-HYF .DX8OS;/.01KI+KL\^^6$.Q3!%LD)[GA$![_FW,YS%*4N8O9B,>
MXO)%=P["Q!0;F^+GWU\U7S%D#+55)G]'<_"U9" 3^#=Y:+&(WBZGO MV-<%$[B(/2&8ORF1]B;9FF5(*)W4!^[@U)-IO724J+3SS+LVRIM1,M Z/? E MST4\:P([.A@1L(H$! 4)Y*
[_^RN[\[1*N.6<@I$'BIQA)XN 8I>)B>),_K.(M8F6&; Q)$QN:S!EK!EO*"*'M_\6$3XMDS_-DSQ?GGK,3QQ_S,)4X1LWP*&(A MGPWIJ[06U=:?]KZ-\RUI2'K76 @;)=
]XY!I7,IBI)D^_6>5U_LC\) M'GST81LJ5% OEVJYJ3,\#D+8\IV8F\T>)/1(Z)'0&QW><,_C/FA1[-KQ3#4D M;D+'CYPQ1F3-QA])%9(J)%5DZ$*F6A@J473>QYM1^-
LA>W==6EBEIJ=!$YEE M'PQ^+?%LZ!6_Y_Z"UZYZURM,Q34I#??5H6T-[:[5[K=*79;ZE0HP$0JMTANR M5!T'9A;L-*WW2"5.CI@Y(&&+L%75_:MAABY#!;M7"W:/*E^P>Q<8Q$
%SRQ# MO ;UM8^#2!RV"6MA@INJ$]E6R^Y9MEUFOPDSB5$'ZINK$1/5ZTCU:I.:L$78 MJLR Y9C5)B@K9%;7T*PVE2?,DK=F&=$UJ&W\/@RB"(O93-VXXARX$XZMWG!H
MM;H#HYB2@$ >SBKB@+9D,H$(6X2M71MP)_:OA@F:S!I+>VIS/5=6JWS/(QF$"&.M"]U1D:YU\R@11U MH#V%2PA;+Y>-6/*&0GF(JWF(#N4ADJ0E25LM;)FHP9EE2-
<@0OB>^SQT/&%* M.Y.9Z[M1C/"">SHY6M;)T7:K:?7Z?:/XT@1BU('ZW5[7.)EL BGJ0/N6/; & M77/YOM86T)@LH-).)S:;?:O?
+)*)MMZQAG_QDIG$$G=1K4'9675UH+^I\S(7ESLO*5^>W,_I06PX M_DR=%_$%\07Q!?$%\859^#-U7N;RA0'Z_?/\"V9YGVJ0?G(3Q(['@H)Z>Y7V M!>]&,4RKW6];K=;0*
C!Z;OL&^;N!,0"+:H>P[MTLU>@D'),##!Y"6ML Y0,\/8)?=*;0#7 M:+?[UJ!)%B]!;0O:5+LY-&DC-JS71ZE.)V:%K]3ML4GX,)5*@%V5L4MZL?
U\=UV>!SSSN1!RP%\YZ;;,]L)D672F=J(/$EN:B-20[YH@ +1W@D%PH@ M\-/<8U2 >-
LY_,3+Y6I=NZQR$2,;E.E!C%QO\ZG8@V.L8Z\&.2>JJY)7:I+DU/1RRJFHVQ\ZG#AE/>U'D1(@F19LV+$$G' M*X@OB"^(+\S"GZGS(KX@OB"^(+
[X2TG_9E>;K$%^Q)O1X3F/9:7))YJZ5\'K M6^3JA"7X97W?S_(\P3"O-#WBB>EM88WVMCH)0L83R,@D4! V"!LY;"0I%D8C M8V?
A0/C;/*\D"8.5CD#*Q*@A_M($#9)_A+]2=+,DA<,X!)IE86\QFZ/\K8!& MH5%H%!J%1J%1:!0:A4:A4?[**&:I\C4(EKUU(G?,''_")JZWB/F$/7"T*.&# M \ONW'(V#F:SP(?

9!>.O+%C$40R7N_YMQ>-J9D;&7QVVK*;=MNQ!N<=,JRR$ MLJ.\('%->+TJC4*DHE$($#0* :*2]E8M=+L.*'8#:]@OMXZ8V599#8[+KEIE MOLYHG',@P)T34L?LD@ZS-P_J7">!-
FH:A4A%HQ @:!0"!%E=%5'IFCU35+K4 MUH)/HV#RB%_#1V?D\4.&GPM-DG\LS>4?K]-QQ; YLT-9' M,T:&EJI74V[4-^[A->?,&8^#V=SQ'UW_%FRB&$:) Q;?<;;PG<7$11-H'@:P
MF/!0-@[\"=80FF!L:N3Z\&'J^HX_=AT/INW$? 9#16]^_& MGA-%O[^Z?/_VCU?+.&HV?RTZ2:B^$5@77[T2CUMZWKN;JU=%0E7WP,H,HN[/ M/>!NNA\&#_J7Y9_&W//8Y?
OSSY\VCE%LSFJV6,:'-L[AVIX:]3<85D\N_9S] M>)=X&"Z/WI_NO[TZ/?IC_^C=S>G5/YGC/3B/D3X?BN:SSW,O_IK=<;F*K?FW MUTSY#?[6%/\4N1343Z]^*UKQ#R?%*XZD^QGK?
7-Q_-'UOR;+)-'TS)7*?"KV M4JR@^YFB28%R^85?3$3D!<+H\'/"\I? \N\$RQ\G+'^L6?Y:,SH+INPB+86= MG/E\R3G"K(1X^C=W0G8*FD/*267/W,48%@]T+K3"R_93O-9$]C1P8B
520@*$<@ M=_W?7]F=I]7!%S&*=JOA+%#L,C%/G,E_%E&L3)"-]2>(#4WFC#6#+45#:?O_ M<7;[CJJ\B41JD4!ZGD#ZXMQS=N+X8QZF8LBH&1Y%+.3S(1394N"\J^5#RMY
M%L0"WPNP=V[(I]ZCH?_YXLPB,8N!Q8U=(K$H<2A+PJP3SR\Y2$S%?Y;U^3_M&ORW##;M=COH_;I[R#O'*)/95"5Q\MTZK^M/]B?!@\^"J:$R!=5RJ96;*O6. M@Q"V?"?
F9G,'R3R2>23S1H.9:DC.AAD*V)I3Z[5FD#$QB $,8J)6:I;[H 855XZ#2)PC M"FOA.#!5D>M:[5[?ZO4'1C&C"<2H _7-5>.)ZG6D>K5)70=L->S2-3NR>VKH
M&#"6'U#!ZI6N8!%/U- 78"I/F*5_F&7XUZ !QOM05%4-@ZD;5YP#=\(;U[)Z M=L=J#?M&L25!@1RSE00"[OH;J_5LGH]\@24/F I/B![V#-.*IM C#I0 MO]-
L&DW[6NNI#NFI95EM5JO=LKH=(Y,]:\T3Y,DHS[/7'C8MV^X13QC&$^3/ M*(DGVE:_WX5MPJRB1V9Y-+:8T& B*NO !N8&%(GJ1'6B.CD,;J((3D@1)%E(
MVA5AB["U@P/6'EMF&:Y;#,6;B$:"/YDP1'6B>E6HWN\/C?/4DN&J#%=.ABO) M0M*N"%N$K1TV^ MU6J7FQUD(BGJ0'NSQ+$)1""JDX)7F0%+23?M6OVA3;FFAGEJ*/^ZM
+43=OJ M=*@5M&D<0=G7I'X8YP.HP3GR*QYQ)QS?"?M_PN^Y%\QGP*+$C<2-1A"A#E3O M=\SNPD*TKR/'5YO4A"W"5F4&)&P1MBJ$+1/U(;,LTQI$IV^"V/%84-"\J=*6
MZ4ZT5NM:@T[+LMLMHUB4H%!*]89NGRJ?$11>8RO9KN'IX3M+?P+6]@2V-:6[NL,6['0$-@+;RRO8=I=J8M4^.OLQB"(V#8.9MH,#G^Q? M
]BST;9:K;XU:!N92$0PV!X,FOWRF\P3#,K7# TP?$DSK /8T.2U2S=YRF=I3V!;X]'K=?LF;:5FV;PUB/N^&1U>Q'<\9*X_#F:< M-53@=T\V'%]K_&Z',7_>*"9T;:_
8$2L'1J,B+5#@Y6OX^_HPE5W,(($#4:0 MJ,Y@9ADW-0CHG>'A9Q[%.IO58CZGLY9E.;::;:O5-=*M171_2;I3R*[L >G M$OFP*X0ML9.TAL8BK-:E9:C84EFU+,MM_$P,0;66S&
((PS1/LZS_&H0VWSNN MSP*?18['63!E_,^%&S\RU[_G48Q5ET05IHC'L9Q8N9QCCX.6U6V5F_YK(BGJ0'MS+4FB>AVI7FU2UP%;#1.V$RI+
M2[X#8SB"I"UAJQ[8,LL*KT$,7EOAGAN[M]*63DUN$O7<3 MB%$'ZILED$T@ E&=5+S*#%C.H443-A0RJD8F4J /IS67X M:I.:L$78JLR A"W"5H6P9:
Z9):)6H.H[[J:4F25EG)>SNJ67$_01$K4@?2= MKGG"V 12U('V+0S*&4OY6D?EIK05EE:%Q.IWRCTZ3F%J"E,;PQ!VMTU;A(D< M02&F:TU"+O?!+'CL:".P?>=:+AF6_UVRVJWS?
6Y M$A2VY6;L]R@R3T 0FW;'ZO0ZIFS:I!)6%VIR_^G:Y>X_!+8Z@,T>F+NY[2SE M"6K%20RVU6V;E>%JENU;@U/1'X,H8M,PF*DBW@O7OV7!7!7PCMB(XR%I;1;' MSC>8!Q8
3\J"8W,PYN%3@BESIE/7I=X*_L;[,L&MUF^5F952XC=1N MP*!E]9JMTJUF@D'ITF (^UF3K!@"VQ8.473M@=6SS2V5N;/T)\"MD6[-5MNR M;6.B> 2VZH*M
TIUSZ2MU"RSN08AX[/$'F:-$??YU(WW=+_LBMN^QJ9Q=$#K M&!C9GH3(_H)>S-(M6Q,)40?*4TX@8>NEJ-MN]JV^P0E'M<[PIV//I;F2>UW+
M[E"]>M,X@HX]D_9H"N@!A'T#N!4W4'?#C61;O>&@]$+S%;97=P,&%)TE&%!T MEL"VW;YPW9[5LC)$3[YK?18<6-T2((P@K\(E_=+,:$>35:5K/=L3KM[I,3W,(J M[6UU$H2-)
[&1A&H)&X2-'#8R\5NCL;&S@" $;IY7R^H/6U:GV6:E(Y#,EQKB M+XWQDOPC_)6 OTS@US@$FF5D;S$&7/Y60*/0*#0*C4*CT"@T"HU"H] H?V44
MLU3Y&L3+WCJ1.Q:-6B>NMXCYA#UPM"CA@P/+[MQR-@YFL\"'V07CKRQ8Q%$, ME[O^;<5C:Z8&N&UKV!E8_=ZPYE[(]8SR@L0UX?6J- J1BD8A0- H!(A*JEIU
MT.U:'BME_$^Y'\!W<-7)]^#!U?<_ MN8>;W^>GK]K$O6=CSXFBWU]=OG_[QZME'#6;OQ8 0'\CL"Z^>B4>M_2\=S=7 MKXJ$JEI7EAE$W9][P-
UT/PP>]"_+/XVYY['+]^>?/VTW5Z],?^T;N;TZM_,L=[MHNGL\]R+OV9W7*YB:_[M-5,^@[\UQ3]%[@3UTZO?BE;\PTGQBB/I?L9ZWUP< M?W3]K\DR230]E$'=/;&Y+"0;1S-
;1PQ_FT>\@AEG^NSS[Z0C-.Z0?XHC>A MXT?.6&4C/(6 GS /^;KL1<;*,.%_%E'L3A_SPU_X[#RXYX+(-OI#FZVVQ;XX M]_P$]D,>6NS,'Q\P!Q;)6,X1E681! M-
'8Y3..93U2W%L_Y6"H4R5AB Q-L YJ%X[.CVY +/4',XM)S!'C4)!M.!,+P MD8U -8%K)JAA8-)+#!04F@G\U\J.INY+'JJ'/6 W<-'RK^P!GJ\?#"_T+\=? M..$CLUN"@IWL&T8Q.\
(K'.W=\)W\=<= 3@9+P'8C(1Q8\H,H8+4:1.W%QW8'P699)/\O[MQW>.CX\'\>L[$@ ;40MXPFGK:Z3DU5-![17#)AJ*F<'4A7F&29$$JP/W^ER(MMDVK$SPA%)9X ?8/K&]PN?
C_V7O2YL21++_OK\CP=.]418";RP:JNBL"8US% MM N\!O=,?YJ046(T)4NT)'S,K]_W,E,'(,0E(79NSV-.90O,]]].K!1ET;0 MU(>D#\H*M=B):R:-,_PKV$^4S\'G(2%"79V0J[@2/
M#K/*'+@G^//QG4RSIF+ULPO78= A"#DZ@$5>*-S>T&#W!IMQ4:W2X%^X4CR< M2-,&_WA11 3[F0(O>#O8E;@?@/D\\B/#9<_V0?=&H%$^C03&18Z99\7!DH@Y
MNO:>]^R\CEQEXH+1XKKL2C4=S!LX*S@,CSV6#H=XQ; QQFW$1O@M3]TB@.'0 MOR: 97J.G[]I/#.%@"L [*&P@Q'\!#1E^%1[-$Q8#"!B.&JCJ07/\#30)7 G
MSP"M@T84:*D48+9A962JP!L'FCLZ5K8#;.0_<.2^R0EG\.SZJ,@OQYV^ABBQ M)=[:LQ G L%:P9=P%R$9?-! /FF /'/HB@\::&/#8Y8M:T,R#%EAS.24%NU_J@&0(CG
X9QILA$,M&9"O:()$M- M^Y4=WH?'F$T%/)'O12#IZX@R3'NA+NX"!/G$XJ\Y-P4- %@.'C2<-O HAK>/ ME%K(!9R!X3+W@($* =O^J"#@P*TGCS/\A7_IJ-'J$T!B)$ >0?S(*;F*
MP(AL['//\&@C2TP=I,"8EG^$]WB$Y^1&Z"_PI+'MAK>SM@?$L-B7!/W/7Q;P M#?\@ ' XEL)YI11(K:%FP$5HYB1 XFED$7H5 1B]O,!O>"+HS'$@>L=!!#-Z;?^ M^0I(^6,ZFJMK?
PGI]EUS?E#//_LHC1H "-,W^-_N=B=^K#SR ;;OQ. M.YZ) MJ:$YNH!!,M0QG@'?#+A1(/XA2'?[%6\U*ME\UH BS7LGH*K!BH"J#B+P&,B9
MXRLH"E$$@1_42S_[=ZD]P;I/B#>K\CJ&]U'5:-W5:S\O>C1'_IGC\EG1T'A# M9A,YE20&QACYT$0A%:,0165\E MBKE2_*A0_)P7_YW>H&^,H?/AV7;H*=#&[C@W6D,3++(
!FB;QL"8DRQ1$QJ1 ME8&)OMXX"'5S-ORCZA24*ZHN%$/CC;@I3/P'SY@,"%^.K0L>UP>A3$/D-5;"\1 MJA7?XN1\+_9W/[N_!: A$P=M"4WQB-J/"@LS$)ABXY.JA=J-,-
NFW1E^<,W@ MFJ\V=[Q<4"UZ0 ,>;?N'T/P>8?F)Z^M; M!OH]X$SS:'812_,F#HB@CDV>;%MG2\,&N2$*JCD(&N/1I#Z@L^+YD>&._60! M+NMP,W!_: N[:,I8+K VX4'TT(,!?!&=
(/:+4&SF-=^E1R*$,K\QS8IP282& MR^!SI 77HMWHSH/O@;<]6P'LVCA<4_P!S-UX@*:TRK"+DB&L@ M^=KY M!\=@@!&%>K/.]6:4KR;U9H(Y_*ELM\"'
7+#UKG($@N%'H]'7U?T9?PC]QU7(^/EVB44N MRUC>+,=;X7CJE]7ZY^7%*]K$LW<,V#)TC/.T"-Q$#0GL<9TIQ+&J&C*=F*PV MSD)7Y4C,>8;Q,(TAO7"QW0#XL*O\
[["R&66PI8+@>$%L\.&\A^XP)5A$O==JBJBR?*F(BH:.BH9"#A_EZZG1TPKZP Q-873V_T!D@T(. MDO>>6?A(5#Z=_5^4SD"N5V:I#(A'T8ZBG;1I9]9.7U7X+! R[B(IHW!7X>ZN
M<7>*Z2]C]>OS=(7""H731F&T1GV_# M^@#W*RN.[LNZ_ZY9VA,74".67JM3XL*WC2&@*[SI9Y (72](#W%]'4VG&"(MCN%G>B^,4)Z3AKMU/#
(:%J5CS6'NL#!+Q65N',RXL]#;$T#/G?KX1)-H(FD? M8Q(.][0WXFHO\(&+-#ZP72_X MF_DY_=QPU[4'!EMD)AWWF"\M$K!:+LQ9\BFC(DZ?H1MCJ[N':YZY]8C3]H6M
MS"X*O:T?BA_AXH$&/)QPP2PB:<\B&L>R%DL?R5 ;>!-&F>YDC-8@ M?IE[K>,3(D08T'?9"G=PA$OYGF.'ACP$;&*6>,O\[9-&_&9[S@2I7P$]@2'P7W.#M5,3N3Y8=, MDV1X&;&
[]H.^^/"IC!#?:SUMJN=\HG'H"TO8Q(BIR'V>N5R>K^]&S@/WBL%E MC,YJ!^")*@ZY* Y95W%(%8?<3);\:D2:7%VS)E?DG_X(SH88P=GDF;T]GL39 MC<[@W'LAX]K6G$
+$&%]_&D\VT@FO34Z#:QH)X9 ?:,LM_ILD>F8=C>WG?9I MVT>/#B(N.\]/!MYEIQR[-/ A0 7KM[-2+*O9>5\+@:=14 G3U5@'O4*.X/]_
MW&N#NYC]3_>\^_7Q2YE\YVZ>%KIY@G1)J6 ,?$]R@H<.L1 R:0A"T6+6:/%/ M#$U+3(?12(:<$&)X12Y2E*N/Z]ZF:?A*?14TKL/U=/6SNZ(5D7.%2CS%G/L(
M_@K"TLPG*@SS.$=+#G[GCGG-D/FNFL/"-TO[;R56J?,1]86"5,V;I;@.=?^J M>?>I-.]N!=70T]61^^7+&VCGNX!B5>572II>&7HLHC\@T4MRUW) H3!.'HR3 M2_:

0\@?S8P[^]YG]K\7^=\S^U_FHV/]AR+^8*]:KN7+E0BKJE^(VU/4KYG\B M>GR0"J.)5)BI)H+1$,)T;Y)H_ !+V%Q>PX8!!%8T>K@X@?(.[-$[4,H5BN5<
ML79(3[0D%RX'%*>!=D4> +D\Y$"=3'JF3L"X*YIUED%8O!+U5 /M5R]:I4S.(P=RX'%*>$>?#OQ65-?LP[MCK1R!K1C/6B MGS/'^J>6SPE*BQLF+1J14BO,ILL3^-I#4*<4?
K$95"Q=B<9E/6QZ(_&ML9[_8O-8VJ/IE\1&^AVF @X:2?,Z(WS[0L ;F1 _+ M617!9IY@!QDAV$1L0^?MQ/182PR-M:'K+IHSNEE1Q[8 MC@OG_229K8Z>XHM"(5=0J?
*G[12^C4XEY&/)CIT\3R,25+VLYXKUR\.&^;)' M\B>0V="W/=$[ZE0DLJ2TC%D"I7V3:>8H\@2$< C<>3X]@I'%9)TP?,OF MF5//,WDCZJG,Z2!$%LVM-J?
<$W[$BP;CF;'U[727U]F8%T;6,)B$,;-W'@1C M,T4IY5$XG%]IN:SQRU202O2,97.98663/F%':8MU8QU2-K<'W@@>X^(X2);S M@.V*W3DHE*-?.?J/W-'/_0J14H@H\8I6[=
[QNQY_BJ.4M=3ZSQ[.4&=!LE)G<\XF% M/" FXE(S?82BSG.LQDU2JY0^D89E:6.PK "D[]\N1 M/QH_%;KCD=@)>Y#+. %0L$7).PX'"B87B\Q]GQ=@5!P?9KA1
'F5)^X\T\I%C*58MEXE=GAT$$R)=/OV7%RIB[P9(]@()TZE=H P/QR[NG$+Q4+N8*I:(O89M\-*\@_R?C M14S %I.468X,\A;X>LAMD,1FYULK5)<>U4=90?
6(/NK0B$;*WWBQS1>>CF4Q MO!P O@,?%\T"L&7]$DTR?*;2'(\"L8V,(;:??Q29"L\Z>8,R,38\ST
M3YQWPKO@L8EO\S7\,U8:9D78ED5Y>P#L[.U3#'7]:5CW<UBKPNAVP@=W+9> MZ#L:7&B#1"@B@I_$BL]%0_ GMGEQ20\@ E@;L]_CFL^B3YEW
M@5$17"4B$)L=$6G#BB:"!WLFC^^$,WG4LWXJG0-08W^F$'KSC&&@>8T=[A3Q M/057+OXF?QAFV!ZDZ = M>D.TC+WC7QI.22K>/Y:ORU+SC6Q@C(W8F'R; 8N[*
[YK%CR7*8+H MY-%,U_9E7N'\XF)ZC?'$&8R88T5S',U/ZD>I^[[XQ/G3^+70-^H,#'C V-_' MDN>#W@IG?U$X)P^!>ZE2*^3(K\:7:\-%H3XQW!%N+]I3@;''UE\3PWN'K_YB
M?'F>V28P51=;)K)^6W PG+DLQAIA!RZ!EB$71CJ,H<&9+V4P*!XJ+P]=QJ_, M;+#59C !V@^T(BY,9B;0JYR69]1>5G8PK:PYQ;2%<#X8K#> M=--
]'8%!1A\K/+7#B3=Q@*_42KEBL<8F/&,MS_0*,Y[(6B57O;Q$/JN1H68X M84$VT'[I@KQ0UXOR-,Y+QD%C[7 TM&&Q=T37L(AU'?48\W-J:JD.6:)6M:3!?<&I X/@7,P'&[!\
[,8H_UMZ.$)SNR[<(&MH!5S MD)!:%U"@B&6PH5E(T]0?Y8M2^.*K[0"' MP8X)EC7!\5SVT'MES2=!&3#M,:." .V9DJ -1EQO 96'L1KZ_$4)Y?T,<8$N=CVAB8P1M[%RBX7"
[GRN7*S(X?-9=WT_3GA(6% M@:&+.6 Y@:JGJ%->ZEQ&"=;1$FP1J7 IR?[$*:$\1ZZAP-3T9\,"/3K2#]9W M#@",/]#S$*<*[)FB*Y5*#OY5%'WL%#UU/G96R%?HF=I46
41KQ)Z,^"!QL 8 M\UKWB.J)=>N,G!YM(-&(1X]E3 B77G3294R5O*:_@$W-J^MSD9KYB.,[J+=G M!N\K=7CMDL&-!CUV5H BE(P0RC@;A+*1B3HM""Z+N7*I,",'9@+\[,E BZ$T
MB+,I0U\>$.=TQIU?W">(C3Z/3?O=[SBA!=DZV S^?2Z[8%I,%TNY2J%V,'OU MVA@.@=11H?#-\ZFCF(YQX?9T^A@I/HZF>,U'$D@DDC ;M\-VVW-:"QQ&I<28
MW>PILI8@_CG/)#,I+I0-+O3747*A9UN'1W!&,.>\ML=\RG1 0")YSIEE"XC] MA?-",<)VM"?-L%#V8Y+3- -B1#C#A?P'3U-4Y0+UBX/Q%UQ6#WG,(_5>*15Q MB"@C0?)&]]B
;8\=*>!Q-"N G^1:',>=.A?\92)KEI6/J,J9194SQ17K053E MC*JLPV]'LB<7[HY9T /1J8X/I/%UZJC3 MKEBM8CY^HH4BJR12Q#ES/F[FB+-X4E%'CC=@]$C/Y4KQ5RM7
G]M_CM*Q/D;+XW&-DF; 541&J>D]_I.R]" M\1_%RX(B>:2!*LZL>K <#?<'&:)#VA$05\[+%S_G2.%GT%1?#,!+G;P;U-1S M(46_V.A>8X4V\(-2M0#?]YM4LB^8QI]ZX)[M!4!9X2
O:P0\-H!H%+I8K6(M;?4B-F#[.'$-"Q/6H@';_]6>QY]EB/<4A=]9T5UH]$J[+^CJDBSMAFBC=6K@0QYR#* MK$\#)U$B#L)*<8VU*$\:G:8//1#9X=UI61E.IY$KELL+\C&!^1J9T
M1_Q,]6KN ECTC)MIOB* MSP"M<2P1:T-"8XN_OT\NK%PC\KO)9UJ?K$K MU?Q/["7$5?)K.J#/C\#HA?)35EKYX;ERUK3R+*2?RLI!%/(?D3*^J4G*FKO1 M>(8\E\E8K6-
JY_K6*.H-KAA7%LCU*/28%H:Z E8R/W'M)\18\+.@Z8;(!F4.B#8>@(#@7#, M)L':KZ"IH6@Y([2<&?-">L.Z>E'-U2]5Q6Y6,'^SX9TJNTIE5RGBW#EQ9J9I
M>$"NZB4IOS>RD'E*)M&6D[(QW.4ZA(K%SD:J79 M#CK[JTB<:RAS<7&YQDP/_..C/G'HIT\,,^(3I2>'HU(_O_PY(N'C!-C& M#R^<5W?V[(OSXL^+Q>E.D/I.>Z(!
[L;)B*C"LNGLT*4WM8M$.+_R[X;U.[0X,U-ASI&T-SG-!F@!/E&3! M'>-M.F'R'Q.+DG+!SY>$KTSE#L3CU38XN0SG5IM.O>GP:$D18,&=7XDFZCUL MHNZ*!DO3-
_8A0)R/[/9BTD#V<8W,9/#E.+M)$J/FG'VYR9=.C+:7$O8T.4>2 M?/ ZT?QWZ A^AB[R6XRH3J?EXY=Z0-13Z?F+B%HN3"@?C,C7O),FJZY!#R90 M(I@W8G"'B([PL^&-
PLF':SYLY&-P32M?CC3W4E$4FH@-.(WSQK1?W77O.*(. M2W3=%R"G=#K;U!?"U#;.XDK[,QSV@A=9%6GW=&SS7*4V?#"F[%-R3Y\,%TX%
MD\TGCZ8Q((TPO190XUFNF[O)%T]--BVW_F*R2@/2D^SR#B>:)+B\3:VZ/QG+ M75#2(>]=5T^94%.T%C-Z_;6#D?JF)EM2Y53DG.4YXOJ)45A@IF7.)"L5I EQ
M'TMP&_!?!;=3QXCEH>&P,^L;"2]KX>W][U\3V_L\ RE_7L>XD'/D!,\^H [;R#\M^M5#[7FP\?]P[MD '_K/D -[N=ZU:GU[HF*K7O6U?-_KPQU7CMH$'VOO6:LTD!^SO,!L]TKTA
M_WCHM$*G:*-S3:Y;S=;WJ];]&C7+N[GL=H?TOW4?>@!4+T=:_VJV[OIP9(W[M%H%C;.S_?N/IE?.>M=,H!*,:&E8??QK/_#>F[-GVSC&IAR+# I65$)9O5$.(MSQ;)6YZUL#D(<
MRVV6F2(/(NB#Q&PLVBJ[YMIL0K[I5]G";3&7$L M&8ZGQ:&M#*H)_O]'Z5!_JLFB5)!%TH]V3I,K7]YND7I3,#*"^R2^&$0NM)O/ M4=S%10N=.GIBBP3#GJ1 C&+6K+9U?=^
M#0+I;"]J&74I>UA&%I8U&Y?8R?X/PJ:"?^N!;TYT+P?C@6*\0K&N4UQ&7=8FV27L/QJ MO'VR;.O&\1L:Z+^=#8K%:N&R""AWQIKR 43W=/C;F?%O] [D"Y?
YS?/GL2_FB]NLOTU#/ M\88]7>3>L$@A[&H(>QF#L.5\L90O%P^'L*5LKPT914U*+J'P\C!X6=M4EJ6/EQ49 M\5(6Z74Z)MJ=:"7EMR7?E_!:(3JRV_6WBP8>C,&L#'(BR5!
<^P2,T"!(U+<]S0P&W2X) M%65;ZU^=J)-B#1G@28_);*FXJ11O,.S8CAU=%.(LB,7'O/_[/Z@1G&$1?N14 M4]I4F*=!-:47-GGST&W&R';J3_5,Z^7!;D<&)(MA"XGC)F5S?
UJZV/FT'BC>OZ_U+%GE?*\C#@IB^ Z ;U;"*ZVY6G6DX'5\5SI M/E8!=MK._(T3($/\X)X X#6M-QQ*!R;U5]O6<4#7QJ&PPX3CE2--D<^:Y+-Q M.N8.R:=!"@85C.;<5*K758CL
M."7[D1/.QFFJ*1%.O#Q7,;+3M=6%'._V&[=D20>'C,ONI51=!JK6[0FZ*>;) M^B>I&5(BZ(D<:>.$5[/,]]^]3SU?/E_;YLA#^L2OQM^W&5?NVW6^W5!>V M$UU&78K*:I.
<5RWNPF8:VJ-A&IY!55;NB2ZC+N5(^-?QZEJSR4U]1],I&,3O MQ]JB)LL]KJJ;5_+Q":SN';]8=LO;52@5.0FZ=C M$@)6.1.0FU,.K..3FB>=K5_=N-A%(,=MB!O;
<9UZ]3#=WE0>K**9-6EFXPJ7 MM&FFF*L72JJP11F^*S9]6R4R=2+"_+@3]*L;5[:DQIM*N4HQ3J*KZI;L2_4C M)YZ-JUM2))Z+&KE/K$]<'2K5:*=P[?CW[M*=,G>Y/E0]ZD+
Q3:4KJ^>KY2E,Z.DVI]ZUQW_K6O;UNW3/'YO_^K58J5C_# M)Z3U?P_M_I_DPW7KIMUL]Y6Z=*++J$M12HSDO"QFA.Z0.@Z%_8TT!Q_]TRJZ M;J%XMI).7
#KIG!>@'^*@5+,_H,%#^1%,R< ^DH/*J^X8.7L2[F0@P7QWYDU M^1:)-O%&M@.GIG]>;>V+%=>NHHNU7*WD2L7ZS-
:I:^VUN6:]7.OA0OO#"L)Z(YI%_3"Q*X'P(AFK8%Z[I@"5QDW*1O5O. M$3BC,1UXQ@LUWX\P?"=?YM\LFWN&NS;IDE2_VL9UEP'-]SQ[\.,/),(CF3NA M4%0N%-
VXXO)X4506%>=XS;59%:=I/S\#8JZGW]17$\/%0DKZ37%%A:I88LD/ MU915G.**ZE415*%*/5>OU'+5XNS:J^HXQ*G[)H-Z?
CP&GHNH&WKYF@P:6VK2:_T@WS_JK57+4N9>&\0LS#(.;F9:+I(N9EKEH^ M3&UU1@39Z9CIC<%@\CSAW9!T.C0&AAI?*@_61GN#XE\9^/:SWOJ:89%]9;F M6&#GNQ%LN>;
(LME0;^+"^<KX7U7*$HR83OE4_[8W905CZ(LDI$&]> [H:(MRE$BNLQ=E@XS#GC^M.,*3@*2D47 'Z^E&BT*32-YZD0$?_;+WY*YU\95H\Q9 M-K)-_,-
M_34QO/=MN54Q5RK&F<7[J8?;ZHP_RE7KJ@AIWW6D]8WK2-.BHR_% M0ET5DRJ;?GD?"%99IE0 -=PQEI%MG,<6*8AO6'IZ;$T-3DT)2$5;AZ:MC1/P
M=D1;61VI^HOW:.OO^!?VL/Y"_H> ;-*-%_XJ5M+.@/@YA(8!,R5+A2B-(-F MPJTYGX5LG09KO-=54:"/*-$&_MYK%GOF&5EV1XFF3GP-B <_.;)8?%GQR/V
MD'@CZE+$.YU:+M7Q%=-PF6M_;%B:-3#@ZZX';SS#BNXY"23^X8X3;I,,3,T% M3+W[>O7[V2PB%@H_QY&J>(?Q!/;6&7O5[*B&5"/WU;P7V3YQJ*SXZ^R5N_]^N[V/WCPW?
Y).Z^&^VVNV6YUF2R0QMCO-\T-0 M#OIXD.E3QWPG/RS[U2*:2VX,AP[AC0Z=.+8[,*@UH "C-3C_N'<@@^!BS0?X MH=-XN&
[W6ZS%Q76KT^.O>MW;]G4#W^[UX3^\$4;WAG3O6O>-?AN^(-IB?+\# MZP5^UOZC16Z[O=Z!SOVF>T_ZWUKP[WVKQ>VJ]K_(]VZG_ZU'6K"Q:_*/ATXK MS'_%KR"V' I/VAV
M?O0 SAZ.=+Z5[-UU^>V(,-CEG\!;?06 %1=D+EG&,Q MV2XXXF]GZ%^AIBETAN!O=ZP-@K\Y>P.1UL>?QHN,9&Z^ACK##MM H9G[(_MET[ZM-^&X4*)X,*/>--
%D3@!IMBAHH"]DH!?M&1 M8H$* 13K.P765XK%?'GBQX>A#['_.?) 6W1?I+%)SH*TT"A\VQ3?R@K?%+XI M_J;P[4CQ;7_\+3Z1>JG^J91-
M8Q:1BVCEE'+J&72\NI(EKR\0[5#A%$O2C\? M-I_YOO5'J_/06J9N[3HY>2\KQGE:?TI>OBY5;X-R8:8P0A?YQ/#_Q37*C5^H M-=ELT%8%*R/B2R /=H7[1B.%N!L@;C$&<-
]A0(:Y"W3+<>SW.)>6>ZE[)@KF0DRVS+A&*T^M8Q: M1BVCEE'+G/@RDLG>_;G_#NKR$^4_G:^D]:\[+!;J?3JZS,[Y_BAJ-75A)[&: MNK",K:8N;&>K2:9@[-.X/VS?
XR*O3;ZG+M6Z8/@9?EA4&R[FB;!A<324 N0,MHB2]%B&9X7+T MGM%9PZ5'39.-W 2[!;[V@WKXE[):I.8WM12L%G'QP&Z^^]>^G;@LU1?,@)*' MV4B!3 I]ZRF8+*FC;
[&JDB;E7%$R]"TN2$U?RUY)'7TO*BIU4LX594/?!0GJ M:QDKJ:-ON;!@WI0\Z"N9I7)R(9:OU*+8H!HM%4U_-BS#]1R-X?>!S)552^IW M#48JG20.Q:U6'Z63Q-06U"ZL91$)!
.FUHB@UPO=THM8DBLS/%5LD1:-I04L MH_2UH,1B+9-M-_15EBS.=!IH+"U@&:6O!7D(:]F4NZ$O'*0DEV?D-!!96L R
M2F$+\B36,GMWI"'6)=,0Y>X4=K*AN\^1N8SSI0VGT=AD\[&Q6>1GB7/ARL4% MB3-K&;W=,44>%OCO-BV +N9*EPF#9&7"#AFKGXA-2]
M4EB<<:OBOUN8>8>,ILK%S!0T"AH%C8)&0:.@4=#L'1H5MI X;!$&+*;FKJM@ MQ1$9HA^2+-%2&AW= TNT;0WL9WIKNQMZ>X@+QP>O6.#BXN".U:V._:.4/BI%
M;P>FMS0:T>^ WLK%FJ(V16W'1FUI-,]/B=HJ$6HKY>(["2EZ4_26:7I+H^?_M#J1;[3*NCNW U!9O&,?0EF2F\=&%.-0R:AFUC%I&+:.646YI*=S2_6^M>]+N M-+O?
6^2#R*7_J*8$J-74A1W':NK",K::NK"=K2:9CG$Z+6SJ#(:VY5&'NAYK M8?.H63_(D*H>FX=KDY7L84QC-$#;>H'[QD:^W,78H=ZV'GWIH)_E V3%.Z6
MTA@*D!+N3L5^%>K*MJ)TJ)O&-(=H&Y1MO::"G?EP]TTY@"-,,B@-* 8A3.G-"WP4BSGJ@R4&3LXUM*8PC #;_JYL1Q MJ#5X[SN:Y?*UO@(R8$)$B!^;]N>3JWF8K-BE\#F-
J0!IX//0>*-Z_K_4L6=1 M.:\P6H_NQNR78!PS3:4Q M"2!MFE(DI4@JPR251O/_M$FJJFA*T52&:2J-=O_'+:;BJP)5:.[0)0G8'X=< MM6ZZ]RV_,*'?^)?JF'-R-<[E-/K[AZ7--
X[]W(3'&=8$R%[4/MN6>T4QX,N_ MU]?>J-MZ\QP-]F!8FO/>]NBS"SP0 7%L-O733V--H?..C-72JC>!HMOMZ#:- MJ0$2TVVY%!)I;V3LV"^&"YK;T7OP M)0TJ)F>X5M)H31^8!B)
(>$4M.C06JO\93F:5 H44TJ;1WUTAK4+:O2)M&FW2 M%=(JI-TKTJ;1:_QTD%8RL^/H7'YJ3JJ"1D&CH%'0*&@4- J:7>D/DNEQ1^\^ MY@'T3JO/)J221N>:-+O?

[^Y;WUJ=7ON/U@D-3MTJ6^2G8\YVJ:31E;9#O53G MIZHL[N/(*U-DMY#LTFBHFRK9J21L173'3G1HM).E>A4#K4BN^,GNS2Z&*=*
M=BH%6L5#U#)J&;6,6D8MHY91*=!R^["O&KUVDSFPK]NW#_W6-?=HW[7N2>]; MX[Y%3M2++:WML()1L,FT@3OJ]$::0V>-@Y;F6* ZN_[G5YIK# (CH;"RD=#N
MW$2LA,)Y03Z7V"&,;H7JVZ'Z)H,(]H[J<5,U%*HK5%\+U2\VF52P=U2_4*BN M4'UK5-]DBH%28)1+4Q)+5BVCEE'+J&74,B>^C&2R]T1-KBW0>OE^U[DGWAKLT>_BJV?
W^O=LAO7ZW^3OI/O1[_4;GNMWYFB-S'M&3 M\(!*WH%N W+0X2BI=)FKEBNYNH0R*=ERA9>/MO[. M/H#7VJ-)OY#_P=>Z\<)?Q9IZ?Y^![N^?
0T@8(%/FG+#FA#$W#=4X89691599 M(X+; XJ=GZ=7!9SKCRC1!@/[>:Q9[W#Q8&MZL J@]$ ^$W3XYFDK'F>,0> M$F]$78J(J&.W&!U?L6QN#7"*# U+LP8&?!W0R*//L*)
['IB4>]S7S&G"Y9&! MJ;F GW=?KWX_F\6X0N'G.%(5[S">P-XZ8X^;>=Y-_SYX8)25"+A(9!'Q^ZD' MC(9YQW[U/YG]:$!-D]Q]!:L^<8UX]X%/0+/G&WA#;O)EGP1_)YZ'7TY"EPZ
M=XVOK?S5?:OQ>[YQTV_=?R*:^:J]NWZJ/[HK+#JU\<]D1/DIEL9OGXEPU/RM MP/Z)\^&(C\Y^B3OQ;]?Q)XY7E\9Y][O-6\/Z$1P3QZ853VH9JR!SO&)%)B:0
MO>MJ\;^':O#__YWNKTN:?O6Z/SM=6#(^;NOV_=V^O6 M/:O._]^_U4K%ZF=X)FG]WT.[_R?Y<-VZ:3?;_?WO4Z!(]Y[TO]5(K_TO\KW;
MZ7_KD1;L\9K\XZ'3(N5"#O&EPKR3B#CD4#@#A]G_UGWH 2"]'&G]J]FZZXN$ M4;B#Q@K'E[IZ$/(=IJ,(QLOT-.1@H@8H^-L=:X/@;\[K0%3W\:?QLC#"@FIS MXF0-?8R=KH&Z
A.@;[[H^354LWBT((3J&]40]@"N'080.)7M)#+ 3DT<:0DT MVMW'9:(K)BP(\A6PP?KMK%A8KE&D -&F]8#!5NH_IQYA"5%Z+L 2=Q1S09<[
MD!C4<2A>GSWXL2QFLK_+5=B406QJVL_/8.N?.BKM<,%5_$&[Q%H!R^6JL!SJ M#-1EJ\M6E[T!+#49+WLV(4>IV/M6BDK9T(E^3@A*R*4J\6@%L8>AGB03>"X+
MHNQ+ATOQEO=".#N'5]'=SNF.R$QXQ+/)(Y441,-U)U17O$'QAB/C#8UG>V)Y M"K$58A\98F=#Z"G"4X2G"$]IFTK;E A>Q1N4MJD06R'V.HBMZP8F2&NFI")E
MK!EZWK#D!&Z@C0U/,Q5?4'SAV/C"8#!YGI@LO5Y.VM/IT!@82B8KVCLVVNO; MGK3BF!5LC6P33EYD=KN20DK_FAC>._D@^,3'?3&*N$$(R='[_;\
[$WAUC,R*G;!G:^:/3)=:O98KU9RT76V:"\WUZKW-6TQR9= M00^+57MQ7>ZL%U>\XWIYRZV9X5(&[[-5+.7+Q7_W_ Y'+>;?;-K/8]O"AD>- M-\/-!R7B/2SK_4XQHVE9:R[>@ZO-
4G<4\A M^UJ32.HI8?MT3[F^?44Y3B=3@68,AY]F?[+U[))B)7=1K>5JY0-.,$FXD/W- MZCD(16P^J:MA>BD-3#^\FB.U=G/L M)'!,NDUY)YQ?*38*U^7C_96-<3U,T;_3#+UM-
7G2>;IXG\#R$?FKV%E=<7M% M 5LX>BXO-B:!>^IAD5U?]#L/G$_=.H $5R6*O(1@7+H+ :B)IT@N%Q,!7MB MYL5"73XDECR"N)>9RM)$$'OP4WCR%0E;#C/L0\R%"W
!8XX^@KC*@OL7LLD2 MMKK2U*M0V#:Q-V-WR.Z6"5I^\5=QKN,=1!Z; 38)&+B#@K_M4;VX$P?% 9G< M1\GP]P0()I%>:K+0RV9.O2G-@/_@>N* @GP'8-EZE)HXD3W
8]QC(RHI$7WO M"Q[NT>?H[K))V)8(_@Q?I3_]1?ZK+#B\ O*Q6^KA$FB2P*.BGVTL2NB5K[,%6H7 M M @M-(I;2X8AEV_*E;0EG23)\O:(\'A(N*!G]E
]'/QO7/BF)&+E4^@6R3]J+L4Q.<]C:KD:HQ#ZAJ^I"@4J)X.28@HK%%9D MT_6T;IEE2C&KAOZ?B>OA]V^O<"L9J*'29YF1/#B> M#NPGBSV%*4?
*$#@*8E$L5&&%P@J%%=D3K/5UZP/3B,XHJ:HH14[^F40IZT8_MTP[-'(IJEK4V*L9UY57$HX@G2CSK1D-3B\LH6:/()7.AG/IJP4\Y,3_S\D*N
M.,YI579UJ$=,VW6//%X#R./HU(E.K">N;1HZN_-"CN#_?Y14U*\,O$3NB-5 MED ^IHH9LL*E,%9A;+;@VK?7;G6,35(CURVV32EJ!D*\;0WL9WH+DCQ;!I*B M.IG@4G)"86RVX%
(8JS V6W!E4[-9MY(WC;"E4FND@33;<,DK)!:37*602J; M%O%/17[20)IMN*0EOZ1.Q)5"*OD'FX105R*\52=ZE7+EVJ5, :"5;V=_385/ M@@KW'7%-B0I72V0X:8(::R#DK:?
H2<^0CUP1UM.JE/OU\5U M-2\AT+@QVKL*GJ\^_>/L"S,QVU4L_5*[5UUE1$626"'+7@E%FZDP,V!8+&Y/GQFV MZ;+2B2^6ZWG"@Z
MGX\R,I/C(U%I$RJ6DFAQ,8GN1PJ&U%;,E8J'EH:K9E3$D)9&,(NE& =L*5\LYRU$\3[!<@F82+9F-F ,^^AC@C(VHY5J$L)ZF728D62X(EK>EH.FYZ6 M4^]5]N_>Y-$U=$-
SWGL@IN!K^)M9 UYPE("AK.*ZPM^%J\T^(25/EJ*? R]X M (]5OWC7/=DGY2I9.(RLBH9/8'["G=,6[,55./CX=,E/*AL$(*K$ABGA=I M,, ^5 U^[T#RFS'"^V/7$,:PG/EB;
P*GR#YR-XTGETNYB_*E;-W@)<7Q4]=(MXB:#;D-42AU1-')L@J>:!HTDQN!DHY ME'S)%*$<(*271"AQ,TSC"$4NG,^\C) K('A:E8(]^"D\^8H$SDP1'+2'\"

A435&XY);UDP8H$Z56.&T>:I.8U3-T2_,W),F>P69;/-$QW36N=I3IEL6:8RI0HI MK) "*Y)X;^5PO#>-N.86>E!<3A7P9#JC":FTJN.@.\ETGG4S W9#=TKA421V
MM*)MW3R!%$ELT\CI8UI5G)['U'(U1EGT#5]3%<-5CDLE M_116**S(I%NMLFYD/Z6FH0W]/Q/7PP>Z?7N!\<]$#Y,\S8C@N:< @6MX%-2J M%V- N2YT3P?
VD\6>HI(XCX=8I&*AI5HE5[^L*$8JQX)2X882KY(L*)EX73=: MG$8;2R5;%:7(R3^3*"65RN\MFF >BFJ6^> J)^9G7E[(% EL!K($\C%5S) 5+H6Q"F.S!=>^O7:K8VR"&GE1
M.$SL#(1XVQK8S_06)'FV#"1%=3+!I>2$PMALP:4P5F%LMN#*IF:32@_S-<.6 M2JV1!M)LPR6OD$@BN50R!;:(?RKRDP;2;,,E+?DESEN[2"7_8),0ZDJ$M^JH MMEI5JH;P*]_-
QVSBNJQP[3O>FA(-KI;&<,+D--9 P%M/T7.>(1ZYHJNG52OW MZ^.7J\9MH]-LD4:?_..ATR)E0'S$7#ZG4@5=/_)C\D&3;3SQ.GM(Y&1Q,^M3 MB0?$=Z9DC9=XA7!*[9?
V.=M5Z>^*]-(CO5I*I)?<8BVY2=K,3W;1$U81:)8(M="MT7V& N;QNYB746M^5H-QJ,OIZ?BY%BEDB124K ^J[+&Q,?4G!G8UUU&7R
ML)2KE:NY:B$NQ5D1H2+";!)A,0TBE$!;39Q)JL@S2^2IU-4%M%K:BQF0E_GX'Y[Y]#^(H(S53Z@<@^$,D' MTS)YG+#*S"*KK!'![0'P:.I,KPJGT1]1H@VP-;!FO<-Y$ W
M3XYFPFDZ'K&'Q!M1ER+FZ=@]&'L*6PQ_02;H9&A8FC4PX.NN+R3<\R!U8H_[MFCE-N#PRP&;@OYW=?;WZ_6P6#PN%G^,P2+S#>)[ZXP];N9Y-_W[X(%15B+@
M(I%%Q.^G'C :YAW[U?]D]J,!-4UR][7S\#UQC0@UL".;)JO9\PWR>&[R%9\$ M?/R>>AU].0IRD>X:7UOYJ_M6X_=\XZ;?NO]$-/-5>W=]YH;I-1:=VOAG,J+\ M%$M
A42D&/VMP/Z)RSX2'YW]$G?BWZ[C3QRO+HWS[G>;MX;U(S@FCDTKGM0R M5D'F>$4":RM&\% @Y>R&XY"= 1Y O0RBG;"5F_9]Z^;V3])I/=QW>\UV"[.J M4$3E2+O3/
A30)&*XHTZYCOY8=FO%M%<?]7KWK:O&_AVKP__^=[J]'ND>T.:C=XW=.])_UN+]-K_(M^[G?ZW'FD!W-=3&705TNA<,P0@A[K[=@? [#[T M)#>"G>;NDP/F053+
2W9&YZ9#M"7PG^=L?:(/B;,RB0KWW\:;P 2Q8":^A6 M["P-E/!,[+WY N/74#GBR:DA6-^HAL '@.TP7[7(#W+^.!&T*!0(>L)*&0R"4PFHA_5*:)$29PXK0,"$W]]WOI'O7
MNF_TVYVOI-'LM_]H]]NMWJ<#2O#=++-*QI-:35W805>3C#GNI8EK<=^V380A M!O^6JN/#]'%=A:9VL&*<=?G3DN5+.XO)+00I.=065]9<">31P*^#LP3$HL M(3_Q77P]T-
P1F6 \VK"(/::.YF$H&W'JQ? ,ZBHS0ZVF+DR9&2=B9I0O&1#7 M= P\T]!0LAZ]J;'BB@=0RQ*ULEH*QD7TGN&U2?%%P](;SS90VG_9^QNFNE8@KA,%WJY1+-T8AK:HV$REYL*
[:O5U(6=NL_MY(P)SB$9 M@_1&U,&@!35>,&O_^*/]&=7%2BG8$6UKX%!0Q:XI_V_;ZN+UWX>WOW65K>SJ
MF1S(=1+HG!CHKZXV_>DP^/RE+!D:2QSR/QT#8TYVCATZU@S=]\ IT2DKKXD; M>[6][+SCU]_BM[\II[F0F-7(@4X*@:NKS8TZ" *79 N^2BPK3]C.]!Q-IV2L
MO2LC4V(C,XTD\GD^TQ@,@!0\]X[??A]181-N4SG[4BL6)&,WDF*6PN4T,LEW MA\L@.2]ELS)5+$M:\>E0DS4OPPYG[TJ,2LYZTDB77,IZ[CE*W %&&(L=71G.
M.),#MQ0VIY$TF1(V+]$.R](KAY))U!,V2+7!P)G0J600)4[E='_5TLBAC.5 MB &W(0)L&_VLQW88EL49)@=RG00Z)V)S&EF5N\/F+T7I"IYEEZ(G;)?J8CPF M&*@OU)H
MLD%!M30RM "[FH!<=X[]8NA4OWI_ "QK6UT?QQH!BFW?VJQ2/.!DO11N8W^3 MNXY$Y3@1.DPCT6Q_=%@O'W *]'J:2/)(+QD4DGUZ,0[:KU\MHY8YEF4DXR%'
M;]1\CFT:W^[\T>JHO%J-75AAUY-,H9X.J$AX>6YFSB#D>92',-*_YH88VR, M>_3N'%E=TLM\S6GD^]]I[ZSY<=]N#.#"'0J&'YAZWON="4C3L/26CP:;YDG+
M7&$D!V*=!"HG8G(:V?[;8_+"V&3HLY ^[58R";K'F53"]1VF>_3!(Q@DKD:ZVJ7/8@JYDUQGBXAE95"1. MSA2/2[@PK!?JJH2+DP_TUM,HJ5@0Z&W[.)9>H+=
<+,D7Z%7I%HH*E^XBD0C3 MJ 39G@C72ZC>*QX?B^ZQS[CHD4>\U3)JF9/,K3AZ^R4^M^*FW6ETFBJW0JVF M+DSE5IQ4LME<;H5C#RC573)T[&?
B@BZ/618N#MC9=^^*!5G.TMJ31^RWKJ=1 MC>NCU@U@5MMU)^BU[CH]0+'N$*/>WON&8:%Z1:X&Q]EWC60;L(S26!I%N3NC
ML6*N5)*,RE84#Y)I%$=O8B6%B,;"@T@>W\G0L [59CHU!W4.RS+O?%1;-LH MT0(50\)XBVK^H2AO5I2W2/%0,2+ESECDW_UPW6K>MQJ]UD?2[O!7 M\((PM^])J!B2<[
5;1UG!(!QM6GD3&&N;JM8,SNOBKVG-JB:*7 MN$M())'IA'9Y?[1.QTXB5PU;AN=9HMT;[BL;_1)_UN+ M7+6^MCL=#._"!W>M^W;W^@!:0-;"&5)SQ-1LH)E"%X-
SRV(I7R[ND%L&?/': M<,>VJYE?@6;'\ OX&\$QK G513,CV]JX7"97K,3-_\E(3JNTE"$M8*=!LO48 MDBT="2-CR+YMQEA-Q=0B5!Y&$P)_=&_\5*D#^ZT;??X7J4*MS?5!%Z ,
M="MF]-,1<].+0B&&F^[>N[(?;EH^/#M541M%O3NDWF*L^7(DU%NI'IZCR7N MH_JNJF74,AE;1C(>=21KR4%B+<%%(9WI>?R.[^#2 M.W3]?I3RMZ&4
W<4MJ8SCN[8L54R"7CT]L R"3BPGRGQM#/MO[./H#7VJ-)OY#_P=>Z\<)?Q0J/ MO\]]_?/(20,D"D!(>2#$ _34(T35IE99)4U(@@YH*C53*^*4?P1)=H KGFL
M6>]806G9'JRB.?"VQ6RS)T\8L$FS8,_1!DF M?-WUX W61O8\<"M<5\SIPF71P:FY@)&WGV]^OUL%N,*A9_C FOB'4;(]*TS M]KB9YW4>O@73\NB.J(16?
&%&^IQ+&H(0B]K<"^R=.1Q,?G?T2 MM_]OU_>Q^\>#G%I6[(;?S?2&CIB^;MKWK9O;/TFG]7#?[37;+4PJ1OZ;PWJB M@U '%LP@[Z:.^4Y^6/:K1327W!@.'<(;'3IQ;'=@4&M
49K+AN]UO7I-GM7+GUXXWNKT^\=ZF3; M'=+_UGWH-3K7O1QI_:O9NNN3WK?&?8O 6Y@J)?X"T!LK'&WJN(^D]C]10HQ0 M'Y?4G0G@AC%83>&=UABN)JYA4=>]IN[,
<8H[QN6?J6YAML=WH%1C<$0?+X:5U?>"R!05:+8AOYE3Y'E_H$ M G $1X%?*7[Z]1?Z_(59]^Z[?[G:BM[BG:]S%H8B#T+R)
MPUHUVM*>>+MW/%Z=OE#39F.+AQPO8!^/E,=?16X4^, 2JM\!V/#D86J"U/[Z (F?8K_G8$V@X!WF.;_*NQB 4P1XLR@\;U?S.: M J21T+9PPG^HQ?YF1B!RE=B(%: M]-
J)L$80(Q+QO7#)\1U45>JP&P!\#VZCAS8(_M%V'8V:'#N3'TF^:^^@G!4K M.<*>S'?C"9!!IB[6= M'Z1A:>:[9PS?XRJ8@_"#@-P_=!J]Z\;_?2+_;/QQC:JG94^89/5&F@=(2T8@4YE]
MRO0J0$X4L$,FSH VGF>N8TJO%7?5\#\,%GTUO!&)$$D.D1Y$]2.8!('*!/8" M12T G8? ?/*N!R8> 99MN=S[>T[Z_*OX,ST0]:^&BBS'%L:AXRUQSH[,9@ MQ/27L0.ZI#UQ@8Y]6?
+XSM8!,7-.'L8(G6F#&?24\S<]O1,#3OYM3#'5'8'G M>@Z-Z"B,GRQF)5Q/@1/3*1X%_J*CN;KV%ZC08P,S";\ST7.\#.,A."I X.= MGYM%S!RA&MP:ZR?L?V<6&7BS8?
P4$0>.D^.CX;H3H97:$_UX 7B&D/"1^;> MQDBX3SO^3X-GA11)'C7T@J/V1U@(!.Z>RP["M)0G+^_>T[7& T93(#;O,,/ MX209R#Z^L2TRLP\UAC?C&7
3WEX<22J5RI7XLJY:OECZ=Q?,7,<=&>/&F^'F M;YAI*=9"WM;#XQ9@?&=L+Q)PNILX=-9_]-T) '0_12,X/EW0/7H.WJB5^]W M)8880Y1_H-R[0%<# MP3%!'@%=4C?
@)6A(/$^>83.>9IBA\V&6QZ)XJO040J;$]8^ZX"SA"O0?6&Z MF,W[Q@5C]J/014/)B&KZ7Q,-^ \@F_],%UP',.#*I&?#'4H; P#NF'R1,F) 8FG.+PG:MYB^7 MW'Y >' T&CL&&
(BHECC$!0HP0?114'>XF HV&*IK0C0--,3C0.YAS0H$E]SYL/@5"QB/T(*,+=1$(OLH&2/2J(!O^K M"R]/BI?![N)H20N1+'K#B.SQH%RX6_L/52/ MP7HBTDH6'Y]P6XJ4DR"J?
^"P_I9Q?3^@.+/7N,16-Y7&WA1TT9^MR!N69$W;ED2<Q:UNQV MFJW[; P ME;)#[U$7!86YI3D6X)O;"%>_YHMO4OQ>B;0%K=9SA6)A3F4G'Y+.ZIH.N'@L M%
[EX_,3/*_D4XAHKK=0+;3>G$&V.6KW,798J_9_A@A$XY?8DZ,H6;_*B7X5PE;C!K2GWON_[&P^[; MS< [MVU?AO!22KE*8=XP3\;,Z$FMA)65N%*FE+J4QYS3MF=2+U_.8RE8I!,'
MD,[)D6F.Y6+@:)J.N H:,]H_C*EGIFZH!(]](5:$SJ%SG!Q8'R/P *>>IB! MNKI'G\>>\, R]9QC*'@KMP*64 #2>82S2/JI[V@_K?]OTKSU1S MXFH?C(]A<=(\.-K$
ML_<)3H<^V9BCQ/'8FY;A2BI(HI<.V3-E$P>#B$Y4 MGP*](TJEC.^SD+]OG\UK)$'@)-;#= QY^/,9]PU+[\$U8G($0 AVM3W! WRZ MLTTPJZD;[]FZD->S5?
8S\AN]=H^UH;UO]5J=?@-3\EFQ1>_A^_?&_9_X6:_] MM=.^:3<;G3YI-)O=ATX?_6%WW=MVL]WJ';5##'O[(CX@A8XC&''4FYXK; 0; M:0+LA!^I;[9"3#S@!6]H@U!0;*(
M,V'[U=@)PU/^,[%$O&PF#RZT]2UK@K''$(8E*_N;>:>:LX*S8\X3&T:]6;Z0 M/14V9ILQK'/2%#'52-LYMN>A;7OX&^8;,&VN_'+BXNG[_#D"7U??51*=!$@= MH:OPKN X[&?
#\R*K;DW YZ1APIT\(R7RLF:Q77\1, 3@-$!3Q R1L2?RR?" M +G\O_C/.06FP%10H..58%1>TY%]L?=S[*?":K4MK"(:^LZ94-F<^H$ &LC1 MQ@M_-5B>-R-
&JN<"&GWG5$6&FN&$@.#C#0Y.',!CVS6X<||G:*P)"SR'/" ? M^,G=6?V/K0@;Y#3J^I*'ZOO/6I'6"-N;/8/-GX6T3[!0MM<[FP$J 8HPS?)] M5J_DSOA:
[7)6LY3WFO9X2]KY=$_0PYO" %1$?6&IM)$[GH'V= S?&)5C"=<7 M(I6;I,$7HF)YAH/Z):71*E(N@P*K.5S4)28H9R;3C'S'/L]KQWH V]31&A?. M+I,Y32,@\/S0Z6=S^SU!(?%>;::
Y&$Y9QHKR+.M4_-3TJ]MBW*UDF7]\R3J M%YN)/M9QP^55">(M'T3^X(]!VF12-(FB2)Y;0R-_8?&GQ[55#0N_?-/(?H5] MV"\H]D-#.1KPY;&B,=.5T
4Q!O7)$O6.T9^(^!L(P$1Q,]OA M2DIP[M%5H:[2'F/[#OL'!@\.C5+ 6>-*@1>"9&!EE $4]$7 $>Q:-OD(H+9KGX#&B, MAKJ 0_EG[JT5V! 64,2B1*B;,45/4-)4_34>1*"
<^KJWB]48W)AB?CYN:4Q< M$9USF2_)\Q_,OB+\)?S21"TP)YE'S41=U_5+./P<.Y< 9H'18AIPANRZ>)%+ M2##[U(EF?5Z[6E'I7_O7OQY/%$$DN+GD.PR @_$!RT!/FR^#NA
%SL^D&G(3#\Y*\D>U& M3FZ95-QI2OEJ8G(7[OI5\]EO^O$IVC'Y[")N,_V$T3#OV*_!1[.?(>\GR[/F M-TR4CZ3*)R;+5R/)\M/I\M.Y\T>01[_A%?6[S5O#^A$YV6@F_FIGMDJ2?LQW
M=M6#JC=E?\VIWD,4>%[MH@.(O MCS8WNSX=Y3_+=#*Q ':ZI@$TI('!#5"XLO OKK(\HU'L=\G"-F*:.1 _Y08R M,Z#!SD5VF3?
1_!,083KW(G"XG1"E.,OZ'!B@F+R0@/SG"LLTVZGB&M1R'_9YA MU#\H%8TX7FL8(([DN3@V;Y/"&!J/321'*&K*7HZYN8&,]G(;F,? XV8)*J88 MP19-/D*AR1I]:(Y^VE9QU+\?
^H_%:45R5GK^:9$'49*^BNOWG8*>HMMCO^O? M(S4-^L*%/?\@#'1@+46P".MTL,H*+'- (R@;'!:]$%=O^;'L-5J3'ZW/=?^5 ML[>V9KD=U.OZV+NH8>E=U._N63<[I"CW.O!;Q*
<:S@6$Y4DUK(A4PV[_6^N> MW+>:K?8?C:O;(\|;O&;=45C6!XO,..%=^J$.'MH1]LH!2G$LJO;Q?^.Q=,Z)+FSIM54#8<4#9V*KQ>L*RVA\=9L"H9"L
T1+.J(VCV2"7X?/:69N^2VAF*YV6>YTJ$Z*CD[M1W%USS+<Z"APO]NPKJ]X&FA<*ZW5F#*\G?MK-IA_N? MSO?3HG7E&J]8FYT'NKS-$S,X9^W,*];SHX'&,UK3-
[;3=*AN>+=2^)@+&9EN#\DLJ++5"1HVDRH.-^%[B!,:.5#_I@=3)4/ MHJS23C45,7ZTM!/OAOLHET#?@RU[.(&.D\5M3S.7I8ID573'Z=V/: 8\+D3Y
M0Y@"C\G6P,:]BF+J$E8NG$OZ;2P=+Y9M 08FI"T M%I/[L^.$C)G69GM//KK#L9:.]WYG8FLS2P_2H)?E',VE>,J3=:Q0FKF<]LV@I3L9C8EWE%:D@MW3!SZRF?:B\(I57I/**%,O-
(,N5 M#M557M')W+/**SKRO*+OL^6O.58;?"(NVJRD:10+BQVS_UYH5UZ]]_'E,V- M%M<],X;@$.%Y<[-:5#,>'QAO5_^ECCV+ MWGD9L5L6H7K4&4NWV$R#M5/!
(>X+FFHRD%%M*(NU^L?=CVFZ,ZS'&S&YDV?X$CQ7-/9^]L=VL>E>P94'S<%9 M||VDUJU^Z@2V;15]K[*7?-4;C*@^,6EW>&/@I,5;XX7.$<#B+D_(254VEDH- M6!
R1KU19H1)9@4)2E* MVA9-_\GF7LDKE> M09$";-%?8CZ6HI91EY*99=2E2+B,NI0MEY%%YA]O;G7P;_F2 7'5:8!2/?1> M-8>>1"+5RC&>A94>Q6SF?
R8TA/QW0A3WZOV[]A_;:6(@AQ6&X("S"9@0/8$U M,S]8I4XD8;FMJJ"*A\G#7M%./60:F(3)V%N@^9*D,HD)=$GN65SC2?EH-.)A MC[JRLY3CIDA6"=-MA&E":T>)"'7#;&DE2C-
&E^E)#$I)LRM_443.92J'NAD MZX'\=LAK^*SWA1_9$,]'JU&7$EI]2&2C'JBPXVA%F1RG=KQ4%==<9%NJ.@*K M4A&8(K!T"&SC1AA[M :S25.2$-+>P4@,ZNV22-8AB<5VG@\
[,_5V%Y559C_FQ8_^'#CSL,6]8^->3@_V<-$LG6D2T$ZR< M)8\4GDIL[$F/)9:1W[J31Q=8F&=HIOG.:B]-ZE'V&/QFL#1\U:&:_HXLC1@> M+NI12ZW2<]*?^3Y]&\,B\
W/!@""9^OD\9T]&WZ^I)"3EUIAE2S" M,])> # R<2D.UC.-(64_QP1*_P%YEP[RQEM^9.@ZM3YQ5E\J7=3/O@R!7?_Z M"W[Y"WFGFN.>'Z(DE+X-S(E._5I,W7CQR[?
NOG8>OB=F@:Y1;SF+C&>L.AO^ MNU@HPZ;6#;,:,V-N M6XR33%U+])ZF*^!GOGF (2'4DP'WM=PH\T^%?)[R;%B:7V?//V&[^^E%T"+H1E :0Y$8^#E$I]6ORSGA#@ MF89/Q-
]KUCMK8EC][:;!#G(Q*5G>"870,_PL!%(.)VRY@*@G6@>"!,'3&$F M118:"J72Y6HM=N!LZ-2LPN]\R6N^XCVL=$<=9.;=84\S-><]L!3RI95-A0KP MY_/R_-
"QG\4A&TZP59"MX!'L&L8L&,TV USI'*# M7VF#_;!T]C7VJS6NW8'+AJN.WA09.O8S82\F'AS8-.;RE6%10&_4'?B>0+D(M+_:1,1@Q=#$LQMHQ*UN<'5,[L)Y%/P5?D/AZS\EXLQ,
M)I#/WRNS_'WAI,LF_-HQ'B?X:+=O!]N*[@HVM?&@RSD,8IM-WE0U?E-S0NM MFRK-#XUGZBJB1P*Z>B.'TE#-3/BF:[SQ[S$2J#4 L;5,XRW+J_'6A,;;
['[_WNZC.MLCC&B(@?')GPN: HX[#R!1/ -Y%X]3VB_%!S M\"98W4]"AVHW?@!][+F.;P*>HYJ":96%W<6!7-FO:=YY$&1V;4X9X#M.Y'#8)E:MH M*_F-8/'D[Y7/^1N;+&/'@$?
@+AD81'L"#B\T1_&YA5LWR8MF M3MC!#L&H@O?@+ K;DX-=*%+\#QW]J6#O]I MXP?Y*\WZ0;K#(7Q')VA$D \"VV_;5]U[@>@?N8,.KIQU]X+C06F'X(08$#P_
M43(G9=TQIT.4#V-Z7=O0!-6&G\SEU,T91_<")1K^@8IG"!-)>Z*;6$>ELR_E M_DFI,PXNNHTX+ JM=)GCM'GI&?X#E'@+E%;F)TLOV P=R9X\EW0+RST7Y$; M?
K]PBU.WT>O>A)>!7E4PTV$CH.+!M9C:)[!'HOMZ\#NI'BA##,$/09H,%R M<,SR80WRX![Q%_#0'_A?)'HX-<2X(=5DC##;$_3U"+Q)BS <_"U'N7?N$?8?. !TMSUT(KNV
M!4B*ICAW0? KL"<>;(3Z8(>;\AW9X@./#D:6;=I/7'<&7'4-(%V7?6@:FMB] M[W,66H+'?1[P"M1$_W$,#7)DQ.XA<;=\L^'31W".CY2BH3JPGRQ6R[MF6T*N MP2U1$TET1A_3_,
[Y[_JCJ"TAO6 +.E\TPCK\R88:^47N MLAJCE"^U-&IQ45Y_1HN<^UQDQNX:M1)LBJ/3FWIP-3$<1>@FR!P]H*?_3C%(MH0XA;V;"U@4#E,6W*1Y*(US6AN_$_@DM3&P8-
.EAWF#G:9T0!4706@9 U M]3RPK4>VB1(7>V][[QW;H\OL[XJ\]G<],J*^_RF50@AMS)?7,7 M9,9[]G@Z3]U_9"TQUWSN"&92/F9YP](301_ ^;(\?L)F/-/8((: MM@X'R=X,D]
+*RMR[<[-V9=JKE8LY2X*\^8H@P;PDFJ#$7O-K1@7M?DE-@0(M-7^DX/?=>Y1<,?>,MZ>^)K+ M+WMK% '='E!@'E%B@6J*[=^)W=_AYC=%F>)YJ3:/+6/0T1&X<\+QG(HND/
M8+!=-_2C+B.&>EP\; ?'%C]1A<%X [8-GA3ZAKH.VD?=(=?P-AP&5,P5JO.\ M;]HI9%B#"6-9R:=3.MSIB#P!\3#_@)JVZVU:G52,L^\9;W79< O7QN%O<"9! M:H,A5CU?
S.P%:;*L%W9IW% QA@9SEH.I.N')%2P_E'O24=]D;BO^BW/20GGD MBPR1/,/]:CYO=YAC21NP#*25)$F]O%R2<$&RFMBH)R3C;"4VD@5 $(2,6Z'U MAIY*P?
N##UWQJ5O6>#;QI MW7='(T(=K_^GL=19.^<>BPA$ +.R78P8=H"FPIS,M'WSC*:A%=)D.K5'*FB M#]YSC*,$_K3-)QU1JU ?J&/US*0^-:$_E^T&:P"'\'G
MKMYAD;\F]!K,=L<8LV0*WDHA\D4&W]4T3^W;34;82QDLD]DS_-@_U7"5&WZF M7;%77U;U 8%=]$)LK&CE"C%Z^3EI,&UI.@RXZ")S+ MQ'+S):%+$*=W)&'/B M_=1WM%P!-
K2\31]G/-[^TUZ-:E?0QQGTZT0@(@B=B#FUU:3OOI HGB_/+LXM M]Z9_U!OSX&(E=U&MY6HQ*9<+D(.+-(8&X4TOL7[K=77&\6[P
MKZX]Z=JGE*I#7+DL[=#VT.#;S[.X./10CUZLF;+/SFCRS+LO%?;=$B:YD6@I MH>/O(2EPI M*V]C<3679J;$5>KBJKP%EU@K(5Z)*ZF6DDY<)>50[PT1MW-1EG+E:B57*M;E
ME5TGV[=ZS1RV,(7-8P.&PG2U,/D/4VU9$HTB97F]@@A_-R M/C-\&HWWG*:A3+SJ'HZ)3)]1I.FKO;XY?&3Z9#R)>JZYQVPY6WQZ M]:5*KS[Y].I5,@.ES*0F"ZY3N@SK,,LP% 92
>@SB]UG?V][LU*,C%H9/$5) M:2,JZP5&=4GIJ('MS)^HI-#Y!>^$5;PK6E>TG@E:EU5HRDWL]_19,RRTO"0% M\-88[H$'K5%M=OP1RZ#NXN+ =1?

=B8<=UO%F?)L?'OH/S9K@^)[BDE+K>= M$N>-^BN6#A!\2IZ\6[Y8W(MDJ;,ZK@%/! NVB"?5+G.7U:H\0WCE"6#N>I_+ M9DQ+B,()[72D["154(BMV/%B-
_'4["V!Q6F*81SZX$GLWWB-VF->Q%>7[^X4$X5TI((Q\: MRP=11@EKM1YSFS;"YF0UI<"FVO=4$94BJ@,1U>(,D+S(^3@$:BJ'I!3JZV(G MY$K=T+)M\ZY.0U*:QNN
GR1:*]MDW^[(H5G.E4KP;V%^H,2^C.L5HXB'= l) M*$VW0E*YO*BID==J>=_R.%MCJU(4TI;C;0K%^*#PFJD7<)
(N\4SIW@ARM2\J77F(FXX8*I#K%63N,X,2X'/@QI8%+10PT"Z>8G9.; M=:NYMAN"F(0OQ15']Z6$.O,T/(L-V]75+XIIS=P9C]7NOX9UR03SFW[\4.Z8 M">9^A=K4$T;#O&._!A_-?
H:U:F3YG/1X/Z*OILZJ8L%\|,AP],3QZ-B5-9B/ M/CTA?7I<^A&,3M_PCOK=YJUA_8@<;73X^FIGMLI<]ICO9*'*>@H?=S$W>R#C M,._6\]BTWT&P"*7 9N.RR-
C4K),MK6Z(0FJTQOP#"6JF@:#%,+P[.".<5+A^ M6P\T4$"+M)X O0'O6 MT=REEJOAV3+MO,N.V6V(8V9ESK-%U:!65&I75Z5\H5QKY"OP3[[6*A7SUZT;
M^+_&5>FJ6)VIN&;P&A:(Y0;(^F:A<'%1O"[E&\4Z/*!0:N2OBHU*_J)6O2[5 MRM?-JWI1%6FK(FU5;G9Z1=K<=238D*K>5-6;4I.3JM3> CI5J:UH/8.T+JOD
M%,0N*WC2EVHWX:?H49QHIJP@]JGSK/BDXI-2\|G&TY-#GS"P(BD5M8'.#X9XMV<-0X?/+('A[FUZ MRZ/^AE_57G77$.B((:[43;..\@5;PNYFYNB*GN7KY^#A)A/UY(D(7$C0^3/
MY5-F5%-7B*NI4Z1P9AQ_@PX0,PA_6HWPI[41'MJM$?L0[;#B7/;P34+V\,U5 MH2H&XE3P?>)L/JXX\!C6?T.67QH'S'S*&3JI31G=EV6XH_LD@+KLEA9)]TR M1>")/&-
&'D9&3LYXRJA&:._<)Y-.#>7M6J!DQ:X^\W8I-L_._^PZWM+,?.D. M%U1E<(KHUB2Z+-JCI"8];RW:V\0@5"2I2/(82%*&YBH*F@J:DD)S\|+DP]M@
MY]3W)XQNJ;8_Z_9+D)@#)'N2KK50P48%>TI$9F-B(S+:93E]7+1XPM3XRBXC MK@1-$RGL.J9G$RYQ\NO?I.N$(__KPPLMO"\.0.J-*1;M4^N- PZ+&@($H;)P M:?
ZX')J&0>T/X:)4WGVJE$&8X+UI%C$N]CN3FW4TBUB. 9%$5!VT)(QN*V]/ M-=!-E[R@;)IVQ0B3+=*\POS$-FL^-6V@D? 3GD"/8R%[2H/((NS-3[9I12&9
MZG=E_KM<\,/%A3/#]H]P]7"E@A5T(O[2C9J)F"G?\'KV#=\G#1.M1F"P^"!Z M?J49Z&9FH(O]=RPY2)^82!//?_R]6BQ4/GK8,XJ\4 \))-CN-;+J!)-0@BX!6I5]'S8Q6#'40
MQI/$=52QEI*R)PGLO19$;5,/E5Z\'AOT91&I)YW)'XA4KKJ=H$3-)C5K__PI M];S?)_&QFWQV GH+V^#W#,WB0K62JY3B#AF5.:GNXFB@+M^,)":^1-I+=SC6 M?JSSWW=MFL?
6T,B*D;?4E#G15(;AFW8/,S"_9)7FS;86@/*[X&] Y M"N7%O$A5 B&S\K&S$H@CILELJ@0E#Q.4#Q!CK MRL*$8MR9QJFJ?L+$BU^N.Y[<<_T*P_2=9QL6
MRHB>A+=A@GDI)DN?I:?B^/!6;CC8;-%)'Z83K3BQ@^DOI'K/'H"X_[Q1=98H M\')#QK-$O^JVSGE])JS/4*T;2>RK=K8-2U2G&=;00)Y2&O1,UD])$O31Y8X M *[##H$?
B]/H"9Y$&AY_@3PSB?$MB6' /\7(1XF"&X[\&'8.CVQ@.7Z9YZ];YA>WYD 0<$O\('LB"QM"5%!^)D>)CQ M!!YFPNN;-KZN";MIPMCCR9-E]A%%E!42O(=K^.-
B_F/SL4UZL"T>7S_V;>'C M10[&T5$Z>!/+9X^+&W?)6C]1',0RN2SA/VWIGJ'_Q1.5R5?=_4Z!8[@P20=E M-XG(J,A;T!^\ @+O]%W=F#[. 49]"1\NV5+!
T;LD5>!=V&&4B9C_#.)/DK% M[.A#%M_XF@0"7UL6B_W@;B< M73#<:!D6Z^6(1,9(P#;P\53O#PG. MW39TEQ>EL'T#.A"E*6EIKAQ6PT6(#F &S)>?\I7 =P%K, V>HEF^XGP7:
[3P M3?&W,(?1@A!#LN6Z]C-^.QD'L.L#-EUJF@AD(%"1?BA=7BN5!%$LJHV)9!^2 Z&$E MDJ#D,.I4JF4BB[M>JENRT\GP;'F;:2']F+4E[X5"$+?P4ZV LR8TM <3ETEN M?
0P;N;QKR;(M,1B:@I:& $1[G_"'CK+?;[L=='"Q$O4NO"?U:J ",VD.O%#] M@U"FQMU;\'!QX\;J1+E4S.5+Y45U@K\/J:%,#]X(,)'Y47528MXNWP14VE; M7A/58V-C+>GV.E3H]
LY5:U#. MK[\&NCD8B 7H.7=TNT6 *>0JI>O4BP!,Y(F&2Y%(S87BYLKB0>J3P>2P)@8- M"HX-\R6HVWW\?-_K))[;&=$*@HKEF2<,!Y>N\QI>FK^&N@9Y_-SZ]G7UZ:!+
MJY7GI<^[3V(P0NXO@X$3=ZS =RR8XR\PR?!E(G_,?!Z&>LYC[;-V>=?1:K]= MUNY[6@>4!^M5?_."L 7&B&TZLU8?R9#Y_S^0(GK(15C\[WGVO[B(N;CT[I?8 M7?K2B-
\E=+EGLT>]=OW!M+]'EI8#:9TU8\0V [8H^@)@+MRS+XTCF:LO&MWAEINN<$!B,??Y, MY_P8KC$A MC$TQC<$LW U3=>N<_0WA*DCL<) ^C+K4?
PZ(3!8*K^@!3X,@H3BN:.@4P""T MX-CSA5UG[&OG9O"W_BTJY;=O!:OI+GHXO8#3]N#W=Q9LB&C8 M6JR4"P4THB@PSS%J/.Z$OLL8;--U(<&_U3"QK]W3$M7)_
>^CW>U;K-.:JT& M:30?OO6T!FEI/?+0[G;)H]8AW2^UCA8Z>$Z1).]T; AF \NW'(_+HX#"F%AB MHF(TGOC5,O>C/L.@P23H8T#Y3#C F,G9\D!481S/P>"7&+AU0 M%]V_.;
<5*7$!T3#SJS'(X"M/PU(H]KG<5]&P/&O$A7]ZR4I[PM-0.%=@Q>= M*N(:MWJ,>]<9U:+=6_P#F#8K=,QT)L*6$ZF-,!*Y1(EE';2!7%[! M!O:H/9_!TW)BVHP:R$6XJV0(% ?X!]",=
(,&@>$% H^";@ED!N;S!+_?H'GC M1ET;T8>:W+11*(1 QL42E]-"-OG8(X!D/9#R:I_HDW&A>AA28*.WW M(I1VJU-TN,K\J+O^6R1VZ35,KP]
<Y)ZQ:U&!FX#K$*_3_1HY#4,OT_RS!U]Q:]PIAR0\2%TC3F M?7#L9SR?H$&?_$W;[U9B'-M)G5!9[U..IN3UB&^S./%'EQZ((9ZV],78&E-2C0PM[L MNL/T?
P]"E*#M3I@X2P;8\J2]0@K:8^":ADOO*14^O'7 J?&XU@MM\PS$-"!= M-A^F('GM0>2[33!X]$T[2#OU1) \FC@P M@-=G?CC7X$' 9VJ#%FIQTC9&I@V6B3MSNH%<9QG$=#U/
:%2?%?Z\EQ7^O.# M4"&_6/2;8CW+Z;K\G]]Z%HLQ20D2T4_LJ0'[EZIK1O!7Q=;7: N^-- >AME3 MI$6<3"3];XMQ\#6#W4M"WOMWN7MP +#3QZJ%?,J0I[;]*>:J:!EK+S7NT*O,
<"WJ[Y0T%7\F,&3DR^%!6) MK@7]Q!Y0F4WPY(Z-4>!*":[EIW,H7G.&<%"\1O&:(^8U$NIO,AP353SP,5%X M#C&&TI\=Q^"91T'V\@E(G\0.E5'2"!SU69H&26,?
W3!JIXYE&+53QS*,VJE= M#".+$G'2[;%%3\E3['Z]N5;_TY+IWIUVY?RM>+5>H2 MG*RE1,VID<--NBSG Y-#\3!GQ"A1HVAK"]JJI$M7/KBHB3OT0.8##PYO89[T MR8[HFL;#
$[UD*6=G>XB,9M:<;C+DM.8RTD'SNW#FE2'))VBF#]9,HHKP5RT M+0]@..Z'CI3Q>*[(KZQ]6O">;$0E0)0 .2(RBNN"M&@Q'L Z3I:FJG MI%Q"M5/'LH1JIXYE"56R[F'4AT?'M-
D)J3X\ZP1CJ2N&VKLC+CDAH[+\W-Z9 M9">N\8F^; ,\|^>SXQBS^1G!-9<:-9]M<]/&V>XA86.QU9L*[IPKHE-VF#PT MH@?F#VI<_H^ZSCR8+Q68%9@%F)>4/DMB=B6%(-
L::GMD=A42:(BCET1QY+Z@RTMOST21V'QF"1Y,*/$D**T M@-*6E"AL:9'N50RI<)E]=4FVBRA65T%=DE)Z,EE2;J')%)4!. M'/E+$D%4N:
(2((J,TI/1DNP35:ZXRB3\19S1]@L[7BYR[.'Z%'=[0\;@ '+&8^H[==L \^]GOC4[3H#_U5W:5)#Y- ML12>IMC5:IWZ%U)K-
4A#^UU[:#]^U5H]HOW[46MUM>YQG;.HFX/!AVY_2(V) M1?%X1;Z/L'F1K=3$07.G51@?>TP:M.74RC7BZ) M+RB1DQ'5JO.KU.%H64]#@4OFP]$4KSDB."A>HWC-$?,:=1#CS-
!2',38U2W= M?6/'+]+1V'+>P(1^HC8=F+YW%NDD$K7=3\Y=JZ:L5VC:?6=$N[[N4W1#/CA]
M'9_%=&!P\.L.M>#YAOCEADDDQ0,=H72VD>_CP7K*BS64^;?'P_6B]=E&;$NBQUUTJGW=.>HO4D6TU0,K.YW29/GJ5XB TV[6=@%]WI[L(7VUD^ M%67X*)@&,-
TF#WV',$6C1=DL"J8!3+=)&M\M3"L*I@JF 4RW2+4R+4EK% MLE@*)]U-JD''+F"!&;',5-!'#BSS_]@7RE X-,]8TGEQKY&5*$1:CCWFIR+# M'YLZX61D-
@K?!\'WDCZ,>XVFK(WO(^O*J*!]$&@O"8KO-7BB6+?"]Z[PO200 MOM> R:FS;EE,H-,.EEBFC8M*?+C-4M&1@W.6)6D':T1'Q([VV(:N\(T<&4M0
MF#P()I>D!ZP1"ED'DZNB'TH/4\CDR+S-+XDEKQ']4-Q283);3"X)'*\1ZLB2 M6][*B$Q95/N3CFX$G4[()7'\(75/4+<_XZ;)M_ETYP8F^Q#:"(Q$3\2&?.?F
M,/V051,Y147K45&ZLPH/1$7J; L%^]W /MVIAH>"O3JX0DF/HR"C=$/[N.M^D1#J5K582B%4X33 :;I"]X/(_:*4+18*'\FSRRK77=JGY@LU5-
1&%M:2B<>@L'7U>SP'^LQ0TQ&@.98$!N5P M4^2S'OEL795_2N1S)CKF60-^Z_K^4P*\DA>*?-8CGZW[#IP2^:C(C*0&H#HM
M_,Q.J;PMI&MNL.J4RHR#QDOC3^H(6'G%NR*N!>)*UUEAS\2U-&BF#A97Y+!3 M-?:YW?M![^=1('C2?MU_)3QF_4 M*>/JR%=U4/-J5YDZ95R!][3!JTX93Z-
JE/&=TNUZG!6=?)OUM-0X)+YY%_% M:XX(#HK7*%YSQ+Q&G3(^,[1PSJA3QM4)G6D*EPKIVL(F-IQ>[J;<_['+%564 MIX >"_1TO6:/
NAE/%]M+*#^K#=/%4F)81T^D:SLJ/Z4*YJ%"M4"U0G:[_J_RH MEI)3RV+3G'3OJ9ZKOU!+&3*YB3I.M+ND)-P(,"/-0P3^[HI9]"!6LE*A? MX>EZV1X9P@]SS(T"N(P 3]<$]\@
7E8(5P@/$)ZN?>XQ(1QC]%*&Z&4Q?DXZ MH--6YR+*Q'TR:?E6VJ;#[LR9/,M9U:9)$JHIXM%TNCAG"MJFR>Z6%"1;R\0S MT4//&N[;M-C=K<
X3$Z=$AB*@M:CH&VZ[)Z8P#CF'KLG'>A2/7;/K35;*8L> MNYG+].)MG!FHFA[**]D592U05A8-=C.GK$*EH+KK*EK8-RUDT5TW[!)=JLZO@H'B-XC6G
MP6M4F]V9H56;71EBA$?3JZZ409O=%;[*_??:+1^F[.!L(^+'@_8,>NW*AW;5 MSF#KKNRH;U4D+))IBSVU$E7:JO6N])Q MF Q:[V; 83)]@%^?0["5=A]YXYL#R
MV7%;61U*N*E;MF:4D4$H)N%4-=!3=+0>'671CW6'=%24,G%;29 30'X6W5=W MB/S8EL2R($))$$5' 1UET6MUAW14/@P='?-I'B<=*%.G>9Q;-^CK=+T9DCG4
M;IC333$NGT0U6Y=7TBOR6B"O=,T@#D%>I=LX\U&=ZZ$(8I<$<9.N7\0A"**0 M*]P>[J@;)7$4@65"8.E:5!Q$H;L]G$)W]&=\S!S_0'_TK8E!@U,7#/,EZ"3]
M^+GU[6MB"\DU3E:8FSK,A8U'R/TE'SGQ&(T2/T6#3S$\;00^#T,C_K'V6;N\ MZVBUWRYK]SVM\X'HUJO^Y@74@':J3>?F/*1(BQ]($;=0F.9_S[/_Q5GMXM*[
M7V)7ZTNC$[M:B(F9<<-WY]NQ\%H,$C/[$MVHV7-:YN[/_C7! MQ($7^+\E9[3<2GQ&RXTXHZ7[[:ZK_>N;UNH1[7?X_\.T-*O'#O"&6;1YZHY;P2W:7 T/[KN,'7\ G8MNUQ3NL1?
ZC[Q.GW)ZY+ M#:(/@!O =S1IF3WS!U]FUN"?C.%KQPC:_"__&0EZ[1.$8(ZP9SQ-?)@IB O* M1C4];X))_<09X-\>11P;*%VP&:[-1!\V-R(#$Y/_3=V"T41.C7=%<"7X>P=O M&
[S8$_5?*;57S,]Z(P4^/3X[K M-^D5M\@P;0@IE_B..OI/%63MY^<1B5&?V M%S>U[HS&NOT&&S@:6Q1W#[_M6XX'LA=W6B<_+5=>BJ7*7,35%#RL"O_\IT&? M_*8-JL@$,
<#RJ;H4-IT:CZXS CPY[EO+\:G'TZC^,\?D>F]CRG\T^WV:I*O9 MH>_U/JV-0,;XFP9N\XNF-V@N[%W(.'P9$'[P-E?D<>X;\DI=3D!P^ZL)A*D3 MP_3Z."-X$0:XNT>73HR)Z--
#;Q%ZX[5 M@T>1Z](^!477(*!$>!YN1I]2PUN]K'&1'KF6]5&\RST,U!3> %/'ZBZ7 CJ0.OQ!)!C4?JHOZM/T]MI\MBZE4N8KNAA37^.0=6#=B'3#9;;\&2FR L MQ["P^BC@!PFL_"?
&BE#"L[V!R<#+,:)XHIC&2HP)_W.LO[&CW9Q4DJ%8XJ+A MZK3%I#88T#[:Q:E4A^)R<3G4[6?@.2;H,8@K,@# DGO3I0/04UIT KRH;U*@
MUQQIVOTKXCNQ5Y.F@:9_CF\U/N)D]P2,AZ_4?<:DUA,V!-(I:$F0F]'01FS% MN"[QA_Y"&R@;W"M2\T"U $XVL7RNIYM>U*;(S8A.YPFST;GZ[KN.A;^(/@S9
M$PS[).X1/P*;0D>=!BQV88\P"E@._ASC1^GX4('SH=+B^S_19Y!!\"X&TTQM M-G)+]PS]+U+7QZ8/')0?;4O>MVK=1NU?'TBM>7]_<44V6GO@RVB/.5PA!OMF M,AHQ!4?
8/X2#-A=9,4(9>YDP*TA/M(;9$)<@32Z3I&=U2:%.];)0C'YL.3;(M%.KK[EMONMFA?.0S[8#=Y7H@WIS^]^[8,OT=2%7V*%C 3(\[:^)Z3/Y/1VR M[M@X"9AR$,K6?
&K1VFS=O_NT6+,)H&>O!RL.@Q$/1\.=0@X-T(7E$5?> MX][]X^_58C'_42P)81,D;(;L2N'C!0$M?N*BSN4'(58>3-[CZI/;N46;@Y M0O7^D/!WQYN0QL(5"&>
(6X'ZXQ);CUC;TB&0&#,6&]T'Q_8X^@/[A0 M1+70='+HS$"=\1D6Z#F%HE@M+5,4 =]W$S!'J>?5^H ISPRK!OJ
MZ"L$11GGS.X#3BYNK;/785>VA'\7EV@>_Y''L^M>>XJ"3;%>R54K^5SQ.L86 M6KW[NA\:\Q/V_[GLSNU3-3H0+EQ8O(M+^*\VHQBQF 5_X#9^!3N2-R_F^WW+T-
A'#/BU*IM#WYW?'B]P/+E=X'IO:&Y M>[M87_XSMT.9'A7A3W%KG+BJ%2E6E;&2]JL-LQZ:X^E"WL,249H9)0-=)["U#MI6_'1-5]0GWBT]#[C=/*8C0OAUTUR>F>2&()%6&D_
MLOA(\68]"R8BG4(SB\6.*"' 5M60]T7LX[^[RH&7X!<_4G M/C^;P 1%'RC=]7+XPU"/?AV:H"5'!V1/8QHN\X\SGN%1RR+OS8MDOK#$M5BY M+-[\1XB_/W07["&_[78P
LUH_M$<4T:M?\#D:WU!44! XMZ]B,0F"P5L;/WD M\C>WN6)UL55_(VC1LYC\U$C?-C0N%E+6N*.O#=A-\8NO1Q,6"SQE2_6W$AP M_9Y?%XLY'1'V-P309(Q_)NYM7!9FL+?
IMAGX/YM*,),L]Y7)@MBQ@]'X!C> M=NSG1Q:$W72SR[EJ&38[IAG:K)6V>B-SP4["5L;NWY:;=KLD4S#]ID7HY-BW MK9*[+51SU]>+:M&ZVP:L%!CQ6(B]
<2#VYBAO3B@&6RAB#,$FPE-X)\Y*Z:< M@2%#CS##@(!*%YR'.VV(T;9G>;AJF[;UW8LZCU(Q8H7)^X\-NC4.-FX/(H MENX15PZ>R/9NR9R]S8W+\)GW=&81
2:OF_JEO7&=VHT=F#VU)EX\ U3Q9(5/3ZMJ4=N+F#. M0EC,SSEU(?/$A5D+.!E&<3UW8F3 /O&1*JSN\B=SIW6(AYOT]^ S*F'Q3D4$X^X3AX-)U7L-+\]?
ZJ+ROSFK=,)$UDLJ:G,Q: MCB2SSJ:SSN:VGD">ZX9[U&O7'TS[>V1IHYFRZ=8L31(MR3:7=M6U*95-S>H? MBZ9UM#Y@*0P3$MCGZ(XM\,*XG:O_CM$[ZO9G
MOO@%T]GYVZU?8)S:_1!'GK-EQC-OJB82%'5\^M4#36*&2D$B."RN G>R"+EE M(I_PTQ 7+.09!.^'F-*+J@$'?IL>MSC\CAYLLP^0?UD8J-K%KW2HU]_P2$^ M 95\FCJZ]B%
(=KBZLRMYY^BN@>O2,%W:1Y<14V.C'M4]SVAY*L,)+C\'^D\!CG<9U;I3\H&>HOH I/##/(P9DQM&8RX)]T MBV7*>T-*?6;I)Z2&Z>R&!NTSU964"B(#!HD
/A1SH1WH\M.#9\>:YMBSK .6 MG<.J!_!7.$&@(FI[F#H YH>7$[EK'KH5O B-"=\#Y@N !DS>&W1@]DW_@@_? MU[TA&5C.JX<*,;<_A7'AOSKDC>HN>R(S5Z-%!POOM?
@Z/$7Z/6A%%D_.LS"K M=T!9<0!ZH3T2<76L+#68NCZ:@.>)"VO"L)T+S:/$GZ.7TT/6/-!-UWK+,?<+ MS[2$]X);X?(8YNDE/F_L\&!49GL_,PY/\/*"_):Y36M3(27R5RW8PF=>A
BO"M?IV&=A!#;$-YM1#>,?;-HUINSH\%04_/SF4_M.[ABP%S[U+7/C87V$EEF+"DREON$M4% E&.=54&!P3[BV1:ZSQ./,$GJC:=#
MH^O!M#&*A'F0SXX8!I>;Y49BT<7$\S@P,36-% .RX%P(V,W*:>6BPPYA)&\R M&# 5SL5H&?J.&:NEPJE^0'8("(MX4R>?*(_.1.?D;O^9%HX&S[]Y4OP5;?U9_86__30E6PS)H#^(-
<0D4(/B])\ M'X/SS#%L>0XQJ-=WS:?HL@79H:NVT'!P9>%WS.(C+.)G($+X9?9^(S3%@JS5 MT T%[\82VH,TUHDM(HW^VYFQC3O=,SD?%VK:&;(.+PW8=%&JB"(:;C8%50@*
MYQ0;QEA&(2UZS7 MVG?O+GALP,7%X8D^^'I/%"AS:HVR\81^LZQD06@NJ!7!+%R#*;KA1+]==:_(M@!JH!T23!RS]U0MU&7T\AK=AU2GN!!4'O "O/;$$FQ0;UIW^'N\(\OAP&;
Z M"#"1[R;-A"W_PVMM)'W=ZBJUEF\)2A C=@"/\,7)C552)_1*%ZA0K"0, MQ3Q&8487#IEV.(+5VOB**"9$T'",VXO10L[$1/KO+!\3-0N@CV :W2RK_.=Z
MK\N0!Q_1:,+5%*S3=D!U0?.#CYM(I.D)J#CMR7) W^ 2^FQ'29(I/B$-<9/) MZ5-CXG)]4T=-D9NXKNE]]Y;B?YJULU)!32247)2FY^?#]$TF"85"B!AB\[HB
M7=S&R,WAN]$?.C:=L9]SB"H=ELCS4?B9,!7Z8AJLU(UKF4&B-"]VY(P=M7)0 MF,4ST[TCE]EBD9F2.IW-BVY-N"8=N&D6;=4)2F:6:P8;:0Y '&%[!MC-$3-1
M1SHHJT]O$24AAPKU*\9-X+]S0R!1H(] N YF8J\IWN0/UAG!I"^"]4:X!:PV MKA\KZ@KY[%.H#T;<&QG1U7; GX^(S 4Z8*UGXAS!W_L)<\1[]#SJOC"[,D%\ M "-
D^P$K#EP4L(R.D=TO^$'8V^R@#8"U#E3< Q+?O1L^!<*^ZF^D*%(C]JCN M^9SP6.R7I8E@!%6TJ K_]L9Z/_@[.J5-PHOS_;&B@6;L8_DSK<@'9=PS51=>Y.P-
(DA3+FO!QZEH)/,39% M*M>L4NC0<^I1BXZ'@/\/Y+92O"R6;B\+-S=Y%LC M(A[O>^9,*'9Z]<23-P! M7>8>3+$/I%JI7%:O2Y?EPNW.)[8Z;>(/^@0"V(?
G^(R_>,A=KOK.**GU>:GX M\ZH.EZ72SQ_)DO[T00Y-F'="(BH-J'/Z7/;&S%>_?(HFS"0V*=R+&)O),+K[M[=W<.O TIL5.E^(;EZ308+X739MMO[C'M:IU2?N>-
+2Z]O5.ZTPCW[56@T6^#S2M]\T6Z7UI?^O" M/+HYHOV[KCWV8*5J'8W ZM4N#C&OV?S>7Z?)EVM;)8+H!Z;=PY_&__,;!;V M6B8++; DS!G#)3*7+U07Q>'[.2EF1V?
Q*L8.WL^R M,#61)ZJODXHZ. -C? MJ3>IN%PT=V7I@3B[V8_PL".%ZNW;?"^'>C$6ZO*T>C\,08CW7Z '%*@[IX,M MSQ@X]#04M#:%5G'WT%K-'&0Y9&X/1XX'!EXEOZ%[-
ZL#YVK=;M1NV)O"D_GS MX5V"(1;/M%##J$W9R3"RL*S3/1U!VSHTZRI6V"3JNC<\BW-]W^'A;O'C%O=]LEOB$>'7A;A.*:7+0O&R5$AN M/(&;6;,-__VF7C1+E1;,5#*L@B9..:
M*QZERWJ"^-K0RY1+V;BO@LZ*8: M%_HX%-$5^5U+!YE)0$J91%:9Z!S"Z'5Q-8ZSZ;H#$FQ+YU-?>5/.P.' M?W'C',DI: 0WHK[&3@N"K?SL. :V^=Z0+Y6JLD0
CM>)=6PS.E+RV3A?-9F1[Q,MX%3X[?CE_XH2S<6+K M+HUV%4$[7VM>R/9VK_9 5G1\V(<\+^U9GJ^D=)@0.X8)#S%9(/6?5C&I'3 I*L.4=DQ!!Q7SFU/0QIFP6U%0
MH2135MEJWBZ+>-^+&;_GOI'J^>KYTCY?%L(_=;W^H5F[:SXT>TU--7([TV'4 MIJ@T.,EYU?)&;I;)CSPVJ4KC/=-AU*:<"/\Z75UK/B.JY^*QDF/][53;W!QS
MDZSBYI5__!PY[Y%O+-OE[>J9RK%5@ ?/H50PE0"FFQ?:90O3,L"TF)<1IK((MMC-0S(5@ZU"+G6^,YYV_!0+N!.6;=.F&R;RBE%"B\A^Q9X^X9< +;(_P+M[
MBUZI_3"]R^@77]D1.VMQFBT;;564+%20#B&=4.5R1)"NR AI6>3F^1B$@"IW M G)SQIVEI.:!6(NNY9O1B1//QN5A M&1)/Z4:F8LOCD?BG&
[:*UH*GJ1Q1TOUD&=3&29(1!J7$NA+KYT4U&^=L9D$U M2IY+;,&?4O&N>KYZOBK^EE^1K[>_?FWVOFJM7I?46@U2;[=ZS=9GK54'I9Z\ M;SD^A0=>J,+*S8;QQKH=C"IT?
ZE^>-R:!H&M3]PA:!8K9:G[XZW'W]]X=GN MY/4A=U(6CJE4)?5\]7RE*IVW M9N]/\KZAW3?KS9Y2E\YT&+4I2HF1G)?-)VT_ND'6MC?477ST3VETW4+E72J= MN%!]]RE_E8?
_%4*EF/T'ZX/)BVY-8.JI'G2;;L!B_MVG4CX' ^*_Y OQ[>UV9 MFQD.F>HAQ92#@55I._&O;WH>%IKAD,[$]WSX8-K/R4N1(_#+,>W[Y@NUWE1F M_Z&SI\L;GS@8$GS7=_K??
T<*5(G\"HI;0"CPP9/%XJRZ#&G:Y/-ZS%U9S0" M8*ZEQ!2O4PK3FXR4F&)*K:E8Q6!MN;)?/2:EA@54_:ETG2O=W.:JE4WUF%(^ MY6!%ENQQ7T[P)RR:##GXXFI
M&8:)NZ];H%:8QJ5ID[X^-GW=4F+JX.QA\|,,PUU]A$UMVG6^I1MF\%5NL].]3739L:FN[:L'U>!$(-CJ#-^!+Q8/W@$Y.<-\6R' PJ]6I?']D MY9O1L1+1QG6?
>R"BCQZP#'3SK)VL#&Y:)9T*- M1&04S]UA12_D2R@\7>M_24,(5DVV4B\XJ#:P>-;T@07!.9Z"?KUQ(END'KYF
M&YFI"L7<35FF(OG4"WTPV2S#E!1MQ='6QIEY.Z*M0BDN1""+_K H#[CV\(O_MY!AO^!<>]_*)_(V N#+,%_XI5N3.3?'C=#9L,C-"50PI?ZDB=KT5^NO?
M\^Q_<:JMN/3NE[@%^-+HQ"X KN3,L.)U^.;,OM J.OOGW-+\,PU(5D""S2:< MS/XI'6CNOMG1[A_^)"WM6Z?=K3>U5EW+D6:K?K6::A;0DE:GCP-I3+^(5K?]
MT&S4>AJH]SWX#^\=T;XG[4>M4^LUX0;12>+K(RC_6JO;_%TC#^UN]Q 4CXO9 M[I#>%XW\J=4Z7:*U&C#SAE;7OMYIG6F"*$X9I>.!)OF^V8))MK]U81[='-'^ M7=
<>>]Q^8E.#M15_P=+7+E;/4P:FKOU+*$, W_]L9Z/_R; MLP20 SW\:3R?36:!:TA^MMBF;5";<>7 M0,P(I[';*M3]#P.2 ;.S_^_=3:+TVV7VQ_[<(*E8YI]4=PD%/!JSWHZ][@U7
M917V%?;WBOU((88"_YF OQ@+?GE"+H^2&.3,)^TLU%XVQ1O MQ;WA;67^13Q_5LQ8#:.&4<,3OD'T*_T@E__-A@_L=[7>M]4U;)39V M78VSEQ'CC*J?
5@PO64W0]5S.D,%#ZOD"_+-&1CX[PW?35O/EVVI\FO#!-G'? M0%+0W0"Z-_D8Z!:GT$V9!Y\,W;4KL>7!K&2R<#Z[_135#S6,&N:DAI&,A^Q/
MGSZH#BVBXZW/1/OWH];J:MT/!_2([V:8Q5Q\-9K:,,E&DXS][5.%.FQW@$*5 M3:)#/:J[_2%KR6: JFXY8TP))/3'F-H>'A1]XBZ&E"/*9IH5,O$J\,VOV49C MNO4:W_E-6X_$INM+9;;)
2@%X6(FWH7L(5S(%6_C"E2E K%D@O/D[89YP=FE MEL7ZFX+:%'[+&8C, MS/%[O:R3DSSXE4Q:GIV9^9G:%.O24%KJQLBT3<]W=89O)3+E9CG7&8A,L?W MH%
(QO,I"U(E<;5*!L)Y"JWV MX,&QGQ^ HQDUSZ.^]X5:QKWC?EO.VXXE>R=;M$@+8VDG=J3T58G*VYOC'2%>XQ=27\|@DW[R%Y5%RM>1>5#=9)*6WQQ3MG]!]N&EV
M>BEW74GH9"D3/&0P^8]?8S@+$JMDD3R?'8F5RW%.^KV26)QRH)P/$J0>;F+1 MR\7-U&S4;-1LCJ32_\S-L*D!-M.&3QE?IZ09)AXC4,DB>3=4#9MVWQG1!\?;
M4#F<'BE0RN4K<87">]42MUKV"RFM1D5PAR:X+%*-=T)P$IAE&QWE(:4"<7*& MF1I/JPTC&0\[%".E]T3K8P[S]52/O123H0M5 J]'4ANU[-,DXX/GDUMWR
MU#KLEDP]/P<+8G\G PIC8IZZY>@V^^ODW3.RYO"L.)NYDD4U5]-^@;W'[!QN MUK7HUN"M9E')E!-YR!+SE6)@3E=]LE\(2 M_X\:Y%DW;?(><]$O,!D=H$9AZ0G]T1_J]C-

5,E/*,IA*%M5<]WROZQ/7I7;_MK>?JML?'^@R@0+_H%">;YJM4)&-"DL+K+_"=+$>S*.S:/:(CVF%)MFIHB07L MN=FB#T%MUP\,-
$U,;\A*OIP!H.EIWX5>B@>E%*I95&$AH_%P^ZG7MK69[6\/ M&K#YQUZ!)2V:S@*_R3(TBS*GC0&<5G!>RU7K)+7J8C419X[!VS[P+L0*0).[9W1S$JPN_KZ3^H!U:1J\,
[F+;NOC5].O* (^)$7(>U9 PR M$;:UE(JYFWQ<1RF5QW^R^L>9$&X6>?P2$VXI=YM7]0!'Z04Y\2QM-8P:YBSK M
4[>.%K(AF4^5%__0<:N\V)Z((%.WCZ2U7^S(FY3S28!5J@YPA=S1VTZ,#=4 M93[)=OB/2GV5+EQ>S2;S=2W4+@V23W5OZ:/ED@G&DU.N51MU6W^KAVJ+=
("7DJ'Z6N_TGT*\R*& M,WFR:(S_]*=C< GOD&RR9-% <-J#S#<84T0#(^.BU_4?-\UGR:^#E/N.;N+ MVL3%L^6*VB1NW8'#-LOGIHA8*B+.HF9#3B(^D@A.245PI'%XJV'4,"?
6H=4CW2ZVCD?/(=(MS1DNJ4*50E#:I+'ND M;G>HNW1>8=)TUP8=P NNW^F>V0_UG7QJ?:?9NH\H//FKO'PM8P]AC"BL;XGU M38K0]HOUXE55/@-=J?
%R:#UJ,20TC&0\Y$S7^#ZWY^0MJ[[7?M4[MLT9: MW[[>@0[?ON=J?!<_U=M?O[9;I-MKUW\C[6^];@_T_F;KY0DF^"A-I,[4U$.HWZY=37HXJ!=RI6H^E[^.2VJ4#ND1<0T?
GQSCC5V MSQCO^$3^AI\-\X5_BI5O_YR;W3_3F?")C(CPX0($Q)L=E;CA%'F!EE[##S) M=DB)WN\[H[%NO\$N@SCUX9FP]T0'N &ZGEW=(F/=9;V3_"'U***.):/H !LR M,&W=
[HMP$R#%I]BEQ+L*9666[W][-HRJ? M_SDNOB.^8>3-OGK"C?WO/M>)WQ@E"N(>9'((.+W,P\8#BY=YS6X,G^I3RV+ M/'X&=25QC'B]*""2^?4-U;S[RT(EP'D XIG/T8_#4%E]!
WJ\JZCU7Z[K-WW MM,X'HENO^IL7!#-1$;/IS)M_)$/*E[&()=Q"!?U[GOTO3CL5E][]$K?D7QKQ M2XY[E\6"@P;X8-K?PW7B<$JY4JOX 5E@""DYE4#E_O'H9U-/)SUJAEE3W_
M3>Z;'>W^X4_2TKYUVMUZ4VO5M1R6B*=@" N(3:OXQ]'&@C%0;[>Z[8=FHX8& M 2CY/>VKUNIQ$^!+K?49K(%FB]L%7]H/#:W#\J;^\?=JL5#Y"+\GVK^^-7M_MDO<-
[;Y9;_8N#L'A<(7;'=+[HI$_M5JG2[16 UZGH=4U9MF 0DE0QV56"VH M!YKD>UC*WI?VMR[,HYLCVK_KVF-/Q$Y@!VHI%B]S 3HE6B;%"=*\B.4S;0;_M]L9Z/_R;

0;CV\/UY\1!!ZN\"!UU!3V)*:MD%M)G/BFE\L"B9<:ZZ=1'P* M&2A*M^+167H#V.H$2W?[\ZS6M<.A8D8"60/[;/_?NP+L,@@%\<=J49O!M!9W M-;(F9-X?-#(-PZ)KU7P_NG1 79?
B@CK][Z%RO=,E7C;Q_6URZAF<].;7G=$(M;$2U\R>Q\[*M(3.*4=),)>,7JJ/\#-=PAP[M7]B^LL]U%IUC=1Z"Z5;A:5>GVR+H;DW)1YONQAIL=)^<<";G578QWM: M5Q?
8SQT*9&)5?8%7U?^G&Q0[:\QO5W=&8\?&VN?:#].[#.MPNEB,\95B!L;J M0GR>QMQDN0:;UME7"S>Y8O$V5[Z^65YIO].]7E%AKQ!]4$27]X)HW1P,!)Q[MSAU-
AG3\@4(,S7$'"2D,[Q@_/QT5H*]W!>B8/NGL1AY+\O@C-SS:K9@K%V\5 MMA5_7H#SS<9PYL6?>U8W"KGKI)ZU"LAG"^3*[H&LM(QC /!):!G5G:!Y*Q5C MZ3F<"L*SZOP?
+LQGJ?)QH^Z:33M.L^>W:OZ?%/(5:M*[5 H3^Z#?Y//;PSS M#O5UTZ9&T/U^G_B>=LF_J>1*I826F8> P,5^1E=07P_JA>50WS=J2[E\(>'@ MM@.#5I)HU_PY#B<:
[>K"3^')-3)M3,8 1X*2RI.+="6.= #&D<0TBJD:2$]% M91T3O]L#MH-,3/+MK<6Y4G<1(,-;N9G?F+AX&B4,[QC[\TE\L2PM7URFP"URQ=]U M:T(7F>)ZEG;<&5V*
(,Z/(.*.BM\30:P?U]I*2U@S3J"(X32)0>D%4HPD&1N, M.T-6 C:8M5*P7FA)$<+Y$4*Z V9W0@C;!J!VI2E7%&DHTH!IQIT_N"?2V#AH
MI02%HH:=4$,AW1&%FU'#@9A]^=VGLHPN8DD"6V=2QE5W;%Q@/&B'MR]U!H#T MZ/DK*K*U6[Z3& \O%-9D/)D%J3@P/)B08&/<\13BI;!A?&H:7Z\6DVJ\#L&&
M+@X.OU,&NG)&R3&2;"RNM <6%Z-8+3 XWLXXAL%MF#]4S)5C3T17G.W4\)T(M[W6#L-E$CY:(;VY(;"J[/Q5RA7PA5[F)2XM3O/LTL7U,4CMKRTR&!BT[W.YH MSY:$?
0[F%;/9^UL&1=3[$ECK1@?W&=Z(BK5O\(Q-PQPRZ6:2H/!L\;YN$' O M,8O40%>Q"X7O9'RGB^0IJ,H9ASB7 IO8Z(,JKU%6G@3[H79>[;S:>;7S)[/S M">IB,9-
PS)ZK'5;YK:\+N6)5V?OG W#%VJ0823+6MF[YEZI@4)"6'-(W$COK MMTU/+5[+F)^J4+Y_E&<2DE)E!0K7DN$Z7>A)<6 I/?-G4B'0H$\^HE3$>)0O M7AFO:N?
5SJN=5SNO=GZW^F%IW<:&>_#%1[,]1*V$^631+NW#K;ZY1=_"7.FV MG"M7KB74.!7V%==3.[\OKK?SBIDM$MR269YR "FHKP7U3")2>\BU7POV*W+O
MRSEV/JS"O\)_*9/PU2YS[Q6_5WC/$._I EF*9Q]9*.!,DO3_T%T7+GLJ+5\9 MR!+LA]IYM?-
JY]7.JYU7.Z]V7NW\4>Y\@K58WGDI3HQU63/^._%\?)K7],XCQ;.+\S@_JJGOI2NDX4XO>/^$S"/9NXNQ575QC? M$\;3A7049Y;>J7TF^>TLK>WR2?>H@;UGQM3V=
(9J^@,_4^7E5M:OVGFU\VKG M]Z9"K'OV5$8=X=-H'4Q:,&%1C\B*#H49>*9/N]1],?N41^0[M.\|V^PI+#BO M=&I%$(H5JIU7.Z]V?J40O-YY[8^2@(H:CH8:,@F%[3A6L O*6-
&@X4;&_@R* M/O9/'YG$TG8565 B0Y'$_DDB7;!-3G0?(]N7)&QQ)KGX3*!&$&<2:QLQ]&!$/1-6_O1IY[7 M'LS[6S<^S+92O5&4<"Z4\#Z1%#()E&T2"$C'U(\
(RA<'Q]8IHS@1Q.FB66>L M9$CB:S^3$H$6]8GE>-[).=@!)ZY!W4L.%WCT^ ?Q',LTV/;F:2> MM0PF;[JY'E*5R@8$TDU(H5*A4KX)R8O*)'TLD_.WUB_(+G;M/O.B#Z \#V2
M1"!%68JR%+]7J%2H5*B4=D+RHC)!"ZGD#Q"J4BJ(O"B6;D+'25:91("W")XI M$I,7T=)-2%H22XS*53()4&\2E4M%7,E!N6DDI)2[S9>EB(:DWI8]!/$4IGBW^=)-
&,=I+3]'%WB*8E($E(\D_*=7Y\^W=4>:JVZ1FH]TM#JVM<[K4-* M!7AQ0.FOOSQ].M]H(RQ.,*>G990B+7N"R2R$LW!P-!6SWGCBKZ.@?ZV@JT/YTBL=WL
MBMB6'7LW="R8N,4IC1&16N*UN9HK9K?F-:V".BG MI[L5U8"50JYR&]>B0E&@HD!Y*# Q(%DM;$R"F\3[LZ*]:?RR4L[E8X])V@L1
M;K4Q%U)Q"D6&AR3#XG(RW#=%%7/%8ER1^X$(*CXK8)9\)$D..)-Z8V[G$-[B M\]$U7T!*D$=+[S-9<7)Y 9(E(LE1&Z%ZJ\C6E:(:UY6B-$TM*VT<^/I/=_+D MF8:INV]=$"SM
;LV[_(0C"#D VF)%B** M'*.$^1^PI[3'^&*>.F= D<(6I!!WX/':I+#@VMZ%3)@Q:;A(:$QVF+LNW>1*TC3RD@2V9TL@<=TCY"00I30I0M@A(51E)@2E,2DZ
MV!,=Q/7.7YL.$@.4LM'$BD!GH512I*%(HW!S&]?C8FW2B \NCY+72Q+@.Y/JWR[\%)Y\1T(/J CV.0/X$UBVBO$=E/'$M>M(MDL)U2\?S'*:,AV_P7;R#.TN?>.Q
;8$B&;R!A7+NNE+-5:7D>HJV=K+$B9DX MMW$=.DZ.N.(\B4!==(Z\-J2J:2Z1=.2E3LTXF-1:-S_A6 AK65+>HLQB>OFB MR%*&IZ(DE>.E=CX%#UTWF)\A#UTGL".M9B*?
0B()SL^6HM:-_A\%12F51)'1 M?LEHW=R!#,EHTTCK84EJY4F3-_FJHBU%6T!;Z^8C9$A;:X=JE9Q2M"0O+57R MZR8PK$=+DI+%D I:="OW+PK[0Y)ROX5WU?3O2Z MQ*'?
W#50=:$D1_=[:0!_TJ2EO.I2C"094\THY"\=4UU3CZP[-JA8'BQ/>\"$ MOC*S%$5M1E$9Q?HWH:CUO>H'U%%459XB):66R#*29$PTHV"_7$Q4Z22*G Y# M3AE%^CC-(!-
:&S#4.6AB4O)+453R325 M4?A_"4U)3AY'*GLD"5V>2[TJ.ELNGW2/&H3^&%/;HRI,>4B>5/8_]\A3' D@(F.,U>^.05SY9M3.Z]V7NU\"M&V;K XH],OLY-K*P_)K)9S MMSS1@
KRIPAYQ4@5JO;-2-.%VA0SE-]+?RX%1@@H MXM(Q\+NAKEST!^8?F70YW]A%WPEA8-1LHT-]TXWS;"C?O,*W_/VM)7BNKV?,PP_;"FS5\4=RKEBH2()S%6;6"6W MU<[O66YG,?
Q',LTV#;F\|1_.=" M-H:2>M8R6,/IYGI(P90-"*2;D$*E0J5\$Y(7E0DZ6FD?16VY5EDA:R_I I8(<%8JEF]!QDE4FP>$M
M8FB*Q.1%M'03DI;$$G/+2IG$J3<)X:4BKN02D^F9XWBZ;>ECVDFRE* MDXG2T@7+SY-HQCI(:?LYNL13IDI'@F)5N_/GVZJSW46G6-U'JDH=6UKW=: MAY0*\.* TE]_>?
ITOM%&6)Q@3D_+*$5:]@233V10<_D.YHY+PECB."]$W?@X MIYM< ?Z]O8G+(5^Z04K=/@XEX-B)+5D=J.Z%VG1S,!"DUG/NZ%;D-M4<"N7< M=:6:JY;BU(>]T-
U6&W,A%7/8(^5MM6H_'2D9)E+A[:ZH<%DNX-"Q8.(>?V0V M/B6)L*P$W3D*NB0**^.2T6&,I%A(A5>+Z?"/0FS0O[V M4$04ERZ0KC#Y%__),=[P+_W)HI_(WPCY]1?#?.&?
8@/N_YR;XC_3J=3P'%F MHNHBJ"YBZK/3&">,0N9&F7EI-LR2Z'T4O7U@M=2-B>CWAI3H_3ZP8]U^@Y6# M7_LP&C9GU0%8*MG5[=@75V?.
/B#ZE'$5\,FL#2#3(P;=WNFW"3%_!X[RI, M!ECZ6O-OE6+I(B\DWB=I,6'O@D[UKXACQ,%B&FG>?^%CD M_K)0%<.&^)[Y'/TX#'-K'FN?MIO7L"X$'E-
KU;4<:;;J!V$(,*%ZN]5M/S0;M9[6(-T>_.>KUNIU2?N>U&O=+^3^H?U' M]T!SNV]W2.^+1O[4:ITNT5H-F.)"5A6IM1KXH7B@2;YOMF"2[6]=F$?W0@ZV M+HB/"6K!?
9B+&9M[W2FN>BM*V \E%&,I M(3N[=@DAI#9L#T,OXOT7R&4QI7EW6[>)6T7:V2B\;8JWXM[P%E]5L9(_[XD9 MIZVSV.$""96PDL^^WB()* NHF!HIY+[3_DK:CUJGUFNV/I-
:O=?\O=EK:MT/ M!Y3@NQEF,1E'C:8V3++1)&..\WTM=[DD!V&(X;_%RCB^P^7B*V<;84A#4SL8 M,T,R\:A! M3)LX8^KJ/D:$$5,OIF]23QD::C2U8>LCY8@'T-
02%;4L#D2/;CQ\MBA^J-E&+;+_F35_.YBV)BF@%(3C MSN1>U];8!L*KLCQE,SM4^$(RP8D>NF<=;(F!ZXR(!QC#%%+ZU\04 M?.VO3UX=-&>]-\>+9V7@# $K"T\IWX/)44E'5$V
ME]UUW 'PZXK1[>"\0I!6EYQSK?QWROC\Q%HJ7#[A"8&$_AA3VZ-*;LHI-XM9 MG J)VWV'NXT5DK#;VVCHQ=MKR3B+I$A2V(T[IV)=(9D==LOO/MWD98>N9)+Q
M_*Q+Q[YD$2LL4G2IYQ, -8"8;0!6AACT2=F8DO*;= =X)/,;WJWC-].&_^<(M4,Y8!=@= 3;N-(QU!61ZP*X0CF4E'97=F"P=T5N! A$:]K/$],;HH<"_:]* M+,K+9;+(DD1?
E8?;3[VVK1)]FT^R[5/=J@ M_+]-NXW[WYEN_X8!K!O9XEB\R2(U7F&5N=EF,__WVY(\#2V/%,7TE.21G/-JF2[*2Q1:[S)N/>]\06[^A
MW+R636Y*BBB%X6U2)G>+81764J9F2I'IN[I!R5A_4UY:B5E-%MF2B]RFUN\# M*?C>(]_]'D)A0XY3DLU1*RFPS@+*R3Z3+!(I=X?E$326R!*E225E/UDD6&YDOUT."0>
1%F!J$CB=F0'"@["UPGPCJ+?,N, M8'W$Q3:2"=4SMDOU?M^=T)FD2B52Y60]N\D@JG$ /$SW?],V5;E\6?K<"SF0 MI;"\FURBS+!*SV0)9.@9VR6&G1 71=JM?
J#W9MT6:]HBA74\CDY.U#L:N M4D_T>BM["9/J2$0UN$ V];,O8T]-?QPW"WUVN_1'LX6SM).3%XZ2R2SW:13 M94!FV#+@6BYOMCJ"3G*%8EH!V5N@5672\ W35 M 5R/KO-
B&M2X>_L&*&O:[0!CM1!BVY_X5*C$^=)7[I <:@;LQL6>)WOTVL:9 MT&$6W?OV28?56PGI,%XAB:$ZR522??HX#GJ0N1I,JPTC&0T[>K/D8>YIV
ML_6[UE6G::O1U(8=>C3)&.+Y!(Z$GP?T_CZEAJ?.ZI'+2%SAI.F"UPH_Z&SO_=YQ M!;ZT*;PV32U5"9%R>K=9P,%282 M81;U(KLFPB4^B[W"^504DGTZ,TX\ JZ&4<.<9:
[%R1LU\;D6]\U6K557N19J M-+5A*M?BW"-$,;D6ZNAJ2:S#9)]S-8MBVFB@NC[=]XU.YU0I%K*.*!MRLZA/ MW0"Y*QNT5,K2MP^53&2>O V13F1Z0]W=>V,HU=E"FOAO-
8L"U"A':WK>!*._M;9>GCV&ZF/^V(6,KYV[*.>V)%261;EI;NALO*[3\5;U=A"&>'9 MI5H,3!NPJ1(LSCRT6\VBLF)):/<^@-C6H=UE*H:$N0HR>_J.7\TX#]K+HA9D
MY[17S.5CCSU1B17*H;$L*-ILU3M:K:N1]PV-?[H@S19AL=*S4#(DYV"K65,6 MYT<@7\)_T>YY KYK]GUJX(6:;? MM8#MZ#[5!@/:W[C2+9>O'IR]2: S*!J)HY'$W.1J%J=1'
.13/.;KV]EI!7Y MFU>=O-N![\)=[:'6JFND?<]E?:U'>E\T8^V&;(8-LF-[8\73K,U#L&'X!?^-T3'M"#=$1T+$W/F*Y*AVK M/'['@+03.P]ZO8VAU*)T.O-]<%=C*<293D3-X=0=Q
D!/YLWP>?4/D)/M=Z MP2=4A;16XX!*D.*?A^6?M_D8_KE[7\I^^&CJ8*$ (\06JM0%Z^#D/42RUA0D%PO<9E&2TQ1[_B;WJ*J M)%:A=5=HS:*TY?
31*ID$/'E[8)4$[#LC2GS]Q]YK7Q5?2:;)][N$V MGRYKD0,^"K!9E%R/+\>;'[3]GQW@@[3V@@(PR\<:[]^)2BEPG-B<<-M%L4-VP)Z95EPOEB0 M#- 7\3(4/CXYQAN[
)_U)XM^(G_#SX;YPC_%"IU_SDWLGQ^GDV!SF!$L0JX(ML3*+OG'"*&1NE-0"+(K8/D4'04S IS>D1.^#SC36[3?L.& [/HRFN_"US1R= MSZYN@>'G^MCMR!]2CR+V6+J&CM)/-
"N FSP?OF"'EER%4:*EKS7_5BF6+O)" MXGVFBQF*Z$(I;F5A(TG?TCT Y^/GN]_>S0,OG_\Y+D]%?,/HG7WUCCUN[GFM M;U_#!\8M^LP@\9NW;*^%,G5_6;CEZ P027X=AGK?
8^VS=GG7T6J_7=;N>UKG M]&M5_W-"_)L$!(VG9O'D/*7*F)2A]#F_IYG_XM3],2E=[_$+<"71B=V 7 E M9X85K\,W9_:%Y""VC%'):>R^V='N'_XD+>U;I]VM-[567FU2;
[>Z[8=FH];3&D%WY-H#Z?;@BZ]:J]<]T 0;6EW[>J=U2*D 5@5H M:*36:N"'XH$F]+[9(KTO[6]=F$0WJ]5USC I#S3;N M=,_T\!1-D#RVSW(0>O#@.\OI?W_'U:)BI5PH7.??$?
BA/D8FY$YHP*JS%:IQ M5N%ME*[(KW04'?$#"-$AK C>4OCPZR]T](GLV6UJW2QI:M]YI/O::[584 M,GO:S>P(:('!Z/[$9>T1'?=9M\W_L6T#C<(@3V*3C_I](PSCOQ//-P=OL^/>
MFRX=6&_PT(GK>'V3VGT*'-_N7Y'WH$*QLSB+^8]UKG:QOPH?+]CZF+Y'7H>. M!;]V7FW0K[S)DV<:)DP 9AGW8/+@&_!^V_!#HGM$LT:F;>CL^D4N M_#,!H)S#
(D1QKCFBDP:U]%?4!ON..W9X1FO26/B[BROV)L%7==W6Q15\(OL3 M%C/ZQ!Q3.*G]K#^S,\90SP1[XH5:#CLI-X=T]YWR,\?@T8:)J;E/$S8;0-F(M&NCXPI^8?51?X1Z?]H!;8S
D[[H MUD0/GHO30-W8HC^(C4M^.1Z^@;D$3V7CL40 X'0V9>:-%_QF. $@D2=7-^VK MLP(YQ^(K ,($TQ., KB.L2*^T["WN,:PHB.\F8/="1.E$4=Z=-N)L$L0$8FH
MS=]PU(+"2EVV X#:<#>Z:)?@'TW/U:F5XW26^$CR57\#?:-0SA'V9/XVOI@R MJ %)@!1-V]Y@<-"A 7%K4][)8J:9O.K_;V+-+#ONWK>K[A6Y=QR.G88[>28U M]835URP(\%.
[QNUD)7V+0HLQ4A@F'=(G?"]_^JXWTG-UJTWW^Q[[)CDRD?R M_JZ%3RM7B_"TL3A/&4.?TXT7? K0<$7:R2_6I6,PC9\ G 6FT0VC0Z.:Q0DK$^PJ<]@AQ*PM4-
^M4(!!/K'R(XJF"P*-Q ^>VC^O7K+^:I M+LJ[3U%]0\B;B)01E!DR_E"+<9+)M#9V38L4N=%9O&(4>K)+N()E,5Y\S5=" M,*NH0DF>:!]1J$\5U#=3%UO&'(M+L? 6"?
7WSEZ/:]KUECDG/U6V/.Z,#'GJ\ M3''+'8X();'/?)N1HR3]KMWW'?Q5L1S]%NMK&-YG(,37S>,7]FEZ,& M MLIV.A861W>O522YY#IC5$#!\7Q[51W,U8.=*>D03HAYP>Q?]*\?
Q7CTNT) M,J-B989Y13C(E%DX$]_S 5VH*74I,[%KY!& 1EW4'KN^T_^>"Z[<+;U27WJE ML7@%P2RN:O-7<4[+5=871Z0;B-P#)##3C;S..'R:QYX&]JD3N8R&%TA ;_5(
MW\:.+2S?J"WL3[EG+N'70]T@R^.7Q=)M7*L2%K\L5B)!2X;NA37^R?MFSQ&(M<_H;E?%PS ?&&_^D&<;(Z M!E#:_8RM1^F=\EA40M!P:Y\93QZU;K,_B:SI2GE"K?
57#DFE!M9FF64$R6O M4^7+*]D1\R24E[$BI*J1_E_'14-OAC6E)]:0+80JUBQ?L$FBZZ' YG2Y\@[R MA)YX9FB*)PLU6]BOI[O#3>2%@9./O)K^D+WWO$*96V5>S*K4[[FR=1&
[L\); M'"C9-E>+703">_,BF?0LG$T L+F:C4;%9WM@R?2Z]F*,7U_E7#WX4C'?IT?ZE^>-R:!JP MJ1]"K-Y@I+5RG8=UQ]L_X5ZGR5IB^Z9;5N0BSX9B%$/YB2SQ CHGY'0(L. +
M9RQ"&QP2()6!ESA]'DL8NRQ:-=1?*'!Z:L- "A=6+)$-W#1<66$'\1Y9;"B MK%UP +M42U(12Q*L2+C2;))LI5>A= ?PF8EY;N&&ITX)GOL',)D&GGCF!HD(PBTZO1 &E=ZW:MU&
[5\?R!^U MWQN8EF #[/K,H:?[!)CR$#@2(SHF"($W8=AVP(*DP,I&<]LQXX45>U4++H:# MAFJUD PY[N@8/8&X#0/QNFURNP-8'G#J2\Z_(FX)+MC%SXPP@/QJ(EMW^A-F
M#HDF7CNYR<>CYS02^68.U^4F!?<_P8H9+!J"OVCIGJ'_1>KZV,2V+U]9@/-T ME99OX5(!@$>A%3X/S!RA.NP:UT7$/?-@6&*MBQ &+G34P&:4V0OIC'ZHK,BCA&N4XP
MUT1A.M+?@OP??GP',0U*,'HG T&<'+^+II30/2 M\SQ&2"O.\&.<[,CMO*C(E00M<\Q&2A(;HERI04%)V"W@#^ K1&&@9>*1J&*A.\Q MS:H84MWX:Z(#SP8"#9YK.?
T@V:#GN+!:P([;@'K7=/B^SFUD5&P_T8CANRJ[MK5@^\4P$/)6,I>:9OSP"EX [;)X@:@\L$Z!_SOI\$&ROS&CSJ/ZZ".K$=7MR MG>\451 0[!Z#=.+M@,//^O_"#$QD*9B".;$,[J+
00WN-S"!7/N,<2!+8;H& M4LVSY3S!1YXBAXQW"'P")N#.9'F"/I7PQK;C<*8^ M6-O>!? T4,V ,\- +CRRCZ:0C]0+BKS!>@.SI=6%^H4S')!
M$M@^%_FNZ7T'%@&F!TPBM[@!:%ZE62&,L^H$50(7[9'IIL2QU"#Q?E^*_5SE MR"\SY2%[J";I3IY0\|8DY(8S>?)K3T (GQW8X[J#^[&DBJ2P1A7)5GF,8?E(M-
6WY2%&4CWQNXW%-]7:KKG6.NVYD%6^L,BOZ)E-1?DK4I6\V/12@@ZH?Z*>:[MJ .:\V';W!!]_VO+?*30YF MN!C[>+_.>A4_\/5*7H7*IGW6][
*\87FO)C&IL\Z,V.GK6R9RBFDT[>"UMCU8>+J\Q5RALFC1L@J@;18K'>QN M=W<&\TZ6JAIC_%^ O3)Q47_(D5FFA'$E,/TQ" RVA(<&)?/F,.,1Q#G&:.P)
MG4$LZ"^!5A5]&%@7H++0T=@7/DUFH((Q;!LLC05HNDO,"L,8+*BK!^F)X?!MM"NR\,XPF3 M5[RE-Q7TQ$!)3W04]?%VY1.JAV\BAXZ=U,"KCIX=84ZC9L"63"=C%H?(8"\
M5VJ]4"Z8V7)&K%I4[]*V3""O%/1B[CEDKPI6JN/26="D\E4\H3<8FU@P(%#N MRL;=U@%C(LIIF%X?UO:97[!,OB["M\Z%,VK^J.K#ZX>J(^JLG@\&]3/,*E[- MM$Q
D8%K+'P>^!8>I6Q"@PD6)BP2@J]_I\'=@6T_HKH'-WL?]J[=L X@(D[' M$A+ZU++$81CAWQ[HVL'?<(_H3;6LX'EAF>8:J,S'2U>NVGOS8MKO:G$Z^L1W]CF=%GUVL$2/><
YPV7\ MCSO>@:V&3(4K!MC4_@5L8,?UI@P3]UBXSH5O[V/D'5G'F*!93+11C(),6LC(MA9F>_AT!@;'23T!^^%,U)CTN<0-Y7!P/L+3Q+69RU !)5.@R(64 M>D1_0L@$!:$
CF=J4U%Z%VAS'GK7KM(!XL0L]J_3*J#9F"F3\^@GTSV':R?< M'\Y]=RRQ8"8M3+>G&AHR9\:YI^R9-UP,(S!1?0[TCBB5,K[/0O2!S;*HD:C< MI]2Y3P65^S27^[0D RK6XZEZ
:7M!;38]:=F&UW81JW5([5ZO?VMU4,O\&/[H5EO:MV3=@/C<;ZL]@1$2A01)_W2"YT95[L0 MIKZ6L4O'.L_.8P]Q#>9M88;09Z:P8)H$T! =^^S*E)Q@A4UX\MB:%OA\LTV?
MU73I/L]0JC&ZUL,<0M:CXW.M]GBXFFH%>N]Z:A)?K5[/%LAU><85(1/+%$ MN0#%"X?)G9&:G+8B@<>EN>DYO2%R'-^\EAVT$(MV#>/9*-."BW!0#Q2B9U21 M@?
#YQ_/5<4<7\&,YR$9%'-@,#!L179'F (.L[!X6D @?G1@V"',9>%*43N"9+._$ MY/YJ3VP!+L53H .(#6;YM6S2&)'!+M:7(^[1$6B8)D7'0H)C5^>2+\R1F^FW MAPL1RM+ ?
O0PPQJ^=%SV4!$FF 0)>1ZS-_W@P>P6H:+R31-=XSC)/.D6"F O M2,L.,L9$0(!:)JPAVRZ>N#XE&"5C#R)CGV24L1WZP@B :\@F)77E9+[D&.'
MY:S>V4K=)77Z)MUS>YOC]P0E16+10/#DHCF\&0Q5R%=GQZHC?P?V%P3'-99F M[4WI[D] M#"A\MT.!&[I3 P")U,#7E(F%(0RQPFCBI@0+BK,Q6P3=MD%A(L%1J>9(",D<
M>6*!>1WC+"ZF=P;K*-*"4+*TA@'D?=[95FHH"!$528Q.9YZR=OY3+-,M\WF M$0BN,?C"+*VW'"X^,[&QB,MC];MA-1=7!V96)ZJELZ89$U2LYT@<-_*X,!J) M[FFNX.-
>E.33#R,23N&ZZ*PFX.9CRA'R@% M7:D<(-W[,JH'\WR-QB*?S!>AUO(>P\Q9H7A#5;$56E8_UME@#WKHOK5I\)_2#3 M[Y)/# 46;"2G"K&I.?*=OD5!#*_!W#-
,JNJB%H27W[*V&G..,7[=%: #^AE0 M,SRC0!#",UC? !5^:UBM99F#\&'\SIQP*>#4+=&W*[8Z>#J;2'&K-;"M?Q?1$NN5L/J)0B[PYP F6SEH'"U=$
M4"+0'#/',!;@C,P^6(\OINO83)T*(R0SR8#>?!C&]%B>^H1Q 9-S#::G&8YE M@4'Z_MU/[] \?M=@?[\3[OS9I_S3F]5ON&9$F>P#HG$"QS#,"9XM'BVB/5/W M=,_[!C'
6)RUF"CA\]H_8UF1!G7?BT_LB4F#$ID>LT\8#BY=YS6\-'\-N199 MG6RU87Y5),,J.<>J&,FQFLVRFDVY.H'TJPWWJ->N/YCV]\C21A.XTJV9Y'VM MD(H%MQB8SRP5F1-
^Z.73/5$NX7V8C1RQ<[:"N%+0Y!#;8LPR#<$P@B"7\!SI M05OIL#NBL+>NR%WP3%8D8E^*Z0EV$L3+ L$2]+<)AN$!LJ&).??L]"36<$EX M/J-];40M'HXP J3ZR(SQWO"/X-
T.W?E=:4&@<% IM:"IOB\2^9GT/FL])Y#R M$W21)&=I#,'$B.1I1*RG(?R-\25>0H=,&<:*^H$HZZ"YQ/^'G.?[[M@..S!)SP+?G$4FTBP4T,I,=@7G0HKAG#-:/G9,\+Q9N/ZW'0 M?
4[P @I[&V*OF(P]1R2UZ7: / &Y!02).(@[MP\>IR?/+@E9$+*(];4QDB_,;\ %C2Q!&,M^R,%ME>J*G SA! M7=;FC !W;ZR;O!DKVLL8?=1#SO F6APS8K?
>9CH)/E'_E;73$!)41V(UQSJS MT&L\4)&+JL,X>7&W"+!%32(V86\8S#CB7ICVGIT/%L<,+=Y9G#:*B\1]C]/7 MC;R=:'NINRY+AXK$3Z]*;Q@69)V.Q_J;N"?TBV#7:G2J8L@W2)/"-
WH3C:!9CUX3>2X_!"#2@%68 M"Y$U-B8TZ*L+:^GZ?!8C/ 8].-B'9?_8>$8;B[I>D29+]2<>@[,<5 MQ9KILK=8NCD''?XJFC(E=@ZS@K"!G<\B2F@:\ +;H'.)-UMM,)VT,A8.X6(9
M2.YBP8AZ'%S.UMV"':=B.=0\-YIE/.)[GJ'3][L3.IDY7\S%;#U(E.&]0'.'0'.%91H[0B8)Y M2]K?0\>%?8W[B&J2H-XP'SNQIUA8Y\;9PE"DG0CM*;?$',T%73"P?0T+3S/^ MPY\!=](?
V,'$F\VA-NT!T#WKQ/8B:J6B/S-1S_P^6_K'RJ["!HI!Z14H--$7 MU2W/X<50!CLE1!Q!,'W]L,XLVM^ZZ#MS['KZ.77T5#-%FY=0[D\8FPUP]ES4,%Z>Y M(=D:[O]G[UN?$T>2?;_?
OT+1NW.V.P(\O,$]>SH"/[K'9[MM7]L]<\^G#1D5 MMG9 8B1AM^>OOYE957J $ ($*J F=G8P2*525;XK\Y?F*X\2HM\L$W5$/2DE M;D?^(Y^49>>KIL5V%-D5+['C(0%;B3$AY
ZGH_B,PQYL8+F$4;]4^%RJR)?H;@-WA$=Z,F2)WU"#&@QE MBHA=TI+QV--T9'I4Q_9BLU=AUH;S>XR$-#_L'A \ITR]CJ4.X2M[HG6+>&L. MT2 RL,$#ELF-*<'#6)1(@=))GS&

((9)R.>R*44%C1DN0AKH,'CX.J>RE)S* MILZI5#>G4NMY4*G_45'/G[MA/5\|$GFTVOY4Q_%Y M=(-G1.=]# /I(>*LK.:"'Q)FR3\2];("=$A8'0NF1">4HC3,$B!:0T9-IQ %
MZ4V\:,Q<$U%D?*(B8'9/&?J?7$4PZO"&K; T1S8.RK&.P(/S9 M\,+H[V&'E<@MG3".?FX^F1BP3^P^NIP./H.2"D 1V.-5;)V(N&B58H]/U-(E
M5U;B5OC2RQ5GXX@E**J,86;S+Y0ZUUARZ*+18J?R%(,;V6QH^-A^(C#B5C-W M)X M:!G+XDQ\'SM0C*6=.#/^)IU* M/B24"R=W/T3$= ZZ8!I\(QM:CD
MRM/4YF!$(+LBH)T8^ND]=FLV/\6<74]I_Q*5]CRH>2-"YI;24J4.QI2YXB[J!GP7MD M7]^KMV=F!3^\T$+RI?Z564 >3RM. X9-3(-[X4MNZM;GD)@BE "12$<=C(W9
M'U:8&3PD,3,1;8FH,(HAS^$E8EEVV.H[-1T"T7>P[1&==2W?*O&Z8\8$8@;F M[H?]+./)8JN-&]EM.+(9E9TF&D!18$F [M&%:3-415SDT[46C.V9#&.]>@L
MCOV(.I//1ITP&W%!IW4DG/BPL2;:B:=PE(\X]J;,@A2$@3$Z2C[S&697RGPL MI!TRH0>V-YB.?0Z6C$W=@0H6E>Z+\|M$\]"XP[!P:9'<['B4;29ETX\7C(") M-
$03D2IZI>U8258>B_RQ,*P?Z[HU)S:Y;\)[WD>U,5$=,7DLKV'KL<0&QKK< M8WMF3_@KW#FPN(R?D=&81CA#?P,@'83&6KQ %6YO)IX=MIB61\PR\,K!:\<3
M<%6X_HBUC\#^ M&Y>ZM-\B' I,QGBN,.,GV>80IGABG%-E9@CP%#D^252-5,T^,_N!^^10QA+M M#M9H$=.AAT+& ?HZ8KXQ#SB![*9-]%),])&*)CI7^!*_YVB#4G'#_(FSFY]8
MF1B8(!M/1NX;"\&[,'>(>J")SHP8E/!QK<#R1'BEV#C&!,0$!ZI(?"T>B5DT M0E+ \|)V:_S7RFRNSR-9U\#9X12$_N3)BB!5N/!=,-]*"JP/&?ZO.*P=JPT5 MXH2F0;*-
CXNR)QR;BDTGRZV:R A%,RE*HL\9G)+2FYN5LD MN/Y2JX)41,Q-[H!%/6HS.R[(KL!^P";Q,GMEF3>S!>2N&5RQ]K("J/U-GMD1 MR;WW/W"BBY(^*GM>S*L8#2A,!$(D\'A*+*
<[PM8L#F<8QM_4RF)U73!P $(1:U*(6L80&L(3TY!DV][$P M'JP(BJORUEEX<.4/*>BI1,"YI_!UBS,75;4^DNTD-
L/*MU16D$J7/"FD(<)Q\9&Q)]+;4NQR$,RFKPL>IB0'P<>5F3RC!%9 M9ZP,>\$;S,F)!=?!Z%)T\.IP8^+:'+$8C[5TVGDI:>F;O)4SDGR8N1.8/Y@O M-0X3,#CR]E@2J1G
8=)E41<7*>)PRGHX"[/%;92.11QM3L970 MZ)D5@5P2IPNT<"WL0*2\HI2D/ -S!&1/B$IT9($B]D1D8LW_PI[HPNQ"R]2[ORRQZ&T4(;#,"#D\AK!>9 M#,4-
)PY&MM"^BEIUKG6$(9I-$O(9M]N%'+=F7T2FX\1;&/H;]!G-<4K*YX8' MH)8'R^5@*6:XAGF7+B/< 5[%<(A <(]OX6LFLX$6Q4FH"S*F<8W [&T)"Q% M$KHJ2L*
[9:UNCU8T+ET9LHC$'\1]8!U.208)[$,4I*(1CCVBTF[@3Q]])X\0 M6W(@ +8ABG")UF7V9?8 M%\&S[5D1GIE-@3C"&\:FPY1R'79@B(?#/!=S!1$H-6WR?/\%)*)\?RO>^E/4 M
)'Q%B<<<,B>>-Y_'1MJ"]RN2";QWRF/GEL=/%,Z5LGX3,6JX\@S-N5LXT#* MX4RC,MM'T;224,*IFVO S3K1E_G$Z!-0D1_$1+)XI5A2/AO" %%=&/(:+!U MT\D3 4Q29K?
S;,I(;M3[*]9Q,)Q?A-<6+>2)<1Y;U91%CW>/AM< @Y:PS;O"Q*8LDI$DD"8X1A.B9*:3.MM\5YJ!5:& M OM3105VY0 A,1YT.UJ5%5\$+G-X%:60ASS?-A#U=L'/47G;F 7/F)+\G4[@
MZ,R/?U6)?&<8=6'#:2\=UISW?&8$!BZ!&*.ZO9D&BC \WKBL&78BF!N]$7-, M7FH.PWAA$^Z1^1J+M,[4H^-)%T<4"C54?,*S=Z!3[:$"N7*DV*,Z1([*@,]%
M,4SZ@^,>C4;1_4GL!BYP0^3.6 <->HT0_2E9%82/@!?"R*BWWVVS5SJ(MMP) MKN"RNH%6+9' *ECA 5EAU1+55FVF>);'KD',>_R4D\>4.+V'>C4LDD1"9@X; MHLHB+
5>V39#?>$OJ&6):AF0B!-K%! J8CM%RZ?AF$C^7?Y^*8?$.5$I9(Z% M)$CQICR"96+IJBR#P5\)QY'6!]%/0I@1@C,9V7\PJHPP,V%0PM*.\$_,; T M^GR@(Y.D#W4T-\.=>7R3-
Y&DB4Y5*LFCH(-GAU"/DOB6\@G:6.C%&/#4]'8 M^,K,8PY^]3D?A@DM875QF#(2%RQSN2&)DU7\@. Y6&V/JYH>^?^>'5VO=W@* M4L9%M4:RP(%OX:JP"JU&1@5#: %%KXH
&]$I+8>MYJ_Y^!85 5+X8#BW+B_L MC:L:#QVP6>AQ4:-N)HY-R&ZJD+%GRGHVW!R, ,SF,R7.OD\,OB#<-(F*BP7. M"%:NAWCD_ 40>4ITRZ8ODFO!\-
[7\D>.O>3B:B1BQ7U),$2EN<^P>:$ \80 MA6ERH!KO\2LC]I6TPD1I"ZF79_.%A5M$U[J9,/+U1@+?%^NK@=9YS-5E^=Y? MHB!C,R+.3HAB.?
5@JWS1O]*A'D6DOZC73Z@*\6E,>LH2@RM4P&X(?C5#J'FG MQI>#(*-P+J(0([8ZV Y(FJZYETGG2962)]76>5+JYDEI6P_,*E]%6^]25+"' M/MW1FGWWD5)ELXO"$\#D'VA>
<)]Y.$4H@Q#PAW*LI1\LLHVSSC5>V>@E":$O M3$WF6/)CY E3I;OMQ%+-QI2M07>!L35C)'=$LA8\O#TQ"7 THELLW\V-L(M!5WA[01-QYG"LT
)OLBO?'OPA_SBF9FC@)^Z1LE\Z*6[W%G'?MD$1(.&A_TX M%2D8/, PS/ZZ-UEC7;:$3#@ MO)AC/NL3Z 8$A/UC9N[<:*9H#EF=.1JOAJ2*GDS@3?FA9I)>X6D@@SR)#Q9[
MG'"XAM-5;'4$/P/90S N8G0*\|Z)0YY,B[%I-_HU+'\0\3P!BH\O/@%7S1,> M&TB@\|14Q=8LWG+;D<>ZQ%_AUF&DF 7"A^*SG<>
((]PQR44*+JT%D9YE2@HCEUSPBA)CK\.5ISZB8,J/A\ M3>0Y&N=RG@#!H?4$=+-!GB*("LQC=Y[,)YYW8CSB,1C%'<+!]8SXSO.-Z4AID^6%WY Q]>R^4F!'%O!&
M_=E([@[\9YD\LO_=L=$ZN ^(.S$RBT=F Y,8E1N0 MG).C"BSX@: HI3Z*XD_I[@O(XPAF>WXLZ)F$Q1;!] /.[6,9P41X ME>LIO3.92["P=VSXW^^L?V-
)0+56A__QC_5&M5E_9SCF&*8U]:M/ICGY>#]X M9M9TQ&Z& F7)_^RYX\L?/"TK1%?J.]97UWGZBK45?5JOL[>(6,U1'ZGU >GQ M
29P!BORQSO#MO[[W:#1;=7K]>8[<)T&Y@3#9=Z4R="7$$4YY4^"_?[KSZD; M_#*SH/S+&4:<#V8*!C]M@QSCRUO%P!W*L2#\QN/A0B$%YF5;4;-)R,,T@2FG
MVT*Q6]Q3%\FU318V0;^&(& C'B"5W"Y6F2]Y'MF7;XWJ[0-8(QF$GULB"806 M+8U2TT,IHW=M#W>MH7=M;EFNP4)0=,>DX:+H]
(0]I>CLM)#2Y'YS!_[7;'[2YBY/A#FS9(DAXCY\]@5U$_EJ]WJUU MZJ>=QKL\[N2_[V7";\(;_&'[U?/^.V,*SCG=_OW^8M;SE/XFN'=P"_P /N(/
MW_[HV"/A)/[\22%>JBJ]6\V4W6I$N]70NZ72;K62NV47PU \+G,=GH[IK2I@ MJ]HI6[4Y-QW 5NW:BFBWR8#05D2T'8M"WV4SE%(F&^.#_]
[MJ\]VG5K='Z9FQ%RC=;\UJM988LVZ(#T&WJ;=7I6F;($6R5#F:4;H;P0_:RV6=?C(YN;5.C MX^KK]HR.%E8P[I7-T:UO:G.LLYY[(ATU)V913F,M^V<9N60IU15L_V:OHQP?
M[LW.-MF;B4+]$7%U-0[-N"(G03BQ"$$ M7<=%B!7*%S_:5-6KS(JF"*4YAM",Z:.?^_=GLM5\/UI4CFKO6;[QG:#B8V@0 MWP7THX75AF1<5/?)23%$UQ1$'G25-0XW_,>$F[\W@ -
YM M01ZBP0-6/1#@%)56(9H'XD\FRQ*>LZL.PEHQ"5Q%:&J^H#'Y#(+499B/[C2((ZC*(4*<[,,E0)09?,E96#6>6!NL]D[(
MLU@MQ#_\L&_[,H$VVY.@%>M)$,3G,+_9LY/(KL9'<2E$FRS5?108P-1:(?!< M"2V,=$'57\G"5OB+^>A:E-!EH(PRFBP1;\,E4K 7(VA$AXF5]8'&XRD%CZ>C
M\7@4P>-9@,J3YOSC-&DZ_)[_$W_6YI5A7UW3\:_!]O,?$&2\[U@WB%QP1QUV M4 /[D7)/+_IJI19]%2;\(JXVY+^],)WYYN$RB^!;'SG!WSS\>GEGW%V>7U[] MUC_[>GD?NK&'J
XN6&#:(\P4X2B_7K27(5*[397,O+AQGPH:37LX_,A?T+\9 MSI)J1FEB.[,T<850E! 8H-7H:>FQJ6Q!OD(@-3O(%%GM9$X:KB!DUO-KVU\4'IP-
8Z__VNLUPM%Q$%GZM"52S8CHWH0LM^871R M.]L1'O%KHBZ(J!LE$;60IE6^/7#9Y(=![@#E5M0J!O[O@WJTGUDS5M@$A6Z)
MKT[^%=LN*:T[#4UQVRC*W2K%+9"].Q*T:Z1=%?9H8:=UP4S;)3W$]C[\]Y3H MX&;62,\Z$JP7>M*?+DZV*@TR^?OBY[;V.J#$YQ)Z!_+T@PRZGC2,PG(29GU
M3<[8T/58'QTN], ^N]ZYQRP[^.HB+-6:20;UT[3TD5*VTI#+9SM/65N>2 M2;89-4VEDRUZ%^J1K2IJ,*,(JC@F4D'UA61%9U&6.WT,L*'?@>O"S8S]TL1-
M[GF_SQ1+G4*T:=$"J9Z6K5>"0%I@K'_0+'! +- M1#,?)PNHHJ-WX*JJH:/_M^?CIP0W,T;)DU7T51>LS.:S,W_FJ[)MX@IEG"JB,DM'LW/E9&;6F+.JU4D31 MXH4NDAQ2P[-
'Z^[FIBAUO.+\3)#% 1F5N#OA@/II*I7JI0EF6BP^W0: MVGY>0;0L;Z:C;MY,6^3-?+VY_F(\7-Y],RXN;V_NKQX..W$&L:]YDT&+40]> MGLEH^YC&Z%(G)^RK%/Z(0OOJ5U(-
W"I],+#Q$5T\M)-=*D7B#:7=9#=XG,NN M;4;)M=D9FZ+EX2OSF/%//)&3UU9]-JC:/ZK/MF4QYR.7"V['!M,.+ M>8[MWQ>+1;AA;;%XP=>,CKW3Z=)+4Q:J;=TULJZ M.8)#
MZ7C*$074Y0!03W\1M('F \T'V^G_P91ML*$UE.;,(^;,WZE.6F'UA V^GYCQ MU1XRI?R]P\|#D24+[49I)0N,QJM@11U#ST>S0),ZN^V"1#X-7TV,ZH31/ M$MWI7N;0]6H9P-L9!
[EG;]_,_[C>.9[C\#9;[G@R!:_D7A#-S W?Z# J._TD MXW$4MB\4O5N5\HE2TU8+*O%0@S&79'HKS)_9B=Z]^EZP:"QZ'X^2+V+:H?V# M6=6_F.?.\FNUM+1RS;%:E6Z@2K-
Z6*C#I]>LV#88JI"\9LLMS$AA3LQ 6O_9 M%#F4*M=BE._-'FYU9*PB\X M*Y_\%N9;:/K83@KR>/^3Z5,ILQ=2][M!\&HAHN <]3R++K7GSYB>S/L?
S9ZH^++$0N8(1L:A8^&2SUF6F\&M:\+?.IP M1*V.)E-OXLIJ[_CUV'9J(%K9/;)P;,MX?,LJW_R_O/_.DI+O5M0=B1KPF,;4 M9XBA-[*'C I$<]2!UT$8#T&VRSIP; -
UV%VR8&=XE7Q&L7L]S<7+5>R>HB(O MJ=TYB%E 8W3G99&EQV_?P% M>PR6UV\:+H>MATC1\X8,@OO7L M%VP0>FY.; S,?0VL$^/6] *'>?ZS/3'>X\J(=HAXW^UY^$4=O_A
$O0&[!'3 M>'AUC5_=$3*KCYU.9V^FJ]Y].."U?O?I)KN3Y6?VZ$VQHVF#2P_1_H^OG]29 MLB,=MF+$=H3&O6TQXRL+ H:=7PVRU5 I>J;M@^P"8P@%&FS?<(H](T&$98*1
MU-.\F;HX%$,6OW)\8%VT$NCL"Q_/G\Z/N?[]U7;8S9!#)WXVL:]L\$97_CX9 M8!\L?)L\)V+)9\%(C->*K.,6==Y]]E=JM=J\F.<--4EK<4,"NW+:5M0B5ZQW M!<7_!&@?%Q"_=^$];
(=P:QY%\[]7N$0T"%W:?['.50.9-? *4_CAS:">Q6)\ M&!9>FUH[XKCP'MC_5UA%,+?5]!"G).3!P ,C[YD1(8 M!7\%V+>8?VOTB<[. M/O 5H8>*-WJ/WRY6R0CLE3P__M+1L@
EJEEQ(?6(Y1U$A+.Y/K02?A-\/?^8+?>'?H@(J3 M<8<.R\",PA>!%[\/P"805_H%KY4<%NZA*?@WTX#:*W.\@G76J]7M+8-'2O24 M1L+TJ$^L,
<+"=5C&>:+.7NF9["$KOM(E$>$7TW9\CH-[XUPFWN=FB!-9;W5) MB<&G=Y_:W12BQ%;>J-&HDX=H2?Y>M!O^($6&.1CPI<XQJ-!+A
:4*IX5/K=@\1WUPG]CU)$R[FAYX[!DX3 M%RUCK+1TGUUPTRWS[A' +ENTQT3E>?C^M_AF]05>;19W75U_!I?FI#W/5;#2 MVO<7$//,&Z#) MS:F1C#9NDE2(>.6=9Y%A0D;6
*VBT6@U$\N(]02WN6 +K4=LUNVQ,8AL%(G) MATDC*=N %#$R"EAQ'B.+5(XO[3IAY\T:<<29CPP?'JD^7(4EAML<=^/U\^N- MYEPV
:=Y,+L@X"V;;HW*:7,MTRT=&)^OQP&;;NWV?#N<)98;4.9?9+L]F131 M7MEVZZ7;;K34)5'AEFRW3^W:/)BR-MER(CCEV""!31D/WV MR_7W;\NQ)!;B+]K]<5L_N+OO_
MJO8_/US>?02M]VJ^^?*P$I,,'998JU^,9P*#^&@T\%1:Y%7^K4;_I*5 M_9RZ2[]>I.\2'G,7LT@+5_?K+==^8*PZ WMB MCO!<=QK%W!PT1=&&S=1WS051H?
8")4>/OWKY.I$ZSG6>$!D<+WUXF[TPV/7 MEE8+[.QV2J186MQX- U61""=4EHI4&D>+3U8K08ENQD>FLN9BY=6)K;MQ;N= M+G.PKL3[W<'\[U$?6^"8H58PGUBXGM5&
[@6MPWK.+^=/Y&*9#MS("3%U63&* M+%;69V.[BM=3*@%N!OAGE'Q@3,PW@AP6=R;"Z17PKT8#@5$G+G@T?9OB$#"7 M*8:507$8;&1.?&;-3 :NRZI;< .NQ>0,P, 9F/ZS\3@-
\.0E.D688[/DZ[C+ M@BL.,YJU7(#U<2N'WP ORLS!,UE)_/5&KND8SR9*BKFSAXRA0:-&CB'W"\.H M/AI^L"M@M!&=!_*P(GI =EY&./;8]81!A]:=F MMHA7*V@6BP<]I 4HI2(GN
IL-QM' MKL1<(XJ6H+A_X!)QS$QP"YRF9^Q(+ 8#@%,(-Q4_EU.)B%; AWN@_= CPQH'04'?S"Y\,:S.P(+
MG'MG-.,I"!_V@EX=?:2S4GX@1YF*XIFXEL#U)$CX5&G!Q6B'FS=56&!]HT@Z MC\U94[C$7C&NWEP07SHN";$LK-Y,Z_Z6$0_:^U6:CZJGQ(O-^)G\X-ETGD+5 M%B-
=;E141+)&SGAS3+32@V1(;^Q:]M >F#($G;UKIVL']+;EZVPKGC=_SGVT M,O>>30)A0]?F).^AAKY*Z#Z@]A?7BT.7#%IKU=)I[;3:K,4_XAY' M3'KV]MVQ_YP"^?
@#SR9&B5$67L&IHN]8TK.#_[KG[GCL.A317Q9OGB'D&'4N M%"S1P_EVT?<07?Y5Q2K6%NZM.N5[NE\YRI@>GPPDV;2!-Y"F"W,X@8%>7X#
M>GUQ5?)$>G^I/O$0Q'Y.BZ!Q.L0[W2GFV;\ 08#U<,Q!M04FUERFY9B!9K5&FYN^WYU$.)B5>GAC]9)AQF@54&?!*V,K3WM9;*_ M?8+U,>J=92'$>?MPY,JW#
]BLP^1Z^(4V7;("9E29;^@-H-$'\@"1%&@WH_^ M=ZSX@B4MA("C L3R!S-5=FM!FLG!_XQQR):=&P\.L3$
M^XRE"EY=OGU(S!A569170Z)7U)Q9J;'4.8++&U2E>"H7$FRY=,C*%]F2="@G MD+I2$-64"?%QW0@L[,K&DHL,2EIX^$\ Y"ART>76B@MYC&N5J&QKQ6C"!DI.
MH0#"9F%8'8'5$=@]B@8LB#SM*!I0H PI,4I0[_4JW69K7I#DBP3PHG.\U(G M(04\PQ8^HF,6QA30RV/#$0D6=&!2X@_B7A0)]%@9R'0'($(\;B1F$>"U^\+I
MK]$\@E*#U*R@\]E@<&3XR@,0,LMT'"/?49%EQ?*$XLN*2@4X$6/EX>7_X!9O MK%12BK3JT&/<9)6^R72"F>@,7AB[BPS+R O2EU2Q-42Y\X/@8PK>%50%=?X=F^#0=':-3
M6P$=8RX%>Y,>(J=Y03)Z B3CXO+SY=W=Y85Q=_G;Y?7WRX-6NU=Y81MJ]=.4 MD#K[:YB0/HVTZ=OIV1:U4^Q/K'1^S=''(?9N4!_''7\[NH;F$E?/'>+3(,D"?/+OX.')L;
[:YB.=]:T3I&YC55([#5?! CH?N9.P_!\]:>%F4YX* M_4">YMW)U8F!;V+0JW"4D5AA3BAP_($[0=/CQ1V]X!&%QTP^GF/)Q^&?9]=] MN*75:_QBG-E MX?L&"\!._"#$P,RQI7SM
S40L)$-$OG-N'\# MVWYLO!^XHY&L%N)#","2WUWO#^/6)Q\((^(54_>YHQ>^,*)F61A3 M@#]+)$4#649.A-8ZPRO_)<9CV/'1"^7H',5EJM+GP5AL%[HW<%'\.Y2
M&$>^N7AQ>&]E)% S10+QM9+K@K'">$6J#R-P"Y)"3#")Y1A#NKZQQ/K&GJYO M//;ZQJ62/PKL+I/]3AS(#63\;F7[%N1ZIY$JU^NQJ%T=CS?V2*XO*AR,#$<9
M64587/;G%'=$VI*'(_UWQ5LBN+Q!_7\SA>4LAMEH%(2C4U([,'S@ W]HXTD> M^&;@CA%!$)$_PO0XEU#^'C8">D;V]&?X,X9\@ON9S1FM?/'L_>*,5AIG@) 0
MY'RXQG\2/FC)25\42FK-46B>L FA 8F\R9FH -(N)5H2#D]EG;!R-!F,F7B9 MP5U')#UQ%QF>].\!H(Q]2WZ?N(RR\YDZS];F!ZWAOE.R!]O6".E(QH
M"Q3Q$'QL<7@D'XNFA$1RLJB*(1&$.6RG@+D@!DL,R&7W/+HQ)'7:VA%X>-^Q MPC5\P!.,](!\/34@;_R3>@4(4YP.@M"@%8T'PK_]B3D(_^:F[]!VZ&FA99VP MW[-
=DA5Z(L2/T(T:[W\@VAP$7FPNOS)3X"OMI]_=ECK6;;<_Q]SXX#XAH/]_MO^LL=S +;US3:$YVVZ0O[=7F&O?%5,7"9GW;V8^P-:.FZH*HNI%*U=*VV299
MYVXT4TZ+RC16(.I'_;-ULM^W;D6:O HDK\;VR2N];=*1=L&5\|=12/FH>.0T/G2S=20/.>IC2<495YN.;]61RZ_TSY K&,U9FZ MPP,M?)34<T-IF.LC:',VMNIAP]E/%\
MS[@(S*I+;O'M%+EB\EWNP]F>2]0='*@_""J9HYUVFJ+,&A'D@I3"1OF2'&,* M41&#$2\X&\-@SR/,2IVX/C!)A6-$>^%HL+RF]U8!P68Q M :(,OR+/BE1!!]B0WI3WZ;)I$?
F^^>%=LPF&*ZRL!^L)JYG(O>.0X_AA2C69 M">+@3X:'RMQU>B?79]':+2R%S+-_X2,P83 [K5J@6N8HKN<7$IA%9C9AM[V! M[4K%Y:1^!:*4_^"&;QI_47C/-?5N,P6(:VG3P6YG
[-B!R^5TALPV=99@O28 M!'="Q2.45\N9AQ8@%$Z/0H?)]G"6.L4[]\T?,&Q=L!S MIT_"S+CJ4WG'Q','C%D"WQ6T!:\ZF$ALAPA? .[@& ,(-1KP\@@!'?G$;;1
M&EFD2TZRY,ZUJ+YXBK5^#JOTEE:."1-GJ2DD*LQX)3I'4L4"$VDX3SP;AL"W MI&E$11<"C2-"*^;M/^"V(9CV#A8?&J;OV]R CY471ACD'-,X@E8,P9:_NHX% M_R%PP^J9Z?
QAW R'#&MB$&(Z+)/_>G5VV*3@Z^F4Y3NZ=((F^7% QQF8HN0VP]$[2L+.3!:!$ MT2?&O8U;0QW(1W;<(Z.5Y1M\CQ"IL&PWH $<#(89G_G^PBXF=N/^YG.T&5%Q MY
@KL8HHV.6(L5@)B#69G#YA.E-?UA[2HY)E1#GAO$7U8"1PJ 2);V6R MP'8 Y.XB/)CINPX0::Q,D:,)3P/JM!QVSEF SQ"PP;/CCMRGMQ"3QR:@6,+> MD_$ZG,XC
?!Q&RS@GC=\$OV8R7=',J@8S[0/.>K HM%#",UD@>O6,,Z$D!)X MP?*5HOG("K5E$"Z]M$9XFW-W2C1U9K!U/9P*3'H-SZV7#O^M\'N"LSG_GL5[
M\HG6\0<;NKLW1RQ%7@C+ T5? 'SS5T+\"6,')2_O[P6.^X#C%ECX30QY&ZX) MXU[F! 0LZ/Y2"@LU0LFI1BA1!*%D 4[)[J,P!&TK\-XQ_YR">L0XU;(3$OA M $Q=!&
N_^]W/)C1H98%H9:$;)E;@IG8Q*QD6KHB&%PY65C#M#"XLO5),R11<4W2S(L *"7&XP_A>FS=\I!T MG#[;CU$W-06*3FV1SN$]!Y[]R'&P,]>[E=
['AQ99K.WOO*O+C7>'QA,M%^=, MO#1CX<1].1MRI#[LFCI7P$:%3SDW1_"69V]R<'%A1->K8MIMZ.?U1']J[>:[;12VFOD.P.M:S++&5N++@E M7].OT[0(5+&KF]'O*]ZJ@C"
HPO76];62:^;T>*+:-!\@JEBD'1E1;8 HFD[M1+E+E=1(J5@\6ID7 J:)EK9ID'[<%:V $L!YT9GN5&M=^(?]U: -1N5=K-3 M:?92XJ19THJ+I8@CES+=:6J(O,C5VZ6 JIW4:FE Y0O
3Q>)JK#1IXLGD=0# M('L=.[6T4NNM$>3.A!?VX4RQ];3P$GW=TH27*TZOIY,EKD2GMJ"0M5%M-.,? ME[EN9VFN6[GRJUZK=$]/*_5FIOP2?
O#9G!\,LBR;W=+/[8M9KMT*K'JOG6*H MQMJF+B');Y1J(OR'-'JT'>R[X@M'-Y1H0)LY*'1!D593V&3RXSY2:*O2[O8J MO317=CF%5J)L9;F^QB/#=4TD0_#SL@A'-
:6Q7]Y.DG*'3_@.]S15@L/D.'W'N@WS4>B;M=LH=1?VA(CQ'N\7FKUB"]+)=[%B(HU>#"87 M[=SU8P&B%8N^4L09V:HP)":)N0.;4F@B!A(//5FL#ZC1NL6++=^-L?X
M#GLS^KQQ$T^=P\,;RE/A=Q!(\9HLD[EY:6GSAR\B%VX5[X4MPZDRH0!G>+16 MXS<3O-V%,ICR,5BFO]NH<5&@++:X>$P_WC'1LA;MZ87O,4:0,D^J:*]V6?&
M1(AYT0W^V5O\%X[N$/NB .KDWW]V/:"D%^RGL"Z5-GJMRFDG?\=H[+"!]4PD MA#";]XTG*]PX>W+_MSZ*,;KT79301XV YU)3(@6)I4GA58^*.'NDG9D&WCL$(H>1-
,)Z'INW)'%TG MROHQ+-3P2XWK!3&!;Z* MYJ1T[._PDS\OF#96F-U*K[Z@NR;.QJ\8S 1G#3_S5%X_$!9UQIJ[#N-"(HSH M"=U[/N\VHQCAQW")4[A_(I"O'!_;'E?
M']5GV[*8\S'UA<=E;D MD3_9RY.>EN&T\BCGW<'VZL5]K-7J7>3#$- MB!MECY\E'O!2JD[WW@I?N)T&?<&BFH?N6,>WK:>[1SM9G>)]VT[*\>=JONV\ MT"
[$M[U$O2)%O\AL\64C'9)2'B5FF ,"=#P*5X:2=W"*>1;HC6:^'A'7W,Y>[>,R%ACQ[@X?\.647#(-WD[A?'UV8%JQ\<,^)[):J9K+W
M9C2Y7,WH*9_Y6MZ(=Y56S@/(/A]+'=8W"&NI$?L^]8A,ED,O/OA!3*!)^&4\ M N-/)Q/*U>/EF)@=#W/#[/Z1I)6 =/H2Q[B1596\JUV+US!']F;\?OZ P'X<
ML>A9=Y@GMV"#4*_A)KV"^>(S9VY_R-A(%6VSDFU3ORAS]=///.%I2MPHPS3 C5D@WUK8H4FLJ"LUC0>IP$? M5A8\(Z=-'Q%>(+")G6;'XG%3E(RQ<;3V6J?\6F"?
Q>,'SR;/'ABZHY'[BJOL M4)XY8;YQX)*_$F<]@E8^[E\#ROO!,[.F86[6V1OY#>EE=.W,9I,;=I@\;6^U MP602))/*R^17'B_Y%-5=\S5K!>+C'%(;/HR@>>ZK^*.$3I-AD=Q<>A&(E?
RQ!%1.=*S2\6.%%TAGX:V(KFE4/F%55)43.+9A95 M=EIY9N$Q>$4GI_GDZ/A$44J46;%JSJX4/CFB_J,2;[3=^&FGK#.WT?>IQ^K+
ML!>+;)BWPS:.2QYUNNN.C$M:+;879^(L3]$(DV6J_?#MCXX]$BFI/ZL@,S21[IY(&[593,I$6RA- MI"I1SA$3:5:%VLZ(--M>&]H_F%7]BWGNG*E65=%$TY1<"B6G5>WM7-
P>%B6K MXFSLX#A"!6=CKMKU\$YI4TYF"Y8;2Z1$.@92/BFQ%D9D?J-LI1!:_@COOM/* MX=)B>BLC38O[9 4=L<&5<3B[._+=+-2;46ZO@/FEZ;H4NLXXSE6%KK4CH4\M
M,AR).?@B[4@4;KQE'*<7"])9?'1WWS?]<(DJXQ#\V(E*FT [-($V.5\MC XW M-.T7P@\K8]ILBZ#K&<1[\L1KX=HV?\L0*I^)N@M@07V2D/-Q9+C YN-,E"OE4O.7MA;ULEN'M#(T-
?*Q81GT5NM&3+>/6HD3)#]&(RF%I,(M@I;](A$Q;K]\?KC++"F44K=6^TE"$"9&>!Y6/?'R[N/L*.OYILO 5HP9N&PQ%K]8CPSCG380#Q$$:;Y6XW^28O@ MB)_
]TC;I5\OTG<)%5"_1P<_[5=OZ(+2TGI%76C+@A06QQZI.$.7<-1[3D M2QF"66:!6\X8!+3<""2LY&YP)TDXV1RR-YLK"L>C#+F=Z! #_KQT^.) ML2P15\!GEC1!WK_,(/
1$!35,"I!:49YM.!64JQ?FFSZ@U4UQ [[DQXLS3; M,Q!FG'G^?_VMUZAW?S%>7%+UGEA4AZ/ATI_4:,E$FK4GV(#!=OA39D88,X9#
MP*XE[J1+*]BDS8QUAYAXKN&9@0DR"*R,"HYYYCI3WY"EHIYQ@<#)]N.4>JD9 M[TT?%."0FC+93MP.$_WC7/DJR%P%F\2<>4,7&_B(O:RZWQ +/HL&W)LOG&K
M\9&AHAV1UES"%)P)X-E], M>T12!^X&A>UZ[$-E?NE-L63PU@B)[U,;%@:;1)LYLN$9%KTC/B%NG]+"U'\A MQ0]O#_>@?1$\K[-^'/@X_;[[%&((.[L?+D#U W4VF$')7\AGFL%483
B9F*. M1NT7TX_:%M!7]5_DBA7'B'##)&S(C",%"P5UHNGEL_D":V7[X_AL*;W!G]A MATY\29R>Y>9"I:=QL".HQ<8$VD^-= Z;,Q<=TP%3.'_PSB1\'V135**^^.)2 MPZ$8BY /E;
[A%;S0=T?B.@]L80?M1FP1F:2%C\!G'T 4.S9/]XP?C M/]/XE8N2&"O&Z[,]>,[H+NV0J0M,F-+8A=J^^B0$!..S%UR1N?9Z?%U\M(-E M(R^?#:9 ;?A4#(#

F#ZQKTU,)BX"H6(Z:#>+KF$4:9GO09>'E$?(=L$SC)W9 M%::9E8.HN\+P(%MAAG FIH^[W'&JO R[(WZZJ9*LF4-T)H^7;[LN[B)7^3 M+[_V##ZB!0-TC9_ M
/O,10T51ADYFQ$O)S<@5,6SAL?A"O,\ MN=L'^=[VIQMB"9"5$:EB=.-PWYEZ/,XV 4[19J'1AIV9J&4O\H@[B8LL;B=R MR\|=\KZ^(,$"F+5A#@/1#2O>41 ;Q%'D?RIGX?-.5O1%=#
(PG*)Q.3%MW@X& M>)RXUB=+'JBI:::8Y?THX'\0L[8G(W(&O=A0J78"=INT\?1_: C$WY.6P?.)EZR-*"*0P&W_/.6QY[$BVY:#AQ M) WF@Q
70/^A3=L?!$LLT_HLRE.$8'5P.APL&7A>QPG9)?X<)(QP&7%1I5(M\KP/;CCQV2G=L:?IB,^VOW"6OY"W$$HTL)"3[CL]#&0)NJV1/R%_?<_] WAZ MA4P2]*9']M@.^&-!
[KR:9/Q1&]MTXWOK@WR'V#I? M_AB Y_'$\I%%*YLLXH.%1,';B\7G3&3.L*TJ$#?U,<66U$ <'IN 3*>0$H^"
M<'E/\GOY:S;#]5EI,9(KX.%,]Q0K"O:4J'5Y;ZYHM@<V<3P=%^&2MO8Y%+!UEQ1X&-D[5!P4 M^)53[^0'3;@ H=;H\A7&!NJ(&>^N&CW@>P&Q@B80QDC(I(6&> \@R:VL^9_
M7')]Q56@:E!WD!T<*?O%@2X11D>A:J#!@%T(N=(@KC?]:M2&5@9R42&M]!AA MG2;;VSZR*%0L_((%MCY7O>9D @8).05D;,S;X7D,Z0.V>7/44ASD>VO'?E%L
M7COVNW#LY]:='R@FO?OS(_#N=5+:NT_8/U4GI:F:E*;C3SK^M%:<*-73KL1B M$1_6C1A%*4'94:/*)F&C\"$SH:.*,6;>$_/((:%9TKG9XQ3V#MUQV*1'VQ$) M*?L494H$5@J)
NEPS7KAFHQBAHT+F)0)PS1V'X;99KUCV>&53KOH\(H_@2>0 MO,\.M*P;69GWO83X)S=*NB?RP>*!VXF^S$]E*]$7BR)ZCSR[,8^3LWM_9*]+ M$*2)56R2OU5H%
<)VYOB[Z7DF:MVC+3RXF))%FJ_8$C.=I8P:@T%#W!?3*+_? MGL>C0,;[:Y1"&6-W:=P/E?F$Q>R2OG;FR0S71&)O;SRJ-B&5] !?#)Y97VY[
MOC+EU/%X^S@\49"FT3D(.V:=OA4NJW3E#)(+FE!2 8BK 2K M)5X-3+]EY9#MS%.596MWMA=KU^B F=2NK[AV9^#T\.?S7.XA-S5"FUS^:KR" MLX&:])&-W-
>/!^MEAS3U<0\473:JPYPR3*B1N2V:41ZSNB/'CIUVNJ>_K*;[MBM)L.>"P4E7KNT^7/Y@WL'T1U?UHO,]RA+GHSG8=VEDHB!O(:? :;IF77^+(M%[O%]PI_#,5,?
5TY4SOIMN>%C*C>XA1Y)4M;T.0/W;)LS_?O=>&54!**AW8P M3-ZJ9&Y((]>&9/G(1[,A\3"AB3X(VAT5X^KV!EVFNX<;?IPUGHP8Z@?A\&4M M?E,L_F3J#9Y-
R4&QHBY0(],1>6!#SQU'YTR9N]5)@V0I9K<23O?R+;H5[T5_ M$&8)NN5KFS8+L]$$&H6S^,%!)4ES4+0/#;54TDG,G)03_)9\(JJL 4R>1.]
M5HH2V5/=]PUM/3MX^_GRQ\0687(,_/"R+WM)I)*+:A0@"5F3<8_K,'[3&S.] M^.DW&]E -V_A,3A^F>V>B7- F:\>^$T MQ>PHV 2CYN2] [60S[2%?!P6\FVQ^GTC\WBQ*UZV?
J]K!:\5O&K3U@H^=?@A M3"::IZ]5_(R*O\E-_IJ,WHT78A8V* "_T$X'R>XX8\!5S-[PP*0)DMEM) M3QT4]T4171%WA/]&]2B!6T!XHO6WZY1K76KM=;!1P.,JZ$@]J7[V^;[R[=W
M]6A.:C G,\FDQZ\>P_?/O*8\,UI4BQZ Z:2D745>:<9]P;/'$JQ/>;FT) 5$ MFKII8)E'0UN1%/78P)S8L"/V7Y'.(0B2)0/+EM12LUB[H:,>K:U'ZC M8Y7YXQ9^H#+
C"0\!SK5F!:^#0[M2/I5L]LN"596OS M5'V4+3Z,_O0)YFK4.XF[5CR1[:6C1]=ZU7HG@]W/HQ6X@ 7H.SSO9R\.&>NG MO4JKUY@7
IASXXXDHE1XS!A2._PNDP!YJEP:*>"NS4&%$/\DN89Q^48N#R77 MY#%)PWJ.1/[-3%X8B@UI>I@<94:8)YF"OY?>:K1H2E!%#\SWQIK9I6?3HA0O
M[GV$5O4*BOEPY>$2X_HS>_2FJ$KJ78X.+F13N+:(OB=UW72"?V929CK$4:U1 MK7*I^=EQVC%:[' MFB><5OH^X>>AW9.6NE21 I0EO:](R)J8>6U-!WRELD5?
6G.TS0A,%3%7.ZG5 M6MT4XHJ,2XF\QS"^(@0=KAZLAO19,1=T%8^$K-2Y;#."0$Q1A;%2/OXH$P9@ M+,Q?%8GJMN,'WI003HWOE#K?OS_/FE:OWHYU&^#E(,
(!C$\+W]5QQU0 84B+\F[#5/G0S!NX?J AW,T87XDBR>&O/)H MJ?5Q.N,A64(Y]*J-T_C'0EOMT/'/=_A)--;AZ;ZW5(\$"TE?KFUP="N].K4D MF=<*.!OJ1#
(&K>KS+A:+ZQ>B]=/'&RN;5F?-'KI ME@].[L0@C 1IWL(+VL%(-!R2B [Y"C[XZ0)/9^--5- R;9RT M.UEFZ9#*87D)YHJ.=V1_QC$IBK(]U^B.)110YM9WTB5B'?Z7+[U@)2J89\?9
MC=VL46&W?5KI=5+\CN3R=CO%[^A4XAL#02/U>,QVD@@O[8J\PB M$RI95#X[V& IC$=7<0&*L5UBKKVY2=EXCQUOIB,F])^ VKHD\8#E4K/L M\P#CGXW@RG>
<"!O=5KW> 29GL-\3)CK.2L-[Y=078?(/;>_WS66.]9;:7XI"*_*MP*6.'9KYH,T =18CXQ5:<7%M0I.C_RQ;3PT,)C MJ\)#4>)77';R0S@O<>*?85&>B[PX*;]H9R'EI ;Y
ML%'#M*MF#_ZOW?ZP'9="'NNTVS^5EEY/>W\3@P62@8**\3^FPX_@>2;9,OB7 M^D_%;ENY=S]GM/2V8 M%:."HI-6LE:VP+U,6\4=$M+.'K6
6OZ^9P2<=C8U3\"JG$QT3U+BJIJPCTX8 M+XP6UZ-H<3T9+5Y\L"F-:F&]AE8B6F/ODMS23)!KU6>#C];4PY,MS.?JA>4+ M8GZJD*8J]ER[3:;<-
NVY\FRX$/E.G+/$TS@YLCL=/^=(2N>0L%1*,J6Z(U&N M<)"67_:CRI R6>JRE7)0V8AD3B/;],N008F3QWCZ2]&U% J((TV\Y1!O>U7B M72D_B)-
NPO);NP+D)"592RG"W=L3S91P:\%D"42X.+-!S@830G;RRJJ8/CL(M9:EI^LRBVLY:0 =HU&QX.E.:^L@]]TPMDY;+M9&)%(8-OHD*J:+Q?]4AB5(M MIX+
(5KT9[2DC];9JKDEF*L1@2X5NV 6!I)UE;; ?:AZ7JS6-;7)2;KXIU<+< MHQ/4@XZX+3PUG MEO&H"I%H.UNS5LA::3DDF:Q5UC%*@Z$.@;!8813%9F&CNKJJ*X:1F?NJ&Y3
M1W4/Q"%.UY/IT)^E1G4;E6:O4^ETNSJNNU?VIH[KSK-76C>)7+9G27'=FF:Z M_6*ZHU-C:V!8%1+7[67&=5N=_8OKIK;!FGF+@X3O3\ @\MH@D*/8\N"%&8_8
MJF3P;#I/'!/18\,1 F?SICC8\HH)8$M_,K()4/N?B+,AYXZ44;5_5)]MRV+. MQQ!][_3=I_K';KM6^>?/>/DG 7_J#JBGAK4,)_[:?>%V.6+]X3'#B?#3=@PD MIVB3PAVV 51A
!^V5[1DDZ"VYB4P"D.^Z[-HFOIWG=AKR&'&?7V0FSL)UP] M1'F>7= 4D&>$>'QZ\M@3 JUF6(+=6GI/]%JG6F\OA=QG4JMU:NT MTF!MTR&@<0$'P.6@+F*ZM8:LJTF5U
S6,)A]X>HCT78Q,D>(4KP; \2Z@-' MX*?8"&4Z@3T;,T9@J,"O?[# F.DQ]^3"*X<-.81J= :BU=S(_G-J6_@@4,.(M1'QOXV^1)N>XK/)YKI-G%*&&8:IYH&
(GGOM("A#75[2LF[@^)^TE[3BZ]9YH MQY&C8RLBT#/'Y\N"[3:,5W)G:?BS7;G]N+$R-/6MS=GV63- MQH$U"U'>$32-0*_A8<9[O!4GTZC]<@M?T,?
Z+Q^X[,=O4,&,,4,%KR2S"1_" M)XSTR/LKP9- FW%11A$%WW@OAKWOW_ERV JVNPI <082HT&DO\B+[^Z_QRZV M$G .,Y=>Q"[E'A[S2-
^B,$R[X39VPXD!6P]SF8A^2>'[X%M&UE[41W2!=4,* M$R7>E+HU!7+1X/+1*)>Z83\&++OE;O#*1K(1-KSC@#EANS"13H1O'^MENFBR M9'6]&1/7AA&P\QDPU.Q"X&Y5#-
R&BH$K3&/CRGTTWMN\A>O8_$&MA3=9)M#% MM$YVOH<7NY[,*6(QEP+XQQGU%^,]/=,6:SC;IG;QFX=+1Y[(&S5IM0?V!!EQ
M=C6+7*6PX\>F)$>O"Y0F!S#!C"FACZYN+/;N4[.I&XOIQF*HV8>F[6%O; ZF MQ+!)D+!!B#W15P)%#>YIP,.6\48SW B8^LCVIG$V@CTT[@?/+C86$H/@R-P8 M&+L60U?
%Q#L8MR)@P:=CKG"!8O)H@WG$'Q<]Q7')9MSOUMHH$ \,WUFW9IO MV%6GCPM+C35N^+O_)A>I'ZT'=;I([ZO1U7TU=%\-#0!>$$)T9MJ3(F?)94]# M$]?
ZQ+6X4OH(TRQW"#_>K94)/WYG^W]0JD;DJBO6@ MZQ9.9;Q9K.1I95IZ4)F04/S$I7IY0\|.F"6))5UA4P5I(PR0+E:E99* MY0WE5.DA4[DJFO2@X2G\(%3J03NGH4H-F#
ME\N3QU7DR0/00CU94]AL9]04-N<+"A5JS:*I=L=4NQBU<.=4V]DSJE5%YQV' M&SFRATSK/,6DQQ9U'FR\[='%FP(2RZ&<(BI9-GZ<)"$^DAJK@E1)J%[: B MD1XY?D/?
#L%OGF+JG,,]*Y?L(AIIMAF>2G&'.*9*)S"*@:. ^$;%D&HTJA(M%?C!,1@\B;*A)Q[S&96,/[*1^WH@JE(W\^[?5KM7J]VNVU M+ZNM>J]>/?
O<^EP];9^U>K7+]MEYJS&3JBQ*=J?,Z@/[#4Y/SQO-LT:G>G'> M/*VVFI?GU=[G7J_:O+BDVR_.+SLZO5G!]&:99->B)+LM)ZU&,G=O$U.-V5T>
MVY8U8LEW4RQW]3JL28LR6)6:(,DI0P@J55*X<^VT$EG>Z\Q4\]OVR%G"DZG* M;@(V3=7I23065>='*#%:2FDII:74$4NI$'12U0F>PZUX>CTU1ZI.$8\IM"#5
M@G2_!6D_0A)4D\VN0!#8CF\/5)T@'6.64UVYD&F.Z/@Q&0-2I+?%C81O.I:& MQ:J"?2]%RV^>KM]B>.T<0$$>,8KA4:YUH3I;I^U*MZ50>U2%#AVW_)[*M9%8 M2O&M?
$VU,V!H"Z3[&3#\0KJ;M4ZZ:54EFA6.3-Z7<>B_E,)#SSOFX:(GV4BF M![3J&>D!G9/3TEKZ'@E]'XBH;^05]5L4\:$#1X[2(J$^M'\PJ_H7\]PY>5Y5 M59BKXF7MH+!!#2]+$)?LEK
K/RH'LI$:#9<42[\KI*MN:[.&U44)M"^\N;7(MY?OBN?[:/2NZX*V=UA6ITMKC]F+[-J,]Y;\BNEKGYD)_)3;:9S6*YU.0[>=WBLO3/=ZG^?'WJ:]WA4_RVN9#![B3JY
M0"%57Z(6*.WYW#?1/3?98\]-GJ4;LKLX84UPF(DU:=%QQ[9CCHK9E]ZJ8)VQ M]3;MX7!C$VOVX!?^NH"]"P',UJ3DSNE\^$'LDQU6/(2;1:W5Q8;%NYQB"WDL MC9'+C/9;U?
Y1?;8MBSD?PU4\???I[XX]^N?/>'%NCLDS=*.>&/K#[H%(2D& M2>N_#5M9?6$^=:@4>[4=))@UN%.,NCIPS!86,@5)1N"QF!'_EX/)(NP:C[>(M;?\41M]/VUL%:4D.5/4>C[D?+&
[+U@_I3I L MBLYO9T@QJV0M:L[;"\[3L <;38^L]ZJBDT.OPD"W0M75*['0^>BS/SJ]DK,_ MKL&Y^8T[-[JX.?V)3>7]?]KU#8N;-XB; ,%P9YA;BP+E<^VD^6:C7>FUFZJ6 M
AT*J:]3]Z8@W>>N>\M,BRB"^F>.93/BARMG1C24K7)614$?=,>?DHKA%))[M90B>+*FC*]6TPCUT&M]I-=@FQ6"%:%KJ4'M24Z9)K8I*]J!;#$DERXTY77"^
M4F;;SF57[GF_SY1Q[>+T^ 8NQ&\%>L^-5J?2ZZ5YSV7D)*93]P?-6/O/6)E\ ME99CM9'ML#%W;V$IZIM6 M5:H3IN]U6V!H*(1$6CJ)E_W\[96$["^_%5,UJ?
3Q0.VDK=#Q0&XC9&'-2#Q# M]$#SB]?.%0[@"F8L+0-II)V*Y:J$"NL^+!D'=,MK*:8 6W;SR;+\QX9,P1B>FT;!X;CM@@H.7Q M&$@QN-ZG]$M_,K(#
(ND\902PD_6/W7:M(FL47I_MP;/A#@93S\--<3)9X]I] MX:R!3(&'O2<"K6;'>[5R)OJ,%*9FH-D]/!IMLSMP0SPGU6 MMB]=$="]3R?+G!AS&K@[GM0WTS&Y;I9$/C/)#
5T8(Q^D\U+_S,=O1F]60TC MRUU"L+'$"#;ME8P*W/B91]BP MRW]B7R[8/#.+D!KMGW@=F67[W<*C =WX("V[T_E: MJJ>)V%@;9CR%P6QX M?=O!U[5A/VUX]F3Z.+
('2&.,:J/>PV]X=>&7@F58T'"@PKPH?JK14,,"8ACR1H:($KTPG^&:*;(+GQD[YJ*PR4T V.YRL M.1?8C@^&YHC 2Y$GB6- S,%LF D6#+ZJ8YFPGS#,,VTSL,V$)$9N%CU]!R+8
M8TD>-8:>.Z;G64)DDFCF1:3R5>#;\9SF0Q[F#M43?CN=2!KDUI;#^1*F-<-+ M)\:]33]**Q$D1&R<]%& ;8"9+61GL_A,F[98>GJXC4&)N*+//'<1[*I9'TR M\,#$]?
EV]^_/LP;IUGL54)_9'X_!R:V;?] M+Y?5L[O+_K^J_<\/EW=@NXY>S3=?!J,PW.^PQ%K]8CPS7D#:P-).<<+QMQK] MDW;X(7YZ]W/J+OUZD;Y+&%TI9H\>;LZ_VLX?
L:7EA+3*FI%43A!;G/HD85?27[D"!@(5&EC[J5S(4M,^TF<]T=_^=##GPBP*P/>*]&5VCT%&: MT^$X&-V$W %W&!#J8K+]RA\"(N^=G@Y
M\H*7HO6(^RRQ6^!:>HS8'FG>T'>';=O$[!A)5K&M5,ZD27)]&H@4ZC727_S2 M_Q-73IOC]%V:'CH*OCP/>H#[ST9 7@)-K]%MH:G^SF#@VDQ047M3]JY@$16M
MBR'_[86I!38+F?]^ZMSHW]]85Q]RI)M4]1&1[)G@<2*_S$H%^XRPB2LM@! MQ=L*Z!6'C+.%&H++7F0@ 2D)6D](8@YU$QL7G6!T3$^,"WM$RYE[T9]@T6&2
M;#BDHP770$=^X@8@<3#X8^%X]@O+%/FO&+[*?O-7U#GDK_,'P2SDT"?&;>[' M84 3=&9L W!)B#Q(/P_P9,GS<7WA$E!H0T9'&OSB2A1?PP'B0=4*ZO'0"*-? MR
BKD+'P:GH4?CS)XOMKH0%,"YF!!RFBTAH\#)P9$NK72 L??*EQFN92TKNEK'D4#X$*[&M+) MD2C .VXOW)I>\!8+"/D7MC\ EIXN4HEUA55B4ZC$N\NO?52$M_V[A_\U'N[Z
MU_?]\X>KF^O[@U:$%QNCBC6$IY.9=="JYT-6O&"/P7G(R&=OWQTP-=D%4(]G M$Y\2XF)TQ&,?G$&_N$+80O^V/T3NIKXG MV$PIS$71X^ \C8GY)BV'Z%R,E!478\
(JSUS2AA)+FGI@D'SFN7RE*P>$ZA3U M#S\#N"*CH;YV>G6M4^G4YQ$4%RFJ]_A"F>X4$?(AHQ>&YMF&$(+9S-Y:G&+T M[T4ZY.PM_@O1I*3#/&S\U76>$-D<*6_-
'*)Z=TNPLJW.8B""/5N/#T@_4F*! M&0_SY6(+B VL\YA=1<$KL+:XO+/<7+&01Z1*#)79&!;",SNTQ= WD (3EM9B MP T6#XY%IW'U!(S;_E[W].89N@ M[UC7KL-
C..M20PI0K5AS5%0^SPE,*#9S9D^2A_R2/L*=V@*)'*PSU3(-Y2+&^CFP]P?!MI1F^MA-F@HGS!YD!AK)["*]/ MD6E(=S8[J_NIL6HFII?7CFSST1Z%^7X4
MXQL,^)TX^*,Y,O$HRG]F+/ /5\DO.6S^9KX9"! QZ[XFFW\8#"9]<3-2KK0R7T6I733OXLPQ1SU_0Q MPX\G0Y(>BBF\R%SVW!<;Z/]HJ3AGRD0Y">;MTW0.Z43ILYV=)YCO+K=
<"-^! M.;&QBBKIORV/IM7K)T\|H%;)7.5.6FQX?I6W+%:4V*-&I=OM5'J=>GHQ&SG, MDA5(OTK^H!JL2/J ZLQU(#B?$I), =EFHNL69,V*F:_+0)M#QEGSUW+'MH_FX'S^= ?
BX,FG[> MV5CAO'..=-8 %@G_/X52:[[H6#T_+$X =F]?;&#\3EE,_1F_*5AZCBA@[:+AB<8QZ M-CZ[L4?U\TO8:Z^*A9X*@+3CYGTP5O/=>:#H(;>>!.IV_B<[YT-(K8K@W[
M>#I_FJDJM*GFG*/@G$XM7V+HMCEG:/]@5O4OYKFS3%/=&Y911<C8@^8?X)^TUC4IIP0E\H]J!PC['*LX>)=%'R <5\"TK0\0M!+7_!#R0T>P-->SC\>#]X
M9M9TQ+#TF.\C;%YL*R\%8%E&17);5R3K B)=D:PKDH^'J'5]J*Y(UA7)BE.< MKD@^)-FKQ]?C*SO^$47IU:A(OC='IO=&=<@22=-X9 X;4F_7(XC@JW2>N.2@
M,&05H#85=&X!YT)=QY#H";(C^FC[)GJ>H>H9Y<]2C5I MLTD5'(7_(_1[D!?WT?;"%QN*C5,5I8:FTW+H=)/JM.W2:;T]WSM) 4)51;T= M=-K7!9MX0 QD>?
%^+F,7EODO^D)KM]*E1LX,[:W:TG$:N7:="<>\R.@MIEK2 MJ=:(2M)VSNQIM6A[F2[5GN+1>HHCV\%%-0*X;*1=P_(%S";YS=SD%EOZ0#NZ MF97=5%$P:,HLAS(WR30NEC);
[SYUYEN]*D":JNBL@W;_9&JK43748_ EG)LO@R;#8L[DV"^>ZZ];PMIMS3=Z5AXU&/&GZF^G] MP6+YTGXZF$]'81RFCL!ANK_\^O7J^@O!,'WKW_WK\@'_.@@0IJS]6HS U-4(
M3!HP02,P:02FXR%JC8>C$9@T I/B%*<1F Y)]NKQ]?C*CJ]*L%XC,&D$)N72 MM)]YHZ$OE!(_A>21GFY2 Y6H]5\LJ];-)-V;+%+-"8?
M"9N406V9$\J!2]SG4JB#]F)U*=31E4*=%E$*5;A@ZC332CUT'93"'*+. 6TQ M6KN(.JC"^:+=V#>-K4N@AA^_,(=Y)@9,^M;8=FP_\,S ?F'9=5]A>N@NJ(. MZLOE]>5=_RO50?
4OOEU=7]T_W/4?KFZN#Z,8:NG.+:Z(.M4543J!65=$Z8JH MXR%J79^B*Z)T193B%*J6A9E]P3=WE4'WI'/L/5&=!YUD=@=D22[JV+2!GAW3&3"M
M/4N7+P5T>'("RG0)=W4S_I4R8H039YED&>]5D!?IV+)L]%4LJ6T*BKLH+T_ M7@!G,)$%I+57Z>(A7[71MJWCK11&:J@,3>>K)=I'.N\J&>U019T>M$=X M9EI #
(\'>4:Y;P*FB'*@6\]]L3%&]-GU+MSI8S"]4J[58[OO/< %PGL_9C,)I: M3$(.6/:+++2[_7+]_5MFT>0*L (S4X>YT/,,XW.5/SD+0Z+9X1 2?(HAU 9\ M?
@XMHMO^E\OJV=UE_U_5_N>'R[N/ACEZ-=]\R0BH]!TV,^=GAFSXT6C@%@H[MYV\U^B?-!!(_O?LY=;5^O;A+72VDB<1SPW?GVS'W6D02B7V);U02I&3FRMVA
ME23L\VO7<2<,V=IYXN=)>.##^3L5\J)74QBQI"<02VX>?KV\,]Y?79_??+O\ M8/PL<4KV"Z8D!!@*D4H6;)G8,LQ49B')JY9L&F>E9H #)IBRZ?8^B;U8@53;"M&L:U6
M3462544#'G2"X'?'8["'>?S'+>/]DVLX'T'>^;P#E B4Q6&>#_1@\F\Z3+HX7D3_JL]\7\^GGL>B^@RM7UZC=EN30T!5^%W@-BM9VGJ>T_HY%EN$,J]/:KW1A4D05 M&
(H,'W>:^3?.96*G;X87L,^+),C0_L&LZE_,FRHXCR+FD;WS@7 MMC]Q?1L?F>U!$GN>6?+FTV*IPAHC^@BD7T<3TM>%VN]K4B<
M#^P%!ZBB>@_:H]1%S0=9U)PME(K(P5E8(+2I#]#JEE?6G%="P0I_V-&<]H-9 MU$GF*:2PN5%$SD^A'-("QNB4D_!S0 7-1=6/QBCZ/U,_L(=OR>=>.5D5I,9G M]NA-
L;T>DE+%H')2,/.,GPSXCP;N.EOT?<3EUF@B#*? M%/!'#4R/VF_"O\B!=O!&8@"FDP]H%=&KYQ8RTKB21X;N$\.Y0AF@R#R?\)_OKO!MZ67A7?/ /9_#@W
2O\,NRK&^VN:C/8(WO&,O MS)FRNW#B:T=XYD](<;%4@L:P*PG\ /P>H/MN3"0&+8D) M0>.!^0.>:-G#(7"L,03%S@4&B3'C]=D>/!NO[A2,C4<&-#.>3 ,NV,S)9/2&
MRADO_WX?&\| >Q:?R1..'QGF&R<>=V+@I#QF^J[C2YGE,S$+!B+<)W%KXH^C MD?OJ?]QGL(Q+>"LRD4+^N8,%0A'F#$"HF2A\,B SFMN&S!!VNL>!;-H_A65; MIVV-
H;$7)84:0T-C:!PT46M$ Q4Q-#1?=R,MLDZOS$)Z[/ T M#5SO;=;8/\!3P66/:JJ56MI8N8#P%KSW69\ECZ?2#SXS"]%80VI(7!S&8ZJ- MW $9#
!W3THZNDA9Z)\4H*\C)N65:PL5(N46-LDX:2O30.HGM53E3O)D#@DL M2(^OQ]=@4XHGR*7;Q:!J8+7?#M(V7IC+4X(MD9G'UBBBMCBR"A+F0_BUR-DY M8PX;VD%>JV+-
W+>N.C!4!Y:&OD]D7405LE)D7:_4ZTW%"%L5Y:FM9CV^'E]; MS8=E-8/ZP!009KP'E4"?/F >7SQ19(=GMGI\/;[*XZLBD@ZWTBW\M]FA25R[M#EBME-
V.B5;NA*QPQHWB0\2,WK=S@B+05!;X0+#WT=8+/^C^V?38&:@I"].G MX1NZ\MSUUT1K^E1OME5Q>)2AL2,FYR*@5THE9XTY=I2F_*S>!.JCS.2!.;$Q M[7RV;LL.
<"^:AJ4RJI#)$ M=;STVRRF^=#.Z+?][E.CIB0!JZ(4[J4+ QYCKI(3N M.Z?F>^@4OIBC*1&;82+:!6(8': R+ CE=^?"IQ"TP.86\Y Y(5TY%PSLC/:4S[;8F+T]OFL=UI.1L#Z
M\)WE&PS'XRS__'3551?)!*1C/>RT.B#<;0 W4T0%98[Q5/GO*##I8NWQ7/. ME&^%)CTE*SSVRA7/N9I*V0:+MUSS4AF\5&C&53Y>4NVX>%;S-W<%W#TSW;V" MTYR#S_5A+
[E-2*K9)*N0LIM& KC69B'0)6GN :)H#J?!U./:'.C09W]..?8E M@O:R\<3U$!DY#HKYR()7QAP:A=!_$7]3(@[CX_''.[1]&T:9\%4\.\!&&R8 MFD4#56%RKZ9GP9TC-&#]99BV6UC:%
A.]F,PFEI,0EY:]HO$U+O]'R[N/ACEZ-=]*AJ:N X%DE:+V3T7 ML\J1^-]W;#'H33Z"35;Y$"^DCOJ[PK>H5$I(\0GFHA('P.SP8O(1\UU0]6/T MIFSE,:I(M!WD,89- 6HG[=+:
J2AILC*;^K_E3A>$!W&SDW'M,P#3%58]JB= MMSI><@(Z4T-KQV+$_PY/-OO3X-GU[.#MVAPS:NK(]T_T8NP_,6?PEJ>SXUQP M^4;V/L8NJ^=(*)).1.'1OARCZL( ).6U>F5%KJ
(LK0TA'3+/UQ;I3'9IM=SLJTJPJ MNO!XBNERZ<(KWS/92.O#TF5+8SVWD^]?_">US/)VI=52$@11TWDY=-Y\>CP]Z'[B#/P0VME:LI0N<5F&.)GR0WXG*ECA,<-^Q1*&+ M7SB.
<$DUL%J%*DG1[<+_9.;>>.V"^?\=\9GJ#9Y J%^R%C5Q".%]3?#2:2@:Y-+F60Z[= MPC3B=LBUU6BI2*ZJJ+L=^(8*9O%G:44@/N]%%"6[P3/S=J84#Q:\:>68G-G+6=OD,[
MO5UD!JYHG12&RJV2 M"9U[E3_L#ZFJ-Z-]99Z,?,/2F$L \[Q) _^_'3-0M203D/%HC;[>+R$X%P]B5:K:'J-:^LP2O%93[N$:^4AD?_CYGY_F.O$.F= M!6KTV7QAQB-"QKO#
(7QC/+X99EJ_.;AH8$Y]9MB!8?M9<.>.&W"\|['K,6-D M_\%&;T;P;#JY;@IB\/FO]FAD> Q>[2]&/SSR!%P!UNVGPG6?&'$$?@LLY#R/ M#9'Z#;R+$/)%LB]"?
#&4C0'Y8X6E';9"PV!,%R@S]O#[; M@V<@_WRD3!P2THAEN*+%@NN0$T9@[T/; 4:QX>G4L1@3Y."Q[,?$3N#%+X.# M+WY_-
T=_GXX1+O]FN+A@+!WRO:TAWY5';I4@8UF=B#"1615FD<$31T*2*+ <'.(THWGUJU)JM M0XR"ICCTBYH+-FJ*I4^EE=]L IGY;[C\EF%K*;H._OI?9GJX\WE 'Q:;[/L2
M\3F2+,&]IODU86*O4(PYYDA0_3WS7NP!N[J[+X?RES6YKRF)JZD90 $&2*NS MV "P2LO\O.@:MF^%V;EL8AEFY)6)?
A@]7Z74;FNHUU4NJ3\L&IFOF0.RKEFIB;UL"CQF8E\W^6-5:U)3N4K6Y+$' M*7O:FBQ=\JR9=;.Z-=G3HD>3>5EDWETSQ6-=:U(3>]D4>,S$OFZBQZK6I*9R ME:S)8X]-
GFIKLG3)LV:RS>K6Y*D6/9K,2R/S-3,[UK4F-;&738''3.SKYG>L M:DUJ*E?)FCSRV&2KIJW)TB7/FCDV*UN3K9H6/9K,2R/S-1,ZUK0F-;&73H'' M3.SKIG6L:$UJ*E?
*FCSRV&2KKJW)TB7/FCDVJUN3=2UZ-)F71N;KPJBL:4UJ M8B^; H^8V'OKIG6L:DUJ*E?)FCSVV&1#6Y.E2YXU+W3-EJ8B^'V-?-[5C5I-14KI))>=0!RBO'8D,;R) =H&%9
M3+O:W8NIW//.E&9K)N_D-5,CRA&"[3B$6KZM4:K9Y*'TC=Y71EP7+V8E&WI' M[+@4@K-QVM1\J?ER'_ARW>2;?.:^ @S9>O>ITZW VRK1:[:>N]=L^3[!+L+,
M:7VJ$GZ"*GZZ;E,A!$;1O8ET8%<3MA*$O9T&1#LF[TZEU2S']M0DKCZ)%]QB MZ'C,N%P6V\^BP?//U)M:=,[^.=$ZN^!VZ0?2D]UX-BW#- ;3\70$%//"C &2
M2U70BS%QW1$V7)=MVN^8#Z[$X)EZMU^ W!VY$^R5CIW2F6/9P=2#E[1Y@W5S M#(8M]6O_>P9O=#,/^8#TSST& \?)F%A#3B4/0Z2/0M-;4]KW>J=S[&"\S]@- M>*?
&1]Z//GLUTN*F#<57HU[I->9UWP?C]=D&6GFU1R/CD>@!W*F_F 7?!,^" M2!QXT2PJ#IX]QOBZO<$;^B=+V.P?,WSVC[WAYH<86P[M$0P_!<7@4&#!#
MALP"N3Z"Q4%]803F#\-CP'&.;UCPA4^NZNB->!-6%_:/P<.,_TP]V[=LVA/_MQ'A(<+]ON,"X-!8MKS'TW+'Q3^S<+%^[ZK-!U?Y1?;8MBSD?0T+M(%'7>__\ M&2_^9 1NUC8B2_-
=Q+VGYR7FA2\UFJ+#;G!_I6)\/[FOT+MPX4,S]QF?+Y\K M\HD);SH -QW_"^0*%J$/=&4&\.-T9"'9^=/'_[!!@!.T[.$0)@0/L=%VG,#R MF?

SQ(*3,R60$*P@*A*8W,E]]>KS'GD@XPF4P'QR=O<&7\!7#,;F4JQB!/8:! M*X;K\7?QD;-A6.__M_>M78TC5[O?\RNTR"0+WB,;2[YW]_19QL"$3_P IV< M?,J2K3+6M"QY)
OP_/JS]ZXJJ23+Q@8#PBB93+"M2UV>?:U]X=HI?Q:QR9"] M 8J!-MD#+K$0C]H7V[G3AJX5 @U?_G)Z<[6R3;<4[;7:W_;$ U)/&(\J@7\? M_Y3];;@2^<*THU(DMS>U_%RS3MM")?
O J$6/8/(2C'> B# MC">C?$C]/8Z]09>]7TXJ1U6_-0^@/QX--CJ;7ZK(T9 M:IZ@D:+[2?AX_EJC_^2Y?\1/>X>YN_2/X_Q=0NUH.WMT<]'_YG@_E*7E0-ID MS4@0I,"FHH_3\
(STH;#I.'P>_ZBONM+ZO*4X+2Y&E$SX!]%H\@*PY,@ M\(.^'P2,&-$-W'[D^L,?>UPJF^V&0:Y:!H)QBLL>1&SOQ91)3?ZOPTV*P=?S MBYN3U8Q5:!57)_\ZNSZ[.-?
Y712DQQ&Q^$>DDI8(3J.JRK:C+^/F6>23.\6_+!N'AA+. *^'Q<\1+ M4FI "#(K'K#/33T48?@<4 Q J(WA9GR,"^8?J@'T#!29&NCH\(1-C :SRHV&
M*W;GA%)4SD@2<\D'+PYP&48N4!"SY9!'ONOZ][@N9)/ML-X&1$J+ W/OJ_MT M9+F6-V3:]9BQV9L0W+.9X_5PS.S(91>C#)L,>YY]&3A^($Z<;%P9Q&288:#' M]7:]
<]JN5^JU6K_2..H9E6ZGTZFT&KU6YZA[VNB>FAGF2@-U0&6R>V!]G/;Z MC6.SWJ@K2%%VA>"FI#&/^]AB@;(-'$0 M%'\&=748?^;2;^1X-WCK7M:302)\M5:R@7.#D.0
"7KDRWB@DQWNN9@%REC^ MP2P<<3R:ESZ&>I$#IF6>P1=[/FA0:(G\O&?4'E.>"@8 01LZ@<@C%\4],\,8WGK893@ M>A*X8I6GQ%:)K1=@7&11O"RV\D*D/FY E-
#YF\VW2Y* K1\.P0:R-=>Q!H[K MS!P6[F!FQ&.O,HMU>M_-2_:79W)7+';(T$G<-= T[+%_B23L1Z$[OQ)*R#IG M7 5G]'"L[KXYA/%TVFB6& M2PQ+#.>%BYC2?
_F:N.PT"XG+HNALKY#8^G9ZVHT_LUQMR/%3:FN%8A!Y>?0O MHZUMC968NMEH%9&9E!A^&PROB@+%\"O'D9QVMI:%ODI_66441(M%D4Y>P6'VELK9Z525B2>D)?
M_.)*6:F-E>#=!GCS,F]?4ALKU; 2M<]';5Y: M[:9J6*E_EUW9=[]8*HZ,=% !N'Q?99FV3_DGZVV&7C,+H]P=%$NO^P!^M7!L!6SLNS8+PK__M6,:
M[<^EEE<N\2SLN$R3+3N\S&+02XRDSO$ELOR;C*3.^/ MF.E]M:PVG"S^5CK3WSB"RJQE MEM[L")JZ:]5/ $!T;/LY4*VR<<%4]OC-4N
M^V^4R(Z1W7H:LI\1/+%]4)OMMEHB6BVVLA^DU8;W>Q5T !@%H4C6^G0V%_M65+D%]!;ZGF%X1V=M]#S!#2 U_12U9^?RVX:S481V4V)[;?!=O>5-;V7@76G M4V*ZQ+3
M%';@J[W4NRWV2BDH5T4;>\#!,CZLOU>J>(5AV48;Z'BQ8T8!5-Y M:CIE7:^;A;0A2S2_#9K-5U;JM@7D @7'%@9;'QC&]2WH<=OCL8U&(0WGHFAN M.^VGPTA:;
<"P9Z;&^S%K-]9#J;>]>1"]T7@+Q8U# $%Q&OB3OD\QR\!CDFCL M(\)*W+J;A2%6ZE8/@WQN)']=;^?T'BXS M3#XD<3PQ0.')>F"!Z:) JF5)%6]+%>L%-
[Q;I&/ID\)HJF7^_>LIJ>=L1BE? M2S/!2FWUK5G/>E$H6]96 1<)NRKURQ+.6X/S$P,CGJQ?;A7)I498XEC@>+T@ MB%?ELD75X9;FXZL)WQ\T(Q\3\OM6.-9.7?
^^.)GW91I]F5Y'[;*-/J/FD://G&W='X7P67SJ_2Z?ANX#S M$T/&2^=WB>-"X7B]8/'2^5T(Q6VGHVS[8\N[99KC:=9P&$3,+IMT%HM5K!>0
MO_U@VX!9(3MF_/_/O!Y'Q[/[T"GBL##YPZ4T?,N4$_.)X>3/B9A](7 72<4K M#-P^,++7BP5_,[1V"UFMJRAJW\['K0XQ;"+"T K0_I(,>43"7:G^%43]>V)5 MP&
<[\#"FYC+P[QR;V4?S[X"2,R_.Z^S%$'E^$Y1.MS#%.4H]\$VEY1,#M9_C MW'LFRD?. [,K?[+ SXK62E$P71BT[3:P5S/Q]6*V2Y[\;@)ATR&@>;VQOMC. MW5<<"+^4KL*OZ+?
TV)X2HYG5YS(#2HUG$7OU!'MUB;U,N[-H$+(_(BRU>H=] MKV[@_B/7'_[8X\@VVPW#Z-;V- 98FV)(!)@D>UL.#DX67I/_Z\BHX/.+FQ/M
M"YNHK_H$BNP89HR7F,;G+X=L\E6[_GYT??*_WT_.;[23?\&_K]\D1OBUXJ5O MQDP+X[W3&&V>-F"N?Z]9 0/4_.X'\FN,M PL+^04'FJSL373_.$P"@(P"JS1 MC/%03&
QCF^+8,P5:[X0J%G7-=J$0323E1SP>4X81I8W9!B[#9]#A@A-8KM' MC@>_.MC7-NZ[5M5P9GP>"C7@)026F:]%4]Q5 M;0A6O 5V)F!J$HJ-!P Z, 2LQ1O?
S2&P:BSG_AT'F='D(*ORP2! ^,M"N'SH M1C:\E4XW0AS'T(45&6Q\"TTNZ=V3B97T)0>"W<-[2"P($Y^4@$<^W?UAT[1O0'.ES,K)G,
M8L"W8P:IYD6VC4C,K9D?],R,X;^93Q@WR]/<+]LDU MMO"64MAR1J-/W^&G\(Q&=AP%L)V7Q(9A[>C+1,VKK:WFG9V?[GWMF#6];BPJ M>#06GL@< !\'D($,N
4ZN$7ZO0TPRWD:^$/&;"+@GU8N5]ZQU1:72U&0:;$N MQ<"P,L"9$"\7(UK"IZC##2P;6FO6%A:IJIU8PS&-@X26$Y+/#);C"P:)2A16 M0C:L. ^5L6/;S/L4KPH\U_?
8ET.\]BMOVX[W7L/. EGTMHW2YLA M> !RDVD4 $<#>;G6RYKY+QOZDXF/-\,+=&0L%GXU<#QX:_P"8'9Y8QW MRE&WMH\)$Q>C?_/A7P17:
(71YN*VB*]#OK//P0&018IX8A46OQ0$=(G322Y\ M&N$857/QR!*5(QJ.0(;<+1BL,W-1]* ")98U($ED#?^('-B+%5R+]@VUU]Q= MXYNVYA9U"KQ%N>_>6#!T
D9[5G\8RA^#8VG;I]9;2ZV6Z;MXXL,S\)5Y;KN MN@3=W0-! JJ"I#+,6@JU$7 AVGA2?>!9)&!>7P3#9-D#:4(RU1!,4)G)=/G+ MZ50+_/OXI^QMF+6J7OYQ__^WQP/FE-
G!68=C[*EZF M::<5^>)5I%3O7HZJ3W:Z5W>G-R]4FSW'MK M'LJH?#Q@\5AJK3YK8X90_:29TX?/FCA3^FN-_I-WW"1^VCO,W:5_'.?O$GI) MMK-'-Q?];X[W0UE:#J1-
UHPH*P4V%7UIKTGFRF>Z3UZ(>I*W*(LN,+O=]WYQ M)K> *F!C]]:=C>RYUC7K_PT-^+Y6:U5_GV*N83!<_;OJE3/JG<\"@X;9^0S
MBF=5H'7=GET@MB6;.7YZ=G5R^NT_VOG)]ZN+Z_[9R7G_1-?.SOM5U0>T<]/N M=FNZT34UK@!1@CQ7'DBGW.FI?Y^B@M6L-?2Z65^R -IW#_BV.T>]'?3MRFE$
MK@JI9WR]>F8=;U9KZVU/LX=JC"7KC7D[I /M$Q&JZ/7VL8:RQ3;;Q]H=5J& MWFFUUE^SF%8LO@FXK0)?R?.[U/,>,]]2!LA?-%6U3-D';VI2/=FB M6CJA'5:;+WM7-]K9V2?
0E$\OKG[KW9Q=G&OG%S?:U5^AA^T)80P!N8 M%S!BK.RJ&?6J=C$#LU^3;0>0\4IG,+E2C[&EE#.(T/6S(S; TE/@D>^Z_CW*
M&%Y>*F2S$'U,JH$&/X4$57A6P6^K"!8H?'BOYGL>X MBY'.O-0KY!$4?B=]E5SZ#1@.@E_'T+4-6\0&\^HKK_W&1;8VWRIA?"._4KFM M%N#8^JZD:KVFHFC^7Q4FN"*IO?
6)3E>AQ4O>$09D,G<(7CJS% M!F]O@)["@$^!"T=+"HUF30\[9K%^<801WZAJ9P#RB>>, M8(ND57GL!&!X^@&7U1MPYXD!C_:#2:TM 6#;/! MB JFOC"XQ/
MPF"PY&$S7W/$;LPUC)2Z96,)OC)_S!P: GC&QE'@\! M'F#! M=)HX,^+E.,#+, D[<76,X/XDI%BLCD,+0W'0FBV0J\,=A%H=U]KUYXS&9MTJ MT;_*JW2QM.(Y(0ON2-68":?
+'Q%,*><^;:.76AY?C-2+<8\ 5N'8F>K:[SXH M.1K&=44!PX#E**2MX/>1_Q#TH!!^LFXMQX,?8W?2/@_"YL.>H5=I'HK 9E*[M#^#ID7U+X?TZ!OT+3=R:H$T7PC@A;'>
(^L.'K$>4XMI <D"EPKML#?R[)_&#+9 WQ5RR$;Z0UBEA'3!BA?;C12P@O;.'(9N*]?<2 ML$EM*,Y'(0PY7LP5B)_/\93+F>@\XA0',8'%AF%;Y-^_'SM#P03%'/CCQM8=
MCHW!/&T$23P1+ ;F,CEZ%5C ')CH>^9[[EQ> B2'RQVCI^]' 6_2,::D%P(M M?Q;^X'CJF#*;@^0T 'L-HNCITL13,^+N<.^C'0,LPBIUER K['<',<0FF/.%99">F
M499H.J23<%V'=C0%U3'B",$-*PL[&X)(TWS.-S'BE&="TH+?@RHC66K,1SA= MK5 :XJ0-VG>>?RE2*E%W1Y0LRA==<._,:Y:0+PZ..9Z>0[O$;@2/H)2=%^&[M*0)(,5X:&G+?
SWR+L@Q+;*!-A !/4C>9SP#YY(1P.D\$H9+'13%DG!2(FG M,#%*)%7FS67IQ$)>'%/B9YI2ZM)U1Z5+#I< ([X'C \/SV/&?@!XMW&?$&HX M#ET3N>A,L%Q+51
0B4.LXB3YZYJZ.LZ"KQ4\.6")-/'8RF6T:7&S,G"%&@ ML&$4&\^*?01?55,3M]S03_2>/%5"Y@>1SQ. 1NF&@+CUR;ZP&DX2 $TKIN:I#JP)6"H1K&T@8JIEY;5+UH
M+-03$F96Y&*\:KJ,8;0>R=]X[Z%:3UKO;.I+$NJUQDH]%MND+:![S0HH I39 M";^]7E8S09'9;Q]('HL^Q(R&EE*]$K<"NMQ)^/)\.$_E/2BT46I:9&?1XR@@
M!&PJ='#,A"6,G^COQ 2S7(6MDMX7*X0Y)@L*CUG([=XQL6 \?#EN AY_";40YE#\\'GAVY_AN8GU9]_1.>&E&2+0; M*IQ(GNT[=\G\U9(*E%F9*(#Q>L$#><(Z",D)-Y(2B
@U:5>MIIYM.WPG7-0& MH@"MR0"M!L)9N @TO,:.CU0$8, JU?S.NA)"T(V<,N<=X@,:0&P"QA@U_MTW7B*EFS(TPK+JG92G68VQ?\'(E/BNMN0B$DQ2GV-M
8\3$#WPHH.3A^7I5' M\],,X]HF-)VLQ9$,3\>5PN,8U%B=(.4P@/%*:D_O$HU1#%A?=\]HCP1QA=G3 M(%UZOP96Z,272<<%8S&'$30?
5W=YQ&&8/$'1U=7)I(SU!54>KY2J/"F_%H, MN9 ZKV -L;H-7Q%R)E$XRVQ\:H^5U92*.-ZSQ5;%13@],JK/PPPYR" C-/\>Y MJ9QCH7^?' ?)SB!^"N,V:Y!SIW93"XFB2K
M+QZK<^-4/A OBI_'I!T2NZ9UX4)(.:X5I[?J.]&YBV-;YWDT :P "8L)QAE_ M-?, ($.^)MPS/EMTI$8QW2ZE5%YU:CDA@ M/PUKB5Z11S\2,/F*B+"^'7HS8%2Q'^6H8,3H!P?
3S>41X>Y<97P+#W.X>I#C MZXP7"/A#!(RQ)]U97*'*N6HYAR.=$*85H5,!KK+N+,?ERP;[1@P^A,>$W"Z5 M3KW9V GL"O<$B3=+0H]"X;.('TLN8CIK1')&'7"NO 8K5X6/:
S/#6*),Q>: M5>V*H8&G75LN=SU_]Y2(^21X>I>S%J[C(R1>Y\U!1L8K?(CP=ABPBUV(IU& 9S=",J)+ MA0D^1@Y?1J<$@!,13Y$4]A)1%=J$@?!2ZWV=><.JSM\
(V\H0MN*$CWQELL 8 M5]^],)I,4GD5HC89]]+FC. 42&GDSE.O%[_!3D6!'PX=O(1(@G@)J,"-%:I8[M. M8+Q,E!@*IRYW+"_B-U[;?#5%02I\U8MN42F3A0/?Z^IG^?87Y^MCK#I;[
\7 MCP>L[2P'AU6)2X#";ALY]0,0G(([])2TYYV-X[OPDJJH1HV(P- 57& G7UNK MFQV]VVG+E#GTD,W"E36_ZK5JHZ:0.2I$2,"6*_1C7XHQ,B='J#N+I\M#'-09 MD\)D]P!?
*4JMN(S9+?X;F2I7 94Z9G'0B7HL!$K4DI)E*4Z2G4RC6:TID]$3 M1A(7P&2*ACI9O#0=#W7NBY=!$X@[)ML*=K6>^4\:]"9*[53LESZZN[H3)DI4[
MTNGPL30E$#DT<5XQ'U0EN>%"X5>DB3P8CS5O5;^/ICQ:71$8 "RC#1I+K;5, M5*E)1\GR2]M/IB!Q7_OB[_PX$%XI+ "U-G4]+6 EKKKE)/THD";IR>:I.#"
MB"9V]@=QB<4+8;2E^;,&)45'NXM^]':SENM)YYU;(AJJ.@"<.M&LHH6I@Z'? MKL0#>?G(:WQ@G+E+ >Z2<$5R1(K<1>K :GH61R2KIZ[C>2FZU_"1HB73ZCL6
MA"H:F_E*1(.S0IQ.I[;"\M5EPI-SQS#>B=R;:.'F:@@U8'6-=OV9W&ZMU3G(MZ 59C+];#^2"_,_C6S>8 (!BZ(-PL-
\L$.2)^_EQ[A6*@(,!UYZA>879A"HBG5E@SK6L9D].URE\6)Y'&4Q:LVX")-LZ6W&]UE M&M4R/K'_<,!YA2%# JC)'(]^X0&TO!W>"BLJ5$20/^7GXK!\AW3"[U'-$1R[
MS0;$;9BL@)?VOZ7+4=] MDA+VH#Q+U_;G*Y8D;S$P*H.R%P>802E025^.-"4R@2(*,0-&["OZ.I.5E"%E MI+<*<(/2/'"=(<8&L8""Q9)(-LSDQ -MBG05655SV
@13RTE<:HKF_6#@?2E MY;IS+!%K%<(#7"N(Q@L-VX)IS1EPY $6@8>I?SG@8Q%%\(ETS\)((A155B> M+NX(XXC0<)1.9K(;(F!SAA5]-"\BW0#C3'&)DTPS7;L#MF0GC ;I$X-
YSR" M$#]ZOE?!]0TYK2RAA&13\+T>9@[AML7A@>*IMN-&%$^*(:(KZ9-??T=A;VG- M_YFFM3 0=D5Z?K##;]I"V:EQ';\3C](2:[2!$ZJEUQH=O=%>RPVUL EI6WKA
MYQ5.J'[O&-FD\;B*R7D]FT4=NU:0G-A+%D]\Y^1Q^0*=\B,7N6#6C(_BAM2 M\@@T90IRARCJ%M@#[[^J'-(O67 B:B1W(O&4[K!L;O(=%$B;8(6S*"X&7$H(
ML9$7HERZ]S7V1T11#\"_7)?'Y<9O!#C^8#,,''?@5^?/W#K%-%I*LL'I@8Q, MV#(N-;#IY(LTGK V)>IOAWG;D>@Z M?#&<^13,_.'-;6UZCY96(I*&4VTI?PR!]4O (:'.:OQ
2]LC.E0L))ZY,< M5LW'W6HUE0>K#3'DX&@@=/;]:%=*[,5('#VQ?EW+Y3GMN7Y_;/E:[''\%P M.%L,*^?9"A1[SDUJ2AG$!(@ 76HHF=9.:/#5""RCFY72PCB1>N_"PN>(.!#U
MW=1!7JKATPKWM%%K:/N*;,Y[U):* M)ETU!? %T@S@LLYFX3!P!CP50-4NU'=A]F/F?5BVWUUJIL3&O[!KNCNL-2^T M "NI^FE4O81\,^N[3CP+[]ZV*3$WJ]W.*]!R=CZ;.=?
R7.D6T3(O=7&WJ%SN M2 K/&J3(>T)<"PCN,"7V* P>,X]%MQT_.5UW:1$6Z1!^RA630$"]JG;$O,K- MGW>.KO7LNZI6T?A:TAFI]IOE6;?SA-#>*\Z611SFI#EJ MCT-L"P.
(VVZ_:)_"E0Y@LR5UK(VY>;H0B)KWFQ2CDPGY7*8D6):/8I MZNI, U89\<;"N6>Z.8V'XXB.10$E&QHGA$)57E(N%*HR2>5U'29RB2G5&N2.\,UO\ 3;C1,&.OTK*G+:S:&D\U
MNGR$B]0W=*DT[V*6JIXYQ<2",U@6,>#]7>";V..S(M&8WKHTLR(^$53/)LD# MELD&JE>;&M"G2YGG P:L&@^1L=H2.>/C/G[R>#0I,C*UYKSI71Q:]%YYZF-\
MYAP3#V4Q&EB@6Y\LE&1EXR(V-E7 H(( ]\!']A._(E\]%C,B@K0\]3\N"B6 MJ$:5.8P6+D?Q[H -G:E#1Q#H1E5J%'@+I:Q "YM,A6\Q5:V .70B#<]B5-,* M7HRUW"T;#SH 2!;5N\ Z
E0;6=0LHK1Y;1"%CJS8(NJF,EZ#"RM7\L)!:E$% M:X#%$M3,3* G 1:=2IUQK11@Q/$'C(U"D2=JDHM:S!@#.^%2TJL(?0 MT)G%]
<@LFR(B0EK"Y,%4_5+HJRM>0SN&!_D>KX#M.J3@J@=-DVE2,(QOC;+$ MHF3+1.[48FF(M)20ML\;>-6KH] M=2FZQG;7XO&>Y,?D9B:1GK-
"Z79_CZ_:S)^^_+8^WK[/K!IDCC4^XY:U/V^P M[^H,'MWTM]O-?)%@:6-0,'_>&\]FTT^'A_?W]U50*JW_MUA#^P^4'K#0V;? M6L&A;PT6X?WUIV-]EK-,+O_#1M6=3R; MQ%RG
L^LP% "T+<_"8:+KJ_868!2"(Q!,MNDU\$FS2W.SD@"UP9SV9R*;,QL M3:33TW-9].@Z&LAO%64ZIV05W[+]I!:RZ(WN>+S"IJCP10XVSV,/6J]B2,^) M$I-*;7Y
H*"OV%3M.M*X["G"^$2VZ[7)_V<\/ &IEM9.T-B9DE5N51E=,Q6 MJVT069E&O0LD9=;:M99I'#++:'6 P-B#63'^^\.-;,"DL19Q87H#(>\NTVX?LX;^M;@W^NSFA
MF6L3&L4*MXM%94+SU4 =6D9G?:QQ"S.[8O"LA+XZE5^741?-U#1VD;0:)6D= M.@__U_:'/[^"OL@//R[E@41"90,1 'PE9(@/*0<6'7MVG?IZ"F4I)*O6FXB
MB$Y+,;09K=2K1DDKZVI_=?BGW6RC]M=NUEMU]E '[<]C6!E^QEQW;;&430WN MIWN_G*5ZORAY: OR8S/Q4=^F^,@<".X6490FT0:Z6:O6J:-NU@8ZZ9A/)@+1
M+V45W#=4EV ?2[RO@?=&U?B?CP9XQ"LP>&,MO!(VU%P?$4*Q4Q@H>=X&/*^. MJ@%BJ-9H&K5-,"2C;S;B9(WM&GX8;];=13Y6^E2>BN&UG)<2PSE19AO">8N" M>8?
AW/BP8KG^!+$;_O-4^9%:GVVANLCKI; B^-N^<,IJ@L'X4 MTKB8.IYP_S#FGLB O#(]SVPB;Y]NZP6E]D]-C50G(R_OM8VJC>_(W%M=.N&
MV:RAC=UH=0]MFXV,]=RR9JW6$H'I8#IC_ZD[Q@\]-CG96R:G,0![GO:DRM@T MS6CTEAG1T\!Q13YIK55T8;T&?LT2OZOQ6V\V&IT.3+/6ZIKFH6,YP_]N@F&C MJ!BF@S-C%S!
<+S&\ELED@'U1-[J$82R)"Y^;&V'9-)Z-Y<9VL2Q+\XCL,V,' MT-SX\&A^O9/?$W<"FKFE?9O959'#=L&32C;%-;J"90S1>@AO?GB$/^%HRN@T MUW/3+C][H@SE;
[YW6[G!8@!I)KY!J*KT@N%6OM7Y%/PE4P+@3\Q:R*1)I(K\ MK$Y)^OL?D3_[G($__*5\ZS><^TKLR;>6M:^VIG:5^\N'0BV'(;C_;QG[A53 M]K7>3/:E=EL.
[P7$5*VQB7/WW/>PMJLS"98ST>;^A,+5?K M\^KLVMD9GOGUXUP5,%0[HCO6IJ#>=D 1=XB;YNY VJCM/*;7TC6O5/?;%1H3
MX7)$(RPR^1Y/PO/3./6VPXIV$-3&_]DY5&=CV=:*Z56*&2WR:9F+9%$\>J9 M7RH-4 %;7)LM:3!6*'8UG&F42X1/SI>KUM7+9OX$Z18&NT2!T;,>B<-?-,L>-A 3]6P- M&A0DN-
L)4&;]HV9 M9OMM3PK?>S5Q7LLW42!A_8JV+@>$^6K!4\'9;[ZK7I9 MQ<9C-ILR6F5Q?,\KU?/2H%B.%ML;8-M')YCL%I+,#Q..K(B-S296!36QJ'2 MZ)(5-:O&08&#EC?:[8^8.?
G7J6\]QBXN_7O>G;4'8P9V,4_,>8X'4866VT<1 M]H6U;MDCQ1P/=H=-C>G9^_5&P<^:Y#LB*_W=T]0W,"2P;#MK)L3^,DAJ= M.[&EU_U_?,0MO;$>?,^?S('%SYA'O9LQ]G1B[>
(>]WO?RCVF/>Y;[E#6]<8@ MG0&ZT'9PQX]/3LL=IQT_9B/JH;GC&_ZM=U1N.&WX-VO W)W>Z\NKDW*O::\O M X;6W*[S\P^34]_W84#:)=I59QB:;%%/=NW8FEG:J>,R;9\W.1'G
RHZT(S' MCCX6-9=6;'>@F%VQW8U:^Z,@(>/RJ[?7*_;AN.B@.V4,N,7 9<_+)U"G6)BV M"ZFP>!4D)V'_%.95?C86T2"?$.'AKTLOV(Q-7Q0/D!I&ID?
(#_9Y)]Y92*W'6%C">JNP7A4D4PA *QUP M4?5$943T%^1->#&(:DHEVP.-2AG=LI+Y;9_Y/=)EIQ!0N?0#WK%2GA MV0 @SN 00J+](3&X-#M+\;O6"NMF(Q5W.\9+)T_9+3-
HEV70&N*M90;MSF30 MOGH3QG95^RY:IP+_W_DVB]1\%4_A@54&2=@^6F.#>=)$-OST3AHIOIJ0-MNI M8:^0E>+*=<2YW*8M2O1]X^#9XOR%AXBV
QBUNF9'U)V;>DC#Q3Y);]Y^GII) M<^N&=T$.4-#CU=A/60>C8^J'LPJ#R[B;,[:.8R,H/ZCD$S6JIY[/%)K"WQ[X MX10>%(6R#S)9W++'L5%#7:%^D-
\7^3/O;P^/Q&AJN$7VA5>>BB\9@8)",V)W MU&09B".DZ8] "G*C+IZ-+3I#++1I3JKA[/O\I@FL W7&AN^6KPGOSGS 5Y?" M]9P[QXZHESL\2(PX;LVNPQ.G_'P EGH$? &?
A1D\PS%JXO(&M7%VR&;8:1P4 M+O'CDA:MVKD_0[T,PT)L1Z14Q"W*=5HKV)R X7$$C,UFXF]X[)WO1A.6Z21. M6($=VW?
X@LU\'*CMNZX5:'>6&RV[X=Z/7!OD_0P42FQ!#W=;,P' >RM4 AD/ M> 8(C,QF=XZ5[J.-C6JQ([F#G<<].S;1XS[T$^O!F423I!\]63/P]1P=/ (U
M7'<5:T%9K0I^,G'Q_;@)>ZHG]Q46_VJ8C?W!@>:,])Q=Q8]\!T-E.7%NT\ 9 M,F77/1^0!40'2^(!!,S:WS);+R<5/SV9'G_6 A[(TU+[K(81<&=#@I)3QN@J M Y@0201Q:X+I?%!]ICD
'2[2-FY!@$V55:S22L),<7FE3V(J^H/9^'QG0*V* M"!RP)'>.'X5 *O#;T/7#9*^6E:H*TN\62P=O"J/A.#64E0_ZK'UQO@(.@%:9 M_>70^:KC%V/_'GA(P#\39J=68-T&UG2,8>('.N=
(R9+8/DT$.]<#;:UD*\ X MDSI;AI+BE(PX9I$SD.*<36Z]09?7I0^J>C[5-C]RAW4 MB;UFYFDMI_%E]$SC<-0FV$LQ4Q[:[+B*9Q9?Q0.TZ@ARSEDC()R0I+#-@"-.
M'$_J?:YC#1S7F0G;(T>]TC5F *I2TDGYWG7[KQ:=?-&8F/M 8:;DI$@+9-V$6]\:ND/=(W4).*53";3@E M0XAKV_R/-R*O- 'C9Q("UR^H6P@'X0H M2A!*K&]V]A6UK7
\#Y!K6MM\\1*+!-K'8V+3&W.R\%"0LV'>QKR;T57C#LG MQ!RIT]?8F"%D_!LU-F[0I[V0JE;"*?G4-& MVL@)PID6H9^ >_=B >FQ,*RB#7_YN%'O^_BQ+>!<(@#)Z_D?
D!XI5R8S>9U;VV\\/AZ'&:R_A-8 M;@>9F4C?<#PCDCGZ)"17%E0 6V$P"Q^0&,!62(,V3XEPQA#WR7PIB1Q..0D:4. MPM31@T:.UI!WJ)>RY=X)A=]BL'3(DO:IV
M)CSH=S%CLS!DP)G0IF3') =$ U9W;%^1M*3O6O/$K9M:'!@:C)YY(9TQ#+'2 M"$F0J>7P.-9X ^/]TWGD5W;WV3+%TM'FQ.&$=M2K-;6A5P9H;4L0LLL([3*""*U'HY4$S+
(!6M=GOYSW;KY? MG5SO<%#6948;$8>KW.K-C3?)U49LK/4XM"*NC"R-?A%VK@@ $_'W P;&\$@R M825"3*@5$5IV] +0+\=^/.UX^""/OJV8)R_,F]"ZL?U3-@GN$S_\8,?.O4F
M8U,8 6\]]@4,L"7*.NKJF)98$?1LF+6_D:OMRR'<])57(JN^D]BT#9##F4K7 M?,'J@2(GD;])/&>#G,:U;X\+B-:7%1!-/:K9J;YF#=$XU-HTZI+/G)Y=G9Q^ M^X]V?O+]ZN*Z?
W9RWC_1M;/S?A(,^N3LU]=:]35NKS>KKYF'&J]TO9W)R#7: M35KZHWG6U;W%E>#D6N&W?0I!3[4U8_H0*P6K'H]%W5XJ41D>>Q@>:O_$9HQN MR+R=@]
<;O7[[>_:8Y"ZWL/!;F*Z/,';82#MY &6*CJHON+E/%FE_;#EP1^QQ M./*M@ (YCZ6OJ:"FY^MIXU\LS;%_WJ-B@#-GAN^DOT610+CFT/IZ>?'ODROM MXE3KW=Q<7)V?
_&>'-7=^0,9]0_<4V9A4-[2F4V8%J%IC<+#(KH O?0?5>@IH MPCKSDH,LEMM&:PUH!>.S=?)I8;R4BP58N0,%]/"(1TF07T[74.?'(&3TT041 MO\RU[M%#9HF:C"!_*QB$KG/G%?
SD:E-9N#&,!C#'6<2]9_(E/'Z8:_V@YX,= MP(A^XD,1S^*G+TJ,%JT(#^.FH&EX2QP5$LH2H3@?.0O7F3B\#(V^-)PD/'@D MKE^-6M7IK 0V(ST(4-CQ'LM===F[9,/#?-
MM?"DLTP$GO%T";ZZRT:NEDS'Z=]R9QX_(X-%B-.Q95\"?#)WZ8QJMKGGR7!7MB_/U6LI0#(0HIGFX]35X3/EROMZ@ MPE6NB+(BQT#Q.0NR:7&R3*6NM[6_"GG[8RM:*-
QD49)QM;PD_12)/E:9NM*B M_1@KH9X[\-.#YS$,/*!X#>PN!50*1"I(M\]4H,U6+E6[7TC2J% :E,"B>,$@Y M[#^,+,@Y*"LEP?,QE0'36P'I'3&'DL5N0!&[R'F/6=_"U*@/PGI?
W7&S\]PV M =#NL]N78A0E%_ZP7/B7@-UJWYQI.!P[LS]++EQRX0UQE 50R85++ES Q2TV M%^X%D:?]QCSKWIJ5/+CDP1NB* V?D@.7'+B BUML#GR$5VB7?NCQ\CTE!RXY
M\ 8H2L.GY, E!R[@XA:; U_/F.M:VK\\W_]1LZO.M=WU32>K2+*W34[CZ.W7QUK6KRGPYY/OZY7 \F[A?_S]02P,$% M @ J#([67XIO&@0#0 Q T !D !W879D,C R-# Y,C-?0@/
9(0%!01$)A;,B8O+B@H+2&C+R2LJJJJK"9R]HGX?!%5148;\/ 3$S M,T-9H7QL;'PP44%1V+\MVA> DPF(3!@D!A QPD"GG?" P*#@F]$W8W_M[]!P\?/<8\3W[Q,N75ZS>I
MV3FY>?GO"@J+/I655U3BJZIKFIJ_MK2VM7=T#@X-CQ!&Q\:)4],SLW/S"XM+ MRY2?FUO;.[M[O_9_CO DYZ!E%EQI-Z M2(AK)<8+):)^]*SK-)&9G$5*S+/]=L#++P2JE.2E-
]H_R+[_X'%_4=D_P/V MOUQ$ H&'0\/S GH KO[TMDQ+'_;Q!$7'.GC?N:@<.9^I'-,EMPJ0ZJ\+\=#,-*% M$M+9&."?-HF;7V<];X8_F1N0-
(W&O,;26=R85259["$VYBR(3HO+:*N7'LJY5#><\NJ(S.L(99()OY%O[^["A\9ZE,.U"H3L+I9_]CT5U'QDQ%B$ M=*H=4+ T9PE0*\C&=+?_\Y(P;B3<]
(VW@6"OONP+)T.QFG6FZNJ6WCNE)%*F?3]Z93UR MN7<;PO B2JV/!C0I:WRG$H_R"Y;!B MJ.*7'PJV%>\1Q:@_#(*&EIYMA%<=/D;

1;G\NH#Q8;&UQ;W=%H,^5'4;)U.3\^)T>DT$Z+00L_I>=0)3@LD'"$L".% M9W4UZJ?$/<6YH:WBE#]8(C1\XL@=*B?6CZ)9HGJ?1,E,# BT*AV8%1=`&,?-M!#]\D)EL69\\Z\##G!).S<L,"LC'2?QM4!<%=^Wf'WZ_9 MV3O4 GWK6XDYDEJ.VK(QO*G%*6V(PBX>O_T/(#Q5'+L9>^F!M]#5G)NG-FAPW.1P-"2]3#N@2Y,EQ\ M4,U$Y_IGV8[$+YA,0U8.'4J;8T6A?4OATM!XSZ[DI=S\!$AQNE 7\(IC,'W-M?,X^3^<$FF3',_4E4N]J;DV:*M+@NM(_>CYVW"85?E-W)3E:%LB-0&31Z1'*-M)XWH3^?2 &\=[1W-/_SWF761XU$1WYP3"1,=:J&dB;B)"J9)\T#;!V<=;S:\ M$_'\++L5)\0&U)<$^<2H@#\S$O;6L|/:.D(BO>?I*0\P*MU|TF+|%[0\NATW&MS@/CC)PKEB\N4G[KVS<&1"C4\\K;C*8F&])=K-M42?Q_:+DM=IT 3Q&"#:S._#H18'O[D+Z\'O8[/Y.DI]*LPX.S5UPJT.R28Z] M0"JO?"1H3>^-[\>U#PZ&]OJP:N1&OO(.W12R_^1CMIQ+X-,[B'#%N,1[>,E M,%)-]!>?$1WA)++!3>S$;[;5 MOF;0< 066V(4& R%,>F^8FF?,GNZ6)]?V]96$[P0#T>R?STGH'Z'F6.%M^LP M(&AB+VO)O(&.POJ6X0!:7\H!8IBG"[%,3TG13374%H1%7:)JA{'+/3CL)(MYRH5+RHRUW.D1\H 9.+%S/9S^)tV%NX3[IBJ*W&4@>^"VX4/|^,*W&;=ME% ML@#/17)-\1Z(/;0&_KH</<],/>W'F>P7R H9X3X4X38-#=[D%OI=X^O/^HLZ M&@_>-4S9P .F^M8V$NJY3.N4-U2S ,Y7G^/W>M@Y!KU{L#E794G/W_NC]A0 M7N?ZZDQ;>+(@+.2U"FY*?,=W NCCA-30K1MQ19<*7NU9-\"WK]|%=8F<2PC:H MPBLIA)++:LAY76:.33\]4K6,@N"#9Y:Y]>\YE-I$@#UE^A-!%,6EPVZ'DC$=_MK63>DIT+,T4BF4AZ;Z7IG:C/N6>7=\PZ].-67"/_'M_PHI5&'#;%-?4T]CYL-=M^G8=`_RKFEU):4A2:KVT_/S"\,V4V'7F]H;+G0F MCQ8LN?SY+!<]:^"T#[7^V+D2:IWBMJU^\"JQ;IH:dIZ\D+KZ&A#287/M@=2@[3?MH<0FFRE!ELK$SQ9L=&;WDI#/N_?4L5.4FZ;_C@!"7ALC$643U%[M+TS%T#/;+)H0HPQWA>)UH37!^HI#OJY5PWXY4W2@?<-]PFO>'79ME#A!+])Q MJO'SB0;$KN<6XA7!G8M=U0[&VXS/)(P.$G%)ZJA^\,)?VWZZ'>Q&;J2*N^-_MRZT-6WB<2]]$>KWA$K4"=3?2[\.9?EA2^;9?1-@\.+<^9?#$'Q7N?8GC*_;- M/6P;,LOXF44:S'45LR[DV(?$EZ6L74\T3I=V!K.-B1RN0GR#-ZXFW@^E 4Q7 MZO]4NCE8-B^N+=+?"7S">4 M?[XP,,@9OCM?X)6[UE+1B[5AW^3^J3]JJB=.1Y:LRHT@/+I<=W682.L^I=DQ M%\)QO&L+D(E- 1+O9V;|KOIH19;$!\;4(8YN{(//.?/Z(+[2F\[O3DBZ1D,]M-WG/W5;].P/M&%/CC}[-<_L;?7P40,#P-,)U".5E]_]^*#*+-U3?*YSTDZW8'&S M:^9U,..@^O0WB8MFYW!.H@QEFY^93_%#YGC&!BX*KG_,FW#R82UP4$+@UBJ;M',B)I&K#,_=*UQK??;=WL9A"F?XAOMO^)_]:0NR\[$O%,^O8&*,LI7|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f$Z M%U5V>M$N'B$.PZ7]MCBZ+ U&9KA+]BRZA^13M*O&5)$3ZY"^B>|E\.#GP0S M@3E'XS4]C,M.Q(D8*BNJ%(3H'@%*OX=Z48)S]#,2>_[E+A5*$\]?"6B3'P-@^#L8 MJP]C)@9?%("S>[*T:AX!.]_1/E9:HINU:#]RL64"3EBN_UP;C+KT#V%ONZM MB**A!04"R'|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|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|=/C MS?)E2&]XG3Q359)@]*|=,_U!5-+$5Q;0E&:D.8O+D^C^)]?_"ZW['WC*V4^= @I1 M=5)]WQP@UBC8 ,4XHVGN&$9_UI2-P6V"U#D:T;,AOJ"D3D?T0 M_2=%;S=L M@A/F01(6KA/|VXRBHNA5X;3@3[MJ29&.N3NS/&1'&?]\"QT?>%WCX$F3*L:M M&]#R@SI>++F/5Q7?=U%_1;C_ZV$2] #@ EKLG7F4OE\:M5Y_;X3$TC[0W)?V! MC',3C/5<"UOS5/I:S_R$@=XJ.5;T!5L(1L"EUE6OO9X[*I(_O.+!)QC\1MW/5'\ H8U>0+#A5)IS3(*P\GC6MCOQ^U3W;!54HB'M<.B0&C|IH,8GHT=*M-PQ'/<;S0:H>WB9I;.'^MF3)C|HR :E2 NR.P>WU#4E+<1!!5F=[$W>_]A6Z!M*;L$#10B<)/_1^**"6XG6.^M#%WE4)IX_I+C>>Y]1F_F2S_(^!%F$&6I2>0 MA9%[ZGGHBZEDE% ZGVM^M4DW9L^;*G7+"(1TB!*$5WU+B'"T]P@Y-MERJ[DYEG$K62VK#7OE+T96%['4\'S66^;,)-S+UQTO6SYO&[O-5K M"%O+KS/XY+'&5#K0(T!3H\Y/N5W%VU0$00[$&9]RNAV\0M'\:N?%+DT.6WL+M'>*C(=I,,"ZACKT#AH#ZK$T<%{IWWU.50@FV7D$4(!2C%KG/&TV&WU.GGN' M&B5+3O[ND5'=O& C+FF/Q1,7VDC8.TXH1B=[K?83TB+^D=!%\L6FT!M5J_8:NC M11:EK,R)IE)64K$/XI+SR ^=B0D+>U(OV-;JS8NBBYZT]9P/B25)>/GW6]UH M8P."E#]7/-RW&6V"A3U"7AY,V89!>A,"68/!$@/8S';V42:K"(6R;_QPUTS, MG"E\S6J>$T%X\&#/-VLR5#Y=-M#I 'P5DG3PK'2@LD-%FF=8-!I^,)=PCNP+K Y$_2Q3_PV8YIL)B=T72IE< . M3';G5F5\JC5OC[\1([P1=RQ2Q6TV>266,3V/OR[VMPUEAE&--[$7 ?ZP(=TY&=C9CFV,%*SS>K(O!IF&T5)!/=_5?\@# M@]YYB/ZV&C@]M0ML,"PBV7/AV8%,*B|_IPT[&M.! !LV5Z.IS0VC6>G9G M$;+^K(0D))"WLJ@=eY1#[$4H8YN9RX^5=C)RG*X,K MHN9Y!U8+FU.V[>ADRW!>CH'@3]Q)EQB^Z6;_M5.9^^UM"5/QAHCHU$&N0"GK M[SMH,7.S]"W-C5:MD,)8FC<,FB]Q4)G.-24JFUKNQ%DA983@/?R H,J5;,] MYA+2!.K$FCIX,:R%*>;.^>@2)40+F^TSZ"H]LSF>(W.*HA6GEI5+9[EW8*

)\'T7Q:Y5RPW]K^Z22Y4 6#D8 >KLVK^_M M^KCL4]?6Y=E]1];8IO>"1UFCO]F09[Q_6@@_],(8N1"!,UT\;!H0/P($0%D< MGED\L4!_G!',(.>2GPD3GY[2AW!&=2O!<2V]<.3EYSUB,*8G.!,Y/L6,K%W= M\?T\?7?1V0D"V'8M2+8-& _=F^F^O@UM+!.)R 4F.$)1 #5BN 'W-WM3UCQ*# M((__+D-#)BZY:::6;I82M.OB,\?P[|8'B Hj9#;59K[H5 (^42.9>[$>*"[> M@^T>W,D-K'";IR)"ZN4B[]=#U0UCWM54#==ZHC@XV(>8]1U'-&7*$$Y;5=G$ MB1B-QFA$508,EYK,5;$96VA4B*[]YIK@R#EDS.-"/VOX%HL<91%VD,I9VG@2 M?HLN,$FAZRB:8O<=H7-Y$E JEPR7)XC;R\H#4@F0G +$XO3J+XG2?2)@NW0$ MO. [978R,6B%\0]OL;5!OOW@'1+RWJK3]$M%U,+Q MV"C]H[?A@T$B[?N_@UIGY8GKI8$WD1QU76@U>4.WV]6/@!]9HE@.-R>965 : M_L^H 3^_G4P_S23[5@<4M%;E_A2O\'%PQ!\+]YPGKOO8O:?2(V(5A8W^V_MA)5[,5KLT$;ZFT&K[\4'\'$%1[F<&6)6V(R\;C]GX1V!K M[NK2IK@;56@1C[S[*,0 3Y0K M#*>3(.FPM4.OZI@B<9>Z_EU)^:7[M9-@IG;TH@>|>K70Q;!8\Y$C&SA')1GR M*R;&&?=@FE\ZI<@\-&K %_Z*F)CE*++G#V-9[4!Q2@"2|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}(OQV4T/7,)/OM/_P9/+QY0+IYP M-Q5A5XA:]2V6$-% N .L[WQ4]=3!8((MQ32X)Q79R?5'^2=3+GPCGW?CGIO8F?> 2FG-))]442+0/D7L:@B!BV#41GM M;FEM]Y0A?F'@5:"-_"T6ED]AGQARNU$!'FZEWS!^W,Z[V@UN=X9U MTA?G0B>M ?#I>M88T&LC#/FU*($L)$$F5V18RE)2RG_0KT@*$SH]AQ/O+TX:= M+K]AS5Z7["8W2>'GR5BG#%'$3(0;RNYU|/6E,[*IH-6"KY3FK!,P;ATS+0M& M3LB Z@)KS4F)?AI$@;IW J_(L+V;$C^'!S033Z[]AO_68BYD12N)=.B"\<&L M0],X^SOWU G8@MH/^_PH"MVXTU,*O62MK?=B.BYR!KZN[/2]J2\TX'WK'4YZ M?XGY U&B,I+O?8&61@]1Z%,,U9$VS//H-0&U-P6))E^?L2HWVW2AHSRC I M5N$>]{G8@-'4!E^5HQ!++KY0]@ZU6\:KI/(.Y*XI M<,XA^*9UY+KQKBKRWT=BKXQ%;T,)FO>S@Z[7@>2R]N167%ZT{EAO)"BF!? MX'@62C"*1;6[3:L"2D)ZGV4V]^8L[T_B9[?R@S0;,06.@97OA6OLN>2=B4>^MBN<.+8'>H!7;7DUN(SNMFEB9E;BAJ'VDNB]WOPU>$;XXD\YQF:WS4L'2D\>7 M>;.^E]@A80$DBNZ.G3[B)$P@0*JFLH)*%E]"S9FUP.(!,Y$MG' UUY=-6Q_5Z M3I>XJFZ9N(8!{ZTU)WO=2"-S1F*#U"NB&@3OABRMQ_I%9\;#4K]S!C82M M[E]V9UWC-.4LUFI!KA=TS9LO\")ZV!RI;,,+F,#EC(:Z7'AX>+ _F1[GU'WE M8LE16(P!4R$$#ZVLXH>:"R=9;X;[06 63":!:K/3)4_V3QB3:<$["ZY_A.W MTPQ+.^9+C8(WH7?DOV"%&A0'<()IRG6$RG31$"]^7G^0(,]^99!BSA[" +MC, M/>^IG'@%?JUP^/7T")(5' ^#W'M)QUVW^O/*K7"L#0]T;=N5#3/"FZ>-[28!"A#Bs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{$Y<_1FNG 17L%QR RH5)LKSDV.KH!6)7#]P<'RNE2#! M+.VC!&ZAG>#LKC^X(YSV250W8>C7^4D/WF_,)4LT)';2Z[E^,%]]'<=DIU]9D@%V^'?O>T./5/XLS||BW1!+M=)&1L4[P[V0',O%.5>YF;^NU#0L?O%U5S"KO8A@"G>.[")/*D![,S5X0GFR X MKI*:IO!7GAQ7Z.(3KIP](90DVN<>0]++LWN0EZ+DZKI#17@&7)S)"<8E.7WL1M4@C=Z!Q5H _H,2<>BW&BU84P\|_<-KI3VY5&<>[ZA ZOWME?@D?VHMED_]3 MG.#!PT0?]6.6NTZX"I3:(;;?*ZH/K2)U9ND(=I2/ "T;R!!A*@L-KP-$"GA M+M:)EZA[VP,!X9@IOT0Y@ M-+@G[.]Q=+*X4M@X7U7S1G0@^S(W](Y1,9L<>#P3)WM=!$>;[PO?!F"SM4$WR; ?[(?4GL,IO61M\&61;HS53K\"9_IHX6)H@:5[$RX[BF73]8#PQ8>N?2XC(X*[L,$WKG1M5P_5 M:W2Z8Y8!Q0!3;S9E."CGS'RELF>E[\8;:DB"9]5 :="3Y]7R/C;[1!C11%+] M0%!-)/#A2XL5V2?R'1(:+Q7^FZHI.J&TRI@U>>8A" =T.3#2 M(^)\E]8A@]-FXG\<,+S+T Q#ITMI"'1-M?]'G"2. ^8V+ -?/![]HKF:\OR5W= MX)$NTZ]{<6?K%!?LMW8D.GO@TE-XHVCX10?/@W!_VS#5C]L&F1,&Y(RF&HX[M+IG-,#N]^/U3A%,.!W]/1XGF[&-21NDH=;SZ,M^5[[))Y]'M< !74YVQXP M)\7X#)0DXL,MY!,&Y)*D5&.I=]5^!%2H)#WSNP]#NXFT>]!>4(1A#EBFD6A3 MF4M*T{;!<%SX,'<6]J7+]$<=;R+<7B^!US5W;, ^4SVIMX0-ZGL-LE:F>*,)I MD#*1'LJTWX0V+>"3,E,$<=+H@RL2@Q6$'!+?+@\\@C -R=!%Y@I:5O,JST_E-M>;G(XI8{?G@Z"U'Y2'=[.6MU",3_T\7B6:MW,VZQ9#]4M>*34SK#HCQH9 M8-W'0/N99>PL%)^AZQW.YZ7?'A,V&%5PN,PDZYC7@3 M0$O;8]3IS4_'3;,2 M2H:F2=ZO(31Z2UF=+*PSRITE;@H3CM*UI$(TU9VKC)F(C*_)V1MYC6[3]>/W=V%#T'@6ACGSC@QM&"U%N%BENN/I[E)JG5!E+,+_L(-13/|$K9X MZ=1<|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

AA^87.M:++C 22VD107!FEMPNMI$=-.1,FR;!L@4Z/V9GB.-P?GC(4G;BP. M%*.N7@"_%66S \"|%,-5V|GG7+X}R(*E5+XMI[6]HGI01EOOF>1_QZ)#E$* MT(7,@ WJJIK'7BF-|7O+'"GIP@R6DGM2!V% P@-5\PV)+CO\V9$.5$F(6RLE M*LK;=Q"-=H04KMWND)GZXAAM4FGDC8!_>DLCQTY\A5B"[;5/Z7V]I5'=NPU!
MAOO+VU!'SG|}5QA3_7^8&.=VZM0R7US"H0?2!GG3GE-DBGPRZ0F?:N6+A%;69NT/U=O$X MBQF&$'#?(6*Q /X/\Y?C+ ^R2GN0\,6! ^;'~HK@L9%P3-;L)R+90XYJKR:]
M=J/1W#'AOL(R#'<[PE("?$!>[=?.> %<61>;ZO#W*7CD6KRZI>Q8"#&K,D8V MW&"TCG_2R[;]1:*LO-6Q/-C\?7:HI6X OCG\G@=E"HK+[WEOH<4=T6^7Y0;
MQ0W\DP#BSHT"D+]3DZ2]R,M-^7D# $U<)M76'K)W C92FJK)9[;!0=GBOO9Y M_W!=K\P;(SUNF-\00{@^Z*[+L2V=N?/L]R>5F,"/< 9SZ?$^/A<6P25/_7U^ MK5%?
\LYVV7O^N%T>*SW#1O 60IZ*)ZN\/3X @C726H _ML/-QY]AJK]^7R0C<]{PS'?2R?S ;FU?\W5G5)69\M:VN.SRP%=]:9:BL1\R,X4-65KZPL@Q>^, M>DT PQ?"]E
14]?|;$@2W$0>1-_>?)7MI@PH/;,&=G'>R_QS&:_6V/U/=. M%1_)RY\%/(&/O6@.M9UBE>NU.Q1)U4O4D?3[TI2_A/ HDBM0;>B$TQ?(-/#4NG.GR"-#1?
Z2)9/>[?:QSSO>LTY4V+^1'C>3!JF48P22\8H5[^ACQ=<6J85,JG;G9E@I1P39->S05U/"JT"VV MN3C'A*W-;|JH1XW0\#'#\)A+7(Z?LR4T9@?!9FLMSG8E;_G3Y ,P*$*,8\+C9
=TE$@$/):(AIJ;I2VO?-C^ M37:B9&MN%$_KGZF@B+6NI\R/XL-K]^Q?KGTRUOB92BS?C7%/!N M#]&@Q]CAYSZA4?M&%T"D-&O3BUXF27 MM! !-
\PFC,R'N<20^S12V9<+],X>M=T]3Y6U?4WJ#-S$XG*^(B M,YZ<.AJI;9VGH>/W[N@H=T$R#/6W*VT?-V= 73$A]<.C;OIH2 MQ?M)TNU/U3+_BLYA%V_>Y]
[LA7P/M593F&,$X1+V*#A81WL8E3I)]HJAQLKE8KA+$FP[S2CY,Z\(7P!D:ME:D@_N,"NXW6TA+%*7]-AVHZ/&:N"S(J,K+4$<2YX(U]J$V9LJFQ@T'YR)5@8 MJ>YLB,1"PV&
<\#[SJW[4[%)-^+L^-8S4ZR &!7F&,(<6)];U5EL%83YFM%V M65DSO'&2C1;EU^#D_SJ>8*U4@"\TXHH+0ZPVM\!F6F%<^YH7Y^) MHU2C(8CC@,V'!ZI3?
6QFMZ0F^U#$>U.\F@_-(I&3.-M),]TQ$>XD$_O9!ZN; MS!X4;6 >M'B[> ^BDB)H&-NTQ@XFBYUO'|-ERJFEY\OZ$7L%YXGT=#9DYB6QR
MT]R$E#]7890.44P;3QT%.*1\4/FX9U17(@":?5P_I<@CU$ <&CH&KYB-?M M0G&#L^F#8^_<++P\Z2CS]N^9N1BK\(*P55[Z85H6&S5VDF^$L?CIS>DHK YHL_M+EU?
F"XQ4:]ZEY\W1"\A73"FGZ|-H+=5]M%5Q!!#J!G"&[_]Y9BV:#{(WS*:M64Q#QB$PN,20HHOIF-M",&B]2@^:DQ269T4Y/(PW22I)YLM_,^?$BOY51S -
MV)!4KA,=.]Q;]A8S(V?.2),]'$_XY%^4PI]F0CDQ2JW,=V<#NDSQ-[/>);J M4"AB<8BVNP27R!*/3E%3R\<7T^<*6Y32))*5ZA4O^4*U,TMA\.AM7,")@35I MAZM2FL*-
;@L2HH9U7_;]_"<!96<6/B0|NVR>T&& &R^D);WWJ7|Z\1NW6A4! M^@O -YCD3&I=A4))KD=8,$*K% 0NA&%L7M%_?W#V6WGJ,.9*AOT"\+H 2,ZD MOT%BCJ58QP--M%D-
&W0=U?=^LYAT^YZ*_|W]RBO2* G4BM&*"4S+,Z-OT?=,%T!E\ 3T"H''K88N*2@"I-0X;,EBM9A3C[=6CBC/$3K$9@ MR6K= ?A8@^CU;J9')N>+@&"O@/UC[?G1
M*83>MW,YR;X/;*R-\69CY/1LA0X9+LM<=2L2"SXX?1QEK:VIB*@+$EI M_!Y.U9'0SI'LY?WAK90<-X[^!Z^],=L[B6?#K8LKO.6Y M(1(RD6*/'C5#;E,.-
AWK) P6A>Y]]H'O%@>TRLW34"\+-(_ &N]6G#$(410\3 #]/>X@>AYKD]27P>HU8L.V=5@+%/G M1?DTL&HHF2!$OO&&9SIG I1\;H9OT ME2'(%O'FG:#PL5<8"6-
*3$PGUYB/].) ^(9 (4;F(5X]6P*DCE[(B%YO?VIF MNWM9EI%:TP![U-@^ZJ"UBET750^@O0 $0; --BH9P3[AIP-3N5C,]=$\KDET M4;-VHM2ZL]8[0 !>ON70 >Y]TU%O-3*+
5=A7,_-C9=S:I (;,HH/926H#^ M(.#]DB95E^GYE2+:?!S5,@18HU+V/W:7(^\59E7@17,+>:/[M+733@4H4Q@Z3M(<*6G:#&1QI7QG- T#TIOHO<,>3|9JR+*SSY1MG+,N(^K?-
M30EW-A2TG]Y6E+&9-%NRK[Y0 ^U2S:*19RUM2;W&&$+9I2]CP(.GHZ;9^)3 M^U3|O_ &G$V&&;:* Y5[Y89(RINH=;,TD_<[*;_Q1;$(.[56DOR3?MY:G\6
MW<|FC3KI;Z5FZPW'OA7S,E7]S_8[OE)XI3CN>#@M5?6T8W0V5N[C6QQR=_W M-,#D6]TG]LNR=6/54]K'FXZOBG0MZR7EBV#OZ(.=&OU91E ME4"NUKH=<760/XY9J:&-
=()&[7R,'+1*I5E%8] BP9)K7\^99RWV1]HWAWP MK=77/N2U2\L 46#(R)&[2] :RAKK.?:'G?A .G4=D?N*PNM*YB,,*7HGDK?8 MM(5"7Z"E[@-FN>^6VR|
2E;M">D^^-8[3:N92EP5A#0<7F?C9$X!%I>F&V8:./W1#B-Z<[\!B8&VV%M_D'TEC$M_MZ@H_2Z M02:!,?*;=@NWYPB"'LR\G0Y\RLVNK:/]PE0G)4,5H)3I275ZNC(=;MR@\2%R
MAA5^IH^0>M*V!|;1?N*|O(V;9|-C WN$PT,RT;O,*Q9+?+^U:VWT"-MO]SDCW3R$ R^,@:]=?5S|K*F/;14M0A*(##W$;BX?*/_M8;W1DC5+,MICV6_(I_A-
#G6C!A5)\,5,^>6I_8]NNUX%;8@HU:U<\U4^]_M)_1\,'EE1=2*-@$!)8]V^3=A)R,U]-U;'-/QAB I=@PW]=`KY3&]WIHX1%4O ME*VYGSS4O9'QOBG>W>1:N.H%T,;_ S364M,EBL;?
30#AUW?]<1,N$UW0,+9]> M4N"4XB3:=R">9I46$)/@$W9[,7V%/4]<7<5"%M65HZDL"P8T\^)*-Z(HR?@ M1-%7Q?
V&3A:&&R[YND.?)ZRX,;NSQ8>P9= 25Q)@RAPE:*C@VQ[8\##X675F M(?\6G^N?1,?50=8F]> M+ ++/]-6XU^Y"*5O-#,,T3]K:3U/^YZO%]!F;V ^ M^)9=F^T_C[=/0""
^85Y<9.. ^;_.&R!?7MFZXA;QY^"9V5ZA@G&A]:E MA8:KR+0'RXY2C9&QY@3PMFX .PYQ7W7R9A[MN\;MJU2_?5QS3.)?+GJ^[0E MR?&VS!Z0QRSCFM&)%=>U-?
5M*^/2!NT=7QX%^SWRF\-1!L57M4I&2@QN-)$O M")A{}>D-YVY646LB9'"%_5$.H5M899_O(3[C9BGI1)PLS?IW>1.NZMVZB"B*<-MEC=X0C3E3W5^!
W>:1FUQ?!;8OT22:N2*0(2)/C>[@1-HY((/(H?!PS.S.BT M'4M<8'#.Q=2/S?]:.G?BGS@\4*0 (D5C/3X09QAI.WA8#Q=M1PK]/"??TP"-MYRN5F61LF50L]%Y$RY1]= MYGO;Z0>
[$31O#L_6(.'"?:.3VC4\;"B/F%VXL3":864W]AQ*8!XQ=2UK@3!8 M3K,L?[X0*5.YNG/WW.537M073N/"OBM-1(-H9F[\@M%J8I$[DC0]) 4X^KTBM MQ4Q%U*-S'9!?/L,K=X&$.
[I.N*)%'_59_)9E$QZF(7:FF)LRR+(@=@GK%,%TR MIE>H4&8Y[?N"2&MGO9\8+\?IH) U/ULT>UW<#;8O;(F;M! .',Z.YF$=LD%PN5 MKUZL$1*GCE?X,W_M=D7W>MXPX)Q*.3?
\>>UD:7>7FI?+4@+VL?&N8BP-Q4,= M /A^HXF"WI_/QXBATF\TP%C5U3H)*=)"0D_YLO>9=N(ZP3>$OT=!LB[SP*FM0>5Z]ML=1 N 85QO.L\%<7G6QW
MG62J6P3<&DW<4#H.&U40V!^PF"-QW]NWJ*%G<7IH>U,Y&RMIYH]U7GA&YR>& M4G/U%7K)<+UOL2'&0R,9E:>8([?PLO< U<; MYT7?ZIZ)!N\5#|QO<':$?
&I_3D0'FFRR'Y&E=YZ?X1R+P#X+HWZT(@BE?,Y"R/+@?I^/H5_ MC1_,;)!^C5)F,)0OH@++EL3F0?%_ CS[E^XPR=4)#3AY%-ABH\H2?B@B]3O= M[5(8YEDQ]*I3?
>IF[XBEU%!=EZ&'8-CW09N M_SL^/7ZQC!ZX=3GUD EK>N+Y%ZFN"]C>C\^+_3< 2]KCO%YW\!4$L#!!0 (*@R.UGS$?H@ M[2L |V 9 =V%V9#(P,C0P.3(S7W,Q:6UG,#
T+FIP9|5!;<7;=E M$S1(" 0(#@E. |%= @D>W!MWZ XNP2$0(&DL2",=W!MW=W=W=W<+$F#XWILW M\V;JGZFO[|4_IVM5W:Y[Z|99^^R]$16L=#_,/*X 7L]R4H!D)"0
$9/'\#C M/. #_.-#1T-%0,=`?WY@G2\^?/L;&PB7%PB#G?D+_A_-|> MCRT / PDT#,'9*2W@&=X2,AX2(\= "H D5Z5|&X#V/I&?(*^AHZ!C/;,& > M'JA\"7B&A(S\# 49%14%Y>FN]]-]
H>*OX;#G&T5RK&Z&\="#B_1]9AT$B4 MMA*JCI[0ZMKZQN;6]LL[MW>G9^<7GU^_KF M]B}>2 !DI'_Y 7WA.O9R@HR"CH?_%">O;EKP?P4%#?<*#ABZN@&SN\>LOY M%8-
(C*MM4/4Y#9?["=&)XR@F$2WW*MW17]3<A_&C' _R-F_X787^A4:U\|& &M1GL/&0\@<C@]RUCNA_F+/RGPH8RIJ.E01L# _A\!]H%!FWP%IMX'@F$6;U2'-M+P]OFIKT
[JQ;!U= ED^PGI7,J360!Y)N3:]X[==?!\A;=*XH3;C8I* MJ%# }8:M4:W^2%\4[I4B&'0VDQW[G*^=1]]+E'K0 9UD=6L:?,SF5MWJ*CQ MY67]BRXH6+ 'NN-
8P(EQQ#0!4)$D^%L0HRO8"50>8^]5=M851;A/7#:T50T M4Q#QT@W.2L[*P3SHN-Q>3X:,> 1@GM?OWR7)K0R[,$7>>>3!>/*O97UM7DLSG M0.A(2]8N+[E-
RU>;E)*P81P3KY_SQ^^_%+AQ/A+9? 3L:Q%*VO>3;312A'Q M^QL||?3:OLU453W429[X;R(YZ"+1 M6'.1 (-WO E4=(D(GDC(Q 2#G9HE@&LN/IVm/F$6K3C.LW8W7
>EV(SCN[QF1-MDQKJX;>;VTG]7)1H;I@CJB'.;"O;;PH;+XKAQ8/6VKX]0/5'@((/0W0BJ$,2Z M:%O;9J0AN 1!//5YT9!;%G\9B*J2W'2BZ54>%VTG.B]>+,A*2L(S;6*N!GDIY
MT9\+$B'3"" 5^#!>&^KU)P?-CWU:O@D2Y*XK^^]UN<\'ZCL,WK% QMI&C'H5/TU[OVXYOL/1S_|%EVWH8#*U4:= M0]O8,0M6[!RLZ-^Z?X#5QJC"O:R_7
MY(C4)NF<=73$ZK#1NV<[G@GT<^PIR%/|. GR14.PY*E)WGAB^A=;GO6[-&9W M.R\R!U261B8'-06S|S%OW](.PA05/>L= UA=I=#'9%#L7MZF1??**^].EQ'BR&=[0;F> M6^3?
4F]-FCNA|UVW$WE(H'5!T"++U.&^N3B8TSO!)L5?0M"AQ(C*1=NW(M4X-5;>Q(82L.XNA0)S/YBI)FJTBK*6ER6%(H-1W*Y/>O 4KW6\'Y;!:/@I, MS<_1/50N3N.L==* >LFYY0-
N1M!(-#&?]R+MR*Q,1"[(${AV1'R+ .:Q3..B> M|($<2BO\+=1*&&,$HS!(5CPH$|=QKG[1#L,"^21ZS&;K$T_/#E.Q;3DE=@7|-M"\)@)D*3(3:]1T-KLJMQD#[\&Q*4>Z >V%6)P ?2-
9";5!!LZU6"3B%ZJ?"9 ME1Y_^\-LJW"+)5Q"C>MYA>LV-U(94XN5E>#K'XV#?:\(\?%16XQVU%Q)BM] M(@L:\)\XBM"G[
!>YW%KD^ZF5TCFT%N(KSWGE.A=6$9PY1T8=*S#95QV)_L MOO:B>+]FOO#*9VI_1NQ*@U8OAB%@PVLF@]&W:JDKS#W:P7VLRW(#6P&>?\@ M*4V M.7?06//A#R?
[/61H0)0X<28I$D>4A/)YE%49)5>M(E>H&M!3HF&\XLZ;MI|% M/%;));]H??W<.GPKH$+_[F\)_FHEH6)P9*OE6@:6?,7R+UFR4W2)NQL+$X&
M"QN47LY]P6@5FM@X\2Z!V&I&_PXIEW<24Y[B8=4D'MN3rB\?5=ABNG]D?;9? M5S!%9>*NVZLQ-Z,4'R&!41UZ(#[@=K8^[+#O25 O7D M%4%:]K3>,]R-K\Y?
J=3NC%^_?/+CS]H5:l0?P[#J454FX"W-T_%5 M_:*OZR/_Y >3Q2NW=L/S;UQXLJ1<|-_=7^P%L+3@.JG3371V61]<|\;PJ+4N ML[CYW \4FYC0..)HW0Z0\4AQ*JI:VT]+2?
P7\G*,8XJ*X[' -U12=> MZA'@YC!\F8I#D[IV2?U:-V&B9"XY^2%X*E']P-/Y4P4@[L)L!BE&POJ8(O M(RBS'FK?G45M0>7R_99<&;TI(|N=8#2]>#8Q=Y&,]P.^'_(>.JC&.43ID%Z)
M7HUH)$]@M3QL<)GRA6__%AI.Q.SW#_<"+1U]T3NM$YY1*T.])7(9"1 MMBURVIW3Y,53;6NK?;GXO?8SHQCU UOEU]9=3=9CRT]86=B9NA$Z60QN6O';
M%TQW/6LA^@HJJY5G%I^OFN=EOE0!4OZA8EU4"U&\$TUY?=I0>=G;0]2U;Z+ M_Z.=[S^N!*'-MUJ6BS<\K+,(V-IL18+2]Y9V%,P6@Z'E-#AVUZSO 3G5-9[M?/;^F))1DA(A-
($,0A_(+7<5U/T]T;GM2GUU*L.G#HF(A>,7^9BCOIC>IWI0 M@8<.%2TM;88ZXR]9'"&&[74L=97C=8%G*^TO[TG]F:X0*BX,5I>$M5EI.Z2H MS;/.0/[O[>
[&\51]O86"7173Z7<2,WMX9&3#=7@(&RE'?!)BH)EB#R(566E$QS M<,2G8'5XRWM.'?*]N.+,#!:'7&.UX$05+9\MJ M<[9)&$?7!](KBBO2,#Y7LP\N?U1B&,NJ'E6?
*^R<{ZB2NTNM"HK4,O;==R# M_=:L1HCI(/0\KV%-B.LFXW/9FDYGR*B,SQF4+"S>)OCB#F/2(RE++;Z0X*O5EM0IQ6>B0)DG:Q<9V)7./A@X]$#4T?+F!**R> M4"O&H-
VU2+&960!^ZJH)EN2QBY6.7$-?O1/LQ3USQ8W7NWO!LHKG=`S)2 MKWOOMEM,[^@ -@! 2@>+-8G/-^PHH>4'3[@^/"K26;L!V0Y](OE7)ANXVM*J.P_DG$4O@S'>&9U==
M&1T5-XA'H.2J+--7=X? &,'O,&*KB(4F0G% M#,|?AY4 J<4MI:UMPKM<\0?\K:\[OK_K701X8TBZYKTKPE MHJF8|0,6GU#@UY&\ZA"|^\2X#Y30!24,B-
WPK+IO(_63*U^3:$3IR]G,"+#G M*'7|S@LB+4@]X)&S.7 B8#IPRE\L4 &R>(-4&Y >>';G+&^0+- -$;*"4B= "M4S2|H\/,_F-I!_1]!#Z$694HYXH*3?
LMZ6^H!RJ9SW04+%=5>]B"0J0[MK6 ^1$%>-9XMB4NO+0!MR(*$YCY.>'L?/I=9N*#&?3]X!.EW;=^4)!CYI#AK M"L,L>P1$3&BR6NUK4?
]DME#%BL5HNOC8)*XET[QFM8W]_OO$^8:)[8"Y-7EK-MB__P*UO^;V7,8GW*[-@]^]>>WT.'! 3NFB9)+$BUH47D"Z5[FF_3<\CFCM-P
M+OR]):$=)5QXVTCSB6/7@=_]9|$7]Z17-8X/5WI",GS*9*>MD.&U0-U\7H?4 M)),$:%ZC^EZE:%,_]%0F9Z4:7|<.V3NW5EWl;#-D0M@PB:Z73]?2H|%8*$ M%#@^AI?
T,O::N%_MJ_/(IOGWD1'3OE#?_((\"9K7\2=![>O;J3&WG53/(=;R MJH+)M -(CZ=[:\%U4E6]?7F5":7VY91[!S6ZDY%O*RG$"=()D2B2I)'@%7<
MK]*1FP\.H[S!GKDV/%^@JVP:ST+Y11QT%..8QO*#VGH-$T0>[KV@H1M9I+#7 M$DV5YS.S/X;[,G84BX#V!K7!&1=/OIC13Y<#.P1R2M:R^8\B[6HIX]4DZ
M1WGW3F76*X@M9MI&Y1^AV=RP9O&\%5{|LG!UP*0\%F[6]%ND(-CF*7XP>5- MXFP@[UKVYU%)PM_H/_\.W?>|=*#6O\4+|-W%R!)%87(]YVT]>XBZVR$-(
MD3HSM8U#$P=;N+2@_Z7YF=T%]F4[&98;B26[$L@,2$6:Y<,^M&)VZU%,V=6 M0.Q;_/Q\2]_]3+|6^M3O, LG+?=\;9$O> MVF)ZG&N>(23YF+*,O:U%
(B.D@.8LG]=_9K!'CF*9Y@H(^\4,OS >?Z<)CU] M$5FF;N\0"@Q,K/K5;/S?>RLBI.#3X4,+Y,;]:4)'[<[$/3G"|/WF)&X3-M4H M4# U4=<=R:C]8/ 1A>]#%/9^[&K] ^
.9%OS!,CQE*&'UX:%@ ME?(;0]G(2AXG(C.ZDS*&/]WPV4="@CDE4Z%,#X MWXK&I@(\&5T4Q.W-RTF^57HG-^N4C OO4R&K[7+/!$GWXD|;PE^&,>N,=83; M"A>68ZKP1 +_%
()WPK]M] =#[YE@+*_BL58_ (NF4-:A?7$T\[\6'XTM%Z M9V"[$&,$;/\]YFOK#\?#V<;R3.7"^S=O9VP0FH7\53$'N0S'|);%LI>2=!S5.3B]H!*E[4FANL/;QITB4O/F:;?@1W7S?LE;^
3%2]&&90O_RYM^0^, M7@3*5DA ,=6IBWLF+/\%|))=8@'3;TW#'PUJ1-!FBT"O_FH#.#Y5L?(I38:CNE(Z^D0@_O)TFXB1?-5F;)91-M:!+O@;/AZ#@4 BKG
M&ER?,*0'MAZD(:.G+U;U6"_3,7Tl:'K^X+B26C3F@/MP*MOB1$Q-@Z@"W18B M9;%L8OFD+LRIQZ\60++D]>:!#V>\F"EMM?OF,4H1X//*>)\K'<#Y6X\'LE2[;.,GNA :,7J-O%M
Z%_T%)(;'N"A^!U+K*R$ M(AT:I CGJ?VVSA?[_CG)*,K2S,B?V)9BZ ?YMVPF)MVG9-IMT%5?HA+R9 MSJQPY\))+?N*-
>Z;W95':DUTC!3)4@>I%2Q4;'05Q72!HW^3ZYV%_*;D#,Z.K MVTF=%2@=O<"7U=)KDTQ2\W9 "Y.JFU#=W21GEC9B[P6.^7>O$CGU6[_^G((*
M6!N4$1#MQZD$/A^K'9%%;:A6_9ZF/R1-LGL]=15=*+G9;9DKP3V_:<>BV[>. M;UK')X4^GP)*D1[*#_'&?KCK!:S?I1>"!^Q MJ/L?\]7GU-TNFE',@\[(FVA6TWC>6[@P105F
N%*. 6IM2LB9(6!1EE M!GSUC\8I, ^0"(O)ZH"K8 <C[AL[UV2$!;Z@68?O=(2@* M'KZCS@%6H,K"2 +2E"@9M%8DR7?1O 8GK?Z'G27ZJA9\&T2W41PVXLW353/G G M[3?
O$[_[L7">%;_NBUEZ2/0(((@COF6B41>07$PDO0/)*#VE#T/8$,%A%;&/-M !?A%N)'0(L2SWD2Y99OX0#O1N^A;QO48Y<.8_;_RN]:9^YSQ"@6+211=8W<52G&S#NE38<"
M:8S^C_KQ_W,@_96L07_MRT%'JZRL=#4_5VE4NT\0^;#3P]'@\WA HT%JM2-! M^%2@F+4J^Y'3VKXG)CYBEM+!UYT^+5?A"\,2K-]TQ)6P?L5]D2?GF\TLK4(I
M<)@"F)| *Y5[^0"<^MA9D99KJ4M6TU%C6S@%XFO$YS_X?'1 O>P)0R8'5C?>5FXF7 AD:4'@&%2N2=4'#N@DJQ9*A9=5O2X[#GI5<87]V?WV
MV'C#=@X/5<]%=Q&9I^2'B$XG @Y).WSBJ4F?K?9)I:F;/..\VOIW*; J$6;M M.,P<@N7^H=];=^'Y$F(GD;M3U1[QLA;^.X$VJ;;$0[B%@%KNO+6I$#O/RK#,
M/*.VK^7%A+\HT5A#9S]$.4#]J_E-! MD^V=9QJ0/^RC2W_Q<-3\-}4)"E$#2 71%3+7F=M6R%+,MLY26'NSQS5_4DQY. [N=W-&MVJ-DVA5Q38P=&T4.B3 M@Z0)BVDP\54-
BWE&'Z"TR;3ATMB%"+(QB+?\6HQ[%4B8IR5@G@2,M'=884 M0<ZJ52C--HI6INCOI_=DZ7|@VL/HX0GQ32WXU@N6H-SQ(+T>& ZV)-I;==%O|KFT MO1X5?2*_6/4[
5;W<.!0$8O>BPM/6=^\L%"S/)%9V!CDH8Z M?UMB9]^M'=8A!7O1!Y.7FT1+Z0C0:+DA&7UN$%I'?&-J+/\%@$HI@,)+3J%,IC M4LW)+^.ZH04|8Q=[D:R7J"#PT.)
(V)&HY^5>6D0O8|2L7[&22M_OZS@JS*X MB$;'63^"ZU68DU[)#&-6WO2TK*FQ@PM3VPT'|TN04_X(5LCCR-$E<_5>LO)IT_>FGA=A(8 MZY27QZK9B+:>F[U)?
=ES+C70R55&*IE#+BW8E] ,Q7M1[%M1IHS7LD^]55A(MZ[U[6K#))%8NHS]^('!8>! M@$,D1W=0H\ J/1ZHZG@>*B6DY5*.8=N62P?^6@M-S#:'6U$E-,A=40<@^Z M:O[O##
<^K6E67KU_"76^SCLM5.+UQO<>BP^Y,.RF82|H%83ETJ8NTEALJ MX>+W0"R#L]:BD%!2*2[$-7LM#[%'[++7M%,4]P2,-\Y?0-T8XXIG9B!..!O+?X;.RF\[9!D&)A-
G"BLL0VK,[(FV.NUI"DPF[M M_F-7WXRY)G#1WV^YT*2=NV]6YA-57N&DS/QI:0=/_/$Y9[Q\SH>VSHJQ5&= M6\I,>-4/2Z](46?Q*PVH46R*'[K1-],]++*5VQZNZ
MV(_[+W5'[8Y)4EQ(N75$5O?T21>3__$ZV*0'W10$=`4B" =,6N-IX9O:1\4VM#;B?4G99+@
ML8V&OF@Y'W1Z!)Q$[$D1Q5EH#5UBK#BZ6,6:W&JZP%:-POG@0'RO4QYQ//)"'2IF9S MO DT(.EMD1[\;F0K-ND!KO%036ZX0+.|\^-:2K$7"0M&;#:0H@6[AM:Q@<6ON
M?;+L.F<^+O?,7X!#"EC2=+//1>N'@%^"H3\[}#MV*=Z;&5=)GPQ.PA7']>M&QU(/@H9BD!7PQ>F;|>N% >ID4\(VY;?5TV/OP^<52G!5ZV MZ0^&=TNG;GHY0BI)TKI33 7!?
S#0GJ:=LF)\ 7;$)W M/+|)/3U2!GI,JH+POJ|IWK&+QD+W0VE0K?)I>,<7Y$",>2^U.$[13"\7? ; M=21\S+24|'Z'L^)L!U0RQN"WL:[@VD+D#$EKDR!W K[EYX\ VT]A67UI<)R=
M'?.\0%N?UJ;8!^47_G6%KW7&C<<^?Z\4/>|DW.|;Y97+BVE+_(}4KU4MP%T$ M&T[Y|II72Z"6;0N^1&R>E$PLCL!@? >UK6/OT$&D3FG+H1NFK M8JVS8'Y15RC?*_64[
SD]PG_4KPQ+'HN{ON;A\+UM<<2 MC#++2W<[RK7LUT3+[JF2Z-B]+BZHOJVG7=O-IV2L'TI_MRN$?]3YMWTY;ZL6U0]1L5O)5V$L$W'Y'@%3154-H.6..,3QR .![U-U6! F
M\7>5FTQ_M=PV']Z-L+'P"/|@N[[64'M[3E=_ZQI#4%D: M9@_A|>RD-N\-:WKAFAU ZBF*K_*[P<*ZG2.B>58"P'1X]*?4B MTX,_OE#_EV{}*KV73*[%T)PZ8$%MEQ'-;Q*Q>
[[K$7.EQ1$3RT'#XD*R<@_4 M^CA2X,(" D)[<77.&=`5&!<%8E[G9]3HHD QT2IKZ7OP#U!FE"?Q<_!&QK# MB4TI*@9L6BD)[N@HE*G3E7(Y54'A
R<0U2L>'BUI"^$WV41ECP"E!'QK$I(- MS'35E^QG#YDK%KE@4N_DI@7?$7B%H]IRUUW-\RUN0=5A8RJ;UGD$_1F5@IJ9(8!OK9B^[]9MAA-MAA=M8>;)O_(#;,"O#
(,;7OZ2"+PD&T,=`##^]/T(4&_TN(4/9=Y_HZR#]V;O M3X"L7*MB1V=GVVWP \-I,5(],.%08->RVH)<7^O3]L;^MZGZ#_)]>(JE%&X M=,7MZRT":D.&7FD'
..5R#ZZY'C;!ZFH'R"QY(5#R"&3\]2L:3'U"7_*] M.0SNDAPE(-UY;'4=&4QXVMTG&^NK^'A9$H4]K33B0>5]=_"9/L+2 MI\5D)=_"9/L+2 MI\5D)='=**B@24GT(NZ3];+G+'W)(T8M6-
%C&,!U^_# EQ?V-A MKJ6:B6CM-!I>=8G=E5 JZV<>?+$<;T,.6 P$V/4* M?$\&Y++]&O71G(8Z[">[L(.%DTZ"*Z)!%!9ML_1+5_47??S7'GY:D ->9A.@[M[Q'HP9\[QP;CC,I(7'DQ%H?
%BN4 XU%6Z1)G,GFI9E>]M[I%"WNB"@/NZOA MLSPN*\?2Q3@+^%,7<'J'9?8E]T?X/*+;'VWSLGO]YF=S3|;AF*'7W<"K&Y&+2E- M+.,!7%:*V.(+,X-S;Y"4%,PU"QD3'/\O9C>2-
4N(W4L;@P@+6Y<;N(/9YF"P) M>K.(@!"HDS^6EEFB$OE@Z>-?>!:,$HEXZYM\ 6$^2B=7{7[<^B"3L?MP^;]G8A.^H%WG1OIEF-]KU2P?
JF3M>C1N:71%-8:KUCO<922V_4]T\]-7Z<++?&<_Z.= M\3)E=CT(\(0ZQ2QN#$LD\8|K0C$9TU-+_ M8:-0.[W".9-!DA/.OZ'I2R?. MCUY#?2*2#RH3EF[857W["*_$S,W8S*
[@@@"-QH/?T/NM'L3/[CA%;_()D[(-MAM,[7-GN4^KO5]\'T\X*6O%_EH?[BV&L8I_!X+6\1?3#QCLL?H(YK!OP(N B%4O^=\K^/3#FE.'/M^X[_[H*_-<|)/H_?VM@>UHX
MIYN,;]0_)LD)CX WNG:W,\"ZHE>?'@$_"ZOOG0D7[_FP?>N'IR^X!WR_-SX1 M .Y&\/^C_?0_"G)/MB3Z]Q*I{(\X=^RM<+DT;20GH:@)N M_AY6Q^1*&"EC^,YG/1F-
$5FBSYINW#CAZSDINX]MYOI8>>;26;@'[UY'7_*] M.0SNDAPE(-UY;'4=&4QXVMTG&^NK^'A9$H4]K33B0>5]=_"9/L+2 MI\5D)=_"9/L+2 MI\5D)='=**B@24GT(NZ3];+G+'W)(T8M6-
M]Y$HY41'#K7IA3;'1/7THX1U{O'R)Q?*%?\O9[&$.),3O)'NY4T30UQJ3(Q%-MUD)O,N?+Z+*RI=_VD_8$,[=3WZDALN%U+U6GI)H=>-!JCN#D)3*YI-6RP5.L: MZMRV?

W+FF3F$.QEXG3,K=[(E1+NN_9Q&>3G"L/|H7@BT__X4]Y$9FI5ST'P%%+9R5]PXO:N39=@Y,'@$$?9>9 M!|;S2AD^ZK\45R$&"W=/B*

MJA:M)SI^/SX]%FT|O"CB#=RQLJR!QR;E4-;ZVH552B|@AN^&!OCIH,%9N_7-@$B\2O3>$%#KM6;4N,I=;[, M5'AK[D5/ A;WX-;U.D(\7'M3>;2N1

2#^W;M0B<61XX!UB>%);)XXJ#/M7>% M47LG42U"8#;=[#>0\2/CD)E-EYSGY^CQQA3A45,HKUR7K&,4^ZF+EI_X(K^N MJ}:)=YF[#WR,U]4T"D2;'O[,I$32.LPUVO0A)7!

(FA_XXM1R9^F/T,A,E/G M=R&Q4/Y(@-H(O+|QPM:L(89N//YW4KT2<1Z_1%0:=E8&,GX,\:Q G+3B'S.M.$??;L>Y&U>.RU%R?Q0#DN>\/OAGW^PLMGO_=>

*<2_I((<*ZY'SQ>^9Q[ZHO, MEV/B;9YY]?ES=T:9$-/F.E#I=R89M3"*0>W=TS%,,13%IL4\/^//B)D)F%- M@W]TI'\N\5'U5)|01M,?RK>Q\9HJTZUU5,,);+<=;OZL^3VGAWKD?*

E.6V)}TNSUVA+!%)#F>Z%^I;-WHI,P MIT=>Q"3O"3!P9QS^!P_ ?U=U?E]ME79,U|6L9]F M1N;D+%|(YGSF;[RH",;NLZ^MIG[NAU[[49+D_54RD]/4JT%2DD3O5<>|/#R_I*

*M7*T^M}>U;Q8\!FIU#\;OPVNTY53,|X6L#HH-!$T012G%,G:S*&>[6*3D9]M=.#4(+65!_]_9>P++>?FCISMT8-4_^]-P7ZA\N8VTH'>#4?0?,<0+$PCTUFV-3*

M%@P$=M4/;#Z#&&T+#U5%EAO4RE&(R"?W6/SZ)RX]1>BU39,9Z/5^JJ"A:V/EPDI]F*B;X/WS>>_]DW4,GZS3X+Q6=]D '19)7GJ^YC@>4&T2BOU28'L".IU+7U%= M2SV,[?*

@2 56.'[V0Z+VT]3!?5;^PPR&)63M2\|@O9%:6R.5OQ.?&-I ,P\ M_F>9.4;_+']Q0 KBML#NR8KCIW7DTM'2&9]:W2:ROPGG+04FBR:AR]5+ JB1 MW@, Z.^9K/X)1-0_&?Y5.S/|-5@

!D !W879D,C R-# Y,C-?!(?@KAT@0&CNY_GWGO.ZJ=^K;7FK%$U:]28W;-A?V#K@#>RDC*2 #@X.,"7EP\ M@00 M!Z @(2$C(:

((@(R.CH]@8>"^OD!'QR#$>8N%2TI$3D9*1$)"0=E8&;GX,;F}J?C%^;C%&+EXN;\:Q X5%14#'0,@M>O"(3@I22@Y_W!?L$X M-@H#@JP"ML.'AL.%@O@!P @$,$^\<%^,!+[A4*

*B(2,@HJ&OK+ W5O M_*_@X.%?(< C(B(@O-SU?KD/0,!&Q*D$$-Z]_P5FE|,W*@L%^+&]"T[E M\IR;ZYN#'RK;.WP"0B(;6CIZ!D9NGO>\|?/"X\(D)*6D9615U=0U-+6T=8R, M34S-*

S"TL'9V<75S=W#W\?P8$!OT*!D?'Q,,%)R0F)6?GY.,E%Q06%5??U-;5 M-S0V-7?W]/;U#_P>`)]:GIF=F_^SL+BQN;6]L[NW?W!X<7EU?7-[!{E_^ L7 M' >[I_7_X@+ ^P77*P0$>

3DOW#!O7+!JZP%L!$1*#B0<,67DK_9O]3A]47__M1F55=;$"N53.\,XY3"]H^>>H+GX"]H_D/U__^;W?X3L7|^ C6L1@$ &)Y(\ M>&R *_#N@3Y?>NF;Z37"Q0=4ZLF/+7E1V-*

*[;/PJWVNJ2Z@<\6RIVE+"PW.F,Z]2$P[MD+B*AAKY)9O,N<1EDANA%PT29JU*\[XXA-FE]ZUWC5FDG'] M?K64.REI9(8^^8/T_D0*

*<\NJTDG'16E%V4!IL2#8*25,FE..938MK)7)84A6 M.E#\|=AI&??J5)BQUS4=.$WK?USW@IC\-UV+ I49O.1B49NC.);Q8/6N1TO,ZMOJ!M<[>WMK(N*

M#$FD;0P@>SP6?/I.DXUL>H!82KC&/!E0, HPX-AD^3J9R?>^<+*>PK>/&KX? M+DY=M0".#7+R4H;!03C2VL!4R^%8+C^-$?]W'|=^NS,R&P@P/!?AMD>,"50 MR(R+8Q^M

*"B8,VB" %5H*JAVLK]Z M.58;"YT5<6S\|#*TG<5]M+HX %\|HA"B3!H6E18/*+!1"DFUNJSCC{J2R6]L- M\:WLBP?>Y]9?#5@!BY]_-37%F1BK#YR? GR\-*

'Y">95B)/VFAY)F5K>C=,M MN#Y'O4)B@P7;KB)95QO_9Z??3LV7RRR"<+&O1 M4.<_?AL[->]'>@=*/OF+#F0H/$NP%0\G]3\B"]2-2V>W{EH;*L|YIZ"W,*P< M9W*

),G,@FR:(DW$?(Z,=Z/;AC M5CY-CKM,DM.2CMNE_$#.A"?D!Q>6D-DL4[F2N]"[TC7D]8$!S"C!7-]-=(/A MZX%D/Z%.WA!ZRV4P@+3/I,Y>EK)>>>$;IE:L('70P#<'J'6M^S)>!Z.'+

*>BY M=X](B+*E".5,6:L<;1QA3]ML1V2ZF& F4Q*Q2"]YGM3LC]>['O]L^!CXL@(B M?1-<-G*

*,#!)%B#QU4U*I6FVET/ 3(%.5OC]P:F M9'N!F)!]'5?-=V#Z(@)E"5S ?YJ;XQ&.^?@(I_RB>[:%3L1%0!'=42Q.(K3 K*BJ+* M'5R37@'@MC&>M\;L!QG+&D*=FJR%[K?*

*-13VI$.A'[((0&TDP4Q]GTPP_0>>2 MEP<[]97ZAT|0BB/[%,00+@N678H=W#Y;C[;G<..P)U$[2PA&2S)KIB?2^2N(M]/4YVO ,6LL-;^I3G@'K=*M-8VPFJZJN7@^/L7,R-*

CS1+!\0D M411G?C8.C4AT<"+_>/%9$M47#82^L[<>)_/RQ\?S]I4>2 72WHH M/1BZ:NZR?X3MHR61N.0E@S2ZZ(FP(052"7 V?,.H93!/39?{IDE/1S565N-*

*MC&.X-7[HX8&U"8/I.V@%<-@E%3BYIC*L-P(CE.4>TR2M4@*B],+#U$B K.S(.M)#QB, "%9>)3X$R!E5.@%N6O;.B)(>$>(=|-87XX[4U&F%QL^1;!M*

*M<15G_1PT#;PJPN^I!)E:S+WF.M7X7'8%|SCR"B":#D++PO=CWJAZ-^CX7BB) MRFS+T>9+9\QA+H926T#:(_257CS=;*NV57ZM[YOQ'>I ^29B[?=L;8*G)++//*

M@AK0J.K&9/J$.P=.]K/^X#0,3OW ^V@;NQ\W'3GZREYQB&:,\NP_@\Y?"<_ M+TD%LAS|NS1 P-DRL[;H?_ EK5=[JY#K#]2*85%#:R!Z8C@02&(CK?*

*5RW{F3=,WN;WMK[P7'T&[H1 MGH5GR!8^LJJ/-MG?NFARVVCI9R^:MM@6W(\WH#J-QI=R=QI*54-;@(FB;9;+UF M/9(&WV!D)7PE<&/?CEMQ93SG_WW*F-N.HMF^FIS7K?*

U<;.K=]19_*EL)U"53V[Q.:+M\.V2E@8DJ*&+CM MX461__@22!\[$-;K^H:.."K6^Z,]D0E<7 3^F&)[#5O?TJIZ%ZHKEE0Q+R'T8 M10!>'O\@)Y*;"X6=!,XMRSZ#I^*

*^E\I%[XM^,2)MY;9#*7X4S$*]QG&\Y,9O M0[2 &I%K!/_X;= 06T?8 MW7D9U%SE*?Q6:"^].B/[H+ H!FT:'G#!D"C572-@98\$C/0_%QN+\L#!-AHQ MF4=&'+'*

I;1\6^'T_:!\]6^OQ]1K;!GU5M>;N;I1PD]FXJQX'!RSXW?O& 9XI M=VPC,A4C@I>`M'I@)@ '$\)4AD>E-)491)P;(^+BME<"XCEA[&9B,. -$R>A09V!=:,CU5 6-F

*MI]BBMNQ^_T)N>6QKK7';O3F96#Q.+*GE# C5Y!3"MV/Y#B2;2;<,>8O181(2 MP-" :,_X%-71VYBN^K3D<6YN\|VNR5?HNA:L ^RO'19">]_?E1^AZ<*>H*

MXUUB:#BG%QI.9ZBO99(V;WNF7-D6Q4:-# P1_98LMIWN5H4,QEKZ&V%"B MSU^]<3A_W@T<:-Z(HA|SV=WF9:QHOY.Q:UOXURT;1-04.Q&+_TO8"ZZ>0&EV4XQHQT

+AA^%V@CZ6$\;=_#VP)M%W-/9MI\?ETZ.M%ZC^!'ME:YZG_+[-S%'2]2X0IPN% >2TJU)1B&G,BD!!IH?=TITND@159G@ 5/4]=, MX(P$AO+W3]X,V(^EAC0M]+Z$OIV?

*P=UTY$_4<7LRWMSH.;E6@6JKS2V/VT1 M'(EK.5V!SGJOB^I15EZDE%-&^8LAX.X.WF4E<275<.IFOO-]X#L965-?MVW.#74?5Y?O3CA?/W\ MAGJ)(2I*Q>8.JS-JN>YG?*

*FT:8.6U\OOH"_A(~^=,_]0:7>]J3;<,^5./?D M@81(§I4BA%&$1^BVWVUVY;0A70[QZ2)$D4SY'>^R6^7[1PFA!1^?)U_,F*Z MSO@UDX9@VP+-*

^GH]DC&'6WCU8KI'IXAP5XKQ[]+8]B MTP%;Q$CT.SU6)2I|/8M9=!N029'572AX$Q?^/IX=/=#"29V/I*%R-U>$8^(C M,.5F\8)|[?:I1YWOVI)7HY#C:G7"QDZ[CN+M=]*

*[H4K2+$;"R%O-PEQ>H5]!" M\;-ZB2)BEP6)'U.I#$V.KB##*6POFI1#K?]XE7)[%=YG+U_'%(&OE:*$'LR)H/\^G*2 DYT>$8%'06% MT37KL]3]6!@'-*

^M3=HQQ$[;$>]/6/&F1'6PMF1>HL=IE8D=;5RN!BE\|\ M(D!C[&!@>+]:BOC7%N5_MUP*;/^)F[SL'WR>,$# _;*$UMP[N <-D<).5K MY#RUH T)/VDB?=F#3F%\YC $A M5:;,*

(P-%U#?<&5<;]3+C?VK014|&3QWOZPIP80%K7)ZS\D2#@WT84A+I/_'_I!@X&OCV MX=5:+5+#/]L4F5B1>544'U0-DB_;;OK)11<_>MQ.+S7]+8L|A7IUZ;4OIUI*

M@H^?@iKD#LJL9?OKFV1RNY9+[2|OI]+ USH,SU^=?ST71+WT20LKP\4N(L_>MR&79ZIY;^4DI HT_757CYW?;%VK;LT\?G5HXJU?H:3_<(6$;VTFNOC)FV"LD

MU[G^C"7+\;%7PCN6;-%HH:K+A9ISS;=R)#+U+Z%9+-46<)1>,0/3)_YZI]6 MG?E"Z\EWT++;O,,!$;IG.D#]4TFKMX>:%'3]&%PO+ZLN_;"%S(_^G_/QEI:,. M4*%U&*"B$'3-H>.<5*

X;2"N_N<&\"|C)F75.*APF\OQ/65+{)O_&M-?^EC\ M_TJ;,&W>38%"A%7^0,B@#*F*!M36A2>[H,.]) MT^1LSWP*.FL@W2N#TS4:4I7PA,WC.^$RZ\V08-*

8.$56:;\NXK(\7)>ZMS,= M@*4##NT_%#ETJ;BIHLUMRXI1T5U*8N=_M%73T-7;X2\4^F\(_](VK"N>X3)@ M@%?($,TD91V0Z49'PH6)MT&&T31HPX;M&2X%"@-$G.=

WVV^9(&PXPP" Z!= M,=)#QWI ,)L|A]>/9"DP +HU:!\#!KA[@6H1FQ&EU?8.SY'K@EQY\)V?OM M33\77QV&@;9V8(!E\KF(XV.!1]$0HBS%JD/1\P9\Z(1\& T %%^&<;^99BU*

*MOT9QC\,%F7OI(<>7;0YO(0#X,T+UL+ #/^ PP@/#>^TP0*RC>KIKR M_L|B!('0=T|F+P7K;/B\/5I-I*J4F^SW301:MUPH&^ & & W1L/3%>$>WT!4R9QI^6L;H,"W$H?*

RD:6&; KLF^>#I-HPK6BO64-MW3!X+Z',DU\V9FX'(!O&:=O)Y,\+'0^S]) C9&LDU9M&\@T##@FVPI=5FW#% M=NC40O;;1Y#.%JL#BH@%I8V!XE>_>-*

CZTL9Q12')%I/T#X'DE=X]$49_8(- M3[9G]'$8P%<V&6XXYKMO]ZK]4&+)(5=$RNEO/G5A%B,/A2 U1G;D[5,>B\ M+08:L <#=&;! +V3+_%>$-TW

*#VAD3,)NZW@MF<%G=S'W<@*1QC_-77&-9OH M/Z;.^/MT5OWI.8<$/FN)W@H11@NB&YYT__8Y!XK?#/HWN&;EO'! ELDU&5@7&R 2\P"|=^ ^0?W^A&C31_M\O7-*

+X/PY<%KWRG=#\Y.#!IA'!6L^&^IJ2.+U> MA-\,;K(@>DX/NN ^@QC 0P-N_QO&?-2D+G,&6H-AB-#]YM(B UFS"&^%-QP, M<$[!\BRH^\SP 2

\18AX'2$87'$<2O>2O.&EF5./NR?6FY=E!/\"2_I%EOD+ MYM6.:P#H"?4E',ZO<4'&7T5?UM_MC6!ZVTNHVD#[@!LO?.Q1OH@ M7"X%T8Q4N7?RA_[N?]F&@9-

#5^%LMK!D(_+5_Q?@G'.MH=,I@,: P&V[-3- M\;.1%4L4/D94=[U9>ER@?'SAAREG\;+KY_-Y&=SUKYZVSIT7(!]D'YBO/&

*M(F[E1*5R#1>;C*J/@#"/KD6#VZDGZP=H.CL:R"_']N*?B"NN*D3:)50$IN)& MC8+UE:_E\7K=;#==@BIP_5P?$;?L=Q1\-$2/&\0?-+^C"($O+">+)/7]\)(F M'1F8LE[(:23S?*

^3,L_O$CG]\)U!&- 8#)(5 5T"WEH5A1-S*$M)^F]#>Z1B:43T.-E M,N2F&YIYGUWC;QZ'.FJI:U$3,BE\\J-,PN5AS>@^@>L1+ZRY MV_,]HN1TVL MJ;EB'G$849#)S6Z/#B=+

*(UA$N:9$Z=)^X5'==W_[@I8(!A@8A@$:1 MO#H>_I\F$&+_NCMH&HXR_+M+S:=VN*3PY-OJL^**\LR\L+TCS4S+MN@' 30% M#=8WWVMBS(IO_L__$>4!Q8TOFS_,;J$ H*

*M+X-3^8$9W3:7AIW+&*8=?;3>,_^%A"-FR/+2&#MYIO"WZ >B%'H/L4CKN%F'5% M$*HO>WH)HL@&,XY]^<_XYIU IOY:+W#TV6# ?X;RNZM\O#L#A\]?V=6Q#:MUM*

M.M^EL6TR!|0')-YG'ZNA7]A:1]B#WB\<[%LA5]DWH]ANE2@H.TWAB^?]8=B(.M?&__ME)\UYSD>8D%EJ6,=X&'49S/BX3&\'\L%00_X'>3<51=V&3L=GJ5-'9>

MG21>!LUX5+1YI8NRI!->26E!I;P9ASR$QZ+\|+!7,R_]TZ9_&) @U97MTA@$6 M2B1K.G;_P0 -AL_)Q4#) #%W=\2 U 973I2-8#E!LNZ""@I(R;+C.V2=!WH*

M6LI[^0#YV3@\0^P&E>/CWDTHZR++1YN26OH5DM.]3T8SXS4WXE(531$DC%QT MQQ,@R6E_Z%.6!?N .KO4 M2%F6A>

\7]7TKJ7,;>;KG]XL6L2=I$=58=EUDHTS0]G/R@$2BM:IA!42Y8C- MWT=+AQ;-E?)'E8Y $?!IK;5__F 6?;^[9TK$I [02+^ONRNIU__B86:9!. M3[%HLE3B>WKPBEG<6#G-*

*QP;/YG8RQ\P *8#BK"@ID!_WW!& [VOKP MN^SF9HD8RC8Q=I%2*2W 0-DFNI87[#G).P#9U)DK)47/C%/[M&,E]]K^4, 3HX:,V5]M>C+W>;4L3->D;?(R-^4NT:,5Q:[GQ53Z*

MF[O?WXFZ0?0514@<R[DY>+ MGZB4)>30;/B%D67M0F)+?U7H<%LT_7927K<1]E2K53;(_9)=&A%9H>.UIBQ#+7T6.:MK80/0X]-4 M=C4^?2@L3*

*G_$<;WQ.+.7",9TIFJUB[FC*$VN.(8SG'HMEL"^J. FYQPIF+Y M5[)M30OI$NI;U"W']773P%FVTE.Z\$.*T#*.Q $A0P?QIP^@]*G(P_G(CR'4*

*M2K;F.MSITNV.;XV_D"LHO/I25M<@X9G7Y"4@M//N[A.JZTY/)-^91"W?Y>'3 M5DS?RN\L"-TU-PD3OX^F^/;F'"%#.$>T@I5#W^7|>,X(U22IHH2^^0FN+J3= -*5-NG4VK'L ;\]AO*

MLMQ(L%7A$Z/C,P>TH:=X7S, .$SN!"@ 8# M?%'3Q'=8SOVH@A+*KH?A_&W@AK:<,6^>ZS7*2\G_^9>6+ED4J?#.LHP\?(_C M|MCK018N6'3+(PE2=0@++I*3;^^NV-I*

*#MIG9VT:S[6?%+DZ+''XC48 MK+1N-!!&D=0#BO M'/C6 1)EL:^0DR\C'59>9*ZVCHO5VB/8!8]BM#*&M[]0#P%B0J^ JRSU\,/DF$#RLOYV4&>Y1@KL\H];#T#F-@*

*M"U4W=6>SRCPQU4RU$QS>%5<;RI%&DV^('D+%?>_GA64FKY)W M$]Z"I2B.3?;'!^L'^8AL X$3T<2MZW)RE:F*VI0(H%*=&_5)H!V;^.1\'MIU MR4!\;G@*

*WZ@.M.FNM#'7S31<[?&B MT7F\D'>WJP^OE2*3&6]NNJHG>Q^(FFZM3Z@GA4N28EVSEWW0ND]?9DS\;2")-M$3E3_$5[>_+/:LF63[*DF%;O E$;)T<)#,.CKX3<'H&R'FD*

*IJD0NUOBDY8 MC8@8.7?1_K67R"T<^"^&FG=O9CB<%U%[A2]*G>8=!%7MSC$EI'''FWJY#UJ_: MYOC@YW<_,(.Z]HHR;@'T'6C&2C$AL/3WN.Q-UQ*1P #QU\E&I"!$D\'19;X6F*

*M/N@V*QW]|SR6W@-B/ M6LKBV/5P%J0Y.O.=],N)D)07Z&[B +)9K9#FPH;\UX5_9>O!=7EV#;_.%KP MB\9:D)=%B9O[4^;/H]_/4M6=AIH&%$R*

]OR$V5GUA.XZ^Q"I_53."IJVVICM4I:K8P9R(]S_5^5]OK>R:-[HS]:A,C4\;AY.G0 MKNE3P_M1R[6%*VW=CY_;G;BDXKUB&FS$]CT(" E@&]5C=C$2106T?0]=&Z-*

*MDMCLPU\!!+*K"]2& G;H?89 M6UK;/,3U+)Y<$GU4>]<(!75*9);NB@)H$%VHCVEP576^?4W";4 Q7*+75Z0 MS]0.3&O2K).O(@SI(0!!"[DQ/.*

*[DZD'N.JOZ*VI=%IGV0F@W;TW)XX>Y7L MCJ9GIF\O:1P/DQGY:.5^ 9-I7Y. 2;5<$8S5XL[GA"G^0UC",2%KM>MS[H]> M-(M_&+1:7RV\FF[VK1>6S@.I=@H5U8]A-^& 2AU-*

XH>98N%1QG+;0N\UWC M%]7X7;^-*#I8T&>W-S&9>_C]\&/ZNV^22EBS(_%VM:7OC0Q5STZTS\581GOM M/@;LQ'53A6_/MT&,/OCW- NY5/V8RDBV*

*.RL=6S\T<04Q#^F/#T=L5+?UK&A M]=U{?<Q%^R9ZQ;&HV-6%788MT[.CC1<=5DI]*7*!.90S/G6>[P_ C)7MW?I?V MS;?^C@DR7K^+/3<>V ZH(#D?#[M1A$@\R9*))?*

6<8O/;Q@K-F>?"EGTX+?"Q<&<][NXT>.!N=-M&_MTHYM:5Q4 MR@NH@WH 3!H2$P/4^= M?I%W9MV9]..6QDRY.WH^BW!OH"3=6N8#9ES-*

*>N*QU^^M]IE=Z=+K:U!%EN@^_MGWUX2/@QB:>FH:\?1.CS[QR\]0TWA[+7];9D:AZQ\\TFMVWOVI#R#H%8E]'1XTX]E6R&79A1DL&51NO6WH5;<%V-#=FK>Z80#K3W6!*

*MEZNG[:6VI]D,VR(' CNDG)OEV1D@&Z#2]GP &V(O6*5_VX>E3_E1YO<-[^O- MK*76MR"X5T[\'1Z0Q1$7Z'+1]-<3>S*[= MI&P9Y&(_ Y]6FIKT)L5#<57*

[TYG/SK[\ZK:G[']?P@";)0O2?T3_MGX25,46&5)\'$"4 V_2SBD!]$<0(ED'C$8\Y3E)9Y-A^<'X-]8?A(MF5"): M1;++;N$M+O8RW]^CH9FS$[]WD9&UP"%L(=L|/IPJ^_M^)9\4YW')-[%

M:]P^G#3+Y2Q+X8Q=Q">KUNLQ#-BTFH45LLD4& M_9EK\?3DZ5_)6MHQ/*?? MT#PG*+Z9!IET;>H,W^?&]- ':;A:L!]FV<@;B?Z_0\%7H](AD$9]9A*

*Z#24.LQ*E;K20\C^>]'$f]"3%?%WLPG^>@=&,?=(&01(BF"MSZG0I#:=UHC-IK&V;\(L$=_07;QV!>'AC@S7IA-OC!<5+0,-!#]^WB|>KO MIO!15SB;HHYWHY_FJ>?CS_&7:_'?*

*[B&1=OX+]3%!P^4.[(7OAWB\)?'3)K=P,S MWR?Y"^O^O*U';^#G>$E_1:EPMZL?4U'Q_^7X$6,E$ =RK,&-EA,Z5?5+UO* MX&[PRLXG7.:[G&]XII)>'%]GO;F6GOT)NI6B_<<(=8|*

*MZ)XE_@2IG[I==BUS=>(-,,7G,[P_#H$RRIUA&^0%IE\|UH7.VW2&F4X@K*C&^Z!?6+0 MEN_%,E5Z@CB4-5.,=K7'BS"G6H1K@>;P:?=S7HC!A*CP$2[*8VBP:?!AU]W5*

M,4:@4D(O?!# >5IZ+&ZT94|)/GH>ARIS[5L>'?;)W]33[\-CM-3#/.M-:\N6:VG6I19_4@IJQ8AFOP53H1M99Y!?!:]0%$BI62;04RGQ:.E85 G&4-*

*M7S+ZFCR17W1B{R\4;79DH*C.*"0G#ST-AU0"_RX^(E#TF!?YIL_E-C[^]GW5 MXF)W9!?.B?26'B+\A(8KV+IO/]".7GK,>CFBD)!\[(5]EE1@,OI4GM%.7;,]*]GXPM\$D>L2Y*0RH*

;MEG&O"/9#M_%W7. M-^R9=T>+E7$>&I"$50%GBO32K=E_J/,JIL)3]XF;I3/(#R?I5IX\O@B-IE!R M12L5:WKA0-6E)Y&ZN"R(RY$,)"7O0"!7D%HNS\;G^(>QG[8GS&D_N#,ZVNI

*MGDS;]"O5^BV:'?(V4)&B;)47@548FB6-D%^QO&8/(7<[9K7LP!?5]FAI"&A- MQ3%,/TB"G5RDJ\Y+AN],T^=W9L+Z'6?-3!!4ZW 0.4#MB)^!XH*M@[W<79D;?*

M9VFFOZ:S;"$Y6[ZJ^W/1Z^[7K|[-O;?;[^TY&M=5X&0F!/?49L0':TJ.4(H9 M],"K<5M>>;$B0K|\,Z:?\0P4<=EQA-3B@1HD_]J2EK+[R0[RYIQ@A@_# &G" M4T^-

*_KP55BMI5F//7AS)KR9HD@Z*A&3K."'"T#D_;.-;X+[7QU-$LQ803@;$,_MMBD\]E$#4\5+"Z/,BM3O+ ^2HRI'E$TD-TW.ORS*

*M3L!|M=O&B]|"RA,Z'VX2@IP76&\0DD[RZMU(OQ+2N0AZV.L=3Q*8F@^.37?= MD(9QEMNK X=N3609[6L$@9$<8%)6S=:2T&XVA;_3FP7?"'1QZ>[^\^ LA M9DKODG\;8?**

*.Bi&& 0%;B/@.L62$.#Z^%XTS>9*=0A\&&8BS M?2M41^6[^N>Y7?-9F/C0OPR-$PRDOX9*C(N"!A]>|'/8K<3(1%0]GGA+\ M'UX.Y1B+0?[']5OZ["4*7+*

{DFY#POIG^7A)$DDK%DV"ETMA){5>'WJT#^>P00/%IT^)Q$P"?-TYA\E'R M.3!\)58XH>FW]D^7{(24^-1H5]^",$O;1SA4%O7'C9O)1VL#^7/X-XR9/3U'_-E"Z5>IU=]R1O;VU?

*H?!]#NY[MXB=V5KPVQ3V%"2]>Q_+[*_=)[8/;'N?1XSU4\LH;D5F;6B/%=(]7\BU4?H8C MR7K)=@NW[C0X#22GI/S%=7/$BH#>53G+YIG1B64IFRR1%D6^8H_Q@-'P],.Z*

*M)$^R@MP:,U[L\KG@-FK#C=*OX()1*QZ?PWF&KE2HQ0>6;K\]8<"BPE@R?O-+K=6E:O?+IF?DB2YWTE"R+C. ^HF'/D3=*Q6.RW PUMZM_%'VCPB)=C*

*MR]TQ(H=1#-\S %>&SE2X/CG*X,C^6M)0^[-%*BDVL(NH+-,G*;O(=-2L`). M1S8A\U\LUC@\%3D/Z5@BBE@DVB+NQ\QF2H.=1TQ:ZU:.SB1.#H*

*M]U4#.';2\N\6*TO5@#T1%VST%6Y-3*(=NF*SUATPN6" S(BA/&!.)7MH(_QL MDI&2,1]3-/]I..J1K7R\<8?5Y.RX9B3=4"+['ODS< M$Z9EN7W:\R76Y3])?*

*^:*L.5+CBWZ]LI'X"KK &L@6C:?.EX3MYIH94,^ OC4 M!(V!%O=.?:,=GV%HA\)S*+A0-92;'S*+]f<4:,9@/>^:.H^@7_]-.:L]D< M5?9'U,CFI9V15>1%@?[*5OZ["4*7+*

{DFY#POIG^7A)$DDK%DV"ETMA){5>'WJT#^>P00/%IT^)Q$P"?-TYA\E'R M.3!\)58XH>FW]D^7{(24^-1H5]^",$O;1SA4%O7'C9O)1VL#^7/X-XR9/3U'_-E"Z5>IU=]R1O;VU?

*H?!]#NY[MXB=V5KPVQ3V%"2]>Q_+[*_=)[8/;'N?1XSU4\LH;D5F;6B/%=(]7\BU4?H8C MR7K)=@NW[C0X#22GI/S%=7/$BH#>53G+YIG1B64IFRR1%D6^8H_Q@-'P],.Z*

*M)$^R@MP:,U[L\KG@-FK#C=*OX()1*QZ?PWF&KE2HQ0>6;K\]8<"BPE@R?O-+K=6E:O?+IF?DB2YWTE"R+C. ^HF'/D3=*Q6.RW PUMZM_%'VCPB)=C*

*MR]TQ(H=1#-\S %>&SE2X/CG*X,C^6M)0^[-%*BDVL(NH+-,G*;O(=-2L`). M1S8A\U\LUC@\%3D/Z5@BBE@DVB+NQ\QF2H.=1TQ:ZU:.SB1.#H*

*M]U4#.';2\N\6*TO5@#T1%VST%6Y-3*(=NF*SUATPN6" S(BA/&!.)7MH(_QL MDI&2,1]3-/]I..J1K7R\<8?5Y.RX9B3=4"+['ODS< M$Z9EN7W:\R76Y3])?*

*^:*L.5+CBWZ]LI'X"KK &L@6C:?.EX3MYIH94,^ OC4 M!(V!%O=.?:,=GV%HA\)S*+A0-92;'S*+]f<4:,9@/>^:.H^@7_]-.:L]D< M5?9'U,CFI9V15>1%@?[*5OZ[^+-*

]=5304TV(O?H4L\X5W;BQ'4L1_WE5:[*R6M(_M!3,9>:T[0Z7L"PV;-=WPC/YR9LY1M"]QYK<&R0?)S+Y,I37|$]*6]V=CLP-; M*-;0:-!Q7M37UI.QM?I-!@L/4P.:C-*

*0+CX2"&]RODV3/94+ M%@VROU?S /#A'2_*H4"1]ES)%Z;N8 "/5GKO20,-,8*F&:\2]:PVJ]PP4IPA M%BE-ORG[]X,R"-U-P'"LZ;F&)[$-A,EK@O*O4?GQ=#" M)>=V/Z'DW!1@=W:*

M9]DSN;9'B=1^!@Z_#[^!${LM@{D.FN+;>EUMCNEQ?X&!GE?L6C!U/)O%.7I-17$,?LSRFO/2NB_/O9P+>^.1_(;LX5%6F]-M-56 .W 4XC! !/F!08]>1(\W92T(88$ZN-[JAPTUVS=F0N:]O1]$.T8 #T\(P-R+SO,&[DY_.A .HP M<'-Z9GAV>PQ+KZ>L7H63!Y_[E>1*H+($WGY* O>SRMEG!^OM>\75L";-)Z;I M^@N)W$Z6;B$,CZ@K%@=N39KO>$1CESIW7>XX[M(T'&,>6K%B\H@AN[F33_NO6BN3 A^SY>W-2[A&!LO M\CBXO%MP(s]&LSM]H+'@,>MQ61>TQI,Q=P0#<-$MCC<-BI]?]4R+[Q:VJU^[-MWV;\E_!-+@\0^\OTZ_L[C>-<_QD;]MV5_*8;Z2.]XB?P4 M/O^R>&" :SB#<%V#/-DR!=YN5"V[K:>VCVV!4?AK4)R M)[]AR*SE/H^@8:VNB=09<-OS45-46T8[C3UNXB6I(?^/$Q'_9;Z<6KJO&^;S M%-6ZNGZ76"XE\"PM%INQ1LW-P0 M8R0E4(Q,7!^O@3P37@?.+6'"S-S6:'BB?DLSO?S2AL6XJ]VC]T!%1S#%>&% MUC7BO/-3@R++9HH?]{=&@(:L'R>YAR;,Q1GW^)["'+;DF^H,DLT\';?QWE+) MHO?]_D#)B]"(9Y+X*8Z?'%4K(Z*P+W"6.J M]91>=''P$!N\?I4U5&RAY8$9U#/(+.'(WZC]O4/#@$(E/QK]O\(NS$![?@O9 ML&*(UX=:-,&BA/-X9Z9BfA:QEC05I\ABM<+OF/E NJTBG? :L5$#C5M\'#8L8!&& O M#^5F4RN9K4=^$"M=(Q40N"7XX>:945!N3OIU:GR1*fK(=7"#B6&^6H70@W7> M>V.X(:T+,#]"?+5/,TK&YD:,]>,*T-V+R;9IH])*I0S'!\-"8'KJ#.=A S[9UQ@C[G@8 MP,QE@,;59GR>Q[YN)GJ*)KD?=3?IL+D/L\"X5H3&;3$I[01]H? M_"K2[#*#$TMSO$R@IQM++#Z[%]RXX"!\65AEP/G89T"USMK[Q[M,76)EM7;5= MH 0?#"%7QUE/^?!Q4(_-_-[M7%YNQU??]$UC_M!,P2_=6J:% (00$L%-=Z;XMF&>F'U5PF@W8%^0O&MR<6M50Z%&US7\1-9+IYDZFR5(AP#-08 M&7J;'>WB)]_D\>;[6+NT6X)\3YQ?07]N*L@A3B_[#5^&MYT*VXS M_2&![MIDN,YHCIEV#-R3^=:M<%X3 MW-2;F93'%'53 M6^ 3%>*3CTOJNF+MY)BR'DAT=]J?@;I35ACL?E?',0^ G/-MLVWX16G3;I?U!ZD7=H-UP9FR)BA>@7Z3.TEVH3('PO%%76;X'R)M7ZW2]!53E_SH,_[?C ME?]MBE*^A^)TP.3)-2,-T[###Z?"M/CD3/6RL\"*&Z*^1263/V=F)R_Y4H7V M%;/%)'#5$_]OJOX_CL#?JVV"JG#D RUU]0)0@L)XMVHH:X,[GM# MTYFS;VG#@KWO0.R]0O7(N^2K@G9ZZ-TU5S$I@IS-52S!Z..K55 MZ!Q87)RG>WSW':OCPO;RT7PL3N.U:[H6@4=WFY0X8;4]LQ41%2?>]&_-2V M2=XXH)RHC-L+#P_4)6O M99@+8:64\U\7G9QR+\FPG+*T#Y*87V6[^^KG]E0=$"@!\J3\)OQE2EM\XR^N2 MWA]?T(=_Z=YF0C! RU7)%'=ZL[5U!="]I>GF-9VFH1VQAP!N7,,&"&,5 M4J*IRZ2DPG-?D!I.97AQC?N\B.V8,H&WD_U>A!0B_"1?&A(2*[H0'TZD(H7# MJY2Q=7)3D?4!+1/N!{D)L3H[YK<>[.*0T((+?51DI9{1WC(E_ZN2ZPYJ;FOB M45"]{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{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}E+GAM;%!+ 0(4 Q0 (*@R.UE&X%0H!R .GR - M " 2=W 0!E>%)W,C8V,3(N;'1M4$L! A0#% @]#([60KD97=+(M$,X T (!69%\]W,CWO.O)!0 .AH M T (!E>\! &5X7S XML 152 wavd20240923_s1_htm.xml IDEA: XBRL DOCUMENT 0000803578 2024-01-012024-06-30 0000803578 2024-06-30 0000803578 2023-12-31 0000803578 us-gaap:RelatedPartyMember 2024-06-30 0000803578 us-gaap:RelatedPartyMember 2023-12-31 0000803578 2024-01-012024-06-30 0000803578 2023-01-012023-06-30 0000803578 us-gaap:PreferredStockMember 2023-12-31 0000803578 aiff:PreferredStockNumberOfSharesToBeIssuedMember 2023-12-31 0000803578 us-gaap:CommonStockMember 2023-12-31 0000803578 aiff:CommonStockNumberOfSharesToBeIssuedMember 2023-12-31 0000803578 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000803578 us-gaap:RetainedEarningsMember 2023-12-31 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberaiff:PreferredStockNumberOfSharesToBeIssuedMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberaiff:CommonStockNumberOfSharesToBeIssuedMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesCPreferredStockMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesCPreferredStockMember 2024-01-012024-06-30 0000803578 us-gaap:PreferredStockMember 2024-01-012024-06-30 0000803578 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-06-30 0000803578 us-gaap:RetainedEarningsMember 2024-01-012024-06-30 0000803578 us-gaap:PreferredStockMember 2024-06-30 0000803578 aiff:PreferredStockNumberOfSharesToBeIssuedMember 2024-06-30 0000803578 us-gaap:CommonStockMember 2024-06-30 0000803578 aiff:CommonStockNumberOfSharesToBeIssuedMember 2024-06-30 0000803578 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000803578 us-gaap:RetainedEarningsMember 2024-06-30 0000803578 us-gaap:PreferredStockMember 2022-12-31 0000803578 aiff:PreferredStockNumberOfSharesToBeIssuedMember 2022-12-31 0000803578 us-gaap:CommonStockMember 2022-12-31 0000803578 aiff:CommonStockNumberOfSharesToBeIssuedMember 2022-12-31 0000803578 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000803578 us-gaap:RetainedEarningsMember 2022-12-31 0000803578 2022-12-31 0000803578 aiff:PreferredStockNumberOfSharesToBeIssuedMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-06-30 0000803578 us-gaap:PreferredStockMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-06-30 0000803578 aiff:CommonStockNumberOfSharesToBeIssuedMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-06-30 0000803578 us-gaap:CommonStockMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-06-30 0000803578 us-gaap:AdditionalPaidInCapitalMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-06-30 0000803578 us-gaap:RetainedEarningsMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-06-30 0000803578 aiff:CommonStockPrivatePlacementMember 2023-01-012023-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberaiff:PreferredStockNumberOfSharesToBeIssuedMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberaiff:CommonStockNumberOfSharesToBeIssuedMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:RetainedEarningsMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-06-30 0000803578 us-gaap:SeriesBPreferredStockMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-06-30 0000803578 us-gaap:PreferredStockMember 2023-01-012023-06-

30 0000803578 us-gaap:CommonStockMember 2023-01-012023-06-30 0000803578 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-06-30 0000803578 us-gaap:RetainedEarningsMember 2023-01-012023-06-30 0000803578 us-gaap:PreferredStockMember 2023-06-30 0000803578 aiff:PreferredStockNumberOfSharesToBeIssuedMember 2023-06-30 0000803578 us-gaap:CommonStockMember 2023-06-30 0000803578 aiff:CommonStockNumberOfSharesToBeIssuedMember 2023-06-30 0000803578 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000803578 us-gaap:RetainedEarningsMember 2023-06-30 0000803578 2023-06-30 0000803578 aiff:FormerFirefly2023StockholdersMember 2024-08-12 0000803578 aiff:FormerFireflyStockholdersMember 2024-08-12 0000803578 aiff:MedicalEquipmentMember 2024-06-30 0000803578 aiff:MedicalEquipmentMember 2023-12-31 0000803578 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-06-30 0000803578 aiff:IiaRoyaltyCommitmentMember 2024-06-30 0000803578 aiff:IiaRoyaltyCommitmentMember 2023-12-31 0000803578 us-gaap:SeriesCPreferredStockMember 2023-08-292023-08-29 0000803578 aiff:SeriesCPreferredUnitWarrantsMember 2023-08-29 0000803578 aiff:SeriesCPreferredUnitWarrantsMemberus-gaap:SeriesCPreferredStockMember 2023-08-29 0000803578 aiff:SeriesCPreferredUnitWarrantsMember 2024-06-30 0000803578 aiff:ConversionOfSeriesBPreferredStockToCommonStockMember 2023-12-31 0000803578 aiff:ConversionOfSeriesBPreferredStockToCommonStockMember 2024-01-012024-06-30 0000803578 us-gaap:SeriesAPreferredStockMember 2024-06-30 0000803578 us-gaap:SeriesBPreferredStockMember 2024-06-30 0000803578 us-gaap:SeriesCPreferredStockMember 2024-06-30 0000803578 2023-01-012023-12-31 0000803578 aiff:SeriesCPreferredUnitWarrantsMember 2024-01-012024-06-30 0000803578 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0000803578 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0000803578 us-gaap:EmployeeStockOptionMember 2023-04-012023-06-30 0000803578 us-gaap:EmployeeStockOptionMember 2023-01-012023-06-30 0000803578 2024-04-022024-04-02 0000803578 aiff:SeriesAPerformanceWarrantsMember 2024-03-15 0000803578 2024-03-15 0000803578 us-gaap:WarrantMember 2024-04-012024-06-30 0000803578 us-gaap:WarrantMember 2023-04-012023-06-30 0000803578 srt:DirectorMember 2024-06-30 0000803578 srt:DirectorMember 2023-06-30 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2024-04-012024-06-30 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2024-01-012024-06-30 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2023-04-012023-06-30 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2023-01-012023-06-30 0000803578 us-gaap:ServiceMember 2024-04-012024-06-30 0000803578 us-gaap:ServiceMember 2023-04-012023-06-30 0000803578 us-gaap:ServiceMember 2024-01-012024-06-30 0000803578 us-gaap:ServiceMember 2023-01-012023-06-30 0000803578 us-gaap:TransferredAtPointInTimeMember 2024-04-012024-06-30 0000803578 us-gaap:TransferredAtPointInTimeMember 2023-04-012023-06-30 0000803578 us-gaap:TransferredAtPointInTimeMember 2024-01-012024-06-30 0000803578 us-gaap:TransferredAtPointInTimeMember 2023-01-012023-06-30 0000803578 us-gaap:TransferredOverTimeMember 2024-04-012024-06-30 0000803578 us-gaap:TransferredOverTimeMember 2023-04-012023-06-30 0000803578 us-gaap:TransferredOverTimeMember 2024-01-012024-06-30 0000803578 us-gaap:TransferredOverTimeMember 2023-01-012023-06-30 0000803578 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0000803578 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0000803578 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-06-30 0000803578 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-06-30 0000803578 us-gaap:SellingAndMarketingExpenseMember 2024-04-012024-06-30 0000803578 us-gaap:SellingAndMarketingExpenseMember 2023-04-012023-06-30 0000803578 us-gaap:SellingAndMarketingExpenseMember 2024-01-012024-06-30 0000803578 us-gaap:SellingAndMarketingExpenseMember 2023-01-012023-06-30 0000803578 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0000803578 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0000803578 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-06-30 0000803578 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-06-30 0000803578 aiff:SecuredPromissoryNotesMemberus-gaap:SubsequentEventMember 2024-08-08 0000803578 aiff:SecuredPromissoryNotesMemberus-gaap:SubsequentEventMember 2024-08-082024-08-08 0000803578 aiff:MergerReverseStockSplitMemberus-gaap:SubsequentEventMember 2024-08-122024-08-12 0000803578 aiff:FireflyMemberaiff:NewFireflyCommonStockMemberus-gaap:SubsequentEventMember 2024-08-12 0000803578 aiff:FireflyMemberus-gaap:SubsequentEventMember 2024-08-12 0000803578 aiff:PipeShareWithAccompanyingWarrantMemberus-gaap:SubsequentEventMember 2024-07-26 0000803578 aiff:PrefundedWarrantsMemberus-gaap:SubsequentEventMember 2024-07-262024-07-26 0000803578 aiff:CommonStockWarrantsMemberus-gaap:SubsequentEventMember 2024-07-262024-07-26 0000803578 aiff:PipeShareWithAccompanyingWarrantMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember 2024-07-26 0000803578 aiff:PrefundedWarrantsMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember 2024-07-26 0000803578 us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember 2024-07-262024-07-26 0000803578 us-gaap:RelatedPartyMember 2022-12-31 0000803578 2022-01-012022-12-31 0000803578 us-gaap:PreferredStockMember 2021-12-31 0000803578 us-gaap:CommonStockMember 2021-12-31 0000803578 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000803578 us-gaap:RetainedEarningsMember 2021-12-31 0000803578 2021-12-31 0000803578 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2022-01-012022-12-31 0000803578 us-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMember 2022-01-012022-12-31 0000803578 us-gaap:SeriesAPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember 2022-01-012022-12-31 0000803578 us-gaap:SeriesAPreferredStockMemberus-gaap:RetainedEarningsMember 2022-01-012022-12-31 0000803578 us-gaap:SeriesAPreferredStockMember 2022-01-012022-12-31 0000803578 us-gaap:PreferredStockMember 2022-01-012022-12-31 0000803578 us-gaap:CommonStockMember 2022-01-012022-12-31 0000803578 us-gaap:AdditionalPaidInCapitalMember 2022-01-012022-12-31 0000803578 us-gaap:RetainedEarningsMember 2022-01-012022-12-31 0000803578 us-gaap:PreferredStockMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-12-31 0000803578 us-gaap:CommonStockMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-12-31 0000803578 us-gaap:AdditionalPaidInCapitalMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-12-31 0000803578 us-gaap:RetainedEarningsMemberaiff:CommonStockPrivatePlacementMember 2023-01-012023-12-31 0000803578 aiff:CommonStockPrivatePlacementMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesBPreferredStockMemberus-gaap:RetainedEarningsMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesBPreferredStockMemberaiff:SeriesBPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMemberaiff:SeriesCPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMemberaiff:SeriesCPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:AdditionalPaidInCapitalMemberaiff:SeriesCPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:RetainedEarningsMemberaiff:SeriesCPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:SeriesCPreferredStockMemberaiff:SeriesCPreferredStockOfferingMember 2023-01-012023-12-31 0000803578 us-gaap:PreferredStockMember 2023-01-012023-12-31 0000803578 us-gaap:CommonStockMember 2023-01-012023-12-31 0000803578 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-12-31 0000803578 us-gaap:RetainedEarningsMember 2023-01-012023-12-31 0000803578 2022-01-27 0000803578 us-gaap:SeriesAPreferredStockMember 2022-01-27 0000803578 us-gaap:CommonStockMember 2022-07-052022-07-05 0000803578 us-gaap:SeriesAPreferredStockMember 2022-07-052022-07-05 0000803578 2022-07-052022-07-05 0000803578 aiff:ReverseStockSplitMember 2022-11-232022-11-23 0000803578 aiff:FormerFirefly2023StockholdersMember 2023-11-16 0000803578 aiff:FormerFireflyStockholdersMember 2023-11-16 0000803578 country:CA 2023-01-012023-12-31 0000803578 country:CA 2022-01-012022-12-31 0000803578 country:CA 2023-12-31 0000803578 country:CA 2022-12-31 0000803578 country:US 2023-01-012023-12-31 0000803578 country:US 2022-01-012022-12-31 0000803578 country:US 2023-12-31 0000803578 country:US 2022-12-31 0000803578 country:IL 2023-01-012023-12-31 0000803578 country:IL 2022-01-012022-12-31 0000803578 country:IL 2023-12-31 0000803578 country:IL 2022-12-31 0000803578 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0000803578 aiff:SideLetterMemberaiff:WpcAndOrigaMember 2021-12-31 0000803578 aiff:SideLetterMemberaiff:WpcAndOrigaMember 2022-02-02 0000803578 aiff:ConvertibleDebtAndStockWarrantsMemberaiff:WpcAndOrigaMember 2022-02-02 0000803578 aiff:SideLetterMemberaiff:WpcAndOrigaMember 2022-02-022022-02-02 0000803578 aiff:SideLetterMemberaiff:WpcAndOrigaMember 2022-07-04 0000803578 aiff:ConvertibleDebtAndStockWarrantsMemberaiff:WpcAndOrigaMember 2022-07-04 0000803578 aiff:SideLetterMemberaiff:WpcAndOrigaMember 2022-07-042022-07-04 0000803578 aiff:PhytoIvLpMemberus-gaap:ConvertibleDebtMember 2022-05-04 0000803578 aiff:PhytoIvLpMemberus-gaap:ConvertibleDebtMember 2022-07-04 0000803578 aiff:PhytoIvLpMemberus-gaap:ConvertibleDebtMember 2022-07-042022-07-04 0000803578 aiff:ConversionOfDebtAndInterestIntoCommonStockMemberaiff:PhytoIvLpMember 2022-09-302022-09-30 0000803578 aiff:ConvertibleDebtIssuedToVariousInvestorsMember 2022-07-04 0000803578 aiff:ConversionOfDebtAndInterestIntoCommonStockMemberaiff:ConvertibleDebtIssuedToVariousInvestorsMember 2022-09-302022-09-30 0000803578 aiff:ConversionOfDirectorNotesIntoCommonStockMember 2022-01-012022-12-31 0000803578 aiff:RIMindGroupLtdMember 2019-02-28 0000803578 aiff:RIMindGroupLtdMember 2019-02-012019-02-28 0000803578 aiff:PasitheaClinicsIncMember 2022-08-012022-08-31 0000803578 aiff:PasitheaClinicsIncMember 2022-11-012022-11-30 0000803578 aiff:PasitheaClinicsIncMember 2022-01-012022-12-31 0000803578 aiff:RIMindGroupLtdMember 2022-01-012022-12-31 0000803578 aiff:PasitheaClinicsIncMember 2023-01-012023-12-31 0000803578 aiff:RIMindGroupLtdMember 2023-01-012023-12-31 0000803578 aiff:IiaRoyaltyCommitmentMember 2022-12-31 0000803578 us-gaap:SeriesAPreferredStockMemberaiff:SecuritiesPurchaseAgreementMember 2022-08-172022-08-17 0000803578 aiff:August2022SecuritiesPurchaseAgreementWarrantsMember 2022-08-17 0000803578 aiff:SecuritiesPurchaseAgreementMember 2022-09-152022-09-15 0000803578 aiff:SecuritiesPurchaseAgreementMember 2022-09-15 0000803578 aiff:SecuritiesPurchaseAgreementMember 2023-02-162023-02-16 0000803578 aiff:SecuritiesPurchaseAgreementMember 2023-02-16 0000803578 us-gaap:SeriesBPreferredStockMember 2023-02-232023-02-23 0000803578 us-gaap:SeriesBPreferredStockMember 2023-02-23 0000803578 us-gaap:SeriesBPreferredStockMember 2023-03-152023-03-15 0000803578 aiff:ConsultingFeesMemberus-gaap:RelatedPartyMember 2023-05-012023-05-01 0000803578 aiff:ConsultingFeesMemberus-gaap:RelatedPartyMember 2023-05-01 0000803578 us-gaap:SeriesCPreferredStockMember 2023-12-312023-12-31 0000803578 aiff:SeriesCPreferredUnitWarrantsMember 2023-12-31 0000803578 2023-10-162023-10-16 0000803578 aiff:ConversionOfSeriesBPreferredStockToCommonStockMember 2023-12-312023-12-31 0000803578 us-gaap:SeriesAPreferredStockMember 2023-12-31 0000803578 us-gaap:SeriesAPreferredStockMember 2022-12-31 0000803578 us-gaap:SeriesBPreferredStockMember 2023-12-31 0000803578 us-gaap:SeriesBPreferredStockMember 2022-12-31 0000803578 us-gaap:SeriesCPreferredStockMember 2023-12-31 0000803578 us-gaap:SeriesCPreferredStockMember 2022-12-31 0000803578 aiff:TrancheAWarrantsMember 2023-12-31 0000803578 aiff:TrancheBWarrantsMember 2023-12-31 0000803578 aiff:TrancheAWarrantsMember 2022-07-04 0000803578 aiff:ConvertibleDebtAndStockWarrantsMember 2022-08-16 0000803578 aiff:WpcWarrantsMember 2023-02-17 0000803578 aiff:SeriesCPreferredUnitWarrantsMember 2023-01-012023-12-31 0000803578 2021-01-012021-12-31 0000803578 aiff:SeriesAWarrantsMember 2023-06-15 0000803578 us-gaap:EmployeeStockOptionMember 2023-01-012023-12-31 0000803578 us-gaap:EmployeeStockOptionMember 2022-01-012022-12-31 0000803578 2023-07-082023-07-08 0000803578 srt:DirectorMember 2023-12-31 0000803578 srt:DirectorMember 2022-12-31 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2023-01-012023-12-31 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2022-01-012022-12-31 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2023-12-31 0000803578 aiff:ConsultingFeesMembersrt:ExecutiveOfficerMember 2022-12-31 0000803578 2023-06-082023-06-08 0000803578 us-gaap:RelatedPartyMember 2023-06-082023-06-08 0000803578 us-gaap:ServiceMember 2023-01-012023-12-31 0000803578 us-gaap:ServiceMember 2022-01-012022-12-31 0000803578 us-gaap:TransferredOverTimeMember 2023-01-012023-12-31 0000803578 us-gaap:TransferredOverTimeMember 2022-01-012022-12-31 0000803578 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-12-31 0000803578 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-012022-12-31 0000803578 us-gaap:SellingAndMarketingExpenseMember 2023-01-012023-12-31 0000803578 us-gaap:SellingAndMarketingExpenseMember 2022-01-012022-12-31 0000803578 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-12-31 0000803578 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-012022-12-31 0000803578 2022-02-012022-02-28 0000803578 us-gaap:CanadaRevenueAgencyMember 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMember 2022-12-31 0000803578 us-gaap:IsraelTaxAuthorityMember 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMember 2022-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2034Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2034Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2034Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2035Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2035Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2035Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2036Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2036Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2036Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2037Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2037Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2037Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2038Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2038Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2038Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2039Member 2023-12-31 0000803578 us-

gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2039Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2039Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2040Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2040Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2040Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2041Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2041Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2041Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:TaxYear2042Member 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:TaxYear2042Member 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:TaxYear2042Member 2023-12-31 0000803578 us-gaap:CanadaRevenueAgencyMemberaiff:IndefiniteTaxYearMember 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMemberaiff:IndefiniteTaxYearMember 2023-12-31 0000803578 us-gaap:IsraelTaxAuthorityMemberaiff:IndefiniteTaxYearMember 2023-12-31 0000803578 us-gaap:InternalRevenueServiceIRSMember 2023-12-31 0000803578 us-gaap:ResearchMember 2023-12-31 0000803578 us-gaap:ResearchMember 2022-12-31 0000803578 srt:ScenarioPreviouslyReportedMember 2022-12-31 0000803578 srt:RestatementAdjustmentMember 2022-12-31 0000803578 srt:ScenarioPreviouslyReportedMember 2022-01-012022-12-31 0000803578 srt:RestatementAdjustmentMember 2022-01-012022-12-31 0000803578 us-gaap:SubsequentEventMember 2024-02-282024-02-28 0000803578 us-gaap:SeriesCPreferredStockMemberus-gaap:SubsequentEventMember 2024-02-282024-02-28 0000803578 aiff:UnitWarrantsMemberus-gaap:SubsequentEventMember 2024-02-28 thunderdome:item iso4217:USD iso4217:USD shares shares pure utr:Y0000803578FIREFLY NEUROSCIENCE, INC.falseQ22024 0.000010.000013000000030000000237421923742191611695716116957O.000010.000012470000000247000000049948710499487103536987735369877P4YP5Y11P3Y1746 0.000010.000013000000030000000161169571611695700.000010.000012470000000247000000035369877353698772552744255274475075OOP5Y11P3Y750P5Y00750P51 2019 2020 2021 2022 202311P3YS-1DE54-1167364Non-accelerated Filertruefalse3580002143000830008400063000280005040002255000600000634000386000694000386000119800026410001265000455000175000175000973000190200079010000-76624000-1215000109000119800026410001000045100022000456000350000199000639000320000293000171000542000304000626000399000119100069600012690007690002372 1259000-318000-2350000-864000-10000-3000-12000-1000031000030000260002000270002000-1264000-323000-2386000-8760000000-1264000-323000-2386000-876000-0.03-0.01-0.05-0.03499487103527701849948710267349181611696 7-1457883303536987714578833076733000-766240001090001457883314578833145788331457883338608500094500009450000011700001170000023860002386000237421900499487100077795000-79010000-121500000025527440071795000-74021000-222600000325363860133000013300058979320001092000010920000014800001480000-876000-876000058979320283770832536386073168000-74897000-1729000-2386000-876000400001170001480000-1000300035000240008100006300003000-9290001760000-450000-2418000-936000640000-0248000-0-3120000945000122500094500012250000-1785000289000214300058000358000347000000 NOTE 1. BUSINESS DESCRIPTION   Nature of organization and business   Firefly Neuroscience, Inc. (the "Company") and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.), Firefly Neuroscience Canada Inc., a Canadian corporation, and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain.   Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc.   In July 2014, the U.S. Food and Drug Administration ("FDA") cleared Firefly Neuroscience Ltd.'s Brain Network Analytics ("BNA" ™) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European ("CE") approval for BNA™ allowing use in Europe.   Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc.   Merger agreement   On November 16, 2023, WaveDancer, Inc. ("WaveDancer") (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the "Merger Agreement") with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Company's Artificial Intelligence driven BNA™ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market.   Under the terms of the Merger Agreement, each share of the Company's shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancer's ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. Following the merger, WaveDancer, Inc. will be renamed "Firefly Neuroscience, Inc." and the corporate headquarters will be located in Buffalo, NY.   On January 12, 2024 and June 17, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates included changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Company's warrants at the effective time, deletion of certain closing obligations, and to extend the end date of the original agreement dated November 15, 2023.   The transaction was completed effective August 12, 2024.   0.920.08 NOTE 2. GOING CONCERN   As of June 30, 2024, the Company had an accumulated deficit of $79,010 (December 31, 2023: $76,624) and negative cash flow from operating activities for the six months ended June 30, 2024 of $2,402 (June 30, 2023: $936). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the six months ended June 30, 2024 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Company's liquidity in the foreseeable future, the Company has taken the following measures: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 27pt;"> (i) </td><td style="width: auto;"> Negotiating further funding with existing and new investors to raise additional capital; </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 27pt;"> (ii) </td><td style="width: auto;"> Taking various cost control measures to reduce the operational cash burn; and </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 27pt;"> (iii) </td><td style="width: auto;"> Commercializing product to generate recurring sales. </td></tr></tbody></table>   Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future. -79010000-76624000-2402000-936000 NOTE 3. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United States of America ("U.S. GAAP"). The results reported in these unaudited condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for any subsequent period or for the entire period. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company's annual audited consolidated financial statements for the year ended December 31, 2023 and the notes included therein. Certain information and footnote disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in the accompanying unaudited condensed consolidated financial statements. All amounts are disclosed in thousands, except share and per share amounts. The accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, except as otherwise indicated, necessary for a fair statement of its consolidated financial position, results of operations, and cash flows of the Company for all periods presented.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> a. </td><td style="width: auto;"> Principles of consolidation </td></tr> </tbody></table>   These unaudited consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities ("VIE"). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation. <p style="font-family:'Times New Roman';font-size:10pt;font-

variant:normal;margin:0pt;"> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td></tr> </tbody></table><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> b. </td><td style="width: auto;"> Use of estimates in the preparation of consolidated financial statements </td></tr> </tbody></table>   The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.   Significant accounting policies   The following significant accounting policies should be read in conjunction with the Company's annual audited consolidated financial statements for the year ended December 31, 2023 and the notes therein.   i) Equipment Equipment is stated at cost less accumulated depreciation. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of four years for medical equipment.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td></tr> </tbody></table><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> c. </td><td style="width: auto;"> Impact of recently issued accounting standards </td></tr> </tbody></table>   The Company has evaluated issued Accounting Standards Updates not yet adopted and believes the adoption of these standards will not have a material impact on its condensed consolidated financial statements.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> a. </td><td style="width: auto;"> Principles of consolidation </td></tr> </tbody></table>   These unaudited consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities ("VIE"). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation. <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> b. </td><td style="width: auto;"> Use of estimates in the preparation of consolidated financial statements </td></tr> </tbody></table> The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates. <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> c. </td><td style="width: auto;"> Impact of recently issued accounting standards </td></tr> </tbody></table>   The Company has evaluated issued Accounting Standards Updates not yet adopted and believes the adoption of these standards will not have a material impact on its condensed consolidated financial statements.   NOTE 4: OTHER RECEIVABLES   Detail of other receivables balance is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Other receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">195</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Allowance for doubtful receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

font-variant: normal; text-align: center; margin: 0pt;">2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Other receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">195</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Allowance for doubtful receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 19500019600011200011200083000840000 NOTE 5: EQUIPMENT   Equipment balance is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Medical equipment, cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less – accumulated depreciation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Equipment, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Medical equipment, cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less – accumulated depreciation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size:

10pt;"> Equipment, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </tbody></table> 6400000000-0600000 NOTE 6: INTANGIBLE ASSETS   The following tables summarize the composition of intangible assets as of June 30, 2024:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Gross Carrying Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Accumulated Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Net Carrying Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Unamortized intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> BNA software </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">n/a</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> </tbody></table>   The BNA software enhancement project is in progress and amortization will begin once the project is substantially complete and the software is ready for its intended purpose. The software is expected to be completed by the end of 2024 and have a useful life of five years.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Gross Carrying Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Accumulated Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Net Carrying Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-

family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Unamortized intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> BNA software </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">n/a</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> </tbody></table>
6340000634000634000034000 NOTE 7: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT   Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Company's employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, severance payments, which are included in salary and employee benefits, were $11 and $25 for the three and six months ended June 30, 2024, respectively and $11 and $16 for the three and six months ended June 30, 2023, respectively. 0.083311000250001100016000 NOTE 8: COMMITMENTS AND CONTINGENCIES   a. Royalty Commitment - Israeli Innovation Authority ("IIA")   The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2024 or 2023. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate ("LIBOR") is repayable in form of royalties based on 3.0% of BNA™ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate ("SOFR") subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of June 30, 2024 and December 31, 2023. The contingent liability amounts to $5,676 and $5,625 for June 30, 2024 and December 31, 2023 respectively.   Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIA's approval.   0.035676000562500 NOTE 9: EQUITY   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> a. </td><td style="width: auto;"> Shares </td></tr> </tbody></table>   On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. During the six months period ended June 30, 2024, the Company issued 836,085 units and received aggregate gross proceeds of $1,070. The Company incurred $125 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.   As of December 31, 2023, the mandatory conversion feature of the Series B Preferred Stock was triggered, as the proceeds from the Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of June 30, 2024, the 14,578,833 of Series B Preferred stock were converted to 14,578,833 shares of common stock.   As of June 30, 2024, the Company had the following number of authorized and issued shares: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of authorized shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of issued shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 54%;"> Shares of common stock </td><td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,470,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,948,710</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series A Preferred Stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series B Preferred Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series C Preferred Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,374,219</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   As of June 30, 2024 the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shares of all classes.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> b. </td><td style="width: auto;"> Warrants </td></tr> </tbody></table>   The following table summarizes the Company's warrant activity for the six months ended June 30, 2024:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Number of Warrants </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Remaining Life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Outstanding warrants, January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,386,677</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.07</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.46</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued pursuant to units offering</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">836,531</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.56</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding warrants, June 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,223,208</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue. The warrants were determined to be a freestanding equity instrument. For the six month period ended June 30, 2024, 836,531 warrants were issued.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> c. </td><td style="width: auto;"> Employees stock option plan </td></tr> </tbody></table>   A summary of option activity under the Plan as of June 30, 2024 and changes during the period then ended is presented below.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Number of Stock Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Remaining Contractual Term </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Aggregate Intrinsic Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Outstanding Options, December 31,2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,291,662</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding Options, June 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,291,662</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> $</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.67</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   The share-based compensation expense related to options for the three and six months ended June 30, 2024 was $58 and $117, respectively and 74$ and $148 for the three and six months ended June 30, 2023, respectively. The fair value of options granted for the six months period ended June 30, 2024 and 2023 was $nil and $nil, respectively. The intrinsic value of the options outstanding as of June 30, 2024 is $nil (December 31, 2023; $nil).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A summary of the Company's non vested options as of <em style="font: inherit;"> June 30, 2024, and changes during the <em style="font: inherit;">six months period ended, is presented below.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Number of Stock</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Options</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted Average</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant-Date Fair Value</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 54%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-Vested Options, December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">874,886</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal;

margin: 0pt;">Options vested </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(107,739</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.62</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-Vested Options, June 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">687,147</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.46</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   As of June 30, 2024, there was $317 of total unrecognized compensation cost related to nonvested options granted under the Plan.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> d. </td><td style="width: auto;"> Management options </td></tr> </tbody></table>   On April 2, 2024, the Company granted stock options to its officer to purchase an aggregate of 106,000 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Company's equity securities in an initial public offering (an "IPO Transaction"), that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 106,000 shares of common stock shall vest in 36 equal installments at the end of each calendar month over a period of three years beginning March 1, 2024. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> e. </td><td style="width: auto;"> Consulting agreement </td></tr> </tbody></table>   On March 15, 2024, the Company entered into a consulting agreement ("Consulting agreement"), which was further approved by the board of directors of the Company on April 2, 2024. Under the Consulting agreement, the Company will receive services of promoting the Company's stock; in return for 432,034 Series A performance warrants and 195,313 shares of common stock issued immediately upon execution of the agreement, and 234,735 shares of common stock to be issued in 12 equal installments at the end of each calendar month.   Series A performance warrants to purchase up to an aggregate 432,034 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share and are set to expire on June 15, 2028. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event.   As of June 30, 2024, the shares of common stock and Series A performance warrants were not issued and no services were received.   78125001.2883608510700001250002.5610001457883314578833 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of authorized shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of issued shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 54%;"> Shares of common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,470,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,948,710</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series A Preferred Stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series B Preferred Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series C Preferred Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,374,219</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 247000000049948710300000000 0 2374219250000000024700000003000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Number of Warrants </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-

variant: normal; text-align: center; margin: 0pt;">Average Remaining Life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Outstanding warrants, January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,386,677</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.46</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued pursuant to units offering</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">836,531</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.56</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding warrants, June 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,223,208</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>
23866772.07P2Y5M15D8365312.5632232082.19P2Y2M8D781250078125001.282.56836531 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Number of Stock Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Weighted Average Remaining Contractual Term </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> Aggregate Intrinsic Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Outstanding Options, December 31,2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,291,662</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding Options, June 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,291,662</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td

style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 5.67</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> -</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Number of Stock</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Options</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted Average</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant-Date Fair Value</p> </td></tr><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 54%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-Vested Options, December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">874,886</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options vested </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(187,739</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.62</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-Vested Options, June 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">687,147</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.46</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>
12916622.16P6Y2M4D00012916622.16P5Y8M1D0580001170001480008748860.5001877390.626871470.463170001060001060004320341953132347354320340.01 NOTE 10: BASIC AND DILUTED NET LOSS PER SHARE   Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that were outstanding during the period when the effect is dilutive. Potential dilutive shares of common stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding shares of common stock figures for the six months ended June 30, 2024 or 2023, as the assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted stock units would be anti-dilutive. 0 NOTE 11: RELATED PARTY TRANSACTIONS   As of the period ended June 30, 2024, $175 (2023: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand.   The Company incurred $140 and $244 in officers' consulting fees recorded in general and administration expenses for the three and six months ended June 30, 2024, respectively and $102 and $223 for the three and six months ended June 30, 2023, respectively.
17500017500014000024400010200022300 0 NOTE 12: REVENUE   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Type of goods and services </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-

color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Service </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Timing of recognition of revenue </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Point in time </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Over time </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin:

0pt;">Six months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Type of goods and services </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Service </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Timing of recognition of revenue </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Point in time </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Over time </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0,

0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">451</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>
10000451000220004560001000045100022000456000300007000070000451000150004560001000045100022000456000 NOTE 13: RESEARCH AND DEVELOPMENT EXPENSES   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six months ended June 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">210</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">167</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">443</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">254</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Consultants and subcontractors </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Clinical trials </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expenses - other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,

0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">350</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">639</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less - grants received </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">350</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">199</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">639</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">210</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">167</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">443</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">254</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Consultants and subcontractors </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align:

right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Clinical trials </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expenses - other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">350</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">639</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less – grants received </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">- </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">350</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">199</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">639</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>
2100001670004430002540007000017000770002300040000400000140000190006600010001150002400035000019900063900032000000003500001990006390003200002 NOTE 14: SELLING AND MARKETING EXPENSES   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:

10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">160</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">289</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">89</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">542</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">160</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">289</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">89</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">542</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>
1790001600003470002890008900050001420005000220006000460001000030000700002930001710005420003040000 NOTE 15: GENERAL AND ADMINISTRATION EXPENSES   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six months ended June 30, </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">319</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">417</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">183</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">822</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent and maintenance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">71</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">626</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">399</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">696</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six months ended June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">319</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family:

"Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">417</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">183</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">822</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent and maintenance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">71</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> $</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">626</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> $</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">399</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,191</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">696</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>

*1430001420002610003190004170001830008220002460004000330006000650002300012000310002500039000290007100041000626000399000119100096000 NOTE 16: SUBSEQUENT EVENTS   The subsequent events below are major events or transactions that occurred after the six month period ended June 30, 2024, but before the issuance of these condensed consolidated financial statements. The below events occurred between July 1, 2024 and August 14, 2024.   On August 8, 2024, the Company completed the closing of a $209 secured promissory notes. Promissory notes were issued with a discount of $11 and the Company received gross proceeds of $198. The promissory note will bear an annual interest rate of 18%, paid monthly. The principal amount of $209 will mature and become due and payable on August 23, 2024.   Effective August 12, 2024, the Company changed its name from Firefly Neuroscience, Inc. to Firefly Neuroscience 2023, Inc.   Merger   On August 12, 2024, the Company completed the merger with WaveDancer. As a result of this transaction, the Company obtained control of WaveDancer. The combined company operates under the name Firefly Neuroscience, Inc., and on August 13, 2023 the Company began trading on the Nasdaq Capital Market (NASDAQ: AIFF). On August 12, 2024, prior to the consummation of the Merger, WaveDancer effectuated a 1-for-3 reverse stock split of its common stock (the "Reverse Stock Split") . Pursuant to the terms of the Merger Agreement, each holder of outstanding shares of the Company's shares of common stock is entitled to receive the number of shares of WaveDancer common stock equal to the number of shares of the Company's shares of common stock they hold multiplied by the exchange ratio, or an aggregate of 7,870,251 shares of WaveDancer common stock at closing using an exchange ratio of 0.1040. Following the closing of the merger, there are 7,870,251 shares of the combined company's common stock outstanding with Firefly stockholders owning approximately 92% and prior WaveDancer stockholders owning 8% of the combined company's outstanding securities.   Private Placement   On July 26, 2024, prior to the consummation of the merger, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,069,287 shares (the "PIPE Shares") of the combined company's common stock and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 4,849,265 shares of combined company's common stock, and (iii) warrants (the "Warrants") to purchase up to 7,918,552 shares of combined company's common stock in a private placement (the "Private Placement"). The purchase price of each PIPE Share and accompanying Warrant was $0.442 and the purchase price of each Pre-Funded Warrant and accompanying Warrant was $0.4419. The Private Placement closed on August 12, 2024, substantially contemporaneously with the consummation of the merger. The aggregate gross proceeds from the transaction were approximately $3,500. *

2090001100019800001837870251010478702510.920.0830692874849265791855204420.441935000000002143000580000840001900028000600022550000830000520003876624000-74021000109000-22260002641000135000498000074100012990006390005240002196000154200007900035760003444000-3078000-34440000-18000-44000037000-1340000-5900045700017300026020000-39040001000-0-2603000-3904000-0.08-2.833108913213800518162294560242900015080061888000-67331000-30140001000000030000037000040000-826229456-2432000110176424320000051282025000002500001394475040210000402100003210000321000006000006000003715-027860002786000-0000-3904000-3904000000025527440071795000-74021000-22260000032536386001330000133000014578833-

1457883301457883302608000026080001538134000190200001902000028496429500029500000421700000002603000-260300001611696714578833035369877145788330767330007662400010900026030003904000001400008700029500060000046000000-0-5900065000-2700022000-300052000900035000-80000-2000010470009700090900045000021720002892000026200038600000-0-38600026200001745000464300029000046430002035000208500059500058000653000214300058000000004021000 NOTE 1: BUSINESS DESCRIPTION   Nature of organization and business   Firefly Neuroscience, Inc. (the "Company") and its wholly owned subsidiaries Firefly Neuroscience Ltd. (formerly known as Elminda Ltd.), Elminda 2022 Inc., a Delaware corporation (formerly known as Elminda Inc.), and Elminda Canada Inc., a Canadian corporation, are engaged in the development, marketing and distribution of medical devices and technology allowing high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain.   Firefly Neuroscience Ltd. was initially incorporated and commenced its operations as a development company in 2006 under the laws of the State of Israel, and in May 2014, initiated its USA marketing and distribution activity through Elminda 2022 Inc.   In July 2014, the U.S. Food and Drug Administration ("FDA") cleared Firefly Neuroscience Ltd. Brain Network Analytics' (BNA™) product for marketing in the USA. On September 11, 2014, the Company received the Conformity European ("CE") approval for BNA™ allowing use in Europe.   Reorganization   Name change and corporate restructure   Elminda Inc. was incorporated in the State of Delaware on April 21, 2022.   On July 5, 2022, Elminda Ltd. became a subsidiary of Elminda Inc. via a share exchange agreement wherein Elminda Inc. issued shares to shareholders of Elminda Ltd. against shares of Elminda Ltd. (the "Flip Transaction").   On September 15, 2022 and October 24, 2022 management changed the name from Elminda Inc. and Elminda Ltd. to Firefly Neuroscience Inc. and Firefly Neuroscience Ltd., respectively.   Shareholder Restructuring   On January 27, 2022, holders of shares of outstanding Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock of Firefly Neuroscience Ltd. voted to convert their shares of preferred stock into shares of common stock of Firefly Neuroscience Ltd. Upon completion of the transaction, Firefly Neuroscience Ltd. had 1,085,605 shares of common stock and 3,198,421 shares of Series A Preferred Stock outstanding.   On May 24, 2022, holders of the majority of shares of common stock of Firefly Neuroscience Ltd. voted to exchange their shares on a 1-1 basis for shares in the Company.   In connection with the Flip Transaction, on July 5, 2022, (a) Firefly Neuroscience, Inc. became an issuer of (i) 1,085,605 common shares, (ii) 3,198,421 Series A preferred shares and (c) 3,715 shares of common share dividends. The original shareholders of Firefly Neuroscience Ltd. remained in control of the new group and the Company.   On November 23, 2022, the Company completed a reverse share split on a ratio of 1:750. These consolidated financial statements and all financial notes referencing shares of common stock, stock dividends, stock options and their associated prices have been retroactively adjusted as to show the effect of the 1:750 reverse stock split.   Merger agreement   On November 16, 2023, WaveDancer, Inc. ("WaveDancer") (NASDAQ: WAVD) announced that it has entered into a definitive merger agreement (the "Merger Agreement") with the Company, to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize the Company's Artificial Intelligence driven BNA™ platform, which was previously cleared by the FDA. Upon closing, the combined company is expected to operate under the name Firefly Neuroscience, Inc., and trade on the Nasdaq Capital Market.   Under the terms of the Merger Agreement, each share of the Company's shares of common stock issued and outstanding will be converted into common shares of WaveDancer based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. At the effective time of the merger, securityholders of Firefly will own approximately 92% of the combined company and securityholders of WaveDancer will own approximately 8% of the combined company, on a fully diluted basis. WaveDancer's ownership may increase if it raises capital in excess of the minimum detailed in the Merger Agreement. The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by WaveDancer, and the receipt of required shareholder approvals from the Company's and WaveDancer shareholders. Following the merger, WaveDancer, Inc. will be renamed "Firefly Neuroscience, Inc." and the corporate headquarters will be located in Toronto, Ontario. The transaction is expected to be completed in 2024.   Israeli/Palestinian conflict   On October 7, 2023, an armed Israeli/Palestinian conflict broke out. As the Israeli/Palestinian conflict in Gaza develops, it could have an adverse impact on regional and global markets. While our operations are not directly impacted by these events, the duration of hostilities, imposition of sanctions and related events (including cyberattacks), among others, cannot be predicted. As a result, those events present uncertainty and risk. To date, conflict in Gaza has not had a material impact on the Company's business.   1085605319842110856053198421371 50.920.08 NOTE 2: GOING CONCERN   As of December 31, 2023, the Company had an accumulated deficit of $76,624 (December 31, 2022: $74,021) and negative cash flow from operating activities for the year ended December 31, 2023 of $2,172 (for the year ended December 31, 2022: $2,892). Further, the Company has recurring losses with minimal revenue from operations. While the Company is attempting to raise funds for commercialization, its monthly cash requirements during the year ended December 31, 2023 have been met through issuance of shares to new and existing shareholders. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these consolidated financial statements were issued. Therefore, the Company may be unable to realize its assets and discharge its liabilities in normal course of business. To strengthen the Company's liquidity in the foreseeable future, the Company has taken the following measures: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 27pt;"> (i) </td><td style="width: auto;"> Negotiating further funding with existing and new investors to raise additional capital; </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 27pt;"> (ii) </td><td style="width: auto;"> Taking various cost control measures to reduce the operational cash burn; and </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 27pt;"> (iii) </td><td style="width: auto;"> Commercializing product to generate recurring sales. </td></tr> </tbody></table>   Management of the Company has a reasonable expectation that the Company can continue raising additional equity capital to continue in operational existence for the foreseeable future.   -76624000-74021000-2172000-2892000 NOTE 3: BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Presentation   The accompanying consolidated financial statements have been prepared in accordance with Generally Acceptance Accounting Principles in the United States of America ("U.S. GAAP").   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> a. </td><td style="width: auto;"> Principles of consolidation </td></tr> </tbody></table>   These consolidated financial statements include the financial information of the Company and its subsidiaries. The Company consolidates legal entities in which it holds a controlling financial interest. The Company has a two-tier consolidation model: one focused on voting rights (the voting interest model) and the second focused on a qualitative analysis of power over significant activities and exposure to potentially significant losses or benefits (the variable interest model). All entities are first evaluated to determine whether they are variable interest entities ("VIE"). If an entity is determined not to be a VIE, it is assessed on the basis of voting and other decision-making rights under the voting interest model. The accounts of the subsidiaries are prepared for the same reporting period using consistent accounting policies. All intercompany balances and transactions were eliminated on consolidation.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> b. </td><td style="width: auto;"> Revision of Prior Period Financial Statements </td></tr> </tbody></table>   In connection with the preparation of the consolidated financial statements for year ended December 31, 2023, we identified an

immaterial error related to certain general and administration and research and development expenses in the consolidated financial statements for year ended December 31, 2022. In accordance with SAB No. 99, "Materiality," and SAB No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements," we evaluated the error and determined that the related impact was not material to our consolidated financial statements for any prior annual or interim period, but that correcting the cumulative impact of the error would be significant to our results of operations for the year ended December 31, 2023. Accordingly, we have revised previously reported financial information for such immaterial error. A summary of revisions to certain previously reported financial information presented herein for comparative purposes is included in Note 20.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> c. </td><td style="width: auto;"> Use of estimates in the preparation of consolidated financial statements </td></tr> </tbody></table>   The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.   i) Share based payments In calculating share-based compensation expense, key estimates are used such as, the stock price of the Company, the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company's stock price, and the risk-free interest rate.   ii) Warrants In calculating the fair value of warrants issued, the Company includes key estimates such as the stock price of the Company, the expected life of the warrant, the volatility of the Company's stock price, and the risk-free interest rate.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> d. </td><td style="width: auto;"> Functional currency and foreign currency translations </td></tr> </tbody></table>   The currency of the primary economic environment in which the operations of the Company is conducted is the U.S. dollar ("$" or "Dollar"). All of the Company's revenues and finance are denominated in U.S dollars. The reporting and the functional currency of the Company is the U.S Dollar.   The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> e. </td><td style="width: auto;"> Fair value measurement </td></tr> </tbody></table>   The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> • </td><td style="width: auto;"> Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> • </td><td style="width: auto;"> Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> • </td><td style="width: auto;"> Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. </td></tr> </tbody></table>   Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The carrying amounts of cash and equivalents, accounts receivable, other receivables, long-term deposits, trade payables, balances to and from related party and convertible notes approximate their fair value due to the short-term maturity of such instruments. It is management's opinion that the Company is not exposed to any significant market or credit risks arising from these financial instruments.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> f. </td><td style="width: auto;"> Fair value of financial instruments </td></tr> </tbody></table>   Cash, other receivables, trade payables, related party payable and accrued liabilities are carried at amortized cost, which management believes approximates their respective fair value due to the short-term nature of these instruments.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> g. </td><td style="width: auto;"> Related party </td></tr> </tbody></table>   Parties are related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, and related parties may be individuals or corporate entities. A transaction is a related party transaction when there is a transfer of resources or obligations between related parties. The Company has disclosed its transactions with related parties.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> h. </td><td style="width: auto;"> Cash </td></tr> </tbody></table>   The Company considers all highly liquid investments, which include short-term bank deposits that are not restricted as to withdrawal or use and the period to maturity of which did not exceed three months at time of investment, to be cash.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> i. </td><td style="width: auto;"> Other receivables </td></tr> </tbody></table>   Other receivables are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses ("allowance for doubtful receivables") is based on the Company's assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> j. </td><td style="width: auto;"> Contingent liabilities </td></tr> </tbody></table>   Certain conditions may exist as of the date the consolidated financial statements are issued, that may result in a loss to the Company but that will only be resolved when one or more future events occur or fail to occur. Such losses are disclosed as contingent liabilities if it is not both probable and reasonably estimable. The Company's management assesses such contingent liabilities and estimated legal fees, if any. Such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> k. </td><td style="width: auto;"> Warrants </td></tr> </tbody></table>   The Company accounts for the warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and the applicable authoritative guidance in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 480, "Distinguishing Liabilities from Equity" ("ASC 480") ASC 815, "Derivatives and Hedging" ("ASC 815"), and ASC 718, "Compensation—Stock Compensation" ("ASC 718"). The assessment considers whether they are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480 or meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own shares of common stock and whether the holders of the warrants could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the warrants and as of each subsequent reporting date while the warrants are outstanding. For issued or modified warrants and that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of

issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> l. </td><td style="width: auto;"> Stock options </td></tr> </tbody></table>   The Company grants stock options to certain employees and directors through an established stock option plan. All stock option grants or changes to existing grants, are subject to board of directors' approval. For employees and directors, the fair value of the award is measured on the grant date. For non-employees, as per ASC 718, remeasurement is not required. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Determining the appropriate fair value model and the related assumptions requires judgment. During the year ended December 31, 2023 and 2022, the fair value of each option grant was estimated using a Black-Scholes option-pricing model.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> m. </td><td style="width: auto;"> Revenue recognition </td></tr> </tbody></table>   Revenue is recognized in accordance with ASC 606, "Revenue from Contracts with Customers" ("ASC 606"). The Company performs the following five steps: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> (i) </td><td style="width: auto;"> identify the contract(s) with a customer, </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> (ii) </td><td style="width: auto;"> identify the performance obligations in the contract, </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> (iii) </td><td style="width: auto;"> determine the transaction price, </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> (iv) </td><td style="width: auto;"> allocate the transaction price to the performance obligations in the contract, and </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> (v) </td><td style="width: auto;"> recognize revenue when (or as) the entity satisfies a performance obligation. </td></tr> </tbody></table>   The Company applies this five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the goods or services promised within each contract, related performance obligation and assesses whether each promised good or service is distinct. The Company recognizes as revenue, the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied at a point in time.   The Company's revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> n. </td><td style="width: auto;"> Deferred revenue </td></tr> </tbody></table>   Deferred revenue consists of payments received from customers in advance of satisfying a performance obligation identified in accordance with ASC 606. The change in the deferred revenue balance for the years ended December 31, 2023, and 2022 was driven by payments from customers in advance of satisfying the performance obligations, offset by revenue recognized as performance obligations were completed.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> o. </td><td style="width: auto;"> Research and development expenses </td></tr> </tbody></table>   Research and development expenses are expensed as incurred and consist primarily of personnel, facilities, equipment and supplies related to the Company's research and development activities.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> p. </td><td style="width: auto;"> Software development costs </td></tr> </tbody></table>   The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel, facilities, equipment and supplies and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage - when the research stage is complete, and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in intangible assets, net on the consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> q. </td><td style="width: auto;"> Income taxes </td></tr> </tbody></table>   Income taxes are accounted for using the asset/liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than enactment of changes in the tax law or rates.   The Company adopted ASC 740 "Income Taxes" ("ASC 740"), which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> r. </td><td style="width: auto;"> Leases </td></tr> </tbody></table>   At the inception of the contract, the Company assesses whether the contract contains a lease in accordance with ASU 2016-02, "Leases" ("ASC 842"). The Company determines whether an arrangement is a lease by establishing if the contract conveys the right to control the use of an identified asset, for a period of time in exchange for consideration. Leases are classified either as operating lease or finance lease. The Company elects not to apply the recognition requirements of ASC 842 to short-term leases. Short term leases are contracts that have a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company does not have any lease with a lease term longer than 12 months.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> s. </td><td style="width: auto;"> Employee benefits </td></tr> </tbody></table>   Short-term employee benefits are benefits for which full settlement is expected within twelve months of the end of the financial year in which the members of staff rendered the corresponding services. These benefits include, paid annual leave, paid sick leave, health and governmental social security contributions which are expensed as the services are rendered. A liability for a cash bonus or plan profit-sharing is recognized when the Company has a legal or implied obligation to make such payments because of past services rendered by a member of staff, and it is possible to make a reasonable estimate of the amount.   For post-employment the Company has a defined contribution plan pursuant to section 14 to the Israeli Severance Compensation Act, 1963 under which the Company pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold enough to pay all employee benefits relating to employee service in the current and prior periods. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed monthly, concurrently with performance of the employee's services.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> t. </td><td style="width: auto;"> Segment reporting </td></tr> </tbody></table>   Operating segments are

defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> u. </td><td style="width: auto;"> Geographic areas </td></tr> </tbody></table>   The Company has operations in Canada, the United States of America and Israel. The revenues and non-current assets of the Company are generated and located in the following locations: <table cellpadding="0" cellspacing="0" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 95%; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Geographic areas </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenue 2023 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenue 2022 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non- current assets 2023 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non- current assets 2022 </td></tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Canada </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td></tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> United States of America </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 478 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td></tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Israel </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 20 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 386 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 52 </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> v. </td><td style="width: auto;"> Recent accounting pronouncements </td></tr> </tbody></table>   In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-09 “Income Taxes (Topics 740): Improvements to Income Tax Disclosures” to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning January 1, 2025, with early adoption permitted. The Company has not adopted this standard early and is currently evaluating the potential effect that the updated standard will have on its consolidated financial statements disclosures.   In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses.   The expanded annual disclosures are effective for the Company’s year ending December 31, 2024, and the expanded interim disclosures are effective in 2025 and will be applied retrospectively to all prior periods presented.   The Company is currently evaluating the impact that ASU 2023-07 will have on its consolidated financial statements.   <table cellpadding="0" cellspacing="0" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 95%; margin-left: 0pt; margin-right: auto;"><tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Geographic areas </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenue 2023 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenue 2022 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non- current assets 2023 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non- current assets 2022 </td></tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Canada </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td></tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> United States of America </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 478 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> - </td></tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: top; width: 40%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Israel </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-

family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">20 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 386 </td><td style="vertical-align: top; width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 52 </td></tr> </tbody></table> 478000 20000 38600052000 NOTE 4: OTHER RECEIVABLES   Detail of other receivables balance is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Other receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">131</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Allowance for doubtful receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Other receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">131</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Allowance for doubtful receivables </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> 196000131000112000112000840019000 NOTE 5: LONG TERM DEPOSITS   Long term deposits consisted of rental deposits for month-to-month shared office lease. The balances as of December 31, 2023 and 2022 were $nil and $52, respectively.   52000 NOTE 6: INTANGIBLE ASSETS   The following tables summarize the composition of intangible assets as of December 31, 2023:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gross Carrying Amount </td><td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Accumulated Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Net Carrying Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Unamortized intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> BNA software </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> </tbody></table>   The BNA software enhancement project is in progress and amortization will begin once the project is substantially complete and the software is ready for its intended purpose. The software is expected to be completed by Q3 2024 and have a useful life of five years.   There were no intangible assets as of December 31, 2022.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gross Carrying Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Accumulated Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Net Carrying Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Unamortized intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> BNA software </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0,

0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">n/a</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> </tbody></table>
38600003860003860003860000 NOTE 7: CONVERTIBLE NOTES   Windsor Private Capital Ltd. Partnership ("WPC") and Origa Two Holdings Inc ("Origa")   On February 2, 2022, Origa and the Company signed a Side Letter in order to raise additional funds of $1,000 which were to be provided to the Company, as part of the original debt that was issued in 2021. The maturity date of the debentures was also extended to December 31, 2022. Two tranches of warrants (Tranche A and B) were also issued (Note 11.d). This amendment and issuance of warrants resulted in the extinguishment of the original debt, and recognition of the amended debt and warrants at their fair value of $1,886 and $478, respectively. The Company recorded a loss on extinguishment of $576 within other income (expense) in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2022.   On July 4, 2022, the board of directors of the Company agreed to amend the conversion price on the convertible debt from a price of $7.5 to $3 per share. Additionally, Tranche A warrants' exercise price was amended, the Tranche B warrants were cancelled (Note 11.d) and the expiration date of all remaining warrants were amended to 3 years from the date of amendment. This resulted in the debt being extinguished, and recognition of the amended convertible debt and Tranche A warrants at $2,936 and $551 respectively. The Company recognized a gain on extinguishment of $509 within other income (expense) in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2022.   Phyto IV Convertible debt issuance   On May 4, 2022, the Company issued a convertible debenture to Phyto IV LP. The principal amount of the note was $150 and the interest on the note accrued at a fixed rate 10% per annum. The interest on the note is accrued semi-annually and shall be payable on the maturity date, calculated on the basis of actual days elapsed. The interest is not payable in cash but added to the principal amount semi-annually on June 30 and December 31 of each year. The loan had a maturity date of one year from issuance with an option to extend maturity by one more year for a 1.5% fee of the then outstanding principal. The notes were convertible at a price of $7.5 per share. The conversion price for the convertible debt was also subject to adjustments resulting from subdivision, consolidation or any stock securities issuance by the way of stock dividend or other distribution. These adjustments were standard anti-dilution adjustments to compensate the warrant holders for any such event such that their rights were on par with other shareholders.   On July 4, 2022, the board of directors agreed to amend the conversion price on the convertible debt and reduce it from a price of $7.5 to $3. This resulted in a fair value change of the conversion option, which resulted in the debt being extinguished resulting in a gain on modification of $8.   On September 30, 2022, the convertible debt including accrued interest was converted to 51,792 reverse stock split adjusted shares of common stock of the Company.   Convertible debt issued to various investors   On July 4, 2022, the Company signed a memorandum of understanding with Origa and WPC to raise funds. As part of the memorandum of understanding, between July 4, 2022, and August 16, 2022, the Company issued convertible debt along with warrants to 13 individual investors on identical terms. The raise resulted in a total issuance of $555. Interest is accrued at a fixed rate of 10% per annum. The interest on the note is accrued semi-annually and shall be payable on the maturity date, calculated based on actual days elapsed. The interest is not payable in cash but added to the principal amount semi-annually on June 30 and December 31 of each year.   Each loan matures after two calendar years from the date of issue and had an option to extend the maturity date by one year at a fee of 1.5% of the then outstanding principal. The notes are also convertible into the common stock of the Company at any time at the option of the holder at a price of $3 per share. The conversion price for the convertible debt was subject to adjustments resulting from subdivision, consolidation or any stock securities issuance by the way of stock dividend or other distribution. These adjustments were standard anti-dilution adjustments to compensate the warrant holders for any such event such that their rights were on par with other shareholders.   On September 30, 2022, the convertible debt including accrued interest was converted to 188,734 shares of common stock of the Company. The share number has been adjusted to reflect the reverse stock split number of shares, which occurred on November 23, 2022.   Conversion option added to director loans   On July 4, 2022, the board of directors added a conversion option to certain directors' loan which were interest-free and payable upon demand. During 2022, the loans were converted to 106,612 shares of common stock.   No convertible debt remained outstanding as of December 31, 2023 and 2022, except for the non-interest bearing director's loan payable on demand (Refer to Note 13).   10000001886000478000-5760007.532936000551000509000150000.100.0157.57.538000517925550000.100.01531887341066120 NOTE 8: DEFERRED REVENUE   In February 2019, the Company executed a $2,500 development and consulting agreement with R.I. Mind Group Ltd. The Company's scope involved creating and developing BNA™ Biomarkers, the Database Infrastructure and the Delivery System (collectively, the "Work Products"), as well as consulting and advising on the development of Work Products or on the proper use of the Work Products. In accordance with the agreement, the Company received an advance of $500 against which the parties agreed to offset invoices amounting to $41.   In August 2022, the Company executed a Memorandum of Understanding ("MoU") with Pasithea Clinics Inc. to enter into an agreement with respect to the marketing and commercialization of the BNA™ System. The Company received an advance of $300. The advance was recognized as deferred revenue in 2022.   In November 2022, the Company executed an additional MoU with Pasithea Clinics Inc. to enter into an agreement with respect to the marketing and commercialization of BNA™ System. The Company received an advance of $150 to offset certain subsequent invoices. The advance was recognized as deferred revenue in 2022.   During the year ended December 31, 2023, the Company determined that it satisfied its performance obligation under both MoUs with Pasithea and recognized $450 of revenue.   Additionally, on February 24, 2023, the agreement with R.I. Mind Group Ltd. expired in accordance with its terms, and, as of December 31, 2023, there are no amounts owed by the Company to R.I. Mind Group Ltd. As the Company did not carry any activity for the purposes of the agreement, the Company recognized $459 of other income.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 23pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 23pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 23pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Pasithea Clinics Inc. </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">450</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> R.I. Mind Group Ltd </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">459</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">909</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table>   2500000500000-410003000001500004500004590000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 23pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 23pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 23pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Pasithea Clinics Inc. </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">450</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> R.I. Mind Group Ltd </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">459</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">909</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table> 045000004590000909000 NOTE 9: LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT   Israeli labor law requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain circumstances. Pursuant to Section 14 of the Israeli Severance Compensation Act, 1963, all the Company's employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments made in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. In accordance with the Israeli Severance Compensation Act, payments for 2023 and 2022 were $33 and $51, respectively, which are included in salary and employee benefits within research and development expenses (Note 15).   3300051000 NOTE 10: COMMITMENTS AND CONTINGENCIES   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> a. </td><td style="width: auto;"> Royalty Commitment - Israeli Innovation Authority ("IIA") </td></tr> </tbody></table>   The Company is committed to pay royalties to the State of Israel, through the IIA, on proceeds from sales of products which the IIA participated by way of grants for research and development. No grants were received in 2023 or 2022. Under the terms of the prior IIA grant agreements, the principal value of financial assistance received along with annual interest based on London Inter-Bank Offered Rate ("LIBOR") is repayable in form of royalties based on 3.0% of BNA™ sales. Since the elimination of LIBOR, the Secured Overnight Financing Rate ("SOFR") subsequently replaced LIBOR as a reference rate of interest for IIA grant agreements. In the case of lack of commercial feasibility of the project that was financed using the grant, the Company is not obligated to pay any royalty. The Company cannot reasonably determine the outcome of the commercialization of the technology and considers the liability to be contingent upon generation of sales, hence no liability has been recognized as of December 31, 2023 and 2022. The contingent liability amounts to $5,625 and $5,576 for 2023 and 2022 respectively.   Sale of the technology developed utilizing the grants from IIA is restricted and is subject to IIA's approval.   0.0356250005576000 NOTE 11: EQUITY   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> a. </td><td style="width: auto;"> Shares </td></tr> </tbody></table>   On <em style="font:

inherit;"> August 17, 2022, the Company closed a securities purchase agreement for the sale of 10 million Series A Preferred Stock for gross proceeds of $40. This agreement also entitled the subscriber to 13,333 warrants to purchase shares of common stock of the Company.   On September 15, 2022, the Company closed a securities purchase agreement for the sale of 51,282 consolidation adjusted shares of common stock at a consolidation adjusted price of $4.87 per share for aggregate gross proceeds of $250.   On February 16, 2023, the Company sold 32,536,386 shares of common stock at a price per share of $0.0041. The Company received aggregate gross proceeds from the offering of $133.   On February 23, 2023, the Company offered up to 10,799,136 shares of Series B Preferred Stock at $0.1852 per share. On March 15, 2023, the Company increased the offering to up to 14,578,833 shares of Series B Preferred Stock, with the increase being subsequently approved by the board of directors on November 15, 2023. As of December 31, 2023, the Company received aggregate gross proceeds from the offering of $2,700. The Company incurred $92 of costs associated with the issuance. Series B Preferred Stock issued are equity classified instruments and are recorded as equity. As of December 31, 2023, 14,578,833 Series B Preferred Stock were subscribed and issued.   On May 1, 2023, the Company granted 284,964 shares of common stock to a related party as a payment for consulting services provided. The shares awarded are under the scope of ASC 718 and were accounted for as equity-classified awards. The shares were measured at fair value on the grant date at $0.0041 per share.   On August 29, 2023, the Company offered up to 7,812,500 units, each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. As of December 31, 2023, the Company issued 1,538,134 units and received aggregate gross proceeds of $1,969. The Company incurred $67 of costs associated with the issuance. Series C Preferred Stock issued are equity classified instruments and are recorded as equity. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.   On October 16, 2023, 4,217 shares of common stock were repurchased for a nominal amount and cancelled by the Company.   As of December 31, 2023, mandatory conversion feature of Series B Preferred Stock was triggered, as the proceeds from Series C Preferred Stock Units offering exceeded $1,000. As per the terms of Series B Preferred Stock, all preferred shares were supposed to be automatically converted into one share of common stock. As of December 31, 2023, the 14,578,833 shares of common stock were not issued from an administrative perspective but were considered substantially issued from an accounting perspective.   As of December 31, 2023 and 2022, the Company had the following number of authorized and issued shares: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt; margin-right: auto;"><tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="14" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">December 31</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of authorized shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of   authorized   shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of   issued shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of issued   shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Shares of common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,470,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,470,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,369,877</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,552,744</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series A Preferred Stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series B Preferred Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">30,000,000</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">30,000,000</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,578,833</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series C Preferred Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,538,134</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   As of December 31, 2023 and 2022, the total number of shares of all classes the Company is authorized to issue is 2,500,000,000 shares, consisting of 2,470,000,000 shares of common stock and 30,000,000 preferred shared of all classes.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> b. </td><td style="width: auto;"> Rights attached to shares </td></tr> </tbody></table>   The shares of common stock confer upon their holders' voting rights and the right to participate in shareholders' meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Company's Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), and the right to a share in excess assets upon liquidation of the Company – all as set forth in the Company's Certificate of Incorporation and in the Company's Shareholders' Agreement.   The preferred shares confer upon their holders voting rights and the right to participate in shareholders' meetings, the right to share, on a per share pro rata basis, in Bonus Shares or Distributions (as defined in the Company's Certificate of Incorporation) as may be declared by the board of directors and approved by the shareholders, if required (out of funds legally available therefore), on an "as converted" basis, and the right to a share in excess assets upon liquidation of the Company in preference to the shares of common stock. The shares have discretionary dividends and do not have a redemption date.   The Series C Preferred Stock rank, as to the payment of dividends and the distribution of assets upon liquidation, dissolution or winding up of the Company: (a) senior to the shares of common stock, (b) junior to the Series B Preferred Stock, which Series B Preferred Stock include mandatory conversion provisions in the event the Company issues and sells equity securities to investors in an equity financing with total gross proceeds of not less than $1,000 with at least a pre-money valuation of the Company of $18,000, and (c) on parity with all other classes and series of the Company's preferred shares.   Series B Preferred Stock   Optional Conversion   Each share of Series B Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series B Preferred Stock "Series B Certificate of Designations"), which conversion price shall initially be equal to the original issue price.   Mandatory Conversion   Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") (or a qualified offering statement under Regulation A under the Securities Act; (b) the date that the Company or a successor to the Company (including, without limitation by way of acquisition of all or substantially all of the Company's assets) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is subject to the periodic and current reporting requirements of Section 13 or 15(d) of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $1,000 with at least a minimum pre-money valuation of the Company of $18,000, or (d) the date and time, or the occurrence of an event, by vote or written consent of the holders of at least a majority of the outstanding shares of Series B Preferred Stock, voting as a single class on an as-converted basis, all outstanding shares of Series B Preferred Stock shall automatically be converted into shares of common stock at the applicable ratio set forth in the Series B Certificate of Designations.   Series C Preferred Stock   Optional Conversion   Each share of Series C Preferred Stock is convertible, at the option of the holder thereof, at any time after the date of issuance of such shares into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of such shares by the conversion price (subject to any adjustments as set forth in the Certificate of Designations of Series C Preferred Stock, the "Series C Certificate of Designations"), which conversion price shall initially be equal to the original issue price.   Mandatory Conversion   Upon (a) the closing of the sale of shares of common stock to the public in a public offering pursuant to an effective registration statement under the Securities Act or a qualified offering statement under Regulation A of the Securities Act, as amended); (b) the date that the Company or a successor to the Corporation (including, without limitation, by way of acquisition of all or substantially all of the Corporation's assets, merger, or any other business combination) becomes an issuer with a class of securities registered under Section 12 or subject to Section 15(d) of the Exchange Act and is subject to the periodic and current reporting requirements of the Exchange Act or is required to file reports under Regulation A of the Securities Act; (c) the issuance and sale by the Company of its equity securities to investors in an equity financing with total gross proceeds to the Company of not less than $2,000 with at least a minimum pre-money valuation of the Company of $65,000, or (d) the date and time, or the occurrence of an event, specified by vote or written consent of at least a majority of the outstanding shares of Series C Preferred Stock at the time of such vote or consent, voting as a single class on an as-converted basis, all outstanding shares of Series C Preferred Stock shall automatically be converted into shares of common stock at the applicable ratio described in Series C Certificate of Designations.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> d. </td><td style="width: auto;"> Warrants </td></tr> </tbody></table>   During 2022, part of the modification of the WPC convertible (Note 7), the Company issued 526,749 stock split adjusted Tranche A and 262,051 stock split adjusted Tranche B warrants. The features of the warrants were as below: Tranche A: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> Exercise price: (1) $0.75 – If funds of a minimum of $15,000 are raised, (2) $0.75 – If the sale of a company, IPO or RTO is completed or the (3) purchase price per share resulting from dividing $50,000 by the total number of valid issued ordinary shares outstanding. </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt; text-align: justify;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> Maturity/Expiration date: (a) if no IPO – one year after the delivery date of the 2021 audited financial statements (b) if IPO – then one year after the date of such IPO. </td></tr> </tbody></table>   Tranche B: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> Purchase price per share resulting from dividing $150,000 by the total number of valid issued ordinary shares outstanding. </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt; text-align: justify;"> </td><td style="width: 18pt;"> ● </td><td style="width: auto;"> Maturity/Expiration date: (a) if no IPO – one year after the delivery date of the 2021 audited financial statements (b) if IPO – then five years after the date of such IPO. </td></tr> </tbody></table>   On July 4, 2022, as part of the Senior Lender's Memo, the conversion price of the Tranche A warrant was amended to: (1) $0.75 – If after July 5, 2022 funds of a minimum of $5,000 are raised 18 months and $10,000 in total in the three years thereafter, (2) $0.75 – after the recapitalization date, if the sale of a company, IPO or RTO is completed or (3) the purchase price per share resulting from dividing $20,000 by the total number of valid issued ordinary shares outstanding. The Tranche B warrants were cancelled.   <p style="font-family:Times New Roman;font-

size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As part of the convertible debt issuance to various investors between July 4, 2022, and August 16, 2022, the Company issued 198,482 consolidation adjusted warrants concurrent with the convertible debt and preferred shares. The warrants were exercisable into one share of common stock of the Company per warrant at a price of $3. The warrants had a maturity date of three years.   On February 17, 2023, warrants to purchase up to 123,333 shares of common stock, issued to WPC in 2021, were modified pursuant to antidilution provision in the warrant agreement, triggered by common stock private placement on February 16, 2023. As a result of the modification, exercise price of the warrants was reduced to $0.00473 per share and the expiry date was extended to be three years from the modification date. The warrants were determined to be a freestanding equity instrument. Under ASC 815, the effect of a modification was nominal and was recorded as an equity issuance costs.   On August 29, 2023, the Company offered up to 7,812,500 units, comprised of Series C Preferred Stock and warrants to purchase up to 7,812,500 shares of common stock, which were sold at a combined purchase price of $1.28 per unit. Each warrant entitles the holder to acquire one share of common stock at a price of $2.56 per share for a period of <em style="font: inherit;">three years from the date of issue. The warrants were determined to be a freestanding equity instrument. As of <em style="font: inherit;"> December 31, 2023, 759,863 warrants were issued. Additionally, as of <em style="font: inherit;"> December 31, 2023, 781,250 warrants were <em style="font: inherit;">not issued from an administrative perspective, but were considered substantially issued from an accounting perspective.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Number of </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Warrants</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Weighted </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Average </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Price</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Weighted</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Average </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Remaining </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Life</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding warrants, January 1, 2022</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">123,333</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.85</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants issued pursuant to issue of convertible debt and preferred shares to individual investors </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">198,482</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants issued pursuant to modification of convertible debt </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526,749</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.75</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding warrants, December 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">848,564</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued pursuant to units offering</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,538,113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.56</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding warrants, December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,386,677</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.07</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.46</td><td style="width: 1%; font-family: "Times

New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   The warrants and prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> e. </td><td style="width: auto;"> Series A warrants </td></tr> </tbody></table>   On June 15, 2023, the Company granted Series A warrants to purchase up to an aggregate 6,048,456 shares of common stock to certain investors at an exercise price of $0.01 Canadian dollars per share for a period of five years from the issuance date. The exercisability of the warrants is contingent upon meeting market capitalization goals and the occurrence of a liquidity event. Since warrants are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to warrants until the occurrence of a liquidity event.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> f. </td><td style="width: auto;"> Employees stock option plan </td></tr></tbody></table>   In 2010, the Company's board of directors approved an employee and service provider's stock option plan. On July 8, 2023, the board of directors approved new equity incentive plan (the "Plan"). The Plan permits the grant of options, share appreciation rights ("SARs"), restricted share units ("RSUs"), deferred share units ("DSUs") and performance share units ("PSUs"). In respect of options, the aggregate number of shares of common stock issuable under the Plan shall not exceed twelve percent of the issued and outstanding shares of common stock at any point in time. In respect of SARs, RSUs, DSUs and PSUs: (i) the maximum aggregate number of shares of common stock issuable under this Plan in respect of SARs, RSUs, DSUs and PSUs shall not exceed ten percent of the issued and outstanding shares of common stock as of July 8, 2023; (ii) the total number of SARs, RSUs, DSUs and PSUs issuable to any participant under this Plan shall not exceed one percent of the issued and outstanding shares of common stock at the time of the award.   The fair value of each option award is estimated on the date of grant using a Black Scholes option valuation model that uses the assumptions noted in the following table.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Risk free rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.35</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected term (in years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected life (in years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr></tbody></table>   A summary of option activity under the Plan as of December 31, 2023, and changes during the year then ended is presented below.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Number of Stock Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Weighted Average Remaining Contractual Term </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Aggregate Intrinsic Value </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Outstanding Options, December 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-

left: 0pt;">495,746</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.70</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">795,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.58</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Outstanding Options, December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,291,662</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   The share-based compensation expense related to options for December 31, 2023 was $295 (2022: $60). The fair value of options granted for the year ended December 31, 2023 was nominal (2022: $692). The intrinsic value of the options outstanding is $nil (2022: $nil).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A summary of the Company's non-vested options as of <em style="font: inherit;"> December 31, 2023, and changes during the year ended <em style="font: inherit;"> December 31, 2023, is presented below.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">of Stock </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Options</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Weighted </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Average </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Grant-</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Date Fair </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Value</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-Vested Options, December 31, 2022</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">325,853</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">795,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options vested </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(246,883</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-Vested Options, December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">874,886</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table>   As of December 31, 2023, there was $434 of total unrecognized compensation cost related to nonvested options granted under the Plan.   The options and exercise prices have been changed to reflect the reverse stock split of 1:750, which occurred on November 23, 2022.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> g. </td><td style="width: auto;"> Management options </td></tr> </tbody></table> <p style="font-family:'Times New

Roman';font-size:10pt;font-variant:normal;margin:0pt;"> On July 8, 2023, the Company granted stock options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock at an exercise price with a term of five years, where the exercise price is equal to a 25% discount to the issue price of the Company's equity securities in an initial public offering (an "IPO Transaction"), that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. Options to purchase up to 362,584 shares of common stock shall vest immediately with the remaining options vesting in 36 equal installments at the end of each calendar month over a period of three years from the date of grant. The vesting of management options is contingent upon the occurrence of an IPO Transaction. Since options are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost would be recognized related to options until the occurrence of a liquidity event.   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> h. </td><td style="width: auto;"> Restricted share units </td></tr></tbody></table>   On July 8, 2023, the Company granted RSUs to certain management and directors. The vesting of the RSUs is contingent upon a transaction that results in the Company's shares of common stock being listed on the Nasdaq Stock Market or another recognized securities exchange or traded on the over-the-counter market. When vested, the RSUs represent the right to be issued the number shares of common stock that is equal to the number of RSUs granted. Since RSUs are contingent on the occurrence of a liquidity event which is not probable for the purposes of ASC 718, no compensation cost related to RSUs is recognized until the occurrence of a liquidity event.

"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 247000000024700000003536987725527 44 00300000003000000014578833 0 1538134025000000002470000000300000001000180001000180002000650005267492620510.750.75500001500000.750.751984823123333 0.004737812500781250012 82.5 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle;"> Number of Warrants </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Outstanding warrants, January 1, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 123,333</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> 0.85</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued pursuant to issue of convertible debt and preferred shares to individual investors</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">198,482</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued pursuant to modification of convertible debt</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526,749</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.75</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding warrants, December 31, 2022</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">848,564</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants issued pursuant to units offering </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,538,113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.56</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding warrants, December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,386,677</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.07</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.46</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> 1233337.5 P0Y10M6D 19848235267490.758485642.26 P2Y6M 15381132.5623866772.07 P2Y5M 15 D60484560.01 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-

size: 10pt; font-variant: normal; margin: 0pt;">Risk free rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.35</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected term (in years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected life (in years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 0.04350.045000.860.86P3YP3YP5YP5Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Number of Stock Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Weighted Average Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Weighted Average Remaining Contractual Term </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;"> Aggregate Intrinsic Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Outstanding Options, December 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">495,746</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.70</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">795,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.58</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Outstanding Options, December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,291,662</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">of Stock </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Options</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Weighted </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Average </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Grant-</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Date Fair </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Value</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-Vested Options, December 31, 2022</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">325,853</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">795,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options vested </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(246,883</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-Vested Options, December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">874,886</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table>

4957464.7P6Y10M24D07959160.5812916622.16P6Y2M4D0295000060000692000 3258532.279591602468831.158748860.5434000314828 8362584 NOTE 12: BASIC AND DILUTED NET LOSS PER SHARE   Basic net loss per common share is computed by dividing net loss attributable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Weighted average number of shares of common stock outstanding during the period computation includes shares of common stock to be contractually issued as of the period end date. Diluted net loss per common share is computed by giving effect to all potential dilutive shares of common stock that were outstanding during the period when the effect is dilutive. Potential dilutive shares of common stock consist of shares issuable upon conversion of preferred shares, exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding shares of common stock figures for the years ended December 31, 2023 or 2022, as the assumed conversion of preferred shares, exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.   NOTE 13: RELATED PARTY TRANSACTIONS   During the year ended December 31, 2022, $320 of notes payable to directors were converted to 106,612 shares of common stock (Note 7).   As of the year ended December 31, 2023, $175 (2022: $175) of director loans were still outstanding. These notes do not bear any interest and are payable on demand. The remaining related party payables of $nil (2022: $2) relate to services payable to a related party of the Company. These payables do not bear any interest and are payable on demand.   The Company incurred $222 and $420 in officers' consulting fees recorded in general administration expenses on consolidated statements of operations for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023 and 2022, $106 and $56, respectively remained outstanding and were accrued by the Company, and are included in accrued liabilities in the accompanying balance sheets.   On May 1, 2023, the Company issued 284,964 shares of common stock to a related party as a payment for consulting services provided.   On July 8, 2023, the Company granted options to its employees, officers, directors and consultants to purchase an aggregate of 3,148,288 shares of common stock in the capital of the Company (Note 11.g). 2,776,861 of these options were granted to related parties. No compensation cost is recognized related to options until the occurrence of a liquidity event.

3200001066121750001750002000222000420000106000560002849643148288 2776861 NOTE 14: REVENUE   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Type of goods and services </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Service </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Timing of recognition of revenue </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Over time </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 70%;"> Type of goods and services </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Service </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Timing of recognition of revenue </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-

family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Over time </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">498</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>
498000049800004980000498000049800004980000 NOTE 15. RESEARCH AND DEVELOPMENT EXPENSES   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">527</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">944</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Consultants and subcontractors </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">152</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Clinical trials </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expenses - other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">129</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,299</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less – grants received </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">741</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,299</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size:

10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">527</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">944</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Consultants and subcontractors </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">152</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Clinical trials </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expenses - other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">129</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,299</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less - grants received </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">741</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,299</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> 527000944000990001520000140003000600001120001290007410001299000074100012990000 NOTE 16: SELLING AND MARKETING EXPENSES   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">611</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">432</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;

margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">639</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">524</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">611</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">432</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">639</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">524</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> 611000432000600027000210005100010001400063900052400 0 NOTE 17: GENERAL AND ADMINISTRATION EXPENSES   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">512</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">418</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,252</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">724</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent and maintenance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">233</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Bad debts </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> $</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,542</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Salary and employee benefits </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">512</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">418</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,252</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">724</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Rent and maintenance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">233</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Travel expenses </td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Bad debts </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,542</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> 5120004180001250007240009100023300056000720001000-200028400097000219600015420000 NOTE 18: OTHER (INCOME) / EXPENSE   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Interest, bank fees and loan fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">440</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unrealized (gain) loss on foreign exchange </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">134</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss on extinguishment of debt </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gain on sale of equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(166</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(457</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(476</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">460</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table>   In February 2022, the Company sold equipment for $262 resulting in a gain on sale of $166.   On February 24, 2023, the agreement with R.I. Mind Group Ltd. expired in accordance with its terms, and, as of December 31, 2023, there are no amounts owed by the Company to R.I. Mind Group Ltd. As the Company did not carry any activity for the purposes of the agreement, the Company recognized $459 of other income (Note 8).   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Interest, bank fees and loan fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">440</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unrealized (gain) loss on foreign exchange </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">134</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss on extinguishment of debt </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Gain on sale of equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(166</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(457</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(476</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">460</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> -18000-44000037000-134000-0-590000-1660004570007000-476000460000262000166000459000 NOTE 19. INCOME TAX   The total provision for income taxes differs from the amount which would be computed by applying the US income tax rate to loss before income taxes. The reasons for these differences are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Statutory income tax rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27.60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28.51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Statutory income tax recovery </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(718</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman",

Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Increase (decrease) in income taxes </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-deductible option expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">135</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Taxable capital gain on sale of investment and equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Difference in foreign tax rates </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> US state tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Change in valuation allowance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">553</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">895</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income tax expense (recovery) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities and certain carry-forward balances.   The primary components of the deferred tax assets and liabilities are as follows, for the periods indicated below: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>$ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Deferred tax assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 60.5%;"> Non-capital loss carry-forwards from Canada </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-capital loss carry-forwards from US </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,418</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size:

10pt;"> Non-capital loss carry-forwards from Israel </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,449</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,479</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock option </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">95</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> R&D expenditures </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">236</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">424</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Reserves and others </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">127</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,325</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,497</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Valuation Allowances for deferred tax assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,325</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19,497</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net deferred tax assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   The net deferred tax assets have been offset by a valuation allowance because it is not more likely than not the Company will realize the benefit of these deferred tax assets. The Company did not recognize any tax benefits as of December 31, 2023 and December 31, 2022.   At December 31, 2023, the Company's Canadian, US, and Israeli non-capital income tax losses, the benefit of which has not been recognized on the consolidated financial statements, expire as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Canada </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> US </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Israel </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2034 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">501</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2035 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,767</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2036 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,872</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2037 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2038 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2039 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2040 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2041 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2042 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> Indefinite </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,293</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; width: 31%;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,433</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">67,170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   At December 31, 2023, the Company had a cumulative carry-forward pool of Israeli Research and Development expenditures in the amount of $889 (2022: $1,823) which will be amortized within the next three years.   The Company files unconsolidated federal income tax returns domestically and in foreign jurisdictions. The Company has open tax years from 2018 to 2023 with tax jurisdictions including Canada, U.S, and Israel. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations, as they relate to amount, timing, or inclusion of revenues and expenses.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom:

1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Statutory income tax rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27.60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">28.51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Statutory income tax recovery </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(718</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Increase (decrease) in income taxes </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-deductible option expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">135</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Taxable capital gain on sale of investment and equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Difference in foreign tax rates </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> US state tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Change in valuation allowance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">553</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">895</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income tax expense (recovery) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 0.2760.2851-718000-1113000135000190000030000200000 1000-1000553000895000100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times

New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Deferred tax assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 60.5%;"> Non-capital loss carry-forwards from Canada </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-capital loss carry-forwards from US </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,418</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-capital loss carry-forwards from Israel </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,449</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,479</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock option </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">95</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> R&D expenditures </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">236</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">424</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Reserves and others </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">127</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,325</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,497</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Valuation Allowances for deferred tax assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,325</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19,497</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net deferred tax assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
0100014180001576000154490001747900095000170002360004240001270000173250001949700017325000194970000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Canada </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> US </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Israel </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> 2034 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">501</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2035</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,767</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2036</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,872</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2037</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2038</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2039</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2040</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2041</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2042</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Indefinite</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,293</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; width: 31%;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,433</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">67,170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>

0501000001767000002872000000000000000000020000001293000671700002000643300067170000088900018230000 NOTE 20: REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS   During 2023, management of the Company became aware of certain errors in the recording of expenses within research and development and general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. Revisions of these amounts are reflected in the following tables.   Revised Consolidated Balance Sheet   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> As of December 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As reported </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Adjustment </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As revised </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Accrued liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">855</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total current liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accumulated deficit </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(73,906</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(74,021</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total shareholders' deficit </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,111</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,226</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table>   Revised Consolidated Statements of Operations and Comprehensive Loss   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> For the year ended December 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As reported </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Adjustment </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As revised </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Research and development expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,272</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,299</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:

0pt;">General and administration expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,454</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">88</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,542</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,329</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,444</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss before Income Tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net Loss and Comprehensive Loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table>   Revised Consolidated Statement of Cash Flows   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> For the year ended December 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As reported </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Adjustment </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As revised </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Net loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Change in accrued liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">97</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net cash used in operating activities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,892</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,892</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> As of December 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As reported </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Adjustment </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As revised </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt; width: 55%;"> Accrued liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">855</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total current liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accumulated deficit </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(73,906</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(74,021</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total shareholders' deficit </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,111</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,226</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> For the year ended December 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As reported </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Adjustment </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As revised </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Research and development expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,272</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,299</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administration expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,454</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">88</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,542</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,329</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,444</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss before Income Tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align:

right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net Loss and Comprehensive Loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> For the year ended December 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As reported </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Adjustment </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As revised </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> Net loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,789</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Change in accrued liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">97</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net cash used in operating activities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,892</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,892</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table>
740000115000855000224600011500023610002246000115000236100-73906000-115000-74021000-2111000-115000-22260001272000270001299000145400088000154200033290001150003444000-3789000-115000-3904000-3789000-115000-3904000-1800011500097000-28920000-2892000 NOTE 21: SUBSEQUENT EVENTS   The subsequent events below are major events or transactions that occurred after the period ended December 31, 2023, but before the issuance of these consolidated financial statements. The below events occurred between January 1, 2024 and May 22, 2024:   On January 12, 2024, the Merger Agreement was amended to update certain terms of the original agreement dated November 15, 2023. The updates include changes to clarify that the effective time of the Merger Agreement shall be prior to or simultaneous with certain transaction to be carried out by WaveDancer, treatment of the Company's warrants at the effective time and deletion of certain closing obligations.   On February 28, 2024, the Company issued 820,312 units and received aggregate gross proceeds of $1,050. Each unit consisting of one share of Series C Preferred Stock and warrant to purchase one share of common stock, at a combined purchase price of $1.28 per unit. Each warrant entitles the purchasers to acquire one share of common stock at a price of $2.56 per share for a period of three years from the date of issue.
820312105000012822.56